<SEC-DOCUMENT>0001493152-24-014832.txt : 20240416
<SEC-HEADER>0001493152-24-014832.hdr.sgml : 20240416
<ACCEPTANCE-DATETIME>20240416163332
ACCESSION NUMBER:		0001493152-24-014832
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		114
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240416
DATE AS OF CHANGE:		20240416

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Neuraxis, INC
		CENTRAL INDEX KEY:			0001933567
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				455079684
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41775
		FILM NUMBER:		24848232

	BUSINESS ADDRESS:	
		STREET 1:		11611 N. MERIDIAN ST
		STREET 2:		SUITE 330
		CITY:			CARMEL
		STATE:			IN
		ZIP:			46032
		BUSINESS PHONE:		(812) 689-0791

	MAIL ADDRESS:	
		STREET 1:		11611 N. MERIDIAN ST
		STREET 2:		SUITE 330
		CITY:			CARMEL
		STATE:			IN
		ZIP:			46032
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>form10-k.htm
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:NRXS="http://neuraxis.com/20231231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_024_US%2DGAAP%2D2023_stpr -->
<!-- Field: Set; Name: xdx; ID: xdx_03B_NRXS_neuraxis.com_20231231 -->
<!-- Field: Set; Name: xdx; ID: xdx_04A_20230101_20231231 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_05B_edei%2D%2DEntityCentralIndexKey_0001933567 -->
<!-- Field: Set; Name: xdx; ID: xdx_076_XDX_form10%2Dk.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000004" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000005" name="dei:EntityCentralIndexKey">0001933567</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0045" name="dei:AuditorFirmId">89</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:DeferredCosts" contextRef="AsOf2023-12-31" id="xdx2ixbrl0082" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember" id="xdx2ixbrl0112" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember" id="xdx2ixbrl0115" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="AsOf2023-12-31" id="xdx2ixbrl0118" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="xdx2ixbrl0128" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-12-31_custom_ConvertibleSeriesAPreferredStockMember" id="xdx2ixbrl0155" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-12-31_custom_ConvertibleSeriesSeedPreferredStockMember" id="xdx2ixbrl0174" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-12-31_custom_ConvertibleSeriesSeedPreferredStockMember" id="xdx2ixbrl0193" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0267" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OtherNonoperatingExpense" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0273" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember" id="xdx2ixbrl0316" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember" id="xdx2ixbrl0317" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0318" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0320" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember" id="xdx2ixbrl0323" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember" id="xdx2ixbrl0324" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0327" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember" id="xdx2ixbrl0332" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember" id="xdx2ixbrl0333" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0334" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0335" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="NRXS:StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember" id="xdx2ixbrl0352" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="NRXS:StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember" id="xdx2ixbrl0353" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="NRXS:StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0356" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="NRXS:StockIssuedDuringPeriodValueCommonStockIssuedUponPreferredStockConversion" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0365" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="NRXS:StockIssuedDuringPeriodValueCommonStockIssuedUponPreferredStockConversion" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0366" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember" id="xdx2ixbrl0374" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember" id="xdx2ixbrl0375" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0378" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember" id="xdx2ixbrl0383" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember" id="xdx2ixbrl0384" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0387" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember" id="xdx2ixbrl0392" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember" id="xdx2ixbrl0393" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0394" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0396" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="NRXS:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember" id="xdx2ixbrl0399" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="NRXS:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember" id="xdx2ixbrl0400" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="NRXS:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0403" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember" id="xdx2ixbrl0408" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember" id="xdx2ixbrl0409" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl0410" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0411" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember" id="xdx2ixbrl0415" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember" id="xdx2ixbrl0416" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember" id="xdx2ixbrl0422" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember" id="xdx2ixbrl0424" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="NRXS:NoncashInterestExpense" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0450" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0452" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0456" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="NRXS:IssuanceOfCommonStockForNoncashConsideration" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0459" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0513" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="NRXS:DeferredOfferingCostsPaid" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0515" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0519" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0551" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0552" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="NRXS:PriorYearOfferingCostsPaid" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0564" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="NRXS:ReclassificationOfWarrantLiabilityToEquity" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0567" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="NRXS:ConversionOfPreferredStockToCommonStock" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl0570" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="AsOf2023-12-31" id="xdx2ixbrl0636" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="NRXS:WarrantLiabilities" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0695" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="NRXS:WarrantLiabilities" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0696" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0699" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0700" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0701" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0702" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0705" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0706" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="NRXS:WarrantLiabilities" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0710" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="NRXS:WarrantLiabilities" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0711" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0715" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0716" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0720" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0721" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="xdx2ixbrl0730" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_custom_ConvertibleSeriesAPreferredStockMember" id="xdx2ixbrl0742" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_custom_ConvertibleSeriesSeedPreferredStockMember" id="xdx2ixbrl0745" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl0751" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_custom_ConvertibleBridgeDebtMember" id="xdx2ixbrl0757" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:PreferredStockDividendsAndOtherAdjustments" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0768" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NotesAndLoansReceivableNetCurrent" contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember" id="xdx2ixbrl0946" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:InterestReceivable" contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember" id="xdx2ixbrl0948" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="NRXS:InterestIncomeCurrent" contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember" id="xdx2ixbrl0950" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NotesAndLoansReceivableNetCurrent" contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember" id="xdx2ixbrl0976" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:InterestReceivable" contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember" id="xdx2ixbrl0978" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="NRXS:InterestIncomeCurrent" contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember" id="xdx2ixbrl0980" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:LoansPayable" contextRef="AsOf2023-12-31_custom_ShareHolderMember" id="xdx2ixbrl0988" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="NRXS:InterestAndServiceFeeAccrued" contextRef="AsOf2023-12-31_custom_ShareHolderMember" id="xdx2ixbrl0990" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:LoansPayable" contextRef="AsOf2023-12-31_custom_ShareHolderOneMember64718796" id="xdx2ixbrl0998" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="NRXS:InterestAndServiceFeeAccrued" contextRef="AsOf2023-12-31_custom_ShareHolderOneMember64718796" id="xdx2ixbrl1000" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:LoansPayable" contextRef="AsOf2023-12-31_custom_OtherConvertiblesMember" id="xdx2ixbrl1008" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:InterestPaid" contextRef="From2023-01-012023-12-31_custom_OtherConvertiblesMember" id="xdx2ixbrl1012" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:LoansPayable" contextRef="AsOf2023-12-31" id="xdx2ixbrl1014" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:InterestPaid" contextRef="From2022-01-012022-12-31_custom_ShareHolderMember" id="xdx2ixbrl1028" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:InterestPaid" contextRef="From2022-01-012022-12-31_custom_ShareHolderOneMember" id="xdx2ixbrl1038" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:LoansPayable" contextRef="AsOf2022-12-31_custom_OtherConvertiblesMember" id="xdx2ixbrl1044" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:InterestPaid" contextRef="From2022-01-012022-12-31_custom_OtherConvertiblesMember" id="xdx2ixbrl1048" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:InterestPaid" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1054" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2022-12-31_custom_LicensesMember" id="xdx2ixbrl1111" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="NRXS:UnderwriterFees" contextRef="AsOf2023-12-31" id="xdx2ixbrl1133" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="NRXS:RelatedPartyInterestPayableCurrent" contextRef="AsOf2023-12-31" id="xdx2ixbrl1139" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2023-12-31" id="xdx2ixbrl1181" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DeferredFinanceCostsCurrentNet" contextRef="AsOf2023-12-31" id="xdx2ixbrl1184" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="AsOf2023-12-31" id="xdx2ixbrl1187" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DeferredFinanceCostsNet" contextRef="AsOf2023-12-31" id="xdx2ixbrl1190" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:LongTermDebt" contextRef="AsOf2023-12-31" id="xdx2ixbrl1193" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2023-12-31" id="xdx2ixbrl1343" unitRef="USD" xs:nil="true"/>
  <ix:nonNumeric contextRef="AsOf2022-12-31_custom_TwoThousandTwentyTwoConvertibleNotesMember" id="xdx2ixbrl1404" name="us-gaap:WarrantsAndRightsOutstandingTerm">P5Y</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2023-06-30_custom_TwoThousandTwentyThreeConvertibleNotesMember" id="xdx2ixbrl1410" name="us-gaap:WarrantsAndRightsOutstandingTerm">P1Y</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2023-08-09_custom_TwoThousandTwentyThreeConvertibleNotesMember" id="xdx2ixbrl1414" name="us-gaap:WarrantsAndRightsOutstandingTerm">P5Y</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2023-08-14_custom_TwoThousandTwentyThreeConvertibleNotesMember" id="xdx2ixbrl1417" name="us-gaap:WarrantsAndRightsOutstandingTerm">P5Y</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl1434" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="NRXS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl1436" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl1438" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl1440" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="xdx2ixbrl1460" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember64724375" id="xdx2ixbrl1474" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember64724375" id="xdx2ixbrl1476" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember64724375" id="xdx2ixbrl1478" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="NRXS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember64724375" id="xdx2ixbrl1480" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember64724375" id="xdx2ixbrl1482" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember64724375" id="xdx2ixbrl1484" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember64723875" id="xdx2ixbrl1490" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember64723875" id="xdx2ixbrl1492" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember64723875" id="xdx2ixbrl1494" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="NRXS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember64723875" id="xdx2ixbrl1496" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl1502" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember" id="xdx2ixbrl1504" unitRef="USDPShares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2021-12-31" id="xdx2ixbrl1628" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1630" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1632" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1634" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1636" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2022-12-31" id="xdx2ixbrl1644" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl1646" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl1648" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl1650" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl1652" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2023-12-31" id="xdx2ixbrl1660" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" contextRef="AsOf2023-12-31" id="xdx2ixbrl1668" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1692" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1694" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="NRXS:AdditionToWarrantLiabilities" contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1698" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="NRXS:AdditionToWarrantLiabilities" contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1700" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1704" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1706" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1710" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1712" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="NRXS:AdditionToWarrantLiabilities" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1716" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="NRXS:AdditionToWarrantLiabilities" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1718" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1722" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1724" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="NRXS:ReclassifiedToEquity" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1728" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="NRXS:ReclassifiedToEquity" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1730" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1734" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1736" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1754" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1756" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl1758" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="NRXS:AdditionToDerivativeLiabilities" contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1760" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="NRXS:AdditionToDerivativeLiabilities" contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1762" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1766" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1768" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1772" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1774" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="NRXS:AdditionToDerivativeLiabilities" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1778" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="NRXS:AdditionToDerivativeLiabilities" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1780" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1784" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1786" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="NRXS:ExtinguishmentOfDerivativeLiabilities" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1790" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="NRXS:ExtinguishmentOfDerivativeLiabilities" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1792" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1796" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1798" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl1800" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2023-12-31" id="xdx2ixbrl1874" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2022-12-31" id="xdx2ixbrl1875" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl1885" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1886" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="NRXS:EffectiveIncomeTaxRateReconciliationNontaxableIncome" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl1888" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="NRXS:EffectiveIncomeTaxRateReconciliationNontaxableIncome" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1889" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl1894" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2022-01-012022-12-31" id="xdx2ixbrl1895" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl1960" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl1964" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl1968" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl1972" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl1976" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl1980" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl1984" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl1988" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl1992" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl1996" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2000" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2012" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2016" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_NonrelatedPartyMember" id="xdx2ixbrl2020" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2024" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:Deposits" contextRef="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2028" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="NRXS:ShareLiabilitiesCurrent" contextRef="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2032" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="NRXS:WarrantLiabilities" contextRef="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2036" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2040" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2044" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2048" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember_custom_ConvertibleSeriesAPreferredStockMember" id="xdx2ixbrl2055" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_custom_ConvertibleSeriesAPreferredStockMember" id="xdx2ixbrl2056" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-09-30_custom_ConvertibleSeriesAPreferredStockMember" id="xdx2ixbrl2057" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember_custom_ConvertibleSeriesSeedPreferredStockMember" id="xdx2ixbrl2059" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_custom_ConvertibleSeriesSeedPreferredStockMember" id="xdx2ixbrl2060" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-09-30_custom_ConvertibleSeriesSeedPreferredStockMember" id="xdx2ixbrl2061" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2064" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2076" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2080" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-07-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2084" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2087" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2023-07-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2091" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2094" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2023-07-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2098" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2101" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:SellingExpense" contextRef="From2023-07-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2105" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:SellingExpense" contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2108" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-07-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2112" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2115" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-07-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2119" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2122" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-07-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2126" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2129" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="NRXS:FinancingCharges" contextRef="From2023-07-012023-09-30_srt_ScenarioPreviouslyReportedMember" id="xdx2ixbrl2139" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="NRXS:FinancingCharges" contextRef="From2023-07-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2140" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="NRXS:FinancingCharges" contextRef="From2023-07-012023-09-30" id="xdx2ixbrl2141" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="NRXS:FinancingCharges" contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2143" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2023-07-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2147" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2150" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:InterestAndOtherIncome" contextRef="From2023-07-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2154" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:InterestAndOtherIncome" contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2157" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-07-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2161" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2164" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2023-07-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2168" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2171" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="From2023-07-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2175" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2178" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OtherNonoperatingIncome" contextRef="From2023-07-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2189" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OtherNonoperatingIncome" contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2192" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OtherNonoperatingExpense" contextRef="From2023-07-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2196" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OtherNonoperatingExpense" contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2199" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2229" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2233" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2237" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="NRXS:NoncashLeaseExpense" contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2241" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="NRXS:NoncashInterestExpense" contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2245" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember" id="xdx2ixbrl2248" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2249" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-01-012023-09-30" id="xdx2ixbrl2250" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="NRXS:IssuanceOfCommonStockForNoncashConsideration" contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2257" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="NRXS:FinanceCharges" contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2261" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2265" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2269" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2277" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2281" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2285" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2289" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2293" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="NRXS:IncreaseDecreaseInCustomerDeposit" contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2297" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2301" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2305" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2313" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2317" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2321" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2329" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="NRXS:OfferingCostsInAdvanceOfSaleOfCommonStock" contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2333" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2337" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2341" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2345" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2349" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2353" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2357" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="xdx2ixbrl2361" unitRef="USD" xs:nil="true"/>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="nrxs-20231231.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2023-01-01to2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-04-12">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-04-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_NonrelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_NonrelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ConvertibleSeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ConvertibleSeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ConvertibleSeriesSeedPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesSeedPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ConvertibleSeriesSeedPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesSeedPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesSeedPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesSeedPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesSeedPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesSeedPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesSeedPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-122023-01-12">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-12</xbrli:startDate>
        <xbrli:endDate>2023-01-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-08-092023-08-09_us-gaap_CommonStockMember_custom_AlexanderCapitalLPMember_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">NRXS:AlexanderCapitalLPMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-09</xbrli:startDate>
        <xbrli:endDate>2023-08-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-08-09_us-gaap_CommonStockMember_custom_AlexanderCapitalLPMember_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">NRXS:AlexanderCapitalLPMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-08-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-08-09_us-gaap_IPOMember_custom_AlexanderCapitalLPMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">NRXS:AlexanderCapitalLPMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-08-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-08-092023-08-09_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-09</xbrli:startDate>
        <xbrli:endDate>2023-08-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-08-112023-08-11_us-gaap_CommonStockMember_custom_AlexanderCapitalLPMember_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">NRXS:AlexanderCapitalLPMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-11</xbrli:startDate>
        <xbrli:endDate>2023-08-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-102022-07-11_custom_TrademarkAgreementMember_custom_InitialPaymentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:TrademarkAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">NRXS:InitialPaymentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-10</xbrli:startDate>
        <xbrli:endDate>2022-07-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-102022-07-11_custom_TrademarkAgreementMember_custom_SecondAndFinalPaymentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:TrademarkAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">NRXS:SecondAndFinalPaymentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-10</xbrli:startDate>
        <xbrli:endDate>2022-07-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-112023-04-12_custom_LicensingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:LicensingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-11</xbrli:startDate>
        <xbrli:endDate>2023-04-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_CustomerMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_CustomerOneMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_CustomerTwoMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_CustomerThreeMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerThreeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_CustomerFourMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerFourMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_CustomerMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_CustomerOneMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_CustomerTwoMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_CustomerThreeMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerThreeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_CustomerMember_us-gaap_SalesRevenueProductLineMember_us-gaap_RevenueFromRightsConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:RevenueFromRightsConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_CustomerMember_us-gaap_SalesRevenueProductLineMember_us-gaap_RevenueFromRightsConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:RevenueFromRightsConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-08-09_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-08-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-08-112023-08-11_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-11</xbrli:startDate>
        <xbrli:endDate>2023-08-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MachineryAndEquipmentMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MachineryAndEquipmentMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FurnitureAndFixturesMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FurnitureAndFixturesMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_ComputerEquipmentMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_ComputerEquipmentMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_ConvertibleSeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">NRXS:ConvertibleSeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_ConvertibleSeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">NRXS:ConvertibleSeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_ConvertibleSeriesSeedPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">NRXS:ConvertibleSeriesSeedPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_ConvertibleSeriesSeedPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">NRXS:ConvertibleSeriesSeedPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_OptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:OptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_OptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:OptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">NRXS:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">NRXS:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_ConvertibleBridgeDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">NRXS:ConvertibleBridgeDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_ConvertibleBridgeDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">NRXS:ConvertibleBridgeDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_stpr_CA">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_stpr_WI">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_stpr_OH">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:OH</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_stpr_OH">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:OH</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_stpr_WI">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_stpr_CA">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_stpr_FL">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_stpr_FL">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_stpr_MA">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_country_MO">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MO</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_AllOtherStatesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">NRXS:AllOtherStatesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_AllOtherStatesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">NRXS:AllOtherStatesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_HospitalAMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:HospitalAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_HospitalAMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:HospitalAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_HospitalBMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:HospitalBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_HospitalBMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:HospitalBMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_HospitalCMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:HospitalCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_HospitalCMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:HospitalCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_HospitalMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:HospitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_HospitalMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:HospitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ShareholdersOneAndTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">NRXS:ShareholdersOneAndTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_MrWatkinsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NRXS:MrWatkinsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_MrWatkinsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NRXS:MrWatkinsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_MrSealeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NRXS:MrSealeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_MrSealeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NRXS:MrSealeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_MrSealeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NRXS:MrSealeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_MrSealeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NRXS:MrSealeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ShareHolderOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">NRXS:ShareHolderOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ShareHolderTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">NRXS:ShareHolderTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ShareHolderOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">NRXS:ShareHolderOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ShareHolderTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">NRXS:ShareHolderTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_ShareHolderMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:ShareHolderMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ShareHolderMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:ShareHolderMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_ShareHolderOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:ShareHolderOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ShareHolderOneMember64718796">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:ShareHolderOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_OtherConvertiblesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:OtherConvertiblesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_OtherConvertiblesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:OtherConvertiblesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_ShareHolderMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:ShareHolderMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ShareHolderMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:ShareHolderMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_ShareHolderOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:ShareHolderOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ShareHolderOneMember64718843">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:ShareHolderOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_OtherConvertiblesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:OtherConvertiblesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_OtherConvertiblesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:OtherConvertiblesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MachineryAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_MachineryAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_SoftwareImplementationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">NRXS:SoftwareImplementationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_SoftwareImplementationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">NRXS:SoftwareImplementationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_TrademarksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_TrademarksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_LicensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">NRXS:LicensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_LicensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">NRXS:LicensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-02-15_custom_ExchangeListingLLCMember_custom_PromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NRXS:ExchangeListingLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:PromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-02-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-08-312023-08-31_custom_ExchangeListingLLCMember_custom_PromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NRXS:ExchangeListingLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:PromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-31</xbrli:startDate>
        <xbrli:endDate>2023-08-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-16_custom_ChannelPartnersCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NRXS:ChannelPartnersCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-03-162023-03-16_custom_ChannelPartnersCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NRXS:ChannelPartnersCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-03-16</xbrli:startDate>
        <xbrli:endDate>2023-03-16</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-16_custom_ChannelPartnersCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NRXS:ChannelPartnersCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-01-01_custom_ChannelPartnersCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NRXS:ChannelPartnersCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-01-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-09-16_custom_ChannelPartnersCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NRXS:ChannelPartnersCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-09-16</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-24_custom_ChannelPartnersCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NRXS:ChannelPartnersCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ChannelPartnersCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NRXS:ChannelPartnersCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_ChannelPartnersCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NRXS:ChannelPartnersCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-12-31_srt_ScenarioForecastMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-07-31_custom_ConvertiblePromissoryNoteMember_custom_AccreditedInvestorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NRXS:AccreditedInvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-03-012023-07-31_custom_AccreditedInvestorsMember_custom_ConvertiblePromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NRXS:AccreditedInvestorsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-03-01</xbrli:startDate>
        <xbrli:endDate>2023-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-07-31_custom_ConvertiblePromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-07-31_custom_ConvertiblePromissoryNoteMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-03-012023-07-31_custom_ConvertiblePromissoryNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-03-01</xbrli:startDate>
        <xbrli:endDate>2023-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-04-13_custom_SignatureBankMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NRXS:SignatureBankMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-04-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_AlexanderCapitalLPMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NRXS:AlexanderCapitalLPMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_AlexanderCapitalLPMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NRXS:AlexanderCapitalLPMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-08-08_custom_ChannelPartnersCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NRXS:ChannelPartnersCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-08-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-08-082023-08-08_custom_ChannelPartnersCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NRXS:ChannelPartnersCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-08</xbrli:startDate>
        <xbrli:endDate>2023-08-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-03-31_custom_TwoThousandTwentyThreeConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyThreeConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-03-012023-03-31_custom_TwoThousandTwentyThreeConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyThreeConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-03-01</xbrli:startDate>
        <xbrli:endDate>2023-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-08-08_custom_TwoThousandTwentyThreeConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyThreeConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-08-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-08-082023-08-08_custom_TwoThousandTwentyThreeConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyThreeConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-08</xbrli:startDate>
        <xbrli:endDate>2023-08-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-08-142023-08-14_custom_TwoThousandTwentyThreeConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyThreeConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-14</xbrli:startDate>
        <xbrli:endDate>2023-08-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-11-30_custom_TwoThousandTwentyTwoConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-012022-11-30_custom_TwoThousandTwentyTwoConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-01</xbrli:startDate>
        <xbrli:endDate>2022-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-032022-11-30_custom_TwoThousandTwentyTwoConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-03</xbrli:startDate>
        <xbrli:endDate>2022-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-11-30_srt_MinimumMember_custom_TwoThousandTwentyTwoConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-11-30_srt_MaximumMember_custom_TwoThousandTwentyTwoConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-032022-11-30_us-gaap_CommonStockMember_custom_TwoThousandTwentyTwoConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-03</xbrli:startDate>
        <xbrli:endDate>2022-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-032022-11-30_custom_ChannelPartnersCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NRXS:ChannelPartnersCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-03</xbrli:startDate>
        <xbrli:endDate>2022-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-19_custom_TwoThousandTwentyTwoConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-19</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-12-192022-12-19_custom_TwoThousandTwentyTwoConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-12-19</xbrli:startDate>
        <xbrli:endDate>2022-12-19</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_TwoThousandTwentyTwoConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_InvestorsMember_custom_TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NRXS:InvestorsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_InvestorsMember_custom_TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NRXS:InvestorsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_InvestorsMember_custom_TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NRXS:InvestorsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_ConvertibleNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_ConvertibleNotesPayableMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-012017-01-01_custom_VersaillesIndianaMember_custom_LeaseOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">NRXS:VersaillesIndianaMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">NRXS:LeaseOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-01-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-012017-01-01_custom_VersaillesIndianaMember_custom_LeaseTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">NRXS:VersaillesIndianaMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">NRXS:LeaseTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-01-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-01-01_custom_VersaillesIndianaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">NRXS:VersaillesIndianaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-01-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-03-012016-03-01_custom_CarmelIndianaMember_custom_LeaseThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">NRXS:CarmelIndianaMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">NRXS:LeaseThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-03-01</xbrli:startDate>
        <xbrli:endDate>2016-03-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-03-01_custom_CarmelIndianaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">NRXS:CarmelIndianaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-03-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-08-082023-08-08_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-08</xbrli:startDate>
        <xbrli:endDate>2023-08-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-08-082023-08-08">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-08</xbrli:startDate>
        <xbrli:endDate>2023-08-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-08-08">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-08-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_custom_ConvertibleSeriesSeedPreferredStockMember64722968">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesSeedPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-08-082023-08-08_custom_VendorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">NRXS:VendorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-08</xbrli:startDate>
        <xbrli:endDate>2023-08-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-08-082023-08-08_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-08</xbrli:startDate>
        <xbrli:endDate>2023-08-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-092023-01-10">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-09</xbrli:startDate>
        <xbrli:endDate>2023-01-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-102023-01-10">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-10</xbrli:startDate>
        <xbrli:endDate>2023-01-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-18_us-gaap_CommonStockMember_custom_BrianHannaschMember_custom_WarrantOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NRXS:BrianHannaschMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">NRXS:WarrantOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-09-182018-09-18_us-gaap_CommonStockMember_custom_BrianHannaschMember_custom_WarrantOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NRXS:BrianHannaschMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">NRXS:WarrantOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-09-18</xbrli:startDate>
        <xbrli:endDate>2018-09-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-06_custom_WarrantTwoMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">NRXS:WarrantTwoMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-09-062019-09-06_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-09-06</xbrli:startDate>
        <xbrli:endDate>2019-09-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-09-062019-09-06_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-09-06</xbrli:startDate>
        <xbrli:endDate>2019-09-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-06_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-09-062019-09-06">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-09-06</xbrli:startDate>
        <xbrli:endDate>2019-09-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-04-09_custom_MasimoCorporationMember_custom_WarrantTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NRXS:MasimoCorporationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">NRXS:WarrantTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-04-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-04-09_custom_MasimoCorporationMember_custom_WarrantThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NRXS:MasimoCorporationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">NRXS:WarrantThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-04-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-04-09_us-gaap_SeriesAPreferredStockMember_custom_WarrantThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">NRXS:WarrantThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-04-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-08-142023-08-14_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-14</xbrli:startDate>
        <xbrli:endDate>2023-08-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-08-142023-08-14_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-14</xbrli:startDate>
        <xbrli:endDate>2023-08-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-08-142023-08-14">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-08-14</xbrli:startDate>
        <xbrli:endDate>2023-08-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_custom_TwoThousandTwentyTwoConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:TwoThousandTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_TwoThousandTwentyThreeConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:TwoThousandTwentyThreeConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-08-09_custom_TwoThousandTwentyThreeConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:TwoThousandTwentyThreeConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-08-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-08-14_custom_TwoThousandTwentyThreeConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:TwoThousandTwentyThreeConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-08-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember64723875">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_PreferredStockMember64724375">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_PreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_InvestorWarrantOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">NRXS:InvestorWarrantOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_InvestorWarrantPSAOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">NRXS:InvestorWarrantPSAOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_InvestorWarrantPSAOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">NRXS:InvestorWarrantPSAOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_TwoThousandTwentyTwoConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">NRXS:TwoThousandTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_TwoThousandTwentyTwoConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">NRXS:TwoThousandTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_TwoThousandTwentyThreeConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">NRXS:TwoThousandTwentyThreeConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_TwoThousandTwentyThreeConvertibleNotesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">NRXS:TwoThousandTwentyThreeConvertibleNotesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_ConsultingAgreementWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">NRXS:ConsultingAgreementWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_UnderwriterWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">NRXS:UnderwriterWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_ConvertibleSeriesAPreferredStockMember64725046">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_ConvertibleDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-12-312023-12-31_custom_ConvertibleSeriesSeedPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesSeedPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-12-31</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_SeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_ConvertibleSeriesSeedPreferredStockMember64725125">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesSeedPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-11-08">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-11-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-11-082023-11-08">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-11-08</xbrli:startDate>
        <xbrli:endDate>2023-11-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-11-08_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-11-08</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-10-12_custom_TwentySeventeenStockCompensationPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">NRXS:TwentySeventeenStockCompensationPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-10-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-13_custom_TwentySeventeenStockCompensationPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">NRXS:TwentySeventeenStockCompensationPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-13</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_TwentySeventeenStockCompensationPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">NRXS:TwentySeventeenStockCompensationPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_TwentySeventeenStockCompensationPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">NRXS:TwentySeventeenStockCompensationPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputSharePriceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-01-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-112022-07-11_us-gaap_IPOMember_custom_TrademarkAgreementMember_custom_InitialPaymentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:TrademarkAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">NRXS:InitialPaymentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-11</xbrli:startDate>
        <xbrli:endDate>2022-07-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-112022-07-11_us-gaap_IPOMember_custom_TrademarkAgreementMember_custom_SecondAndFinalPaymentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:TrademarkAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">NRXS:SecondAndFinalPaymentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-11</xbrli:startDate>
        <xbrli:endDate>2022-07-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012022-10-01_srt_MinimumMember_custom_ExecutiveEmploymentAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:ExecutiveEmploymentAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2022-10-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012022-10-01_srt_MaximumMember_custom_ExecutiveEmploymentAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:ExecutiveEmploymentAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2022-10-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012022-10-01_custom_ExecutiveEmploymentAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:ExecutiveEmploymentAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2022-10-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-12-31_custom_ExecutiveEmploymentAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:ExecutiveEmploymentAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-02_us-gaap_SubsequentEventMember_custom_ExecutiveEmploymentAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:ExecutiveEmploymentAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-01-02_us-gaap_SubsequentEventMember_custom_ExecutiveEmploymentAgreementsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:ExecutiveEmploymentAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-01-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-04-30_custom_ExecutiveEmploymentAgreementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:ExecutiveEmploymentAgreementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-04-30_custom_ExecutiveEmploymentAgreementsMember_us-gaap_IPOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:ExecutiveEmploymentAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-02-052019-02-06">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-02-05</xbrli:startDate>
        <xbrli:endDate>2019-02-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-132022-07-14">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-13</xbrli:startDate>
        <xbrli:endDate>2022-07-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_TaxYear2038Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">NRXS:TaxYear2038Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_TaxYear2039Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">NRXS:TaxYear2039Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_TaxYear2040Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">NRXS:TaxYear2040Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_TaxYear2041Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">NRXS:TaxYear2041Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_TaxYear2042Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">NRXS:TaxYear2042Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-12-31_custom_TaxYear2043Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">NRXS:TaxYear2043Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-24_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-03-232024-03-24_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-03-23</xbrli:startDate>
        <xbrli:endDate>2024-03-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-12-312023-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-12-31</xbrli:startDate>
        <xbrli:endDate>2023-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-24_us-gaap_SubsequentEventMember_us-gaap_SeriesBPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember_us-gaap_NonrelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_NonrelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_us-gaap_NonrelatedPartyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember_custom_ConvertibleSeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_custom_ConvertibleSeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_custom_ConvertibleSeriesAPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesAPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember_custom_ConvertibleSeriesSeedPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesSeedPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_custom_ConvertibleSeriesSeedPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesSeedPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-09-30_custom_ConvertibleSeriesSeedPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesSeedPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012023-09-30_srt_ScenarioPreviouslyReportedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-01-01</xbrli:startDate>
        <xbrli:endDate>2023-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001933567</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 12pt"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b>FORM
<span id="xdx_904_edei--DocumentType_c20230101__20231231_z3okLzy2FIM6"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000012" name="dei:DocumentType">10-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--DocumentAnnualReport_c20230101__20231231_zTSeEvMq1Cc4"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleantrue" id="Fact000013" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric></span>
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the fiscal year ended: <span id="xdx_90D_edei--DocumentPeriodEndDate_c20230101__20231231_zbs0YlN0HH65"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:datemonthdayyearen" id="Fact000014" name="dei:DocumentPeriodEndDate"><span id="xdx_903_edei--CurrentFiscalYearEndDate_c20230101__20231231_zubCEvGURsZj"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:datemonthdayen" id="Fact000015" name="dei:CurrentFiscalYearEndDate">December 31</ix:nonNumeric></span>, <span id="xdx_90B_edei--DocumentFiscalYearFocus_c20230101__20231231_z49xMBksejn3"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000016" name="dei:DocumentFiscalYearFocus">2023</ix:nonNumeric></span></ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">or</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--DocumentTransitionReport_c20230101__20231231_zoV537JQcjhd"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleanfalse" id="Fact000017" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span>
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the transition period from _________ to ________</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission
File Number: <b><span id="xdx_90A_edei--EntityFileNumber_c20230101__20231231_zYiNyAkfyuT5"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000018" name="dei:EntityFileNumber">001-41775</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 18pt"><b><span style="text-decoration: underline"><span id="xdx_902_edei--EntityRegistrantName_c20230101__20231231_zJsL9eHZoSMc"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000019" name="dei:EntityRegistrantName">Neuraxis,
Inc.</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_907_edei--EntityIncorporationStateCountryCode_c20230101__20231231_z809n39aj772"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt-sec:stateprovnameen" id="Fact000020" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90C_edei--EntityTaxIdentificationNumber_c20230101__20231231_zQQu0JkRaAd2"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000021" name="dei:EntityTaxIdentificationNumber">45-5079684</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
    or other jurisdiction</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of
    incorporation)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
    Employer</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
    Number)</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 49%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90A_edei--EntityAddressAddressLine1_c20230101__20231231_zYFVXptSSKU7"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000022" name="dei:EntityAddressAddressLine1">11611
    N Meridian St</ix:nonNumeric></span>, <span id="xdx_905_edei--EntityAddressAddressLine2_c20230101__20231231_zhzBb8ni9vj1"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000023" name="dei:EntityAddressAddressLine2">Suite 330</ix:nonNumeric></span></b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90E_edei--EntityAddressCityOrTown_c20230101__20231231_zy6YUkEKPlff"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000024" name="dei:EntityAddressCityOrTown">Carmel</ix:nonNumeric></span>,
    <span id="xdx_906_edei--EntityAddressStateOrProvince_c20230101__20231231_zXKOsOa7uQuk"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000025" name="dei:EntityAddressStateOrProvince">IN</ix:nonNumeric></span> <span id="xdx_90B_edei--EntityAddressPostalZipCode_c20230101__20231231_zcH000vrpdof"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000026" name="dei:EntityAddressPostalZipCode">46032</ix:nonNumeric></span></b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_907_edei--CityAreaCode_c20230101__20231231_ztEplQWY83sd"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000027" name="dei:CityAreaCode">(812)</ix:nonNumeric></span>
    <span id="xdx_904_edei--LocalPhoneNumber_c20230101__20231231_zc5CJYvFZjbh"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000028" name="dei:LocalPhoneNumber">689-0791</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
    of principal executive offices and zip code)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant&#8217;s
    telephone number, including area code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 36%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of each class</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
    Symbol(s)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 42%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of each exchange on which registered</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--Security12bTitle_c20230101__20231231_zr8pUCVaK9Ml"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000029" name="dei:Security12bTitle">Common Stock</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--TradingSymbol_c20230101__20231231_zwpxHb41PsLl"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000030" name="dei:TradingSymbol">NRXS</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_edei--SecurityExchangeName_c20230101__20231231_zEmpivxJH2le"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt-sec:exchnameen" id="Fact000031" name="dei:SecurityExchangeName">NYSE American LLC</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(g) of the Act: None</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes &#9744; <span id="xdx_90D_edei--EntityWellKnownSeasonedIssuer_c20230101__20231231_zkmHg1VfFx9j"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000032" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes &#9744; <span id="xdx_901_edei--EntityVoluntaryFilers_c20230101__20231231_zuE74B5SfqU5"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000033" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></span> &#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. <span id="xdx_902_edei--EntityCurrentReportingStatus_c20230101__20231231_z55gDhpn7i8h"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000034" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files). <span id="xdx_901_edei--EntityInteractiveDataCurrent_c20230101__20231231_zQpJe5MKgaO4"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000035" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company,
or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller
reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer &#9744;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer &#9744;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_edei--EntityFilerCategory_c20230101__20231231_zZqGEn97RLNj"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt-sec:entityfilercategoryen" id="Fact000036" name="dei:EntityFilerCategory">Non-accelerated
    filer</ix:nonNumeric></span> &#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company&#160;<span id="xdx_908_edei--EntitySmallBusiness_c20230101__20231231_zvGDpJfVXq5b"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleantrue" id="Fact000037" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company&#160;<span id="xdx_905_edei--EntityEmergingGrowthCompany_c20230101__20231231_zWKXmwuhzM4"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleantrue" id="Fact000038" name="dei:EntityEmergingGrowthCompany">&#9746;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span id="xdx_908_edei--EntityExTransitionPeriod_c20230101__20231231_z9Tgv4XOUcXi"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleantrue" id="Fact000039" name="dei:EntityExTransitionPeriod">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report. <span id="xdx_901_edei--IcfrAuditorAttestationFlag_c20230101__20231231_zDppkctO9jVg"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleanfalse" id="Fact000040" name="dei:IcfrAuditorAttestationFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">If
securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant
included in the filing reflect the correction of an error to previously issued financial statements. <span id="xdx_90E_edei--DocumentFinStmtErrorCorrectionFlag_c20230101__20231231_znv6hTZvnJZ8"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleanfalse" id="Fact000041" name="dei:DocumentFinStmtErrorCorrectionFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">Indicate
by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation
received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes &#9744; No <span id="xdx_902_edei--EntityShellCompany_dbF_c20230101__20231231_zW6D8W53AvZf"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt:booleanfalse" id="Fact000042" name="dei:EntityShellCompany">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
registrant was <span id="xdx_902_edei--EntityPublicFloat_iI_do_c20230630_z5h2R6n4ieja"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2023-06-30" id="Fact000043" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></span>t a public company as of June 30, 2023, the last business day of its most recently completed second fiscal quarter,
and therefore, cannot calculate the aggregate market value of its voting and non-voting common equity held by non-affiliates as of such
date. The registrant&#8217;s common stock began trading on the NYSE American on August 9, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
registrant had <span id="xdx_90C_edei--EntityCommonStockSharesOutstanding_iI_pid_c20240412_zMhFG5BJYwS2"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2024-04-12" id="Fact000044" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,594,897</ix:nonFraction></span> shares of its common stock, par value $0.001, issued and outstanding as of April 12, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt; border-bottom: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TABLE
OF CONTENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b> </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_001">PART I</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    1.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_002">Business</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">5</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    1A.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#a_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">35</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    1B.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_004">Unresolved Staff Comments</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    1C.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_005">Cybersecurity</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">60</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    2.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_006">Properties</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">61</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    3</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_007">Legal Proceedings</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    4.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="#a_008">Mine Safety Disclosures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">62</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#s_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART II</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    5.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#s_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">63</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    6.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#s_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reserved</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">63</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    7.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#s_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">64</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    7A.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#s_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quantitative and Qualitative Disclosures About Market Risk</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">68</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    8.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#s_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Statements and Supplementary Data</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">68</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    9.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#s_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">68</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    9A.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#s_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controls and Procedures</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">68</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    9B.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#s_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other Information</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">69</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    9C.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#s_010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosures Regarding Foreign Jurisdictions that Prevent Inspections</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">69</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#s_011"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART III</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    10.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#s_012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors, Executive Officers and Corporate Governance</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">70</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    11.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#s_013"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Compensation</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">75</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    12.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#s_014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">84</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    13.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#s_015"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain Relationships and Related Transactions, and Director Independence</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">85</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    14.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#s_016"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Accounting Fees and Services</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">85</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#s_017"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PART IV</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    15.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#s_018"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibits and Financial Statement Schedules</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">86</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
    16</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#s_019"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form 10-K Summary</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">88</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><a href="#s_020"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signatures</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom">90</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FORWARD-LOOKING
STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report on Form 10-K (&#8220;Annual Report&#8221;) contains forward-looking statements within the meaning of the federal securities
laws. All statements contained in this Annual Report, other than statements of historical fact, including statements regarding our future
operating results and financial position, our business strategy and plans, potential growth or growth prospects, future research and
development, sales and marketing and general and administrative expenses, and our objectives for future operations, are forward-looking
statements. Words such as &#8220;believes,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;estimates,&#8221; &#8220;potential,&#8221;
&#8220;continues,&#8221; &#8220;anticipates,&#8221; &#8220;intends,&#8221; &#8220;expects,&#8221; &#8220;could,&#8221; &#8220;would,&#8221;
&#8220;projects,&#8221; &#8220;plans,&#8221; &#8220;targets,&#8221; and variations of such words and similar expressions are intended
to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections
about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term
and long-term business operations and objectives, and financial needs. These forward-looking statements are subject to a number of risks,
uncertainties and assumptions, including those described in the &#8220;Risk Factors&#8221; in this Annual Report. Readers are urged to
carefully review and consider the various disclosures made in this Annual Report and in other documents we file from time to time with
the Securities and Exchange Commission (the &#8220;SEC&#8221;) that disclose risks and uncertainties that may affect our business. Moreover,
we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for us to predict
all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors,
may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks,
uncertainties, and assumptions, the future events and circumstances discussed in this Annual Report may not occur and actual results
could differ materially and adversely from those anticipated or implied in the forward-looking statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should not rely upon forward-looking statements as predictions of future events. The events and circumstances reflected in the forward-looking
statements may not be achieved or occur. Although we believe that the expectations reflected in the forward-looking statements are reasonable,
we cannot guarantee future results, performance, or achievements. In addition, the forward-looking statements in this Annual Report are
made as of the date of this filing, and we do not undertake, and expressly disclaim any duty, to update such statements for any reason
after the date of this Annual Report or to conform statements to actual results or revised expectations, except as required by law.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
should read this Annual Report and the documents that we reference herein and have filed with the SEC as exhibits to this Annual Report
with the understanding that our actual future results, performance, and events and circumstances may be materially different from what
we expect.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report also contains or may contain estimates, projections and other information concerning our industry, our business and the
markets for our products, including data regarding the estimated size of those markets and their projected growth rates. Information
that is based on estimates, forecasts, projections or similar methodologies is inherently subject to uncertainties and actual events
or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated,
we obtained these industry, business, market and other data from reports, research surveys, studies and similar data prepared by third
parties, industry and general publications, government data and similar sources. In some cases, we do not expressly refer to the sources
from which these data are derived.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXPLANATORY
NOTE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report on Form 10-K for the year ended December 31 2023 (&#8220;Form 10-K&#8221;) includes the restatement of our unaudited financial
statements as of and for the three and nine month periods ended September 30, 2023. The Board of Directors (the &#8220;Board&#8221;)
of the Company, upon recommendation of the Audit Committee of the Board and discussion with management, concluded that the Company&#8217;s
previously issued unaudited financial statements as of and for the three and nine month periods ended September 30, 2023, filed with
the Securities and Exchange Commission (&#8220;SEC&#8221;) on November 20, 2023, should no longer be relied upon and should be restated
due to the identification of an accounting error.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
disclosed in Note 19 to the financial statements included in this Form 10-K, we restated our unaudited financial statements as of
and for the three and nine month periods ended September 30, 2023 to correct an error that understated the extinguishment of debt
expense and net loss in the Statement of Operations and understated additional paid in capital in the Balance Sheet. Management also
concluded that the Company&#8217;s disclosure controls and procedures were not effective as of December 31, 2023 due to the
existence of this material weakness.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not filed and do not intend to file amendments to our Quarterly Report on Form 10-Q as of and for the three and nine month periods
ended September 30, 2023. Comparative amounts for 2023 presented in our 2024 Quarterly Reports on Form 10-Q will be changed retrospectively
to reflect the restatement. Accordingly, investors should only rely on the financial information and other disclosures as of and for
the three and nine month periods ended September 30, 2023 in this Form 10-K or in future filings with the SEC and not any previously
issued or filed reports.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
impact of the restatement and the unaudited restated financial statements as of and for the three and nine month periods ended September
30, 2023 are described and included in Note 19 to our audited financial statements included in this Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_001"></span>PART
I</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_002"></span>ITEM
1. BUSINESS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
Neuraxis, Inc. (&#8220;we&#8221;, &#8220;us&#8221;, the &#8220;Company&#8221; or &#8220;Neuraxis&#8221;) is a medical technology
company focused on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults. We
are dedicated to advancing science with our proprietary IB-Stim therapy, based on our Percutaneous Electrical Nerve Field
Stimulation (PENFS) technology, which was developed internally by the Company. We believe that superior science and evidence-based
research, are necessary for adoption by the medical and scientific community. With one FDA indication (functional abdominal pain
associated with IBS in adolescents 11-18 years old) on the market, additional clinical trials of PENFS in multiple pediatric
conditions are underway focused on unmet healthcare needs in children, see &#8220;&#8212;<i>Our Pipeline</i>&#8221; for more
information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
first product, IB-Stim, is a PENFS system intended to be used in patients 11-18 years of age with functional abdominal pain associated
with IBS. IB-Stim is a US FDA Class II medical device that has received one regulatory clearance: IB-Stim (DEN180057, 2019), under the
regulation name of &#8220;non-implanted nerve stimulator for functional abdominal pain relief.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Mission</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
mission is to provide solutions that create value and provide better and safer patient outcomes. We believe in improving lives and minimizing
suffering; particularly in the pediatric population, where research and therapeutics are usually lacking. The Company already has market
clearance for its IB-Stim &#174; that targets functional abdominal pain associated with IBS, in children, with a total addressable market
of up to 6 million children. Through innovation and research, we are reimagining the future of patient care.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Corporate History</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
Inc. was established in 2011 and incorporated in the state of Indiana on April 17, 2012, under the name of Innovative Health Solutions,
Inc. The name was changed to Neuraxis, Inc. in March of 2022. Additionally, the Company filed a Certificate of Conversion to become a
Delaware corporation on June 23, 2022. The authorized shares were increased, and a par value established. On September 7, 2021, the Company&#8217;s
board of directors authorized a 4-for-1 stock split. They also increased the number of authorized common stock shares from 2,700,000
to 10,800,000. Furthermore, on September 9, 2021, the board authorized and increase of authorized shares of common stock from 10,800,000
to 13,400,000 in anticipation of a capital offering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the conversion to a Delaware corporation, the total number of shares of all classes of stock which the Corporation shall have
authority to issue is 101,120,000 shares, consisting of (i) 100,000,000 shares of common stock, par value $0.001 per share, and (ii) 1,120,000
shares of Preferred Stock, par value $0.001 per share (&#8220;Preferred Stock&#8221;), 1,000,000 of which is designated as &#8220;Series
A Preferred Stock&#8221; and 120,000 of which is designated as &#8220;Series Seed Preferred Stock&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
on January 10, 2023, the Company&#8217;s board of directors authorized a 1-for-2 reverse stock split. All per share information has been
adjusted for this reverse stock split. The reverse split became effective on January 12, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have developed three FDA cleared products, the IB-Stim (DEN180057, 2019), the NSS-2 Bridge (DEN170018, 2017), and the original 510(K)
clearance (K140530, 2014), all of which were developed internally by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The IB-Stim is a PENFS
    device that is indicated in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome.
    The IB-Stim currently is the only product marketed and sold by the Company.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The NSS-2 Bridge is a percutaneous
    nerve field stimulator, or PNFS, device indicated for use in the reduction of the symptoms of opioid withdrawal. The NSS-2 Bridge
    device was licensed to Masimo in April 2020, and we received a one-time licensing fee of $250,000 from Masimo. Masimo markets and
    sells this product as its&#160;<i>Masimo Bridge</i>, and we will not receive any further licensing payments or other revenue from
    this product.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The original 510(K) device
    was the electroacupuncture device (&#8220;EAD&#8221;), now called&#160;<i>NeuroStim</i>. The EAD is no longer being manufactured,
    sold or distributed but reserved only for research purposes.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pediatrics
Industry Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pediatric
providers, as a whole, had expressed concern about the lack of attention given to children with functional abdominal pain disorders (including
IBS) and the limited treatment options available for a population that suffers from significant disabilities. With 20% of the United
States population under age 18, our Company focus is on opportunities in pediatrics industry. The pediatrics industry has multi-billion-dollar
market opportunities. The following points clearly outline the unmet need in children:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Functional abdominal pain
    in children is one of the most common conditions seen by pediatricians and pediatric gastroenterologists.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Children with functional
    abdominal pain report lower quality of life compared with their healthy peers and equal to those with inflammatory bowel disease.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Overall, 40-45% of children
    with functional abdominal pain disorders continue to have symptoms into adulthood, which impacts quality of life and healthcare spending.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A study published in 2021
    demonstrates insufficient evidence for the use of medications in pediatric functional abdominal pain disorders. This lack of evidence
    for drugs has been supported in by the American Academy of Pediatrics and NASPGHAN.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IB-Stim
    is the only medical therapy that has shown to improve pain, global symptoms, and functional disability in children with FAP and
    IBS.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IB-Stim
    is the only currently used medical therapy that is better than placebo in a randomized controlled trial and received FDA clearance
    for pediatric IBS.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Opportunity</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
years, physicians and qualified healthcare professionals have resorted to the use of off-label medications without proper evidence of
efficacy or safety. This is despite a technical report from the American Academy of Pediatrics and NASPGHAN which found very little evidence
to endorse the use of any drugs in the treatment of FAPDs in children. Medications including tricyclic antidepressants, SSRIs and gabapentinoids
continue to be used off-label despite lack of evidence to support efficacy or safety. Not only have the most commonly used medications
(amitriptyline and citalopram) failed to beat placebo in clinical trials, but new studies also suggest significant risks with the potential
for serious side effects with these drugs. The absence of conclusive data to support treatments based on scientific evidence, and the
fact no drug therapies have been approved by the FDA for the treatment of FAPDs or IBS in children, presents a unique market opportunity
for Neuraxis. Below are the current standard treatments in children with functional abdominal pain and IBS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img src="form10-k_001.jpg" alt=""/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Solutions</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
entered the pediatric market with clinical evidence, key opinion leaders and society endorsement, including a signed letter from the
American Academy of Pediatrics and NASPGHAN supporting our request for insurers to pay for our IB-Stim device. Our IB-Stim&#174; is a
non-drug alternative to reduce functional abdominal pain in patients with IBS. In June 2019, the FDA cleared IB-Stim, a
non-surgical, neuromodulation device for children and adolescents who suffer from IBS, through a de novo process (DEN180057, 2019).
The FDA created a new classification of PENFS for the IB-Stim device. This is based on pre-clinical and clinical studies
demonstrating the mechanism of action and efficacy. Based on this new class of devices, the IB-Stim falls under 21 CFR Part 876,
Subpart F &#8211; Therapeutic Devices, 876.5340, Product Code QHH. As a PENFS device, it is non-implantable and provides field
stimulation to cranial nerves V, VII, IX and X in the ear to access the CNS. It stimulates remotely from the source of pain to
modulate central pain regions, such as the limbic system, and relieve functional abdominal pain associated with IBS. Studies have
demonstrated long-term benefits in functional disability, psychological co-morbidities, and pain. For example, the table below is
from a recently published study of IB-Stim in a population of patients with chronic functional abdominal pain. The follow-up was
done at 6-12 months post-treatment and shows improvements in validated questionnaires compared to baseline (API), functional
disability index (FDI), pain catastrophizing scale (PCS), Screen for Childhood Anxiety Related Disorders (SCARED) and the Promis
Anxiety.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Santucci
NR, King C, El-Chammas KI, Wongteerasut A, Damrongmanee A, Graham K, Fei L, Sahay R, Jones C, Cunningham NR, Coghill RC.&#160;<i>Effect
of percutaneous electrical nerve field stimulation on mechanosensitivity, sleep, and psychological comorbidities in adolescents with
functional abdominal pain disorders.</i>&#160;Neurogastroenterol Motil. 2022;34:e14358.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><img src="form10-k_002.jpg" alt=""/>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have only submitted one FDA De Novo request and have not submitted any additional 510(k) premarket notifications for our pipeline indications
to date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compliance
with treatment so far has been outstanding with the four weeks of therapy required to sustain long-term benefits. Compliance has been
an issue with non-pharmacological treatment for children, particularly with some of the psychological approaches such as cognitive behavioral
therapy or guided imagery, which sometimes requires 8-12 weeks of treatment. In fact, 95% of adolescents who used IB-Stim said that they
would recommend this treatment to family and friends. Many children&#8217;s hospitals across the country are already treating children
with IB-Stim successfully since it provides a better alternative for therapy in children with IBS and disability and allows them to treat
them safely and effectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have concentrated our marketing focus on the 260 children&#8217;s hospitals within the United States. To date, we have sold our IB-Stim
product to approximately 57 children&#8217;s hospitals within our target market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img src="pg_001.jpg" alt="" style="height: 257px; width: 670px"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Competition</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
competitive landscape for therapies includes off-label drugs and drugs with FDA approved only for adults with IBS while there is no
FDA indicated treatments for patients 11-18 years of age with functional abdominal pain associated with IBS and prescriptions often
contain FDA black box labels. Psychological treatments such as cognitive behavioral therapy (CBT) or guided imagery have been shown
to be some of the most effective treatments for these conditions, however, these are limited by access to trained therapists. It also
includes devices that could theoretically be used, but do not have supporting data or FDA clearance for functional bowel disorders
or IBS. Digital therapeutics that offer CBT for IBS have been developed for adults with IBS with limited success in terms of
reaching large numbers of patients. Virtual reality could potentially be used in the future to also deliver CBT to patients with
IBS. Our method patents also limit other devices from targeting IBS through stimulation of cranial nerve branches in the
ear.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img src="form10-k_004.jpg" alt=""/><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Approved
drugs for Adults with IBS</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rifaximin: an intraluminal
    antibiotic approved for IBS-diarrhea</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amitiza: a drug that stimulates
    fluid secretion from the intestine, approved for IBS-diarrhea</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Linzess<b>:</b>&#160;a
    drug that stimulates fluid secretion from the intestine, approved for IBS-constipation</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Plecanatide: a drug that
    stimulates fluid secretion from the intestine, approved IBS-constipation</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Eluxadoline:&#160;a schedule
    IV-controlled substance that is a mixed opioid receptor agonist/antagonist in the intestine approved for IBS-diarrhea</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Devices</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">gammaCore:&#160;a transcutaneous,
    cervical vagal nerve stimulator cleared for cluster and migraine headaches. Recent studies using this device for adults with gastroparesis.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transcranial Magnetic Stimulation:
    Multiple devices cleared to treat major depressive disorder and obsessive-compulsive disorder. To date, no known gastrointestinal
    indications.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Roo System and Sparrow
    therapy system: Transcutaneous auricular stimulation devices-cleared for neonatal and adult opioid withdrawal.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
neurostimulation market is predominantly comprised of surgically implanted, invasive technologies that are not directly competitive with
our technology. Several neurostimulation companies are large, publicly traded companies that have a history in the market, have significantly
easier access to capital and other resources and have an established product pipeline. The combined clinical research and product development
done by the industry, including by us and all our competitors, is uncovering the beneficial effects of neurostimulation which now establishes
neuromodulation as a valid and scientifically supported approach to the treatment of neurological conditions, and accordingly, we expect
for competition in the non-implanted space to grow in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
many companies have joined the neuromodulation space, there are no companies targeting the CNS or the brain-gut axis through auricular
nerves for functional bowel disorders or IBS. Currently, the Neuraxis method patents protect access to the brain, particularly the limbic
systems through branches of cranial nerves in the ear.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Competitive Strengths</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that the following competitive strengths will enable us to compete effectively:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First to market</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Strong portfolio of device and method patents</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large Market Opportunities</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Strong pediatric pipeline</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Academic Society Support</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lower capital expenditures in nurse, trainers, and
    representatives for first line therapy</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Strong clinical data carried out in leading academic
    institutions in the U.S.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Growth Strategies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">List price of our product is $1,195 per device and
    $4,780 per patient</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Strong&#160;gross margin</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Direct sales force</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Target customers are children&#8217;s hospitals and
    pediatric clinics</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Our
Pipeline</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
IB-Stim device is to be used for the indication of functional abdominal pain associated with IBS and functional nausea in children.
The same underlying technology will be used for the remaining pipeline indications, but we may use a name other than
&#8220;IB-Stim&#8221; for marketing and commercialization purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
one FDA indication&#8212;functional abdominal pain associated with IBS in adolescents 11-18 years old&#8212;on the market, additional
clinical trials of PENFS in multiple pediatric conditions are underway focused on unmet healthcare needs in children. These indications
consist of chronic nausea, post-concussion syndrome, chemotherapy-induced nausea and vomiting, cyclic vomiting syndrome.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
chart below shows our status in the FDA review process for IB-Stim and each of the following pediatric indications:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1. <i>Chronic
nausea:</i>&#160;RCT completed, and data being analyzed. ClinicalTrials.gov Identifier: NCT03675321,&#160;<i>Defining Adolescent
Nausea Through Brain-Gut Physiology and Non-Invasive Neurostimulation Response.</i>&#160;A randomized, double blind,
placebo-controlled trial to evaluate the efficacy of IB-Stim in children with functional nausea. The primary endpoint was to measure
improvements in nausea using the Nausea Severity Scale after IB-Stim therapy compared to a placebo device. The study enrolled 110
participants and was conducted at Children&#8217;s Wisconsin/Medical College of Wisconsin.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2. <i>Post-concussion
syndrome:</i>&#160;RCT currently enrolling patients. ClinicalTrials.gov Identifier: NCT04978571,&#160;<i>A Prospective Study on the
Effect of Auricular Percutaneous Electrical Nerve Field Stimulation (PENFS) in Patients with Post-Concussion Syndrome
(PCS).</i>&#160;A randomized, double blind, placebo-controlled trial to evaluate the efficacy of IB-Stim in children with
post-concussion symptoms. The primary endpoint will be to measure improvements in validated measures, including the Immediate
Post-Concussion Assessment, Post-Concussion Symptom Scale, and Balance Error Scoring Symptom compared to placebo. The study will
enroll 100 participants and is being conducted at Children&#8217;s Hospital of Orange County.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3. <i>Chemotherapy-induced
nausea and vomiting:</i>&#160;RCT currently enrolling patients. ClinicalTrials.gov Identifier: NCT05143554,&#160;<i>Efficacy of
Auricular Neurostimulation for Children Adolescents and Young Adults with Chemotherapy Induced Nausea and Vomiting.</i>&#160;Subject
will be randomized to five days of active vs placebo device during administered chemotherapy known to cause moderate to severe
nausea/vomiting. With the next scheduled identical chemotherapy cycle, each subject will cross over to the other device (active vs
placebo). The primary endpoint will be to measure improvements in validated measures of nausea and vomiting including the Baxter
Retching Faces Scale, Rhodes Index of Nausea, Vomiting and Retching, and also assessment of rescue medication. The study will enroll
50 participants and is being conducted at Children&#8217;s Wisconsin/Medical College of Wisconsin.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4. <i>Cyclic
vomiting syndrome:</i>&#160;Pilot study completed, see ClinicalTrials.gov Identifier: NCT03434652.&#160;<i>Auricular
Neurostimulation for Children with Cyclic Vomiting Syndrome: A randomized, placebo-controlled trial.</i>&#160;RCT anticipated to
begin enrolling patients in the second half of 2023. This will be a double blind, placebo-controlled trial
to evaluate efficacy of IB-Stim in pediatric patients with cyclic vomiting syndrome. The primary endpoint will be to measure
decreases in the frequency and severity of cyclic vomiting episodes compared to a placebo device. The study will include a minimum
of 120 patients and the site is yet to be finalized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
step in the FDA review process differs in duration and cannot be predicted with accuracy. Timing of FDA review and approval, if ever
received, cannot be assured and the process and any approval is within the sole control and discretion of the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<img src="pg_002.jpg" alt="" style="height: 377px; width: 670px"/></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Products</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
IB-Stim is a percutaneous PENFS system intended to be used in patients 11-18 years of age with functional abdominal pain associated with
IBS. IB-Stim already has market clearance from FDA for functional abdominal pain associated with IBS in children. FDA has classified
the non-implanted nerve stimulator for functional abdominal pain relief as Class II devices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
IB-Stim is intended to be used for 120 hours per week for three (3) consecutive weeks, and not to exceed four (4) weeks, through application
to branches of Cranial Nerves V, VII, IX and X, and the occipital nerves identified by transillumination, as an aid in the reduction
of pain when combined with other therapies for IBS (DEN180057, 2019). In published studies, patients treated with IB-Stim demonstrated
significant improvement in pain, disability and global symptoms with no serious adverse events, and minimal to no side effects, including
localized skin irritation. See&#160;<i>Neurostimulation for abdominal pain-related functional gastrointestinal disorders in adolescents:
a randomized, double-blind, sham-controlled trial</i>, Kovacic K, et.al., Lancet Gastroenterol Hepatol. 2017;2:727-737;&#160;<i>Efficacy
of Auricular Neurostimulation in Adolescents With Irritable Bowel Syndrome in a Randomized, Double-Blind Trial</i>, Krasaelap A et.al.,
Clin Gastroenterol Hepatol. 2020;18:1987-1994;&#160;<i>Effect of percutaneous electrical nerve field stimulation on mechanosensitivity,
sleep, and psychological comorbidities in adolescents with functional abdominal pain disorders</i>, Santucci et.al., Neurogastroenterol
Motil. 2022;34:e14358.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ability of the IB-Stim to produce systemic effects by modulating the central nervous system has been demonstrated in a pre-clinical animal
model of IBS (see Business&#8212;<i>Pre-Clinical Data</i>). In patients with IBS, the largest effect on all pain measures, including
composite pain scores, worst pain, disability and global symptoms, was seen after completing three consecutive weeks of treatment (see
Business&#8212;<i>Clinical Data</i>). A fourth consecutive week of treatment was included in clinical testing; no safety concerns were
identified with this extra consecutive week of treatment. In the trial of 115 subjects, 10 patients reported side-effects and only three
discontinued the study because of side-effects. Of such 10 patients, six experienced ear discomfort (three in the PENFS group, three
in the sham group), three experienced adhesive allergies (one in the PENFS group, 2 in the sham group), and one experienced syncope due
to needle phobia (in the sham group). There were no serious adverse events.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical
providers are trained to place the IB-Stim through IB-Stim Training and Certification. Once the provider is trained, the device can be
placed in the outpatient clinic and can be removed by the provider in the clinic or the patient at home. IB-Stim stays on for a total
of five-days to allow delivery of gentle electrical pulses to nerves below the skin that access the central nervous system. A study in
adolescents showed greater improvement in functional abdominal pain and global symptom improvement with every week of treatment (up to
four weeks). At the end of the four-week study, 95% of adolescents stated they would recommend the treatment to family or friends. Safety
of percutaneous electrical nerve field stimulation has also been reported in a separate study of over 1200 adult patients with no serious
adverse events and minimal to no side-effects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
wearing our IB-Stim device and following an easy-to-learn and efficient procedure, patients can still attend school and extracurricular
activities, exercise or play non-contact sports, shower, wear ear buds or headphones, and travel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
IB-Stim device costs $1,195 per device, and each patient will use four (4) devices. Potential patients with other indications are expected
to use six (6) or more devices per patient.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Technology</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
maladaptive central nervous system can process pain and emotions differently. This often occurs in children following a traumatic event,
viral infections, inflammation or trauma. Changes in brain pathways are known to be involved in the pathophysiology of functional bowel
disorders and IBS. The IB-Stim works by sending gentle electrical impulses into cranial nerve bundles located in the ear. This stimulation
targets brain areas that process pain and helps reduce functional abdominal pain associated with IBS. An animal model of IBS demonstrated
that the firing of neurons in the amygdala could be reduced by more than 50% in just 15 minutes of stimulation with the IB-Stim technology.
A recent human study in adults with pain related to fibromyalgia suggested that the IB-Stim technology exerts its effect by modulating
emotional and executive control centers related to pain processing, see&#160;<i>Feasibility of Auricular Field Stimulation in Fibromyalgia:
Evaluation by Functional Magnetic Resonance Imaging, Randomized Trial</i>, Woodbury et.al.<i>,</i>&#160;Pain Med. 2021;22:715-726. The
field of art pertains to an electrical stimulation device, including a stimulator containing a generator to deliver electrical pulses
with defined parameters, and a power supply for supplying the electrical energy through four separate needles, and at least one of which
is a needle array.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img src="form10-k_006.jpg" alt=""/><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pre-Clinical</b>&#160;<b>Data</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
an animal model of IBS, extracellular, electrophysiologic recordings were performed from neurons in the rat amygdala before and 15 minutes
after PENFS treatment. There was a 65% decrease in the spontaneous firing of these neurons after 15 minutes of PENFS.This dampening of
neurons in the CNS likely accounts for the modulation of pain responses in a model of post-inflammatory visceral and somatic hyperalgesia.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img src="form10-k_007.jpg" alt=""/><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Clinical
Data</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have over 700 published patients specific to our first FDA indication which is functional abdominal pain associated with irritable bowel
syndrome in patients 11-18 years of age. A published patient is defined as a patient who went through a study, the study was analyzed
and now the study has been published in a peer-reviewed journal.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
randomized, controlled study in children 11-18 year of age used primary endpoint of improvements in abdominal pain. The Pain Frequency-Severity-Duration
(&#8220;PFSD&#8221;) questionnaires was completed at baseline by all subjects and after each week of treatment (weeks 1&#8211;3), as
well as at extended follow-up occurring in the 8&#8211;12 weeks following the end of treatment. The PFSD scale incorporates multiple
aspects of the pain experience and was administered weekly during treatment and at extended follow-up appointments. The PFSD scale validated
for chronic pain in children (aged 8&#8211;18 years). The PFSD was also used to rate weekly worst abdominal pain on a numerical rating
scale (0 for no pain, 10 for worst pain). Patients were followed up for a median of 9.2 weeks from the last week of treatment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the active PENFS group, median worst pain at follow-up remained lower (baseline: 8.0 vs. follow-up: 6.0), whereas there was no difference
at follow-up in the control group (baseline: 7.5 vs. follow-up: 7.0). The between-group differences in worst pain ratings after 3 weeks
of treatment showed that the PENFS group improved to a greater extent, with the control group reporting significantly higher worst pain
(median 7.0) than the PENFS group (median 5.0).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
long-term follow-up, median PFSD composite scores were 12.6 (IQR 3.6&#8211;22.5) in the PENFS group and 16.8 (4.8&#8211;33.6) in the
control group. A comparison of changes in PFSD composite scores (baseline to follow-up) showed that patients in the PENFS group reported
significantly greater improvement in pain (median &#8211;8.4) than those in the control group (median 0.0). This study was published
in the Lancet Gastroenterology Hepatology, (Kovacic K, et.al. Lancet Gastroenterol Hepatol. 2017;2:727-737).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img src="form10-k_008.jpg" alt=""/><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
secondary endpoint in the same study used the&#160;functional disability index (FDI) to assess functional disability in those treated
with PENFS and compared to sham treatment. Those treated with PENFS changed from moderate disability to minimal at the 2&#8211;3-month
follow-up while the sham device group had no change.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img src="form10-k_009.jpg" alt=""/><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
separate published paper looked at 51 pediatric patients with IBS and used the symptoms response scale (SRS) to assess global symptoms
improvement following PENFS treatment compared to sham. Global symptom improvement was assessed with a validated pediatric questionnaire,
Symptom Response Scale (SRS). Symptoms were recorded as better, worse, or no change based on a 15-point scale across individual domains
for both improvement and deterioration of overall symptoms. Findings from several studies that used the SRS have shown that using 7-point
scale response options in disease-specific measures, a change score of 0.5 represents the minimal clinically important difference (Juniper
et.al. J Clin Epidemiol 1994; 47: 81&#8211;87 and Guyatt GH et.al.1987; 42: 773&#8211;78). As previously noted, a minimum change in score
of &#8805; 2 was chosen for this study as a more stringent criterion for global improvement before and after PENFS treatment and to compare
between groups. Patients and providers were blinded in terms of those who received active PENFS or sham. At the end 3 weeks of therapy
using the change of &#8805; 2, 81% of the PENFS group compared with 26% of the sham group (*p&#8804; 0.001, #p=0.002) reported overall symptom
improvement. When applying an even more stringent criteria with a change &#8805; 3 on the SRS, 67% of the PENFS group compared with 22%
of the sham group reported symptoms improvement (p=0.002) (Krasaelap A et.al. Efficacy of Auricular Neurostimulation in Adolescents With
Irritable Bowel Syndrome in a Randomized, Double-Blind Trial. Clin Gastroenterol Hepatol. 2020;18:1987-1994).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img src="form10-k_010.jpg" alt=""/><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recently,
the largest, prospective, multicenter registry for any drug or device in pediatric patients with pain associated DGBIs was
published. It evaluated outcomes of pediatric patients (8-18 years) following a 4-week course of IB-Stim in a real-world clinical
setting. Overall, 292 patients met Rome IV Diagnostic criteria for any pain associated disorder of the gut-brain interaction
(DGBIs). In this cohort, 92% had failed medication therapy and 61% of patients had failed 4 or more medications when they entered
the study. Patients were asked to fill out several validated pediatric measures, including the abdominal pain index (API) and a
validated questionnaire that assesses frequency, duration, and intensity of abdominal pain episodes. Data were collected weekly for
the first 3 weeks and at 3, 6, 9 and 12 months. Compared to baseline scores, there were significant improvements in the API after 4
weeks of IB-Stim treatment at every time point, including 6 month (p&lt;0.001) and 12 months (p&lt;0.001). Although there were many
dropouts by the end of the 12 months, the results were still significant and sustained. No serious adverse effects were recorded
during the entire 12 month follow-up. (Chogle, A. et. al. A multicenter registry study on percutaneous electrical nerve field
stimulation for pediatric disorders of gut-brain interaction. J Pediatr Gastroenterol Nutr. 2024 Mar 7.)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 11pt Times New Roman, Times, Serif; margin-left: auto; width: 60%; border-collapse: collapse; margin-right: auto">
  <tr style="vertical-align: bottom; background-color: white">
    <td colspan="7" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Abdominal
    Pain Index (API)</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Time
    point</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>n</i></b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 26%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Median
    (IQR)</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>p
    Value</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Baseline</b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>288</b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.68(1.84,
    3.58)</b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>N/A</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3
    weeks</b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>209</b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.99
    (1.13, 3.27)</b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&lt;0.001</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3
    months</b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>75</b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.81
    (0.85, 3.20)</b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&lt;0.001</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6
    months</b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>60</b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.70
    (0.93, 2.72)</b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&lt;0.001</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9
    months</b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>26</b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.90
    (1.33, 2.82)</b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>0.002</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>12
    months</b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>22</b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>220(0.41,
    3.21)</b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&lt;0.001</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An open-label study of 20 patients treated with PENFS in a &#8220;real-world&#8221; clinical setting at Cincinnati Children&#8217;s
Hospital demonstrated that after PENFS, abdominal pain (p &lt; 0.0001), nausea (p=0.001), pain catastrophizing (p = 0.001), functional
disability (p&lt;0.0001), and anxiety (p = 0.03) exhibited significant improvements, and were sustained 6-12 months after treatment (Santucci
et.al. Effect of percutaneous electrical nerve field stimulation on mechanosensitivity, sleep, and psychological comorbidities in adolescents
with functional abdominal pain disorders. Neurogastroenterol Motil. 2022;34:e14358). Validated questionnairesincluded the abdominal pain
index (API), nausea severity scale (NSS), functional disability index (FDI), as well as psychological measures of catastrophizing (PCS-C)
and anxiety (SCARED). The table below summarizes the results pre, during and post PENFS results at long-term follow-up (Santucci et.al.
Effect of percutaneous electrical nerve field stimulation on mechanosensitivity, sleep, and psychological comorbidities in adolescents
with functional abdominal pain disorders. Neurogastroenterol Motil. 2022;34:e14358).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img src="form10-k_011.jpg" alt=""/><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
clinically meaningful endpoint is the number needed to treat (NNT) used in treatment for abdominal pain-related functional gastrointestinal
disorders in adolescents. NNT means the number of patients that need to be treated for one patient to get the targeted improvement (&#8805;30%
improvement).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reimbursement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A PENFS procedure-specific Category III CPT
Code (0720T) was published on December 30, 2021 and became effective for utilization on July 1,2022. Category III CPT Codes are
temporary codes issued to define and track the utilization of new procedural technology. In collaboration with the American Medical
Association, we withdrew our initial Category I CPT Code application submitted in 2023. We continue to work diligently with the
American Academy of Pediatrics and other specialty medical societies on the pursuit of a Category I CPT Code for PENFS procedures.
To expand patient access to PENFS procedures and IB-Stim technology, we launched our internal Prior Authorization team under our
Guidance &amp; Patient Support function in 2023. This continues to address the Prior Authorization process barriers for providers
and children&#8217;s hospitals and streamlines a patient&#8217;s access to our Patient Advocacy and Financial Assistance offerings,
if needed. Six (6) commercial health insurers, including certain Blue Cross Blue Shield licensees, have instituted formal medical
policy coverage for PENFS. The total membership of these health insurers is approximately 9,000,000 covered lives; an additional
health insurer, with approximately 7,000,000 members, will institute formal medical policy coverage for PENFS in the second quarter
of 2024 bringing the total number of covered lives to approximately 16,000,000 over seven (7) commercial health insurers. Patients
who are appropriate clinical candidates may have policy-covered access to PENFS and IB-Stim technology under their specific health
plan. We continue to actively leverage clinical evidence and peer-reviewed publications to expand patient access to IB-Stim
technology. In addition, we anticipate academic medical society support in the form of a position paper and an update to treatment
guidelines to support the use of PENFS as a potential standard of care.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Marketing</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
market our products through search engine optimization, or SEO, internet channels and to physicians via the academic society. We plan
to extensively ramp-up our marketing efforts to patients and physicians as we gain additional indications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Patients/Customers</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
current patient base is children 11-18 years of age and suffering from functional abdominal pain. Our customers are primarily children&#8217;s
hospitals who serve these children.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img src="form10-k_012.jpg" alt=""/><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Intellectual
Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
intellectual property consists of patents, trademarks, and trade secrets. Our trade secrets consist of product formulas, research, and
development, and unpatentable know-how, all of which we seek to protect, in part, by confidentiality agreements. To protect our intellectual
property, we rely on a combination of laws and regulations, as well as contractual restrictions. Federal trademark law protects our registered
trademarks. We also rely on the protection of laws regarding unregistered copyrights for certain content we create and trade secret laws
to protect our proprietary technology. To further protect our intellectual property, we enter into confidentiality agreements with our
executive officers and directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Trademarks</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has 10 registered trademarks, eight (8) of which are being used in commerce:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trademark</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reg.
    No.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reg.
    Date</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 41%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Class/Goods</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Status</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEURO-STIM and Design</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5105257</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20-Dec-2016</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10 Int. nerve stimulator
    apparatus</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registered</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NSS THE NEUROSTIM SYSTEM
    and Design</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4905470</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23-Feb-2016</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10 Int. nerve stimulator
    apparatus</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registered</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THE NEURO-STIM SYSTEM and
    Design</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5105258</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20-Dec-2016</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10 Int. nerve stimulator
    apparatus</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registered</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NSS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4852008</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Nov-2015</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10 Int. Medical apparatus,
    namely, electrical nerve stimulators; medical device, namely, a non- implantable neurological pain management generator, with percutaneously-implantable
    needle arrays; medical system and apparatus consisting of a non-implantable modulating frequency generator, providing neuromodulation
    therapy to cranial and peripheral nerves; medical system and apparatus consisting of implantable arrays for transmitting current
    into auricular and peri-auricular tissue; medical device for peripheral nerve and nerve field stimulation; medical system and apparatus
    consisting of a non-implantable modulating frequency generator and implantable needle arrays for transmitting current into auricular
    and peri-auricular tissue for use in pain management, namely, patient stimulators for auricular and peri-auricular peripheral nerve
    field neuromodulation therapy; medical apparatus, appliances and instruments for peripheral nerve field stimulation in cranial and
    peripheral nerves and occipital nerve branches, for pain control, headache control, control of phantom limb pain, stump pain, reflex
    sympathetic dystrophy (RSD), peripheral neuropathies and other types of sympathetically mediated pain</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registered</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 14%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IB-STIM</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5926831</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">03-Dec-2019</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 41%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10 Int. medical
    apparatus, namely, electrical nerve stimulators; medical device, namely, a non- implantable modulating frequency generator, providing
    neuromodulation therapy to cranial and peripheral nerves; medical apparatus consisting of percutaneously implantable arrays for transmitting
    current into auricular and peri-auricular tissue; medical device for peripheral nerve and nerve field stimulation; medical device
    consisting of a non-implantable modulating frequency generator and percutaneously implantable needle arrays for transmitting current
    into auricular and peri-auricular tissue for use in pain management and FGID (functional gastrointestinal disorders), namely, patient
    stimulator for auricular and peri-auricular peripheral nerve field neuromodulation therapy; medical apparatus, for peripheral nerve
    field stimulation in cranial and peripheral nerves and occipital nerve branches, for pain control, FGID, irritable bowel, functional
    dyspepsia, functional abdominal pain, nausea, functional nausea, abdominal migraine, Crohn&#8217;s Disease, visceral hypersensitivity,
    chronic inflammatory bowel disease, changes in FGID co-morbidities, sleep disturbances, psychological disorders, including mood and
    anxiety, satiety and changes in autonomic nervous system and other types of sympathetically mediated pain</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registered</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 14%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trademark</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reg.
    No.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reg.
    Date</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 41%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Class/Goods</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Status</b></span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 14%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IB-STIM and Design</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5926832</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">03-Dec-2019</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 41%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10 Int. medical apparatus,
    namely, electrical nerve stimulators; medical device, namely, a non- implantable modulating frequency generator, providing neuromodulation
    therapy to cranial and peripheral nerves; medical apparatus consisting of percutaneously implantable arrays for transmitting current
    into auricular and peri-auricular tissue; medical device for peripheral nerve and nerve field stimulation; medical device consisting
    of a non-implantable modulating frequency generator and percutaneously implantable needle arrays for transmitting current into auricular
    and peri-auricular tissue for use in pain management and FGID (functional gastrointestinal disorders), namely, patient stimulator
    for auricular and peri-auricular peripheral nerve field neuromodulation therapy; Medical apparatus, for peripheral nerve field stimulation
    in cranial and peripheral nerves and occipital nerve branches, for pain control, FGID, irritable bowel, functional dyspepsia, functional
    abdominal pain, nausea, functional nausea, abdominal migraine, Crohn&#8217;s Disease, visceral hypersensitivity, chronic inflammatory
    bowel disease, changes in FGID co-morbidities, sleep disturbances, psychological disorders, including mood and anxiety, satiety and
    changes in autonomic nervous system and other types of sympathetically mediated pain</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registered</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IB-STIM AURICULAR STIMULATOR</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5978411</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">04-Feb-2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10 Int. medical apparatus,
    namely, electrical nerve stimulators; Medical device, namely, a non- implantable modulating frequency generator, providing neuromodulation
    therapy to cranial and peripheral nerves; Medical apparatus consisting of percutaneously implantable arrays for transmitting current
    into auricular and peri-auricular tissue; Medical device for peripheral nerve and nerve field stimulation; Medical device consisting
    of a non-implantable modulating frequency generator and percutaneously implantable needle arrays for transmitting current into auricular
    and peri-auricular tissue for use in pain management and FGID (functional gastrointestinal disorders), namely, patient stimulator
    for auricular and peri-auricular peripheral nerve field neuromodulation therapy; Medical apparatus, for peripheral nerve field stimulation
    in cranial and peripheral nerves and occipital nerve branches, for pain control, FGID, irritable bowel, functional dyspepsia, functional
    abdominal pain, nausea, functional nausea, abdominal migraine, Crohn&#8217;s Disease, visceral hypersensitivity, chronic inflammatory
    bowel disease, changes in FGID co-morbidities, sleep disturbances, psychological disorders, including mood and anxiety, satiety and
    changes in autonomic nervous system and other types of sympathetically mediated pain</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registered</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IB-STIM AURICULAR STIMULATOR
    and Design</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5978412</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">04-Feb-2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10 Int. medical apparatus,
    namely, electrical nerve stimulators; medical device, namely, a non- implantable modulating frequency generator, providing neuromodulation
    therapy to cranial and peripheral nerves; medical apparatus consisting of percutaneously implantable arrays for transmitting current
    into auricular and peri-auricular tissue; medical device for peripheral nerve and nerve field stimulation; medical device consisting
    of a non-implantable modulating frequency generator and percutaneously implantable needle arrays for transmitting current into auricular
    and peri-auricular tissue for use in pain management and FGID (functional gastrointestinal disorders), namely, patient stimulator
    for auricular and peri-auricular peripheral nerve field neuromodulation therapy; medical apparatus, for peripheral nerve field stimulation
    in cranial and peripheral nerves and occipital nerve branches, for pain control, FGID, irritable bowel, functional dyspepsia, functional
    abdominal pain, nausea, functional nausea, abdominal migraine, Crohn&#8217;s Disease, visceral hypersensitivity, chronic inflammatory
    bowel disease, changes in FGID co-morbidities, sleep disturbances, psychological disorders, including mood and anxiety, satiety and
    changes in autonomic nervous system and other types of sympathetically mediated pain</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registered</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 14%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trademark</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reg.
    No.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reg.
    Date</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 41%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Class/Goods</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Status</b></span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEURAXIS</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 41%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10 Int. Nerve
    stimulator apparatus; nerve stimulator apparatus for FGID, irritable bowel, functional dyspepsia, functional abdominal pain, nausea,
    functional nausea, abdominal migraine, Crohn&#8217;s Disease, visceral hypersensitivity, chronic inflammatory bowel disease, changes
    in FGID co- morbidities, sleep disturbances, psychological disorders, including mood, anxiety, and satiety, pain control, headache
    control, control of phantom limb pain, stump pain, reflex sympathetic dystrophy (RSD), peripheral neuropathies and other types of
    sympathetically mediated pain</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NEURAXIS (STYLIZED)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10 Int. Nerve stimulator
    apparatus; nerve stimulator apparatus for FGID, irritable bowel, functional dyspepsia, functional abdominal pain, nausea, functional
    nausea, abdominal migraine, Crohn&#8217;s Disease, visceral hypersensitivity, chronic inflammatory bowel disease, changes in FGID
    co- morbidities, sleep disturbances, psychological disorders, including mood, anxiety, and satiety, pain control, headache control,
    control of phantom limb pain, stump pain, reflex sympathetic dystrophy (RSD), peripheral neuropathies and other types of sympathetically
    mediated pain</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has no unregistered trademarks.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Patents</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has eight (8) granted patents and nine (9) applied for patent applications in the United States and nine (9) applied for foreign
patent applications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Owner</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Serial
    No.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Actual
    Filing Date</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Patent
    No.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Issue
    Date</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Anticipated
    Expiration Date</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Application
    Status</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Licensing
    Status</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CA</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis, Inc.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3096494</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25-Apr-2019</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AURICULAR NERVE FIELD STIMULATION
    DEVICE</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">applied for</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CN</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis, Inc.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">201980027574.9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25-Apr-2019</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AURICULAR NERVE FIELD STIMULATION
    DEVICE</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">applied for</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EP</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis, Inc.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">19850021.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25-Apr-2019</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AURICULAR NERVE FIELD STIMULATION
    DEVICE</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">applied for</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">JP</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis, Inc.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021-509961</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23-Oct-2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AURICULAR NERVE FIELD STIMULATION
    DEVICE</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">applied for</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">KR</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis, Inc.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-2020-7034010</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25-Apr-2019</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AURICULAR NERVE FIELD STIMULATION
    DEVICE</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">applied for</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis, Inc.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17/040766</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23-Sep-2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11369791</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">28-Jun-2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21-Jun-2039</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AURICULAR NERVE FIELD STIMULATION
    DEVICE</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">granted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis, Inc.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17/715121</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">07-Apr-2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AURICULAR NERVE FIELD STIMULATION
    DEVICE</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">applied for</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis, Inc.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63/314028</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25-Feb-2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AURICULAR NERVE FIELD STIMULATION
    DEVICE AND METHODS FOR USING THE SAME</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">applied for</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis, Inc.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63/315371</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">01-Mar-2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AURICULAR NERVE FIELD STIMULATION
    DEVICE AND METHODS FOR USING THE SAME</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">applied for</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis, Inc.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/014169</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21-Jun-2018</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10322062</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18-Jun-2019</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14-May-2034</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AURICULAR PERIPHERAL NERVE
    FIELD STIMULATOR AND METHOD OF OPERATING SAME</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">granted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Out-licensed</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis, Inc.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/408004</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">09-May-2019</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11077019</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">03-Aug-2021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14-May-2034</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AURICULAR PERIPHERAL NERVE
    FIELD STIMULATOR AND METHOD OF OPERATING SAME</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">granted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Out-licensed</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Country</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Owner</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 11%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Serial
    No.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 6%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Actual
    Filing Date</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 6%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Patent
    No.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Issue
    Date</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Anticipated
    Expiration Date</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Application
    Status</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; padding-bottom: 1.5pt; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Licensing
    Status</b></span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis, Inc.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 11%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17/363620</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 6%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30-Jun-2021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 6%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 18%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AURICULAR PERIPHERAL NERVE
    FIELD STIMULATOR AND METHOD OF OPERATING SAME</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">applied for</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis, Inc.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17/830411</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">02-Jun-2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DEVICE AND METHOD FOR ERADICATING
    PATHOGENS IN NASAL PASSAGES</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">applied for</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>

<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis, Inc.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 11%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17/589082</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31-Jan-2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 18%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXTERNAL AUDITORY
    CANAL PHOTOBIOMODULATION AND AUDIO THERAPY DEVICE</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">applied for</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis, Inc.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17/861646</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11-Jul-2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXTERNAL AUDITORY CANAL
    THERAPY DEVICE</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">applied for</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CA</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis, Inc.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3143304</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Dec-2021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXTERNAL AUDITORY CANAL
    PHOTOBIOMODULATION DEVICE</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">applied for</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CN</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis, Inc.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">202080060202.9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23-Jun-2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXTERNAL AUDITORY CANAL
    PHOTOBIOMODULATION DEVICE</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">applied for</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EP</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis, Inc.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">20830917.9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10-Dec-2021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXTERNAL AUDITORY CANAL
    PHOTOBIOMODULATION DEVICE</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">applied for</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">JP</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis, Inc.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021-576915</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24-Dec-2021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXTERNAL AUDITORY CANAL
    PHOTOBIOMODULATION DEVICE</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">applied for</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis, Inc.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17/617364</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">08-Dec-2021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXTERNAL AUDITORY CANAL
    PHOTOBIOMODULATION DEVICE</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">applied for</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis, Inc.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15/488416</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14-Apr-2017</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10413719</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17-Sep-2019</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14-April-2037</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">METHODS OF TREATING DISEASE
    USING AURICULAR PERIPHERAL NERVE FIELD STIMULATION</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">granted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Out-licensed</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis, Inc.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/534159</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">07-Aug-2019</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11331473</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17-May-2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14-April-2037</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">METHODS OF TREATING DISEASE
    USING AURICULAR PERIPHERAL NERVE FIELD STIMULATION</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">granted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis, Inc.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15/595185</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15-May-2017</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9839577</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12-Dec-2017</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14-May-2034</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SYSTEM AND METHOD FOR AURICULAR
    PERIPHERAL NERVE FIELD STIMULATION</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">granted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Out-licensed</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis, Inc.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15/811278</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13-Nov-2017</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10010479</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">03-Jul-2018</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14-May-2034</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SYSTEM AND METHOD FOR AURICULAR
    PERIPHERAL NERVE FIELD STIMULATION</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">granted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Out-licensed</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis, Inc.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14/277158</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14-May-2014</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9662269</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30-May-2017</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14-May-2034</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SYSTEMS AND METHODS FOR
    AURICULAR PERIPHERAL NERVE FIELD STIMULATION</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">granted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Out-licensed</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis, Inc.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17/725,761</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21-Apr-2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AURICULAR NERVE FIELD STIMULATION
    DEVICE AND METHODS FOR USING THE SAME</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>License
Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>TKBMN
Exclusive License Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 7, 2020, the Company entered into an exclusive license agreement with TKBMN, LLC to obtain an exclusive license under certain
patent rights (the &#8220;Patent Rights&#8221;) owned by TKBMN. Dr. Thomas Carrico, our Chief Regulatory Officer, is the manager of
TKBMN. Brian Carrico, our Chief Executive Officer, and Matt Carrico, our National Sales Director, are members of TKBMN. TKBMN owns
the Patent Rights set forth in the patents listed in the following table (the &#8220;TKBMN Patents&#8221;) by virtue of an
assignment from Dr. Carrico, who is the sole inventor listed on the TKBMN Patents. TKBMN has assigned the auricular portion of the
TKBMN Patent Rights to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Licensed TKBMN Patents</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: top; text-align: left">
  <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; width: 10%"><b>Country</b></td>
    <td style="width: 2%">&#160;</td>
  <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; width: 10%"><b>Owner</b></td>
    <td style="width: 2%">&#160;</td>
  <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; width: 14%"><b>Application No.</b></td>
    <td style="width: 2%">&#160;</td>
  <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; width: 10%"><b>Patent No.</b></td>
    <td style="width: 2%">&#160;</td>
  <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; width: 12%"><b>Issue Date</b></td>
    <td style="width: 2%">&#160;</td>
  <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; width: 14%"><p style="margin-top: 0; margin-bottom: 0"><b>Anticipated</b></p>
                                                                                                       <p style="margin-top: 0; margin-bottom: 0"><b>Expiration</b></p>
                                                                                <p style="margin-top: 0; margin-bottom: 0"><b>Date*</b></p></td>
    <td style="width: 2%">&#160;</td>
  <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; width: 18%"><b>Title</b></td></tr>
<tr style="vertical-align: top; text-align: left; background-color: rgb(204,238,255)">
  <td style="text-align: center">US</td>
    <td>&#160;</td>
  <td style="text-align: center">TKBMN, LLC</td>
    <td>&#160;</td>
  <td style="text-align: center">15/981,082</td>
    <td>&#160;</td>
  <td style="text-align: center">10,792,500</td>
    <td>&#160;</td>
  <td style="text-align: center">October 2, 2020</td>
    <td>&#160;</td>
  <td style="text-align: center">October 18, 2037</td>
    <td>&#160;</td>
  <td style="text-align: center">Systems and methods for electro-therapy treatment</td></tr>
<tr style="vertical-align: top; text-align: left; background-color: White">
  <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
  <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
  <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
  <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
  <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
  <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
  <td style="text-align: center">&#160;</td></tr>
<tr style="vertical-align: top; text-align: left; background-color: rgb(204,238,255)">
  <td style="text-align: center">US</td>
    <td>&#160;</td>
  <td style="text-align: center">TKBMN, LLC</td>
    <td>&#160;</td>
  <td style="text-align: center">17/014,450</td>
    <td>&#160;</td>
  <td style="text-align: center">11,684,782</td>
    <td>&#160;</td>
  <td style="text-align: center">June 7, 2023</td>
    <td>&#160;</td>
  <td style="text-align: center">October 18, 2037</td>
    <td>&#160;</td>
  <td style="text-align: center">Systems and methods for electro-therapy treatment</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">* If all maintenance fees remain paid</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the exclusive license agreement, TKBMN agreed to grant an exclusive, worldwide, non-transferable, royalty-free license under Patent
Rights, which including three patents applications filed by TKBMN in connection with systems and methods for elector-therapy treatment,
to the Company to develop, market, and sell licensed products, in the field of electro-therapy treatment by stimulation of cranial nerves,
cranial nerve branches, auricular nerves, auricular nerve branches, auricular nerve bundles, and/or auricular anatomical structures in
human patients (the &#8220;Field&#8221;), in consideration of a one-time license fee of $1.00. The Company has the right to grant sublicenses
to the Patents Rights in the Field. The exclusive license agreement expires upon the expiration of the last to expire valid claim within
the Patent Rights and may be terminated by the Company upon 60 days prior written notice. Upon expiration or termination of the exclusive
license agreement, all rights in the Patent Rights will revert to TKBMN. There are no royalties or any other form of committed revenue
to TKBMN or any of its members Under the agreement, the Company has agreed to cover fees and expenses associated with maintenance, prosecution,
and additional associated/continuation patent filings for the TKBMN Patents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Masimo
License and Collaboration Agreement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 9, 2020, the Company entered into a license and collaboration agreement with Masimo. As consideration, in part, Masimo entered
into a Series A Preferred Stock purchase agreement with the Company. Under the license and collaboration agreement, the Company grants
an exclusive, fully paid-up, royalty-free license to specifically identified patents and trademarks in a limited Field of use. At all
times, the Company remains the owner of all licensed intellectual property rights, and there is a possibility of joint ownership of collaboratively
developed products and methods. The licensed patents are generally directed to a device and the treatment of opioid withdrawal symptoms.
The licensed trademarks are generally directed to the NSS-2 Bridge mark. The license agreement includes a collaboration component to
efficiently develop, obtain regulatory approval, and commercialize products for the limited field of use. The term of the agreement is
in effect until the expiration or lapse of the last intellectual property rights. Masimo paid a one-time fee of $250,000. The license
and collaboration agreement may not be terminated by the Company for any reason, and the sole remedy for any breach or default by Masimo
shall be to seek monetary damages and equitable remedies. The license and collaboration agreement may be terminated by Masimo if there
is material breach by the Company that remain uncured for thirty (30) days or without cause by providing thirty (30) days prior written
notice. See<i>&#8220;&#8212;Our Corporate History</i>&#8221; for more information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Implications
of Being a Smaller Reporting Company</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a &#8220;smaller reporting company&#8221; as defined in Rule&#160;10(f)(1)&#160;of&#160;Regulation S-K. Smaller reporting companies
may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial
statements. We will remain a smaller reporting company until the last day of the fiscal year in which (1) the market value of our shares
held by non-affiliates equals or exceeds $250 million as of the prior June 30<sup>th</sup>, or (2) our annual revenues equaled or exceeded
$100 million during such completed fiscal year and the market value of our shares held by non-affiliates equals or exceeds $700 million
as of the prior June 30<sup>th</sup>. Such reduced disclosure and corporate governance obligations may make it more challenging for investors
to analyze our results of operations and financial prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
additional information, see &#8220;<i>Risk Factors &#8211; Because the Company is a &#8216;smaller reporting company,&#8217; we may take
advantage of certain scaled disclosures available to us, resulting in holders of our securities receiving less Company information than
they would receive from a public company that is not a smaller reporting company&#8221; and &#8220;As a smaller reporting company,&#8221;
we may at some time in the future choose to exempt our Company from certain corporate governance requirements that could have an adverse
effect on our public stockholders.&#8221;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Implications
of Being an Emerging Growth Company</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an &#8220;emerging growth company&#8221; as defined in the&#160;JOBS Act. We will remain an emerging growth company until the earlier
of (1) December 31, 2028, (2) the last day of the fiscal year in which we have total annual gross revenue of at least $1.235 billion,
(3) the last day of the fiscal year in which we are deemed to be a &#8220;large accelerated filer&#8221; as defined in Rule&#160;12b-2&#160;under
the&#160;Securities Exchange Act of 1934, as amended, or the&#160;Exchange Act, which would occur on the date on which we have issued
more than $1.0 billion in non-convertible debt securities during the prior three-year period. An emerging growth company may take advantage
of specified reduced reporting requirements and is relieved of certain other significant requirements that are otherwise generally applicable
to public companies. As an emerging growth company, we may:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">present only two years
    of audited financial statements, plus unaudited condensed financial statements for any interim period, and related management&#8217;s
    discussion and analysis of financial condition and results of operations in this prospectus;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">avail ourselves of the
    exemption from the requirement to obtain an attestation and report from our auditors on the assessment of our internal control over
    financial reporting pursuant to the&#160;Sarbanes-Oxley Act&#160;of 2002;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">provide reduced disclosure
    about our executive compensation arrangements; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">not require stockholder
    non-binding advisory votes on executive compensation or golden parachute arrangements.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, under the&#160;JOBS Act, an emerging growth company can delay the adoption of certain accounting standards until those standards
would otherwise apply to private companies. We have elected not to take advantage of the extended transition period for complying with
new or revised accounting standards provided to emerging growth companies under the&#160;JOBS Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Government
Regulation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
products and our operations are subject to extensive regulation by the U.S. Food and Drug Administration, or FDA, and other federal,
state, and local authorities in the United States, as well as comparable authorities in foreign jurisdictions. Our products are subject
to regulation as medical devices in the United States under the Federal Food, Drug, and Cosmetic Act, or FDCA, and its implementing regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>United
States Regulation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA regulates, among other things, the development, design, non-clinical and clinical testing, manufacturing, safety, effectiveness,
labeling, packaging, storage, installation, servicing, recordkeeping, premarket clearance or approval, adverse event reporting, advertising,
promotion, marketing and distribution, and import and export and post-marketing surveillance of medical devices in the United States
to ensure that medical devices distributed domestically are safe and effective for their intended uses and otherwise meet the requirements
of the FDCA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>FDA
Premarket Clearance and Approval Requirements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
an exemption applies, each new or significantly modified medical device commercially distributed in the United States requires FDA clearance
of a 510(k) premarket notification. The 510(k) clearance can be resource intensive, expensive, and lengthy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the FDCA, medical devices are classified into one of three classes&#8212;Class I, Class II or Class III&#8212;depending on the degree
of risk associated with each medical device and the extent of manufacturer and regulatory control needed to ensure its safety and effectiveness.
Class I devices are those for which safety and effectiveness can be assured by adherence to the FDA&#8217;s general controls for medical
devices, which include compliance with the applicable portions of FDA&#8217;s current good manufacturing practices for devices, as reflected
in the Quality System Regulation, or QSR, establishment registration and device listing, reporting of adverse medical events, and truthful
and non-misleading labeling, advertising, and promotional materials. Some Class I devices, also called Class I reserved devices, also
require premarket clearance by the FDA through the 510(k) premarket notification process described below. Most Class I devices are exempt
from the premarket notification requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class
II devices are subject to the FDA&#8217;s general controls, and any other special controls deemed necessary by the FDA to ensure the
safety and effectiveness of the device. These special controls can include performance standards, special labeling requirements, post-market
surveillance, patient registries and FDA guidance documents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Most
Class II devices are required to submit to the FDA a premarket notification under Section 510(k) of the FDCA requesting permission to
commercially distribute the device. The FDA&#8217;s permission to commercially distribute a device subject to a 510(k) premarket notification
is generally known as 510(k) clearance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a new medical device does not qualify for the 510(k) premarket notification process because no predicate device to which it is substantially
equivalent can be identified, the device is automatically classified into Class III. The Food and Drug Administration Modernization Act
of 1997 established a new route to market for low to moderate risk medical devices that are automatically placed into Class III due to
the absence of a predicate device, called the &#8220;Request for Evaluation of Automatic Class III Designation,&#8221; or the de novo
classification process. This process allows a manufacturer whose novel device is automatically classified into Class III to request down-classification
of its medical device into Class I or Class II on the basis that the device presents low or moderate risk. If the manufacturer seeks
reclassification into Class II, the manufacturer must include a draft proposal for special controls that are necessary to provide a reasonable
assurance of the safety and effectiveness of the medical device. The FDA may reject the reclassification petition if it identifies a
legally marketed predicate device that would be appropriate for a 510(k) or that general controls would be inadequate to control the
risks and special controls cannot be developed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Obtaining
FDA marketing authorization, de novo down-classification, or approval for medical devices is expensive and uncertain, and may take several
years, and generally requires significant scientific and clinical data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
pre-amendment devices are unclassified, but are subject to FDA&#8217;s premarket notification and clearance process in order to be commercially
distributed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Investigational
Device Process</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials are sometimes required to support a 510(k) submission. In the United States, absent certain limited exceptions, human clinical
trials intended to support medical device clearance or approval or to determine safety and effectiveness of a device for an investigational
use must be conducted in accordance with the FDA&#8217;s investigational device exemption, or IDE, regulations which govern investigational
device labeling, prohibit promotion of the investigational device, and specify an array of recordkeeping, reporting and monitoring responsibilities
of study sponsors and study investigators. If the device presents a &#8220;significant risk,&#8221; to human health, as defined by the
FDA, the FDA requires the device sponsor to submit an IDE application to the FDA, which must become effective prior to commencing human
clinical trials. The IDE application must be supported by appropriate data, such as animal and laboratory testing results, showing that
it is safe to test the device in humans and that the testing protocol is scientifically sound. The IDE application must be approved in
advance by the FDA for a specified number of subjects. Generally, clinical trials for a significant risk device may begin once the IDE
application is approved by the FDA and the study protocol and informed consent are approved by appropriate institutional review boards
at the clinical trial sites. There can be no assurance that submission of an IDE will result in the ability to commence clinical trials,
and although the FDA&#8217;s approval of an IDE allows clinical testing to go forward for a specified number of subjects, it does not
bind the FDA to accept the results of the trial as sufficient to prove the product&#8217;s safety and effectiveness, even if the trial
meets its intended success criteria.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the device under evaluation does not present a significant risk to human health, then the device sponsor is not required to submit an
IDE application to the FDA before initiating human clinical trials, but must still comply with abbreviated IDE requirements when conducting
such trials. A significant risk device is one that presents a potential for serious risk to the health, safety or welfare of a patient
and either is implanted, used in supporting or sustaining human life, substantially important in diagnosing, curing, mitigating or treating
disease or otherwise preventing impairment of human health, or otherwise presents a potential for serious risk to a subject. An IDE application
must be supported by appropriate data, such as animal and laboratory test results, showing that it is safe to test the device in humans
and that the testing protocol is scientifically sound. The IDE will automatically become effective thirty (30) days after receipt by
the FDA unless the FDA notifies the company that the investigation may not begin. If the FDA determines that there are deficiencies or
other concerns with an IDE for which it requires modification, the FDA may permit a clinical trial to proceed under a conditional approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regardless
of the degree of risk presented by the medical device, clinical studies must be approved by, and conducted under the oversight of, an
Institutional Review Board, or IRB, for each clinical site. The IRB is responsible for the initial and continuing review of the IDE,
and may pose additional requirements for the conduct of the study. If an IDE application is approved by the FDA and one or more IRBs,
human clinical trials may begin at a specific number of investigational sites with a specific number of patients, as approved by the
FDA. If the device presents a non-significant risk to the patient, a sponsor may begin the clinical trial after obtaining approval for
the trial by one or more IRBs without separate approval from the FDA, but must still follow abbreviated IDE requirements, such as monitoring
the investigation, ensuring that the investigators obtain informed consent, and labeling and record-keeping requirements. Acceptance
of an IDE application for review does not guarantee that the FDA will allow the IDE to become effective and, if it does become effective,
the FDA may or may not determine that the data derived from the trials support the safety and effectiveness of the device or warrant
the continuation of clinical trials. An IDE supplement must be submitted to, and approved by, the FDA before a sponsor or investigator
may make a change to the investigational plan that may affect its scientific soundness, study plan or the rights, safety or welfare of
human subjects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
a study, the sponsor is required to comply with the applicable FDA requirements, including, for example, trial monitoring, selecting
clinical investigators and providing them with the investigational plan, ensuring IRB review, adverse event reporting, record keeping
and prohibitions on the promotion of investigational devices or on making safety or effectiveness claims for them. The clinical investigators
in the clinical study are also subject to FDA&#8217;s regulations and must obtain patient informed consent, rigorously follow the investigational
plan and study protocol, control the disposition of the investigational device, and comply with all reporting and recordkeeping requirements.
Additionally, after a trial begins, we, the FDA or the IRB could suspend or terminate a clinical trial at any time for various reasons,
including the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The FDA or other regulatory
    authorities do not approve a clinical trial protocol or a clinical trial, or place a clinical trial on hold;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patients do not enroll
    in clinical trials at the rate expected;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patients do not comply
    with trial protocols;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patient follow-up is not
    at the rate expected;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patients experience serious
    adverse events;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patients die during a clinical
    trial, even though their death may not be related to the products that are part of the trial;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Device malfunctions occur
    with unexpected frequency or potential adverse consequences;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Side effects or device
    malfunctions of similar products already in the market that change the FDA&#8217;s view toward approval of result in the imposition
    of new requirements or testing;</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Institutional review boards
    and third-party clinical investigators may delay or reject the trial protocol;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third-party clinical investigators
    decline to participate in a trial or do not perform a trial on the anticipated schedule or consistent with the clinical trial protocol,
    investigator agreement, investigational plan, good clinical practices, the IDE regulations, or other FDA or IRB requirements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third-party investigators
    are disqualified by the FDA;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We or third-party organizations
    do not perform data collection, monitoring and analysis in a timely or accurate manner or consistent with the clinical trial protocol
    or investigational or statistical plans, or otherwise fail to comply with the IDE regulations governing responsibilities, records,
    and reports of sponsors of clinical investigations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third-party clinical investigators
    have significant financial interests related to us or our study such that the FDA deems the study results unreliable, or the company
    or investigators fail to disclose such interests;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Regulatory inspections
    of our clinical trials or manufacturing facilities, which may, among other things, require us to undertake corrective action or suspend
    or terminate our clinical trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in government regulations
    or administrative actions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The interim or final results
    of the clinical trial are inconclusive or unfavorable as to safety or effectiveness; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The FDA concludes that
    our trial design is unreliable or inadequate to demonstrate safety and effectiveness.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>510(k)
Clearance Process</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the 510(k) process, the manufacturer must submit to the FDA a premarket notification submission demonstrating that the proposed device
is &#8220;substantially equivalent,&#8221; as defined in the FDCA, to a legally marketed predicate device.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
predicate device is a legally marketed device that is not subject to premarket approval, i.e., a device that was legally marketed prior
to May 28, 1976 (pre-amendments device) and for which a PMA is not required, a device that has been reclassified from Class III to Class
II or I, or a device that was found substantially equivalent through the 510(k) process. A device is considered to be substantially equivalent
if, with respect to the predicate device, it has the same intended use and has either (i) the same technological characteristics; or
(ii) different technological characteristics, but the information provided in the 510(k) submission demonstrates that the device does
not raise different questions of safety or effectiveness than the predicate device.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Before
the FDA will accept a 510(k) premarket notification for substantive review, the FDA will first assess whether the submission satisfies
a minimum threshold of acceptability. If the FDA determines that the 510(k) submission lacks necessary information for substantive review,
the FDA will issue a &#8220;Refuse to Accept&#8221; letter which generally outlines the information the FDA believes is necessary to
permit a substantive review and to reach a determination regarding substantial equivalence. An applicant must submit the requested information
before the FDA will proceed with additional review of the submission. If a 510(k) submission is accepted for substantive review, the
Medical Device User Fee Amendments sets a performance goal of 90 days for FDA review of a 510(k) submission, but the review time can
be delayed if FDA raises questions or requests additional information during the review process. As a practical matter, clearance often
takes longer, and clearance is never assured. Thus, as a practical matter, clearance often takes longer than 90 days. Although many 510(k)
premarket notifications are cleared without clinical data, the FDA may require further information, including clinical data, to make
a determination regarding substantial equivalence, which may significantly prolong the review process. If the FDA agrees that the device
is substantially equivalent, it will grant clearance to commercially market the device.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"></p>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the FDA determines that the device is substantially equivalent to a predicate device, it will grant 510(k) clearance to commercially
market the device. If the FDA determines that the device is &#8220;not substantially equivalent&#8221; to a previously cleared device,
the device is automatically designated as a Class III device. The device sponsor must then fulfill more rigorous requirements of the
PMA approval process, or can request a risk-based classification determination for the device in accordance with the &#8220;<i>de novo</i>&#8221;
process, which is a route to market for certain novel medical devices that are low to moderate risk and are not substantially equivalent
to a predicate device.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical
devices can only be marketed for the indications for use for which they are cleared or approved. After a device receives 510(k) clearance,
any modification that could significantly affect its safety or effectiveness, or that would constitute a major change or modification
in its intended use, will require a new 510(k) clearance or, depending on the modification, PMA approval or&#160;<i>de novo</i>&#160;reclassification.
The FDA requires each manufacturer to determine whether the proposed change requires submission of a 510(k),&#160;<i>de novo</i>&#160;request
or a PMA in the first instance, but the FDA may review this determination to evaluate the regulatory status of the modified product at
any time and may require the manufacturer to cease marketing and/or request the recall of the modified device until 510(k) marketing
clearance or PMA approval is obtained or a&#160;<i>de novo</i>&#160;request is granted. Also, in these circumstances, the manufacturer
may be subject to significant regulatory fines or penalties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Over
the last several years, the FDA has proposed reforms to its 510(k) clearance process, and such proposals could include increased requirements
for clinical data and a longer review period, or could make it more difficult for manufacturers to utilize the 510(k) clearance process
for their products. For example, in November 2018, FDA officials announced steps that the FDA intended to take to modernize the premarket
notification pathway under Section 510(k) of the FDCA. Among other things, the FDA announced that it planned to develop proposals to
drive manufacturers utilizing the 510(k) pathway toward the use of newer predicates. These proposals included plans to potentially sunset
certain older devices that were used as predicates under the 510(k) clearance pathway, and to potentially publish a list of devices that
have been cleared on the basis of demonstrated substantial equivalence to predicate devices that are more than 10 years old. These proposals
have not yet been finalized or adopted, although the FDA may work with Congress to implement such proposals through legislation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">More
recently, in September 2019, the FDA issued revised final guidance describing an optional &#8220;safety and performance based&#8221;
premarket review pathway for manufacturers of &#8220;certain, well-understood device types&#8221; to demonstrate substantial equivalence
under the 510(k) clearance pathway by showing that such device meets objective safety and performance criteria established by the FDA,
thereby obviating the need for manufacturers to compare the safety and performance of their medical devices to specific predicate devices
in the clearance process. The FDA has developed and maintains a list device types appropriate for the &#8220;safety and performance based&#8221;
pathway and continues to develop product-specific guidance documents that identify the performance criteria for each such device type,
as well as recommended testing methods, where feasible.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>PMA
Approval Process</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class
III devices require PMA approval before they can be marketed, although some pre-amendment Class III devices for which FDA has not yet
required a PMA are cleared through the 510(k) process. The PMA process is more demanding than the 510(k) premarket notification process.
In a PMA, the manufacturer must demonstrate that the device is safe and effective for its intended use, and the PMA must be supported
by extensive data, including data from preclinical studies and human clinical trials. The PMA must also contain a full description of
the device and its components, a full description of the methods, facilities, and controls used for manufacturing, and proposed labeling.
Following receipt of a PMA, the FDA conducts an administrative review to determine whether the application is sufficiently complete to
permit a substantive review. If it is not, the agency will refuse to file the PMA. If FDA accepts the application for substantive review,
it has 180 days under the FDCA to complete its review of a filed PMA application, although in practice, the FDA&#8217;s review often
takes significantly longer, and can take up to several years. During this review period, the FDA may request additional information or
clarification of information already provided, and the FDA may issue a major deficiency letter to the applicant, requesting the applicant&#8217;s
response to deficiencies communicated by the FDA. The FDA considers a PMA or PMA supplement to have been voluntarily withdrawn if an
applicant fails to respond to an FDA request for information (e.g., major deficiency letter) within a total of 360 days. Before approving
or denying a PMA application, an advisory panel of experts from outside the FDA may be convened to review and evaluate the application
and provide recommendations to the FDA as to whether the FDA should approve the submission, approve it with specific conditions, or not
approve it. The FDA may or may not accept the panel&#8217;s recommendation. Prior to approval of a PMA, the FDA may conduct inspections
of the clinical trial data and clinical trial sites, as well as conduct inspections of the applicant or its third-party manufacturers&#8217;
or suppliers&#8217; manufacturing facility or facilities to, among other things, ensure compliance with the QSR. PMA applications are
also subject to the payment of user fees, which for fiscal year 2021 includes a standard application fee of $365,657.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Overall, the FDA review
    of a PMA application generally takes between one and three years, but may take significantly longer. The FDA can delay, limit or
    deny approval of a PMA application for many reasons, including:</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The device may not be shown
    safe or effective to the FDA&#8217;s satisfaction;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The data from pre-clinical
    studies and/or clinical trials may be found unreliable or insufficient to support approval;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The manufacturing process
    or facilities may not meet applicable requirements; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in FDA approval
    policies or adoption of new regulations may require additional data.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the FDA evaluation of a PMA is favorable, the FDA will issue either an approval letter, or an approvable letter, the latter of which
usually contains a number of conditions that must be met in order to secure final approval of the PMA. When and if those conditions have
been fulfilled to the satisfaction of the FDA, the agency will issue a PMA approval letter authorizing commercial marketing of the device,
subject to the conditions of approval and the limitations established in the approval letter. The FDA may approve a PMA with post-approval
conditions intended to ensure the safety and effectiveness of the device, including, among other things, restrictions on labeling, promotion,
sale and distribution, and collection of long-term follow-up data from patients in the clinical study that supported PMA approval or
requirements to conduct additional clinical studies post-approval. The FDA may condition PMA approval on some form of post-market surveillance
when deemed necessary to protect the public health or to provide additional safety and effectiveness data for the device in a larger
population or for a longer period of use. In such cases, the manufacturer might be required to follow certain patient groups for a number
of years and to make periodic reports to the FDA on the clinical status of those patients. Failure to comply with the conditions of approval
can result in material adverse enforcement action, including withdrawal of the approval. If the FDA&#8217;s evaluation of a PMA application
or manufacturing facilities is not favorable, the FDA will deny approval of the PMA or issue a not approvable letter. The FDA also may
determine that additional tests or clinical trials are necessary, in which case the PMA approval may be delayed for several months or
years while the trials are conducted and data is submitted in an amendment to the PMA, or the PMA is withdrawn and resubmitted when the
data are available. The PMA process can be expensive, uncertain and lengthy and a number of devices for which the FDA approval has been
sought by other companies have never been approved by the FDA for marketing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
changes to an approved medical device, such as changes in manufacturing facilities, methods, quality control procedures, sterilization
(if applicable), packaging, expiration date, labeling, device specifications, materials, or design of a device, or other changes which
affect the safety or effectiveness of the device that has been approved through the PMA process require submission of a new PMA or PMA
supplement. PMA supplements often require submission of the same type of information as a PMA, except that the supplement is limited
to information needed to support any changes from the device covered by the original, approved PMA and may not require as extensive clinical
data or the convening of an advisory panel, depending on the nature of the proposed change. Certain other changes to an approved device
require the submission of a new PMA, such as when the design change causes a different intended use, mode of operation, and technical
basis of operation, or when the design change is so significant that a new generation of the device will be developed, and the data that
were submitted with the original PMA are not applicable for the change in demonstrating a reasonable assurance of safety and effectiveness.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"></p>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Ongoing
Regulation by the FDA</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
after the FDA permits a device to be marketed, numerous and pervasive regulatory requirements continue to apply. These include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Establishment registration
    and device listing with the FDA;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">QSR requirements, which
    require manufacturers, including third-party manufacturers, to follow stringent design, testing, control, supplier/contractor selection,
    compliant handling, documentation and other quality assurance procedures during all aspects of the design and manufacturing process;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Labeling regulations, advertising
    and promotion requirements, restrictions on sale, distribution or sale of a device, each including the FDA prohibition against the
    promotion of products for any uses other than those authorized by the FDA, which are commonly known as &#8220;off-label&#8221; uses;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Medical Device Reporting,
    or MDR, regulations, which require that a manufacturer report to the FDA if a device it markets may have caused or contributed to
    a death or serious injury, or has malfunctioned and the device or a similar device that it markets would be likely to cause or contribute
    to a death or serious injury, if the malfunction were to recur;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical device correction
    and removal reporting regulations, which require that manufacturers report to the FDA field corrections or removals if undertaken
    to reduce a risk to health posed by the device or to remedy a violation of the FDCA that may present a risk to health;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recall requirements, including
    a mandatory recall if there is a reasonable probability that the device would cause serious adverse health consequences or death;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An order of repair, replacement,
    or refund;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Device tracking requirements;
    and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Post-market study and surveillance
    requirements.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
a device receives 510(k) clearance, any modification that could significantly affect its safety or effectiveness, or that would constitute
a major change in its intended use, will require a new 510(k). The FDA requires each manufacturer to make this determination initially,
but the FDA can review any such decision and can disagree with a manufacturer&#8217;s determination. If the FDA disagrees with a manufacturer&#8217;s
determination not to seek a new 510(k) clearance, the FDA may retroactively require it to seek 510(k) clearance. The FDA could also require
the manufacturer to cease marketing and distribution and/or recall the modified device until 510(k) clearance is obtained. Also, in these
circumstances, the manufacturer may be subject to significant regulatory fines and penalties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA
regulations require us to register as a medical device manufacturer with the FDA. Additionally, some states also require medical device
manufacturers and/or distributors doing business within the state to register with the state or apply for a state license, which could
subject our facility to state inspection as well as FDA inspection on a routine basis for compliance with the QSR and any applicable
state requirements. These regulations require that we manufacture our products and maintain related documentation in a prescribed manner
with respect to manufacturing, testing and control activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturing
processes for medical devices are required to comply with the applicable portions of the QSR, which cover the methods and the facilities
and controls for the design, manufacture, testing, production, processes, controls, quality assurance, labeling, packaging, distribution,
installation and servicing of finished devices intended for human use. The QSR also requires, among other things, maintenance of a device
master file, device history file, and complaint files. As a manufacturer, we are subject to periodic scheduled or unscheduled inspections
by the FDA. Failure to maintain compliance with the QSR requirements could result in the shutdown of, or restrictions on, manufacturing
operations and the recall or seizure of marketed products, which would have a material adverse effect on our business. The discovery
of previously unknown problems with any of our products, including unanticipated adverse events or adverse events of increasing severity
or frequency, whether resulting from the use of the device within the scope of its clearance or off-label by a physician in the practice
of medicine, could result in restrictions on the device, including the removal of the product from the market or voluntary or mandatory
device recalls.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA has broad regulatory compliance and enforcement powers. If the FDA determines that a manufacturer has failed to comply with applicable
regulatory requirements, it can take a variety of compliance or enforcement actions, which may result in any of the following sanctions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warning letters, untitled
    letters, fines, injunctions, consent decrees and civil penalties;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recalls, withdrawals, or
    administrative detention or seizure of our products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating restrictions
    or partial suspension or total shutdown of production;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Refusing or delays in processing,
    clearing, or approving submissions or applications for new products or modifications to existing products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Suspension or withdrawal
    of 510(k) clearances or PMA approvals that have already been granted;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA refusal to issue certification
    to foreign governments needed to export our products for sale in other countries; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Criminal prosecution.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
facilities, records and manufacturing processes are subject to periodic unscheduled inspections by the FDA. Failure to comply with the
applicable United States medical device regulatory requirements could result in, among other things, warning letters, untitled letters,
fines, injunctions, consent decrees, civil penalties, unanticipated expenditures, repairs, replacements, refunds, recalls or seizures
of products, operating restrictions, total or partial suspension of production, the FDA&#8217;s refusal to issue certificates to foreign
governments needed to export products for sale in other countries, the FDA&#8217;s refusal to grant future premarket clearances or approvals,
withdrawals or suspensions of current product clearances or approvals and criminal prosecution.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Regulation
of Medical Devices in the European Union</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
European Union, or EU, has adopted specific directives regulating the design, manufacture, clinical investigations, conformity assessment,
labeling and adverse event reporting for medical devices. EU directives must be implemented into the national laws of the EU member states
and national laws may vary from one member state to another.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the EU, there is currently no premarket government review of medical devices. However, the EU requires that all medical devices placed
on the market in the EU must meet the relevant essential requirements laid down in the Council Directive 93/42/EEC, or the Medical Devices
Directive, and the Council Directive 90/385/EEC, or the Active Implantable Medical Devices Directive. The most fundamental essential
requirement is that a medical device must be designed and manufactured in such a way that it will not compromise the clinical condition
or safety of patients, or the safety and health of users and others. In addition, the device must achieve the performances intended by
the manufacturer and be designed, manufactured, and packaged in a suitable manner. The European Commission has adopted various standards
applicable to medical devices. These include standards governing common requirements, such as sterilization and safety of medical electrical
equipment and product standards for certain types of medical devices. There are also harmonized standards relating to design and manufacture.
While not mandatory, compliance with these standards is viewed as the easiest way to satisfy the essential requirements as a practical
matter. Compliance with a standard developed to implement an essential requirement also creates a rebuttable presumption that the device
satisfies that essential requirement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
demonstrate compliance with the essential requirements laid down in Annex I to the Medical Devices Directive, medical device manufacturers
must undergo a conformity assessment procedure, which varies according to the type of medical device and its (risk) classification. Conformity
assessment procedures require an assessment of available clinical evidence, literature data for the product, and post-market experience
in respect of similar products already marketed. Except for low-risk medical devices (Class I non-sterile, non-measuring devices), where
the manufacturer can self-declare the conformity of its products with the essential requirements (except for any parts which relate to
sterility or metrology), a conformity assessment procedure requires the intervention of a Notified Body. Notified Bodies are independent
organizations designated by EU countries to assess the conformity of devices before being placed on the market. A Notified Body would
typically audit and examine a product&#8217;s technical dossiers and the manufacturers&#8217; quality system (which must, in particular,
comply with ISO 13485:2016 related to Medical Devices Quality Management Systems). If satisfied that the relevant product conforms to
the relevant essential requirements, the Notified Body issues a certificate of conformity, which the manufacturer uses as a basis for
its own declaration of conformity. The manufacturer may then apply the CE Mark to the device, which allows the device to be placed on
the market throughout the EU.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notified
Body certificates of conformity are valid for a fixed duration (which shall not exceed five years). Throughout the term of the certificate,
the manufacturer will be subject to periodic surveillance audits to verify continued compliance with the applicable requirements. In
particular, there will be a new audit by the Notified Body before it will renew the relevant certificate(s).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a general rule, demonstration of conformity of medical devices and their manufacturers with the essential requirements must be based,
among other things, on the evaluation of clinical data supporting the safety and performance of the products during normal conditions
of use. Specifically, a manufacturer must demonstrate that the device achieves its intended performance during normal conditions of use,
that the known and foreseeable risks, and any adverse events, are minimized and acceptable when weighed against the benefits of its intended
performance, and that any claims made about the performance and safety of the device are supported by suitable evidence. All manufacturers
placing medical devices into the market in the EU must comply with the EU medical device vigilance system. Under this system, incidents
must be reported to the relevant authorities of the EU member states, and manufacturers are required to take Field Safety Corrective
Actions, or FSCAs, to reduce a risk of death or serious deterioration in the state of health associated with the use of a medical device
that is already placed on the market. An incident is defined as any malfunction or deterioration in the characteristics and/or performance
of a device, as well as any inadequacy in the labeling or the instructions for use which, directly or indirectly, might lead to or might
have led to the death of a patient or user or of other persons or to a serious deterioration in their state of health. An FSCA may include
the recall, modification, exchange, destruction or retrofitting of the device. FSCAs must be communicated by the manufacturer or its
legal representative to its customers and/or to the end users of the device through Field Safety Notices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
advertising and promotion of medical devices is subject to some general principles set forth by EU directives. According to the Medical
Devices Directive, only devices that are CE-marked may be marketed and advertised in the EU in accordance with their intended purpose.
Directive 2006/114/EC concerning misleading and comparative advertising and Directive 2005/29/EC on unfair commercial practices, while
not specific to the advertising of medical devices, also apply to the advertising thereof and contain general rules, for example requiring
that advertisements are evidenced, balanced and not misleading. Specific requirements are defined at national level. EU member states
laws related to the advertising and promotion of medical devices, which vary between jurisdictions, may limit or restrict the advertising
and promotion of products to the general public and may impose limitations on promotional activities with healthcare professionals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Many
EU member states have adopted specific anti-gift statutes that further limit commercial practices for medical devices, in particular
vis-&#224; -vis healthcare professionals and organizations. Additionally, there has been a recent trend of increased regulation of
payments and transfers of value provided to healthcare professionals or entities. In addition, many EU member states have adopted national
&#8220;Sunshine Acts&#8221; which impose reporting and transparency requirements (often on an annual basis), similar to the requirements
in the United States, on medical device manufacturers. Certain countries also mandate implementation of commercial compliance programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
May 25, 2017, Regulation 2017/745, or the EU Medical Devices Regulation, entered into force, which repeals and replaces the Medical Devices
Directive and the Active Implantable Medical Devices Directive. Unlike directives, which must be implemented into the national laws of
the EU member states, regulations are directly applicable, without the need for adoption of EU member state laws implementing them, in
all EU member states and are intended to eliminate current differences in the regulation of medical devices among EU member states. The
Medical Devices Regulation, among other things, is intended to establish a uniform, transparent, predictable and sustainable regulatory
framework across the EU for medical devices and ensure a high level of safety and health while supporting innovation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Medical Devices Regulation was originally intended to become applicable three years after publication, but in April 2020 the transition
period was extended by the European Parliament and the Council of the EU by an additional year &#8211; until May 26, 2021. Devices lawfully
placed on the market pursuant to the Medical Devices Directive and the Active Implantable Medical Devices Directive prior to May 26,
2021 may generally continue to be made available on the market or put into service until May 26, 2025. Once applicable, the new regulations
will among other things:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Strengthen the rules on
    placing devices on the market and reinforce surveillance once they are available;</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Establish explicit provisions
    on manufacturers&#8217; responsibilities for the follow-up of the quality, performance and safety of devices placed on the market;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Improve the traceability
    of medical devices throughout the supply chain to the end-user or patient through a unique identification number;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Set up a central database
    to provide patients, healthcare professionals and the public with comprehensive information on products available in the European
    Union, or EU; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Strengthen the rules for
    the assessment of certain high-risk devices, which may have to undergo an additional check by experts before they are placed on the
    market.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aforementioned EU rules are generally applicable in the European Economic Area, or EEA, which consists of the 27 EU member states plus
Norway, Liechtenstein and Iceland. Other countries, such as Switzerland, have entered into Mutual Recognition Agreements and allow the
marketing of medical devices that meet EU requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
EU-UK Trade and Cooperation Agreement, or TCA, came into effect on January 1, 2021. The TCA does not specifically refer to medical devices.
However, as a result of Brexit, the Medical Devices Regulation will not be implemented in the UK, and previous legislation that mirrored
the Medical Devices Regulation in the UK law has been revoked. The regulatory regime for medical devices in the UK will continue to be
based on the requirements derived from current EU legislation, and the UK may choose to retain regulatory flexibility or align with the
Medical Devices Regulation going forward. CE markings will continue to be recognized in the UK, and certificates issued by EU recognized
Notified Bodies will be valid in the UK, until June 30, 2023. For medical devices placed on the UK market after this period, the UK Conformity
Assessment, or UKCA, marking will be mandatory. In contrast, UKCA marking and certificates issued by UK Notified Bodies will not be recognized
on the EU market. The TCA does provide for cooperation and exchange of information in the area of product safety and compliance, including
market surveillance, enforcement activities and measures, standardization related activities, exchanges of officials, and coordinated
product recalls (or other similar actions). For medical devices that are locally manufactured but use components from other countries,
the &#8220;rules of origin&#8221; criteria will need to be reviewed. Depending on which countries products will ultimately be sold in,
manufacturers may start seeking alternative sources for components if this would allow them to benefit from no tariffs. The rules for
placing medical devices on the Northern Ireland market will differ from those in the UK.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Healthcare
Fraud and Abuse Laws</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, we are subject to a number of federal and state healthcare regulatory laws that restrict business practices in the
healthcare industry. These laws include, but are not limited to, federal and state anti-kickback, false claims, transparency and other
healthcare fraud and abuse laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
U.S. federal Anti-Kickback Statute prohibits, among other things, any person or entity from knowingly and willfully offering, paying,
soliciting, receiving or providing any remuneration, directly or indirectly, overtly or covertly, to induce or in return for purchasing,
leasing, ordering, or arranging for or recommending the purchase, lease, or order of any good, facility, item or service reimbursable,
in whole or in part, under Medicare, Medicaid or other federal healthcare programs. The term &#8220;remuneration&#8221; has been broadly
interpreted to include anything of value, including cash, improper discounts, and free or reduced-price items and services. Among other
things, the Anti-Kickback Statute has been interpreted to apply to arrangements between medical device manufacturers on the one hand
and prescribers and purchasers on the other. Although there are a number of statutory exceptions and regulatory safe harbors protecting
some common activities from prosecution, the exceptions and safe harbors are drawn narrowly. The government can exercise enforcement
discretion in taking action against unprotected activities. Further, a person or entity does not need to have actual knowledge of the
statute or specific intent to violate it in order to have committed a violation. The majority of states also have anti-kickback laws,
which establish similar prohibitions, and in some cases may apply to items or services reimbursed by any third-party payor, including
commercial insurers and self-pay patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
federal false claims, including the civil False Claims Act, prohibit, among other things, any person or entity from knowingly presenting,
or causing to be presented, a false, fictitious or fraudulent claim for payment to, or approval by, the federal government, knowingly
making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government,
or knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. federal government. A claim
includes &#8220;any request or demand&#8221; for money or property presented to the U.S. government. Actions under the civil False Claims
Act may be brought by the Attorney General or as a qui tam action by a private individual in the name of the government. Moreover, a
claim including items or services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent
claim for purposes of the federal civil False Claims Act. In addition, various states have enacted false claim laws analogous to the
federal False Claims Act, although many of these state laws apply where a claim is submitted to any third-party payor and not merely
a federal healthcare program.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
federal Health Insurance Portability and Accountability Act of 1996 created additional federal criminal statutes that prohibit, among
other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including
private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a
criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up a material fact or
making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits,
items or services. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the
statute or specific intent to violate it in order to have committed a violation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment
is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually
to CMS, information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists,
podiatrists and chiropractors), and teaching hospitals, and applicable manufacturers and applicable group purchasing organizations to
report annually to CMS ownership and investment interests held by physicians and their immediate family members. Beginning in 2022, such
obligations will include payments and other transfers of value provided in the previous year to additional healthcare professionals,
including physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, anesthesiologist assistants
and certified nurse midwives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Violations
of fraud and abuse laws, including federal and state anti-kickback and false claims laws, may be punishable by criminal and civil sanctions,
including fines and civil monetary penalties, the possibility of exclusion from federal healthcare programs (including Medicare and Medicaid),
disgorgement and corporate integrity agreements, which impose, among other things, rigorous operational and monitoring requirements on
companies. Similar sanctions and penalties, as well as imprisonment, also can be imposed upon executive officers and employees of such
companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Coverage
and Reimbursement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, our currently cleared products are not separately reimbursed by any third-party payors and if covered, are paid for
as part of the procedure in which the product is used. Outside of the United States, there are many reimbursement programs through private
payors as well as government programs. In some countries, government reimbursement is the predominant program available to patients and
hospitals. Our commercial success depends in part on the extent to which governmental authorities, private health insurers and other
third-party payors provide coverage for and establish adequate reimbursement levels for the procedures in which our products are used.
Failure by physicians, hospitals, ambulatory surgery centers and other users of our products to obtain coverage and adequate reimbursement
from third-party payors for procedures in which our products are used, or adverse changes in government and private third-party payors&#8217;
coverage and reimbursement policies, may adversely impact demand for our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on our experience to date, third-party payors generally reimburse for the procedures in which our products are used if medical necessity
is met and a prior approval is completed with a favorable response. Some payors are moving toward a managed care system and control their
healthcare costs by establishing coverage policies that categorically restrict coverage of certain procedures, or by limiting authorization
for procedures, including elective procedures using our devices. No uniform policy of coverage and reimbursement among payors in the
United States exists and coverage and reimbursement for procedures can differ significantly from payor to payor. Third-party payors are
increasingly auditing and challenging the prices charged for medical products and services with concern for upcoding, miscoding, using
inappropriate modifiers, or billing for inappropriate care settings. Some third-party payors must approve coverage for new or innovative
devices or procedures before they will reimburse healthcare providers who use the products or therapies. Even though a new product may
have been cleared for commercial distribution by the FDA, we may find limited demand for our product unless reimbursement approval can
be obtained and/or maintained from governmental and private third-party payors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to uncertainties surrounding coverage policies, there are periodic changes to reimbursement levels. Third-party payors regularly
update reimbursement amounts and also from time to time revise the methodologies used to determine reimbursement amounts. This includes
routine updates to payments to physicians, hospitals and ambulatory surgery centers for procedures during which our products are used.
These updates could directly impact the demand for our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe the overall escalating cost of medical products and services being paid for by the government and private health insurance has
led to, and will continue to lead to, increased pressures on the healthcare and medical device industry to reduce the costs of products
and services. Third-party payors are developing increasingly sophisticated methods of controlling healthcare costs through prospective
reimbursement and capitation programs, group purchasing, redesign of benefits, and exploration of more cost-effective methods of delivering
healthcare. In the United States, some insured individuals enroll in managed care programs, which monitor and often require pre-approval
of the services that a member will receive. Some managed care programs pay their providers on a per capita (patient) basis, which puts
the providers at financial risk for the services provided to their patients by paying these providers a predetermined payment per member
per month and, consequently, may limit the willingness of these providers to use our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
international markets, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted
price ceilings on specific product lines and procedures. In the European Union, member states are facing increased pressure to limit
public healthcare spending. There can be no assurance that procedures using our products will be covered for a specific indication, that
our products will be considered cost-effective by third-party payors, that an adequate level of reimbursement will be available or that
the third-party payors&#8217; reimbursement policies will not adversely affect our ability to sell our products profitably. More and
more, local, product specific reimbursement law is applied as an overlay to medical device regulation, which has provided an additional
layer of clearance requirement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Healthcare
Reform</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
United States and some foreign jurisdictions are considering or have enacted a number of legislative and regulatory proposals to change
the healthcare system in ways that could affect our ability to sell our products profitably. Among policy makers and payors in the United
States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare
costs, improving quality or expanding access. Current and future legislative proposals to further reform healthcare or reduce healthcare
costs may limit coverage of or lower reimbursement for the procedures associated with the use of our products. The cost containment measures
that payors and providers are instituting and the effect of any healthcare reform initiative implemented in the future could impact our
revenue from the sale of our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
implementation of the Affordable Care Act (the &#8220;ACA&#8221;) in the United States, for example, has changed healthcare financing
and delivery by both governmental and private insurers substantially, and affected medical device manufacturers significantly. The ACA,
among other things, provided incentives to programs that increase the federal government&#8217;s comparative effectiveness research,
and implemented payment system reforms including a national pilot program on payment bundling to encourage hospitals, physicians and
other providers to improve the coordination, quality and efficiency of certain healthcare services through bundled payment models. Additionally,
the ACA expanded eligibility criteria for Medicaid programs and created a new Patient-Centered Outcomes Research Institute to oversee,
identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research. Since its enactment,
there have been judicial, executive and political challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court
dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality
of the ACA. It is unclear how healthcare reform measures of the Biden administration or other efforts, if any, to challenge, repeal or
replace the ACA will impact the law or our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, other legislative changes have been proposed and adopted since the ACA was enacted. For example, the Budget Control Act of
2011, among other things, reduced Medicare payments to providers by 2% per fiscal year, effective on April 1, 2013 and, due to subsequent
legislative amendments to the statute, will remain in effect through 2030, with the exception of a temporary suspension from May 1, 2020
through March 31, 2021, unless additional Congressional action is taken. Additionally, the American Taxpayer Relief Act of 2012, among
other things, further reduced Medicare payments to several providers, including hospitals, and increased the statute of limitations period
for the government to recover overpayments to providers from three to five years. The Medicare Access and CHIP Reauthorization Act of
2015 repealed the formula by which Medicare made annual payment adjustments to physicians and replaced the former formula with fixed
annual updates and a new system of incentive payments that began in 2019 that are based on various performance measures and physicians&#8217;
participation in alternative payment models, such as accountable care organizations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect additional state and federal healthcare reform measures to be adopted in the future, any of which could limit the amounts that
federal and state governments will pay for healthcare products and services, which could result in reduced demand for our products or
additional pricing pressure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Data
Privacy and Security Laws</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Numerous
state, federal and foreign laws, including consumer protection laws and regulations, govern the collection, dissemination, use, access
to, confidentiality and security of personal information, including health-related information. In the United States, numerous federal
and state laws and regulations, including data breach notification laws, health information privacy and security laws, including HIPAA,
and federal and state consumer protection laws and regulations (e.g., Section 5 of the FTC Act), that govern the collection, use, disclosure,
and protection of health-related and other personal information could apply to our operations or the operations of our partners. In addition,
certain state and non-U.S. laws, such as the CCPA, the CPRA and the GDPR, govern the privacy and security of personal information, including
health-related information in certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other
in significant ways and may not have the same effect, thus complicating compliance efforts. Failure to comply with these laws, where
applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation. Privacy and security
laws, regulations, and other obligations are constantly evolving, may conflict with each other to complicate compliance efforts, and
can result in investigations, proceedings, or actions that lead to significant civil and/or criminal penalties and restrictions on data
processing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
Europe, the GDPR went into effect on May 25, 2018 and introduces strict requirements for processing the personal data of European Union
data subjects. Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory
enforcement of data protection requirements and potential fines for noncompliance of up to &#8364;20 million or 4% of the annual global
revenues of the preceding financial year of the noncompliant company, whichever is greater.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Among
other requirements, the GDPR regulates transfers of personal data subject to the GDPR to third countries that have not been found to
provide adequate protection to such personal data, including the United States, and the efficacy and longevity of current transfer mechanisms
between the EU and the United States remains uncertain. For example, in 2016, the EU and United States agreed to a transfer framework
for data transferred from the EU to the United States, called the Privacy Shield, but the Privacy Shield was invalidated in July 2020
by the Court of Justice of the European Union.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
from January 1, 2021, companies have to comply with the GDPR and also the United Kingdom General Data Protection Regulation, or the UK
GDPR, which, together with the amended UK Data Protection Act 2018, retains the GDPR in UK national law. The UK GDPR mirrors the fines
under the GDPR, i.e., fines up to the greater of &#8364;20 million (&#163;17.5 million) or 4% of global turnover. The relationship between
the United Kingdom and the European Union in relation to certain aspects of data protection law remains unclear, and it is also unclear
how United Kingdom data protection laws and regulations will develop in the medium to longer term, and how data transfers to and from
the United Kingdom will be regulated in the long term. Currently there is a four- to six-month grace period agreed in the EU and United
Kingdom Trade and Cooperation Agreement, ending June 30, 2021 at the latest, while the parties discuss an adequacy decision. The European
Commission published a draft adequacy decision on February 19, 2021. If adopted, the decision will enable data transfers from EU member
states to the United Kingdom for a four-year period, subject to subsequent extensions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Environmental
Matters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on our current operations, environmental protection requirements do not have a significant financial and operational effect on the capital
expenditures, earnings and competitive position of our Company in the current financial year and are not expected to have a significant
effect in the reasonably foreseeable future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Manufacturing
Services Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 21, 2020, the Company entered into a Manufacturing Services Agreement with GMI Corporation (&#8220;GMI&#8221;), dated as of August
21, 2020 (&#8220;MSA&#8221;), for the manufacture and supply of the Company&#8217;s IB-STIM device based upon the Company&#8217;s product
specifications as set forth in the MSA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company provides the necessary equipment to GMI and retains ownership. GMI bears the risk of loss of and damage to the equipment and
consigned materials. Performance under the MSA is initiated by orders issued by the Company and accepted by GMI.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
initial term of the MSA was 24 months and automatically renews for terms of twelve months unless either party provides a written termination
notice to the other party within 180 days prior to the end of the then-current term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GMI
was established in 1990 and manufactures our IB-Stim device in its 69,000 square foot facility that including offices, factory, environmentally
controlled room, warehouse, parts processing, assembly, quality control, of which approximately 1,000 square feet is dedicated to producing
our product, located in Indiana.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
controlled, repeatable, monitored production process, GMI has kit production capacity that is sufficient for all our projected needs.
There is a new, dedicated, environmentally controlled build room built in 2022 for our equipment and production. All of our material
are now maintained in this room.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GMI
has a quality management system that is ISO 13485:2016 certified, FDA registered, and ITAR registered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the MSA, the Company entered into a quality agreement with GMI, dated as of August 24, 2020, for GMI to test product
provided by the Company and perform quality assurance services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employees</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, we had 19 full-time employees.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_003"></span>ITEM
1A. RISK FACTORS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Relating to Our Business and Our Product</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
business and prospects depend entirely on our current product, IB-Stim. Even though we have received FDA clearance for our product, it
will remain subject to ongoing regulatory review. If we are unable to maintain regulatory clearance and commercialize our product or
are significantly delayed or limited in our commercialization efforts, our business and prospects will be materially harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Almost
all of our revenues have been derived from sales and royalties from sales of IB-Stim, and we expect to develop, market, and sell other
neuromodulation therapy devices for the treatment of chronic and debilitating conditions in children. The commercial success of our products
and our ability to generate and maintain revenues from the sale of our products will depend on a number of factors, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to develop
    and obtain additional regulatory clearances and further commercialize our products for additional indications;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to expand into
    new markets and future indications;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the acceptance of our products
    by patients and the healthcare community, including physicians and third-party payers (both private and governmental), as therapeutically
    effective and safe;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the accomplishment of various
    scientific, engineering, clinical, regulatory and other goals, which we sometimes refer to as milestones, on our anticipated timeline;</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the relative cost, safety
    and efficacy of alternative therapies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to obtain and
    maintain sufficient coverage or reimbursement by private and governmental third-party payers and to comply with applicable health
    care laws and regulations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the ability of our third-party
    manufacturers to manufacture our products in sufficient quantities with acceptable quality;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to provide
    marketing, distribution and customer support for our products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the potential presence
    of competitive products in our active indications;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">results of future clinical
    studies relating to our products or other competitor products for similar indications;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">compliance with applicable
    laws and regulatory requirements;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the maintenance of our
    existing regulatory clearance; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the consequences of any
    reportable adverse events involving our products.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, the promotion of our products is limited to approved indications, which vary by geography. The labelling for our device in
the U.S. is limited in certain respects, which may limit the number of patients to whom it is prescribed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to generate future revenues will also depend on achieving regulatory approval of, and eventual commercialization of, our products
for additional indications and in additional geographies, which is not guaranteed. Our near-term prospects are substantially dependent
on our ability to obtain regulatory approvals on the timetable we have anticipated, and thereafter to further successfully commercialize
our products for additional indications. Regulatory changes or actions in areas in which we operate or propose to operate may further
affect our ability to obtain regulatory clearances on our anticipated timetable. If we are not able to receive such approvals, meet other
anticipated milestones, or further commercialize our products, or are significantly delayed or limited in doing so, our business and
prospects will be materially harmed and we may need to reduce expenses by delaying, reducing or curtailing the development of our products
and we may need to raise additional capital to fund our operations, which we may not be able to obtain on favorable terms, if at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>To
date, we have not generated any operating profits, and due to our long-term research and development efforts, we have a history of incurring
substantial operating losses.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
were founded in 2011 and have a history of incurring substantial operating losses. We anticipate continuing to incur significant costs
associated with developing and commercializing our products for approved indications including signal development, device hardware and
software development, product sales, marketing, manufacturing, and distribution expenses. We expect our research, development, and clinical
study expenses to increase in connection with our ongoing activities and as additional indications enter clinical development and as
we advance our product development. Our expenses could increase beyond expectations if, for example, we are required by the FDA, or other
regulatory agencies or similar governing bodies, to change manufacturing processes for our products or to perform clinical, nonclinical
or other types of studies in addition to those that we currently anticipate. Our revenues are dependent, in part, upon the size of the
markets in the jurisdictions in which we receive regulatory approval, the accepted price for our products and the ability to obtain reimbursement
at the accepted applicable price. If the number of addressable patients is not as significant as we or our strategic partners and licensees
estimate, the indications approved by regulatory authorities are narrower than we expect or the eligible population for treatment is
narrowed by competition, regulatory approvals, physician choice or treatment guidelines, we may not generate significant revenues. If
we are not able to generate significant revenues, we may never be sustainably profitable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
clinical studies could be delayed or otherwise adversely affected by many factors, including difficulties in enrolling patients.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
testing can be costly and take many years, and the outcome is uncertain and susceptible to varying interpretations. Moreover, success
in pre-clinical and early clinical studies does not ensure that large-scale studies will be successful or predict final results. Acceptable
results in early studies may not be replicable in later studies. A number of companies in therapeutics industries have suffered significant
setbacks in advanced clinical studies, even after promising results in earlier studies. Negative or inconclusive results or adverse events
or incidents during a clinical study could cause the clinical study to be redone or terminated. In addition, failure to appropriately
construct clinical studies could result in high rates of adverse events or incidents, which could cause a clinical study to be suspended,
redone or terminated. Our failure or the failure of third-party participants in our studies to comply with their obligations to follow
protocols and/or legal requirements may also result in our inability to use the affected data in our submissions to regulatory authorities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
timely completion of clinical studies depends, among other things, on our ability to enroll a sufficient number of patients who remain
in the study until its conclusion. We may experience difficulties in patient enrollment in our clinical studies for a variety of reasons,
including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the severity of the disease
    under investigation;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the limited size and nature
    of the patient population;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the patient eligibility
    criteria defined in our protocol and other clinical study protocols;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the nature of the study
    protocol, including the attractiveness of, or the discomforts and risks associated with, the treatments received by enrolled subjects;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulties and delays
    in clinical studies that may occur as a result of the COVID-19 pandemic;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the ability to obtain IRB
    approval at clinical study locations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinicians&#8217; and patients&#8217;
    perceptions as to the potential advantages, disadvantages and side effects of our products in relation to other available therapies,
    including any new drugs or treatments that may be approved for the indications we are pursuing;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">availability of other clinical
    studies that exclude use of our products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the possibility or perception
    that enrolling in a product&#8217;s clinical study may limit the patient&#8217;s ability to enroll in future clinical studies for
    other therapies due to protocol restrictions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the possibility or perception
    that our software is not secure enough to maintain patient privacy;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patient referral practices
    of physicians;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the ability to monitor
    patients adequately during and after treatment;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the availability of appropriate
    clinical study investigators, support staff, drugs and other therapeutic supplies and proximity of patients to clinical sites;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">physicians&#8217; or our
    ability to obtain and maintain patient consents; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the risk that when we collaborate
    with a third-party for research of a product in a particular institution, we can expect to relinquish some or all of the control
    over the future success of that study to the third-party.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we have difficulty enrolling and retaining a sufficient number or diversity of patients to conduct our clinical studies as planned, or
encounter other difficulties, we may need to delay, terminate or modify ongoing or planned clinical studies, any of which would have
an adverse effect on our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
we are unable to develop an adequate sales and marketing organization or contract with third parties to assist us, we may not be able
to successfully commercialize our products for current and future indications.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
achieve commercial success for our products, we must compliantly develop and grow our sales and marketing organization and, as necessary,
enter into sales and distribution relationships with third parties to market and sell our products. Developing and managing a sales and
marketing organization is a difficult, expensive and time consuming process. We may not be able to successfully develop adequate sales
and marketing capabilities to achieve our growth objectives. We compete with other medical device, pharmaceutical and life sciences companies
to recruit, hire, train and retain the sales and marketing personnel that we anticipate we will need, and the nature of our products
may make it more difficult to compete for sales and marketing personnel. In addition, because our current products require, and we anticipate
our future products will require, physician training and education, our sales and marketing organization may need to grow substantially
as we expand our approved indications and markets. As a consequence, our expenses associated with building up and maintaining our sales
force and marketing capabilities may be disproportionate to the revenues we may be able to generate on sales of our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to establish adequate sales and marketing capabilities or successful sales and distribution relationships, we may fail
to realize the full revenue potential of our products for current and future indications, and we may not be able to achieve the necessary
growth in a cost-effective manner or realize a positive return on our investment. In our future sales and distribution agreements with
other companies, we generally may not have control over the resources or degree of effort that any of these third parties may devote
to our products, and if they fail to devote sufficient time and resources to the marketing of our products, or if their performance is
substandard, our revenues may be adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 37; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
success of our business may be dependent on the actions of our collaborative partners.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business strategy includes, in part, the consummation of collaborative arrangements with companies who will support the development and
commercialization of our products and technology. We may also enter into clinical collaborations with third parties to test our products
and technology together with other products and technologies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
we collaborate with a third party for commercialization of a product in a particular territory, we can expect to relinquish some or all
of the control over the future success of that product to the third party in that territory. In addition, our collaborative partners
may have the right to terminate applicable agreements, including payment obligations, prior to or upon the expiration of the agreed-upon
terms. We may not be successful in establishing or maintaining collaborative arrangements on acceptable terms or at all, collaborative
partners may terminate funding before completion of projects, our products may not achieve the criteria for milestone payments, our collaborative
arrangements may not result in successful product commercialization, our products may not receive acceptable pricing and we may not derive
any revenue from such arrangements. Additionally, our collaborators may not perform their obligations as expected or in compliance with
study protocols or applicable laws. Acts or omissions by collaborators may disqualify study data for use in regulatory submissions and/or
create liability for us in the jurisdictions in which we operate. Any disagreements with collaborators, including disagreements over
proprietary rights, contract interpretation or the preferred course of commercialization, might cause delays or termination of the commercialization
of products, might lead to additional responsibilities for us with respect to commercializing products, or might result in litigation
or arbitration, any of which would be time-consuming and expensive. To the extent that we are not able to develop and maintain collaborative
arrangements, we would need to devote substantial capital to undertake commercialization activities on our own in order to further expand
our reach, and we may be forced to limit the territories in which we commercialize our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be successful in achieving market acceptance of our products by healthcare professionals, patients and/or third-party payers
in the timeframes we anticipate, or at all, which could have a material adverse effect on our business, prospects, financial condition
and results of operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not achieve market acceptance of our products for current or future indications within the timeframes we have anticipated, or at
all, for a number of different reasons, including the following factors:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">it may be difficult to
    gain broad acceptance of our products because they are new technologies and involve a novel or derivative mechanism of action and,
    as such, physicians may be reluctant to prescribe our products without prior experience or additional data or training;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">physicians may be reluctant
    to prescribe our products due to their perception that the supporting clinical study designs have limitations, as they are, for example,
    unblinded;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">physicians at large academic
    universities and medical centers may prefer to enroll patients into clinical studies instead of prescribing our products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">it may be difficult to
    gain broad acceptance at community hospitals where the number of patients seeking treatment may be more limited than at larger medical
    centers, and such community hospitals may not be willing to invest in the resources necessary for their physicians to become trained
    to use our products, which could lead to reluctance to prescribe our products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patients may be reluctant
    to use our products for various reasons, including a perception that the treatment is untested or difficult to use or a perception
    that our software is not secure;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our products may have side
    effects and our products cannot be worn in all circumstances; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each patient will use more
    than one device and therefore, as the duration of the treatment course increases, the overall price will increase correspondingly
    and, when used in combination with other treatments, the overall cost of treatment will be greater than using a single type of treatment.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
particular, our products may not achieve market acceptance for current or future indications because of the following additional factors:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">achieving patient acceptance
    could be difficult because not all patients are willing to comply with requirements of treatment with our products, and other patients
    may forego our products for financial, privacy, cosmetic, visibility or mobility reasons;</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 38; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">achieving patient compliance
    may be difficult because the recommended use of our products is 120 hours per week for three (3) consecutive weeks, and not to exceed
    four (4) weeks, which to some extent restricts physical mobility because our products cannot be worn in all circumstances, and the
    patient or a caregiver must ensure that it remains continuously operable and this may also impact the pool of patients to whom physicians
    may be willing to prescribe our products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">there may be certain perceived
    limitations to our study designs or data obtained from our clinical studies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">efficacy may also be limited
    in instances where patients take a break from the device when experiencing skin rashes, or while bathing or swimming (because our
    products should not be immersed in water); and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patients may decline therapy
    or prescribers may be unwilling to prescribe our products due to certain adverse events attributable to the device reported in clinical
    studies by patients treated with our products.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, even if we are successful in achieving market acceptance of our products for IBS or other indications, we may be unsuccessful
in achieving market acceptance of our products for other indications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
may be other factors that are presently unknown to us that also may negatively impact our ability to achieve market acceptance of our
products. If we do not achieve market acceptance of our products in the timeframes we anticipate, or are unable to achieve market acceptance
at all, our business, prospects, financial condition and results of operations could be materially adversely affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Failure
to secure and maintain adequate coverage and reimbursement from third-party payers could adversely affect acceptance of our products
and reduce our revenues.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect that the majority of our revenues will come from third-party payers, primarily children&#8217;s hospitals, either directly to
us in markets where we provide our products or plan to provide our device candidates to patients or indirectly via payments made to hospitals
or other entities providing our products or which may in the future provide our device candidates to patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the U.S., private payers cover the largest segment of the population, with the remainder either uninsured or covered by governmental
payers. The majority of the third-party payers outside the U.S. are government agencies, government sponsored entities or other payers
operating under significant regulatory requirements from national or regional governments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third-party
payers may decline to cover and reimburse certain procedures, supplies or services. Additionally, some third-party payers may decline
to cover and reimburse our products for a particular patient even if the payer has a favorable coverage policy addressing our products
or previously approved reimbursement for our products. Additionally, private and government payers may consider the cost of a treatment
in approving coverage or in setting reimbursement for the treatment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Private
and government payers are increasingly challenging the prices charged for medical products and services. Additionally, the containment
of healthcare costs has become a priority of governments. Adoption of additional price controls and cost-containment measures, and adoption
of more restrictive policies in jurisdictions with existing controls and measures, could further limit our revenues and operating results.
If third-party payers do not consider our products or the combination of our products with additional treatments to be cost-justified
under a required cost-testing model, they may not cover our products for their populations or, if they do, the level of reimbursement
may not be sufficient to allow us to sell our products on a profitable basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reimbursement
for the treatment of patients with medical devices is governed by complex mechanisms. These mechanisms vary widely among countries, can
be informal, somewhat unpredictable, and evolve constantly, reflecting the efforts of these countries to reduce public spending on healthcare.
As a result, obtaining and maintaining reimbursement for the treatment of patients with medical devices has become more challenging.
We cannot guarantee that the use of our products will receive reimbursement approvals and cannot guarantee that our existing reimbursement
approvals will be maintained in any country.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
failure to secure or maintain adequate coverage or reimbursement for our products by third-party payers in the U.S. or in the other jurisdictions
in which we market our products could have a material adverse effect on our business, revenues and results of operations and cause our
stock price to decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 39; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be successful in maintaining reimbursement codes necessary to facilitate accurate and timely billing for our products or physician
services attendant to our products</i>.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third-party
payers, healthcare systems, government agencies or other groups often issue reimbursement codes to facilitate billing for products and
physician services used in the delivery of healthcare. Our technology specific CAT III CPT Code (0720T) was published on December 30,
2021 and effective on July 1, 2022. We may not be able to maintain the CPT code for physician services related to our products. Our future
revenues and results may be affected by the absence of CPT codes, as physicians may be less likely to prescribe the therapy when there
is no certainty that adequate reimbursement will be available for the time, effort, skill, practice expense and malpractice costs required
to provide the therapy to patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outside
the U.S., we have not secured codes to describe our products or to document physician services related to the delivery of therapy using
our products. The failure to obtain and maintain these codes could affect the future growth of our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may depend on single-source suppliers for some of our components. The loss of these suppliers could prevent or delay shipments of our
products, delay our clinical studies or otherwise adversely affect our business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
certain jurisdictions, we may source some of the components of our products from only a single vendor. If any one of these single-source
suppliers were to fail to continue to provide components to us on a timely basis, or at all, our business and reputation could be harmed.
We will seek and maintain second-source suppliers, but we can provide no assurance that we will secure or maintain such suppliers. We
have developed or are in the process of developing and obtaining regulatory approval for second sources for components in all jurisdictions.
Various steps must be taken before securing these suppliers, including qualifying these suppliers in accordance with regulatory requirements,
but we may never receive such approvals. The risks associated with the failure of our suppliers to comply with strictly enforced regulatory
requirements as described below are exacerbated by our dependence on single-source suppliers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we experience any deficiency in the quality of, delay in or loss of availability of any components supplied to us by third-party suppliers,
or if we switch suppliers or components, we may face additional regulatory delays and the manufacture and delivery of our products would
be interrupted for an extended period of time, which could materially adversely affect our business, prospects, financial condition and
results of operations. If we are required to obtain prior regulatory approval from the FDA or regulatory authorities or similar governing
bodies in other jurisdictions or to conduct a new conformity assessment procedure for our products, regulatory approval for our products
may not be received on a timely basis, or at all, which would have a material adverse effect on our business, prospects, financial condition
and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Quality
control problems with respect to devices and components supplied by third-party suppliers could have a material adverse effect on our
reputation, our clinical studies or the commercialization of our products and, as a result, a material adverse effect on our business,
prospects, financial condition and results of operations</i></b><i>.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
products, which are manufactured by third parties, are highly technical and are required to meet exacting specifications. Any quality
control problems that we experience with respect to the devices and components supplied by third-party suppliers could have a material
adverse effect on our reputation, our attempts to complete our clinical studies, our operating expenses or the commercialization of our
products. The failure of our suppliers to comply with strictly enforced regulatory requirements could expose us to regulatory action,
including warning letters, product recalls, suspension or termination of distribution, product seizures or civil penalties. If we experience
any delay in the receipt or deficiency in the quality of products supplied to us by third-party suppliers, or if we have to switch to
replacement suppliers, we may face additional regulatory delays and the manufacture and delivery of our products would be interrupted
for an extended period of time, which would materially adversely affect our business, prospects, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 40; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
currently do not own a manufacturing facility and rely on a sole manufacturer for the production of our product</i></b>.&#160;<b><i>Any
significant disruption to the sole manufacturer&#8217;s operations or facilities could have a material adverse effect on our business,
financial condition and results of operations</i></b>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely on a sole manufacturer for the production of our products. We do not have control over the operations of the facilities of the third-party
manufacturer that we use. A significant disruption to our manufacturer could have a material adverse effect on our business, financial
condition and results of operations. Our reliance on our manufacturer poses a number of risks, including lack of control over the manufacturing
process and ultimately over the quality and timing of delivery of our product. A change in our relationship with our manufacturer could
result in a material adverse effect on our business, financial condition and results of operations. A decision to change manufacturers
would result in longer times for design and production as we secure any necessary licenses or clearances, develop quality control measures,
and implement manufacturing processes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Continued
testing of our products may not yield successful results and could reveal currently unknown aspects or safety hazards associated with
our products</i></b><i>.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
research and development programs are designed to test the safety and efficacy of our products through extensive pre-clinical and clinical
testing. Even if our ongoing and future pre-clinical and clinical studies are completed as planned, we cannot be certain that their results
will support our claims or that the FDA and other regulatory authorities will agree with our conclusions. Success in pre-clinical studies
and early clinical studies does not ensure that later clinical studies will be successful, and we cannot be sure that the later studies
will replicate the results of prior studies and pre-clinical studies. The clinical study process may fail to demonstrate that our device
candidates are safe and effective for the proposed indicated uses, which could cause us to abandon a device candidate and may delay development
of others. It is also possible that patients enrolled in clinical studies will experience adverse side effects that have not been previously
observed. In addition, our pre-clinical and clinical studies for our device candidates involve a relatively small patient population
and, as a result, these studies may not be indicative of future results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may experience numerous unforeseen events during, or as a result of, the testing process that could delay or prevent further commercialization
of our products, including the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pre-clinical and clinical
    testing for our products may not produce the desired effect, may be inconclusive or may not be predictive of safety or efficacy results
    obtained in future clinical studies, following long-term use or in much larger populations;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unanticipated adverse events
    or other side effects that are not currently known may occur during our clinical studies that may preclude additional regulatory
    approval or result in additional limitations to commercial use if approved; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the data collected from
    our clinical studies may not reach statistical significance or otherwise not be sufficient to support FDA or other regulatory approval.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
unacceptable side effects arise in the development of our products for future indications, we could suspend or terminate our clinical
studies or the FDA or other regulatory authorities could order us to cease clinical studies or deny approval of our device candidates
for any or all targeted indications, narrow the approved indications for use or otherwise require restrictive product labeling or marketing
or require further clinical studies, which may be time-consuming and expensive and may not produce results supporting FDA or other regulatory
approval of our products in a specific indication. Treatment-related side effects could also affect patient recruitment or the ability
of enrolled patients to complete the study or result in potential product liability claims. In addition, these side effects may not be
appropriately recognized or managed by the treating medical staff. We expect to have a need to train medical personnel using our devices
for clinical studies and upon any commercialization of our products for future indications. Inadequate training in recognizing or managing
the potential side effects of our products could result in patient injury or death. Any of these occurrences may harm our business, prospects
and financial condition significantly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
delay or termination of our clinical studies will delay the filing of submissions for regulatory approvals of our products and ultimately
our ability to commercialize our products and generate revenues. Furthermore, we may abandon our products for indications that we previously
believed to be promising. Any of these events could have a material adverse effect on our business, prospects, financial condition and
results of operations and cause our stock price to decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 41; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>As
we expand, we may experience difficulties managing our growth</i></b>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
anticipated growth will place a significant strain on our management and on our operational and financial resources and systems. We could
face challenges inherent in efficiently managing a more complex business with an increased number of employees over large geographic
distances, including the need to implement appropriate systems, policies, benefits and compliance programs. Failure to manage our growth
effectively could materially adversely affect our business. Additionally, our anticipated growth will increase the demands placed on
our third-party suppliers, resulting in an increased need to carefully monitor the available supply of components and services and to
scale up our quality assurance programs. There is no guarantee that our suppliers will be able to support our anticipated growth. Any
failure by us to manage our growth effectively could have an adverse effect on our ability to achieve our development and commercialization
goals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
size and expected growth of our available market has not been established with precision and may be smaller than we estimate.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
data on the available market for our current products and future products is based on a number of internal and third-party research reports,
estimates and assumptions. While we believe that such research, our assumptions and the data underlying our estimates are reasonable,
these assumptions and estimates may not be correct. In addition, the statements in this prospectus relating to, among other things, the
expected growth in the market for our IB-Stim are based on a number of internal and third-party data, estimates and assumptions, and
may prove to be inaccurate. If the actual number of consumers who would benefit from our products, the price at which we can sell future
products or the available market for our products is smaller than we estimate, it could have a material adverse effect on our business,
financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
physicians and patients do not accept our current and future products or if the market for indications for which any product candidate
is approved is smaller than expected, we may be unable to generate significant revenue, if any.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
when any of our product candidates obtain regulatory approval, they may not gain market acceptance among physicians, patients, and third-party
payers. Physicians may decide not to recommend our treatments for a variety of reasons including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">timing of market introduction
    of competitive products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">demonstration of clinical
    safety and efficacy compared to other products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">cost-effectiveness;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">limited or no coverage
    by third-party payers;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">convenience and ease of
    administration;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">prevalence and severity
    of adverse side effects;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions in the label
    of the device;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other potential advantages
    of alternative treatment methods; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ineffective marketing and
    distribution support of its products.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of our product candidates is approved but fails to achieve market acceptance or such market is smaller than anticipated, we may not
be able to generate significant revenue and our business would suffer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Because
of the specialized nature of our business, the termination of relationships with our key employees, consultants and advisors may prevent
us from successfully operating our business, including developing our products, conducting clinical studies, commercializing our products
and obtaining any necessary financing</i></b><i>.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are highly dependent on the members of our executive team, the loss of whose services may adversely impact the achievement of our objectives.
While we have entered into employment agreements with each of our key executives, any of them could leave our employment at any time.
We do not have &#8220;key person&#8221; insurance on any of our employees. The loss of the services of one or more of our current employees
might impede the achievement of our business objectives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
competition for qualified personnel in the medical device fields is intense, and we rely heavily on our ability to attract and retain
qualified scientific, technical and managerial personnel. Our future success depends upon our ability to attract, retain and motivate
highly skilled employees. In order to commercialize our products successfully, we will be required to expand our workforce, particularly
in the areas of research and development and clinical studies, sales and marketing and supply chain management. These activities will
require the addition of new personnel and the development of additional expertise by existing management personnel. We face intense competition
for qualified individuals from numerous pharmaceutical, biopharmaceutical and biotechnology companies, as well as academic and other
research institutions. We may not be able to attract and retain these individuals on acceptable terms or at all. Failure to do so could
materially harm our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 42; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Customer
or third-party complaints or negative reviews or publicity about our company or our products could harm our reputation and brand.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are heavily dependent on customers who use our IB-Stim device to provide good reviews and word-of-mouth recommendations to contribute
to our growth. Customers who are dissatisfied with their experiences with our products or services may post negative reviews. We may
also be the subject of blog, forum or other media postings that include inaccurate statements and/or create negative publicity. In addition,
any negative news regarding similar products may adversely impact our business. Any negative reviews or publicity, whether real or perceived,
disseminated by word-of-mouth, by the general media, by electronic or social networking means or by other methods, could harm our reputation
and brand and could severely diminish consumer confidence in our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Adverse
global economic conditions could have a negative effect on our business, results of operations and financial condition and liquidity.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
general slowdown in the global economy, including a recession, or in a particular region or industry, an increase in trade tensions with
U.S. trading partners, inflation or a tightening of the credit markets could negatively impact our business, financial condition and
liquidity. Adverse global economic conditions have from time to time caused or exacerbated significant slowdowns in the industries and
markets in which we operate, which have adversely affected our business and results of operations. Macroeconomic weakness and uncertainty
also make it more difficult for us to accurately forecast revenue, gross profit and expenses, and may make it more difficult to raise
or refinance debt. Sustained uncertainty about, or worsening of, current global economic conditions and further escalation of trade tensions
between the U.S. and its trading partners, could result in a global economic slowdown and long-term changes to global trade. Such events
may also (i) cause our customers and consumers to reduce, delay or forgo spending, (ii) result in customers sourcing products from other
suppliers not subject to such restrictions or tariffs, (iii) lead to the insolvency or consolidation of key suppliers and customers,
and (iv) intensify pricing pressures. Any or all of these factors could negatively affect demand for our products and our business, financial
condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
economic conditions in certain regions may also be affected by natural disasters and public health emergencies, such as extreme weather
events, and could have a significant adverse effect on our business, including interruption of our commercial and clinical operations,
supply chain disruption, endangerment of our personnel, fewer patient visits, increased patient drop-out rates, delays in recruitment
of new patients, and other delays or losses of materials and results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
COVID-19 pandemic could materially adversely impact our business</i></b>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the COVID-19 pandemic continues around the globe, we have experienced and will likely continue to experience disruptions that could severely
impact our business and clinical studies, which could include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays and/or difficulties
    in onboarding active patients and enrolling patients in our clinical studies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays and/or difficulties
    in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">declines in prescriptions
    written due to a perception that our products are difficult to administer remotely or if patients are unwilling to travel to treatment
    sites or receive in-home treatment assistance from us or other caregivers;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reductions in third-party
    reimbursements, which could materially affect our revenue, as most of our patients rely on third-party payers to cover the cost of
    our products and a material number of our patients could lose access to their private health insurance plan if they or someone in
    their family lose their job;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">diversion of healthcare
    resources away from conducting clinical studies, including the diversion of hospitals serving as our clinical study sites and hospital
    staff supporting the conduct of our clinical studies;</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 43; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">interruption of key clinical
    study activities, such as clinical study site monitoring, due to limitations on travel imposed or recommended by federal or state
    governments, employers and others;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">staff disruptions and turnover
    internally and at treatment sites and third-party providers who provide support, either directly as a result of illness or indirectly
    as a result of vaccine mandates and other changes in terms of employment;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in receiving approval
    from local regulatory authorities or IRBs to initiate our planned clinical studies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in clinical sites
    receiving the supplies and materials needed to conduct our clinical studies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">interruption in shipping
    that may affect the transport of active patient and clinical study materials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in local regulations
    as part of a response to the COVID-19 outbreak that may require us to change the ways in which our clinical studies are conducted,
    which may result in unexpected costs, or to discontinue the clinical studies altogether;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays in necessary interactions
    with local regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or
    forced furlough of government employees;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disruption of our supply
    chain as our suppliers and common carriers are unable to meet our requirements to provide us the materials we need for clinical study
    and active patient care needs;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">indirect consequences of
    the COVID-19 pandemic on the economy in general, such as an increase in bankruptcies of our key suppliers, or the inability of our
    third-party payers to meet their obligations reimburse us in a timely fashion or at all;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">postponements and cancellations
    of key conferences and meetings and travel restrictions could interfere with our ability to interact with key thought leaders in
    the field, leading to a disruption in the rate of adoption of our technology;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">access restrictions at
    offices, hospitals, and treatment centers, and stakeholder illness could interfere with the ability of our sales force to engage
    in face-to-face visits with providers, leading to a disruption in the rate of adoption of our technology;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">increases in expenditures
    for technology and other tools necessary to provide patient care in an environment where both patient and care-giver travel is restricted
    and access to in-person interaction is limited;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal of the FDA to accept
    data from clinical studies in affected geographies outside the United States; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patient delays in seeking
    or receiving treatment, either due to fear of infection or lack of access to treatment and study sites, leading to fewer diagnoses
    of the indications our products are approved to treat or more advanced procession of the disease, which may contraindicate the use
    of our products or disqualify the patient from participating in a given study.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
global status of the COVID-19 pandemic continues to rapidly evolve. The extent to which the pandemic may impact our business and clinical
studies will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate
geographic spread of the disease, the duration of the pandemic, travel restrictions and social distancing guidelines, business closures
or business disruptions and the effectiveness of actions taken to contain and treat the disease. The response to the pandemic may result
in permanent changes to the environment in which we operate as described above in ways we are unable to predict. The COVID-19 pandemic
may also have the effect of heightening many of the other risks described herein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Developing
medical technology entails significant technical, regulatory and business risks</i></b>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may fail to adapt our technology to user requirements or emerging treatment standards. Neuromodulation therapies are not currently considered
standard of care for IBS and may not ever be considered standard of care. Treatment standards may not evolve to incorporate our product.
New industry standards for the development, manufacture and marketing of medical devices may evolve and we may not be able to conform
to the changes, meet new standards in a timely fashion or maintain a competitive position in the market. In particular, regulatory standards
for electrical treatments of medical conditions are evolving. If we face material delays in introducing our products and new technology,
we may fail to attract new customers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
Company has an evolving business strategy and investors must be willing to accept a substantial degree of uncertainty.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s strategic focus is on the development of developing neuromodulation therapies to address chronic and debilitating conditions
in children. The Company may engage in ongoing discussions with potential licensees, other strategic partners and institutional or private
financing sources, the result of which could add to or alter its current strategic focus, cash needs or ownership structure. Investors
must be willing to accept a substantial degree of uncertainty and must be willing to rely upon the Company&#8217;s board of directors
and management to complete an appropriate business strategy to commercially exploit targeted business opportunities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 44; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be able to compete with treatments now being marketed and developed, or which may be developed and marketed in the future by
other companies.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
products will compete with existing and new therapies and treatments for chronic and debilitating conditions in children. We are aware
of a number of companies currently seeking to develop alternative therapies or treatment for such diseases and conditions at least in
part. Numerous pharmaceutical, biotechnology, drug delivery and medical device companies, hospitals, research organizations, individual
scientists, and nonprofit organizations are engaged in the development of alternatives to our technology. Some of these companies have
greater research and development capabilities, experience, manufacturing, marketing, financial, and managerial resources than we do.
Collaborations or mergers between large pharmaceutical or biotechnology companies with competing treatment technologies could enhance
our competitors&#8217; financial, marketing, and other resources. Developments by other medical device companies could make our products
or technologies uncompetitive or obsolete. Accordingly, our competitors may succeed in developing competing technologies, obtaining FDA
clearances and/or approval for products or gaining market acceptance more rapidly than we can.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Due
in part to our limited financial resources, we may fail to select or capitalize on the most scientifically, clinically or commercially
promising or profitable indications or therapeutic areas for our product candidates, and/or we may be unable to pursue the clinical trials
that we would like to pursue.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have limited technical, managerial, and financial resources to determine the indications on which we should focus the development efforts
related to our product candidates. Due to our limited available financial resources, we may have curtailed clinical development programs
and activities that might otherwise have led to more rapid progress of our product candidates through the regulatory and development
processes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may make incorrect determinations with regard to the indications and clinical trials on which to focus the available resources that we
do have. Furthermore, we cannot assure you that we will be able to retain adequate staffing levels to run our operations and/or to accomplish
all of the objectives that we otherwise would seek to accomplish. Our decisions to allocate our research, management, and financial resources
toward particular indications or therapeutic areas for our product candidates may not lead to the development of viable commercial products
and may divert resources from better opportunities. Similarly, our decisions to delay or terminate product development programs may also
cause us to miss valuable opportunities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
have material weaknesses in our internal control over financing reporting. If we fail to establish and maintain proper and effective
internal control over financial reporting, our operating results and our ability to operate our business could be harmed.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ensuring
that we have adequate internal financial and accounting controls and procedures in place so that we can produce accurate financial
statements on a timely basis is a costly and time-consuming effort that needs to be re-evaluated frequently. Our internal control
over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and
the preparation of financial statements in accordance with generally accepted accounting principles. Due to accounting resource
constraints, we have had limited review controls. These constraints have resulted in (1) a lack of segregation of duties, since we
have a limited administrative staff, (2) lack of internal controls structure review and (3) misapplication of U.S. GAAP. As a result
of these constraints and the restatement our unaudited financial statements as of and for the three and nine month periods ended
September 30, 2023, management concluded material weaknesses in our internal control over financial reporting existed as of December
31 2023 and, accordingly, our internal control over financial reporting and disclosure controls and procedures were not
effective as of such date. Specifically, management identified a material accounting error that understated extinguishment of debt
expense and net loss in the Statements of Operations and understated additional paid in capital in the Balance Sheet as of and for
the three and nine month periods ended September 30, 2023 as described and restated in Note 19 to the audited financial statements
included in this Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management is composed of a small number of individuals resulting in a situation where limitations on segregation of duties exist. All
responsibility for accounting entries and the creation of financial statements is held by a single person, though the Company engages
multiple accounting consultants for accounting, tax and audit support. To remedy this situation, we would need to hire additional staff
or financial consultant support. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 45; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
document, review and improve our internal controls and procedures for compliance with Section 404 of the Sarbanes-Oxley Act, which require
annual management assessment of the effectiveness of our internal control over financial reporting. To comply with the requirements of
being a public company, the Company has undertaken various actions, and will take additional actions, such as remediating the material
weaknesses described above, implementing additional internal controls and procedures and hiring internal audit staff or financial consultants.
Testing and maintaining internal controls can divert our management&#8217;s attention from other matters that are important to the operation
of our business. Additionally, when evaluating internal controls over financial reporting, the Company may identify additional material
weaknesses that it may not be able to remediate in time to meet the applicable deadline imposed upon us for compliance with the requirements
of Section 404 of the Sarbanes-Oxley Act. If the Company identifies any additional material weaknesses in its internal control over financial
reporting or is unable to remediate the material weakness described above or comply with the requirements of Section 404 of the Sarbanes-Oxley
Act in a timely manner or if the Company&#8217;s independent registered public accounting firm is unable to express an unqualified opinion
as to the effectiveness of our internal control over financial reporting once it is no longer an emerging growth company, or if the Company
is unable to conclude in our quarterly and annual reports that our disclosure controls and procedures are effective, investors may lose
confidence in the accuracy and completeness of the Company&#8217;s financial reports and the market price of our common stock could be
negatively affected, and the Company could become subject to investigations by the stock exchange on which our securities are listed,
the SEC or other regulatory authorities, which could require additional financial and management resources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if the Company fails to remediate any material weakness, including the material weaknesses described above, our financial statements
could be inaccurate and the Company could face restricted access to capital markets. Our small size and internal control deficiencies
may adversely affect our financial condition, results of operation and access to capital.&#160;<span style="background-color: white">Moreover,
our internal control over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well
designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Because
of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to
error or fraud will not occur or that all control issues and instances of fraud will be detected.</span>&#160;If we cannot provide reliable
financial reports or prevent fraud, we may not be able to manage our business as effectively as we would if an effective control environment
existed, and our business and reputation with investors may be harmed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Legal and Regulatory Matters</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Product
liability suits, whether or not meritorious, could be brought against us due to alleged defective devices or for the misuse of our products,
which could result in expensive and time-consuming litigation, payment of substantial damages and/or expenses and an increase in our
insurance rates</i></b><i>.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
our current or future devices are defectively designed or manufactured, contain defective components or are misused, or if someone claims
any of the foregoing, whether or not meritorious, we may become subject to substantial and costly litigation. For example, we may be
sued if our products cause or are perceived to cause injury or are found to be otherwise unsuitable during clinical testing, manufacturing,
marketing or sale. This may occur if our products are misused or damaged, have a sudden failure or malfunction (including with respect
to safety features) or are otherwise impaired due to wear and tear. Even absent a product liability suit, malfunctions of our products
or misuse by physicians or patients would need to be remedied swiftly in order to maintain continuous use and ensure efficacy of our
products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent
in the device, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection
acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required
to limit commercialization of our products. Even successful defense may require significant financial and management resources. Regardless
of the merits or eventual outcome, liability claims may result in:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">decreased demand for our
    products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injury to our reputation;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawal of clinical
    study participants and inability to continue clinical studies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">initiation of investigations
    by regulators;</span></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 46; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">costs to prepare for and
    defend the related litigation;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a diversion of management&#8217;s
    time and our resources;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">substantial monetary awards
    to study participants or patients;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product recalls, withdrawals
    or labeling, marketing or promotional restrictions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">loss of revenues;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exhaustion of any available
    insurance and our capital resources;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the inability to commercialize
    any device candidate; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a decline in our share
    price.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product
liability claims could divert management&#8217;s attention from our core business, be expensive to defend and result in sizable damage
awards against us. We may not have sufficient insurance coverage for all claims. Any product liability claims brought against us, with
or without merit, could increase our product liability insurance rates or prevent us from securing continuing coverage, could harm our
reputation in the industry and could reduce revenues. Product liability claims in excess of our insurance coverage would be paid out
of cash reserves, if any, which could have a material adverse effect on our business, prospects, financial condition and results of operations
and cause our stock price to decline. Even if our agreements with our third-party manufacturers and suppliers entitle us to indemnification
against losses, such indemnification may not be available or adequate should any claim arise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Other
future litigation and regulatory actions could have a material adverse impact on the Company</i></b><i>.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, we may be subject to litigation and other legal and regulatory proceedings relating to our business or investigations or
other actions by governmental agencies. No assurances can be given that the results of these or new matters will be favorable to us.
An adverse resolution of lawsuits, arbitrations, investigations or other proceedings or actions could have a material adverse effect
on our financial condition and results of operations, including as a result of non-monetary remedies. Defending ourselves in these matters
may be time-consuming, expensive and disruptive to normal business operations and may result in significant expense and a diversion of
management&#8217;s time and attention from the operation of our business, which could impede our ability to achieve our business objectives.
Additionally, any amount that we may be required to pay to satisfy a judgment, settlement, fine or penalty may not be covered by insurance.
Subject to the Delaware General Corporation Law, our certificate of incorporation permit us to indemnify any director against any liability,
to purchase and maintain insurance against any liability for any director and to provide any director with funds (whether by loan or
otherwise) to meet expenditures incurred or to be incurred by such director in defending any criminal, regulatory or civil proceedings
or in connection with an application for relief (or to enable any such director to avoid incurring such expenditure). In addition, under
our Articles of Incorporation and bylaws (the &#8220;Bylaws&#8221;) we are obligated to indemnify each of our directors and officers
against certain liabilities and expenses arising from their being a director or officer to the maximum extent permitted by Delaware law.
In the event we are required to make such payments to our directors and officers, there can be no assurance that any of these payments
will not be material.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are subject to consumer protection laws that regulate our marketing practices and prohibit unfair or deceptive acts or practices. Our
actual or perceived failure to comply with such obligations could harm our business, and changes in such regulations or laws could require
us to modify our products or marketing or advertising efforts.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the marketing or advertisement of our products, we could be the target of claims relating to false, misleading, deceptive
or otherwise noncompliant advertising or marketing practices, including under the auspices of the FTC and state consumer protection statutes.
If we rely on third parties to provide any marketing and advertising of our products, we could be liable for, or face reputational harm
as a result of, their marketing practices if, for example, they fail to comply with applicable statutory and regulatory requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are found to have breached any consumer protection, advertising, unfair competition or other laws or regulations, we may be subject
to enforcement actions that require us to change our marketing and business practices in a manner that may negatively impact us. This
could also result in litigation, fines, penalties and adverse publicity that could cause reputational harm and loss of customer trust,
which could have a material adverse effect on our business, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 47; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are increasingly dependent on information technology systems and are subject to privacy and security laws. Our products and our systems
and infrastructure face certain risks, including from cyber security breaches and data leakage</i></b><i>.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
increasingly rely upon technology systems and infrastructure. Our technology systems, including our products, are potentially vulnerable
to breakdown or other interruption by fire, power loss, system malfunction, unauthorized access and other events. Likewise, data privacy
breaches by employees and others with both permitted and unauthorized access to our products and our systems may pose a risk that protected
patient information (&#8220;PI&#8221;) may be exposed to unauthorized persons or to the public, or may be permanently lost. The increasing
use and evolution of technology, including cloud-based computing, creates additional opportunities for the unintentional dissemination
of information, intentional destruction of confidential information stored in our systems or in non-encrypted portable media or storage
devices. We could also experience a business interruption, information theft of confidential information, or reputational damage from
industrial espionage attacks, malware or other cyber incidents, which may compromise our system infrastructure or lead to data leakage,
either internally or at our third-party service providers or other business partners.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
size and complexity of our computer systems, and scope of our geographic reach, make us potentially vulnerable to information technology
system breakdowns, internal and external malicious intrusion, cyberattacks and computer viruses. Because the techniques used to obtain
unauthorized access, or to sabotage systems, change frequently and generally are not recognized until launched against a target, we may
be unable to anticipate these techniques or to implement adequate preventative measures. If we do not allocate and effectively manage
the resources necessary to build and sustain the proper technology infrastructure or properly manage third-party contractors who perform
data management services on our behalf, then a security breach could subject us to, among other things, transaction errors, business
process inefficiencies, the loss of customers, damage to our reputation, business disruptions or the loss of or damage to intellectual
property. Such security breaches could expose us to a risk of loss of information, litigation, penalties, remediation costs and potentially
significant liability to customers, employees, business partners and regulatory authorities, including, for example, under the Health
Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) in the United States and Regulation 2016/679 on the protection
of natural persons with regard to the processing of personal data and on the free movement of such data under GDPR in the EU. If our
data management systems (including third party data management systems) do not effectively collect, secure, store, process and report
relevant data for the operation of our business, whether due to equipment malfunction or constraints, software deficiencies, or human
error, our ability to effectively plan, forecast and execute our business plan and comply with applicable laws and regulations will be
impaired. Any such impairment could materially and adversely affect our financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we have invested heavily in the protection of data and information technology and in related training, there can be no assurance that
our efforts will prevent significant breakdowns, breaches in our systems or other cyber incidents or ensure compliance with all applicable
security and privacy laws, regulations, and standards, including with respect to third-party service providers that utilize sensitive
personal information, including PI, on our behalf.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
security breach, whether of our products, systems or third-party hosting services we utilize, could disrupt treatments being provided
by our products, disrupt access to our customers&#8217; stored information, such as patient treatment data and health information, and
could lead to the loss of, damage to or public disclosure of such data and information, including patient health information. Such an
event could have serious negative consequences, including possible patient injury, regulatory action, fines, penalties and damages, reduced
demand for our products, an unwillingness of customers to use our products, harm to our reputation and brand and time-consuming and expensive
litigation, any of which could have a material adverse effect on our financial results. We currently carry cyber and privacy liability
insurance with an aggregate limit of $1,000,000, but the amount of insurance coverage that we purchased and may purchase in the future
may be inadequate. In the future, our insurance coverage may be expensive or not be available on acceptable terms or in sufficient amounts,
if at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 48; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may choose to, or may be required to, suspend, repeat or terminate our clinical studies if they are not conducted in accordance with
regulatory requirements, the results are negative or inconclusive or the studies are not well designed</i></b><i>.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
studies must be conducted in accordance with the FDA&#8217;s cGCPs and the equivalent laws and regulations applicable in other jurisdictions
in which the clinical studies are conducted. The clinical studies are subject to oversight by the FDA, regulatory agencies in other jurisdictions,
ethics committees and institutional review boards at the medical institutions where the clinical studies are conducted. In addition,
clinical studies must be conducted with device candidates produced under the FDA&#8217;s QSR and in accordance with the applicable regulatory
requirements in the other jurisdictions in which the clinical studies are conducted. The conduct of clinical studies may require large
numbers of test patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA or regulatory agencies in other jurisdictions might delay or terminate our clinical studies of a device candidate for various reasons,
including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the device candidate may
    have unforeseen adverse side effects or may not appear to be more effective than current therapies;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we may not agree with the
    FDA, a regulatory authority in another jurisdiction or an ethics committee regarding the protocol for the conduct of a clinical study;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">new therapies may become
    the standard of care while we are conducting our clinical studies, which may require us to revise or amend our clinical study protocols
    or terminate a clinical study; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fatalities may occur during
    a clinical study due to medical problems that may or may not be related to clinical study treatments.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furthermore,
the process of obtaining and maintaining regulatory approvals in the U.S. and other jurisdictions is lengthy, expensive and uncertain.
It can vary substantially, based on the type, complexity and novelty of the product involved. Accordingly, any of our device candidates
could take a significantly longer time than we expect to, or may never, gain regulatory approval, which could have a material adverse
effect on our business, prospects, financial condition and results of operations and cause our stock price to decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Legislative
and regulatory changes in the U.S. and in other countries regarding healthcare insurance and government-sponsored reimbursement programs
(such as Medicare in the United States) may adversely affect our business and financial results</i></b>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
rely to a material degree on highly regulated private and government-run health insurance programs for our revenue in most of the countries
in which we operate. The laws and regulations regarding health care programs, both public and private, are driven by public policy considerations
that may be unrelated to the direct provision of patient care, such as lowering costs or requiring or limiting access to healthcare options.
These laws and regulations are very complicated and there are many requirements we must satisfy in order for our products to become and
remain eligible for reimbursement under these programs. In many cases we may have limited negotiating power when negotiating reimbursement
rates for our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the future, lawmakers and regulators could also pass additional healthcare laws and implement other regulatory changes at both the national
and local levels. These laws and regulations could potentially affect coverage and reimbursement for our products. However, we cannot
predict the ultimate content, timing or effect of any future healthcare initiatives or the impact any future legislation or regulation
will have on us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
respect to countries outside the U.S., the national competent authorities in the EU member states, the UK, Switzerland, Israel, Japan,
and other jurisdictions are also increasingly active in their goal of reducing public spending on healthcare. We cannot, therefore, guarantee
that the treatment of patients with our products would be reimbursed in any particular country or, if successfully included on reimbursement
lists, whether we will remain on such lists.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are subject to extensive post-marketing regulation by the FDA and comparable authorities in other jurisdictions, which could impact the
sales and marketing of our products and could cause us to incur significant costs to maintain compliance. In addition, we may become
subject to additional regulation in other jurisdictions if we market and sell our products outside of the U.S</i></b><i>.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
market and sell our products subject to extensive regulation by the FDA and numerous other federal, state and governmental authorities
in other jurisdictions. These regulations are broad and relate to, among other things, the conduct of pre-clinical and clinical studies,
product design, development, manufacturing, labeling, testing, product storage and shipping, premarket clearance and approval, conformity
assessment procedures, premarket clearance and approval of modifications introduced in marketed products, post-market surveillance and
monitoring, reporting of adverse events and incidents, pricing and reimbursement, interactions with healthcare professionals, interactions
with patients, information security, advertising and promotion and product sales and distribution. Although IB-Stim already has market
clearance from FDA for functional abdominal pain associated with IBS in children, we will require additional FDA clearances to market
our products for treating other indications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 49; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, before our products can be marketed in the EU, our products must obtain a CE Certificate from a notified body. New intended
uses of CE marked medical devices falling outside the scope of the current CE Certificate require a completely new conformity assessment
before the device can be CE marked and marketed in the EU for the new intended use. The process required to gather necessary information
and draw up documentation in order to obtain CE Certification of a medical device in the EU can be expensive and lengthy and its outcome
can be uncertain. We may make modifications to our products in the future that we believe do not or will not require notifications to
our notified body or new conformity assessments to permit the maintenance of our current CE Certificate. If the competent authorities
of the EU member states or our notified body disagree and require the conduct of a new conformity assessment, the modification of the
existing CE Certificate or the issuance of a new CE Certificate, we may be required to recall or suspend the marketing of the modified
versions of our products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
Japan, new medical devices or new therapeutic uses of medical devices falling outside the scope of the existing approval by the MHLW
require a new assessment and approval for each such new device or use. Accordingly, we may be required to obtain a new approval from
MHLW before we launch a modified version of our products or the use of our products for additional indications. Approval time frames
from the MHLW vary from simple notifications to review periods of one or more years, depending on the complexity and risk level of the
device. In addition, importation into Japan of medical devices is subject to &#8220;Quality Management System (QMS) Ordinance,&#8221;
which includes the equivalent of &#8220;Good Import&#8221; regulations in the U.S. As with any highly regulated market, significant changes
in the regulatory environment could adversely affect our ability to commercialize our products in Japan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the U.S. and other jurisdictions, we also are subject to numerous post-marketing regulatory requirements, which include regulations under
the QSR related to the manufacturing of our products, labeling regulations and medical device reporting regulations, which require us
to report to the FDA or comparable regulatory authorities in other jurisdictions and our notified body if our products cause or contributes
to a death or serious injury, or malfunction in a way that would likely cause or contribute to a death or serious injury. In addition,
these regulatory requirements may in the future change in a way that adversely affects us. If we fail to comply with present or future
regulatory requirements that are applicable to us, we may be subject to enforcement action by the FDA or comparable regulatory authorities
in other jurisdictions and notified bodies, which may include any of the following sanctions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">untitled letters, warning
    letters, fines, injunctions, consent decrees and civil penalties;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unanticipated expenditures
    to address or defend such actions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">patient notification, or
    orders for repair, replacement or refunds;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">voluntary or mandatory
    recall, withdrawal or seizure of our current or future devices;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">administrative detention
    by the FDA or other regulatory authority in another jurisdiction of medical devices believed to be adulterated or misbranded;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">operating restrictions,
    suspension or shutdown of production;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal or delay of our
    requests for approval for new intended uses for or modifications to our products or for approval of new devices;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal or delay in obtaining
    CE Certificates for new intended uses for or modifications to our products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension, variation or
    withdrawal of the CE Certificates granted by our notified body in the EU;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">prohibition or restriction
    of products being placed on the market;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">operating restrictions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension or withdrawal
    of approvals that have already been granted;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal to grant export
    approval for our products or any device candidates; or</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">criminal prosecution.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
occurrence of any of these events could have a material adverse effect on our business, prospects, financial condition and results of
operations and cause our stock price to decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 50; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Over
time, we expect to make modifications to our products that are designed to improve efficacy, reduce side effects, enhance the user experience
or for other purposes. Modifications to our products may require approvals, modified or new CE Certificates and analogous regulatory
approvals in other jurisdictions or even require us to cease promoting or to recall the modified versions of our products until such
clearances, approvals or modified or new CE Certificates are obtained, and the FDA, comparable regulatory authorities in other jurisdictions
or our notified body may not agree with our conclusions regarding whether new approvals are required</i></b><i>.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, any substantial change introduced to a medical device or to the quality system certified by our notified body requires a new
conformity assessment of the device and can lead to changes to the CE Certificates or the preparation of a new CE Certificate of Conformity.
Substantial changes may include, among others, the introduction of a new intended use of the device, a change in its design or a change
in the Company&#8217;s suppliers. Responsibility for determination that a modification constitutes a substantial change lies with the
manufacturer of the medical device. We must inform the notified body that conducted the conformity assessment of the products we market
or sell in the EU of any planned substantial changes to our quality system or changes to our products that could, among other things,
affect compliance with the MDR or the devices&#8217; intended use. The notified body will then assess the changes and verify whether
they affect the product&#8217;s conformity with the Essential Requirements laid down in Annex I to the MDD or the conditions for the
use of the device. If the assessment is favorable, the notified body will issue a new CE Certificate or an addendum to the existing CE
Certificate attesting compliance with the Essential Requirements laid down in Annex I to the MDD. There is a risk that the competent
authorities of the EU member states or our notified body may disagree with our assessment of the changes introduced to our products.
The competent authorities of the EU member states or our notified body also may come to a different conclusion than the FDA on any given
product modification.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, medical devices that have obtained a CE Certification under the MDD may in principle continue to be marketed under such CE
Certificate until the CE Certificate expires and at the latest until May 27, 2024, provided that the manufacturer complies with the MDR&#8217;s
additional requirements related to post-marketing surveillance, market surveillance, vigilance, and registration of economic operators
and of devices. However, if such medical devices undergo a significant change in their design or intended use, we would need to obtain
a new CE Certificate under the MDR for these devices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the FDA disagrees with us and requires us to submit a new application for then-existing modifications and/or the competent authorities
of the EU member states or our notified body disagree with our assessment of the change introduced in a product, its design or its intended
use, we may be required to cease promoting or to recall the modified product until we obtain approval and/or until a new conformity assessment
has been conducted in relation to the product, as applicable. In addition, we could be subject to significant regulatory fines or other
penalties. Furthermore, our products could be subject to recall if the FDA, comparable regulatory authorities in other jurisdictions,
or our notified body determine, for any reason, that our products are not safe or effective or that appropriate regulatory submissions
were not made. Any recall or requirement that we seek additional approvals or clearances could result in significant delays, fines, increased
costs associated with modification of a product, loss of revenues and potential operating restrictions imposed by the FDA, comparable
foreign regulatory authorities in other jurisdictions, or our notified body. Delays in receipt or failure to receive approvals/certification,
or the failure to comply with any other existing or future regulatory requirements, could reduce our sales, profitability and future
growth prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 51; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>In
addition to FDA requirements, we will spend considerable time and money complying with other federal, state, local and foreign rules,
regulations and guidance and, if we are unable to fully comply with such rules, regulations and guidance, we could face substantial penalties</i></b><i>.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to extensive regulation by the U.S. federal government and the states and other countries in which we conduct our business.
U.S. federal government healthcare laws apply when we submit a claim on behalf of a U.S. federal healthcare program beneficiary, or when
a customer submits a claim for an item or service that is reimbursed under a U.S. federal government-funded healthcare program, such
as Medicare or Medicaid. The laws that affect our ability to operate our business in addition to the Federal Food, Drug, and Cosmetic
Act and FDA regulations include, but are not limited to, the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the U.S. federal
    Anti-Kickback Statute, an intent-based federal criminal statute which prohibits knowingly and willfully offering, providing, soliciting
    or receiving remuneration of any kind to induce or reward, or in return for, referrals or the purchase, lease, order or recommendation
    or arranging of any items or services reimbursable by a federal healthcare program;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Federal Civil False
    Claims Act, which imposes civil penalties, including through civil whistleblower or &#8220;qui tam&#8221; actions, for knowingly
    submitting or causing the submission of false or fraudulent claims of payment to the federal government, knowingly making, using
    or causing to be made or used a false statement or record material to payment of a false claim or avoiding, decreasing or concealing
    an obligation to pay money to the federal government;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Federal Criminal False
    Claims Act, which is similar to the Federal Civil False Claims Act and imposes criminal liability on those that make or present a
    false, fictitious or fraudulent claim to the federal government;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medicare laws and regulations
    that prescribe requirements for coverage and reimbursement, and laws prohibiting false claims or unduly influencing selection of
    products for reimbursement under Medicare and Medicaid;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">healthcare fraud statutes
    that prohibit false statements and improper claims to any third-party payer;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Federal Physician Self-Referral
    Law, commonly known as the Stark law, which, absent an applicable exception, prohibits physicians from referring Medicare and Medicaid
    patients to an entity for the provision of certain designated health services (&#8220;DHS&#8221;), if the physician (or a member
    of the physician&#8217;s immediate family) has an impermissible financial relationship with that entity and prohibits the DHS entity
    from billing for such improperly referred services;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Federal Beneficiary
    Anti-Inducement Statute, which prohibits the offering of any remuneration to a beneficiary of Medicare or Medicaid that is likely
    to influence that beneficiary&#8217;s choice of provider or supplier. This can include, but is not limited to, inappropriate provision
    of patient services including financial assistance. Recent government investigations have focused on this particular prohibition.
    There are established exceptions from liability, but we cannot guarantee that all of our practices will fall squarely within those
    exceptions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the U.S. Foreign Corrupt
    Practices Act, which can be used to prosecute companies in the U.S. for arrangements with physicians or other parties outside the
    U.S. if the physician or party is a government official of another country and the arrangement violates the law of that country;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Federal Trade Commission
    Act, the Lanham Act and similar federal and state laws regulating truthfulness in advertising and consumer protection; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Federal Physician Payments
    Sunshine Act, the French Sunshine Act and similar state and foreign laws, which require periodic reporting of payments and other
    transfers of value made to U.S. and French-licensed physicians, teaching hospitals, and in the U.S., physician assistants, nurse
    practitioners, clinical nurse specialists, certified nurse anesthetists, and certified nurse-midwives.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Similar
laws exist in the EU, individual EU member states and other countries. These laws are complemented by EU or national professional codes
of practices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA
provides data privacy and security provisions for safeguarding medical information. Additionally, states in the U.S. are enacting local
privacy laws (e.g., California). In the EU, the GDPR harmonizes data privacy laws and rules on the processing of personal data, including
patient and employee data, across the EU. The GDPR has a number of strict data protection and security requirements for companies processing
data of EU residents, including when such data is transferred outside of the EU. Additionally, we need to comply with analogous privacy
laws in other jurisdictions in which we operate, such as the Israeli Privacy Protection Law, the Asia Pacific Economic Cooperation Privacy
Framework, and Japan&#8217;s Act on the Protection of Personal Information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
laws and codes of practices applicable to us are subject to evolving interpretations. Moreover, certain U.S. federal and state laws regarding
healthcare fraud and abuse and certain laws in other jurisdictions regarding interactions with healthcare professionals and patients
are broad and we may be required to restrict certain of our practices to be in compliance with these laws. Healthcare fraud and abuse
laws also are complex and even minor, inadvertent irregularities, or even the perception of impropriety, can potentially give rise to
claims that a statute has been violated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 52; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
violation of these laws could have a material adverse effect on our business, prospects, financial condition and results of operations
and cause our stock price to decline. Similarly, if there is a change in law, regulation or administrative or judicial interpretations,
we may have to change our business practices or our existing business practices could be challenged as unlawful, which likewise could
have a material adverse effect on our business, prospects, financial condition and results of operations and cause our stock price to
decline. Fines and penalties for violations of these laws and regulations could include severe criminal and civil penalties, including,
for example, significant monetary damages, exclusion from participation in the federal healthcare programs and permanent disbarment of
key employees. Any penalties, damages, fines, curtailment or restructuring of our operations would adversely affect our ability to operate
our business, our prospects and our financial results. In addition, any action against us for violation of these laws, even if we successfully
defend against it, could cause us to incur significant legal expenses, divert our management&#8217;s attention from the operation of
our business and damage our reputation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, although we believe that we have the required licenses, permits and accreditation to dispense our products in the future, a
regulator could find that we need to obtain additional licenses or permits. We also may be subject to mandatory reaccreditation and other
requirements in order to maintain our billing privileges. Failure to satisfy those requirements could cause us to lose our privileges
to bill governmental and private payers. If we are required to obtain permits or licenses that we do not already possess, we also may
become subject to substantial additional regulation or incur significant expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
ensure compliance with Medicare, Medicaid and other regulations, federal and state governmental agencies and their agents, including
MACs, may conduct audits of our operations to support our claims submitted for reimbursement of items furnished to beneficiaries and
health care providers. Depending on the nature of the conduct found in such audits and whether the underlying conduct could be considered
systemic, the resolution of these audits could adversely impact our revenue, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we, our collaborative partners, our contract manufacturers or our component suppliers fail to comply with the FDA&#8217;s QSR or equivalent
regulations established in other countries, the manufacturing and distribution of our products could be interrupted, and our product
sales and results of operations could suffer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We,
our collaborative partners, our contract manufacturers and our component suppliers are required to comply with the FDA&#8217;s QSR and
the equivalent quality system requirements imposed by the laws and regulations in other jurisdictions, which are a complex regulatory
framework that covers the procedures and documentation of the design, testing, production, control, quality assurance, labeling, packaging,
sterilization, storage and shipping of our products. We cannot assure you that our facilities or our contract manufacturers&#8217; or
component suppliers&#8217; facilities would pass any future quality system inspection. If our or any of our contract manufacturers&#8217;
or component suppliers&#8217; facilities fails a quality system inspection, the manufacturing or distribution of our products could be
interrupted and our operations disrupted. Failure to take adequate and timely corrective action in response to an adverse quality system
inspection could force a suspension or shutdown of our packaging and labeling operations or the manufacturing operations of our contract
manufacturers, and lead to suspension, variation or withdrawal of our regulatory approvals or a recall of our products. If any of these
events occurs, we may not be able to provide our customers with our products on a timely basis, our reputation could be harmed and we
could lose customers, any or all of which could have a material adverse effect on our business, prospects, financial condition and results
of operations and cause our stock price to decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
products may in the future be subject to recalls that could harm our reputation, business and financial results</i></b><i>.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA and similar governmental authorities in other jurisdictions have the authority to require the recall of commercialized products in
the event of material deficiencies or defects in design or manufacture. In the case of the FDA, the authority to require a recall must
be based on an FDA finding that there is a reasonable probability that the device would cause serious injury or death. In addition, governmental
bodies in other jurisdictions have the authority to require the recall of our products in the event of material deficiencies or defects
in design or manufacture. Distributors and manufacturers may, under their own initiative, recall a product if any material deficiency
in a device is found. A government-mandated or voluntary recall by us or one of our manufacturers could occur as a result of component
failures, manufacturing errors, design or labeling defects or other deficiencies and issues. The FDA requires that certain classifications
of recalls be reported to the FDA within ten working days after the recall is initiated. Requirements for the reporting of product recalls
to the competent authorities are imposed in other jurisdictions in which our products are or would be marketed in the future. Companies
are required to maintain certain records of recalls, even if they are not reportable to the FDA or to the competent authorities of other
countries. In the future, we may initiate voluntary recalls involving our products that we determine do not require notification of the
FDA or to other equivalent non-U.S. authorities. If the FDA or the equivalent non-U.S. authorities disagree with our determinations,
they could require us to report those actions as recalls. A future recall announcement could harm our reputation with customers and negatively
affect our sales. In addition, the FDA and the equivalent non-U.S. authorities could take enforcement action if we fail to report the
recalls when they were conducted. Recalls of our products would divert managerial and financial resources and could have a material adverse
effect on our business, prospects, financial condition and results of operations and cause our stock price to decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 53; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
our products cause or contribute to a death or a serious injury, or malfunction in certain ways, we will be subject to medical device
reporting regulations, which can result in voluntary corrective actions or agency enforcement actions</i></b><i>.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the FDA Medical Device Reporting regulations and the equivalent regulations applicable in other jurisdictions in which our products are
or may be marketed in the future, medical device manufacturers are required to report to the FDA and to the equivalent non-U.S. authorities
information that a device has or may have caused or contributed to a death or serious injury or has malfunctioned in a way that would
likely cause or contribute to death or serious injury if the malfunction of the device or one of our similar devices were to recur. If
we fail to report these events to the FDA or to the equivalent authorities in other jurisdictions within the required time frames, or
at all, the FDA or the equivalent authorities in other jurisdictions could take enforcement action against us. Any such adverse event
involving our products also could result in future voluntary corrective actions, such as recalls or customer notifications, or agency
action, such as inspection or enforcement action. Any corrective action, whether voluntary or involuntary, as well as defending ourselves
in a lawsuit, will require the dedication of our time and capital, distract management from operating our business, and may harm our
reputation and financial results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may be subject to fines, penalties or injunctions if we are determined to be promoting the use of our products for unapproved or off-label
uses</i></b>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical
devices may be marketed only for the indications for which they are approved. Our promotional materials and training materials must comply
with FDA regulations and other applicable laws and regulations governing the promotion of our products in the U.S. and other jurisdictions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the FDA or the competent authorities in other jurisdictions determine that our promotional materials or training constitutes promotion
of an unapproved use, they could request that we modify our training or promotional materials or subject us to regulatory or enforcement
actions, including the issuance of an untitled or warning letter, an injunction, seizure, civil fines and criminal penalties. It is also
possible that authorities in other federal, state or national enforcement in other jurisdictions might take action if they consider our
promotional or training materials to constitute promotion of an unapproved use, which could result in significant fines or penalties
under other statutory authorities, such as laws prohibiting false claims for reimbursement. In that event, our reputation could be damaged
and the commercialization of our products could be impaired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are affected by and subject to environmental laws and regulations that could be costly to comply with or that may result in costly liabilities</i></b>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are subject to environmental laws and regulations, including those that impose various environmental controls on the manufacturing, transportation,
storage, use and disposal of hazardous chemicals and other materials used in, and hazardous waste produced by, the manufacturing of our
products. We incur and expect to continue to incur costs to comply with these environmental laws and regulations. Additional or modified
environmental laws and regulations, including those relating to the manufacture, transportation, storage, use and disposal of materials
used to manufacture our products or restricting disposal or transportation of batteries, may be imposed that may result in higher costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, we cannot predict the effect that additional or modified environmental laws and regulations may have on us, our third-party
suppliers of equipment and our products or our customers.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>The
pediatrics and medical device industries are characterized by patent and other intellectual property litigation and disputes, and any
litigation, dispute or claim against us may cause us to incur substantial costs, could place a significant strain on our financial resources,
divert the attention of management from our business, harm our reputation and require us to remove certain devices from the market</i></b><i>.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whether
a product infringes a patent or violates other intellectual property rights involves complex legal and factual issues, the determination
of which is often uncertain. Any intellectual property dispute, even a meritless or unsuccessful one, would be time consuming and expensive
to defend and could result in the diversion of our management&#8217;s attention from our business and result in adverse publicity, the
disruption of research and development and marketing efforts, injury to our reputation and loss of revenues. Any of these events could
negatively affect our business, prospects, financial condition and results of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 54; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third
parties may assert that our products, the methods employed in the use of our products or other activities infringe on their patents.
Such claims may be made by competitors seeking to obtain a competitive advantage or by other parties, many of whom have significantly
larger intellectual property portfolios than we have. Additionally, in recent years, individuals and groups have begun purchasing intellectual
property assets for the purpose of making claims of infringement and attempting to extract settlements from companies like ours. With
respect to our current products, the risk of infringement claims is exacerbated by the fact that there are numerous issued and pending
patents relating to the treatment of cancer. Because patent applications can take many years to issue, and in many cases remain unpublished
for many months after filing, there may be applications now pending of which we are unaware that may later result in issued patents that
our products may infringe.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
could also be existing patents that one or more components of our products or other device candidates may inadvertently infringe. As
the number of competitors in the market or other device candidates grows, the possibility of inadvertent patent infringement by us or
a patent infringement claim against us increases. To the extent we gain greater market visibility, our risk of being subject to such
claims is also likely to increase. If a third party&#8217;s patent was upheld as valid and enforceable and we were found to be infringing,
we could be prevented from making, using, selling, offering to sell or importing our products or other device candidates, unless we were
able to obtain a license under that patent or to redesign our systems to avoid infringement. A license may not be available at all or
on terms acceptable to us, and we may not be able to redesign our products to avoid any infringement. Modification of our products or
development of device candidates to avoid infringement could require us to conduct additional clinical studies and to revise our filings
with the FDA and other regulatory bodies, which would be time-consuming and expensive. If we are not successful in obtaining a license
or redesigning our devices, we may be unable to make, use, sell, offer to sell or import our devices and our business could suffer. We
may also be required to pay substantial damages and undertake remedial activities, which could cause our business to suffer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may also be subject to claims alleging that we infringe or violate other intellectual property rights, such as copyrights or trademarks,
may have to defend against allegations that we misappropriated trade secrets, and may face claims based on competing claims of ownership
of our intellectual property. The confidentiality and assignment of inventions agreements that our employees, consultants and other third
parties sign may not in all cases be enforceable or sufficient to protect our intellectual property rights. In addition, we may face
claims from third parties based on competing claims to ownership of our intellectual property.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may employ individuals who were previously employed at other medical device companies, and as such we may be subject to claims that such
employees have inadvertently or otherwise used or disclosed the alleged trade secrets or other proprietary information of their former
employers. Any such litigation, dispute or claim could be costly to defend and could subject us to substantial damages, injunctions or
other remedies, which could have a material adverse effect on our business, prospects, financial condition and results of operations
and cause our stock price to decline.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Changes
in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our devices</i></b><i>.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
is the case with other medical device companies, our success is heavily dependent on our intellectual property rights, and particularly
on our patent rights. Obtaining and enforcing patents in the medical device industry involves both technological and legal complexity,
and is therefore costly, time consuming and inherently uncertain. In addition, the U.S. has recently enacted and is currently implementing
wide-ranging patent reform legislation. Certain U.S. Supreme Court rulings have narrowed the scope of patent protection available in
certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard
to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents
once obtained. Depending on decisions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents
could change in unpredictable ways that could further negatively impact the value of our patents, narrow the scope of available patent
protection or weaken the rights of patent owners.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 55; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Future
regulatory action remains uncertain.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
operate in a highly regulated and evolving environment with rigorous regulatory enforcement. Any legal or regulatory action could be
time-consuming and costly. If we or the manufacturers or distributors that supply our products fail to comply with all applicable laws,
standards, and regulations, action by the FDA or other regulatory agencies could result in significant restrictions, including restrictions
on the marketing or use of the products we sell or the withdrawal of the products we sell from the market. Any such restrictions or withdrawals
could materially affect our reputation, business and operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Our
product candidates will remain subject to ongoing regulatory review even after they receive marketing clearances, and if we fail to comply
with continuing regulations, we could lose these clearances and the sale of any of our approved commercial products could be suspended.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
as we received regulatory clearance to market the IB-Stim, the manufacturing, labeling, packaging, adverse event reporting, storage,
advertising, promotion, and record keeping related to IB-Stim will remain subject to extensive regulatory requirements. If we fail to
comply with the regulatory requirements of the FDA and other applicable domestic and foreign regulatory authorities or discover any previously
unknown problems with any approved product, manufacturer, or manufacturing process, we could be subject to administrative or judicially
imposed sanctions, including:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions on the products,
    manufacturers, or manufacturing processes;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warning letters;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">civil or criminal penalties;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product seizures or detentions;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">pressure to initiate voluntary
    product recalls;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension or withdrawal
    of regulatory clearances and/or approvals; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal to approve pending
    applications for marketing clearances and/or approval of new products or supplements to approved applications.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Intellectual
property litigation and infringement claims could cause us to incur significant expenses or prevent us from selling certain of our products.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
therapeutic medical device and pharmaceutical industries are characterized by extensive intellectual property litigation and, from time
to time, we may become the subject of claims of infringement or misappropriation. Regardless of outcome, such claims are expensive to
defend and divert management and operating personnel from other business issues. A successful claim or claims of patent or other intellectual
property infringement against us could result in payment of significant monetary damages and/or royalty payments or negatively impact
our ability to sell current or future products in the affected category.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
depend extensively on our patents and proprietary technology and the patents, and we must protect those assets in order to preserve our
business.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we expect to seek patent protection for any devices,&#160;<i>in silico</i>&#160;products (if any), systems, and processes we discover
and/or for any specific use we discover for new or previously known compounds, devices, biologics, products, systems, or processes, any
or all of these may not be subject to effective patent protection. In addition, our issued patents may be declared invalid or our competitors
may find ways to avoid the claims in the patents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success will depend, in part, on our ability to obtain patents, protect our trade secrets and proprietary knowledge and operate without
infringing on the proprietary rights of others. We are the sole assignee of numerous granted United States patents, pending United States
patent applications and international patents. The patent position of pharmaceutical and biotechnology firms like us are generally highly
uncertain and involves complex legal and factual questions, resulting in both an apparent inconsistency regarding the breadth of claims
allowed in United States patents and general uncertainty as to their legal interpretation and enforceability. Accordingly, patent applications
assigned to us may not result in patents being issued, any issued patents assigned to us may not provide us with competitive protection
or may be challenged by others, and the current or future granted patents of others may have an adverse effect on our ability to do business
and achieve profitability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 56; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
others may independently develop similar products, may duplicate our products, or may design around our patent rights. In addition, as
a result of the assertion of rights by a third-party or otherwise, we may be required to obtain licenses to patents or other proprietary
rights of others in or outside of the United States. Any licenses required under any such patents or proprietary rights may not be made
available on terms acceptable to us, if at all. If we do not obtain such licenses, we could encounter delays in product market introductions
during our attempts to design around such patents or could find that the development, manufacture or sale of products requiring such
licenses is foreclosed. In addition, we could incur substantial costs in defending suits brought against us or in connection with patents
to which we hold licenses or in bringing suit to protect our own patents against infringement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Due
to legal and factual uncertainties regarding the scope and protection afforded by patents and other proprietary rights, we may not have
meaningful protection from competition.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
long-term success will substantially depend upon our ability to protect our proprietary technologies from infringement, misappropriation,
discovery and duplication, and avoid infringing the proprietary rights of others. Our patent rights and the patent rights of biotechnology
and pharmaceutical companies in general, are highly uncertain and include complex legal and factual issues. Because of this, our pending
patent applications may not be granted. These uncertainties also mean that any patents that we own or will obtain in the future could
be subject to challenge, and even if not challenged, may not provide us with meaningful protection from competition. Due to our financial
uncertainties, we may not possess the financial resources necessary to enforce our patents. Patents already issued to us or our pending
applications may become subject to dispute, and any dispute could be resolved against us. Because a substantial number of patents have
been issued in the field of neuromodulation therapy and because patent positions can be highly uncertain and frequently involve complex
legal and factual questions, the breadth of claims obtained in any application or the enforceability of our patents cannot be predicted.
Consequently, we do not know whether any of our pending or future patent applications will result in the issuance of patents or, to the
extent patents have been issued or will be issued, whether these patents will be subject to further proceedings limiting their scope,
will provide significant proprietary protection or competitive advantage, or will be circumvented or invalidated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Also,
because of these legal and factual uncertainties, and because pending patent applications are held in secrecy for varying periods in
the United States and other countries, even after reasonable investigation, we may not know with certainty whether any products that
we (or a licensee) may develop will infringe upon any patent or other intellectual property right of a third party. We believe that the
patents that we own or have applied for do not infringe any third-party patents; however, we cannot know for certain whether we could
successfully defend our position, if challenged. We may incur substantial costs if we are required to defend our intellectual property
in patent suits brought by third parties. These legal actions could seek damages and seek to enjoin testing, manufacturing and marketing
of the accused product or process. In addition to potential liability for significant damages, we could be required to obtain a license
to continue to manufacture or market the accused product or process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
the third parties on which we rely for the conduct of our clinical trials and results do not perform our clinical trial activities in
accordance with good clinical practices and related regulatory requirements, we may be unable to obtain regulatory approval for or commercialize
our product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may use independent clinical investigators and other third-party service providers to conduct and/or oversee the clinical trials of our
product candidates for the foreseeable future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA requires us and our clinical investigators to comply with regulations and standards, commonly referred to as good clinical practices,
for conducting, recording, and reporting the results of clinical trials to assure that data and reported results are credible and accurate,
and that the trial participants are adequately protected. Our reliance on third parties that we do not control does not relieve us of
these responsibilities and requirements. Third parties may not complete activities on schedule or may not conduct our clinical trials
in accordance with regulatory requirements or the respective trial plans and protocols. The failure of these third parties to carry out
their obligations could delay or prevent the development, approval, and commercialization of our product candidates or result in enforcement
action against us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 57; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risks
Related to Our Common Stock </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
may not be able to maintain a listing of our common stock on NYSE American.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed on NYSE American. We must meet certain financial and liquidity criteria to maintain such listing. If we violate
NYSE American&#8217;s listing requirements, or if we fail to meet any of NYSE American&#8217;s listing standards, our common stock may
be delisted. In addition, our board of directors may determine that the cost of maintaining our listing on a national securities exchange
outweighs the benefits of such listing. A delisting of our common stock from NYSE American may materially impair our stockholders&#8217;
ability to buy and sell our common stock and could have an adverse effect on the market price of, and the efficiency of the trading market
for, our common stock. The delisting of our common stock could significantly impair our ability to raise capital and the value of your
investment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
do not expect to declare or pay dividends in the foreseeable future.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not expect to declare or pay dividends in the foreseeable future, as we anticipate that we will invest future earnings in the development
and growth of our business. Therefore, holders of our common stock will not receive any return on their investment unless they sell their
securities, and holders may be unable to sell their securities on favorable terms or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
securities industry analysts do not publish research reports on us, or publish unfavorable reports on us, then the market price and market
trading volume of our common stock could be negatively affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
trading market for our common stock may be influenced in part by any research reports that securities industry analysts publish about
us. We do not currently have and may never obtain research coverage by securities industry analysts. If no securities industry analysts
commence coverage of us, the market price and market trading volume of our common stock could be negatively affected. In the event we
are covered by analysts, and one or more of such analysts downgrade our securities, or otherwise reports on us unfavorably, or discontinues
coverage of us, the market price and market trading volume of our common stock could be negatively affected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Future
issuances of our common stock or securities convertible into, or exercisable or exchangeable for, our common stock, or the expiration
of lock-up agreements that restrict the issuance of new common stock or the trading of outstanding common stock, could cause the market
price of our common stock to decline and would result in the dilution of your holdings.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Future
issuances of our common stock or securities convertible into, or exercisable or exchangeable for, our common stock, or the expiration
of lock-up agreements that restrict the issuance of new common stock or the trading of outstanding common stock, could cause the market
price of our common stock to decline. We cannot predict the effect, if any, of future issuances of our securities, or the future expirations
of lock-up agreements, on the price of our common stock. In all events, future issuances of our common stock would result in the dilution
of your holdings. In addition, the perception that new issuances of our securities could occur, or the perception that locked-up parties
will sell their securities when the lock-ups expire, could adversely affect the market price of our common stock. In addition to any
adverse effects that may arise upon the expiration of these lock-up agreements, the lock-up provisions in these agreements may be waived,
at any time and without notice. If the restrictions under the lock-up agreements are waived, our common stock may become available for
resale, subject to applicable law, including without notice, which could reduce the market price for our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 58; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Future
issuances of debt securities, which would rank senior to our common stock upon our bankruptcy or liquidation, and future issuances of
preferred stock, which could rank senior to our common stock for the purposes of dividends and liquidating distributions, may adversely
affect the level of return you may be able to achieve from an investment in our common stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the future, we may attempt to increase our capital resources by offering debt securities. Upon bankruptcy or liquidation, holders of
our debt securities, and lenders with respect to other borrowings we may make, would receive distributions of our available assets prior
to any distributions being made to holders of our common stock. Moreover, if we issue preferred stock, the holders of such preferred
stock could be entitled to preferences over holders of common stock in respect of the payment of dividends and the payment of liquidating
distributions. Because our decision to issue debt or preferred stock in any future offering, or borrow money from lenders, will depend
in part on market conditions and other factors beyond our control, we cannot predict or estimate the amount, timing or nature of any
such future offerings or borrowings. Holders of our common stock must bear the risk that any future offerings we conduct or borrowings
we make may adversely affect the level of return, if any, they may be able to achieve from an investment in our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>If
our shares of common stock become subject to the penny stock rules, it would become more difficult to trade our shares.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
SEC has adopted rules that regulate broker-dealer practices in connection with transactions in penny stocks. Penny stocks are generally
equity securities with a price of less than $5.00, other than securities registered on certain national securities exchanges or authorized
for quotation on certain automated quotation systems, provided that current price and volume information with respect to transactions
in such securities is provided by the exchange or system. If we do not retain a listing on NYSE American or another national securities
exchange and if the price of our common stock is less than $5.00, our common stock could be deemed a penny stock. The penny stock rules
require a broker-dealer, before a transaction in a penny stock not otherwise exempt from those rules, to deliver a standardized risk
disclosure document containing specified information. In addition, the penny stock rules require that before effecting any transaction
in a penny stock not otherwise exempt from those rules, a broker-dealer must make a special written determination that the penny stock
is a suitable investment for the purchaser and receive (i) the purchaser&#8217;s written acknowledgment of the receipt of a risk disclosure
statement; (ii) a written agreement to transactions involving penny stocks; and (iii) a signed and dated copy of a written suitability
statement. These disclosure requirements may have the effect of reducing the trading activity in the secondary market for our common
stock, and therefore stockholders may have difficulty selling their shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>We
are subject to ongoing public reporting requirements that are less rigorous than&#160;Exchange Act&#160;rules for companies that are
not emerging growth companies, and our stockholders could receive less information than they might expect to receive from more mature
public companies.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are required to publicly report on an ongoing basis as an &#8220;emerging growth company&#8221; (as defined in the&#160;JOBS Act) under
the reporting rules set forth under the&#160;Exchange Act. For so long as we remain an emerging growth company, we may take advantage
of certain exemptions from various reporting requirements that are applicable to other&#160;Exchange Act&#160;reporting companies that
are not emerging growth companies, including but not limited to:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">not being required to comply
    with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">being permitted to comply
    with reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">being exempt from the requirement
    to hold a non-binding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously
    approved.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to take advantage of these reporting exemptions until we are no longer an emerging growth company. We would remain an emerging
growth company for up to five years, although if the market value of our common stock that is held by non-affiliates exceeds $700 million
as of any June 30 before that time, we would cease to be an emerging growth company as of the following December 31.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
we are subject to ongoing public reporting requirements that are less rigorous than&#160;Exchange Act&#160;rules for companies that are
not emerging growth companies, our stockholders could receive less information than they might expect to receive from more mature public
companies. We cannot predict if investors will find our common stock less attractive if we elect to rely on these exemptions, or if taking
advantage of these exemptions would result in less active trading or more volatility in the price of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 59; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Because
the Company is a &#8220;smaller reporting company,&#8221; we may take advantage of certain scaled disclosures available to us, resulting
in holders of our securities receiving less Company information than they would receive from a public company that is not a smaller reporting
company.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a &#8220;smaller reporting company&#8221; as defined in the&#160;Exchange Act. As a smaller reporting company, we may take advantage
of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures
for so long as (i) our common stock held by non-affiliates is less than $250 million measured on the last business day of our second
fiscal quarter, or (ii) our annual revenue is less than $100 million during the most recently completed fiscal year and our common stock
held by non-affiliates is less than $700 million measured on the last business day of our second fiscal quarter. To the extent we take
advantage of any reduced disclosure obligations, it may make it harder for investors to analyze the Company&#8217;s results of operations
and financial prospectus in comparison with other public companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a smaller reporting company, we are permitted to comply with scaled-back disclosure obligations in our SEC filings compared to other
issuers, including with respect to disclosure obligations regarding executive compensation in our periodic reports and proxy statements.
We have elected to adopt the accommodations available to smaller reporting companies. Until we cease to be a smaller reporting company,
the scaled-back disclosure in our SEC filings will result in less information about our company being available than for other public
companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
investors consider our common stock less attractive as a result of our election to use the scaled-back disclosure permitted for smaller
reporting companies, there may be a less active trading market for our common stock and our share price may be more volatile.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>As
a &#8220;smaller reporting company,&#8221; we may at some time in the future choose to exempt our Company from certain corporate governance
requirements that could have an adverse effect on our public shareholders.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
NYSE American rules, a &#8220;smaller reporting company,&#8221; as defined in Rule&#160;12b-2&#160;under the&#160;Exchange Act, is not
subject to certain corporate governance requirements otherwise applicable to companies listed on NYSE American. For example, a smaller
reporting company is exempt from the requirement of having a compensation committee composed solely of directors meeting certain enhanced
independence standards, as long as the compensation committee has at least two members who do meet such standards. Although we have determined
not to avail ourselves of this or other exemptions from NYSE American requirements that are or may be afforded to smaller reporting companies
while we will seek to maintain our shares on NYSE American, in the future we may elect to rely on any or all of these exemptions. By
electing to utilize any such exemptions, our Company may be subject to greater risks of poor corporate governance, poorer management
decision-making processes, and reduced results of operations from problems in our corporate organization. Consequently, if we were to
avail ourselves of these exemptions, our stock price might suffer, and there is no assurance that we would be able to continue to meet
all continuing listing requirements of NYSE American from which we would not be exempt, including minimum stock price requirements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_004"></span>ITEM
1B. UNRESOLVED STAFF COMMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_005"></span>ITEM
1C. CYBERSECURITY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CYBERSECURITY RISK MANAGEMENT
AND STRATEGY. </b>NeurAxis has developed and implemented a cybersecurity framework intended to assess, identify and manage risks from
threats to the security of our information, systems, products and network using a risk-based approach. The framework is informed in part
by the National Institute of Standards and Technology (NIST) Cybersecurity Framework and International Organization for Standardization
27001 (ISO 27001) Framework, although this does not imply that we meet all technical standards, specifications, or requirements under
the NIST or ISO 27001.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our key cybersecurity processes include
the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: transparent"><tr style="vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Risk-based
                                            controls for information systems and information on NeurAxis&#8217; networks:</b> We seek
                                            to maintain an information technology infrastructure that implements physical, administrative
                                            and technical controls that are calibrated based on risk and designed to protect the confidentiality,
                                            integrity and availability of our information systems and information stored on NeurAxis&#8217;
                                            networks, including customer information, personal information, PHI/PII, intellectual property
                                            and proprietary information.</span></td></tr>
                                                                                                                                                                          <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cybersecurity
                                            incident policies: </b>We have cybersecurity incident policies, an incident response plan and
                                            a dedicated team to respond to cybersecurity incidents, including experienced counsel. When
                                            a cybersecurity incident occurs or we identify a vulnerability, the dedicated team is responsible
                                            for leading the initial assessment of priority and severity, including external experts that
                                            may also be engaged as appropriate. NeurAxis&#8217; response to incidents depends on the
                                            severity level and seeks to improve its cybersecurity incident response plan. NeurAxis, through
                                            experienced cybersecurity and HIPAA/HITECH counsel, has developed a security manual and a
                                            privacy policy.</span></td></tr>
</table>

<p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="text-align: center; margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Page; Sequence: 60; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0; background-color: transparent">
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Training:
                                            </b>We provide security awareness training to help our employees understand their information
                                            protection and cybersecurity responsibilities at NeurAxis. We also provide additional role-based
                                            training to some employees based on customer requirements, regulatory obligations, and industry
                                            risks.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Supplier
                                            risk assessments: </b>We have participated in several third-party risk assessment processes
                                            that include expectations regarding information and cybersecurity. NeurAxis also seeks contractual
                                            commitments from key suppliers to appropriately secure and maintain their information technology
                                            systems and protect NeurAxis information that is processed or stored on their systems. This
                                            may or may not include business associate agreements, downstream vendor agreements
                                            and vendor auditing in some cases.</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Third-party
                                            assessments of NeurAxis: </b>We have third-party cybersecurity companies engaged to assess
                                            NeurAxis&#8217; cybersecurity readiness and to assist in identifying and remediating risks
                                            from cybersecurity threats. NeurAxis has a &#8220;real time&#8221; cybersecurity partner
                                            that monitors our servers 24/7/365 for any attempted intrusions.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have not identified risks
from known cybersecurity threats, that have materially affected us, including
our operations, business strategy, results of operations, cash flows or financial condition. We face certain ongoing risks from cybersecurity
threats, including active interactions with children&#8217;s hospitals while assisting with insurance prior approvals, that, if realized,
are reasonably likely to materially affect us, <span style="font-family: Times New Roman, Times, Serif; background-color: white">including
our operations, business strategy, results of operations, cash flows or financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CYBERSECURITY GOVERNANCE.
</b>NeurAxis&#8217; Board of Directors is responsible for oversight of cybersecurity risk. The Board receives reporting about NeurAxis&#8217;
practices, programs, notable threats or incidents and other developments related to cybersecurity throughout the year, including through
periodic updates from NeurAxis&#8217; Chief Regulatory Officer/Privacy Officer and VP of IT/Security Officer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NeurAxis&#8217; Security Officer
reports to NeurAxis&#8217; Chief Regulatory Officer and together, they lead the Company&#8217;s overall cybersecurity function. The Security
Officer has over 12 years of experience in managing and leading IT or cybersecurity teams and participates in various cyber security trainings
frequently. The Security Officer collaborates with NeurAxis personnel and our outside IT vendors to identify and analyze cybersecurity
risks to NeurAxis, considers industry trends, implement controls, as appropriate and feasible, to mitigate these risks and enables business
leaders to make risk-based business decisions that impact cybersecurity considerations. The Security Officer meets with senior leadership
to review and discuss NeurAxis&#8217; cybersecurity program, including emerging cyber risks, threats, and industry trends. The Security
Officer also supervises efforts to prevent, detect, mitigate, and remediate cybersecurity risks and incidents through various means, including
by collaborating with external security personnel and business stakeholders, and incorporating threat intelligence and other information
obtained from governmental, public, or private sources to strengthen our cybersecurity technologies and processes.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_006"></span>ITEM
2. PROPERTIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">O<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ur </span>corporate
headquarters are located in Carmel, Indiana, where we lease office space for employees, pursuant to a lease agreement with SePRO
Development Company II, LLC. The term of this lease commenced on March 1, 2021 and ended on February, 28, 2024. Over the term of the
lease, monthly base rent was $1,676 through March 1, 2023 and $1,717 thereafter. Prior to the end of the lease term, the Company
moved its corporate headquarters to another location in Carmel, Indiana, pursuant to a lease agreement with Zeller-Carmel Property,
LLC. The term of this lease commenced on January 1, 2024 and is scheduled to end on May 31, 2029. Over the term of the lease, the
monthly base rent is $6,721 with an annual 2.5% escalator. We received a 50% reduction in our monthly rent for the first 10 months
of the lease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We also lease office space in Versailles,
Indiana, pursuant to two lease agreements with Hashbo Properties, LLC. The original lease term of each agreement commenced January
1, 2022 for a period of one year with automatic one year renewals unless termination notice is provided 60 days in advance. The
monthly base rent is $2,308 with an annual 4% escalator upon renewal.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.2in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 61; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_007"></span>ITEM
3. LEGAL PROCEEDINGS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, the Company may be involved in litigation relating to claims arising out of operations in the normal course of business.
As of April 16, 2024, other than those described below, there were no pending or threatened legal proceedings that could reasonably
be expected to have a material effect on the results of the Company&#8217;s operations. There are also no proceedings in which any of
the Company&#8217;s directors, officers or affiliates is an adverse party to the Company or has a material interest adverse to the Company&#8217;s
interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 6, 2019, plaintiff Ritu Bhambhani, M.D., initiated a lawsuit against Innovative Health Solutions, Inc. and others in the United
States District Court for the District of Maryland. Plaintiffs Bhambhani and Sudhir Rao subsequently amended the complaint, with the
Third Amended Complaint (&#8220;Complaint&#8221;) containing the most recent set of allegations. The Complaint asserted claims under
the RICO Act, as well as of fraudulent misrepresentation, intentional misrepresentation by concealment, and civil conspiracy and sought
compensatory damages in excess of $5 million, pre-judgment interest, punitive damages, attorney&#8217;s fees, court costs and designation
of the case as a class action. The Complaint states that the Company, distributors of the Company&#8217;s product, and medical billing
and coding consultants allegedly made misrepresentations to the plaintiffs that the Company&#8217;s NeuroStim device and related procedures
could be billed to, and reimbursed by, Medicare and other insurance payors as a surgically implantable neurostimulator. Plaintiffs claim
to have suffered damages when Medicare administrative contractors declined to pay plaintiffs for their use of the device.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 11, 2022, the Company filed a motion for summary judgment based upon the plaintiffs not being proper parties to assert claims
against the Company. On June 14, 2022, the Court granted the Company&#8217;s motion for summary judgment and dismissed the Complaint.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 14, 2022, plaintiffs Ritu Bhambhani and Sudhir Rao filed a notice of appeal with the Fourth Circuit Court of Appeals. The Company
filed a motion to dismiss.&#160;On January 4, 2023, the Court issued an order that stated it was deferring a ruling on the motion to
dismiss the appeal and that&#160;it would address those arguments at the same time that it addressed the substantive merits of the case. While it is too early to predict the ultimate
outcome of this matter, we continue to believe we have meritorious defenses, that the dismissal of the Complaint should be upheld, and
intend to continue to defend this matter vigorously.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
July 14, 2022, plaintiffs Ritu Bhambhani, LLC; Box Hill Surgery Center, LLC; Pain and Spine Specialists of Maryland, LLC; and SimCare
ASC, LLC initiated a lawsuit against the Company and others in the United States District Court for the District of Maryland. The plaintiffs
in this lawsuit are business entities owned or partially owned by the plaintiffs that initiated the litigation described above. The Complaint
asserted claims under the RICO Act, as well as fraudulent misrepresentation, intentional misrepresentation by concealment, and civil
conspiracy and seeks compensatory damages in excess of $75,000, pre-judgment interest, punitive damages, attorney&#8217;s fees, and court
costs. The Complaint states that the Company, distributors of the Company&#8217;s product, and medical billing and coding consultants
allegedly made misrepresentations to the plaintiffs that the Company&#8217;s NeuroStim device and related procedures could be billed
to, and reimbursed by, Medicare and other insurance payors as a surgically implantable neurostimulator. Plaintiffs claim to have suffered
damages when Medicare administrative contractors declined to pay plaintiffs for their use of the device.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On
September 28, 2022, the Company filed a motion to dismiss all claims. On May 25, 2023, the Court issued an Order and a Memorandum
Opinion which dismissed the plaintiffs&#8217;claims related to the RICO Act. The remaining claims are still pending, and no trial date
has been set for the case. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Court has vacated its Scheduling Order
at the parties&#8217; request so that the parties could try to resolve the disputes in both cases through an independent <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">third-party</span>
mediator. No mediation date has been set. While it is too early to predict the ultimate outcome of this matter, we believe the Company has meritorious
defenses and intends to defend this matter vigorously.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="a_008"></span>ITEM
4. MINE SAFETY DISCLOSURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.2in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Page; Sequence: 62; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="s_001"></span>PART
II</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="s_002"></span>ITEM
5. MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Market
Information and Holders of Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is listed on the NYSE American, under the symbol &#8220;NRXS&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of April 12, 2024, there were approximately 425 record holders of our common stock. The number of record holders does not include
beneficial owners of common stock whose shares are held in the names of banks, brokers, nominees or other fiduciaries and holders of
unissued shares common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
last reported sales price for our Common Stock as reported on the NYSE American on April 12, 2024 was $3.10.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dividends</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have not declared or paid any cash dividends on our common stock, and we do not anticipate declaring or paying cash dividends for the
foreseeable future. We are not subject to any legal restrictions respecting the payment of dividends, except that we may not pay dividends
if the payment would render us insolvent. Any future determination as to the payment of cash dividends on our common stock will be at
the discretion of our board of directors and will depend on our financial condition, operating results, capital requirements and other
factors that the board of directors considers to be relevant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recent
Sales of Unregistered Securities </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 9, 2023, the Company entered into a securities purchase agreement (the &#8220;SPA&#8221;) with Flagstaff International, LLC
(&#8220;Flagstaff International&#8221;) for the issuance and purchase of the Company&#8217;s Series B Convertible Preferred Stock, par
value $0.001 per share (the &#8220;Series B Preferred Stock Financing&#8221;), at price per share of $2.38 (the &#8220;Series B Preferred
Financing&#8221;). The aggregate purchase price is $3,000,000, to be paid in 15 monthly installments of $200,000 each, commencing on
the later of January 10, 2024 or a date after stockholders approve of an amendment to the Company&#8217;s Certificate of Incorporation
to authorize the creation of the Series B Preferred Stock (the &#8220;Stockholder Approval&#8221;). The Series B Preferred Stock is convertible
at any time into shares of common stock of the Company without any further consideration. The closing of this transaction is subject
to the Stockholder Approval following which the Company will file the Series B Preferred Stock Certificate of Designation with the Secretary
of State of the State of Delaware. Following the issuance of the Series B Preferred Stock, it will rank senior to the common stock with
respect to payments upon the liquidation, dissolution and winding up of the Company. As of December 31, 2023, Flagstaff International,
LLC has not yet paid for or been issued any Series B Preferred Stock shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company previously issued (i) warrants exercisable for an aggregate of 793,655 shares of common stock with an exercise price of $5.25
per share to Leonite Fund I, LP, Emmis Capital II, LLC, Bigger Capital Fund, LP, District 2 Capital Fund, LP, and Exchange Listing, from
June through November 2022 (the &#8220;2022 Warrants&#8221;), (ii) warrants exercisable for an aggregate of 505,570 shares of common
stock with a strike price at $5.25 per share to certain investors from March through July 2023 (the &#8220;the 2023 Warrants&#8221;),
and (iii) 120,235 warrants to the placement agent for the 2023 financing with the same terms as the 2023 Warrants (the &#8220;PA Warrants&#8221;,
and together with the 2022 Warrants and the 2023 Warrants, the &#8220;Warrants&#8221;). In connection with the Series B Preferred Stock
Financing, pursuant to Section 2(c) of the 2022 Warrants and pursuant to Section 3(b) of the 2023 Warrants and the PA Warrants, as a
result of the execution of the SPA, the Company adjusted the exercise price of each Warrant to $2.38 per share and issued (i) new 2023
Warrants to purchase 609,760 shares of common stock and (ii) new PA Warrants to purchase 144,990 shares of common stock pursuant to Section
3(b) of such warrants. The number of shares of the Company&#8217;s common stock issuable upon exercise of the 2022 Warrants remain unchanged.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="s_003"></span>ITEM
6. RESERVED</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 63; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="s_004"></span>ITEM
7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a growth stage company focused on developing neuromodulation therapies to address chronic and debilitating conditions in children.
Our mission is to provide solutions that create value and provide better and safer patient outcomes. Our IB-Stim device is a PENFS system
intended to be used in patients 11-18 years of age with functional abdominal pain associated with IBS. Our device already has market
clearance from FDA for functional abdominal pain associated with IBS in children. Other indications in our pipeline are comprised of
functional nausea in children, post-concussion syndrome in children, and cyclic vomiting syndrome in children. For more information,
see &#8220;<i>Business&#8212;Our Pipeline</i>&#8221; and <i>&#8220;&#8212;Products</i>.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
our inception, we have incurred significant operating losses. Our net loss was $14,626,683 and $4,780,061 million for the years
ended December 31, 2023 and 2022, respectively. Our auditors have expressed substantial doubt about our ability to continue as a
going concern in their audit opinion. We expect to incur significant expenses and operating losses for the foreseeable
future as we continue to pursue widespread insurance coverage of our IB-Stim device and seek FDA clearance of our device for other
indications. There are a number of milestones and conditions that we must satisfy before we will be able to generate sufficient
revenue to fund our operations, including FDA clearance of our IB-Stim device to treat future indications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Factors
Affecting our Business and Results of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Revenue</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
revenue is derived from the sale of our IB-Stim device to healthcare companies, primarily hospitals and clinics. Sales generally are
not seasonal and only mildly correlated with economic cycles. Our IB-Stim device sells for $1,195 per device, and each child being
treated for functional abdominal pain associated with IBS will use three to four devices. Potential patients with future indications
are expected to use six or more devices per patient.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
sales typically are made on a purchase order basis rather than through long-term purchase commitments. We enter into sales agreements
with customers for IB-Stim devices based on purchase orders and standard terms, which vary slightly based on the customer&#8217;s form,
and conditions of sale. Standard payment terms generally are that payment is due within 30 days. Our largest sales were to three
hospitals representing approximately 45% and 52% of total sales for the years ended December 31, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inflation
did not have a material impact on our operations for any applicable period, and we do not expect inflation to have a material impact
on our operations for the foreseeable future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have four categories of expenses: cost of goods sold, selling expenses, research and development (&#8220;R&amp;D&#8221;), and general
and administrative (&#8220;G&amp;A&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
of goods sold consist of costs paid for the IB-Stim device to our contract manufacturer along with periodic inventory adjustments and
expired inventory write-offs. We ramped up production in 2018 and 2019 to meet expected demand and avoid any inventory shortages. This
resulted in some excess inventory that did expire. The costs of expired inventory were $25,008 and $10,026 for the years ended December
31, 2023 and 2022, respectively, representing 8.2% and 3.4% of our costs of goods sold, respectively. Expired inventory expense is related
to our FDA clearance for our device in the treatment of functional abdominal pain associated with IBS in children. Specifically, a certain
component of our IB-Stim device is cleared for a two-year period after the date the device is manufactured, and if the device is not
sold in such period, we must take the device out of inventory and write it off. Expired inventory has not been material to our results,
averaging 1% or less of revenue over the past five years. We have a fixed-price contract with the manufacturer of our IB-Stim device
to produce the device. We expect production costs to remain relatively constant and only nominal inventory expirations in the foreseeable
future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 64; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
core selling expenses primarily consist of commissions and shipping costs. These expense items are generally correlated with sales.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expense is attributable to our clinical trials and related efforts to have our IB-Stim device cleared by the FDA for
other indications.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expense primarily consists of wages and benefits, professional fees including legal and audit, insurance,
investor relations, advertising, facility costs, utilities and travel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Gross
Profit and Gross Margin</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management uses gross profit and gross margin to evaluate the efficiency of operations and as a key component to determining the effectiveness
and allocation of resources. We calculate gross profit as revenue less cost of goods sold, and gross margin as gross profit divided by
revenue. Our gross margin has been and will continue to be affected by a variety of factors, primarily the average selling price of our
IB-Stim device, production volume, order flows, change in mix of customers, third-party manufacturing costs related to components of
our IB-Stim device, and cost-reduction strategies. We expect our gross profit to increase for the foreseeable future as our revenue grows,
both through broader insurer acceptance of our IB-Stim device in the near term and approval of our technology for the treatment of other
indications over the longer term. Our gross margin may fluctuate from quarter to quarter due to changes in average selling prices, particularly
as we introduce enhancements to our IB-Stim device and new products to address other indications, and as we adopt new manufacturing processes
and technologies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Results
of Operations</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Comparison
of Year Ended December 31, 2023 and Year Ended December 31, 2022</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents our statements of operations for the years ended December 31, 2023 and 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; font-weight: bold; text-align: left">Net sales</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">2,460,049</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">2,684,735</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Cost of goods sold</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">303,345</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">297,060</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Gross profit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,156,704</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,387,675</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Selling expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">323,569</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">410,883</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">169,315</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">225,610</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,328,315</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,123,420</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Operating loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(6,664,495</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,372,238</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Other (expense) income, net:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Financing charges</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,772</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,322,216</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(476,416</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(318,666</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in fair value of warrant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">844,854</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">606,049</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Change in fair value of derivative financial instruments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">198,551</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">713,989</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Amortization of debt discount and issuance cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,881,622</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(98,935</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Extinguishment of debt liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,649,561</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,778</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,956</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total other (expense) income, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,962,188</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,407,823</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(14,626,683</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(4,780,061</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>


<!-- Field: Page; Sequence: 65; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Net
Sales</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
sales declined $224,686, or 8.4%, to $2,460,049 in the year ended December 31, 2023 due to (i) management&#8217;s focus on gaining further
insurance coverage for our products, funding and the initial public offering and (ii) fewer shipments to certain customers as they manage
through the insurance reimbursement process.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Gross
Profit and Gross Margin</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gross
profit declined $230,971, or 9.7%, to $2,156,704 in the year ended December 31, 2023 due to (i) lower sales volume and (ii) gross margin
declining 120 bps from 88.9% to 87.7% in the years ended December 31, 2023 and 2022, respectively, due to growth in our patient assistance
program that provides discounts to patients without insurance coverage.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Selling
Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selling
expenses declined $87,314, or 21.3%, to $323,569 in the year ended December 31, 2023 due to (i) lower sales volume and (ii) a reduction
in the commission rate paid to the sales team in the middle of the year ended December 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Research
and Development</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expense declined $56,295, or 25.0%, to $169,315 in the year ended December 31, 2023 due to more patient trials conducted
in the year ended December 31, 2023 as the Company prepared for more FDA submissions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General
and Administrative</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expense increased $3,204,895, or 62.6%, to $8,328,315 in the year ended December 31, 2023 due to (i) incremental headcount
to build out market access and patient assistance teams including recruiting costs, (ii) higher insurance, investor relations and board
of director costs post-IPO, (iii) one-time IPO advisory costs and (iv) higher advertising costs in order to expand market awareness.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Operating
Loss</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
operating loss increased $3,292,257, or 97.6%, to $6,664,495 in the year ended December 31, 2023 primarily due to lower sales volume
and higher general and administrative expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 66; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
(Expense)</i></span> <i>Income</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">Other
expense increased $6,554,365, or 465.6%, to $7,962,188 in the year ended December 31, 2023 due to the full amortization of the
unamortized debt discount upon the IPO, a loss on the extinguishment of debt
upon the IPO, higher interest expense&#8239;and a lower year-over-year change in the fair value of the derivative financial
instrument liability partially offset by the absence of convertible note financing fees in the year ended December 31, 2023 and a
larger year-over-year change in the fair value of the warrant liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Net
Loss</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
net loss increased $9,846,622, or 206.0%, to $14,626,683 in the year ended December 31, 2023 primarily due to lower sales volume, higher
general and administrative expenses, the full amortization of the debt discount upon the
IPO and the loss on the extinguishment of debt upon the IPO.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity
and Capital Resources</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
had cash on hand of $78,560 and $253,699 as of December 31, 2023 and 2022, respectively. We maintained negative working capital of $1,643,058
and $6,501,101 as of December 31, 2023 and 2022, respectively. The increase in working capital was primarily due to the conversion of
notes payable upon the IPO along with the corresponding elimination or reduction of the fair value liability of warrants and derivatives
and payments of employee bonuses and to vendors with proceeds from the IPO.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have incurred losses since inception and have funded our operations primarily with a combination of sales, debt, and the sale of
capital stock. As of December 31, 2023, we had an stockholders&#8217; deficit of $1,403,241 with no outstanding long-term
debt.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future capital requirements will depend upon many factors, including progress with developing, manufacturing, and marketing our
technologies, the time and costs involved in preparing, filing, prosecuting, maintaining, and enforcing patent claims and other
proprietary rights, our ability to establish collaborative arrangements, marketing activities and competing technological and market
developments, including regulatory changes and overall economic conditions in our target markets. Our ability to generate revenue
and achieve profitability requires us to successfully market and secure purchase orders for our products from customers currently
identified in our sales pipeline and to new customers as well. The primary activity that will drive all customers and revenues is
the adoption of insurance coverage by commercial insurance carriers nationally, so this is a top priority of the Company. These
activities, including our planned research and development efforts, will require significant uses of working capital through the
rest of 2024 and beyond. Based on our current operating plans, we believe that our existing cash at the time of this filing will only
be sufficient to meet our anticipated operating needs through the end of 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
we will have to meet all the financial disclosure and reporting requirements associated with being a publicly reporting company. Our
management will have to spend additional time on policies and procedures to make sure it is compliant with various regulatory requirements,
especially that of Section 404 of the Sarbanes-Oxley Act. This additional corporate governance time required of management could limit
the amount of time our management has to implement our business plan and may delay our anticipated growth plans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 67; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes our cash flows from operating, investing, and financing activities for the years ended December 31, 2023 and
2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Years Ended December 31,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2023</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Net cash used in operating activites</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(6,693,978</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(2,298,004</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net cash used in investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(71,781</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(61,205</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,590,620</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,292,050</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net decrease in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(175,139</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(67,159</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Cash and cash equivalents at beginning of period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">253,699</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">320,858</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Cash and cash equivalents at end of period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">78,560</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">253,699</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Operating
Activities</i> &#8211; Net cash used in operating activities increased $4,395,974, or 191.3%, in the year ended December 31, 2023 primarily
due to higher general and administrative expenses and the payment of vendors and employee bonuses, partially offset by the issuance of
common stock for non-cash consideration of IPO services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Investing
Activities</i> &#8211; Net cash used in investing activities increased $10,576, or 17.3%, in the year ended December 31, 2023 due to
purchases of equipment, trademarks and licenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Financing
Activities </i>&#8211; Net cash provided by financing activities increased $4,298,570, or 187.5%, in the year ended December 31, 2023
due to proceeds from the issuance of common stock via an IPO and convertible notes partially offset by repayments of notes payable and
the payment of IPO costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="s_005"></span>ITEM
7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="s_006"></span>ITEM
8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
Index to Financial Statements and Financial Statement Schedules from page F-1 of this annual report on Form 10-K, which are incorporated
herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="s_007"></span>ITEM
9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.45in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="s_008"></span>ITEM
9A. CONTROLS AND PROCEDURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 12.95pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Application
of U.S. GAAP</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s financial statements are maintained in accordance with U.S. GAAP. Our application and compliance with U.S. GAAP is
based on guidance and interpretations issued by the Financial Accounting Standards Board through the Accounting Standards
Codification and Accounting Standards Updates. Our conclusions are communicated to our management, including our principal executive
officer and principal financial officer, to allow timely and accurate decisions and reporting. Our management, with the participation of our
principal executive and principal financial officer, evaluated our Company&#8217;s controls over the application of U.S. GAAP as of
the end of the period covered by this Form 10-K. Based on this evaluation, our principal executive officer and principal financial
officer concluded that as of December 31, 2023, our controls over the application of U.S. GAAP were not effective as evidenced by
the restatement of our unaudited financial statements as of and for the three and nine month periods ended September 30, 2023
included in Note 19 to this Form 10-K that constituted a material weakness. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Disclosure
Controls and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
maintain &#8220;disclosure controls and procedures,&#8221; as that term is defined in Rule 13a-15(e), promulgated by the SEC
pursuant to the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). Disclosure controls and procedures
include controls and procedures designed to ensure that information required to be disclosed in our Company&#8217;s reports filed
under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules
and forms, and that such information is accumulated and communicated to our management, including our principal executive officer
and principal financial officer to allow timely decisions regarding required disclosure. Our management, with the participation of
our principal executive officer and principal financial officer, evaluated our Company&#8217;s disclosure controls and procedures as
of the end of the period covered by this Form 10-K. Based on this evaluation, our principal executive officer and principal
financial officer concluded that as of December 31, 2023, our disclosure controls and procedures were not effective. The
ineffectiveness of our disclosure controls and procedures was due to material weaknesses as a result of the (i) lack of segregation
of duties, (ii) lack of internal controls structure review and (iii)</span> misapplication of GAAP.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 68; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Management&#8217;s
Annual Report on Internal Control Over Financial Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 12.95pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report on Form 10-K does not include a report of management&#8217;s assessment regarding internal control over financial reporting due
to a transition period established by the rules of the SEC for newly public companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Changes
in Internal Control Over Financial Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no changes in the Company&#8217;s internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the
Exchange Act) during the year ended December 31, 2023, that has materially affected, or is reasonably likely to materially affect,
the Company&#8217;s internal control over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="s_009"></span>ITEM
9B. OTHER INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="s_010"></span>ITEM
9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 69; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="s_011"></span>PART
III</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="s_012"></span>ITEM
10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table and biographical summaries set forth information, including principal occupation and business experience, about our directors
and executive officers as of April 12, 2024:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 31%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 60%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian
    Carrico</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">42</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">President,
    Chief Executive Officer, and Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Timothy  Henrichs (1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Adrian Miranda</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">54</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Medical Officer, Senior Vice President of Science and Technology</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Thomas Carrico</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Regulatory Officer, Compliance Officer and Privacy Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
    Christopher Robin Brown</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">70</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bradley
    Mitch Watkins</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">49</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beth
    Keyser</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">55</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kristin
    Ferge</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">50</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
                                            January 30, 2024, our former Chief Financial Officer John Seale resigned from his position,
                                            effective as of the close of business on January 30<sup>th</sup>. On the same day, Timothy
                                            R. Henrichs resigned as a member of the board of directors, effective February 2, 2024. On
                                            January 26, 2024, the board of directors appointed Mr. Henrichs to serve as the CFO, effective
                                            on February 5, 2024.</span></td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Brian
Carrico, President, Chief Executive Officer and Director</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian
Carrico joined the Company in 2012. During his tenure, Mr. Carrico has held multiple leadership positions of increasing responsibility,
including Vice President of Sales and President before becoming CEO on January 1, 2018. As an early employee in the Company&#8217;s life
cycle, Mr. Carrico was instrumental in setting the strategic agenda for the Company, raising start-up capital, championing new product
development, and bringing the Company&#8217;s technology to market. Prior to joining Neuraxis, Mr. Carrico worked selling in the operating
room at Bard Medical and in the Cath lab at St. Jude Medical. He attended Indiana State University and holds a Bachelor of Science in
Business Marketing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Timothy
Henrichs, Chief Financial Officer </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Timothy
Henrichs currently serves as the Company&#8217;s Chief Financial Officer since February 5, 2024 and was a director of the Company
from August 9, 2023 to February 2, 2024. Mr. Henrichs&#8217; global leadership experience spans over 20 years and across several
industries, including healthcare, home improvement, retail, software and education. Previously Mr. Henrichs served as the Chief
Financial Officer of Renovo Home Partners since 2022. He also served as the Executive Vice President and Chief Financial Officer of
Follett Corporation from 2008 to 2022 and Global Controller of General Electric Company&#8217;s Healthcare Clinical Systems division
responsible for the manufacture and distribution of medical devices to the ultrasound, patient monitoring and anesthesiology markets
form 2005 to 2008 in addition to leadership positions at Federal Signal Corporation and Ernst &amp; Young LLP. Mr. Henrichs earned
his bachelor&#8217;s degree in accounting from the University of Notre Dame and is a Certified Public Accountant with an inactive
license in the State of Illinois.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 70; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Dr.
Adrian Miranda, Chief Medical Officer, Senior Vice President of Science and Technology</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Adrian Miranda has served as our Chief Medical Officer since 2018 and brings a unique background of research and clinical expertise
to his role. Prior to joining Neuraxis, Dr. Miranda was an Assistant professor at the Medical College of Wisconsin. He is a
board-certified pediatric gastroenterologist. He obtained his undergraduate degree in Biology from San Diego State University and
obtained his medical degree from the Medical College of Wisconsin. He completed his residency and subspecialty training in pediatric
gastroenterology at Children&#8217;s Hospital of Wisconsin.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a physician scientist, he has spent the past 20 years of his career investigating the pathophysiology of visceral and somatic pain, as
well as exploring new therapeutic options. His focus has been on studying the effects of adverse early life events, neuroplasticity and
the development of chronic pain. He has an extensive publication record and has lectured nationally and internationally.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Dr. <i>Thomas
Carrico, Chief Regulatory Officer, Compliance Officer and Privacy Officer</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Thomas Carrico has served as our Chief Regulatory Officer since November 2017. He joined the Company in February 2012 as Director of
Regulatory Affairs. Prior to and during his early years with Neuraxis, he was President &amp; Clinic Director at Spine and
Neuromuscular Associates in Lawrenceburg, Indiana from January 2002 to December 2018. He has over 40 years of experience in the
healthcare field and has been involved in the study and application of techniques and treatments that directly affect the autonomic
nervous system, especially regarding homeostasis and balance of the parasympathetic and the sympathetic nervous system. Dr. Carrico
has a history of working with attorneys while serving on state and national boards, which has positioned him to integrate into
regulatory responsibilities at the Company. Dr. Carrico received his undergraduate education from Indiana University and his
Doctorate from Palmer College of Chiropractic.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Dr.
Christopher Robin Brown, Director</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Chirstopher Robin Brown is a co-founder of the Company. He developed clinical protocol, initial practice guidelines, designed and
implemented the practitioner certification program and personally financed the first two years of the Company. After developing the
technique of transillumination to isolate auricular neurovascular bundles, he authored and designed the initial studies establishing
neurovascular and tissue energy transfer theories upon which the devices&#8217; use are based. Dr. Brown is listed as the sole or
principal inventor on all Neuraxis patents and is currently active in further device development working closely with compliance,
product design and engineering.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
graduation from the Indiana University School of Dentistry in 1982, while serving as clinic chief in the United States Army Reserve (USAR)
dental corps at Fort Benjamin Harrison in Indianapolis, Indiana, Dr. Brown started a private practice (current) concentrating in head,
neck, and facial pain developing the first hospital based facial pain clinic in Indiana. He received his master&#8217;s degree in Biomechanical
Trauma in 1996 from Lynn University, one of only 12 dentists in the United States to hold the combination of DDS and MPS degrees. Dr.
Brown has authored several textbook chapters, published peer reviewed articles on the physics of soft tissue trauma, pain, financial
management, was regional editor for a national facial pain management Journal, and has lectured extensively nationally and internationally.
He served on the Board of Directors of the American Academy of Pain Management for 15 years, helping grow the organization from 800 members
to over 5,000. Throughout his tenure, he developed educational tracks, served as Industry liaison, one term as treasurer and one term
as President. He served on the national board of The Alliance of TMD practitioners, serving one term as president.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Throughout
his career, Dr. Brown has been active in the purchasing and management of several destressed clinics and re-structuring them into
profitable enterprises. He has performed extensive volunteer work overseas providing surgical care in the Dominican Republic, local
dental clinics serving the underprivileged, and recently provided dental screenings for the deployment of soldiers in the USAR and
National Guard.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 71; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Bradley
Mitch Watkins, Director</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i></i></b></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bradley
Mitch Watkins has overseen four companies through their early commercialization periods within the medical device sector over the last
20 years. He has directly reported to the CEO or board of directors and operated as the lead for all field operations. Over his 20 years
in a multitude of medical device markets, Mr. Watkins has overseen $410 million in company acquisitions in an array of leadership roles.
He has thrived in early commercialization, recruitment, and strategic company direction. These duties have groomed Mr. Watkins with a
wide array of responsibilities beyond sales, including marketing, clinical study design, manufacturing, R&amp;D, FDA submissions, and
fiscal oversight. Mr. Watkins has been the National Sales Manager of Terumo Interventional Systems since 2015, where he has led multiple
new technology sales teams within the peripheral IV and Electrophysiology markets. Mr. Watkins received his bachelor&#8217;s degree in
behavioral science from the University of Maryland.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Beth
Keyser, Director</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
more than 20 years of experience in executive roles in population health, Beth Keyser is skilled at understanding the unique,
complex needs of multiple market segments and devises solutions that meet their specific goals. Ms.Keyser is the President, BCBS of
Indiana at Anthem, Inc. since 2020. From 2018 to 2020, Ms. Keyser served as the President, Create at Brighton Health Plan Solutions.
From 2015 to 2020, Ms. Keyser served as the Senior Vice President, International and Hawaii Markets at Sharecare, Inc. Ms. Keyser
received her master&#8217;s degree in Executive Master of Science, Health Administration, from University of Alabama at
Birmingham.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Kristin Ferge, Director</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kristin Ferge has been President and Chief Financial Officer of Capri Communities and Bridges Home Healthcare, a Wisconsin-based privately
held senior living corporation, since 2016. Prior to joining Capri, Ms. Ferge was an executive for 18 years with Brookdale Senior Living
Inc. or one of its predecessors. Ms. Ferge ended her tenure at Brookdale, a publicly traded senior living company, as Executive Vice
President, Treasurer, and Chief Accounting Officer. Prior to Brookdale, Ms. Ferge was an auditor with KPMG. Ms. Ferge is a certified
public accountant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Family
Relationships</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian
Carrico, our Chief Executive Officer and Director, is the son of Dr. Carrico, our Chief Regulatory Officer. There are no other
family relationships between or among any of our executive officers or other directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Role
of the Board</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
is the paramount duty of the board to oversee our management in the competent and ethical operation of the Company on a day-to-day basis
and to assure that the long-term interests of the stockholders are being served. To satisfy this duty, the directors take a proactive,
focused approach to their positions, and set standards to ensure that we are committed to business success through maintenance of ambitious
standards of responsibility and ethics.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Director
Terms; Qualifications</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
directors are elected for a term of one year and until their successors qualified, nominated, and appointed or elected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">When
considering whether directors and nominees have the experience, qualifications, attributes and skills to enable the board of directors
to satisfy its oversight responsibilities effectively in light of the Company&#8217;s business and structure, the board of directors
focuses primarily on the industry and transactional experience, and other background, in addition to any unique skills or attributes
associated with a director.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Director
or Officer Involvement in Certain Legal Proceedings</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are no material proceedings to which any director or officer, or any associate of any such director or officer, is a party that is adverse
to our Company or any of our subsidiaries or has a material interest adverse to our Company or any of our subsidiaries. No director or
executive officer has been a director or executive officer of any business which has filed a bankruptcy petition or had a bankruptcy
petition filed against it during the past ten years. No director or executive officer has been convicted of a criminal offense or is
the subject of a pending criminal proceeding during the past ten years. No director or executive officer has been the subject of any
order, judgment or decree of any court permanently or temporarily enjoining, barring, suspending or otherwise limiting his involvement
in any type of business, securities or banking activities during the past ten years. No director or officer has been found by a court
to have violated a federal or state securities or commodities law during the past ten years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 72; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Directors
and Officers Liability Insurance</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company maintains directors&#8217; and officers&#8217; liability insurance insuring its directors and officers against liability for
acts or omissions in their capacities as directors or officers, subject to certain exclusions. Such insurance may also insure the
Company against losses, which it may incur in indemnifying its officers and directors. In addition, officers and directors also have
indemnification rights under applicable laws, and the Company&#8217;s Certificate of Incorporation and Bylaws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Director
Independence</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
listing rules of NYSE American require that independent directors must comprise a majority of a listed company&#8217;s board of directors.
In addition, the rules of NYSE American require that, subject to specified exceptions, each member of a listed company&#8217;s audit,
compensation, and nominating and governance committees be independent. Audit committee members must also satisfy the independence criteria
set forth in Rule 10A-3 under the Exchange Act. Under the rules of NYSE American, a director will only qualify as an &#8220;independent
director&#8221; if, in the opinion of that company&#8217;s board of directors, that person does not have a relationship that would interfere
with the exercise of independent judgment in carrying out the responsibilities of a director.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors has undertaken a review of the independence of our directors and considered whether any director has a material relationship
with it that could compromise his or her ability to exercise independent judgment in carrying out his or her responsibilities. Based
upon information requested from and provided by each director concerning his background, employment and affiliations, including family
relationships, the board of directors has determined that three are &#8220;independent&#8221; as that term is defined under the applicable
rules and regulations of the SEC and the listing standards of NYSE American. In making these determinations, our board of directors considered
the current and prior relationships that each non-employee director has with the Company and all other facts and circumstances our board
of directors deemed relevant in determining their independence.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Board
Committees</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, the following three standing committees have been established: Audit Committee; Compensation Committee; and
Nominating and Corporate Governance Committee. Each of our independent directors, Bradley Mitch Watkins, Beth Keyser and Kristin Ferge, serve on
each committee. Our board has adopted written charters for each of these committees. Copies of the charters are available on our
website. Our board may establish other committees as it deems necessary or appropriate from time to time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Audit
Committee</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee, among other things, is responsible for:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">appointing;
    approving the compensation of; overseeing the work of; and assessing the independence, qualifications, and performance of the independent
    auditor;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    the internal audit function, including its independence, plans, and budget;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approving,
    in advance, audit and any permissible non-audit services performed by our independent auditor;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    our internal controls with the independent auditor, the internal auditor, and management;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    the adequacy of our accounting and financial controls as reported by the independent auditor, the internal auditor, and management;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing
    our financial compliance system; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing
    our major risk exposures regarding the Company&#8217;s accounting and financial reporting policies, the activities of our internal
    audit function, and information technology.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 73; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
board of directors has affirmatively determined that each member of the Audit Committee meets the additional independence criteria applicable
to audit committee members under SEC rules and listing standards of NYSE American All members of the Audit Committee are able to read
and understand fundamental financial statements, are familiar with finance and accounting practices and principles and are financially
literate. The board of directors has adopted a written charter setting forth the authority and responsibilities of the Audit Committee.
The board of directors has affirmatively determined that each member of the Audit Committee is financially literate, and that Kristin Ferge meets
the qualifications of an Audit Committee financial expert.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Audit Committee consists of Kristin Ferge, Bradley Mitch Watkins, and Beth Keyser and Ms. Ferge serves as chair of the Audit
Committee. The functioning of the Audit Committee complies with the applicable requirements of the rules and listing standards of
NYSE American and the SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Compensation
Committee</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Compensation Committee is responsible for:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and making recommendations to the Board with respect to the compensation of our officers and directors, including the CEO;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing
    and administering the Company&#8217;s executive compensation plans, including equity-based awards;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">negotiating
    and overseeing employment agreements with officers and directors; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing
    how the Company&#8217;s compensation policies and practices may affect the Company&#8217;s risk management practices and/or risk-taking
    incentives.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Compensation Committee consists of Bradley Mitch Watkins, Beth Keyser, and Kristin Ferge, and Mr. Watkins serves as chair of the Compensation
Committee. The board of directors has affirmatively determined that each member of the Compensation Committee meets the independence
criteria applicable to compensation committee members under SEC rules and listing standards of NYSE American. The Company believes that
the composition of the Compensation Committee meets the requirements for independence under, and the functioning of such Compensation
Committee comply with, any applicable requirements of the rules and regulations of listing standards of NYSE American and the SEC.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Nominating
and Corporate Governance Committee</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Nominating and Corporate Governance Committee, among other things, is responsible for:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing
    and assessing the development of the executive officers and considering and making recommendations to the Board regarding promotion
    and succession issues;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">evaluating
    and reporting to the Board on the performance and effectiveness of the directors, committees and the board of directors as a whole;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">working
    with the Board to determine the appropriate and desirable mix of characteristics, skills, expertise and experience, including diversity
    considerations, for the full Board and each committee;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">annually
    presenting to the Board a list of individuals recommended to be nominated for election to the board;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing,
    evaluating, and recommending changes to the Company&#8217;s committee charters;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending
    to the Board individuals to be elected to fill vacancies and newly created directorships;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing
    the Company&#8217;s compliance program, including the Code of Conduct; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">overseeing
    and evaluating how the Company&#8217;s corporate governance and legal and regulatory compliance policies and practices, including
    leadership, structure, and succession planning, that may affect the Company&#8217;s major risk exposures.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Nominating and Corporate Governance Committee consists of Bradley Mitch Watkins, Beth Keyser, and Kristin Ferge and Ms. Keyser
serves as chair of the Nominating and Corporate Governance Committee. The Company&#8217;s board of directors has determined that
each member of the Nominating and Corporate Governance Committee is independent within the meaning of the independent director
requirements for independence under the NYSE American listing standards and SEC rules and regulations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 74; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Compensation
Committee Interlocks and Insider Participation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None
of the Company&#8217;s executive officers serves, or in the past has served, as a member of the board of directors or compensation committee,
or other committee serving an equivalent function, of any entity that has one or more executive officers who serve as members of the
Company&#8217;s board of directors or its compensation committee. None of the members of the Company&#8217;s compensation committee is,
or has ever been, an officer or employee of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Code
of Business Conduct and Ethics</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s board of directors has adopted a code of business conduct and ethics (&#8220;Code of Conduct&#8221;) applicable to its
employees, directors and officers, in accordance with applicable U.S. federal securities laws and the corporate governance rules of NYSE
American. The Code of Conduct is effective and is publicly available on the Company&#8217;s website. Any substantive amendments or waivers
of the Code of Conduct may be made only by the Company&#8217;s board of directors and will be promptly disclosed as required by applicable
U.S. federal securities laws and the corporate governance rules of NYSE American.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span id="s_013"></span>Item
11. Executive Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Summary
Compensation Table</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information concerning all compensation earned by our Chief Executive Officer and two other persons
who served as executive officers as, at, or during the year ended December 31, 2023, and who earned compensation exceeding $100,000 during
2023 (the &#8220;Named Executive Officers&#8221;), for services as executive officers for the last two years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Name and Principal Position</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Salary ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Bonus</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Insurance</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; text-align: left">Brian Carrico</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2023</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">375,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">441,346</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">23,052</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">839,398</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Chief Executive Officer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">373,578</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,601</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">392,179</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dr. Thomas Carrico</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">278,837</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">116,716</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,544</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">411,097</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Chief Regulatory Officer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">271,962</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,234</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">287,196</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dr. Adrian Miranda</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">300,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23,052</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">323,052</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Chief Medical Officer</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">266,346</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,601</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">284,947</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Represents
    payments to our executive officers pursuant to their respective employment agreements. For more information, see &#8220;<i>&#8212;Employment
    Agreements.&#8221;</i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 75; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Outstanding
Equity Awards at Fiscal Year-End</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth information regarding equity awards held by the Named Executive Officers as of December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Name</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Securities Underlying Unexercised Options, Exercisable (#)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Securities Underlying Unexercised Options, Not Exercisable (#)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Price</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>($)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Expiration</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></p></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Brian Carrico</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">320,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">6.94</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 12%; text-align: right">09/13/29</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Dr. Thomas Carrico</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">306,236</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.94</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">09/13/29</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dr. Adrian Miranda</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">337,204</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.94</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: right">09/13/29</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    option awards were granted under the Innovative Health Solutions, Inc. 2017 Stock Compensation Plan and vested fully upon grant.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Innovative
Health Solutions, Inc. 2017 Stock Compensation Plan, As Amended</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 12, 2017, the Company adopted the Innovative Health Solutions, Inc. 2017 Stock Compensation Plan, as amended on September 13,
2019, September 9, 2021, and November 1, 2022 (collectively, the &#8220;2017 Plan&#8221;). The purpose of the 2017 Plan is to grant incentive
stock options, nonqualified stock options, or restricted stock awards to our officers, employees, directors, advisors, and consultants.
The maximum numbers of shares of common stock that may be issued pursuant to awards granted were 1,319,394. Cancelled and forfeited stock
options and stock awards may again become available for grant under the 2017 Plan. As of the date of December 31, 2023, options to purchase
all 1,319,394 shares of common stock have been granted under the 2017 Plan and remain outstanding, and no shares remain available for
issuance under the 2017 Plan. The following summary briefly describes the principal features of the 2017 Plan and is qualified in its
entirety by reference to the full text of the 2017 Plan, which is filed as an exhibit to the registration statement of which this prospectus
forms a part.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Purpose
of the 2017 Plan</i>: The purposes of the 2017 Plan are to encourage ownership of shares by eligible employees and key non-employees
in order to attract and retain such eligible employees in the employ of the Company or an affiliated entity, or to attract such key non-employees
to provide services to the Company or an affiliated entity, and to provide additional incentive for such persons to promote the long-term
success of the Company or an affiliated entity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Administration
of the Plan</i>: The 2017 Plan is administered by the board of directors, or the committee to which the board of directors delegates
the power to act. Among other things, the administrator has the authority to select persons who will receive awards, determine the types
of awards and the number of shares to be covered by awards, and to establish the terms, conditions, restrictions and other provisions
of awards. The administrator has authority to establish, amend and rescind rules and regulations relating to the 2017 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Eligible
Recipients</i>: Persons eligible to receive awards under the 2017 Plan are those officers, employees, directors, advisors, and consultants
of the Company or an affiliated entity who are selected by the administrator.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Shares
Available under the 2017 Plan</i>: The maximum number of shares of our common stock that may be delivered to participants under the 2017
Plan is 1,319,394 shares, subject to adjustment for certain corporate changes affecting the shares, such as stock splits. No new grants
will be made under the 2017 Plan, and shares subject to an award under the 2017 Plan for which the award is canceled, forfeited or expires
will become available for grants under the 2022 Plan described below. Shares subject to an award that is settled in cash will not again
be made available for grants under the 2017 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 76; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock
Options</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">General</span><i>.
</i>Subject to the provisions of the 2017 Plan, the administrator has the authority to determine all grants of stock options, although
there are currently no shares of common stock remaining reserved for grants under the 2017 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Option
Price</span>. The exercise price for stock options is determined at the time of grant. The exercise price may not be less than the fair
market value on the date of grant. Additionally, incentive stock option grants to any person owning more than 10% of our voting stock
must have an exercise price of not less than 110% of the fair market value on the grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Exercise
of Options</span><i>.</i> An option may be exercised only in accordance with the terms and conditions for the option agreement as established
by the administrator at the time of the grant. The option must be exercised by notice to us, accompanied by payment of the exercise price.
Payments may be made in cash or, at the option of the administrator, by actual or constructive delivery of shares of common stock to
the holder of the option based upon the fair market value of the shares on the date of exercise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Expiration
or Termination</span><i>.</i> Options, if not previously exercised, will expire on the expiration date established by the administrator
at the time of grant. In the case of incentive stock options, such term cannot exceed ten years provided that in the case of holders
of more than 10% of our voting stock, such term cannot exceed five years. Options will terminate before their expiration date only if
the holder&#8217;s service with our Company or an affiliate terminates before the expiration date and the holder is terminated for cause.
The option may remain exercisable until the expiration date of the option after terminations of employment for any reason other than
for cause, including terminations as a result of death, disability or retirement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Incentive
and Non-Qualified Options</span><i>.</i> An incentive stock option is an option that is intended to qualify under certain provisions of
the Internal Revenue Code, for more favorable tax treatment than applies to non-qualified stock options. Any option that does not qualify
as an incentive stock option will be a non-qualified stock option. Under the Code, certain restrictions apply to incentive stock options.
For example, the exercise price for incentive stock options may not be less than the fair market value of the shares on the grant date
and the term of the option may not exceed ten years. In addition, an incentive stock option may not be transferred, other than by will
or the laws of descent and distribution and is exercisable during the holder&#8217;s lifetime only by the holder. In addition, no incentive
stock options may be granted to a holder that is first exercisable in a single year if that option, together with all incentive stock
options previously granted to the holder that also first become exercisable in that year, relate to shares having an aggregate market
value in excess of $100,000, measured at the grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restricted
Stock Awards:</i> Restricted stock awards could have also been granted under the 2017 Plan, although there are currently no shares of
common stock remaining reserved for grants under the 2017 Plan. A restricted stock award is a grant of shares of common stock or of a
right to receive shares in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
Material Provisions</i><b>:</b> Awards are evidenced by a written agreement, in such form as may be approved by the administrator. In
the event of various changes to the capitalization of our Company, such as stock splits, stock dividends and similar re-capitalizations,
an appropriate adjustment will be made by the administrator to the number of shares covered by outstanding awards or to the exercise
price of such awards. The administrator is also permitted to include in the written agreement provisions that provide for certain changes
in the award in the event of a change of control of our Company, including acceleration of vesting. Except as otherwise determined by
the administrator at the date of grant, awards will not be transferable, other than by will or the laws of descent and distribution.
Prior to any award distribution, we are permitted to deduct or withhold amounts sufficient to satisfy any employee withholding tax requirements.
Our board of directors also has the authority, at any time, to discontinue the granting of awards. The Plan may be amended by the board
of directors and such amendment shall become effective upon adoption by the board of directors; provided, however, that any amendment
shall be subject to the approval of the stockholders of the Company at or before the next annual meeting of the stockholders of the Company
if such stockholder approval is required by applicable laws. No amendment that would adversely affect any outstanding award made under
the Plan can be made without the consent of the holder of such award.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
new grants can be made under the 2017 Plan. The terms and conditions of awards granted under the 2017 Plan prior to the effective date
of the 2022 Plan will not be affected by the adoption or approval of the 2022 Plan, and the 2017 Plan will remain effective with respect
to such awards.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 77; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc. 2022 Omnibus Securities and Incentive Plan, As Amended</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 1, 2022, the Company adopted the Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan (as amended January 18, 2023, the
&#8220;2022 Plan&#8221;). The purpose of the 2022 Plan is to attract, retain and provide incentives to key management employees and non-employee
directors of, and non-employee consultants to, the Company and its affiliates, and to align the interests of such employees, non-employee
directors and non-employee consultants with those of the Company&#8217;s stockholders. The maximum numbers of shares of common stock
that may be issued pursuant to awards granted are 300,000. Cancelled and forfeited stock options and stock awards may again become available
for grant under the 2022 Plan. As of the date of this prospectus, no awards have been granted under the 2022 Plan, and 300,000 shares
of common stock remain available for issuance under the 2022 Plan. The following summary briefly describes the principal features of
the 2022 Plan and is qualified in its entirety by reference to the full text of the 2022 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Purpose
of the 2022 Plan</i>: The purposes of the 2022 Plan is to benefit the stockholders of the Company, by assisting the Company to attract,
retain and provide incentives to key management employees and non-employee directors of, and non-employee consultants to, the Company
and its affiliates, and to align the interests of such employees, non-employee directors and non-employee consultants with those of the
Company&#8217;s stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Administration
of the 2022 Plan</i>: The 2022 Plan shall be administered by the board of directors or the committee designated by the board of directors.
Among other things, the administrator has the authority to select persons who will receive awards, determine the time or times when an
award shall be made, what type of award shall be granted, the term of an award, the date or dates on which an award vests (including
acceleration of vesting), the form of any payment to be made pursuant to an award, the terms and conditions of an award (including the
forfeiture of the award (and/or any financial gain) if the holder of the award violates any applicable restrictive covenant thereof),
the restrictions under a restricted stock award and the number of common stock which may be issued under an award, all as applicable.
In addition, subject to the express provisions of the 2022 Plan, the administrator is authorized to construe the 2022 Plan and the respective
award agreements executed thereunder, to prescribe such rules and regulations relating to the 2022 Plan as it may deem advisable to carry
out the intent of the 2022 Plan, to determine the terms, restrictions and provisions of each award, and to make all other determinations
necessary or advisable for administering the 2022 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Eligible
Recipients</i>: Persons eligible to receive awards under the 2022 Plan will be those officers, employees, directors, advisors, and consultants
of the Company or an affiliated entity who are selected by the administrator.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Shares
Available under the Plan</i>: The maximum number of shares of our common stock that may be delivered to participants under the 2022 Plan
is 300,000 shares, subject to adjustment for certain corporate changes affecting the shares, such as stock splits. Shares subject to
an award under the 2022 Plan for which the award is lapses, expires, is canceled, terminated unexercised or ceases to be exercisable
again become available for grants under the 2022 Plan.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock
Options</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>General.
</i>Subject to the provisions of the 2022 Plan, the administrator has the authority to determine all grants of stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Option
Price.</i> The exercise price for stock options is determined at the time of grant. The exercise price may not be less than the fair
market value on the date of grant. Additionally, incentive stock option grants to any person owning more than 10% of our voting stock
must have an exercise price of not less than 110% of the fair market value on the grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Exercise
of Options.</i> An option may be exercised only in accordance with the terms and conditions for the option agreement as established by
the administrator at the time of the grant. The option must be exercised by notice to us, accompanied by payment of the exercise price.
Payments may be made in cash or, at the option of the administrator, by actual or constructive delivery of shares of common stock to
the holder of the option based upon the fair market value of the shares on the date of exercise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 78; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Expiration
or Termination.</i> Options, if not previously exercised, will expire on the expiration date established by the administrator at the
time of grant. In the case of incentive stock options, such term cannot exceed ten years provided that in the case of holders of more
than 10% of our voting stock, such term cannot exceed five years. Options will terminate before their expiration date if the holder&#8217;s
service with our Company or a subsidiary terminates before the expiration date. The option may remain exercisable for specified periods
after certain terminations of employment, including terminations as a result of death, disability or retirement, with the precise period
during which the option may be exercised to be established by the administrator and reflected in the grant evidencing the award.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Incentive
and Non-Qualified Options.</i> As described elsewhere in this summary, an incentive stock option is an option that is intended to qualify
under certain provisions of the Code, for more favorable tax treatment than applies to non-qualified stock options. Any option that does
not qualify as an incentive stock option will be a non-qualified stock option. Under the Code, certain restrictions apply to incentive
stock options. For example, generally, the exercise price for incentive stock options may not be less than the fair market value of the
shares on the grant date and the term of the option may not exceed ten years. In addition, an incentive stock option may not be transferred,
other than by will or the laws of descent and distribution, and is exercisable during the holder&#8217;s lifetime only by the holder.
In addition, to the extent that the aggregate fair market value of common stock with respect to which incentive stock options are exercisable
for the first time by an individual during any calendar year under all plans of the Company and any parent corporation or subsidiary
corporation thereof which provide for the grant of incentive stock options exceeds $100,000, the portion of such incentive stock options
that exceeds such threshold shall be treated as non-qualified stock options. Incentive stock options shall be granted to employees only.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restricted
Stock Awards:</i> Restricted stock awards can be granted under the 2022 Plan. A restricted stock award is a grant of shares of common
stock or of a right to receive shares in the future. These awards will be subject to such conditions, restrictions and contingencies
as the administrator shall determine at the date of grant. Those may include requirements for continuous service and/or the achievement
of specified performance goals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Unrestricted
Stock Awards</i>: Unrestricted stock awards can also be granted under the 2022 Plan. An unrestricted stock award is a grant of shares
of common stock which is not subject to restrictions, in consideration for past services rendered thereby to the Company or an affiliate
or for other valid consideration.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Restricted
Stock Unit Awards</i>: Restricted stock unit awards (&#8220;RSUs&#8221;) can be granted under the 2022 Plan upon the satisfaction of
predetermined individual service related vesting requirements. The holder of a restricted stock unit shall be entitled to receive a cash
payment equal to the fair market value of shares of common stock, for each unit awarded to the holder.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Performance
Stock Unit Awards</i>: Performance stock unit awards can be granted under the 2022 Plan. A holder of performance stock units shall be
entitled to receive a cash payment equal to the dollar value or number of shares of common stock assigned to such units if the holder
and/or the Company satisfy the predetermined performance goals and objectives.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Distribution
Equivalent Rights</i>: Distribution equivalent right awards can be granted under the 2022 Plan. A distribution equivalent right award
entitles the holder to receive bookkeeping credits, cash payments and/or common stock distributions equal in amount to the distributions
that would have been made to the holder had the holder held a specified number of common stock during the period the holder held the
distribution equivalent right.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock
Appreciation Right</i>s: Stock appreciation rights can also be granted under the 2022 Plan, which is a right, granted alone or in connection
with a related Option, to receive a payment on the date of exercise. The base value of the stock appreciation right shall be set forth
by the administrator and shall not be less than the fair market value of the common stock at the date of grant for the stock appreciation
right which is not a tandem stock appreciation right. No stock appreciation right shall be exercisable after the expiration of ten (10)
years from the date of its grant. Upon the exercise of some or all of the portion of a stock appreciation right, the holder shall receive
a payment from the Company, in cash or in the form of common stock having an equivalent fair market value or in a combination of both.
If the administrator grants a stock appreciation right which is intended to be a tandem stock appreciation right, the tandem stock appreciation
right shall be granted at the same time as the related option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 79; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Other
Material Provisions</i>: Awards are evidenced by a written agreement, in such form as may be approved by the administrator. In the event
of various changes to the capitalization of our Company, such as stock splits, stock dividends and similar re-capitalizations, an appropriate
adjustment will be made by the administrator to the number of shares covered by outstanding awards or to the exercise price of such awards.
The administrator is also permitted to include in the written agreement provisions that provide for certain changes in the award in the
event of a change of control of our Company, including acceleration of vesting. Except as otherwise determined by the administrator at
the date of grant, awards will not be transferable, other than by will or the laws of descent and distribution. Prior to any award distribution,
we are permitted to deduct or withhold amounts sufficient to satisfy any employee withholding tax requirements. Our board of directors
also has the authority, at any time, to discontinue the granting of awards. The 2022 Plan may be amended by the board of directors and
such amendment shall become effective upon adoption by the board of directors; provided, however, that any amendment shall be subject
to the approval of the stockholders of the Company at or before the next annual meeting of the stockholders of the Company if such stockholder
approval is required by applicable laws. No amendment that would adversely affect any outstanding award made under the 2022 Plan can
be made without the consent of the holder of such award. The 2022 Plan shall continue in effect, unless sooner terminated, until the
tenth (10th) anniversary of the date on which it is adopted by the board of directors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employment
Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Brian
Carrico</i>, our Chief Executive Officer, entered into an employment agreement with the Company, dated August 9, 2022 and amended on
May 4, 2023, which has a five-year initial term and provides for a base salary of $330,000, which shall be increased each year by not
less than 3% per annum. Mr. Carrico also will receive a one-time incentive payment in the amount of $435,577, which amount consists of
accrued and unpaid salary and a bonus to incentivize Mr. Carrico to remain with the Company for future service. Neither the accrued and
unpaid salary nor bonus was the subject of any contract or agreement between Mr. Carrico and the Company prior to the execution of the
employment agreement. The agreement contemplated that the incentive payment would be paid by December 15, 2022, but due to administrative
impracticability, payment was made with a portion of the proceeds from the IPO in August 2023. In addition, Mr. Carrico is entitled to
payment of a deferred bonus in an amount equal to (i) the aggregate of the strike price or exercise price of all 320,000 unexercised
options to purchase stock or shares of the Company held by Mr. Carrico (the &#8220;Aggregate Strike Price&#8221;) plus (ii) a tax gross-up
payment on the Aggregate Strike Price reasonably calculated by the Company at the highest marginal rates so that after payment of all
ordinary income taxes on such Aggregate Strike Price, there remains an amount sufficient to pay such ordinary income taxes. The special
deferred bonus will be paid in substantially equal 20% installments (the &#8220;Annual Deferred Bonus Payment&#8221;) on January 2 on
each of 2024, 2025, 2026, 2027, and 2028 (the &#8220;Scheduled Payment Dates&#8221;), with a condition that on or before each Scheduled
Payment Date, Mr. Carrico shall exercise at least 64,000 of the stock option. None of stock options has been exercised, therefore, no
special deferred bonus has been paid as of the date of this prospectus. Mr. Carrico may exercise any portion of the stock options after
a Scheduled Payment Date; provided, however, an exercise after the applicable Scheduled Payment Date shall result in forfeiture of the
related Annual Deferred Bonus Payment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the employment agreement is terminated by the Company without cause (as defined in the employment agreement), Mr. Carrico will receive
any accrued compensation (as defined in the employment agreement) and is entitled to severance payments as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    termination occurs during the initial term, the severance payment shall be the amount equal to the greater of (a) three times Mr.
    Carrico&#8217;s base salary as of the termination date; and (b) three times the total amount of Mr. Carrico&#8217;s bonus payments
    the Company paid Mr. Carrico over the one year prior to the termination date, to be paid in substantially equal monthly installments
    over the course of the three years.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    termination occurs after the initial term, the severance payment shall be the amount equal to the greater of (a) one and one half
    (1.5) times Mr. Carrico&#8217;s base salary as of the termination date; and (b) one and one half (1.5) times the total amount of
    Mr. Carrico&#8217;s bonus payments the Company paid Mr. Carrico over the one (1) year prior to the termination date, to be paid in
    substantially equal monthly installments over the course of 18 months following the termination date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    addition, as part of the severance payment, we agreed to pay Mr. Carrico monthly COBRA premiums for continuation of health coverage
    for 18 months post termination.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 80; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the employment agreement is terminated by the Company for cause, Mr. Carrico will forfeit any unpaid Annual Deferred Bonus Payment, but
will receive any unpaid base salary that has been earned at the time of such termination, reimbursement of any expenses properly incurred
prior to the Mr. Carrico&#8217;s termination date; and accrued and unused paid time off (&#8220;PTO&#8221;), if any, in accordance with
the Company&#8217;s PTO policy in effect on Mr. Carrico&#8217;s termination date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Carrico may terminate the employment agreement without good reason upon more than thirty (30) days&#8217; prior written notice or for
good reason without prior written consent, and will receive accrued compensation (as defined in the employment agreement) and the unpaid
balance of the deferred bonus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event that Mr. Carrico is terminated without cause, non-forfeited portions of the deferred bonus will be paid in equal installments
over the remaining scheduled payment dates, if vested options as scheduled are exercised before the scheduled payment dates. A deferred
bonus tranche will be forfeited if its corresponding options have expired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
a change in control (as defined in the employment agreement), full vesting of the Annual Deferred Bonus Payment will occur and be paid
in a single lump sum within 30 days after the change in control. The offering shall not be considered a change in control.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the employment agreement, Mr. Carrico also agreed to (i) not disclose to any unauthorized person or use for his own account any confidential
information without the prior written consent of the Company or the board of directors, (ii) will not, directly or indirectly encourage,
solicit, induce (or attempt to encourage, solicit or induce) any employee or agent of the Company that was employed (or otherwise engaged)
at the time of his separation during his employment and for 24 months after his separation from that employment for any reason; (iii)
will not, directly or indirectly, have any ownership interest in, work for, advise, manage, act as an agent or consultant for, or have
any business connection or business or employment relationship with any entity or person which competes with Company; (iv) will not,
directly or indirectly, have any ownership interest in, work for, advise, manage, act as an agent or consultant for, or have any business
connection or business or employment relationship with any entity or person which competes with the Company during his employment and,
(v) will not, directly or indirectly and in a competitive capacity own, manage, finance, operate, control or participate in ownership,
management, or operation of, act as an agent, consultant, or be employed with, any business engaged in the design, manufacture, marketing,
sale or servicing of any service or product with which Mr. Carrico was involved during his last year of employment with the Company;
or which the Company is developing, producing, marketing, selling or servicing (or plans to develop, produce, market, sale or service)
and about which Mr. Carrico gained any confidential information in the course of his employment with the Company for a period of 24 months
after his separation from the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Dr.
Adrian Miranda</i>, our Chief Medical Officer and Senior Vice President of Science and Technology, entered into an employment
agreement with the Company, dated August 17, 2022, which has a two-year initial term and provides for a base salary of $300,000 with
annual compensation increase. In addition, Dr. Miranda shall be entitled to payment of a special deferred bonus in an amount equal
to (i) the aggregate of the strike price or exercise price of all 337,204 unexercised options to purchase stock or shares of the
Company held by Dr. Miranda (the &#8220;Aggregate Strike Price&#8221;) plus (ii) a tax gross-up payment on the Aggregate Strike
Price reasonably calculated by the Company at the highest marginal rates so that after payment of all ordinary income taxes on such
Aggregate Strike Price, there remains an amount sufficient to pay such ordinary income taxes. The deferred bonus will be paid in
substantially equal 20% installments (the &#8220;Annual Deferred Bonus Payment&#8221;) on January 2 on each of 2024, 2025, 2026,
2027, and 2028, with a condition that on or before each scheduled payment date, Dr. Miranda shall exercise at least 67,441 of the
stock options.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 81; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the employment agreement is terminated by the Company without cause (as defined in the employment agreement) occurs during the term of
the agreement, Dr. Miranda will receive any accrued compensation (as defined in the employment agreement) and is entitled to certain
amount of severance payments as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    termination occurs during the initial term, the Company shall provide Dr. Miranda with severance compensation in the form of salary
    continuation at his Base Salary as of the termination date and ending the later of (i) 6 months or (ii) on the expiration date of
    the initial term.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    termination occurs after the initial term, the severance payment shall be the amount equal to one half (1/2) of Dr. Miranda&#8217;s
    Base Salary as of the termination date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    addition, if termination occurs during the initial term, as part of the severance payment, we agreed to pay Dr. Miranda reimbursement
    of his monthly COBRA premiums for continuation of health coverage for 18 months post termination.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the employment agreement is terminated by the Company for cause, Dr. Miranda will forfeit any unpaid Annual Deferred Bonus Payment, but
will receive any unpaid base salary that has been earned at the time of such termination, reimbursement of any expenses properly incurred
prior to the Dr. Miranda&#8217;s termination date; and (iii) accrued and unused PTO, if any, in accordance with the Company&#8217;s PTO
policy in effect on Dr. Miranda&#8217;s termination date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Miranda may terminate the employment agreement without good reason upon more than thirty (30) days&#8217; prior written notice or for
good reason without prior written consent, and will receive accrued compensation (as defined in the employment agreement) and the unpaid
balance of the special deferred bonus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event that Dr. Miranda is terminated without cause, non-forfeited portions of the deferred bonus will be paid in equal installments
over the remaining scheduled payment dates, if vested options as scheduled are exercised before the scheduled payment dates. A deferred
bonus tranche will be forfeited if its corresponding options have expired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
a change in control (as defined in the employment agreement), full vesting of the Annual Deferred Bonus Payment will occur and be paid
in a single lump sum within 30 days after the change in control. The offering shall not be considered a change in control.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the employment agreement, Dr. Miranda also agreed to (i) not disclose to any unauthorized person or use for his own account any confidential
information without the prior written consent of the Company or the board of directors, (ii) will not, directly or indirectly encourage,
solicit, induce (or attempt to encourage, solicit or induce) any employee or agent of the Company that was employed (or otherwise engaged)
at the time of his separation during his employment and for 24 months after his separation from that employment for any reason; (iii)
will not, directly or indirectly, have any ownership interest in, work for, advise, manage, act as an agent or consultant for, or have
any business connection or business or employment relationship with any entity or person which competes with Company; (iv) not, directly
or indirectly, have any ownership interest in, work for, advise, manage, act as an agent or consultant for, or have any business connection
or business or employment relationship with any entity or person which competes with the Company during his employment and (v) will not,
directly or indirectly and in a competitive capacity own, manage, finance, operate, control or participate in ownership, management,
or operation of, act as an agent, consultant, or be employed with, any business engaged in the design, manufacture, marketing, sale or
servicing of any service or product with which Dr. Miranda was involved during his last year of employment with the Company; or which
the Company is developing, producing, marketing, selling or servicing (or plans to develop, produce, market, sale or service) and about
which Dr. Miranda gained any confidential information in the course of his employment with the Company for a period of 24 months after
his separation from the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 82; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Dr.
Thomas Carrico</i>, Chief Regulatory Officer, entered into an employment agreement with the Company, dated August 9, 2022 and
amended on May 4, 2023, which has a two-year initial term and provides for a base salary of $275,000 with annual compensation
increase. Dr. Carrico will also receive a one-time incentive payment in the amount of $135,655, which amount includes accrued and
unpaid salary and a bonus to incentivize Dr. Carrico to remain with the Company for future service. Neither the accrued and unpaid
salary nor bonus was the subject of any contract or agreement between Dr. Carrico and the Company prior to the execution of the
employment agreement. The agreement contemplated that the incentive payment would be paid by December 15, 2022, but due to
administrative impracticability, payment was made with a portion of the proceeds from the IPO in August 2023. In addition, Dr.
Carrico shall be entitled to payment of a deferred bonus in an amount equal to (i) the aggregate of the strike price or exercise
price of all 306,236 unexercised options to purchase stock or shares of the Company held by Dr. Carrico (the &#8220;Aggregate Strike
Price&#8221;) plus (ii) a tax gross-up payment on the Aggregate Strike Price reasonably calculated by the Company at the highest
marginal rates so that after payment of all ordinary income taxes on such Aggregate Strike Price, there remains an amount sufficient
to pay such ordinary income taxes. The special deferred bonus will be paid in substantially equal 20% installments (the
&#8220;Annual Deferred Bonus Payment&#8221;) on January 2 on each of 2024, 2025, 2026, 2027, and 2028 (the &#8220;Scheduled Payment
Dates&#8221;), with a condition that on or before each Scheduled Payment Date, Dr. Carrico shall exercise at least 61,274 of the
stock option. None of stock options has been exercised, therefore, no special deferred bonus has been paid as of the date of this
prospectus. Dr. Carrico may exercise any portion of the stock options after a Scheduled Payment Date; provided, however, an exercise
after the applicable Scheduled Payment Date shall result in forfeiture of the related Annual Deferred Bonus Payment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the employment agreement is terminated by the Company without cause (as defined in the employment agreement), Dr. Carrico will receive
any accrued compensation (as defined in the employment agreement) and is entitled to certain amount of severance payments as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    termination occurs during the initial term, the Company shall provide Dr. Carrico with severance compensation in the form of salary
    continuation at his Base Salary as of the termination date and ending the later of (i) 6 months or (ii) on the expiration date of
    the initial term.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    termination occurs after the initial term, the severance payment shall be the amount equal to one half (1/2) of Dr. Carrico&#8217;s
    Base Salary as of the termination date.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    addition, if termination occurs during the initial term, as part of the severance payment, we agreed to pay Dr. Carrico reimbursement
    of his Medicare, Medicare Supplement and prescription drug coverage insurance premiums for continuation of health coverage for 18
    months post termination.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the employment agreement is terminated by the Company for cause, Dr. Carrico will forfeit any unpaid Annual Deferred Bonus Payment, but
will receive any unpaid base salary that has been earned at the time of such termination, reimbursement of any expenses properly incurred
prior to the Dr. Carrico&#8217;s termination date; and (iii) accrued and unused PTO, if any, in accordance with the Company&#8217;s PTO
policy in effect on Dr. Carrico&#8217;s termination date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Carrico may terminate the employment agreement without good reason upon more than thirty (30) days&#8217; prior written notice or for
good reason without prior written consent, and will receive accrued compensation (as defined in the employment agreement) and the unpaid
balance of the special deferred bonus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event that Dr. Carrico is terminated without cause after this offering, non-forfeited portions of the deferred bonus will be paid
in equal installments over the remaining scheduled payment dates, if vested options as scheduled are exercised before the scheduled payment
dates. A deferred bonus tranche will be forfeited if its corresponding options have expired.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
a change in control (as defined in the employment agreement), full vesting of the Annual Deferred Bonus Payment will occur and be paid
in a single lump sum within 30 days after the change in control. The offering shall not be considered a change in control.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the employment agreement, Dr. Carrico also agreed to (i) not disclose to any unauthorized person or use for his own account any confidential
information without the prior written consent of the Company or the board of directors, (ii) will not, directly or indirectly encourage,
solicit, induce (or attempt to encourage, solicit or induce) any employee or agent of the Company that was employed (or otherwise engaged)
at the time of his separation during his employment and for 24 months after his separation from that employment for any reason; (iii)
will not, directly or indirectly, have any ownership interest in, work for, advise, manage, act as an agent or consultant for, or have
any business connection or business or employment relationship with any entity or person which competes with Company; (iv) not, directly
or indirectly, have any ownership interest in, work for, advise, manage, act as an agent or consultant for, or have any business connection
or business or employment relationship with any entity or person which competes with the Company during his employment and (v) will not,
directly or indirectly and in a competitive capacity own, manage, finance, operate, control or participate in ownership, management,
or operation of, act as an agent, consultant, or be employed with, any business engaged in the design, manufacture, marketing, sale or
servicing of any service or product with which Dr. Carrico was involved during his last year of employment with the Company; or which
the Company is developing, producing, marketing, selling or servicing (or plans to develop, produce, market, sale or service) and about
which Dr. Carrico gained any confidential information in the course of his employment with the Company for a period of 24 months after
his separation from the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 83; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Non-Employee
Director Compensation</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents the compensation awarded to or earned by or paid to all individuals who served as non-employee directors during
the year ended December 31, 2023. We do not provide additional compensation to directors who are our employees for also serving as a
director.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Name</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fees Earned <br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Stock Awards</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Earned<br/> ($)</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total<br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Timothy R. Henrichs (1)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">23,836</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">19,863</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">43,699</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Bradley M. Watkins</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23,836</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,863</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">43,699</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Jane E. Keyser</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23,836</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,863</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">43,699</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
On January 30, 2024, Timothy R. Henrichs resigned as a member of the board of directors, effective February 2, 2024 and became
the Company&#8217;s Chief Financial Officer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="s_014"></span>ITEM
12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table sets forth certain information known to us with respect to the beneficial ownership of our common stock as of April
12, 2024 based on 6,594,897 common shares outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have determined beneficial ownership in accordance with the rules of the Securities and Exchange Commission, and the information is not
necessarily indicative of beneficial ownership for any other purpose. These rules generally attribute beneficial ownership of securities
to persons who possess sole or shared voting power or investment power with respect to those securities as well as any common stock that
the person has the right to acquire within 60 days of April 12, 2024 through the exercise of stock options or other rights. These shares
are deemed to be outstanding and beneficially owned by the person holding those options for the purpose of computing the percentage ownership
of that person, but they are not treated as outstanding for the purpose of computing the percentage ownership of any other person. Unless
otherwise indicated, the persons or entities identified in this table have sole voting and investment power with respect to all shares
shown as beneficially owned by them.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="4" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Beneficially
    Ownership Common Stock</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Percentage</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of beneficial owner</b></span> <b>5% shareholders:</b></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Masimo
    Corporation <sup>(1)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 17%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">821,327</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 16%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.9</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian
    P. Hannasch <sup>(2)</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">562,420</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">PBF Venture Group LLC <sup>(3)</sup></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">415,258</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6.3</td>
    <td style="font: 10pt Times New Roman, Times, Serif">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Gary Peterson</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">400,120</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">6.1</td>
    <td style="font: 10pt Times New Roman, Times, Serif">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif">108 Sussex LLC <sup>(4)</sup></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">372,171</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">5.6</td>
    <td style="font: 10pt Times New Roman, Times, Serif">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Named
    executive officers and directors:</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian
    Carrico</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">84,118</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Timothy
    Henrichs</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adrian
    Miranda</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">67,441</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thomas
    Carrico</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">66,247</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span>%</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher
    Robin Brown</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">792,837</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.0</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bradley
    Mitch Watkins</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span>-</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"/></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beth
    Keyser</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif">Kristin Ferge</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">-</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">*</td>
    <td style="font: 10pt Times New Roman, Times, Serif"/></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>All
    executive officers and directors as a group ( eight (8) persons)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1,010,643</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>14.9</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>%</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 24pt; text-align: justify; text-indent: -24pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<tr style="vertical-align: top">
  <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
  <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less than 1%.</span></td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The business address for Masimo Corporation is 52 Discovery, Irvine, California 92618. Shares of common stock beneficially owned
includes 289,779 warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2) Shares of common stock beneficially
owned includes 12,852 warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
The business address for PBF Venture Group LLC is 5501 Woodrow Avenue, Austin, Texas 78756.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white">(4) The
business address for 108 Sussex LLC is 304 South Euclid Avenue, Westfield, New Jersey 07090.</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 0; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 84; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span id="s_015"></span>Item
13. Certain Relationships and Related Transactions and Director Independence</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following includes a summary of transactions since January 1, 2022, to which we have been a party in which the amount involved exceeded
or will exceed the lesser of (i) $120,000 and (ii) one percent (1%) of the average of our total assets at year-end for the prior two
fiscal years, and in which any of our directors, executive officers or, to our knowledge, beneficial owners of more than 5% of our capital
stock or any member of the immediate family of any of the foregoing persons had or will have a direct or indirect material interest,
other than equity and other compensation, termination, change in control and other arrangements, which are described under &#8220;Item
11. Executive Compensation.&#8221; We also describe below certain other transactions with our directors, executive officers and stockholders.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has two demand notes receivable from its two founding shareholders, Christopher Robin Brown and Gary Peterson, related to the
sale of common stock on January 1, 2016. The initial balances of both notes were $506,400, with interest calculated monthly based on
applicable federal rates. No payments have been received on the notes. As of December 31, 2023, the balances of both notes were $506,400.
The entire $1,012,800 balance has been fully reserved as of December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has loans payable to Christopher Robin Brown, one of our founders and a member of our board of directors, related to funding
needs for operations with original principal amounts of $55,000 and $50,000 each bearing interest at 15% per annum. In August 2023, the
Company used a portion of the proceeds from the IPO to repay these loans payable in full, including $37,103 in interest.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Watkins, Director, provided certain sales, marketing and commercialization consulting services to the Company prior to his appointment
to the Board of Directors. For the fiscal years ended December 31, 2023 and 2022, the Company paid Mr. Watkins $11,083 and $3,523, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
Seale, our former Chief Financial Officer, is also the managing partner of RBSK. Mr. Seale, through RBSK, has provided accounting
services since 2017. For the fiscal years ended December 31, 2023 and 2022, the Company paid RBSK $312,803 and $116,542,
respectively, for accounting services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have adopted a formal policy that our executive officers, directors, holders of more than 5% of any class of our voting securities, and
any member of the immediate family of and any entity affiliated with any of the foregoing persons, are not permitted to enter into a
related party transaction with us without the prior consent of our Audit Committee, or other independent members of our Board of Directors
if it is inappropriate for our audit committee to review such transaction due to a conflict of interest. Any request for us to enter
into a transaction with an executive officer, director, principal shareholder, or any of their immediate family members or affiliates,
in which the amount involved exceeds the lesser of $120,000 or 1% of the average of our total assets at year-end for the last two completed
fiscal years must first be presented to our audit committee for review, consideration and approval. In approving or rejecting any such
proposal, our Audit Committee is to consider the relevant facts and circumstances available and deemed relevant to the audit committee,
including, but not limited to, whether the transaction is on terms no less favorable than terms generally available to an unaffiliated
third party under the same or similar circumstances and the extent of the related party&#8217;s interest in the transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><span id="s_016"></span>Item
14. Principal Accounting Fees and Services</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fees
Billed for Audit and Non-Audit Services</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents for each of the last two fiscal years the aggregate fees billed in connection with the audits of our financial
statements and other professional services rendered by our independent registered public accounting firm Rosenberg Rich Baker Berman,
P.A.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left">Audit Fees (1)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">221,570<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">162,165</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
<i>Audit Fees</i>. These are fees for professional services for the audit of our annual financial statements, and for the review of the
financial statements included in our filings on Form 10-K and Form 10-Q, and for services that are normally provided in connection with
statutory and regulatory filings or engagements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 85; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="s_017"></span>PART
IV</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="s_018"></span>ITEM
15. EXHIBIT AND FINANCIAL STATEMENT SCHEDULES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 12.95pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
    Financial Statements</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    financial statements and Report of Independent Registered Public Accounting Firm are listed in the &#8220;Index to Financial Statements
    and Schedules&#8221; on page F-1 and included from F-2 onwards.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
    Financial Statement Schedules</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    schedules for which provision is made in the applicable accounting regulations of the Securities and Exchange Commission (the &#8220;Commission&#8221;)
    are either not required under the related instructions, are not applicable (and therefore have been omitted), or the required disclosures
    are contained in the financial statements included herein.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
    Exhibits (including those incorporated by reference).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Exhibits</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.75in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    Description</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex3-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Incorporation (incorporated by reference to exhibit 3.1 to Registration Statement on Form S-1, filed on January 10, 2023)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1933567/000149315223002577/ex3-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to Certificate of Incorporation (incorporated by reference to exhibit 3.2 to Registration Statement on Form S-1, filed on January 26, 2023)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex3-3.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bylaws (incorporated by reference to exhibit 3.3 to Registration Statement on Form S-1, filed on January 10, 2023)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex4-1.htm">Description of the Company&#8217;s Securities</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex4-21.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second Amendment to Shareholders&#8217; Agreement, dated January 8, 2023 (incorporated by reference to exhibit 4.21 to Registration Statement on Form S-1, filed on January 10, 2023)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1933567/000149315223019787/ex4-23.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Warrant related to 2023 Private Placement (incorporated by reference to exhibit 4.23 to Registration Statement on Form S-1, filed on June 1, 2023)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex10-12.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement between Neuraxis, Inc. and Brian Carrico, dated as of August 9, 2022 (incorporated by reference to exhibit 10.12 to Registration Statement on Form S-1, filed on January 10, 2023)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1933567/000149315223019787/ex10-13.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Amendment to Executive Employment Agreement between Neuraxis, Inc. and Brian Carrico, dated as of May 4, 2023 (incorporated by reference to exhibit 10.13 to Registration Statement on Form S-1, filed on June 1, 2023)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex10-13.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement between Neuraxis, Inc. and Adrian Miranda, dated as of August 17, 2022 (incorporated by reference to exhibit 10.13 to Registration Statement on Form S-1, filed on January 10, 2023)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex10-14.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement between Neuraxis, Inc. and Thomas Carrico, dated as of August 9, 2022 (incorporated by reference to exhibit 10.14 to Registration Statement on Form S-1, filed on January 10, 2023)</span></a></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 86; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1933567/000149315223019787/ex10-16.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Amendment to Executive Employment Agreement between Neuraxis, Inc. and Thomas Carrico, dated as of May 4, 2023 (incorporated by reference to exhibit 10.16 to Registration Statement on Form S-1, filed on June 1, 2023)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex10-15.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement between Neuraxis, Inc. and Dan Clarence, dated as of August 9, 2022 (incorporated by reference to exhibit 10.15 to Registration Statement on Form S-1, filed on January 10, 2023)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1933567/000149315223019787/ex10-18.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Amendment to Executive Employment Agreement between Neuraxis, Inc. and Dan Clarence, dated as of May 4, 2023 (incorporated by reference to exhibit 10.18 to Registration Statement on Form S-1, filed on June 1, 2023)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex10-16.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement between Neuraxis, Inc. and Christopher Robin Brown, dated as of August 9, 2022 (incorporated by reference to exhibit 10.16 to Registration Statement on Form S-1, filed on January 10, 2023)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1933567/000149315223019787/ex10-20.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Amendment to Executive Employment Agreement between Neuraxis, Inc. and Christopher Robin Brown, dated as of May 4, 2023 (incorporated by reference to exhibit 10.20 to Registration Statement on Form S-1, filed on June 1, 2023)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex10-17.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement between Neuraxis, Inc. and Gary Peterson, dated as of August 9, 2022 (incorporated by reference to exhibit 10.17 to Registration Statement on Form S-1, filed on January 10, 2023)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1933567/000149315223019787/ex10-22.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Amendment to Executive Employment Agreement between Neuraxis, Inc. and Gary Peterson, dated as of May 4, 2023 (incorporated by reference to exhibit 10.22 to Registration Statement on Form S-1, filed on June 1, 2023)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex10-20.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Innovative Health Solutions, Inc. 2017 Stock Compensation Plan, as amended (incorporated by reference to exhibit 10.20 to Registration Statement on Form S-1, filed on January 10, 2023)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex10-21.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan (incorporated by reference to exhibit 10.21 to Registration Statement on Form S-1, filed on January 10, 2023)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14&#8224;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1933567/000149315223002577/ex10-26.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First Amendment to Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan (incorporated by reference to exhibit 10.26 to Registration Statement on Form S-1, filed on January 26, 2023)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1933567/000149315223019787/ex10-32.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Securities Purchase Agreement related to 2023 Private Placement (incorporated by reference to exhibit 10.32 to Registration Statement on Form S-1, filed on June 1, 2023)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1933567/000149315223019787/ex10-33.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Senior Secured Convertible Note related to 2023 Private Placement (incorporated by reference to exhibit 10.33 to Registration Statement on Form S-1, filed on June 1, 2023)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1933567/000149315223019787/ex10-34.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Security Agreement related to 2023 Private Placement (incorporated by reference to exhibit 10.34 to Registration Statement on Form S-1, filed on June 1, 2023)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1933567/000149315223019787/ex10-35.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Registration Rights Agreement related to 2023 Private Placement (incorporated by reference to exhibit 10.35 to Registration Statement on Form S-1, filed on June 1, 2023)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1933567/000149315223040826/ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities purchase agreement, dated November 9, 2023, between the Company and Flagstaff International, LLC (incorporated by reference to exhibit 10.1 to current report on Form 8-K, furnished to the SEC on November 14, 2023)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1933567/000149315223040826/ex10-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registration rights agreement, dated November 9, 2023, between the Company and Flagstaff International, LLC (incorporated by reference to exhibit 10.2 to current report on Form 8-K, furnished to the SEC on November 14, 2023)</span></a></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 87; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.75in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1933567/000149315223001110/ex21-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">List of Subsidiaries of Neuraxis, Inc. (incorporated by reference to exhibit 21.1 to Registration Statement on Form S-1, filed on January 10, 2023)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex31-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act Of 2002</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex31-2.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act Of 2002</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1**</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ex32-1.htm">Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act Of 2002</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">97.1*</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><a href="ex97-1.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NeurAxis, Inc. Compensation Recovery Policy</span></a></p>
</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Instance Document.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Schema Document.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Calculation Linkbase Document.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Definition Linkbase Document.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Label Linkbase Document.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline
    XBRL Taxonomy Extension Presentation Linkbase Document.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover
    Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8224; Executive compensation plan or arrangement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">* Filed herewith.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">** Furnished herewith.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="s_019"></span>ITEM
16. FORM 10-K SUMMARY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
Applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 88; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Index to Financial Statements</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FOR
THE YEARS ENDED DECEMBER 31, 2023 AND 2022</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page(s)</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#Z_001">Report of Independent Registered Public Accounting Firm</a> (PCAOB Firm ID <span id="xdx_90E_edei--AuditorFirmId_c20230101__20231231_zOkpODSifRY7"><span style="-sec-ix-hidden: xdx2ixbrl0045">0089</span></span>)</p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">F-1</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#f_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance Sheets as of December 31, 2023 and 2022</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#f_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statements of Operations for the Years Ended December 31, 2023 and 2022</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-</span>4</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#f_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statements of Stockholders&#8217; Deficit for the Years Ended December 31, 2023 and 2022</span></a></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-</span>5</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="#f_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Statements of Cash Flows for the Years Ended December 31, 2023 and 2022</span></a></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#f_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to Financial Statements</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-</span>7</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 89; Options: NewSection; Value: 89 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b><span id="Z_001"></span></b>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Board of Directors and<br/>
Stockholders of Neuraxis, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion
on the Financial Statements</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying balance sheets of Neuraxis, Inc. (the Company) as of December 31, 2023 and 2022, and the related statements
of operations, stockholders&#8217; equity (deficit), and cash flows for each of the years in the two year period ended December 31, 2023,
and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements present fairly,
in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and
its cash flows for each of the years then ended, in conformity with accounting principles generally accepted in the United States of
America.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restatement
of Previously Issued Financial Statements</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
discussed in Note 19 to the financial statements, the Company restated its 2023 quarterly information for an error in the classification
of warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emphasis
of Matter Regarding Going Concern</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note
2 to the financial statements, the Company is not profitable, has recorded negative cash flows from operations, and will need substantial
capital to support its operations. This raises substantial doubt about the Company&#8217;s ability to continue as a going concern. Management&#8217;s
plans in regard to these matters also are described in Note 2. The financial statements do not include any adjustments that might result
from the outcome of this uncertainty.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basis
for Opinion</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities
laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits,
we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion
on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits
provide a reasonable basis for our opinion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    <span id="xdx_909_edei--AuditorName_c20230101__20231231_z4wXGs5f03zf"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000046" name="dei:AuditorName">Rosenberg Rich Baker Berman, P.A</ix:nonNumeric></span>.</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    have served as the Company&#8217;s auditor since 2022.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--AuditorLocation_c20230101__20231231_zpbi4ozW1YDl"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact000047" name="dei:AuditorLocation">Somerset,
    New Jersey</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
    16, 2024</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 90; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="f_001"></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc. </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>
Balance Sheets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_307_111_zAkNL3RaOIT3" summary="xdx: Statement - Balance Sheets" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_499_20231231_zTFhcV3s54Hf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_495_20221231_zpYOwUfZSSK6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"/><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AssetsAbstract_iB_zxn6Axmhh6Nc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><b>Assets</b></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AssetsCurrentAbstract_i01B_zQ4tukaqkFbf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maACzGAE_ziieCadYAwjj" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Cash and cash equivalents</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 16%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-12-31" id="Fact000055" format="ixt:numdotdecimal" decimals="0" unitRef="USD">78,560</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2022-12-31" id="Fact000056" format="ixt:numdotdecimal" decimals="0" unitRef="USD">253,699</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AccountsReceivableNetCurrent_i02I_maACzGAE_zTIrRZxe716h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accounts receivable, net</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2023-12-31" id="Fact000058" format="ixt:numdotdecimal" decimals="0" unitRef="USD">73,167</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2022-12-31" id="Fact000059" format="ixt:numdotdecimal" decimals="0" unitRef="USD">174,399</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--InventoryNet_i02I_maACzGAE_z0jY4V3XGBld" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Inventories</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2023-12-31" id="Fact000061" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,220</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2022-12-31" id="Fact000062" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,133</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maACzGAE_zIHUc0xTLEb4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Prepaids and other current assets</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000064" format="ixt:numdotdecimal" decimals="0" unitRef="USD">69,663</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2022-12-31" id="Fact000065" format="ixt:numdotdecimal" decimals="0" unitRef="USD">726</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AssetsCurrent_i01TI_mtACzGAE_maAz13B_zbZImHaeaDS2" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 20pt; text-align: left">Total current assets</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-12-31" id="Fact000067" format="ixt:numdotdecimal" decimals="0" unitRef="USD">242,610</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2022-12-31" id="Fact000068" format="ixt:numdotdecimal" decimals="0" unitRef="USD">476,957</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_i01I_maPPAENzICW_zwyytYn5Yyq" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Property and Equipment, at cost:</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31" id="Fact000070" format="ixt:numdotdecimal" decimals="0" unitRef="USD">436,626</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31" id="Fact000071" format="ixt:numdotdecimal" decimals="0" unitRef="USD">405,845</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_i02NI_di_msPPAENzICW_zRW3JBK5v7d7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Less - accumulated depreciation</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2023-12-31" id="Fact000073" format="ixt:numdotdecimal" decimals="0" unitRef="USD">348,074</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2022-12-31" id="Fact000074" format="ixt:numdotdecimal" decimals="0" unitRef="USD">317,834</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentNet_i01TI_mtPPAENzICW_maAz13B_zMdP711xEcBe" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 20pt; text-align: left">Property and equipment, net</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-12-31" id="Fact000076" format="ixt:numdotdecimal" decimals="0" unitRef="USD">88,552</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-12-31" id="Fact000077" format="ixt:numdotdecimal" decimals="0" unitRef="USD">88,011</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OtherAssetsNoncurrentAbstract_i01B_zeOGOSGUyC36" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredCosts_i02I_maAz13B_zbHu11o8MSPb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Deferred offering costs</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0082">&#8212;</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredCosts" contextRef="AsOf2022-12-31" id="Fact000083" format="ixt:numdotdecimal" decimals="0" unitRef="USD">736,736</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeaseRightOfUseAsset_i02I_maAz13B_z2Frmp45najh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Operating lease right of use asset, net</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-12-31" id="Fact000085" format="ixt:numdotdecimal" decimals="0" unitRef="USD">70,263</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2022-12-31" id="Fact000086" format="ixt:numdotdecimal" decimals="0" unitRef="USD">101,382</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsNet_i02I_maAz13B_zoSPPI6CRpMa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Intangible assets, net</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2023-12-31" id="Fact000088" format="ixt:numdotdecimal" decimals="0" unitRef="USD">108,073</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2022-12-31" id="Fact000089" format="ixt:numdotdecimal" decimals="0" unitRef="USD">77,558</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--Assets_iTI_mtAz13B_zX2tLumc2pNl" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">Total Assets</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-12-31" id="Fact000091" format="ixt:numdotdecimal" decimals="0" unitRef="USD">509,498</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2022-12-31" id="Fact000092" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,480,644</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Notes
to financial statements are an integral part of these statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 91; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc. </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>
Balance Sheets</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"/><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zNYUNzs1Y114" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Liabilities</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LiabilitiesCurrentAbstract_i01B_zYyVVl09KVFi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Current Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AccountsPayableCurrent_i02I_maLCz0L4_zXrt5J6QmHdb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Accounts payable</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 16%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-12-31" id="Fact000100" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,204,219</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2022-12-31" id="Fact000101" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,592,116</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AccruedLiabilitiesCurrent_i02I_maLCz0L4_z4voiHG8w7wl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accrued expenses</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000103" format="ixt:numdotdecimal" decimals="0" unitRef="USD">401,088</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31" id="Fact000104" format="ixt:numdotdecimal" decimals="0" unitRef="USD">834,062</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NotesPayableCurrent_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_maLCz0L4_zWuqMrUmD9Ej" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Notes payable</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2023-12-31_us-gaap_NonrelatedPartyMember" id="Fact000106" format="ixt:numdotdecimal" decimals="0" unitRef="USD">148,062</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2022-12-31_us-gaap_NonrelatedPartyMember" id="Fact000107" format="ixt:numdotdecimal" decimals="0" unitRef="USD">202,834</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_maLCz0L4_zJjo0vt0k2H4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
portion of operating lease payable <b></b></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><b><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-12-31" id="Fact000109" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,127</ix:nonFraction></b></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2022-12-31" id="Fact000110" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,395</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NotesPayableCurrent_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zF5C5HZdxpM" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Notes payable - related party</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0112">&#8212;</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember" id="Fact000113" format="ixt:numdotdecimal" decimals="0" unitRef="USD">58,051</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--NotesPayableCurrent_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_maLCz0L4_zgTTntvZLCOe" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
    payable</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0115">&#8212;</span></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember" id="Fact000116" format="ixt:numdotdecimal" decimals="0" unitRef="USD">58,051</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_40A_eus-gaap--ConvertibleNotesPayableCurrent_i02I_maLCz0L4_z6OUnTXEKO11" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Notes payable - convertible notes, net of unamortized discount of <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span id="xdx_906_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iI_c20231231_z42zYQVENZCj" title="Unamortized discount, net"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountCurrent" contextRef="AsOf2023-12-31" id="Fact000121" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span>
    and $<span id="xdx_90F_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iI_c20221231_zLxVyuOwoAX8" title="Unamortized discount, net"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountCurrent" contextRef="AsOf2022-12-31" id="Fact000123" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,327,213</ix:nonFraction></span> as of December 31, 2023 and December 31, 2022 <b></b></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0118">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ConvertibleNotesPayableCurrent" contextRef="AsOf2022-12-31" id="Fact000119" format="ixt:numdotdecimal" decimals="0" unitRef="USD">228,342</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--Deposits_i02I_maLCz0L4_zn2ZzJuHFJIf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Customer deposits</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Deposits" contextRef="AsOf2023-12-31" id="Fact000125" format="ixt:numdotdecimal" decimals="0" unitRef="USD">74,947</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Deposits" contextRef="AsOf2022-12-31" id="Fact000126" format="ixt:numdotdecimal" decimals="0" unitRef="USD">59,174</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DerivativeLiabilitiesCurrent_i02I_maLCz0L4_z2l3DklfMjRf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Derivative liabilities</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0128">&#8212;</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2022-12-31" id="Fact000129" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,735,700</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--WarrantLiabilities_i02I_maLCz0L4_zas1SFf9zGqk" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Warrant liabilities</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="NRXS:WarrantLiabilities" contextRef="AsOf2023-12-31" id="Fact000131" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,225</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="NRXS:WarrantLiabilities" contextRef="AsOf2022-12-31" id="Fact000132" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,234,384</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LiabilitiesCurrent_i01TI_mtLCz0L4_maLzwXC_znG4ApV6Vtzi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 20pt; text-align: left">Total current liabilities</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact000134" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,885,668</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2022-12-31" id="Fact000135" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,978,058</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LiabilitiesNoncurrentAbstract_i01B_z3cy10rMccSg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Non-current Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingLeaseLiabilityNoncurrent_i02I_maLNzyOg_zBaDksaDITyk" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
lease payable, net of current portion <b></b></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><b><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2023-12-31" id="Fact000140" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,071</ix:nonFraction></b></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2022-12-31" id="Fact000141" format="ixt:numdotdecimal" decimals="0" unitRef="USD">76,199</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LiabilitiesNoncurrent_i01TI_mtLNzyOg_maLzwXC_zAXmB6jcVZ0i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
non-current liabilities </span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><b><ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="AsOf2023-12-31" id="Fact000143" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,071</ix:nonFraction></b></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="AsOf2022-12-31" id="Fact000144" format="ixt:numdotdecimal" decimals="0" unitRef="USD">76,199</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--Liabilities_iTI_mtLzwXC_maLASEz1VI_z90h0XZ1sJv" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 20pt; text-align: left">Total liabilities</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2023-12-31" id="Fact000146" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,912,739</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2022-12-31" id="Fact000147" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,054,257</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CommitmentsAndContingencies_iI_maLASEz1VI_zOG7SnsF6ml" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commitments and contingencies (see note 14) <b></b></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--StockholdersEquityAbstract_i01B_zwMkajlzUMh4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Stockholders&#8217;  Deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PreferredStockValue_i02I_hus-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesAPreferredStockMember_zRJxnWHtMMQg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> Convertible Series A
    Preferred stock, $<span id="xdx_903_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesAPreferredStockMember_zwYYyMGQ9jX7" title="Preferred stock, par value"><span id="xdx_901_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesAPreferredStockMember_zns1JnCsW7Yj" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31_custom_ConvertibleSeriesAPreferredStockMember" id="Fact000158" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31_custom_ConvertibleSeriesAPreferredStockMember" id="Fact000160" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> par value; <span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesAPreferredStockMember_zgJ5ERulgVLj" title="Preferred stock, shares authorized"><span id="xdx_90E_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesAPreferredStockMember_z1VbF1Tatfoh" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31_custom_ConvertibleSeriesAPreferredStockMember" id="Fact000162" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-12-31_custom_ConvertibleSeriesAPreferredStockMember" id="Fact000164" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesAPreferredStockMember_zAgMBiNMyrH4" title="Preferred stock, shares issued"><span id="xdx_907_eus-gaap--PreferredStockSharesOutstanding_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesAPreferredStockMember_zIIkxQPYtjq9" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-12-31_custom_ConvertibleSeriesAPreferredStockMember" id="Fact000166" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-12-31_custom_ConvertibleSeriesAPreferredStockMember" id="Fact000168" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></ix:nonFraction></span></span> issued and outstanding as of December 31, 2023 and <span id="xdx_90D_eus-gaap--PreferredStockSharesIssued_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesAPreferredStockMember_zVGaY5wO9Eu5" title="Preferred stock, shares issued"><span id="xdx_902_eus-gaap--PreferredStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesAPreferredStockMember_zJttgfitsZM1" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-12-31_custom_ConvertibleSeriesAPreferredStockMember" id="Fact000170" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-12-31_custom_ConvertibleSeriesAPreferredStockMember" id="Fact000172" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">506,637</ix:nonFraction></ix:nonFraction></span></span> as of
    December 31, 2022</span></td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0155">&#8212;</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2022-12-31_custom_ConvertibleSeriesAPreferredStockMember" id="Fact000156" format="ixt:numdotdecimal" decimals="0" unitRef="USD">507</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PreferredStockValue_i02I_hus-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_zXdaYW5Srok" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Convertible Series Seed Preferred Stock, $<span id="xdx_908_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_zCWcqWEWmDKa" title="Preferred stock, par value"><span id="xdx_90D_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_zvBVmWv0Kzk4" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31_custom_ConvertibleSeriesSeedPreferredStockMember" id="Fact000177" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31_custom_ConvertibleSeriesSeedPreferredStockMember" id="Fact000179" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> par value; <span id="xdx_908_eus-gaap--PreferredStockSharesAuthorized_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_zkXSccjg3S3l" title="Preferred stock, shares authorized"><span id="xdx_90C_eus-gaap--PreferredStockSharesAuthorized_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_zg0ztaxXaAWg" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31_custom_ConvertibleSeriesSeedPreferredStockMember" id="Fact000181" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2022-12-31_custom_ConvertibleSeriesSeedPreferredStockMember" id="Fact000183" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">120,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_907_eus-gaap--PreferredStockSharesIssued_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_zmeY6DjP1GBc" title="Preferred stock, shares issued"><span id="xdx_90D_eus-gaap--PreferredStockSharesOutstanding_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_zSmeWUyIo5Sj" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-12-31_custom_ConvertibleSeriesSeedPreferredStockMember" id="Fact000185" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-12-31_custom_ConvertibleSeriesSeedPreferredStockMember" id="Fact000187" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></ix:nonFraction></span></span> issued and outstanding as of <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
31, 2023 and <span id="xdx_907_eus-gaap--PreferredStockSharesIssued_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_zrqmtHaveHke" title="Preferred stock, shares issued"><span id="xdx_907_eus-gaap--PreferredStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_zEh8pOWhPTL" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-12-31_custom_ConvertibleSeriesSeedPreferredStockMember" id="Fact000189" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-12-31_custom_ConvertibleSeriesSeedPreferredStockMember" id="Fact000191" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">115,477</ix:nonFraction></ix:nonFraction></span></span> as of December 31, 2022</span></td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0174">&#8212;</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2022-12-31_custom_ConvertibleSeriesSeedPreferredStockMember" id="Fact000175" format="ixt:numdotdecimal" decimals="0" unitRef="USD">115</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--PreferredStockValue_i02I_hus-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_maSEzjMr_zVzR5U0e5qXl" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred
    Stock, value</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0193">&#8212;</span></span></td><td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2022-12-31_custom_ConvertibleSeriesSeedPreferredStockMember" id="Fact000194" format="ixt:numdotdecimal" decimals="0" unitRef="USD">115</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr id="xdx_404_eus-gaap--CommonStockValue_i02I_maSEzjMr_zxY3Dhr25CP1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Common stock, $<span id="xdx_902_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20231231_zEQl5ecbvqWl" title="Common stock, par value"><span id="xdx_90E_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20221231_zZKZ3JLQixUc" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" id="Fact000199" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2022-12-31" id="Fact000201" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> par value; <span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_iI_c20231231_ziJ5mbYsYff2" title="Common stock, shares authorized"><span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_iI_c20221231_zgP5gsbtwQN2" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact000203" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-12-31" id="Fact000205" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_905_eus-gaap--CommonStockSharesIssued_iI_c20231231_zSdxgqxm2rn" title="Common stock, shares issued"><span id="xdx_907_eus-gaap--CommonStockSharesOutstanding_iI_c20231231_z390z98nGeu2" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-12-31" id="Fact000207" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31" id="Fact000209" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,508,897</ix:nonFraction></ix:nonFraction></span></span> issued and outstanding as of
<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2023 and <span id="xdx_906_eus-gaap--CommonStockSharesIssued_iI_c20221231_zRSHHkbxpPn4" title="Common stock, shares issued"><span id="xdx_90F_eus-gaap--CommonStockSharesOutstanding_iI_c20221231_zmsGad09iqY3" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-12-31" id="Fact000211" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-12-31" id="Fact000213" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,963,322</ix:nonFraction></ix:nonFraction></span></span> as of December 31, 2022</span></td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-12-31" id="Fact000196" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,509</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2022-12-31" id="Fact000197" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,963</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AdditionalPaidInCapital_i02I_maSEzjMr_zUJpXTekClMe" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Additional paid in capital</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-12-31" id="Fact000215" format="ixt:numdotdecimal" decimals="0" unitRef="USD">47,148,361</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2022-12-31" id="Fact000216" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,355,230</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maSEzjMr_zI7s6ULsKNqi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Accumulated deficit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-12-31" id="Fact000218" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">48,558,111</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2022-12-31" id="Fact000219" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">33,931,428</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--StockholdersEquity_i02TI_mtSEzjMr_maLASEz1VI_zfsIpUk6Jx9g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 20pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total stockholders&#8217;
 deficit </span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000221" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,403,241</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" id="Fact000222" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,573,613</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_mtLASEz1VI_zlk3seRTOpAl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">Total Liabilities and Stockholders&#8217;  Deficit </td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000224" format="ixt:numdotdecimal" decimals="0" unitRef="USD">509,498</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2022-12-31" id="Fact000225" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,480,644</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Notes
to financial statements are an integral part of these statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 92; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span id="f_002"></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc. </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>
Statements of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" id="xdx_306_113_zASqgGqj74Lh" summary="xdx: Statement - Statements of Operations" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49A_20230101__20231231_zeQAoyxW4KZ" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_497_20220101__20221231_zcBqHmKtgRTf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: left">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: left">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_maCzEo3_zkU9zsaiq5e1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; font-weight: bold; text-align: left">Net Sales</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 14%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-01to2023-12-31" id="Fact000227" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,460,049</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-012022-12-31" id="Fact000228" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,684,735</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--CostOfGoodsAndServicesSold_msCzEo3_zoiLiJjSi8sf" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Cost of Goods Sold</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2023-01-01to2023-12-31" id="Fact000230" format="ixt:numdotdecimal" decimals="0" unitRef="USD">303,345</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2022-01-012022-12-31" id="Fact000231" format="ixt:numdotdecimal" decimals="0" unitRef="USD">297,060</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--GrossProfit_iT_mtCzEo3_maCzyZB_zBMe5ZxSkLs5" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Gross Profit</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2023-01-01to2023-12-31" id="Fact000233" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,156,704</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2022-01-012022-12-31" id="Fact000234" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,387,675</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--SellingExpense_i01_msCzyZB_zsdVGm9pE52f" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Selling Expenses</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:SellingExpense" contextRef="From2023-01-01to2023-12-31" id="Fact000236" format="ixt:numdotdecimal" decimals="0" unitRef="USD">323,569</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SellingExpense" contextRef="From2022-01-012022-12-31" id="Fact000237" format="ixt:numdotdecimal" decimals="0" unitRef="USD">410,883</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ResearchAndDevelopmentExpense_i01_msCzyZB_z0FZCC2Awfbf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and Development</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-01to2023-12-31" id="Fact000239" format="ixt:numdotdecimal" decimals="0" unitRef="USD">169,315</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-01-012022-12-31" id="Fact000240" format="ixt:numdotdecimal" decimals="0" unitRef="USD">225,610</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--GeneralAndAdministrativeExpense_i01_msCzyZB_zOAmnMJhaJJ4" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">General and Administrative</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-01to2023-12-31" id="Fact000242" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,328,315</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2022-01-012022-12-31" id="Fact000243" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,123,420</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingIncomeLoss_iT_mtCzyZB_maCz7fC_zua0t77PtWH6" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">Operating Loss</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-01-01to2023-12-31" id="Fact000245" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,664,495</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-01-012022-12-31" id="Fact000246" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,372,238</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zYoAyjEbRAG4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other (Expense) Income:</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--FinancingCharges_i01N_di_msCzhXJ_z8msmcaJvWee" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Financing charges</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="NRXS:FinancingCharges" contextRef="From2023-01-01to2023-12-31" id="Fact000251" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,772</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="NRXS:FinancingCharges" contextRef="From2022-01-012022-12-31" id="Fact000252" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,322,216</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--InterestExpense_i01N_di_msCzhXJ_z8TQccRxkrwb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Interest expense</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2023-01-01to2023-12-31" id="Fact000254" format="ixt:numdotdecimal" decimals="0" unitRef="USD">476,416</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2022-01-012022-12-31" id="Fact000255" format="ixt:numdotdecimal" decimals="0" unitRef="USD">318,666</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--FairValueAdjustmentOfWarrants_i01N_di_msCzhXJ_zYAT4BpKijNl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of warrant liability</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-01-01to2023-12-31" id="Fact000257" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">844,854</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-01-012022-12-31" id="Fact000258" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">606,049</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DerivativeGainLossOnDerivativeNet_i01_maCzhXJ_zsKGEvNmvsr1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of derivative liability</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2023-01-01to2023-12-31" id="Fact000260" format="ixt:numdotdecimal" decimals="0" unitRef="USD">198,551</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2022-01-012022-12-31" id="Fact000261" format="ixt:numdotdecimal" decimals="0" unitRef="USD">713,989</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_i01N_di_msCzhXJ_zPbn9h5xVnOf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Amortization of debt discount and issuance cost</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="From2023-01-01to2023-12-31" id="Fact000263" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,881,622</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="From2022-01-012022-12-31" id="Fact000264" format="ixt:numdotdecimal" decimals="0" unitRef="USD">98,935</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i01_maCzhXJ_zT3Kda73kCr2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Extinguishment of debt liabilities</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2023-01-01to2023-12-31" id="Fact000266" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,649,561</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0267">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OtherNonoperatingIncome_i01_maCzhXJ_zr99b80NA4i7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Other income</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncome" contextRef="From2023-01-01to2023-12-31" id="Fact000269" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,133</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncome" contextRef="From2022-01-012022-12-31" id="Fact000270" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,956</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OtherNonoperatingExpense_i01N_di_msCzhXJ_zVcCpNZL8GO9" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Other expense</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingExpense" contextRef="From2023-01-01to2023-12-31" id="Fact000272" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,355</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0273">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OtherNonoperatingIncomeExpense_i01T_mtCzhXJ_maCz7fC_z8esqv2aqjq5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 20pt; text-align: left">Total other (expense) income, net</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2023-01-01to2023-12-31" id="Fact000275" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,962,188</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2022-01-012022-12-31" id="Fact000276" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,407,823</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLoss_iT_mtCz7fC_zI4WPJkkA831" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">Net Loss</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-01to2023-12-31" id="Fact000278" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,626,683</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31" id="Fact000279" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,780,061</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--EarningsPerShareAbstract_iB_zKK1FdUiVXmf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; font-weight: bold; text-align: left">Per-share Data</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Basic and diluted loss per share</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span id="xdx_909_eus-gaap--EarningsPerShareBasic_i01_pid_uUSDPShares_c20230101__20231231_z3qMjLCi64t7" title="Per-share Data, basic loss per share" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__"><span id="xdx_903_eus-gaap--EarningsPerShareDiluted_i01_pid_uUSDPShares_c20230101__20231231_z6Slkts96Qw8" title="Per-share Data, diluted loss per share" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-01to2023-12-31" id="Fact000284" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-01to2023-12-31" id="Fact000286" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">4.50</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90D_eus-gaap--EarningsPerShareBasic_i01_pid_uUSDPShares_c20220101__20221231_z2scwKlBVuf6" title="Per-share Data, basic loss per share" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__"><span id="xdx_903_eus-gaap--EarningsPerShareDiluted_i01_pid_uUSDPShares_c20220101__20221231_zhSkf0MqNqUj" title="Per-share Data, diluted loss per share" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-01-012022-12-31" id="Fact000288" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-01-012022-12-31" id="Fact000290" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">2.77</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--WeightedAverageNumberOfSharesOutstandingAbstract_iB_zJ5MzCGw8sGl" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Weighted Average Shares Outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Basic and diluted</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span id="xdx_908_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i01_pid_c20230101__20231231_zHgCsQHqUIxf" title="Weighted Average Shares Outstanding, Basic" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__"><span id="xdx_900_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_i01_pid_c20230101__20231231_zG7wFWoCSGS3" title="Weighted Average Shares Outstanding, Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-01to2023-12-31" id="Fact000295" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-01to2023-12-31" id="Fact000297" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,252,328</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90E_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i01_pid_c20220101__20221231_zA2osirOySFb" title="Weighted Average Shares Outstanding, Basic" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_i01_pid_c20220101__20221231_zAoTzg4imFH6" title="Weighted Average Shares Outstanding, Diluted" class="xdx_phnt_U3RhdGVtZW50IC0gU3RhdGVtZW50cyBvZiBPcGVyYXRpb25zAA__"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-01-012022-12-31" id="Fact000299" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-01-012022-12-31" id="Fact000301" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,003,322</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Notes
to financial statements are an integral part of these statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 93; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="f_003"></span>Neuraxis,
Inc. </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>
Statements of Stockholders&#8217;  Deficit</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>For the Twelve
Months Ended December 31, 2023 and 2022</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<table cellpadding="0" cellspacing="0" id="xdx_30B_114_zCvluUFm1QVk" summary="xdx: Statement - Statements of Stockholders' Deficit" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares</b></span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" id="xdx_4B9_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_custom--ConvertibleSeriesAPreferredStockMember_zLmH381Nr2je" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amount</b></span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares</b></span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" id="xdx_4B0_us-gaap--StatementEquityComponentsAxis_us-gaap--PreferredStockMember_us-gaap--StatementClassOfStockAxis_custom--ConvertibleSeriesSeedPreferredStockMember_zQv4DBUPXzn4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amount</b></span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares</b></span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" id="xdx_4B8_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zOw4nZ9RV3e5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amount</b></span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" id="xdx_4BA_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zMKup6pKVFd5" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Capital</b></span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" id="xdx_4BC_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zefNS3II2XVh" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Deficit</b></span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" id="xdx_4B8_zLnHqtGCTW25" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Deficit)</b></span></td><td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Convertible Series A Preferred Stock </td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Convertible Series Seed Preferred Stock </td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Common Stock</b> </td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><b>Additional Paid In </b></td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Accumulated </td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center"><b>Stockholders&#8217;</b></td><td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><b>&#160;</b></td><td style="text-align: center; font-weight: bold"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>Shares</b></td><td style="text-align: center; font-weight: bold"><b>&#160;</b></td><td style="text-align: center; font-weight: bold"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>Amount</b></td><td style="text-align: center; font-weight: bold"><b>&#160;</b></td><td style="text-align: center; font-weight: bold"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>Shares</b></td><td style="text-align: center; font-weight: bold"><b>&#160;</b></td><td style="text-align: center; font-weight: bold"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>Amount</b></td><td style="text-align: center; font-weight: bold"><b>&#160;</b></td><td style="text-align: center; font-weight: bold"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>Shares</b></td><td style="text-align: center; font-weight: bold"><b>&#160;</b></td><td style="text-align: center; font-weight: bold"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><b>Amount</b></td><td style="text-align: center; font-weight: bold"><b>&#160;</b></td><td style="text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Capital</b></td><td style="text-align: center"><b>&#160;</b></td><td style="text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Deficit</b></td><td style="text-align: center"><b>&#160;</b></td><td style="text-align: center"><b>&#160;</b></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>Deficit</b></td><td style="text-align: center"><b>&#160;</b></td></tr>
  <tr id="xdx_432_c20220101__20221231_eus-gaap--StockholdersEquity_iS_zXPkELp8eixi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; font-weight: bold; text-align: left">Balances as of January 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--SharesOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesAPreferredStockMember_zmRIloeX6qsc" title="Balance, shares" style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember" id="Fact000310" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">506,637</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember" id="Fact000303" format="ixt:numdotdecimal" decimals="0" unitRef="USD">507</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharesOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_zFv5TfmUSKb9" title="Balance, shares" style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember" id="Fact000312" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">115,477</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember" id="Fact000304" format="ixt:numdotdecimal" decimals="0" unitRef="USD">115</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharesOutstanding_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBA6sYzhMWAc" title="Balance, shares" style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" id="Fact000314" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,928,004</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" id="Fact000305" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,928</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000306" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,323,157</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember" id="Fact000307" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">29,151,367</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 4%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-12-31" id="Fact000308" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">825,660</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zb5B0xiXOBOg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Stock based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0316">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0317">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0318">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000319" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,319</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0320">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2022-01-012022-12-31" id="Fact000321" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,319</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_z077JgUbhVWj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Common stock issued upon signing of notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0323">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0324">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z2veZk9k2cT1" title="Common stock issued upon signing of notes payable, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="Fact000330" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">35,318</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="Fact000325" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000326" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,754</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0327">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2022-01-012022-12-31" id="Fact000328" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,789</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLoss_zsGABLTWsI5c" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0332">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0333">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0334">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0335">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember" id="Fact000336" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,780,061</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31" id="Fact000337" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,780,061</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_431_c20230101__20231231_eus-gaap--StockholdersEquity_iS_zZPAvlY1u85" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Balances as of December 31, 2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesAPreferredStockMember_zYYI86tEfvva" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember" id="Fact000346" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">506,637</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember" id="Fact000339" format="ixt:numdotdecimal" decimals="0" unitRef="USD">507</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_zTelQcxkfRO9" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember" id="Fact000348" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">115,477</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember" id="Fact000340" format="ixt:numdotdecimal" decimals="0" unitRef="USD">115</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--SharesOutstanding_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4I8jLq7oLI4" title="Balance, shares" style="text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000350" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,963,322</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact000341" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,963</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000342" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,355,230</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember" id="Fact000343" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">33,931,428</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-12-31" id="Fact000344" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,573,613</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_ecustom--StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering_zG94mszEwCL3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Common stock issued upon initial public offering</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0352">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0353">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--StockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zGmfmmrU5hGl" title="Common stock issued upon initial public offering, shares" style="text-align: right"><ix:nonFraction name="NRXS:StockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000359" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,098,667</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="NRXS:StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000354" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,099</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="NRXS:StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000355" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,109,578</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0356">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="NRXS:StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering" contextRef="From2023-01-01to2023-12-31" id="Fact000357" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,110,677</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--StockIssuedDuringPeriodValueCommonStockIssuedUponPreferredStockConversion_zaDuw6W0YUwd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Common stock issued upon preferred stock conversion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--StockIssuedDuringPeriodSharesCommonStockIssuedUponPreferredStockConversion_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesAPreferredStockMember_zHrHs2CoggMi" title="Common stock issued upon preferred stock conversion, shares" style="text-align: right">(<ix:nonFraction name="NRXS:StockIssuedDuringPeriodSharesCommonStockIssuedUponPreferredStockConversion" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember" id="Fact000368" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">506,637</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="NRXS:StockIssuedDuringPeriodValueCommonStockIssuedUponPreferredStockConversion" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember" id="Fact000361" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">507</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--StockIssuedDuringPeriodSharesCommonStockIssuedUponPreferredStockConversion_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_zqhbQT3GLtAf" title="Common stock issued upon preferred stock conversion, shares" style="text-align: right">(<ix:nonFraction name="NRXS:StockIssuedDuringPeriodSharesCommonStockIssuedUponPreferredStockConversion" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember" id="Fact000370" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">115,477</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="NRXS:StockIssuedDuringPeriodValueCommonStockIssuedUponPreferredStockConversion" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember" id="Fact000362" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">115</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--StockIssuedDuringPeriodSharesCommonStockIssuedUponPreferredStockConversion_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zP4cnvkr5Iuf" title="Common stock issued upon preferred stock conversion, shares" style="text-align: right"><ix:nonFraction name="NRXS:StockIssuedDuringPeriodSharesCommonStockIssuedUponPreferredStockConversion" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000372" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,244,228</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="NRXS:StockIssuedDuringPeriodValueCommonStockIssuedUponPreferredStockConversion" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000363" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,244</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="NRXS:StockIssuedDuringPeriodValueCommonStockIssuedUponPreferredStockConversion" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000364" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">622</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0365">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0366">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--StockIssuedDuringPeriodValueConversionOfUnits_zp81Xf9AjRhh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Common stock issued upon debt conversion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0374">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0375">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBAb9gvdykJg" title="Common stock issued upon debt conversion, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000381" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,649,900</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000376" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,650</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000377" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,897,833</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0378">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfUnits" contextRef="From2023-01-01to2023-12-31" id="Fact000379" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,899,483</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zCl91dptoHN6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Common stock issued from agreements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0383">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0384">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zvnUqKT0ehq5" title="Common stock issued from agreements, shares" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000390" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">425,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000385" format="ixt:numdotdecimal" decimals="0" unitRef="USD">425</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000386" format="ixt:numdotdecimal" decimals="0" unitRef="USD">749,575</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0387">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2023-01-01to2023-12-31" id="Fact000388" format="ixt:numdotdecimal" decimals="0" unitRef="USD">750,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AdjustmentsToAdditionalPaidInCapitalWarrantIssued_zhPKYdfeMYy1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 24%; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reclassification
    of warrant liability to equity</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0392">&#8212;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0393">&#8212;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0394">&#8212;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000395" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,720,997</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0396">&#8212;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2023-01-01to2023-12-31" id="Fact000397" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,720,997</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_ecustom--StockIssuedDuringPeriodValueWarrantsExercised_zDqf34qffxhh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Warrants exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0399">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0400">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--StockIssuedDuringPeriodSharesWarrantsExercised_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAcQ0MmoHqm6" title="Warrants exercised, shares" style="text-align: right"><ix:nonFraction name="NRXS:StockIssuedDuringPeriodSharesWarrantsExercised" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000406" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">127,780</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="NRXS:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact000401" format="ixt:numdotdecimal" decimals="0" unitRef="USD">128</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="NRXS:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000402" format="ixt:numdotdecimal" decimals="0" unitRef="USD">315,770</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0403">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="NRXS:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2023-01-01to2023-12-31" id="Fact000404" format="ixt:numdotdecimal" decimals="0" unitRef="USD">315,898</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLoss_zBxGYRXJZkK9" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0408">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0409">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0410">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0411">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember" id="Fact000412" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,626,683</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-01to2023-12-31" id="Fact000413" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,626,683</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_431_c20230101__20231231_eus-gaap--StockholdersEquity_iE_z9qxFeN8xGzi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">Balances as of  December 31, 2023</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharesOutstanding_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesAPreferredStockMember_zr2LjG8PR6uj" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0422">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0415">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharesOutstanding_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_zpM4OrNevczj" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0424">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0416">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharesOutstanding_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLJAvQz5UpRe" title="Balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000426" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,508,897</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact000417" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,509</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember" id="Fact000418" format="ixt:numdotdecimal" decimals="0" unitRef="USD">47,148,361</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember" id="Fact000419" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">48,558,111</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000420" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,403,241</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Notes
to financial statements are an integral part of these statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i></i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 94; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="f_004"></span>Neuraxis,
Inc. </b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>
Statements of Cash Flows</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<table cellpadding="0" cellspacing="0" id="xdx_30A_112_zXzmgFzUPu3b" summary="xdx: Statement - Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20230101__20231231_z24QXNo8LhN5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20220101__20221231_z0C5gt7LwcNg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zVI3q6jLs4Zi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash Flows from Operating Activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--NetIncomeLoss_i01_maNCPBUzNsH_zWZnrMjKqSzg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 64%; text-align: left">Net Loss</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 14%; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-01to2023-12-31" id="Fact000431" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,626,683</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31" id="Fact000432" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,780,061</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zD40PShEdKmk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Adjustments to reconcile net loss to net cash used by operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_i02_maNCPBUzNsH_z7Ggh2yNMJua" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Amortization of debt discount and issuance cost</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="From2023-01-01to2023-12-31" id="Fact000437" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,881,622</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="From2022-01-012022-12-31" id="Fact000438" format="ixt:numdotdecimal" decimals="0" unitRef="USD">98,935</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DepreciationDepletionAndAmortization_i02_maNCPBUzNsH_zEABOGGKViO5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Depreciation and amortization</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2023-01-01to2023-12-31" id="Fact000440" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,725</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2022-01-012022-12-31" id="Fact000441" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,133</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ProvisionForDoubtfulAccounts_i02_maNCPBUzNsH_zZgGISbGd52d" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Provisions for losses on accounts receivable</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="From2023-01-01to2023-12-31" id="Fact000443" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,281</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="From2022-01-012022-12-31" id="Fact000444" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,505</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--NoncashLeaseExpense_i02_maNCPBUzNsH_zn9OTl3IImoe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Non-cash lease expense</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="NRXS:NoncashLeaseExpense" contextRef="From2023-01-01to2023-12-31" id="Fact000446" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,119</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="NRXS:NoncashLeaseExpense" contextRef="From2022-01-012022-12-31" id="Fact000447" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,593</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--NoncashInterestExpense_i02_maNCPBUzNsH_zRJ7HxgiorJc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Non-cash interest expense</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="NRXS:NoncashInterestExpense" contextRef="From2023-01-01to2023-12-31" id="Fact000449" format="ixt:numdotdecimal" decimals="0" unitRef="USD">260,777</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0450">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--ShareBasedCompensation_i02_maNCPBUzNsH_zP62oNT64pW1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Stock based compensation</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0452">&#8212;</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-01-012022-12-31" id="Fact000453" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,319</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i02N_di_msNCPBUzNsH_zMcNIHbw3w67" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Extinguishment of debt liabilities</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2023-01-01to2023-12-31" id="Fact000455" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,649,561</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0456">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--IssuanceOfCommonStockForNoncashConsideration_i02_maNCPBUzNsH_z0YyujfwuBO3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Issuance of common stock for non-cash consideration</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="NRXS:IssuanceOfCommonStockForNoncashConsideration" contextRef="From2023-01-01to2023-12-31" id="Fact000458" format="ixt:numdotdecimal" decimals="0" unitRef="USD">750,000</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0459">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--FinanceCharges_i02_maNCPBUzNsH_zHremZUySZJ4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Finance Charges</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="NRXS:FinanceCharges" contextRef="From2023-01-01to2023-12-31" id="Fact000461" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,772</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="NRXS:FinanceCharges" contextRef="From2022-01-012022-12-31" id="Fact000462" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,322,216</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DerivativeGainLossOnDerivativeNet_i02N_di_msNCPBUzNsH_zzKkNLrMunie" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Change in fair value of derivative liabilities</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2023-01-01to2023-12-31" id="Fact000464" format="ixt:numdotdecimal" decimals="0" unitRef="USD">198,551</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2022-01-012022-12-31" id="Fact000465" format="ixt:numdotdecimal" decimals="0" unitRef="USD">713,989</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--FairValueAdjustmentOfWarrants_i02_maNCPBUzNsH_zlW66JAYRHUb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Change in fair value of warrant liabilities</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-01-01to2023-12-31" id="Fact000467" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">844,854</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-01-012022-12-31" id="Fact000468" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">606,049</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i01B_zdthDDsg6Xyk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncreaseDecreaseInAccountsReceivable_i02N_di_msNCPBUzNsH_z9BbDzlZoAT9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left">Accounts receivable</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2023-01-01to2023-12-31" id="Fact000473" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">75,951</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2022-01-012022-12-31" id="Fact000474" format="ixt:numdotdecimal" decimals="0" unitRef="USD">78,603</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--IncreaseDecreaseInInventories_i02N_di_msNCPBUzNsH_zcFdg4JgM6Kj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left">Inventory</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2023-01-01to2023-12-31" id="Fact000476" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">26,913</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2022-01-012022-12-31" id="Fact000477" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,953</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i02N_di_msNCPBUzNsH_z8dXDMDVOuk" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left">Prepaids and other current assets</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2023-01-01to2023-12-31" id="Fact000479" format="ixt:numdotdecimal" decimals="0" unitRef="USD">68,937</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2022-01-012022-12-31" id="Fact000480" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,944</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--IncreaseDecreaseInAccountsPayable_i02_maNCPBUzNsH_z3MHniRbaMJ1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left">Accounts payable</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2023-01-01to2023-12-31" id="Fact000482" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">387,897</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2022-01-012022-12-31" id="Fact000483" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,108,326</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--IncreaseDecreaseInAccruedLiabilities_i02_maNCPBUzNsH_zK7pzXzNsSo8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left">Accrued expenses</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2023-01-01to2023-12-31" id="Fact000485" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">294,154</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2022-01-012022-12-31" id="Fact000486" format="ixt:numdotdecimal" decimals="0" unitRef="USD">272,425</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--IncreaseDecreaseInCustomerDeposit_i02_maNCPBUzNsH_zTipTMXA4Odf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left">Customer deposits</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="NRXS:IncreaseDecreaseInCustomerDeposit" contextRef="From2023-01-01to2023-12-31" id="Fact000488" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,773</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="NRXS:IncreaseDecreaseInCustomerDeposit" contextRef="From2022-01-012022-12-31" id="Fact000489" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,163</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_i02_maNCPBUzNsH_zhu1gTlEiIc9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left; padding-bottom: 1.5pt">Operating lease liability</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2023-01-01to2023-12-31" id="Fact000491" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">33,396</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2022-01-012022-12-31" id="Fact000492" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">27,582</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iT_mtNCPBUzNsH_maCCERCz0RV_zcOt3UvK3A7c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Net cash used by operating activities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-01-01to2023-12-31" id="Fact000494" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,693,978</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-01-012022-12-31" id="Fact000495" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,298,004</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zPmaK6cB2X5l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash Flows from Investing Activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_msNCPBUz0df_zUDDEpwhZJf6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Additions to property and equipment</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2023-01-01to2023-12-31" id="Fact000500" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,781</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2022-01-012022-12-31" id="Fact000501" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,390</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--PaymentsToAcquireIntangibleAssets_i01N_di_msNCPBUz0df_zsTJFm0rPjNj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Additions to intangible assets</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2023-01-01to2023-12-31" id="Fact000503" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2022-01-012022-12-31" id="Fact000504" format="ixt:numdotdecimal" decimals="0" unitRef="USD">59,815</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInInvestingActivities_iT_mtNCPBUz0df_maCCERCz0RV_zf4cyonzuvCc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Net cash used by investing activities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2023-01-01to2023-12-31" id="Fact000506" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">71,781</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2022-01-012022-12-31" id="Fact000507" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">61,205</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_ztvCBpI1rfM9" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Cash Flows from Financing Activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_maNCPBUzbVV_zM9UvU8E0EIb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Proceeds from issuance of common stock, net of issuance costs</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-01-01to2023-12-31" id="Fact000512" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,847,457</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0513">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--DeferredOfferingCostsPaid_i01N_di_msNCPBUzbVV_zakitcSrRUai" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Deferred offering costs paid</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0515">&#8212;</span></td><td style="font-weight: bold; text-align: left"/><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="NRXS:DeferredOfferingCostsPaid" contextRef="From2022-01-012022-12-31" id="Fact000516" format="ixt:numdotdecimal" decimals="0" unitRef="USD">736,736</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--ProceedsFromIssuanceOfWarrants_i01_maNCPBUzbVV_zjzN95R8G5eb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Proceeds from exercised warrants</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfWarrants" contextRef="From2023-01-01to2023-12-31" id="Fact000518" format="ixt:numdotdecimal" decimals="0" unitRef="USD">209,097</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0519">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--RepaymentsOfNotesPayable_iN_di_msNCPBUzbVV_z9RHesWKqtE6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Principal payments on notes payable</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" contextRef="From2023-01-01to2023-12-31" id="Fact000521" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,533,765</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" contextRef="From2022-01-012022-12-31" id="Fact000522" format="ixt:numdotdecimal" decimals="0" unitRef="USD">163,214</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--ProceedsFromNotesPayable_i01_maNCPBUzbVV_zFnP80SERrFl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Proceeds from notes payable</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="From2023-01-01to2023-12-31" id="Fact000524" format="ixt:numdotdecimal" decimals="0" unitRef="USD">159,831</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="From2022-01-012022-12-31" id="Fact000525" format="ixt:numdotdecimal" decimals="0" unitRef="USD">122,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ProceedsFromConvertibleDebt_i01_maNCPBUzbVV_z1OMe5HeCBdf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Proceeds from convertible notes</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2023-01-01to2023-12-31" id="Fact000527" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,460,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2022-01-012022-12-31" id="Fact000528" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,200,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PaymentsOfFinancingCosts_i01N_di_msNCPBUzbVV_z74FmW6nhkr4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Financing fees paid</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsOfFinancingCosts" contextRef="From2023-01-01to2023-12-31" id="Fact000530" format="ixt:numdotdecimal" decimals="0" unitRef="USD">552,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsOfFinancingCosts" contextRef="From2022-01-012022-12-31" id="Fact000531" format="ixt:numdotdecimal" decimals="0" unitRef="USD">130,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtNCPBUzbVV_maCCERCz0RV_zTyGuKsRfHm5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Net cash provided by financing activities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-01-01to2023-12-31" id="Fact000533" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,590,620</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-01-012022-12-31" id="Fact000534" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,292,050</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_mtCCERCz0RV_zc2zEagrwOQe" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Net Decrease in Cash and Cash Equivalents</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2023-01-01to2023-12-31" id="Fact000536" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">175,139</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2022-01-012022-12-31" id="Fact000537" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">67,159</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_zwHNm54FOQQf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Cash and Cash Equivalents at Beginning of Period</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31" id="Fact000539" format="ixt:numdotdecimal" decimals="0" unitRef="USD">253,699</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2021-12-31" id="Fact000540" format="ixt:numdotdecimal" decimals="0" unitRef="USD">320,858</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_zxb8OZyxB54i" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Cash and Cash Equivalents at End of Period</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-12-31" id="Fact000542" format="ixt:numdotdecimal" decimals="0" unitRef="USD">78,560</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31" id="Fact000543" format="ixt:numdotdecimal" decimals="0" unitRef="USD">253,699</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--SupplementalCashFlowInformationAbstract_iB_z4zzYL6kUi5e" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Supplemental Disclosure of Non-Cash Operating Activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--InterestPaidNet_i01_zbjEFDdyXodi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Cash paid for interest</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2023-01-01to2023-12-31" id="Fact000548" format="ixt:numdotdecimal" decimals="0" unitRef="USD">214,562</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2022-01-012022-12-31" id="Fact000549" format="ixt:numdotdecimal" decimals="0" unitRef="USD">202,781</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IncomeTaxesPaidNet_i01_zMZWpuRXZIBg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Cash paid for income taxes</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0551">&#8212;</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0552">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_iB_zGjGZO5Z4gBj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Supplemental Schedule of Non-Cash Investing and Financing Activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--FairValueOfWarrantLiabilitiesOfWarrantsFromConvertibleNotes_i01_zpjs0Tizq2bh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Fair value of warrant liabilities of warrants from convertible notes</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="NRXS:FairValueOfWarrantLiabilitiesOfWarrantsFromConvertibleNotes" contextRef="From2023-01-01to2023-12-31" id="Fact000557" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,446,502</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="NRXS:FairValueOfWarrantLiabilitiesOfWarrantsFromConvertibleNotes" contextRef="From2022-01-012022-12-31" id="Fact000558" format="ixt:numdotdecimal" decimals="0" unitRef="USD">884,118</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--FairValueOfDerivativeLiabilitiesOfConversionFeatureFromConvertibleNotes_i01_zSZn1H1btU9l" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Fair value of derivative liabilities of conversion feature from convertible notes</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="NRXS:FairValueOfDerivativeLiabilitiesOfConversionFeatureFromConvertibleNotes" contextRef="From2023-01-01to2023-12-31" id="Fact000560" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,375,378</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="NRXS:FairValueOfDerivativeLiabilitiesOfConversionFeatureFromConvertibleNotes" contextRef="From2022-01-012022-12-31" id="Fact000561" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,075,098</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--PriorYearOfferingCostsPaid_i01_zbrskYC2jWj7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Prior year offering costs paid </td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="text-align: right"><b><ix:nonFraction name="NRXS:PriorYearOfferingCostsPaid" contextRef="From2023-01-01to2023-12-31" id="Fact000563" format="ixt:numdotdecimal" decimals="0" unitRef="USD">736,736</ix:nonFraction></b></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0564">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--ReclassificationOfWarrantLiabilityToEquity_i01_zwNciBfVMYJb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Reclassification of warrant liability to equity</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="text-align: right"><b><ix:nonFraction name="NRXS:ReclassificationOfWarrantLiabilityToEquity" contextRef="From2023-01-01to2023-12-31" id="Fact000566" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,720,997</ix:nonFraction></b></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0567">&#8212;</span></td><td style="text-align: left"/></tr>
  <tr id="xdx_409_ecustom--ConversionOfPreferredStockToCommonStock_i01_zSbD9ayxtQd3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Conversion of preferred stock to common stock</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="text-align: right"><b><ix:nonFraction name="NRXS:ConversionOfPreferredStockToCommonStock" contextRef="From2023-01-01to2023-12-31" id="Fact000569" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,244</ix:nonFraction></b></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0570">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Notes
to financial statements are an integral part of these statements.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<!-- Field: Page; Sequence: 95; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000572" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock"><p id="xdx_80B_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zH2wWjEwj3B" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="f_005"></span>1.
<span id="xdx_82B_zbY3G2UDua66">Basis of Presentation, Organization and Other Matters</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
Inc. (&#8220;we,&#8221; &#8220;us,&#8221; the &#8220;Company,&#8221; or &#8220;Neuraxis&#8221;) was established in 2011 and incorporated
in the state of Indiana on April 17, 2012, under the name of Innovative Health Solutions, Inc. The name was changed to Neuraxis, Inc.
in March of 2022. Additionally, the Company filed a Certificate of Conversion to become a Delaware corporation on June 23, 2022. The
authorized shares were increased, and a par value established.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 10, 2023, the Company&#8217;s board of directors authorized a <span id="xdx_908_eus-gaap--StockholdersEquityNoteStockSplit_c20230112__20230112_zDLrnaI022Xl" title="Description of stock split"><ix:nonNumeric contextRef="From2023-01-122023-01-12" id="Fact000574" name="us-gaap:StockholdersEquityNoteStockSplit">1-for-2 reverse stock split</ix:nonNumeric></span>. All per share information has been
adjusted for this reverse stock split. The reverse split became effective on January 12, 2023. All share and per share amounts for the
common stock have been retroactively restated to give effect to the splits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the conversion to a Delaware corporation, the total number of shares of all classes of stock which the Corporation shall have
authority to issue is (1) <span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_iI_c20231231_zE6pBmT85IFe" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact000576" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000,000</ix:nonFraction></span> shares of Common Stock, par value $<span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20231231_zRIQqgSYhHPe" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" id="Fact000578" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span> per share (&#8220;Common Stock&#8221;) and (ii) <span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_c20231231_znenjB02donb" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact000580" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,120,000</ix:nonFraction></span>
shares of Preferred Stock, par value $<span id="xdx_903_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20231231_z4hpc59X6ykh" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-12-31" id="Fact000582" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span> per share (&#8220;Preferred Stock&#8221;), <span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesAPreferredStockMember_zY6HuNczpML" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31_custom_ConvertibleSeriesAPreferredStockMember" id="Fact000584" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span> of which is hereby designated as &#8220;Series
A Preferred Stock&#8221; and <span id="xdx_90C_eus-gaap--PreferredStockSharesAuthorized_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_zCVdjr9FKXZc" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31_custom_ConvertibleSeriesSeedPreferredStockMember" id="Fact000586" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">120,000</ix:nonFraction></span> of which is hereby designated as &#8220;Series Seed Preferred Stock&#8221; with the rights, preferences,
powers, privileges and restrictions, qualifications and limitations set forth in this Article IV of the Delaware Certificate of Incorporation.
All share amounts have been retroactively restated to give effect to these changes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 9, 2023, the Company consummated an initial public offering, conducted on a firm commitment basis, pursuant to which it sold <span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230809__20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_ztY6zd7Dq7j3"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2023-08-092023-08-09_us-gaap_CommonStockMember_custom_AlexanderCapitalLPMember_us-gaap_IPOMember" id="Fact000587" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,098,667</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of its common stock at a price of $<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_c20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zMoeySb90b9h"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-08-09_us-gaap_CommonStockMember_custom_AlexanderCapitalLPMember_us-gaap_IPOMember" id="Fact000588" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.00</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share, resulting in gross proceeds to the
Company of $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230809__20230809__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_ztgrFZDFvVS1"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-08-092023-08-09_us-gaap_CommonStockMember_custom_AlexanderCapitalLPMember_us-gaap_IPOMember" id="Fact000589" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,592,002</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
Net proceeds to the Company, after deducting underwriting discounts and commissions, 2022 deferred offering costs totaling $<span id="xdx_905_eus-gaap--DeferredOfferingCosts_iI_c20230809__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_zhC2gGNwt281" title="Deferred offering costs"><ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="AsOf2023-08-09_us-gaap_IPOMember_custom_AlexanderCapitalLPMember" id="Fact000591" format="ixt:numdotdecimal" decimals="0" unitRef="USD">736,736</ix:nonFraction></span> and
offering expenses paid by the Company, were $<span id="xdx_901_eus-gaap--DeferredOfferingCosts_iI_c20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_zV6v3NzRmZY"><ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="AsOf2023-08-09_us-gaap_CommonStockMember_custom_AlexanderCapitalLPMember_us-gaap_IPOMember" id="Fact000592" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,110,721</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
All shares sold in our IPO were registered pursuant to a registration statement on Form S-1 (File No. 333- 269179), as amended, declared
effective by the SEC on August 9, 2023. Alexander Capital L.P. (&#8220;Alexander&#8221;) acted as sole book-running manager for the offering
and Spartan Capital Securities, LLC acted as co-manager for the offering. The underwriters did not exercise their option to purchase
up to an additional <span id="xdx_90D_ecustom--PurchaseOfAdditionalStockOnNumberOfOptionsNotExercised_c20230809__20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zGrudURXDg37"><ix:nonFraction name="NRXS:PurchaseOfAdditionalStockOnNumberOfOptionsNotExercised" contextRef="From2023-08-092023-08-09_us-gaap_CommonStockMember" id="Fact000593" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">164,801</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock. The Company paid the
underwriters an underwriting discount of seven percent (<span id="xdx_90B_ecustom--UnderwritersDiscountPercentage_iI_dp_uPure_c20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_zqqAadAuMlF3"><ix:nonFraction name="NRXS:UnderwritersDiscountPercentage" contextRef="AsOf2023-08-09_us-gaap_CommonStockMember_custom_AlexanderCapitalLPMember_us-gaap_IPOMember" id="Fact000594" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7</ix:nonFraction>%</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)
of the amount raised in the offering. In addition, we also paid the underwriters a non-accountable expense allowance in the amount of
<span id="xdx_908_ecustom--NonaccountableExpenseAllowancePercentage_iI_dp_uPure_c20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_zRyspjKU45kg"><ix:nonFraction name="NRXS:NonaccountableExpenseAllowancePercentage" contextRef="AsOf2023-08-09_us-gaap_CommonStockMember_custom_AlexanderCapitalLPMember_us-gaap_IPOMember" id="Fact000595" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1</ix:nonFraction>%
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(such <span id="xdx_90C_ecustom--CashFeePercentage_iI_dp_uPure_c20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_zIQHuZkPDxl9"><ix:nonFraction name="NRXS:CashFeePercentage" contextRef="AsOf2023-08-09_us-gaap_CommonStockMember_custom_AlexanderCapitalLPMember_us-gaap_IPOMember" id="Fact000596" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction>%
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in commissions and fees amounted to a total of
$<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20230809__20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_zBfHc0TaETDc"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2023-08-092023-08-09_us-gaap_CommonStockMember_custom_AlexanderCapitalLPMember_us-gaap_IPOMember" id="Fact000597" format="ixt:numdotdecimal" decimals="0" unitRef="USD">527,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)
at closing, as well as $<span id="xdx_901_ecustom--ReimbursementExpenses_c20230809__20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_zIh7n8oUPECd"><ix:nonFraction name="NRXS:ReimbursementExpenses" contextRef="From2023-08-092023-08-09_us-gaap_CommonStockMember_custom_AlexanderCapitalLPMember_us-gaap_IPOMember" id="Fact000598" format="ixt:numdotdecimal" decimals="0" unitRef="USD">175,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for the reimbursement of certain of the underwriters&#8217;
expenses. Additionally, as partial consideration for services rendered in connection with the offering, the Company issued Alexander
unregistered warrants to purchase an aggregate of <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230809__20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_zzNsczBfs904"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2023-08-092023-08-09_us-gaap_CommonStockMember_custom_AlexanderCapitalLPMember_us-gaap_IPOMember" id="Fact000599" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">65,921</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Company common stock, representing
<span id="xdx_902_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_c20230809__20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_zGdQeHnWxP37"><ix:nonFraction name="us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction" contextRef="From2023-08-092023-08-09_us-gaap_CommonStockMember_custom_AlexanderCapitalLPMember_us-gaap_IPOMember" id="Fact000600" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6.0</ix:nonFraction>%
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of the aggregate shares sold in the offering.
The warrants have an initial exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_zAoxC9D5n5Ab"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-08-09_us-gaap_CommonStockMember_custom_AlexanderCapitalLPMember_us-gaap_IPOMember" id="Fact000601" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.20</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share (equal to <span id="xdx_907_ecustom--OfferingPricePerPercentage_iI_pid_dp_c20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_zzDtOD5Oi6y8"><ix:nonFraction name="NRXS:OfferingPricePerPercentage" contextRef="AsOf2023-08-09_us-gaap_CommonStockMember_custom_AlexanderCapitalLPMember_us-gaap_IPOMember" id="Fact000602" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">120</ix:nonFraction>%
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of the offering price per share), have a term
of five years from the commencement of sales in the offering, and are exercisable at any time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is headquartered in Carmel, Indiana. The Company specializes in the development, production, and sale of medical neuromodulation
devices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has developed three FDA cleared products, the IB-STIM (DEN180057, 2019), the NSS-2 Bridge (DEN170018, 2017), and the original
510(K) clearance (K140530, 2014).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    IB-STIM is a percutaneous electrical nerve field stimulator (PENFS) device that is indicated in patients 11-18 years of age with
    functional abdominal pain associated with irritable bowel syndrome. The IB-STIM currently is the only product marketed and sold by
    the Company.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    NSS-2 Bridge is a percutaneous nerve field stimulator (PNFS) device indicated for use in the reduction of the symptoms of opioid
    withdrawal. The NSS-2 Bridge device was licensed to Masimo Corporation in April 2020, and the Company received a one-time licensing
    fee of $<span id="xdx_901_ecustom--LicenseFees_c20230811__20230811__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zgUrrZX24mmg" title="License fees"><ix:nonFraction name="NRXS:LicenseFees" contextRef="From2023-08-112023-08-11_us-gaap_CommonStockMember_custom_AlexanderCapitalLPMember_us-gaap_IPOMember" id="Fact000604" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span> from Masimo. Masimo markets and sells this product as its Masimo Bridge, and the Company will not receive any further
    licensing payments or other revenue from this product.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    original 510(K) device was the EAD, an electroacupuncture device, now called NeuroStim. The EAD is no longer being manufactured,
    sold or distributed but reserved only for research purposes.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 96; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000606" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_805_eus-gaap--SignificantAccountingPoliciesTextBlock_zUbBKSWPsjz5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
<span><span id="xdx_82A_zYcCYzAt0rk6">Summary of Significant Accounting Policies</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
summary of significant accounting policies of Neuraxis, Inc. is presented to assist in understanding the Company&#8217;s financial statements.
The financial statements and notes are representations of the Company&#8217;s management, who are responsible for their integrity and
objectivity. These accounting policies conform to U.S. generally accepted accounting principles and have been consistently applied in
the preparation of the financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preparing
the Company&#8217;s financial statements in conformity with accounting principles generally accepted in the United States of America
(&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities
and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and
expenses during the reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000608" name="us-gaap:UseOfEstimates"><p id="xdx_84F_eus-gaap--UseOfEstimates_zVDuaXrTLydg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span><span id="xdx_862_zEz0MUIIsalf">Use
of Estimates and Critical Accounting Estimates and Assumptions</span></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements
and the reported amounts of revenues and expenses during the reporting periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
significant accounting estimates or assumptions bear the risk of change due to the fact that there are uncertainties attached to these
estimates or assumptions, and certain estimates or assumptions are difficult to measure or value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
bases its estimates on historical experience and on various assumptions that are believed to be reasonable in relation to the financial
statements taken as a whole under the circumstances, the results of which form the basis for making judgments about the carrying values
of assets and liabilities that are not readily apparent from other sources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available information, changes
in facts and circumstances, historical experience, and reasonable assumptions. After such evaluations, if deemed appropriate, those
estimates are adjusted accordingly. The Company uses estimates in accounting for, among other items, revenue recognition, allowance
for credit losses, stock-based compensation, income tax provisions, excess and obsolete inventory reserve, and impairment of property and
equipment, and intellectual property. Actual results could differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000610" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zGfQ3Arrc5Ke" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span><span id="xdx_867_zpZR0i4lMbte">Cash
and Cash Equivalents</span></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. The Company
did not hold any cash equivalents as of December 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000612" name="us-gaap:TradeAndOtherAccountsReceivablePolicy"><p id="xdx_844_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zQyLIdQUqMOa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span><span id="xdx_86D_zsWTh5OrDIQg">Trade
Accounts Receivable and Allowance for Credit Losses</span></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade
accounts receivable are stated at the amount management expects to collect from outstanding balances, net of an allowance for credit
losses. Management evaluates many factors when determining the collectability of specific customer accounts, including, but not limited
to, creditworthiness, past transaction and payment history, current economic industry trends and changes in payment terms. We use assumptions
and judgment based on the best available facts and circumstances to estimate and record an allowance. The allowance for credit losses
was $<span id="xdx_903_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20231231_zNeKr5x0pjbf" title="Allowance for doubtful accounts"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2023-12-31" id="Fact000614" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,993</ix:nonFraction></span> and $<span id="xdx_906_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20221231_zt6UU4ntIW9g" title="Allowance for doubtful accounts"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2022-12-31" id="Fact000616" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,275</ix:nonFraction></span> as of December 31, 2023 and 2022, respectively. The Company recorded credit losses for the years ended December
31,2023 and 2022 of $<span id="xdx_905_eus-gaap--ProvisionForOtherCreditLosses_c20230101__20231231_z1fCU75qdmHl" title="Credit losses"><ix:nonFraction name="us-gaap:ProvisionForOtherCreditLosses" contextRef="From2023-01-01to2023-12-31" id="Fact000618" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,281</ix:nonFraction></span> and <span id="xdx_90E_eus-gaap--ProvisionForOtherCreditLosses_c20220101__20221231_zJXQSNTHatn3" title="Credit losses"><ix:nonFraction name="us-gaap:ProvisionForOtherCreditLosses" contextRef="From2022-01-012022-12-31" id="Fact000620" format="ixt:numdotdecimal" decimals="0" unitRef="USD">64,197</ix:nonFraction></span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 97; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000622" name="us-gaap:DepositContractsPolicy"><p id="xdx_84D_eus-gaap--DepositContractsPolicy_z3G9pKnFRuKc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span><span id="xdx_86C_zmrJGQX99vDl">Customer
Deposits</span></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer
deposits consists of billings, payments, and returned devices from clients in advance of revenue recognition. The Company will recognize
the customer deposits over the next year. As of December 31, 2023, and 2022, the Company had customer deposits of $<span id="xdx_902_eus-gaap--Deposits_iI_c20231231_zqIUNH3DZJc8" title="Customer deposits"><ix:nonFraction name="us-gaap:Deposits" contextRef="AsOf2023-12-31" id="Fact000624" format="ixt:numdotdecimal" decimals="0" unitRef="USD">74,947</ix:nonFraction></span> and $<span id="xdx_90F_eus-gaap--Deposits_iI_c20221231_zPLa3GeMgKU6" title="Customer deposits"><ix:nonFraction name="us-gaap:Deposits" contextRef="AsOf2022-12-31" id="Fact000626" format="ixt:numdotdecimal" decimals="0" unitRef="USD">59,174</ix:nonFraction></span>,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000628" name="us-gaap:InventoryPolicyTextBlock"><p id="xdx_846_eus-gaap--InventoryPolicyTextBlock_zMI6ujuN7rw1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span><span id="xdx_866_zves0DdFNTW3">Inventories</span></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories
are valued at the lower of cost or net realizable value. Cost is determined using the weighted average method. The inventory is comprised
of finished medical devices on hand. Certain components within the devices have an expiration date that are removed from current inventory
and expensed at the date of expiration. For the years ended December 31, 2023 and 2022, $<span id="xdx_90B_ecustom--InventoryExpenses_c20231231_zoQihQ2ttyu6" title="Inventory expenses"><ix:nonFraction name="NRXS:InventoryExpenses" contextRef="AsOf2023-12-31" id="Fact000630" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,008</ix:nonFraction></span> and $<span id="xdx_90D_ecustom--InventoryExpenses_iI_c20221231_zzHCNhEaXkRc" title="Inventory expenses"><ix:nonFraction name="NRXS:InventoryExpenses" contextRef="AsOf2022-12-31" id="Fact000632" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,026</ix:nonFraction></span> were expensed as expired
inventory, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000634" name="us-gaap:DeferredChargesPolicyTextBlock"><p id="xdx_84C_eus-gaap--DeferredChargesPolicyTextBlock_zKApjnvqDPCi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span><span id="xdx_865_zn9V9ttt6wmf">Deferred
Offering Costs</span></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
offering costs consist of costs incurred in connection with the preparation of an initial public offering. These costs, together with
the underwriting discounts and commissions, were charged to additional paid in capital upon the IPO. As of December 31, 2023 and 2022,
the Company had deferred offering costs of $<span id="xdx_90F_eus-gaap--DeferredOfferingCosts_iI_dxL_c20231231_zduETi4XjJ34" title="Deferred offering costs::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0636">0</span></span> and $<span id="xdx_906_eus-gaap--DeferredOfferingCosts_iI_c20221231_zJ5duxanWdb7" title="Deferred offering costs"><ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="AsOf2022-12-31" id="Fact000638" format="ixt:numdotdecimal" decimals="0" unitRef="USD">736,736</ix:nonFraction></span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000640" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_84B_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zqhPQolYI7fb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_866_zfGsnuflXkyf">Property
and Equipment</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are recorded at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated
useful lives of the assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000642" name="NRXS:ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock"><p id="xdx_89D_ecustom--ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_zuDWFlazwtT8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
is calculated using the following estimated useful lives:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B0_zRYzhM4FObAj" style="display: none">Schedule of Estimated Useful Lives</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 60%; border-collapse: collapse; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Classification</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Years</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Machinery and Equipment </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MinimumMember_z6T4sUWWoWNi" title="Property and equipment, estimated useful lives"><ix:nonNumeric contextRef="AsOf2023-12-31_us-gaap_MachineryAndEquipmentMember_srt_MinimumMember" format="ixt-sec:duryear" id="Fact000644" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span>-<span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MaximumMember_zd3L5zgGES5d" title="Property and equipment, estimated useful lives"><ix:nonNumeric contextRef="AsOf2023-12-31_us-gaap_MachineryAndEquipmentMember_srt_MaximumMember" format="ixt-sec:duryear" id="Fact000646" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">10</ix:nonNumeric></span> </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture and Fixtures</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zkpRYICgli12" title="Property and equipment, estimated useful lives"><ix:nonNumeric contextRef="AsOf2023-12-31_us-gaap_FurnitureAndFixturesMember_srt_MinimumMember" format="ixt-sec:duryear" id="Fact000648" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span>-<span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_zy9KJtQEgs4a" title="Property and equipment, estimated useful lives"><ix:nonNumeric contextRef="AsOf2023-12-31_us-gaap_FurnitureAndFixturesMember_srt_MaximumMember" format="ixt-sec:duryear" id="Fact000650" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">10</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer Hardware</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MinimumMember_zdqGof3t1oI" title="Property and equipment, estimated useful lives"><ix:nonNumeric contextRef="AsOf2023-12-31_us-gaap_ComputerEquipmentMember_srt_MinimumMember" format="ixt-sec:duryear" id="Fact000652" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span>-<span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MaximumMember_zcRNd7T4hdqb" title="Property and equipment, estimated useful lives"><ix:nonNumeric contextRef="AsOf2023-12-31_us-gaap_ComputerEquipmentMember_srt_MaximumMember" format="ixt-sec:duryear" id="Fact000654" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">10</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold Improvements</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MinimumMember_zZHzaJmx9lfj" title="Property and equipment, estimated useful lives"><ix:nonNumeric contextRef="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember_srt_MinimumMember" format="ixt-sec:duryear" id="Fact000656" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">10</ix:nonNumeric></span>-<span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MaximumMember_zFLCxUzN8HYh" title="Property and equipment, estimated useful lives"><ix:nonNumeric contextRef="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember_srt_MaximumMember" format="ixt-sec:duryear" id="Fact000658" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">20</ix:nonNumeric></span></span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A6_zEuDpQt8YXCc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
expense was $<span id="xdx_907_eus-gaap--Depreciation_c20230101__20231231_zq9Hcvf7e1Dh" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2023-01-01to2023-12-31" id="Fact000660" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,240</ix:nonFraction></span> and $<span id="xdx_901_eus-gaap--Depreciation_c20220101__20221231_zu5aKm0Y6C1c" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2022-01-012022-12-31" id="Fact000662" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,920</ix:nonFraction></span> during the years ended December 31, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000664" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_84E_eus-gaap--ResearchAndDevelopmentExpensePolicy_zLl5UkZpEoJ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_862_zsTqLJDzE2Yb">Research
and Development</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
for research and development are expensed as incurred. Research and development expenses consist primarily of clinical research studies
and new product development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000666" name="us-gaap:IntangibleAssetsFiniteLivedPolicy"><p id="xdx_841_eus-gaap--IntangibleAssetsFiniteLivedPolicy_z8qWp4Ka2Tj4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86E_zMTjD8n9M7D4">Intangible
Assets</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets consist of software, patents and a trademark. Intangible assets are stated at their historical cost and amortized on
a straight-line basis over their expected useful lives. Capitalized patent costs, net of accumulated amortization, includes legal costs
incurred for patent applications. In accordance with ASC 350, once a patent is granted, we amortize the capitalized patent costs over
the remaining life of the patent using the straight-line method. If the patent is not granted, we write off any capitalized patent costs
at that time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an agreement for a trademark related to the Company&#8217;s name on July 11, 2022. The agreement called for an initial
payment of $<span id="xdx_907_eus-gaap--PaymentsToAcquireIntangibleAssets_c20220710__20220711__us-gaap--TypeOfArrangementAxis__custom--TrademarkAgreementMember__us-gaap--OtherCommitmentsAxis__custom--InitialPaymentMember_zitNuSg2qFZk" title="Initial payment upon execution"><ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2022-07-102022-07-11_custom_TrademarkAgreementMember_custom_InitialPaymentMember" id="Fact000668" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000</ix:nonFraction></span> upon execution of the agreement. A second and final payment of $<span id="xdx_903_eus-gaap--PaymentsToAcquireIntangibleAssets_c20220710__20220711__us-gaap--TypeOfArrangementAxis__custom--TrademarkAgreementMember__us-gaap--OtherCommitmentsAxis__custom--SecondAndFinalPaymentMember_zIBof3crmvG2" title="Second and final payment of contingent"><ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2022-07-102022-07-11_custom_TrademarkAgreementMember_custom_SecondAndFinalPaymentMember" id="Fact000670" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,000</ix:nonFraction></span> was contingent upon the completion of the Company&#8217;s
planned initial public offering. The trademark does not have a determinate life and therefore the cost is not being amortized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an option agreement on April 12, 2023 to enter into a royalty-bearing licensing agreement to bring the optionor&#8217;s
invention to commercialization. The agreement required an initial payment of $<span id="xdx_907_eus-gaap--PaymentsToAcquireIntangibleAssets_c20230411__20230412__us-gaap--TypeOfArrangementAxis__custom--LicensingAgreementMember_zu7IJvU0Ivja" title="Initial payment upon execution"><ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2023-04-112023-04-12_custom_LicensingAgreementMember" id="Fact000672" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></span> upon execution of the agreement. The agreement does
not have a determinate life and therefore the cost is not being amortized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 98; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
review intangible assets for impairment annually or when events or circumstances indicate that their carrying amount may not be recoverable.
During the years ended December 31, 2023, and 2022, the Company recorded no impairment charges for intangible assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
expense was $<span id="xdx_900_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20231231_zEfBkB15rWa9" title="Amortization expense"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2023-01-01to2023-12-31" id="Fact000674" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,485</ix:nonFraction></span> and $<span id="xdx_90D_eus-gaap--AmortizationOfIntangibleAssets_c20220101__20221231_zFaUgEMJOp63" title="Amortization expense"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2022-01-012022-12-31" id="Fact000676" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,213</ix:nonFraction></span> during the years ended December 31, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000678" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_zL1OMXiuVgO6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86D_zWbZejgz59Z6">Income
Taxes</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in
the Company&#8217;s financial statements and tax returns. Deferred tax assets and liabilities are determined based upon the differences
between the financial statement carrying amounts, and the tax bases of existing assets and liabilities for the loss and credit carryforwards
using enacted tax rates expected to be in effect in the year in which the differences are expected to reverse. Deferred tax assets are
reduced by a valuation allowance if it is more likely than not that these assets may not be realized. The Company determines whether
a tax position will be sustained upon examination. If it is more likely than not that a position will be sustained, none of the benefit
attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more likely than not
recognition threshold is calculated as the largest amount that is more than 50% likely of being realized upon resolution of the contingency.
The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the results of management&#8217;s evaluation, adoption of the rules did not have a material effect on the Company&#8217;s financial
statements. Further, no interest or penalties have been accrued or charged to expense as of December 31, 2023 and 2022 and for the years
then ended.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s income tax returns are subject to examination by the taxing authorities until the expiration of the related statutes
of limitations on those tax returns. In general, the federal and state income tax returns have a three-year statute of limitations. As
of December 31, 2023, the following tax years are subject to examination:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1.5pt solid; width: 32%; text-align: center">Jurisdiction</td><td style="padding-bottom: 1.5pt; text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 32%; text-align: center">Open Years for Filed Returns</td><td style="padding-bottom: 1.5pt; text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Return to File in 2024</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">Federal</td><td>&#160;</td>
    <td style="text-align: center">2020 &#8211; 2022</td><td>&#160;</td>
    <td style="text-align: center">2023</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">Various States</td><td>&#160;</td>
    <td style="text-align: center">2020 &#8211; 2022</td><td>&#160;</td>
    <td style="text-align: center">2023</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000680" name="us-gaap:AdvertisingCostsPolicyTextBlock"><p id="xdx_845_eus-gaap--AdvertisingCostsPolicyTextBlock_zMkGAZaOZrki" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_869_zYreRTxzU1b3">Advertising
Cost</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advertising
costs are expensed as incurred and amounted to $<span id="xdx_900_eus-gaap--AdvertisingExpense_c20230101__20231231_z0GjCaNfpWY5" title="Advertising cost expense"><ix:nonFraction name="us-gaap:AdvertisingExpense" contextRef="From2023-01-01to2023-12-31" id="Fact000682" format="ixt:numdotdecimal" decimals="0" unitRef="USD">192,400</ix:nonFraction></span> and $<span id="xdx_90A_eus-gaap--AdvertisingExpense_c20220101__20221231_zp2itMDg3Lc1" title="Advertising cost expense"><ix:nonFraction name="us-gaap:AdvertisingExpense" contextRef="From2022-01-012022-12-31" id="Fact000684" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,900</ix:nonFraction></span> for the years ended December 31, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000686" name="NRXS:DerivativeLiabilityPolicyTextBlock"><p id="xdx_840_ecustom--DerivativeLiabilityPolicyTextBlock_zGVqCK5z85Mc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_869_zHMq8XLsXJ6i">Derivative
Liabilities</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for derivative financial instruments as either equity or liabilities in accordance with ASC Topic 815, <i>Derivatives
and Hedging</i>, or ASC 815, based on the characteristics and provisions of each instrument. Embedded derivatives are required to be
bifurcated from the host instruments and recorded at fair value if the derivatives are not clearly and closely related to the host instruments
on the date of issuance. Derivative instrument liabilities are classified in the balance sheets as current or non-current based on whether
or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilizes a Monte Carlo simulation model for the common stock conversion feature of the notes payable that have an option to
convert at a variable number of shares to compute the fair value of the derivative and to mark to market the fair value of the
derivative at each balance sheet date. The inputs utilized in the application of the Monte Carlo model included a stock
price, an expected remaining term of each note as of the valuation date, estimated volatility, drift, and a risk-free rate. The
Company records the change in the fair value of the derivative as other income or expense in the Statements of Operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 99; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000688" name="NRXS:WarrantLiabilityPolicyTextBlock"><p id="xdx_84B_ecustom--WarrantLiabilityPolicyTextBlock_z69GwGVVBVcc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_869_zV7p8awBt4kc">Warrant
Liabilities</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
evaluates all of the Company&#8217;s financial instruments, including issued warrants to purchase its Class A common stock, to
determine if such instruments are liabilities or contain features that qualify as embedded derivatives, pursuant to ASC 480 and ASC
815-15. The classification of derivative financial instruments, including whether such instruments should be recorded as liabilities
or as equity, is reassessed at the end of each reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilizes a Monte Carlo simulation model for warrants that have an option to convert at a variable number of shares to compute
the fair value of the derivative and to mark to market the fair value of the derivative at each balance sheet date. The inputs utilized
in the application of the Monte Carlo model included a starting stock price, an expected remaining term of each warrant as of the valuation
date, estimated volatility, drift, and a risk-free rate. The Company records the change in the fair value of the warrant as other
income or expense in the statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000690" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p id="xdx_840_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zXaEEhNVRUzl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86B_z42RAGNx2Pke">Fair
Value Measurements</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for financial instruments in accordance with ASC 820, Fair Value Measurements and Disclosures (&#8220;ASC 820&#8221;).
ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy
gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and
the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under ASC 820 are described
below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 &#8211; Quoted prices (unadjusted) for identical unrestricted assets or liabilities in active markets that the reporting entity has
the ability to access as of the measurement date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 &#8211; Significant other observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities: quoted
prices in markets that are not active; or financial instruments for which all significant inputs are observable or can be corroborated
by observable market date, either directly or indirectly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 &#8211; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets
or liabilities. These unobservable inputs reflect that reporting entity&#8217;s own assumptions about assumptions that market participants
would use in pricing the asset or liability. Level 3 assets and liabilities include financial instruments whose value is determined using
pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair
value require significant management judgment or estimation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s Level 1 assets/liabilities include cash, accounts receivable, accounts payable, prepaids, and other current assets. Management
believes the estimated fair value of these accounts on December 31, 2023 approximate their carrying value as reflected in the balance
sheets due to the short-term nature of these instruments or the use of market interest rates for debt instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s Level 3 assets/liabilities include derivative and warrant liabilities. Inputs to determine fair value are generally
unobservable and typically reflect management&#8217;s estimates of assumptions that market participants would use in pricing the
asset or liability. The fair values are therefore determined using model-based techniques, including option pricing models and
discounted cash flow models. The valuation techniques involve management&#8217;s estimates and judgment based on unobservable
inputs. The fair value estimates may not be indicative of the amounts that would be realized in a market exchange. Additionally,
there may be inherent uncertainties or changes in the underlying assumptions used, which could significantly affect the current or
future fair value estimates. Unobservable inputs used in the models are significant to the fair values of the assets and
liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 100; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000692" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"><p id="xdx_89E_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zXrb3Ha5bbbh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables provides a summary of the relevant assets and liabilities that are measured at fair value on recurring basis:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Fair Value Measurements as of</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">December 31, 2023</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_8B5_zBcTe0bNWWrd" style="display: none">Schedule of Fair Value On a Recurring Basis Assets and Liability</span>&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zZgb1nNnOIB1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z90tT0VJCng4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Level 1)</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_znhoBmNvawL8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Level 2)</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z8GtVuYWyEwa" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;(Level 3)</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--WarrantLiabilities_i02I_maLFVDzwLw_z6rpvKyALug1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 36%; text-align: left">Warrant liabilities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="NRXS:WarrantLiabilities" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember" id="Fact000694" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,225</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0695">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0696">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="NRXS:WarrantLiabilities" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="Fact000697" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,225</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DerivativeLiabilitiesCurrent_i02I_maLFVDzwLw_zJzlXGtSZDO9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Derivative liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0699">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0700">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0701">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0702">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LiabilitiesFairValueDisclosure_i02I_mtLFVDzwLw_zV9UcwYYQyjl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Total Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember" id="Fact000704" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,225</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0705">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0706">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="Fact000707" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,225</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair Value Measurements as of</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
31, 2022</b></span></p>


<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zmHu3a3OQ26c" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z5PTqsJi0jad" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zkDLZOyMUWCb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zrrRyAbSdmol" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--WarrantLiabilities_i02I_maLFVDzwLw_zowQ4vO09hL" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 36%; text-align: left">Warrant liabilities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="NRXS:WarrantLiabilities" contextRef="AsOf2022-12-31_us-gaap_FairValueMeasurementsRecurringMember" id="Fact000709" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,234,384</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0710">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0711">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="NRXS:WarrantLiabilities" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="Fact000712" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,234,384</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DerivativeLiabilitiesCurrent_i02I_maLFVDzwLw_zbXoob1TDTJ8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Derivative liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2022-12-31_us-gaap_FairValueMeasurementsRecurringMember" id="Fact000714" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,735,700</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0715">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0716">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="Fact000717" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,735,700</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LiabilitiesFairValueDisclosure_i02I_mtLFVDzwLw_zhUioZYfLqQe" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Total Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueMeasurementsRecurringMember" id="Fact000719" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,970,084</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0720">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0721">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="Fact000722" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,970,084</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

</ix:nonNumeric><p id="xdx_8A7_zUdX8zDeETDg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000724" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"><p id="xdx_890_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zYMTrkf1t5pf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows the valuation methodology and unobservable inputs for Level 3 assets and liabilities measured at fair value on
recurring basis as of December 31, 2023 and December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><span id="xdx_8BF_zcWaoIpk4QNi" style="display: none">Schedule of Unobservable Inputs for Level 3 Assets and Liabilities</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Fair Value As of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Fair Value</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">Valuation</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">Unobservable</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Methodology</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Inputs</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 20%; text-align: justify">Warrant liabilities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--WarrantLiabilities_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zshO0OaVLGL4" title="Warrant liabilities" style="width: 13%; text-align: right"><ix:nonFraction name="NRXS:WarrantLiabilities" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="Fact000726" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,225</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_ecustom--WarrantLiabilities_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zk5YFe91k1u1" title="Warrant liabilities" style="width: 13%; text-align: right"><ix:nonFraction name="NRXS:WarrantLiabilities" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="Fact000728" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,234,384</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 19%; text-align: center">Monte Carlo model</td><td style="width: 2%">&#160;</td>
    <td style="width: 23%; text-align: center">Project simulated cash flows</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Derivative liabilities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zljGNFsh3REk" title="Derivative liabilities" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0730">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z5BnVDl7ijHc" title="Derivative liabilities" style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember" id="Fact000732" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,735,700</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">Monte Carlo model</td><td>&#160;</td>
    <td style="text-align: center">Project simulated cash flows</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A9_zjTAxKrFNlr2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no transfers between any of the levels during the years ended December 31, 2023 and year ended December 31, 2022. In addition
to assets and liabilities that are recorded at fair value on a recurring basis, the Company&#8217;s assets and liabilities are also
subject to nonrecurring fair value measurements. As of December 31, 2023 and 2022, the Company had no assets that were measured on a
nonrecurring basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000734" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zDXVnNedKCu8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_863_zD1TKYEnGW6l">Basic
and Diluted Net Income (Loss) per Share</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Earnings
or loss per share (&#8220;EPS&#8221;) is computed by dividing net income (loss), net of preferred stock dividends, by the weighted average
number of shares of common stock outstanding during the period. Diluted EPS is computed by dividing net income (loss) by the weighted
average of all potentially dilutive shares of common stock that were outstanding during the periods presented. Preferred stock dividends
(not declared or paid) were $<span id="xdx_90B_eus-gaap--DividendsPreferredStock_c20230101__20231231_zmgcGg3rUjO4" title="Preferred stock dividend"><ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2023-01-01to2023-12-31" id="Fact000736" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_902_eus-gaap--DividendsPreferredStock_c20220101__20221231_zO9qN9bbbF1d" title="Preferred stock dividend"><ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="From2022-01-012022-12-31" id="Fact000738" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,190,102</ix:nonFraction></span> as of December 31, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common
shares outstanding during the period. Diluted net loss per common share is determined using the weighted-average number of common shares
outstanding during the period, adjusted for the dilutive effect of common stock equivalents. In periods when losses are reported, which
is the case for December 31, 2023 and 2022 presented in these financial statements, the weighted-average number of common shares outstanding
excludes common stock equivalents because their inclusion would be anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 101; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000740" name="us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock"><p id="xdx_894_eus-gaap--ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_zNwURusR6vu2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had the following potentially dilutive common stock equivalents at December 31, 2023 and 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B9_zNje6TLH5oU8" style="display: none">Schedule of Dilutive Common Stock Equivalents</span>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20230101__20231231_z51OT7QLFr38" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20220101__20221231_zWMVb7whmDXe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleSeriesAPreferredStockMember_z2UCsBz9SQg5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Convertible Series A Preferred Stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0742">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31_custom_ConvertibleSeriesAPreferredStockMember" id="Fact000743" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,013,270</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleSeriesSeedPreferredStockMember_zB4vs5QaziT1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Convertible Series Seed Preferred Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0745">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31_custom_ConvertibleSeriesSeedPreferredStockMember" id="Fact000746" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">230,954</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--OptionMember_zvy1eobwixR5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_us-gaap_OptionMember" id="Fact000748" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,319,394</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31_us-gaap_OptionMember" id="Fact000749" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,319,394</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--PreferredStockMember_z33AI0MMLE5f" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; text-align: left">Pre-Funded Warrants for Convertible Series A Preferred Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0751">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember" id="Fact000752" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">289,779</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_zIYhQ9G4GrF8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-012023-12-31_custom_WarrantsMember" id="Fact000754" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,822,358</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31_custom_WarrantsMember" id="Fact000755" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">365,962</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleBridgeDebtMember_zP5fRYEVMiTa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Convertible Bridge Debt</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0757">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31_custom_ConvertibleBridgeDebtMember" id="Fact000758" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">376,653</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zuWn8sTcwH0j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Totals</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-01-01to2023-12-31" id="Fact000760" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,141,752</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-01-012022-12-31" id="Fact000761" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,596,012</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A5_zViJxKGPpRP9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000763" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"><p id="xdx_89D_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zxBv4WY9fsXf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows the calculation of the basic and diluted net loss per share and the effect of preferred stock dividends.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_zqUi5n0z7Kfl" style="display: none">Schedule of Basic and Diluted Net Loss Per Share</span>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20230101__20231231_zX5oRcjTJW1g" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20220101__20221231_zBMbJ08DzJ84" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Numerator</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--NetIncomeLoss_iT_mtNILzQKI_zy8h4Qz1xuO1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-01to2023-12-31" id="Fact000765" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,626,683</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-01-012022-12-31" id="Fact000766" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,780,061</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--PreferredStockDividendsAndOtherAdjustments_zgKkCa9mWffi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Preferred stock dividends</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0768">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PreferredStockDividendsAndOtherAdjustments" contextRef="From2022-01-012022-12-31" id="Fact000769" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">764,893</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zk1oVBBRjz5i" style="vertical-align: bottom; background-color: White">
    <td>&#160;<span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Net income (loss) available to common stockholders</span> </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2023-01-01to2023-12-31" id="Fact000771" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,626,683</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2022-01-012022-12-31" id="Fact000772" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,544,954</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Denominator</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Weighted-average shares of common stock outstanding - basic
    and diluted</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231_znEzxgGfUxea" title="Weighted average shares of common stock outstanding - basic"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231_zbww0nP4YRg1" title="Weighted average shares of common stock outstanding - diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-01-01to2023-12-31" id="Fact000774" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-01-01to2023-12-31" id="Fact000776" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,252,328</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20220101__20221231_z6Tas7DWLb8e" title="Weighted average shares of common stock outstanding - basic"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20220101__20221231_zmjpPawtofr9" title="Weighted average shares of common stock outstanding - diluted"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-01-012022-12-31" id="Fact000778" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-01-012022-12-31" id="Fact000780" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,003,322</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Basic and diluted net loss per share</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_908_eus-gaap--EarningsPerShareBasic_c20230101__20231231_zG5fKt9oFUC8" title="Basic net loss per share"><span id="xdx_905_eus-gaap--EarningsPerShareDiluted_c20230101__20231231_z2RhTCLdmDCb" title="Diluted net loss per share">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-01-01to2023-12-31" id="Fact000782" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-01-01to2023-12-31" id="Fact000784" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">4.50</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_909_eus-gaap--EarningsPerShareBasic_c20220101__20221231_zZJe1K2BfZ76" title="Basic net loss per share"><span id="xdx_90C_eus-gaap--EarningsPerShareDiluted_c20220101__20221231_zds8oPl0kjM3" title="Diluted net loss per share">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-01-012022-12-31" id="Fact000786" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-01-012022-12-31" id="Fact000788" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">2.77</ix:nonFraction></ix:nonFraction></span></span></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A4_z0tCcqsbBemd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000790" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy"><p id="xdx_84E_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zz4yjkKUeCzk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_861_zFhESh1uvKod">Stock-Based
Compensation</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for all stock-based payments and awards at fair value. The Company recognizes its stock-based compensation
expense using the straight-line method. Compensation cost is not adjusted for estimated forfeitures, but instead is adjusted upon an
actual forfeiture of a stock option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for the granting of stock options to employees and non-employees using the fair value method whereby all awards are
measured at fair value on the date of the grant. The fair value of all employee stock options is expensed over the requisite service
period with a corresponding increase to additional paid-in capital. Upon exercise of stock options, the consideration paid by the option
holder is recorded in additional paid-in capital, while the par value of the shares received is reclassified from additional paid in
capital to common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
payments to non-employees are measured based on the fair value of the equity instrument issued. Compensation expense for non-employee
stock awards is recognized over the requisite service period following the measurement of the fair value on the grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company uses the Black-Scholes option-pricing model to calculate the fair value of stock options. The use of the Black-Scholes option-pricing
model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common
stock consistent with the expected term of the option, risk-free interest rates, the value of the common stock and expected dividend
yield of the common stock. Changes in these assumptions can materially affect the fair value estimate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000792" name="us-gaap:RevenueRecognitionPolicyTextBlock"><p id="xdx_848_eus-gaap--RevenueRecognitionPolicyTextBlock_zQiivN3OJYcj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_868_zdikTs1WOXe1">Revenue
Recognition</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
Inc. specializes in the development, production, and sale of medical neuromodulation devices to healthcare providers primarily located
in the United States. Patented and trademarked neuromodulation devices is the Company&#8217;s major product line. Products are generally
transferred at a point in time (rather than over time). Essentially all the Company&#8217;s revenue is generated from purchase order
contracts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 102; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with FASB&#8217;s ASC 606, Revenue from Contracts with Customers, (&#8220;ASC 606&#8221;), the Company recognizes revenue
when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects
to be entitled in exchange for those goods or services, in an amount that reflects the consideration which the Company expects to be
entitled in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within
the scope of ASC 606, it performs the following five steps:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identify
    the contract(s) with a customer&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identify
    the performance obligations in the contract&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determine
    the transaction price&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">allocate
    the transaction price to the performance obligations in the contract&#894; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recognize
    revenue when (or as) the entity satisfies a performance obligation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company applies the five-step model to contracts when it determines that it is probable it will collect substantially all the consideration
it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined
to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that
are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the
amount of the transaction price, after consideration of variability and constraints, if any, that is allocated to the respective performance
obligation when the performance obligation is satisfied.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company estimates credit losses on accounts receivable by estimating expected credit losses over the contractual term of the receivable
using a discounted cash flow method. When developing this estimate of expected credit losses, the Company considers all available information
(past, current, and future) relevant to assessing the collectability of cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company offers a Patient Assistance Program for patients without insurance coverage for IB-Stim. This program extends potential self-pay
discounts for IB-Stim devices, based upon household income and size.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Also,
the Company offers providers an opt-in program to address adequate insurance claim payments on IB-Stim devices. This program may extend
a rebate or invoice credit where the insurance payment and patient responsibility (i.e., deductible, co-payment, and/or co-insurance
amounts required by the Payer) are less than the acquisition cost of the IB-Stim device. The Company recognizes revenue at such a time
that collection of the amount due is assured.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000794" name="us-gaap:DisaggregationOfRevenueTableTextBlock"><p id="xdx_89B_eus-gaap--DisaggregationOfRevenueTableTextBlock_zX6RXuuRv7o2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table disaggregates the Company&#8217;s revenue based on the customer&#8217;s location by state for the years ended December
31:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zAzVuhoIgill" style="display: none">Schedule of Disaggregation of Revenue</span>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 25%; text-align: left">California</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td id="xdx_987_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--CA_zAnDptrXJjOb" title="Revenues" style="width: 20%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-01-012023-12-31_stpr_CA" id="Fact000796" format="ixt:numdotdecimal" decimals="0" unitRef="USD">601,235</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 25%; text-align: left">Wisconsin</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__stpr--WI_z2SwOYl8cNh9" title="Revenues" style="width: 20%; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-01-012022-12-31_stpr_WI" id="Fact000798" format="ixt:numdotdecimal" decimals="0" unitRef="USD">670,245</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Ohio</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--OH_zDI0OkZvXUch" title="Revenues" style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-01-012023-12-31_stpr_OH" id="Fact000800" format="ixt:numdotdecimal" decimals="0" unitRef="USD">407,632</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">Ohio</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__stpr--OH_zJhs6wESToS2" title="Revenues" style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-01-012022-12-31_stpr_OH" id="Fact000802" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,260</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Wisconsin</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--WI_z9ynHKka95Xd" title="Revenues" style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-01-012023-12-31_stpr_WI" id="Fact000804" format="ixt:numdotdecimal" decimals="0" unitRef="USD">292,601</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">California</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__stpr--CA_zRGqfRRI4PZ9" title="Revenues" style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-01-012022-12-31_stpr_CA" id="Fact000806" format="ixt:numdotdecimal" decimals="0" unitRef="USD">408,645</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Florida</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--FL_z1o4pUWGGbRe" title="Revenues" style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-01-012023-12-31_stpr_FL" id="Fact000808" format="ixt:numdotdecimal" decimals="0" unitRef="USD">186,840</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">Florida</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__stpr--FL_zwbktOHvOlP2" title="Revenues" style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-01-012022-12-31_stpr_FL" id="Fact000810" format="ixt:numdotdecimal" decimals="0" unitRef="USD">231,480</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Massachusetts</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--MA_zL8Z9URoL8Rf" title="Revenues" style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-01-012023-12-31_stpr_MA" id="Fact000812" format="ixt:numdotdecimal" decimals="0" unitRef="USD">127,300</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">Missouri</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__country--MO_zmIB5JUxFlka" title="Revenues" style="text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-01-012022-12-31_country_MO" id="Fact000814" format="ixt:numdotdecimal" decimals="0" unitRef="USD">174,980</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">All other states</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__custom--AllOtherStatesMember_zgxis1XpHgTj" title="Revenues" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-01-012023-12-31_custom_AllOtherStatesMember" id="Fact000816" format="ixt:numdotdecimal" decimals="0" unitRef="USD">844,441</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1.5pt">All other states</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__custom--AllOtherStatesMember_zqkBp0QJB9Bd" title="Revenues" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-01-012022-12-31_custom_AllOtherStatesMember" id="Fact000818" format="ixt:numdotdecimal" decimals="0" unitRef="USD">699,125</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_986_eus-gaap--Revenues_c20230101__20231231_zmLHQlhg1K4a" title="Total revenue" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2023-01-01to2023-12-31" id="Fact000820" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,460,049</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98B_eus-gaap--Revenues_c20220101__20221231_zVi8nS1HELrg" title="Total revenue" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2022-01-012022-12-31" id="Fact000822" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,684,735</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</ix:nonNumeric><p id="xdx_8A6_z18moQNeosPi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following economic factors affect the nature, amount, timing, and uncertainty of the Company&#8217;s revenue and cash flows as indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Type
of customer:</b> Based on dollar amounts of revenue, essentially all of the goods sold by the Company are sold to healthcare customers
including hospitals and clinics. Sales to healthcare customers lack seasonality and have a mild correlation with economic cycles.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Geographical
location of customers:</b> Sales to customers located within the United States represent essentially all of the Company&#8217;s sales.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 103; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Type
of contract:</b> Sales contracts consist of purchase order contracts that tend to be short-term (i.e., less than or equal to one year
in duration).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Company&#8217;s
Performance Obligations with Customers:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Timing
of Satisfaction</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company typically satisfies its performance obligations as the goods are delivered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goods
that are shipped to customers are typically shipped FOB shipping point with freight prepaid by the Company. As such, ownership of goods
in transit transfer to the customer when shipped and the customer bears the associated risks (e.g., loss, damage, delay). </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shipping
and handling costs are recorded as general and administrative expenses in the Statement of Operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Significant
Payment Terms</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment
for goods sold by the Company is typically due after an invoice is sent to the customer, within 30 days. However, other payment terms
are frequently negotiated with customers ranging from due upon receipt to due within 90 days. Some payment terms may call for payment
only after the healthcare provider receives their insurance reimbursement. Invoices for goods are typically sent to customers within
three calendar days of shipment. The Company does not offer discounts if the customer pays some or all of an invoiced amount prior to
the due date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None
of the Company&#8217;s contracts have a significant financing component.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Nature</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical
devices that the Company contracts to sell and transfer to customers are manufactured by one specific third-party manufacturer. The manufacturer
is located within the state of Indiana. In no case does the Company act as an agent (i.e., the Company does not provide a service of
arranging for another party to transfer goods to the customer).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Returns,
Refunds, etc.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Orders
may not be cancelled after shipment. Customers may return devices within 10 days of delivery if the goods are found to be defective,
nonconforming, or otherwise do not meet the stated technical specifications. At the option of the customer, the Company shall either:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Refund
    the price paid for any defective or nonconforming products.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supply
    and deliver to the customer replacement conforming products.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reimburse
    the customer for the cost of repairing any defective or nonconforming products.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the time revenue is recognized, the Company estimates expected returns and excludes those amounts from revenue. The Company also maintains
appropriate accounts to reflect the effects of expected returns on the Company&#8217;s financial position and periodically adjusts those
accounts to reflect its actual return experience. Historically, returns have been immaterial, and the Company currently does not provide
a provision for this liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 104; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000824" name="us-gaap:ExtendedProductWarrantyPolicy"><p id="xdx_844_eus-gaap--ExtendedProductWarrantyPolicy_zsmzImPWWnw7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86D_zcAlCuDLdeMh">Warranties</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
most cases, goods that customers purchase from the Company are covered by manufacturers&#8217; warranties. The Company does not sell
warranties separately.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
manufacturer guarantees the product for the period up to the expiration date printed on the device&#8217;s label or twelve months from
the date of purchase, whichever comes first. The guarantee applies to flaws of material and workmanship. The Company&#8217;s warranties
provide customers with assurance that purchased devices comply with published specifications, inspection standards, and workmanship.
At the time revenue is recognized, the Company estimates the cost of expected future warranty claims but does not exclude any amounts
from revenue. The Company maintains appropriate accounts to reflect the effects of expected future warranty claims on the Company&#8217;s
financial position and periodically adjusts those accounts to reflect its actual warranty claim experience. Historically, warranty claims
have been immaterial, and the Company currently does not provide a provision for this liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company typically satisfies its performance obligations for goods at a point in time. In most cases, goods are shipped by common carrier
to customers under &#8220;FOB Shipping Point&#8221; terms. As such, customers typically obtain control of the goods upon shipment. The
Company&#8217;s management exercises judgment in determining when performance obligations for goods have been satisfied. In making such
judgments, management typically relies on shipping information obtained from common carriers to evaluate when the customer has obtained
control of the goods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s contracts with customers typically do not involve variable consideration. The information that the Company uses to determine
the transaction price for a contract is similar to the information that the Company&#8217;s management uses in establishing the prices
of goods to be sold.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000826" name="us-gaap:LesseeLeasesPolicyTextBlock"><p id="xdx_843_eus-gaap--LesseeLeasesPolicyTextBlock_z4OfpCedWO8j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_860_zDo0Qt7M55Dk">Leases</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with Accounting Standards Updated (&#8220;ASU&#8221;) No. 2016-02, <i>Leases (Topic 842)</i> (&#8220;ASU 2016-02&#8221; or
&#8220;ASC 842&#8221;), at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based
on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the balance
sheet as right-of-use assets and current and non-current lease liabilities, as applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
lease liabilities and their corresponding right-of-use assets are initially recorded based on the present value of lease payments over
the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received.
The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental
borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis
the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. Prospectively, the Company
will adjust the right-of-use assets for straight-line rent expense, or any incentives received and remeasure the lease liability at the
net present value using the same incremental borrowing rate that was in effect as of the lease commencement or transition date. The Company
has elected not to recognize leases with an original term of one year or less on the balance sheet. The Company typically only includes
an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in the Company&#8217;s assessment
unless there is reasonable certainty that the Company will renew.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assumptions
made by the Company at the commencement date are re-evaluated upon occurrence of certain events, including a lease modification. A lease
modification results in a separate contract when the modification grants the lessee an additional right of use not included in the original
lease and when lease payments increase commensurate with the standalone price for the additional right of use. When a lease modification
results in a separate contract, it is accounted for in the same manner as a new lease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entities
may elect not to separate lease and non-lease components. The Company has elected to account for lease and non-lease components together
as a single lease component for all underlying assets and allocate all the contract consideration to the lease component only.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 105; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>


</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000828" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"><p id="xdx_844_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zQnGpcSL7M39" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86F_zBrB3zgiolB3">Impairment
of Long-Lived Assets</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-lived
assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset group may
not be recoverable. If events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable,
we compare the carrying amount of the asset group to future undiscounted net cash flows, excluding interest costs, expected to be generated
by the asset group and their ultimate disposition. If the sum of the undiscounted cash flows is less than the carrying value, the impairment
to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the fair value of the asset group.
Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000830" name="us-gaap:ConcentrationRiskCreditRisk"><p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zx8dJc3KAyve" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_864_zpHzMrGs96Kj">Concentrations
of Credit Risk</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s business activity consists of the sale of medical neuromodulation devices to doctors, clinics, and hospitals across the
country.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Receivables
consist of unsecured amounts due from customers. As of December 31, 2023, accounts receivable from four customers with balances due
in excess of <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zHt7e9wt7Xlf" title="Risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-12-31_custom_CustomerMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember" id="Fact000832" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span>%
of total accounts receivable were approximately <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z1sgDO6lIT0f" title="Risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-12-31_custom_CustomerOneMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember" id="Fact000834" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">28</ix:nonFraction></span>%, <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zOpddKc3C56k" title="Risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-12-31_custom_CustomerTwoMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember" id="Fact000836" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">28</ix:nonFraction></span>%, <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerThreeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_ztyL1NBusNqe" title="Risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-12-31_custom_CustomerThreeMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember" id="Fact000838" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">17</ix:nonFraction></span>%
and <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerFourMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zn5iv9oSMJNe" title="Risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-12-31_custom_CustomerFourMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember" id="Fact000840" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">11</ix:nonFraction></span>%, respectively. As of December 31, 2022, accounts receivable from three customers with balances due in excess of <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_znlKTOeeo93f" title="Risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-12-31_custom_CustomerMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember" id="Fact000842" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span>%
of total accounts receivable was <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zdf0D1ndQga7" title="Risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-12-31_custom_CustomerOneMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember" id="Fact000844" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">23</ix:nonFraction></span>%, <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zJM0GLgbRMti" title="Risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-12-31_custom_CustomerTwoMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember" id="Fact000846" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15</ix:nonFraction></span>%,
and <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerThreeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zFGIT1ta9kQ" title="Risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-12-31_custom_CustomerThreeMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember" id="Fact000848" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12</ix:nonFraction></span>%,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below sets forth the Company&#8217;s customers that accounted for greater than <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueProductLineMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--RevenueFromRightsConcentrationRiskMember_zSykzU9jrsr5" title="Risk percentage"><span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueProductLineMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--RevenueFromRightsConcentrationRiskMember_z8AOKkMvCXI4" title="Risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-12-31_custom_CustomerMember_us-gaap_SalesRevenueProductLineMember_us-gaap_RevenueFromRightsConcentrationRiskMember" id="Fact000850" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-12-31_custom_CustomerMember_us-gaap_SalesRevenueProductLineMember_us-gaap_RevenueFromRightsConcentrationRiskMember" id="Fact000852" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></ix:nonFraction></span></span>% of its revenues for the years ended December
31, 2023 and 2022, respectively.</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000854" name="us-gaap:ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock"><p id="xdx_89F_eus-gaap--ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock_zK2CTGYbN3Sb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zCjfnL75gsbi" style="display: none">Schedule of Customers Accounted Revenues</span>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">Percentage of </td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">Percentage of </td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><b>Sales</b></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><b>Sales</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: left">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: left">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left">Hospital A</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--MajorCustomersAxis__custom--HospitalAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z8DYsvEFfc62" title="Revenue" style="width: 15%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-12-31_custom_HospitalAMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember" id="Fact000856" format="ixt:numdotdecimal" decimals="0" unitRef="USD">452,680</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 15%; text-align: center"><span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--HospitalAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zOU9fy3LjPDl" title="Risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-12-31_custom_HospitalAMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember" id="Fact000858" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">18</ix:nonFraction></span>%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20221231__srt--MajorCustomersAxis__custom--HospitalAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z6VZ0fIq4lbg" title="Revenue" style="width: 15%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-012022-12-31_custom_HospitalAMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember" id="Fact000860" format="ixt:numdotdecimal" decimals="0" unitRef="USD">355,613</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 15%; text-align: center"><span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--HospitalAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zGUAamau5Wg7" title="Risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-12-31_custom_HospitalAMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember" id="Fact000862" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">13</ix:nonFraction></span>%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Hospital B</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--MajorCustomersAxis__custom--HospitalBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zWtmDNKLOmZ8" title="Revenue" style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-12-31_custom_HospitalBMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember" id="Fact000864" format="ixt:numdotdecimal" decimals="0" unitRef="USD">382,082</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--HospitalBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zxGlw7LXQHJh" title="Risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-12-31_custom_HospitalBMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember" id="Fact000866" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">16</ix:nonFraction></span>%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20221231__srt--MajorCustomersAxis__custom--HospitalBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zkkJm06MFCPb" title="Revenue" style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-012022-12-31_custom_HospitalBMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember" id="Fact000868" format="ixt:numdotdecimal" decimals="0" unitRef="USD">484,900</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--HospitalBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z8N4M2GNQ1Cg" title="Risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-12-31_custom_HospitalBMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember" id="Fact000870" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">18</ix:nonFraction></span>%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Hospital C</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--MajorCustomersAxis__custom--HospitalCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zoNS5KYKLCJ8" title="Revenue" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-12-31_custom_HospitalCMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember" id="Fact000872" format="ixt:numdotdecimal" decimals="0" unitRef="USD">274,581</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--HospitalCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_ztiAPuHBO464" title="Risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-12-31_custom_HospitalCMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember" id="Fact000874" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">11</ix:nonFraction></span>%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20221231__srt--MajorCustomersAxis__custom--HospitalCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zAa3xtGHtem9" title="Revenue" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-012022-12-31_custom_HospitalCMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember" id="Fact000876" format="ixt:numdotdecimal" decimals="0" unitRef="USD">554,325</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--HospitalCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zSTXRgI9fhP9" title="Risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-12-31_custom_HospitalCMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember" id="Fact000878" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21</ix:nonFraction></span>%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--MajorCustomersAxis__custom--HospitalMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zPVkIhkG8i96" title="Revenue" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-12-31_custom_HospitalMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember" id="Fact000880" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,109,343</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--HospitalMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zAj2qbvuPNlj" title="Risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2023-01-012023-12-31_custom_HospitalMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember" id="Fact000882" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">45</ix:nonFraction></span>%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20221231__srt--MajorCustomersAxis__custom--HospitalMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zdpQH4bigBYb" title="Revenue" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2022-01-012022-12-31_custom_HospitalMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember" id="Fact000884" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,394,838</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--HospitalMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zx1dh6xGR3J3" title="Risk percentage"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2022-01-012022-12-31_custom_HospitalMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember" id="Fact000886" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">52</ix:nonFraction></span>%</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</ix:nonNumeric><p id="xdx_8AE_zG8dOe1t08F5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, the Company&#8217;s bank balances may exceed the FDIC limit of $<span id="xdx_909_eus-gaap--CashFDICInsuredAmount_iI_c20231231_znBb1ljAlu7f" title="Cash, FDIC insured amount"><ix:nonFraction name="us-gaap:CashFDICInsuredAmount" contextRef="AsOf2023-12-31" id="Fact000888" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span>; however, management does not feel that this has
a material impact on the financial condition. At December 31, 2023 and 2022, the Company didn&#8217;t have any uninsured cash balance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000890" name="NRXS:GoingConcernPolicyTextBlock"><p id="xdx_848_ecustom--GoingConcernPolicyTextBlock_zXajKJKS6Kod" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_861_zZ5dSeb3IfU">Going
Concern</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have incurred losses since inception and have funded our operations primarily with a combination of sales, debt, and the sale of capital
stock. As of December 31, 2023, we had a stockholders&#8217; deficit totaling $<span id="xdx_903_eus-gaap--StockholdersEquity_iNI_di_c20231231_zUPTVUFQnusl" title="Stockholders deficit"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-12-31" id="Fact000892" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,403,241</ix:nonFraction></span>. At December 31, 2023, we had short-term outstanding
borrowings of approximately $<span id="xdx_905_eus-gaap--ShortTermBorrowings_iI_c20231231_zGK76rC9Za7g" title="Short term borrowing"><ix:nonFraction name="us-gaap:ShortTermBorrowings" contextRef="AsOf2023-12-31" id="Fact000894" format="ixt:numdotdecimal" decimals="0" unitRef="USD">148,062</ix:nonFraction></span>. As of December 31, 2023, we had cash of $<span id="xdx_90F_eus-gaap--Cash_iI_c20231231_zMSBuQjxhUv2" title="Cash"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2023-12-31" id="Fact000896" format="ixt:numdotdecimal" decimals="0" unitRef="USD">78,560</ix:nonFraction></span> and a working capital deficit of $<span id="xdx_900_ecustom--WorkingCapitalDeficit_iI_c20231231_zojtMzfW66Z2" title="Working capital"><ix:nonFraction name="NRXS:WorkingCapitalDeficit" contextRef="AsOf2023-12-31" id="Fact000898" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,643,058</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 9, 2023, the Company consummated its initial public offering, conducted on a firm commitment basis, pursuant to which it sold <span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230809__20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zes7IYSmLHEe" title="Number of shares issued in transaction"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2023-08-092023-08-09_us-gaap_CommonStockMember" id="Fact000900" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,098,667</ix:nonFraction></span>
shares of its common stock at a price of $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_c20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zMs9Emp2MZu3" title="Share issued price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-08-09_us-gaap_CommonStockMember" id="Fact000902" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.00</ix:nonFraction></span>
per share, resulting in gross proceeds to the Company of $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230809__20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zduBimLlqvCd" title="Proceeds from issuance of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-08-092023-08-09_us-gaap_CommonStockMember" id="Fact000904" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,592,002</ix:nonFraction></span>.
Net proceeds to the Company, after deducting underwriting discounts and commissions, 2022 deferred offering costs totaling $<span id="xdx_908_eus-gaap--DeferredOfferingCosts_iI_c20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zGr67oXbOBul" title="Deferred offering costs"><ix:nonFraction name="us-gaap:DeferredOfferingCosts" contextRef="AsOf2023-08-09_us-gaap_CommonStockMember" id="Fact000906" format="ixt:numdotdecimal" decimals="0" unitRef="USD">736,736</ix:nonFraction></span>
and offering expenses paid by the Company, were $<span id="xdx_906_eus-gaap--PaymentsOfStockIssuanceCosts_c20230811__20230811__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSo5An9DMAvc" title="Payment fees"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2023-08-112023-08-11_us-gaap_CommonStockMember" id="Fact000908" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,110,721</ix:nonFraction></span>.
All shares sold in our IPO were registered pursuant to a registration statement on Form S-1 (File No. 333- 269179), as amended,
declared effective by the SEC on August 9, 2023. Alexander Capital L.P. acted as sole book-running manager for the offering and
Spartan Capital Securities, LLC acted as co-manager for the offering. <span style="background-color: white">The underwriters did not
exercise their option to purchase up to an additional </span><span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230809__20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKV7ofq1xkai" title="Purchase of common shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-08-092023-08-09_us-gaap_CommonStockMember" id="Fact000910" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">164,801</ix:nonFraction></span> <span style="background-color: white">shares
of common stock.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 106; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future capital requirements will depend upon many factors, including progress with developing, manufacturing, and marketing our
technologies, the time and costs involved in preparing, filing, prosecuting, maintaining, and enforcing patent claims and other
proprietary rights, our ability to establish collaborative arrangements, marketing activities and competing technological and market
developments, including regulatory changes and overall economic conditions in our target markets. Our ability to generate revenue
and achieve profitability requires us to successfully market and secure purchase orders for our products from customers currently
identified in our sales pipeline and to new customers as well. The primary activity that will drive all customers and revenues is
the adoption of insurance coverage by commercial insurance carriers nationally which is a top priority of the Company. These
activities, including our planned research and development efforts, will require significant uses of working capital through the
rest of 2024 and beyond. Based on our current operating plans, we believe that our existing cash at the time of this filing will
only be sufficient to meet our anticipated operating needs through the end of 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
evaluates whether there are conditions or events that raise substantial doubt about the Company&#8217;s ability to continue as a going
concern for a period of one year from the date the financial statements are issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, the Company has experienced operating losses and negative cash flows from operations. Management believes that increased sales
and acceptance of their product by insurance providers will allow the Company to achieve profitability in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
the Company believes in the viability of its strategy to further implement its business plan and generate sufficient revenues and in
its ability to raise additional funds by way of a public or private offering of its debt or equity securities, there can be no
assurance that it will be able to do so on reasonable terms, or at all. The ability of the Company to continue as a going concern is
dependent upon its ability to further implement its business plan and generate sufficient revenues and its ability to raise
additional funds by way of a public or private offering. Neither future cash generated from operating activities, nor
management&#8217;s contingency plans to mitigate the risk and extend cash resources through the evaluation period, are considered
probable. As a result, substantial doubt is deemed to exist about the Company&#8217;s ability to continue as a going concern. As we
continue to incur losses, our transition to profitability is dependent upon achieving a level of revenues adequate to support its
cost structure. We may never achieve profitability, and unless and until doing so, we intend to fund future operations through
additional dilutive or nondilutive financing. There can be no assurances, however, that additional funding will be available on
terms acceptable to us, if at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the
amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000912" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zFcm1uYaKtoj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_863_zu6wtfWyMFre">Recently Adopted Accounting Pronouncements</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2016, the FASB issued ASU 2016-13, Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial
Instruments, which requires measurement and recognition of expected credit losses for financial assets held and requires enhanced disclosures
regarding significant estimates and judgments used in estimating credit losses. In November 2019, the FASB issued ASU 2019-10, Financial
Instruments &#8211; Credit Losses (Topic 326), Derivatives and Hedging (Topic 815) and Leases (Topic 842): Effective Dates, which amended
the effective date of ASU 2016-13. Public business entities meeting the definition of an SEC filer, excluding entities eligible to be
a Smaller Reporting Company (&#8220;SRC&#8221;) as defined by the SEC, are required to adopt the standard for fiscal years beginning
after December 15, 2019, including interim periods within those fiscal years. All other entities are required to adopt the standard for
fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company meets the definition
of an SRC and therefore the standard was adopted as of January 1, 2023. The adoption of this guidance did not have a material impact
on the Company&#8217;s financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="text-decoration: underline">Recently Issued Accounting Pronouncements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">In December 2023, the FASB issued ASU 2023-19,
Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires the enhancement of income tax disclosures to
provide better insight into how an entity&#8217;s operations and related tax risks, planning and opportunities affect its tax rate
and prospects for future cash flows. The enhanced disclosures require (i) specific categories in a tabular rate reconciliation
including both amounts and percentages and (ii) additional information for reconciling items and income tax paid that meet a
quantitative threshold. Public business entities are required to adopt the standard for annual periods beginning after December 15,
2024. All other entities are required to adopt the standard for annual periods beginning after December 15, 2025. The adoption of
the standard is not expected to have a material impact on the Company&#8217;s financial statements.</p>
</ix:nonNumeric><p id="xdx_858_z0Ouvom4LnTj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 107; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000914" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_80E_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_z4b3bNdgdusd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.
<span><span id="xdx_827_z27BacDLLdMl">Related Party Transactions</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has two demand notes receivable from shareholders related to the sale of common stock on January 1, 2016. Both notes&#8217; initial
balances were $<span id="xdx_902_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholdersOneAndTwoMember_z8BtQJFbJrS4" title="Loan Receivable"><ix:nonFraction name="us-gaap:NotesAndLoansReceivableGrossCurrent" contextRef="AsOf2023-12-31_custom_ShareholdersOneAndTwoMember" id="Fact000916" format="ixt:numdotdecimal" decimals="0" unitRef="USD">506,400</ix:nonFraction></span>, with interest calculated monthly based on applicable federal rates. No payments have been received on the notes.
Since repayment is not assured, the Company provided an allowance for the entire balance of principal and interest as of December 31,
2019. The current allowance is $<span id="xdx_90B_ecustom--AllowanceForInterestReceivableCurrent_iI_c20231231_zJnTyvcFx3r3" title="Allowance for interest receivable current"><ix:nonFraction name="NRXS:AllowanceForInterestReceivableCurrent" contextRef="AsOf2023-12-31" id="Fact000918" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,154,541</ix:nonFraction></span> as of December 31, 2023. The current loan balances are as follows:</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000920" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock"><p id="xdx_896_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zqWIyjUVS18e" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8B5_z8l6ORobyzp1" style="display: none">Schedule of Related Party Transactions</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Loan</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Interest</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Interest</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Receivable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Receivable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Income</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Shareholder 1</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderOneMember_zNjeGS834uJ1" title="Loan Receivable" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:NotesAndLoansReceivableGrossCurrent" contextRef="AsOf2023-12-31_custom_ShareHolderOneMember" id="Fact000922" format="ixt:numdotdecimal" decimals="0" unitRef="USD">506,400</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--InterestReceivableCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderOneMember_zAr7UCbfco9d" title="Interest Receivable" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:InterestReceivableCurrent" contextRef="AsOf2023-12-31_custom_ShareHolderOneMember" id="Fact000924" format="ixt:numdotdecimal" decimals="0" unitRef="USD">70,938</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--InterestIncomeGrossCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderOneMember_zjUqYewZQEKe" title="Interest Income" style="width: 14%; text-align: right"><ix:nonFraction name="NRXS:InterestIncomeGrossCurrent" contextRef="AsOf2023-12-31_custom_ShareHolderOneMember" id="Fact000926" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,867</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Shareholder 2</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderTwoMember_zUaBQuPkUcs4" title="Loan Receivable" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NotesAndLoansReceivableGrossCurrent" contextRef="AsOf2023-12-31_custom_ShareHolderTwoMember" id="Fact000928" format="ixt:numdotdecimal" decimals="0" unitRef="USD">506,400</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--InterestReceivableCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderTwoMember_zbnY9eWJLBr5" title="Interest Receivable" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:InterestReceivableCurrent" contextRef="AsOf2023-12-31_custom_ShareHolderTwoMember" id="Fact000930" format="ixt:numdotdecimal" decimals="0" unitRef="USD">70,803</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_ecustom--InterestIncomeGrossCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderTwoMember_zW2gG27f91Bk" title="Interest Income" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="NRXS:InterestIncomeGrossCurrent" contextRef="AsOf2023-12-31_custom_ShareHolderTwoMember" id="Fact000932" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,867</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zYEz6pYsAt8" title="Loan Receivable" style="text-align: right"><ix:nonFraction name="us-gaap:NotesAndLoansReceivableGrossCurrent" contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember" id="Fact000934" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,012,800</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--InterestReceivableCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zV6zGTWgKfwd" title="Interest Receivable" style="text-align: right"><ix:nonFraction name="us-gaap:InterestReceivableCurrent" contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember" id="Fact000936" format="ixt:numdotdecimal" decimals="0" unitRef="USD">141,741</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--InterestIncomeGrossCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zuqvBNoFFs89" title="Interest Income" style="text-align: right"><ix:nonFraction name="NRXS:InterestIncomeGrossCurrent" contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember" id="Fact000938" format="ixt:numdotdecimal" decimals="0" unitRef="USD">47,734</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Allowance for Collection Risk</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AllowanceForNotesAndLoansReceivableCurrent_iNI_di_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zVsT3J8XqlA7" title="Allowance for collection risk, loan receivable" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AllowanceForNotesAndLoansReceivableCurrent" contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember" id="Fact000940" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,012,800</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--InterestReceivableCurrent_iNI_di_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z9RIPUINte28" title="Allowance for collection risk, interest receivable" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:InterestReceivableCurrent" contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember" id="Fact000942" format="ixt:numdotdecimal" decimals="0" unitRef="USD">141,741</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_ecustom--AllowanceForInterestIncomeCurrent_iNI_di_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z5Uz45E9BYme" title="Allowance for collection risk, interest income" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="NRXS:AllowanceForInterestIncomeCurrent" contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember" id="Fact000944" format="ixt:numdotdecimal" decimals="0" unitRef="USD">47,734</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Net Balance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98E_eus-gaap--NotesAndLoansReceivableNetCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zwvDYzL2T28i" title="Loan Receivable" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0946">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98E_eus-gaap--InterestReceivable_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zGC81YvfHKMf" title="Interest Receivable" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0948">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98D_ecustom--InterestIncomeCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zbLdMijari3b" title="Interest Income" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0950">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Loan</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Interest</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Interest</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Receivable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Receivable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Income</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Shareholder 1</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderOneMember_zsr2M5KfUG5h" title="Loan Receivable" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:NotesAndLoansReceivableGrossCurrent" contextRef="AsOf2022-12-31_custom_ShareHolderOneMember" id="Fact000952" format="ixt:numdotdecimal" decimals="0" unitRef="USD">506,400</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--InterestReceivableCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderOneMember_z6I6OQcmRgol" title="Interest Receivable" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:InterestReceivableCurrent" contextRef="AsOf2022-12-31_custom_ShareHolderOneMember" id="Fact000954" format="ixt:numdotdecimal" decimals="0" unitRef="USD">47,071</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_ecustom--InterestIncomeGrossCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderOneMember_zGimIoPsSCJ7" title="Interest Income" style="width: 14%; text-align: right"><ix:nonFraction name="NRXS:InterestIncomeGrossCurrent" contextRef="AsOf2022-12-31_custom_ShareHolderOneMember" id="Fact000956" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,523</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Shareholder 2</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderTwoMember_zxtDmMfOnRn5" title="Loan Receivable" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NotesAndLoansReceivableGrossCurrent" contextRef="AsOf2022-12-31_custom_ShareHolderTwoMember" id="Fact000958" format="ixt:numdotdecimal" decimals="0" unitRef="USD">506,400</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--InterestReceivableCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderTwoMember_za9yIQZuCwQb" title="Interest Receivable" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:InterestReceivableCurrent" contextRef="AsOf2022-12-31_custom_ShareHolderTwoMember" id="Fact000960" format="ixt:numdotdecimal" decimals="0" unitRef="USD">46,936</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_ecustom--InterestIncomeGrossCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderTwoMember_zrl9RjcqPpS3" title="Interest Income" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="NRXS:InterestIncomeGrossCurrent" contextRef="AsOf2022-12-31_custom_ShareHolderTwoMember" id="Fact000962" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,523</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z1NAQRx3RRtl" title="Loan Receivable" style="text-align: right"><ix:nonFraction name="us-gaap:NotesAndLoansReceivableGrossCurrent" contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember" id="Fact000964" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,012,800</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--InterestReceivableCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_znAiqJpIor4" title="Interest Receivable" style="text-align: right"><ix:nonFraction name="us-gaap:InterestReceivableCurrent" contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember" id="Fact000966" format="ixt:numdotdecimal" decimals="0" unitRef="USD">94,007</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--InterestIncomeGrossCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z2U5TqiSdRQe" title="Interest Income" style="text-align: right"><ix:nonFraction name="NRXS:InterestIncomeGrossCurrent" contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember" id="Fact000968" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,046</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Allowance for Collection Risk</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AllowanceForNotesAndLoansReceivableCurrent_iNI_di_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zSgT36uVkLzc" title="Allowance for collection risk, loan receivable" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AllowanceForNotesAndLoansReceivableCurrent" contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember" id="Fact000970" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,012,800</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--InterestReceivableCurrent_iNI_di_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zjME8N49EpH6" title="Allowance for collection risk, interest receivable" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:InterestReceivableCurrent" contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember" id="Fact000972" format="ixt:numdotdecimal" decimals="0" unitRef="USD">94,007</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_ecustom--AllowanceForInterestIncomeCurrent_iNI_di_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_ztt179JuzVad" title="Allowance for collection risk, interest income" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="NRXS:AllowanceForInterestIncomeCurrent" contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember" id="Fact000974" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,046</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Net Balance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98B_eus-gaap--NotesAndLoansReceivableNetCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zEGLcV60i0Oi" title="Loan Receivable" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0976">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98D_eus-gaap--InterestReceivable_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zACWZJZhkB3c" title="Interest Receivable" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0978">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_982_ecustom--InterestIncomeCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zASJ0ABNa47e" title="Interest Income" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0980">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A4_ztT2hNMVbB7a" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has loans payable to shareholders related to funding needs for operations. The current loan details for all related party loans
are as follows:</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact000982" name="NRXS:ScheduleOfRelatedPartyLoansTableTextBlock"><p id="xdx_894_ecustom--ScheduleOfRelatedPartyLoansTableTextBlock_zWYBz5E1QISc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8B8_z9ZoAHflmhHk" style="display: none">Schedule of Related Party Loans payable to shareholder</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Interest &amp;</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Interest</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Loan</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Service Fee</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Interest</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Due Date</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Rate</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Balance</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accrued</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Paid</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%; text-align: left">Shareholder 1</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--DebtInstrumentMaturityDateDescription_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderMember_zLmrcLwwzZT9" title="Due date"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_ShareHolderMember" id="Fact000984" name="us-gaap:DebtInstrumentMaturityDateDescription">June, 2019</ix:nonNumeric></span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderMember_zdKQbLO41w0a" title="Debt instrument percentage"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2023-12-31_custom_ShareHolderMember" id="Fact000986" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15.00</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--LoansPayable_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderMember_ztyIiCuOam1d" title="Loan payable" style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0988">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_ecustom--InterestAndServiceFeeAccrued_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderMember_zkwUyLgjw5ic" title="Interest payable" style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0990">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--InterestPaid_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderMember_zUEbQib1hql4" title="Interest payable" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:InterestPaid" contextRef="From2023-01-012023-12-31_custom_ShareHolderMember" id="Fact000992" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,047</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Shareholder 1</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--DebtInstrumentMaturityDateDescription_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_z6UYuTOdv2T7" title="Due date"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_ShareHolderOneMember" id="Fact000994" name="us-gaap:DebtInstrumentMaturityDateDescription">June, 2019</ix:nonNumeric></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_zDuwTD5kyGze" title="Debt instrument percentage"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2023-12-31_custom_ShareHolderOneMember64718796" id="Fact000996" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15.00</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--LoansPayable_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_zPaik7XCGSSf" title="Loan payable" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0998">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--InterestAndServiceFeeAccrued_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_zwzShwpllCt5" title="Interest payable" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1000">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--InterestPaid_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_ztf8UkLpAEc1" title="Interest payable" style="text-align: right"><ix:nonFraction name="us-gaap:InterestPaid" contextRef="From2023-01-012023-12-31_custom_ShareHolderOneMember" id="Fact001002" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,056</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other Convertibles</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--DebtInstrumentMaturityDateDescription_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zPnt1LgV7VAh" title="Due date"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_OtherConvertiblesMember" id="Fact001004" name="us-gaap:DebtInstrumentMaturityDateDescription">Various</ix:nonNumeric></span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zLPY1MG1DDU3" title="Debt instrument percentage"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2023-12-31_custom_OtherConvertiblesMember" id="Fact001006" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.00</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--LoansPayable_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zchp3VXWcIvd" title="Interest payable" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1008">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_ecustom--InterestAndServiceFeeAccrued_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zOxnLZn5lmwh" title="Interest payable" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="NRXS:InterestAndServiceFeeAccrued" contextRef="AsOf2023-12-31_custom_OtherConvertiblesMember" id="Fact001010" format="ixt:numdotdecimal" decimals="0" unitRef="USD">66,648</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--InterestPaid_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zlYzcLAKuAU7" title="Interest payable" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1012">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Total</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--LoansPayable_iI_c20231231_zYL0tJxjI3ih" title="Loan payable" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1014">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98E_ecustom--InterestAndServiceFeeAccrued_iI_c20231231_zEsgLv7iBl9j" title="Interest payable" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="NRXS:InterestAndServiceFeeAccrued" contextRef="AsOf2023-12-31" id="Fact001016" format="ixt:numdotdecimal" decimals="0" unitRef="USD">66,648</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_982_eus-gaap--InterestPaid_c20230101__20231231_z3n7s4J8fFB" title="Interest payable" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:InterestPaid" contextRef="From2023-01-01to2023-12-31" id="Fact001018" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,103</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Interest &amp;</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Interest</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Loan</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Service Fee</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Interest</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Due Date</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Rate</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Balance</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accrued</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Paid</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%; text-align: left">Shareholder 1</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--DebtInstrumentMaturityDateDescription_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--ShareHolderMember_zg9pF0o9AWS1" title="Due date"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_ShareHolderMember" id="Fact001020" name="us-gaap:DebtInstrumentMaturityDateDescription">June, 2019</ix:nonNumeric></span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><span id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20221231__us-gaap--DebtInstrumentAxis__custom--ShareHolderMember_zMFYZMyHe3v5" title="Debt instrument percentage"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2022-12-31_custom_ShareHolderMember" id="Fact001022" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15.00</ix:nonFraction></span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--LoansPayable_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--ShareHolderMember_zwWXBFlgBprk" title="Loan payable" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:LoansPayable" contextRef="AsOf2022-12-31_custom_ShareHolderMember" id="Fact001024" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,051</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--InterestAndServiceFeeAccrued_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--ShareHolderMember_zlY1frgGimk4" title="Interest and service fee accrued" style="width: 10%; text-align: right"><ix:nonFraction name="NRXS:InterestAndServiceFeeAccrued" contextRef="AsOf2022-12-31_custom_ShareHolderMember" id="Fact001026" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,161</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--InterestPaid_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--ShareHolderMember_zgKxFVTIYmt4" title="Interest payable" style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1028">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Shareholder 1</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--DebtInstrumentMaturityDateDescription_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_z7K6IKNGNO3f" title="Due date"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_ShareHolderOneMember" id="Fact001030" name="us-gaap:DebtInstrumentMaturityDateDescription">June, 2019</ix:nonNumeric></span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20221231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_zBlYt2yMTJ48" title="Debt instrument percentage"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2022-12-31_custom_ShareHolderOneMember64718843" id="Fact001032" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15.00</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--LoansPayable_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_zl1hWiioUS49" title="Loan payable" style="text-align: right"><ix:nonFraction name="us-gaap:LoansPayable" contextRef="AsOf2022-12-31_custom_ShareHolderOneMember64718843" id="Fact001034" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--InterestAndServiceFeeAccrued_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_zArwiydQevl6" title="Interest and service fee accrued" style="text-align: right"><ix:nonFraction name="NRXS:InterestAndServiceFeeAccrued" contextRef="AsOf2022-12-31_custom_ShareHolderOneMember64718843" id="Fact001036" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,481</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--InterestPaid_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_zYe1fTJeAwyg" title="Interest payable" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1038">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other Convertibles</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--DebtInstrumentMaturityDateDescription_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zSBIQTQfuLCg" title="Due date"><ix:nonNumeric contextRef="From2022-01-012022-12-31_custom_OtherConvertiblesMember" id="Fact001040" name="us-gaap:DebtInstrumentMaturityDateDescription">Various</ix:nonNumeric></span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20221231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zpfbQRoNeyk3" title="Debt instrument percentage"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2022-12-31_custom_OtherConvertiblesMember" id="Fact001042" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.00</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--LoansPayable_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zTlga8JpcJl9" title="Interest payable" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1044">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_ecustom--InterestAndServiceFeeAccrued_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_z90rDfXZ7UGe" title="Interest and service fee accrued" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="NRXS:InterestAndServiceFeeAccrued" contextRef="AsOf2022-12-31_custom_OtherConvertiblesMember" id="Fact001046" format="ixt:numdotdecimal" decimals="0" unitRef="USD">66,648</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--InterestPaid_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zBsDBBqJJqX9" title="Interest payable" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1048">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Total</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_982_eus-gaap--LoansPayable_iI_c20221231_zHcLjkkKEjAb" title="Loan payable" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LoansPayable" contextRef="AsOf2022-12-31" id="Fact001050" format="ixt:numdotdecimal" decimals="0" unitRef="USD">58,051</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98C_ecustom--InterestAndServiceFeeAccrued_iI_c20221231_zHVxGTsufhVd" title="Interest payable" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="NRXS:InterestAndServiceFeeAccrued" contextRef="AsOf2022-12-31" id="Fact001052" format="ixt:numdotdecimal" decimals="0" unitRef="USD">98,290</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_983_eus-gaap--InterestPaid_c20220101__20221231_zOs1DvDDPMqe" title="Interest payable" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1054">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AD_zNIjMHVU5Wwa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Bradley Mitch Watkins, Director, provided certain sales, marketing and commercialization consulting services to the Company prior to his
appointment to the Board of Directors. For the years ended December 31, 2023 and 2022, the Company paid Mr. Watkins $<span id="xdx_90C_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20230101__20231231__srt--TitleOfIndividualAxis__custom--MrWatkinsMember_z7AGuBQFAHO1" title="Related party transaction amounts"><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2023-01-012023-12-31_custom_MrWatkinsMember" id="Fact001056" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,083</ix:nonFraction></span> and
$<span id="xdx_905_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20220101__20221231__srt--TitleOfIndividualAxis__custom--MrWatkinsMember_z65mqWDJ9A3d" title="Related party transaction amounts"><ix:nonFraction name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" contextRef="From2022-01-012022-12-31_custom_MrWatkinsMember" id="Fact001058" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,523</ix:nonFraction></span>, respectively. No amounts were owed to Mr. Watkins as of December 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s former Chief Financial Officer is contracted for services through a third-party public accounting firm. He is the firm&#8217;s
managing partner and majority shareholder. The firm is engaged by the Company to provide accounting and tax services on a continuous
basis. Fees paid for services were $<span id="xdx_906_eus-gaap--PaymentsForFees_c20230101__20231231__srt--TitleOfIndividualAxis__custom--MrSealeMember_zhjJ53Wz5hxg" title="Payments for fees"><ix:nonFraction name="us-gaap:PaymentsForFees" contextRef="From2023-01-012023-12-31_custom_MrSealeMember" id="Fact001060" format="ixt:numdotdecimal" decimals="0" unitRef="USD">312,803</ix:nonFraction></span> and $<span id="xdx_90D_eus-gaap--PaymentsForFees_c20220101__20221231__srt--TitleOfIndividualAxis__custom--MrSealeMember_z2AvaPk195M6" title="Payments for fees"><ix:nonFraction name="us-gaap:PaymentsForFees" contextRef="From2022-01-012022-12-31_custom_MrSealeMember" id="Fact001062" format="ixt:numdotdecimal" decimals="0" unitRef="USD">116,542</ix:nonFraction></span> for the years ended December 31, 2023 and 2022, respectively. The Company owed
RBSK for open invoices of $<span id="xdx_900_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_c20231231__srt--TitleOfIndividualAxis__custom--MrSealeMember_z9X7hyR4a0o" title="Accounts payable"><ix:nonFraction name="us-gaap:AccountsPayableCurrentAndNoncurrent" contextRef="AsOf2023-12-31_custom_MrSealeMember" id="Fact001064" format="ixt:numdotdecimal" decimals="0" unitRef="USD">84,279</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_c20221231__srt--TitleOfIndividualAxis__custom--MrSealeMember_znMsRxC62bik" title="Accounts payable"><ix:nonFraction name="us-gaap:AccountsPayableCurrentAndNoncurrent" contextRef="AsOf2022-12-31_custom_MrSealeMember" id="Fact001066" format="ixt:numdotdecimal" decimals="0" unitRef="USD">68,142</ix:nonFraction></span> that are included in accounts payable as of December 31, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 108; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001068" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p id="xdx_80F_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zF17IdNShTAb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.
<span id="xdx_826_z1ddV1dKNutk">Property and Equipment</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001070" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><p id="xdx_898_eus-gaap--PropertyPlantAndEquipmentTextBlock_zguBbBQHPIWi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment, net consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_zePKoEMzzgeh" style="display: none">Schedule of Property And Equipment</span>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20231231_zoUeCkXV1L2k" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20221231_zAgqC9cPGbKf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zbxSKBFBSOh2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Machinery and equipment </td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_us-gaap_MachineryAndEquipmentMember" id="Fact001072" format="ixt:numdotdecimal" decimals="0" unitRef="USD">282,181</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31_us-gaap_MachineryAndEquipmentMember" id="Fact001073" format="ixt:numdotdecimal" decimals="0" unitRef="USD">282,181</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zdkx0YCHKhQ9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Furniture and fixtures </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_us-gaap_FurnitureAndFixturesMember" id="Fact001075" format="ixt:numdotdecimal" decimals="0" unitRef="USD">96,768</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31_us-gaap_FurnitureAndFixturesMember" id="Fact001076" format="ixt:numdotdecimal" decimals="0" unitRef="USD">87,148</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zUhyHyzfSund" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Computer hardware </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_us-gaap_ComputerEquipmentMember" id="Fact001078" format="ixt:numdotdecimal" decimals="0" unitRef="USD">36,613</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31_us-gaap_ComputerEquipmentMember" id="Fact001079" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,452</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zmHgNTK87a9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Leasehold improvements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember" id="Fact001081" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,064</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31_us-gaap_LeaseholdImprovementsMember" id="Fact001082" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21,064</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzDOd_zddlUWZrSspl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Total property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-12-31" id="Fact001084" format="ixt:numdotdecimal" decimals="0" unitRef="USD">436,626</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2022-12-31" id="Fact001085" format="ixt:numdotdecimal" decimals="0" unitRef="USD">405,845</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzDOd_zUnCInTIaywh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2023-12-31" id="Fact001087" format="ixt:numdotdecimal" decimals="0" unitRef="USD">348,074</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2022-12-31" id="Fact001088" format="ixt:numdotdecimal" decimals="0" unitRef="USD">317,834</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzDOd_z5wE7aUzCJF4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Property and equipment, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-12-31" id="Fact001090" format="ixt:numdotdecimal" decimals="0" unitRef="USD">88,552</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2022-12-31" id="Fact001091" format="ixt:numdotdecimal" decimals="0" unitRef="USD">88,011</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AC_z1Bmw1qI1eie" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
expense was $<span id="xdx_907_eus-gaap--Depreciation_c20230101__20231231_zGLbNuXWEs23" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2023-01-01to2023-12-31" id="Fact001093" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,240</ix:nonFraction></span> and $<span id="xdx_909_eus-gaap--Depreciation_c20220101__20221231_zderGWo0iL79" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2022-01-012022-12-31" id="Fact001095" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,920</ix:nonFraction></span> for the years ended December 31, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001097" name="us-gaap:IntangibleAssetsDisclosureTextBlock"><p id="xdx_800_eus-gaap--IntangibleAssetsDisclosureTextBlock_zfZcXInclVuj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.
<span id="xdx_82D_zRJnBmqYISka">Intangible Assets</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001099" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"><p id="xdx_89A_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zD03jdz2fjR1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets, net consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_z35rKqZHVCC4" style="display: none">Schedule of Intangible Assets</span>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20231231_zE5N7uh8RSrg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20221231_zrjV3ucEDmJk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwareImplementationMember_zo4cyPJFQBYf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Software Implementation </td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2023-12-31_custom_SoftwareImplementationMember" id="Fact001101" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,815</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2022-12-31_custom_SoftwareImplementationMember" id="Fact001102" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,815</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z0H2p6hAGYl3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Patents </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2023-12-31_us-gaap_PatentsMember" id="Fact001104" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,463</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2022-12-31_us-gaap_PatentsMember" id="Fact001105" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,463</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zM2CejhHnq33" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Trademark </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2023-12-31_us-gaap_TrademarksMember" id="Fact001107" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2022-12-31_us-gaap_TrademarksMember" id="Fact001108" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zUyhI90nG0O5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Licenses </td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2023-12-31_custom_LicensesMember" id="Fact001110" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1111">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_maFLIANzh0b_zz55gQdRG0qh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Total intangible assets </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2023-12-31" id="Fact001113" format="ixt:numdotdecimal" decimals="0" unitRef="USD">133,278</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2022-12-31" id="Fact001114" format="ixt:numdotdecimal" decimals="0" unitRef="USD">92,278</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_msFLIANzh0b_zJkYwCTbzNv8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Less: accumulated amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2023-12-31" id="Fact001116" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,205</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2022-12-31" id="Fact001117" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,720</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_mtFLIANzh0b_z8Ukw9YsX001" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Intangible assets, net </td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2023-12-31" id="Fact001119" format="ixt:numdotdecimal" decimals="0" unitRef="USD">108,073</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2022-12-31" id="Fact001120" format="ixt:numdotdecimal" decimals="0" unitRef="USD">77,558</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A1_zOzwTMmkQakd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
expense was $<span id="xdx_907_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20231231_z2ZnjCpobEul" title="Amortization expense"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2023-01-01to2023-12-31" id="Fact001122" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,485</ix:nonFraction></span> and $<span id="xdx_90C_eus-gaap--AmortizationOfIntangibleAssets_c20220101__20221231_zC5v6fBBI2oa" title="Amortization expense"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2022-01-012022-12-31" id="Fact001124" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,213</ix:nonFraction></span> for the years ended December 31, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001126" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"><p id="xdx_804_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_z4OCsv82yKCb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6.
<span id="xdx_82B_zcvbo45c4x5c">Accrued Expenses</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001128" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock"><p id="xdx_897_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zbJ7IyG2Sda6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
expenses consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span><span id="xdx_8B1_zPhMWXUSqlO6" style="display: none">Schedule of Accrued Expenses</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20231231_zDSqQEtsenai" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20221231_z7de2MycamP3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_ecustom--AccruedCompensationAndBenefitsCurrent_iI_maALCz2hn_z2TNu5bnhvf4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Compensation and benefits</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right"><ix:nonFraction name="NRXS:AccruedCompensationAndBenefitsCurrent" contextRef="AsOf2023-12-31" id="Fact001130" format="ixt:numdotdecimal" decimals="0" unitRef="USD">333,477</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right"><ix:nonFraction name="NRXS:AccruedCompensationAndBenefitsCurrent" contextRef="AsOf2022-12-31" id="Fact001131" format="ixt:numdotdecimal" decimals="0" unitRef="USD">539,558</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--UnderwriterFees_iI_maALCz2hn_z45JncJLH3w6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Underwriter fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1133">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="NRXS:UnderwriterFees" contextRef="AsOf2022-12-31" id="Fact001134" format="ixt:numdotdecimal" decimals="0" unitRef="USD">88,259</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--InterestPayableCurrent_iI_maALCz2hn_zza25uYKYpgi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2023-12-31" id="Fact001136" format="ixt:numdotdecimal" decimals="0" unitRef="USD">66,648</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2022-12-31" id="Fact001137" format="ixt:numdotdecimal" decimals="0" unitRef="USD">173,826</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--RelatedPartyInterestPayableCurrent_iI_maALCz2hn_zWTl8aaECLO5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Related party interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1139">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction name="NRXS:RelatedPartyInterestPayableCurrent" contextRef="AsOf2022-12-31" id="Fact001140" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,642</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccrualForTaxesOtherThanIncomeTaxesCurrent_iI_maALCz2hn_zONABGuKRwcc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent" contextRef="AsOf2023-12-31" id="Fact001142" format="ixt:numdotdecimal" decimals="0" unitRef="USD">963</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent" contextRef="AsOf2022-12-31" id="Fact001143" format="ixt:numdotdecimal" decimals="0" unitRef="USD">777</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>


  <tr id="xdx_40A_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCz2hn_zdp6dpeqfAH2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Total accrued expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact001145" format="ixt:numdotdecimal" decimals="0" unitRef="USD">401,088</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2022-12-31" id="Fact001146" format="ixt:numdotdecimal" decimals="0" unitRef="USD">834,062</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AE_zZZaB8IwTJZa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001148" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_80F_eus-gaap--DebtDisclosureTextBlock_zNWKjMjJOzwg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7.
<span id="xdx_82B_zF2DyNRZfIja">Notes Payable</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 15, 2023, The Company signed a note with Exchange Listing, LLC in the amount of $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_c20230215__dei--LegalEntityAxis__custom--ExchangeListingLLCMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zEytrpZtMVa" title="Promissory note"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2023-02-15_custom_ExchangeListingLLCMember_custom_PromissoryNoteMember" id="Fact001150" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,600</ix:nonFraction></span>.
The note carried an interest rate of <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20230215__dei--LegalEntityAxis__custom--ExchangeListingLLCMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zvkHO1vzwtr9" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2023-02-15_custom_ExchangeListingLLCMember_custom_PromissoryNoteMember" id="Fact001152" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1</ix:nonFraction></span>%.
The note shall be paid on the earlier of (i) three months or (ii) the Company receiving financing in the minimum of $<span id="xdx_905_eus-gaap--NotesPayable_iI_c20230215__dei--LegalEntityAxis__custom--ExchangeListingLLCMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zd42GigdxUUi" title="Promissory note"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2023-02-15_custom_ExchangeListingLLCMember_custom_PromissoryNoteMember" id="Fact001154" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,000,000</ix:nonFraction></span>.
 In August 2023, the Company used proceeds from the initial public offering to pay the note back in full, including interest, in
the amount of $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pp2d_c20230831__20230831__dei--LegalEntityAxis__custom--ExchangeListingLLCMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zFfyeyXTLDLg" title="Proceeds from issuance of ipo"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2023-08-312023-08-31_custom_ExchangeListingLLCMember_custom_PromissoryNoteMember" id="Fact001156" format="ixt:numdotdecimal" decimals="2" unitRef="USD">52,858</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 109; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company borrowed $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_c20211216__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zSDEKwnTbNak" title="Debt instrument face amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2021-12-16_custom_ChannelPartnersCapitalMember" id="Fact001158" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
December 16, 2021, from Channel Partners Capital. The note called for 65 weekly payments of $<span id="xdx_904_eus-gaap--DebtInstrumentPeriodicPayment_pp2d_c20230316__20230316__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zw97kZ5dDyMk" title="Debt instrument, periodic payment"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPayment" contextRef="From2023-03-162023-03-16_custom_ChannelPartnersCapitalMember" id="Fact001160" format="ixt:numdotdecimal" decimals="2" unitRef="USD">4,923</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
the final payment scheduled for March 16, 2023. The note&#8217;s interest rate computes to a nominal rate of <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230316__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_znXMfdp5KGKg" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2023-03-16_custom_ChannelPartnersCapitalMember" id="Fact001162" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">40.9</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%.
The principal outstanding at January 1, 2022 was $<span id="xdx_90A_eus-gaap--LongTermDebtAverageAmountOutstanding_c20220101__20220101__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zP1EkF7CMHpj" title="Principal outstanding"><ix:nonFraction name="us-gaap:LongTermDebtAverageAmountOutstanding" contextRef="From2022-01-012022-01-01_custom_ChannelPartnersCapitalMember" id="Fact001164" format="ixt:numdotdecimal" decimals="0" unitRef="USD">244,048</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The Company borrowed $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_c20220916__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zTs1aL8IQfsl" title="Borrowed amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2022-09-16_custom_ChannelPartnersCapitalMember" id="Fact001166" format="ixt:numdotdecimal" decimals="0" unitRef="USD">122,000</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
September 16, 2022, to bring the principal balance back to $<span id="xdx_902_eus-gaap--DebtInstrumentRepurchasedFaceAmount_iI_c20220916__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zVZhMbJMnIXc" title="Principal balance back"><ix:nonFraction name="us-gaap:DebtInstrumentRepurchasedFaceAmount" contextRef="AsOf2022-09-16_custom_ChannelPartnersCapitalMember" id="Fact001168" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
After making scheduled payments, the Company borrowed $<span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_c20230524__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_z55zJIDmX5Gc"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2023-05-24_custom_ChannelPartnersCapitalMember" id="Fact001169" format="ixt:numdotdecimal" decimals="0" unitRef="USD">107,231</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
May 24, 2023, to bring the principal balance back to $<span id="xdx_903_eus-gaap--DebtInstrumentRepurchasedFaceAmount_iI_c20230524__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_z1YWV2ASyxHh" title="Principal balance back"><ix:nonFraction name="us-gaap:DebtInstrumentRepurchasedFaceAmount" contextRef="AsOf2023-05-24_custom_ChannelPartnersCapitalMember" id="Fact001171" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The terms of the note are the same as the previous note with the final payment scheduled for August 22, 2024. The principal
outstanding at December 31, 2023 and 2022 was $<span id="xdx_900_eus-gaap--NotesPayable_iI_c20231231__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zMmZIZlewifl" title="Principal outstanding"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2023-12-31_custom_ChannelPartnersCapitalMember" id="Fact001173" format="ixt:numdotdecimal" decimals="0" unitRef="USD">148,062</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
and $<span id="xdx_902_eus-gaap--NotesPayable_iI_c20221231__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zw427gx3GhC" title="Principal outstanding"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2022-12-31_custom_ChannelPartnersCapitalMember" id="Fact001175" format="ixt:numdotdecimal" decimals="0" unitRef="USD">202,834</ix:nonFraction></span>,
respectively. The Company believes that the advancement of additional funds is a minor modification to the terms of the existing
loan since the difference in present value of the cash flows under the terms of the new loan is less than 10% of the present value
of the remaining cash flows under the terms of the original loan. As a result, the modification was accounted for as a modification
of debt.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
lender was granted and assigned a continuing security interest in all the Company&#8217;s personal property assets including, but not
limited to, business equipment, inventory, accounts, accounts receivable, intellectual property, chattel paper, instruments, deposit
accounts, commercial tort claims, contract rights, licenses, claims, and general intangibles.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
future minimum principal payments to be paid in 2024 is $<span id="xdx_906_eus-gaap--DebtInstrumentAnnualPrincipalPayment_iI_c20241231__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zCvJIGSbdhMh" title="Minimum principal payment"><ix:nonFraction name="us-gaap:DebtInstrumentAnnualPrincipalPayment" contextRef="AsOf2024-12-31_srt_ScenarioForecastMember" id="Fact001177" format="ixt:numdotdecimal" decimals="0" unitRef="USD">148,062</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Convertible
Notes</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001179" name="us-gaap:ConvertibleDebtTableTextBlock"><p id="xdx_89C_eus-gaap--ConvertibleDebtTableTextBlock_zwnV5CftQj64" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents a summary of the Company&#8217;s convertible notes:</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_zaDohGEoCEnk">Schedule
of Convertible Notes</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20231231_zojZPyu68nuh" style="border-bottom: Black 1.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_493_20221231_zKQQj3MCvMdf" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31,</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--DebtInstrumentFaceAmount_iI_zUfbL3EZ46u4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1181">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2022-12-31" id="Fact001182" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,555,556</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--DeferredFinanceCostsCurrentNet_iNI_di_zeR6aqvMYHkl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less:
    Original issue discount</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1184">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:DeferredFinanceCostsCurrentNet" contextRef="AsOf2022-12-31" id="Fact001185" format="ixt:numdotdecimal" decimals="0" unitRef="USD">355,556</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_403_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di_zQwpEjFULmVd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: Debt discount</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1187">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="AsOf2022-12-31" id="Fact001188" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,841,658</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_400_eus-gaap--DeferredFinanceCostsNet_iNI_di_zkKCDx6O8T62" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: Deferred financing fees</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1190">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:DeferredFinanceCostsNet" contextRef="AsOf2022-12-31" id="Fact001191" format="ixt:numdotdecimal" decimals="0" unitRef="USD">130,000</ix:nonFraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40C_eus-gaap--LongTermDebt_iI_zTA5lO8vLnec" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Notes
    payable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1193">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LongTermDebt" contextRef="AsOf2022-12-31" id="Fact001194" format="ixt:numdotdecimal" decimals="0" unitRef="USD">228,342</ix:nonFraction></span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</ix:nonNumeric><p id="xdx_8A5_zlqYDRny3Kq2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">From March to July of 2023, the Company conducted
multiple closings of a private placement offering to accredited investors for aggregate gross principal amounts of $<span id="xdx_906_eus-gaap--DebtInstrumentCarryingAmount_iI_c20230731__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember_z8U0BwR54WTb" title="Debt instrument gross"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2023-07-31_custom_ConvertiblePromissoryNoteMember_custom_AccreditedInvestorsMember" id="Fact001196" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,066,667</ix:nonFraction></span> and net
proceeds of $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfDebt_c20230301__20230731__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_z1fWFFjxUKWc" title="Net proceeds of debt"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="From2023-03-012023-07-31_custom_AccreditedInvestorsMember_custom_ConvertiblePromissoryNoteMember" id="Fact001198" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,908,000</ix:nonFraction></span>. The offering consisted of a convertible promissory note that accrues interest at <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20230731__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zY0bAAGExbQ1" title="Debt instrument interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2023-07-31_custom_ConvertiblePromissoryNoteMember" id="Fact001200" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12</ix:nonFraction></span>% that can be paid in cash
or PIK and an original issue discount of <span id="xdx_90D_ecustom--DebtInstrumentDiscountRate_iI_pid_dp_uPure_c20230731__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zRsXE9HjmJD5" title="Debt instrument discount rate"><ix:nonFraction name="NRXS:DebtInstrumentDiscountRate" contextRef="AsOf2023-07-31_custom_ConvertiblePromissoryNoteMember" id="Fact001202" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span>%. The convertible promissory notes automatically convert into common shares at a <span id="xdx_900_ecustom--DebtInstrumentDiscountRate_iI_dp_uPure_c20230731__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zUkLsczMB1Ka" title="Discount rate"><ix:nonFraction name="NRXS:DebtInstrumentDiscountRate" contextRef="AsOf2023-07-31_custom_ConvertiblePromissoryNoteMember_us-gaap_CommonStockMember" id="Fact001204" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">30</ix:nonFraction></span>% discount
to the IPO. The notes mature on the sooner of the six-month anniversary date from issuance or a successful IPO on primary exchange in
the U.S. and include <span id="xdx_904_ecustom--DebtWarrantConversionDescription_c20230301__20230731__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zCZswwovk4Vf" title="Debt warrant conversion, description"><ix:nonNumeric contextRef="From2023-03-012023-07-31_custom_ConvertiblePromissoryNoteMember" id="Fact001206" name="NRXS:DebtWarrantConversionDescription">a five-year warrant to purchase common stock equal to fifty percent (50%) of the shares into which the convertible
notes can be converted into at issuance.</ix:nonNumeric></span> The warrants have a strike price at a <span id="xdx_90A_eus-gaap--DebtInstrumentConvertibleConversionRatio1_dp_uPure_c20230301__20230731__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zp5RqvNclAmc" title="Strilke price"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionRatio1" contextRef="From2023-03-012023-07-31_custom_ConvertiblePromissoryNoteMember" id="Fact001208" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">25</ix:nonFraction></span>% premium to the conversion price subject to anti-dilution,
issuable on a pro rata basis at each funding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As facilitators to the 2023 convertible notes,
Signature Bank received a $<span id="xdx_901_eus-gaap--EscrowDeposit_iI_c20220413__dei--LegalEntityAxis__custom--SignatureBankMember_zuTSDDKzlco4" title="Escrow deposit"><ix:nonFraction name="us-gaap:EscrowDeposit" contextRef="AsOf2022-04-13_custom_SignatureBankMember" id="Fact001210" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,000</ix:nonFraction></span>
escrow fee and Alexander Capital, L.P. received (i) a cash commission of nine percent (9%) of the proceeds raised in the offering
from investors introduced to the Company and (ii) warrants for the purchase of a number of shares of Common Stock equal to 6% of the
number of underlying securities. Alexander Capital, L.P., received (i) fees totaling $<span id="xdx_90B_eus-gaap--ProceedsFromFeesReceived_c20230101__20231231__dei--LegalEntityAxis__custom--AlexanderCapitalLPMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zS9shkQlxxC1" title="Deferred financing fees"><ix:nonFraction name="us-gaap:ProceedsFromFeesReceived" contextRef="From2023-01-012023-12-31_custom_AlexanderCapitalLPMember_us-gaap_WarrantMember" id="Fact001212" format="ixt:numdotdecimal" decimals="0" unitRef="USD">546,000</ix:nonFraction></span>
in 2023 which were recorded in deferred financing fees as a reduction to notes payable on the balance sheet and (ii) <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231231__dei--LegalEntityAxis__custom--AlexanderCapitalLPMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfeNJzCsk77g" title="Number of warrants received"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="AsOf2023-12-31_custom_AlexanderCapitalLPMember_us-gaap_WarrantMember" id="Fact001214" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">120,235</ix:nonFraction></span>
warrants which were recorded at fair value in the warrant liability and debt discounts on the balance sheet.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">After the closing of the initial public offering
on August 8, 2023, the Company converted the notes payable plus $<span id="xdx_902_eus-gaap--NotesPayable_iI_c20230808__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zgLLIztHSYK1"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2023-08-08_custom_ChannelPartnersCapitalMember" id="Fact001215" format="ixt:numdotdecimal" decimals="0" unitRef="USD">226,391</ix:nonFraction>
</span>in interest into <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230808__20230808__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zfMiiMMOIFGg"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-08-082023-08-08_custom_ChannelPartnersCapitalMember" id="Fact001216" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,498,332</ix:nonFraction>
</span>shares of common stock. The shares were to be issued at a discounted price of $<span id="xdx_90A_eus-gaap--SharesIssuedPricePerShare_iI_c20230808__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zG2CJJA0Vky7"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-08-08_custom_ChannelPartnersCapitalMember" id="Fact001217" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.20</ix:nonFraction>
</span>per share resulting in a $<span id="xdx_903_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20230808__20230808__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zc8twd5kEnsj"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2023-08-082023-08-08_custom_ChannelPartnersCapitalMember" id="Fact001218" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,115,223</ix:nonFraction>
</span>loss to the Company which is recorded in extinguishment of debt liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March of 2023, the Company used borrowings from
the 2023 convertible notes to pay the principal balance of some of the 2022 notes totaling $<span id="xdx_904_eus-gaap--NotesPayable_iI_c20230331__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zg2u9GbOjWzb"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2023-03-31_custom_TwoThousandTwentyThreeConvertibleNotesMember" id="Fact001219" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,650,000</ix:nonFraction></span>
which resulted in a $<span id="xdx_905_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20230301__20230331__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zA0Trmkpmai4" title="Gain on extinguishment of debt liabilities"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2023-03-012023-03-31_custom_TwoThousandTwentyThreeConvertibleNotesMember" id="Fact001221" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,129,653</ix:nonFraction></span> gain to the Company which is recorded in extinguishment of debt liabilities. Upon payment, the
terms for the remaining balance of those notes were also updated. The remaining balance accrued interest at <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20230331__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zPJ3DIUwf5we"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2023-03-31_custom_TwoThousandTwentyThreeConvertibleNotesMember" id="Fact001222" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction></span>%
per annum without maturity or default rights. The new balance shall also automatically convert into shares of common stock at a <span id="xdx_90E_ecustom--DebtInstrumentDiscountRate_iI_dp_uPure_c20230331__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zOAJcyb69USb"><ix:nonFraction name="NRXS:DebtInstrumentDiscountRate" contextRef="AsOf2023-03-31_custom_TwoThousandTwentyThreeConvertibleNotesMember" id="Fact001223" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">27.5</ix:nonFraction></span>%
discount to the per share offering price in the Company&#8217;s initial public offering or $<span id="xdx_90B_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20230331__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zXfhwPQ9wnEc"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2023-03-31_custom_TwoThousandTwentyThreeConvertibleNotesMember" id="Fact001224" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.35</ix:nonFraction>
</span>per share. After the closing of the initial public offering on August 8, 2023, the Company converted the notes payable plus $<span id="xdx_907_eus-gaap--NotesPayable_iI_c20230808__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_z101SOBxFrC4"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2023-08-08_custom_TwoThousandTwentyThreeConvertibleNotesMember" id="Fact001225" format="ixt:numdotdecimal" decimals="0" unitRef="USD">173,205</ix:nonFraction>
</span>in interest into <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230808__20230808__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zUcBo3fQDa9d"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2023-08-082023-08-08_custom_TwoThousandTwentyThreeConvertibleNotesMember" id="Fact001226" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">107,509</ix:nonFraction>
</span>shares of common stock. The shares are to be issued at a discounted price of $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_c20230808__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zzxajDKfLMNl"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-08-08_custom_TwoThousandTwentyThreeConvertibleNotesMember" id="Fact001227" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.35</ix:nonFraction>
</span>per share resulting in a $<span id="xdx_904_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20230808__20230808__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zvnEs2bvb6eh" title="Extinguishment of debt"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2023-08-082023-08-08_custom_TwoThousandTwentyThreeConvertibleNotesMember" id="Fact001229" format="ixt:numdotdecimal" decimals="0" unitRef="USD">663,991</ix:nonFraction></span> loss to the Company which is recorded in extinguishment of debt liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The remaining investors of the 2022 notes did
not convert their notes and, as such, the Company used proceeds from the initial public offering to pay the remaining promissory
notes back in full, including interest in the amount of $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20230814__20230814__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zizLG4TxWnDe" title="Proceeds from issuance of ipo"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2023-08-142023-08-14_custom_TwoThousandTwentyThreeConvertibleNotesMember" id="Fact001231" format="ixt:numdotdecimal" decimals="0" unitRef="USD">445,554</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 110; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The convertible notes signed between June 3, 2022
and November 30, 2022 had aggregate gross principal amounts totaling $<span id="xdx_902_eus-gaap--DebtInstrumentCarryingAmount_iI_c20221130__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_znWiHUAbEPIe" title="Debt instrument gross"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2022-11-30_custom_TwoThousandTwentyTwoConvertibleNotesMember" id="Fact001233" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,333,333</ix:nonFraction></span> and net proceeds of $<span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfDebt_c20220601__20221130__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_z0DQXaOtuNXd" title="Net proceeds of debt"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="From2022-06-012022-11-30_custom_TwoThousandTwentyTwoConvertibleNotesMember" id="Fact001235" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,870,000</ix:nonFraction></span> and consisted of an <span id="xdx_904_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20220603__20221130__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zn1OPr3XrPQb" title="Debt instrument description"><ix:nonNumeric contextRef="From2022-06-032022-11-30_custom_TwoThousandTwentyTwoConvertibleNotesMember" id="Fact001237" name="us-gaap:DebtInstrumentDescriptionOfVariableRateBasis">original
issue discount of 10% with an interest rate of the greater of (i) Prime rate plus 8.5% or (ii) 12%.</ix:nonNumeric></span> The notes convert into common shares
at the lower of (i) $<span id="xdx_90F_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20221130__srt--RangeAxis__srt--MinimumMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zrmEVcETlc54"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2022-11-30_srt_MinimumMember_custom_TwoThousandTwentyTwoConvertibleNotesMember" id="Fact001238" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.44</ix:nonFraction></span> or (ii) a <span id="xdx_90F_ecustom--DebtInstrumentDiscountRate_iI_dp_uPure_c20221130__srt--RangeAxis__srt--MaximumMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zw1JXskujnUc"><ix:nonFraction name="NRXS:DebtInstrumentDiscountRate" contextRef="AsOf2022-11-30_srt_MaximumMember_custom_TwoThousandTwentyTwoConvertibleNotesMember" id="Fact001239" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">30</ix:nonFraction></span>% discount to the price per share of any subsequent offering. The notes matured on the one-year
anniversary date from issuance and contain <span id="xdx_907_ecustom--DebtWarrantConversionDescription_c20220603__20221130__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zi4XKE81u4Wc" title="Debt warrant conversion, description"><ix:nonNumeric contextRef="From2022-06-032022-11-30_custom_TwoThousandTwentyTwoConvertibleNotesMember" id="Fact001241" name="NRXS:DebtWarrantConversionDescription">a five-year warrant to purchase common stock equal to one hundred percent (100%) of the shares
into which the 2022 Convertible Notes can be converted into at issuance.</ix:nonNumeric></span> The warrants have an exercise price at the lower of (i) $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221130__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zF4TgXjAhR5h" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2022-11-30_custom_TwoThousandTwentyTwoConvertibleNotesMember" id="Fact001243" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.80</ix:nonFraction></span>
per share or (ii) a <span id="xdx_905_ecustom--ClassOfWarrantDiscountRate_iI_dp_uPure_c20221130__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_z6ocuv9JmTI7" title="Class of warrant discount rate"><ix:nonFraction name="NRXS:ClassOfWarrantDiscountRate" contextRef="AsOf2022-11-30_custom_TwoThousandTwentyTwoConvertibleNotesMember" id="Fact001245" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12.5</ix:nonFraction></span>% discount to the price per share of any subsequent offering, (c) shares of the Company&#8217;s common stock
equal to <span id="xdx_902_ecustom--DebtInstrumentPrincipalAmount_iI_dp_uPure_c20221130__srt--RangeAxis__srt--MaximumMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zuKGgPz3QRie" title="Principal amount in percent"><ix:nonFraction name="NRXS:DebtInstrumentPrincipalAmount" contextRef="AsOf2022-11-30_srt_MaximumMember_custom_TwoThousandTwentyTwoConvertibleNotesMember" id="Fact001247" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span>% of the principal amount of these notes, at a value per share equal to the conversion price. The <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220603__20221130__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zd1udFHNT9bj" title="Issuance of shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-06-032022-11-30_us-gaap_CommonStockMember_custom_TwoThousandTwentyTwoConvertibleNotesMember" id="Fact001249" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">35,318</ix:nonFraction></span> shares of common
stock issued to investors had a relative fair value of $<span id="xdx_90F_eus-gaap--FairValueAdjustmentOfWarrants_c20220603__20221130__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_z2udrEx7iBLa" title="Fair value adjustment of warrants"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-06-032022-11-30_us-gaap_CommonStockMember_custom_TwoThousandTwentyTwoConvertibleNotesMember" id="Fact001251" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,789</ix:nonFraction></span>. Due to the second prong of the conversion equation after the IPO an additional
<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220603__20221130__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zoZbk3MP2oBg" title="Issuance of shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2022-06-032022-11-30_custom_ChannelPartnersCapitalMember" id="Fact001253" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">44,048</ix:nonFraction></span> commitment shares are to be issued. The shares are to be issued at a discounted price of $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_c20221130__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zTP1G4CMOynj" title="Shares issued price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2022-11-30_custom_TwoThousandTwentyTwoConvertibleNotesMember" id="Fact001255" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.20</ix:nonFraction></span> per share resulting in a loss to
the Company which is recorded in extinguishment of debt liabilities.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The convertible notes signed on December 19, 2022
had aggregate gross principal amounts totaling $<span id="xdx_903_eus-gaap--DebtInstrumentCarryingAmount_iI_c20221219__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_z6bldzpYQIP7" title="Debt instrument gross"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2022-12-19_custom_TwoThousandTwentyTwoConvertibleNotesMember" id="Fact001257" format="ixt:numdotdecimal" decimals="0" unitRef="USD">222,222</ix:nonFraction></span> and net proceeds of $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfDebt_c20221219__20221219__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zS5aGAcKlIuh" title="Net proceeds of debt"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="From2022-12-192022-12-19_custom_TwoThousandTwentyTwoConvertibleNotesMember" id="Fact001259" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,000</ix:nonFraction></span> and consisted of an original issue discount of <span id="xdx_902_ecustom--DebtInstrumentDiscountRate_iI_dp_uPure_c20221219__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zNKTch3JiVO3" title="Debt instrument discount rate"><ix:nonFraction name="NRXS:DebtInstrumentDiscountRate" contextRef="AsOf2022-12-19_custom_TwoThousandTwentyTwoConvertibleNotesMember" id="Fact001261" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span>%
of the principal amount with an interest rate of <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20221219__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zpulGE3O1BE" title="Accrued interest"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2022-12-19_custom_TwoThousandTwentyTwoConvertibleNotesMember" id="Fact001263" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">12</ix:nonFraction></span>% per annum. The notes matured at the earlier of (i) twelve (12) months from the issue
date or (ii) the date upon which the Company completes a registered public offering of shares of the Company, which encompasses the closing
of the IPO. The notes are convertible into shares of common stock at the higher of (i) $<span id="xdx_901_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20221219__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zP140MdMlMBd" title="Conversion price"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2022-12-19_custom_TwoThousandTwentyTwoConvertibleNotesMember" id="Fact001265" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.44</ix:nonFraction></span> per share or (ii) the price per share of
common stock issued pursuant to the next registered public offering of shares of the Company made prior to the conversion of any portion
of the note. Interest accrues on the aggregate principal amount (which includes original issue discount) and is payable on the maturity
date, at the Company&#8217;s election, in cash or in-kind. The holders of the notes are entitled to piggyback registration rights on any
registration statement filed by the Company, other than any registration statement filed on Form S-4 or Form S-8. The warrants and conversion
shares are subject to anti-dilution provisions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
investors of the notes signed on December 19, 2022 above did not convert their notes and, as such the Company used proceeds from the
initial public offering to pay the remaining promissory notes back in full, including interest in the amount of $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20221219__20221219__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zU2sV3uccL83" title="Proceeds from issuance of ipo"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2022-12-192022-12-19_custom_TwoThousandTwentyTwoConvertibleNotesMember" id="Fact001267" format="ixt:numdotdecimal" decimals="0" unitRef="USD">239,104</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company paid $<span id="xdx_908_eus-gaap--PaymentsOfDebtIssuanceCosts_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zQpHgT4rWVfa" title="Offering costs"><ix:nonFraction name="us-gaap:PaymentsOfDebtIssuanceCosts" contextRef="From2022-01-012022-12-31_custom_TwoThousandTwentyTwoConvertibleNotesMember" id="Fact001269" format="ixt:numdotdecimal" decimals="0" unitRef="USD">130,000</ix:nonFraction></span>
in fees to law firms related to the 2022 convertible note offerings and were recorded as deferred financing fees as a reduction to
notes payable on the balance sheet.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has applied ASC 815 due to
the potential for settlement in a variable quantity of shares. Since these convertible notes and warrants have the option to convert or
be exercised at a variable amount, they are subject to derivative liability treatment. The conversion feature has been measured at fair
value using a Monte Carlo model at the date of issuance and is adjusted to fair value at each reporting period. The fair value of the
embedded derivative and the warrant liability at date of issuance was $<span id="xdx_906_eus-gaap--EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_iI_c20231231_zn5dsw6KR9ci" title="Fair value of embedded derivative"><ix:nonFraction name="us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" contextRef="AsOf2023-12-31" id="Fact001271" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,375,378</ix:nonFraction></span> and $<span id="xdx_90D_eus-gaap--WarrantsNotSettleableInCashFairValueDisclosure_iI_c20231231_znXcdJCHCI5l" title="Embedded derivative warrant liability"><ix:nonFraction name="us-gaap:WarrantsNotSettleableInCashFairValueDisclosure" contextRef="AsOf2023-12-31" id="Fact001273" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,446,502</ix:nonFraction></span>, respectively. See Notes 12 and 13.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The 2023 and 2022 convertible notes transferred
fair value to investors in the form of principal, warrants and common shares totaling $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_c20221231__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember_zCxrJK0O9hd1" title="Principal of warrants and common shares fair value"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2022-12-31_custom_InvestorsMember_custom_TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember" id="Fact001275" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,947,212</ix:nonFraction></span>.
As the Company received cash proceeds of $<span id="xdx_904_eus-gaap--ProceedsFromNotesPayable_c20230101__20231231__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember_zWingHw0dEpj" title="Cash proceeds fair value of incentivies"><ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="From2023-01-012023-12-31_custom_InvestorsMember_custom_TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember" id="Fact001277" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,660,000</ix:nonFraction></span>,
net of an original issue discount of $<span id="xdx_903_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iI_c20231231_zARY6Z3amQEi" title="Original issue discount"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" contextRef="AsOf2023-12-31" id="Fact001279" format="ixt:numdotdecimal" decimals="0" unitRef="USD">962,223</ix:nonFraction></span>, the remaining fair value of incentives in excess of principal of $<span id="xdx_90B_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iI_c20231231__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember_z2CZj7yPXii4" title="Debt discount"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountCurrent" contextRef="AsOf2023-12-31_custom_InvestorsMember_custom_TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember" id="Fact001281" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,234,988</ix:nonFraction></span>
was expensed as finance charges totaling $<span id="xdx_90D_eus-gaap--PaymentsOfFinancingCosts_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember_zNtliDvlieBb" title="Financing fees"><ix:nonFraction name="us-gaap:PaymentsOfFinancingCosts" contextRef="From2023-01-012023-12-31_custom_TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember" id="Fact001283" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,772</ix:nonFraction></span>
and $<span id="xdx_90B_ecustom--PaymentsOfFinancingCost_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember_zHUrapMMV084" title="Financing fees"><span id="xdx_902_ecustom--PaymentsOfFinancingCost_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember_zU0nI075VT47" title="Financing fees"><ix:nonFraction name="NRXS:PaymentsOfFinancingCost" contextRef="From2022-01-012022-12-31_custom_TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember" id="Fact001285" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="NRXS:PaymentsOfFinancingCost" contextRef="From2022-01-012022-12-31_custom_TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember" id="Fact001287" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,322,216</ix:nonFraction></ix:nonFraction></span></span>
for the years ended December 31, 2023 and 2022, respectively. On August 8, 2023, the Company amortized the remaining original issue
discount, debt discount reflective of the fair value of embedded warrants and financing fees as the 2023 and 2022 convertible notes
were either paid in full or converted to common stock pursuant to the initial public offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the years ended December 31, 2023 and 2022,
the Company accrued interest on these convertible notes totaling $<span id="xdx_906_eus-gaap--InterestPayableCurrent_iI_c20231231__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_ziueDiJJwFkc" title="Accrued interest"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2023-12-31_us-gaap_ConvertibleNotesPayableMember" id="Fact001289" format="ixt:numdotdecimal" decimals="0" unitRef="USD">399,597</ix:nonFraction></span> and $<span id="xdx_904_eus-gaap--InterestPayableCurrent_iI_c20221231__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_z9WriA2Jvz68" title="Accrued interest"><ix:nonFraction name="us-gaap:InterestPayableCurrent" contextRef="AsOf2022-12-31_us-gaap_ConvertibleNotesPayableMember" id="Fact001291" format="ixt:numdotdecimal" decimals="0" unitRef="USD">107,544</ix:nonFraction></span>, respectively, which was paid or converted into
common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<ix:exclude><!-- Field: Page; Sequence: 111; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001293" name="us-gaap:LesseeOperatingLeasesTextBlock"><p id="xdx_80E_eus-gaap--LesseeOperatingLeasesTextBlock_zX8seumS0IE" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8.
<span id="xdx_825_zwX2aOaesGig">Leases</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s leases are comprised of operating leases for office space. At the inception of the lease, the Company determines whether
the lease contract conveys the right to control the use of identified property for a period of time in exchange for consideration. Leases
are classified as operating or finance leases at the commencement date of the lease. Operating leases are recorded as operating lease
right-of-use assets, other current liabilities, and operating lease liabilities in the Balance Sheets. The Company did not have any finance
leases at December 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had three leases primarily consisting of office space in Versailles, Indiana and Carmel, Indiana. <span id="xdx_900_eus-gaap--LesseeOperatingLeaseDescription_c20230101__20231231_zHpDfrxcFjo" title="Operating lease description"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" id="Fact001295" name="us-gaap:LesseeOperatingLeaseDescription">Two of the leases in Versailles
started January 1, 2017. Both have an initial term of five years with an option for an additional five-year term. The monthly lease payments
for these leases are $<span id="xdx_90F_eus-gaap--OperatingLeasePayments_c20170101__20170101__us-gaap--GeographicDistributionAxis__custom--VersaillesIndianaMember__us-gaap--LeaseContractualTermAxis__custom--LeaseOneMember_z9GjoNdR8Aje" title="Operating lease payment"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2017-01-012017-01-01_custom_VersaillesIndianaMember_custom_LeaseOneMember" id="Fact001297" format="ixt:numdotdecimal" decimals="0" unitRef="USD">550</ix:nonFraction></span> and $<span id="xdx_90B_eus-gaap--OperatingLeasePayments_c20170101__20170101__us-gaap--GeographicDistributionAxis__custom--VersaillesIndianaMember__us-gaap--LeaseContractualTermAxis__custom--LeaseTwoMember_zbXbKuGA9Lp8" title="Operating lease payment"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2017-01-012017-01-01_custom_VersaillesIndianaMember_custom_LeaseTwoMember" id="Fact001299" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,600</ix:nonFraction></span> with a <span id="xdx_909_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_dp_uPure_c20170101__us-gaap--GeographicDistributionAxis__custom--VersaillesIndianaMember_zb58exyLfY26" title="Discount rate"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseDiscountRate" contextRef="AsOf2017-01-01_custom_VersaillesIndianaMember" id="Fact001301" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3</ix:nonFraction></span>% per annum increase starting with the optional five-year term. The lease in Carmel started
March 1, 2016. The initial term is five years and three months with an option for an additional three-year term. The monthly lease payment
started at $<span id="xdx_907_eus-gaap--OperatingLeasePayments_c20160301__20160301__us-gaap--GeographicDistributionAxis__custom--CarmelIndianaMember__us-gaap--LeaseContractualTermAxis__custom--LeaseThreeMember_zuOLk605kPfe" title="Operating lease payment"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2016-03-012016-03-01_custom_CarmelIndianaMember_custom_LeaseThreeMember" id="Fact001303" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,472</ix:nonFraction></span> with an annual increase of approximately <span id="xdx_90B_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_uPure_c20160301__us-gaap--GeographicDistributionAxis__custom--CarmelIndianaMember_zMMV28YBoiLb" title="Operating lease payment rate"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseDiscountRate" contextRef="AsOf2016-03-01_custom_CarmelIndianaMember" id="Fact001305" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.7</ix:nonFraction></span>%. On December 16, 2020, the Company entered into an amendment of the Carmel
lease that extended the initial term by two years.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
lease right-of-use assets and liabilities are recognized at the commencement date based on the present value of lease payments over the
lease term. As the implicit interest rate is generally not readily determinable, the Company uses an incremental borrowing rate based
on the information available at the commencement date in determining the present value of lease payments. The incremental borrowing rate
reflects the estimated rate of interest that the Company would pay to borrow on a collateralized basis over a similar economic environment.
Lease expense for the operating lease is recognized on a straight-line basis over the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases
may include renewal options, and the renewal option is included in the lease term if the Company concludes that it is reasonably certain
that the option will be exercised. Certain leases may contain rent escalation clauses, either fixed or adjusted periodically for inflation
of market rates, that are factored into the calculation of lease payments to the extent they are fixed and determinable at lease inception.
The Company also has variable lease payments that do not depend on a rate or index, primarily for items such as common area maintenance
and real estate taxes, which are recorded as expenses when incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2023 and 2022, the Company recognized $<span id="xdx_906_eus-gaap--OperatingLeaseExpense_c20230101__20231231_zE4mSeS3loE6" title="Operating lease expense"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2023-01-01to2023-12-31" id="Fact001307" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,051</ix:nonFraction></span> and $<span id="xdx_90B_eus-gaap--OperatingLeaseExpense_c20220101__20221231_zIvy1SKO2cMl" title="Operating lease expense"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2022-01-012022-12-31" id="Fact001309" format="ixt:numdotdecimal" decimals="0" unitRef="USD">47,571</ix:nonFraction></span> of operating lease expense, including short-term
lease expense and variable lease costs, which are immaterial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001311" name="us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock"><p id="xdx_89A_eus-gaap--OperatingLeasesOfLesseeDisclosureTextBlock_zL1DVsEOIMZj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information related to the Company&#8217;s operating leases:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B9_zbkU8aI0hBH7" style="display: none">Schedule of Operating Leases</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49D_20231231_zbQj9ZkbBWz2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_492_20221231_zYHSdHBiFm09" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseRightOfUseAsset_iI_zEZZBTAfoqd7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left; padding-bottom: 1.5pt">Operating lease right-of-use assets</td><td style="width: 2%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 16%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-12-31" id="Fact001313" format="ixt:numdotdecimal" decimals="0" unitRef="USD">70,263</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2022-12-31" id="Fact001314" format="ixt:numdotdecimal" decimals="0" unitRef="USD">101,382</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OtherLiabilitiesCurrent_iI_zm9zZg5Nwu86" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other current liabilities</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2023-12-31" id="Fact001316" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,127</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2022-12-31" id="Fact001317" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,395</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zy2McdHD9408" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Operating lease liabilities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2023-12-31" id="Fact001319" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,071</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2022-12-31" id="Fact001320" format="ixt:numdotdecimal" decimals="0" unitRef="USD">76,199</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingLeaseLiability_iI_zJsruRK1nMR" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2023-12-31" id="Fact001322" format="ixt:numdotdecimal" decimals="0" unitRef="USD">76,198</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2022-12-31" id="Fact001323" format="ixt:numdotdecimal" decimals="0" unitRef="USD">109,594</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Weighted-average remaining lease term (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20231231_zFFRP2qAZvg7" title="Weighted average remaining lease term (in years)"><ix:nonNumeric contextRef="AsOf2023-12-31" format="ixt-sec:duryear" id="Fact001325" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">3.75</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_zomxZrgZidyk" title="Weighted average remaining lease term (in years)"><ix:nonNumeric contextRef="AsOf2022-12-31" format="ixt-sec:duryear" id="Fact001327" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">4.00</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Weighted-average discount rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_uPure_c20231231_zBeFiyvgElC7" title="Weighted average discount rate"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2023-12-31" id="Fact001329" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15.0</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_uPure_c20221231_zAkKHF1tgYWl" title="Weighted average discount rate"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2022-12-31" id="Fact001331" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15.0</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A8_zhTFKMFizYai" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001333" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><p id="xdx_895_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zxxn8qAlvrSc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, the maturities of the Company&#8217;s operating lease liabilities were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span><span id="xdx_8B5_zeZ9qs2gWW39" style="display: none">Schedule of Maturities Operating Lease Liabilities</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 65%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49C_20231231_zoyDNcpF1jfk" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzyNu_zJrYMlclNNZ" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2023-12-31" id="Fact001335" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,072</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzyNu_zFmSJqgVaoyh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2023-12-31" id="Fact001337" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,316</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzyNu_zov6zadw8H07" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2026</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2023-12-31" id="Fact001339" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,810</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzyNu_zWn2N5fJhg9d" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2023-12-31" id="Fact001341" format="ixt:numdotdecimal" decimals="0" unitRef="USD">76,198</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_z1Yfm0NWn5V3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1343">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseLiability_iI_zirh2xyENqp9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total present value of lease payments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2023-12-31" id="Fact001345" format="ixt:numdotdecimal" decimals="0" unitRef="USD">76,198</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

</ix:nonNumeric><p id="xdx_8A8_zWz7UB68bOyd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001347" name="NRXS:CommonStockAndWarrantsDisclosureTextBlock"><p id="xdx_803_ecustom--CommonStockAndWarrantsDisclosureTextBlock_zprAyyGdMAf2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9.
<span id="xdx_82C_zqrrMh9ztpI">Common Stock and Warrants</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company authorized <span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_c20221231_pdd"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2022-12-31" id="Fact001348" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000,000</ix:nonFraction></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
of common stock, of which <span id="xdx_90F_eus-gaap--CommonStockSharesOutstanding_c20231231_pdd"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-12-31" id="Fact001349" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,508,897</ix:nonFraction></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and <span id="xdx_901_eus-gaap--CommonStockSharesOutstanding_c20221231_pdd"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2022-12-31" id="Fact001350" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,963,322</ix:nonFraction></span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
were issued and outstanding as of December 31, 2023 and 2022, respectively. In conjunction with <span id="xdx_90B_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230808__20230808__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zp8HaJUB3Oba" title="Number of shares issued in transaction"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2023-08-082023-08-08_us-gaap_CommonStockMember" id="Fact001352" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,098,667</ix:nonFraction></span> common shares issued upon
the completion of the initial public offering on August 8, 2023, the Company also issued (i) <span id="xdx_900_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20230808__20230808_zJxZAxtFtyK1"><ix:nonFraction name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" contextRef="From2023-08-082023-08-08" id="Fact001353" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,244,228</ix:nonFraction></span>
common shares upon conversion of <span id="xdx_904_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20230808_zOZQjCbyYfgf"><ix:nonFraction name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" contextRef="AsOf2023-08-08" id="Fact001354" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">506,637</ix:nonFraction></span>
shares of Convertible Series A Preferred Stock and <span id="xdx_901_eus-gaap--ConversionOfStockSharesConverted1_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_zKFjCyjTZxQa" title="Stock value converted"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2022-01-012022-12-31_custom_ConvertibleSeriesSeedPreferredStockMember64722968" id="Fact001356" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">115,477</ix:nonFraction></span>
shares of Convertible Series Seed Preferred Stock, (ii) <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20230808__20230808__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWOX6ufGTUm5" title="Common stock issued upon debt conversion, shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" contextRef="From2023-08-082023-08-08_us-gaap_CommonStockMember" id="Fact001358" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,649,900</ix:nonFraction></span>
common shares upon conversion of convertible notes, (iii) </span><span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230808__20230808__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VendorsMember_zrwlgZ1FlP8i" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2023-08-082023-08-08_custom_VendorsMember" id="Fact001359" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">425,000</ix:nonFraction> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">commons
shares as payment to vendors for services and (iv) </span><span id="xdx_904_eus-gaap--ConversionOfStockSharesIssued1_c20230808__20230808__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYOjhq6xGnni" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:ConversionOfStockSharesIssued1" contextRef="From2023-08-082023-08-08_us-gaap_WarrantMember" id="Fact001360" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">127,780</ix:nonFraction> </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">common
shares upon the exercise of warrants. On January 10, 2023, the Company&#8217;s board of directors authorized a </span><span id="xdx_908_eus-gaap--StockholdersEquityNoteStockSplit_c20230109__20230110_zNOcnW6oS9K" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="From2023-01-092023-01-10" id="Fact001361" name="us-gaap:StockholdersEquityNoteStockSplit">2-for-1
reverse stock split</ix:nonNumeric></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. All share information in these
financial statements has been adjusted for this reverse stock split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 10, 2023, the Company&#8217;s board of directors authorized a <span id="xdx_90C_eus-gaap--StockholdersEquityNoteStockSplit_c20230110__20230110_zqw3nJFmfy9e" title="Description of stock split"><ix:nonNumeric contextRef="From2023-01-102023-01-10" id="Fact001363" name="us-gaap:StockholdersEquityNoteStockSplit">2-for-1 reverse stock split</ix:nonNumeric></span>. All share information in these financial
statements has been adjusted for this reverse stock split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt">On August 9, 2023, the Company consummated an initial public offering, conducted on a firm commitment basis, pursuant to which it sold
<span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230809__20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zhQs53cZ3pJh" title="Number of shares issued in transaction"><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="From2023-08-092023-08-09_us-gaap_CommonStockMember" id="Fact001365" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,098,667</ix:nonFraction></span> shares of its common stock at a price of $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_c20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zlYaxgRcWhzg" title="Share issued price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-08-09_us-gaap_CommonStockMember" id="Fact001367" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.00</ix:nonFraction></span> per share, resulting in gross proceeds of $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230809__20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zEmHOvxrvNYi" title="Proceeds from issuance of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-08-092023-08-09_us-gaap_CommonStockMember" id="Fact001369" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,592,002</ix:nonFraction></span>. See Note 1.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 112; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with a bridge loan, the Company issued a warrant on September 18, 2018 that allows the holder to purchase common
stock from the Company at a share price of $<span id="xdx_901_eus-gaap--SharePrice_iI_pid_c20180918__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--BrianHannaschMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_zU6anbLDWfnf" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2018-09-18_us-gaap_CommonStockMember_custom_BrianHannaschMember_custom_WarrantOneMember" id="Fact001371" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.38</ix:nonFraction></span>
per share. The number of shares was based on a formula tied to the final amount of loans made by the holder of $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20180918__20180918__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--BrianHannaschMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_zxcybR51McLa" title="Final amount"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2018-09-182018-09-18_us-gaap_CommonStockMember_custom_BrianHannaschMember_custom_WarrantOneMember" id="Fact001373" format="ixt:numdotdecimal" decimals="0" unitRef="USD">375,000</ix:nonFraction></span>,
multiplied by <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20180918__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--BrianHannaschMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_z0twKBxIqGrf" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="AsOf2018-09-18_us-gaap_CommonStockMember_custom_BrianHannaschMember_custom_WarrantOneMember" id="Fact001375" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">150</ix:nonFraction></span>%,
and divided by $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20180918__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--BrianHannaschMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_zQnffytKIu8g" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2018-09-18_us-gaap_CommonStockMember_custom_BrianHannaschMember_custom_WarrantOneMember" id="Fact001377" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">70.03</ix:nonFraction></span>.
The number of shares based on this formula is <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20180918__srt--TitleOfIndividualAxis__custom--BrianHannaschMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zVWbBAxj6Y2a" title="Number of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2018-09-18_us-gaap_CommonStockMember_custom_BrianHannaschMember_custom_WarrantOneMember" id="Fact001379" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,852</ix:nonFraction></span>.
The warrant contains certain rights in the event of liquidation, merger, or consolidation of the Company. If the fair market value
of one share is greater than the warrant price, the holder may elect to receive a number of shares equal to the value of the
warrant. If the exercise is in connection with the sale of the Company, the holder may, at its option, condition its exercise of the
warrant upon the consummation of such transaction. The warrant expires on <span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20180918__srt--TitleOfIndividualAxis__custom--BrianHannaschMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z1W9WUuzvjIg" title="Date of Expiration"><ix:nonNumeric contextRef="AsOf2018-09-18_us-gaap_CommonStockMember_custom_BrianHannaschMember_custom_WarrantOneMember" format="ixt:datemonthdayyearen" id="Fact001381" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">September
18, 2028</ix:nonNumeric></span> and can be exercisable either in whole or from time to time in part prior to the expiration date.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company issued a second warrant on September 6, 2019, under similar terms but is a penny warrant that allows the holder to purchase
<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20190906__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zy347P2O8vMk" title="Number of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2019-09-06_custom_WarrantTwoMember_us-gaap_CommonStockMember" id="Fact001383" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,000</ix:nonFraction></span> shares of common stock and is subject to adjustment for certain equity events. The warrant contains certain rights in the event
of liquidation, merger, or consolidation of the Company. The warrant expires on <span id="xdx_904_ecustom--WarrantsExpirationDateDescription_c20190906__20190906__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zf5TzJrxXLS7" title="Date of Expiration"><ix:nonNumeric contextRef="From2019-09-062019-09-06_us-gaap_CommonStockMember" id="Fact001385" name="NRXS:WarrantsExpirationDateDescription">September 6, 2029</ix:nonNumeric></span>. This warrant was converted to <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20190906__20190906__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAYlTCf768y9" title="Number of shares, conversion of convertible securities"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2019-09-062019-09-06_us-gaap_WarrantMember" id="Fact001387" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">39,924</ix:nonFraction></span>
shares of common stock on December 28, 2023. The fair market value of the stock on that day was calculated as the average of the daily
closing prices per share for the 30 consecutive trading day period ending on the second trading day prior to such date or $<span id="xdx_903_eus-gaap--SharePrice_iI_pid_c20190906__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zuxnhpcpMTn6" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2019-09-06_us-gaap_WarrantMember" id="Fact001389" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.61</ix:nonFraction></span> per share.
<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20190906__20190906_zdMKXcgMd2u8" title="Warrant, description"><ix:nonNumeric contextRef="From2019-09-062019-09-06" id="Fact001391" name="us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees">Since the fair value was greater than the warrant price of $0.01 per share the holder elected to receive the number of shares equal
to 40,000 times the difference between the fair market value and the exercise price divided by the fair market value, resulting in 39,924.</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company issued a third warrant to Masimo Corporation on April 9, 2020. This warrant was pre-funded in the amount of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20200409__dei--LegalEntityAxis__custom--MasimoCorporationMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTwoMember_z3MWXhxiJUt6"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2020-04-09_custom_MasimoCorporationMember_custom_WarrantTwoMember" id="Fact001392" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,734,340</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The warrant allows the holder to purchase <span id="xdx_909_eus-gaap--WarrantsAndRightsOutstanding_iI_c20200409__dei--LegalEntityAxis__custom--MasimoCorporationMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantThreeMember_zXB3BgL8LLhh"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2020-04-09_custom_MasimoCorporationMember_custom_WarrantThreeMember" id="Fact001393" format="ixt:numdotdecimal" decimals="0" unitRef="USD">289,779</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
of Series A Preferred Stock at $<span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20200409__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantThreeMember_zsLkqODTsfI8"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2020-04-09_us-gaap_SeriesAPreferredStockMember_custom_WarrantThreeMember" id="Fact001394" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.44</ix:nonFraction> </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
share and is subject to adjustment for certain equity events. The warrant contains certain rights in the event of liquidation,
merger, or consolidation of the Company. There will be no additional purchase price for the Warrants. In the event that all
outstanding shares of Series A Preferred Stock are converted, automatically or by action of the holders thereof, into Common Stock,
including, without limitation, in connection with the Company&#8217;s initial, underwritten public offering and sale of its Common
Stock pursuant to an effective registration statement under the Act, then from and after the date on which all outstanding shares of
Series A Preferred Stock have been so converted, this Warrant shall be exercisable for such number of shares of Common Stock into
which the Warrant Shares would have been converted had the Warrant Shares been outstanding on the date of such conversion, and the
Exercise Price shall equal the Exercise Price in effect as of immediately prior to such conversion divided by the number of shares
of Common Stock into which one share of Series A Preferred Stock would have been converted, all subject to further adjustment
thereafter from time to time in accordance with the provisions of this Warrant. On August 14, 2023, the <span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant_c20230814__20230814__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zKJJUzNR5Yak" title="Converted to preferred stock warrant"><ix:nonFraction name="NRXS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant" contextRef="From2023-08-142023-08-14_us-gaap_SeriesAPreferredStockMember" id="Fact001396" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">144,890</ix:nonFraction></span> Series A Preferred
Stock warrants were converted to <span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants_c20230814__20230814__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z26PCTlfwxN4" title="Converted to common stock warrant"><ix:nonFraction name="NRXS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants" contextRef="From2023-08-142023-08-14_us-gaap_CommonStockMember" id="Fact001398" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">289,779</ix:nonFraction></span> common stock warrants after giving effect to the <span id="xdx_906_eus-gaap--StockholdersEquityNoteStockSplit_c20230814__20230814_zjC2pZF8eSx8" title="Common stock split, description"><ix:nonNumeric contextRef="From2023-08-142023-08-14" id="Fact001400" name="us-gaap:StockholdersEquityNoteStockSplit">2-for-1</ix:nonNumeric></span> common stock split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2022, the Company issued <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zJzxEqAvBdTj" title="Number of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2022-12-31_custom_TwoThousandTwentyTwoConvertibleNotesMember" id="Fact001402" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">793,655</ix:nonFraction></span> <span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_z5KxziaQhAK5" title="Warrant term::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl1404">five-year</span></span> warrants to purchase common stock equal to one hundred percent (100%) of the shares into which
the 2022 convertible notes can be converted at issuance. The warrants have an exercise price of $<span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zBMpc4ENsbZg" title="Share issued price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2022-12-31_custom_TwoThousandTwentyTwoConvertibleNotesMember" id="Fact001406" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.25</ix:nonFraction></span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
March to June of 2023, the Company issued <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230630__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zT9VShby2Tbe" title="Number of warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-06-30_custom_TwoThousandTwentyThreeConvertibleNotesMember" id="Fact001408" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">505,570</ix:nonFraction></span> <span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20230630__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zSdGuqTadD3i" title="Warrant term::XDX::P1Y"><span style="-sec-ix-hidden: xdx2ixbrl1410">one-year</span></span> warrants to purchase common stock equal to fifty percent (50%) of the shares
into which the 2023 convertible notes can be converted at issuance. The warrants have an exercise price of $<span id="xdx_90A_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230630__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zV4CjY7CXfy5" title="Share issued price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-06-30_custom_TwoThousandTwentyThreeConvertibleNotesMember" id="Fact001412" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.25</ix:nonFraction></span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 9, 2023, the Company issued <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230809__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zeiKL6HUAEte"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-08-09_custom_TwoThousandTwentyThreeConvertibleNotesMember" id="Fact001413" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">122,202</ix:nonFraction>
</span></span><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dpxL_c20230809__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_ziGSl6ZTAYZk" title="::XDX::P5Y" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1414">five-year
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants to purchase common stock pursuant to an advisory
agreement with a consulting firm upon closing of the Company&#8217;s initial public offering. The warrants have an exercise price of
$<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230809__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zFYXRRYxXEH5"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-08-09_custom_TwoThousandTwentyThreeConvertibleNotesMember" id="Fact001415" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.00</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 14, 2023, the Company issued <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230814__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zXsaF3WrPxAg"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-08-14_custom_TwoThousandTwentyThreeConvertibleNotesMember" id="Fact001416" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">186,156</ix:nonFraction>
</span></span><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20230814__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zh3aVBO5Qeue" title="::XDX::P5Y" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1417">five-year
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants to purchase common stock pursuant to an agreement
with an underwriter upon closing of the Company&#8217;s initial public offering. The warrants have an exercise price of $<span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230814__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zwKZT2yKcEVa"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2023-08-14_custom_TwoThousandTwentyThreeConvertibleNotesMember" id="Fact001418" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.20</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" escape="true" id="Fact001420" name="NRXS:ScheduleOfWarrantActivityForCommonStockTableTextBlock"><p id="xdx_897_ecustom--ScheduleOfWarrantActivityForCommonStockTableTextBlock_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zT0tVLJd8Fb1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of warrant activity for common stock during the years ended December 31, 2023 and 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><span id="xdx_8BB_zbPdy6YRoh12" style="display: none">Schedule of Warrant Activity for Common Stock</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Warrants for Common
    Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted-Avg. Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted-Avg. Remaining Contractual
    Life</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; font-weight: bold; text-align: left">Outstanding as of January 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFtfkHit6nal" title="Number of Warrants, Outstanding at beginning of period" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" id="Fact001422" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">52,852</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4GsLYC1p5P9" title="Weighted Average Exercise Price, Outstanding at beginning of period" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_us-gaap_CommonStockMember" id="Fact001424" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.13</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zl6qZXq8dUt6" title="Weighted Average Remaining Contractual Life - Warrants, Outstanding at beginning of period"><ix:nonNumeric contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember" format="ixt-sec:duryear" id="Fact001426" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">7.45</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQ7wIfObdtu2" title="Number of Warrants, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="Fact001428" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">793,655</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPw6fxB9ydqh" title="Weighted Average Exercise Price, granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" id="Fact001430" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.25</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageRemainingContracualLifeOutstandingNumberGranted_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkS3ZdEjg8hk" title="Weighted Average Remaining Contractual Life - Warrants Granted"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt-sec:duryear" id="Fact001432" name="NRXS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageRemainingContracualLifeOutstandingNumberGranted">4.42</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cancelled/Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRsBQtlIFENd" title="Number of Warrants, Cancelled Expired" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1434">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLbhtOkKExjk" title="Weighted Average Exercise Price, Cancelled Expired" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1436">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwxWiNfdMXFh" title="Number of Warrants, Exercised" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1438">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIHWoLLJqhIa" title="Weighted Average Exercise Price, Excercised" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1440">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Outstanding as of December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjGjArh6kWl3" title="Number of Warrants, Outstanding at beginning of period" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact001442" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">846,507</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsVBLIE98wNh" title="Weighted Average Exercise Price, Outstanding at beginning of period" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_us-gaap_CommonStockMember" id="Fact001444" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.06</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z1bupKrRyEVb" title="Weighted Average Remaining Contractual Life - Warrants, Outstanding at beginning of period"><ix:nonNumeric contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember" format="ixt-sec:duryear" id="Fact001446" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">4.72</ix:nonNumeric></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHXGtkRBVef7" title="Number of Warrants, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact001448" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">813,928</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrvhplVZaaea" title="Weighted Average Exercise Price, granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact001450" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.81</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z3Rw1vMLMbgi" title="Weighted Average Remaining Contractual Life - Warrants Granted"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" format="ixt-sec:duryear" id="Fact001452" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">4.38</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Converted Prefunded Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBKOw27Iswof" title="Number of Warrants, Converted Prefunded Warrants" style="text-align: right"><ix:nonFraction name="NRXS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact001454" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">289,779</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsConvertedPrefundedWarrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLHJQsNqGfSf" title="Weighted Average Exercise Price, Converted Prefunded Warrants" style="text-align: right"><ix:nonFraction name="NRXS:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsConvertedPrefundedWarrantsInPeriodWeightedAverageExercisePrice" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact001456" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNNkyqPnU1p2" title="Number of Warrants, Exercised" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact001458" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">127,856</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxn1kG8yXWhh" title="Weighted Average Exercise Price, Excercised" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1460">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Outstanding as of December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z52slLer13Yi" title="Number of Warrants, Outstanding at Ending of period" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact001462" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,822,358</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWcR3HmB7P4d" title="Weighted Average Exercise Price, Outstanding at Ending of period" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31_us-gaap_CommonStockMember" id="Fact001464" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.69</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zUlKG5KBXfV6" title="Weighted Average Remaining Contractual Life - Warrants, Outstanding at Ending of period"><ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" format="ixt-sec:duryear" id="Fact001466" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">3.05</ix:nonNumeric></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A6_zUzkMtJhQeOc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>


<ix:exclude><!-- Field: Page; Sequence: 113; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<ix:nonNumeric contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember64723875" escape="true" id="Fact001468" name="NRXS:ScheduleOfWarrantActivityForPreferredStockTableTextBlock"><p id="xdx_891_ecustom--ScheduleOfWarrantActivityForPreferredStockTableTextBlock_hus-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z8rPRlYi2yr7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of warrant activity for preferred stock during the years ended December 31, 2023 and 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_zBDZzq1ZH1Jg" style="display: none">Schedule of Warrant Activity for Preferred Stock</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted-Avg.</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Warrants for</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Preferred Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; font-weight: bold; text-align: left">Outstanding as of January 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zHjGmEHAR7n" title="Number of Warrants, Outstanding at beginning of period" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember" id="Fact001470" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">144,890</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zWxVdZmPzCXb" title="Weighted Average Exercise Price, Outstanding at beginning of period" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember" id="Fact001472" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zKrzoDZ974Kf" title="Number of Warrants, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1474">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zvx7V26CALq4" title="Weighted Average Exercise Price, granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1476">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cancelled/Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zmgoHNJLFe2j" title="Number of Warrants, Cancelled Expired" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1478">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zU6SDG16jVpf" title="Weighted Average Exercise Price, Cancelled Expired" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1480">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zOoHjZDVMd15" title="Number of Warrants, Exercised" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1482">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zNvu6Eca2qs9" title="Weighted Average Exercise Price, Excercised" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1484">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Outstanding as of December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zVJNx44x0VJ7" title="Number of Warrants, Outstanding at beginning of period" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember" id="Fact001486" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">144,890</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zd50OkTmeHT3" title="Weighted Average Exercise Price, Outstanding at beginning of period" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember" id="Fact001488" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_znFCYHiQfpJh" title="Number of Warrants, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1490">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zEdXTAJWHEFk" title="Weighted Average Exercise Price, granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1492">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cancelled/Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zz4SGnNOQE3f" title="Number of Warrants, Cancelled Expired" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1494">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zyZcFmgWqHc2" title="Weighted Average Exercise Price, Cancelled Expired" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1496">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Converted to Common Stock Warrant</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zFfOb5Qk5Rzl" title="Converted to Common Stock Warrant" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="NRXS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember64723875" id="Fact001498" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">144,890</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zIxM4IoiAYx5" title="Weighted Average Exercise Price, Converted to Common Stock Warrant" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="NRXS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant" contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember64723875" id="Fact001500" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0.01</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Outstanding as of December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zDXqtRsfiNk9" title="Number of Warrants, Outstanding at Ending of period" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1502">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zBEYAb8ItwJd" title="Weighted Average Exercise Price, Outstanding at Ending of period" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1504">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A7_zYQuG8ICw7M4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001506" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><p id="xdx_898_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zPFQXUl3FwJ" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s warrants outstanding and exercisable as of December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_zON6lmiXJCBf" style="display: none">Schedule of Warrants outstanding and Exercisable</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Warrants</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">Expiration</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Date</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Investor Warrant W-01</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantOneMember_z2ZvJ9G75a15" title="Number of Warrants" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-12-31_custom_InvestorWarrantOneMember" id="Fact001508" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,852</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantOneMember_zwlOEHMDF2ha" title="Exercise Price" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-31_custom_InvestorWarrantOneMember" id="Fact001510" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.76</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 16%; text-align: center"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantOneMember_zMwK10K6gYG1" title="Expiration Date"><ix:nonNumeric contextRef="AsOf2023-12-31_custom_InvestorWarrantOneMember" format="ixt:datemonthdayyearen" id="Fact001512" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">September 18, 2028</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Investor Warrant PSA-01</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantPSAOneMember_z5b83TdI0T1e" title="Number of Warrants" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-12-31_custom_InvestorWarrantPSAOneMember" id="Fact001514" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">289,779</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantPSAOneMember_z60RpMMDxE3c" title="Exercise Price" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-31_custom_InvestorWarrantPSAOneMember" id="Fact001516" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_908_ecustom--WarrantExpirationDateDescription_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantPSAOneMember_zy7hRhHg4Klj" title="Expiration Date"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_InvestorWarrantPSAOneMember" id="Fact001518" name="NRXS:WarrantExpirationDateDescription">None</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2022 Convertible Notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zYyUIcsWsEP4" title="Number of Warrants" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-12-31_custom_TwoThousandTwentyTwoConvertibleNotesMember" id="Fact001520" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">793,655</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zGQo7QUjUPvf" title="Exercise Price" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-31_custom_TwoThousandTwentyTwoConvertibleNotesMember" id="Fact001522" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.38</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_909_ecustom--WarrantExpirationDateDescription_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_z8cPQMcjQYf2" title="Expiration Date"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_TwoThousandTwentyTwoConvertibleNotesMember" id="Fact001524" name="NRXS:WarrantExpirationDateDescription">Various</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2023 Convertible Notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zZjaNLkOEind" title="Number of Warrants" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-12-31_custom_TwoThousandTwentyThreeConvertibleNotesMember" id="Fact001526" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">417,714</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zijUSrhPJjM" title="Exercise Price" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-31_custom_TwoThousandTwentyThreeConvertibleNotesMember" id="Fact001528" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.38</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90D_ecustom--WarrantExpirationDateDescription_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zjdnEypDoDEd" title="Expiration Date"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_TwoThousandTwentyThreeConvertibleNotesMember" id="Fact001530" name="NRXS:WarrantExpirationDateDescription">Various</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Consulting Agreement Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ConsultingAgreementWarrantsMember_zaTFTmhJzFW2" title="Number of Warrants" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-12-31_custom_ConsultingAgreementWarrantsMember" id="Fact001532" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">122,202</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ConsultingAgreementWarrantsMember_zEc7yGgxrfQ1" title="Exercise Price" style="text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-31_custom_ConsultingAgreementWarrantsMember" id="Fact001534" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.38</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ConsultingAgreementWarrantsMember_z1XkTYMX6pjc" title="Expiration Date"><ix:nonNumeric contextRef="AsOf2023-12-31_custom_ConsultingAgreementWarrantsMember" format="ixt:datemonthdayyearen" id="Fact001536" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">August 8, 2028</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Underwriter&#8217;s Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantsMember_zd1m9zDelivk" title="Number of Warrants" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-12-31_custom_UnderwriterWarrantsMember" id="Fact001538" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">186,156</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantsMember_zh5p3ZM7xNF9" title="Exercise Price" style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2023-12-31_custom_UnderwriterWarrantsMember" id="Fact001540" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.38</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantsMember_zWlJXInjWwXl" title="Expiration Date"><ix:nonNumeric contextRef="AsOf2023-12-31_custom_UnderwriterWarrantsMember" format="ixt:datemonthdayyearen" id="Fact001542" name="us-gaap:WarrantsAndRightsOutstandingMaturityDate">August 8, 2028</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231_z0KOtmJoNRN4" title="Number of Warrants" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="AsOf2023-12-31" id="Fact001544" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,822,358</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1.5pt">&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A7_zkf8bYhzroK" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
<!-- Field: Split-Segment; Name: 001 -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001546" name="us-gaap:PreferredStockTextBlock"><p id="xdx_80B_eus-gaap--PreferredStockTextBlock_zs9hdNNL4B0g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10.
<span id="xdx_827_zexSBGvOofpb">Preferred Stock</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has authorized <span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_c20231231_zCacb4cxvNLa" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31" id="Fact001548" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,120,000</ix:nonFraction></span> shares of preferred stock of which <span id="xdx_90B_eus-gaap--PreferredStockSharesAuthorized_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesAPreferredStockMember_zCfSG835SzE7" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31_custom_ConvertibleSeriesAPreferredStockMember" id="Fact001550" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span> has been designated Series A Preferred and <span id="xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_zNVIiF11gUte" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-12-31_custom_ConvertibleSeriesSeedPreferredStockMember" id="Fact001552" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">120,000</ix:nonFraction></span> has
been designated Series Seed Preferred, of which <span id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesAPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zEME85xvnQNj" title="Preferred stock, shares issued"><span id="xdx_907_eus-gaap--PreferredStockSharesOutstanding_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesAPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zjuI1Yw375H5" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember" id="Fact001554" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember" id="Fact001556" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_909_eus-gaap--PreferredStockSharesIssued_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesAPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zVC1fg5TKzYc" title="Preferred stock, shares issued"><span id="xdx_904_eus-gaap--PreferredStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesAPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z64XvUB2uIrk" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember" id="Fact001558" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember" id="Fact001560" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">506,637</ix:nonFraction></ix:nonFraction></span></span> shares of Series A Preferred and <span id="xdx_90F_eus-gaap--PreferredStockSharesIssued_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_zi7HmkBtYEl3" title="Preferred stock, shares issued"><span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_z2eTfUJdZ3C7" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-12-31_custom_ConvertibleSeriesSeedPreferredStockMember" id="Fact001562" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-12-31_custom_ConvertibleSeriesSeedPreferredStockMember" id="Fact001564" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_90D_eus-gaap--PreferredStockSharesIssued_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_zAwhmIWxs9Wh" title="Preferred stock, shares issued"><span id="xdx_902_eus-gaap--PreferredStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_zz395C0wmmq8" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2022-12-31_custom_ConvertibleSeriesSeedPreferredStockMember" id="Fact001566" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2022-12-31_custom_ConvertibleSeriesSeedPreferredStockMember" id="Fact001568" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">115,477</ix:nonFraction></ix:nonFraction></span></span> shares of Series Seed Preferred
are issued and outstanding as of December 31, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate purchase price of the Series A Preferred Stock was $<span id="xdx_904_ecustom--AggregatePurchasePrice_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesAPreferredStockMember_z83A0w8LvXF4" title="Aggregate purchase price"><ix:nonFraction name="NRXS:AggregatePurchasePrice" contextRef="From2023-01-012023-12-31_custom_ConvertibleSeriesAPreferredStockMember64725046" id="Fact001570" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,321,165</ix:nonFraction></span>, of which $<span id="xdx_90C_eus-gaap--ConversionOfStockAmountConverted1_c20230101__20231231__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zEOWtQxubI37" title="Cash value of purchase price"><ix:nonFraction name="us-gaap:ConversionOfStockAmountConverted1" contextRef="From2023-01-012023-12-31_us-gaap_ConvertibleDebtMember" id="Fact001572" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,692,664</ix:nonFraction></span> was comprised of cash and the remaining
$<span id="xdx_902_eus-gaap--ConversionOfStockAmountConverted1_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSjb4XdIQgQ3" title="Cash value of purchase price"><ix:nonFraction name="us-gaap:ConversionOfStockAmountConverted1" contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember" id="Fact001574" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,628,501</ix:nonFraction></span> was comprised of converted debt and common stock. The aggregate purchase price of the Series Seed Preferred shares was $<span id="xdx_902_ecustom--AggregatePurchasePrice_c20231231__20231231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_zD6OGdJbRbZe" title="Aggregate purchase price"><ix:nonFraction name="NRXS:AggregatePurchasePrice" contextRef="From2023-12-312023-12-31_custom_ConvertibleSeriesSeedPreferredStockMember" id="Fact001576" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span>,
as all the Series Seed shares were converted from common stock as an incentive to reinvest in Series A Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 114; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of Preferred Stock terms:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Voting
Rights</span> - The Series A Preferred and Series Seed Preferred shall vote together with the Common Stock on an as-converted basis, and
not as separate classes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Conversion
</span>- The Series A Preferred and Series Seed initially convert 1:1 to Common Stock at any time at option of holder, subject to adjustments
for stock dividends, splits, combinations, and similar events and as described below under &#8220;Anti-dilution Provisions.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Dividends
</span>- The Series A Preferred will carry an annual <span id="xdx_904_eus-gaap--PreferredStockDividendRatePercentage_dp_uPure_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zbQVwC996jZk" title="Preferred stock dividend rate percentage"><ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" contextRef="From2023-01-012023-12-31_us-gaap_SeriesAPreferredStockMember" id="Fact001578" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8</ix:nonFraction></span>% cumulative dividend, payable upon any liquidation, dissolution or winding up of
the Company (the &#8220;Accruing Dividend&#8221;). For any other dividends or distributions, participation with Common Stock on an as-converted
basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Liquidation
</span>- In the event of any liquidation, dissolution or winding up of the Company, the proceeds shall be paid in the following priority:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First,
to the Series A Preferred in proportion to each holder&#8217;s respective pro rata Series A Original Purchase Price, plus any pro rata
share of the Accruing Dividend until the entire Series A Original Purchase Price and Accruing Dividend are paid;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second,
to the Series Seed Preferred in proportion to each holder&#8217;s respective pro rata Series Seed Original Purchase Price until the entire
amount of the Series Seed Original Purchase Price is paid; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thereafter,
the Series A Preferred and Series Seed Preferred participate with the Common Stock pro rata on an as-converted basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
merger or consolidation (other than one in which stockholders of the Company own a majority by voting power of the outstanding shares
of the surviving or acquiring corporation) and a sale, lease, transfer, exclusive license or other disposition of all or substantially
all of the assets of the Company will be treated as a liquidation event (a &#8220;Deemed Liquidation Event&#8221;), thereby triggering
payment of the liquidation preferences described.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Anti-dilution
Provisions</span> - The Series A Preferred have full-ratchet anti-dilution protection so that the conversion price will be reduced to <span id="xdx_90F_eus-gaap--DebtInstrumentConvertibleConversionRatio1_dp_uPure_c20230101__20231231_ztvOgwbYgCe3" title="Conversion ratio"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionRatio1" contextRef="From2023-01-01to2023-12-31" id="Fact001580" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">80</ix:nonFraction></span>%
of the price at which any future shares are issued, if less than the Series A Original Purchase Price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration for shareholders to make an additional investment in the Company, upon the purchase of the Series A Preferred stock by
the shareholder, the Company converted the existing common shares held by shareholders to Series Seed Preferred Stock at a $<span id="xdx_90C_eus-gaap--ConversionOfStockAmountConverted1_pn6n6_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_zM4U9bgl39f4" title="Conversion amount"><ix:nonFraction name="us-gaap:ConversionOfStockAmountConverted1" contextRef="From2023-01-012023-12-31_custom_ConvertibleSeriesSeedPreferredStockMember64725125" id="Fact001582" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">100</ix:nonFraction></span> million
valuation and at a <span id="xdx_909_ecustom--SharePremiumPercentage_iI_pid_dp_uPure_c20231231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_zrSCIvVvtUtl" title="Share premium percentage"><ix:nonFraction name="NRXS:SharePremiumPercentage" contextRef="AsOf2023-12-31_custom_ConvertibleSeriesSeedPreferredStockMember" id="Fact001584" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">120</ix:nonFraction></span>% share premium. As of December 31, 2022, there were <span id="xdx_90D_eus-gaap--ConversionOfStockSharesConverted1_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_z38nHRwBSmgi" title="Stock value converted"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2023-01-012023-12-31_custom_ConvertibleSeriesSeedPreferredStockMember64725125" id="Fact001586" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">97,702</ix:nonFraction></span> common shares converted into <span id="xdx_901_eus-gaap--ConversionOfStockSharesConverted1_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_z1JyhTpKbzSb" title="Stock value converted"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2022-01-012022-12-31_custom_ConvertibleSeriesSeedPreferredStockMember64722968" id="Fact001588" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">115,477</ix:nonFraction></span> shares
of Series Seed Preferred shares that have no par value and are outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
As of December 31, 2023, all preferred stock has been converted pursuant to the initial public offering.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company signed a Convertible Promissory Note on November 8, 2023 for a principal amount of $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20231108_zPfNWYYZXC1b" title="Debt instrument, face amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2023-11-08" id="Fact001590" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,000,000</ix:nonFraction></span>
bearing interest at <span id="xdx_907_eus-gaap--DebtConversionOriginalDebtInterestRateOfDebt_dp_uPure_c20231108__20231108_zswg4uXI9nL2" title="Debt conversion, original debt, interest rate of debt"><ix:nonFraction name="us-gaap:DebtConversionOriginalDebtInterestRateOfDebt" contextRef="From2023-11-082023-11-08" id="Fact001592" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8.5</ix:nonFraction>%</span>
per annum payable quarterly in either cash or common stock with a 15 month maturity date. The agreement calls for $<span id="xdx_90B_eus-gaap--DebtInstrumentPeriodicPayment_c20231108__20231108_zAs54X6L9Wjh" title="Debt instrument, periodic payment"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPayment" contextRef="From2023-11-082023-11-08" id="Fact001594" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,000</ix:nonFraction></span>
monthly installments from January 2024 through March of 2025; there was no outstanding balance as of December 31, 2023. The Convertible
Promissory Note allows for a voluntary conversion by the investor into Series B Preferred Stock at $<span id="xdx_903_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20231108__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zSkVAOA9aiZ5" title="Debt instrument, convertible, conversion price"><ix:nonFraction name="us-gaap:DebtInstrumentConvertibleConversionPrice1" contextRef="AsOf2023-11-08_us-gaap_SeriesBPreferredStockMember" id="Fact001596" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.38</ix:nonFraction></span>
per share any time prior to the maturity date with mandatory conversion by the Company at the maturity date. The Company shall use
the proceeds solely for working capital and general corporate purposes and not pay any dividends or distributions or to advance any
funds to its officers, directors or affiliates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001598" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><p id="xdx_800_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zzt5ILb6sjM2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>11.
<span><span id="xdx_82E_zfy7ZY3HJZH1">Stock Options and Awards</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 12, 2017, the Company adopted the 2017 Stock Compensation Plan authorizing the issuance of <span id="xdx_90C_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20171012__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_zPekARoQxeM1" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2017-10-12_custom_TwentySeventeenStockCompensationPlanMember" id="Fact001600" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,435,652</ix:nonFraction></span> shares of common stock.
On September 13, 2019 the Company entered into a Stock Option Cancellation agreement with all holders of these stock options effective
on that date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
plan was then amended on September 13, 2019, to increase the share amount to <span id="xdx_902_eus-gaap--SharesIssued_iI_pid_c20190913__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_zSGluU1RUmCh" title="Shares issued"><ix:nonFraction name="us-gaap:SharesIssued" contextRef="AsOf2019-09-13_custom_TwentySeventeenStockCompensationPlanMember" id="Fact001602" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,638,788</ix:nonFraction></span>. This plan was enacted to enable the Company to
retain the services of certain key employees, officers, and directors of the Company. The Plan provides for the grant of stock options,
including incentive stock options, or ISOs, and nonqualified stock options, or NSOs and restricted stock, and they were estimated using
the Black-Scholes option-pricing model with the following weighted-average assumptions:</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001604" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_898_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zSodkXedL2Fg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B6_zrJM8IbVxkhe" style="display: none">Schedule of Option-pricing Model with Following Weighted-average Assumptions</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 65%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Assumptions as of December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Fully Vested</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; text-align: left">Number of Shares</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_zOvAN9zZQDL6" title="Number of Shares" style="width: 22%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2023-12-31_custom_TwentySeventeenStockCompensationPlanMember" id="Fact001606" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,319,394</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--SharePrice_iI_c20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_zd7QjgdqJJwc" title="Stock price" style="text-align: right"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-12-31_custom_TwentySeventeenStockCompensationPlanMember" id="Fact001608" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.67</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Exercise price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_zvltKuMCnOj8" title="Exercise price" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2023-12-31_custom_TwentySeventeenStockCompensationPlanMember" id="Fact001610" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.94</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_zMoDvJx5aIT9" title="Expected term"><ix:nonNumeric contextRef="From2023-01-012023-12-31_custom_TwentySeventeenStockCompensationPlanMember" format="ixt-sec:duryear" id="Fact001612" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.75</ix:nonNumeric></span> years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_zn0fdwdxlpD" title="Expected volatility" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2023-01-012023-12-31_custom_TwentySeventeenStockCompensationPlanMember" id="Fact001614" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">31.90</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_zAef3CWeZzr1" title="Risk-free interest rate" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2023-01-012023-12-31_custom_TwentySeventeenStockCompensationPlanMember" id="Fact001616" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.84</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dividend rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_zVd9PeRGxHdd" title="Dividend rate" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2023-01-012023-12-31_custom_TwentySeventeenStockCompensationPlanMember" id="Fact001618" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

</ix:nonNumeric><p id="xdx_8A5_zDNrwjbD9Sri" style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 115; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001620" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z0SXezbnXQoe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of stock option activity for the years ended December 31, 2023 and 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none"></span></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B9_z6hMbd0cxl3k" style="display: none">Schedule of Stock Option Activity</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Options</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Avg. Remaining Contractual Life (in years)</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Avg. Exercise Price</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-weight: bold; text-align: left">Outstanding as of January 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231_zZCrZxld5Pja" title="Number of Options, Outstanding, Beginning balance" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-12-31" id="Fact001622" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,319,394</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_z21YhOqhwyda" title="Weighted Average Remaining Contractual Life (in years), Outstanding"><ix:nonNumeric contextRef="From2021-01-012021-12-31" format="ixt-sec:duryear" id="Fact001624" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">7.69</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20220101__20221231_z5Fb9NxZcFG5" title="Weighted Average Exercise Price, Outstanding, Beginning balance" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-12-31" id="Fact001626" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.94</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20220101__20221231_zgfl9C219dV8" title="Aggregate Intrinsic Value, Outstanding, Beginning balance" style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1628">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20220101__20221231_zGdVdEKNR3Pf" title="Number of Options, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1630">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_uShares_c20220101__20221231_zTmrillIZ9ja" title="Number of Options, Forfeited" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1632">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Cancelled/Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_pid_uShares_c20220101__20221231_zNJ5RE84Xqkk" title="Number of Options, Cancelled/Expired" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1634">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20220101__20221231_z9OSd5tPk48a" title="Number of Options, Exercised" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1636">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Outstanding as of December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231_zfQeHbfbiMJg" title="Number of Options, Outstanding, Beginning balance" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-12-31" id="Fact001638" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,319,394</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zRiad09Ik3Ma" title="Weighted Average Remaining Contractual Life (in years), Outstanding"><ix:nonNumeric contextRef="From2022-01-012022-12-31" format="ixt-sec:duryear" id="Fact001640" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">6.69</ix:nonNumeric></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20230101__20231231_z4F1SfXgrd9d" title="Weighted Average Exercise Price, Outstanding, Beginning balance" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-12-31" id="Fact001642" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.94</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20230101__20231231_zX6U9TmDrwS9" title="Aggregate Intrinsic Value, Outstanding, Beginning balance" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1644">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20230101__20231231_zIbrWIgFhoSc" title="Number of Options, Granted" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1646">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_uShares_c20230101__20231231_zzrO0z8gual2" title="Number of Options, Forfeited" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1648">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Cancelled/Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_pid_uShares_c20230101__20231231_zsIq9wAYQfXc" title="Number of Options, Cancelled/Expired" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1650">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20230101__20231231_zDsA0ZPH3ep3" title="Number of Options, Exercised" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1652">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Outstanding as of December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231_zMLNl3Ld1DX3" title="Number of Options, Outstanding, Ending balance" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-12-31" id="Fact001654" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,319,394</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zDCGuIK6aXWi" title="Weighted Average Remaining Contractual Life (in years), Outstanding"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt-sec:duryear" id="Fact001656" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">5.69</ix:nonNumeric></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20230101__20231231_zKmIVAqODHM9" title="Weighted Average Exercise Price, Outstanding, Ending balance" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-12-31" id="Fact001658" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.94</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20230101__20231231_z8MijdMiMTx9" title="Aggregate Intrinsic Value, Outstanding, Ending balance" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1660">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Vested and Exercisable as of December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iE_pid_c20230101__20231231_zF6kLe4J8jHi" title="Number of Options, Vested and Exercisable, Ending balance" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" contextRef="AsOf2023-12-31" id="Fact001662" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,319,394</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231_zooQYAqcfhUh" title="Weighted Average Remaining Contractual Life (in years), Vested and Exercisable"><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" format="ixt-sec:duryear" id="Fact001664" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">5.69</ix:nonNumeric></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20230101__20231231_zUPUhEvHEX5g" title="Weighted Average Exercise Price, Vested and Exercisable, Ending balance" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2023-12-31" id="Fact001666" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.94</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iE_c20230101__20231231_zAlGieIzA6ae" title="Aggregate Intrinsic Value, Vested and Exercisable, Ending balance" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1668">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A4_zbpDEIyVxru6" style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
compensation expense is classified in the Company&#8217;s statements of operations as general and administrative expense. The amounts
were $<span id="xdx_904_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z2zVBKfgkt6g" title="Stock-based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact001670" format="ixt:numdotdecimal" decimals="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_90E_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zjinxtJywC09" title="Stock-based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember" id="Fact001672" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,319</ix:nonFraction></span> for the years ended December 31, 2023 and 2022, respectively. As of December 31, 2023, there was <span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_do_c20231231_zc7pRq0SMW1e" title="Unrecognized compensation expense"><span id="xdx_90B_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_do_c20221231_zrzdlQWS22a" title="Unrecognized compensation expense"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="AsOf2023-12-31" id="Fact001674" format="ixt-sec:numwordsen" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="AsOf2022-12-31" id="Fact001676" format="ixt-sec:numwordsen" decimals="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span> unrecognized
compensation expense related to unvested options granted under the Company&#8217;s share-based compensation plans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001678" name="NRXS:WarrantLiabilitiesDisclosureTextBlock"><p id="xdx_80E_ecustom--WarrantLiabilitiesDisclosureTextBlock_zzo8RXWpQknk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>12.
<span><span id="xdx_825_zRPCqI4aKDv1">Warrant Liabilities</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has evaluated financial instruments arising from an adjustable exercise price for warrants that are issued and outstanding as
of December 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilizes a Monte Carlo simulation model for warrants that have an option to convert at a variable number of shares to compute
the fair value of the liability and to mark to market the fair value of the derivative at each balance sheet date. The inputs utilized
in the application of the Monte Carlo model included a starting stock price of $<span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zf9c74pRMbT7" title="Warrants and rights outstanding, measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputSharePriceMember" id="Fact001680" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.91</ix:nonFraction></span> per share, an expected remaining term of each warrant
as of the valuation date, estimated volatility of <span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zx6QjEVsKMWk" title="Warrants and rights outstanding, measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember" id="Fact001682" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">75</ix:nonFraction></span>%, drift, and a risk-free rate ranging from <span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_z3vjS6wCdOOc" title="Warrants and rights outstanding, measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember" id="Fact001684" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">3.46</ix:nonFraction></span>% to <span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zPAmnsOCnuwk" title="Warrants and rights outstanding, measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember" id="Fact001686" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">59.01</ix:nonFraction></span>%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free
interest rate: The Company uses the risk-free interest rate of a U.S. Treasury Note adjusted to be on a continuous return basis to align
with the Black-Scholes option-pricing model.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend
yield: The Company uses a <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zzjWhuGuqev3" title="Warrants and rights outstanding, measurement input"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember" id="Fact001688" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0</ix:nonFraction></span>% expected dividend yield as the Company has not paid dividends to date and does not anticipate declaring
dividends in the near future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 116; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Volatility:
The Company calculates the expected volatility based on comparable company&#8217;s historical stock prices with a look back period commensurate
with the period to maturity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
term: The Company&#8217;s remaining term is based on the remaining contractual maturity of the warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001690" name="NRXS:ScheduleOfChangesInWarrantLiabilitiesTableTextBlock"><p id="xdx_897_ecustom--ScheduleOfChangesInWarrantLiabilitiesTableTextBlock_z6Toq9XoRvDd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following are the changes in the warrant liabilities during the years ended December 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B1_zAN13vAF9yx" style="display: none">Schedule of Changes in Warrant Liabilities</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; font-weight: bold; text-align: left">Warrant liabilities as of January 1, 2022 </td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--WarrantsAndRightsOutstanding_iS_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zTiROgSGmUp5" title="Warrant liabilities, Beginning balance" style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1692">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--WarrantsAndRightsOutstanding_iS_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zjQgzvavEJ" title="Warrant liabilities, Beginning balance" style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1694">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--WarrantsAndRightsOutstanding_iS_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zNRT00QtzTL1" title="Warrant liabilities, Beginning balance" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact001696" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,102</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Addition </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--AdditionToWarrantLiabilities_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zFqbeCr72do1" title="Addition" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1698">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--AdditionToWarrantLiabilities_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z9PhqYq2ZPOb" title="Addition" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1700">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--AdditionToWarrantLiabilities_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zWQMNmJimNia" title="Addition" style="text-align: right"><ix:nonFraction name="NRXS:AdditionToWarrantLiabilities" contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact001702" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,808,331</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Changes in fair value of warrant liabilities </td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zmkKASd2yON2" title="Changes in fair value of warrant liabilities" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1704">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z4abHtkC2ypb" title="Changes in fair value of warrant liabilities" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1706">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_ziDEp9njSkCd" title="Changes in fair value of warrant liabilities" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact001708" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">606,049</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Warrant liabilities as of December 31, 2022 </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--WarrantsAndRightsOutstanding_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zaPRSuOKnSHe" title="Warrant liabilities, Beginning balance" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1710">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--WarrantsAndRightsOutstanding_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zCuCE8c0iAlf" title="Warrant liabilities, Beginning balance" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1712">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstanding_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z6BtnMSYqUtd" title="Warrant liabilities, Beginning balance" style="text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact001714" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,234,384</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Addition </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--AdditionToWarrantLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zn3FBnvSlvEa" title="Addition" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1716">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--AdditionToWarrantLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zrw1BWKii3eh" title="Addition" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1718">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--AdditionToWarrantLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zoRdUKE3rUJ" title="Addition" style="text-align: right"><ix:nonFraction name="NRXS:AdditionToWarrantLiabilities" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact001720" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,446,502</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Changes in fair value of warrant liabilities </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--FairValueAdjustmentOfWarrants_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zTA1HjtEEgIi" title="Changes in fair value of warrant liabilities" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1722">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--FairValueAdjustmentOfWarrants_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zWkjqqijvVH7" title="Changes in fair value of warrant liabilities" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1724">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--FairValueAdjustmentOfWarrants_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z4dUUpRfRLva" title="Changes in fair value of warrant liabilities" style="text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact001726" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">844,854</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Reclassified to equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ReclassifiedToEquity_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z2cqdPeE1ixg" title="Reclassified to equity" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1728">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--ReclassifiedToEquity_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zYBZUn1D477b" title="Reclassified to equity" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1730">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--ReclassifiedToEquity_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zuLnj3rlaVj6" title="Reclassified to equity" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="NRXS:ReclassifiedToEquity" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact001732" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,827,807</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Warrant liabilities as of December 31, 2023 </td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_981_eus-gaap--WarrantsAndRightsOutstanding_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zVDzO5JoXFJb" title="Warrant liabilities, Ending balance" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1734">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstanding_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zS2JS6R6igP1" title="Warrant liabilities, Ending balance" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1736">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstanding_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zhDRrmhElhV6" title="Warrant liabilities, Ending balance" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact001738" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,225</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AB_z9QfYeSfYbb8" style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001740" name="us-gaap:DerivativesAndFairValueTextBlock"><p id="xdx_80D_eus-gaap--DerivativesAndFairValueTextBlock_zRWD11MTfSx3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>13.
<span id="xdx_825_zB63Zc6ElSi9">Derivative Liabilities</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has identified derivative instruments arising from the conversion shares discussed in the Convertible Notes section of Note 7
as of December 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilizes a Monte Carlo simulation model for commitment shares that have an option to convert at a variable number of shares to
compute the fair value of the derivative and to mark to market the fair value of the derivative at each balance sheet date. The inputs
utilized in the application of the Monte Carlo model included a starting stock price of $<span id="xdx_90B_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zhmP5pD8e4Oj" title="Derivative liability, measurement input"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputSharePriceMember" id="Fact001742" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">7.91</ix:nonFraction></span> per share, an expected remaining term of
each warrant as of the valuation date, estimated volatility of <span id="xdx_900_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zUMFYGm5hlLg" title="Derivative liability, measurement input"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember" id="Fact001744" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">70</ix:nonFraction></span>%, drift, and a risk-free rate ranging from <span id="xdx_90C_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_znYRZFgGftvd" title="Derivative liability, measurement input"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember" id="Fact001746" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">3.46</ix:nonFraction></span>% to <span id="xdx_90B_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zvB1Y5MAlpZ4" title="Derivative liability, measurement input"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember" id="Fact001748" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">5.47</ix:nonFraction></span>%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free
interest rate: The Company uses the risk-free interest rate of a U.S. Treasury Note adjusted to be on a continuous return basis to align
with the Black-Scholes option-pricing model.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend
yield: The Company uses a <span id="xdx_909_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zKyTOTQA3O9j" title="Derivative liability, measurement input"><ix:nonFraction name="us-gaap:DerivativeLiabilityMeasurementInput" contextRef="AsOf2023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember" id="Fact001750" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0</ix:nonFraction></span>% expected dividend yield as the Company has not paid dividends to date and does not anticipate declaring
dividends in the near future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Volatility:
The Company calculates the expected volatility based on comparable company&#8217;s historical stock prices with a look back period commensurate
with the period to maturity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
term: The Company&#8217;s remaining term is based on the remaining contractual maturity of the warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001752" name="us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"><p id="xdx_89F_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zJdwQatXOJT7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following are the changes in the warrant liabilities during the years ended December 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B8_zUOQofGvwwp" style="display: none">Schedule of Changes in Derivative Liabilities</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Derivative liabilities as of January 1, 2022 </td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--DerivativeLiabilitiesCurrent_iS_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z9jhwzhVpE86" title="Derivative liabilities, Beginning balance" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1754">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--DerivativeLiabilitiesCurrent_iS_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zRx91dD0QrO2" title="Derivative liabilities, Beginning balance" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1756">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--DerivativeLiabilitiesCurrent_iS_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z9IMVBdcuuFb" title="Derivative liabilities, Beginning balance" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1758">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 46%; text-align: left">Addition </td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_ecustom--AdditionToDerivativeLiabilities_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zoxD020vegNl" title="Addition" style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1760">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_ecustom--AdditionToDerivativeLiabilities_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_ziYC6HGpNHe6" title="Addition" style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1762">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_ecustom--AdditionToDerivativeLiabilities_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zaaoT3YzJxqe" title="Addition" style="width: 14%; text-align: right"><ix:nonFraction name="NRXS:AdditionToDerivativeLiabilities" contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact001764" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,449,689</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Changes in fair value of Derivative liabilities </td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zAZjwjhblxuf" title="Changes in fair value of Derivative liabilities" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1766">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zR5TmpePO1ng" title="Changes in fair value of Derivative liabilities" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1768">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zYddEwPOCxEd" title="Changes in fair value of Derivative liabilities" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact001770" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">713,989</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Derivative liabilities as of December 31, 2022 </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--DerivativeLiabilitiesCurrent_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zTnpau9Rhcqd" title="Derivative liabilities, Beginning balance" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1772">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--DerivativeLiabilitiesCurrent_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zKCP0izm4NMk" title="Derivative liabilities, Beginning balance" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1774">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--DerivativeLiabilitiesCurrent_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zedFJURVBnq4" title="Derivative liabilities, Beginning balance" style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact001776" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,735,700</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Addition </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--AdditionToDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zNHky8oLN51c" title="Addition" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1778">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--AdditionToDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_ziMUjDmHdjM9" title="Addition" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1780">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--AdditionToDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zWqpB46QAE4k" title="Addition" style="text-align: right"><ix:nonFraction name="NRXS:AdditionToDerivativeLiabilities" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact001782" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,375,378</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Changes in fair value of Derivative liabilities </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zO7swFuSYcIi" title="Changes in fair value of Derivative liabilities" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1784">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zsbDKxp0tjte" title="Changes in fair value of Derivative liabilities" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1786">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zv1DJ5mLg454" title="Changes in fair value of Derivative liabilities" style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact001788" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">198,551</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Extinguishment of Derivative liabilities </td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--ExtinguishmentOfDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zno7fW0abtFb" title="Extinguishment of Derivative liabilities" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1790">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_ecustom--ExtinguishmentOfDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zWWLnmwhY4Wj" title="Extinguishment of Derivative liabilities" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1792">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_ecustom--ExtinguishmentOfDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zKKG6mL1xKxg" title="Extinguishment of Derivative liabilities" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="NRXS:ExtinguishmentOfDerivativeLiabilities" contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member" id="Fact001794" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,912,527</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Derivative liabilities as of December 31, 2023 </td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_989_eus-gaap--DerivativeLiabilitiesCurrent_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zrw5GW8U6Vf1" title="Derivative liabilities, Ending balance" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1796">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--DerivativeLiabilitiesCurrent_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zgHhWXlCDkz6" title="Derivative liabilities, Ending balance" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1798">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98B_eus-gaap--DerivativeLiabilitiesCurrent_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zfaAC5RwmNgg" title="Derivative liabilities, Ending balance" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1800">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A8_zcdKM1Q5Bu6k" style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 117; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001802" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock"><p id="xdx_801_eus-gaap--PensionAndOtherPostretirementBenefitsDisclosureTextBlock_zQcHPpmX8I0i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>14.
<span id="xdx_826_zd2VxD42aQO8">Retirement Plan</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company sponsors a 401(k)-retirement plan for its employees. Employees are eligible to participate in the elective deferral portion of
the plan after twelve months and 1,000 hours of service. The Company matches the employees&#8217; contribution up to <span id="xdx_90F_eus-gaap--DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_dp_uPure_c20230101__20231231_zZ7DXKw6wWtc" title="Employee contribution percentage"><ix:nonFraction name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" contextRef="From2023-01-01to2023-12-31" id="Fact001804" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3</ix:nonFraction></span>%. The Company
can also make a discretionary profit-sharing contribution to the employee accounts on an annual basis. Expense totaled $<span id="xdx_90C_eus-gaap--DefinedContributionPlanAdministrativeExpenses_c20230101__20231231_z4JY1QuDSDfh" title="Profit sharing contribution expenses"><ix:nonFraction name="us-gaap:DefinedContributionPlanAdministrativeExpenses" contextRef="From2023-01-01to2023-12-31" id="Fact001806" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,980</ix:nonFraction></span> and $<span id="xdx_909_eus-gaap--DefinedContributionPlanAdministrativeExpenses_c20220101__20221231_zIhw0T9M57Wk" title="Profit sharing contribution expenses"><ix:nonFraction name="us-gaap:DefinedContributionPlanAdministrativeExpenses" contextRef="From2022-01-012022-12-31" id="Fact001808" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,183</ix:nonFraction></span>
for years ended December 31, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001810" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_809_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zdr9r6ZoLDHh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>15</b>.
<b><span id="xdx_827_zcI7DZSDJVEk">Commitments and Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Manufacturing
Services Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 21, 2020, the Company entered into a Manufacturing Services Agreement (MSA) for the manufacture and supply of the Company&#8217;s
IB-STIM device based upon the Company&#8217;s product specifications as set forth in the MSA. This agreement terminated any prior manufacturing
agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company provides the necessary equipment to the manufacturer and retains ownership. The manufacturer bears the risk of loss of and damage
to the equipment and consigned materials. Performance under the MSA is initiated by orders issued by the Company and accepted by the
manufacturer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
term of the MSA is 24 months and shall automatically renew for renewal terms of twelve months unless either party provides a written
termination notice to the other party within 180 days prior to the end of the then-current term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trademark
Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an agreement for a trademark related to the Company&#8217;s name on July 11, 2022. The agreement called for an initial
payment of $<span id="xdx_90D_eus-gaap--PaymentsForRepurchaseOfInitialPublicOffering_c20220711__20220711__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--TypeOfArrangementAxis__custom--TrademarkAgreementMember__us-gaap--OtherCommitmentsAxis__custom--InitialPaymentMember_zwCmaO39YmNe" title="Payments for repurchase of initial public offering"><ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfInitialPublicOffering" contextRef="From2022-07-112022-07-11_us-gaap_IPOMember_custom_TrademarkAgreementMember_custom_InitialPaymentMember" id="Fact001812" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,000</ix:nonFraction></span> upon execution of the agreement. A second and final payment of $<span id="xdx_905_eus-gaap--PaymentsForRepurchaseOfInitialPublicOffering_c20220711__20220711__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--TypeOfArrangementAxis__custom--TrademarkAgreementMember__us-gaap--OtherCommitmentsAxis__custom--SecondAndFinalPaymentMember_zsCbdSjUdMUf" title="Payments for repurchase of initial public offering"><ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfInitialPublicOffering" contextRef="From2022-07-112022-07-11_us-gaap_IPOMember_custom_TrademarkAgreementMember_custom_SecondAndFinalPaymentMember" id="Fact001814" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,000</ix:nonFraction></span> was contingent upon the completion of the Company&#8217;s
planned initial public offering. The second payment has been accrued and is recorded in accounts payable and intangible assets on the
balance sheet. The trademark does not have a determinate life and therefore the cost is not being amortized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Executive
Employment Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company, as authorized by the board of directors, entered into employment agreements with nine key employees to provide incentives to
improve shareholder value and to contribute to the growth and financial success of the Company. The agreements had an employment start
date of October 1, 2022, with initial terms from <span id="xdx_904_ecustom--ExecutiveEmploymentAgreementsTerms_dtY_c20221001__20221001__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember_zrOo1cIDeiD1" title="Executive employment agreements renewals"><ix:nonNumeric contextRef="From2022-10-012022-10-01_srt_MinimumMember_custom_ExecutiveEmploymentAgreementsMember" format="ixt-sec:duryear" id="Fact001816" name="NRXS:ExecutiveEmploymentAgreementsTerms">2</ix:nonNumeric></span> to <span id="xdx_90A_ecustom--ExecutiveEmploymentAgreementsTerms_dtY_c20221001__20221001__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember_zPeqIA3bvnO1" title="Executive employment agreements renewals"><ix:nonNumeric contextRef="From2022-10-012022-10-01_srt_MaximumMember_custom_ExecutiveEmploymentAgreementsMember" format="ixt-sec:duryear" id="Fact001818" name="NRXS:ExecutiveEmploymentAgreementsTerms">5</ix:nonNumeric></span> years and <span id="xdx_900_ecustom--DescriptionOfExecutiveEmploymentAgreementsRenewals_dtY_c20221001__20221001__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember_zT02Ac9G2ARk" title="Description of Executive employment agreements renewals"><ix:nonNumeric contextRef="From2022-10-012022-10-01_custom_ExecutiveEmploymentAgreementsMember" id="Fact001820" name="NRXS:DescriptionOfExecutiveEmploymentAgreementsRenewals">optional one-year renewals</ix:nonNumeric></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
total base salaries for the nine key employees in the agreements are $<span id="xdx_906_eus-gaap--SalariesAndWages_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember_ztNGYbdIZ0oc"><ix:nonFraction name="us-gaap:SalariesAndWages" contextRef="From2023-01-012023-12-31_custom_ExecutiveEmploymentAgreementsMember" id="Fact001821" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,920,000</ix:nonFraction>
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per year with various provisions for annual increases.
In addition to base salaries, eight of the employees have a provision for a special one-time incentive payment to be paid in a lump sum
after the start date. The total amount of these special incentive payments is $<span id="xdx_90C_eus-gaap--IncentiveFeeExpense_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember_z3wBPMLu5LMa"><ix:nonFraction name="us-gaap:IncentiveFeeExpense" contextRef="From2023-01-012023-12-31_custom_ExecutiveEmploymentAgreementsMember" id="Fact001822" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,100,000</ix:nonFraction></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The special incentive payment amount includes any accrued backpay wages for the employee. The amount for backpay of $<span id="xdx_902_eus-gaap--DepositLiabilitiesAccruedInterest_iI_c20221231_zcYHS5KsKxT7"><span id="xdx_906_eus-gaap--DepositLiabilitiesAccruedInterest_iI_c20231231_zBzu1gXsKQi6"><ix:nonFraction name="us-gaap:DepositLiabilitiesAccruedInterest" contextRef="AsOf2022-12-31" id="Fact001823" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:DepositLiabilitiesAccruedInterest" contextRef="AsOf2023-12-31" id="Fact001824" format="ixt:numdotdecimal" decimals="0" unitRef="USD">417,390</ix:nonFraction></ix:nonFraction></span></span> was accrued
as of December 31, 2022 and paid in the year ended December 31, 2023. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are seven key employees that have stock options of the Company totaling <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_pid_uShares_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember_zGN4ztPM74pl" title="Seven key employees stock options"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" contextRef="From2023-01-012023-12-31_custom_ExecutiveEmploymentAgreementsMember" id="Fact001826" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,238,712</ix:nonFraction></span> shares. These key employees have a provision in their
agreements whereas the Company will pay a special bonus equal to the aggregate of the strike price or exercise price of all their stock
options plus a tax gross-up payment. The special bonus shall be paid in twenty percent (<span id="xdx_90D_ecustom--SpecialBonusPercentage_iI_pid_dp_uPure_c20240102__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember_zBTPchefe9bl" title="Special bonus percentage"><ix:nonFraction name="NRXS:SpecialBonusPercentage" contextRef="AsOf2024-01-02_us-gaap_SubsequentEventMember_custom_ExecutiveEmploymentAgreementsMember" id="Fact001828" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">20</ix:nonFraction></span>%) installments starting January 2, 2024, and
the same date each of the next four years. As a condition of the payment, the key employee must exercise at least <span id="xdx_90C_ecustom--KeyEmployeeExercisePercentage_iI_pid_dp_uPure_c20240102__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember__srt--RangeAxis__srt--MinimumMember_zt6ObCrqokhj" title="Key employee exercise percentage"><ix:nonFraction name="NRXS:KeyEmployeeExercisePercentage" contextRef="AsOf2024-01-02_us-gaap_SubsequentEventMember_custom_ExecutiveEmploymentAgreementsMember_srt_MinimumMember" id="Fact001830" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">20</ix:nonFraction></span>% of their stated
number of stock options. There are additional provisions to cover termination and change of control events. None of the key employees
exercised the options on January 2, 2024</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2023, the Company amended the employee agreements to, among other things, clarify that the special one-time incentive payment and
the deferred bonus are contingent upon the effective date of the planned initial public offering. The amendment also sets forth a process
for executives to exercise the stock options in accordance with the terms of the stock option agreement in effect as of the date of the
employment agreement and to clarify that there is no modification to the stock option agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<ix:exclude><!-- Field: Page; Sequence: 118; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The Company has recorded the backpay portion of the incentive
bonus notes above. The balance of the incentive bonuses of $<span id="xdx_901_eus-gaap--AccruedBonusesCurrent_iI_c20230430__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember_zikAkNLpoOud" title="Incentive bonus"><ix:nonFraction name="us-gaap:AccruedBonusesCurrent" contextRef="AsOf2023-04-30_custom_ExecutiveEmploymentAgreementsMember" id="Fact001832" format="ixt:numdotdecimal" decimals="0" unitRef="USD">694,056</ix:nonFraction></span> and the special options bonuses of $<span id="xdx_90E_eus-gaap--AccruedBonusesCurrent_iI_c20230430__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zaaEuPADg5y6" title="Incentive bonus"><ix:nonFraction name="us-gaap:AccruedBonusesCurrent" contextRef="AsOf2023-04-30_custom_ExecutiveEmploymentAgreementsMember_us-gaap_IPOMember" id="Fact001834" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,821,830</ix:nonFraction></span> were contingent upon
a successful IPO. The incentive bonuses have been paid in full while the special options bonuses will be recorded when paid.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt"><b>Litigation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">From time to time, the Company may be involved
in litigation relating to claims arising out of operations in the normal course of business. As of the date of issuance, other than those
described below, there were no pending or threatened legal proceedings that could reasonably be expected to have a material effect
on the results of the Company&#8217;s operations. There are also no proceedings in which any of the Company&#8217;s directors,
officers or affiliates is an adverse party to the Company or has a material interest adverse to the Company&#8217;s interest.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">On February 6, 2019, plaintiff Ritu Bhambhani, M.D.,
initiated a lawsuit against Innovative Health Solutions, Inc. and others in the United States District Court for the District of Maryland.
Plaintiffs Bhambhani and Sudhir Rao subsequently amended the complaint, with the Third Amended Complaint (&#8220;Complaint&#8221;) containing
the most recent set of allegations. The Complaint asserted claims under the RICO Act, as well as of fraudulent misrepresentation, intentional
misrepresentation by concealment, and civil conspiracy and sought compensatory damages in excess of $<span id="xdx_901_eus-gaap--LossContingencyDamagesSoughtValue_pn6n6_c20190205__20190206_zPxZIpYxqCr1" title="Sought compensatory damages"><ix:nonFraction name="us-gaap:LossContingencyDamagesSoughtValue" contextRef="From2019-02-052019-02-06" id="Fact001836" format="ixt:numdotdecimal" decimals="-6" scale="6" unitRef="USD">5</ix:nonFraction></span> million, pre-judgment interest,
punitive damages, attorney&#8217;s fees, court costs and designation of the case as a class action. The Complaint states that the Company,
distributors of the Company&#8217;s product, and medical billing and coding consultants allegedly made misrepresentations to the plaintiffs
that the Company&#8217;s NeuroStim device and related procedures could be billed to, and reimbursed by, Medicare and other insurance payors
as a surgically implantable neurostimulator. Plaintiffs claim to have suffered damages when Medicare administrative contractors declined
to pay plaintiffs for their use of the device.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">On February 11, 2022, the Company filed a motion for
summary judgment based upon the plaintiffs not being proper parties to assert claims against the Company. On June 14, 2022, the Court
granted the Company&#8217;s motion for summary judgment and dismissed the Complaint.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">On July 14, 2022, plaintiffs Ritu Bhambhani and Sudhir
Rao filed a notice of appeal with the Fourth Circuit Court of Appeals. The Company filed a motion to dismiss.&#160;On January 4, 2023,
the Court issued an order that stated it was deferring a ruling on the motion to dismiss the appeal and that&#160;it would address those
arguments at the same time that it addressed the substantive merits of the case. While it is too early to predict the ultimate outcome of this matter, we continue to believe we have
meritorious defenses, that the dismissal of the Complaint should be upheld, and intend to continue to defend this matter vigorously.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">On July 14, 2022, plaintiffs Ritu Bhambhani, LLC;
Box Hill Surgery Center, LLC; Pain and Spine Specialists of Maryland, LLC; and SimCare ASC, LLC initiated a lawsuit against the Company
and others in the United States District Court for the District of Maryland. The plaintiffs in this lawsuit are business entities owned
or partially owned by the plaintiffs that initiated the litigation described above. The Complaint asserted claims under the RICO Act,
as well as fraudulent misrepresentation, intentional misrepresentation by concealment, and civil conspiracy and seeks compensatory damages
in excess of $<span id="xdx_900_eus-gaap--LossContingencyDamagesSoughtValue_c20220713__20220714_zJpRVxmhzaac" title="Sought compensatory damages"><ix:nonFraction name="us-gaap:LossContingencyDamagesSoughtValue" contextRef="From2022-07-132022-07-14" id="Fact001838" format="ixt:numdotdecimal" decimals="0" unitRef="USD">75,000</ix:nonFraction></span>, pre-judgment interest, punitive damages, attorney&#8217;s fees, and court costs. The Complaint states that the Company,
distributors of the Company&#8217;s product, and medical billing and coding consultants allegedly made misrepresentations to the plaintiffs
that the Company&#8217;s NeuroStim device and related procedures could be billed to, and reimbursed by, Medicare and other insurance payors
as a surgically implantable neurostimulator. Plaintiffs claim to have suffered damages when Medicare administrative contractors declined
to pay plaintiffs for their use of the device.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">On September 28, 2022, the Company filed a motion to dismiss all
claims. On May 25, 2023, the Court issued an Order and a Memorandum Opinion which dismissed the plaintiffs&#8217;claims related to the
RICO Act. The remaining claims are still pending, and no trial date has been set for the case. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The Court has vacated its Scheduling Order
at the parties&#8217; request so that the parties could try to resolve the disputes in both cases through an independent <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">third-party</span>
mediator. No mediation date has been set. While it is too early to predict the ultimate
outcome of this matter, we believe the Company has meritorious defenses and intends to defend this matter vigorously.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 119; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001840" name="NRXS:HealthBenefitPlanDisclosureTextBlock"><p id="xdx_801_ecustom--HealthBenefitPlanDisclosureTextBlock_zsgutNsRxR7e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>16.
<span id="xdx_821_zCZZocpiAC2i">Health Benefit Plan</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into a self-funded program employer agreement in 2018 in conjunction with a group health plan for the benefit of eligible
employees. This plan is a level funded plan, and the services and products include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    self-funded employer health benefit plan.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stop
    loss insurance purchased from a stop loss insurance company.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third
    party administrator to provide administrative services with regard to the plan.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company maintains a stop loss contract that reimburses the Company for claims paid under the plan if they exceed a predetermined level.
The Company makes contributions for health care costs and associated expenses that are expected during the plan year. The amount of contributions
is determined annually based on the Company&#8217;s maximum liability for expected claims, administrative expenses, and premiums for
the stop loss policy. The Company paid premiums of $<span id="xdx_90C_eus-gaap--HealthCareOrganizationStopLossInsurancePremiumExpense_c20230101__20231231_zgAx37ltp1q7" title="Stop loss insurance premium expense"><ix:nonFraction name="us-gaap:HealthCareOrganizationStopLossInsurancePremiumExpense" contextRef="From2023-01-01to2023-12-31" id="Fact001842" format="ixt:numdotdecimal" decimals="0" unitRef="USD">255,715</ix:nonFraction></span> and $<span id="xdx_909_eus-gaap--HealthCareOrganizationStopLossInsurancePremiumExpense_c20220101__20221231_zGfPfHjLs6H1" title="Stop loss insurance premium expense"><ix:nonFraction name="us-gaap:HealthCareOrganizationStopLossInsurancePremiumExpense" contextRef="From2022-01-012022-12-31" id="Fact001844" format="ixt:numdotdecimal" decimals="0" unitRef="USD">196,929</ix:nonFraction></span> for the years ended December 31, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is responsible for the monthly premiums, as established, and nothing further. The stop loss policy covers the claims if they
exceed the claims funds. After a certain time, and if there is a surplus in the claims fund, the Company may be entitled to receive a
<span id="xdx_90F_ecustom--HealthCareOrganizationStopLossInsurancePremiumPercentage_pid_dp_uPure_c20230101__20231231_zi24CLyZG2F8" title="Stop loss insurance premium percentage"><ix:nonFraction name="NRXS:HealthCareOrganizationStopLossInsurancePremiumPercentage" contextRef="From2023-01-01to2023-12-31" id="Fact001846" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">48.5</ix:nonFraction></span>% refund from the fund. This amount is recognized by the Company when received.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001848" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_802_eus-gaap--IncomeTaxDisclosureTextBlock_zs7jTnMhY58c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>17.
<span id="xdx_82C_zq1S6XHJZQGi">Income Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Inflation Reduction Act (IRA) was signed
into law on August 16, 2022, imposing a 15% corporate alternative minimum tax on adjusted financial statement income and a 1% excise
tax on stock repurchases after January 1, 2023. The IRA did not have an impact on the Company&#8217;s 2023 or 2022 financial
statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Tax Cuts and Jobs Act (TCJA) requires taxpayers
to capitalize and amortize research and developmental (&#8220;R&amp;D&#8221;) expenditures undersection 174 for tax years beginning after
December 31, 2021 and, therefore, became effective for the Company during the year ended December 31, 2022. The TCJA resulted in the capitalization
of R&amp;D costs of $<span id="xdx_90E_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_c20231231_zHxmYUO7SED7" title="Research and development expense"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="AsOf2023-12-31" id="Fact001850" format="ixt:numdotdecimal" decimals="0" unitRef="USD">169,315</ix:nonFraction></span> and $<span id="xdx_90E_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_c20221231_zQsy7EgEb3B9" title="Research and development expense"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="AsOf2022-12-31" id="Fact001852" format="ixt:numdotdecimal" decimals="0" unitRef="USD">225,466</ix:nonFraction></span> for tax purposes for the years ended December 31, 2023 and 2022, respectively. The Company is
amortizing these costs over 5 years if the R&amp;D was performed in the U.S. and over 15 years if the R&amp;D was performed outside the
US. The Company did not recognize a current provision for income taxes for 2023 and 2022 since there were net operating losses reported
in both years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Deferred income taxes are provided for temporary
differences between the financial reporting basis and the tax basis of the Company&#8217;s assets and liabilities. Differences are primarily
attributable to net operating loss carryforwards and stock-based compensation. The Company does not reflect any deferred taxes in its financial
statements due to a full valuation allowance. The net deferred tax amounts include the following components:</p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001854" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><p id="xdx_897_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zgxHJDSet3c6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B6_zsvq5IwiPWJk" style="display: none">Schedule of Deferred Tax Asset</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_491_20231231_zUAjjHz2OOWb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_492_20221231_zwxwQFFiRWaj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net deferred tax assets - Non-current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--DeferredTaxAssetsDepreciation_iI_maDTANzFzE_zpjtVKHNnBh7" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">Depreciation</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 16%; font-weight: bold; text-align: right">(<ix:nonFraction name="NRXS:DeferredTaxAssetsDepreciation" contextRef="AsOf2023-12-31" id="Fact001856" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">15,175</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(<ix:nonFraction name="NRXS:DeferredTaxAssetsDepreciation" contextRef="AsOf2022-12-31" id="Fact001857" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">16,098</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_403_ecustom--DeferredTaxAssetsAmortization_iI_maDTANzFzE_zr2UKuOK9QLf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Amortization</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(<ix:nonFraction name="NRXS:DeferredTaxAssetsAmortization" contextRef="AsOf2023-12-31" id="Fact001859" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,195</ix:nonFraction></td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="NRXS:DeferredTaxAssetsAmortization" contextRef="AsOf2022-12-31" id="Fact001860" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">19,290</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_iI_maDTANzFzE_z14UjS7TVmNc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrual to cash</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" contextRef="AsOf2023-12-31" id="Fact001862" format="ixt:numdotdecimal" decimals="0" unitRef="USD">718,893</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" contextRef="AsOf2022-12-31" id="Fact001863" format="ixt:numdotdecimal" decimals="0" unitRef="USD">767,861</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTANzFzE_zqfagDjdXrQ9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock based compensation</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2023-12-31" id="Fact001865" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,653,490</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2022-12-31" id="Fact001866" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,653,490</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTANzFzE_zlDyBEzatgGf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected income tax benefit from NOL carry-forwards</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2023-12-31" id="Fact001868" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,573,406</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="AsOf2022-12-31" id="Fact001869" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,309,340</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzFzE_zzVF2dVXevJ" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less valuation allowance</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2023-12-31" id="Fact001871" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,916,419</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2022-12-31" id="Fact001872" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,695,303</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzFzE_znuM3OXHLwsl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Deferred tax assets, net of valuation allowance</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1874">&#8212;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1875">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A5_zQBkM4bX6Rh2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 120; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001877" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><p id="xdx_892_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zICFLbegfY6a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the federal statutory income tax rate and the effective income tax rate as a percentage of income before income
taxes is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BC_zpruKJf8hmd5" style="display: none">Schedule of Federal Statutory Income Tax Rate and Effective Income Tax Rate</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_498_20230101__20231231_z59WnKOa1Zi6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_492_20220101__20221231_zzwnLnAc0SWc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maEIT001_zP3M6DNxZ3p" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Federal statutory income tax rate</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 14%; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2023-01-01to2023-12-31" id="Fact001879" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.0</ix:nonFraction></td><td style="width: 1%; font-weight: bold; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2022-01-012022-12-31" id="Fact001880" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21.0</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maEIT001_zuk7jKPhTKNg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State tax rate, net of federal benefit</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2023-01-01to2023-12-31" id="Fact001882" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.9</ix:nonFraction></td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2022-01-012022-12-31" id="Fact001883" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.7</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_pid_dp_uPure_maEIT001_zpBL7zNHp4Ig" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Nondeductible expenses</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1885">&#8212;</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1886">&#8212;</span></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--EffectiveIncomeTaxRateReconciliationNontaxableIncome_pid_dp_uPure_maEIT001_zHe6GGriUl68" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Nontaxable income</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1888">&#8212;</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1889">&#8212;</span></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maEIT001_zTYwymOSv2yb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance on net deferred tax assets</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2023-01-01to2023-12-31" id="Fact001891" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">25.9</ix:nonFraction></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2022-01-012022-12-31" id="Fact001892" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">25.7</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtEIT001_zaePfdx4WEW6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Effective income tax rate</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1894">&#8212;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1895">&#8212;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AC_zF2UMsOv6J8h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had no income tax expense due to the operating loss incurred for the years ended December 31, 2023 and 2022. The
Company&#8217;s management has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax
assets and has determined that it is more likely than not that the Company will not recognize the benefits of the net deferred tax
assets. As a result, the Company recorded a full valuation allowance at December 31, 2023 and 2022. The valuation allowance
increased by $<span id="xdx_90A_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_c20230101__20231231_zOfIjaWhPGM6" title="Deferred tax assets valuation allowance"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2023-01-01to2023-12-31" id="Fact001897" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,221,116</ix:nonFraction></span>
and $<span id="xdx_906_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_c20220101__20221231_zJ8K0yRbxiGh" title="Deferred tax assets valuation allowance"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2022-01-012022-12-31" id="Fact001899" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,136,470</ix:nonFraction></span> for the years ended December 31, 2023 and 2022, respectively, primarily due to net operating loss (NOL)
carryforwards.  </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 31, 2023, the Company had federal and state net operating loss (NOL) carryforwards totaling $<span id="xdx_90D_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_c20231231_zttitOLQQve8" title="Federal and state net operating loss"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" contextRef="AsOf2023-12-31" id="Fact001901" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,238,445</ix:nonFraction></span> and $<span id="xdx_90C_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_c20221231_zXCAFy0TSdye" title="Federal and state net operating loss"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" contextRef="AsOf2022-12-31" id="Fact001903" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,543,000</ix:nonFraction></span>, respectively.
These loss carryforwards may be offset against future taxable income. There is no limitation on the number of years to utilize the federal
NOL. The federal deduction will be limited to 80% of modified taxable income. The state NOL allows up to 100% of taxable income to be
offset and can be carried forward no longer than 20 years after the year of the taxable loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal
and state tax laws impose limitations on the utilization of NOLs and credit carryforwards in the event of an ownership
change for tax purposes, as defined in Section 382 of the Internal Revenue Code. Accordingly, the Company&#8217;s ability to utilize
these carryforwards may be limited as a result of an ownership change. Such
an ownership change could result in a limitation in the use of the net operating losses in future years and possibly a reduction of the
net operating losses available.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001905" name="us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock"><p id="xdx_89B_eus-gaap--SummaryOfOperatingLossCarryforwardsTextBlock_zuWUZHLVUHcg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
not used, the state carryforwards will expire as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BB_zACIjTRNE0Bj" style="display: none">Schedule of State Carryforwards</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_495_20231231_z2i4eP1rf9I4" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--TaxYear2038Member_zcmuelte7Jx8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: justify">2038</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" contextRef="AsOf2023-12-31_custom_TaxYear2038Member" id="Fact001907" format="ixt:numdotdecimal" decimals="0" unitRef="USD">888,389</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--TaxYear2039Member_zcaDcM4YT0b7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">2039</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" contextRef="AsOf2023-12-31_custom_TaxYear2039Member" id="Fact001909" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,039,949</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--TaxYear2040Member_zJD30KX1QMbf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">2040</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" contextRef="AsOf2023-12-31_custom_TaxYear2040Member" id="Fact001911" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,457,495</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--TaxYear2041Member_zHbzhjCnguzj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">2041</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" contextRef="AsOf2023-12-31_custom_TaxYear2041Member" id="Fact001913" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,406,225</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--TaxYear2042Member_z25W3LxayKI7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">2042</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" contextRef="AsOf2023-12-31_custom_TaxYear2042Member" id="Fact001915" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,730,141</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--TaxYear2043Member_zzAtvMCDGtJ9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">2043</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" contextRef="AsOf2023-12-31_custom_TaxYear2043Member" id="Fact001917" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,915,439</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--TaxYear2043Member_z7JUo4OntuBc" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">State Carryforwards</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" contextRef="AsOf2023-12-31_custom_TaxYear2043Member" id="Fact001919" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,915,439</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
</table>

</ix:nonNumeric><p id="xdx_8A1_z7vr3pLjO0Hb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001921" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_806_eus-gaap--SubsequentEventsTextBlock_zqnerVpk7s2d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>18.
<span id="xdx_828_z8bf7jYhx8qc">Subsequent Events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluated events through the date of issuance. Subsequent to December 31, 2023, the Company entered into a series of
Convertible Promissory Notes totaling $<span id="xdx_906_eus-gaap--DebtInstrumentAnnualPrincipalPayment_iI_c20240324__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zUkkjB5ELwEd" title="Total principal amount"><ix:nonFraction name="us-gaap:DebtInstrumentAnnualPrincipalPayment" contextRef="AsOf2024-03-24_us-gaap_SubsequentEventMember" id="Fact001923" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,135,000</ix:nonFraction></span>
with terms identical to the $<span id="xdx_907_eus-gaap--ConvertibleDebt_iI_c20231231_zTpgm5fsv7N8" title="Convertible debt"><ix:nonFraction name="us-gaap:ConvertibleDebt" contextRef="AsOf2023-12-31" id="Fact001925" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,000,000</ix:nonFraction></span> Convertible Promissory Note issued on November 8, 2023 (see Footnote 10). The Company has
received $<span id="xdx_907_eus-gaap--DebtInstrumentPeriodicPayment_c20240323__20240324__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zec4KbELuR23" title="Principal amount due in monthly installments"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPayment" contextRef="From2024-03-232024-03-24_us-gaap_SubsequentEventMember" id="Fact001927" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,535,000</ix:nonFraction></span>
of the principal amount with the remainder due in monthly installments through the maturity date of March of 2025. &#160; The Convertible Promissory Notes bear interest at <span id="xdx_904_eus-gaap--DebtConversionOriginalDebtInterestRateOfDebt_dp_uPure_c20231231__20231231_ztKKlywvCTq4" title="Debt conversion, original debt, interest rate of debt"><ix:nonFraction name="us-gaap:DebtConversionOriginalDebtInterestRateOfDebt" contextRef="From2023-12-312023-12-31" id="Fact001929" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8.5</ix:nonFraction>%</span> per annum payable quarterly in either cash or common
stock. The Convertible
Promissory Notes contain a provision that allows for a voluntary conversion by the investors into Series B Preferred Stock at $<span id="xdx_904_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20240324__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zHTIUvcJOCf1" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-03-24_us-gaap_SubsequentEventMember_us-gaap_SeriesBPreferredStockMember" id="Fact001931" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.38</ix:nonFraction></span>
per share any time prior to the maturity date with mandatory conversion by the Company at the maturity date. The Company shall
use the proceeds solely for working capital and general corporate purposes and not pay any dividends or distributions or to advance
any funds to its officers, directors or affiliates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001933" name="us-gaap:ErrorCorrectionTextBlock"><p id="xdx_80F_eus-gaap--ErrorCorrectionTextBlock_z7bbO2JVEdK9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>19. <span id="xdx_82E_zasZZ9iYQKN7">Restatement of Interim Financial Statements (Unaudited)</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the preparation of the Company&#8217;s
financial statements as of and for the year ended December 31, 2023, management identified a material accounting error in the unaudited
interim financial statements as of and for the three and nine month periods ended September 30, 2023 relating to the improper classification
of the reduction of the fair value of warrant liabilities as a reduction to the extinguishment of debt charge on the Statement of Operations
rather than an increase to additional paid in capital on the Balance Sheet.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon the consummation of the Company&#8217;s IPO,
the exercise price of certain warrants issued prior to the IPO became known. As a result of the exercise price becoming known, our warrant
liability was reduced by $<span id="xdx_904_ecustom--IncreaseDecreaseInWarrantLiability_c20230101__20230930_ziFwUb6LOkc3" title="Reduced warrant liability"><span id="xdx_90E_ecustom--IncreaseDecreaseInWarrantLiability_c20230701__20230930_z80RaeguLGXh" title="Reduced warrant liability"><ix:nonFraction name="NRXS:IncreaseDecreaseInWarrantLiability" contextRef="From2023-01-012023-09-30" id="Fact001935" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="NRXS:IncreaseDecreaseInWarrantLiability" contextRef="From2023-07-012023-09-30" id="Fact001937" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,721,007</ix:nonFraction></ix:nonFraction></span></span>. This warrant liability reduction should have triggered a reclassification to additional paid in capital
instead of an extinguishment of debt charge. This accounting error resulted in a (i) $<span id="xdx_90F_eus-gaap--GainsLossesOnExtinguishmentOfDebt_iN_di_c20230701__20230930__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zT4JceRxahp2" title="Extinguishment of debt expense"><span id="xdx_90E_eus-gaap--GainsLossesOnExtinguishmentOfDebt_iN_di_c20230101__20230930__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zFfyYJd4ZaOl" title="Extinguishment of debt expense"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2023-07-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact001939" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact001941" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,721,007</ix:nonFraction></ix:nonFraction></span></span> understatement of the extinguishment of
debt expense on the Statement of Operations, (ii) $<span id="xdx_909_eus-gaap--NetIncomeLoss_iN_di_c20230701__20230930__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zOuSte5O6ULj" title="Net loss"><span id="xdx_90D_eus-gaap--NetIncomeLoss_iN_di_c20230101__20230930__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zKyZzcheCPE1" title="Net loss"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact001943" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact001945" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,721,007</ix:nonFraction></ix:nonFraction></span></span> understatement of the net loss on the Statement of Operations, and (iii)
$<span id="xdx_903_eus-gaap--AdditionalPaidInCapital_iI_c20230930__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zB1iRpev7Fq6" title="Additional paid in capital"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact001947" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,721,007</ix:nonFraction></span> understatement of additional paid in capital on the Balance Sheet as of and for the three and nine month periods ended September
30, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board of Directors of the Company, upon the recommendation
of the Audit Committee and after discussion with management, concluded that the Company&#8217;s previously issued unaudited financial
statements as of and for the three and nine month periods ended September 30, 2023 should no longer be relied upon and should be restated
due to identification of the material accounting error.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following tables present the amounts previously reported, the restatement
impact and the restated amount in the respective unaudited financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 121; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NeurAxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Balance
Sheet</b></span></p>

<ix:nonNumeric contextRef="From2023-01-01to2023-12-31" escape="true" id="Fact001949" name="us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock"><p id="xdx_89F_eus-gaap--ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_zoiTHtkJXvUd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zaX6evkBfrL">Schedule
of Restatement of Interim Financial Statements (Unaudited)</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20230930__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zftlwQXmGNHd" style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20230930__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zg7s8K2a85xf" style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20230930_zfy7Wt4pZfTg" style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="10" style="text-align: center">(Unaudited)</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">As of September 30,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">As Reported</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Adjustments</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">As Restated</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AssetsAbstract_iB_z7la7edj9gPa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1.5pt">Assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AssetsCurrentAbstract_i01B_zDv5FQtG0KWd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maCzVMo_zq10uP42Nw23" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 52%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact001959" format="ixt:numdotdecimal" decimals="0" unitRef="USD">761,249</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1960">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-09-30" id="Fact001961" format="ixt:numdotdecimal" decimals="0" unitRef="USD">761,249</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AccountsReceivableNetCurrent_i02I_maCzVMo_zjUE7Rhi6MZb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accounts receivable, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact001963" format="ixt:numdotdecimal" decimals="0" unitRef="USD">132,382</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1964">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2023-09-30" id="Fact001965" format="ixt:numdotdecimal" decimals="0" unitRef="USD">132,382</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--InventoryNet_i02I_zSC1t8b8tO9b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Inventories</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact001967" format="ixt:numdotdecimal" decimals="0" unitRef="USD">34,530</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1968">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2023-09-30" id="Fact001969" format="ixt:numdotdecimal" decimals="0" unitRef="USD">34,530</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_zcfA0J0lcHlc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Prepaid and other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact001971" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,693</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1972">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2023-09-30" id="Fact001973" format="ixt:numdotdecimal" decimals="0" unitRef="USD">38,693</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AssetsCurrent_i01TI_zdcR5KulT93c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Total current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact001975" format="ixt:numdotdecimal" decimals="0" unitRef="USD">966,854</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1976">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-09-30" id="Fact001977" format="ixt:numdotdecimal" decimals="0" unitRef="USD">966,854</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_i01I_zGo7D0gswd6a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Property and equipment, at cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact001979" format="ixt:numdotdecimal" decimals="0" unitRef="USD">420,586</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1980">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2023-09-30" id="Fact001981" format="ixt:numdotdecimal" decimals="0" unitRef="USD">420,586</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_i02NI_di_zZuhB7zBbJge" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less - accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact001983" format="ixt:numdotdecimal" decimals="0" unitRef="USD">340,260</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1984">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2023-09-30" id="Fact001985" format="ixt:numdotdecimal" decimals="0" unitRef="USD">340,260</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentNet_i01TI_zgh4NmQxFQk7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact001987" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80,326</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1988">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2023-09-30" id="Fact001989" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80,326</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseRightOfUseAsset_i02I_zXYHXdwCrPh1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating lease right of use asset, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact001991" format="ixt:numdotdecimal" decimals="0" unitRef="USD">78,043</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1992">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-09-30" id="Fact001993" format="ixt:numdotdecimal" decimals="0" unitRef="USD">78,043</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsNet_i02I_z1YBTPAJ1jI2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Intangible assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact001995" format="ixt:numdotdecimal" decimals="0" unitRef="USD">110,695</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1996">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2023-09-30" id="Fact001997" format="ixt:numdotdecimal" decimals="0" unitRef="USD">110,695</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--Assets_iTI_zAoHqfrMaTwb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact001999" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,235,918</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2000">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-09-30" id="Fact002001" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,235,918</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zG7f7RL4oc1d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Liabilities and Stockholders&#8217; Deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LiabilitiesCurrentAbstract_i01B_zH2U1qauwbPi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AccountsPayableCurrent_i02I_zwdfH5oTCP4a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002011" format="ixt:numdotdecimal" decimals="0" unitRef="USD">566,649</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2012">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-09-30" id="Fact002013" format="ixt:numdotdecimal" decimals="0" unitRef="USD">566,649</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AccruedLiabilitiesCurrent_i02I_zKE4L5NjSPn8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002015" format="ixt:numdotdecimal" decimals="0" unitRef="USD">280,063</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2016">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2023-09-30" id="Fact002017" format="ixt:numdotdecimal" decimals="0" unitRef="USD">280,063</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NotesPayableCurrent_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zHHPrOoNPO41" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember_us-gaap_NonrelatedPartyMember" id="Fact002019" format="ixt:numdotdecimal" decimals="0" unitRef="USD">194,249</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2020">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2023-09-30_us-gaap_NonrelatedPartyMember" id="Fact002021" format="ixt:numdotdecimal" decimals="0" unitRef="USD">194,249</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_zVnk1tRVOWDe" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Current portion of operating lease payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002023" format="ixt:numdotdecimal" decimals="0" unitRef="USD">45,194</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2024">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-09-30" id="Fact002025" format="ixt:numdotdecimal" decimals="0" unitRef="USD">45,194</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--Deposits_i02I_z6pclX04VZc6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Customer deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Deposits" contextRef="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002027" format="ixt:numdotdecimal" decimals="0" unitRef="USD">68,972</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2028">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Deposits" contextRef="AsOf2023-09-30" id="Fact002029" format="ixt:numdotdecimal" decimals="0" unitRef="USD">68,972</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--ShareLiabilitiesCurrent_i02I_zKLRKH4hH2je" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Share liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="NRXS:ShareLiabilitiesCurrent" contextRef="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002031" format="ixt:numdotdecimal" decimals="0" unitRef="USD">934,256</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2032">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="NRXS:ShareLiabilitiesCurrent" contextRef="AsOf2023-09-30" id="Fact002033" format="ixt:numdotdecimal" decimals="0" unitRef="USD">934,256</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--WarrantLiabilities_i02I_z270JvRkjKU4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Warrant liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="NRXS:WarrantLiabilities" contextRef="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002035" format="ixt:numdotdecimal" decimals="0" unitRef="USD">168,269</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2036">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="NRXS:WarrantLiabilities" contextRef="AsOf2023-09-30" id="Fact002037" format="ixt:numdotdecimal" decimals="0" unitRef="USD">168,269</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LiabilitiesCurrent_i01TI_zKajPzaog211" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Total current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002039" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,257,652</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2040">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-09-30" id="Fact002041" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,257,652</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseLiabilityNoncurrent_i02I_zPlW0LG4lAoi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Operating lease payable, net of current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002043" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,353</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2044">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2023-09-30" id="Fact002045" format="ixt:numdotdecimal" decimals="0" unitRef="USD">39,353</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--Liabilities_iTI_zHvU4k8V1lJg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002047" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,297,005</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2048">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2023-09-30" id="Fact002049" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,297,005</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--StockholdersEquityAbstract_i01B_z2Rb0PKBuovf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stockholders&#8217; deficit:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PreferredStockValue_i02I_hus-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesAPreferredStockMember_zPo6fwv8hbrh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Convertible Series A preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2055">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2056">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2057">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PreferredStockValue_i02I_hus-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_zNMiNBhKlRFj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Convertible Series Seed preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2059">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2060">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2061">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--CommonStockValue_i02I_zNrRZtQV4sP2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002063" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,149</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2064">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-09-30" id="Fact002065" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,149</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AdditionalPaidInCapital_i02I_z937TPMgFl93" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Additional paid in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002067" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,178,570</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact002068" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,721,007</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2023-09-30" id="Fact002069" format="ixt:numdotdecimal" decimals="0" unitRef="USD">45,899,577</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_zkVc8A6CdQ46" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002071" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">43,244,806</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact002072" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,721,007</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-09-30" id="Fact002073" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">46,965,813</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--StockholdersEquity_i02TI_z4DofNsPbSVj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Total stockholders&#8217; deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002075" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,061,087</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2076">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-09-30" id="Fact002077" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,061,087</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_zXG1JwsN9SK9" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total liabilities and stockholders&#8217; deficit</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002079" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,235,918</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2080">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-09-30" id="Fact002081" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,235,918</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 122; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NeurAxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Statements
of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20230701__20230930__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z4rksagAY03j" style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20230701__20230930__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_ziSlrYk208r2" style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20230701__20230930_zMpNIDudqAGf" style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20230101__20230930__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zYmcWZhttVj4" style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20230101__20230930__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zfmnf9oMi2v7" style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20230101__20230930_zn0J8Gj06WIg" style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="10" style="text-align: center">(Unaudited)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="10" style="text-align: center">(Unaudited)</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">For the Three Months Ended September 30, 2023</p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">For the
Nine Months Ended September 30, 2023</p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">As Reported</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Adjustments</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">As Restated</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">As Reported</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Adjustments</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">As Restated</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zhe49lSI3Pn5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Net sales</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-07-012023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002083" format="ixt:numdotdecimal" decimals="0" unitRef="USD">477,460</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2084">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-07-012023-09-30" id="Fact002085" format="ixt:numdotdecimal" decimals="0" unitRef="USD">477,460</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002086" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,928,590</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2087">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2023-01-012023-09-30" id="Fact002088" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,928,590</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CostOfGoodsAndServicesSold_zxb0rqhPN23c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Cost of goods sold</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2023-07-012023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002090" format="ixt:numdotdecimal" decimals="0" unitRef="USD">67,287</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2091">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2023-07-012023-09-30" id="Fact002092" format="ixt:numdotdecimal" decimals="0" unitRef="USD">67,287</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002093" format="ixt:numdotdecimal" decimals="0" unitRef="USD">231,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2094">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2023-01-012023-09-30" id="Fact002095" format="ixt:numdotdecimal" decimals="0" unitRef="USD">231,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--GrossProfit_iT_zLQL6hS1wAtc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gross profit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2023-07-012023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002097" format="ixt:numdotdecimal" decimals="0" unitRef="USD">410,173</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2098">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2023-07-012023-09-30" id="Fact002099" format="ixt:numdotdecimal" decimals="0" unitRef="USD">410,173</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002100" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,697,590</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2101">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2023-01-012023-09-30" id="Fact002102" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,697,590</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--SellingExpense_i01_z2VS80dLjIb8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Selling expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SellingExpense" contextRef="From2023-07-012023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002104" format="ixt:numdotdecimal" decimals="0" unitRef="USD">64,210</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2105">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SellingExpense" contextRef="From2023-07-012023-09-30" id="Fact002106" format="ixt:numdotdecimal" decimals="0" unitRef="USD">64,210</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SellingExpense" contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002107" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,933</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2108">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SellingExpense" contextRef="From2023-01-012023-09-30" id="Fact002109" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,933</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_i01_zD5d2npTYDW8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-07-012023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002111" format="ixt:numdotdecimal" decimals="0" unitRef="USD">44,950</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2112">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-07-012023-09-30" id="Fact002113" format="ixt:numdotdecimal" decimals="0" unitRef="USD">44,950</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002114" format="ixt:numdotdecimal" decimals="0" unitRef="USD">171,536</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2115">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-01-012023-09-30" id="Fact002116" format="ixt:numdotdecimal" decimals="0" unitRef="USD">171,536</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--GeneralAndAdministrativeExpense_i01_zLKoElMbPSra" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-07-012023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002118" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,323,352</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2119">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-07-012023-09-30" id="Fact002120" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,323,352</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002121" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,316,411</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2122">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2023-01-012023-09-30" id="Fact002123" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,316,411</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingIncomeLoss_iT_zj534qStsWJa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-07-012023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002125" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,022,339</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2126">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-07-012023-09-30" id="Fact002127" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,022,339</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002128" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,041,290</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2129">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-01-012023-09-30" id="Fact002130" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,041,290</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zZ8XVlIsgQHe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other (expense) income, net:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--FinancingCharges_i01N_di_zXZ9M4yERMSl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Financing charges</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2139">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2140">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2141">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="NRXS:FinancingCharges" contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002142" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,772</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2143">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="NRXS:FinancingCharges" contextRef="From2023-01-012023-09-30" id="Fact002144" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,772</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--InterestExpense_i01N_di_zMuzULvx6tGl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2023-07-012023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002146" format="ixt:numdotdecimal" decimals="0" unitRef="USD">102,628</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2147">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2023-07-012023-09-30" id="Fact002148" format="ixt:numdotdecimal" decimals="0" unitRef="USD">102,628</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002149" format="ixt:numdotdecimal" decimals="0" unitRef="USD">453,869</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2150">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2023-01-012023-09-30" id="Fact002151" format="ixt:numdotdecimal" decimals="0" unitRef="USD">453,869</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--InterestAndOtherIncome_i01_zKdzXBdfMf86" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestAndOtherIncome" contextRef="From2023-07-012023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002153" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,103</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2154">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestAndOtherIncome" contextRef="From2023-07-012023-09-30" id="Fact002155" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,103</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestAndOtherIncome" contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002156" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,103</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2157">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestAndOtherIncome" contextRef="From2023-01-012023-09-30" id="Fact002158" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,103</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--FairValueAdjustmentOfWarrants_i01N_di_zfQly2l0YzQ5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of warrant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-07-012023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002160" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">592,853</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2161">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-07-012023-09-30" id="Fact002162" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">592,853</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002163" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">791,610</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2164">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-01-012023-09-30" id="Fact002165" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">791,610</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DerivativeGainLossOnDerivativeNet_i01_z0jMSfMEIBrf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of derivative financial instruments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2023-07-012023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002167" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,394</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2168">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2023-07-012023-09-30" id="Fact002169" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,394</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002170" format="ixt:numdotdecimal" decimals="0" unitRef="USD">198,551</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2171">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2023-01-012023-09-30" id="Fact002172" format="ixt:numdotdecimal" decimals="0" unitRef="USD">198,551</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_i01N_di_zrCWwUMRlmK6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Amortization of debt discount and issuance cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="From2023-07-012023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002174" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,331,030</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2175">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="From2023-07-012023-09-30" id="Fact002176" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,331,030</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002177" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,881,622</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2178">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="From2023-01-012023-09-30" id="Fact002179" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,881,622</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i01_zvopJgfCJMXa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Extinguishment of debt liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2023-07-012023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002181" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,058,062</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2023-07-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact002182" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,721,007</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2023-07-012023-09-30" id="Fact002183" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,779,069</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002184" format="ixt:numdotdecimal" decimals="0" unitRef="USD">71,436</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact002185" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,721,007</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2023-01-012023-09-30" id="Fact002186" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,649,571</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--OtherNonoperatingIncome_i01_z2X83oyskdr1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Other income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncome" contextRef="From2023-07-012023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002188" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,931</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2189">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncome" contextRef="From2023-07-012023-09-30" id="Fact002190" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,931</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncome" contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002191" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,483</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2192">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncome" contextRef="From2023-01-012023-09-30" id="Fact002193" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,483</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OtherNonoperatingExpense_i01N_di_zeNbxJg4tk4a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Other expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingExpense" contextRef="From2023-07-012023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002195" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,578</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2196">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingExpense" contextRef="From2023-07-012023-09-30" id="Fact002197" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,578</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingExpense" contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002198" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,008</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2199">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingExpense" contextRef="From2023-01-012023-09-30" id="Fact002200" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,008</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--OtherNonoperatingIncomeExpense_i01T_zVZVcNoeOdq3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Total other (expense) income, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2023-07-012023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002202" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,882,017</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2023-07-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact002203" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,721,007</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2023-07-012023-09-30" id="Fact002204" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,603,024</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002205" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,272,088</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact002206" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,721,007</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2023-01-012023-09-30" id="Fact002207" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,993,095</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--NetIncomeLoss_iT_zhajvwVO5DA" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002209" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,904,356</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact002210" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,721,007</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012023-09-30" id="Fact002211" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,625,363</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002212" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,313,378</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact002213" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,721,007</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-09-30" id="Fact002214" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,034,385</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<ix:exclude><!-- Field: Page; Sequence: 123; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NeurAxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Statements
of Cash Flows</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20230101__20230930__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zpfSAs8uMX59" style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20230101__20230930__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zh943Te2cEQi" style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20230101__20230930_zOLmPb5LR2vi" style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="10" style="text-align: center">(Unaudited)</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">For the Nine Months Ended September 30, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">As Reported</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Adjustments</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">As Restated</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zNFzEruN5ZAl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Cash flows from operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NetIncomeLoss_i01_z10UihQjbdJe" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 52%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002220" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">9,313,378</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact002221" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,721,007</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-01-012023-09-30" id="Fact002222" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,034,385</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zzi9wRZSgvSg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Adjustments to reconcile net loss to net cash used by operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_i02_ztAF6zIZgWCe" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Amortization of debt discount and issuance cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002228" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,881,622</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2229">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="From2023-01-012023-09-30" id="Fact002230" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,881,622</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DepreciationDepletionAndAmortization_i02_zvs5dEhNDTb8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002232" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,290</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2233">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2023-01-012023-09-30" id="Fact002234" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,290</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ProvisionForDoubtfulAccounts_i02_zyoj3shroaxf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Provision for losses on accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002236" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,380</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2237">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="From2023-01-012023-09-30" id="Fact002238" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,380</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--NoncashLeaseExpense_i02_zhsMTmwQdue2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Non-cash lease expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="NRXS:NoncashLeaseExpense" contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002240" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,339</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2241">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="NRXS:NoncashLeaseExpense" contextRef="From2023-01-012023-09-30" id="Fact002242" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,339</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--NoncashInterestExpense_i02_zLbjShbxGpVd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Non-cash interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="NRXS:NoncashInterestExpense" contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002244" format="ixt:numdotdecimal" decimals="0" unitRef="USD">260,777</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2245">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="NRXS:NoncashInterestExpense" contextRef="From2023-01-012023-09-30" id="Fact002246" format="ixt:numdotdecimal" decimals="0" unitRef="USD">260,777</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ShareBasedCompensation_i02_zNJigtRGPydl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Stock based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2248">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2249">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2250">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i02N_di_zuQcvCuJFq3d" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Extinguishment of derivative liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002252" format="ixt:numdotdecimal" decimals="0" unitRef="USD">71,436</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" id="Fact002253" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,721,007</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2023-01-012023-09-30" id="Fact002254" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,649,571</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--IssuanceOfCommonStockForNoncashConsideration_i02_zKSGiwUwIzh9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Issuance of common stock for non-cash consideration</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="NRXS:IssuanceOfCommonStockForNoncashConsideration" contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002256" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,550,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2257">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="NRXS:IssuanceOfCommonStockForNoncashConsideration" contextRef="From2023-01-012023-09-30" id="Fact002258" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,550,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--FinanceCharges_i02_zsF40VPD0lNi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Finance charges</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="NRXS:FinanceCharges" contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002260" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,772</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2261">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="NRXS:FinanceCharges" contextRef="From2023-01-012023-09-30" id="Fact002262" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,772</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DerivativeGainLossOnDerivativeNet_i02N_di_zo7ywTDh0YT4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Change in fair value of derivative liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002264" format="ixt:numdotdecimal" decimals="0" unitRef="USD">198,551</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2265">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2023-01-012023-09-30" id="Fact002266" format="ixt:numdotdecimal" decimals="0" unitRef="USD">198,551</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--FairValueAdjustmentOfWarrants_i02_zjyPkTjTyWf5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Change in fair value of warrant liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002268" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">791,610</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2269">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-01-012023-09-30" id="Fact002270" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">791,610</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i01B_ztYvW3n5HgJl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncreaseDecreaseInAccountsReceivable_i02N_di_zWuX2vDKsDY4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left">Accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002276" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">35,637</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2277">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2023-01-012023-09-30" id="Fact002278" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">35,637</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--IncreaseDecreaseInInventories_i02N_di_zrUt99gZAia7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt">Inventory</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002280" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,603</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2281">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2023-01-012023-09-30" id="Fact002282" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,603</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i02N_di_zPv9dtAskbh4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left">Prepaids and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002284" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,967</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2285">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2023-01-012023-09-30" id="Fact002286" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,967</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--IncreaseDecreaseInAccountsPayable_i02_zdEpC1lp1Qpl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002288" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,025,467</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2289">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2023-01-012023-09-30" id="Fact002290" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,025,467</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--IncreaseDecreaseInAccruedLiabilities_i02_zFHeer2YnTL9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002292" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">415,181</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2293">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2023-01-012023-09-30" id="Fact002294" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">415,181</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_ecustom--IncreaseDecreaseInCustomerDeposit_i02_zjNmO8vtUBp1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left">Customer deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="NRXS:IncreaseDecreaseInCustomerDeposit" contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002296" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,798</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2297">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="NRXS:IncreaseDecreaseInCustomerDeposit" contextRef="From2023-01-012023-09-30" id="Fact002298" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,798</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_i02_zDKLy320Bbg8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left; padding-bottom: 1.5pt">Operating lease liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002300" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">25,047</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2301">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2023-01-012023-09-30" id="Fact002302" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">25,047</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iT_z7dem0rvwNCl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Net cash used by operating activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002304" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,064,419</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2305">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-01-012023-09-30" id="Fact002306" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,064,419</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zOTi5ssP65Ch" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Cash flows from investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_z5M3aprakQZ1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Additions to property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002312" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,741</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2313">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2023-01-012023-09-30" id="Fact002314" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,741</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--PaymentsToAcquireIntangibleAssets_i01N_di_zKWMrYHZxS03" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Additions to intangible assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002316" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2317">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2023-01-012023-09-30" id="Fact002318" format="ixt:numdotdecimal" decimals="0" unitRef="USD">41,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--NetCashProvidedByUsedInInvestingActivities_iT_ziEHqD2gApR" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Net cash used by investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002320" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">55,741</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2321">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2023-01-012023-09-30" id="Fact002322" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">55,741</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_ztFbpQvVc30j" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Cash flows from financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_z6X2ddTMc9d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Proceeds from issuance of common stock, net of issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002328" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,464,642</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2329">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-01-012023-09-30" id="Fact002330" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,464,642</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--OfferingCostsInAdvanceOfSaleOfCommonStock_i01_zlYzRftG3QYi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Offering costs in advance of sale of common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="NRXS:OfferingCostsInAdvanceOfSaleOfCommonStock" contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002332" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,417,185</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2333">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="NRXS:OfferingCostsInAdvanceOfSaleOfCommonStock" contextRef="From2023-01-012023-09-30" id="Fact002334" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,417,185</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--RepaymentsOfNotesPayable_iN_di_zfRmgUe6Bybi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Principal payments on notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002336" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,487,578</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2337">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" contextRef="From2023-01-012023-09-30" id="Fact002338" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,487,578</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--ProceedsFromNotesPayable_i01_z0L6AF8g7nia" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Proceeds from notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002340" format="ixt:numdotdecimal" decimals="0" unitRef="USD">159,831</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2341">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="From2023-01-012023-09-30" id="Fact002342" format="ixt:numdotdecimal" decimals="0" unitRef="USD">159,831</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ProceedsFromConvertibleDebt_i01_zUBKSXgYTFe3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Proceeds from convertible notes, net of fees</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002344" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,908,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2345">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2023-01-012023-09-30" id="Fact002346" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,908,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NetCashProvidedByUsedInFinancingActivities_iT_zqeQpze91eo9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002348" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,627,710</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2349">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-01-012023-09-30" id="Fact002350" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,627,710</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_zucVxobTAm4c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Net decrease in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002352" format="ixt:numdotdecimal" decimals="0" unitRef="USD">507,550</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2353">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2023-01-012023-09-30" id="Fact002354" format="ixt:numdotdecimal" decimals="0" unitRef="USD">507,550</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_zSnT6Ik9cfKe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Cash and cash equivalents at beginning of period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember" id="Fact002356" format="ixt:numdotdecimal" decimals="0" unitRef="USD">253,699</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2357">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2022-12-31" id="Fact002358" format="ixt:numdotdecimal" decimals="0" unitRef="USD">253,699</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_zH5FxgHwPqVi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Cash and cash equivalents at end of period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember" id="Fact002360" format="ixt:numdotdecimal" decimals="0" unitRef="USD">761,249</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2361">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2023-09-30" id="Fact002362" format="ixt:numdotdecimal" decimals="0" unitRef="USD">761,249</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_z4l6shcK1Zsd" style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

</ix:nonNumeric><p id="xdx_81E_zFAM7BGXjGIk" style="font: 10pt Times New Roman, Times, Serif; display: none; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 124; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 0pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 0pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="s_020"></span>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NEURAXIS,
    INC.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">Dated:
April 16, 2024</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Brian Carrico</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian
    Carrico</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
April 16, 2024</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Timothy R. Henrichs</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Timothy
    R. Henrichs</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 36%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Signature</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 20%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Brian Carrico</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer and Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">April  16, 2024</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian
    Carrico</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Timothy R. Henrichs</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer (Principal</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">April  16, 2024</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Timothy
    R. Henrichs</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial
    Officer and Principal Accounting Officer)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Christopher Robin Brown</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">April  16, 2024</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher
    Robin Brown</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Bradley Mitch Watkins</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">April  16, 2024</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bradley
    Mitch Watkins</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/
    Beth Keyser</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">April  16, 2024</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Beth
    Keyser</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><i>/s/
    Kristin Ferge</i></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif">April
    16, 2024</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">Kristin Ferge</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 125; Options: NewSection Last; Value: 90 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>







































<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KgkAQhZ/Adxj2Wky3nwsvE4vIIiSi2yXHWNIdmd3KHqm3bFOiYWAYzvnOESIUa1rpBhnOy7KAI7ZdoxxCiTUymgt6R7bZpuBviVdtHSvjhvcHZuQZ9Mw8klJ5YbA+tMUqhXg6kclEziCepfMFHHYi+OoZmVpXaJxWDShTwYGpY41O8WtMOKqeDLWvoeqEbDWZFJIoHuU3yDiRsKeHehLfLBRFJoJwmECsme6dd+W9Q/MlIW+w9XV2pP8bfAAGqEqN -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>ex4-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
4.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DESCRIPTION
OF THE REGISTRANT&rsquo;S SECURITIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of April 12, 2024, Neuraxis, Inc. (the &ldquo;Company&rdquo;) has one class of securities registered under Section 12 of the
Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;): common stock, par value $0.001 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following description summarizes the most important terms of our common stock. This summary does not purport to be complete and is qualified
in its entirety by the provisions of our certificate of incorporation a copy of which have been incorporated by reference as an exhibit
to the Annual Report on Form 10-K of which this Exhibit 4.1 is a part. For a complete description of our capital stock, you should refer
to our certificate of incorporation and to the applicable provisions of Delaware General Corporation Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
certificate of incorporation authorizes us to issue up to 101,120,000 shares of capital stock, consisting of 100,000,000 shares of common
stock, par value $0.001 per share, and 1,120,000 shares of preferred stock, par value $0.001 per share, 1,000,000 of which are designated
as Series A Preferred Stock and 120,000 of which are designated as Series Seed Preferred Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
shares of common stock trade on the NYSE American under the symbol &ldquo;NRXS.&rdquo; The outstanding common stock are fully paid and
nonassessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
holders of common stock are entitled to one vote per share on each matter submitted to a vote at any meeting of stockholders. Shares
of common stock do not carry cumulative voting rights and, therefore, a majority of the shares of outstanding common stock will be able
to elect the entire board of directors and, if they do so, minority stockholders would not be able to elect any persons to the board
of directors. Our bylaws provide that a majority of our issued and outstanding shares constitutes a quorum for stockholders&rsquo; meetings,
except respecting certain matters for which a greater percentage quorum is required by statute or the bylaws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stockholders have no pre-emptive rights to acquire additional shares of common stock or other securities. The common stock is
not subject to redemption and carries no subscription or conversion rights. In the event of our liquidation, the shares of common stock
are entitled to share equally in corporate assets after satisfaction of all liabilities and after the payment of liquidation preferences,
if any, on any outstanding shares of preferred stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of common stock are entitled to receive such dividends as the board of directors may, from time to time, declare out of funds legally
available for the payment of dividends. We seek growth and expansion of our business through the reinvestment of profits, if any, and
do not anticipate that we will pay dividends in the foreseeable future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Dividend
Rights</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to preferences that may apply to any shares of preferred stock outstanding at the time, the holders of our common stock are entitled
to receive dividends out of funds legally available if our Board, in its discretion, determines to declare and pay dividends and then
only at the times and in the amounts that our Board may determine.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Voting
Rights</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Holders
of our common stock are entitled to one vote for each share held on all matters properly submitted to a vote of stockholders on which
holders of common stock are entitled to vote. We have not provided for cumulative voting for the election of directors in our Certificate
of Incorporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>No
Pre-emptive or Similar Rights</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is not entitled to pre-emptive rights, and is not subject to conversion, redemption or sinking fund provisions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Right
to Receive Liquidation Distributions</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we become subject to a liquidation, dissolution or winding-up, the assets legally available for distribution to our stockholders would
be distributable ratably among the holders of our common stock and any participating preferred stock outstanding at that time, subject
to prior satisfaction of all outstanding debt and liabilities and the preferential rights of and the payment of liquidation preferences,
if any, on any outstanding shares of preferred stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 33; Options: Last -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>ex31-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
OF PRINCIPAL EXECUTIVE OFFICER<BR>
PURSUANT TO SECTION 302<BR>
OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Brian Carrico, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have reviewed this annual report on Form 10-K of Neuraxis, Inc. (the &ldquo;registrant&rdquo;);</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
    the period covered by this report;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
    respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in
    this report;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
    (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
    Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
    within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such internal controls over financial reporting, or caused such internal control over financial reporting to be designed under our
    supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
    for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about
    the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
    and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
    or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
    reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing
    the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
    reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
    and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
     April 16, 2024</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Brian Carrico</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian
    Carrico</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Principal
    Executive Officer)</I></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>ex31-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
OF PRINCIPAL EXECUTIVE OFFICER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURSUANT
TO SECTION 302</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OF
THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Timothy R. Henrichs, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have reviewed this annual report on Form 10-K of Neuraxis, Inc. (the &ldquo;registrant&rdquo;);</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to
    the period covered by this report;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
    respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in
    this report;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
    (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
    Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
    within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such internal controls over financial reporting, or caused such internal control over financial reporting to be designed under our
    supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
    for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about
    the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
    and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
    or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
    reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing
    the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
    reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
    and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    April 16, 2024</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Timothy R. Henrichs</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Timothy
    R. Henrichs</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer (Principal Financial Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>ex32-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Annual Report on Form 10-K of Neuraxis, Inc. (the &ldquo;Company&rdquo;) for the year ended December 31, 2023, as
filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, Brian Carrico, Chief Executive Officer
of the Company and I, Timothy R. Henrichs, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of
    the Company.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    April 16, 2024</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Brian Carrico</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brian
    Carrico</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer (Principal Executive Officer)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    April 16, 2024</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Timothy R. Henrichs</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Timothy
    R. Henrichs</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer (Principal Accounting and Financial Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. &sect; 1350,and is not being filed for
purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing
of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed
original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the
signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will
be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>6
<FILENAME>ex97-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
97.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NeurAxis,
Inc. Compensation Recovery Policy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.
Purpose.</B> The purpose of this Compensation Recovery Policy of the Company (as amended from time to time, the &ldquo;<U>Policy</U>&rdquo;),
dated as of November 30, 2023 to describe the circumstances in which current and former Executive Officers will be required to repay
or return Erroneously Awarded Compensation to members of the Company Group. The Company has adopted this Policy to comply with Section
954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, as codified by Section 10D of the Exchange Act, Exchange
Act Rule 10D-1 promulgated thereunder, and the rules and requirements of the NYSE American (including Section 811 of the NYSE American
Company Guide) (such legal requirements, and rules and requirements of the NYSE American, collectively, the &ldquo;<U>SEC/NYSE American
Clawback Rules</U>&rdquo;). Each Executive Officer shall be required to sign and return to the Company the form of acknowledgment to
this Policy in the form attached hereto as <U>Exhibit A</U> pursuant to which such Executive Officer will agree to be bound by the terms
and comply with this Policy.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.
Administration.</B> This Policy shall be administered by the Committee. The Committee is authorized to interpret and construe this Policy
and to make all determinations necessary, appropriate, or advisable for the administration of this Policy, and any such determinations
made by the Committee shall be in the Committee&rsquo;s sole discretion and shall be final and binding on all affected individuals. Except
as otherwise required by applicable legal requirements or the rules and requirements of the NYSE American, any determinations of the
Committee hereunder need not be uniform with respect to one or more Executive Officers (whether current and/or former).</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.
Definitions.</B> For purposes of this Policy, the following capitalized terms shall have the meanings set forth below:</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
&ldquo;<U>Accounting Restatement</U>&rdquo; shall mean an accounting restatement due to the material noncompliance of the Company with
any financial reporting requirement under the securities laws, including any required accounting restatement (i) to correct an error
in previously issued financial statements (a &ldquo;Big R&rdquo; restatement) that is material to the previously issued financial statements,
or (ii) that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current
period (a &ldquo;little r&rdquo; restatement).</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
&ldquo;<U>Board</U>&rdquo; shall mean the Board of Directors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
&ldquo;<U>Clawback Eligible Incentive Compensation</U>&rdquo; shall mean all Incentive-Based Compensation Received by any current or
former Executive Officer on or after the NYSE American Effective Date, provided that:</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
such Incentive-Based Compensation is Received after such individual began serving as an Executive Officer;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
such individual served as an Executive Officer at any time during the performance period for such Incentive-Based Compensation;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
such Incentive-Based Compensation is Received while the Company has a class of securities listed on the NYSE American; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
such Incentive-Based Compensation is Received during the applicable Clawback Period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
&ldquo;<U>Clawback Period</U>&rdquo; shall mean, with respect to any Accounting Restatement, the three completed fiscal years of the
Company immediately preceding the Restatement Date and any transition period (that results from a change in the Company&rsquo;s fiscal
year) of less than nine months within or immediately following those three completed fiscal years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
&ldquo;<U>Committee</U>&rdquo; shall mean the Compensation Committee of the Board.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
&ldquo;<U>Common Stock</U>&rdquo; shall mean the common stock, par value $0.001 per share, of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
&ldquo;<U>Company</U>&rdquo; shall mean NeurAxis, Inc., a Delaware corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
&ldquo;<U>Company Group</U>&rdquo; shall mean the Company, together with each of its direct and indirect subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
&ldquo;<U>Erroneously Awarded Compensation</U>&rdquo; shall mean, with respect to any current or former Executive Officer in connection
with any Accounting Restatement, the amount of Clawback Eligible Incentive Compensation Received by such current or former Executive
Officer that exceeds the amount of Clawback Eligible Incentive Compensation that otherwise would have been Received by such current or
former Executive Officer had such Clawback Eligible Incentive Compensation been determined based on the restated amounts as reflected
in connection with such Accounting Restatement, taking into account any discretion that the Committee had applied to determine the amount
of Clawback Eligible Incentive Compensation originally Received and computed without regard to any taxes paid.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
&ldquo;<U>Exchange Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
&ldquo;<U>Executive Officer</U>&rdquo; shall mean any officer as defined in Rule 10D-1(d) (or any successor provision thereof) under
the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
&ldquo;<U>Financial Reporting Measures</U>&rdquo; shall mean measures that are determined and presented in accordance with the accounting
principles used in preparing the Company&rsquo;s financial statements, and any other measures that are derived wholly or in part from
such measures. For purposes of this Policy, stock price and total shareholder return (and any measures that are derived wholly or in
part from stock price or total shareholder return) shall be considered Financial Reporting Measures. For the avoidance of doubt, a Financial
Reporting Measure need not be presented within the Company&rsquo;s financial statements or included in a filing with the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)
&ldquo;<U>Incentive-Based Compensation</U>&rdquo; shall mean any compensation that is granted, earned or vested based wholly or in part
upon the attainment of a Financial Reporting Measure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)
&ldquo;<U>NYSE American</U>&rdquo; shall mean NYSE American LLC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)
&ldquo;<U>NYSE American Effective Date</U>&rdquo; shall mean October 2, 2023 (which is the effective date of the final NYSE American
listing standards).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)
&ldquo;<U>Received</U>&rdquo; shall mean when Incentive-Based Compensation is received, and Incentive-Based Compensation shall be deemed
received in the Company&rsquo;s fiscal period during which the Financial Reporting Measure specified in the Incentive-Based Compensation
award is attained, even if payment or grant of the Incentive-Based Compensation occurs after the end of that period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)
&ldquo;<U>Restatement Date</U>&rdquo; shall mean the earlier to occur of (i) the date the Board, a committee of the Board or the officers
of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the
Company is required to prepare an Accounting Restatement, or (ii) the date a court, regulator or other legally authorized body directs
the Company to prepare an Accounting Restatement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r)
&ldquo;<U>SEC</U>&rdquo; shall mean the U.S. Securities and Exchange Commission.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recovery
    of Erroneously Awarded Compensation.</B></FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
In the event that the Company is required to prepare an Accounting Restatement, (i) the Committee shall determine the amount of any Erroneously
Awarded Compensation for each applicable current or former Executive Officer (whether or not such individual is serving as an Executive
Officer at such time) (the &ldquo;<U>Applicable Executives</U>&rdquo;) in connection with such Accounting Restatement, and (ii) the Company
will reasonably promptly require the recovery of such Erroneously Awarded Compensation from any such Applicable Executive, and any such
Applicable Executive shall surrender such Erroneously Awarded Compensation to the Company, at such time(s), and via such method(s), as
determined by the Committee in accordance with the terms of this Policy.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
For Incentive-Based Compensation based on (or derived from) stock price or total shareholder return where the amount of Erroneously Awarded
Compensation is not subject to mathematical recalculation directly from the information in the applicable Accounting Restatement, (i)
such amount shall be determined by the Committee based on a reasonable estimate of the effect of the Accounting Restatement on the stock
price or total shareholder return upon which the Incentive-Based Compensation was Received, and (ii) the Company will maintain documentation
of the determination of that reasonable estimate and provide such documentation to the NYSE American.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
The Committee shall determine, in its sole discretion, the method(s) for recovering any Erroneously Awarded Compensation from any Applicable
Executive, which may include one or more of the following:</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
requiring one or more cash payments to the Company Group from such Applicable Executive, including, but not limited to, the repayment
of cash Incentive-Based Compensation previously paid by the Company Group to such Applicable Executive;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
seeking recovery of any gain realized on the vesting, exercise, settlement, sale, transfer or other disposition of any equity-based awards
previously made by the Company to such Applicable Executive and/or, subject to applicable legal requirements, otherwise requiring the
delivery to the Company of shares of Common Stock held by such Applicable Executive;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
withholding, reducing or eliminating future cash compensation (including cash incentive payments), future equity awards and/or other
benefits or amounts otherwise to be paid or awarded by the Company Group to such Applicable Executive;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
offsetting amounts against compensation or other amounts otherwise payable by the Company Group to any Applicable Executive;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
cancelling, adjusting or offsetting against some or all outstanding vested or unvested equity awards of the Company held by such Applicable
Executive; and/or</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)
taking any other remedial and recovery actions with respect to such Applicable Executive permitted by applicable legal requirements and
the rules and regulations of the NYSE American, as determined by the Committee.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Notwithstanding anything herein to the contrary, the Company shall not be required to recover Erroneously Awarded Compensation from any
Applicable Executive pursuant to the terms of this Policy if both (1) the Committee determines that such recovery would be impracticable,
and (2) any of the following conditions is met:</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
the direct expenses paid to a third party to assist in enforcing the Policy would exceed the amount to be recovered, provided that, before
concluding that it would be impracticable to recover any amount of Erroneously Awarded Compensation based on expense of enforcement pursuant
to this clause (i), the Company has (x) made a reasonable attempt to recover such Erroneously Awarded Compensation, (y) documented such
reasonable attempt(s) to recover, and (z) provided such documentation to the NYSE American;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
recovery would violate home country law where that law was adopted prior to November 28, 2022, provided that, before determining that
it would be impracticable to recover any amount of Erroneously Awarded Compensation based on violation of home country law, the Company
has obtained an opinion of home country counsel, acceptable to the NYSE American, that recovery would result in such a violation, has
provided copy of the opinion is provided to the NYSE American; or</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the
Company Group, to fail to meet the requirements of 26 U.S.C. 401(a)(13) or 26 U.S.C. 411(a) and regulations thereunder.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.
No Indemnification, Etc.</B> The Company Group shall not (x) indemnify any current or former Executive Officer against (i) the loss of
any Erroneously Awarded Compensation that is repaid, returned or recovered pursuant to the terms of this Policy, or (ii) any claims relating
to the Company Group&rsquo;s enforcement of its rights under this Policy, or (y) pay or reimburse any current or former Executive Officers
for insurance premiums to recover losses incurred under this Policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.
Supersedure.</B> This Policy will supersede any provisions in (x) any agreement, plan or other arrangement applicable to any member of
the Company Group, and (y) any organizational documents of any entity that is part of Company Group that, in any such case, (a) exempt
any Incentive-Based Compensation from the application of this Policy, (b) waive or otherwise prohibit or restricts the Company Group&rsquo;s
right to recover any Erroneously Awarded Compensation, including, without limitation, in connection with exercising any right of setoff
as provided herein, and/or (c) require or provide for indemnification to the extent that such indemnification is prohibited under <U>Section
5</U> above.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.
Amendment; Termination; Interpretation.</B> The Committee may amend or terminate this Policy at any time, subject to compliance with
all applicable legal requirements and the rules and requirements of the NYSE American. It is intended that this Policy be interpreted
in a manner that is consistent with the SEC/NYSE American Clawback Rules. This Policy is separate from, and in addition to, any other
compensation recovery or recoupment policy of the Company or any applicable provisions of plans, agreements, awards or other arrangements
of the Company that provide for the recoupment or recovery of compensation from Executive Officers that is voluntarily adopted by the
Company and intended to provide for discretionary recoupment beyond the scope of this Policy and the SEC/NYSE American Clawback Rules.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.
Other Recoupment Rights; No Additional Payments.</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
Subject to <U>Section 8(b)</U> of this Policy below, any right of recoupment under this Policy is in addition to, and not in lieu of,
any other remedies or rights of recoupment that may be available to the Company Group pursuant to (i) the terms of any recoupment provisions
in any employment agreement, incentive or equity compensation plan or award or other agreement, (ii) any other legal requirements, including,
but not limited to, Section 304 of Sarbanes-Oxley Act of 2002, and (iii) any other legal rights or remedies available to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Notwithstanding anything herein to the contrary, to prevent duplicative recovery:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
to the extent that the amount of any Erroneously Awarded Compensation is recovered from any current or former Executive Officers under
this Policy, the Company will not be entitled to recover any such amounts under any other compensation recovery or recoupment policy
of the Company or any applicable provisions of plans, agreements, awards or other arrangements of the Company that provide for the recoupment
or recovery of compensation from Executive Officers; and</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
to the extent that any Erroneously Awarded Compensation includes any amounts that have been actually reimbursed to the Company Group
from any Applicable Executive pursuant to Section 304 of the Sarbanes-Oxley Act (any such amounts that have been reimbursed to the Company
Group, the &ldquo;<U>Applicable SOX Recoupment Amount</U>&rdquo;), the amount of any Erroneously Awarded Compensation to be recovered
from any such Applicable Executive shall be reduced by the Applicable SOX Recoupment Amount.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.
Successors.</B> This Policy shall be binding and enforceable against all current and former Executive Officers and their beneficiaries,
heirs, executors, administrators or other legal representatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Exhibit
A</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Form
of Acknowledgement</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
signing below, the undersigned acknowledges and confirms that the undersigned has received and reviewed a copy of the NeurAxis, Inc.
Compensation Recovery Policy (such policy, as amended from time to time, the &ldquo;Policy&rdquo;). Capitalized terms used but not otherwise
defined in this acknowledgement shall have the meanings ascribed to such terms in the Policy.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By
signing this acknowledgement, the undersigned acknowledges and agrees that the undersigned is and will continue to be subject to the
Policy and that the Policy will apply both during and after the undersigned&rsquo;s employment with the Company Group. Further, by signing
below, the undersigned agrees to abide by the terms of the Policy, including, without limitation, by returning any Erroneously Awarded
Compensation to the Company group to the extent required by the Policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Print
    Name</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>form10-k_001.jpg
<TEXT>
begin 644 form10-k_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #U G # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#U&G+TIM.7
MI0 57:[MA>"S-Q']J*[UAS\Q'K5@8&<YP.3CDUY/.FN2^(V\81Z9)LAO0B-G
MY_('RL G<'K6M."EUL1*5MD>FI?V+R(L=U$SF0HHSR6')'UJQ)+%:P//*P2%
M1EW;L/>O-M(M9SJNFRBUF5#J]Q("T9&%*\&I/'CWTFHZC:S/?BW:T3[%';(2
MDKD_,'JO9+FM<7/I>QZ, )5613N5AD,.A':E$9KS26#6FMM9N8KG4$-E! +:
MWCX4C:-V!W(I+[7-4N8M1N;>6]BL3);*6*%7"<>84![TW13=DPY^MCTSRSZ&
MD=EB1I'8(JC+,QX KR*;4M5FL+H6>HZ@]O#?,D8D!W,FT;0Q R#77:K<7<WP
MN:>6.>*=X%$JR_? +#.>G:IE2Y;7>XXSO?0ZFVN[6\++:S),R@,RJ<[0>A_&
MI(9XKAY!#*LAB;;)@_=:O--0M+^TU/6-2TR2[@,7V/R$@7"2J< \8Y %.O;O
M4+:[F2>2\M]/DU1Q.]NN)"-@V@<?=SWJ_8ZVBR>>RV/2/-C%RML9%%P5++$?
MO%?6HYK^SMY'BFNHDD0 LI;E<\ _C7E>GQZCK4=I?-=WWG1V5SMN%^^Q#?*I
M.*M70U.XEDNW@G-S)8V8=_*SEMW/&.OK2]BN^H<]];'J?EG;G'&/P^M103PW
M,'VB"9)(>?W@/R\=>?:O,3J^HKK\*3W]\MXVIF*2(?ZCRMIP!4=CINJ6^E00
MPRWZQWB7:RPC[J=2N!CC-/V'=C]IY'J2,LJAXV#H>0RG((IDUQ#:QB2XE6)&
M8(&;H6/05Y+]HUJWTW1X+.:^BMUM?D.QL^?NY4X':K.L_P!IWNH&+43?O=K?
M0&*W2,^1Y7&6SCKFE['S#G\CU)[B&.>.!Y%6:3)CC/\ %]*F(."HX)X!_I7*
M>,!>1ZUITEFLIVVTY+1IDA@O'/;FJWA!-4MM=MX[JZO)[>?3$N)/M!X$N><5
M/(N6]Q\UW:QT[:II]M<-#-?0)*"!L+<@^E.GU73K67RI[V&.08^1FYKA]7TN
M_GO=<GCB#6XG7S5,7[QD[E#0RI%KUQ*&EB@98C&6M?-+ *.I[5YSKU$[-'TL
M<KH-*7/=VUVWL=P=7TT3>2;ZW$G]TMWJS#/%+)(B2*[Q';(H/*D],UY_/Y#+
MKML]A--=7,JFU=83QP.<XXK:T%)(?'%_"&##[!";@CH9?4^^*VHR<]UT//QV
M$AAXQE![OKZ=+>MM3J90<@XJ,*WH:\QNM3UEO%4DD!U!(O,F1E<$@*%.TCC
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ML;:,YEGS\HDP..,5"HWBO>#G\CUC#8SBC! R17E5S?\ B4WO^F3:C%J@%O\
M8X((\PR XW[NWUKJ/"<%_-J^JWVHW5UN2X:.*W<XCVX'('?FATK*_,-3N]CK
ML'TJ&XN(;6+S9Y5B0$#<W3)Z5YC9S>);_P 5W5I+<W4$DDTJ,NUMBQ8^4CC
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M+_\ /Q/_ -^Z/8U>S%[2/<[-^<9J,CK[UR+?%#PQ_P _$_\ WZI/^%G^%_\
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MXQW8^5LYFDS0PV$A\JPZ@]JL"QN3IKZ@(Q]E201,^X<,?;TJKH5F5Z*3<I.
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M').3WR:9)XXU,S120P6EL(W>3RX8L*[L,%F]Z2IU.K'SP.HETRTDTV"62,"
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MX._\BQ>?]?)_E7BHKVKX/ _\(M=GL;HC]*Y<2_W;-Z*]X]#ZUXI\4>/&+_\
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M5UVS3YF<'U/3]*\<\$>&)O$^OQ0[3]DA(>XDQP!V'U-?1R(L:+$B[410%7T
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$@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>form10-k_002.jpg
<TEXT>
begin 644 form10-k_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $S G # 2(  A$! Q$!_\0
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MP5W+][CH>,4Z*V\2V@$<3JZD.Y,@5BS%C@$YX^7&,<>M '69HS7,RIKZS&:
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MM/\ \\!^=9=% &I_;3_\\!^=']M/_P \!^=9=% &I_;3_P#/ ?G1_;3_ //
M?G6710!J?VT__/!?SH_MI_\ G@/SK+HH U/[:?\ YX+_ -]4?VT__/ ?G671
M0!J?VT__ #P'YT?VT_\ SP'YUET4 :G]M/\ \\!^=']M/_SP'YUET4 :G]M/
M_P \!^=']M/_ ,\%_P"^JRZ* -3^VGQ_J%_[ZH_MI_\ G@/SK+HH U/[:?\
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M .> _.C^VG_YX#\ZR^:.: -3^VG_ .> _.C^VG_YX#\ZR^:.: -3^VG_ .>
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M;FB*Y\40Q,HLTD"AL"09)//.<_3B@#J**KV#W,EA ]XJI<,N9%48 /T[58H
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MW\M9@N1@L/E,?T.=WX5&MUXJMR(1:1R)'(J>:R;F*XY;KR3^E &UC6/73_\
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MM9&JPZG+J5DUD[+;QI(TPWE0[#[JDCUK),_BJ2XCG%HR[,83 57/?(R?_KT
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M[?\ CM']B'_GM_X[6O12 R/[$/\ SV_\=H_L0_\ /;_QVM>B@#(_L0_\]O\
MQVC^Q#_SV_\ ':UZ* ,C^Q#_ ,]OTH_L4]?/Y]=M:]% S(_L0_\ /?CTVT?V
M(?\ GO\ ^.UKT4 9']B'_GO^E']B'_GM_P".UKT4",C^Q#_SV_\ ':/[$/\
MSV_\=K7HH R/[$/_ #W_ /':/[$./]?^E:]% S(_L0_\]_\ QVC^Q3_SW_\
M':UZ,4 9']BG_GO_ ..T?V(?^>W_ ([6OBC%%P,C^Q#_ ,]O_':/[$/_ #V_
M\=K7HH$9']B'_GM_X[1_8G'^N_2M>B@9D?V(?^>__CM']B'_ )[_ /CM:]&*
M ,C^Q#_SW_2C^Q#_ ,]O_':U\44",C^Q#_SV_P#':/[$/_/;_P =K7HH R/[
M$/\ SV_\=H_L0_\ /?\ \=K7HH&9']B'_GO_ ..T?V(?^>_Z5KT4 9']B?\
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MEV\ 'K^=)?6.J7QLIP=LBH-PWF/RWW EL=\@$8K1L-;L[ZWGG1C'% VUVDP
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MSYVP1\N < >N<C/M0!?D\.:=++$_EL%1=NP,=K#L#ZTC^&-)=&0VN$;!*AB
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M!R3CH.:>^BV4B6ZRH7^SC:A)QD=<''7GFJ$%WK%GI^HSWL >99,P)NRNT@<
M@9_&DO;G5)FL9K9)E5T!*Q $;]PR'R,[=N: +\^B65SYGF^:Y=0A8R'( (.!
MZ<BM,8  ]*YB]?Q')<WC6D(2)X,6_P P&TYZX/\ '[=*Z&S\TV4!G4B7RUW@
M]=V.: )Z*** $/2JEQI]O=7$4\@?S(@P0JY&,\&K9Z5AW\FI1ZU%Y*SFW&T[
M8P"C#)W[N^<8QB@"8^'=.;S=R2/YLGF,6D).[&#C\.*F.E0MJ4=]N82QKL5<
M# 'Y9K N[CQ&_P!H\J&53YV4*+]U0#A<=\\'/J:VVU&=-8ALC #$T>6D).0W
MITQ^M #HM%LH%D,(DC,G5DD(('H/0<GBI+32K2RG$L"%&$0BQN)&T$GI]2:Q
M[677/(NT\N9[AEQ&9P JR9.=I'\.-N/>I-+.O&_M/ML;"V%N5?YER9./F;T/
M7@4 ='12#I2T %!Z44AZ&@#*&@:<$=%B90YR<2$8QTQZ8SQZ5+::196ERL\,
M3*ZIL7+$A1WP.V?UK%2;61IU^)&O!/Y8V.(U8K(,[@@[KC&,U=TM]3;57^TB
M<0[6+"0#8.FS;COC.: -ZBBB@ HHHH BEMX971Y(D=D.5+#)7Z5**@G^T^9'
MY"Q%"?GWDY ]JF' H 6BBB@ HHHH **** $-1PP10!O*C1-QRVU<9/K4AJ*W
M^T?/]H6(<_+Y9/3WS0!-1110 4444 %%%% $5Q<PVEM)<3N$BC4L['L!5&37
M]+CF$3W2JQ56!(."&&1S[U/J.GQ:E:_9K@MY18,RJV-V#G!]JSH_"U@B2*3*
M[,%56=LF,*> /\: -S.>E&*11C\L4Z@ HHHH **** "BBB@ HHHH *JWFHVM
MCY?VB79YC;5R#UJR1D51U#3C?&#-S)$D3[RB@$28Z!LCI0 XZI9+<S6[7"K)
M"I>0'^$#KS5B"XBNK>.>%P\4BAD8=P>AK(D\-6<]U-/<22RM,,.,A<]/3Z#C
MI2RZ"&33XHIV5++[N_)+?B"* +RZI9-=R6HG7SHP2RX/&.M1P:YI]Q)#'#/N
M>5F55VG.1UR.U1#18TU![R.XE1B68+@$*S8#$9'? J*+P^D8@#W<TIAD\TNR
MJ&=LYY8#- &W10.E% !110>E %)=5LFEN(Q,-UN,R#!X']:C@UO3[F:*&&Y5
MI)1E5P??KZ'@\>U1II3I<W,XOI]\YZE5R@[!3CH.M,L_#]K:3P3Y,DL(;:S
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MRI(&))V;"I)/?%4IM+EDU*6[6:) T31 >7R V,DG.">.*KV'AYK":UD6:)C
M[L<H=V&7;@'/\Z -SM1110 4444 ,9(@"S)&!U+%1V[FF13VLSHT4D#LRDIL
M()(Z''M3YD:2"1$V;F4@;UW+GW'<5E6.C/9W-K.9;<O$CK(R1$&0L<YZ\#VH
M T5@M+5'<10Q*1EVP "/]J@36@CB?S+<*Y_=G(PQ]JI6]C?*MZLUPK^>V8Q(
MWF*OL1@<54D\.226EG UVFVV8L"(R#R<GOV[9_&@9N1O$X8PLC ,0Q3!&X=>
MG>GU3TVQ:PAFC+1E7F>51&FT*&.<?_7JY0(*9*\<<3/,R)$HRS.< #WI]07L
M,L]G-% \:2LN%>1-ZJ?4CO0 )+:22"..2W9RH8*I7.WL<#M2AK7S%"F .6(4
M#;G(Z@>]9-KX?DM)DDBN8DVY(VQG.XKM/.>GH/6ELM >RDLW%Q&PMI6D&Y"3
MAA@@$G(SU/O0!K+;6\,CSK#$CD$M)@ D>YI@GL?LZRB2V\ECA7RH4G/;\>U5
MH;2]6\O'EN T4PQ&C-N"^GRX'\ZHR^')9K!;1[J, 3-,2D9 W'/3G/>@#<CF
MAE9UBD1BC8<*1P?>GUG:9IIT^2=A(A24@B-%( Q_%R>I[]JT: "BBC]/>@""
M2>T60I-+;B0+O*R,,A?7Z4>?9A(3YENJR$>5RN&]-O\ ]:L[4=%DU"]\YIH5
MC"#RU\LE@P(.XG/S#C&/2H6\.RND:&ZCP P8K%T#/O.WGY3N''M0,V62WN5>
M%UBE56PZ$!@#Z$4TFTMA%$WDQ\XB1L#)]%!K-CT66SL+Z&TO'+W4GF"1VP5.
M,$YQS4D^EW%U!9)+-'NA96=F&]B5((PPQUQZ4"+S7%I"9-TT"-'@OR,KZ9J8
M$, 000>F*P9O#CS7-W<27$3O<#[K1G )(YX/;'&/QK;AC,-O%$SM(44*7;J<
M#K0!)1110 =J@9[2*18V,"2$?*IPI([X]JGK+U727U26(-+&L"J=RE/G+=B&
M]O2@"]'/:& SQRPF ]9%(VGMU'>E-K;M-YY@C,O9]H)_.L:7PVUQ826LUX%#
MR"3]S'M7<, <'MQ^=7FM;PZQ#<B<_95388]^-Q[G&W^M %H3VC+*XDMRJ$^8
M<@A3WW>]"7%NS"**6)F*A@J,.1ZUE2:#-(EZK7,(%T5R%B(  Z=_Y4_3]$-A
M=0S^<G[N(HVU2#)GH&.>@[=Z -BBCZ]:* "CO10.M %<SV1BE<RVQC0XE;*X
M4^A]ZE2:%W"1R1LP0,%5@2%['Z5B)X>ECB9%NHNJ;28>#L)(W#/)YYJUIVCG
M3[L3+)&R^0(FPF&8AB<YSTYX% &I1110 4444 (45B"54D<\C-5Y+FPBRLLU
MLN&VD$C[WH?>K(ZCTK)_L4F:X+R0^3-<"X,:QXS@8P3WR0": -'S+>4RP[XG
M(&)$R#@>XI!!;6L#+Y4,,*_,P*@*/<CH*SK71Y;:^O+P7"O+<HV  5P2<Y[@
M?E]:8VB3WF@_V=>W<F[<3O5M^3Z'(&1STH&:C36L4H!D@23:7&2 <=R.]/BD
MCEB5XG5T/W2IX-9$^@O<7'F23Q.A"@JT9^;:I4#.>ASR*T-.M&L;".V,GF%,
M\] !DG Z\ 4"+5%%% !4<TD$*&2=XD3@;I, 9[=:DJCJ>GG4(8PDBH\;;@73
M<IR"#D?0F@"PTUJDH1I(%E*%@"1DKW/TIL=Q9R&-(I;=BZDQJC DKWQ61/X:
M:X&QKM1'L5<B/YOD7"\YZ>HJ:UT6:WU"&X>:!U1VE9%BVG>>X.>@[#ZT#-A0
MJJ H4+V"C K1M/\ CW_$UGUH6G_'O^)H$6*S;K_CX;\*TJJS6GF2E]^,^U(9
MC:C>FRM5E1%9FD6-0S;5!8XR3V%9USKES;3R0&V@DD$6]-DA*RMGG![ >AYK
MI7TY)4*.5=&&"K+D&H3HMI@@P6^"-O\ JAR/3Z4P,#_A(@;&2Y2$2!954;<_
M,"NXG%26NMO-=Q6[I"796=O)<L$&T,.>_6MTZ3"RA=J *P8 (!@CITI8])MX
M<^5'%'DD_)&!UZT 8 \3V!12$G)==P0)R1G![\8/!II\56!!_=7&[&[!4<#\
M^AK?_L:V5PX2,$+L&$' )SC\Z:=$M#<1SM##YL8PK;!P* ,)?$]IY*R/#,K,
M!\H4'D@':.>O(I&\3VC(!%'*')Z2 +Z=\]<'(KH1H]NO(B@!Q@D1#IU_G22:
M+:RGYXH3@@_ZL9&.E B,T5;^Q?\ 33]*/L/_ $T_2@"I15O["?\ GI^E'V$_
M\]/TH J4=2,U;^PG_GI^E'V$_P!_]* .9DUN=)M0C^Q<VH!&6/(SWX].>,\5
M:CUB$6EE+<J\3W8&U-A.,^OH/K6PVE1.6W*AW'YOD&3V_/%-FT>"X='F4.R'
M*GD;?RH&9J7S-JMQ9-&@$<2R(QDY?)/!';I3M+O&U#3HKEXUC<EE**VX @D=
M:TCI,+2F5DB,A !<H,G'3FEBTR.&,)%LC0$D*B8% BO15O["?^>GZ4?83_ST
M_2@"I15O["?^>GZ4?83_ ,]/TH P;G5)+2^GCD2)K:&#S692=X/15QZL?TJ&
MSUQ[J[M(V@6..=2&8DY609RF/8#K70MID;DEE1B3D[D!SVYIJ:3!&ZLD<2LJ
M[5*Q@%1Z ^E S,75(9XKLVP\R2V!#(X* D#IDU"NK%H]*<1H5O2H?]X/W>5W
M# [UKQZ+;0^9L15\W[_!(;Z@THT:V&T"*$;.5Q$./IZ4"(J*M_823S)^E'V$
M_P#/3]* *E%6_L)_YZ?I1]A/_/3]* ,^YD:&VDD4Q@HI;]YPHQZ]ZR1KS(VF
M130 3WC#?M)VQJ<[3G'4X'%=*VGAU*,P*D8(*Y!%)_9R]<H.=W"?Q>M &;'?
MP3W4]M$S--!]Y2"HR?>J*:R[:997?D1[IYEBD3S1B/+;<CUK<31H(IGF10)'
M^^W.6_,T@T6U"A1!!M!R%\H8'?\ G0,S=/OI+V:[1HX@L+[ \4F\-ZCZCC/:
MKU30Z3#!N$*1Q!CEO+C"[CZG'XU+]A/_ #T_2@14HJW]A/\ ST_2C["?^>GZ
M4 9]S.EI:S7$@)2)"Q ZD5CR^()%T^UN8[0NTLGERQY.4;/W?7/OTKJ#8!@0
MS@@]BO!^M1+I,";=D<:XZ;8P,?2D,QH-8!MKRYN4C6*W<KOA8NK<<CIVZ5)/
MJ0C.GM$@>"[DVF1FVE?ESG'>M+^P[7[.\(AB6-SED1-H/UQ3_P"Q[?RT3RXV
M2/\ U89=VWZ9S3$8-YK4EL]ZJPV^;?RRA>;_ %@;/H.I/ %:Z$E%++M8KDK_
M ':D;1+23.^WMWSC.Z$'..E6/L&!C?\ I0!4HJW]A/\ ST_2C["?^>GZ4 5*
MI:G>7%E!')!'%)(\@0)(Q!8D]L?YQ6Q]A/\ ST_2D;3PV"S*V.F5SB@#F;_7
MI[*6Z1+-)1 T8!63=N##.2 .,G@"M(W]NNH1V+EA.Z;MI4X [Y/K6@ND6ZOO
M6*(-P=PC&>.G/MVI#H\#7(N64&8# ?G('YXH&8W]K2?9-2E^SQF:SD95C,V-
MX !Y/;@_I3K34WN=0%N(XC'Y"R[T?)7(Z,.V><?2M<Z/;DOF*$[\[_W8^;/!
MSZTL>CV\+^9%'%'(1@LD8!(^HH AHJW]A/\ ?_2C["?^>GZ4"*E%6_L)_P">
MGZ4?83_ST_2D,Y:+Q$TEO(_D0JY,?E R_+AR1\Y[$8YJUINK/?W/E- L8-NL
MP._))W%3QZ<<?6MDZ-;%6!BA.\DL/*&&)ZY]:<NE1)*'58U<+MW! #CTSZ>U
M,1!15O["?^>GZ4?83_ST_2@"I15O["?^>GZ4?83_ ,]/TH J?Y^E8J:^LVGW
MUU!"#);99(I&V[T_O$^^#^5=+]A(_P"6GZ5"='MB&4PPD-G</*&&SUS]: ,6
MSUR*\O[BV"%8X85D,AS\V>N!CH/7O3I]93^Q6U*TC$J#'RR$IQG![=O2MO\
MLR,IL^4+MVX"XX]..U1IHEM';_9UBC\GJ8RNX'\\T#,R?4&CU2UM42&19@=Q
M$GS@>N.F/>K]2C1K<2K*(H?,48#^6-P^AJ;["?\ GI^E BI15O["?^>GZ4?8
M3_ST_2@"I5'5+]]/@B:..-WD8J/,;:HP"3D_05L_83_ST_2F2Z9',FR4)(AZ
MJZ!A]<&@#F+GQ-Y!#K;*T?EH2"^&W,N1Q_=&,$U-::U-<7D%L8;?YV9'"2[B
M-O\ $!CE.@S6_P#V3#OW^7%OP1N\L9YZTB:-;1R))'#"CH-JLL0!4>@- R*M
M"T_X]_Q-1?83_P ]/TJS#%Y4>W.>:!$E9^N6<^H:'>VELP6>:(HC$D $^XK0
MH[4AG%OHOB#28)(]-OFEC6'<BMC'G;AP%Q]TC/?CM2SZ+XCFD0G427@E+Q2[
MP 1LP 5QZYS71:QJ0TK3VNC&'PZI@MM^\0.N#ZU0@\037,,TT>G.1"OSQEP)
M-^,[0OI@]: ,E]'\62R+.]_$98BVT[ASD$';QQG@#.<=:KFR\73ZE]EDF<1Q
MI&Z3$+Y>X$'GC)(]NM=$=?C>VM6@1)KBX("QA\*#@DY8CV-;$19HPS*%8@$@
M'(!^M ''3Z3XJNDMX6N(U@$8$X:7)=]P.1@#'0XJ>?0-7@U#4M2L9XS<3S*8
MD8X_=A0"-V..><>U==10!QT.F^+8Y8FFU$2QEP9D5PIZG&TXX&,9]:A&A^)X
M-QM[T;LL"S2 LP+L00<< 9''MBNWHH XM]%\5/Y9?4D>0/N+Y *Y)!V\<#&.
MM3Z''XCB\1R0ZH\\MFD.(Y?EV,??@'-=;10 4444 %&12$X&:P9_$$D!N2UB
M"L$@1F68$8/]>F1VH WLCUI<U@77B+R-1N+**S:=XH]R[&^^< D#CWJ[%K%F
M;>SEEF1#=8\L#)R?2@#1R*7(K,.IL-6:Q:#'[HR1OO'SXQD>W6J$/BB)[JUM
M9(-DT\QC&) R@#^('OR,4 =%12#I2T %&:*JW]T;&PGNEB,OE1E]@8 G SU-
M %G(SBER*Y\^(U6XN8GM7588//R6^\./RSG@^QI]AX@^UW-LC6C11SJW[QFX
MWC/RCCK@9YQ0!NTF1ZU1.IV\\5S]E99Y;<[63=M^;TR:HG7C_9MK>+:@K,Y5
MT\T;EP<<>IXS^% &[G-%9FC:O#K$=S)"I5(IC&"3RP'1L=LUIT %&:*J:E=M
M8Z?/=+"TQB3=Y:L 3^)H MYHS6"GB2%KB\C,#*MM$92V?O 8R![Y-0IXG!O(
M+:2T*2NX23$@8)GISWZ^U '24F151=2MI9KBWAD62>!<M'G'4<<GBL[^WG_L
MQ[S[(OF),8GC\X#H<<'OGL/>@#=S16;I]_->7=S"]N(U@*C>'W DC)'3@CO6
ME0 4444 %)D>M1SR-%!)(J%V520H.,^U9-EXA@O+JVM]AC>6!926/"L1G8#W
M.,F@#;R*,BLBUUR*2VNI[M#:_9W(=7Y('8GZCFG7FK"V2TEBC$T$[JN]7QM#
M$ ''?K0!J9'K2Y%8E]K4EK<7,*VJ,L,7F[S*,?0^F>WK6K;2/+;12R1F-W4,
MR$YVD]J )J*** "C(I#TJA>:@;6]MK?R&D$X<APPX*C.,=R: -#-%<[+XH@M
M](%]/#LF,GEFWW?,K9Y!)QC .:UFU&T6\2T,R^>Z[E3U% %S-&16/%JS2O?1
MFW59+4 @&888$'G/;I3;+69[R[MHOL859HC(S"3)0 X!QCH3TH VJ*0=.*6@
M HHI#T- "Y'K1D5ST7B,2V\CK:_/F/RE,H^<.2%)/\/W3FHAXL1AN%FQ#-Y2
MYD _><?+[+S]Z@#ILT5@V7B6"[U&WLA%MED5]_S#",IZ>^>O%;HH 6BBB@ H
MR*H:EJ(T\VQ:(M'+*(W?< (Q@G)]>G:LS_A*H'TB34([=V G,*INY;WQ_2@#
MH<CUI<BL33O$$6HWD\ B,:Q)OWEL@CO4MQK47]DOJ%F%N8USQNV].O\ *@#5
MR*6L*;Q' EW;6D<>^:>$RX,@4)QD D^O/Y5HZ==M?645RT1B+C[I.>_8]Q0!
M<HHHH *,XHK/U;43I\412'S9)&*HI;:. 6.3VX!H OY'K1D>M<]=>*(K<"3[
M.S0^6AWAP#N=<J,>GJ>U6++7#=WD-LUJ49Q(&;>&"LAZ>^0>M &UUHH'2B@
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M\B1WD1* $G=QR,\'Z5H@Y&:QW\-V#B-0KA4DCDV[N"4Z?_7]:UQZ4 +1110
M4444 (W2LE_$%FLTT16;=%.L!PF?F;C\O>M<C-9D^B6D\CRR-.7=E)82$8VG
M( ]!GM0 V?6[:"_>RV2R7"Q[]J+U'M^%6;;4;>YM+>X#>6LXS&LGRL?PJM+H
M-C/<//()&D=2K$R'D$8_EQ3[[2(;Z6U=FV_9CN0*H(_6@"0:E$=0:R,<JR*A
M<,4.U@,9P>_4557Q! S(HM;H%IO).8_NMVS^'-6!I, OIKL23B68 -^].,#L
M!V%-L]%M+/RBGFN8F=T,LA8@MU/UH TATHH P,44 %4]0U*WTVT:YN6*H"
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ME3MSA@.A&:NYJ#R.WFR?]]4OD]?WLO\ WU0!/FC-0>1_TUD_[ZI?(_Z:R_\
M?5 $N:R=<GU2*&'^SH2Y,BF0J1N"YY !]?6M P?]-)?^^J3R.>99?^^J .<M
M]0UI;+4=\4AN-^+<O&<*,X.<=<#FKQUFXMX--$MHQDN#MD#-@I[XQ6MY&/\
MEK(/^!4>0.,R29]VH R?MMV-=N43[1)"D8Q&\6$9SC&UOYD^OM5G0I=1ELY#
MJ:%)Q,P XQM[8QU'O5WR?^FLO_?5'D>DLG_?5 $V:7-0>1_TUE_[ZI?(_P"F
MLO\ WU0!-FDJ'R>?];+_ -]4>1_TUE_[ZH Y[4+C7!=:@%#P0+&OV=D3?N(/
M/3G)_2KL5Y>/JMB"LR0O _FQ-'PKC'5OSK4\C_IK+_WU2^1_TUE_[ZH R!K,
MMS:ZE^ZDB-L2$:$;W8>PQUJJ]YK3:98_9HY)9=ZFX<IM8*6^[@^W4^U=!]G
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M[Y%-GU>ZNO#[74<<\%QYFT) OF'/('4=.ASZ5NF#I^\DP/\ :I/(P!^]D'_
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MLO$[RB83Q(^XK@-DA,@XZ8S[^E6]0TJ]U-;)6G:$1.YE<G+=\$8X]"*Z&C%
M')'1[_\ LUX/)+7:R@FX^T9$Y&>6![>HJ_<V%[+?VTTR)=Q(N/*5S&(VR#N'
M]ZMZB@#GKW2[W4-2M[T.;<10Y$8;GS <XST ]ZK0V?B4[I);F%'Z_*0<XS@'
MCZ5U5% '/RV6H)J-Y/'"LTL@)MYFFP(^,;=OU[U4BM/$\9#&='DD=&=BXVJ
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M&CD(8$08&<M_7ZUHOI=E(\+-:H3$I6,D<JOIFGQZ?:11)&EK$$0DJ-O&3UH
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M7'S;EW'CM@?G6S]FAQCR8\=/N#_/>AK:%QAX8VY!Y4'D=* .>M_%L+&;SX6
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M^9K:L+G[98P7.PIYJ!]I[9IS6L#*R-!&4;&Y2HP<>HJ8 *    . !0 M%%%
M!1110 4444 %%%% !1110 4444 &!G..:*** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
B**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>pg_001.jpg
<TEXT>
begin 644 pg_001.jpg
M_]C_X  02D9)1@ ! 0$ V #8  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 1,"S8# 2(  A$! Q$!_\0
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M^W'_ -N**/V%_P#F=O\ MQ_]N**\O$_Q7_70[Z?PHT****]0X HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH S_P!A?_F=O^W'_P!N**/V
M%_\ F=O^W'_VXHKR\3_%?]=#OI_"C0HHHKU#@"BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#/_87_ .9V_P"W'_VXHH_87_YG;_MQ_P#;
MBBO+Q/\ %?\ 70[Z?PHT****]0X HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*MX>_P"NS?\ HMJ,+",J=5R6R_S%BIRC4IJ+M=_Y'W&?NFOA?XS<?%+Q$?\
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M!@Z,YPYE-I7V.4^.?C#4_!7@.74M(N!;7HGC19&C5Q@GGA@17-?LY_$G7OB
MNO?V[>+=M:F#R=L*1[=WF;ON@9^Z.M6OVG^/AC)_U]1?SKC/V0OO>)_K;?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MMH##Z@Y'X5\^?M;?\C)H?_7M)_Z$*Y\&K8A)^9T8QWP[:\CUG]G7_DD>B?\
M;;_T=)7I=>:?LZ_\DCT3_MM_Z.DKTNN6M_%GZO\ ,ZJ'\*'HOR/G_P#:Y_Y
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MI%_[-7V-7QW^T[_R5"3_ *](OYM48#^-\C3,/X/S/IKX6_\ )./#'_8,MO\
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M7-E9;B]TH^620X&%]5 '7OGTYK?#XB=:HE*"]>QSXC#PHTVU/Y=SUG]D\_\
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MA'_P16O_ ,;H_P"% ?"__HF_A'_P16O_ ,;J_P#\+?\  ?\ T.WAW_P:P?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#/_87_ .9V_P"W'_VXHH_87_YG;_MQ_P#;BBO+Q/\ %?\ 70[Z
M?PHT****]0X HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX6?>-%%%;F04444 %%%% !1110!X?^U9_P B'9_]A"/_ -%R5\HU]7?M6?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBB>0Q@]"VT''';K76:;J5KK%A;WME.ES:7""2*:,Y5E/0BOESXR_!_Q%K'Q
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M*?!CQA(BL-)X89'^DQ?_ !5=+\-_A+XJTGQWH5]<Z:(K:VNXY9)//C.%!R>
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 9_["_P#S.W_;C_[<44?L+_\ ,[?]N/\ [<45
MY>)_BO\ KH=]/X4:%%%%>H< 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MK^TJ2IVV.CHKY(^*'PS\7ZQX^UN^LK)WM+BX+Q,+F-<K@=BV17+?\*A\<?\
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M5T(PQ$/F?<%<U\2O^2?^(_\ L'7'_HIJS?A#\1(OB/X1@O25748,0WD2\;9
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MUJ?.&N)Y"P'MO8X'TS5RZ^#_ (NLXR[Z/(Z@9/E2QN?R#9KT/J=./NSJ)/\
MKS/.^NU):PIMK^O(^[*^?/VN?^0-H/\ U\2?^@T_]E:SU>UAUW^T'O([>-HX
M8K6X+A48 ER%/0X*TS]KG_D#:#_U\2?^@UE1I^SQ2@G>W^1K6J>UPKFU:_\
MF:_[*/\ R3^]_P"PC)_Z+CKUB7Q5HL$QADU>PCE!P8VN4#9^F:^%M'UCQ%?:
M5_PC6E2W3VDLK3-:6H(\QB%!+8ZC"CKP*W8_@?XNDMO-^P1JV,^4TZ;OYX_6
MNFMAH>T<JDTKG-1Q4U34:<&['VY#/'<1K)%(LL;='0@@_B*DKX/\-^+_ !-\
M)_$#"WEFLIH7Q/8S$F*3V9<X.1T8?@:^UO!OBFU\:>&=/UJS!6&ZCW;&.2C
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MCT->31Z?=36,]ZD#M:0NJ22J/E5FS@'\C7U3^S+XWL]<\,_V(ZQP:GIJXV*
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M([-;0OT) 0+GV-%;V%TZ+8J+KM-5D?(G[/?_ "5O1/I-_P"B7K[7_A_"O'/
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MN(4=@.,*.U2ZT/JRI=;E*C/ZRZO2Q7^.'_)+?$/_ %['^8KP;]E'_DH&H?\
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M0OO26W(5U[$9(/!^G85MA<1["?O?"]S'%8?V\=-UL?./[-O_ "56Q_ZX3?\
MH-?9G\->0?#KX$Z;X'\2Q:M;SWTD\:,@6>1"F&&#P$!_6O7^U&*K1K5.:&U@
MPE*5&GRSWN?%_P"T=_R5?4_^N4/_ *+%?5WPY_Y$/P]_UX0?^BUK@?B!\!],
M\;^)YM7N;B_CFF"JRP2(%PH & 4)Z#UKU'P_I::+HME81EC':PI"A<Y;:J@#
M/O@55:M"I2A".Z)HT9TZLYRV9H4445PG<>#_ !^^,VK^!O$>E:;H4RPRQQFY
MNO,C#I(&.%0Y[<$G'J.:H>'OVN;1H%77=#FCF'633W#JWOM<C'_?1KV'Q=X(
MT_Q=!Y5_:PW:=EF0''N#U!^E>2ZO^S%HL\K-;->68SPL4H9?_'@3^M>A3J89
MP4*L=5U/.J4\2IN=.6CZ&AJ7[67AF"W8V.F:G=W&W*K*J1)GT+;B1^ -?/?B
MSQ1K/Q6\8?:YHC->W)6&WM802L:CHJY[=23[DU[/:_LN:;Y@\V]U"0>BLB_^
MRUZ9X)^$>B^#_GLK)(9&X:5LO(W_  (\X]AQ6T<1AJ%W13;,94,1B+*J[(O?
M"7PG_P (7X)T_36P9D3?*PZ&1CEL>V3@>P%=G3401J%48 IU>7*3DW)[L]:,
M5%**Z!1114C$KX9^-7_)4_$7_7P/_0%K[F->*^,/V>=*\5>*+W5;BYU!);I]
M[K#)&%!P!QE">WK7=A*T*$W*?8X<91G6@HP[GK^C_P#(+M?^N:_RJY4%G#]G
MM8HAT10M3UPG<>,?M)> Y_%7AR"^LHC+>Z>S2!%Y+QD#>![\*?P]Z\&^%/Q9
MO?ACJ$P^S_;],N#^_LV;;AO[ZG!PV./?\B/MJYMUNHBC#(->1>-_V?\ 1/$M
MU)="![2Z<[FFM&"ECZD$$'ZXS[UZ%#$PC!T:RO$\[$8:<I^UI.TB6Q_:4\!W
M4(>:6[LWQDQS6K,0?3*Y%96O?M3>%K&,C2]-O-4F[;U$$?YG)_\ ':Y-OV7%
M\SC5KC9Z?9QG\\_TK8TO]E_28Y%:YN+VZ'=2ZHI_(9_6K_V):W;(OC9:62/:
MO!OB.W\9>$].UBV41QWD(<Q@YV-T9<]\,"/PKY2_: \ W'AGQ?<ZI%&3IVHR
M&7>HX24_>4_4Y8?4^E?5_A#PS9^$=%ATVP@6VM8R2L:DGDG).22>M/\ $7AN
MT\0V,MM=0I/%(NUXY%RK#W%<U&O["ISP6GZ'36H>WIJ,M_U/F_X6_M+-X6TF
MWTCQ!9S7UI;((X+JUP9E4=%96(# #@'(X'>O1+C]JKP;#;[XX-4GDQQ&L"@Y
M]"2^*YS7OV8M+GN&>QFNK!3_ ,LU(D0?3//ZUF6O[+D.[]_JEU(/^F<2I_/-
M=DIX*H^9W3..,<937*K,]$^$_P =(?B=XAU'3CIPTWR81-;AI=[2*&PV>  >
M5X'J:Y+]KG_D#:#_ -?$G_H-=O\ #GX-:-X%OEOK2V<WBJ4^TS2%GP>HQ]W]
M*O\ Q6^&EG\2+.S@O)+F(6SF1#;,JG)&.<J>*YHU:4*ZG!6BCIE3JSH.$W>3
M.0_91_Y)_>_]A&3_ -%QU[97&?"_P#;?#O0Y-.M))Y(I)FG+7#*S;B .P'&%
M%=G6%::J5)2CLSHHQ=.G&+W1X%^UQ_R+>B?]?;?^@&KG[)?_ "(>I_\ 83?_
M -%15V_Q5^&]I\2-.M+6\DN(EMY?-4VS*IS@C!RIXYJ7X6_#ZU^'6BSZ?:27
M$D<TYN&:X96;<55>, <845O[:'U;V76YS^QG]9]KTL>9?M=?\@70?^OE_P#T
M"M7]D_\ Y)_??]A&3_T7'78?%;X:V?Q(L[."\EN8A;.9$-LRJ22,<Y4U:^%_
M@&V^'>ARZ=:27$L4DS3EKAE9MQ"C' ''RBCVT/JRI=;@J,_K+J]+'9UX%^UQ
M_P BWHG_ %]M_P"@&O?:X7XJ_#>T^)&G6EK>27$2V\OFJ;9E4YP1@Y4\<UC0
MFJ=6,Y;(WQ$'4I.$=V<1^R7_ ,B'J?\ V$W_ /145;'[07P]E\:^&5DLUW:A
M9,9H5QRXQAD_'C\0*Z3X6_#ZU^'6BSZ?:27$D<TYN&:X96;<55>, <845V,T
M*SQE&&0:JI6_?.K3[D0H_N52GV/A_P"%_P 4=4^%.M3-'";BSF(2[L925S@]
M1_=8<]O8U]"6?[4G@NXM5DF^WVLN.86M]Q!^H)%6O'GP-T7Q=,]S+;M%=,,?
M:;=MC_CV/XBO-IOV7%\S]WJUPJ>C0 G\\BNV5;"XCWJB:9Q1I8K#^[3LT8OQ
MB_:"E\>V+Z-H]O)8:0Y!FDF(\V?!R 0#A5Z'&3G]*U_V9_AW<3:M_P )->1&
M.&-6CM%8<L3PSCVQD#UR?2NI\*_LUZ-IMPDUX)M2=2"!<$",?\!'7\<BO;=-
MTV+3H%CC4* ,<"LZN)IJG[&@M'NS2EAJDJGM:[U+$O\ J6^E?#/AG_DL6F_]
MAQ/_ $>*^Z)%W1L/:O%=._9YTFP\70ZTEQJ!FANQ=JK2)LW!]V"-F<9]ZRPU
M:%%34NJ-<51G5<''HSV:6/S;8KZBOB;XO> ;KP%XLGDB1ETZXE,UM,@("$G.
MS/8KV]L&OMY1A0*P_$WA2R\2V,MM=P1W$4@PT<BY!K/#UWAY<VZ>YIB*"Q$;
M;-'B'P__ &J+:'3H;/Q5:SFXC7;]OM5#"3'=UR"#[C.?05T'B#]JKPS8V+G2
M;:\U.\(.Q7C\J,'U8GG'T%8.N_LPZ;-<,]C<W5BI_P"6?$BCZ9Y_6L^Q_9<A
M\P?:=4NI4SR(XE0_F2:[.;!2?-JO(XTL;%<NC\SR&ZNM<^*WC-IG!NM3OY!P
MH(2->@^BJ/Y5]J?#[PS%X1\*:?I41W+;Q!2V,;FZLV/<DG\:R/ GPLTCP7"5
MLK18F;[\C$L[X]6/\NE=TJA5 %<^(Q'MK1BK11T8;#NC>4G>3/GO]J'P'/J5
MO;>(+.,R26:&.X51DF(G(;_@))S[-GM7FGP<^-5S\,9IK2Y@:_T6X;>\*, \
M3\#>F>#D#D'K@<BOL>^LDOH61QD&O$O%W[-VC:M=O<6@ETV1F)86V#&3_NGI
M^&!6M#$P5/V-9:&5?#3]I[:B]36N/VIO!<5L)$74II/^>*VX#?F6 _6OGGXJ
M_%*^^*.M1W4T(M+&U4I;6JL6V GEF/=CQZ=!7I=K^RW%YP\[5;EX\]$A5#CZ
MDG^59OQH\&Z+\-?!=CIEC%LO;^Y#M(YW2/&@.23Z99>!Q730EAHU$J2;;.:O
M'$SIMU;)(WOV0?N^)O\ >M_Y25]'5\[_ +(ELRV7B&X_@DEBC'U56)_]"%?1
M-<.,_CR_KH>A@_X$?ZZGS7^U5X.V_8/$,*?</V:<@?PG)0_@=P_X$*\ :XN]
M6:QM2SSM$HM[>/J0"[,%'_ G/YU]A?M&:M9:7\-+]+I5DFO"MO!&W=R<Y_X"
M 6_ 5X#^SWX0/B;QY#=2)NM=-'GMD<>9T0?GEO\ @->EA:O)AG*7V=CS,52Y
ML0HQ^T?4?PS\*1^#_"&G::@&Z&(>8P_B<\L?Q8FNLID:"- HZ"GUX+;D[O=G
MO12BDD%%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110!G_L+_P#,[?\ ;C_[<44?
ML+_\SM_VX_\ MQ17EXG^*_ZZ'?3^%&A1117J' %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4E+10 FT>E&T>E+10 F*6BB
M@ HHHH **** "BBB@ HHHH **** $VCTHVCTI:* "BBB@ HHHH 3:/2BEHH
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M/[S'C)[_ $P*^GO@/\/V\$>%$%R@&H71\ZX]B1POX#]<U7\ _ O1?"-REU'
MT]VO2XN6#.OTX 'X#->JPQ+#&%48 KIQ&)C4BJ5)6BCGP^&E3DZE5WDQ]%%%
M>>>@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% &?^PO\ \SM_VX_^W%%'["__
M #.W_;C_ .W%%>7B?XK_ *Z'?3^%&A1117J' %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 E&T>E+10 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %)M'I2T4 )@>E+110 4F :6B@!*6BB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,_\ 87_YG;_MQ_\ ;BBC
M]A?_ )G;_MQ_]N**\O$_Q7_70[Z?PHT****]0X HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH S_V%_P#F=O\ MQ_]N**/V%_^9V_[<?\
MVXHKR\3_ !7_ %T.^G\*-"BBBO4. **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH/\ SZ:E_P!^H_\ XNC_ (7KH/\ SZ:E_P!^H_\ XNOH[_A67@__ *%/0_\
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MPO70?^?34O\ OU'_ /%U]'?\*R\'_P#0IZ'_ ."Z'_XFC_A67@__ *%/0_\
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M_"]=!_Y]-2_[]1__ !='_"]=!_Y]-2_[]1__ !=?1W_"LO!__0IZ'_X+H?\
MXFC_ (5EX/\ ^A3T/_P70_\ Q-&@>V78^<?^%ZZ#_P ^FI?]^H__ (NC_A>N
M@_\ /IJ7_?J/_P"+KZ._X5EX/_Z%/0__  70_P#Q-'_"LO!__0IZ'_X+H?\
MXFC0/;+L?./_  O70?\ GTU+_OU'_P#%T?\ "]=!_P"?34O^_4?_ ,77T=_P
MK+P?_P!"GH?_ (+H?_B:/^%9>#_^A3T/_P %T/\ \31H'MEV/G'_ (7KH/\
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M[]1__%T?\+UT'_GTU+_OU'_\77T=_P *R\'_ /0IZ'_X+H?_ (FC_A67@_\
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M31H'MEV/G'_A>N@_\^FI?]^H_P#XNC_A>N@_\^FI?]^H_P#XNOH[_A67@_\
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M (5EX/\ ^A3T/_P70_\ Q-&@>V78^<?^%ZZ#_P ^FI?]^H__ (NC_A>N@_\
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M_GTU+_OU'_\ %T?\+UT'_GTU+_OU'_\ %U]'?\*R\'_]"GH?_@NA_P#B:/\
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M /!=#_\ $T:![9=CYQ_X7KH/_/IJ7_?J/_XNC_A>N@_\^FI?]^H__BZ^CO\
MA67@_P#Z%/0__!=#_P#$T?\ "LO!_P#T*>A_^"Z'_P")HT#VR['SC_PO70?^
M?34O^_4?_P 71_PO70?^?34O^_4?_P 77T=_PK+P?_T*>A_^"Z'_ .)H_P"%
M9>#_ /H4]#_\%T/_ ,31H'MEV/G'_A>N@_\ /IJ7_?J/_P"+H_X7KH/_ #Z:
ME_WZC_\ BZ^CO^%9>#_^A3T/_P %T/\ \31_PK+P?_T*>A_^"Z'_ .)HT#VR
M['SC_P +UT'_ )]-2_[]1_\ Q='_  O70?\ GTU+_OU'_P#%U]'?\*R\'_\
M0IZ'_P""Z'_XFC_A67@__H4]#_\ !=#_ /$T:![9=CYQ_P"%ZZ#_ ,^FI?\
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M'_"]=!_Y]-2_[]1__%U]'?\ "LO!_P#T*>A_^"Z'_P")H_X5EX/_ .A3T/\
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M_P!"GH?_ (+H?_B:- ]LNQ\X_P#"]=!_Y]-2_P"_4?\ \71_PO70?^?34O\
MOU'_ /%U]'?\*R\'_P#0IZ'_ ."Z'_XFC_A67@__ *%/0_\ P70__$T:![9=
MCYQ_X7KH/_/IJ7_?J/\ ^+H_X7KH/_/IJ7_?J/\ ^+KZ._X5EX/_ .A3T/\
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MZ/\ A>N@_P#/IJ7_ 'ZC_P#BZ9_PCNE?] RS_P# =/\ "C_A'=*_Z!EG_P"
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M_P!^H_\ XNF?\([I7_0,L_\ P'3_  H_X1W2O^@99_\ @.G^%'LT'MUV'_\
M"]=!_P"?34O^_4?_ ,71_P +UT'_ )]-2_[]1_\ Q=,_X1W2O^@99_\ @.G^
M%'_".Z5_T#+/_P !T_PH]F@]NNP__A>N@_\ /IJ7_?J/_P"+H_X7KH/_ #Z:
ME_WZC_\ BZ9_PCNE?] RS_\  =/\*/\ A'=*_P"@99_^ Z?X4>S0>W78?_PO
M70?^?34O^_4?_P 71_PO70?^?34O^_4?_P 73/\ A'=*_P"@99_^ Z?X4?\
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M_P#%T?\ "]=!_P"?34O^_4?_ ,73/^$=TK_H&6?_ (#I_A1_PCNE?] RS_\
M =/\*/9H/;KL/_X7KH/_ #Z:E_WZC_\ BZ/^%ZZ#_P ^FI?]^H__ (NF?\([
MI7_0,L__  '3_"C_ (1W2O\ H&6?_@.G^%'LT'MUV'_\+UT'_GTU+_OU'_\
M%T?\+UT'_GTU+_OU'_\ %TS_ (1W2O\ H&6?_@.G^%'_  CNE?\ 0,L__ =/
M\*/9H/;KL/\ ^%ZZ#_SZ:E_WZC_^+H_X7KH/_/IJ7_?J/_XNF?\ ".Z5_P!
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M_P#/IJ7_ 'ZC_P#BZ/\ A>N@_P#/IJ7_ 'ZC_P#BZ9_PCNE?] RS_P# =/\
M"C_A'=*_Z!EG_P" Z?X4>S0>W78?_P +UT'_ )]-2_[]1_\ Q='_  O70?\
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M$=TK_H&6?_@.G^%'_".Z5_T#+/\ \!T_PH]F@]NNP_\ X7KH/_/IJ7_?J/\
M^+H_X7KH/_/IJ7_?J/\ ^+IG_".Z5_T#+/\ \!T_PH_X1W2O^@99_P#@.G^%
M'LT'MUV'_P#"]=!_Y]-2_P"_4?\ \71_PO70?^?34O\ OU'_ /%TS_A'=*_Z
M!EG_ . Z?X4?\([I7_0,L_\ P'3_  H]F@]NNP__ (7KH/\ SZ:E_P!^H_\
MXNC_ (7KH/\ SZ:E_P!^H_\ XNF?\([I7_0,L_\ P'3_  H_X1W2O^@99_\
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M='_"]=!_Y]-2_P"_4?\ \73/^$=TK_H&6?\ X#I_A1_PCNE?] RS_P# =/\
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M3_"CV:#VZ[#_ /A>N@_\^FI?]^H__BZ/^%ZZ#_SZ:E_WZC_^+IG_  CNE?\
M0,L__ =/\*/^$=TK_H&6?_@.G^%'LT'MUV'_ /"]=!_Y]-2_[]1__%T?\+UT
M'_GTU+_OU'_\73/^$=TK_H&6?_@.G^%'_".Z5_T#+/\ \!T_PH]F@]NNP_\
MX7KH/_/IJ7_?J/\ ^+H_X7KH/_/IJ7_?J/\ ^+IG_".Z5_T#+/\ \!T_PH_X
M1W2O^@99_P#@.G^%'LT'MUV'_P#"]=!_Y]-2_P"_4?\ \71_PO70?^?34O\
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M_P +UT'_ )]-2_[]1_\ Q='_  O70?\ GTU+_OU'_P#%TS_A'=*_Z!EG_P"
MZ?X4?\([I7_0,L__  '3_"CV:#VZ[#_^%ZZ#_P ^FI?]^H__ (NC_A>N@_\
M/IJ7_?J/_P"+IG_".Z5_T#+/_P !T_PH_P"$=TK_ *!EG_X#I_A1[-![==A_
M_"]=!_Y]-2_[]1__ !='_"]=!_Y]-2_[]1__ !=,_P"$=TK_ *!EG_X#I_A1
M_P ([I7_ $#+/_P'3_"CV:#VZ[#_ /A>N@_\^FI?]^H__BZ/^%ZZ#_SZ:E_W
MZC_^+IG_  CNE?\ 0,L__ =/\*/^$=TK_H&6?_@.G^%'LT'MUV'_ /"]=!_Y
M]-2_[]1__%T?\+UT'_GTU+_OU'_\73/^$=TK_H&6?_@.G^%'_".Z5_T#+/\
M\!T_PH]F@]NNP_\ X7KH/_/IJ7_?J/\ ^+H_X7KH/_/IJ7_?J/\ ^+IG_".Z
M5_T#+/\ \!T_PH_X1W2O^@99_P#@.G^%'LT'MUV'_P#"]=!_Y]-2_P"_4?\
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MX>$Y.3.V-1\JL?H71115GD!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!\U_MD_\ ,H?]OG_M"O+/A-_S%?\ ME_[/7J?[9/_ #*'_;Y_
M[0KRSX3?\Q7_ +9?^SUK$ZG_  ?Z[GH5%%%;'$%%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% 'COC_ /Y&Z_\ ^V?_ *+6BCQ__P C=?\
M_;/_ -%K163W/5A\*/T'HHHK$\T**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** /FO]LG_F4/\ M\_]H5Y9\)O^8K_VR_\ 9Z]3_;)_YE#_
M +?/_:%>6?";_F*_]LO_ &>M8G4_X/\ 7<]"HHHK8X@HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH \=\?_P#(W7__ &S_ /1:T4>/_P#D
M;K__ +9_^BUHK)[GJP^%'Z#T445B>:%%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% 'S7^V3_S*'_;Y_P"T*\L^$W_,5_[9?^SUZG^V3_S*
M'_;Y_P"T*\L^$W_,5_[9?^SUK$ZG_!_KN>A4445L<04444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 >.^/_ /D;K_\ [9_^BUHH\?\ _(W7
M_P#VS_\ 1:T5D]SU8?"C]!Z***Q/-"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH ***JZCJUEI$(FO[RWLH2=HDN)5C7
M/IDGK0(M45B)XX\.2.J)K^EL[' 5;R,DGT^]6W3LUN%PHHHI#"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#QWQ_\ \C=?_P#;/_T6M%'C
M_P#Y&Z__ .V?_HM:*R>YZL/A1^@]%%%8GFA1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)!5,^@!(_O5X5K7Q$\4^))VFU3Q%JE_(W>XO)&'T )P!["N?&3P.37IOA/\
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MEXG#J"YX;'H4*SD^66YZ51117GG:%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'COC_\ Y&Z__P"V?_HM
M:*/'_P#R-U__ -L__1:T5D]SU8?"C]!Z***Q/-"BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@#QWQ_\ \C=?_P#;/_T6M%'C_P#Y
M&Z__ .V?_HM:*R>YZL/A1^@]%%%8GFA1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 07G^H?Z5^6?QP_Y*_XP_P"PG/\
M^AFOU,O/]0_TK\L_CA_R5_QA_P!A.?\ ]#->KE_\27H<.+^!',>'?^1@TO\
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M%Q/_ #\)_P"BDK]+=#8MI-F3R?*7^59XBC&G"$H]5_D52J2G*2?0O5XGX_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M";$_#71QZ"7_ -&O6=^T!_R(,G_7>/\ G50CRUE'LQ3?-2;\CEOV9_\ F/\
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M%K!,O6+?N<?4#)%>6?''XH75I>OX=TF=K?8O^F3QG#$D9$8/;@\X]<>M>?\
MA;X4ZSXHM5NU"6=J_*//G+CU ';W.*J%"*ASU961,JTG+DIJ[/H:Q^*WA+4I
M5CAURV#L< 2[H\GZL!75JP90RD,I&01T-?*_B3X.ZQX?L7NXWCOH8QND6,$.
MH[G!ZBMSX'?$:YTG6;?0;V9I--NFV0!CGR9#T ]B>,>I!]:<J$)0<Z4KV$JT
MHR4:BM<^BW=8U9F8*JC)9C@ >M4]/UW3=6=TL=0M;QT&66WG60@>IP:;X@8K
MH=^1_P \)/\ T$U\<:/JFHZ;+,FFSS0RW4?V=Q!G<ZD@[1CGD@=*BC1]LGK:
MQ=6K[-K3<^MM6^(7AO0YVAO=9M(IE.&C#[V4^A"Y(_&C2OB%X;UJ=8;/6;26
M9ONQE]K-] V,U\]Z/\%==U.$2W#0V 89"2$L_P"(' _.LSQ=\,]6\(VXNIO+
MN;3.#+#GY/3<".,UJJ-"3Y5/4S=2LES.&A]<5@^.KG4;7PIJ+:3"9]1,16)5
M(!!/!89[@$G\*\W^ ?Q"NM7\[0-1F:XEAC\VVFD.6*# *$]\9!'MGTKV.2,2
MJ5;I7+.#I3L^AT0DJD;H^8/A#X)N=6\9)+=V[Q0Z:PDE652I\S^!<'OGG\/>
MOJ!%VJ!5>WT^.W<LHYJS15JNM+F84Z:IQY45]0U*TTFU>YO;F*TMU^]+,X51
M^)KF9/BYX0AD\MM=MRWJJNP_,#%?/_Q*\17_ (X\=W-LC-+'%<&TM(%/R\-M
M!'NQYS[^U;EO\ ]2DM@\NHPQRXR46,LH_'(_E73[&E3BG5E9LP]K4FVJ<;V/
M?='\6Z-X@)&G:I:WCCJD<H+#_@/6M:O _AM\)=2T'QQ;WFH"&2UM5:2.2-LA
MGQA>#@C&2?PKWNN:HH1=H.Z-X.37OJPM%%%9&AXA^TM_QZZ)_P!=)?Y+6U^S
MG_R)-S_U^R?^@)6+^TM_QZZ)_P!=)?Y+5'X-?$K0/!_AB:SU2[>"X:Y:0*L+
MO\I50#D ^AKT>5RPR45?4XN91KMM]#WVBN _X7KX-_Z"4G_@-)_\31_PO7P;
M_P!!*3_P&D_^)KC]C4_E9T^TA_,CC_VEO^/71/\ KI+_ "6MK]G3_D2;C_K]
MD_\ 04KA?C;X]T7QG;Z6FDW+7!@>0R;HF3&0N.H'H:[K]G3_ )$FX_Z_9/\
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MCX9ZSX4M3=7"Q7%J#AI8&)"9.!D$ UZ7^SYXZN;R2?P[?3-,L<?G6KN<E5!
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M -%K163W/5A\*/T'HHHK$\T**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@""\_P!0_P!*_+/XX?\ )7_&'_83G_\ 0S7Z
MF7G^H?Z5^6?QP_Y*_P",/^PG/_Z&:]7+_P")+T.'%_ CE_#O_(P:9_U]1?\
MH8K];]+_ ./6/Z5^2'A[_D/Z9_U\Q?\ H8K];]+_ ./6/Z568[P^9.#VD7**
M**\@] 1ONU\,_MZ0E?%GAF7'#6LRY^CJ?ZU]S-TKXV_;XTXM;^%+T+Q'-<0E
MO]Y4('_CAKLP;M7C_70Y\0KTF?'U?H!^Q%<";X/1H.L-].A_,-_[-7Y_U]O_
M + ^K";P3X@TXG+6^HB;Z"2-0/UC->MCE>C\S@PK_>'U91117SIZX4444 <!
M\=+H6?PE\7RG^'2;K'U,3 ?K7Y9U^E'[6.KC2?@;XE<'#311VZCUWRHI_0G\
MJ_->O=R]>Y)^9Y>,?O)'LG[(]JUQ\<M&<#(AAN)#]/*9?_9A7Z1P_P"K7Z5\
M ?L0Z4UW\4M0O2N8[73F7/HSR)C]%:OT B&$'TKBQSO6]$=.%5J0^BBBO/.L
M*\T_:0_Y(EXO_P"P?)_*O2Z\T_:0_P"2)>+_ /L'R?RK2G\<?5$3^%GR'^P[
M_P EHF_[!<W_ *,BK]!Z_/C]AW_DM$W_ &"YO_1D5?H/79COXWR.?"_PQLB"
M1"IZ$5^>W[97P^/A7XC)K,$6VTUB/<Q X$R8#?FNT^YW5^A=>)?M7_#O_A.?
MA?J!@B\R^L1]LM\#G<@.0/JI8?4BL<-4]E53Z;&M:'M*;0W]C_X@?\)M\';"
MUGDWW^BL=.ER>2B@&(_3857ZJ:^9_P!M;XA?\)9\5!HMO+OL=!B^SX!X,[X:
M4_A\B_5#6+^R_P#&9/A%X@UYKL[K"]TV5Q$3@-<1*SQ#\?G3ZN*Y'X9^&;OX
MN?%>QM;PM<O?W;7=_*>Z;B\A/UY'U85ZL**HUIU7LM3@E4=2G&"W9]J?L@_#
MO_A#?AG:7=Q%LOM4_P!-ER.0& V+^" <>I-0_MN?\D4N/^OVW_\ 0J]UTFR3
M3[&*%%"JJ@  8 KPK]MS_DBEQ_U^V_\ Z%7E4I.I74GU9WSBHTG%=$>8?\$_
MK>.>[\:EU#;198S_ -MZ^SU4+P!BO@[]A7QM9:!X_P!6T2\F6!]9@C^SLY #
MRQEB$^I5VQ]/I7WE6F-35=OO_D1AW>DD97B+2;?5M+N()XEDC="K*PR"",$&
MORZ^'C-H?Q>\-^4=[6NN6ZC'\6V=1^N*_2_XJ>-K/X=^ =9UZ]D5$M8&,2M_
MRTE(Q&@]RQ K\XO@+H<_BKXS>%XE^=DOTO96([1'S"3]=N/QKHP7NTZDGL8X
MC64(K<^N_P!N347M_@Q;PJ3BZU*"-L>@5W_FHKY:^ 'QIT_X+ZAJM[=Z%)K,
MUVL:1E+@1>6%+$CE3G)*_P#?-?67[:&@RZQ\%+B6)2YT^XANBH&3M!V$_@')
M_"OD?]G?0?"OB[QJVA>)X(I#?1A;&269XQYP/W,JPY8$XSW4 <GG3#\CPLN9
M75]?P)K<WMURNS/>_P#AX-9*,+X'GQ_V$E'_ +2KSWXU?M96?Q<\$7N@CPDV
MFRSM&R7;7PEV%9%;[OEC.0".O>O=%_8_\&_] */_ ,"9O_BZ</V0O!H_Y@47
M_?\ E_\ BZYXUL)%J2@[K^NYLZ5>2:<E_7R/%/V#/.7XI:RR_P"H_LIE?_>,
MT>W] U?1G[4WPNG^*'P_-K9D#4;.475MN.%9@""I/;(8CZXK;^%OP3T+X8WM
MU=:3IL=E-<*$D97=BP!R!\Q/K7I,T*7$91QE36%:OSU?:PT-*=+EA[.6I^6?
MA?QMXY^!/B"8:?<76A7AXGM+B,&*4#^\C JP]&'KP:^C_AU^WK'<3PVGC;1%
MMT8A6U+2\E5]VA8DX]2K$^BU]#>*_A/H_BBW:&\LK>[A;GR[B(.OUY'%?'O[
M3'[/&G?#?24\0:3FS@:=8);-F+(2V<,A/(/'3IZ8QSV1K4<5)1JQLWU.>5*I
M17-3E='WCH^KV6OZ7:ZCIMS'>6%U&)89X6RKJ1D$&KE?+G[!/B2ZO_ 6N://
M(TD&GWH>W#=$61<LH]MRD_5CZU]1UYM6G[*;AV.NG+GBI!7SO^W+JTEA\&4M
MD9@M[J4$+@=P \F#^,8KZ(KPC]LKPW/XA^#5\]NF^33Y8[W;C^%<AS^"LQ_"
MJH-*K%ON*JFX2MV/#OV$_"=OJ_B7Q'JLR!I+.&&"//82%BW_ *+7]:^Y8XEC
M4*H  K\__P!BGXD67@OXC7>CZE,MM::[$D,<KG"BX0GRP3V#!W'U*BOT#K?&
MQ:K-OJ989KV:2*U]91WENZ.H.17YB_M%>'(?"WQF\36-NH2$SK<*H[&1%=O_
M !YC7Z<ZIJ=KHNFW-_?7$=K9VT;2S32MA44#))/TK\M/BAXID^*WQ6UC5K.)
MG_M2]$=I'C#,@Q'$"/4JJ_B:VR]/GE+I8SQ;7*EU/TL^%NJ/K7PV\+7\K,\E
MSI=M*S-R26B4DG\Z^2?V_?\ D:O"O_7K/_Z$E?8/@/23H/@_1M-)!^QVD5OD
M=#L0+_2OC[]O[_D:O"O_ %ZS_P#H25EA/]X5O,TQ'\)_(]Q_8X_Y(%X?_P!^
MZ_\ 2F6O;J\2_8W_ .2 ^'_^NEU_Z42U[;7-6_BR]6;4_@CZ(****Q- (SP:
MQ]4\,VFI*=T8#>H%377B32;'6+72;G4K2WU.Z0R06<LRK+*H."54G)_"M*AK
MN"?8^;_BM^RGH/BJVN+BUM4T[42"5N[5=OS?[:CAOY^]?%]U;^(?@U\0 $F:
MPUS29UDCFB.0>,@CU5@>0>H)![BOU>=0RD$9%?FK^U;XBT[Q%\:-6;3)$FM[
M-$LVEC^ZTB9W\]\,2O\ P&O6P-2<I.F]8V.#%1BDIK1GZ&?#_P 6Q>//!.B^
M((4\I=0M8[@Q]=C%?F7\#D?A7S)_P4"_Y _A+_KXG_\ 05KVK]F:QFTWX(^%
M()PPD^R"3#=0'8N/T85XM_P4"4_V/X3../M,PS_P!:Y\.DL2DN[-:MW1;?8[
MG]B3_DBEM_U^7'_H5?0!Z&OGG]AV\BN?@SY4;;GM]0GCD'HQVM_)A7T,WW36
M&(_BS]36E_#CZ'YB?M-?\EU\7?\ 7PG_ **2OTMT'_D#V?\ UR7^5?FS^U+9
MO9_'CQ2'! DDBD4XZ@PH?YY'X5^A?PL\26_B[X=^'M7MI/-CNK*-RWHP7#*?
M<,"#[BNW%+]S2?E^B.:A_$J(ZEONFOS*_:E_Y+WXM_ZZP_\ HB.OTU;[IK\N
M?VA-<M_$?QH\67UI(DUNUWY221MN5O+58\@]P=M&7_Q&_(>+^!>I^F/A<X\,
MZ:?^G>/_ -!%?FC^T7JSZU\;O&%Q([.5OF@&X]!&!&!_X[7Z3>";R/4O!>C7
M4)S'/912)]&0$?SK\XOVE]!FT'XU^)4E3:EU.+N-NS*X!)_[ZW#\*,!I5:?8
M6+^!,_1'X;^%[;PKX1TK3X(PJ6UM'",>BJ!755YS\ /B)9_$KX7Z-J4$RO>0
MPK;7L61NCG0 -D=L_>'LPKT:O-E%QDU+<[4TTFCY'_;^C5= \+$#!-W+_P"@
M"NB_8-_Y)/J?_87E_P#145>8?MY>-K/5O%VA^&[67S)M*BDFN]IX5Y=FU#[A
M5S]'%>D?L$7D<OPSUJV!_>PZJ[,/9HHL']#^5>G*+6#7J<46GB'8VOVWO^2+
MS?\ 7[!_,UYS_P $^?\ 6>-?K9_RFKT;]M[_ )(O-_U^P?S-><_\$^?]9XU^
MMG_*:IA_N<O7_(<O]YCZ?YG??MT:@]K\&X(%)VW.IPQMCT"N_P#-17RQ\ /C
M3I_P7U#5;V[T*369KM8TC*7 B\L*6)'*G.25_P"^:^M?VU-#EUCX,W4T2EC8
M7,-V5 R=H.PG\ Y/X5\B?L[Z#X5\7>-6T+Q/!%(;Z,+8R2S/&/.!^YE6'+ G
M&>Z@#D\[X?D>%ES*ZOK^!G5YO;KE=F>]_P##P:R487P//C_L)*/_ &E7GOQJ
M_:RL_BYX(O=!'A)M-EG:-DNVOA+L*R*WW?+&<@$=>]>Z+^Q_X-_Z 4?_ ($S
M?_%TX?LA>#1_S HO^_\ +_\ %USQK82+4E!W7]=S9TJ\DTY+^OD>*?L&><OQ
M2UEE_P!1_93*_P#O&:/;^@:OHS]J;X73_%#X?FULR!J-G*+JVW'"LP!!4GMD
M,1]<5M_"WX)Z%\,;VZNM)TV.RFN%"2,KNQ8 Y ^8GUKTF:%+B,HXRIK"M7YZ
MOM8:&E.ERP]G+4_+/POXV\<_ GQ!,-/N+K0KP\3VEQ&#%*!_>1@58>C#UX-?
M1_PZ_;UCN)X;3QMHBVZ,0K:EI>2J^[0L2<>I5B?1:^AO%?PGT?Q1;M#>65O=
MPMSY=Q$'7Z\CBOCW]IC]GC3OAOI*>(-)S9P-.L$MFS%D);.&0GD'CIT],8Y[
M(UJ.*DHU8V;ZG/*E4HKFIRNC[QT?5[+7]+M=1TVYCO+"ZC$L,\+95U(R"#5R
MOES]@GQ)=7_@+7-'GD:2#3[T/;ANB+(N64>VY2?JQ]:^HZ\VK3]E-P['73ES
MQ4@HHHK(T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M /FO]LG_ )E#_M\_]H5Y9\)O^8K_ -LO_9Z]3_;)_P"90_[?/_:%>6?";_F*
M_P#;+_V>M8G4_P"#_7<]"HHHK8X@HHHH **** "BBB@ HHHH **** "BBB@
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M%^TLI_M#0VQP4F'ZI_C6>%_BK^NA>(_AL[SX$_\ )-]/_P!^;_T8U>@UYO\
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M $".O4IXU9&) SBO+?V<?^1+N_\ K^?_ - CKU6;_5M]*YZ_\21O1^")\H>
M5S\5-/';[:__ +-7U<L*8'RBOE'P"P7XJZ?DX_TYO_9J^L5^Z*Z,9\<?0PPW
MPOU/&_VD]0>'1-(LE;"33M(RCOL7 _\ 0ZYCX*Z_X:\-V=[<ZM?QVM[++L56
M1V/E@ CH#U)/Y5O_ +2UJS6.BW./DCEDC)]V4$?^@FO._A_\.T\=P7;+J!M9
MK=E#1"'?E2.#G<.X/Y5M!0>&]]V7_!,Y<ZK^XKL]Y_X6]X*48_MF/_OS+_\
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M %%%% $%Y_J'^E?EG\</^2O^,/\ L)S_ /H9K]3+S_4/]*_+/XX?\E?\8?\
M83G_ /0S7JY?_$EZ'#B_@1R_A_\ Y#VF_P#7S%_Z&*_6_2_^/6/Z5^2'A_\
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M\;QS+D8L\?\ D>OI'5/@KH6J7!FN-.L[ER<[IK='/YD5Z>(Q,8U'3J0YDO\
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M7'*NGV=M9B7&\6\*Q[L=,X SU-=E;$PK1UA:7<YZ=&5-_%='S?\ MA? V_\
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MU!;./PI.IATGRQ=QJ%>]Y21TOB3_ )%_4?\ KWD_]!-?,OP3_P"2E:5])?\
MT4U?4UW:K=6DL#C<DBE&'J",$5QGAWX5:'X<UB+4+*P\FXBSL?SI&QD$'@L1
MT)J*=94X2BUN7.FYRC)/8[FJ6N?\@>]_ZXO_ "-7JANH1<V\D3#*NI4CU!KG
M-CY5^#'_ "4O1OK+_P"B7KZO7I7#>'_A3H7AW6(=0L[#R;F$G8_G2-C((/!8
MCH37<UT5ZJK2YHHQHTW2CRL6JFK:E#H^EW=]<'$-M$TK_1035NHKJ!;F%XV
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M(H=7TIY;A!@SVK !_<J>A_'\J]7\3>$;#Q-;F&]MH[F/KAQR#Z@]0?I7 3?
M+1&ERJW4:Y^ZLW'Z@FJ^L4IQ4:L=43[&I&3E3>YQOCKXS7OCBU_L;2-/:T@N
M2$?YM\TV?X1@< ]^N?6N(T.[F\$^,K2:ZC*R6%T/.0>@.&Q^&:^D_"OPSTGP
MSEK2T5)3P96)9S^)Z?05FZ]\'])USQ,=4N8Y)"RJ'A#;4<CC<<<],#KVJHXF
MG&\5&T?Q%+#SE:3E[QZ LR7-FLL3!XY$#*RG(((R#7R7H/\ R5"Q_P"PNO\
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M#.6)/0"MVHJ252;DNI4(\D5%]#Y"\565YX)\=W+)F*:WNOM-O(1P5W;D/O\
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M8KB]*^%.CZ3<226MG;V@D8LRV\*Q[B3DDX'-=5"NJ%WRW9A4I>ULN:R/F_\
M95_9UO-'U6/Q/XBM_*O54BTM'Y,((P7;_:(X [ G//3[&C01H%'05#96,5C$
M$B0*!5BL:E2567//<TC"-./+$*^?OVW/^2*7'_7[;_\ H5?0-9/B3P_;^(]/
M:TNHHYH6QE)$#*<<C@T4Y^SFI=ARCS1<>Y\D_P#!/G_CZ\;_ $LO_:]?9E<W
MX3\$V'A/SC96T%L9<;_)B5-V,XS@<]3^==)55JGMJCG:UR:</9Q4;W"BBBL3
M0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*** "BBB@ I*6B@ HHHH **** "BBB@ HHHH **** "BBB@ I*6B@ I*6B@
MHHHH **** "BBB@!*6BB@ HHHH **** "BBB@ HHHH *2EHH **** "BBB@
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MDCA6,  8I]<7FSH;[!1113$%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% 'S7^V3_ ,RA_P!OG_M"O+/A
M-_S%?^V7_L]>I_MD_P#,H?\ ;Y_[0KRSX3?\Q7_ME_[/6L3J?\'^NYZ%1116
MQQ!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5;R$S*15JDI#.?
M;269B<58L]/,+YK8VCTHVCTJ.1%<S$4;5Q3J**T("BBB@!#6?>V?G5HTE)JX
MT['.R:2P[52N?#L%SS-:Q3'_ *:1AOYBNNV@]J0PJ>U1R=B^?N<.W@S3&.3I
M5FQ]3;I_A4T/A>TA_P!78VZ?[L2C^E=EY*^E)Y*^E'*^X<R['/QZ2W''%7;?
M20N,BM78!VI:%! YLAAM5CZ"I@,4M%60%%%%,04444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >.^/_ /D;
MK_\ [9_^BUHH\?\ _(W7_P#VS_\ 1:T5D]SU8?"C]!Z***Q/-"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#YK_;)_P"90_[?/_:%>6?"
M;_F*_P#;+_V>O4_VR?\ F4/^WS_VA7EGPF_YBO\ VR_]GK6)U/\ @_UW/0J*
M**V.(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /'?'__
M "-U_P#]L_\ T6M%'C__ )&Z_P#^V?\ Z+6BLGN>K#X4?H/1116)YH4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?-?[9/_,H?]OG_M"O
M+/A-_P Q7_ME_P"SUZG^V3_S*'_;Y_[0KRSX3?\ ,5_[9?\ L]:Q.I_P?Z[G
MH5%%%;'$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'CO
MC_\ Y&Z__P"V?_HM:*/'_P#R-U__ -L__1:T5D]SU8?"C]!Z***Q/-"BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#YK_;)_
MYE#_ +?/_:%>6?";_F*_]LO_ &>O4_VR?^90_P"WS_VA7EGPF_YBO_;+_P!G
MK6)U/^#_ %W/0J***V.(**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/PS^*WB?XT6WBOPG:ZS!H>NK:Z<DTLJ_9XB]P-HVN,C"+USTKZZ_X8&^ /\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \=\?_\ (W7_
M /VS_P#1:T4>/_\ D;K_ /[9_P#HM:*R>YZL/A1^@]%%%8GFA7PE_P %5/\
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M_P!&&O>:FLE&I)+N53;<$V%%%%8F@4444 %%%% !1110 4444 %%%(2%!).
M* ,SQ1XHTGP3X=U#7=>U"#2M'L(C/<WER^V.)!W)_0 <DD <FOC&3XI?%[]N
M+4[JP^%L]Q\+_A#%*T%QXSN(V74-2P<,+9005&?[I!&/F<'Y*S]6:^_X*(?'
M"\T6"ZFM_@#X(O MW-;.5&OWR_PAAU3K@CHAW<-(NW[FT?1['P]I-IIFEV<&
MGZ=9Q+!;VMM&(XXHU&%55'  '85AK4]/S.C2DM?B_(\1^#W[$/PE^#BI=6OA
MR/Q'K^?,EUSQ$!>73R'DN-PV1G.>44'U)KWE5"J%48 X %5M4U2RT33[B_U&
M[@L+&W0R375U*L<42CJS,Q  'J:FM[B*\MXIX)4G@E4/'+&P974C(8$<$$=Z
MUC%1T1C*4I:R9)7,^.OAEX2^)VF-I_BSPWIGB&T(($>H6J2E/=21E3[J0:Z:
MBJWW)O;8^--?_8_\;?L^7\_BC]F[Q/<646\SW?@#7+@SZ=>CNL3.<HV!@;CN
MY_UB]*]9_9N_:JT7X]1W^BWMA/X1^(>CY36/"NHY6>!@<%X\@%X\D<X!4D @
M94GW*OFO]K/]FF]\?"S^)/PZE.A?%_PT/M&G7UMA#J**.;6;LV1E5W<<E3\K
M'&+BX:P^XW4E4TGOW_S/I2BO(_V7_P!H"Q_:,^%MIXAC@&G:W;2&QUG2FR'L
M[Q/OK@\A3PRY['!Y!KURM4U)71C*+B[,****8@HHHH **** "BBB@ HIDTGE
MQLWH,UX!^R1\6/$WQ0L/%#^)=0&HR6=XB6["".+8A!ROR*,].^36D8.47-="
M')*2CW/H*BBBLRPHHHH **** "BBB@ HHHH ***;(VU&8#.!F@!U%?)]Y)^T
MFMW,(_$>DB/>=H6UBP!GCK!7$V/Q:^/6H?$*\\&1>)+'^V;2/S),V4'EXVJW
M!\G/1QVKKCA^:]IK3^NQ@ZO+O%GW-17S#X/E_:#/BK2#K.O:7/HXNXC>Q+;Q
M!GAW#S%!$(.2N<8(^M?3PZ5A.*CLT_0TC)RW5@HHHK,L**** "BBB@ HHHH
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M^4/W;/MQUZ+^9KTJJE%QM?J2I*6P4445)04444 %%%% !1110 4444 %%%%
M'S7^V3_S*'_;Y_[0KRSX3?\ ,5_[9?\ L]>I_MD_\RA_V^?^T*\L^$W_ #%?
M^V7_ +/6L3J?\'^NYZ%1116QQ!1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MH-TK*H53Y;K]T@GG/6M9-I72,8I-V;L>V45\*?\ #%/[1?\ T<_K7_?=W_\
M'J/^&*?VB_\ HY_6O^^[O_X]67/+^4V]G#^=?B?==%?"G_#%/[1?_1S^M?\
M?=W_ /'J]'_9_P#V:?C#\,?B1;:[XR^-^I>.=#C@EB?1[IIRCNRX5_GD8?*>
M>E-3E?X1.$4KJ1]245C>,UUZ3PGK"^%Y+*+Q&;60:<^I*S6XGVG89 O.W.,X
MKXN^#/\ P4(/@72?$OA']H."X\/?$#PK&Q>1;89U8#&U45!M\TY7!&$=2&!
MS3E-1=F3&G*:;B?6_P 7?B[X8^!_@6_\6>+-06QTNU&%48,MQ(0=L42Y^9VQ
MP/J20 2.1_99^/%_^T7\,_\ A+KWPE>>$XI;R:*U2YD#I=0JWR2QM@$C!VDE
M0-RM@D=/DSX7?"WQA_P4(^(MM\4_BI;S:/\ "C3I6_X1_P +AV"WB@]>V4)
MWR\%R-JX4?+^AUE96^FV<%I:01VMI;QK%#!"@1(T48554<     >E3&4IOFZ
M%3C&"Y=W^1-7PE_P2K_Y _Q?_P"QE_\ 96K[MKX2_P""5?\ R!_B_P#]C+_[
M*U$OXD?F.'\.?R/NVBBBMC **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%/\ R0O3_P#KZN/_ $8:]YKFQ'\67JS6G\$?0****P-0HHHH **** "BBB@
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MG_T1!6E#:?\ A?Z$5-X^I]0>)O$&G>#_  _J&MZG(L%C8PM/,^.=JC.!ZD]
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M1E&M&2Y4K*Z_KJ:23IN+O>[/K:BBBN(Z0HHHH **** "O@#_ (*>>([/P?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-/K7@;Q#>^%9Y,DK9E@!DY(5E=653QQR/Y57T7]DS7/%'B"VU#Q_XJU#Q/'
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M:5:R7MI#L6[1.@V@J0Q X#HQ7.."/<5[M!^SSX&@F21?#6D;E(8?\2^'J/\
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MN22< <<DD_C5'Q=X!T7QLUF=8TZUO_LDGF0_:85DV-ZC(XZ5K&LHUO:VZO\
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MVOO#OBO5UDCT6:V"O<*A8*"DD3' Y.W<K$#G!KZ1\!_&;PA\3-2O['PUJO\
M:<MC&DDS+#(B ,2!@LHST[5H>,_A[HGCRU6#6+"WOHU.X+<1+( ?4 C@^]5_
M GPOT#X=K<#1=-M;#S\>8;>)4+XZ9(&3C)Z^M*52$X)-.Z5O(<82C)M/1GSW
M\(?^3U/B%_UXS?\ H=M7UE7-Z;\/]$TGQ3>>(;73[6'5KQ=DUW'"JRR#CAF
MR?NC\AZ5TE14J>T:?9)#A'E5CP;]L;P!_P )A\*+N]@CWWND-]MCP.=J@B0?
M]\%C]5%>(?L_W.I_'KXUZ5K^LH9+?PSI<$ +'<&D5=JL?=F,DGU%?37[2'CB
M'P#\']>OW*FYGB^QVJ-SNED^4<=\#<V/137&?L8> /\ A%/A9%J<\>R\UA_M
M;$CGR^D8^FT;O^!FNJ$W##N_>R^>YC**E57X_H?0"KM4 =!2T45P'4%%%% !
M1110 4444 ?-?[9/_,H?]OG_ +0KRSX3?\Q7_ME_[/7J?[9/_,H?]OG_ +0K
MRSX3?\Q7_ME_[/6L3J?\'^NYZ%1116QQ!1110 4444 %%%% !115>^U"VTRU
M>YO+B*UMT&6EF<(H^I-&^B L45Y+XH_:1\-:*SQ:<DVM3+_%$/+BS_O-S^0(
MKSS4OVGO$EY(5T_3K&T0_=#*TK_GD#]*]"G@,145^6WJ<LL52CI<^G:*^4!\
M7/BA>DRP37/EGH(=-C91]"8S_.I(/CYX^T5MM_Y=P0>?MEF$/T^4+6W]F5NC
M7W_\ S^N4^S/JNBOGS0OVJ&W(FLZ(N/XI;&3'Y(W_P 57K/A+XG>&_&H5=-U
M&,W)'-K-^[E'_ 3U_#(KDJX2M1UG'0WA7IU-(LZJBBBN0W"BBB@ HHHH ***
M3</44 +12;AZBEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH P_&GA.T\;>&;[1[P?NKF
M,J&QRK=F'T->*?"GQ_K/PQ\61_#?QJS.F=FE:HWW9%SA5)[]L>G>OH>O/?C1
M\*X/B=X8:&,_9]:M/WMA=KPR2#D#/8$XK"I%_'#=?B=%.:^">S_ ]"K'\8S3
MV_A+6I;8%KE+.9H@O4L$./UKRWX&_&MO$4A\)>)5:R\5:>#$_F#:)]O (]\8
M^M>TD!@01D'M5QDJD;HSE%TY6D?FW\+-2^Q?%_P_?7JL2FH[Y5'WLG.?U-?H
M)XF\:^'?!DEI)K5_;:?+=?)$T@&YN,XSU Y^E?.WQX_9INK;4I/%?@M D@?S
MY[(.%*-U+H3QCU&>]>4>)/&>J_$1K8^-=%O-6FLE\I+W3DR2!_"=OR?B.:_+
M<^R"ICL53J2ORI-.V_E:^GJ?H64YM"A0E&.[:M?;SN?7GC3X^^"_!>F^?)K-
MO?7,J$V]M9/YS2-V7Y<[?QKYR^(/C'Q';_"75SXPOFDU+Q3*K66ER  VL"L&
M$F,9&=I7FN3\.^.-&\$$RZ%\.%N-3SA+S4UD<K[[,E<_A3M'^&WC+XU:Q-X@
M\0W0T[3PVV;4]1811QKUV(IZ<= !BN/+.'OJ]5<L'9-.\K7=M4DE?E5]VW=G
M7CLU<Z;<I=+65[:[WON^RL>Q?L3>&WM= UO6I$RMW(D,;8Z;-V[_ -"%>N_&
M3X9CXG>$9[""Y>SU&,;[:99&5=WHP!Y!&>M:'PMT?P_X>\&V6F^&[J&\T^W&
M#-$X;>_\3-CH2:ZVOUJG32I*#/S>I5;JN:/R]\9>"=:\%7]SI^L6$UI<)N3Y
ME^5_=6Z$?2OTV\4_M8>(OA/\#?AEJ7P]\"GQ-H,VFQI?WXCDDBMFC"I(I$9R
MI)!.6XXJCXJC\/QZ?)=>((K VD*DF2^C5@H[XW#^5>0W7C*>ZT"ZUOX1^*VT
M%HYO*GT^5=UC<J,C_4."@/']T9[UXV(RV55J-/WGVZL]6CF$81<JONKJ^B/M
M;X>_MG?"3XA:''?6_BZRTVX"#S[+4'\B6%^Z_/C=CU%='X1^+7@KQ/=>)-9T
MBQV6.DP^9<^(#8>3'.NTEMDA4%P,<D$BOAO1?B9\0-+4WMQ\"? GBC4Y$)&K
M+'"-S$8):,$*/P%>8?$3XK?M$_%;3;SPW- ^E^'C\K:)H\,$$,:_W,IAMOL3
M7AO+:RDUR-'JK&T9)-33/"OC#\0+GXE?%CQ)XKG9A/?WK2 YS@*=JD?@HK[B
M^ /BFY\7?"W1[V[QYZ)Y#-@C=M &3FOD;1?V6/B#JPWRZ2M@A&0UQ,F3^ )-
M?8OP8\%ZA\/_  #8Z+J<T,]U"6):'.T XP.:^EP5.=.6JLK'B8VI"<59W9W-
M%%%>P>.%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1112 ****8!1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!X[X_P#^1NO_ /MG_P"B
MUHH\?_\ (W7_ /VS_P#1:T5D]SU8?"C]!Z***Q/-"OA+_@JI_P @?X0?]C+_
M .RK7W;7PE_P54_Y _P@_P"QE_\ 95K&M_#9O0_B(^[:**YOQI\2O"/PWAM9
MO%GBC1_#,5TS);R:Q?Q6JRLH!8*9&&X@$9QZUL8;['245YA_PU%\&_\ HJ_@
MK_PH+3_XY1_PU%\&_P#HJ_@K_P *"T_^.5/-'N5RR['I]%>8?\-1?!O_ **O
MX*_\*"T_^.5L>%?CC\.O'>L)I/AOQYX:U_5'5G6RTS5H+B9E498A$<D@#KQ1
MS+N'++L=LRAE((R#P0:^ OV@O^">_B=?B!/J_P #];_X1+1O%Q.G^)M*CN3;
MP6\+G<\B*I&^(XYA'()PORL0OW]3()X[J&.:&198I%#))&P964\@@CJ*4X*:
MLRH5)4W>)YO^S_\ L_\ A7]G+P#;>&/#%MZ27NHRJ//OIL8,DA'Z+T4<#W]+
MKYT_:]_:^TK]F_08=,TR%=?^(FKKLTG0XP7(+':LTJK\VS=P%'S.1@?Q,O2?
MLFZ3\5=+^$UO)\7M734_$]]<27JP>4JRV44AW""1E^5F!). ,("%R0HPHRBG
MR1Z#E&37/+J>SU\)?\$J_P#D#_%__L9?_96K[MKX2_X)5_\ ('^+_P#V,O\
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MV-.3<(R]Y?<+VDTE)K3\3Z/_ &A/B%#X+^&OB$V6N6VF^(5M-]K']H1;C)8
M,J$Y/?MVK&_9\^,&G:Q\(] NO$WBS3VUMEE%PU]>Q),<3.%W D'[H7M7,?M9
M?![0M:\*Z[XVN+=FUBSL56.82N!A6X^4':?O'M7$? 7]F'PE\0OA=H>O:G9/
M+=W0E,K"YD7.V5U'"L .%%.*I>PO*^_9=OR$^?VMEV/KK4]:T[1;!K[4;^UL
M+)<9N;J98XQG@?,Q YK.UKQ]X8\-P6LVK>(M*TR*Z4/;O=WL<0F4]&0LPW#W
M%>-_MDVZZ?\ L_S6L8VQ1W%K&J^P8 #]*\K^"O[-,OQ4\/6_B;QM/<WK7%M'
M%86[2L@BMD0+&>,?P@8 XQR<D\9QI0]G[2;MK8J4Y<_)%'V;I^I6FKV,-Y87
M4-[9S#='<6\@DC<>H8'!'TK"U3XG^#M%OC9:AXKT2QO =IM[C488Y ?0J6R*
M^<_CMKM]\$/A[X5^%O@F>Y@U'5)'C2='_?+$TA^16P"&>23&1R I]:O>$_V)
M_#<>@Q?VQYVHZBZ9DN#.\8W'DE54CCZYH]G3C'GFW9[=PYIR?+%;;GTYI^I6
MFK6JW-E=0WENWW9K>0.A^A!Q7GO[2/\ R0_QA_UX/7S1:VNK?LD_&S1K6VOK
MF?P=KDH2:UD;Y<%@C$CH73<K!N"1QZU]+?M('=\#?&!'_/@]/V:A.#B[IV_,
M.9RC)-6:.?\ V0O^3>?#GUNO_2F6O.OV+_\ D?OBS_U_1?\ HVYKT7]D+_DW
MGP[];K_TIEKSK]B__D?OBS_U_1?^C;FM9?\ +[U_]N(7_+OT_0^KV8*"2< =
M2:YI_B?X.CU 6+^+-#6]_P"?=M1A$G_?.[-?/W[4WC37/%OC[P_\)_#EW+8_
MVD@EU&:)L%T;=\AQSM5$=B/XL@5>A_8F\(+X?\AX;A[WR\?;/M+B3=CKC.S\
M-M8>SA&*=1[]C3FE)M06Q]+QR+-&KHP=&&Y64Y!!Z$&H[R\M]/M9+FZGCMK>
M,;GFF<(BCU)/ %?*_P"RGXFUKP3\2?$WPIUF\DOK73T:>P>1B?*"E?E4'H&6
M16V] 5/K6/\ &[4-7^/7Q]B^&ME>SVGAW2E5[U8CQ(X 9W([XWH@SP#D]ZKZ
MO[[BWHE>_D3[7W;VUVMYGU#I'Q*\(^(KPV6E>*-&U.\P<6]G?Q2R'Z*K$FOG
M/]E7_DO7Q>_Z_P"7_P!*9JM>+OV*]#CT$2^'GFTK6;<>9#=+.[Y<<C<"3CGN
MN".OM7.?L0PW]O\ $KX@Q:J[2:HFU;MW;<S3"60.2>YW9YK6*I^RFX/MOZDM
MS]I!27]6/LJBBBO/.H**** "BBB@"#4-/M=5L;BRO;:*\L[B-HIK>= \<J,,
M,K*>"""00>M?$_B[]DSXB_LV^+;[QS^S9J:/IUV_G:G\/]3DW6L^.?W)8@'V
M!977D*Y!VU]OT5$H*6Y<9N&Q\B_#S_@I!X'O-0_X1_XH:1JOPF\70D)/9ZU;
M2-;[O42!0R@\_P"L10/[QZU])^%OBAX-\<0I-X=\5Z)KL;_=;3M0BG_#Y6//
MM2^.OACX1^)VG?8?%OAK2_$5J 0J:E:),4SW0L,J?=2#7SSXF_X)C_ 7Q!,\
MMOX?U'06<Y(TS4Y0OX+*7 ^@XJ/WD?,O]U+NOQ/J*^U2STN S7MW!9P@9,D\
MBHH'U)KQ?XE_ML_!;X5V\K:IX[TW4+R,<6&BR"^G9O[N(LA3_OE1[UY78_\
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M-+O/#%G;[S-:72%I5 ?8N!M!.XD8X'7TYKR23]M6_P!4D:;PY\,=:UG2U/\
MQ]M*R$@>R1. ?^!5G&C4E>RV*=2,;79]145Y'\$_VD-!^-%Q=Z=#:7&C:[:H
M9)-/NB&R@(!9&&,X) ((!&>E>N5G*$J;Y9*S+C)25T%%%%04%%%% !1110 4
M444 %%%% 'S7^V3_ ,RA_P!OG_M"O+/A-_S%?^V7_L]>I_MD_P#,H?\ ;Y_[
M0KRSX3?\Q7_ME_[/6L3J?\'^NYZ%1116QQ!1110 444V2188VD=@B*"S,>@
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MP7<ZP81#=62-]JMU)P&5=V5]B.GXCM7RBTE]X\\8+YLADOM4NU3>W]YV 'T
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M*2:ZG\A\7XEU\XKT[)1IR<4DK:)_GYA1117:?%A1110 4444 %%%% !1110
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M**NQI.3LC<HJEH^K6^N:;;WUJQ:"9=RDC!J[3O?5!MHPHHHIB"BBB@ HHHH
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MTBUM[@#:)53+X]-QR?UKT=E$<#*HP O%24R7_5O]*YFW)W;N;K31'RE^Q?\
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M54E$8ER<%L=2JCK@D5[M^S!X7U+PC\%=%TC6+4V=_"UP9(696*AIG8<J2.C
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MWPG\8?:,>3_9-T6W>GE-7CW[!JNOPCU/=G:VKRE?IY40_F#6/^U+^T!IFO:
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M86VJ33K'#<R# V+QGKGYL'H?:O(?C!J&L^!Y_#MT]_#/JAN;C461V\WR';:
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
MCN(UDMY$;.UE(.T9.*^?=0\&_ ^35[FYU?QYK=C.'8SZ5#H,BLCY.4#[L?CB
MO=/$%GJ%]ISQ:;>+8W1Z3.FX#\*\-U?]F>]OM=CN&UH3V\QWW4TJ_O W4D?7
M]*\O'4YU4E"-['ZKP/F&"RUUIXS%NES+1+=VUUO%KTZW*.J^%OV?KVW+Z7XZ
M\2:5,HXCO-'>X#'ZJ5Q5"./X7ZAH(T$>.M?T>S68SKY^GM<6[2D %_+!4@D
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MK/Y,[_\ 9[\__A7-IYN[R][B+([;C_6O2ZS?#NGPZ3H]M9P6%QID<*[?LMU
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MGMO%?;%1W%O%>6\MO<1)/!*I22*10RNI&""#P01VJ)QYXN)=.7))2/G31?\
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M_P#1,/#W_@-_]>C_ (8M^!O_ $3#P]_X#?\ UZ/WOD'[GS_ R/\ AOSX ?\
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M&ZCN(OA?X;,D;;E\VQ61<^ZMD'\17K]O;Q6=O%;V\2001*$CBC4*J*!@  <
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MM9-)@:)8(V79*65P7?*[F;$AYSV7L,5[G116<I2EK)W*45'9!1114E!1110
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MIQ45>Q%122CL?$8BM4Q%656L[R>KTM^044459SA1110 4444 %%%% !1110
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M%%%8GFA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MGF'Y0 ><=JPE%>W3YOD;1D_8M<OS.:^/^K7FEC1OLES);[_-W>6Q&<;,5>^
M^I76I:-?/=7$EPRS8!D8G' K&_:.Z:'_ -MO_9*T/V>_^0'J'_78?^@BLDW]
M::_K8T:7U9/^MSUJBBN'\6?%S1/"TSVVYKV[7@QPXPI]"W8UZ$IQ@KR=CBC&
M4W:*.XKA_C'>SZ?X'N)K:5X)1(@#H<'J:Y6V_:*MI)PLVCR119Y=9PQ_+ _G
M5KXD>+],\7?#6ZGTZ?S-LL>^-N'3.>HKEG6A.G)1>MC>-&<)Q<EU.=^!^N7^
MH^*I8[F\FGC\ICMD<D5[U7SQ\ _^1NE_ZXM_*O8_&WC>U\#V=O<7<,DRS.4
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M1116)YH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&#7F?PX_9[\._#/Q/=ZWITEQ+<RADB65N(D;J/?M2ESW7+MU*CR<KYM^A?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MXG^(%C:?%[5KC3[I0/LMI;PF&Q89[2DD'/3->L_LT?\ )'M%_P"!_P Z\_\
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M8  U]T5\9_LOVZ3?'37V903&+AE]CYH%%=>_32%AW[E1OL>M?$S_ (6;X/\
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MXN7U!;P2Q[-JQ%,<@YZFB=.;Q"FEH$:D50<&]3F?VC(F:'19 /E4R@GZ[?\
M"J?P-\7:5HUG?VFH7D-DS,)%:=PJMQC&3]*]6\8^$;3QGH[6-T3&<[HY5ZHW
MK]*\>G_9[U>.;;#?V\D6?OL"I_*LZM.I"M[6"N73G3E2]G-V.M^+%G!XZ\%)
MJ6DR"[%G(7_=#)9>C?EU_"O*_AKXZ;P1K?FRAGLIALF1>H'J/<5[S\._!+^"
M=$FL9KO[:9I/,;Y<*N0 0!DUR_C#X%66L74EWI=Q_9\KG<T++N0GVY&/UHJ4
MJDFJL5[W8=.K32=*6QU]K\2/#-U:B==:M(U(SMDE"M^1YKR_XM?%33O$&E-I
M&F W",X:2X(P..P]?K5:V_9[U=Y@LU_;Q19Y906/Y<5V3?!#3X?#,VG6UQMO
MIBI>]E3<>.P&>!^-.3Q%6+CRV)BJ%.2=[G!_ '_D;I?^N+?RKKOVB/\ D :7
M_P!?#?\ H-:?P^^$LG@C6&OFU)+L,A38L)7KWSDUL?$CP&_CS3[2V2\6S\B4
MR%FC+YR,8ZBB-*:P[@UJ$JD'74T]#B?V=?\ CUU7_>3^M>RUQ7PW^'C^ HKQ
M'O5O//((VQE,8_$UVM=6'BX4U&6YSUI*=1RB?./QJ\(3Z-XDDU*-&:SO3OW@
M<*_<>U=?\+OBY8?V7!I6LSK:SP_)'<2'".O;<>QKU35-*M-:LI+2]@6XMY!A
MD85Y+KW[/<<DSRZ3J!B0](;A-V/^! C^5<LJ52E-U*6M^AT1JPJ04*FECTV3
MQAH<,7FOJ]DL>,[C.N/YUS4'QET&Z\10:7#(SQR?+]K/$8;L.>Q]:\]A_9_U
MIW"RWULB9ZC)_2NU\*_ [2M"F2XOIFU.X0Y4%=D8_#G/YU:GB)M6C8APH17Q
M7._U;_D&77_7-OY5\I^#_P#D==)_Z_8O_0UKZQN[?[3:RP@[=ZE<^G%>2Z-\
M!IM*UNSOSK$<@MYTF*"W(+;6!QG=[48FG.I*+BMAX>I&$9*3W/8*Y?XG?\B'
MK'_7(?\ H0KJ*RO%.BGQ%X?O=-67R#<)M$A7=MY!Z?A79--Q:1RP=I)L^=_@
MU_R/ME]&KZ=KRWP7\%Y?"?B"#4FU5+@1@_NUA*YS[[C7J5<V%IRIPM)&^(G&
MI.\6<%XZ^*]GX,U:ULO*^U.WS3A6P8U/3'OUXK9T7XB>'M=A5[?4X$8_\LIG
M"./P-0>,/AOI'C+]Y=1M#=@86XBP&]@?45YG??L]:C#)_H6IPS+V\Q"A_F:4
MY5X2;2NAQC1E%)NS.Z^(^L^%V\.W:WLMI<SLG[M$93*6[$8YKQKX0VMQ<^/M
M.-N"5C8R28_N#K_,5U-G^SWJEQ*/MFI00IW**7/\Q7JG@SP%IO@FU*6BM)<.
M/WEQ)]YO;V'M6/LZE:HIR5DC;VE.E!QB[MG2T445Z9YP4444 >.^/_\ D;K_
M /[9_P#HM:*/'_\ R-U__P!L_P#T6M%9/<]6'PH_0>BBBL3S0HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^:_P!LG_F4/^WS_P!H5Y9\
M)O\ F*_]LO\ V>O4_P!LG_F4/^WS_P!H5Y9\)O\ F*_]LO\ V>M8G4_X/]=S
MT*BBBMCB"BBB@ HHHH 9-"EQ$\4J+)&ZE61AD,#P017RM\4OASJ/PK\21:[H
MADCTPR^9!/'R;=\_<;V],]1Q7U95?4-/MM5LIK.\@2XM9E*212#*L#V-=F&Q
M,L/*^Z>Z.>M1556ZGSW-#I/[0>C": Q:9XWM(OGC)PETH[CV_5<X.1@UYIHE
M[XC\ ^(Y--2_F\.7,LBQ7!DR$ SPS#!R!DG/H>*[;XC_  6U;P#J!USPT]Q/
MI\3>:IA)\^U(Y[<E1_>_/U,NF_%#P]\0M/BTKQ_9^7=(NR'6K9<.O^]@<?J#
MZ"OH*<ER7I>]3?3JO\_0\N2?-:?NR[]&;WB#X0^-_$T*O!XVCUK3YEW!I)WC
MC<'T5=RD?C3]#_9;CCMTDU3795NLY*V2 *OT9N3^0K-M_A_XT\$QF_\  FOK
MKFCR'>J02*P/U0DJ3[@Y]A5B']HSQ)X?D%OXB\, 3#CH]LQ]\,&_2N6^)DN7
M#S37E9/[C;]RG>K%K\4:%_\ LOK,Q%OXINHX3_!/;^8?S#C^57O#_P"S#HFG
MW EU74;C5PO2%4\A#]<$D_@15:+]JC23'F70[U'_ +JR(P_/C^59NH?M5.RL
MNG^'L/\ PR7%QD?]\JO]:SMF,ER_Y%WPBU_S-"3X-^&)?BC>Z9>6CPV5U8K=
M6,4$A105.V1?<]#]":SO^%C:-\+6GM-*6:\TJ5YH)]!O21-:3+P2&.04<]0<
M]<CTKG+J;XE?%K4K.[CLIK-+?=Y$\,9MHX@X ;$A^8@@#N:OQ^ ?!_PQ_P!,
M\9ZHNMZN#N&E6AW#=U^;N?\ @6T>QK?E6D:TN9V^%:_UZF?-UIQLN[.<\#_#
M&;QW>76MWT<>@>&(W::6;E4"YR4CW=ATR>![]*L?$'Q[_P )>UEX1\(VCP:#
M"ZQ0V\*D-<OG@D=<9YY[\GGI'KGC#Q1\:-3BT;2K,V^FJ1Y6GVO$<:C@-(W
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M#YTP:?:1P"Z^V13+*5&,A5.1^-:OQ'^'NF_$SPO<:-J2E5?YHIE^]$XZ,/\
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M<#@4M?1G\W>@4444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MT7XFW[NGO[S_  /B6Z\5_MP_$:RGU$67A?X2Z,D;2M<7WV=/*B RS2>:9W3
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ML]-LT\R:;:S;1D <*"222!@#O6/X%^+'A+XEI,?#6N6VJ/" TD2;DE0'H2C
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MKR)?VL_A0UX;8>+8P^<;C9W 3_OKR\?K7J.DZQ8Z]IL&H:;>0W]C.N^*XMY
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M$2Q.4;;:7##(.#@B,@_4<5O^#_CAX$\>WBVFA^)[&\O&.$MF8Q2O_NHX5F_
M&OE?]D3X6^'_ (B6?BJ36M,M;][>[18VN(@Y4$,2!GITK5_:>_9WT/P'X,?Q
M;X?B&DW=A-$6^S,45@SJH(&?E8%@01CH?PUE2HJI[*[O\B%.IR>TTL?9E<MX
M=^*'ACQ9XGUCP]I.IB[UC2&*WMMY,B>40VT_,RA6P>/E)K+^!GBV\\;_  C\
M-:SJ#&2^GM )Y",%W4E"Y^NW/XUX/^S:Q_X:=^*W/_+>X_\ 2DUSQIJT[[Q_
MS-7/6-NI]:T445SFP4444 %%%% !1110 4444 %%%% !1110!\X?\%%/^3-?
MB+_USL?_ $OMZ[/]D7_DU_X6?]B[9?\ HI:XS_@HI_R9K\1?^N=C_P"E]O79
M_LB_\FO_  L_[%VR_P#12UC_ ,O?D;_\N?G^AZY1116Q@%%%% !7#_$CXX^
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M[-K&TU=Y/L\9R V^4R.5]5!V@'OSZ5Z!^TM\=M3^'LFE>%?"44=SXNUGB,L
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MKN)5+<NFQF^'YXYM)ME1MQCC56'H<=*TJ**V2LK&+=W<****H04444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% 'COC_P#Y&Z__ .V?_HM:
M*/'_ /R-U_\ ]L__ $6M%9/<]6'PH_0>BBBL3S0HHHH **** "BBB@ HHHH
M^>OVY+Z2U^"ODH2%N=1@CDQW4;GY_%17??L[:9%I?P6\'I%@B3389B1ZN@<_
MJQKG_P!KCPG/XK^"NKI;(9+BR*7J*O4A#EO_ !PM6?\ L=?$6S\8?"6QTGS4
M75=$'V2:WW?,8P<QR ==I4@9]5-=GQ8;3HSGVK:]4>[TR;_5/]*?5"WUG3]3
M:]@L[ZVNYK1O*N(X)E=H7QG:X!^4X[&N,Z#Y>_8O_P"1^^+/_7]%_P"C;FD\
M2L?^&\_#7/\ RY,/_):>E_8O_P"1^^+/_7]%_P"C;FF^)?\ D_+PW_UY-_Z3
M3UZDOXU3_#^B.*/\.'K^IVW[;!/_  HV\_Z_+?\ ]#%<=^SS^S+I%_X4T_Q+
MXECCUN_U*VBGC^V+YJ11,@**%;()"[>3TQ@8 Y[']MC_ )(;=_\ 7Y;_ /H=
M>B_ _P#Y([X)_P"P+9_^B4K#FE'#I1=KO]$:\J=5MKH?+OQ-\&V_P!_:$\!:
MUX>5=/L]2N5BFMXAMCV[T24 = "DHXZ C-?1W[1S9^!OC COI[UXU^VE_P C
MQ\*?^OZ7_P!&6U>Q_M%_\D)\6_\ 8/?^E5)N2I2>_P#P25HZB7]:'*_LNZU%
MX>_9?TK5+C)@L8+ZX<#^ZD\S'^5>._L]_#1?V@O$7B+Q_P",4743+>-%%;R_
M-$K8#$;3U559%4'@8/M7I/P,T^35OV-VL8@QDN=/U*%0O7+2S@8_.JG[!>M6
MUW\-=7TU77[99ZBSR1]PCHNUC]2KC_@-7)N*JRCO?\+L2LW33VM^AM>-_P!D
M/PKKS6T^F0#0KR&176XTU1%T.<%1\OXXR/6NT^+OP3TSXPR:%_;+W#0Z8\CB
MWBEV)(7"@[\#)^Z,8(ZFO2;BYBLX6FGE2&)>6DD8*H^I-?,_[6?Q*\26_B;P
MM\/?#&H/I%SKC*;B\A8I)M>3RT4..57(8G')P!Z@\U-U*DE%2VO\C6?)!-V.
MPU[]G'X=QZ%)8W&EZ39[HRJR>7'%*..H?AL^^:\^_86U*YL_^$[\,27+7%II
ME[&\'.5!8R(Y'L?*4^E2:;^Q%X?^R>=J=YJ%_=L-TLTDX7<W4G ''XD_6LO]
MAFSM]/\ %_Q+M;1Q):P36\43AMP9%>X"G/?@#FMURNC-*3>V_J9N_M(W26_Y
M%S]J+_DX7X0_]?T'_I5%7U@OW17R?^U%_P G"_"'_K^@_P#2J*OK!?NBL:O\
M.GZ/\RX?'+^NAD>+/"NG>,M%FTO5+6&]LI2"\,\8="0002#Z$ U\;?#+X6^'
MM:_:B\:^'+K2[272K.UD>&V>%3&A#P@$*1@?>/YFON&ODSX-_P#)YWQ#_P"O
M.;_T9;TZ$FHSL^GZH55*\?4]D\9>"]*\"_!+QEIVCV<%A:'2[R0Q6\8C7<86
MR<#OP/RKYN^&_P .O^%B?LB:K;0Q>9?VM_/=VN!SYB!3@>[#<O\ P*OJ_P",
MG_))_&/_ &"+O_T2U>3?L11";X(R(PR&U"<?HM5"3C1<EO=!**=11?9FG^QO
M\1O^$V^$MOIUS+OU'06%C(&/)BQF%OIM^7_MF:X[]LCQ-=>*=:\*_"[1WS>:
MI<)<WFWG:FXK&&]L[W/^XIKD?#>J1?LU_M2:I9WTHLO"VO(SF1^(XU8ED;_@
M,@9/8-6U^S787'Q@^,?BKXGZE$WV=9FM[!9/X,@  >ZQA%]]YK=Q4)NNMK77
MJS)2<HJD]]GZ(S/VGO#-KX/U;X+Z19Q^7;6DSPHOLKVPY]Z^QI?^/$_[G]*^
M5/VTO^1^^%/_ %^3?^C;:OJN7_CQ/^Y_2N6K_"I_/\S>'\2?R_(_/S]GCXQ>
M(OA;;^(TT7P9<^*8KFX5Y9(&<"$@, #M1NN?TK1\1_%?Q9^U-XJT_P #WSV/
MA&P\[>]F0_F2R+_"2WWF )(3Y1QGJ!7H/[">GP7VF^,Q/&LF+R/&X?[+5+^V
M/\,!HMCIOCW0D-IJ6EW$?G30C#!=PV/]5?;CV8^E=\IP^L./+9]'YV.51E[%
M2OIV/I?P3X7MO!?A'3=$LU*6UE L* G)P!C)]SU/UKYG_9L_Y.=^*O\ UWN/
M_2DU]%_"_P <0_$?X>Z)XBAVC[=;*\J+T24?+(OX.&'X5\Z?LV?\G._%7_KO
M<?\ I2:XJ::C43WM^IT2:<H-?UH?6U%%%<9T!1110 4444 %%%% !1110 44
M44 %%%% 'SA_P44_Y,U^(O\ USL?_2^WKL_V1?\ DU_X6?\ 8NV7_HI:XS_@
MHI_R9K\1?^N=C_Z7V]=G^R+_ ,FO_"S_ +%VR_\ 12UC_P O?D;_ /+GY_H>
MN4445L8!1139)$AC>21@B*"S,QP !U- 'P/XMMQ^TM_P4NTO0;@?:O"WPQL!
M>2PGF-[E=DA/U\Z6!2.X@-??5?"/_!,6%O'&L?&OXJW*EY_$GB(PQR,.5 +W
M#J/;_2(^/]D5]W5C2U7-W-ZVDE#L%?+O_!1SX21_$[]F?6]1@AW:SX58:W:2
MJ/F5(^+@9ZX\HNV/6-?2N4_X)I_$#Q/X^\-?$N7Q-XBU7Q#+9^(3!;/JE[)<
MF&/9G8A=CM7V'%?7^O:+:^)-#U'2;U/,LK^VDM9T_O1NI5A^1-/2K#U%K1J>
MAYK^RK\5'^,_[/?@GQ9/+YU_=6"PWSYY-S"3%,Q]-SHS?1A7K%?#O_!*G6+K
M3OAW\0_ 5^^Z]\+^(W5E_N+(NPKCTWV\I_$U]Q4Z<N:";%5CRS:04445H9!1
M110 4444 %%%% !1110 4444 %%%% 'QY^V+(GAOXQ?#;Q%,=D$,JL[^BPSQ
MN?T>OK^WD6:&-T8,C*"&4Y!'K7CW[4'P??XL>!A%9[5U:Q?S[5FX!.,%"?1A
M^H![5XM\+_VLM4^$^EP^%?B/H&I2-8*(;:\MXU$WEJ,!65BJN ,8<-R,=>I[
MN5UZ45#>/0YN;V<VY;,^SJ^-=+N(_%W[>%S<V3":VTOS$D9>@*6WE/\ E(Y'
MX5K>-OVV3XDTV72?ASX>U2?6KA=B75W I\G/5EC1GW''3=@#J0>E<?\ L<>+
MO"_A7Q=KD/BF]DTOQ9?2^6LNI?(C#.63<?NR%\DAL9PN.:TIT9TH3DUK:UO7
MJ1*I&<HI/2YVW[?)V^'_  @3P!?/D_\  *^J+/\ X]H_]T?RKPC]L;X>W_C[
MX9PRZ5"UU>Z;<K=+#&,M(FUE8+ZG#9]]N*Y#PE^W'H&G^"[2VUK1]5?Q1:PK
M!);01KY=Q*!C<&)!4$C)!7(S@;JRY)5J45#6U_Q+YE3J-RZV(?BM_P GM> O
M^O&+_P!"N:]U^,OQ;T?X-^$#K6JQ-=R22"&TLXSAIY2"=N<?*  26/0#N< _
M(7AOQ!XJ\7?M4>#==\66AL+O4&\VULL$>1;!90B8/(Y#'GDY)XS7KO[<?@W5
MO$7A30M3TVVDO8]*N)'GMXU+':X7Y]HZ@%1GT#'MFMITX\].$WI;_,B,I<DY
M16M_\C.L_C5\=/&EL+W1?"6B:1IDPWP?; S2E",C.9!GCOL%<U^S/-K5Q^U1
MXID\11P1:U)IDQNDM1B,-YEOT_#%=7I_[;G@^'PO +;P[JD_B$QA!IR1IY9E
MQT$F2=N>^W/M7)?LQWVMZM^U%XDO_$5HMCJ]UI4EQ-;*NT1!WMV1<=L*5Z\^
MO.:I1G&$^:"CI\R;Q<H\LF]3J?V_O^10\+_]?[_^BS7K?[0G_)!?%?\ V#F_
MD*\D_;^!/A'PO@?\Q!O_ $6:]<_:$_Y(+XK_ .P<W\A6'V*7J_S1K]JIZ+\C
M'_8]_P"3??#7^]=?^E,M>9ZI_P GY:5_UYG_ -)9*],_8]_Y-]\-?[UU_P"E
M,M>0_'S4+GX1_M,^'OB#/83W>B>2L<S0KGG8\;KSQNVL& )&<?6JCK7J16[Y
MB9:4X/M8^Q&0.A4C@C%?'48/P-_;&B?_ %&B^*LQMV7=,<?F)E4^P>O>/A'^
MT%H'QHU35;30K+48HM/CC=[B\B5%<N2-H 8\C'>O.?VW/ TFK>!;/Q+9JRWV
MB3B7S$^\(V(#8^AV-_P$UG13A4]G/2^GW[%U&I0YX]-3FOVEIW^*_P >O!GP
MZMV+V=F1<WZJ>A?YF!]Q$@Q_UTKZRL+5+*SA@C4*D:A0H& *^3OV.])O_'OC
M+Q5\2M; EO+N7[-$X& #PS[1Z "-1]"*^N:G$>ZU37V?SZCI:IS[G+_%&ZFL
MOAOXIGMAFXCTNY:,#^\(FQ^M>'?L'Z=:K\+M2NT53<2:I(LC8YXCCP/R/ZFO
MHW6-/CU72[JSE7?%/$T;KZ@C!%?$O@7QAKG['WC+6=)UK1[K5/!]_,9(KBWQ
MN&W(5U)(7<5P&4D= 0>.:HKVE.5-;Z/U%4?+-3>Q]MZK9Q7VGSPS(KQLA!5A
MD$8KY4_8)9HU\=P1\V2W4'E'MG]X#^@6CXA?MF0>-=#G\/?#W0M6N-;U*,VZ
MW%S$J^2&&"R*CL2PSP3@#KSBO4/V6OA/-\*_A\(;Y5&JWTAN+K:<A6(PJ ^@
M 'XYIN+HTI*>CE;3T%S*I-..RN>9_M._\G%_"/\ Z_8/_2F.OK%/NBOD_P#:
M=!_X:*^$?'_+[!_Z4QU]8+]T5%7^'3]'^94/CE_706BBBN4W"BBB@ HHHH *
M*** "BBB@ HHHH *_/?5K;_ALK_@H0=-G O/AY\*U/FQ-\T4]TCC<I'3+3@*
M1T9+8^M?;/Q?\=1_#'X5^+?%DFT_V-I=Q>HK='D2-BB?\"8*/QKYE_X):_#^
M30?V?[WQC?;I=7\8ZI->RW,GWWAB9HD#>OSB=L_]-*PG[TE#YG13]V,I_(^R
M:***W.<^0_\ @IU\2;GPC^SRGAC3&9M8\9:A%I4<47WVA!\R7'UVQQGVEKZ"
M^!?PSMO@W\(?"?@RV50-(L(X9F3I).1NF?\ X%(SM_P*ODK]II?^%J_\%#O@
M7X$;]_I^@P'7)XS]T2!I)R"/=;2$?\" K[OK"/O3E+Y&\_=IQC\PKYD_X*3?
M\F:^//\ ?T__ -+[>OINOF3_ (*3?\F:^//]_3__ $OMZNI\$O0BE_$CZH]+
M_9:_Y-I^%/\ V*NF?^DL=>H5Y?\ LM?\FT_"G_L5=,_])8Z]0JH_"B9?$SY]
M_;P^$Z?%W]F/Q=91P^=J>DP_VU88&6$MN"S!?=HO-3_@=7/V'_BH_P 7OV9?
M!>KW,WGZG9VW]E7S,<L9K<^7N;W9 CG_ 'Z]SN(([J"2&9%EBD4HZ,,AE(P0
M1Z8KX5_X)G22>!/%/QQ^%,SL$\-^(3+;(QSN!:2!V'X6\)_X$*S?NU$^YK'W
MJ378^[:@OK&WU2QN+.\@CN;2XC:&:"50R2(P(96!Z@@D$>]3T5L8'Y_?LC2W
M/[+/[7?CSX"W\SCPUKI;6/#C2L2,A2Z@9ZEH0R,>[6PQUK] :^#O^"EVFS?#
MGQ5\'_C9ID;"^\.ZREC=-']Z6+=Y\:'_ &?W=PO_ &UQ7W78WD.I6=O=VTBS
M6\\:RQ2+T96&01]0:PI^ZW#L=%7WDI]_T)J***W.<**** "BBB@ HHHH ^-?
MVF?#]IXJ_:B\#:1?Q>=9WEI!#+&21N4S2\9!!J_\7OV-M)M?#-WJ/A6&2TU*
MV0RI LKNDV!DKAB2"<<8/6I?CF#_ ,-@?#?C_EC;_P#HZ6OK*:(30,C#(88K
MOG5G3C3<'T_4Y8PC-S4EU/$/V1?B</B)\-S!>%?[;TB06UTP&#(I&8Y"/< @
M^Z$]Z\+^-4WB6Z_:^C7P]]F&LP6\:V'VP;HMHMV9LC!]9,>];G@43? W]KN\
MT,(R:+XFW"-0/E'F$NA _P!F0,GL&-;_ .U'X!\0:'X^T+XF>%+9[N^TW;]I
M@0%LJA)!VCE@0S*P'."/<UK'EA6NMI+3MJ0^:5.SWB]?D/\ [:_:,V[?M'A[
M'3'D#_XFF? WX5^/+#XY7GC7Q0;",W5L\<_V,D"1B$4 +M  ^0$^X]ZT])_;
ML\$2:<C:KHNLZ?J*J/-MXH8Y4W=PK%U)'^\!7;_!;X^2_&37-3CM?"EYH^B6
M\(>#4;I^9W+8VX"[1QSPS=/>LY>VA%W@DO0N/LI-6DVSG_C!^TU/X5\:-X,\
M%>'U\2>*54><TI(A@8C=M(&"Q"D$G<H&>N<@>8?%+QA\;]=^'^N+X@TG0;+1
M7MF^U);J=ZQXYVDNW/XUG:IK\O[/O[37B#Q%XDTFZO\ 0M8:79=0KN(61E?Y
M2< E2NTKD<<^F=;XR?M-)\4_!^K>'? 6@7DUJUK))J6I7D2H(8%4LX4 GD@8
MR2/0 D@C6--Q<'"*:TU9FY)\W,W?L>P_L<_\F^^'?]^Z_P#2F6O./A#_ ,GJ
M?$+_ *\9O_0[:O1_V.?^3??#W^_=?^E,M><?"$'_ (;4^(7'_+C+_P"AVU9?
M;K?/\R_LT_E^1]94V1!)&RGH1BG45YYUGQ]\+F_X51^V!XB\/O\ NM/\01R2
M0KT7<P\Y2/H1*@^M7_@&/^%D?M+_ !"\9O\ O;6S<V=LYZ;=VQ"/^ 0_^/U1
M_;:T>]\*^)?"7CS2B8;RUE^SM,!T8'S(\^W^L_.N\_8F\)G0?A&FHRIMGU:Y
MDN26'.T'8OX83/\ P*O3FU['VO5I+_/\CBBOWG)T6IP?[2BGX7_M">!?'D0\
MJVED6*Z9?[J-MDS[F*0C_@-6/CR__"T?VG/ W@^,^=8Z6BW=RO498^:X/U2.
M,?\  J[W]L[P<?$WP?NKR*/?<Z5,EXN!SM'RO^&UF/\ P&O+OV*M+OO&7C;Q
M%XVU9C<7$4$.GQS,/O$*H/XA8XQ_P*B$E['VO6*:^_;\PDOWG)T=G_F>W_M1
MS2Z?^S_XI%N/F-O'&0/[K2HK?^.DU4_9#TZUM?@3X=F@5=TPF>1@.2WG.#G\
ML?A7H?Q'\)P^./!.KZ%<$K%?6[0EEZJ2.&'N#@_A7R+\(OC9JW[,/VSP;XXT
M*]GTE9FFM;JS 9EW'G;N(5D.-W4$$G/7C"G%U*+IQW3O^!K)\E13>UK'U5\:
M+"VOOA7XL6Z16B&EW+'<.F(F.?PKR7]AF:9_@O>)+_JTU.<1?[NR,G_QXM7!
M_%C]IFZ^.6CR>"/AWH6HN=2_=7=Y=JJ,(L@E0%8A5.,%F(XR,<\?1'P1^':?
M#'X9Z;HF0\\<9DN)!_'*W+GZ9.![ 4Y1=*BX3W;V"+]I4YH[(\*_8UL8+CXC
M_%*>2-6EAO8PC$<@&6XR,_@/R%?6LO\ JG^E?*7[%X/_  GWQ9X_Y?XO_1MS
M7U;-_JG^E1BOXK^7Y(=#^&OZZGRE^Q?_ ,C]\6?^OZ+_ -&W-4O$$:ZO^WAI
M<-XH:.&V @5N0<6KL/R)8_A5W]B\'_A/OBSQ_P O\7_HVYJ+]JCPCKOA'XC:
M#\4/#EJUU+IVS[5&H)X1B02!R5*LRMCH,>YKJ;7UB47U5OP1BK^RB^SO^)]9
M>6K1["HVXQBODSP7"EO^W5XHCC&U%LN /^N%O6O=?MV>'[W0T71/#FK7OB68
M;(M/D1?+\PC^^K$LN?1<GVKS[]G=O$4W[5%_=>*S_P 3ZZT^2XN5&,)O6,JO
M' VJ5&.V,5G3HSIQFYZ:/]"I5(S<5'74^X****\\ZPHHHH **** "BBB@ HH
MHH **** /FO]LG_F4/\ M\_]H5Y9\)O^8K_VR_\ 9Z]3_;)_YE#_ +?/_:%>
M6?";_F*_]LO_ &>M8G4_X/\ 7<]"HHHK8X@HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&X%0!QZ$\U[\ !T&*-HZXJW5G)R;Z[DJG%6786BBBL30**** "BBB@ HHHH
M**** "BBB@ HHHH ^</^"BG_ "9K\1?^N=C_ .E]O79_LB_\FO\ PL_[%VR_
M]%+7&?\ !13_ ),U^(O_ %SL?_2^WKL_V1?^37_A9_V+ME_Z*6L?^7OR-_\
MES\_T/7****V, K@?V@/$!\)_ KXAZPK;)+'P_?SQG_;6W<J/^^L5WU?.O\
MP4'\2+X9_9#^($N_;+=P06,:]V,MQ&C#_O@L?PJ)NT6RX+FDD<U_P3"\.C1/
MV1]!NPNUM6U"^O6]\3- #^4 KZOKQO\ 8X\.-X5_9;^&-@R>6[:)!=LO<&<>
M<<^^9*]DI4U:"0ZCYIMG*> ;CP/<6^H'P3+X?E@6?%Y_8#0%1-C_ ):>5_'C
M^]S75U\;?\$V?AQXJ^'/AOXDP^*?#VI>'Y;WQ ;BV34K9X3-'LQO7<!D>XK[
M)IP?-%.PJD>632=SX2_9%_XH[]OC]HWPJO[M-08ZR(^@YG$@./\ M]_6ONVO
MA*$_\(-_P5JGW_NE\8>&OD[!]ML/ZV)_$5]VU%+9KLV:5MT^Z04445L8!111
M0 4444 %%%% !1110 4444 %%%% ",H92",BL/4_!>E:MG[1:QN#U!4$?E6[
M10!S]AX'TC35"PVJ(HZ*J@#\J\U^+G[,GAOXEAKEH/LFI8PMY;863V!XPP^O
MX8KVJBJC)P?-%V8G:2M+5'!_!WX?3?#WX=6/AJ]OI-5^RF0+-,N#M9RP4#)P
M #CKV[5LOX!T>2\6Z-K&9EZ.5&1^-='12DW)W>XU[JLC,7P[8K=17"PJ)(QA
M6 Y%7+NSBOH3%,@=#V-3T4@.;B^'^C0WGVE;2,3?W]HS^=:EKH-G9WC7,42I
M*PVE@.U:%% [LI:EI%MJRH+B,2!&W+GL:FN+**ZM6MY%W1,-I'M4]% BMI]A
M#IMLL$"A(UZ**@U;0K/6H]EU$L@Z<BM"B@#*T3PW8^'XV2RA6%3_  H !^5>
M$?MN^.F\/_#6U\/6I)O]?N/*"KU\E"&?'U)C7W#&OHRLC6O"VG>()[6:]MHK
MB2V;=$TB!BA]03TZ"M*<E3FI-7L1.+E%JYR_P+\"+\._ACHFCE MQ' 'G([R
MM\SG_OHG\,5W]-C01J%48 XIU0VY-ME))*R"LW4O#]EJO^OA5CZUI44AG/:;
MX#T?2I-]O:1QG.3M4#/Y5T"J$4!1@"EHH HWFBVM]=0W$T8:6(Y1O2KW2BB@
M HHHH **** "BBB@ HHHH **** "BBB@#Y>_X*5>(7T']D+Q;%&Q2349[.R#
M#K@W,;L/Q5&'XUZK^S'X;3PC^SO\-M*1-C0^'[)I !_RT>%7D/XNS&O!O^"K
M"NW[*Y*_=77;,M]-LH_GBN"\&_"O]MNZ\(Z'-I'Q<\(P:5)8P/9Q/!%N2$QJ
M8U/_ !+SR%P.I^M<SERU'I?0ZU'FI+6VI^@5%?"G_"I/V[/^BQ>#_P#OQ%_\
MKJ/^%2?MV?\ 18O!_P#WXB_^5U7[1_RLS]DOYD)\-_\ BJ_^"KWQ)NG^:+0O
M#B+ 6_A/DV49 _&:2ONROR&^%O@C]H^\_:[^).D>'/'>A:?\4[>QWZYK%Q&A
MM[J'-OQ&#:L!RT/2-?NG\?H[_A4G[=G_ $6+P?\ ]^(O_E=65.HTG[KW9M5I
MIM>\MD?==?,G_!2;_DS7QY_OZ?\ ^E]O7E__  J3]NS_ *+%X/\ ^_$7_P K
MJ\A_:R^'?[5^@_ 3Q)??$WXD>&_$'@J-K7[=I^GQ1K-*3<Q"+:19QGB0HQ^<
M< ]>A=2HW!KE9-.FE-/F6Y]\_LM?\FT_"G_L5=,_])8Z]0K\Y/@W\,/VS-0^
M$?@NZ\*?%7PKIOA>;1K.32[.YAC,L%J84,2.38L=P3:#\S<CJ>M=A_PJ3]NS
M_HL7@_\ [\1?_*ZJC4=E[K)E27,_>1]UU\)_!$?\(K_P5(^,^CK\MOJ>B+>!
M1T,C+92Y_P#(DE+_ ,*D_;L_Z+%X/_[\1?\ RNKYQT3P1^T?-^VYK^C67CO0
MD^+\.D+)?:\8T^R/;>3 0@'V7&[8T0_U0Z=>YB=1MQ]U[FE.FK27,MC]>:*^
M%/\ A4G[=G_18O!__?B+_P"5U'_"I/V[/^BQ>#_^_$7_ ,KJU]H_Y68^R7\R
M/5/^"CGAM/$7[(/C9BFZ;3S:7T1Q]TI<QAC_ -\,_P"=>@_LH^(7\4_LT_#+
M496+S/X?LXI'/5GCB6-B?<E":^)?VB/AO^U]H_P3\7WGCSXH>%]7\(0V1;4K
M&TAC$LT6Y1M4BQ0YSC^(?6OK;]@]77]D;X:!_O?V>Y_ SR$?IBHC+FJ;6T+E
M'EI;WU/>J***Z3E"BBB@ HHHH **** *%SHMK=7T5W)&&FC^ZW<5?HHH S[C
M0[2YOH[QX@9X_NMCD5:NK2*\B,<J!U/8U-10!S-Q\/-%NK@326<;R#HS*"1^
M-;.GZ/:Z6N((PGO5VB@=V9>K>&[#6E(NH%DSP<C.:JV'@G2=-@:*"UC1&XVJ
MH _*MZB@+LK:?I\.FVRP0($C7HHJ*#1;6WOY+Q(P)Y!AF[FKU% @HHHH I:I
MH]MK$/E748D3T(J:QLHM/MUAA7;&O  J>B@"&[M([Z!H95W(PP15;2M%M=&C
M,=K&(U)S@"K]% !61JGA73M6W?:(%;=P>.#6O10!A:3X,TK1B#;6L<8'("J
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MS_9%_P"37_A9_P!B[9?^BEKC/^"BG_)FOQ%_ZYV/_I?;UV?[(O\ R:_\+/\
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M5CP"H.UN^"ZUVE4XN.XDT]@HHHJ1A1110 4444 %%%% !1110 4444 %%%%
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MT<EYF]751EY?D%?,G_!2;_DS7QY_OZ?_ .E]O7TW7S)_P4F_Y,U\>?[^G_\
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MO+/A-_S%?^V7_L]:Q.I_P?Z[GH5%%%;'$%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% 'COC__ )&Z_P#^V?\ Z+6BCQ__ ,C=?_\ ;/\
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M\.^(-.\6:!IVMZ1=)?:5J-O'=VEU&"%EB=0R.,C.""#^-:-;& 4444 %%%%
M!1110 4444 %%%% !4-W_P >TG^Z:FJ&[_X]I/\ =- 'RG^P1_R#O&G_ %^Q
M?^@M7UE7R;^P1_R#O&G_ %^Q?^@M7UE75BOXTOZZ&%'^&CQ'XR_&*\\!?%3P
M#X=MM-LKNWURZCAN9[@/YD:M,D>4P0,@,3R#7*_M;>./&NGZ+K&AZ9X=MKGP
MI<:</M6J/)^\B8L=P"[QT 7^$]:QOVHO^3A?A#_U_0?^E45>P?M*0HWP/\6N
M5!<6+8./<5I%1@Z;2W_S)=Y<ZOM_D?.OP"^*/Q1\.^ ="TKP]X*L-5T)9)!'
M>S2['<-,Y<G]X,8)8=.U>^?'3]HK3O@]'9Z?;V,FM^)K] ]KIL1( 4G:&<@$
MX)!  !)(/3K5+]D.UBD^ /AEVC4MFYY(_P"GF6OF_6?B%%IO[5GBG7[_ $*^
M\3"PEEMK>TM 6:$IMB#8P<* &_%\UKRJM6G>.U_GKU,[NG3C9[V^1Z1=?M(?
M&?0K>35]4^'NFG1E&]HX2_G(O<G$K$?4IQ7OWPC^+&C_ !B\)1ZYI(DAVN8;
MFUFQO@E !*G'48((/<'MR!XA=?M:075JT#?"[Q#M(Q_J_P#["LK]B>#4;'QE
MX[_XD][I.BWACFMXKJ)D"8DDV(,@ D*W./0>U1.G>FY2BHM=O^'*C*TTHNZ9
M]=5XY^US_P D!\3_ .[;_P#I1'7L=>.?M<_\D!\3_P"[!_Z41URT?XL?5?F;
MU/@?H6/V8;&";X%^$V>)68VQR2/]MJW/BE\(]%^(GA>\TZ[M8]SQMY4FP%HG
MP<.OH1_]:LG]EW_DA/A+_KV/_H;5ZH_W32J751M=QPU@D^Q\D_L/^)K_ $C5
M_%WP^U&7?_9LK7$*9)$;*YCF SV+;#CU)/>NY^+G[1VN^&?&USX.\&>$9-?U
MFV2-[BYN"1!%O4,HPN,C!')9>>.:\Y_9M"WG[5GQ)O+;YK5?MD>]>A)NDQ^>
MQC7N7Q6^,'@/X1W22>(;II-4F3S(["UC\V=USC=C@*,@\L1G!QTKLJZUKJ-V
MTM/,YZ?\/65DCQF^_:C^*_P_:"]\:^!=-_L=Y LDE@S*R@]MPED /IN STKW
M+Q3\2M2O/A/;^+/ >G1:_=7D<4UM:W#; 49AOW?,/F49!&>H-?/'QB_:>\.?
M$+X>ZUI%GX/UV);J K%>75NBQHP((9L,> 0#UKV+]D)C=?L]^'%E^<*UTHW>
M@N9<4JD.6FJDH)._R8X2O-P4KJQ\O?#_ .('Q TCXY>*]:TOPQ:7OB:ZBD%[
MILCXCA4O&20=XZ$*.IZU];_#;XF^*+[P/K^O>//#\.A/I@DG6&R;>984CWL0
M-[<Y! Y&:\<^"<$<G[7_ ,1D9%*"WFPN./\ 6PU]826L"V\B,JI$1\W88I8F
M:;2Y5L@HQT;OU9\L#]IKXK^-B;OP9\/K.#2CS'-JK,S2+V()DC'/MGZUT7PG
M_:EU76_'T7@KQYX>C\/:U<G;;36Y81.^"0I5B?O8.&#$$\5/X@_:V^&OA749
M--TNVU#Q+.A*L^E6RM%N!P1N=EW?501[UX5XY^*5C\2OCS\.-4T[0M0T&2#4
M;6%Q?(%:0&Y0C&.PRWYUK&FZEU*G96^9$IJ.JG=GWW12+]T4M>6=H4444 %%
M%% !1110 4444 %%%% !1110 5^>WQHF?]C7]NK1/B<-UO\ #[X@H;/6F4?N
MX)CM$KGTPPBGSU.90.]?H37F'[2/P*TK]HKX2:QX-U(K!-,OGZ?>LN3:7: ^
M7+].2K =59AWK*I%R6FZ-:<E&6NS/38Y$FC22-EDC<!E93D$'H0:=7Q/^P7^
MT+JEC<WGP"^)I;3?'_A4M::?]J;!O;6,<1@_Q-&N"I'WXRI&=K&OMBJA)35T
M3.#A*S/EC_@I)\*9/B5^S)J]_91%]4\+3IKD!0?-Y<8*SC/H(G=_K&*]4_9?
M^+4?QN^ _@_Q=YHEO;JR6*_YY6[B_=S9';+JS#V8'O7IE]8V^I65Q9W<*7%K
M<1M%+#(,JZ,"&4CN""17P+^R'JL_[*/[3_C7]GW7IWCT#6ISJOA>YG)VR$KE
M5!/4O$NTG_GI;D#DUG+W9J71Z&L??IN/5:GZ U\R?\%)O^3-?'G^_I__ *7V
M]?3=?,G_  4F_P"3-?'G^_I__I?;U=3X)>AG2_B1]4>E_LM?\FT_"G_L5=,_
M])8Z]0KR_P#9:_Y-I^%/_8JZ9_Z2QUZA51^%$R^)GS-_P41^+:_"O]F/Q##!
M-Y>K>),:%9JI^8B4'SCZX$(D&?5E]:[O]DKX4-\%?V>?!?A:>'R=1ALA<WZD
M<BYF)EE4^NUG*?117RUXBG_X;4_;RT[1[8_;/AM\*R9[N4?-#<W@<%E]#OE1
M$QT*6\A'6OT#K*'O3<_D;3]R"AUW"L_Q!K^G^%=!U'6M6NH['2]/MY+JZN93
MA8HD4LS'V !K0KX)_;'^*6L?M)?$S3_V:_AC<^:9IQ)XLU:'+16L4; M$S#^
M%#AG]7V1@YW"KG+E5S.G#G=N@[]AO2=0_:"^/GQ$_:,UVWDCLIIWTCPY#,/]
M7$ %)'ND0C3(X+22]Q7WI7,_#/X=Z-\)O 6A^$/#\'V?2=)MEMX5/WFQRSL>
M[,Q9F/<L:Z:BG'EC9[A4ESRNM@HHHK0S"BBB@ HHHH \M_:8\=3_  _^#6OZ
MA9RF&_G1;.WD4X96D8*6![$*68>X%>?_ +'/PIL]$^'4&OW4*2ZAJY,YD(Y6
M/.$7/I@;OJU6?VZ(Y)/@U$4SM34H6?Z;7'\R*]'_ &?9H;CX*^#'@ "_V7 A
M _O*@5OU!KL^'#Z=6<^];T1VT^D6EQ&4>!"/I7,:AX1TSPMX3\2MIUG#:F[@
MFFG,,:H9'V$;FP.3@=379UC>,_\ D4=9_P"O.7_T UR+<Z#Y^_8'_P"25:U_
MV&I/_1$%=9K'QCO+']IK1_ "Z;9-IUW:M-)>,&^T*XBE?@YVXR@'3N:Y/]@?
M_DE6M?\ 8:D_]$05C^)?^3\O#?\ UY-_Z33UZ$XJ5>I=;)G)&35.%O(]/_:3
M^-VH_!30]$O=-LK2\>]O/(E%X'(6,*22-I'/^<5YU??M3>//'.H73?#/P9;W
MNBVSE/M^K9!GQ_='F(!],L<$9QTJ+]O[_D3_  O_ -?[?^BS7T5X.\%Z5X5\
M/V>GV%I'!:PQA$C5> ,?Y^M9^Y3I1ERW;N7[TJDE>R5CROX$?M+2_$KQ)>^$
M_$NC#P_XIM59Q$A/ES!<;@ W*L,YQD@C)SQ7I/Q:\4R>"?ASK^NPV\5U/8VK
MS1PSYV,P' ;!!Q]#7SC\0+&+PW^VUX*GM$6-KRV1Y-HQDL)XB3_P$ ?A7N/[
M2'_)#_&'_7@]*<(\\&EI*P1E+EDF]BU\!?'5Q\2?A7HWB*[M;>RNKSSA)#:A
MA&I29T&,DGD*#U[UY?\ $?\ :NU&'QK<^$OAWX=7Q+JMFS1W5U<$^0KJ<,%"
MD9 /!8L!G@9ZU-\ ]8F\/?L>C4[=MEQ9Z?J4\;#LRRSL#^8K#_85\)VC^!=6
MUV:,2WMW?M&TC<DJBK@?FSG\:KDA!U)M7L[)"YI2Y(WW5V5[#]J[Q[X)U>TB
M^)'@J"TTNXD$?VW2PP\O)Z\NZL?]G<IKUWXZ?&X_"&QTJ.RT.X\0ZQJSR1V=
MI 2%^0*6+$ G^(8 '//(KO=4\+Z;J\8CN;6.5,@[64$'!R.*QOB)XH\+^ ]#
M75_%%]'8V43"-&<%F=B.%50"6/!X [$]*QYXSDK0^2ZFG*XI^\?/-U^T'\=-
M/M9-4N/ &D#3$7>T2*[3!>N<"<MG_@/X5[;\#/C5IWQN\)OJEK;M87MM)Y%Y
M9,^\Q/@$$' RI'0X'0CM7E5Y^V9X-OH9(=+\(^(=2A&5\U+6-5/N,.3^>*Y[
M]A*]6Z\1?$<P1-;6LDUM+';N,&,%[C"D>H&!^%=,Z;=*4IPY6K;&,9KG2C*]
MRWXE_P"3\O#?_7DW_I-/7UE7R;XE_P"3\O#?_7DW_I-/7UE6%?:'^%?J:4OM
M>O\ D(WW37R/^SC"D_[3?Q4$BAQY]P>?^ODU]<-]TU\E?LV?\G._%7_KO<?^
ME)HI?!4]/U"?QP]3ZEOO#]C?0O%);H588/%?%/Q,T'_AFW]HCPWXBT;%GI&H
MR@R6\8VIY>Y4G3 XP58,/0GV%?<]?'_[>JI>:EX"L8AOO9I;C:J]<$Q*/S/\
MJK"?Q>7H[W^X5?X+]4?0GQD^+%O\(?!RZW)IT^KSS7"6MM9VYVF25@Q )P<#
M"GD GIQ7A;?M ?'2\C.H6GP]TJ'3L;A!.'\_;]#,K9_X!^%?1WBC5M$\/^%Y
M-4\0W<5CIEJ@>6>8\+T &!R22< #DD\5X7>?MF>!/,EM='\.:]K:(=OG6]HB
MQL/49?=^:BE14G'W:=_-CJ.*?O2L=K^S_P#M"V_QHL]1M+O3SHWB'3,?:K/<
M2K*21O3.",$8*GD$CDYKYE_:N\;^./$5]96?B'P[:Z3IMEJ,PT^XADWM< '"
MEOG/50#T'6NG_9?\10^(OVH?%NHV5E/IEI?Z?/-]CN% ="98"=P'?.3^-=%^
MWE"D>E>#RJ@%KY\D#K\HKKA%4\2HI;_AH82;G1;;V.M^&_Q>^+6N^+M*T[7?
M VGZ=HTKE;F\BF^>-=IP1^\.><=N]3_%S]H_7?#/C:Y\'>#/",FOZS;1QO<7
M-P2((MZAE&%QD8(Y++SQS7N5C9PQPQ,L2JVT<@5YS\5OC!X#^$=TDGB&Z:35
M)D\R.PM8_-G=<XSC@*,@\L1G!QTKAC+GGI!/R5SIDN6.LCQF^_:C^*_P_:"]
M\:^!=-_L=Y LDE@S*R@]MPED /IN STKZB\)>*+#QKX:TW7=,D,MA?P+/$QX
M(!'0CL0<@CL0:^2/C%^T]X<^(7P]UK2+/P?KL2W4!6*\NK=%C1@00S88\ @'
MK7LO['LSS?L_>&]YW;6N5'T%S+BMZU.U)3E'E=[&5.7O\J=U8]HHHHK@.H**
M** "BBB@ HHHH **** /FO\ ;)_YE#_M\_\ :%>6?";_ )BO_;+_ -GKU/\
M;)_YE#_M\_\ :%>6?";_ )BO_;+_ -GK6)U/^#_7<]"HHHK8X@HHHH ****
M"BBB@ HK"\3>.-$\(Q;M4U".WD*[E@'S2OUQA1SR1C/3WKS'6OVE;6-G32='
MEF&/EFO) F#QGY%SD=?XA_2NZA@<3B-:<+KOLOQ.2KBJ-'2<M3VNBOG-OVDO
M$63MTW2<9XW1RD_^C!4EM^TIKBS W.EZ=)'W6$2(3^)9OY5W_P!BXRU[+[SD
M_M3#=W]Q]$45Y5H/[1&@:DRQZC;7&DNQ^\?WT0^K* W_ ([7I>FZI9ZS9I=V
M-S%=VS_=EA<,N?3([^W:O,K86OA_XL6OZ[G=2Q%*M_#E<M4445RG0%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^)DG[0GP3@)G4M)XG\-Q(3%<Q$@RRB,?>1L9=1RK 2+W(C_:8_:6\(?M+?\
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M'2HO(L+8L8XR[/C<Q9N6)/)8G\:F4Z?L_9P3WN-1GS\\GT.CHHHKF-@HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M /VS_P#1:T5D]SU8?"C]!Z***Q/-"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *AN+.&[7$L:N/<5-10!FIX=T^-]PMTS]*T(XUC4*H"CT%.HH"
MY%<6L5W'LE0.OH14%II%K8N6AA5&/<"KE% $%U90WB[9HU<>XJ"WT6SM23'
MJD^U7J* (;>SAM 1$@3)R<4^:%+B,I(H=3V-/HH SH_#]A#)O6W0-]*M+8P1
MS>:L:B3&-V*GHH"[,OQ1K:^&_#>J:LT,ER+&UDN?)B!+R;%+;5 ZDXQ7S/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M8W$4Y?O*E1RL_BY7JON;=[:$%3V5K)?7<,$2EI)&"@"I[#1;[4VVVUK)+_M
M<#ZGH*]'\)^#DT'_ $B<B6\88XZ(/0>_O7'EF4U\PJKW6H=7_EW9]/Q-Q9@>
M'\--N:E6M[L$[N_1OLN[?RU.BMXA;P1QCHBA?R%2445^UI)*R/XHE)RDY2W8
M4444R0HHHH **** "BBB@ HHHH \=\?_ /(W7_\ VS_]%K11X_\ ^1NO_P#M
MG_Z+6BLGN>K#X4?H/1116)YH4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/)6)=?L2_%VWMQ*OAZWG;&3%%J-ON'YN!^1KQ_Q-X>UKPIJSZ5KUA=Z9J%L
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MIAOM4=MA0BR;ANSN$A&[G:5[8%>S5WQES14K'!*/+)Q"BBBK)"BBB@ HHHH
M**** (KJZAL[>2>XE2"&,;GDD8*JCU)/2L?_ (3SPW_T'M-_\"D_QJE\4_\
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MIR4XZM6DMGHU]ST\A8?%5L*Y.C*W,K/T85O^'_"C:]:R3"X$6UMBKMSSCO\
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MYZ>)_BT_7]18?^%4]#[F_:T_Y-W\:_\ 7M'_ .CHZ^4O^">'_)8M=_[ ,O\
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MR<9/O6SHUYSC.5M#)5J,(.,;ZGRM^WW_ ,EVC_[!%O\ ^AR5]J?LYZ'I^A?
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M!J5J1'=0CGA7P<CD_*P9><XS7P9^T'^R3KWP3M7UNSNAKWA;S C7BILFM2Q
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M0QU7"4&GS0O?Y)V/M,PR^I@*6,Q":Y9VM\Y*YY51117WQ^>&OX08)XLT5B<
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M)Y<<]Y;*[JF2=NXC.W))QTY/K71VEI!I]K#:VL,=M;0HL<4,*!4C0# 50.
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MEB.5/_U_;M5IF"J23@#DDU\W_LQ>*9[?7+[09'+6MQ$;B-3_  2*0#CZ@_\
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M35[7ZZ?@&8?6HX9^ULT[7MTU_$^D[[Q#9>%?",>J:C(T5G;PQ>8ZJ6(W;5'
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M,:\\_:<_U?AGZW7_ +1KORV"IYDH+HY+\&<F-ESX)R?5+\T>I> ?^1%\/?\
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M_$SQ]/X+CL$LXH9[BX9F839(5%QV!'))Z^QKK]-OH]4T^UO(O]5<1+*N>N&
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M:+?117LNG2/"RB[@0/)#D?>12""P[9!YQP>E<;\'?CMX/^.6@)J7A?4TGE5
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MV2/PK2EC<#@DWAXMR??^OT,ZF#QV,:6(DE%=OZ_4Y+P)\.+GPK\)M6TZ5?\
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M%!)P,DXYKH:XCX'_ /)'?!/_ &!;/_T2E=O6,M)-&BV04445)04444 %%%%
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M8Y&"/SKNJ)1<7:6XTU)704445(PHHHH ^:_VR?\ F4/^WS_VA7EGPF_YBO\
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M *L*-;&RP->E3DY5*<G&_5I6_&W]7,.5OBA8PB[9TN0HW-;JD+-CTP!D_P#
M3FO1_#5]>ZGH=I=:C:?8;V129(,$;3D@<'D9&#@],XKSFP^+FJZ#,EIXHTB6
M-NGGQH8W('&=IX;GN"!7IFD:Q9Z[8QWEC.MQ;R=&7U[@CL?8UQYG"M&"]K1C
M%7TE!:/RTT^_4[,JG0E.7LJ\Y.VL9O5>>NOW::G'^ /&FH^(O$FN6=X8S!;,
M3"$7!4!RN,]^,=:I?$;XBZCX/\465M;I%+:&V$TD3CER6=?O=L;1TK-^$7_(
MY^)?JW_HPTOQ 4-\7?#0(!&VWX/_ %V>O26&P\<RE"4$XJ%[?]NH\OZUB997
M&I&HU-SM?_MYC(M0^)NN)]KMHA90/\R1&.)/R#Y;\ZT_ OQ$U*?7F\/^(H1%
M?Y*I+M"$L!G:P''(Z$=>.N<UZ77D?Q"C6'XM>&9$&UI&M]Q'?]\1S^'%<V&K
M4<Q<\/*C&/NMIQ5FFO/J=>*H5LM4,1"O.7O)-2=TT][+H>N4445\J?7!1110
M 4444 %%%% !1110 4444 %%%% '*_%/_DG/B+_KRD_E7Q37VM\4O^2<^(O^
MO*3^5?%6UO[I_*OM,B_@S]?T/C<\_C0]/U$HI=K?W3^5&UO[I_*OICYPTO#7
MBC5_!NM6^KZ%J5UI.IVYS%=6DICD7U&1V/<=#7V)\,_^"FWB/0=!ELO&/AZ'
MQ+>Q18MM0M9A:O(PZ"9=I4_[R@=.AZU\4[6_NG\J-K?W3^5<&*P&&QJM7@G^
M?W[G?A<=B<&[T)V_+[CV7XV_M:?$'XYO-;:MJ7]F:$YXT7328[?&<C?SND/^
M\<>@%>,TNUO[I_*C:W]T_E711HTL/!4Z45%>1SUJ]7$3YZLFWYB44NUO[I_*
MC:W]T_E6Y@>J?LV?\E&_[=)?Z5]5U\J_LVJ1\1N01_HDO]*^JJ^#SK_>ODC[
MC)O]V^;"BBBO!/="BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** /'?'_ /R-U_\ ]L__ $6M%'C_ /Y&Z_\ ^V?_ *+6BLGN>K#X4?H/
M1116)YH4444 %%%% !1110 4444 %%%% !1110 4444 ?.7[;OCB31OAU9>&
M+,EM0\07*Q>6GWC"A#-CZL8U]P37H/@[X5V>D_!2U\'W$:O$VGFWN-O\3.I\
MP_BS,?QKYJ^)&F7'[2'[3FH:+9WDMOIF@P&W%Q!U0QGYR.V3*Q'T7VKLO^&0
M-6QC_A-O$'_@1_\ 7KT)1A&G&$I6>^W<Y8N4IRDE=;$?[%/B&X\,Z]XP^&^I
MOBYL+AKJ!3W*L(Y<>W$;#ZDUV_[;/_)#;S_K\M__ $.O =:\(WG[+7QJ\'Z_
M-J%S?Z?=2$75S<<N5)V3 ^N$<,,]Q[5[[^VK(LGP+NG4AE:[MR".A^<5<DG7
MA4CM*W_!(5U2E![HJ_LR_ C0_#_@/2-=DA6XU/5;2*[>Y=1O59$#!%]% ...
MO4^WG/[0/AFV^%OQ\^'7B/1T^QR7UZHG\D!=^R2-6SCNR2E3ZBOI;X'_ /)'
M?!/_ &!;/_T2E>#?MI_\CQ\*?^OZ7_T9;5G2DY8AW>]_R9I42C2LNECV7]HY
MMWP-\7GUT]ZP?V/?^3??#7^]=?\ I3+6Y^T7_P D)\6_]@]_Z5A_L>_\F^^&
MO]ZZ_P#2F6LO^8?_ +>_0O\ Y>_+]3Y^B^&-E\5OVO/%NF:B6:RM7:]DA'_+
M4+Y2A">PRX)^F.]?0GQI^#VAZA\(]:M8[.*/[#8R36VU !$Z(64K_=Y&..Q(
MKS/X0_\ )ZGQ"_Z\9O\ T.VKZ+^)W_).?$W_ &#;C_T6U:5I2YX:[)$4TN67
MFV?*O[&_P=TSQ9I<OB[5@;^YMYS:6J3_ #+ J!3E0>_S?ACCK6A^VQX%L_#&
ME>'O%FF+]EU.&_6W^T1\/RK.I)[E6CX],FNU_85_Y([=?]A.;_T%*J?M[?\
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M7IS46OQ]3GUY:E_ZT/1O@?\ \D=\$_\ 8%L__1*5V]<1\#_^2.^"?^P+9_\
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M<CMD5SX9S]L[^=S:MR^S7RL?4WB[XA>'/A[86MSXCU:#28+AO+B:?/SL!D@
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M"ND^&5E73+-;;S/OMN9F..@RQ)Q[5\V^)M8FU[7KZ_G0Q2S2$^6W5 . OX
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M;\S*A@L5/%1Q6+E&\4TE%/KW;_(\D^$7_(Y^)?JW_HPT[Q__ ,E>\,_[MO\
M^CGKU"UTNRL9IIK:T@MY9SNEDBC56D/)RQ YZGKZTDVE65U>17<UG!+=1#$<
M[Q*73Z,1D=35O-(O%RQ/+HX\MOE8S6536#CAN?52YK_.Y;KR7XC?\E5\+?[U
MO_Z/->M55N-+LKRZAN9[2":XA.8I9(U9T[_*2,C\*\_ XI82JZC5]&OO1Z6/
MPKQE)4XNVJ?W,M4445YYZ04444 %%%% !1110 4444 %%%% !1110 C*&4@C
M(/8U']EA_P">,?\ WR*EHH B^RP_\\8_^^11]EA_YXQ_]\BI:*=V*Q%]EA_Y
MXQ_]\BC[+#_SQC_[Y%2T4786(OLL/_/&/_OD4?98?^>,?_?(J6BB["Q%]EA_
MYXQ_]\BC[+#_ ,\8_P#OD5+11=A88L,<;96-5/J% I]%%(84444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >.^/_P#D;K__ +9_
M^BUHH\?_ /(W7_\ VS_]%K163W/5A\*/T'HHHK$\T**** "BBB@ HHHH ***
M* "BBB@ HHHH *AO%E:TF6%MDQ0A&QG!QP<=ZFHH \0_9V^ DOPCFUN]O]0_
MM;4M2E#-<M#Y9VC)QC<>26))SZ>E>WT454I2F^:3U)C%15D>4?M$?!I?C)X1
MAT^.<6=Y;SK/#<>7OVD @C&1D$$]_3TK/\??!O4_&GP)TSP5/JV;^UBMT:_:
M#/F>5@9*;NX'K7L]%4JDXI)/;43C%W;6YS_P_P##S^$O!&@Z(\OGMIUC#:&7
M;MW^6@7=C)QG&<9KSKX\?!2Y^*WB'P??P:A]A71+EIG7R/,\T,T;8SN&/]7[
M]?:O9:*49RC+F3U&XJ2L]CDOB=X1D\<_#O6?#\<_V:2^MF@$VS?L)[XR,_G6
M?\#_  !-\,?AKI7AN>Y^V26?FDS"/R]V^5W^[DXQNQU[5WM%+F?+R=!V5^;J
M>,>"?@G<^&?CQXE\=/J'G0:K T*VGD;?+W-&<[]QS_J_0=?:O4?%ND-X@\,:
MKIBOY37EK);A\9V[E*YQWQFM:BG*4I--L2BHZ(\N_9X^%5Q\'_ \NB7%Z+^1
M[I[CS1%Y8^8*,8R?[OKWJ']HSX1W'QD\&V>C6]\-/>"]2Z\TP^;G".N,;A_?
MSG/:O5Z*?M)\_M+ZBY8\O+;0Y>\\%6NL> !X:U!!=6KV:VDJL,;P%VY]OZ5\
MTVG[+OCKP1/=VGA#Q]J6CZ5</N:"/>I';)*N 6QW !KZ^HIPJSIWY7N$H1E\
M2/D_2_V.6TK7_"NLIK,\VHV.HK?W]S<QF1[LB1' ^]\G*MS\Q^<DYQ7M'Q\^
M&D_Q8^'DV@6]W]ADDFCE$QB\P#:V<8R.OUKTBBFZU234F]4)4X)-):,Y_P"'
M_AY_"7@C0=$>7SVTZQAM#+MV[_+0+NQDXSC.,UT%%%9-WU984444AA1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >*VOP1NH
M/VB[GXA_VCFWE@\O['Y'(/E+'G?N_P!G/3O7M5%%5*4I6YNA*BH['C'[0'P2
MN?BYJGA6Y@U'[ ND7#RL/(\SS Q0X^\,?<]^M>P-;B:S\F0<,N#4]%#E*247
MLAI)-M=3Y8\7_LCW-AXHGUSP/XAOO"=S+N+"R+ 9)R0I5U90?3)'M6=)^S'X
M[\:,EOXO^(>KZIIX(W6H9]I]_F<KGWVFOKBBMEB*J5K_ )&?LJ?8YK4/!%CJ
MG@/_ (1BZB\_3S9BS,<ASE NT9/K@=?6OF:T_9=\=>")[NT\(>/M2T?2KA]S
M01[U([9)5P"V.X -?7U%1"K.G?E>Y4H1ENCY/TO]CEM*U_PKK*:S/-J-CJ*W
M]_<W,9D>[(D1P/O?)RK<_,?G).<5]&>/O ^G_$'PO=Z+JD"W%I<)M9"<=#D$
M'L00"#[5TE%*52<VG)[!&$8_"CX]L_V7?'WA-KG3?#?Q!U/2]%F8YMXC(N >
MO"N!GW&,UJ+^QE!I\OABXL=1>.\L;T7=[=3P^9)='<C8^\-H&TXZ_>[GK]74
M5K]9J_S?D3[&FN@V,;8U!ZXIU%%<QJ9?BC0;?Q1X?U#2;M!+:WD#P2H?XE8$
M$?D:^4K']E7QOX8:YTKP_P#$#4]*T&YE+O;P!T..G.V0 G  )XSCI7V#16L*
MLZ=U%D2A&7Q(X'XB?"C3/B7X+BT364:Y$:+MF+8D5U7 <-_>Z_F<U\]V_P"R
M_P#$+PK"VG>'/B+JVG:6V1]FB>6-5!.> D@&3Z@#K7V%13A6J4U:+T"4(2U:
M/!_@?^S/I_PVU%];U"XDUC7I"Q:^N1\PW?>VC)P3W)))SUKWBBBHE*4WS2=V
M-145:*"O*OVB_A+<?&+P7;:-;WPT]X;Q+KS3#YF=JNN,;A_?SG/:O5:*49.#
M4H[@TI*S,KPKI3:'X;TS3F?S&M+:. OC&[:H7..W2H/'.@MXH\':UHZ2>2U_
M9S6HDV[MF]"N[&1G&>F:W**5W>XSS']GOX73_"/P'_85Q>"^D^TR3F81>6/F
MQQC)]/6LGX[?L[Z3\7XXKIR]IJL"[8KR'[P&<[2.C#/;\B.:]DHJ_:3Y^>^I
M/+'EY;:'R/'^S]\6+>+^SX_BGK2Z?C:/GFW!?0?O>!CMFO8O@/\ !=/A'H^J
M0M?W6HWFI2K-<W%TW+, 0,#MU/4D\]:]6HJI5JDURMZ>B%&G"+ND?+/C/]E?
M5]/\;WGB7P+XDN_#%W=,SR);@[<L<L 58$*3SM.1GTZ5DWW['^L>*]-U&]\2
M>*;S6O$<Z(D%]=AG6 !P2 I?+9 (Z@#<>*^O**I8BJK6EL+V5-[HYSX?^&6\
M)^ ]#T&67[0VGV,-H9=NW?L0+NQDXSCIFO _B7^RM>7'C27Q1X+URY\,:I,S
M22M:[@&=CEF!5@5)[]0?2OI^BLXU)PES1>I3C&2LT?*%C^R;JWB:2^U+QKXE
MO/$FK/;206LEWN9+=BI 8*6);!.0,@>W>O:?@)\-I_A1\/;;P_<7?VZ2*620
MS"+RP=S$XQD],^M>C454JU2:M)Z!&$(ZI!1116)84444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!XQ^T!\$KGXN:IX5N
M8-1^P#2+AY6'D>9Y@8H<?>&,;/?K7LD*E8D!Z@4^BJ<I-*+V1-DFVNIPWQJ\
M!R_$OX;ZMX<AN?LDEX(P)O+W[=LBO]W(SG;CKWJQ\(O!<GP^^'>C>'IKC[4]
MC%Y9FV;-V23G&3CKZUV-%'-+EY.@65^;J>!_&W]F&P^(VLIKVG74VC:ZA4_;
M;;DG;]TD9'(XP00>/85P;?L^_%;4(O[/O?BEK4FG_=*^9,6=?0YE_F37UQ16
ML:]2*Y4]/D2Z<).[1YW\)?A-:?#7X?MX:266\AE>265[HAB[. &R ,8XZ?SK
MPRZ_94\3^"_$%[=^ O&%_P"';6Z/S6\>[&,D@;E8;@,\9&1ZU];T4HUJD6VG
MON-TX2236Q\>ZK^Q;>Z]H[7&H>)+J^\27%RLMQJEXC2ED"D% I?/)(.2Q^Z!
MQ7U=J6FM?>&[FPW;&FMFAW8SC*XS6I12G5G4MS.]@C",?A1Y-^SC\(;CX,^#
M[[1[B^&H/<7SW?FB'RL91$VXW'^YG.>]<]\?_P!G>3XF:]IWB+2-3FT77K%0
MJ7<"Y.%8LO0@@@DD,#QD]>WO5%'M9\_M+ZAR1Y>6VAXW\"?AOXN\&:AJ]_XJ
M\6WWB6>\CCB1+IG*1!23E=S'DY[ ?C3/!/P3N?#/QX\2^.GU#SH-5@:%;3R-
MOE[FC.=^XY_U?H.OM7L]%#J3;;ON')'16V(KI#);R*.I4BO(?V</@K<?!?2=
M9L[C4/[1-[<B97\CRMH"XQC<<U['14*32<5LQV3:?5!1114E!1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4C#<I'3BEHH ^4?&G[
M(=Y!XJO->\'>([_P[=W$KRMY#-\I8Y(5E9649/3)JA!^R;XI\8WUJ_C?QQJN
MO6L+9%O-)(V/HSNVW/?"_C7U[173]8JI6YOR,O8T[WL<]X?\%Z=X=\)Q:!9V
MT<5A'#Y"P@?+MQC!]??/6OFFZ_94\3^"_$%[=^ O&%_X=M;H_-;Q[L8R2!N5
MAN SQD9'K7UO164*DZ=^5[E2C&7Q(^/=5_8MO=>T=KC4/$EU?>)+BY66XU2\
M1I2R!2"@4OGDD')8_= XKZLU32VU#PS=:=NV--;-!NQG&5QG%:U%.=6=2W,[
MV",(Q^%'D_[.7PCN/@WX.O=&N+X:@\]\]WYHA\K&41=N-Q_N9SGO5[XU?!72
M/C!HJ6U^C+<PY:WN(SB2)B.H/<'C(/!_*O2J*EU).7/?4?+%+EMH?(EG^SI\
M4?#L"Z=H_P 3=7M=,5=B0JTJB)>P4"7 'TQ7J'P&^ TWPOUC4M;U#6;W6]8U
M"(0S7-VW50<]"2<Y Y+'I7M=%:2KU)*S?X(E4X1=TCSGXZ?"6T^,'@UM(N)&
M@ECD$]O/& 6CD (!P>HP2"/0]NM>7?"OX%>//"OBS0YM5\>:EJ&AZ0Q\G329
M!$R["H4@R$  'I@],#%?2]%3&K.,>1/0;A%OF:U."^.L&ES?"3Q2=8.VP6PE
M9SWSM.W;_M;L8]\5X)^P=X ^SZ/J_BRXB^>[D^RVS$?\LTY8CV+''_ *]D_:
M.^'VL_%#X?CP_H]]'8>==1R7+2(6$D2Y.WC_ &MC?\!KJOA?X+@^'W@?2-"@
MY6S@6-GQC>V/F8CU)R?QK15%&BX)ZM_@1RMU%)K1'54445S&P4444 %%%% '
MS7^V3_S*'_;Y_P"T*\L^$W_,5_[9?^SUZG^V3_S*'_;Y_P"T*\L^$W_,5_[9
M?^SUK$ZG_!_KN>A4445L<04444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MB%6.E:K8ZF%Y8V=PDN/KM)K2HVW ****0PHHHH **** "BBB@ HHHH ****
M"BBB@#YK_;)_YE#_ +?/_:%>6?";_F*_]LO_ &>O4_VR?^90_P"WS_VA7EGP
MF_YBO_;+_P!GK6)U/^#_ %W/0J***V.(**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(B".AYN:OZ'^Q)X97PJD-\)[C5&C&^]69T8-CDJN=H&>@(->0^#?!&L_#O\
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MD5\2_LX_"W0OCX?$.O>++QM:\0&[)E@FN&5E1E!$F%(."2RCL-N *^BO@_\
ML_Z;\'_%&K:CI,]REM?P+$UG))OC3#9R">?S)ZGUK2K3ITVX7?,O+0B$IS2E
M;1GK]%%%<IN(S;5)]*^&O!_A.3]J?XT^+]0\1WDTNG:5-Y5M8+(4"Q%W6-1W
M  3+8P2QSFON21=Z,OJ,5\7>/_A_XZ^ ?Q0U#QOX%B:^TZ]D>6YL=AD&&.YT
M=!RR;N05Y7VQD]F'DES13M)[,YZJV;5TMSL?%W[$?A^ZMT?0)I]#O8R&2:&1
MY5!'<J[9_)A7TQI<,MKIMK#-(TTL<2HTC=7( !)]S7AWPD_; \*?$.Z@TK5T
M;POKLA\M8;I\P2OTPDF!@D]F ] 2:]=\>>+K?P'X-UCQ!=(98=/MGG,:G!<@
M<*/J<#\:SJ*M=0J7*@Z=G*!:U[Q3HOA:W6?6M7L=(A8X62^N4A4_0L14&@^.
M/#OBHXT77M,U8XSML;R.8_DI-?'GPD^#NI?M)W%WXZ\=7]S?1W$K16MN'*)L
M4X.W'W4!W*%7'0DUH?&;]EV+X;Z#)XN\%7%WI6H:3_I16"=R=@^\RL3N4J,G
MKR 16OLJ2E[-RU]-+D\\W'G2T_$^SJ^*/B/XM\0?M0?%R[\#Z#?R6/@_3'99
MWA)VS[&"M(V/O9;A >,#=ZU[C\-OB]=>./V=;GQ5,=NKV>GW"7+J!S/$A^<
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MX7_#72_A7X;.C:1$T-HTS3E6D9R78 $Y8D]A^5>(_P##:EW_ -$QU[_OL_\
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M;1 &06=RDI3/3.TG&<'\JA\0>-/#_A,*=;UW3='W#*_;KN.'=]-Q&:XOX4_
MO0/A%/J%SH=J8)[R-4D9IGDR%)('S$XY->7:)^QGIE]J5YJ7BO4;SQ+J-S*T
MCSW,KQ@Y/7"MN)^K'Z"N9*E=W;MZ:F_OV5DKGT1H/B[0O%2.^BZUI^KJ@RQL
M;I)MN?7:3BM:OA/XU?#5?V9/%_A?Q=X3GFL8FN=DEOYK.IVX8KDG)5EW @DU
M]TPR":)''1AFBI3C%1G%W3%"3;<9+5#Z***P-0HHHH **** /FO]LG_F4/\
MM\_]H5Y9\)O^8K_VR_\ 9Z]3_;)_YE#_ +?/_:%>6?";_F*_]LO_ &>M8G4_
MX/\ 7<]"HHHK8X@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH \=\?_P#(W7__ &S_ /1:T4>/_P#D;K__ +9_^BUHK)[GJP^%'Z#T445B
M>:%?)'QS_P"3P?AO_P!<;?\ ]'2U];U\U_%WX>^(-<_:<\"^(+'3VGT>QBA6
MXN1(@$9661CP3D\,.@[UTX>2C)W?1_D8U$VE;NB3]M;X=GQ%\/8O$%I&3?:+
M)Y^Y?O>2<"3\L*W_   UP?Q6_:"D\9_LW^&--L93-XD\2,-/O(XS\^8BHEX[
M>8QCP.ZN:^O->TF#7-%N["YC6:"XB:)XVZ,I&"/R-?&'P/\ V9-:T/XV-<:S
M9D:'I$TDMI.SJPN&!Q$=H.1@?-R!@J*WH5(<GO\ V=5Y^7WF=2$N;W>NC/IS
MX1^ 8?AO\+=.T5 OFPVV9W7^.5OF=OQ8G\,5XG_P3_\ ^13\4?\ 7\G_ *+%
M?4]W'BQD11_ 0/RKYZ_8Q^'^O_#_ ,.^(;?7]/;3YI[Q7C1I$?<H0 GY2>]8
MQG>G4YGJ[?J:./OQLM%<\C^-GA(^*OVO8M)N=1N-,34HHA!=6[A'3]PP55/^
MTZ$?\"KO_P#ACV]_Z'/Q%_X%C_"NK_:9^!-W\1'T[Q!H%S]@\1Z7\T$PRN\
M[E&X<J0PR#V)/KD<3I_QH^/^AVD=A>>#-,U:YC4*MZ^ 7Q_$^R8+GZ!:Z/:2
MG"/LYI-*S3M^IER*,GS1O<[?X/\ [,<'PU\='Q-)JVH:E>^2T(-VZM]X $D@
M9)P,=:\]NWCTW]O6)[QE5+R%1"SG !-IM ^I*$?C7JOP)OOBIK&N:GJ7CZXM
M(;"6$):Z7:QH!"^[);*@]N.6;K[5S_[3WP+U/QM?Z9XK\,3_ &3Q)I>#&P.T
MR!6W)AOX65LD'IR<^M9QG^\:J2O=6N5*/N)PC:SO8^BZQO&?_(HZS_UYR_\
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MK[?(*4;2D[66A8HHHKA.D**** "BBB@#YK_;)_YE#_M\_P#:%>6?";_F*_\
M;+_V>O4_VR?^90_[?/\ VA7EGPF_YBO_ &R_]GK6)U/^#_7<]"HHHK8X@HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \=\?\ _(W7_P#V
MS_\ 1:T4>/\ _D;K_P#[9_\ HM:*R>YZL/A1^@]%%%8GFA3&A1F#%06'0XI]
M% !3%A16+!0&/4XI]% !UX--CB2/.U0OTIU% "$!N",BH6L+=FR84)^E3T4
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M#VI:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *CDMXI&RT:L?<5)10!#]C@_YY)_WR*DCC6-<(H4>PIU% $<D$<PPZ*W
MU%)%:Q0_<C5?H*EHH *@:QMW;+0H3]*GHH :D:QKA5"CV%#QK(N&4,/>G44
M(JA5  P*:T*2$%E#$=,BGT4 %126L,W+QJQ]Q4M% $<5O'#]Q%7Z"I*** &+
M$D;$JH4GK@4YE$BX89'O2T4 (J+&N%&![4UXDD(+*&(Z9%/HH :\:R+M90P]
M#2JH50 ,"EHH CD@CF&'16^HI(K6*'[D:K]!4M% !01G@T44 0/8V\C9:%"?
MI4D<*1#"*%'L*?10 5"UG S;C$I;UQ4U% !C'':H7LH)&W-$I/KBIJ* (S;Q
MG&47Y>G%2444 0R6<$S9>)6/N*=]GCVA=B[?3%244 )PHP.!7RO\4O _B+XJ
M?M/Z'%>:9,GA'0UC9+AL>5*0!(Q'/)9]J$>B5]4U%]FB\WS-B[_[V.:TIU'3
M;:(E%2T8Z&,11*@Z*,4^BBLRPHHHH **** "BBB@ HHHH **** "BBB@ HHH
MH " PP1D5#]C@_YY+^0J:B@!B0I']U%'T%/HHH ;)$DJX=0P]ZCCLX8?N1*O
MT%344 -CC6/A5"_2DDA29<.H8>XI]% $<-O'!_JT5/H*;)9PS'+Q*Q]Q4U%
M$7V:+:%\M=H[8J7IP*** "BBB@ HHHH **** /FO]LG_ )E#_M\_]H5Y9\)O
M^8K_ -LO_9Z]3_;)_P"90_[?/_:%>6?";_F*_P#;+_V>M8G4_P"#_7<]"HHH
MK8X@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \=\?_\
M(W7_ /VS_P#1:T4>/_\ D;K_ /[9_P#HM:*R>YZL/A1^@]%%%8GFA1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\U_MD_\RA_V^?^T*\L
M^$W_ #%?^V7_ +/7J?[9/_,H?]OG_M"O+/A-_P Q7_ME_P"SUK$ZG_!_KN>A
M4445L<04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >.^/
M_P#D;K__ +9_^BUHH\?_ /(W7_\ VS_]%K163W/5A\*/T'HHHK$\T**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /FO]LG_F4/^WS_ -H5
MY9\)O^8K_P!LO_9Z]3_;)_YE#_M\_P#:%>6?";_F*_\ ;+_V>M8G4_X/]=ST
M*BBBMCB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#QWQ
M_P#\C=?_ /;/_P!%K11X_P#^1NO_ /MG_P"BUHK)[GJP^%'Z#T445B>:%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'S7^V3_ ,RA_P!O
MG_M"O+/A-_S%?^V7_L]>I_MD_P#,H?\ ;Y_[0KRSX3?\Q7_ME_[/6L3J?\'^
MNYZ%1116QQ!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4;O_ ..T?\,D_"C_ *%3_P J-W_\=H^M4^S#ZGYG _\ #1WP[_Z&'_R2N?\
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M5&[_ /CM'UJGV8?4_,X'_AH[X=_]##_Y)7/_ ,;H_P"&COAW_P!##_Y)7/\
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M'U/S.!_X:.^'?_0P_P#DE<__ !NC_AH[X=_]##_Y)7/_ ,;KOO\ ADGX4?\
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MJ-W_ /':/^&2?A1_T*G_ )4;O_X[1]:I]F'U/S.!_P"&COAW_P!##_Y)7/\
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M4;O_ ..T?\,D_"C_ *%3_P J-W_\=H^M4^S#ZGYG _\ #1WP[_Z&'_R2N?\
MXW1_PT=\._\ H8?_ "2N?_C==]_PR3\*/^A4_P#*C=__ !VC_ADGX4?]"I_Y
M4;O_ ..T?6J?9A]3\S@?^&COAW_T,/\ Y)7/_P ;H_X:.^'?_0P_^25S_P#&
MZ[[_ (9)^%'_ $*G_E1N_P#X[1_PR3\*/^A4_P#*C=__ !VCZU3[,/J?F<#_
M ,-'?#O_ *&'_P DKG_XW1_PT=\._P#H8?\ R2N?_C==]_PR3\*/^A4_\J-W
M_P#':/\ ADGX4?\ 0J?^5&[_ /CM'UJGV8?4_,X'_AH[X=_]##_Y)7/_ ,;H
M_P"&COAW_P!##_Y)7/\ \;KOO^&2?A1_T*G_ )4;O_X[1_PR3\*/^A4_\J-W
M_P#':/K5/LP^I^9P/_#1WP[_ .AA_P#)*Y_^-T?\-'?#O_H8?_)*Y_\ C==]
M_P ,D_"C_H5/_*C=_P#QVC_ADGX4?]"I_P"5&[_^.T?6J?9A]3\S@?\ AH[X
M=_\ 0P_^25S_ /&Z/^&COAW_ -##_P"25S_\;KOO^&2?A1_T*G_E1N__ ([1
M_P ,D_"C_H5/_*C=_P#QVCZU3[,/J?F<#_PT=\._^AA_\DKG_P"-T?\ #1WP
M[_Z&'_R2N?\ XW7??\,D_"C_ *%3_P J-W_\=H_X9)^%'_0J?^5&[_\ CM'U
MJGV8?4_,X'_AH[X=_P#0P_\ DE<__&Z/^&COAW_T,/\ Y)7/_P ;KOO^&2?A
M1_T*G_E1N_\ X[1_PR3\*/\ H5/_ "HW?_QVCZU3[,/J?F<#_P -'?#O_H8?
M_)*Y_P#C='_#1WP[_P"AA_\ )*Y_^-UWW_#)/PH_Z%3_ ,J-W_\ ':/^&2?A
M1_T*G_E1N_\ X[1]:I]F'U/S.!_X:.^'?_0P_P#DE<__ !NC_AH[X=_]##_Y
M)7/_ ,;KOO\ ADGX4?\ 0J?^5&[_ /CM'_#)/PH_Z%3_ ,J-W_\ ':/K5/LP
M^I^9P/\ PT=\._\ H8?_ "2N?_C='_#1WP[_ .AA_P#)*Y_^-UWW_#)/PH_Z
M%3_RHW?_ ,=H_P"&2?A1_P!"I_Y4;O\ ^.T?6J?9A]3\SY2_:7^(_AWX@?\
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MW?\ \=H^O0[/^OF'U-=SY%_X3_0?^?\ _P#(,G_Q-'_"?Z#_ ,__ /Y!D_\
MB:^NO^&2?A1_T*G_ )4;O_X[1_PR3\*/^A4_\J-W_P#':/KT.S_KYA]37<^1
M?^$_T'_G_P#_ "#)_P#$T?\ "?Z#_P __P#Y!D_^)KZZ_P"&2?A1_P!"I_Y4
M;O\ ^.T?\,D_"C_H5/\ RHW?_P =H^O0[/\ KYA]37<^1?\ A/\ 0?\ G_\
M_(,G_P 31_PG^@_\_P#_ .09/_B:^NO^&2?A1_T*G_E1N_\ X[1_PR3\*/\
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M]"I_Y4;O_P".T?\ #)/PH_Z%3_RHW?\ \=H^O0[/^OF'U-=SY%_X3_0?^?\
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M!_Y__P#R#)_\31_PG^@_\_\ _P"09/\ XFOKK_ADGX4?]"I_Y4;O_P".T?\
M#)/PH_Z%3_RHW?\ \=H^O0[/^OF'U-=SY%_X3_0?^?\ _P#(,G_Q-'_"?Z#_
M ,__ /Y!D_\ B:^NO^&2?A1_T*G_ )4;O_X[1_PR3\*/^A4_\J-W_P#':/KT
M.S_KYA]37<^1?^$_T'_G_P#_ "#)_P#$T?\ "?Z#_P __P#Y!D_^)KZZ_P"&
M2?A1_P!"I_Y4;O\ ^.T?\,D_"C_H5/\ RHW?_P =H^O0[/\ KYA]37<^1?\
MA/\ 0?\ G_\ _(,G_P 31_PG^@_\_P#_ .09/_B:^NO^&2?A1_T*G_E1N_\
MX[1_PR3\*/\ H5/_ "HW?_QVCZ]#L_Z^8?4UW/D7_A/]!_Y__P#R#)_\31_P
MG^@_\_\ _P"09/\ XFOKK_ADGX4?]"I_Y4;O_P".T?\ #)/PH_Z%3_RHW?\
M\=H^O0[/^OF'U-=SY%_X3_0?^?\ _P#(,G_Q-'_"?Z#_ ,__ /Y!D_\ B:^N
MO^&2?A1_T*G_ )4;O_X[1_PR3\*/^A4_\J-W_P#':/KT.S_KYA]37<^1?^$_
MT'_G_P#_ "#)_P#$T?\ "?Z#_P __P#Y!D_^)KZZ_P"&2?A1_P!"I_Y4;O\
M^.T?\,D_"C_H5/\ RHW?_P =H^O0[/\ KYA]37<^1?\ A/\ 0?\ G_\ _(,G
M_P 31_PG^@_\_P#_ .09/_B:^NO^&2?A1_T*G_E1N_\ X[1_PR3\*/\ H5/_
M "HW?_QVCZ]#L_Z^8?4UW/D7_A/]!_Y__P#R#)_\31_PG^@_\_\ _P"09/\
MXFOKK_ADGX4?]"I_Y4;O_P".T?\ #)/PH_Z%3_RHW?\ \=H^O0[/^OF'U-=S
MY%_X3_0?^?\ _P#(,G_Q-'_"?Z#_ ,__ /Y!D_\ B:^NO^&2?A1_T*G_ )4;
MO_X[1_PR3\*/^A4_\J-W_P#':/KT.S_KYA]37<^1?^$_T'_G_P#_ "#)_P#$
MT?\ "?Z#_P __P#Y!D_^)KZZ_P"&2?A1_P!"I_Y4;O\ ^.T?\,D_"C_H5/\
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M!D_^)KZZ_P"&2?A1_P!"I_Y4;O\ ^.T?\,D_"C_H5/\ RHW?_P =H^O0[/\
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M_P!"I_Y4;O\ ^.T?\,D_"C_H5/\ RHW?_P =H^O0[/\ KYA]37<^1?\ A/\
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M1_PR3\*/^A4_\J-W_P#':/KT.S_KYA]37<^1?^$_T'_G_P#_ "#)_P#$T?\
M"?Z#_P __P#Y!D_^)KZZ_P"&2?A1_P!"I_Y4;O\ ^.T?\,D_"C_H5/\ RHW?
M_P =H^O0[/\ KYA]37<^1?\ A/\ 0?\ G_\ _(,G_P 31_PG^@_\_P#_ .09
M/_B:^NO^&2?A1_T*G_E1N_\ X[1_PR3\*/\ H5/_ "HW?_QVCZ]#L_Z^8?4U
MW/D7_A/]!_Y__P#R#)_\31_PG^@_\_\ _P"09/\ XFOKK_ADGX4?]"I_Y4;O
M_P".T?\ #)/PH_Z%3_RHW?\ \=H^O0[/^OF'U-=SY%_X3_0?^?\ _P#(,G_Q
M-'_"?Z#_ ,__ /Y!D_\ B:^NO^&2?A1_T*G_ )4;O_X[1_PR3\*/^A4_\J-W
M_P#':/KT.S_KYA]37<^1?^$_T'_G_P#_ "#)_P#$T?\ "?Z#_P __P#Y!D_^
M)KZZ_P"&2?A1_P!"I_Y4;O\ ^.T?\,D_"C_H5/\ RHW?_P =H^O0[/\ KYA]
M37<^1?\ A/\ 0?\ G_\ _(,G_P 31_PG^@_\_P#_ .09/_B:^NO^&2?A1_T*
MG_E1N_\ X[1_PR3\*/\ H5/_ "HW?_QVCZ]#L_Z^8?4UW/D7_A/]!_Y__P#R
M#)_\31_PG^@_\_\ _P"09/\ XFOKK_ADGX4?]"I_Y4;O_P".T?\ #)/PH_Z%
M3_RHW?\ \=H^O0[/^OF'U-=SY%_X3_0?^?\ _P#(,G_Q-'_"?Z#_ ,__ /Y!
MD_\ B:^NO^&2?A1_T*G_ )4;O_X[1_PR3\*/^A4_\J-W_P#':/KT.S_KYA]3
M7<^1?^$_T'_G_P#_ "#)_P#$T?\ "?Z#_P __P#Y!D_^)KZZ_P"&2?A1_P!"
MI_Y4;O\ ^.T?\,D_"C_H5/\ RHW?_P =H^O0[/\ KYA]37<^1?\ A/\ 0?\
MG_\ _(,G_P 31_PG^@_\_P#_ .09/_B:^NO^&2?A1_T*G_E1N_\ X[1_PR3\
M*/\ H5/_ "HW?_QVCZ]#L_Z^8?4UW/D7_A/]!_Y__P#R#)_\31_PG^@_\_\
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MW?\ \=H^O0[/^OF'U-=SY%_X3_0?^?\ _P#(,G_Q-'_"?Z#_ ,__ /Y!D_\
MB:^NO^&2?A1_T*G_ )4;O_X[1_PR3\*/^A4_\J-W_P#':/KT.S_KYA]37<^1
M?^$_T'_G_P#_ "#)_P#$T?\ "?Z#_P __P#Y!D_^)KZZ_P"&2?A1_P!"I_Y4
M;O\ ^.T?\,D_"C_H5/\ RHW?_P =H^O0[/\ KYA]37<^1?\ A/\ 0?\ G_\
M_(,G_P 31_PG^@_\_P#_ .09/_B:^NO^&2?A1_T*G_E1N_\ X[1_PR3\*/\
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M]"I_Y4;O_P".T?\ #)/PH_Z%3_RHW?\ \=H^O0[/^OF'U-=SY%_X3_0?^?\
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M!_Y__P#R#)_\31_PG^@_\_\ _P"09/\ XFOKK_ADGX4?]"I_Y4;O_P".T?\
M#)/PH_Z%3_RHW?\ \=H^O0[/^OF'U-=SY%_X3_0?^?\ _P#(,G_Q-'_"?Z#_
M ,__ /Y!D_\ B:^NO^&2?A1_T*G_ )4;O_X[1_PR3\*/^A4_\J-W_P#':/KT
M.S_KYA]37<^1?^$_T'_G_P#_ "#)_P#$T?\ "?Z#_P __P#Y!D_^)KZZ_P"&
M2?A1_P!"I_Y4;O\ ^.T?\,D_"C_H5/\ RHW?_P =H^O0[/\ KYA]37<^1?\
MA/\ 0?\ G_\ _(,G_P 31_PG^@_\_P#_ .09/_B:^NO^&2?A1_T*G_E1N_\
MX[1_PR3\*/\ H5/_ "HW?_QVCZ]#L_Z^8?4UW/D7_A/]!_Y__P#R#)_\31_P
MG^@_\_\ _P"09/\ XFOKK_ADGX4?]"I_Y4;O_P".T?\ #)/PH_Z%3_RHW?\
M\=H^O0[/^OF'U-=SY%_X3_0?^?\ _P#(,G_Q-'_"?Z#_ ,__ /Y!D_\ B:^N
MO^&2?A1_T*G_ )4;O_X[1_PR3\*/^A4_\J-W_P#':/KT.S_KYA]37<^1?^$_
MT'_G_P#_ "#)_P#$T?\ "?Z#_P __P#Y!D_^)KZZ_P"&2?A1_P!"I_Y4;O\
M^.T?\,D_"C_H5/\ RHW?_P =H^O0[/\ KYA]37<^1?\ A/\ 0?\ G_\ _(,G
M_P 31_PG^@_\_P#_ .09/_B:^NO^&2?A1_T*G_E1N_\ X[1_PR3\*/\ H5/_
M "HW?_QVCZ]#L_Z^8?4UW/D7_A/]!_Y__P#R#)_\31_PG^@_\_\ _P"09/\
MXFOKK_ADGX4?]"I_Y4;O_P".T?\ #)/PH_Z%3_RHW?\ \=H^O0[/^OF'U-=S
M\_/%^H6^J>(KNZM9/-@DV;6P1G"*#P>>H-%?H'_PR3\*/^A4_P#*C=__ !VB
+E]<I]F="HM*Q_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>form10-k_004.jpg
<TEXT>
begin 644 form10-k_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %  G # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#SY8L-NST]
MP,&G",@>OX\5 29&"')(X' I!_>QA1WZ&O=YCR.5]RP1ZYSCL:4ABG#8!YR3
MBJRC<<#'/?%/?YG)R ,\8-',+E'8<'/'3M_]:G;CT 8-CTJ+8QX&22,>E CD
M(SCCV/-*['9$AP#]P$GIC%*,\ $8]":84[;0 .Q.:7R$;(#?@.OUHU)LB4[M
MAR<9/K2*Q'&-P^E-(0*!C/S9QZ4W<N?D8+GNO-.Y-KDZJ 6W+@=1S2,5],]A
M@5#AB&P3@#OZTWDG;@D'C %',/E)P0%+8/H,M3"W;!&>/:F,&W+M.4''2FE3
M@@8.>O%)R8U$M;RZ-M P5.?K42X9U !QW'K3-_EH57C<1T[8H"_.K*!@_,.>
M:?,Q*-AXWDDA20.3VI[;R,J2>!FH P!^96/&,@8I0"'&U3GIG-3S,;BR1ED7
MY3DC/>F?,&Z #OP*1BA')7*]N>E-X[!O89X%)@D.+/NW;2.O.<4F\D\IR.YZ
MT -R-H&.I _K2J,?QDX]J20]$*'DVX!'MZX]Z [GD9(IZYZ+QGG/^%+SD[W.
M/7'-/4EL;\_'!Z^IHWLK8YQG/U_&E^?;W(]::21N 4?6C4$!F9><#UYYS3A,
M"<'"GL1_6F[2#P1TXP.*0QXS@AF Y&<\52<@LAYD8'G!S[\D?G32SXX(P#V!
M/YTB[E7!1=OX'%.\MR01@YYP?Z4]1Z(:7DY'RGZCI2ABJ$>6OOCO3G#$[AA<
M\<'FF",A2.I/(]11J/00L!G,8Z<XSQ3@X!Y X/*D_P J:(^<Y;GMG\Z-IV\
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M8]CDO^%8^"_^A>M?S;_&G#X:>#1G_B06O/7EO\:ZNBCGEW#E78Y,_#/P8?\
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M9KFDTVVC9*R"BBBI&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBS(27R2%E!)DP3M'OP?R/I5#_A8GAK^RC?KJ,;!8EE>!6!E16*CE0>V]2>>
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M3;F&5&' /(Y'K6#IVN;J5TCH?-C_ +X_.CS8_P"^/SK+-S;!0QN8 I (8R*
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M04.^S6G_ #QB_P"^11]FM/\ GC%_WR*;BC% #OLUI_SQB_[Y%'V:T_YXQ?\
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M0,D'/H:?LWV#G7<[/[6/[A_.C[6/[A_.N,/C3S=*U6^MM-E<60@,*2.%,PE
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M"1_L]Z.5=PN^QVVX@$EB .2<T!B0"&)!Z$'K7$W7AGQ!=.6GOQ,R7 F1FNY
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M316184444 %%%% !2GJ:3M0>IH **** "BBB@ HHH- !_@**/3Z"B@ HHHH
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MSY9.,#.W%:%>?7>M^+-,EM(;T_/-(NS9;(=Y/D[E('106E (YR!U KT)@ Q
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MOXEMIIS*XCF*KS@/N3;\^X# !/R]:.5=PN^QVX8#.%Z^C&DRO]W]:X*W\/\
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MZQ?6&O2)'NFMT3<+=(^3\I))XSC./F4G'0BHW\47#37 AM1Y*AO)D</B7&0
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MLBPILDB11M)(ZHBC+,QP /<TZN?O=+U74-6:"YGADT1I(YRAXD!0?ZK&.5+
M-DGU% &^"",BEHHH *#UH[4'J: "BBB@!KND:,[LJ(HR68X 'J32JP90RD$$
M9!'<5@ZII>JZCJ+6SW$+:)<>6TR'B1-I)9!@<J_RY)/'/K6_^7X4 %%%!H /
M3Z"BCT^@HH *1F"*68@*!DDG  I:P-8TS5M1O&M4N8O['NHU2Y5N)(P#E@F!
MSO'RG)XH W4=9$5T8,C %64Y!![BG4BJJJ%50J@8  X ]*6@ H[_ (44=Q]*
M "BBB@ ILDB11M)(ZHBC+,QP /4FG5S]_I6JZAJC6\]Q$^AR/'*Z'B0;.3%C
M'*LP4DD^H[T = "" 1R#1110 4444 612T@Z4M !1110 4444 %%%% %*:-S
M*Q"$\TSRY/\ GFU:%%5S"L9_ER?\\VH\N3_GFU:%%',%C/\ +D_YYM1Y<G_/
M-JT**.8+&?Y4G_/-J/+D_P">;5H44<P6,_RY/^>;4>7)_P \VK0HHY@L9_ER
M?\\VI1')G[AJ_11S!8Y\6\^/]2_Y4OV:?_GB_P#WS6_16WMY=C#V"[F!]FG_
M .>+_P#?-)]FG_YXO_WS7044?6)=@]@NYS_V:?\ YXO_ -\T?9I_^>+_ /?-
M=!11]8EV#V"[F5!#*( #&P.3QBI?+D_YYM6A163FV[FRC96,_P N3_GFU'ER
M?\\VK0HI<P[&?Y<G_/-J/+D_YYM6A11S!8S_ "Y/^>;4HCDR/D:K]%',%B@8
MY,GY&ZTGER?\\VK0HHY@L9_ER?\ /-J/+D_YYM6A11S!8S_+D_YYM1Y<G_/-
MJT**.8+&?Y<G_/-J5HY-Y^0]:OT4<P6,_P N3_GFU'ER?\\VK0HHY@L9_ER?
M\\VH\N3_ )YM6A11S!8S_+D_YYM1Y4G]QJT**.8+%8JV3\IHVO\ W#5FBI&5
MMK_W#1M?^X:LT4 5MK_W#1M?^X:LT4 5MK_W#05;/W35FB@"MM?^X:-K_P!P
MU9HH K;7_N&C:_\ <-6:* *VU_[AHV/_ '#5FB@"L5?^Z>@HVO\ W#5FB@"M
MM?\ N&C:_P#<-6:* *VU_P"X:-K_ -PU9HH K;7_ +AH*/Q\IZ59HH K;7_N
M&C:_]PU9HH K;7_N&C:_]PU9HH K;7_N&C:_]PU9HH K;7_N&C:_]PU9HR/6
..@ %%&11F@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>pg_002.jpg
<TEXT>
begin 644 pg_002.jpg
M_]C_X  02D9)1@ ! 0$ V #8  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 94"T # 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "H)K59.1\K5/10!F20M$?F'XTRM4@,,$9%5I;,'E./8
MT 4Z*5E*M@C!I* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ K-U=/FC?V(K2JIJB;K;/]TYH R****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@!KQK(,,,U3FLV7E?F'ZU>HH R:
M*T9;=9>HP?453EMWBZ\CU% $5%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7.-VT@$KGC<..1SS4V>X[G<T444AA1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ IDD2R#YA^-/HH H36K1\K\R_K4%:U0S6RR<_=;
MU% &?14DD+Q=1QZU'0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+I=W%!"NERPHK*R%B6WQOSD=L5]*K_P2O^%??Q'XP/TN[4?^VU<Y_P $H?\
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M444 %%%% !1110!^6_[7W_*0#0?^OW1?_0HZ_4BORW_:^_Y2 :#_ -?NB_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH 3KUJO+9AN4^4^G:K-% &6R-
M&<,,&FUJ,BR+AAD54FLRO*<CT[T 5J*4Y'!X-)0 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*SF''^\P)_\ 'JU_ '_!4;Q3HNM-8_$7P?:7-LC;))-(1[6ZA(ZEHY697/\
MLY3ZU^D5>6_'+]F_P3\?M GLO$6EQ1ZELQ;:U;1JMY;,.A#XRR^J-E3Z9P0E
M4IO240Y)K52.H^&GQ.\-_%[PC:>)/"VI1ZEIEP,;EX>)P/FCD7JCC/(/L>00
M:ZJOR@_9U\5>(_V-?VK)O OB&0#2M0O(M*U%=Q$,BR$?9KM?0#>K<_PNX//3
M]7ZSJ0Y'ILRX2YEKN?F7_P %6O\ DJ'@K_L#/_Z/:OT@\*_\BQH__7G#_P"@
M"OS?_P""K7_)4/!7_8&?_P!'M7Z0>%?^18T?_KSA_P#0!6E3^' F'QR&>,->
M/A;PEK>M+"+EM.L9[P0EMHD\N-GVYP<9QC.*^?/V0_VPKS]IS6/$EC=>&(-
M&DP0S*\-X9_,WLPP047&-M>W?%S_ ))3XT_[ M[_ .B'KX)_X)/?\C=\0_\
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MVE9SE&7PJQI%26[N>&?M>?M":G^S;\.]-\2:;HMMK4EYJ::<T=U*T:Q[HI9
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MFO<=?\.Z5XKTJ;3-:TVTU;3IAB6TOH%FB?ZJP(-?EY^VA^R[)^S+XJT?Q_X
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !65JR;9U;^\M:M4=63,2-Z''YT 9=%%% !1110 4444 %%%% !1110
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MV7?AW;RKL9].^T ?[,LCR@_B'!_&O:JR?"/ANV\'>%=&T"R_X\]*LH;&'/\
M<BC5%_116KG'6L).[;-4K)(^&?\ @J5\5O['\#^'O %I-BXUF?\ M"]53S]G
MA.(U8>C2'</>&O4/^"??PM'PU_9VTJ^N8O*U/Q)(=7G+#YA&P"P+]/+56^LA
MK\\_VHOBKI_QB_::UG6;^XG?PO;7T>FQ/:@.XL87V,T0) );]Y( 2.7[5]JV
M7_!33X/Z;96]I:Z)XJ@MK>-8HHDL+<*B* %4?Z1T  %=DH25-1BCFC*+FY-G
MV0TW]VL+QIX6LO'7A+6?#VI+OL=5LY;.?N=LB%21[C.1[@5\M?\ #T#X3?\
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M$E&'^)^@5OA/U/HHHKF-PK\G_P#@HA9GPS^UK%JD2!)+JQL+\$#&YD)C!_\
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M$/\ Z\;3_P!&25^D5;XC^(S*E\"/S/\ ^"K?_)2/ X_ZA,O_ *.-?HA\/>/
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MH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "E7[P^M)2K]X?6@!**** "BBB@ HHHH **** "BBB@ HHHH
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MPS\.?#?P/\1Z[X#\-/I7B#2(A?B1;^YG\R!#F92LDC#_ %>YL@9R@]37._\
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M1_\ KSA_] %;5/X<#.'QR,?XN?\ )*?&G_8%O?\ T0]?!/\ P2>_Y&[XA_\
M7C:?^C)*^]OBY_R2GQI_V!;W_P!$/7P3_P $GO\ D;OB'_UXVG_HR2B'\*02
M^.)^D5?F;_P5:_Y*9X)_[!$G_HYJ_3*OS,_X*M?\E.\%?]@>3_T>U+#_ ,1!
M6^ _1;P'QX&\.C_J'6__ **6MVL/P+QX)\/C_J'6_P#Z*6MRL'N:K8*_._\
MX*T?\?7PN_W-3_G:U^B%?G?_ ,%:/^/KX7?[FI_SM:WH?Q$9U?@9]I?L_?\
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M_P#HA*]Q_;8_Y-9^(7_7BG_HZ.O#O^"4_P#R2KQG_P!AI?\ T0E$?X+]0?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%UVZ62('WCC1%8>S BOIZBM/:SVN3[./8CM[>*SMXH((D@@B4)'%&H544#
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M !1110 4444 9^KI\L;>^*S:V=13=:M_LX-8U !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J"6U63D?*U3T4 9D
MD+1'YA^-,K5(##!&15::S[IQ_LT 4Z*5E*G!&#24 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 54U-=UJ3_=(/]*MU'<)YEO(OJIH P:*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ I8_OK]:2EC_UB_6@!**** "B
MBB@ HHHH **** "BBGQPM)T''J: &5)';O)ST'J:LQVRQ\GYC[U+0!8TM3#)
ML5CMZM[UIU1TU>7;\*O4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %2P?Q5%4L'\5 $U%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 -DC60889JG-9LG*_,/UJ]10!DT5HRVZR]1@^HJG+;O%U&1ZB@
M"*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y^5?+E=?0D4VK.HI
MMNG]^:K4 %%%% !1110 4444 %%%% !1110 4444 %%%% !2Q_ZQ?K24L?\
MK%^M "4444 %%%% !112JI<X49- "4Z.-I#A1FK$=H.K\^PJP %& ,"@"".U
M5>6^8_I4]%% !1110!I:>NVWSZG-6:CMUVPH/:I* "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "I8.]15+!WH FHHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ6A0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !116;#XFT>YU
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MQA_YZ7,JQK^;$5+97UMJ5LEQ:7$5U;ORLL+AT;Z$<&@">BBB@ HHHH ****
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MH5H\]-W04445S&P4444 %%%% $5XGF6L@]LUA5T1Y&#7/.NQV4]CB@!****
M"BBB@ HHHH **** "BBB@ HHHH **** "G1_ZQ?J*;3H_P#6+]10 ^.U9^3\
MH]ZM1PK'T'/K4\_^ND_WC_.HZ "BBB@ HHHH **** "BBB@ JWIRYE8^@JI6
MAIRXC9O4XH MT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MV%\.M8_9H_X7G)>7=AX*2 R3"XMS]IBD$WD>08U)RYEP@P<'(.<<U\.>.O\
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MT"U'X=ZG^S?_ ,$?]=T?6(Y+/6[G16GOH)!M>&2^NT'E,.S*DR(P]0:^7O\
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MT)"*?O4 ?G-_P5=_:EO/BY\8HOA7X4NYY_#OA>4V]W'9LQ%_J;<.N%^\(O\
M5@8^^9.O%>6?\$L[ZYMOVY/AU!#<2Q07 U))HT<A9%&FW3 ,!U (!Y[@&O5/
M^":_[,,WCC1_B#\;?%$#W-CH^FW]MHS766-S?M;OYUP2?O>6K8![O(3G*5Y)
M_P $NO\ D^OX9?74_P#TV7= 'Z'_ /!9;7-0T;]E/14L+V>S6]\5VEM<B"0I
MYL7V6[?8V.J[HT./517YA?LX_LE?%3]JBQUR[\"-:SPZ-)#%=F^U'R"&D#%=
MH/7A#7Z8?\%J/^35_#'_ &.5I_Z17U?#/[!/[>&E_L;Z/XQL=1\(WGB8Z]/;
M3(]K>)!Y7E+(""&4YSO'Y4 >@_"S_@EO^T5X6^)WA'6KUM)M+/3M7M+R>XCU
MK<T<<<R.S  9) !X%?M%7Q%^RY_P5$\/_M-_&+3?A_:^!=2\/W>H07$T5Y-?
M1SH#%&9"I4(#RJMSZXK[=H **** "BBB@ HHHH **** "BBB@ HHHH ^%_\
M@JY\3/B;X)^'/@?0OAG>:O97WB?59;&Y;08W-[-MB#)!&R#>I8EC\F&.S&<9
M!_,[QQ^P-^T/X9\#:CX_\2^!;Y=,MXC>WTTU_;SW<<0&6EDB$C2X Y;(RH!)
M  )K^AFO!OVW_C;H_P "?V:O&FLZG+']LO[";2=+M'(S<W<\;(B@=PH)=O\
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MF5FDPEP6.T G"@GC@5P_[%'[=E]^QI9^+K>T\'V_BH>()+61FFOVMO(\D2C
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M77]0BTZ.]?48Y5B>1MJL5"#(R1GFOT$H **** "BBB@ HHHH **** "BBB@
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MJPK^<?X?^!]=_:(^-.F>'=(MM^L^*-5(VPH2D/F.7DD([)&I9SZ*IH _>O\
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M#$$<%L]*_171_P#@MIX5U36+&SD^&&KV\=Q/'"TPU2)R@9@"VWRQG&<XR,T
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M Z=!7S'\>/\ @I3X3^&7B"\\/^%-&?QGJ5FYBN+S[2(+..0'!57"LTA!R#@
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MMHW?_,\VM6Q6'2G*JGY:'[AP3QW4,<T,BS0R*'22-@RLI&001U!%?@Q\&_\
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M^SS^S]J_A_Q]HZZ'K-[XBN-2CLQ<Q7!$#6UM&I9HF902T+\9SC&:^ /VBO\
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M1$S(&"$[H#T#-T]: /VJ^&O[(?P=^#WBJ'Q+X-\ Z9H6NPQO%'?0&1G17&&
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M;2#MQCBOM_\ X)@_\$__ !-\+?%G_"V?B7IAT75H;>2#0]#N,?:(#(I22XF
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M"CM6K^T+X;U#QE\ ?B7H&D6YN]5U7PSJ=C9VZG!EFEM9$C4?5F _&@#\,?\
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MWZD]":T?%G_!.GXSZ3I6D7]OI4/B#4]0626_M;6]A#639&U7DDD42,V225R
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M'O@U\9&UU?8^B=[:'$_"?]H?X>_&VU\SPCXEM-0N%SOL)"8;M,=287PV/]H
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M*6$:X3)"AB2>I&,'T*D,%]<6.E66MM+K?;[CCC+$_5WAE3?K^)ZY_P $D?\
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MX4444 1R0K+U'/K5.6V>/G[R^HK0HH R:*ORVJR<CY6JG)$T1PP_&@!E%%%
M!5+5DW0JW]UJNU!?)OM9![9_*@#$HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *=%_K$^HIM.B_UB?44 :D_^ND_WC_.HZDG_ -=)_O'^=1T %%%% !11
M10 4444 %%%% $D"[ID'O6O6;8+NN ?09K2H **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "I8/O&HJE@^\: )J*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_,/UJO0!SK JQ!ZBBIKQ/+NI![Y_/FH: "BBB@ HHHH **** "BBB@ HHHH
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M (2S5?\ GZ_\AI_A1_PEFJ_\_7_D-/\ "LBB@#7_ .$LU7_GZ_\ (:?X4?\
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M #]_^0D_PH_X3#5_^?O_ ,A)_A6+10!M?\)AJ_\ S]_^0D_PH_X3#5_^?O\
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M_P#(2?X4?\)AJ_\ S]_^0D_PK%HH VO^$PU?_G[_ /(2?X4?\)AJ_P#S]_\
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M%HH VO\ A,-7_P"?O_R$G^%'_"8:O_S]_P#D)/\ "L6B@#:_X3#5_P#G[_\
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MYD8@^80>@]@*YR@#:_X3#5_^?O\ \A)_A1_PF&K_ //W_P"0D_PK%HH VO\
MA,-7_P"?O_R$G^%'_"8:O_S]_P#D)/\ "L6B@#:_X3#5_P#G[_\ (2?X4?\
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M_P#/W_Y"3_"L6B@#:_X3#5_^?O\ \A)_A1_PF&K_ //W_P"0D_PK%HH VO\
MA,-7_P"?O_R$G^%'_"8:O_S]_P#D)/\ "L6B@#:_X3#5_P#G[_\ (2?X4?\
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M%HH VO\ A,-7_P"?O_R$G^%'_"8:O_S]_P#D)/\ "L6B@#:_X3#5_P#G[_\
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M/_75OYFJ]6-0_P"0A<_]=6_F:KT %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@##HJ]KVB7OAG7-1T?4X#:ZCI]Q):7,!8-Y<L;%'7()!PP(R"1Q5&@ HHHH
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MO^0#9?\ 71?_ $ UPU=SXV_Y -E_UT7_ - - '#4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %=C\._\ 67_T
M3_V:N.KL?AW_ *R_^B?^S4 <MJ'_ "$+G_KJW\S5>K&H?\A"Y_ZZM_,U7H *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *='_K%^M-IT?^L7ZT =M\0_\ CVL_]]OY"N'KN/B'_P >UG_OM_(5P] !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110!W/P]_X\[O\ ZZ#^5<-7<_#W_CSN_P#KH/Y5PU !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!:TO
M_D)VG_79/_0A73?$3_76/^Z_\Q7,Z7_R$[3_ *[)_P"A"NF^(G^NL?\ =?\
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M^5*[!1NKMGQ317U-^Q[\!?"'[1<GQ1@UV-='-I:PW&G7RROMTS?)(6;;O57
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M?_'M9_[[?R%</7<?$/\ X]K/_?;^0KAZ "BBB@ HHHH **** "BBB@ HHHH
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M!6G_ ,E5\+T4?5H]P]LS[H_X>G_"C_H7_&7_ (!6G_R51_P]/^%'_0O^,O\
MP"M/_DJOA>BCZM'N'MF?='_#T_X4?]"_XR_\ K3_ .2J/^'I_P */^A?\9?^
M 5I_\E5\+T4?5H]P]LS[H_X>G_"C_H7_ !E_X!6G_P E4?\ #T_X4?\ 0O\
MC+_P"M/_ )*KX7HH^K1[A[9GW1_P]/\ A1_T+_C+_P  K3_Y*H_X>G_"C_H7
M_&7_ (!6G_R57PO11]6CW#VS/NC_ (>G_"C_ *%_QE_X!6G_ ,E4?\/3_A1_
MT+_C+_P"M/\ Y*KX7HH^K1[A[9GW1_P]/^%'_0O^,O\ P"M/_DJC_AZ?\*/^
MA?\ &7_@%:?_ "57PO11]6CW#VS/NC_AZ?\ "C_H7_&7_@%:?_)5'_#T_P"%
M'_0O^,O_  "M/_DJOA>BCZM'N'MF?='_  ]/^%'_ $+_ (R_\ K3_P"2J/\
MAZ?\*/\ H7_&7_@%:?\ R57PO11]6CW#VS/NC_AZ?\*/^A?\9?\ @%:?_)5'
M_#T_X4?]"_XR_P# *T_^2J^%Z*/JT>X>V9]T?\/3_A1_T+_C+_P"M/\ Y*H_
MX>G_  H_Z%_QE_X!6G_R57PO11]6CW#VS/NC_AZ?\*/^A?\ &7_@%:?_ "51
M_P /3_A1_P!"_P",O_ *T_\ DJOA>BCZM'N'MF?='_#T_P"%'_0O^,O_  "M
M/_DJC_AZ?\*/^A?\9?\ @%:?_)5?"]%'U:/</;,^Z/\ AZ?\*/\ H7_&7_@%
M:?\ R51_P]/^%'_0O^,O_ *T_P#DJOA>BCZM'N'MF?='_#T_X4?]"_XR_P#
M*T_^2J/^'I_PH_Z%_P 9?^ 5I_\ )5?"]%'U:/</;,^Z/^'I_P */^A?\9?^
M 5I_\E4?\/3_ (4?]"_XR_\  *T_^2J^%Z*/JT>X>V9]T?\ #T_X4?\ 0O\
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M2YQJ8U^&-7V^=#<[FFB.,[<[ID^F#CFN_P#C+^R_I_[4FJ7/Q1^!VM:;J_\
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M%K%G9^!/B?K_ (6\3^:C62>*K=#;32*P*C>J(%+$8&7SD\*>E<U_P46A6/\
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M !5'U2H'UB!WG_"/ZE_SXS_]\&C_ (1_4O\ GQG_ .^#7!_\-!^*/^>>G_\
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M&_\ BJ/JE0/K$#O/^$?U+_GQG_[X-'_"/ZE_SXS_ /?!K@_^&@_%'_//3_\
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M\9_^^#1_PC^I?\^,_P#WP:X/_AH/Q1_SST__ +\-_P#%4?\ #0?BC_GGI_\
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M_GQG_P"^#1_PC^I?\^,__?!K@_\ AH/Q1_SST_\ [\-_\51_PT'XH_YYZ?\
M]^&_^*H^J5 ^L0.\_P"$?U+_ )\9_P#O@UU7@73[FQ>\^T020[@FW>N,XS7C
M/_#0?BC_ )YZ?_WX;_XJC_AH/Q1_SST__OPW_P 51]4J!]8@>AWV@ZC)>W#+
M93,K2,00AYY-0?\ "/ZE_P ^,_\ WP:X/_AH/Q1_SST__OPW_P 51_PT'XH_
MYYZ?_P!^&_\ BJ/JE0/K$#O/^$?U+_GQG_[X-'_"/ZE_SXS_ /?!K@_^&@_%
M'_//3_\ OPW_ ,51_P -!^*/^>>G_P#?AO\ XJCZI4#ZQ [S_A']2_Y\9_\
MO@T?\(_J7_/C/_WP:X/_ (:#\4?\\]/_ ._#?_%4?\-!^*/^>>G_ /?AO_BJ
M/JE0/K$#O/\ A']2_P"?&?\ [X-'_"/ZE_SXS_\ ?!K@_P#AH/Q1_P \]/\
M^_#?_%4?\-!^*/\ GGI__?AO_BJ/JE0/K$#O/^$?U+_GQG_[X-'_  C^I?\
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M&_\ BJ/JE0/K$#O/^$?U+_GQG_[X-.3P_J093]AGZ_W#7 _\-!^*/^>>G_\
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M_P#BJ/JE0/K$#O/^$?U+_GQG_P"^#1_PC^I?\^,__?!K@_\ AH/Q1_SST_\
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MZQ [S_A']2_Y\9_^^#1_PC^I?\^,_P#WP:X/_AH/Q1_SST__ +\-_P#%4?\
M#0?BC_GGI_\ WX;_ .*H^J5 ^L0/;/ ]C<6-K<K<0O"6<$!QC/%<?_PC^I?\
M^,__ 'P:X/\ X:#\4?\ //3_ /OPW_Q5'_#0?BC_ )YZ?_WX;_XJCZI4#ZQ
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M?\^,_P#WP:X/_AH/Q1_SST__ +\-_P#%4?\ #0?BC_GGI_\ WX;_ .*H^J5
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MN&GN9I+B9OO22N68_4FH:* +.I:G>:Q>27E_=SWUW)C?<7,C22-@ #+$DG
M'X4ECJ%UI=P)[.YFM)UZ2P2%&'XCFJ]% %[5-<U+6W1]1U"ZOW085KJ9I"/I
MN)JC110 4444 %%%% !1110 4444 %:.G^(M5TF!X++4[RSAD&'CM[AT5OJ
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M.S6&QNKRZ-RDEJ'8KY4I)W)N+\'D$D$#I1";E*S^X)145H2_LI^/Q\,_VAO
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MR^&7_*.?XO\ _8QV7_HRSJ:]L/V.-+NFT47_ (\U3^ ^(+8((P1U8*RJ2/\
MMD:]*\8?"_PW\-?V"?B8_@[Q;#XQ\+ZQJUC?V-ZJ[98E-Q:H8IAVD4KSPIYY
M5>E93G>RMU1I&-KL_/VBO:/V3_@;IO[0?Q,O/"NI7EU8J-)N;NWFM753YZ;!
M&'+(WR9;D 9P."*]JU?X)_LT_ >./0OB1XNUGQ5XVC4#4+7P\3Y%I)W0848(
MZ89]W&2JYQ6DJBB^7J0H-JY\6T5ZW\"OV?=6_:,^(UWHOAHC3=%MBUS=ZE>
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MFD1^,9[ZV\,-.!?S:;C[0L>#DIE6&<X[&OHQ=2_8\BF^Q'2?B-,C?+_:+/"
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M^'=/C$,%M;KM7:/U/.22>6)).2:SZ**\P[0HHHH **** .J^'W_(2N?^N/\
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MZX_[^Q?X4?6J7</83/!:*]Z_X4+X8_Z#UQ_W]B_PH_X4+X8_Z#UQ_P!_8O\
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MO7_"A?#'_0>N/^_L7^%'_"A?#'_0>N/^_L7^%'UJEW#V$SP6BO>O^%"^&/\
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M?\*%\,?]!ZX_[^Q?X4?6J7</83/!:*]Z_P"%"^&/^@]<?]_8O\*/^%"^&/\
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M?\*%\,?]!ZX_[^Q?X4?6J7</83/!:*]Z_P"%"^&/^@]<?]_8O\*/^%"^&/\
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MX>?LY_$N#X@)^T)H-SX<M(Y6%G;7,*27B,A CDV3-Y@&0V%4DE1@ ]/#]/\
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M444 %%%% !5/6O\ D#7_ /U[R?\ H)JY5/6O^0-?_P#7O)_Z":3V!;GZ;_\
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MSL3DL2>22>]?5O\ P3-_Y./G_P"P%=_^AQ5\FUI'XW\B7\*/L?X5ZE-\/?\
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M0-0M+3XG?#Z$V*:7=SJGVRU"HF1GG!5(L,> RLIP&#5\W77[)OQCM-3^P/\
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M&H?\A"Y_ZZM_,U7H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *='_K%^M-IT?^L7ZT =M\0_^/:S_P!]OY"N'KN/
MB'_Q[6?^^W\A7#T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% '<_#W_CSN_^N@_E7#5W/P]_X\[O_KH/Y5PU
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%6>(':Q!5<$CC ]*RJ**8@KI?"GQ+\7> U=?#?BG6O#ZNVYUTS4);=6/J0C
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M[5VC]3SDDGEB23DFL^BBO,.T**** "BBB@ HHHH **** .J^'W_(2N?^N/\
M[,*Q?$'_ "'+[_KLW\ZVOA]_R$KG_KC_ .S"L7Q!_P AR^_Z[-_.@#/HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *[GQM_R ;+_KHO\ Z :X:NY\;?\ (!LO^NB_^@&@#AJ*** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "NQ^'
M?^LO_HG_ +-7'5V/P[_UE_\ 1/\ V:@#EM0_Y"%S_P!=6_F:KU8U#_D(7/\
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MM/\ XW1_PSK\*/\ HF/@W_P06G_QNO0J*+L+'GO_  SK\*/^B8^#?_!!:?\
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M$%I_\;H_X9U^%'_1,?!O_@@M/_C=>A44786//?\ AG7X4?\ 1,?!O_@@M/\
MXW1_PSK\*/\ HF/@W_P06G_QNO0J*+L+'GO_  SK\*/^B8^#?_!!:?\ QNC_
M (9U^%'_ $3'P;_X(+3_ .-UZ%11=A8\]_X9U^%'_1,?!O\ X(+3_P"-T?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8Q:3X=T^,0P6UNNU=H_4\Y))Y8DDY)K/HHKS#M"BBB@ HHHH **** "BBB@
MHHHH ZKX??\ (2N?^N/_ +,*Q?$'_(<OO^NS?SK:^'W_ "$KG_KC_P"S"L7Q
M!_R'+[_KLW\Z ,^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ KN?&W_(!LO\ KHO_ * :X:NY\;?\@&R_ZZ+_
M .@&@#AJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "NQ^'?\ K+_Z)_[-7'5V/P[_ -9?_1/_ &:@#EM0_P"0
MA<_]=6_F:KU8U#_D(7/_ %U;^9JO0 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4Z/_6+]:;3H_\ 6+]: .V^(?\
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M37HU%'M)]V')'L><_P##'_[.?_1/;K_P;7O_ ,DT?\,?_LY_]$]NO_!M>_\
MR37HU%'M)]V')'L><_\ #'_[.?\ T3VZ_P#!M>__ "31_P ,?_LY_P#1/;K_
M ,&U[_\ )->C44>TGW8<D>QYS_PQ_P#LY_\ 1/;K_P &U[_\DT?\,?\ [.?_
M $3VZ_\ !M>__)->C44>TGW8<D>QYS_PQ_\ LY_]$]NO_!M>_P#R31_PQ_\
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M;K_P;7O_ ,DT?\,?_LY_]$]NO_!M>_\ R37HU%'M)]V')'L><_\ #'_[.?\
MT3VZ_P#!M>__ "31_P ,?_LY_P#1/;K_ ,&U[_\ )->C44>TGW8<D>QYS_PQ
M_P#LY_\ 1/;K_P &U[_\DT?\,?\ [.?_ $3VZ_\ !M>__)->C44>TGW8<D>Q
MYS_PQ_\ LY_]$]NO_!M>_P#R31_PQ_\ LY_]$]NO_!M>_P#R37HU%'M)]V')
M'L><_P##'_[.?_1/;K_P;7O_ ,DT?\,?_LY_]$]NO_!M>_\ R37HU%'M)]V'
M)'L><_\ #'_[.?\ T3VZ_P#!M>__ "31_P ,?_LY_P#1/;K_ ,&U[_\ )->C
M44>TGW8<D>QYS_PQ_P#LY_\ 1/;K_P &U[_\DT?\,?\ [.?_ $3VZ_\ !M>_
M_)->C44>TGW8<D>QYS_PQ_\ LY_]$]NO_!M>_P#R31_PQ_\ LY_]$]NO_!M>
M_P#R37HU%'M)]V')'L><_P##'_[.?_1/;K_P;7O_ ,DT?\,?_LY_]$]NO_!M
M>_\ R37HU%'M)]V')'L><_\ #'_[.?\ T3VZ_P#!M>__ "31_P ,?_LY_P#1
M/;K_ ,&U[_\ )->C44>TGW8<D>QYS_PQ_P#LY_\ 1/;K_P &U[_\DT?\,?\
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M)]V')'L><_\ #'_[.?\ T3VZ_P#!M>__ "31_P ,?_LY_P#1/;K_ ,&U[_\
M)->C44>TGW8<D>QYS_PQ_P#LY_\ 1/;K_P &U[_\DT?\,?\ [.?_ $3VZ_\
M!M>__)->C44>TGW8<D>QYS_PQ_\ LY_]$]NO_!M>_P#R31_PQ_\ LY_]$]NO
M_!M>_P#R37HU%'M)]V')'L><_P##'_[.?_1/;K_P;7O_ ,DT?\,?_LY_]$]N
MO_!M>_\ R37HU%'M)]V')'L><_\ #'_[.?\ T3VZ_P#!M>__ "31_P ,?_LY
M_P#1/;K_ ,&U[_\ )->C44>TGW8<D>QYS_PQ_P#LY_\ 1/;K_P &U[_\DT?\
M,?\ [.?_ $3VZ_\ !M>__)->C44>TGW8<D>QYS_PQ_\ LY_]$]NO_!M>_P#R
M31_PQ_\ LY_]$]NO_!M>_P#R37HU%'M)]V')'L><_P##'_[.?_1/;K_P;7O_
M ,DT?\,?_LY_]$]NO_!M>_\ R37HU%'M)]V')'L><_\ #'_[.?\ T3VZ_P#!
MM>__ "31_P ,?_LY_P#1/;K_ ,&U[_\ )->C44>TGW8<D>QYS_PQ_P#LY_\
M1/;K_P &U[_\DT?\,?\ [.?_ $3VZ_\ !M>__)->C44>TGW8<D>QYS_PQ_\
MLY_]$]NO_!M>_P#R31_PQ_\ LY_]$]NO_!M>_P#R37HU%'M)]V')'L><_P##
M'_[.?_1/;K_P;7O_ ,DT?\,?_LY_]$]NO_!M>_\ R37HU%'M)]V')'L><_\
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M(?\ Q[6?^^W\A7#T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% '<_#W_ (\[O_KH/Y5PU=S\/?\ CSN_^N@_
ME7#4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% %K2_\ D)VG_79/_0A73?$3_76/^Z_\Q7,Z7_R$[3_KLG_H
M0KIOB)_KK'_=?^8H X^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MKN?&W_(!LO\ KHO_ * : .&HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^(/^0Y??]=F_G6U\/O\ D)7/_7'_ -F%8OB#_D.7W_79OYT 9]%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
M<^-O^0#9?]=%_P#0#7#5W/C;_D V7_71?_0#0!PU%%% !1110 4444 %%%%
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MFR_^1J/83#VL3]:J*_)7_AL#]HS_ **%:_\ @ILO_D:C_AL#]HS_ **%:_\
M@ILO_D:CV$P]K$_6JBOR5_X; _:,_P"BA6O_ (*;+_Y&H_X; _:,_P"BA6O_
M (*;+_Y&H]A,/:Q/UJHK\E?^&P/VC/\ HH5K_P""FR_^1J/^&P/VC/\ HH5K
M_P""FR_^1J/83#VL3]:J*_)7_AL#]HS_ **%:_\ @ILO_D:C_AL#]HS_ **%
M:_\ @ILO_D:CV$P]K$_6JBOR5_X; _:,_P"BA6O_ (*;+_Y&H_X; _:,_P"B
MA6O_ (*;+_Y&H]A,/:Q/UJHK\E?^&P/VC/\ HH5K_P""FR_^1J/^&P/VC/\
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MV WB'1O$Y^S)<?;M#N//@^8L-A; ^8;>1[BO=_VYE5?"/P"P /\ BB;7H/\
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M6IWW[0?[:WQ.U/Q!\1/ <U[IO_"//?7^D&-;!!)]G$KQ@;^N=HZ]:7X6J/\
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MT'GWPN_Y1W_&;_L/V'_HZTK)?#;S*>_R/E"BBBNLP/KGX]?\F(_ 7_K[O/\
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M3N;RW ]$/2O)/VMOV?;+X!^/-/BT/4FU;PKKMF-2TJYD(+B,G!C8C[V/E(;
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M=;"RYHIVV:UT?5+N<MJ'_(0N?^NK?S-5ZL:A_P A"Y_ZZM_,U7KB/0"BBB@
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MP">5^S738_-1^5?"*J%4*.@&!7?AHK5G)6?06BBBNXY0HHHH **** "BBB@
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M5-V39*5W8\AHKV_]M;P_I?A7]I[QOI>BZ;::1ID$MMY5G8P+##'NM(6;:B@
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M)D;1M6TR2:2WSDF-68H<#H,[_P#>-?(M%#AK=.P*6EFKGV1XL^/WPO\ V?\
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M=&E8JRH<$9JY\/O^0E<_]<?_ &85\>_';]N;XB_#OXO>*/#6DV^AG3M-NS!
M;BTD>0J%'+'S!D\^E=>&PM3%2<:>Z.;$8B&&BI5.I]4?\(_J7_/C/_WP:/\
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M[>'?_ &3_P".T?V/B?+[P_M3#^?W'W'_ ,(_J7_/C/\ ]\&C_A']2_Y\9_\
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MQ6_Y]O#O_@#)_P#':/['Q/E]X?VIA_/[C[C_ .$?U+_GQG_[X-'_  C^I?\
M/C/_ -\&OAS_ (>-?%;_ )]O#O\ X R?_':/^'C7Q6_Y]O#O_@#)_P#':/['
MQ/E]X?VIA_/[C[C_ .$?U+_GQG_[X-'_  C^I?\ /C/_ -\&OAS_ (>-?%;_
M )]O#O\ X R?_':/^'C7Q6_Y]O#O_@#)_P#':/['Q/E]X?VIA_/[C[C_ .$?
MU+_GQG_[X-'_  C^I?\ /C/_ -\&OAS_ (>-?%;_ )]O#O\ X R?_':/^'C7
MQ6_Y]O#O_@#)_P#':/['Q/E]X?VIA_/[C[C_ .$?U+_GQG_[X-'_  C^I?\
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M*O&+LSX2_P"'.?C_ /Y^K3_P*3_&C_ASGX__ .?JT_\  I/\:^[?^%U>,_\
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M_P#DK#_\11]3J=T'UB'8]:_X0_5_^?3_ ,BI_C1_PA^K_P#/I_Y%3_&O)?\
MA=7C/_H,_P#DK#_\11_PNKQG_P!!G_R5A_\ B*/J=3N@^L0['K7_  A^K_\
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M !H_X0_5_P#GT_\ (J?XUY+_ ,+J\9_]!G_R5A_^(H_X75XS_P"@S_Y*P_\
MQ%'U.IW0?6(=CUK_ (0_5_\ GT_\BI_C1_PA^K_\^G_D5/\ &O)?^%U>,_\
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M^%U>,_\ H,_^2L/_ ,11_P +J\9_]!G_ ,E8?_B*/J=3N@^L0['K7_"'ZO\
M\^G_ )%3_&C_ (0_5_\ GT_\BI_C7DO_  NKQG_T&?\ R5A_^(H_X75XS_Z#
M/_DK#_\ $4?4ZG=!]8AV/6O^$/U?_GT_\BI_C1_PA^K_ //I_P"14_QKR7_A
M=7C/_H,_^2L/_P 11_PNKQG_ -!G_P E8?\ XBCZG4[H/K$.QZU_PA^K_P#/
MI_Y%3_&C_A#]7_Y]/_(J?XUY+_PNKQG_ -!G_P E8?\ XBC_ (75XS_Z#/\
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M/_0A73?$3_76/^Z_\Q7-:8"NJ6@(P1,F1_P(5TOQ$_UUC_NO_,5S&YQ]%%%
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M5V5Y1B]+$=$Y+4[GXR?M7;;3Q?X"\>? C1]">6TN+73 L AN+"0JRPS LF'
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MYI;NP44450@HHHH **** "BBB@ K[H_X)8?\F^^(/^QHN/\ TDM*^%Z^Z/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\0$*HP<C/KG%>&_M;_#6'X<_%:X^PPK%I6HH+B!8QA%X&0/SKZ=_:$\.^(/
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR- HHHH ZKX??\A*Y_ZX_P#LPK\M_P!K'_DX[Q]_V$F_]!6OU(^'W_(2N?\
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MXU/1F>W /_D.C^UL+W?W!_9F)[?B?G/17Z)_\.X?AQ_T.FM_]_K;_P"-T?\
M#N'X<?\ 0Z:W_P!_K;_XW1_:V%[O[@_LS$]OQ/SLHK]$_P#AW#\./^ATUO\
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M?\*/\%?]!R[_ / N#_XBCZU3#ZO,\!HKW[_A1_@K_H.7?_@7!_\ $4?\*/\
M!7_0<N__  +@_P#B*/K5,/J\SP&BO?O^%'^"O^@Y=_\ @7!_\11_PH_P5_T'
M+O\ \"X/_B*/K5,/J\SP&BO?O^%'^"O^@Y=_^!<'_P 11_PH_P %?]!R[_\
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MO_P+@_\ B*/K5,/J\SP&BO?O^%'^"O\ H.7?_@7!_P#$4?\ "C_!7_0<N_\
MP+@_^(H^M4P^KS/ :*]^_P"%'^"O^@Y=_P#@7!_\11_PH_P5_P!!R[_\"X/_
M (BCZU3#ZO,\!HKW[_A1_@K_ *#EW_X%P?\ Q%'_  H_P5_T'+O_ ,"X/_B*
M/K5,/J\SP&BO?O\ A1_@K_H.7?\ X%P?_$4?\*/\%?\ 0<N__ N#_P"(H^M4
MP^KS/ :*]^_X4?X*_P"@Y=_^!<'_ ,11_P */\%?]!R[_P# N#_XBCZU3#ZO
M,\!HKW[_ (4?X*_Z#EW_ .!<'_Q%'_"C_!7_ $'+O_P+@_\ B*/K5,/J\SP&
MBO?O^%'^"O\ H.7?_@7!_P#$4?\ "C_!7_0<N_\ P+@_^(H^M4P^KS/ :*]=
M^)'PET/PEX3;5M.O+RYD\U$7S98V0@GD_*@_G7D5;TZD:BO$QE%P=F%>R?"G
MX4Q^3'XB\11B.S0>9;VLHX?T=QZ>B]_IU/A3\*8_)C\1>(HQ'9H/,M[64</Z
M.X]/1>_TZ]?XD\22:U-L3,=HA^1.Y]S[_P JX<1B/L0.JC1^U(LZAXDDUK6K
M1$S':).FQ.Y^8<GW_E5SXB?ZZQ_W7_F*YG2_^0G:?]=D_P#0A73?$3_76/\
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MCN?9%%%%><=H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M &#K/PUXYLFL]3T'QIBQ'G+*C6SP2$,C*2-A:63CU'(!XKCOV//^2,_M(_\
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MAR^_Z[-_.@#/HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0KY;K[._:F^&'B7XD?\ ",?\([IO]H?8OM7G_OXHMF_R=OWV7.=C=/2O!/\
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MCD$D:N.C $5Z.&V9Q5MT.HHHKL.<**** "BBB@ HHHH **** "BBB@ HHHH
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MZECP-D<B'). 3WS7!W7Q8_9(\'6=Y=>&_A=K?B#5Y8F6"'6)"UM$2"!GS)W
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MV;B0H !/4TY*5[Q3O^!,6K>\]"Y_P3/4MX3^.*J"6.F6@ '4_N[ROCWX5_\
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M?BA\/;[]K#]DWX9>+O!$3:QXD\&V7]CZII-N09W5(T5R!U+CRT<*.664XR0
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M%FJ?VM?65E'I\$I@BAV0(S,J8C50<%VY(SSR:TM)M29%TDTB3X.?\E>\#_\
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M^L:Q<:U=&68X4?<C!X0>W^-4*** "BBB@ HHHH **** "BBB@ HHHH ****
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M/ Z*]\_X=P_&[_H;/!O_ ($7'_R)1_P[A^-W_0V>#?\ P(N/_D2CZQ /92/
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MXW?]#9X-_P# BX_^1*/^'</QN_Z&SP;_ .!%Q_\ (E2ZU.2LQJG-.Z.^OO\
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M)V0FU%78?M+_ +2^B?LK^%_L=G]GUCXB:E"3:6+'*6R'CSIL<A 1PO!<C P
M2OY1>*O%6K^-_$5_KNNW\VJ:O?RF:YN[ALO(Q_0 #  &      !1XJ\5:OXW
M\17^NZ[?S:IJ]_*9KF[N&R\C']  ,  8      %95>K3IJFO,\^<W-A1116Q
MF%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%% !1110 4444 %%%% !1110 4444 %=C\._]9?_ $3_ -FKCJ['X=_ZR_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3_XS1_PKGX4?]$A\&_\ @FM/_C-:%%',^X678S_^%<_"C_HD/@W_ ,$UI_\
M&:/^%<_"C_HD/@W_ ,$UI_\ &:T**.9]PLNQG_\ "N?A1_T2'P;_ .":T_\
MC-'_  KGX4?]$A\&_P#@FM/_ (S6A11S/N%EV,__ (5S\*/^B0^#?_!-:?\
MQFC_ (5S\*/^B0^#?_!-:?\ QFM"BCF?<++L9_\ PKGX4?\ 1(?!O_@FM/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ;OAW3=+U9
M_(N99X;D_=VLH5_89'6N"^(GQW^#/PG\43^'O%OBO4-%U>%%D:WFTN[8,C#A
MD=;<JZGD94D9!'4&NA5BK @X(Y!%<_\ &GX+>&_VH/!/]@:_ML/$=HK-I.N(
M@,D$A'0_WD; W)GG (PP!%QY;^]L3*]O=.8_X; _9S_Z*%=?^"F]_P#D:C_A
ML#]G/_HH5U_X*;W_ .1J_,'XH_"[Q'\'?&E]X7\46+6.IVIR",F*>,D[98FQ
M\R-C@^Q! ((')UW_ %:#U3.3VTNQ^M7_  V!^SG_ -%"NO\ P4WO_P C4?\
M#8'[.?\ T4*Z_P#!3>__ "-7Y*T4?5H=V'MY'ZU?\-@?LY_]%"NO_!3>_P#R
M-1_PV!^SG_T4*Z_\%-[_ /(U?DK11]6AW8>WD?K5_P -@?LY_P#10KK_ ,%-
M[_\ (U'_  V!^SG_ -%"NO\ P4WO_P C5^2M%'U:'=A[>1^M7_#8'[.?_10K
MK_P4WO\ \C4?\-@?LY_]%"NO_!3>_P#R-7Y*T4?5H=V'MY'ZU?\ #8'[.?\
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MV!^SG_T4*Z_\%-[_ /(U?DK11]6AW8>WD?K5_P -@?LY_P#10KK_ ,%-[_\
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MWO\ \C5^2M%'U:'=A[>1^M7_  V!^SG_ -%"NO\ P4WO_P C4?\ #8'[.?\
MT4*Z_P#!3>__ "-7Y*T4?5H=V'MY'ZU?\-@?LY_]%"NO_!3>_P#R-1_PV!^S
MG_T4*Z_\%-[_ /(U?DK11]6AW8>WD?K5_P -@?LY_P#10KK_ ,%-[_\ (U'_
M  V!^SG_ -%"NO\ P4WO_P C5^2M%'U:'=A[>1^M7_#8'[.?_10KK_P4WO\
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MH=V'MY'ZU?\ #8'[.?\ T4*Z_P#!3>__ "-1_P -@?LY_P#10KK_ ,%-[_\
M(U?DK11]6AW8>WD?K5_PV!^SG_T4*Z_\%-[_ /(U'_#8'[.?_10KK_P4WO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^N@_E7#5W/P]_P"/.[_ZZ#^5<-0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 6M+_P"0G:?]=D_]"%=-\1/]
M=8_[K_S%<SI?_(3M/^NR?^A"NF^(G^NL?]U_YB@#CZ*** "BBB@ HHHH *\O
M^//[1O@W]G?P]#J/BB[D>ZNBRV6EV:A[FZ8==JD@!1D99B ,@=2 >O\ B'XY
MTWX:>!];\4ZNS+IVDVKW4H499MHX1?=CA1[D5^-WB3QCKGQF\::AXY\6W!O=
M0O9#]FA8DQVL()V1QJ>BKG 'U8Y+$UM3INHS.<^1'O?C#_@HE\7?%]P6\+:/
MI/@_3<DQF:/[5<$9XW-)\IX](QU//3'&?\-@?M&?]%"M?_!39?\ R-7G-%>@
MJ$%T.-U9'HW_  V!^T9_T4*U_P#!39?_ "-1_P -@?M&?]%"M?\ P4V7_P C
M5YS13]C#L+VDNYZ-_P -@?M&?]%"M?\ P4V7_P C4?\ #8'[1G_10K7_ ,%-
ME_\ (U><T4>QAV#VDNYZ-_PV!^T9_P!%"M?_  4V7_R-1_PV!^T9_P!%"M?_
M  4V7_R-7G-%'L8=@]I+N>C?\-@?M&?]%"M?_!39?_(U'_#8'[1G_10K7_P4
MV7_R-7G-%'L8=@]I+N>C?\-@?M&?]%"M?_!39?\ R-1_PV!^T9_T4*U_\%-E
M_P#(U><T4>QAV#VDNYZ-_P -@?M&?]%"M?\ P4V7_P C4?\ #8'[1G_10K7_
M ,%-E_\ (U><T4>QAV#VDNYZ-_PV!^T9_P!%"M?_  4V7_R-1_PV!^T9_P!%
M"M?_  4V7_R-7G-%'L8=@]I+N>C?\-@?M&?]%"M?_!39?_(U'_#8'[1G_10K
M7_P4V7_R-7G-%'L8=@]I+N>C?\-@?M&?]%"M?_!39?\ R-1_PV!^T9_T4*U_
M\%-E_P#(U><T4>QAV#VDNYZ-_P -@?M&?]%"M?\ P4V7_P C4?\ #8'[1G_1
M0K7_ ,%-E_\ (U><T4>QAV#VDNYZ-_PV!^T9_P!%"M?_  4V7_R-1_PV!^T9
M_P!%"M?_  4V7_R-7G-%'L8=@]I+N>C?\-@?M&?]%"M?_!39?_(U'_#8'[1G
M_10K7_P4V7_R-7G-%'L8=@]I+N>C?\-@?M&?]%"M?_!39?\ R-1_PV!^T9_T
M4*U_\%-E_P#(U><T4>QAV#VDNYZ-_P -@?M&?]%"M?\ P4V7_P C4?\ #8'[
M1G_10K7_ ,%-E_\ (U><T4>QAV#VDNYZ-_PV!^T9_P!%"M?_  4V7_R-1_PV
M!^T9_P!%"M?_  4V7_R-7G-%'L8=@]I+N>C?\-@?M&?]%"M?_!39?_(U'_#8
M'[1G_10K7_P4V7_R-7G-%'L8=@]I+N>C?\-@?M&?]%"M?_!39?\ R-1_PV!^
MT9_T4*U_\%-E_P#(U><T4>QAV#VDNYZ-_P -@?M&?]%"M?\ P4V7_P C4?\
M#8'[1G_10K7_ ,%-E_\ (U><T4>QAV#VDNYZ-_PV!^T9_P!%"M?_  4V7_R-
M1_PV!^T9_P!%"M?_  4V7_R-7G-%'L8=@]I+N>C?\-@?M&?]%"M?_!39?_(U
M'_#8'[1G_10K7_P4V7_R-7G-%'L8=@]I+N>C?\-@?M&?]%"M?_!39?\ R-1_
MPV!^T9_T4*U_\%-E_P#(U><T4>QAV#VDNYZ-_P -@?M&?]%"M?\ P4V7_P C
M4?\ #8'[1G_10K7_ ,%-E_\ (U><T4>QAV#VDNYZ-_PV!^T9_P!%"M?_  4V
M7_R-1_PV!^T9_P!%"M?_  4V7_R-7G-%'L8=@]I+N>C?\-@?M&?]%"M?_!39
M?_(U'_#8'[1G_10K7_P4V7_R-7G-%'L8=@]I+N>C?\-@?M&?]%"M?_!39?\
MR-1_PV!^T9_T4*U_\%-E_P#(U><T4>QAV#VDNYZ-_P -@?M&?]%"M?\ P4V7
M_P C4?\ #8'[1G_10K7_ ,%-E_\ (U><T4>QAV#VDNYZ-_PV!^T9_P!%"M?_
M  4V7_R-1_PV!^T9_P!%"M?_  4V7_R-7G-%'L8=@]I+N>C?\-@?M&?]%"M?
M_!39?_(U'_#8'[1G_10K7_P4V7_R-7G-%'L8=@]I+N>C?\-@?M&?]%"M?_!3
M9?\ R-1_PV!^T9_T4*U_\%-E_P#(U><T4>QAV#VDNYZ-_P -@?M&?]%"M?\
MP4V7_P C4?\ #8'[1G_10K7_ ,%-E_\ (U><T4>QAV#VDNYZ-_PV!^T9_P!%
M"M?_  4V7_R-3D_;$_:+C8,?']I(!_"VE66#^5L*\WHH]C#L'M)=SZ,\!_\
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M  R\72> _&^H,T[>&M9B BEE.681KG@DY)\IW '\ %3)W:<MBDM++<^?=/\
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MFO?_ -7<T_Y]?^31_P SYC_6K)_^?_\ Y++_ .1/J.BOES_AMX?]"9_Y5/\
M[31_PV\/^A,_\JG_ -IH_P!7<T_Y]?\ DT?\P_UJR?\ Y_\ _DLO_D3ZCHKY
M<_X;>'_0F?\ E4_^TT?\-O#_ *$S_P JG_VFC_5W-/\ GU_Y-'_,/]:LG_Y_
M_P#DLO\ Y$^HZ*^7/^&WA_T)G_E4_P#M-'_#;P_Z$S_RJ_\ VFC_ %=S3_GU
M_P"31_S#_6K)_P#G_P#^2R_^1/J.BBBOG#ZP**** "BBB@ HHHH *='_ *Q?
MK3:=']]?K0!VWQ#_ ./:S_WV_D*X>NU^(4B-:V>&!^=N_L*XG>O]X4 +12;U
M_O"C>O\ >% "T4F]?[PHWK_>% "T4F]?[PI00>1S0 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 =S\/?^/.[_P"N@_E7#5W/P]_X
M\[O_ *Z#^5<-0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 :GAFUBOM:MX)DWQ.'#*?]QJ=X@\/S:'<=Y+9S^[D_H?>I/!__ ",=
MI_P/_P! :KEQ\0K!O'6J^%-85(X28Q;3-P"6C1MI/8Y)P:N,7*]NA+DH[G,T
M5K>(/#\VAW'>2V<_NY/Z'WK)J"@HHHH M:7_ ,A.T_Z[)_Z$*Z;XB?ZZQ_W7
M_F*YG2_^0G:?]=D_]"%=-\1/]=8_[K_S% ''T444 %%%% !1110!\F_\%-M>
MFT?]FM;2*1D35=;M;.55. ZA99\'CD;H5/U K\_+6 6MK#"HPL:!1^ Q7W;_
M ,%3_P#DWWP__P!C1;_^DEW7PO7HX;9G'7W"BBBNPY@HHHH **** "BBB@ H
MHHH **** "BM'P[X=U+Q;KVGZ+H]G)?ZI?SI;6UK$/FDD8X4#/ Y/4\#O7VE
M9?\ !/?P?X!\.V%Y\7?BQI_A+5+U=RV$4D,:H>ZJ\K9E(R,E5 'J1S42G&.Y
M48N6Q\.45],?M&_L=6WPA\!VGCWPGXWL/&_@ZYN5MOM$&T21LP.TAD9DD7Y2
M"0002..IK8_;F^"'@KX/:'\++CPCHW]DS:SI\\M^WVF:;SG1;<JW[QVV\R/]
MW'7V%)5(MI+J/D:O?H?)]%%>\?!WX/?#7QI\$?'?BCQ1X]C\/^+-'2<Z7HIN
MH(S=%( \9\MQODWR$H A!!'O5RERJ[)2N>#T5]8?LV_!#P5X^_9<^,?BW7=&
M^W>(=!M[E]-O/M,T?V=DM#(IV*X5OFY^8'TKY/I*2DVNPW%I)A178?!OP_8^
M+?B]X'T/5(3<:9J>NV-E=0AV0O%)<(CKN4@C*L1D$$5Z=^V_\+?#/P?^.USX
M>\)::=*T==/MYUMC/)-AV!W'=(S-SCUHYES<HN72YX#1115""BBB@ HHKIOA
MCI=CK?Q*\)Z=JD/VC3+S5K2WNH=Q7?$\R*ZY!!&5)&00: .9HKZ)_;M^&/A3
MX2_'(:!X/TI='TL:7;SO;K-)*/-9I,MF1F/("\9QQ7SM4QES)-#:Y78***]3
M_9G^#=M\>OB_I7@V\U*;2;>[BGE:Z@B$CKY<3.  2!R1BFVHJ[!*[LCRRBNQ
M^,7@.+X8?%+Q1X3@NWOX='OY+1+F1 C2!3@$@$X->I?"7]F&Q^)'[-OC[XFS
MZ[<65WX;DGCBT^.W5HYO+@CERS$Y&?,QP.,=Z3DDKC46W8^?****HD**** "
MBBB@ HHKWC]ISX/?#7X5V'@Z7X?^/8_&DVJ02R:@J74$_P!G*B/8V(@#&&+O
M\KY/R'G@TG))I#MI<\'HKTOX@?L^>+?AI\._"?C76H[-=$\31)+8&"XWR;7C
M$B[UQ\N5.>]>:4)I[":MN%%%?0G[#/PM\,?&#XZ1Z!XNTS^U](_LVXN#;&>2
M$&1=NT[HV5N,GC-$I<JNQI<SL?/=%=9\7-"LO"_Q6\::-ID/V?3M.UJ]L[:'
M<S;(HYW1%RQ).% &22:Y.FM=1!1110 45]G?LY? OX5Z#^S=JOQH^+&FWOB"
MQ6Z:"TTVUF=,*)%A7"JZ;G:0L/F;:%&?6OG3XZZK\/-:\>27GPQTB^T/PQ+;
M1$6.H,6DCFP?, )D<XZ?Q'OCBH4^9M)%.-E=GGE%%%62%%%% !1110 4444
M%%%% !1110 5G>(H1<:'>JPR!$S_ (CG^E:-4]:_Y U__P!>\G_H)I/8:W/U
M/_8I\17'BC]EOX?7MU*TTJ64EGN<Y.V">2!1T'18P/P[]:]MKYZ_X)__ /)H
MW@/_ +?_ /TON:^A:\26[/36P4444AA1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4JL58$'!'((I** ,/XP?
M!OPO^TUX0&@>)D6TUZV5CI.N1K^]MY".AZ;E.!N0\-CC# $?D_\ %SX1^)/@
MGXVO/#'B>S-M?0'=',F3#<Q$G;+$V/F4X^H(((!! _7T$@Y'!K&^+WPA\-_M
M,>"3X9\3 6NLVX9]*UI%!EMY2/\ QY3@!D)PP'9@".FC6<-'L85*?-JMS\9Z
M*[3XN?"/Q)\$_&UYX8\3V9MKZ [HYDR8;F(D[98FQ\RG'U!!! (('%UZB=]4
M<.Q]<?\ !.U@OB+XJ9./^*-NS_X^E?(]%%2HV;?<INZ2"OH/]C/XZZ-\'_'&
MKZ5XNC,O@;Q79'3-7&&81@A@DC*O+* \BD#G$A(R1@_/E%.45)68D^5W1]:^
M//\ @GAXTFU!M2^%][I?C_PA>,9+&\MM1ACE6,]%<NP1B,XW(QSC.%SBO0/@
M_P#!;1/V'X9_BA\6M6T]_%L%M(FA>%K&X$LYE="I8D=6(+)D H@8DL3@#X:T
MOQ!JFA[O[.U*\T_<<M]EG>//UVD55N[RXO[AY[F>2YG?EI)G+,?J363A*2LW
MH7S16J1[!\+_ (8ZS^UM\5/$[/XBTG1=>OO/U4-JDQ1+JXDF!\E ,M_&QX!P
M%Z5ZCX%_X)Y?&33?B%I,M_;V&@Z98W<=S)KRZC$Z1*CABZ(K;RP R,J!G&2.
M2/DGIR*U)_%FMW5D;.;6-0FM",&WDNG:/'IM)Q5.,NCT$G'JCW']O+XA:)\1
M_P!H[6K[0+J&_P!/L[>#3_MENVZ.>2-3O96'# ,2N1P=N1D<UZSJ7PMU/]KG
M]E#X7S> GM=2\5>!DGTG4=%>=()2CE K!G(7[L2,,D AVYRN*^(*NZ7K6H:'
M<&?3;^YT^<C:9+69HF(],J1Q2Y-$D]@YM6WU-/QYX!U[X8^*[WPUXFT]M+UN
MRV?:+1I$D*;T61?F1BIRKJ>#WKGZL7VH76J73W5[<S7=S)C?-/(7=L# R3R>
M *KUKZD$MK=2V5S%<6\C0SPN)(Y$.&5@<@@]B#7WE=ZAX"_X*!>!-#BU/Q#9
M>"_C5H]NMF'OBJ0ZF.N%'&]6.Y@%^9"S?*RG)^"**B4>;7J5&5CZ?NO^"</Q
MMM]1-M'H^F74()'VR+5(A$??#$/C_@-9/Q8_8YN_@K\/[_6?%'C_ ,+1^(X/
M+,/A>SNO,NIU9U5L;MIRH;<<*1@'FO!E\0ZJMI]E&I7@ML8\D3OL_P"^<XK/
MI)3ZL=X]$?8'[-?CSP9\7O@?J7P$^(.L1^'9/M9O_#6M7!'E03DEO+))"@[F
M<X)&\2NH(;;G U'_ ()P_&FUUK['::7I>IV#-A-5M]3B6 J>C;7*R8Q_L'\:
M^7JU;;Q9K=G9_9+?6=0@M<;?(CNG5,>FT'%+EDFW%[AS)KWD?9_C2?PO^Q1\
M /$OP_TW7K/Q'\5_&$?V;5YM.<M'80%65DSU&%:15!PY,A8@  5QG[%; ?";
M]I(9Y_X0N?C_ +87-?)Y)/)Y-)1[/1J^K'SZW"OK'X$L/^&&/C]S_P O.G_^
MC8Z^3J*N4>96)B^4^L?V+_BYX/7PQXQ^#GQ'NET_PGXM DM[^1]D=M=85<LQ
MX0G9$RN> T0SP:7Q9_P38^*6GZMCPQ+I'BW1)CNMM2M[U(-T9^ZSHY&#CGY2
MX]":^3:TK+Q)J^FVYM[/5+VU@/6*&X=%.?8'%0X-.\7N/F5K21ZO\??V9=1_
M9VTW0&UGQ1HFH>(+YG^TZ/IL^^:Q "E&;.&(;+#.T %>"V>/HWX\_!V]_;<T
MOPU\5/A?>:?JVKC2H;#6_#\EW'#<6\ZEFY+$*#EF7YBN0JE<@\?!;NTC%G8L
MS')9CDFI;.^N=.N%GM+B6UG7[LD+E&'T(H<9:.^J#F6JMH?97P9_93O/V=_$
MFG_%#XUWVG^%=$\/R"^M-*6\CN+R^NTRT4:*C%20P#8#$DJ.@R1!^W#\)8O$
MW[3WA;5[+5K&RT'XB06<L&KW$@2WBPL<+R,21\HC\I^V=^.M?'M]J%UJEPUQ
M>7,UW<-]Z6>0NQ^I/-/O]6OM5^S_ &V\N+S[-"MO!]HE9_*B7[J+D_*H[ <"
MER2YN9L?,K<J1]-:]_P3@^,6GZDD6D6FD^)-.E(,>I6.I1)$4/1B)2K=/[H;
MVS72_MJ36GP\^"?PE^$5YK=KKWBWP]')/J4EJ^\6H*D)%GJ!\Q4 @';&I(&1
M7R38>*-9TNW-O9:O?6=N>L5O<NB_D#BLV21I'9W8N[')9CDD^II\LFTY/8.9
M6=D?34'_  3]^(GB+P9HGB7P=?Z%XPM-1M(KB2WL=0C26VD9 S1,7(C)4G;D
M/U!X%>J1?#_4?V2_V.?B/H_Q!U*RM]?\9/'#IGAV&X69XVP%:3Y3@G'S,1E0
M(TYRV*^'--UK4=%D9]/O[JP=N"UM,T9/U*D5'?ZE=ZK<-<7MU->7#=9;B0NQ
M_$G-#A*6C>@*26R/JCX6L/\ AW;\9AGG^W[#_P!'6=<C^QG\==&^#_CC5]*\
M71F7P-XKLCIFKC#,(P0P21E7EE >12!SB0D9(P?GRBGR*S3ZBYM4UT/K7QY_
MP3P\:3:@VI?"^]TOQ_X0O&,EC>6VHPQRK&>BN78(Q&<;D8YQG"YQ7H'P?^"V
MB?L/PS_%#XM:MI[^+8+:1-"\+6-P)9S*Z%2Q(ZL063(!1 Q)8G 'PUI?B#5-
M#W?V=J5YI^XY;[+.\>?KM(JK=WEQ?W#SW,\ES._+23.68_4FI<)25F]!\T5J
MD?0/[*GBF]\:_MI>%?$.IR![_5=9N;R=NWF21RL0/;)P!]*\Z_:(_P"3@/B;
M_P!C/J?_ *5RUY[16G+[UR>;2Q]1_P#!-P_\90Z9_P!@V\_]%U\U:Z<ZYJ!'
M(^T2?^A&J-%'+[SD%]+!1115$A1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110![G^RU
M^U+K?[.?BG(WZEX4OG U'26;AAT\R//1P/SZ&OU$TO5-$\>>%K+Q;X2O4U+0
M;Y-ZM&>8CW5AV(/!!Z5^)%>Y_LM?M2ZW^SGXIR-^I>%+YP-1TEFX8=/,CST<
M#\^AKEK4>?5;F].IRZ/8_3VBI]+U31/'GA:R\6^$KU-2T&^3>K1GF(]U8=B#
MP0>E05YFQW!1110 4444 =5\/O\ D)7/_7'_ -F%8OB#_D.7W_79OYUM?#[_
M )"5S_UQ_P#9A1KEKX;AU:Y6^\265C=%MSV\US$C)D9&03GH0?QII-[";2W.
M5HK<\OPA_P!#=IO_ (&0_P#Q5'E^$/\ H;M-_P# R'_XJJY9=A<T>YAT5N>7
MX0_Z&[3?_ R'_P"*H\OPA_T-VF_^!D/_ ,51RR[!S1[F'16YY?A#_H;M-_\
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MZ&[3?_ R'_XJCR_"'_0W:;_X&0__ !5'++L'-'N8=%;GE^$/^ANTW_P,A_\
MBJ/+\(?]#=IO_@9#_P#%4<LNP<T>YAT5N>7X0_Z&[3?_  ,A_P#BJ/+\(?\
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M_P">;?\ ?)H\B3_GFW_?)K+_ .&E+G_H Q?^!)_^)H_X:4N?^@#%_P"!)_\
MB:/JM7L'MZ?<U/(D_P">;?\ ?)H\B3_GFW_?)K+_ .&E+G_H Q?^!)_^)H_X
M:4N?^@#%_P"!)_\ B:/JM7L'MZ?<U/(D_P">;?\ ?)H\B3_GFW_?)K+_ .&E
M+G_H Q?^!)_^)H_X:4N?^@#%_P"!)_\ B:/JM7L'MZ?<U/(D_P">;?\ ?)H\
MB3_GFW_?)K+_ .&E+G_H Q?^!)_^)H_X:4N?^@#%_P"!)_\ B:/JM7L'MZ?<
MU/(D_P">;?\ ?)H\B3_GFW_?)K+_ .&E+G_H Q?^!)_^)H_X:4N?^@#%_P"!
M)_\ B:/JM7L'MZ?<U/(D_P">;?\ ?)H\B3_GFW_?)K+_ .&E+G_H Q?^!)_^
M)H_X:4N?^@#%_P"!)_\ B:/JM7L'MZ?<U/(D_P">;?\ ?)H\B3_GFW_?)K+_
M .&E+G_H Q?^!)_^)H_X:4N?^@#%_P"!)_\ B:/JM7L'MZ?<U/(D_P">;?\
M?)H\B3_GFW_?)K+_ .&E+G_H Q?^!)_^)H_X:4N?^@#%_P"!)_\ B:/JM7L'
MMZ?<U/(D_P">;?\ ?)H\B3_GFW_?)K+_ .&E+G_H Q?^!)_^)H_X:4N?^@#%
M_P"!)_\ B:/JM7L'MZ?<]+^'Z,EG=[E*_O!U'M7$>1)_SS;_ +Y-9?\ PTI<
M_P#0!B_\"3_\31_PTI<_] &+_P "3_\ $T?5:O8/;T^YJ>1)_P \V_[Y-'D2
M?\\V_P"^367_ ,-*7/\ T 8O_ D__$T?\-*7/_0!B_\  D__ !-'U6KV#V]/
MN:GD2?\ /-O^^31Y$G_/-O\ ODUE_P##2ES_ - &+_P)/_Q-'_#2ES_T 8O_
M  )/_P 31]5J]@]O3[FIY$G_ #S;_ODT>1)_SS;_ +Y-9?\ PTI<_P#0!B_\
M"3_\31_PTI<_] &+_P "3_\ $T?5:O8/;T^YJ>1)_P \V_[Y-'D2?\\V_P"^
M367_ ,-*7/\ T 8O_ D__$T?\-*7/_0!B_\  D__ !-'U6KV#V]/N:GD2?\
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M[J0_>]%8^OH:G$8?[<!T:WV9%BBM;Q!X?FT.X[R6SG]W)_0^]9->:=I:TO\
MY"=I_P!=D_\ 0A73?$3_ %UC_NO_ #%<SI?_ "$[3_KLG_H0KIOB)_KK'_=?
M^8H X^BBB@ HHHH **** /C?_@J?_P F^^'_ /L:+?\ ])+NOA>ONC_@J?\
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M  !E_P#B:.>/<.678P:*WO\ A ?$_P#T+FK?^ ,O_P 31_P@/B?_ *%S5O\
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MUUW^\_46BBBOPD_I$**** "BBB@ HHHH *<GWE^M-IR?>7ZT ?D/_P %,_\
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M?\DAE_Z_)/YUQ+_>'Z'4_P""?5%%%%=QR!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !116_X+\%W_ (XU=;*R7:BX:>X8?)"OJ?4^
M@[_F0FU%78TFW9!X+\%W_CC5ULK)=J+AI[AA\D*^I]3Z#O\ F1]!JNG?#O14
MT;1D'VC&99FP6W$<NQ[L?3M],"A5T[X=Z*FC:,@^T8S+,V"VXCEV/=CZ=OI@
M5R[,TC%F)9F.2Q.237BUZ[JNRV/3I4E35WN6=-9I-6M68EF:=26)R2=PKI?B
M)_KK'_=?^8KF=+_Y"=I_UV3_ -"%=-\1/]=8_P"Z_P#,5RFYQ]%%% !1110
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M*K)3Y;#5-.-S\>J***ZCG"BBB@ HHHH **** "BBB@ HHHH *IZU_P @:_\
M^O>3_P!!-7*IZU_R!K__ *]Y/_032>P+<_3?_@G_ /\ )HW@/_M__P#2^YKZ
M%KYZ_P""?_\ R:-X#_[?_P#TON:^A:\66[/4CL@HHHJ1A1110 4444 %%%%
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M_OHT?\+"N/\ GTB_[Z-<E10!UO\ PL*X_P"?2+_OHT?\+"N/^?2+_OHUR5%
M'6_\+"N/^?2+_OHT?\+"N/\ GTB_[Z-<E10!UO\ PL*X_P"?2+_OHT?\+"N/
M^?2+_OHUR5% '6_\+"N/^?2+_OHT?\+"N/\ GTB_[Z-<E10!UO\ PL*X_P"?
M2+_OHT?\+"N/^?2+_OHUR5% '6_\+"N/^?2+_OHT?\+"N/\ GTB_[Z-<E10!
MUO\ PL*X_P"?2+_OHT?\+"N/^?2+_OHUR5% '6_\+"N/^?2+_OHT?\+"N/\
MGTB_[Z-<E10!UO\ PL*X_P"?2+_OHT?\+"N/^?2+_OHUR5% '6_\+"N/^?2+
M_OHT?\+"N/\ GTB_[Z-<E10!UO\ PL*X_P"?2+_OHT?\+"N/^?2+_OHUR5%
M'6_\+"N/^?2+_OHUT&O:[)H^FP7*1+(TC!2K$@#()_I7F5=SXV_Y -E_UT7_
M - - %/_ (6%<?\ /I%_WT:/^%A7'_/I%_WT:Y*B@#K?^%A7'_/I%_WT:/\
MA85Q_P ^D7_?1KDJ* .M_P"%A7'_ #Z1?]]&C_A85Q_SZ1?]]&N2HH ZW_A8
M5Q_SZ1?]]&C_ (6%<?\ /I%_WT:Y*B@#K?\ A85Q_P ^D7_?1H_X6%<?\^D7
M_?1KDJ* .M_X6%<?\^D7_?1H_P"%A7'_ #Z1?]]&N2HH ZW_ (6%<?\ /I%_
MWT:/^%A7'_/I%_WT:Y*B@#K?^%A7'_/I%_WT:/\ A85Q_P ^D7_?1KDJ* .M
M_P"%A7'_ #Z1?]]&C_A85Q_SZ1?]]&N2HH ZW_A85Q_SZ1?]]&C_ (6%<?\
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M_P"A:L/_  '%?1G_  P+\&O^A2M/R-'_  P+\&O^A2M/R-.[ ^<_^'QFM_\
M0M6'_@.*/^'QFM_]"U8?^ XKZ,_X8%^#7_0I6GY&C_A@7X-?]"E:?D:+L#\]
M_P!K+]NC4?VG-#L--N=)MM/CM@>88PI))K[<_P""2OB.VTS]G^>*6R6Y;^T)
MCN)'][Z5UG_# OP:_P"A2M/R->K?"WX0^&_@[H9TCPQ81Z=8%S)Y,?3<>II
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M_P"%<A11=@=?_P )K9?] E/S7_"C_A-;+_H$I^:_X5R%%%V!U_\ PFME_P!
ME/S7_"C_ (36R_Z!*?FO^%<A11=@=?\ \)K9?] E/S7_  H_X36R_P"@2GYK
M_A7(4478'7_\)K9?] E/S7_"C_A-;+_H$I^:_P"%<A11=@=?_P )K9?] E/S
M7_"C_A-;+_H$I^:_X5R%%%V!U_\ PFME_P! E/S7_"C_ (36R_Z!*?FO^%<A
M11=@=?\ \)K9?] E/S7_  H_X36R_P"@2GYK_A7(4478'7_\)K9?] E/S7_"
MC_A-;+_H$I^:_P"%<A11=@=?_P )K9?] E/S7_"C_A-;+_H$I^:_X5R%%%V!
MW>D^)+/5M0BM1IJ1F3/S':<8!/I[5X%\9XUC^)6L*BA%'DX51@?ZE*]<\'_\
MC':?\#_] :N$\;>"[_QQ\9-7LK)=J+Y#3W##Y(5\E.3ZGT'?\R.S"R49MOL<
MU=7BDNYP_@OP7?\ CC5ULK)=J+AI[AA\D*^I]3Z#O^9'T&JZ=\.]%31M&0?:
M,9EF;!;<1R['NQ].WTP*%73OAWHJ:-HR#[1C,LS8+;B.78]V/IV^F!7+LS2,
M68EF8Y+$Y)-17KNJ[+8JE25-7>X,S2,68EF8Y+$Y)--HHKE-RUI?_(3M/^NR
M?^A"NF^(G^NL?]U_YBN9TO\ Y"=I_P!=D_\ 0A73?$3_ %UC_NO_ #% ''T4
M44 %%%% !1110!\;_P#!4_\ Y-]\/_\ 8T6__I)=U\+U]T?\%3_^3??#_P#V
M-%O_ .DEW7PO7HX;X6<5;<****[#G"BBB@ HHHH **** "BBB@ HHHH ^W?^
M"5&H0Q_%KQC9,J_:)M$$R-W"I/&&'YR+^5?)7Q2T6[\._$KQ7I=^CQWEIJMU
M#*LG7<LK G\>N?>M/X(?%[5?@;\2](\8:2@N)K)RLUH[E4N86&UXF.#C(/!P
M<$ XXK[)\;>,OV2_VGM0A\2^*-7U7P-XIGA7[8((GB>1E&/G80R1.0.-W#$8
M] !SN\)N5M&:JTHVOJCS;_@F+H-YJ'[0UUJ,,3&ST_1IVGE_A4NR(BGW)R0/
M]D^E=W^S#JL.M?\ !1CXAWEOM,$D^L!&7HP6<*&_'&?QH\1_M3_!_P#9N^&N
MI^$_@);3:KKFJ*RW'B"X21#$Q4@2,\BJTCKN.Q0H0')]0WAW[#?Q4\,_"3X[
M)XA\8:K_ &5I3:=<P-=-#+-^\?:0"(U9N<'G%0U*2E*W0M-1Y8W.6_:K\>ZY
MXZ_:!\<7.L7TERUCJMUIEJF2$@MX97C2-!V&!D^I+$\DU['H/['5YJ?PQ\.^
M,/C'\68/!&B36T::18ZBS7<L<##<D:!Y%"?+AA&@; Z@8('S;\7-=LO%'Q6\
M::SIDWVG3=1UN]O+:;8R^9%).[HV& (RI!P0#7VQXB^,'[/_ .U5\)?!EE\1
M_%6I>"?$/AN#8\=M Y)8HBR["(9$='\M2!PPP./6Y<T5%(B-FW<Z#XK>'_#7
MA_\ X)OZQIGA;Q8WCC0["[@%KJKQ&/!.H1ED"GH%+L/QKG?AWXRUGP'_ ,$P
MM9U?0+^73-36^D@2Z@.)$66^CC?:?X24=AD<C.1@\UE_&#X^? YOV0?$7PP^
M'-_=6\L-S;165K>VLPEOMMS#-)<ERNT;L/\ >*G*X"@;17 :?\;O!4'_  3\
MU3X</K6WQG-J"RQZ9]FFR4^VQR[O,V>7]Q2?O=L=:R46UJNIHY*^_0Z'_@EG
MKU]#\<O$FEBXD-C>:#)<30ECM:6.X@".1W($D@_X$:Z;_@GR%T[]K#XHV<-A
M(\(M[V-;E%^6 +>IA6/8-C\U^M>-?L$?%KPI\&?C1J&M^,=6&C:7-HD]HEP8
M)9@96F@8+B-6/(1N<8XKW']@&\%S\1_CAXQDEM#X!9)I;RXN(VWLK2RRH0N,
M[1$)2P(SRO%.HG[S]!0^R=%^S_\ L?>*O@#\=[[XE>,/&.DQ>%=.2[E?4FO&
M5KY9E90T^X!4'SAVRQ^91C/6O,?V7]6T/XK?\%"=;\3VB1MITMSJ>I:>)(\>
M9D,J/M/1BKE_4&M'1?&'[('Q-\36'AH>!O%>CR7UVMK:7,EW/]F5W<*I"+=/
ML!)'_+/ K@?B9X<_X8'_ &LM#OO#EQ-K&EPV\>HQ6]TR^:]K,9(98'8#&["2
M8;'&5...17E=/=H>BLUM<]1_: ^'OP*\:_&?Q/J_BWXZ:CIOB);UH9K'^SI'
M%D8SM$*,(^B;< CKU[YKDOV]?C'\/?B?X*^'&G^%O%?_  EVM:()8;J^-M)&
M[H8XE+N711N=HP<#/>NF^(TG[)W[1GB&3QK?^.=8\$:[?(DFHV*VSKO< #)!
MAD7?@ $QL0<9QDDGYN_:,@^#6GWVA6'P?GU74;>VAE&I:IJ6\?:G)7RRH<+C
M #YPBCD=:<%=J]]!2>CM8\R\):A!I7BK1KVZ026UM>PS2JW0HLBEA^0-?;__
M  5>T2\7Q1X!UG8[:;)97%H) ,HLJNKD9[$JX^NT^AKX*K[K^%G[7OPR^*'P
M;M/AI\>;"<QZ?%'%;:VD<D^_8"L<F8P9(YE4XW ,&&<]2#I434E-*]B(6:<6
M?"E?H!\&=2N?AM_P34\;^)/#LIMM<O;N59;JW^6:/?<0VQ(8<@K&2P(Z9R.:
MR[&;]C3X,SOKUC=ZI\2-3C&^UTJ\ADGB#=LJ\441'_70MCK@D5R?[*O[6'@W
MPEH/C#X>?$C2W7P#XCN9[B/[/&9%LO-&)(F5 &V$!-I095AD#G*S-N:T6Q44
MHO5GD7[(?BS5_"G[27@&;2KB6-[[5H-/ND1CB6WFD$<BN/XAABW/0J#U KZM
M^(6FV>G_ /!4GPG):JB/=I!/<!0!^\^R2KD^Y5%_.LCP+K'[)7[.?B(^.?#_
M (JUSQIKMO&[Z;ITT+OY+,I7Y<P1*&P2,R-P#G&1FOFJ]_:4U?5OVFK?XOWM
MJK7,6J1W:Z>KY"6R800!L#D1#;NQR><<TK.<FTN@:123?4UOV[%*_M8>/PPP
M?/MC^=I":]Q_;._Y,U_9Y_[!UE_Z;XZZ3XE>,OV1OC)XMM_B=XC\0ZL-7\F+
M[7H,5O,GVMT4!5F01'+!0$)20*0HY[UY_P#MN?M)?#[XX?"7P#8^#KC[/=V-
MRTLVBFU>(V,7E;$0G:(^.!A"0.W%*+;<%;8;LE)WW.U^.WC36O"/_!.KX50:
M/J$VG)JXM=/O3 =K2VY@G=H]W4 E%SCJ 0>"0<__ ()N:E<:E\-?C9H%S*\N
MEK80S);L?E1I(;E)"!_M!$S_ +HKSOXZ?&[P5XP_8T^%?@?2-:^U^*-&N;=[
M^P^S3(852"=&.]D"'YG7[K'K1^PS\;O!7P?T/XJ6_B[6O[)FUG3X(K!?LTTW
MG.BW 9?W:-@YD3[V.OL:7*_9M6UO^H<RYUJ=U_P31_Y%'XY?]@NT_P#1=Y7Q
M_P#"OQ]=_"WXC>'/%EEN,^DWL=UY:G'F(#\\?T9"RGV:O??V"/VAO"OP.\6>
M)[#QI*]IH'B&TBB>\6%IEBDB+[0Z("VUEE<9 .#CC!)'$?M*>$_@KX3_ +#B
M^$GBG4O$\\SW#ZD][G9 GR>2J$PQY_Y:9ZG@9QQ6J^.2:W(^RFGL?57[6G[/
MMO\ &;]HCX0>)-%3[5H/C988+ZXA'!BA43&7/JUL6Q_URKQ[_@I5\34\6?&R
MU\*63K_9?A.S6V\N/[@N)0KR8QQPODICL4-?4'[$OQBB_P"&/Y=>\20L;?P*
MUY"EU,HS)#%%YB>63W"2F(8],=Z_+SQ9XFO?&?BC5]?U*3S=0U2[EO+A_621
MRS8]LFLZ2?-9_9+J-<MUU,FOU4^-GQST#X'_  +^#-UK_P /]-\>P7^F6Z)%
MJ#1C[+LM8273?%(,G</3IUK\JZ^MOVOOCEX)^)_P5^$&A>&=:_M/5=#LECU&
MW^S31?9V%M"A!9T4-\RL/E)Z?2M*D>:45T(A+E3/>?VPO$-W\:/V/=&\:_#C
M4YK'P4A1M5T"&%(\Q!P@5]HR/)E !0':0=W103S?[/%G+XN_X)N_$72M)B9]
M0MY;]9$A&7D95BG(QW)0A<=Z\Y_8C_:*\$^"_ /CKX<_$[4S8>%M9C:2WD:W
MEF7=)&8IX\1HQ&5",., JW<UQ'[)/[5 _9E\::O:W,,VO>"M5D"7,</R2H48
MA+B-&XSM)!0D9!'/RBLN22BXI;.YIS)M2?4^<:*^\M<T/]B?QAJTWB0^)]3T
M%9)#+-HUE#<PPECR5$?V=BH/I&P SQBOG;]J'X@?#7QKXFT:U^%OA@>'O#FC
MV1M/.:!8I+U]Y/F-R7;C #2,6/?%=$9\SM9F+CR]3Z(_9O\ ^4</QD_Z_P"^
M_P#26TKX.KZV^"?QR\$^$?V)_B;X$U;6OLGBO5[RYEL=/^S3.9E>"W13O5"@
M^:-^K#&/<5\DTJ::<O4<VK(['X4_%OQ/\%?%7_"1>$KZ/3]5\A[8RR6\<P\M
ML%AM<$?PCGKQ7+ZCJ$^K:A=7UT_F7-S*TTKA0NYV)).!P.2>E5J*ULKW,[]"
MYHVK77A_6+'5+&017ME/'<P2%0P61&#*<$$'! X(Q71?%'XJ>)/C)XLE\2^*
MKV._U>6)(6FC@2$;$&%&U !^-<C1197N%^@4444 %%%% !1110 4444 %%%%
M !1110 53UK_ ) U_P#]>\G_ *":N53UK_D#7_\ U[R?^@FD]@6Y^F__  3_
M /\ DT;P'_V__P#I?<U]"U\]?\$__P#DT;P'_P!O_P#Z7W-?0M>++=GJ1V04
M445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHJOX^\<>&_@5X)N/&7C6?R;6/Y;33UP9[R8@E8T4]6..G0 $M@
M TTFW9"O;5C?'?COPU\#O ]QXT\:7'DV<?RV>GK@SWLQ!*QHIZDX^@ +$@"O
MRE^/WQ^\2_M#>.)=?U^7R;>/='I^EQ,3!8PD_<7U8X!9R,L1V 4 ^/WQ^\2_
MM#>.)=?U^7R;>/='I^EQ,3!8PD_<7U8X!9R,L1V 4#S.O4HT535WN<-2IS:+
M8****Z#$**** /3O@S^T=XZ^ 4>KIX,U*"P753$;H36D<^XQ[]F-X./]8W3U
MKTO_ (>+?''_ *&*Q_\ !5;_ /Q%?,U%0X1;NT4I26B9:U/49]8U*[O[I_,N
MKJ9YY7  W.S%F.!P.2:JT459)]<_LO\ _)H/[1O_ %Z6G\I:^1J]<^%_Q]/P
MW^$/Q'\#?V%_:/\ PF$4,7V_[7Y7V39NY\O8?,SN_O+C'>O(ZB*:;94GH@K]
M%?AK\9O&_A7_ ()_:!K_ ,.FL[S5O"U_/:ZU#- )S%:^9*^_;D$%5D@8G^[N
M/0&OSJKU?]G_ /:2\6?LZZ]<WGA]X+O3;[:NH:3>IN@NE7.,XY5@&;##UY!'
M%34CS(<)<K/46_X*4?&ENE[HJ_335_QK@_C#^V%\1_CEX37PYXIO;&72UN4N
MO+M;-86+J&"Y([?,>/I7H^I?M+? #Q3<2ZGK7[/$,.K._F%-.UAX8'8]21&L
M8&?38:\U^/'[0&A_%C0]'T'PY\-M#\!:-I<S30_V?\]RY9=K!Y J!@< G*DY
M4<^LQBK_  6*;=OB/9OVRO#]QXV_9Y^!?Q&TJ/[5I%MH<6DW\D?(MY@D84$=
MAOCF3/J%'<5\85] _LZ_MA:[\"M%O?#%_H]GXR\#WS,T^AZ@0 I; ?RV*L &
M'565E)YP"23V\?[3_P != U*+7=!_9]@7Q!"1)#]LU-C:Q2 Y5O+PRG!Y^X.
MG;K1'FA[MK@^66MSI/C7\.=9\&_\$Y/AI:ZG:26E[#K_ -ON;>52KPQSB[:/
M<#R#M>/(/0MBN5^%O_*.SXS?]A^P_P#1UG5/7OVZ=8^(WPS^)OAGQWI:ZW+X
ME>&324@;R[?2V4C( .6VKLC91U+!BQ^8FO,?"WQX/AK]G?QG\+/[#^TCQ'?V
M]]_:WVO;]G\IX6V^5L.[/DXSN&-W0XJ5&5K/N-RC?3L>R_L#Z?IWAW0_BY\3
MY=*AUK7/!>C+<:7;3 L$D=)V9\=O]2!N'(!?%>;7W[;WQMOM<?5/^$]OK>5F
M++;P11+;H/01;-N![@GUK _9W_:(\0?LY^+Y]8T>"#4;*]A^SZAI=V2(KJ/.
M1R/NL.<-SC)X()%>QW'[3WP!;4!KD7[.MJ=;\SS?L[:ILL]W_7,)Y9'MY>*I
MQ]YMQN"?NI)V/4OCEXF\8_%S_@GO;^+O%^E6^G:L^L6]Y));VYA-W &\B.X=
M.S.67D<$!2, @5Y#^QG$UY\)_P!HRSA&^YD\(.Z1#[S!8Y\X'?J/S%6YOV_-
M3\;:9\2=,\>:*-4T3Q'I L-+T?3F$4&G2*6V."V3GY]Q?!):-!@ #'C'[.OQ
MYU3]GGXA1^(["TCU2SF@:SU#3)FVI=V[$$INP=I!52#@\C!!!(,QA+D:L-R7
M,G<\OKZR_P""D7_)7/!/_8F6/_H^YKSGXZ?$3X.^.-&C;P!\-+OP5K\EZL]S
M=-J+RP-%M??&D)8JN69"-H  3  S67^TA\>#^T'XNT37#H?]@_V;HL&D>0+O
M[1YGEO(_F;MB8SYF-N#C'4YK364E*Q&B35SE_@Y_R5[P/_V';'_TH2O6OVZK
MQM/_ &Q?&ET@R\$]A*H/JME;G^E>&^#O$!\)^+M#UP0?:CIE]!>^1OV>9Y<B
MOMW8.,[<9P<9KJ?CY\6#\<?BUK_C<Z7_ &+_ &J83]A^T>?Y7EP1Q??VKNSY
M>?NCKBJL^>_D*_NV/HS_ (*2>$Y]8\7^$_BAI:/=^%?$>CV\<5X@RJRC<ZJQ
M'3=&ZD>NUO2OC*OI#X$_MI:Q\*_!K^!_$_AVP^('@1\A=)U/ :%2VXJC%64I
MN.[:RG!Z%:ZNU_:J^!OA6\.K>&OV>[(:V/FB?4M0\V")^S!&5QP?0+TX(K./
M-!<MKE2Y9.]SY$HKH/B!XQG^(7C;6_$MS96>G7.JW3W<MM8(4@1W.6V@DD<Y
M/)ZDUS];F04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M</7<?$/_ (]K/_?;^0KAZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MT4 L2 .&DV[(5[:L/'?COPU\!? ]QXT\:7'DQ1_+9Z>N#/=3$$K&BGJYQ]%
M+$@#C\G_ (_?'[Q+^T-XXEU_7Y?)MX]T>GZ7$Q,%C"3]Q?5C@%G(RQ'8!0#X
M_?'[Q+^T-XXEU_7Y?)MX]T>GZ7$Q,%C"3]Q?5C@%G(RQ'8!0/,Z]2C15-7>Y
MPU*G-HM@HHHKH,0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !5JO+JU74=EL=].GR>H4445SFP4444 %%%% !1110 4444 =5\/O^0E<_\
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M_P"%<_%?_HD/C+_P37?_ ,9K]H**/K$P]C$_%_\ X5S\5_\ HD/C+_P37?\
M\9H_X5S\5_\ HD/C+_P37?\ \9K]H**/K$P]C$_%_P#X5S\5_P#HD/C+_P $
MUW_\9H_X5S\5_P#HD/C+_P $UW_\9K]H**/K$P]C$_%__A7/Q7_Z)#XR_P#!
M-=__ !FC_A7/Q7_Z)#XR_P#!-=__ !FOV@HH^L3#V,3\7_\ A7/Q7_Z)#XR_
M\$UW_P#&:/\ A7/Q7_Z)#XR_\$UW_P#&:_:"BCZQ,/8Q/Q?_ .%<_%?_ *)#
MXR_\$UW_ /&:/^%<_%?_ *)#XR_\$UW_ /&:_:"BCZQ,/8Q/Q?\ ^%<_%?\
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MC+_P(M__ )$KWRBCVT^X>SAV/ _^'</P1_Z&SQE_X$6__P B4?\ #N'X(_\
M0V>,O_ BW_\ D2O?**/;3[A[.'8\#_X=P_!'_H;/&7_@1;__ ")1_P .X?@C
M_P!#9XR_\"+?_P"1*]\HH]M/N'LX=CP/_AW#\$?^AL\9?^!%O_\ (E'_  [A
M^"/_ $-GC+_P(M__ )$KWRBCVT^X>SAV/ _^'</P1_Z&SQE_X$6__P B4?\
M#N'X(_\ 0V>,O_ BW_\ D2O?**/;3[A[.'8\#_X=P_!'_H;/&7_@1;__ ")1
M_P .X?@C_P!#9XR_\"+?_P"1*]\HH]M/N'LX=CP/_AW#\$?^AL\9?^!%O_\
M(E'_  [A^"/_ $-GC+_P(M__ )$KWRBCVT^X>SAV/ _^'</P1_Z&SQE_X$6_
M_P B4?\ #N'X(_\ 0V>,O_ BW_\ D2O?**/;3[A[.'8\#_X=P_!'_H;/&7_@
M1;__ ")1_P .X?@C_P!#9XR_\"+?_P"1*]\HH]M/N'LX=CP/_AW#\$?^AL\9
M?^!%O_\ (E'_  [A^"/_ $-GC+_P(M__ )$KWRBCVT^X>SAV/ _^'</P1_Z&
MSQE_X$6__P B4?\ #N'X(_\ 0V>,O_ BW_\ D2O?**/;3[A[.'8\#_X=P_!'
M_H;/&7_@1;__ ")1_P .X?@C_P!#9XR_\"+?_P"1*]\HH]M/N'LX=CP/_AW#
M\$?^AL\9?^!%O_\ (E'_  [A^"/_ $-GC+_P(M__ )$KWRBCVT^X>SAV/ _^
M'</P1_Z&SQE_X$6__P B4?\ #N'X(_\ 0V>,O_ BW_\ D2O?**/;3[A[.'8\
M#_X=P_!'_H;/&7_@1;__ ")1_P .X?@C_P!#9XR_\"+?_P"1*]\HH]M/N'LX
M=CP/_AW#\$?^AL\9?^!%O_\ (E'_  [A^"/_ $-GC+_P(M__ )$KWRBCVT^X
M>SAV/ _^'</P1_Z&SQE_X$6__P B4?\ #N'X(_\ 0V>,O_ BW_\ D2O?**/;
M3[A[.'8\#_X=P_!'_H;/&7_@1;__ ")1_P .X?@C_P!#9XR_\"+?_P"1*]\H
MH]M/N'LX=CP/_AW#\$?^AL\9?^!%O_\ (E'_  [A^"/_ $-GC+_P(M__ )$K
MWRBCVT^X>SAV/ _^'</P1_Z&SQE_X$6__P B4?\ #N'X(_\ 0V>,O_ BW_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *[GQM_R ;+_KHO\
MZ :X:NY\;?\ (!LO^NB_^@&@#AJ*** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "NQ^'?^LO_HG_ +-7'5V/P[_U
ME_\ 1/\ V:@#EM0_Y"%S_P!=6_F:KU8U#_D(7/\ UU;^9JO0 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4Z/_6+]
M:;3H_P#6+]: .V^(?_'M9_[[?R%</7<?$/\ X]K/_?;^0KAZ "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#N
M?A[_ ,>=W_UT'\JX:NY^'O\ QYW?_70?RKAJ "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"UI?\ R$[3_KLG
M_H0KIOB)_KK'_=?^8KF=+_Y"=I_UV3_T(5TWQ$_UUC_NO_,4 <?1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_GM:_P#?3?\ Q-'_  K_ %'_ )[6O_?3?_$U^%-%'U7^\'M_(_=;_A7^H_\
M/:U_[Z;_ .)H_P"%?ZC_ ,]K7_OIO_B:_"FBCZK_ '@]OY'[K?\ "O\ 4?\
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M\]K7_OIO_B:/^%?ZC_SVM?\ OIO_ (FOPIHH^J_W@]OY'[K?\*_U'_GM:_\
M?3?_ !-'_"O]1_Y[6O\ WTW_ ,37X4T4?5?[P>W\C]UO^%?ZC_SVM?\ OIO_
M (FC_A7^H_\ /:U_[Z;_ .)K\*:*/JO]X/;^1^ZW_"O]1_Y[6O\ WTW_ ,31
M_P *_P!1_P">UK_WTW_Q-?A311]5_O![?R/W6_X5_J/_ #VM?^^F_P#B:/\
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M_A7^H_\ /:U_[Z;_ .)H_P"%?ZC_ ,]K7_OIO_B:_"FBCZK_ '@]OY'[K?\
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MM?\ OIO_ (FC_A7^H_\ /:U_[Z;_ .)K\*:*/JO]X/;^1^ZW_"O]1_Y[6O\
MWTW_ ,31_P *_P!1_P">UK_WTW_Q-?A311]5_O![?R/W6_X5_J/_ #VM?^^F
M_P#B:/\ A7^H_P#/:U_[Z;_XFOPIHH^J_P!X/;^1^ZW_  K_ %'_ )[6O_?3
M?_$T?\*_U'_GM:_]]-_\37X4T4?5?[P>W\C]UO\ A7^H_P#/:U_[Z;_XFC_A
M7^H_\]K7_OIO_B:_"FBCZK_>#V_D?NM_PK_4?^>UK_WTW_Q-'_"O]1_Y[6O_
M 'TW_P 37X4T4?5?[P>W\C]UO^%?ZC_SVM?^^F_^)H_X5_J/_/:U_P"^F_\
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M%?6'[8$21_L__LSE452WAV?) QG]W:5\GU,9<RN.2Y78****H04444 %%%%
M!1110 445]8?\$U(DF_: U,.BN/^$=O.&&?^6D-3*7+%L<5S.Q\GT4450@HK
M[8_9O_9#\.?M ?LHZWJ=O;+9^/TU2XCT_5&GD"-Y<<;+ Z;MNQMS#=MR,@\X
MP?C36M%OO#FL7NE:G:RV.HV4SV]Q;3+M>*120RD>H(-1&:DVET*<7%)E*BBO
MHS]MCX5^%OA/XN\$V7A32ETFVU#PS;7]RBS22^9.TDH9\NS$9"KP,#CI3<K-
M(5M+GSG1115""BBB@ HHHH **** "BBB@ HHHH **** "BBNJ^%OP]O_ (K_
M !$T#PCICI#>:M=+;+-(,K$IY=R.X50S8[XHVU8'*T5]P>/O$W[.O[,NO'P#
M%\,3\2M8TX+#K&LZA=&,^=CYP@(8;AQ\JA5&<9)!->;?M2?!?P3IO@7PC\6_
MAB9[7P5XHD:V;2;HLSV-TH;* DDX)CE!!)P4."588R52[6FY;A;J?-%%%%:D
M!1110 4444 %%%% !1110 4444 %%%% 'W%^Q;^VE%HEO9_#7XE7GF>'WQ!I
M6MW#<V)Z+#*Q_P"6796/W.A^7[GV_K6BRZ/< ,?,@?F.5>C"OP^K[B_8M_;2
MBT2WL_AK\2KSS/#[X@TK6[AN;$]%AE8_\LNRL?N=#\OW.*M1^U$ZJ=3[,C[.
MHK1UK19='N &/F0/S'*O1A6=7GG6%%%% !1110 4444 %%%% '5?#[_D)7/_
M %Q_]F%8OB#_ )#E]_UV;^=;7P^_Y"5S_P!<?_9A6+X@_P"0Y??]=F_G0!GT
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %=SXV_Y -E_UT7_T UPU=SXV_P"0#9?]=%_] - '#4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %=
MC\._]9?_ $3_ -FKCJ['X=_ZR_\ HG_LU '+:A_R$+G_ *ZM_,U7JQJ'_(0N
M?^NK?S-5Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "G1_ZQ?K3:='_K%^M ';?$/_CVL_\ ?;^0KAZ[CXA_\>UG
M_OM_(5P] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110!W/P]_X\[O_KH/Y5PU=S\/?^/.[_ZZ#^5<-0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 6M+_ .0G:?\ 79/_ $(5TWQ$_P!=8_[K_P Q7,Z7_P A.T_Z[)_Z$*Z;
MXB?ZZQ_W7_F* ./HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MLGDVJ!N=II<$X[_-CZ 5IK&23=TR-)1;L</\"OV.M5^*GA";QQXE\0V'P_\
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M7CK]FWX*>"_AQH!U'0+728M2U4)?6UNKW<D2,I(ED4GYI)VX!'SCT%?/"_\
M!/KX\MU\$(OUU>Q_^/5"GS:N5BN7ET4;GFGQN^"?B/X!^.KCPQXDAC\]4$UM
M=0$F&ZA)(61"><9!!!Y!!%=Q\(?A+\'_ !)X)CUSQY\7?^$3U!IY(FT:WTM[
MB954C:^Y"Q(8?[->P_MM>&-?T+]G/X'Q>.HA#XYT\7>GW.9EF=HEVA=TBDAC
MM2(DY/+'N37DWPM_8C^(WQ0\)0^*<Z1X5\-SJ)(-1\17AMTF0G =556;:>Q8
M '(P35J?-"[=B>6TK)7.[M?V.?A[\6-'U%_@S\6H?%6OV,/G_P!A:K9-:33J
M.NTL%8>F=A7) ++G-?)-Q;RVMQ)!/&T,T;%'CD4JRL#@@@]"#7V_\#_V-_B9
M\(?C-X'\8Z1J6A^*M#M]5ABO;SPWJ7F^5;2'RY6=6525V,V0N[CVYKYJ_:>L
M(M-_:*^),$(VQ_V_>.%]-TS,1],M3A*\FKW"4=+VL>8UZG^RUXRMO /[0O@/
M6[V9;>SAU-(IYF^[''*#$S'V D)/TKRROI[]E3]GWPKX@\)^(/BS\4IY+?X=
M>'6\L6L;%7U"X&WY..2N71< @LS@9&&JYM*+N1%-O0Z+XY?L=_$/Q[^UEXPT
MWP_HDTFFZI??VK_;,X*6<,5P=[,TAZE7,B[5RQV' -97[77C'PGX-^'O@WX%
M>"]1_MVT\*3R7>K:LN-DUZV_*I@D<&67(&0N57)*M7T;+\;C^W5\&_%OA/P+
MJ%YX"\9Z:QN;?2%O O\ :EFN5",X (5@=K*#A6V9)4U^:VJ:%J.BZS<:1?V-
MQ9ZI;S&WELYHBLJ2 X*%2,YSVK&G>6DNAK.T?AZE"BOI']I;X"^%/@'\+OAW
MIUR]T?BIJ<+7^KPB<&"&!LX1D(X8,0@*G!\N0G/&/FZMXR4E=&+7*[,****H
M04444 %%%% !1110 4444 %%%% !1110!]Q?L6_MI1:);V?PU^)5YYGA]\0:
M5K=PW-B>BPRL?^6796/W.A^7[GV_K6BRZ/< ,?,@?F.5>C"OP^K[B_8M_;2B
MT2WL_AK\2KSS/#[X@TK6[AN;$]%AE8_\LNRL?N=#\OW.*M1^U$ZJ=3[,C[.H
MK1UK19='N &/F0/S'*O1A6=7GG6%%%% !1110 4444 =5\/O^0E<_P#7'_V8
M5B^(/^0Y??\ 79OYUM?#[_D)7/\ UQ_]F%8OB#_D.7W_ %V;^= &?1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 5W/C;_ ) -E_UT7_T UPU=SXV_Y -E_P!=%_\ 0#0!PU%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !78_#O
M_67_ -$_]FKCJ['X=_ZR_P#HG_LU '+:A_R$+G_KJW\S5>K&H?\ (0N?^NK?
MS-5Z ))K>2W91(A0LH=<]U(R#4=>BR:3:ZOX?TV&=UBG:%%@<D;MVS.!Z\ G
M'H">U<'J&GSZ9=/;W";)%_(CU'M0!6HHHH **** "BBB@ HHHH **** "BBO
M!?B=^U,/AOXXU+P[_P (S_:'V/R_])^W^5OWQ))]WRFQC?CKVKMPF"KXZHZ6
M'CS-*^Z6GSMW//QV88;+::K8J7+%NVS>NKZ)]CWJBOES_AMX?]"9_P"53_[3
M1_PV\/\ H3/_ "J?_::];_5W-/\ GU_Y-'_,\/\ UJR?_G__ .2R_P#D3ZCH
MKY<_X;>'_0F?^53_ .TT?\-O#_H3/_*I_P#::/\ 5W-/^?7_ )-'_,/]:LG_
M .?_ /Y++_Y$^HZ*^7/^&WA_T)G_ )5/_M-'_#;P_P"A,_\ *I_]IH_U=S3_
M )]?^31_S#_6K)_^?_\ Y++_ .1/J.BOES_AMX?]"9_Y5/\ [37J7P0^-_\
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MYA[:)^T%%?B__P +&^*__17_ !E_X.;O_P"/4?\ "QOBO_T5_P 9?^#F[_\
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MQE_X.;O_ ./4?5YA[:)^T%%?B_\ \+&^*_\ T5_QE_X.;O\ ^/4?\+&^*_\
MT5_QE_X.;O\ ^/4?5YA[:)^T%%?B_P#\+&^*_P#T5_QE_P"#F[_^/4?\+&^*
M_P#T5_QE_P"#F[_^/4?5YA[:)^T%%?B__P +&^*__17_ !E_X.;O_P"/4?\
M"QOBO_T5_P 9?^#F[_\ CU'U>8>VB?M!17XO_P#"QOBO_P!%?\9?^#F[_P#C
MU'_"QOBO_P!%?\9?^#F[_P#CU'U>8>VB?M!17XO_ /"QOBO_ -%?\9?^#F[_
M /CU'_"QOBO_ -%?\9?^#F[_ /CU'U>8>VB?M!17XO\ _"QOBO\ ]%?\9?\
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M.F^-;?4K36H]5TY_(U5F,RQO,C+]XD@<].QSWS7H-U_P44^.-S9"!/$=E;2
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M .') (S5M?C9XH^-WQK^&=]XIN+>YN-+O--TZW>& (3&DZ<NW5F8DL23C+'
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M9Y^7)'._"/\ :@^)7P/LY+'PGXDEM-,D<R-I]S$EQ;[CU94<'83W*XSWK?\
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M=^(?_"N_B1\9?"ND^"_BG'+Y5C!=W:0-J$BI^Z9HF.2X^\L;9>,@?2OAQ?\
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M1[@!CYD#\QRKT85G5YYUA1110 4444 =5\/O^0E<_P#7'_V85B^(/^0Y??\
M79OYUM?#[_D)7/\ UQ_]F%<Y\1/B]\)_A[XFETOQ7XBATO6&1;A[=UG8[6S@
M_(I SCI5PA*H[05WY$2G&"O)V1!16!_PTO\  /\ Z'.V_P"_5U_\11_PTO\
M /\ Z'.V_P"_5U_\16WU:O\ \^W]S,OK%'^=?>C?HK _X:7^ ?\ T.=M_P!^
MKK_XBC_AI?X!_P#0YVW_ 'ZNO_B*/JU?_GV_N8?6*/\ .OO1OT5@?\-+_ /_
M *'.V_[]77_Q%'_#2_P#_P"ASMO^_5U_\11]6K_\^W]S#ZQ1_G7WHWZ*P/\
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M _\ H<[;_OU=?_$4?\-+_ /_ *'.V_[]77_Q%'U:O_S[?W,/K%'^=?>C?HK
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M]^KK_P"(H_X:7^ ?_0YVW_?JZ_\ B*/JU?\ Y]O[F'UBC_.OO1OT5@?\-+_
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M^ ?_ $.=M_WZNO\ XBCZM7_Y]O[F'UBC_.OO1OUV/P[_ -9?_1/_ &:O+_\
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M%=1_97A?_H8;?_P*BH_LKPO_ -##;_\ @5%1ROL%T<O174?V5X7_ .AAM_\
MP*BH_LKPO_T,-O\ ^!45'*^P71R]%=1_97A?_H8;?_P*BH_LKPO_ -##;_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MRKR3_@F[_P >?B?_ *[I_P"@BJ>F(2)7\)GW%1117><@4444 %%%% !1110
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M!5RJ)-Z;$*#?4^ :]/\ V;?@W'\>_B[I/@V?4VT>"\CGEDNXX1*RB.)GP%)
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M31O ?_;_ /\ I?<U]"UXLMV>I'9!1114C"BBB@ HHHH **** "BBB@ HHHH
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MY)/%<I<V\MG<2P3QM%-$Y22-QAE8'!!'J#1=; 14444 %%%% !1110 4444
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M?+?5:_\ (_N/GBBOH?\ X8(^,W_0O6G_ (,[?_XNC_A@CXS?]"]:?^#.W_\
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M_BZ/^&"/C-_T+UI_X,[?_P"+H^N8;_GXOO0?5:_\C^X^>**^A_\ A@CXS?\
M0O6G_@SM_P#XNC_A@CXS?]"]:?\ @SM__BZ/KF&_Y^+[T'U6O_(_N/GBBOH?
M_A@CXS?]"]:?^#.W_P#BZ/\ A@CXS?\ 0O6G_@SM_P#XNCZYAO\ GXOO0?5:
M_P#(_N/GBBOH?_A@CXS?]"]:?^#.W_\ BZ/^&"/C-_T+UI_X,[?_ .+H^N8;
M_GXOO0?5:_\ (_N/GBBOH?\ X8(^,W_0O6G_ (,[?_XNC_A@CXS?]"]:?^#.
MW_\ BZ/KF&_Y^+[T'U6O_(_N/GBBOH?_ (8(^,W_ $+UI_X,[?\ ^+H_X8(^
M,W_0O6G_ (,[?_XNCZYAO^?B^]!]5K_R/[CYXHKZ'_X8(^,W_0O6G_@SM_\
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M(^,W_0O6G_@SM_\ XNCZYAO^?B^]!]5K_P C^X^>**^A_P#A@CXS?]"]:?\
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M_@LU_P E^\(?]@G_ -JU[!^RR WP4T0$9!#<5Y!_P6:4_P#"_/!YQP=*P/\
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M_"N?%'_0 U#_ +\-_A1SQ[ARR['.45T?_"N?%'_0 U#_ +\-_A1_PKGQ1_T
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MF;,;D'\/3/UJ?9RM=[WN/G7X'M/_  2X8C]HC5\'&?#=R#_X$6U>8^'?'?Q
M^$_QT\=>-? =I=7!TK4KM=2=+1[BU$#W#_)<;>%1BG!)!RN0017*_ +X\Z]^
MSMXVG\3^'K/3[Z]FLI+!XM3CD>/RW=') 1U.[,:]_7BMSX._M7>-/@CXV\1^
M)-"BTV=_$,IFU&QO(&>"1M[N-N&#KM,CX^;OSFK<7S-V)4E9(^QO ^N>!/\
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M*?8/V+?A3_PMS]H3PW87$/G:5IK_ -K7X(ROE0D,%/LTAC0^S&LW]K3XL?\
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M9<ALC&< 'FNA^/GQNM/V.?$E]\+_ (*:1#X<O;<K<:QK]] EU=3O*BRQQ(9
M045'4?,#UP ""S+GE?EMJ/EC:]]#XDU+2;[1KDV^H6=Q8W&,^5<Q-&^/7! -
M7?"/C#6O 7B&TUWP]J5QI&KVA8P7EJVUTW*5;'L5)!'<$U]W?!'XK']N[P7X
MK^&7Q(L;"[\6V>GOJ.B:Y#;K%(K A<D 84J[1YVX#JS CC)^;/V(UQ^U5\/E
M88(O)<@C_IWEI\^CYEL'+JK/<\;U[7M0\4:U>ZOJUY-J&IWLS3W%U.VYY9&.
M2Q/KFOI+_@H9I]KIOQA\,QVEM#:QMX4L'*0QA 6WS<X'?@?E63J_[0WC']G[
M]H3XOS^#[BTMWU/Q'?1W'VJU68$1W<Q7&>GWC7T;^V+^V-\2/@W\2-#T?PU=
MZ?!8W>@6NH2K<622L9I&E#$$]!A1Q4-RYHV122Y7=GP7X#^)'B?X7ZQ+JOA3
M6[O0=0E@:VDN+-]K-&Q!*GU&54_4 USTTTEQ,\LKM)*[%F=CDL3R23W-?7O_
M  3OUJY\4?M4ZYK%^4>]U#2=0NYV1 JF226-F( Z#+'BO+OV)_\ DZ;X>_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P )9JW_ #^-_P!\K_A6110!K_\ "6:M_P _C?\ ?*_X4?\ "6:M_P _C?\
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M_P )9JW_ #^-_P!\K_A6110!K_\ "6:M_P _C?\ ?*_X4?\ "6:M_P _C?\
M?*_X5D44 :__  EFK?\ /XW_ 'RO^%'_  EFK?\ /XW_ 'RO^%9%% &O_P )
M9JW_ #^-_P!\K_A1_P )9JW_ #^-_P!\K_A6110!K_\ "6:M_P _C?\ ?*_X
M4?\ "6:M_P _C?\ ?*_X5D44 :__  EFK?\ /XW_ 'RO^%'_  EFK?\ /XW_
M 'RO^%9%% &O_P )9JW_ #^-_P!\K_A73>"M6N]4:\%U,9=@3;D 8SG/3Z5P
M5=C\._\ 67_T3_V:@#+O?%&J1WDZ+=L%61@!M7IGZ5#_ ,)9JW_/XW_?*_X5
M0U#_ )"%S_UU;^9JO0!Y1_P47F>X_9W\+2R'=(^O6K,WJ3:7))KYP_9+_9+O
M?CAJ:>(/$"2V'@:TD^>3E'U!U/,49[(#PSCI]T<Y*_>WQ:^">F_';P7X2T76
M;F2#2+#4+?4[J*'A[A$MY4\H-_""91EAS@'&"01?U35++3=,M]!T&WBL-(M(
MU@CCMD"($48"*!T4#\_Y^U3Q[P^%5&G\3OKV_P"">14P*K8EU:GPJWS#5-4L
MM-TRWT'0;>*PTBTC6"..V0(@11@(H'10/S_G@445XNYZX4444 %%%% !1110
M 4444 %?!/[3W_)<O$O_ &[?^DT5?>U?)'QV^!'CCQG\5=;UC1]$^V:=<^1Y
M4WVN!-VV"-#\K."/F4CD=J^OX8KTL/C)2K345RO5NW6/<^%XPP]?%8"$*$')
M\Z=DFW;EEV/FZBO4_P#AF'XE_P#0M_\ D];?_'*/^&8?B7_T+?\ Y/6W_P <
MK]/_ +3P/_/^'_@2_P S\?\ [(S'_H&G_P" 2_R/+**]3_X9A^)?_0M_^3UM
M_P#'*/\ AF'XE_\ 0M_^3UM_\<H_M/ _\_X?^!+_ ##^R,Q_Z!I_^ 2_R/+*
M*]3_ .&8?B7_ -"W_P"3UM_\<H_X9A^)?_0M_P#D];?_ !RC^T\#_P _X?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBVZ\=7/Q9\36!\[3-,L+!H+=9ARCL#E<@XP6?CKL) PE4LK-:E<EW>^AF_\
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M385]J_#GQQK_ ,/?^"=>K:OX:U:ZT75%\7>4MW9R%) K+#N&?0U\55]%:?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M ?\ AU?J/_19+K_P1M_\ET?\.K]1_P"BR77_ ((V_P#DNOOZBCVD^X<D>Q\
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M  1M_P#)=??U%'M)]PY(]CX!_P"'5^H_]%DNO_!&W_R71_PZOU'_ *+)=?\
M@C;_ .2Z^_J*/:3[AR1['P+!_P $K[CS!]J^+UY/!_$D>C%"1WY-R>V>U?2'
MP!_9'\ ?L\"2[T.TFU+7YEV2ZWJC+)<;2.4CP L:GG[HR> Q; Q[512<Y2W8
MU%+8****@H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH ***U-#T-]6D9W;R+.+YI9V. H')Y/?'Y4 &AZ&^K2,[MY%
MG%\TL[' 4#D\GOC\J^$?VU/VU$\:1W7PY^'-T8/",1,.HZM;M@ZD1]Z.-O\
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M?^8H X^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM1_Y_P"Z_P"_S?XUT?69]D8^PB?F1_P[_P#CW_T(?_E8L/\ X_1_P[_^/?\
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M\:/[:U'_ )_[K_O\W^-'UF?9![")^9'_  [_ /CW_P!"'_Y6+#_X_1_P[_\
MCW_T(?\ Y6+#_P"/U^F_]M:C_P _]U_W^;_&C^VM1_Y_[K_O\W^-'UF?9!["
M)^9'_#O_ ./?_0A_^5BP_P#C]'_#O_X]_P#0A_\ E8L/_C]?IO\ VUJ/_/\
MW7_?YO\ &C^VM1_Y_P"Z_P"_S?XT?69]D'L(GYD?\.__ (]_]"'_ .5BP_\
MC]'_  [_ /CW_P!"'_Y6+#_X_7Z;_P!M:C_S_P!U_P!_F_QH_MK4?^?^Z_[_
M #?XT?69]D'L(GYD?\.__CW_ -"'_P"5BP_^/T?\._\ X]_]"'_Y6+#_ ./U
M^F_]M:C_ ,_]U_W^;_&C^VM1_P"?^Z_[_-_C1]9GV0>PB?F1_P ._P#X]_\
M0A_^5BP_^/T?\.__ (]_]"'_ .5BP_\ C]?IO_;6H_\ /_=?]_F_QH_MK4?^
M?^Z_[_-_C1]9GV0>PB?F1_P[_P#CW_T(?_E8L/\ X_1_P[_^/?\ T(?_ )6+
M#_X_7Z;_ -M:C_S_ -U_W^;_ !H_MK4?^?\ NO\ O\W^-'UF?9![")^9'_#O
M_P"/?_0A_P#E8L/_ (_1_P ._P#X]_\ 0A_^5BP_^/U^F_\ ;6H_\_\ =?\
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M?IO_ &UJ/_/_ '7_ '^;_&C^VM1_Y_[K_O\ -_C1]9GV0>PB?F1_P[_^/?\
MT(?_ )6+#_X_1_P[_P#CW_T(?_E8L/\ X_7Z;_VUJ/\ S_W7_?YO\:/[:U'_
M )_[K_O\W^-'UF?9![")^9'_  [_ /CW_P!"'_Y6+#_X_1_P[_\ CW_T(?\
MY6+#_P"/U^F_]M:C_P _]U_W^;_&C^VM1_Y_[K_O\W^-'UF?9![")^9'_#O_
M ./?_0A_^5BP_P#C]'_#O_X]_P#0A_\ E8L/_C]?IO\ VUJ/_/\ W7_?YO\
M&C^VM1_Y_P"Z_P"_S?XT?69]D'L(GYD?\.__ (]_]"'_ .5BP_\ C]'_  [_
M /CW_P!"'_Y6+#_X_7Z;_P!M:C_S_P!U_P!_F_QH_MK4?^?^Z_[_ #?XT?69
M]D'L(GYD?\.__CW_ -"'_P"5BP_^/T?\._\ X]_]"'_Y6+#_ ./U^F_]M:C_
M ,_]U_W^;_&C^VM1_P"?^Z_[_-_C1]9GV0>PB?F1_P ._P#X]_\ 0A_^5BP_
M^/T?\.__ (]_]"'_ .5BP_\ C]?IO_;6H_\ /_=?]_F_QH_MK4?^?^Z_[_-_
MC1]9GV0>PB?F1_P[_P#CW_T(?_E8L/\ X_1_P[_^/?\ T(?_ )6+#_X_7Z;_
M -M:C_S_ -U_W^;_ !H_MK4?^?\ NO\ O\W^-'UF?9![")^9'_#O_P"/?_0A
M_P#E8L/_ (_1_P ._P#X]_\ 0A_^5BP_^/U^F_\ ;6H_\_\ =?\ ?YO\:/[:
MU'_G_NO^_P W^-'UF?9![")^9'_#O_X]_P#0A_\ E8L/_C]'_#O_ ./?_0A_
M^5BP_P#C]?IO_;6H_P#/_=?]_F_QH_MK4?\ G_NO^_S?XT?69]D'L(GYD?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 68--N[J/?#:S3)TW1QEA^8%2?V+J/_/A=
M?]^6_P *L:!KTVAW&5^:W<CS(_7W'O7@7[8_BKX\_"^W?QS\/?&LUYX&< W=
MB-*LI9=+/3.YH"S1'U))4]21@U<8\[M<F4N57/=?[%U'_GPNO^_+?X4?V+J/
M_/A=?]^6_P *_,C_ (> ?'O_ *'S_P H]A_\8H_X> ?'O_H?/_*/8?\ QBNC
MZM/NC'V\3]-_[%U'_GPNO^_+?X4?V+J/_/A=?]^6_P *_,C_ (> ?'O_ *'S
M_P H]A_\8H_X> ?'O_H?/_*/8?\ QBCZM/N@]O$_3?\ L74?^?"Z_P"_+?X4
M?V+J/_/A=?\ ?EO\*_,C_AX!\>_^A\_\H]A_\8H_X> ?'O\ Z'S_ ,H]A_\
M&*/JT^Z#V\3]-_[%U'_GPNO^_+?X4?V+J/\ SX77_?EO\*_,C_AX!\>_^A\_
M\H]A_P#&*/\ AX!\>_\ H?/_ "CV'_QBCZM/N@]O$_3?^Q=1_P"?"Z_[\M_A
M1_8NH_\ /A=?]^6_PK\R/^'@'Q[_ .A\_P#*/8?_ !BC_AX!\>_^A\_\H]A_
M\8H^K3[H/;Q/TW_L74?^?"Z_[\M_A1_8NH_\^%U_WY;_  K\R/\ AX!\>_\
MH?/_ "CV'_QBC_AX!\>_^A\_\H]A_P#&*/JT^Z#V\3]-_P"Q=1_Y\+K_ +\M
M_A1_8NH_\^%U_P!^6_PK\R/^'@'Q[_Z'S_RCV'_QBC_AX!\>_P#H?/\ RCV'
M_P 8H^K3[H/;Q/TW_L74?^?"Z_[\M_A1_8NH_P#/A=?]^6_PK\R/^'@'Q[_Z
M'S_RCV'_ ,8H_P"'@'Q[_P"A\_\ */8?_&*/JT^Z#V\3]-_[%U'_ )\+K_OR
MW^%']BZC_P ^%U_WY;_"OS(_X> ?'O\ Z'S_ ,H]A_\ &*/^'@'Q[_Z'S_RC
MV'_QBCZM/N@]O$_3?^Q=1_Y\+K_ORW^%']BZC_SX77_?EO\ "OS(_P"'@'Q[
M_P"A\_\ */8?_&*/^'@'Q[_Z'S_RCV'_ ,8H^K3[H/;Q/TW_ +%U'_GPNO\
MORW^%']BZC_SX77_ 'Y;_"OS(_X> ?'O_H?/_*/8?_&*/^'@'Q[_ .A\_P#*
M/8?_ !BCZM/N@]O$_3?^Q=1_Y\+K_ORW^%']BZC_ ,^%U_WY;_"OS(_X> ?'
MO_H?/_*/8?\ QBC_ (> ?'O_ *'S_P H]A_\8H^K3[H/;Q/TW_L74?\ GPNO
M^_+?X4?V+J/_ #X77_?EO\*_,C_AX!\>_P#H?/\ RCV'_P 8H_X> ?'O_H?/
M_*/8?_&*/JT^Z#V\3]-_[%U'_GPNO^_+?X4?V+J/_/A=?]^6_P *_,C_ (>
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MA\_\H]A_\8H^K3[H/;Q/TW_L74?^?"Z_[\M_A1_8NH_\^%U_WY;_  K\R/\
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M_,C_ (> ?'O_ *'S_P H]A_\8H_X> ?'O_H?/_*/8?\ QBCZM/N@]O$_3?\
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M]-_[%U'_ )\+K_ORW^%']BZC_P ^%U_WY;_"OS(_X> ?'O\ Z'S_ ,H]A_\
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M\8H_X> ?'O\ Z'S_ ,H]A_\ &*/JT^Z#V\3]-_[%U'_GPNO^_+?X4?V+J/\
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MV+J/_/A=?]^6_P *_,C_ (> ?'O_ *'S_P H]A_\8H_X> ?'O_H?/_*/8?\
MQBCZM/N@]O$_3?\ L74?^?"Z_P"_+?X56GMY;60QS1O$X_AD4J?R-?FC_P /
M /CW_P!#Y_Y1[#_XQ7V7^RC^UEI_[2&CQ>%O%<T&G?$:TC)BF $<>J(HR70#
M #@<L@_WEXR%B="<%=E1JQD['K]%37EG+8W#P3H4D4X(-0USFP4444 %%%%
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M-0!RVH?\A"Y_ZZM_,U7JQJ'_ "$+G_KJW\S5>@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IT?\ K%^M-IT?^L7Z
MT =M\0_^/:S_ -]OY"N'KN/B'_Q[6?\ OM_(5P] !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!W/P]_X\[O_
M *Z#^5<-7<_#W_CSN_\ KH/Y5PU !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!:TO_D)VG_79/\ T(5TWQ$_
MUUC_ +K_ ,Q7,Z7_ ,A.T_Z[)_Z$*Z;XB?ZZQ_W7_F* ./HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "M+2-7^P>;!/$MU87"F.>VD4,KJ1@@@\'CMWK-HH ^%?VT/V
M+_\ A7/VCQ_X MVNO!-PWF7EA$"S:6Q/) ZF'/\ WQT/&#7QS7[A:1J_V#S8
M)XENK"X4QSVTBAE=2,$$'@\=N]? ?[:'[%__  KG[1X_\ 6[77@FX;S+RPB!
M9M+8GD@=3#G_ +XZ'C!KT:-:_NR..I3M[T3XYHHHKL.8**** "BBB@ HJ6UM
M9[ZZAMK:&2XN)G6.*&)2SNQ. J@<DDG  KZL\,_L&RZ'X8MO$GQ>\>:1\,-.
MN$WQ6-UB6]?_ &2A90&P0=JEV'0@'I,I*.XU%RV/DZBOK5?@=^R[<L+2'X\Z
MC'>_=\Z;2)1#GUR8@,?\"KP+XR^!="^'/CR[T/PYXNM/&^EPQ12)K%C&J1.7
M0,5&UW!*Y .&ZY'!&*49J3L-Q:U.'HHHJR0HHHH ***^@?VB/A1X8\ _!KX'
M:]H>GM::IXFTB>ZU69IY)!/(HMRK!68A/]8_"@#FDY6:7<:5TV?/U%>MZU\"
M[#2?V>-$^)J>-=,NK_4;YK1_#2 ?:( &D7<6WY)_=[BI0 !@<GOY)0FGL#30
M4444Q!117MNI?LWJO[+^G?&'2?$!U-?M_P!AU32?LFPV!WL@8R;SNR?)XVCB
M44G)+<:3>QXE115K2],NM:U.STZQA:XO;N9+>"%/O22.P55'N20*8BK17L?[
M3WP$LOV=?&FG>%XO$O\ PD>I26"7E]MM/(6U9R0L8.]MQPI;G'!7CFO'*2:D
MKH;33LPHHHIB"BBB@ HHHH **]4_9U^"MC\=O&MYH-_XOT_P9#;V$EXMY?H'
M$K*R*(U!=!GYLGYN I.#7GD6AW%YX@31[#;J-W-="TM_LYRL[E]B[2>S'&/K
M2NKV'9VN9U%;/C#P=K/@#Q)>Z!X@L)-+UBR95N+24@M&64,,X)'*L#U[UZ%\
M%?@78?%OPOXZU>\\:Z9X6E\-V(NX;2^ +7Q*R-M4EUV@>6 6 8Y=>*'))7"S
M;L>24444Q!1110 4444 %%%% !17J'P!_9Y\4?M$>*)])\/""UM;.,3W^J7I
M*V]K&3@;B <L<'"CK@] "1[/??LZ_LY>%;I],UW]H![K4T.QI-*TIY8%;O\
M-&)5(_X'4.:3L4HMJY\D45W/QD\&^&/ ?C:72O"/BZ/QMHPACF35(K?R1N89
M,>-S9*C&3QR2,#%<-5IW5R=@HHHH **** "BBB@ HKZ$_8?^$_A?XR?&"^T+
MQ;IS:GI<6BW-VD*W$D.)4>,*VZ-E/ 8\9Q7SW2YM6AVTN%%%%,04444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*Y_ZX_\ LPK%\0?\AR^_Z[-_.@#/HHHH **** "BBB@ HHHH **** "BBB@
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M !YW?_70?RKAJ[GX>_\ 'G=_]=!_*N&H **** "BBB@ HHHH **** "BBB@
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MN[2WFURR\R&"=D1\SH#D X/''-5)MW2$DM&SZ>_:Y_9"^+?Q!^/OC3Q7X?\
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M<Z?X!^.&@PA=,\8:='!?A.1%>1IPK'^]M#1_]NYJ^?WEV9/+H^Z/D_0=#O\
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M/_75OYFJ]6-0_P"0A<_]=6_F:KT %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !16EH>CG6KB>!7V2+$9$ST)! P?SJC<6\EK,\,R
M&.1#AE;M0!'1110 4Z/_ %B_6FTZ/_6+]: .V^(?_'M9_P"^W\A7#UW'Q#_X
M]K/_ 'V_D*X>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH [GX>_\>=W_P!=!_*N&KN?A[_QYW?_ %T'\JX:
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#VD>Y^FE%?F7_P /'OC=_P!"GX-_\![C_P"2Z/\ AX]\;O\ H4_!O_@/<?\
MR71[&?8/:1[GZ:45^9?_  \>^-W_ $*?@W_P'N/_ )+H_P"'CWQN_P"A3\&_
M^ ]Q_P#)='L9]@]I'N?II17YE_\ #Q[XW?\ 0I^#?_ >X_\ DNC_ (>/?&[_
M *%/P;_X#W'_ ,ET>QGV#VD>Y^FE%?F7_P /'OC=_P!"GX-_\![C_P"2Z/\
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M#VD>Y^FE%?F7_P /'OC=_P!"GX-_\![C_P"2Z/\ AX]\;O\ H4_!O_@/<?\
MR71[&?8/:1[GZ:45^9?_  \>^-W_ $*?@W_P'N/_ )+H_P"'CWQN_P"A3\&_
M^ ]Q_P#)='L9]@]I'N?II17YE_\ #Q[XW?\ 0I^#?_ >X_\ DNC_ (>/?&[_
M *%/P;_X#W'_ ,ET>QGV#VD>Y^FE%?F7_P /'OC=_P!"GX-_\![C_P"2Z/\
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M#VD>Y^FE%?F7_P /'OC=_P!"GX-_\![C_P"2Z/\ AX]\;O\ H4_!O_@/<?\
MR71[&?8/:1[GZ:45^9?_  \>^-W_ $*?@W_P'N/_ )+H_P"'CWQN_P"A3\&_
M^ ]Q_P#)='L9]@]I'N?II17YE_\ #Q[XW?\ 0I^#?_ >X_\ DNC_ (>/?&[_
M *%/P;_X#W'_ ,ET>QGV#VD>Y^FE%?F7_P /'OC=_P!"GX-_\![C_P"2Z/\
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M#VD>Y^FE%?F7_P /'OC=_P!"GX-_\![C_P"2Z/\ AX]\;O\ H4_!O_@/<?\
MR71[&?8/:1[GZ:45^9?_  \>^-W_ $*?@W_P'N/_ )+I\7_!2#XU)(K3>$?"
M#Q _,L<%PK'Z'[4?Y4>QGV#VD>Y^F-%?(7P'_P""B/AWXB:Y:^&_&VD'P5KU
MPRQ0W+3"2QG<G &XX:,DX !W#_:KZ]K)IQT9HFGL%%%%(84444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!6EI&K_8/-@GB6ZL+A3'/;2*&5U(P00>#QV[UFT4 ?"O[:'[%_\ PKG[1X_\
M 6[77@FX;S+RPB!9M+8GD@=3#G_OCH>,&OCFOW"TC5_L'FP3Q+=6%PICGMI%
M#*ZD8((/!X[=Z^ _VT/V+_\ A7/VCQ_X MVNO!-PWF7EA$"S:6Q/) ZF'/\
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M?\#K'E_>6Z;FG-[E^NQ[!^P?9+\0OA?\<_AI!,D>M:WH\<^GQL0 [*LJ')]
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M_P"B;FI]:_:X^%_Q>T729_BY\)Y?$GB_3[5;1M:TS4GM#<JO\3!"N,G)VG<
M2VW&<5X_\&?CQ_PJ'PC\2M"70_[5'C+1WTGSS=^3]CW)*OF;=C>9_K?NY7IU
MK.TG#EMJK%W2ES7/6?\ @F7_ ,G)N?31+K_T**ODVO6/V9_CP?V=/B0WBP:'
M_P )!NL9K(V?VO[-]\J=V_8_3;TQWKR>M4GS-F;?NI'UE^PC_P @'XZ_]B3=
M?^@/6O\ L-Z6?B+\&_CS\/+)D.NZMI,-Q80LVWS6195P3V <PC_@=>'? GX\
M'X)V'CNV&A_VS_PE&B3:/N^U^1]FW@CS,;&WXS]WY<^M<G\+_BAXA^#OC2P\
M4^&+S['JEF2!N7='*A&&CD7^)6'4?0@@@$9R@WS?(M22L<S>6D^GW4UK<PR6
M]S"[1RPRJ5=&!P5(/0@C&*^S/^"7O@K4K[XL>(O%(MI!HVGZ/+9M=%3L-Q*\
M96,'H3L1R?3CU%4_$7[8?P?^*TG]I_$/X%V^H>(F0":^TS46A\]AT+%0C?\
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M/M4']EWO_/I/_P!^F_PH JT5:_LN]_Y])_\ OTW^%']EWO\ SZ3_ /?IO\*
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MMJ4D97^S"\?SQ[L 93<X55)^8[F/ !^-Z**F,5&Y4I<P44451(4444 %%%%
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M'?RG_P#CE'_#S+QU_P!"MX=_*?\ ^.5\>T4?V?A?Y$'U[$_SGV%_P\R\=?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+[_KLW\ZVOA]_P A*Y_ZX_\ LPK%\0?\AR^_Z[-_.@#/HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *[GQM_R
M ;+_ *Z+_P"@&N&KN?&W_(!LO^NB_P#H!H X:BBB@ HHHH **** "BBB@ HH
MHH *ZWX>_P#'Y=_]<Q_.N2KK?A[_ ,?EW_US'\Z /QX\??\ (]^(_P#L)7/_
M *-:L&M[Q]_R/?B/_L)7/_HUJP:_4(?"C\YE\3"BBBK)"BBB@ HHHH ****
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M=@K\S?V[?^2M3_[W]*_3*OS-_;M_Y*U/_O?TJ<5_#'0^,^_/@O\ \DQ\/?\
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MHN/_ $DM*X\3\*.BCN?9%%%%><=H4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !115G3]/GU.Z2WMTWR
M-^0'J?:@ T_3Y]3NDM[=-\C?D!ZGVKPW]KO]KNP_9^TFX\$^";B*]\?W4>+N
M^ #II:L.&(Z&4@Y5#PH.YNP8_:[_ &N[#]G[2;CP3X)N(KWQ_=1XN[X .FEJ
MPX8CH92#E4/"@[F[!OR_O;VXU*\GN[N>6ZN[B1I9IYG+R2.QRS,QY)))))ZY
MKMHT>;WI;'-4J6]V(7M[<:E>3W=W/+=7=Q(TLT\SEY)'8Y9F8\DDDDD]<U!1
M17H'&%%%% !1110!]K?L2^-]4^&_[./QX\3Z*\<>JZ9'9SV[S1AT# 2CE3UZ
MUR^F_P#!2WXP6MRK7O\ 8.JVV?GMKG3MJL.XRC*:L_LP_P#)H/[1O_7K9_\
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M,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P"NB_\ H!H X:BBB@ HHHH **** "BBB@ HHHH *Z;P/?6]E=W1N)HX0R
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M3J*/KV)_Y^,/J>'_ )$>8_\ # OP7_Z"VM?^#*+_ .-4?\,"_!?_ *"VM?\
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M6G@[XF^+M L#(;'2M8O+&W,S!G,<4SHNX@#)PHR<5^NWP_\ ^0S-_P!>[?\
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M1^C_ /PVM\!/6T_\ HJ/^&UO@)ZVG_@%%7YP?\.L_B/_ -#-8_\ ?+_XT?\
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M"%=-\1/]=8_[K_S%04<?1110 4444 %%%% 'QO\ \%3_ /DWWP__ -C1;_\
MI)=U\+U^@_\ P4G\(WOBC]FN6YLK=[G^Q=5M]2F6,$E8@DL3-@#D#S@3V !/
M:OSPT^\34+&&X0Y$B@_0]Q^=>CAMF<=?=%BBBBNPY@HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *^Z/^"6'_ ";[X@_[&BX_])+2O@_4+Q+"
MQFN'.%C4G\>P_.OT4_X)N^#;KPG^S1:75W$\+:YJ=QJD:2*5/ED)"IP>S"#<
M#W# ]ZX\3LCIH;GU)1117G'8%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !115G3]/GU.Z2WMTWR-^0'J?:@
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M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7<^-O\
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M /&:_:"BCZQ,/8Q/Q?\ ^%<_%?\ Z)#XR_\ !-=__&:/^%<_%?\ Z)#XR_\
M!-=__&:_:"BCZQ,/8Q/Q?_X5S\5_^B0^,O\ P37?_P 9H_X5S\5_^B0^,O\
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M 4444 %%%% !1110 4459T_3Y]3NDM[=-\C?D!ZGVH -/T^?4[I+>W3?(WY
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M% #HY&BD5T9D=3E64X(/J*OWWB/5M4@6"\U2\NX5Z1SW#NH_ FLZB@ HHHH
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MBB@ HHHH **** "BBB@ HHHH **** "NY\;?\@&R_P"NB_\ H!KAJ[GQM_R
M;+_KHO\ Z : .&HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *['X=_P"LO_HG_LU<=78_#O\ UE_]$_\ 9J .
M6U#_ )"%S_UU;^9JO5C4/^0A<_\ 75OYFJ] !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !3H_]8OUIM.C_P!8OUH
M[;XA_P#'M9_[[?R%</7<?$/_ (]K/_?;^0KAZ "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#N?A[_P >=W_U
MT'\JX:NY^'O_ !YW?_70?RKAJ "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@"UI?_ "$[3_KLG_H0KIOB)_KK
M'_=?^8KF=+_Y"=I_UV3_ -"%=-\1/]=8_P"Z_P#,4 <?1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 6=/T^?4[I+>W3?(WY >I]J\-_:[_:[L/V?M)N/!/@FXBO?']U'
MB[O@ Z:6K#AB.AE(.50\*#N;L&^@-(\23Z+"R6]O;DL<M(ZL6/ZU?_X6!J/_
M #QM?^^6_P#BJN+47=JY,DVK)GX87M[<:E>3W=W/+=7=Q(TLT\SEY)'8Y9F8
M\DDDDD]<U!7[K?\ "P-1_P">-K_WRW_Q5'_"P-1_YXVO_?+?_%5V?6O[IS>P
M\S\*:*_=;_A8&H_\\;7_ +Y;_P"*H_X6!J/_ #QM?^^6_P#BJ/K7]T/8>9^%
M-%?NM_PL#4?^>-K_ -\M_P#%4?\ "P-1_P">-K_WRW_Q5'UK^Z'L/,_"FBOW
M6_X6!J/_ #QM?^^6_P#BJ/\ A8&H_P#/&U_[Y;_XJCZU_=#V'F?A317[K?\
M"P-1_P">-K_WRW_Q5'_"P-1_YXVO_?+?_%4?6O[H>P\S\*:*_=;_ (6!J/\
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M6_\ BJ/^%@:C_P \;7_OEO\ XJCZU_=#V'F?A317[K?\+ U'_GC:_P#?+?\
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MM?\ OEO_ (JCZU_=#V'F?A317[K?\+ U'_GC:_\ ?+?_ !5'_"P-1_YXVO\
MWRW_ ,51]:_NA[#S/PIHK]UO^%@:C_SQM?\ OEO_ (JC_A8&H_\ /&U_[Y;_
M .*H^M?W0]AYGX4T5^ZW_"P-1_YXVO\ WRW_ ,51_P + U'_ )XVO_?+?_%4
M?6O[H>P\S\*:*_=;_A8&H_\ /&U_[Y;_ .*H_P"%@:C_ ,\;7_OEO_BJ/K7]
MT/8>9^%-%?NM_P + U'_ )XVO_?+?_%4?\+ U'_GC:_]\M_\51]:_NA[#S/P
MIHK]UO\ A8&H_P#/&U_[Y;_XJC_A8&H_\\;7_OEO_BJ/K7]T/8>9^%-%?NM_
MPL#4?^>-K_WRW_Q5'_"P-1_YXVO_ 'RW_P 51]:_NA[#S/PIHK]UO^%@:C_S
MQM?^^6_^*H_X6!J/_/&U_P"^6_\ BJ/K7]T/8>9^%-%?NM_PL#4?^>-K_P!\
MM_\ %4?\+ U'_GC:_P#?+?\ Q5'UK^Z'L/,_"FBOW6_X6!J/_/&U_P"^6_\
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MEXCC!X4?XUFT45R'0%%%% !1110 4444 %%%% !1110!U7P^_P"0E<_]<?\
MV85B^(/^0Y??]=F_G6U\/O\ D)7/_7'_ -F%8OB#_D.7W_79OYT 9]%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !7<^-O^0#9?]=%_P#0#7#5W/C;_D V7_71?_0#0!PU%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !78_#O\
MUE_]$_\ 9JXZNQ^'?^LO_HG_ +-0!RVH?\A"Y_ZZM_,U7JQJ'_(0N?\ KJW\
MS5>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ IT?^L7ZTVG1_P"L7ZT =M\0_P#CVL_]]OY"N'KN/B'_ ,>UG_OM
M_(5P] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!W/P]_P"/.[_ZZ#^5<-7<_#W_ (\[O_KH/Y5PU !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!:TO_ )"=I_UV3_T(5TWQ$_UUC_NO_,5S.E_\A.T_Z[)_Z$*Z;XB?ZZQ_
MW7_F* ./HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#O\ UE_]$_\ 9JXZNQ^'?^LO_HG_ +-0!RVH?\A"Y_ZZM_,U7JQJ'_(0N?\
MKJW\S5>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ IT?^L7ZTVG1_P"L7ZT =M\0_P#CVL_]]OY"N'KN/B'_ ,>U
MG_OM_(5P] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!W/P]_P"/.[_ZZ#^5<-7<_#W_ (\[O_KH/Y5PU !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110!:TO_ )"=I_UV3_T(5TWQ$_UUC_NO_,5S.E_\A.T_Z[)_Z$*Z;XB?
MZZQ_W7_F* ./HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M110 4444 %%%% !1110!U7P^_P"0E<_]<?\ V85B^(/^0Y??]=F_G6U\/O\
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M$_UUC_NO_,5S.E_\A.T_Z[)_Z$*Z;XB?ZZQ_W7_F* ./HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&YT+Q98-J.EQZ/=7:PK/)#^\0H%.Y&!XW'C.*\!I\VK06TN%%%%,0445ZO\
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MHH **** "NY\;?\ (!LO^NB_^@&N&KN?&W_(!LO^NB_^@&@#AJ*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HIQ5E56((#=#
MZTV@ HHHH *['X=_ZR_^B?\ LU<=78_#O_67_P!$_P#9J .6U#_D(7/_ %U;
M^9JO5C4/^0A<_P#75OYFJ] !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !3H_]8OUIM.C_ -8OUH [;XA_\>UG_OM_
M(5P]=Q\0_P#CVL_]]OY"N'H **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** .Y^'O\ QYW?_70?RKAJ[GX>_P#'
MG=_]=!_*N&H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HIRJS!B 2%&3@=!G']13: "BBB@"UI?\ R$[3_KLG_H0KIOB)
M_KK'_=?^8KF=+_Y"=I_UV3_T(5TWQ$_UUC_NO_,4 <?1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&D^&KO4]/UZ[ELM.DLRDK3S1Y\Q=BL60* 268 8!.< U[O\ M>?\FZ?LR?\
M8 NO_0+.O0O!7QNU_P" _P#P3N\/:QX9$,>KZEX@N=*CNYEW&U#FX<RHIX+
M18&>/FS@XQ4\\N5-;MCY5=IGDL/_  3G^-\NFBZ.@Z?%*5W?9'U2#S?IPVW/
M_ J^?/%GA'6? GB&]T+Q!IMQI.KV;[)[2Y3:Z'J/J",$$<$$$<5;7XB>*5\4
M1^)/^$BU1O$"2B9=3>[D:XW@@@[R<]0*^H_V[+Z'XA?#7X'?$N6&./6]>T:2
M#49(U \QXQ$PZ=@\DWT! [55Y1DE+J*T6FUT/CJBBI(()+J:.&&-I9I&")'&
MI9F8G   ZDFM3,^Q9I+C6O\ @F+;)I6Y4TGQ01JPBYW(9&*[_;=-;_D*Q?\
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M&_@>;PKX!\-:G)H&FW/A^UU"ZO+%VCNIRY=/+\P'*H!'GY<$Y.3CBOC#P?\
M%GQCX"\20:]H7B34K#5(7#^<MPQ$F#G:ZDX=3W5@0>]9T^?E5K%SY>9W.=U;
M2;W0=3NM.U*TFL+^UD:&>UN8S')$X."K*>00>QKZD_:Z_P"3=?V9?^P!=?\
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M#F[_ /CU9]%'LH=@YY=S0_X6-\5_^BO^,O\ P<W?_P >H_X6-\5_^BO^,O\
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M%?\ Z*_XR_\ !S=__'JSZ*/90[!SR[FA_P +&^*__17_ !E_X.;O_P"/4?\
M"QOBO_T5_P 9?^#F[_\ CU9]%'LH=@YY=S0_X6-\5_\ HK_C+_P<W?\ \>H_
MX6-\5_\ HK_C+_P<W?\ \>K/HH]E#L'/+N:'_"QOBO\ ]%?\9?\ @YN__CU'
M_"QOBO\ ]%?\9?\ @YN__CU9]%'LH=@YY=S0_P"%C?%?_HK_ (R_\'-W_P#'
MJ/\ A8WQ7_Z*_P",O_!S=_\ QZL^BCV4.P<\NYH?\+&^*_\ T5_QE_X.;O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#XE>!]&5KKQ-H>KIK45C&,O-"1&V%'4DB*< #J0H[UX7KGQX.M?LV^'?A/\
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MVX\T)2C:5N@>Z[QN?-/A#PGJOCOQ/IGA_1+1[[5=1G6WMX(QRS,<9/H!U)/
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M_7Q \BJBP2%F\L*!D\OMV_*%6*/&<8&?*^=24;%W7*TW<Z_]KS_DW3]F3_L
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M?^BF>'/_  ?V?_Q5?D'11_8E/^=A_;%3^1'Z^?\ ">?"'_HIGAS_ ,']G_\
M%4?\)Y\(?^BF>'/_  ?V?_Q5?D'11_8E/^=A_;%3^1'Z^?\ ">?"'_HIGAS_
M ,']G_\ %4?\)Y\(?^BF>'/_  ?V?_Q5?D'11_8E/^=A_;%3^1'Z^?\ ">?"
M'_HIGAS_ ,']G_\ %4?\)Y\(?^BF>'/_  ?V?_Q5?D'11_8E/^=A_;%3^1'Z
M^?\ ">?"'_HIGAS_ ,']G_\ %4?\)Y\(?^BF>'/_  ?V?_Q5?D'11_8E/^=A
M_;%3^1'Z^?\ ">?"'_HIGAS_ ,']G_\ %4?\)Y\(?^BF>'/_  ?V?_Q5?D'1
M1_8E/^=A_;%3^1'Z^?\ ">?"'_HIGAS_ ,']G_\ %4?\)Y\(?^BF>'/_  ?V
M?_Q5?D'11_8E/^=A_;%3^1'Z^?\ ">?"'_HIGAS_ ,']G_\ %4?\)Y\(?^BF
M>'/_  ?V?_Q5?D'11_8E/^=A_;%3^1'Z^?\ ">?"'_HIGAS_ ,']G_\ %4?\
M)Y\(?^BF>'/_  ?V?_Q5?D'11_8E/^=A_;%3^1'Z^?\ ">?"'_HIGAS_ ,']
MG_\ %5JZI\8/A5J]G%;3?$GPNJ1D,#'KMH#P,=W]Z_&ZBC^Q*?\ .P_MBI_(
MC]?/^$\^$/\ T4SPY_X/[/\ ^*H_X3SX0_\ 13/#G_@_L_\ XJOR#HH_L2G_
M #L/[8J?R(_7S_A//A#_ -%,\.?^#^S_ /BJ/^$\^$/_ $4SPY_X/[/_ .*K
M\@Z*/[$I_P [#^V*G\B/U\_X3SX0_P#13/#G_@_L_P#XJC_A//A#_P!%,\.?
M^#^S_P#BJ_(.BC^Q*?\ .P_MBI_(C]?/^$\^$/\ T4SPY_X/[/\ ^*H_X3SX
M0_\ 13/#G_@_L_\ XJOR#HH_L2G_ #L/[8J?R(_7S_A//A#_ -%,\.?^#^S_
M /BJ/^$\^$/_ $4SPY_X/[/_ .*K\@Z*/[$I_P [#^V*G\B/U\_X3SX0_P#1
M3/#G_@_L_P#XJC_A//A#_P!%,\.?^#^S_P#BJ_(.BC^Q*?\ .P_MBI_(C]?/
M^$\^$/\ T4SPY_X/[/\ ^*H_X3SX0_\ 13/#G_@_L_\ XJOR#HH_L2G_ #L/
M[8J?R(_7S_A//A#_ -%,\.?^#^S_ /BJ/^$\^$/_ $4SPY_X/[/_ .*K\@Z*
M/[$I_P [#^V*G\B/U\_X3SX0_P#13/#G_@_L_P#XJC_A//A#_P!%,\.?^#^S
M_P#BJ_(.BC^Q*?\ .P_MBI_(C]?/^$\^$/\ T4SPY_X/[/\ ^*H_X3SX0_\
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M_P :_,__ ()V?\@#6O\ =3^=?9%>A3PJJ14KG).NXRM8]H_X9Z^#/_/KH?\
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MO"__ $,-O_X%15\OT4?4U_,'UE]CZ@_LKPO_ -##;_\ @5%1_97A?_H8;?\
M\"HJ^7Z*/J:_F#ZR^Q]0?V5X7_Z&&W_\"HJ/[*\+_P#0PV__ (%15\OT4?4U
M_,'UE]CZ@_LKPO\ ]##;_P#@5%1_97A?_H8;?_P*BKY?HH^IK^8/K+['U!_9
M7A?_ *&&W_\  J*C^RO"_P#T,-O_ .!45?+]%'U-?S!]9?8^H/[*\+_]##;_
M /@5%1_97A?_ *&&W_\  J*OE^BCZFOY@^LOL?4']E>%_P#H8;?_ ,"HJ/[*
M\+_]##;_ /@5%7R_11]37\P?67V/J#^RO"__ $,-O_X%14?V5X7_ .AAM_\
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MI7^)"T445VG,%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^.MQH.LZ#X%C\)^)F6677[J(KLO)F*X*[<;NC,790Q+X.<9/M_['/[3W@;P
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MAU9OLYU<6DGV02_W/.QLW<],YK[A^!7Q,'[<7@#Q!\)_B2+>]\865D]_X?\
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M^1%,1D1-)C:KD?PDYKO]%_99^+GB#34U"Q^'FOR6DB[DDDLVC+KUR V"0>Q
MYKZ9_8W^(6G_  H_9'^*'C/4M$A\1+H^N6UQ!8SA=IN#Y$<+Y(.W:[JVX#(
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M#MAR4^D:UC-<\E TC[J<B/\ ;W^&$?P[_:#U2_L47^QO$T:ZW:21\H6D)\X
MCC_6!V^CK7SC7VK\0E_X:$_8&\+>*T_TCQ)\.;G^R[YNKFU^2//J?D-JQ/\
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M/_Q^C_AAGXW?]"3_ .5:Q_\ C]?HU_PF&K_\_?\ Y"3_  H_X3#5_P#G[_\
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MA1_;6(_EC^/^8?V30[O\/\C\Y?\ AAGXW?\ 0D_^5:Q_^/T?\,,_&[_H2?\
MRK6/_P ?K]&O^$PU?_G[_P#(2?X4?\)AJ_\ S]_^0D_PH_MK$?RQ_'_,/[)H
M=W^'^1^<O_##/QN_Z$G_ ,JUC_\ 'Z/^&&?C=_T)/_E6L?\ X_7Z-?\ "8:O
M_P _?_D)/\*ZKQ3JUUIND6L]O+Y<KNH9MH.<J3W%']M8C^6/X_YA_9-#N_P_
MR/R[_P"&&?C=_P!"3_Y5K'_X_1_PPS\;O^A)_P#*M8__ !^OT:_X3#5_^?O_
M ,A)_A1_PF&K_P#/W_Y"3_"C^VL1_+'\?\P_LFAW?X?Y'YR_\,,_&[_H2?\
MRK6/_P ?H_X89^-W_0D_^5:Q_P#C]?HU_P )AJ__ #]_^0D_PH_X3#5_^?O_
M ,A)_A1_;6(_EC^/^8?V30[O\/\ (_.7_AAGXW?]"3_Y5K'_ ./T?\,,_&[_
M *$G_P JUC_\?K]&O^$PU?\ Y^__ "$G^%'_  F&K_\ /W_Y"3_"C^VL1_+'
M\?\ ,/[)H=W^'^1^<O\ PPS\;O\ H2?_ "K6/_Q^C_AAGXW?]"3_ .5:Q_\
MC]?HU_PF&K_\_?\ Y"3_  H_X3#5_P#G[_\ (2?X4?VUB/Y8_C_F']DT.[_#
M_(_.7_AAGXW?]"3_ .5:Q_\ C]'_  PS\;O^A)_\JUC_ /'Z_1K_ (3#5_\
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M+!T_N'_&LJ>(=-62-)T5-W;/"/\ A7/BC_H :A_WX;_"C_A7/BC_ * &H?\
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M_H :A_WX;_"O>/\ A/-2_NP?]\'_ !H_X3S4O[L'_?!_QH^N2[!]7CW/!_\
MA7/BC_H :A_WX;_"C_A7/BC_ * &H?\ ?AO\*]X_X3S4O[L'_?!_QH_X3S4O
M[L'_ 'P?\:/KDNP?5X]SP?\ X5SXH_Z &H?]^&_PH_X5SXH_Z &H?]^&_P *
M]X_X3S4O[L'_ 'P?\:/^$\U+^[!_WP?\:/KDNP?5X]SP?_A7/BC_ * &H?\
M?AO\*/\ A7/BC_H :A_WX;_"O>/^$\U+^[!_WP?\:/\ A/-2_NP?]\'_ !H^
MN2[!]7CW/!_^%<^*/^@!J'_?AO\ "C_A7/BC_H :A_WX;_"O>/\ A/-2_NP?
M]\'_ !H_X3S4O[L'_?!_QH^N2[!]7CW/!_\ A7/BC_H :A_WX;_"C_A7/BC_
M * &H?\ ?AO\*]X_X3S4O[L'_?!_QH_X3S4O[L'_ 'P?\:/KDNP?5X]SP?\
MX5SXH_Z &H?]^&_PH_X5SXH_Z &H?]^&_P *]X_X3S4O[L'_ 'P?\:/^$\U+
M^[!_WP?\:/KDNP?5X]SP?_A7/BC_ * &H?\ ?AO\*/\ A7/BC_H :A_WX;_"
MOI[PGK5QK5O.]P$!1@HV#':N9_X3S4O[L'_?!_QH^N2[!]7CW/!_^%<^*/\
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M^@!J'_?AO\*/^%<^*/\ H :A_P!^&_PKWC_A/-2_NP?]\'_&C_A/-2_NP?\
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MX*G*6_9[T @$A?$]N3[?Z+=U\+5Z.&^%G%6W"BBBNPYPHHHH **** "BBB@
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MO-@MYFS&Z0_P= /K7DE%5RK3R%=A1113$%%%% !1110 4444 %%%% !1110
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M<YP3_"XR=K8.,G@@D'V;6/$/[(GQ"OCK5YI/C3P1>S$R7&EZ0(C;%SDG9G>
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MLYP<'%"4;KW6#;MN=C\+O^4=_P 9O^P_8?\ HZTKY0KVWP;\;M$\._LK^/\
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M@C!SGRRM==R^9;/L?/5?8_PY\,W]O_P33^*-\]NZPWNO6\\&1]^*.>S1G'J
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M7-SXN\/2:38O91QLD4S1RJ#+N=2%S(.5#'@\5+C)INV]AW2:78\0KZR\1?\
M*-;PO_V.S_\ HJXKY-KV[5?CAH=]^R/HWPLCM-0'B"S\1-JTERT<?V4PE)5V
MAM^[?F0<;<<'FM9INUNY$7N>(U]9?\%$?^1T^&7_ &)5E_Z,FKY-KV[]JKXX
M:'\<O$'@^^T*TU"SBT?P[;:3<+J$<:,TT;R,S)L=LI\XP3@]>!2DGS)@G[K1
M]:_&3XS:;X'_ &>?@EXKNOA;X8^(-A?:)#927FMV:3BPF2"+]TK,C8#%9>,C
M_5&O!_\ AMKPPOW/V>OANG_<,B_^-UB?L\_M96?PZ\%WGPZ\?^&(_&WPXOI6
ME:R;!GM&)#$Q;B%(W#<%RI#$L&!Z[T\G['=S(-22+XC6B[B?[(C,)'KC<23C
MM_K,UBH*.C1IS.6J9P/Q^_:BO/CIX9\-^'D\*:/X1T;0Y9I;>ST92D69 /X,
M +CYCP.K&O#Z]4^/GC3X;>,-6TE?AIX+N?!^E6-NT$IO+GS9;P[LJ[C+88<@
MG>V<CIBO*ZZ(I):*QE+5ZL]"^"?Q>_X4SXFN]8_X1?0_%GVBS:T^R:];>?#'
MET;>HSPWR8SZ,:]J_P"&]/\ JC'PX_\ !3_]>OE.BDX1D[L%)K1'0>/O%O\
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M=3QS2]FTVNC0^963[' _'CPM?^"_C/XVT?4HI(;JWU>Y/[T8+HTA>-_HR,K
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MR^_Z[-_.MKX??\A*Y_ZX_P#LPK%\0?\ (<OO^NS?SH SZ*** "BBB@ HHHH
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M^?D/OE_\B?!%>^?L8_\ )4-4_P"P/+_Z/@KWO_AF/X:?]"U_Y/7/_P <K?\
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M$;?_ "71_P .K]1_Z+)=?^"-O_DNCZQ /8R/DVBOK+_AU?J/_19+K_P1M_\
M)='_  ZOU'_HLEU_X(V_^2Z/K$ ]C(^3:*^LO^'5^H_]%DNO_!&W_P ET?\
M#J_4?^BR77_@C;_Y+H^L0#V,CY-HKZR_X=7ZC_T62Z_\$;?_ "71_P .K]1_
MZ+)=?^"-O_DNCZQ /8R/DVBOK+_AU?J/_19+K_P1M_\ )='_  ZOU'_HLEU_
MX(V_^2Z/K$ ]C(^3:*^LO^'5^H_]%DNO_!&W_P ET?\ #J_4?^BR77_@C;_Y
M+H^L0#V,CY-HKZR_X=7ZC_T62Z_\$;?_ "71_P .K]1_Z+)=?^"-O_DNCZQ
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 5W/C;_D V7_ %T7_P!
M-<-7<^-O^0#9?]=%_P#0#0!PU%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !78_#O_ %E_]$_]FKCJ['X=_P"L
MO_HG_LU '+:A_P A"Y_ZZM_,U7JQJ'_(0N?^NK?S-5Z "BBB@ HHHH ****
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M_P#Q[_Z$/_RL6'_Q^C_AW_\ 'O\ Z$/_ ,K%A_\ 'Z/:0[H.278^>:*^AO\
MAW_\>_\ H0__ "L6'_Q^C_AW_P#'O_H0_P#RL6'_ ,?H]I#N@Y)=CYYHKZ&_
MX=__ ![_ .A#_P#*Q8?_ !^C_AW_ /'O_H0__*Q8?_'Z/:0[H.278^>:*^AO
M^'?_ ,>_^A#_ /*Q8?\ Q^C_ (=__'O_ *$/_P K%A_\?H]I#N@Y)=CYYHKZ
M&_X=_P#Q[_Z$/_RL6'_Q^C_AW_\ 'O\ Z$/_ ,K%A_\ 'Z/:0[H.278^>:*^
MAO\ AW_\>_\ H0__ "L6'_Q^C_AW_P#'O_H0_P#RL6'_ ,?H]I#N@Y)=CYYH
MKZ&_X=__ ![_ .A#_P#*Q8?_ !^C_AW_ /'O_H0__*Q8?_'Z/:0[H.278^>:
M*^AO^'?_ ,>_^A#_ /*Q8?\ Q^C_ (=__'O_ *$/_P K%A_\?H]I#N@Y)=CY
MYHKZ&_X=_P#Q[_Z$/_RL6'_Q^C_AW_\ 'O\ Z$/_ ,K%A_\ 'Z/:0[H.278^
M>:*^AO\ AW_\>_\ H0__ "L6'_Q^C_AW_P#'O_H0_P#RL6'_ ,?H]I#N@Y)=
MCYYHKZ&_X=__ ![_ .A#_P#*Q8?_ !^C_AW_ /'O_H0__*Q8?_'Z/:0[H.27
M8^>:*^AO^'?_ ,>_^A#_ /*Q8?\ Q^C_ (=__'O_ *$/_P K%A_\?H]I#N@Y
M)=CYYHKZ&_X=_P#Q[_Z$/_RL6'_Q^C_AW_\ 'O\ Z$/_ ,K%A_\ 'Z/:0[H.
M278^>:*^AO\ AW_\>_\ H0__ "L6'_Q^C_AW_P#'O_H0_P#RL6'_ ,?H]I#N
M@Y)=CYYHKZ&_X=__ ![_ .A#_P#*Q8?_ !^C_AW_ /'O_H0__*Q8?_'Z/:0[
MH.278^>:*^AO^'?_ ,>_^A#_ /*Q8?\ Q^C_ (=__'O_ *$/_P K%A_\?H]I
M#N@Y)=CYYHKZ&_X=_P#Q[_Z$/_RL6'_Q^C_AW_\ 'O\ Z$/_ ,K%A_\ 'Z/:
M0[H.278^>:*^AO\ AW_\>_\ H0__ "L6'_Q^C_AW_P#'O_H0_P#RL6'_ ,?H
M]I#N@Y)=CYYHKZ&_X=__ ![_ .A#_P#*Q8?_ !^C_AW_ /'O_H0__*Q8?_'Z
M/:0[H.278^>:*^AO^'?_ ,>_^A#_ /*Q8?\ Q^C_ (=__'O_ *$/_P K%A_\
M?H]I#N@Y)=CYYHKZ&_X=_P#Q[_Z$/_RL6'_Q^C_AW_\ 'O\ Z$/_ ,K%A_\
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M *$/_P K%A_\?H]I#N@Y)=CYYHKZ&_X=_P#Q[_Z$/_RL6'_Q^C_AW_\ 'O\
MZ$/_ ,K%A_\ 'Z/:0[H.278^>:*^AO\ AW_\>_\ H0__ "L6'_Q^C_AW_P#'
MO_H0_P#RL6'_ ,?H]I#N@Y)=CYYHKZ&_X=__ ![_ .A#_P#*Q8?_ !^C_AW_
M /'O_H0__*Q8?_'Z/:0[H.278^>:*^AO^'?_ ,>_^A#_ /*Q8?\ Q^C_ (=_
M_'O_ *$/_P K%A_\?H]I#N@Y)=CYYHKZ&_X=_P#Q[_Z$/_RL6'_Q^C_AW_\
M'O\ Z$/_ ,K%A_\ 'Z/:0[H.278^>:*^AO\ AW_\>_\ H0__ "L6'_Q^C_AW
M_P#'O_H0_P#RL6'_ ,?H]I#N@Y)=CYYHKZ&_X=__ ![_ .A#_P#*Q8?_ !^C
M_AW_ /'O_H0__*Q8?_'Z/:0[H.278^>:*^AO^'?_ ,>_^A#_ /*Q8?\ Q^C_
M (=__'O_ *$/_P K%A_\?H]I#N@Y)=CYYHKZ&_X=_P#Q[_Z$/_RL6'_Q^C_A
MW_\ 'O\ Z$/_ ,K%A_\ 'Z/:0[H.278^>:*^AO\ AW_\>_\ H0__ "L6'_Q^
MC_AW_P#'O_H0_P#RL6'_ ,?H]I#N@Y)=CYYHKZ&_X=__ ![_ .A#_P#*Q8?_
M !^C_AW_ /'O_H0__*Q8?_'Z/:0[H.278^>:*^AO^'?_ ,>_^A#_ /*Q8?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5W/C;_D V7_71?\
MT UPU=SXV_Y -E_UT7_T T <-1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 5V/P[_ -9?_1/_ &:N.KL?AW_K
M+_Z)_P"S4 <MJ'_(0N?^NK?S-5ZL:A_R$+G_ *ZM_,U7H **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *='_K%^M-I
MT?\ K%^M ';?$/\ X]K/_?;^0KAZ[CXA_P#'M9_[[?R%</0 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 =S\
M/?\ CSN_^N@_E7#5W/P]_P"/.[_ZZ#^5<-0 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 6M+_P"0G:?]=D_]
M"%=-\1/]=8_[K_S%<SI?_(3M/^NR?^A"NF^(G^NL?]U_YB@#CZ*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU'_G_NO^_P W^-']M:C_ ,_]U_W^;_&KO_"'ZO\ \^G_ )%3_&C_ (0_5_\
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M/\:/^$/U?_GT_P#(J?XT 4O[:U'_ )_[K_O\W^-']M:C_P _]U_W^;_&KO\
MPA^K_P#/I_Y%3_&C_A#]7_Y]/_(J?XT 4O[:U'_G_NO^_P W^-']M:C_ ,_]
MU_W^;_&KO_"'ZO\ \^G_ )%3_&C_ (0_5_\ GT_\BI_C0!2_MK4?^?\ NO\
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M_A#]7_Y]/_(J?XT 4O[:U'_G_NO^_P W^-']M:C_ ,_]U_W^;_&KO_"'ZO\
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MK_O\W^-']M:C_P _]U_W^;_&KO\ PA^K_P#/I_Y%3_&C_A#]7_Y]/_(J?XT
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MBI_C0!2_MK4?^?\ NO\ O\W^-']M:C_S_P!U_P!_F_QJ[_PA^K_\^G_D5/\
M&C_A#]7_ .?3_P BI_C0!2_MK4?^?^Z_[_-_C1_;6H_\_P#=?]_F_P :N_\
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M ,_]U_W^;_&KO_"'ZO\ \^G_ )%3_&C_ (0_5_\ GT_\BI_C0!2_MK4?^?\
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M3_&H+SPYJ.GP&:>V*1CJP96Q^1H H3W$MU(9)I'E<_Q2,6/YFHZ** "BBB@
MHHHH **** "BBB@ HHHH **** .J^'W_ "$KG_KC_P"S"L7Q!_R'+[_KLW\Z
MVOA]_P A*Y_ZX_\ LPK%\0?\AR^_Z[-_.@#/HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *[GQM_R ;+_ *Z+
M_P"@&N&KN?&W_(!LO^NB_P#H!H X:BBB@ HHHH **** "BBB@ HHHH ****
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M\-%_%?\ Z*=XR_\ !_=__'*\\HK?E78SYGW/0_\ AHOXK_\ 13O&7_@_N_\
MXY1_PT7\5_\ HIWC+_P?W?\ \<KSRBCE78.9]ST/_AHOXK_]%.\9?^#^[_\
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M_P <KSRBCE78.9]ST/\ X:+^*_\ T4[QE_X/[O\ ^.4?\-%_%?\ Z*=XR_\
M!_=__'*\\HHY5V#F?<]#_P"&B_BO_P!%.\9?^#^[_P#CE'_#1?Q7_P"BG>,O
M_!_=_P#QRO/**.5=@YGW/0_^&B_BO_T4[QE_X/[O_P".4?\ #1?Q7_Z*=XR_
M\']W_P#'*\\HHY5V#F?<]#_X:+^*_P#T4[QE_P"#^[_^.4?\-%_%?_HIWC+_
M ,']W_\ '*\\HHY5V#F?<]#_ .&B_BO_ -%.\9?^#^[_ /CE'_#1?Q7_ .BG
M>,O_  ?W?_QRO/**.5=@YGW/0_\ AHOXK_\ 13O&7_@_N_\ XY1_PT7\5_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBJ+S//G!P9E4445L9A1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M15O2]/?5+Z.UC8*[AMI;ID*3_2H+BWDM9GAF0QR(<,K=J (Z*** "NY\;?\
M(!LO^NB_^@&N&KN?&W_(!LO^NB_^@&@#AJ*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "NQ^'?^LO_ *)_[-7'
M5V/P[_UE_P#1/_9J .6U#_D(7/\ UU;^9JO5C4/^0A<_]=6_F:KT %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %.C
M_P!8OUIM.C_UB_6@#MOB'_Q[6?\ OM_(5P]=Q\0_^/:S_P!]OY"N'H ****
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M_P"2J.678.9'V117QO\ \/3_ (4?]"_XR_\  *T_^2J/^'I_PH_Z%_QE_P"
M5I_\E4<LNP<R/LBBOC?_ (>G_"C_ *%_QE_X!6G_ ,E4?\/3_A1_T+_C+_P"
MM/\ Y*HY9=@YD?9%%?&__#T_X4?]"_XR_P# *T_^2J/^'I_PH_Z%_P 9?^ 5
MI_\ )5'++L',C[(HKXW_ .'I_P */^A?\9?^ 5I_\E4?\/3_ (4?]"_XR_\
M *T_^2J.678.9'V117QO_P /3_A1_P!"_P",O_ *T_\ DJC_ (>G_"C_ *%_
MQE_X!6G_ ,E4<LNP<R/LBBOC?_AZ?\*/^A?\9?\ @%:?_)5'_#T_X4?]"_XR
M_P# *T_^2J.678.9'V117QO_ ,/3_A1_T+_C+_P"M/\ Y*H_X>G_  H_Z%_Q
ME_X!6G_R51RR[!S(^R**^-_^'I_PH_Z%_P 9?^ 5I_\ )5'_  ]/^%'_ $+_
M (R_\ K3_P"2J.678.9'V117QO\ \/3_ (4?]"_XR_\  *T_^2J/^'I_PH_Z
M%_QE_P" 5I_\E4<LNP<R/LBBOC?_ (>G_"C_ *%_QE_X!6G_ ,E4?\/3_A1_
MT+_C+_P"M/\ Y*HY9=@YD?9%%?&__#T_X4?]"_XR_P# *T_^2J/^'I_PH_Z%
M_P 9?^ 5I_\ )5'++L',C[(HKXW_ .'I_P */^A?\9?^ 5I_\E4?\/3_ (4?
M]"_XR_\  *T_^2J.678.9'V117QO_P /3_A1_P!"_P",O_ *T_\ DJC_ (>G
M_"C_ *%_QE_X!6G_ ,E4<LNP<R/LBBOC?_AZ?\*/^A?\9?\ @%:?_)5'_#T_
MX4?]"_XR_P# *T_^2J.678.9'V117QO_ ,/3_A1_T+_C+_P"M/\ Y*H_X>G_
M  H_Z%_QE_X!6G_R51RR[!S(^R**^-_^'I_PH_Z%_P 9?^ 5I_\ )5'_  ]/
M^%'_ $+_ (R_\ K3_P"2J.678.9'V117QO\ \/3_ (4?]"_XR_\  *T_^2J/
M^'I_PH_Z%_QE_P" 5I_\E4<LNP<R/LBBOC?_ (>G_"C_ *%_QE_X!6G_ ,E4
M?\/3_A1_T+_C+_P"M/\ Y*HY9=@YD?9%%?&__#T_X4?]"_XR_P# *T_^2J/^
M'I_PH_Z%_P 9?^ 5I_\ )5'++L',C[(HKXW_ .'I_P */^A?\9?^ 5I_\E4?
M\/3_ (4?]"_XR_\  *T_^2J.678.9'V117QO_P /3_A1_P!"_P",O_ *T_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M"BBB@ HHHH **** .J^'W_(2N?\ KC_[,*Q?$'_(<OO^NS?SK:^'W_(2N?\
MKC_[,*R-?AD;6KXA&(\UNQ]: ,RBI/(D_P">;?\ ?)H\B3_GFW_?)H CHJ3R
M)/\ GFW_ 'R:/(D_YYM_WR: (Z*D\B3_ )YM_P!\FCR)/^>;?]\F@".BI/(D
M_P">;?\ ?)H\B3_GFW_?)H CHJ3R)/\ GFW_ 'R:/(D_YYM_WR: (Z*D\B3_
M )YM_P!\FCR)/^>;?]\F@".BI/(D_P">;?\ ?)H\B3_GFW_?)H CHJ3R)/\
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M#4 >??\ #V[PQ_T)^I?]_$_QH_X>W>&/^A/U+_OXG^->@_\ #J_P..LVI?\
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MZ;_"C^R[W_GTG_[]-_A0!5HJU_9=[_SZ3_\ ?IO\*/[+O?\ GTG_ ._3?X4
M5:*M?V7>_P#/I/\ ]^F_PH_LN]_Y])_^_3?X4 5:*M?V7>_\^D__ 'Z;_"C^
MR[W_ )])_P#OTW^% %6G1_ZQ?K5C^R[W_GTG_P"_3?X4Y-+O-Z_Z)/U_YY-_
MA0!UGQ#_ ./:S_WV_D*X>N\\>6TUS;V@AB>4AVSL4G' ]*XW^R[W_GTG_P"_
M3?X4 5:*M?V7>_\ /I/_ -^F_P */[+O?^?2?_OTW^% %6BK7]EWO_/I/_WZ
M;_"C^R[W_GTG_P"_3?X4 5:*M?V7>_\ /I/_ -^F_P */[+O?^?2?_OTW^%
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M0!5HJU_9=[_SZ3_]^F_PH_LN]_Y])_\ OTW^% %6BK7]EWO_ #Z3_P#?IO\
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M=D4"I:**]0X0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?\SI_P!N7_M>OJ.OES]B#_F=/^W+_P!KU]1U^>\1?\C2K_V[_P"DH_4^%?\
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MM;_Z!FG_ )/_ /%5Y+11["E_*'M9]SUK_AH[6_\ H&:?^3__ !5'_#1VM_\
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M *!FG_D__P 51_PT=K?_ $#-/_)__BJ\EHH]A2_E#VL^YZU_PT=K?_0,T_\
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MO_H&:?\ D_\ \51_PT=K?_0,T_\ )_\ XJO):*/84OY0]K/N>M?\-':W_P!
MS3_R?_XJC_AH[6_^@9I_Y/\ _%5Y+11["E_*'M9]SUK_ (:.UO\ Z!FG_D__
M ,51_P -':W_ - S3_R?_P"*KR6BCV%+^4/:S[GK7_#1VM_] S3_ ,G_ /BJ
M/^&CM;_Z!FG_ )/_ /%5Y+11["E_*'M9]SUK_AH[6_\ H&:?^3__ !5'_#1V
MM_\ 0,T_\G_^*KR6BCV%+^4/:S[GK7_#1VM_] S3_P G_P#BJ/\ AH[6_P#H
M&:?^3_\ Q5>2T4>PI?RA[6?<]:_X:.UO_H&:?^3_ /Q5'_#1VM_] S3_ ,G_
M /BJ\EHH]A2_E#VL^YZU_P -':W_ - S3_R?_P"*H_X:.UO_ *!FG_D__P 5
M7DM%'L*7\H>UGW/6O^&CM;_Z!FG_ )/_ /%4?\-':W_T#-/_ "?_ .*KR6BC
MV%+^4/:S[GK7_#1VM_\ 0,T_\G_^*H_X:.UO_H&:?^3_ /Q5>2T4>PI?RA[6
M?<]:_P"&CM;_ .@9I_Y/_P#%4?\ #1VM_P#0,T_\G_\ BJ\EHH]A2_E#VL^Y
MZU_PT=K?/_$LT_\ \?\ _BJ\EHHK2-.,/A1$IRENSH/!?C2_\$ZLEY9ONC/$
MT#'Y9%]#[^]?0*MI_P 1-'76-'8?:<8EA. V<?=;W]#WKY>KH/!?C2_\$ZLE
MY9ONC/$T#'Y9%]#[^]85Z"J*ZW-:55P=GL>QZ:K1ZM:JP*LLZ@J1@@[A72_$
M3_76/^Z_\Q2Z;-IGCZUM-<TJ15F213-$>H((RK#U'8]Z3XB?ZZQ_W7_F*\5I
MQ=F>DG=71Q]%%%(84444 %%%% !7X4_#_P#Y TW_ %\-_P"@K7[K5^%/P_\
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M!?AJ6.7P[X&TY='A,9RHF&!*H/<*$B3ZQM1+6<5V''2+9\O445[C\&?VH/\
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M2;N6VCUR^A\/QJ99)V9RXE9D8;!(S <9/DKZ8KPK^P/V._\ H9?B+_W[A_\
MC%<L9*5VT]3=JUDGL<]^WS\+D^'/[0FK7MFBC1_$J+K5J\?*%I"1, 1Q_K [
M?1UJ[^PS\,/#GB7Q1XJ\>>-+=+SPGX$TXZG<6LJ!TFF(<QAE/# +%(VWNP4'
M@X/M7[3EGX/^/7[(.B^*_ %[?ZQ!\/+A-->XU./%X;;RXHW$@ &3S;ONQC"L
M?6N _8PTJ7QG^SQ^T-X5TQ&FURZTNWGM[>+_ %EQM2<A%'?Y@%_X&/6CF?LO
MP#E]\\[^*W[<GQ7^(_B*XNK'Q-?>$M(#G[)I>B3&V$,?\(:1,-(V,9+'&<X
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MJM%%=!D%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !7N?[+7[4NM_LY^*<C?J7A2^<#4=)9N&'3S(\]' _/H:\,KZA_8Y
M_8YO/CQJ2^)O$RRZ9\/+&0^;-DQOJ3J>8HCV0$8>0=.57YLE8J.*B^;8J%[^
MZ?HSI]YI'CCPGIWC#PK<B_\ #VI1>=%(HP4Y*D$=L,"I'8@BJM:=]?6=KIMI
MHNBVD6F:%8QK!;6EN@C0(HPH"CH !P*S*\;T/3"BBBD 4444 =5\/O\ D)7/
M_7'_ -F%?EO^UC_R<=X^_P"PDW_H*U^I'P^_Y"5S_P!<?_9A7Y;_ +6/_)QW
MC[_L)-_Z"M?0Y+_&EZ?JCPLW_A1]?T/):***^R/E HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBO9_P!FG]FG6OVA/$^Q
M/,T[PO9./[1U7;T[^5%GAI"/P4')[!LJE2%&#G-V2-*=.562A!7;.H_8?^&/
MCCQ9\5+/7_#=Y-H>BZ5*O]I:IMRDB<$VR@\.[#L>%!W'^$-^D_Q _P"03!_U
MW'_H+5S=K:Z+\-O#%GX2\)6<>G:;9)Y0$/;^]\W5G)R68\DD]ZW_ !M_R ;+
M_KHO_H!KX'&XKZW5Y[62V/ML'AOJM/EO=G#4445YYW!1110!\&P_\G/W?_8S
M7'_I0U?;7[2'[0W_  HNWT ?V#%K0OE_Y:#[F!VY]J^%M8UBW\._M"ZOJEWD
M6UKXAN99-HR<"X8FO1?VM_CIX:^,L/AU/#\DSFQ7$WG1E/7IFOU?%8!XW$X3
MG@W3Y=?N/Q/!YDLOPF-]G-1J.>BZ[D?A7XH+\8OVGO#>NMI<6FJS>7]F505X
MSR1^-=)_P4,BBM_B!X;6.-(Q]DDR$4#/*]<5X/\ !OQ78^!_B5HVMZCN%E:R
M;Y"@R<?2OL#QA^TY\"/'EY#=:_I+:K<0J5CDN+,L5![#BJQ=*I@<?1JT*,I0
MA&VGS(P5:EF&65Z.(KQA4G-/73L>6_L"^$M1O/B=>ZZ()%T^UM3$TK*0"Q/0
M?G7L/A;PQ;?$3]L#7M?VK-9>'HA"6ZJ93N Y]017!^-OVUM \/>&9M#^&WA]
M=/\ ,0JMRR[%3(QD+CK69\&?VE/"/PQ^$NKVTL]U<>,=1\V>64Q,<S,. 6]
M:\W%T,?B95<7[)Q<TH)=4NK9ZN#Q.6X6-'!>V4HTVYRET;6R7<[W]I#PGJ/A
M;XB:;\6(/$,,\.FW$<)L5D7=%'_%C\17*?MW^#(M5TWP[X^T]5:"XB6*9D'W
MLC()_.OD?5-<U#6)[J6ZO9Y/M$K2O&TA*Y)STKZ?MOVCO"/B?]G(^"O$\DPU
MN.#RHF6$L 0<@Y_2N[^S\5E\L-5B^=P?*[+[+_R//_M3"9E#%T9_NU-<RN[^
M\O\ ,K_L0?\ ,Z?]N7_M>OJ.OEO]A]=J^-!G('V( _\ ?^OJ2OCN(O\ D:5?
M^W?_ $E'W_"O_(GH?]O?^E2"BBBOFSZL**** "OSN_X*Z?\ (O\ @?\ Z^I?
M_0#7Z(U^=W_!73_D7_ __7U+_P"@&@!G[+7A:T\;? &YT:^#&WN%"Y5B"IVG
M!XKX^^+GPD\5_LQ_$"'4+.658$E\RRU)%.U^^/>OMO\ 8H_Y)-']4_D:]:^(
MOPZT;XG>&;G1=9MUEAF4JLNT%XB?XE/8UZRHJI2BUN>>ZG)4=]CX%^(/[=&O
M>+_AY!H6GP2:?J;H(KJZX/FKC#8QTS5K]E/]DN[^(-_!XH\5Q.FBHPD2"8'=
M<^X/UKN/AK^P3/H_Q)ENO$$BR^'[>0R6P1@Q?!^4,/I7VQI^GVVDV<5I9P);
M6T2[4BC&%4>@%*G1G-\U7H.=2,5RTPT^PM]+LX;2UB6&WA0(B*,  # KS7]I
MG_DCNM_[H_K7J5>6_M,_\D=UO_=']:[9_"SFC\2/CO\ X)\_\E5U_P#Z]A_Z
M&:_1:OSI_P""?/\ R577_P#KV'_H9K]%JY\+_"-:_P 84445UG.%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM+]E;XW_  W\;_ /4/@7\5=0CT*P9Y#IVIRN(H]KR&;_ %K K'(DI9@6PI!
M]0=SP/\ LM? GX,>+++QGXH^-^B>)-,TR07UII<#P*TK(=R%@DTC3 $?=11D
M@=L@\L9>SNF;N//9HQO^"K3J?B=X)7(W#1Y"5[X,S8_D?RKN_B9\7O$OP@_X
M)\_"^Y\+7ITS4-7BMM,DOH\B:&)H9I&,3?PN?+ W=0"<8."/DO\ :Z^/47[0
MWQBN_$-C#);Z+:6Z:=IJ3#;(T",S;W&>&9W=L=@0.U>Q_M#>._#>M?L)_![0
MM/\ $&EWVMV=U;-<Z;;7D<ES %MKA6+QAMRX+*.0.2/6ERVC!,?-K)H[W]@O
MQ[KWQ/\ A'\:/"_BK5;O7K"WT]7A.I3-<.@GAN5E7<Y)VGRU..F=Q[US_P"Q
M[_R9/^T#_P!>EY_Z0&L+_@GGX[\-^#/#_P 88_$'B#2]#DO=,MUM5U*\CMS.
M52ZW! [#<1N7@9^\/6C]E7QWX;\/_L@_'/1]4\0:7INK7]K=+:6%W>1Q3W!:
MS**(T9@SDMP, \\4I+65NZ'%Z*_F=!_P3;\5V7C#0/B+\'=;??IVM64EY!&3
MV=!!<@9[[6A8?[K&IOV!/A7_ ,*N\<?%;QOXL3[/!X%AN-+>5AP)4+-<.ONL
M<0'N)J^4_P!G7XG-\'OC5X3\5EV2TL[Q4O-O>VDS',,=_D9B/<"ONK]N7XZ>
M ]%^!NL:%X!U_0]2U7QGJ:2:C_8M_'<-L"(997V,=I80Q1\XR"WO3J)\SBMI
M"BURW?0U?V9)+_Q1^S7\2?B!;:_IOA'Q;XTUB\N)?$6H2!8[(&01QJ6)& FZ
M39Z%Q67^S/X!N?@;\19-:UC]H;PKXBT.\BDCO]-DUH.9G(RD@WR$!PV/FZX+
M#O7C7['/QK\!7_PC\6?!/XFZ@NB:-K4CRV6J2MLC1G5=RM(05C9&C21&8;2<
M@]@9%_8=^%>BW)U#6_VB/#C>'E^=?L;6XN)E]%/GL,_16SZ5#5G)2=K^12=T
MFCH?V5H=$M_^"A?C=?#D]K<Z(PU.2UDL6#0%&D1L(5X*@D@8XP.*\;_:K_:6
M^(/BKXU>-=/C\2ZGI&BV-Y=Z)%I>GWDD-NUNCM$P=5(#EP"6+9ZXZ  ;W[#/
MB+PEX!_:LU*>;Q%9V7AF*UO[>RU35ITMEFCWKY18OM 9E ..._%>#_&S4+75
MOC+X]OK&XBO+*YU^_F@N('#QRQM<2%75AP5((((Z@UM&/[S7L9.7NZ=S[]O]
M)TK]M?X ^!-(\ ?$*+PMXG\-V4<=QX?>9HU>18DC(D13OVJ4RDBAAAF&,DX^
M2?&GA'XF>!_VA/ NC?$^YOK[5;.\L8;&ZO+HW*26HN05\J4D[DW%^#R"2"!T
MKV#3OV0?A1K%UI/B?P-^T)INAZ:@CG?^T;B%;ZT8 $D,)(BC9Z!D4CU--_;&
M^/7@_P")/Q\^%]KX>UB'5=-\+W40O=<W#R9&:>(MB3@,JK'DN/E^8XZ5G#25
MH[?D7+57>Y0_X*:ZE=Z/^TMH=[874UE>0^';9HKBWD,<B'[1<\JP.0?I7=?M
M;>-_$>C_ +'_ ,!]0L-?U2RO[RRLVN;JWO)(Y9R;%22[ALL<\\GK7DO_  4@
M\8:#XU^/6FWWA[6M/UZRCT"WA>YTRZCN(UD$]PQ0LA(W ,IQ[BO;+.'X;_M8
M_LF_#KPI??$C1_!.O>%TMXKA=1DB\U/)A,##RWDCRKKM<."1P!UR ;1@VA[R
MDD<Q_P $Y?'D/CFW^(WPG\3W,E[:^([6;4$-PY9Y&=?*NOF.2796C;U^1C5C
M]@WX3_\ "I?'?Q9\:^+4\BW\"0W&EM,R_+YB;GGD3Z1Q+CU$WO7S%X%\86G[
M//[2=IJ^B:LNN:/X?UN2 :C;@;;VS#M%(R[21AXBV,$CD'FOO;_@HIXZT[X;
M? RZT31HXK34_'FHJ]RT/RM-'&D9FE/N1';QGU#433YN5?:"-N6[Z'YF^//&
M%[\0?&VN^)M1.;W5KV6\E&<A2[EMH]AG ]@*^UO^"=]O;>!O@_\ &/XFQVD5
MUK&DV,J6Y?DA(;=[AD]@["//KL'I7P77UE^P;^T)X7^%]]XH\%^.W2W\*>*H
MEC:[E4M'%+M:,K)CHCHY!;L5&< DC:JO<LC*F_>NSRGP?^U!\2?#_P 3[+QA
M+XNUC4+W[8LUU;S7;M#<QELO$T6=NP@D!0,+D;<$#'T5_P %-K63P3\:/"OB
M?0+N?1M8U/27BN;JPF:&5_+?:&+*0>58+]$ [5?\/_LC_ GP/XUM/%^J?'/0
M=5\(6=R+RWTG[1;&6;8VY8GD65O, P-P6,%AD86O!/VSOV@K3]H;XN-JND)(
MGAW3+9;#3C,FQY5#%GE9>VYF.!UVJN0#D5"M*:<5H6[QBTSZ)_X*;>,M?T#4
MOAU!I>N:EIL-UIER;B.TNY(EF^:,?.%(W<$]?6OS\K[._P""DGCSPUXXU;X<
MOX<\0:7KZ6VFSK.VF7D=P(BS1X#;&.TG!X/I7QC5T5:"(J?$S[L^$S%?^"8G
MQ'(."-3D((_ZZVE;/[0D8_:@_8?\(_$V ?:/$OA8;-2*\N0"L-UGZLL4WLN?
M6N)^&?CSPU8_\$Y_B!X=N?$&EV_B"XU)VATF6\C6[E!DM2"L1;<PPK<@?PGT
M-6O^";_QRT'PA>>+? GC+5-.T[P[JT/VV!]8FCBM3, (Y8F,A"GS(RO!Z^5C
MO6+35Y+HS5-.T7U1O_&!?^&6?V$_#G@*/_1?%GCAS<:DOW9%1@LDX/NJ>1 ?
M4%JI?\%(/^2:? 3_ +!EU_Z)LJ\8_;F^-$'QF^/.ISZ9>1WOA[18UTS3IH'#
MQ2JA)DE4C@AI&;##JH2O2_V_?'GAKQA\/?@C;Z#X@TO6[BQTVX6[BT^\CG>W
M)BLP!($8E"2C#!Q]T^AIQBTXM[NXI-6DEY&W^TU_RCS^"7_7W:?^DMS71_MH
M>+M7^ _[./P@\!^$+R;0;34;-C>7&G2&)Y!#%"67>O.)))V=L'DCT)SY_P#M
M#>._#>M?L)_![0M/\0:7?:W9W5LUSIMM>1R7, 6VN%8O&&W+@LHY Y(]:]#L
M_$WPN_;5_9[\)>&/%'C:Q\">//#<<<*37[QIN94$;,BR.HE2145BJL&5E'8?
M-.UFUI=CWNEO9'Q9KGQV\>>)OAZG@G6?$MYJ_AV.[6]CM[YA,\<BJR@+(V7"
MX8_+G&>U?</Q,^+WB7X0?\$^?A?<^%KTZ9J&KQ6VF27T>1-#$T,TC&)OX7/E
M@;NH!.,'!'SW^T'\&?@Y\%_AC;Z=H/CV'QY\1I[^-I+BPD4V\%L%?>NR-F5#
MG9]YV8]@!FNS_:&\=^&]:_83^#VA:?X@TN^UNSNK9KG3;:\CDN8 MM<*Q>,-
MN7!91R!R1ZU<K2Y;+2Y"O&]WT.]_8+\>Z]\3_A'\:/"_BK5;O7K"WT]7A.I3
M-<.@GAN5E7<Y)VGRU..F=Q[US_['O_)D_P"T#_UZ7G_I :PO^">?COPWX,\/
M_&&/Q!X@TO0Y+W3+=;5=2O([<SE4NMP0.PW$;EX&?O#UH_95\=^&_#_[(/QS
MT?5/$&EZ;JU_:W2VEA=WD<4]P6LRBB-&8,Y+<# //%3):RMW1<7HK^9U/_!-
M.&YU#P#\:-/\/R"R\7SV4*V-](IVQ.T5PL)W8XVR')'?CCBN\_8@^&_Q9^#?
MB#QSX@^*=U>:-X32P=YEU;4%G5[A75S< AVP%C63+<;MXZXXY?\ X)Y&VT_]
MGGXJ77B66;PUX2:XS)XDM;MK>=<0XD6-E^92@*$$=3)@ GBKG_")_!_]IR:/
MP=I/[1WC_6=1N03;:7KUS(\,CJI8'RY((ED( )^]NXZU$]9270J.T7U/G7X
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M/U+5O!_BK3OLTUOI<<<DJ2X9,@2.@ ,<CY.<Y5./3S_X#_'+6_V>_B-;^*-
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M[?WOFZLY.2S'DDGO6+7!C<;/%S[16R.W!X..%CWD]V%=SXV_Y -E_P!=%_\
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MP+_T$KC_ ,"D_P#B:JT4>VJ?S![.'8M?\*;\"_\ 02N/_ I/_B:/^%-^!?\
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MZ"5Q_P"!2?\ Q-'_  IOP+_T$KC_ ,"D_P#B:JT4>VJ?S![.'8M?\*;\"_\
M02N/_ I/_B:/^%-^!?\ H)7'_@4G_P 356BCVU3^8/9P[%K_ (4WX%_Z"5Q_
MX%)_\31_PIOP+_T$KC_P*3_XFJM%'MJG\P>SAV+7_"F_ O\ T$KC_P "D_\
MB:/^%-^!?^@E<?\ @4G_ ,356BCVU3^8/9P[%K_A3?@7_H)7'_@4G_Q-'_"F
M_ O_ $$KC_P*3_XFJM%'MJG\P>SAV+7_  IOP+_T$KC_ ,"D_P#B:/\ A3?@
M7_H)7'_@4G_Q-5:*/;5/Y@]G#L6O^%-^!?\ H)7'_@4G_P 31_PIOP+_ -!*
MX_\  I/_ (FJM%'MJG\P>SAV+7_"F_ O_02N/_ I/_B:/^%-^!?^@E<?^!2?
M_$U5HH]M4_F#V<.QI6OP*\'WRLUO=7DP4X)2X4X_\=JO_P *;\"_]!*X_P#
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MO^%-^!?^@E<?^!2?_$T?\*;\"_\ 02N/_ I/_B:JT4>VJ?S![.'8M?\ "F_
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M+(5!."6('7HB]*\ HJ>5<W,/F=K!1115""BBB@ HHHH **** "BBB@ HHHH
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MH **** "BBOI_P#8\_8\NOCIJ \4>*!+IGP[L9/WLV2CZDZGF&(]0@/#./\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"G1_ZQ?K3:='_K%^M ';?$/_ (]K/_?;^0KAZ[CXA_\ 'M9_[[?R%</0 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 =S\/?^/.[_ .N@_E7#5W/P]_X\[O\ ZZ#^5<-0 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '9_#K_F(?]L__ &:J
M/B#Q!"MNNEZ6JP6$2B/]T, @<;5_V?Y_SPX-0GM;6XMXGV1S[?,QU(&>/IS5
M:@ HHHH M:7_ ,A.T_Z[)_Z$*Z;XB?ZZQ_W7_F*YG2_^0G:?]=D_]"%=-\1/
M]=8_[K_S% ''T444 %%%% !1110 5^=?[:W[)6O^'/&U_P#$WP#I<FK:5J;^
M;K&CV<698)C]Z9$4997/S' )#%B<@G'Z*4549.+NB914E9GX8V_C;2YHP9)7
M@;NKH3_+-2_\)AI'_/W_ .0G_P *_9C6_@S\/_$UV]UK'@7PUJMS(V]YK[2+
M>9V;&,EF0DG%9W_#.OPH_P"B8^#?_!!:?_&ZZ_K+['/[!=S\>/\ A,-(_P"?
MO_R$_P#A1_PF&D?\_?\ Y"?_  K]A_\ AG7X4?\ 1,?!O_@@M/\ XW1_PSK\
M*/\ HF/@W_P06G_QNG]:?8/8>9^/'_"8:1_S]_\ D)_\*/\ A,-(_P"?O_R$
M_P#A7[#_ /#.OPH_Z)CX-_\ !!:?_&Z/^&=?A1_T3'P;_P"""T_^-T?6GV#V
M'F?CQ_PF&D?\_?\ Y"?_  H_X3#2/^?O_P A/_A7[#_\,Z_"C_HF/@W_ ,$%
MI_\ &Z/^&=?A1_T3'P;_ .""T_\ C='UI]@]AYGX\?\ "8:1_P _?_D)_P#"
MC_A,-(_Y^_\ R$_^%?L/_P ,Z_"C_HF/@W_P06G_ ,;H_P"&=?A1_P!$Q\&_
M^""T_P#C='UI]@]AYGX\?\)AI'_/W_Y"?_"C_A,-(_Y^_P#R$_\ A7[#_P##
M.OPH_P"B8^#?_!!:?_&Z/^&=?A1_T3'P;_X(+3_XW1]:?8/8>9^/'_"8:1_S
M]_\ D)_\*/\ A,-(_P"?O_R$_P#A7[#_ /#.OPH_Z)CX-_\ !!:?_&Z/^&=?
MA1_T3'P;_P"""T_^-T?6GV#V'F?CQ_PF&D?\_?\ Y"?_  H_X3#2/^?O_P A
M/_A7[#_\,Z_"C_HF/@W_ ,$%I_\ &Z/^&=?A1_T3'P;_ .""T_\ C='UI]@]
MAYGX\?\ "8:1_P _?_D)_P#"C_A,-(_Y^_\ R$_^%?L/_P ,Z_"C_HF/@W_P
M06G_ ,;H_P"&=?A1_P!$Q\&_^""T_P#C='UI]@]AYGX\?\)AI'_/W_Y"?_"C
M_A,-(_Y^_P#R$_\ A7[#_P##.OPH_P"B8^#?_!!:?_&Z/^&=?A1_T3'P;_X(
M+3_XW1]:?8/8>9^/'_"8:1_S]_\ D)_\*/\ A,-(_P"?O_R$_P#A7[#_ /#.
MOPH_Z)CX-_\ !!:?_&Z/^&=?A1_T3'P;_P"""T_^-T?6GV#V'F?CQ_PF&D?\
M_?\ Y"?_  H_X3#2/^?O_P A/_A7[#_\,Z_"C_HF/@W_ ,$%I_\ &Z/^&=?A
M1_T3'P;_ .""T_\ C='UI]@]AYGX\?\ "8:1_P _?_D)_P#"C_A,-(_Y^_\
MR$_^%?L/_P ,Z_"C_HF/@W_P06G_ ,;H_P"&=?A1_P!$Q\&_^""T_P#C='UI
M]@]AYGX\?\)AI'_/W_Y"?_"C_A,-(_Y^_P#R$_\ A7[#_P##.OPH_P"B8^#?
M_!!:?_&Z/^&=?A1_T3'P;_X(+3_XW1]:?8/8>9^/'_"8:1_S]_\ D)_\*/\
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M>9^/'_"8:1_S]_\ D)_\*/\ A,-(_P"?O_R$_P#A7[#_ /#.OPH_Z)CX-_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P#Q[_Z$/_RL6'_Q^C_AW_\ 'O\ Z$/_ ,K%A_\ 'Z/:0[H.278^>:*^AO\
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M?H]I#N@Y)=CYYHKZ&_X=_P#Q[_Z$/_RL6'_Q^C_AW_\ 'O\ Z$/_ ,K%A_\
M'Z/:0[H.278^>:*^AO\ AW_\>_\ H0__ "L6'_Q^C_AW_P#'O_H0_P#RL6'_
M ,?H]I#N@Y)=CYYHKZ&_X=__ ![_ .A#_P#*Q8?_ !^C_AW_ /'O_H0__*Q8
M?_'Z/:0[H.278^>:*^AO^'?_ ,>_^A#_ /*Q8?\ Q^C_ (=__'O_ *$/_P K
M%A_\?H]I#N@Y)=CYYHKZ&_X=_P#Q[_Z$/_RL6'_Q^C_AW_\ 'O\ Z$/_ ,K%
MA_\ 'Z/:0[H.278^>:*^AO\ AW_\>_\ H0__ "L6'_Q^C_AW_P#'O_H0_P#R
ML6'_ ,?H]I#N@Y)=CYYHKZ&_X=__ ![_ .A#_P#*Q8?_ !^C_AW_ /'O_H0_
M_*Q8?_'Z/:0[H.278^>:*^AO^'?_ ,>_^A#_ /*Q8?\ Q^C_ (=__'O_ *$/
M_P K%A_\?H]I#N@Y)=CYYHKZ&_X=_P#Q[_Z$/_RL6'_Q^C_AW_\ 'O\ Z$/_
M ,K%A_\ 'Z/:0[H.278^>:*^AO\ AW_\>_\ H0__ "L6'_Q^C_AW_P#'O_H0
M_P#RL6'_ ,?H]I#N@Y)=CYYHKZ&_X=__ ![_ .A#_P#*Q8?_ !^C_AW_ /'O
M_H0__*Q8?_'Z/:0[H.278^>:*^AO^'?_ ,>_^A#_ /*Q8?\ Q^C_ (=__'O_
M *$/_P K%A_\?H]I#N@Y)=CYYHKZ&_X=_P#Q[_Z$/_RL6'_Q^C_AW_\ 'O\
MZ$/_ ,K%A_\ 'Z/:0[H.278^>:*^AO\ AW_\>_\ H0__ "L6'_Q^C_AW_P#'
MO_H0_P#RL6'_ ,?H]I#N@Y)=CYYHKZ&_X=__ ![_ .A#_P#*Q8?_ !^C_AW_
M /'O_H0__*Q8?_'Z/:0[H.278^>:*^AO^'?_ ,>_^A#_ /*Q8?\ Q^C_ (=_
M_'O_ *$/_P K%A_\?H]I#N@Y)=CYYHKZ&_X=_P#Q[_Z$/_RL6'_Q^C_AW_\
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M#2R)$IBP"[ #J/6LC79%DUF]9&#*96(93D'F@"A1110 4444 %%%% !1110
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M*:.4AVSL8'' ]*XR@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH [GX>_\>=W_P!=!_*N&KM/ =W!;V=T)9HX
MB7& [ 9X]ZXN@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH M:7_R$[3_ *[)_P"A"NF^(G^NL?\ =?\ F*YC
M36"ZE:DG $J$D_45T?CZZAN)K/RI4EVJV=C XY'I0!R=%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% $UO>7%GN,$\D!;KY;E<_E4_]M:C_ ,_]U_W^;_&J5% %W^VM1_Y_[K_O
M\W^-']M:C_S_ -U_W^;_ !JE10!=_MK4?^?^Z_[_ #?XT?VUJ/\ S_W7_?YO
M\:I44 7?[:U'_G_NO^_S?XT?VUJ/_/\ W7_?YO\ &J5% %W^VM1_Y_[K_O\
M-_C1_;6H_P#/_=?]_F_QJE10!=_MK4?^?^Z_[_-_C1_;6H_\_P#=?]_F_P :
MI44 7?[:U'_G_NO^_P W^-']M:C_ ,_]U_W^;_&J5% %W^VM1_Y_[K_O\W^-
M']M:C_S_ -U_W^;_ !JE10!=_MK4?^?^Z_[_ #?XT?VUJ/\ S_W7_?YO\:I4
M4 7?[:U'_G_NO^_S?XT?VUJ/_/\ W7_?YO\ &J5% %W^VM1_Y_[K_O\ -_C1
M_;6H_P#/_=?]_F_QJE10!=_MK4?^?^Z_[_-_C1_;6H_\_P#=?]_F_P :I44
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MS.BO3/\ A#](_P"?3_R*_P#C1_PA^D?\^G_D5_\ &@#S.BO3/^$/TC_GT_\
M(K_XT?\ "'Z1_P ^G_D5_P#&@#S.BO3/^$/TC_GT_P#(K_XT?\(?I'_/I_Y%
M?_&@#S.BO3/^$/TC_GT_\BO_ (T?\(?I'_/I_P"17_QH \SHKTS_ (0_2/\
MGT_\BO\ XT?\(?I'_/I_Y%?_ !H \SHKTS_A#](_Y]/_ "*_^-'_  A^D?\
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M\(?I'_/I_P"17_QH \SHKTS_ (0_2/\ GT_\BO\ XT?\(?I'_/I_Y%?_ !H
M\SHKTS_A#](_Y]/_ "*_^-'_  A^D?\ /I_Y%?\ QH \SHKTS_A#](_Y]/\
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M_"'Z1_SZ?^17_P : /,Z*],_X0_2/^?3_P BO_C1_P (?I'_ #Z?^17_ ,:
M/,Z*],_X0_2/^?3_ ,BO_C1_PA^D?\^G_D5_\: /,Z*],_X0_2/^?3_R*_\
MC1_PA^D?\^G_ )%?_&@#S.BO3/\ A#](_P"?3_R*_P#C1_PA^D?\^G_D5_\
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M]/\ R*_^-'_"'Z1_SZ?^17_QH \SHKTS_A#](_Y]/_(K_P"-'_"'Z1_SZ?\
MD5_\: /,Z*],_P"$/TC_ )]/_(K_ .-'_"'Z1_SZ?^17_P : /,Z*],_X0_2
M/^?3_P BO_C1_P (?I'_ #Z?^17_ ,: /,Z*],_X0_2/^?3_ ,BO_C1_PA^D
M?\^G_D5_\: /,Z*],_X0_2/^?3_R*_\ C1_PA^D?\^G_ )%?_&@#S.BO3/\
MA#](_P"?3_R*_P#C1_PA^D?\^G_D5_\ &@#S.BO3/^$/TC_GT_\ (K_XT?\
M"'Z1_P ^G_D5_P#&@#S.BO3/^$/TC_GT_P#(K_XT?\(?I'_/I_Y%?_&@#S.B
MO3/^$/TC_GT_\BO_ (T?\(?I'_/I_P"17_QH \SHKTS_ (0_2/\ GT_\BO\
MXT?\(?I'_/I_Y%?_ !H \SHKTS_A#](_Y]/_ "*_^-'_  A^D?\ /I_Y%?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK@_C)\
M9-%^!_A>VUW7;:_NK.XO%LE33XT>0.R.X)#NHQB-N^<D<5K2I3K35.FKM[(Q
MK5J>'INK5=HK=G>45\O_ /#PSX<_] ;Q1_X"VW_R11_P\,^'/_0&\4?^ MM_
M\D5ZW]BYC_SY9XG^L&5?]!$3Z@HKY?\ ^'AGPY_Z WBC_P !;;_Y(H_X>&?#
MG_H#>*/_  %MO_DBE_8N8_\ /EA_K!E7_01$^H**^7_^'AGPY_Z WBC_ ,!;
M;_Y(H_X>&?#G_H#>*/\ P%MO_DBC^Q<Q_P"?+#_6#*O^@B)]045\O_\ #PSX
M<_\ 0&\4?^ MM_\ )%'_  \,^'/_ $!O%'_@+;?_ "11_8N8_P#/EA_K!E7_
M $$1/J"BBBO%/H0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BD9@O4XI-P]: '44W</6C</6@!U%-W#UHW#UH =13=P]:7</6@!:*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)KFO:R7_ )&-'U/GN(/^15B/\)^>5%&:3</6OW8_G 6BDW#UHW#UH 6BBB@
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MXF]^-/@C3OBII_PUN?$=G%XYU"T:^MM%;=YTL*AB6!QMSA'.TG.%)Q@9KMJ
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M=3$1OG:VZ.)EYP>^:Y?3_P#@H_\ LW:I<+##\4].1V( -Q9W<"\^K/" /Q-
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MX/\ A9J'A>Q\4ZRNE77B;4H](TB-H)9/M5VY 2,%%8+DL.6P.>M=E0 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ/ :>-0%R>3C$3X4XC:@#[IN+S1O!ND6ZSSV.AZ7;JMO"LCI;P1J!A47.%
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M2J@ 'U]8_'KX9ZGK:Z-9_$3PG=ZPQVC3X-;M7N"<XQY8?=U]J^:?@7<1VO\
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MSN /T-TCXY_#?Q!KBZ+I?Q!\*ZEK#-L73[/6K:6X+>@C5RV?;%=Q7RC\1O\
M@F1\ _&?@F]T;2/!EMX3U1H6%CK6FRS>?:S8^1R"^) #C*OG([@X(SO^";GQ
M7\5^*OA_XT^'?CR_;5O%_P -==E\/W&H2.SO<0J66,L[<L0T<JACR55,\Y-
M'U#JOC[PQH7A[^WM2\1Z3I^A9*_VG=7T45MD$@CS68+G((Z]0:B\&?$CPE\1
MK66Y\)^*=%\46T) DFT74(;M$)Z F-F _&OS>_X)O_LHZ#\</AV?&7Q-N9/&
M?A_1]4O=/\.>$KYV;3]/)E\R>=HL[7=W<\$$ #)W';LVOV]/@;!^RA<^$?B]
M\!YX?A?K5_J \+ZI#I,*K:2Q7*.4E,)!0;#'R O4HP 9,T ?>_B;XT_#WP3K
M TGQ%X[\,Z#JK $6.IZQ;VTY!Z'8[AN?I776MU#>V\5Q;RQSP2J'CEB8,KJ1
MD$$<$$=Z^6_!O_!-CX):3X+_ +,\4^&E\=>(KQ3+JWB?6)YFOKVY?F28.'S'
MEB2 I],ECECYW^P;9:G\ _VB/C1^SM/K-WJ_AG05M]=\-K>/O>WM9MK.@.!_
MSVA!  7>KL -QH ^M[[P%X!NOBQI_BJZTG17^(=M8M!::A(J?;TM3N#!/XMO
MS.,X_B89Y-=9JFJV6AZ?<7^HWEOI]C;H9)KJZE6.*-1U9F8@ >YKX[\;_P#*
M6#X>?]DXN/\ TINJX?\ ;\DT/Q?^UE\"? /Q2U>72/@SJ,-U>7:FZ-M;7=^F
M\(DT@(VJ#Y"[L_*)FP5R6 !]D^'_ (_?##Q9JRZ7HGQ'\):QJ;R");.PURUG
MF9R<!0B2$DD]L5V>J:K9:'I]Q?ZC>6^GV-NADFNKJ58XHU'5F9B ![FO%O#_
M .Q3\!]$USP_XCT/X<:'8ZEH\T5[IM_8;XRDB$-')E6Q)@X(W;NU?-G[?DFA
M^+_VLO@3X!^*6KRZ1\&=1ANKR[4W1MK:[OTWA$FD!&U0?(7=GY1,V"N2P /L
MGP_\?OAAXLU9=+T3XC^$M8U-Y!$MG8:Y:SS,Y. H1)"22>V*G\:^ O /BCQ=
MX3U;Q3I.BWWB/2;AI=!N-15#<0R_*6,&[DD%4/&<$*>N*X+P_P#L4_ ?1-<\
M/^(]#^'&AV.I:/-%>Z;?V&^,I(A#1R95L28."-V[M7DG[:/_ "=Q^R#_ -A_
M5/\ T7:T ?9U<+JWQX^&F@ZNVE:G\1/"FG:HK%&L;O6[:*<,.H*,X;/MBOE[
M]MOQIXQ^+'QL\ _LS^!-:G\,GQ-:OJ_BC6[0D30:8I=?+4CIN\J3(R-Q,:DA
M6;/H'AS_ ()M?L[>'O"J:&WPZL]67R]DNH:E/-)>2G&"YE# JQZ_)M [ 4 ?
M2UK=0WMO%<6\L<\$JAXY8F#*ZD9!!'!!]:CGU*TM;RUM)KJ&&ZNMWV>"20*\
MVT9;8I.6P.3CH*_/KX?:'K/_  3^_:_\)_#6PUB^U3X(_$PS1Z39:A*96TG4
M%Q\B'_?:)>VY9@6RT>3J?\%,/#_B/Q=\7_V:M \)^(I?">OZMJNK:?;ZU 6#
MVBS16T<CKM(.?+=QP0>>HZ@ ^PO$?QT^&W@_5FTK7OB#X5T34U.&LM2UJVMY
M@?0H[AOTKL;*]M]2LX;JTGBNK69!)%/"X='4C(96'!!'<5\Q>!?^":?P!\(^
M$TTC4/!,'BN^DCQ>:UK4TDMW<R'[TFX,/+)/:/;CZY)X#]AFVO\ X$_M$?&C
M]G?^U+C4O"7A\6VN^&H[MM[VMM< /)&&QR 9H@1TW*[ ?,: /N.BBB@ HHHH
M **** /._P!H;_DB/C7_ +!5Q_Z :_&__@E3_P G*:7_ +Y_]!-?LA^T-_R1
M'QK_ -@JX_\ 0#7XX_\ !*==W[2NF<X^9C_XZ: /W1I:_,']M3_@HQXZ^#?Q
MRLO#NB:5)INC6,J274=[!B2X0-AMA]QFON+]GK]I3PG^T+\.[;Q-HU]%&?*#
MW=K)(/,MFQR'':@#UF:9+>-I)76.-1EF8X %?EI_P40_X*+FWFO?AS\-[S=,
M,PW^J0-AHW!P8QZYS2_\%&/^"B0MUOOAM\.;Y7D=3%J.J0D,A0C&U&'1@:\K
M_P""??\ P3]U#XRZU#X]^($$\/AN&02107!*S7;_ 'E<$]5R.: /4_\ @DQ\
M#_B5I6I7GCO4+^[TKPMJ(R+=^1>D$Y!!Z<U\I?M;D-^V8"!@?VU%@?\ ;<5^
M^&DZ39Z'I\%C86T=I:0($CAA0*J@#T%?@=^UI_R>0G_89B_]'B@#]X?!7_(J
MZ7_U[I_Z"*\=_;X_Y,X^+/\ V!)/_0EKV+P5_P BKI?_ %[I_P"@BO'?V^/^
M3./BS_V!)/\ T): '?LH_#GPG??LO_"*YN?"^BW%Q-X1TF22:73X6=V-G$2S
M$KDDGG)KV31O!^@^')I)M)T33M+FD78\EG:1PLRYS@E0,C-?"'[/O[3G[0'A
M_P" _P .=+T3]EJ_\1:/9>'=/MK+6$\66\"WT*6T:QSB,PDH'4!MI)QG&:^L
M/V?OB=\0/B=HNJW?Q ^%MQ\+;VUN%BMK.XU:/4#=1E<F0,B+MP>,$4 ?.&FZ
M#IGB+_@K/XPMM6TZTU.V7X;1R+#>0+,@875J P# C."1GW-?5'B#X _#'Q9;
M^1K7P[\*ZK%C 6\T6VEQ],IQ^%?,WA7_ )2X^,O^R9Q_^E5I7VM0!^9'[2'P
M2O/^"<OC?1OCI\%C?VW@:XU!+3Q;X2,[26@A=L(5!Y"$EE4L28Y&3:<,5'Z4
M:!KEGXFT+3M8TZ47&GZA;1W=M,!C?%(H=&_$$&O!/^"AVFVVJ?L6_%6&[(6)
M=,6=<_\ /2.>*2/_ ,?5:Z?]C>2YD_9/^#[70(E_X1730,G)V?9TV'_OG;0!
MX3_P4LUZ^\=6/PT^ .@W#1ZQ\2-=ACO6CY,.G0.KRNP] VQ_<0O6?_P3MO9O
M@U\2/C-^SCJ<SEO">KMK&@^<V7DTVX*XQ[ - Y_VIVJ/]G1O^&DOV_OBM\6Y
M/])\-> 8!X/\.R'E#-EA/*A[_P#+<_[MRM0?MI-_PSG^UU\%/C]#_H^A:A,?
M"/B>0<)Y,FXQR/ZD(TK_ /;LE 'WI124M 'QA_P40_Y'G]ES_LJ&E_\ HU*^
MQM1U*TT>SDO+^ZALK2/&^>XD$<:Y( RQ.!R0/QKXY_X*(?\ (\_LN?\ 94-+
M_P#1J5V/_!3#_DQWXH?]>]E_Z7V] 'O'C+XG>#OAVL+>*_%FA^&%F_U3:SJ4
M-H'_ -WS&&?PJ[X5\9^'_'6EC4O#6NZ;XATXL4%YI5Y'<PEAU&^,D9_&OCO]
MF[_@GOX'UCPCIOCWXPF3XM^/_$5I#?W%_KDTDEO;))&K)#%$6P0JD#<P/3Y0
MHXKEM<^&.E_L1?MP_">Y^'0?0? 7Q1>?1-9\.QR-);"YC5?)D0,25R\T9'/&
M) ,*Y% 'Z#5PM]\>/AGI>N?V->?$3PI::QO,?]GSZW;)<;AU7RR^[/MBOEW]
MMOQ/XO\ C'\;_ /[,_@K6[CPS!XBLY-:\5:Q9DB:+3%+KY0(Z!_+D!'\1,0.
M%+9[_P ._P#!-?\ 9T\/^%TT1OAU:ZJNP)+?ZA<S27<I[N90X*$_[&T>@% '
M&>(Y$F_X*S>#I(V62-_A:[*RG((-[=8(-?37C7P%X!\4>+O">K>*=)T6^\1Z
M3<-+H-QJ*H;B&7Y2Q@W<D@JAXS@A3UQ7PK\'_@+9?LY_\%.M$\*:/KNJZQX>
M?P%<7NEVNK3F9M+MWNI5^R1N3S&KI(Z\#_6'.3ECZE^VC_R=Q^R#_P!A_5/_
M $7:T ?9U<#JW[0/PNT#4VTW4_B3X1T[458HUI=Z[:Q2AAU!1I <^V*^6/VW
MO$WB_P"-'QX\ ?LR>#=;N/#-EX@LWUKQ5JUF2)5TY3(OE CLPBDRO1F>('"E
ML^F^%_\ @F[^SMX7\.QZ2/AQ8ZMA DE]JDTL]U*<<L7W#:3_ + 4#L!0!]'Z
M;J=GK-C!>Z?=P7UE.N^*XMI%DCD4]U8$@CW%<+JO[1GPHT&X-OJ7Q/\ !NG3
M@[3%=>(+2)L^F&D!S5GX,_!/PA^S_P""(_"7@C3#I.AQW$UTL#3/,WF2-N8E
MW)8XX49)X4"O-8OV$OV=-)9UD^&'ATR7CM\U\'F=V8Y.UI')SSVH ]TT'Q%I
M7BG3(M2T74[/5].ESY=W87"3Q/C@X=20?SKY _X*/?$&PT_PK\*+;3O$MO;7
MT/Q,T=;R&UOU25(@EQO$@5LA0<9W<=,USWP^^&=E^QW^WSX=\&>!YKBP^'7Q
M.T6]N#X?EF>6"TO[5&E9XMQ)'R*!SGAV'0+CF/\ @H]^R[\+M&A\!^+;+PC;
M6_B+Q5\2=-LM9OEGFW7D-P+AIT8%]HW%5.5 /'&* /O[2_%?A[Q1)+::=K&F
M:L_EDR06MU',=G0DJI/'('/K6+\)_ _@3X?^%6TWX=Z7H^D^'WN9)VAT0)Y#
M3' =B5)!;Y5'L% Z 5R_PA_9.^$WP%\07>N> O!EKX<U6ZM3937,%Q/(SPEU
M<IB1V&-R(>!GBO"O^"3<B0_LAI)(P1$U[4F9FZ !QDT ?86M:[IOAO39M1U?
M4+72]/A&9;J]F6&)!_M.Q 'XFN<\*_&7P!XZU V'AOQSX;\0WPSFUTK5[>YE
M&.ORHY/%?"'P0^%G_#R;Q]XD^+WQ4N;Z]^%NEZK+IOA#P='<206SI'C=<2[2
M"205R006?>"0J!3[9\7/^"9OP7\=^%98/"WAR+X>^*;9?,TS7M"DDB>WF7E&
M= VUUR!G(W8SM93S0!]:5B:AXW\.:3X?.NWNOZ79Z&,@ZG<7D:6PP2#^]+;>
MH(Z]0:^;?^">?QR\5_%#X<>)?"/Q#D:?X@_#[5Y- U6YD.Y[E5)$<KG'+Y21
M"?XO+#'EC7R?_P $^/V,](_:,\!Q^+_BCK%]XG\'Z+J=[8Z!X,^TRQV=L_FF
M2::3:PR6>0_*,9_B+#"@ _3'P;\7/ OQ$N9K?PIXT\/>)[B%=TL6C:K!=NB^
MK"-R0/K765^>G[<G[*/A#]GOX81?&[X,Z3#\/_&_@:\M[Q9-)++#=0/*D+I)
M$25/^L!/3<N]6W!N/O+P7XDA\9>#=!\06XVP:M807\8]%EC5Q^C4 ;-%%% !
M1110!XQKW[0-QHNNZCIZZ+'*+2YD@$AN"-VUBN<;>,XJA_PTI<_] &+_ ,"3
M_P#$UYGXZ_Y';Q#_ -A&X_\ 1K5AU[<</2:3L>8ZT[[GJGB;X\7'B30;W3&T
M>.!;J/RS()RQ7GKC;7FVE:K=Z)J$%]8SM;W4+;DD7J/\1[=ZJ45M&G&"M%&4
MIRD[MGU3\-?B5:>/-/VMMM]5A7]_;YX/^VGJO\OR)[6OBS2M5N]$U""^L9VM
M[J%MR2+U'^(]N]?4WPU\=#QYH/VIK=K>ZA;RIQM/EEL9RA[CVZC\B?+Q%#V?
MO1V.^C5Y_=>YUM%%%<1TGQ3_ ,%$_P#DHW[*_P#V4S3O_1T5?:U?%/\ P43_
M .2C?LK_ /93-._]'15]K4 %>>:K^T9\*-!N#;ZE\3_!NG3@[3%=>(+2)L^F
M&D!S7H=?/<7["7[.FDLZR?##PZ9+QV^:^#S.[,<G:TCDYY[4 >Z:#XBTKQ3I
MD6I:+J=GJ^G2Y\N[L+A)XGQP<.I(/YU+<:M8VM_;6,UY;PWMT&,%M)*JR2[1
MEMBDY; Y..E?#7P^^&=E^QW^WSX=\&>!YKBP^'7Q.T6]N#X?EF>6"TO[5&E9
MXMQ)'R*!SGAV'0+CH_VC/^4C'[+/_7IKW_I&] 'V;5.#6+"ZU"YL(;VWFOK4
M*9[6.56EB##*EE!RN1R,]:N5\9?L_P#_ "DH_:@_[!V@?^D4- 'V)_:5I_:/
M]G_:H?M_E>?]E\P>;Y>=N_;G.W/&>F:XN[^/_P +[#6CH]S\2/"-OJP?RC83
M:[:K/O\ [OEF3=GVQ7Q#^V9\+=>^-O\ P4%\!^!=%\6WG@RVUKP(\.K7^GL1
M-+8+>7$DL"X[N8T')QZY'RGWV/\ X)J_L[0^"9/#:_#VVVO"8CJK7$K7X8C'
MFB8MD-DYQ]W/\..* /IU6#*&4@J1D$=#5#7?$&E^%]-EU'6=2L](T^+_ %EW
M?3I#$F>F78@#\Z^1?^";_B[7-(\'_$WX5^*-7?5YOA=XDGT2TO9_O?V>NX0@
MGJ5!BE*YZ*57HH%>0? +X.K_ ,%(O''B7XS_ !<N;_4?AW9:I-IOA'P?'<R0
M6PACQF63:0>05!*D%G#Y.U56@#[Q\-_'3X;^,M473- ^(/A77-19MJV>FZU;
M7$Q/H$1R<_A7S3^VG_R=G^R%_P!C#J7_ *!:UZ'??\$]/V>[R[TJ[B^&NFZ?
M=:9=17<$MA)+"2T;A@'"OB13C!# Y%>$?\%.O!^N_$#XP?LS^&_#6NOX8UO5
M-6U2TM]8C+![0NEH&D7:0VX+NQ@@YQR.H /LKQ%\=/AMX/U9M*U[X@^%=$U-
M3M:RU'6K:WF!]"CN&_2NRL[VWU*TANK2>.ZM9D$D4T+AT=2,AE8<$$=Q7S#X
M&_X)I_ 'PCX332-0\$P>*KZ2/%YK6M322W=S(?O2;@P\LD]H]N/KDG@?V&;>
M_P#@3^T1\:/V=SJMQJ7A/P\+;7?#4=VV][6VN 'DCW8Y ,T0(Z;E=@/F- 'W
M%116?X@UZP\*Z#J6M:I<+9Z9IMM)>75Q)]V**-"[L?8*"?PH ^+_ -K?_C)#
M]K#X2_ &W_TCP]H[_P#":>+D7E##%E;>!_9B2I'_ $\1GM7W!7QA_P $Z=!O
M_B GQ&_:%\0V[1:U\2=8D.G1S<M;:5;L8X(P>PRI7W$,9K[/H ^2?^"@WQO\
M6^"_#O@[X8?#:8VWQ&^).H?V387D<IC>QMP4$TP8<H?WB+O_ (078<J*[#]G
M']AOX8_L[Z#:BVT*T\2>+67S+[Q1K%NEQ>3S-]]D9@?*0G.%7'&-Q8Y)\H^*
MJ)J7_!6/X-6]VH,%CX)O+RUW#(,S&]1L>X4 U]NT 8^O>#]!\4Z<VGZUHFFZ
MO8,NUK6_M(YXB/0JP(Q6I;V\5I;Q001)#!$H2..-0JHH&  !T ':I*\J_:E^
M-B?L[_ /QCX_\F.ZN=*M +.WESLDN9'6*%6QSM\QU)QV!H [3Q=\1/"OP_MX
MY_%'B;1_#<$F=DNKW\5JK8ZX,C '%/\ "7C[PQX^M)+KPQXCTGQ':QD!YM)O
MHKI%)Z M&Q KXQ_9E_8'\/\ C[PM8?%/X^Q7'Q)^)/BFWCU*=-9G<V^GQ2*'
MC@6)2%)5"N01M4_*H 7)R?VK_P!B72_@=X9O/C9^SXL_P^\;>$8FU&ZL=-F<
MVFH6B#=.K1,2!A 6VCY6"L"I)! !]\ZCJ5IH]G)>7]U#96D>-]Q<2".-,D 9
M8G Y('XUSWC/XK>"?APT">+?&.@>%VN!F%=:U2"T,G./E\QESSZ5\E_M8?%F
MW^.?_!+77_'EO"ML-<T?3KF6W4DK#-]NMUFC!/4+(KJ#W S6[^S?^PWX#O?A
MYI?B_P"*=A;_ !8^(/B6R@O]1UOQ*ANPBR1J4@A23*HD:D*" "<'H-JJ ?66
MB^(-+\2:3!JFD:E::KIDZ[XKRRG6:&1?574D$?0UR^F_'+X<:UX@&A:?\0/"
MU_KAD\H:9;:U;27._P#N^4KEL^V*_.CQA^S5J?@G]L9/V=O!OC;5/!WP8^(U
MD/$NH:)8N252(2K/:0NV602>3@D$ HRA@^P _2_Q4_X)C_ _QA\-+W0O#7@Z
MU\)Z]%:L-+UJQFE$\,ZC,;2LS-YJE@ V_)()P0<$ 'UO65=>*]$L=-O]0N=8
MT^WL-/=H[RZEND6*V=<;ED8G"$9&02,9%?.?_!-WXM:W\7/V5]"N?$UY-J/B
M+1+NYT.^NKEBTLC0OF,NQY9A$\0+'DD$GDFOFG]GG]FNQ_:*_:>_:#;QQJEU
MJ?P[\.^/KZZ3P8LSI:7NHR2.HN)PI&X(D:@+W)YP,AP#]"_!OQ<\"_$:XG@\
M)^-/#WB>> ;I8M&U6"[:,9QEA&[$<^M+XQ^+'@?X=W$$'BOQEX?\,SW W0QZ
MQJD%HT@]5$CC/X5\5?MX_LP^%O@;\*T^-GP<TJS^&_CKP+<V]U'<:#;K!'=6
M\DJPO')$/D;'F!B2#N4.I!#<=M\ ?V$_AQXN^&^G>-?BG8K\5?'OC"SAU?5-
M?UIY&.9HU=8H$# 1HBL%! !X[#:J@'U[H^M:?XBTVWU'2K^VU/3[A=\-W9S+
M+%(OJKJ2"/H:GN[R#3[66YNIH[:WA4O)-,X5$4<DDG@ >M? ?P#\$G]CG]O[
M4/A#X?U&[/PS\=^'Y->TK1[F9I5LKN-FW*I;N%AF&>I1HMQ8H#4WQFT.^_;<
M_;4U+X,:GJE[8_"/X>Z?;ZCKUA83M"=5O951XXW8=5 =1_L^7+@AF! !]<:7
M^T9\)]:UB/2=.^)_@V_U21Q&EE;:_:23,QZ*$60DGV KT2OFGQ;_ ,$Y?V?/
M%/@VZ\/Q_#K3=%,D3)#J>F;XKRW<C"R++DEB#SA]RG'((KCO^"=?C+Q5IT/Q
M1^"WC'59M?U/X7ZRFG6>JW&?,N+"7S/L^<DG $+$9)PKJN<** /K.X\4:-:V
M-[>S:O8PV=E(T-U<27*+'!(,91V)PK#(R#SR*I^#_B'X5^(5O<W'A7Q-H_B:
M"UD\F>71[^*[6)^NUS&Q"GV/-?FG\$?V3[+]J;]I+]H&/QQK^I2_#CP[\0-1
MN5\)6=T\,5[?RRNIFE*X( CC5?E.XYX*C.[ZT^*EOX%_X)^_LO\ C[Q-\.O"
M]GH0MXUFAM$:21)[Z4I;PLY=BS ,R$C/13]: /=?%_Q(\)?#Z**7Q3XHT7PU
M'*"8WUC4(;0.!UP9&&:;X/\ B9X/^(B2OX5\5Z'XF2( R-H^HPW80'H3Y;'%
M?&G[,7_!/CPMXP\(Z=\3/CM#=?$GXD^*+>/4[K^VKF1H;)95#)"(P0&94*@[
MLJI&U  .?H7X>?L9_!WX3?$J+QWX/\%VOA[Q#':2V:R6<THA"28W,(BQ0-@%
M=P X8B@#M?A[X"\ ^#=6\4W?@S2=%TW4=5OC/KDFE*@DFNLL29MO1@6<X/0L
MQQR:T?%OQ,\'^ 61?$_BO0_#C2+O0:MJ,-J67)&X>8PR,@\^U?*W[ /_ "5S
M]JW_ +*/>?\ HR6O>OBI^S#\*OC1XDLO$?COP;I_B35+"U^R07%^\A6.$,S[
M=@8(1N9CDC/- '2^#?C!X#^(ER]OX4\;>'/$]Q&"SQ:-JUO=NH'4D1N2,5A_
MM.?\FV?%C_L4M6_](Y:^4_VROV-?AWX%^#.J?%GX1:5;^ ?'/@M!K-CJ7AUV
MBCE2)@94=%.T_(&.0,Y&#D$@_0?Q&\8-\0_V&_%'BID6-M<^'-UJ96,$*#-I
MC28&>WS4 <_^Q;H^C^(/V$?AWIGB&VM;S0KOPX8;ZWO@#!) Q<.'SQMVYSFO
M;/!>C^$/A[X"L+'PQ%I>B>#["$FV6R9$M(HRQ9F# [<%BQ)SR22:^6_A'_RB
M@;_LF^I_^DMQ79?L9^#=&^(7[!?P[\-^(;!-3T34_#_V:\LY&95EC9WRI*D$
M?@: /<O^%I>#/^ANT'_P9P__ !526_Q*\(W=Q%!!XJT6:>5@D<<>HPLSL3@
M -R2>U> Z]_P3_\ V7?"VAW^L:O\.='T[2K"![FZO+B^NDCAB12S.Q,W  !-
M?+O[(_[)?@;]H+X^3?&G1/ \?@OX.>'KE8O"FE;IO,UNYA<D7LOF.Q"*_.T8
M!*JISL?< ?I1XI\<^&_ UM'<>)/$&E^'[>0D)+JE[';(^,9P78 XR/SK#\+_
M !T^&WCC5%TWPY\0O"NOZBQP+/2]:MKF8G&<;$<GI[53^+G[/GP\^/ T<>/_
M  O:^)DTAY)+)+MY L32!0YPK -D(OWL]*\ ^/G_  3Y^#'C#X5Z]<>"/"VG
M^$/%NEVLMWI.L^'6:"2&ZB4N@;8V&!8 '/(SD$$ T ?6VK:UIV@VOVK4[^UT
MZVW!/.NYEB3<>@RQ SP:^-_V&?B=I \:?M)?VOXLLA$?B5J9LOMNI)M\C>=O
ME;F^YZ;>*[3X Z;X?_;8_8Q^'%W\4M*B\5QW5N);I;B22/S;NVDEMC,2C*=Q
M*.3SC+'BOG+]C?\ 8P^"_P 2/%WQ_M/$G@2TU6W\._$'4-'TJ.2ZN%%K:1N0
MD0VR#( [MD^] 'WIXM\%?#SQIXF\':[XBTW0]5UW3I3<^';V\\MYHY#M8O;D
MGYCPC?+G!"GT-=U7Q#^U=X?T_P )?M+_ +%NAZ1:K9:5IFJW]E9VR$E8H8X+
M1(T!))("J!R<\5TW_!03XR>,O#&E^ OA7\-KQM,\>_$O5#I=MJ<;%7L+5"@G
ME5ARA_>I\PY5?,(^8 @ ^A?$_P :?A[X)U+^SO$7COPSH.H9 ^R:IK%O;2Y/
M3Y'<'GZ5T^D:Q8>(-.@U#2[ZVU*PG7=%=6<RRQ2#U5E)!'TKYB^&O_!-'X$>
M!?#,=CJ_A*'QMK,BYOM<UZ22:>ZE/WG W;8P3G 49]23R?!OB)\.YO\ @FG\
M<O!/C;X?7U]#\%?&&KQZ-XC\,7-P\\%C+)]V:(L2>%#NI)+9B92Q5\  _1F]
MU*TTWR/M=U#:^?*L$7G2!/,D;[J+D\L>P')KF?%_QB\!?#Z\2T\4^-_#GAJ[
M<;E@UC5K>T=AZA9'!(KY7_X*Q2:I#\!? SZ)>'3M:7QYI9L;P'!@G$=R8Y,X
M/W6P>AZ5T7PG_P"":?PC\(Z"TOCG21\4/&E]F75O$?B&265[F9N6*(7(09)P
M>7]6- 'U-H>OZ9XGTN#4]&U&TU;3;@;H;RQG6:&0>JNI((^AJ_7P3\#_  BG
M[(G[?FH_"/PS=3P_#/QYX??Q%IVB32-*EC?1LRN(V;D#9#+W.5:,$DH#7WM0
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !114%U?6UC&7N;B*W0=6E<*/S- $]%<=JGQD\!:+N%]XTT&V9>JOJ4.X?
MANS7'ZI^UW\(M))$OC6TE8=K6&:;/XHA%;1H59_#!OY'/+$T:?QS2^:/8:*^
M=M2_;P^%]GG[-)K.IGM]ETYAG_OLK7-WW_!0KPLF?L/A#Q'=GMYD4<8_1C71
M' XJ6U-_<<LLRP<=ZJ^^_P"1]6T5\97W_!11@"+3X<:@Q[&:\Q^@CKGK[_@H
MAXLY-KX!MHAV\^25OY 5LLKQ;^Q^*_S.>6<X".]3\'_D?=U%?GE>?\%#/B(V
M=GAO1[8=OW,QQ^;5B77_  4#^)LA.R/2[?V6US_,FM5D^,?V?Q1B\^P"^W^#
M_P C]***_,>;]O3XK2?=O[&/_=LH_P"HJ _MU?%@]=7M?PLXO_B:O^QL7V7W
MF?\ K!@/YG]S/T_HK\P5_;J^*J]=5MS_ -ND7_Q-7+?]O;XG0X\R[MYOK;Q#
M_P!DJ7D^,7V?Q12S_ /[;^YGZ945^<MC_P %"O'<!'GV=A./]N$?^R[:Z?2?
M^"CFKJRC4/#UC*.YB1T_7>?Y5C+*\9'>G^1T1SG 3VJK\5^:/O.BODO0?^"A
MGA>^95U#1)K3U:&Y#?HZJ/UKUCPK^U/\.O%2QA-9_LZ1^ M]&5'_ 'VN4'XM
M7#4HU:7\2+7JCTJ6(HUOX4U+T=SURBJVGZE::M:I<V-U#>6S\K-;R!T/T(.*
MLUB= 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^>'_!1#P+XE
M\3_&K1;K1_#VJZM:IX?@B::QLI9D5Q<W)*EE4C."#CW%?+O_  J+QU_T)7B+
M_P %4_\ \17[8T5[]#-I4*<::A>QXM;+(UJCJ.5KGXG?\*B\=?\ 0E>(O_!5
M/_\ $57U#X9^+](LIKR^\*:W96<*[I;BXTZ:.-!ZLQ7 'UK]N:\E_:Q_Y-Q\
M??\ 8-;_ -"6NNGG,ZDXPY-WW.6IE,80<N?9'X]U]I?L:_L:GQ4UEX[\=V17
M101-IFCSKS>=UEE4_P#++N%/W^I^7[Q^QK^QJ?%367COQW9%=%!$VF:/.O-Y
MW6653_RR[A3]_J?E^]^A:J$4*H"J!@ =!59EF7+>C1>O5_HB<!@.:U:LM.B!
M5"*%4!5 P .@I:**^3/ICXO_ ."H7@W7/^%6>#?BGX8MI+K6_AGXAM]>,<?:
MV!'FM@=@Z0L?10Y/ -?3GP=^+GASXY_#G1?&GA6^CO=)U.!9 %8%[>3 WPR
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M)!ZAQ7TO7Q9XR_X)WZCX9^)6J>//@)\4=2^#VJZK(9M0TF*U%WIL[DEB1$6
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MDDDDDFOF+XB?L>>/]'^.6O\ Q/\ @?\ $Z'X?7_BB.,>(-(U+31>VEW*G F
M8D!L'IMR"7(8!R* ,;]J2=-#_P""@'[*&J79\NSN#K=BDGK*]LJ*OXM,@_&O
MM&O _C9^RO%^T=\&_#7AOQSX@F@\;Z((+VV\7Z'$+>6WU%$ :>)/X49OF* C
MHN""H(\S;]E_]I_4]-_X1_4OVJ&CT$)Y37UCX5@BU*5,8(\T.&1L?QARV>>:
M .;_ &7_ !MI/B;_ (*4_M.BPNDN#)9Z?$AC.03:1PVT_/\ LR?+3_@'X@M_
M /\ P4S_ &@?">LRK;W_ (MLM.U32&FX-TD, +)&>Y D?CTA;^Z:ZKX:?\$]
M]*^!7QY^'WCCX=:[)I.E:/H]WIGB&WO@9[K76D9G621QM&XNY9F[>1$ I'3M
M?VK?V+/#G[3TVC:XFM:AX)\?:%QI?BK2,^?"NXL$=0REU#$L,,K*2<,,D$ ^
MBJ^"/V3/B)I/CS_@H]^TU=:=<Q7$<UI8P0O"X=)!9K%:R,&'!&]1T]:Z!OV4
M?VH?$&DS>&O$/[4C'PS<)Y,\FG^&X([^2(C#*)QM=21QNWD_7I6_\+?^"?.@
M_ 7XY?#SQG\.M6;1-'T/0KO2-=LYU,MQKC2,6CDD<8&=[EF../(A55P/E .-
M_;OMY?V?OCS\'_VDM.C9;#3[P>&?%0B4G?83;MCL!UVAIN3_ !>2.PK+^%EY
M'^UU_P %&/$WCM)%O_ 7PCL_[(T>13NAGU"3>KRKV;G[00PSQ' ?2O;O^"B6
MN>&-#_8W^)7_  E4:SVEW8?9+*'(#/?.Z_92OJ4E"2'_ &8V/:JW_!.OX$_\
M*%_9:\+V%W;^1KVN+_;NJ;EPPEG52D;>A2(1(1_>5O6@#Z9HHHH **** "OE
MW_@H=_R171?^Q@A_])KFOJ*OE[_@H=_R171?^Q@A_P#2:YKV\E_Y&-'U/GN(
M/^15B/\ "<]^PVZK\&_% + ?Z[J<?\LZ^(-=R->U7YW(^UR]7)'WC[U;TGQA
MKN@6LEMIFL7EA;R??BMYBBMGKD"LAV:1V=CN9CEF/4GUK];PF7RP^*KXB4KJ
MHUIV/P_&YFL5@Z&&C%ITTTWWN?H7^R+IAUS]FV[TV.:.*:Z\R)6<\ G/)KR_
MPS_P3_O;/5()O$OB>P33(W#R" [2P!SC+<5\OZ3XZ\1Z#:"UTS7+^PMLY\FW
MG9%_(&IKSXC>*]1A:&Z\1ZE<1-P4DN6(/ZUY7]DXZG6K3P]=151WVNSV?[:R
M^M0H4\3AW*5)67O61]I_&SQQHGB^Z\-?!GP?/'<Q23Q)>SPG*11+P1GH>M=+
M^T+^T4G[.]IX?T#1]+L]5G:$!X)B=J1@8SP1SD5^>.EZQ?Z'>B\T^\FLKL=)
MX7*OS[BGZSK^I^(KH76JW]QJ-RJ[1+<R%V ],FLX\.4^>G&<N:G&[:ZMOJ:2
MXJJ\E6=./+4E9)K:,5T1]9?LJ?'!?$GQSUX7MM!I=MXA3<+.+B/S!DG@^N:\
M8_:A^'Q^'GQAU:VC ^QW;_:867I\W)'YFO+=/U&ZTF\CN[&XDM+J/E)H6*LO
MT(JUK7B/5O$DZ3:MJ-SJ4R\+)<R%R/Q->M1RUX;&O$T7:#BDUZ;'C5LV6*P"
MPM:-YJ3DI>NZ/V<KXI\*_P#*7'QE_P!DSC_]*K2OM:O%-*_9N&F?M<:S\;_^
M$B\PZCX97P[_ &%]BQY>)8I/.\_S.?\ 58V;!][.[C%?AA_1I[77@7[?'_)G
M'Q9_[ DG_H2U[[7 ?'SX5_\ "\/@WXM\!_VG_8W]O6+6?]H>1Y_D9(.[R]R[
MNG3</K0!B_LC_P#)JOP<_P"Q.TC_ -(XJ[CQ]\0/#OPM\(ZCXG\5ZO;:'H6G
MQF2XO+I]JJ.RCNS$\!1DDD  DU\B^&?V'_CWX0\-Z7X?TG]K34]/T73+6*QM
M+2'PA!B&"- B(K&YSPH !SGBMC1/^"<&B^(?$5GKGQC^)'BWXTW-BZR6VGZY
M<F'3HR.>;=6;//;<%(R"#F@#!_8%T75_C%\6/BK^TSKNG3Z9;>,I%TKPS;W)
MQ(NF0E5+$=,,88!QU:.0\@@GS/\ :1B^(W[4W[?&G>'OA3<>'UD^#EC'J)N/
M$QE.GKJ,KH[9\I')<9A &.#;OSQBOTFL;&VTRS@L[.WBM+2WC6*&W@0)'&BC
M"JJC@    #I7A?[*O[+ _9O_ .$]U+4?$Y\9^*O&>M/J^I:RUA]C+9R5BV>;
M)PKR3-G=_P M,8&.0#S#_A&_V[_^AK^"_P#WZO\ _P"1Z\,^%4'Q0_93_P""
MA&DWOQ<NO#;I\9;:2SFN/"QF%@;R/8(CME1")3((P>H_THG/.!^GM>"_M??L
MJP_M4>$?#MA!XD?P;X@\/:M'JVFZ[%9?:W@900R!/,CX)V-G=P8UZT >]45%
M:K+';Q+/(LTZH!)(B;%9L<D+DX!/;)^M>-_M*_LQ6/[1UEH#MXP\3>"-;\/R
M33Z9JOAN]^SO')($#%QC+@!!C!4C)YY- 'M-?"O[(&F:5HG[?'[4&G^"H(K3
MP7 --$]O9#%M'J!3,JJ!\JD2_:QCL0PZ#%;\G[(?[1DUDVCR?M<ZNVB.NQW3
MPO E[MQ@@7 F\P-C^+=G/->Y_LW_ +-?A+]F'P+)X=\+BYNYKN<WFI:OJ#B2
M[U"X(P9)&P/P4<#GJ220#P;]E^=-)_X*"?M6Z1<G9>W8T2^AC_O1"W)+?^1X
M_P Z^N?&'B2Q\&^$M:U[5)TMM-TNRFO;F:0X5(XT+L2?H#7@'[0G[&\_Q/\
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M%T6Q\.Z3:Z9IMM'9V%K&(H;>(85%'0"C1M'L_#^EVVGV%O';6ENBQQQQJ%
M&.@J[0 5^ ?[6G_)Y"?]AF+_ -'BOW\K\ _VM/\ D\A/^PS%_P"CQ0!^\/@K
M_D5=+_Z]T_\ 017CO[?'_)G'Q9_[ DG_ *$M>Q>"O^15TO\ Z]T_]!%<Y\>_
MA7_PO#X-^+? 9U3^Q?[>L6L_[0^S^?Y&2#N\O<N[ITW#ZT 8G[(__)JOP<_[
M$[2/_2.*O6:Y+X1^ _\ A5GPK\'>#/MW]I_\([H]GI/VWRO*^T>1"D7F;-S;
M=VS.W<<9QD]:ZV@#XI\*_P#*7'QE_P!DSC_]*K2OM:ODGXT?L4^-?'7[1%[\
M6_ ?QHG^&FKWFCQ:-+%;Z EZQA5@S#>\ZC#,B'&W(V]:R;C]B/XT>)(GM?%'
M[6GB^^TZ0;)8=%TF/3)&0]5\Q)VZCV_.@# _X*'?$Z3XN/HO[,7P\N8]5\<>
M+KZ'^VOLSADTFPB=9F:<C[I.U7*]=B-D?.H;VS]I;XA:?^R/^R#K=]H[_93H
M.BQ:+H2,V6$Y1;>V^NWY7/LC5O?L]?LG_#K]F73[R/P=I<KZK?G-_KNIR_:-
M0O#G/SRD# SSM4*N><9YK&_:J_99_P"&IO\ A M.U+Q.=(\+>']:36-3T86'
MG_VOLP%B,GFKY0"&9<[7_P!;G'R\@'R?^RC^S[^U_P#!SX+Z/8>"-7^%ND:1
MJX&MM;ZZMZ]^);B-&(G*P%=X4(I ) VXR<9K2_:1_9Z_;'^./P?USPSXOUCX
M3ZMI 1;[[-I"WJ7K20'S%$!:WVAVVE!D@$.1D9S7Z+@8& ,"EH ^=/\ @G]\
M;/\ A>W[*_@[6;F?S]:TR'^Q-4+'+?:+<!-S?[3Q^5(?^NE?1=> ?LU?LIC]
MFOQM\3M1TKQ0=0\,>,=4_M6U\/'3_)72I"TA8)+YK;P0ZK]Q>(T]*]_H ^,/
M^"B'_(\_LN?]E0TO_P!&I78?\%,_^3'?BA_UPLO_ $OMJ[C]HC]G,?'O7/A=
MJ)\0?V%_PA'BBU\2>7]B^T?;?)8-Y.?,3R]V/O\ S8_NFM?]IGX)C]HSX'>*
M/AT=9_X1_P#MM($_M+[+]I\GR[B.;/E[TW9\O'WAUSVQ0!T'P=X^$7@<?]0.
MQ_\ 2=*^8?V[O^2^?LF?]CR/YP5];^#_  __ ,(GX2T31//^U?V;8P67G[-G
MF>7&J;MN3C.W.,G&>M>8?';]G0?&SQ]\)O$I\0?V-_P@6N_VU]E^Q>?]N^Y^
MZW>8OE_<^]ANO2@#Y\\;>(+?X9_\%9/"=]KDJVVG>,?!']C:==3<1_:1<,PB
M![,6B4#U,JCO7W37BW[4G[*/A#]J[P7:Z-XD:YTW4]-E-SI6N:>0+FQE.,E<
M\,C87<IZ[0000"/$-'_95_:IT+3QX?M?VJ=WA]8_(6ZNO#4,]^L?3(D<F3=C
M^+S<Y[]Z ,"X^(FD^(?^"PFG:;;7,4LNE^!Y-$<QN&!N 9;MD..A"2\CL5-=
M3^VC_P G<?L@_P#8?U3_ -%VM5="_P"":.B_#OQ-\*?$W@OQ1=6WB[PSXBEU
MCQ!XDU13->:W%*@\^)L'C<5" $X59I6)9B=WN7QH_9S'Q>^+GP@\;GQ!_9/_
M  K_ %"ZOOL/V+SOM_G+$-F_S%\K'E==K9W=!B@#YU^)6OVOPD_X*M^!=:UZ
M1;31O&?@]M#L[Z=@(DNQ,Y$>3T)98E^LZ^M?>%>0_M,_LO\ @S]JKP&OAOQ=
M#-%+:R&XT[5;)@EU8S$8W(2""",!D((.!W"D> :/^R/^U!X1TX>']#_:JF;P
MXH\J*74O#D5S>QQ] !+(SOD# XD'MB@#V+]NKXPZU\"?V5_'/B_PX_DZ[;PP
MVMG<%-P@DGGCA\WTRHD+#/&X+D'I7B7PL_X)@_"GQ9X"TKQ!\3+G7?B+XVUJ
MRBOK_7;[6K@'S9$5SY6QQE1G +EB>O? ]F\$?L@V&G_ 'Q1\+_'OC3Q#\3K?
MQ/+)<:GJNMS_ +\2L(\-!G<8PC1)(JLSX89Z'%>/>&_V+OVBOAAI$?A3P)^T
M]/8^"808K6WU3P[!=75G!T6-)'+'"C@;60#' '2@#Q^W^%>A?LS_ /!2KX$^
M$=)\>ZUXCT-+;4I;70M:NS<MH9N;.XB6-'SPLK@,%V@C:"=V[->_?\%.)%M_
MAU\(+J3Y;>V^)^BS32=D0)<Y8^@Y'YUR>K?\$ODL]'T?7=#\?WE]\98/$]GX
MBO?'VO1-+)+Y1;=&D*M\J9*ML+G)0 OC&/J/]I#X!Z'^TM\(M9\!Z]-+9P7H
M66VOH!F2TN$.Z*91D;L'JN1D$C(SD 'IU?$7_!+733K/[%5WIZR>4UUJVK0"
M0<;=QVY_#->L_LY_"OX[?#?6!;?$?XLZ;\0/"UM8-:VENND+;WAD#)Y<LDW5
ML(K@Y+$ELDDC-;W[)?[.8_9;^$:>"!X@_P"$FVZA<WWV[[%]D_UK [-GF/TQ
MUW<^@H \,_X)-^*K5?V==0^'MT%L_%G@G7+VPU;37($L9>9Y%<CT+&1,^L3>
ME?:=Y>0:?9SW5U-';6L"-++-,P5(T499F)X  !))KY<^.'["\7C/XGO\4_A?
MXYU+X1_$J9-EYJ6FQ">TU$<#]_ 64$D*N>=IP"RL>:XKQ%^Q9\>OC59C0/BW
M^T?/J/@QSB[TKPUH<%A)?)D?))(@48/HRNO'W: (_P#@F_J*_$3XB?M)_%+3
MHF7PSXJ\6I#I<I&T3);B8^8!_M+<1D^Y([5J?\$F/^34&/KXCU(_^/K7U-\,
M_AIX<^#_ (%TGPAX3TV/2= TN+RK:VC);J269F/+,S$L6/)))K@/V3?V<Q^R
M[\)_^$*'B#_A)A_:-S?_ &XV7V7_ %K [-GF/TQUW<^@H YK_@HE_P F5_%7
M_L&Q_P#I1%7I7[.__)O_ ,,O^Q8TS_TDBJ/]HCX0?\+\^"OBKX?_ -K?V%_;
MMLMO_:/V;[1Y&)%?=Y>]-WW<8W#K72_#OPG_ ,(#\/\ PSX8%U]N&BZ9:Z;]
MJ\OR_.\F)8]^W)VYVYQDXSU- '0T444 %%%% 'Q[XZ_Y';Q#_P!A&X_]&M6'
M7U_<^ O#EY<2W$^B6,L\KF221X5)9B<DD^I-1_\ "N?"_P#T -/_ ._"UZD<
M7%)*QPO#R;O<^1**^F/B-X&\/Z;X'UBYM=&L[>XC@+))'" RG(Y!KQSX:_#6
M[\>:AN;=;Z5"W[^XQR?]A/5OY?D#TPKQE%S>B1C*E*,E$/AK\-;OQYJ&YMUO
MI4+?O[C')_V$]6_E^0/T]I6E6FB:?!8V,"V]K"NU(UZ#_$^_>C2M*M-$T^"Q
ML8%M[6%=J1KT'^)]^]6Z\JM6=5^1W4Z:IKS"BBBN<V/BG_@HG_R4;]E?_LIF
MG?\ HZ*OM:OGS]KO]E?4/VG+/P.VD>.7\!:OX3UA=9L]1CTP7S><H&PA3+&
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M/[//[/OC3QI\/O$^O_#66.S-K/ID.JS3V>L+*1']DDCD<LV_/7<0,$E3CCZ
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M$KM'\:>(+1RHUFZ1LKI\#C[R@CEAQD;OX8]_V_X?T#3O"NAV&C:/90Z;I5A
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JCK>AV'B32Y]-
MU2TBO["< 2VTZ[DD (.&'<9 X/!J]133:U0;Z,15"*%4!5 P .@I:**0!111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% 'QA\9OV5?B3^U%^TY8R_$34-.M/@-X2NH;W2M%LV)FUF
M;RD9C.N3@!R\99B/D4A%^=GK[.Z<#@4M% !1110 4444 %?+W_!0[_DBVB_]
MC!#_ .DUS7U#7SE^W9X5UKQA\(](L]"TB_UJ[CUR&9[?3[9YY%06]P"Q5 2!
MEE&>F2/6O9R>2CF%&4G97/ SZ,IY77C%7?*?F]17;_\ "C?B-_T(/BC_ ,$U
MS_\ $4?\*-^(W_0@^*/_  37/_Q%?MWUJA_S\7WH_GGZGB?^?<ON9Q%%=O\
M\*-^(W_0@^*/_!-<_P#Q%'_"C?B-_P!"#XH_\$US_P#$4?6J'_/Q?>@^IXG_
M )]R^YG$45V__"C?B-_T(/BC_P $US_\11_PHWXC?]"#XH_\$US_ /$4?6J'
M_/Q?>@^IXG_GW+[F<12UVW_"C?B-_P!"#XH_\$US_P#$4?\ "COB-_T(/BC_
M ,$US_\ $4?6J'_/Q?>@^J8G_GW+[F?KO1117\\']2A1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 >=_M#?\D1\:_P#8*N/_ $ U^"/[(7[0
M,'[.GQ2M?%%Q:+>1PL28VS@\8[5_0WXL\,V?C+PUJ6B:@I>SOX'MY0IP=K#!
MKXO7_@D3\&%S^XU \D\W;4 >9-_P69TC<<>'(<=OF>C_ (?,Z3_T+D/_ 'T]
M>G?\.BO@Q_S[W_\ X%-1_P .BO@Q_P ^]_\ ^!34 >8_\/F=)_Z%R'_OIZ/^
M'S.D_P#0N0_]]/7IW_#HKX,?\^]__P"!34?\.BO@Q_S[W_\ X%-0!YDO_!9G
M2-W/AN''^\]?GM\1/BNGQD_:*T[Q,ENMLEUJT#A%Z#,RFOU6_P"'17P8_P"?
M>_\ _ IJLZ7_ ,$F?@[I.J65_#!?>=:S).F;IB-RG(R._(H ^PO!/_(J:7_U
M[I_Z"*VZJ:7IZ:7I\%I']R% B_0#%6Z "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@#.\0Z+%XBT6ZTV9VCAN5V.R?> R"<>]3:5I5IHFGP6-C MO
M:PKM2->@_P 3[]ZMT4[NUA6UN%%%%(84444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 5FZ'X;TGPS#<0Z/I=EI45Q.UU-'8VZ0K+,V-TC!0,
MN<#+'DX%:5% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[3UO?%.N6ND0M_JUE8M+)_N1J"S?@#7S)^PGXCMO!_[/?C37;S/V33;V>[E
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M*;4'==#["DYNG%U%:5M?4Y33/AIJ6K?#S5/%\>?L5C<) R[<EL]6!]%)7/\
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MA(KI2-^/0.&#8]0]4/V$_A9/XU^+D7B":$_V3X?7[0TC#Y6G/$:@^H.6_P"
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MTU\ ?'D_Q.^"?@CQ3=D->ZII-O/=,!@&?8!*0/3>&H [^BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF_"WXA?VIX?T^._L[>8H)&O(HUNH">5(+9&1ZC@C/:GN!K_MN_Z[PG_N7/\
M.*O7_@&L4GP7T);@*T#6[B02?=*[FSGVQ7$?M.?"_P 4?$Y?#4F@Z5Y[6T<Q
MN(Y+B*,Q%_+(4[F )^4],CBNN\-?#;5;CX$Q>$+VYDT+4Y+5H9)(660QY<G!
MP2"".#@]">:70.IYUKG[)OA?QQ_Q./!WB,6EE<$L(U47,&<\A&# J/8YKR;X
MF?!'Q'\#(['6H]:AEBDF\J*XLI'BE23!8<?0'D&K\GPA^+WPKU"4Z&FH-$6_
MU^CSETE]R@.?^^EI)OAA\8/BWJ%NNN6^H&*,X$VK.(8X@>I"''_CJDTQ'TW^
MS_XZOOB!\-[*_P!2;S+^)VMY9<8\PKT8^Y!&?>O2*Y7X8^ K?X:^#;'0[>3S
MS""TLV,>9(QRQQV'I["NJJ2CFYO"L.K>-K3Q!>IO;2H)+?3HVZ1O)CSI?J0J
MH/0;_P"]72444W)RM?H3&*C>W4****DH**** "BBB@ HHHH *^7/VQ_VL=3^
M#=UHO@/P!IRZ]\3O$F%L[;;Y@LT=MB2%/XG9LA5/'REFX&&^HZ^&OCE^Q]\;
M/%'[5%_\7?A[XK\+:)+&D,>EOJDDLDUN!:+!)F-K66/DF4CK]X'@] #L?V5?
MV,;[X?>*I/BC\4=9?Q9\4;X,^^23S8M/+C!PQ^_)M^7<,*H)51CYJXCXJ3+X
M7_X*H?"_4+X^7::EH1MX96Z>8\5[$JCW+E1C_;'K6G_PJO\ ;D_Z+'X(_P#
M.+_Y6UZ9^UI^RK=?M#>'?#FHZ-K4?A_XA^&9!<:9JWS+&S_*S(S*-RC>BLK
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MOXT,@AD@DB,B#JR;U&X?3GOTJCXO_:$\!>%-:N= O_$,=OJL8*2*D4CI"Y'
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M7GGBWX_>!_!.NS:1JNL-'?6X5KE(+669;<,,@R,BD+U''7FN-US]JKP]X?\
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M>;^&OVB/ 'B[7+?2=*UY;F[F@:Y&8)$1452[;G90%(522">,4>'_ -HGX?\
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M>!H-V=N5=03N(P,9R>!SQ4/@[]H#P'X\UM-(TC7!)J,H+0PW%O+ 9@!G*%U
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M,]'N+QBCS^'IM-1+=5)!9!.HW[@,_CWKF/B#-\6O NO>$=-/Q-AO?^$AU$6
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M<O!?Q"U8Z7HNK^;J'EF9+>XMY8'EC_O)YBC<._'.!FER2UTV'='>T5YGXO\
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MMUTJ+RV<J7('F9'.><;?4T_PQ^T3X"\7Z_;:/INM,U[=$BU$]I-"EP1V1G4
MG^?:IY)=$',CTFBO(O >N:C>?M$?%#39[^ZGTZS@TTVUI),S10EH 6*(3A<D
MY.!S7KM3*/*[#3N%%%%2,**** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME ./:DG^'/A2ZU*ZU&;PSI$M_=(Z3W3V,1DE5P5<,VW)W D'/4'!H]JNOE^
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MHMAH<FBVVD6-OH\BNCZ?%;(L#*^=X* ;2#DYXYS3=5;KR_ .4^3O$CWMK<?
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M^'4F@VVJ_P#"4V.V<+MM%?==!FQ\IA&7!R<=,>]<W^T'_P CY\'_ /L8E_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%?DS_P -S?&[_H=O_*38_P#QBC_AN;XW?]#M
M_P"4FQ_^,5[_ /8N(_FC^/\ D>)_:U#L_P /\S]9J*_)G_AN;XW?]#M_Y2;'
M_P",4?\ #<WQN_Z';_RDV/\ \8H_L7$?S1_'_(/[6H=G^'^9^LU%?DS_ ,-S
M?&[_ *';_P I-C_\8H_X;F^-W_0[?^4FQ_\ C%']BXC^:/X_Y!_:U#L_P_S/
MUFHK\F?^&YOC=_T.W_E)L?\ XQ1_PW-\;O\ H=O_ "DV/_QBC^Q<1_-'\?\
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M38__ !BC_AN;XW?]#M_Y2;'_ .,4?V+B/YH_C_D']K4.S_#_ #/UFHK\F?\
MAN;XW?\ 0[?^4FQ_^,4?\-S?&[_H=O\ RDV/_P 8H_L7$?S1_'_(/[6H=G^'
M^9^LU%?DS_PW-\;O^AV_\I-C_P#&*/\ AN;XW?\ 0[?^4FQ_^,4?V+B/YH_C
M_D']K4.S_#_,_6:BOR9_X;F^-W_0[?\ E)L?_C%'_#<WQN_Z';_RDV/_ ,8H
M_L7$?S1_'_(/[6H=G^'^9^LU%?DS_P -S?&[_H=O_*38_P#QBC_AN;XW?]#M
M_P"4FQ_^,4?V+B/YH_C_ )!_:U#L_P /\S]9J*_)G_AN;XW?]#M_Y2;'_P",
M4?\ #<WQN_Z';_RDV/\ \8H_L7$?S1_'_(/[6H=G^'^9^LU%?DS_ ,-S?&[_
M *';_P I-C_\8H_X;F^-W_0[?^4FQ_\ C%']BXC^:/X_Y!_:U#L_P_S/UFHK
M\F?^&YOC=_T.W_E)L?\ XQ1_PW-\;O\ H=O_ "DV/_QBC^Q<1_-'\?\ (/[6
MH=G^'^9^LU%?DS_PW-\;O^AV_P#*38__ !BC_AN;XW?]#M_Y2;'_ .,4?V+B
M/YH_C_D']K4.S_#_ #/UFHK\F?\ AN;XW?\ 0[?^4FQ_^,4?\-S?&[_H=O\
MRDV/_P 8H_L7$?S1_'_(/[6H=G^'^9^LU%?DS_PW-\;O^AV_\I-C_P#&*/\
MAN;XW?\ 0[?^4FQ_^,4?V+B/YH_C_D']K4.S_#_,_6:BOR9_X;F^-W_0[?\
ME)L?_C%'_#<WQN_Z';_RDV/_ ,8H_L7$?S1_'_(/[6H=G^'^9^LU%?DS_P -
MS?&[_H=O_*38_P#QBC_AN;XW?]#M_P"4FQ_^,4?V+B/YH_C_ )!_:U#L_P /
M\S]9J*_)G_AN;XW?]#M_Y2;'_P",4?\ #<WQN_Z';_RDV/\ \8H_L7$?S1_'
M_(/[6H=G^'^9^LU%?DS_ ,-S?&[_ *';_P I-C_\8H_X;F^-W_0[?^4FQ_\
MC%']BXC^:/X_Y!_:U#L_P_S/UFHK\F?^&YOC=_T.W_E)L?\ XQ1_PW-\;O\
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MFQ_^,4?V+B/YH_C_ )!_:U#L_P /\S]9J*_)G_AN;XW?]#M_Y2;'_P",4?\
M#<WQN_Z';_RDV/\ \8H_L7$?S1_'_(/[6H=G^'^9^LU%?DS_ ,-S?&[_ *';
M_P I-C_\8H_X;F^-W_0[?^4FQ_\ C%']BXC^:/X_Y!_:U#L_P_S/UFHK\F?^
M&YOC=_T.W_E)L?\ XQ1_PW-\;O\ H=O_ "DV/_QBC^Q<1_-'\?\ (/[6H=G^
M'^9^LU%?DS_PW-\;O^AV_P#*38__ !BC_AN;XW?]#M_Y2;'_ .,4?V+B/YH_
MC_D']K4.S_#_ #/UFHK\F?\ AN;XW?\ 0[?^4FQ_^,4?\-S?&[_H=O\ RDV/
M_P 8H_L7$?S1_'_(/[6H=G^'^9^LU%?DS_PW-\;O^AV_\I-C_P#&*/\ AN;X
MW?\ 0[?^4FQ_^,4?V+B/YH_C_D']K4.S_#_,_6:BOR9_X;F^-W_0[?\ E)L?
M_C%'_#<WQN_Z';_RDV/_ ,8H_L7$?S1_'_(/[6H=G^'^9^LU%?DS_P -S?&[
M_H=O_*38_P#QBC_AN;XW?]#M_P"4FQ_^,4?V+B/YH_C_ )!_:U#L_P /\S]9
MJ*_)G_AN;XW?]#M_Y2;'_P",4?\ #<WQN_Z';_RDV/\ \8H_L7$?S1_'_(/[
M6H=G^'^9^LU%?DS_ ,-S?&[_ *';_P I-C_\8H_X;F^-W_0[?^4FQ_\ C%']
MBXC^:/X_Y!_:U#L_P_S/UFHK\F?^&YOC=_T.W_E)L?\ XQ1_PW-\;O\ H=O_
M "DV/_QBC^Q<1_-'\?\ (/[6H=G^'^9^LU%?DS_PW-\;O^AV_P#*38__ !BC
M_AN;XW?]#M_Y2;'_ .,4?V+B/YH_C_D']K4.S_#_ #/UFHK\F?\ AN;XW?\
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MH_L7$?S1_'_(/[6H=G^'^9^LU%?DS_PW-\;O^AV_\I-C_P#&*/\ AN;XW?\
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M )!_:U#L_P /\S]9J*_)G_AN;XW?]#M_Y2;'_P",4?\ #<WQN_Z';_RDV/\
M\8H_L7$?S1_'_(/[6H=G^'^9^LU%?DS_ ,-S?&[_ *';_P I-C_\8H_X;F^-
MW_0[?^4FQ_\ C%']BXC^:/X_Y!_:U#L_P_S/UFHK\F?^&YOC=_T.W_E)L?\
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MUFHK\F?^&YOC=_T.W_E)L?\ XQ1_PW-\;O\ H=O_ "DV/_QBC^Q<1_-'\?\
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M38__ !BC_AN;XW?]#M_Y2;'_ .,4?V+B/YH_C_D']K4.S_#_ #/UFHK\F?\
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M/YH_C_D']K4.S_#_ #/UFHK\F?\ AN;XW?\ 0[?^4FQ_^,4?\-S?&[_H=O\
MRDV/_P 8H_L7$?S1_'_(/[6H=G^'^9^LU%?DS_PW-\;O^AV_\I-C_P#&*/\
MAN;XW?\ 0[?^4FQ_^,4?V+B/YH_C_D']K4.S_#_,_6:BOR9_X;F^-W_0[?\
ME)L?_C%'_#<WQN_Z';_RDV/_ ,8H_L7$?S1_'_(/[6H=G^'^9^LU%?DS_P -
MS?&[_H=O_*38_P#QBC_AN;XW?]#M_P"4FQ_^,4?V+B/YH_C_ )!_:U#L_P /
M\S]9J*_)G_AN;XW?]#M_Y2;'_P",4?\ #<WQN_Z';_RDV/\ \8H_L7$?S1_'
M_(/[6H=G^'^9^LU%?DS_ ,-S?&[_ *';_P I-C_\8H_X;F^-W_0[?^4FQ_\
MC%']BXC^:/X_Y!_:U#L_P_S/UFHK\F?^&YOC=_T.W_E)L?\ XQ1_PW-\;O\
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MFQ_^,4?V+B/YH_C_ )!_:U#L_P /\S]9J*_)G_AN;XW?]#M_Y2;'_P",4?\
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M_AN;XW?]#M_Y2;'_ .,4?V+B/YH_C_D']K4.S_#_ #/UFHK\F?\ AN;XW?\
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MH_L7$?S1_'_(/[6H=G^'^9^LU%?DS_PW-\;O^AV_\I-C_P#&*/\ AN;XW?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
:4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>form10-k_006.jpg
<TEXT>
begin 644 form10-k_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (< G # 2(  A$! Q$!_\0
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M_+5Z/[)C_P">KUH TM,1G?V3'_SU>C^R8_\ GJ]:-% &=_9$?_/1Z3^R(_\
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M@_9="G8_]-' I<\1\LCU)=&LE_Y9D_5JF73K->ENGY5XO/\ ';4<$PZ+ O\
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M.,3RYED]BW.*Z2FKUIU=25E8X)2YFVPHHHIB"BBB@ HHHH **** "N<\2_\
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MTLCSV;6K>Z(VJ8I>XSQ5U-2DM;"/S%S-<-M1>^T=ZPKJQ$FIJT"[;>5RV3V
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M%=#XVN/[5^(]K8D9CM@N1^M=F%[]CEKZ.Q-86PLM*M[;&&"Y;ZUDW%U)#?\
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M1E_6LZOPFE+XCR;5PT6H+*W<@UD:Y:*^)TRA!Q)CN*Z+Q!'YEO'*!G;G-9[
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MSKK_ .Y56SBCM+2.%!M50!BK6B$'Q!)@_P#+.N"]Y7.^UHV.LI:**9(4444
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MJ[+))-E1(J1]#QDUS>JZS8^&5B>X#R17$H5@!RP[FD6MCL_#%BRVBW$B; 0
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M4]"JU[!I=CU<=*6D!&.HHR/45Z9XHM(3Q399%BB:1ONH"QQ[5B:;XHL=24N
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MK6LC9C4^HJ&6AV?Y4[1_^0^__7.F5GS:A<:5>FYMX!,[+C!/2D@9WM)7!_\
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MA<N6O@"SM=5.H?;KJ24R*^&(QE<X_G4USX*MKEK\"[FB6\8LX"C(SUP:S?\
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MLV*>5!,DT8X&[K4BIKLQ*A47\: -NV:"QL5MX0 D?RA:YR:6XNM;6ZLU#K;
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M\8W>F3%X(-3_ -+MI%&#'./O8_G6GXG\':NUHM_IXM7U&S;S8)H08W&.J^C
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M7!L['3&<_O?,#[?09H ]*HID3K)&KJ<JP!!I] !1110 4444 %%%% !1110
M5SOB3_CYLO\ >-=%7.^)/^/BR_WC0 U?NCZ44#[H^E% %<&FEN:3)I:U)&DD
MFC!I<<T\ XYH C I=IIU)OQQ0 FVC;1Y@IP=328#"M&"!4G!HQVI ,!-/#T;
M::5H F4\4AY--4X%.!H&!&:9M(J3-!&: ('7/(I@]Q4[*13&&15"&8[YHSZT
MG2EZB@!PI#2 XIV<T ,- -.-0W,BP6DTIZ(I)H0GL<IIFV_^(%S<$YCM8\?B
M:[3N#ZUR7@F#=:7=\WWKF8D'_9%=6A^7:>M9\M[LTO:R.0+#^WM9G#<1VY&3
M[UN:%&8M#M%/78":Y?)^RZ],#EF<1 _C796D?EV<*=-J #\JB19,.M<UH*E=
M;UCW:NEKF-$S_P )#JP[<']:?074T])_U4W_ %U:K\+;-1MF]R*S](.89S_T
MV:KQ.V>W;TD%/J3T*MH-MU?(>UPU:7A[_D.R_P#7.J'W=;U%!U+A_P ZT?#X
MQKLG_7.@&==WI:2EH$<YJ.F26DDEU9IN1CF2,=<^HK/MKB.^C>-9,2*>5/!%
M=GBLZ[T>TN275!%,?^6B#G\: .:87UIG8%E3T[U _B2.WXNHGA(]1Q6K)HVK
MAML<\#+V9@16;-H=U;3&6^@%WGIY8R!0 Q/$MG)@A^#ST--N;K2K]=LR1D^N
MWFIC=PQ*$_LQQCL(JJW&I:?#CSK01;C@;TQDT -BT>QN('>%?*=1\CKQ3=.F
M>X5H+AN8VP6'<5'-K=A# 2) O'137.RZQ<RN?L$)VMU8\4 =5K TZ[M6L1;1
MW#N-BC:&/U-8J>1+!I]EJ%_)I-SIT?EQRID1R+GU[<5!!JVLV5O(MI90[W&/
M,4;FJ/SH]'MVL[A!>ZM<GS9O-^[$.V: )K;4KG3+R+4Y-:EU V\;NT%NQ<RD
M]%XX KGXM9LF8:WII^=PT.M6I')1SC./]GUK2DUN_AT^6-$MPC#K&@&!Z5ER
MZ?#?645WII2'5 A1D_AN%[JP[T 5/#5Y)9>+S:N#=?8T4J@Y\R-3P??CI7HA
MM+C5KF?4-,\611":Y\\P2/CRU'1"/YUX?IVM2:3XSL;N2.2*XM&:"2)^&P1@
M#Z5[N;#P]HD45QJ.GI>7ES;FX><XY_V0/QH Q=1U:*SL)=#O-4@OKG4+F,(\
M3%UBYY+-VKG-0L/L&HR6UP")<\8Y##L16_XR\.:>GAN/5;.R73I+LA&@1@03
MU1ACOG%5?#]P?$<L.I7&Q7MHEAVYR"PX)- %33[%+MQ&H,(+8:0KTK<CTJQA
MBC5D+.C@%BWWO>M&6/9>")UV*QRN/6E2/#2V['=(O()% &?-IEM+/,54PR#
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M?%E_O&@!J]!3J:/NCZ4Z@"L.E ZT"CO5B%-**0]*44 '>@T4O:@!!1WH%+0
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MZ -E!'%'Y4DFX[<G/:L^Z@$2F6"4 ="!WI(Y=Z3/CY -JD]ZK,[QCYAU 9:
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MC,[*"V !UY^E6-'T>^\1QH%#V]H,%YG&"2/0&@".ZM;S4]7@M],C\QXQAW[
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MQTBT\2:C8VL8N[&8_9RS,0IQP.M22:YJND74-Q?30WD[Z?YX(CV["<87Z<T
M>DY]32Y->=S:[X@T&[C.H7MM?6\MD]P$2,*P<=![CFJ=EXN\1+:SRRAIEEM&
MG222'RUA?L/]H4 >H D^U-+KN*AANQTSS7G0U#Q:UW':'5K8&>P^V^8(?]60
M,[?<&JT_BK4S&;VW2!+MM.1MS+_&7(/X4 >GY(_^O07 !+$ #J2:X5=9UK2;
MN]M-1U&UE/V(7,<[)M$39P0<=1Z5@R^)=1O;#7--N;QKF-;-9XYS#Y)4EL$
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MQ3_=QT-5)]!BUK0(-/UJ)7,>TMM/4K_C2^&-3DU/2MTW-Q;RM!*?5E.*V\4
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M*-X\TF.Z>$QW6R.80RR^5\D;GH"?>I-3\;Z7I=Q-$ZW$B6^/.EAC+)'GH":
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MK7'@LL2W=Y',ZS<"%&RO_P!?ZU-?6]E]B53 EMQE)57+@U6EN7TMA;M&\]H
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M[QKL6QQ+4!T%+4:-D"I*H=BKT-*:2BK) =*6FBG&@0O:D% HH 7% % H'!H
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MEAI45C<W5P"9)KI]\CM[< #V% &A1110 4444 %%%% !1110 4444 %)2T4
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M #\1_P#?0KRC[''_ 'Y/^^S1]CC_ +\G_?9J; >K_;+;_GXC_P"^A1]LMO\
MGXC_ .^A7E(LX_[\G_?9I191_P!Z3_OLT6 ]5^V6W_/Q'_WT*/MEM_S\1_\
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MHN%CU/[;;?\ /Q'_ -]"N?\ $<T<LUGY<BOACT.:XP647]Z3_OLUHZ=9PQS
3_,<?WFS1<+&^.@I:!THJ2C__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>form10-k_007.jpg
<TEXT>
begin 644 form10-k_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %D ,\# 2(  A$! Q$!_\0
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M4$)P,<]L5ZKI^C66EM.;2,HLS[V7.0#[#M4EEIEIIYN#:Q"/[1*9I,=W/4T
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M:^*-'T1-;FNM?\+SWD,IR+NWR_\ WTH/%>E'I5:[N[>QM9+B[FCB@1<N[G
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MKXK:G=&QN[+%A&GEW46QR 3S]*],%</9@?\ "Y-3XY_LR'G\37<#I0 4444
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M(V 4GTKRGA001N0]#7I/PPXL[U3R0XY]J /0.]+1WHH **** "BBB@ HHHH
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M[_"C_A9/@[_H8+3_ ,>_PH ZNBN4_P"%D^#O^A@M/_'O\*/^%D^#O^A@M/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
'"BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>form10-k_008.jpg
<TEXT>
begin 644 form10-k_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #_ G # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#U'4KN6T@1
MX4#.[[?FJF;_ %('!B@_.I]9_P!3;_\ 74&H#UKT#D#^T-1_YY0?G1_:&H_\
M\H/SHHH /[0U'_GE!^=']H:C_P \H/SHHH /[0U'_GE!^=']H:C_ ,\H/SHH
MH /[0U'_ )Y0?G1_:&H_\\H/SHHH /[0U'_GE!^=']H:C_SR@_.BCF@ _M#4
M?^>4'YT?VAJ/_/*#\Z** #^T-1_YY0?G1_:&H_\ /*#\Z** #^T-1_YY0?G1
M_:&H_P#/*#\Z** #^T-1_P">4'YT?VAJ/_/*#\Z** #^T-1_YY0?G1_:&H_\
M\H/SHHH /[0U'_GE!^=']H:C_P \H/SHHH /[0U'_GE!^=']H:C_ ,\H/SHH
MH /[0U'_ )Y0?G1_:&H_\\H/SHHH /[0U'_GE!^=']H:C_SR@_.BB@ _M#4?
M^>4'YT?VAJ/_ #R@_.BB@ _M#4?^>4'YT?VAJ/\ SR@_.BB@ _M#4?\ GE!^
M=']H:C_SR@_.BB@ _M#4?^>4'YT?VAJ/_/*#\Z** #^T-1_YY0?G1_:&H_\
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MV^F:.=]@Y?,];>^LXO+\R[@3S?N%G'S?2L7_ (2RU@8C4E^R;KCR(MS [_\
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M_L;3?^?*/\S_ (TPNRW]J@[7$9/LP%)]JA_Y[Q^Y+#]*K?V-IO\ SY1_F?\
M&C^QM-_Y\H_S/^-+4"S]I@/ N(_IN[>U+]IA/'VB/T^^ *J_V/IO_/FGZ_XT
M'1M-(YLH_P!?\:!V+/VB #'GQ?0-2?:8/^>\7_?55O[&TWM91_F?\:7^QM,_
MY\H_S/\ C3 L?:8/^>\7_?5'VF#_ )[Q?]]57_L?3>UD@_$T?V-IO_/E'^9_
MQI7$6/M,'_/>+_OJC[3!_P ]XO\ OJJ_]C:;_P ^4?YG_&C^QM-_Y\H_S/\
MC3 L?:8/^>\7_?5'VF#_ )[Q?]]57_L;3?\ GRC_ #/^-']C:;_SY1_F?\:
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M0A%K[5!_S\1X]-PYI!<P\G[1'Q_M#BJW]C:;_P ^4?YG_&C^QM-_Y\H_S/\
MC38%IKJ'O<1GVW"J4-GIUOK,^JI,GVJ9!')\V1@4_P#L;3?^?*/\S_C1_8^F
M_P#/E'^9_P :0]2S]HAQCSXR.YWC-+]I@P!]HC([?,.*J_V-IW_/E'^9_P :
M/[&TW_GRC_,_XTA6+/VF$$GSXN>P8<4?:H /^/F/Z[P<56_L?3!S]BC]^3_C
M0-&TS_GR3GGDFF.Q:^U0CC[1&,]@PP?QH^TP_P#/Q%COEA57^Q],_P"?*/\
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MHSN4]"O(I><]Z!%#^U8_^?>X_P"_=']JQ_\ /O<?]^ZO\^]'/O0!0.JQ8/\
MH]Q_W[I#J<.XL+6<D\']W6AS[T<^] &?_:L9X^SW/ _YYT?VK'P?(N<_[E:'
M/O000>01^% S/_M6/H+>Y]_DI?[4B[V]S^"5H8.,X./I2')'0T"*']J1@?\
M'M<?]\4?VK%_S[W'_?NKS$*NYCM4=2:B@N[>\!:WN(I@IP6C(.*!E;^U8_\
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MU8_^?>X_[]U?(;.""#]*.?>@"A_:L7_/O<?]^Z/[5B_Y][C_ +]U?Y/2@YH
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M<'KZ4#K6%X3NKN\T=WNYFGV3,D4S#!D0=#6Z.M.]R2&?_66W_76MX]:P9_\
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M** "CCCIG]:** %ZG!)/X\TGO110 9H!Q[9ZX-%% !R. 0*.W&:** "BBB@
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MW$;22,_6NG\-7IFTJ&WN9&>\0'[PY*@\9IIB-NBBBKL(****0!1110 4444
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MC[1#_P ]D_,4P#R( 21#'D]6VC-+Y,04H(H]F,;=HQBD^T0_\]D_,4?:(?\
MGLGYB@!R11HJJD:H%^Z% &/I0L4:L2J(IQ]X#D^U-^T0_P#/9/S%'VB'_GLG
MYB@!QC0H5*+M[C'!_"FI!#%_JX43G^!0!]:/M$/_ #V3\Q1]HA_Y[)^8H ?L
MCW%M@))Y.!DGUII@A,HF,2-(/XRHW?G2?:(?^>R?F*/M$/\ SV3\Q2L,2\MU
MO+.>U9RJ3+M)]/>F6UE;VUFEJL*&)5"LNT8?'<U)]HA_Y[)^8H^T0_\ /9/S
M%,0Y8HXUPD:CMP ./2F?9;;88_L\01N2H08S2_:(?^>R?F*/M$/_ #V3\Q0
MKP1.?FAB) PIV]!Z4)#%'CRXHXR. 47&*3[1#_SV3\Q1]HA_Y[)^8H &MX)
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>MNBBP<QB)IVI//"TTEOY:-N8 &ML\FC/X44P/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>form10-k_009.jpg
<TEXT>
begin 644 form10-k_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #L >L# 2(  A$! Q$!_\0
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MOCCX3_\ )1]*_P!^OL<]32?4$<-X^^]:_C7&8KL_'WW[:N-[U[N%_A(\FO\
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M&_Q5V7C[[]M7&_Q5[N%_A(\FO\8E%%%=)@%%%% C=\'_ /(?7Z5ZA7E_@_\
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M .L^;_)H^;_)KD_^$.N/^AAU'_OY1_PAUQ_T,.H_]_* .L^;_)H^;_)KD_\
MA#KC_H8=1_[^4?\ "'7'_0PZC_W\H ZSYO\ )H^;_)KD_P#A#KC_ *&'4?\
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MM-\,S6%\+EM8O)P/X'?(_*@#I**** "FLFXTZB@!@4YR0*=@TM% "8HQ2T4
M)BC%+10 F**6B@!,48I:* $Q1BEI#S0!%-<0VT?F32+&G]YC@40W$-Q&)()5
MD0\;E.17)_$@M_8-L%*@&Z3.XX'X^U<KI>K-I>E:C;M,Z2-<?(\&3'@^AH ]
M9#!NF?\ &C<,9P?QKS*'Q)JDNAV%]<7)2%'*3E!\[#/&!4O_  D&NW_B)EMI
M%BCAD"K%(.60]_K0!Z#'?VLDAC292P;:0#WJQGZUYC;7<UEJ$JQH26NI&8L,
MX..U3VFLZY:"TN9[HW9N[>63R=F-I'2@#T;<,'KQVIPP:X+P=JFM:C>I+=31
MM;2QDNG\2-7>("%Y'/>E<!V*,4447 3%&/>EHI@)BC%+10 F*,4M% "8HQ2T
M4 )BC%+10 F*,4M% "8J.:>*WC:2:1411DECC%2UQ_Q'65_#J+"I:1IT &<#
MKW]J .HMKJWNU+V\JRJ.,J<BDFO;:W;;-,L;8)PQ[5PMS<7NF1:=IK21:9%<
M*SR3IR,@<#\:R;J^NM2AM9;DN9$BF19<<2#'!H ]4BFCFC$D3AT/1AWIV[ZU
MY9'K-]#:>6+PVGV*W62WB(YG)ZBI=5\4^(+.1;2(,;J:-+F(;>B?QB@#T[<*
M4MBN3\.:M?:SI%]J3D^4P(@&,=!S^M9%OXLN;E-,B6X#7#0S&X0#H5Z4 >A[
M@<=:KO?VL4RP/.BRM]U&.":\_P##>OZC<ZGIH:_%\+O?Y\:CB$#I5CQB^F:A
MKMMI4++#J>]9'N3GY$% '>O+'%$TDC!$49))Z4V"ZM[F(2P3+(AZ,IS6%->3
M/!<VUY:(EFB!8YW?B0XZGVK"^'K&.?5X64;O-+[HSF(#MB@#T#/UI,@UY8VJ
M^(;B99TU(HLMT;<)Y?\ !_>JS'KVJ%8M-NM0\A5G>-KUEP&P,@4K@>E9Y[T;
MA7F\&KZYJ:V%G'?&$/)(OVD+_K%4<&HDN[W4+SP_/>:A)!AY$=NBR%>F:8'I
M$5U!.I:&0.H."R\@&I-P SG ]Z\JTFXU/2Y'N[>Z;R9;YHO((RN"?O&NF\*:
MI<SZI>V-],9+Q"6W)S&5SQ^- '8#GI2XIB?>(P1]:DH 3%&*6B@!"#ZTF#T[
M>M.HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@""[M;>\@,-S$
MLL9/*L.*K_V38?9A;"TA\@?P;:OD9I,"@"@VEV#B)&M(BL1^10/NTZ73;.:Y
M2Y:",S)]U\8J[M'/;-&!Q[4 5A:6Q;<8(R_4G%"6D"E"L48" A..@/6K!7 &
M,U%+<0P8\V:./)XWL!F@"&WTZSM)WF@MTCD?JP%7%Z572Z@E.([B-S_=5@>*
MIW_B#3-+G2"\O(XI'Z*3DT :M%9]OJUM=7TEE%*IGC02,!V!Z5<#-GD=J )*
M*:2W/3I36=E!.W@4 2451O\ 5+72[5KF]GCA@! WN< Y[5%I^NZ=JN18WD4[
M 9*J>1^% &G14>]NPX[DT-(45BQ&%&2: )**JVE[%?0^=;MOC['&.:GWGT[\
MT .HIN3DCO2YI/0-Q:*C>9(Q\[*OU-(DR2'Y'5N.@-.TMQ<RO8EJ.:&.=0LJ
M!P#D U5?5K*-KA6N8PULF^9<_<'O4%AX@TO5I&CL+Z*:11DJIYQ].](9;N[*
MUOK?R;BWCFB]&'2D%G:X6,P1X1=JC' 6FWNHVFFVIN+V9((AW;O3+/5;.^M4
MGM;E)(G; <G'/I3 =-I=A</%)):1.T?W"1TJ62TMY)5E:&-I5!16(Y /44U+
MV"2]DM4?,\>"R'C /I5C.>?6@!D$4,$*Q0JJQKP !5/^QK "=4M8DDE4AW4<
M\U?'+;?;D>E/VB@#)TC0;#0[?R[2 #N9,<FIIM(TZZG%Q/9Q--V<CFM C-&*
M ()K:*:#R)8U:(C&SM3+:SMK*'R+:%(4ZE5'6K.T?CZTN* *HL;7&/)CQNWC
MCO3)]-LKF-HIK:*16.YE8<9]:N[1[T;0>M %5;.WB2-8X8U$0Q& .@]*9)86
MDR*C6\9C1MRC'W6J[BC:* *OV.VQM\B,+UQCO1:V%K9EVMH%0L<G ZU:  H"
MX[F@!!U'ZTZC'-% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% ",,K7@G[1EQ- =%$,TB9WY",17O;=*R]4T'2]:V?
MVG917.PG87&<9H ^>/@!<W$WC><2SRL/L['#L2*]5\56KZ1K=SXDL9;6Z"1@
M7=E.03L'=!ZUUVF^&=&T:X:?3M/AMY2,%U7'%,OO#&D:G>+=W5H))!T). ?\
M: . VS:QXBU34[&^FT]5T])MB<9] ?:GWGB22^T+3S)?7":DUN9=L)V@XZ$F
MO1ETFRCDED2UC#2IY<F%ZJ.@JI-X8T:Z2)9-/0B$;4.,<>GTH XBUU/5M?\
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MOF1SJ^TRM]:[BY\,:/>VD5M-9J8XFRG8K]*+KPUI-Y#%%-:J?)&V-EX*CZT
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' "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>form10-k_010.jpg
<TEXT>
begin 644 form10-k_010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $T 1\# 2(  A$! Q$!_\0
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M_7=_Y"OG#O0 4444 =1\.?\ DHFA?]?2U]KU\4?#G_DHFA?]?2U]KT %%%%
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MI:3O2T >'_M(_P#("T?_ *[O_(5\X=Z^C_VD?^0%H_\ UW?^0KYP[T %%%%
M'4?#G_DHFA?]?2U]KU\4?#G_ )*)H7_7TM?:] !1110 4444 %%%% !1110
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M=_R4V_\ ]Q?Y5]=5\B_&[_DIM_\ [B_RH \ZHHHH *]X_9K_ .0AKG_7*/\
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MQXRF,,R28MAG::=9^%;6SN$VRO);Q9*0N<@$]34=I9VUGXRE6WA2(&V&=HH
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M9S@9]:PU_P"1TD_Z]1_.MS)K"3_D=)/^O44 ;O>EI.]+0!X?^TC_ ,@+1_\
MKN_\A7SAWKZ/_:1_Y 6C_P#7=_Y"OG#O0 4444 ;W@K_ )';1?\ K[C_ )U]
MP#H*^'_!7_([:+_U]Q_SK[@'04 +1110!GZY_P @.]_ZY-3M%_Y UI_US%-U
MS_D!WO\ UR:G:+_R!K3_ *YB@"]1110 4444 %?(OQN_Y*;?_P"XO\J^NJ^1
M?C=_R4V__P!Q?Y4 >=4444 %>U?LX_\ (T:I_P!>R_S->*U[7^SA_P C/JI_
MZ=U_F: /I2BBB@ [5@>(/^0IHO\ U\'^5;_:L#Q!_P A31?^O@_RH WZ***
M"BBB@ HHHH **** ,)?$4;:HUL\#+#YC1+/GC<O6J":UIG_"7R2_;8MGV<#=
MGOFM5=!M5U)KW=*=Q)$)/R!CU.*LC2=/QS90@]/NT 1_V_I/_/\ P_\ ?5+_
M &_I/_/_  _]]5)_9.G_ //G#_WS1_9.G_\ /G#_ -\4 >*?M"WMMJ&BZ0MG
M*)V69R1'SC@5\^_9YO\ GC)_WR:^[!I6GC'^A0'V* XIPTO3_P#GQM_^_0H
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84 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>form10-k_011.jpg
<TEXT>
begin 644 form10-k_011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $G G # 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%8&INXOI '8#C@'VK?KGM4_Y"$GT'\J *OFR?\]'_P"^C1YLG_/1_P#OHTVB
MF(=YLG_/1_\ OHT>;)_ST?\ [Z--HH =YLG_ #T?_OHT>;)_ST?_ +Z--HH
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M;10 [S9/^>C_ /?1H\V3_GH__?1IM% #O-D_YZ/_ -]&CS9/^>C_ /?1IM%
M#O-D_P">C_\ ?1H\V3_GH_\ WT:;10 [S9/^>C_]]&CS9/\ GH__ 'T:;10
M[S9/^>C_ /?1H\V3_GH__?1IM% #O-D_YZ/_ -]&CS9/^>C_ /?1IM% #O-D
M_P">C_\ ?1H\V3_GH_\ WT:;10 [S9/^>C_]]&CS9/\ GH__ 'T:;10 [S9/
M^>C_ /?1H\V3_GH__?1IM% #O-D_YZ/_ -]&CS9/^>C_ /?1IM% #O-D_P">
MC_\ ?1JQ92.;V$%V(W=R:JU8L/\ C^A_WJ .EKFM:GBMI[B>9PD4:AG8]  .
MM=+7+>(K1+_[99R,RI/'Y;,O4 CM2&5+:]M;N'S8)T=,D9SC!'7(/(J7S(_^
M>B>GWA6#=^$+&ZD4B:6*,1E#&H!#9^\23R2>^:9-X-LKB[FN)+B4^8<B/8NU
M/0 8[ XIB-^6XAAC,DLT:( "69@!@\"G%T'5T'./O"N=_P"$,L 9#Y\AWH$&
MY5;;ALC'MP..E*G@S3U5PTC/N,A&] <%QC/N1V- SHP00"""#T(HJ&TMQ:6<
M-L':01($#MC)QW.*FH$%%%% !1110 4444 %5(M3L9KJ6VCN8S-$2'0\8P<'
MKUP2/SJW7.7/@^VN9[R4WLZ&Z9BP5%XW$$CWZ<>E SH3(B@DNHQUYZ5%;7MM
M>1B2WF613T(XSQGC/L:PV\'6;.K-=3';)Y@4J,9P ?QXSFE3P=8H5)N)V*@
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MVVY.!_.KU07%O#=VTEO<1K)#*I1T89# ]12&8\.KV,DJPR6$L,QCDD,;HC,
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M_P#SQC_[Y%344 0_9;?_ )XQ_P#?(H^RV_\ SQC_ .^14U% $/V6W_YXQ_\
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M^14U% $/V6W_ .>,?_?(H^RV_P#SQC_[Y%344 0_9;?_ )XQ_P#?(H^RV_\
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MDF93'',8698R0"#@DXZ#/<T :]%%% !1110 454^VP?VB+#<WGF(R[=IQM!
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M+!D*L6?<.X(48]ZL:1=7<]Q>QW+>8L<O[MU0JNTY^49 )(XSUZ]: -BBBB@
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M7MMJMO'#N$!"$@0EA)EL/EA]W:OS>]9D^LZL%NRKNA7)1?LC':VYMJ9QR&4
MY_EGA#.MCC6.-8T&%4  >PIU,C9FB1F&&*@D$8P:?3$+1110 UT61&1AE6&"
M/44R"WBM8A%"@1!T ISL51F"EB!D*.IID+M+&'>)XB?X'QD?D2* )J*** "B
MBB@ HHHH *@FM8+AXWEC#-&<H3V-3U!-*\1C"P22AC@E"N%]SDC]* )Z***
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MT 3T444 %%%% !1110!0U:_&FZ9-=;=[* (T_ON3A1^)(K ?Q;.<R0V2R1)
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M N41H=T8=.MV%F\5L^YF((?&0P"''RC/Y@ >M:&C:<^FV\L3E AD+)&A)"#
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MU BD=(TTLK&PM]RG<IV#(.2<C\23^--.B:4>NG6Q^??_ *L?>R3G]3^=7Z*
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MYBABCD7S4+JSX ."00.>3QVK4JI#IEI!*DD<;;H\E=TC, 3U."<9.3SUJW0
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M:,[$QD_F0!^-2U#=VD-]:O;7"EHGQN4,5SWZ@@T 4K37;6\D5526.-E+"64
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M0!4_-\^_O]WI[UGR/K>RX<?;@P96VB-3D^9T3_9V=?>NX^RP_P!S]:/LL/\
M<_6@9FG!.1THK2^RP_W/UH^RP_W/UH$9M%:7V6'^Y^M'V6'^Y^M &;69J4VH
MQW]F+6%GM@2TP4<MR!@GL "3[D 5TOV6'^Y^M'V6'^Y^M SB[Z37&>_6Q6X*
MLT3QM(H0JN/F5..3G@Y]ZTGU"9=9CLQ ODLF6DRV0W&!TQZ]ZZ+[+#_<_6C[
M+#C&W]: .5$UY&-465;^0>9FW,<0W;=HX3MUR 35W2_M']FP?:C(9\?-YBX8
M<]#].F>];OV6'^Y^M'V6'^Y^M &;16E]EA_N?K1]EA_N?K0(S:!UYZ5I?98?
M[GZT?98?[GZT <69-:47@VW19@0IVKA3O/\ J_;9Z]\5$KZVLF7&H&,9V!44
ML8L/][_IK]S'_P"NNY^RP_W/UH^RP_W/UI#,'2OM!TR$W1E\XY)$HPZC)P#Z
MD#C/>M"W_P"/A/K5[[+#_<_6A;>)6#!<$>].XB:J>I6,>I:;<V,K,L=Q&T;%
M>H!&.*N44AG+7W@NQG64VC&V=[<P@J/XBVX2$_>+ \@YZTA\$:<\;Q[I!"S;
MU3:AVMY93.2,G@Y /0UL:U+=PZ:S6(<W!DC4; "<%P#UXZ9Y-9"W6L(9XKNX
M:&ZCB_=*EL7BD^7.\L%/(/&!CITYH C_ .$#TW:0;BZ.2<<K_M=>/FY8\G/8
M=*JCP%&-5\XW6ZT,84CR@)-P;<2I'"@GT'3@#O6D=2U)M)MI/*GA#.!-.8P[
MJOS9(0#U"\[>C9Q6];,6MHF+L^5!W,NTM[D=J .9E\#64RV\4E[=>7;QM%&J
MA%X((YPO)P>IZXJ]=^%[*ZNKRZW21W5R\3^<N"4,>-N,C&/E[YK?HH Y&/P#
MIL2Q>7/.)(SN#D(VX_+C<"N&'R]#ZU+/X*L9Y)&\Z9"9'D ")M!9MQR"N&Y]
M<_H*ZFB@#DCX TKR#$LMRJD$,05RWWNIQS]X]:+#P>-.\3IJ<$L7V94<")HA
MN4L23M(X Y_+BNMHH **** "BBN5U#4=06XU%;>YG"Q !!]C)^?L%.TY7L6Y
MY/&* .JHKF+G4M6_M"W2!'2%H/WA: D!]K9/3H"%[_GFI$UF>ST2">[C>69Y
M?+)9ECW#=C< VWC'.,?6@#HZ*P[F_N4UBT$;R-;,A:5%A+ +M)#;@#GG X/X
M'/&<^J:R6G^QI-<1+=*I=K?8R(&^8!3C(/0'G@$]Q0!UM%%% !1137SL.#@X
MX.,XH =17*6.H:S))I[REG@9&\\_9RG(+#)!&03E, 'USZU%:ZEK;)"TP<'[
M2%:,0$,ZD#(!VX&"3G/I]XT =A166FKA]9ETX0@%(]PD\Q3D\\;<Y]/SK+74
M[U-*O'EFNC(DO[B1;,[F7Y>-NWCDD<CCWQF@#J**P=*NM6GU&2.^B9+<0(4<
M(-KMGYFSUY_ND# K>H ***0YVG!P: %HKD;;5=7:YL1('>,EA,WV9EW8=AD#
M'&%"GJ.O?-1W.K:X$G,*RD[^]L0(N6P <'<"H4YP>O;/ .QV5%8QU@Q7UE9R
M0_/<1AG8NJE#@<;2<^O_ ->JZZC=+=ZFLLD_D(F8G%HQ*-\V0 !\W &.N?QQ
M0(Z&BN=TN;4[JYM'DGF,)C:28/ %!Y(1>@(;N<<<>]=%0 4444 %%%<O=:IJ
MD$]RD4;3A+P $0,N(MH.U>#DDY&[IUZ4 =116(E[=G7U0%GLVBSM$97RR.[$
MCG/08/X4R/66OM/O)(@UN\+E Z;9CC/7"Y_D?QH WJ*YEM2OS9:9^\EBO)F4
M2K]E)7G!)8X^48SZ<D=.:T](-X\,TEU+(X:5O)$B!6"#@9P!U()^A% &G111
M0 4450UB6X@TBZFM6VW"1,T9\LR?-CCY1UH OT5S\6H7J:G*"))[=H%:.-8B
MNU\#AB5ZL2>_&.<5'%K-_9:')=ZE:G[2MPR",E8QC=Q@D\@#OWQF@#I**PKW
M4+E+ZP:W:3R9,-+&L.\;,')W $9'' /YU4GN]2FN+^*SN9QM*I#FUVX<GL2O
M* $9/L<8H ZBBF("J*&;<P&"V,9-/H **** "BL+4;V_M]4MTAW^0=A(6$N)
M,MA\M_#M7D>OO6;)JFL>;)S.D.\[W%H6,/+;0HQ\P8!<GG&>W8"QU]%<@-1\
M0.D^RU=KGRFS%Y("P-D;2"<;\C)QD\CM7364DLMC;R3*RRM&I<,,$-CG(H L
MT444 %%(<[3@X-<M9ZIJ[R6/FPR/;;I!<SB#;NQNQ\O50 !V.<B@#J:6N+GU
M;7U-QY<4G$QV?Z.>%^?"_=ZG"^O7[PSQORZL(M7@L#$"94W%_,48/&!MSGUH
M!FK17.+?ZD)M16-);AE(%LKQ>6 WS9&2!P  >ISZ\XIND7^I7%[#%<M*"+8-
M/&]ML ?C&UNA/4D9P,@4(#I:*** "BBB@ HKEO[3U9?MWR2EN0H^SG]T=Y&%
MX^?Y!N[\_7%,M]1UF2Z1',@C.0C-:G#QX?\ >MP,'A?EXZ].> #K**S]'GFN
MM(M9KG<9WC!DW1E#N[_*>E:% !1110!%<7$-K"TT\J1QKU9S@"H!J5D9C$+N
M$R!/,*[QD+C.?ICFF:E9&_LGMRR#)!#.I8 @Y!X(.?<$8K.70)TM+BS&I.8+
MG!F9H\RL2 &^;/<#TXS0!HG5M.#1J;VW!DC\V/\ >#YDZ[AZC@_E0NLZ8[1*
MM];DR_ZL;Q\W../QK&/A"/@"]E"HACC5ER%4ES@C.#C><'M@4\^&9C"D3WX*
M?9Q;R?N22R!MW!9S@_G[8H Z6BBB@ HHHH **** "BBB@ J"YNK>TB\VYGCA
MCSC=(P49_&IZH:I92W]F;>&X6 L1N8Q[\KW'48R.,T 2I?V<CRHMU"S0C,@#
M@[!ZGTJ6"XBNH5F@D62-ONLO0UE0Z-*DUR[SV[I,GE*GV; 2/!^3[W(R<GUJ
M*71KF/2H;*VO"&27S"P9D &[.T 9('8#- &R]Q$DT<32HLLF=B%N6QUP.^*;
M!=V]TTBP3QRF-MKA&!VGT-9TVC";4X-26YD2YA39@_,F,8Z?CGWXJ:PTU[2Z
MNIY)_,:?;PL>P*%SCN>>>V![=: -.BBB@ HHHH ***BFB\Z)HQ(\>?XD."*
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M\.1(;U1=W'EWI!F!/S<9Z-[Y[YX&*TM-LAIVGPV@D:01+M#L "?RH N4444
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MJ#CCL6QGVKI3;P%MQAC+8VYVC./2F)9VR ;+>$ -N&U!P?7ZT 1C486U"2Q
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M_G%79R"-I&" O/8]?I4ND6%S8W=_-<WBW'VEE<, 01@8/&2 .@&/2M7R(?\
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M;.6\P@C.6&.@R ,8Y]JO:%9R6-BZ31Q0R/*7,<4I=%Z# R!Z?B<GO6IY$/\
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M51U)  I?(A_YY)_WR* '%EP<,H/8US$?A^Y7/VJ:"[/VO[29&RK'"C"]]N6
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MDOM+C,8>>V!DQLY!W9&1C\.: -#>O]X?G1N4]&'YU6MWL;M&:W,$JJQ4E,$
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MPC0P+( $D('S#TQUSSG/X55MM U6VV".>..-.%3?NQ\ZMEOE&]N#S@'IUZT
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MDW,+N+;[,AY4D!64,3@D=1E>0>O:@#3LO#26<L#QW6Y(B"L1C^3'KC/WO?\
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MYA;S+>6*)58_(7VX[=,@T 3VOA\6M_;RQW'[E'ED=!QYA9MRY]=I+<_2HO\
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M]QCH.M-_X193=)-]ON"$D+(C$X5>RCGL<\^]4KFQ\165C'';7#.%5(\0D$X
M X!'&,'G)SD=*N7FEZC)J(O+1DB=H%1VE<%N.R_+\AZY()'M0 G_  BD4<:&
M.X):.(HF1T)0+N!SP<C=FIY-!>2VLD^V.DMN#OG0'S')Y;#9X!/4$$?E5>[T
MS7KF[WQ74,42 &(,Y<JX0C)XYY-;&F1W<-FL5XXDD4?ZS=DM]>!TH QY/"S2
MB)6ORB1Q&+;%%M#>YY.3T/UJS9Z!]DM)[7[29$GCD1I'!+Y; SR<?7U-;U%
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MB6$80J$/& HR<#KQZGC%:U%% !7-ZKKUY9ZE+#!;,UM'"5,OED@3%2RC/I@
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MKCM6AHD]U<6LK7+R.!)B.26+RV9=HSE<#&&W#IVK5HH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>form10-k_012.jpg
<TEXT>
begin 644 form10-k_012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $N G # 2(  A$! Q$!_\0
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M-I=M.MNMWGR8[AA&['., $\GZ5:74;)KK[*MW ;@Y_="5=_'7C.>* +=%%%
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M72^:G]X4GFQ_WQZT >?7F@^-O$?A_4M-U6;2K&.2S6"&*V9G\R0,"6=L JI
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MJ'AF/4;II9+@[650V8P6.!C&?[I[CUIMK92%;R(;KP]H26D-M-.T<18R*%<
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M8R*X 89P<T^FLRJ,LP ]2: &^4F>AZYZFCRDQC!Z8ZFCSHO^>B?]]"CSHO\
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M^>B?]]"CSHO^>B?]]"@ \I/0_F:/*3T/IU-'G1?\]$_[Z%'G1?\ /1/^^A0
M>4F<X[YZFCRDQT/IU-'G1?\ /1/^^A1YT7_/1/\ OH4 'E)Z'\S1Y:>A_,T>
M=%_ST3_OH4>=%_ST3_OH4 )Y2>AZ8ZFE\I,YQWSU-'G1?\]$_P"^A0)8R<"1
M"?\ >H DHHHH **** "BBB@ HHHH *Y'5_ =AJ^N?VE+<2H'(,L*@8?''7M7
M6T9IIM; <_\ \(1X<_Z!<?\ W\?_ !H_X0CPY_T"X_\ OX_^-=!12YGW%9'/
M_P#"$>'/^@7'_P!_'_QH_P"$(\.?] N/_OX_^-=!11S/N%D<_P#\(1X<_P"@
M7'_W\?\ QH_X0CPY_P! N/\ [^/_ (UT%%',^X61S_\ PA'AS_H%Q_\ ?Q_\
M:/\ A"/#G_0+C_[^/_C7044<S[A9'/\ _"$>'/\ H%Q_]_'_ ,:/^$(\.?\
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M]+TZWD/]XH ?S%:E%%[ <P?!Z6Q+:5JVH6)_NB7S$_)O\:-OB^Q'#V&IH.S
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MZ_U'_ E_F* +%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!3U3_D$WG_ %P?_P!!-4/"'_(IZ9_UP%7]4_Y!-Y_UP?\ ]!-4
M/"'_ "*>F?\ 7 4^@NIMT444AA1110 E<?+J>M6DU[>L-UG#-)'MDQ@_,%3:
M ,C&3DDXKK\BN4O/&'V74)(?LN^(;D0*^7+ARIW ?='!QZ\5I!-[*Y$FNY1C
M\7:GM:=K-2I0%8P"-@RH+,3VR2:L/XFU:2W$R6<,",57+[F*_=))[8P3BFOX
MT?[/,XMD5MY\G+9.WY>'7JI^;\:<OC80I(]Q;JRAE"['PQ&/F./;_.*UY7_*
M1?\ O%G4O$UY9ZK=6D=AYB0IN3D[I#M!XQZD[1[U3_X3*\(G*V<<AC !2,MN
MB.$.7SC ^<C_ (":GM_&$C9\VS5F WL(Y!A%!()R>IX'%6[+Q':R6NH72VPB
M6%$G;]XN7W@XW?W6^4 @].*GELM8CO?J9[^*=4$ NO[/ B'RA%)))P,L>VT9
MSUIZ^*=1,'V@Z<@B.$ZMD-LW[SQ]RFQ>.4<R2O:?N%  "R#>&PQ(P>H^7KQB
MI(_&81)3<6BDQRLA$4H/\1"[?[W3DC@4^5_RDW_O$,GB^_22:-+*-_+CW"4,
MP1^ =XSSL.<#W'6K5[K&IE=)N;.--EQ'NDB=6&6)11D]@-Q/X4R3QB8<>;8M
M&VXC'F!MVT[6 ].<4V\\;+:HT?V/;<A7!4R!@CA6(SCJ#MZ\4<KZ1*YEU9"_
MC"^47'F644(A=@7E9@JXW?*<?Q';D?6GW'C&Y2W#16&9% \T$G$3$OP>G4*,
M?[PK0U;Q';V$\MM<V^^)8P9"9%&=RL<;3V^4Y/:J,'C-9"5BL6(0'<F\#9M+
M;CD]>%X&!0HW5^4&[:<P]?$&J2WMFC6L4$,UQM)8,2$#%2#V!)P137\4ZA+J
MD]C;6<9V2%5DDW   L#G'?Y?;K5[4O$JZ;/*S0-)#''%POWF>3=L'_CN/J:H
MCQY:.79+*Y:$(6#@?>ZXX]..M)1;U40;MU)M.\0WE]<W,C6X6..U,JVR@^8K
M9X#''4CD8[50E\1:Q)-'<0K;_9HMN_8K%9LLN<$CMG'US5F/QHKS3*UE(-L7
MF(I.,D=1D]3TP ,XR:Z/3;^+4]/ANXL 2*&VYSBD_=U<1K71,YNV\4ZC<HCC
M3T" YDY.2"R+@8[C><_[IKL***SDT]E8I)K=BT445)04444 %%%% !5>X_UE
MO_UT_H:L57N/]9;_ /73^AH ;=6=M?0B*[MXIX]P8)*@89!R#@]Q65JV@VFH
M:C'=7%P(F"*N,+NPK%@58\KR><5O?C6+JGAVUU6Y,\^"VQ4&4#8 W>OKN_05
M<'9[V)DKK8SV\-6-L@D_M H+4^8A8*=C8Y+?WL^AJQIWA^QL@XCNF>"2W,*H
M^W(4X).>I_'I5-/!]FU\[RW_ )S.#B-D7MGGW(S0W@6V8(GVR4HD;1C<H) .
M>_\ P(Y]>*T;6SE^!G9]A]MX.TZ.)H[>\E8MGS&+*Y*MC</;)&<^I-7++0=/
ML+Z.[AG821Q?9B-PPR\G!'KDY]>*?I^@KI6HW-U;2HD5PX+PB,*H !Z8[Y(_
M*L]_!EO.8V^UDK&Y*XB7D9SDGNV>-U+FONRN6VR)M-TN#[/$(-3;R714=8\
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M8K_8K7RO*^RP^6.-OEC'Y?B:=#:P6Y8PQ)'OQNVC&<# _2ILT9HNQV%HHHI
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M+R,=,0M*<N2J_,?>CFCV"TNYC#Q-I!9[M;.<ND.UV\K&U2Q^7GU()X]*L?\
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MD,IZI_R";S_K@_\ Z":H>$/^13TS_K@*OZI_R";S_K@__H)JAX0_Y%/3/^N
MI]!=3;HHHI#"BBB@ HHJC=WPM9K:$02S27#[0(\?*!U8Y(X'YT 7J*HI?[M2
M:S>WEC(3>DK8V2#OC!SQD=0.M7J "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **:64$ D GH,]:9-/%;Q-+-(D<:_>9C@#
M\: ):*0'(R.E+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%-#*Q(!!(Z^U #J*** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** *>J?\@F\_ZX/_Z":H>$/^13TS_K@*OZI_R";S_K@_\
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MZ717D-E\3M5L=!M)9K"*]6UTJSOK^XDGV2.)>#L7&"V>>PKUM&#HKCHP!&:
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MEJT/F3-.BBBI&%%%% !1110 4444 %%%% !1110 4444 %-"@9P ,G)Q3J*
M,>Y?15DO;:XGMDDGCS<HTN&*XQD\\<5F1VWA.1V@#V[<@$/.Q#E\L.I^8\GZ
M5%>:+;:GKUTDM\BP*0SP)D,LK!=IR>,_(#BI_P#A%],6-,7DBH'4DB11EQQP
M>Q/M6RY4MV9ZOH71IFA><^GE8FF*AFB:4ER!N()R<_QM^=5A;Z)JRR-<02I]
MDC56\]GC*I@E2>>F,]>?6K0T>T_M]M5^TNTZY'EF0%5)4*>.W S6<=/T:#3#
M]IU%YXII&9)R^6W?Q-E>N,=3P,4D_-@_0(H/"=Q&#&]N@).T^<4+;<@D'//&
M1GTS5F:'P_8ETE\I%OF-NY:0E<J"=N2?EQST[U6N?#=A;%KN>^=I(U>4B=AL
M)(8$E1V^8]*LIH-D-)LK%KU@;;*-(KC+LRE6!SW()]ZIM=V)7[(?;#P[!.GD
M7%L9PYP?/W,67<3DD\GYFZ^M0VD/AO\ M%3:M&T[MYJ.LS$%@QX'/7)/'O1)
MX7TG="PN'C6)?)^60#IN(Y[$;C3;7PMIME.EW#>2"\16:.9I <!L \=P<"E>
M/=AKV0[4/^$<MKQ+6\9(9B!@^8R;0Q=OO C&3O\ SQ4DD7AB&*2*22R6./;O
M0S<+SD9&?6I)[#3[S4$GEO0TL<04J'7!!#J&_'<U4D\.Z)IUQ)(URZ>2HE(=
MAA >Y..^W]*$U;=AKV1;GL="@TLP2[/LZ$3A?/.2<?*0=V>@P.<53EC\*Q11
M*3!Y>[R@T<Q.ULJ "0V<_=^G-79M"TS4(K93*6$$!B3:XY5EX)'J.HK/;0M'
MMKZ.T:\N%N)GWPKVSPW'&/X>:(M=V#3[(TT&A)I4ICN(%LBXWR).0 XP!\P.
M0>!WJL%\.7Q6P62%OLQ"H@G*DAL'J#E@3CKG)ICZ+:VMM'I4&H-%<33)<HKD
M$@1LI.U>@Z?3-0_V#I<V@S&QN@82KXG+9"G@,V1W&TD>]"MW8]>PIL?#:31?
M9[B "*=)9%6;?R VW))X49)XJY92Z#8N7M;J.)&(Y-QE)&;ZDY(Q^%9JZ1X>
MNI4(O9/WPPD*G:247D[<9R!SR.]7)?"EEJ40F>^NI?.4%I%< .,8' &.AINW
M5LE7Z)&[:WUI>^9]FN8IO+;:_EN&VGT.*M5GV&DV^G,3!NY0(<GL"3_[,:T*
MQ=KZ&JOU"BBBD,**** $I"R@@$@$]!ZTM4;O2;.]OK*\N(M]Q9,S0-N(VEA@
M_7BA>8#=2CL98H8[Z01AY0L1$AC;S#G 5@0<]:HQ^'=!N$1H[=608 "RN =N
M!TSS]T?E5S5=*CU:*"*<_NHY?,(QR?E(&#V()SGVK*TSPQ/875O-)>K.8CN:
M0QXD8X(VYS@*<Y(]:TBU;>Q#6NQ<@\/Z;& 9E$LOVEK@MN*YD9L\@''8<'TJ
M=]&TUKQKMX5,Q?=DL<!N.0,X!.!GUQ7.S^%+AKS,=W;M!--*6++S&6!&5YY?
M/3TQ4\7@Z:%V;[:DN7)VSH65L_Q$9'SCL:IV_F%KV-B2PTJ2VA#JH1!Y<1WE
M2N6&,'.0=P&#UJS9V%GIT4D=M&L:M@N-Q.> ,G)] *YV+PE+'J4-P^I(RQNI
MV[,%@&#8//M4^I>%Y[Z:Z=+F%!.^XLT1+D<?*3G[HQQQ2:6UPUWL:/\ PC^E
M>;N\@AC$(,"5P-@Z#&<<?_7J==+L$@2V\K]W'NVAG).6SG)SDDY/6L'_ (0Q
MLVS_ &X^:CAI'VD%\!<'KU&WCZFI]4\*#4+R2X2Z$<KR[FX_AV@ ?48R/J:-
M/Y@U[%YO#>D.K(+;@\865QM'/ P?E'S'(&,Y-21:/I68'CA4&V<M'B1L*V>3
MC///K6%_PB=\E]*\-W$J["JRLA+/N\P,7YY8!Q@^PI\W@OS() +W]\T@;>5Z
MK@C:>>F3GZ@4]/YA:_RFW_8MBTS/(#(3*90A<@ D@D8!Y&X;L'/-1W.A:1<R
MO<SP@L^6)\YE&>,D ' /RC)'I6:?!:8)6[*S$-^_"_."6)W9SUP<5';^"]D6
M);L,^ %.S(3YLG'/&1P?K1I_,/7L:$/AS2I%E955X)HHT148C$:Y(^8')SD\
MYK2L;*"Q$QB;B5@W7@  *H'L  *PM.\)RV4=W%]L55N+80?N8]NTXQNZ^W3W
MJ!?!<PCA'V\*8U==JH=IW?CV[>F6]:'9[R!770Z\.IZ,.F?PJ)[NWC$A>>)1
M&N]\N/E'J?05R5QX/NG,LT5S"':(JL,:%(U//R@9^[SDCUJ[#X4,=K?Q.]OF
M\@\M@L/RH<D@ 9^Z,]*GECW'S2['3!@<X(/TIU8.C:(^F7$TKSH^Y=OR(5+?
M,3EN>3S@>P%;U0TD]"E?J%%%%(84444 %%%% %/4/L?]GS"_\L6I7]YOX&*P
M-GAAV\MW!PZL)))WS(6QC+9RPX P>!@5MZQ:+>Z5/ T_D*P!,O\ =P0<_I62
MWA/2;Q1*L\TBEMS,LP(=MV[)[9S6D&DM6R)7OHBNECX6,T@:ZC?S6")&UPV$
M(_N\_D?P!IT<'A%XRB2VY5%S_KVXP<YZ]?FZ]>:M-X0TYI(7>2=_)4(@9P0J
M Y"CCIG\?>GR>%=+N;98R)"F$VD/_=4!3^@JN:/=D\K[(IW$GA2*S9'EA>,
M.521F8Y&T'@YS@_7O5BX&AR:Q-#>2J)D\MO+E8@;L<,#GDXP/PIX\)::+7R
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MY5MV\"6MO'!'G9&H5<G)P*F;71L<4^J)Z***S+"BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
5BB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>19
<FILENAME>nrxs-20231231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWa6FibP9z5Z8eekhvWBzbWlKzyMpxDs0cydwDAi24QAF -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:NRXS="http://neuraxis.com/20231231" elementFormDefault="qualified" targetNamespace="http://neuraxis.com/20231231">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://neuraxis.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/BalanceSheets" id="BalanceSheets">
          <link:definition>00000002 - Statement - Balance Sheets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - Balance Sheets (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/StatementsOfOperations" id="StatementsOfOperations">
          <link:definition>00000004 - Statement - Statements of Operations</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/StatementsOfStockholdersDeficit" id="StatementsOfStockholdersDeficit">
          <link:definition>00000005 - Statement - Statements of Stockholders' Deficit</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
          <link:definition>00000006 - Statement - Statements of Cash Flows</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMatters" id="BasisOfPresentationOrganizationAndOtherMatters">
          <link:definition>00000007 - Disclosure - Basis of Presentation, Organization and Other Matters</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
          <link:definition>00000008 - Disclosure - Summary of Significant Accounting Policies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
          <link:definition>00000009 - Disclosure - Related Party Transactions</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/PropertyAndEquipment" id="PropertyAndEquipment">
          <link:definition>00000010 - Disclosure - Property and Equipment</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/IntangibleAssets" id="IntangibleAssets">
          <link:definition>00000011 - Disclosure - Intangible Assets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/AccruedExpenses" id="AccruedExpenses">
          <link:definition>00000012 - Disclosure - Accrued Expenses</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/NotesPayable" id="NotesPayable">
          <link:definition>00000013 - Disclosure - Notes Payable</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/Leases" id="Leases">
          <link:definition>00000014 - Disclosure - Leases</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/CommonStockAndWarrants" id="CommonStockAndWarrants">
          <link:definition>00000015 - Disclosure - Common Stock and Warrants</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/PreferredStock" id="PreferredStock">
          <link:definition>00000016 - Disclosure - Preferred Stock</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/StockOptionsAndAwards" id="StockOptionsAndAwards">
          <link:definition>00000017 - Disclosure - Stock Options and Awards</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/WarrantLiabilities" id="WarrantLiabilities">
          <link:definition>00000018 - Disclosure - Warrant Liabilities</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/DerivativeLiabilities" id="DerivativeLiabilities">
          <link:definition>00000019 - Disclosure - Derivative Liabilities</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/RetirementPlan" id="RetirementPlan">
          <link:definition>00000020 - Disclosure - Retirement Plan</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
          <link:definition>00000021 - Disclosure - Commitments and Contingencies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/HealthBenefitPlan" id="HealthBenefitPlan">
          <link:definition>00000022 - Disclosure - Health Benefit Plan</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/IncomeTaxes" id="IncomeTaxes">
          <link:definition>00000023 - Disclosure - Income Taxes</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>00000024 - Disclosure - Subsequent Events</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/RestatementOfInterimFinancialStatements" id="RestatementOfInterimFinancialStatements">
          <link:definition>00000025 - Disclosure - Restatement of Interim Financial Statements (Unaudited)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
          <link:definition>00000026 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
          <link:definition>00000027 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/RelatedPartyTransactionsTables" id="RelatedPartyTransactionsTables">
          <link:definition>00000028 - Disclosure - Related Party Transactions (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/PropertyAndEquipmentTables" id="PropertyAndEquipmentTables">
          <link:definition>00000029 - Disclosure - Property and Equipment (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/IntangibleAssetsTables" id="IntangibleAssetsTables">
          <link:definition>00000030 - Disclosure - Intangible Assets (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/AccruedExpensesTables" id="AccruedExpensesTables">
          <link:definition>00000031 - Disclosure - Accrued Expenses (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/NotesPayableTables" id="NotesPayableTables">
          <link:definition>00000032 - Disclosure - Notes Payable (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/LeasesTables" id="LeasesTables">
          <link:definition>00000033 - Disclosure - Leases (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/CommonStockAndWarrantsTables" id="CommonStockAndWarrantsTables">
          <link:definition>00000034 - Disclosure - Common Stock and Warrants (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/StockOptionsAndAwardsTables" id="StockOptionsAndAwardsTables">
          <link:definition>00000035 - Disclosure - Stock Options and Awards (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/WarrantLiabilitiesTables" id="WarrantLiabilitiesTables">
          <link:definition>00000036 - Disclosure - Warrant Liabilities (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/DerivativeLiabilitiesTables" id="DerivativeLiabilitiesTables">
          <link:definition>00000037 - Disclosure - Derivative Liabilities (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
          <link:definition>00000038 - Disclosure - Income Taxes (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/RestatementOfInterimFinancialStatementsTables" id="RestatementOfInterimFinancialStatementsTables">
          <link:definition>00000039 - Disclosure - Restatement of Interim Financial Statements (Unaudited) (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative" id="BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative">
          <link:definition>00000040 - Disclosure - Basis of Presentation, Organization and Other Matters (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/ScheduleOfEstimatedUsefulLivesDetails" id="ScheduleOfEstimatedUsefulLivesDetails">
          <link:definition>00000041 - Disclosure - Schedule of Estimated Useful Lives (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/ScheduleOfFairValueOnRecurringBasisAssetsAndLiabilityDetails" id="ScheduleOfFairValueOnRecurringBasisAssetsAndLiabilityDetails">
          <link:definition>00000042 - Disclosure - Schedule of Fair Value On a Recurring Basis Assets and Liability (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/ScheduleOfUnobservableInputsForLevel3AssetsAndLiabilitiesDetails" id="ScheduleOfUnobservableInputsForLevel3AssetsAndLiabilitiesDetails">
          <link:definition>00000043 - Disclosure - Schedule of Unobservable Inputs for Level 3 Assets and Liabilities (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/ScheduleOfDilutiveCommonStockEquivalentsDetails" id="ScheduleOfDilutiveCommonStockEquivalentsDetails">
          <link:definition>00000044 - Disclosure - Schedule of Dilutive Common Stock Equivalents (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails" id="ScheduleOfBasicAndDilutedNetLossPerShareDetails">
          <link:definition>00000045 - Disclosure - Schedule of Basic and Diluted Net Loss Per Share (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/ScheduleOfDisaggregationOfRevenueDetails" id="ScheduleOfDisaggregationOfRevenueDetails">
          <link:definition>00000046 - Disclosure - Schedule of Disaggregation of Revenue (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/ScheduleOfCustomersAccountedRevenuesDetails" id="ScheduleOfCustomersAccountedRevenuesDetails">
          <link:definition>00000047 - Disclosure - Schedule of Customers Accounted Revenues (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
          <link:definition>00000048 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/ScheduleOfRelatedPartyTransactionsDetails" id="ScheduleOfRelatedPartyTransactionsDetails">
          <link:definition>00000049 - Disclosure - Schedule of Related Party Transactions (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/ScheduleOfRelatedPartyLoansPayableToShareholderDetails" id="ScheduleOfRelatedPartyLoansPayableToShareholderDetails">
          <link:definition>00000050 - Disclosure - Schedule of Related Party Loans payable to shareholder (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
          <link:definition>00000051 - Disclosure - Related Party Transactions (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/ScheduleOfPropertyAndEquipmentDetails" id="ScheduleOfPropertyAndEquipmentDetails">
          <link:definition>00000052 - Disclosure - Schedule of Property And Equipment (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/PropertyAndEquipmentDetailsNarrative" id="PropertyAndEquipmentDetailsNarrative">
          <link:definition>00000053 - Disclosure - Property and Equipment (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/ScheduleOfIntangibleAssetsDetails" id="ScheduleOfIntangibleAssetsDetails">
          <link:definition>00000054 - Disclosure - Schedule of Intangible Assets (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/IntangibleAssetsDetailsNarrative" id="IntangibleAssetsDetailsNarrative">
          <link:definition>00000055 - Disclosure - Intangible Assets (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/ScheduleOfAccruedExpensesDetails" id="ScheduleOfAccruedExpensesDetails">
          <link:definition>00000056 - Disclosure - Schedule of Accrued Expenses (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/ScheduleOfConvertibleNotesDetails" id="ScheduleOfConvertibleNotesDetails">
          <link:definition>00000057 - Disclosure - Schedule of Convertible Notes (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/NotesPayableDetailsNarrative" id="NotesPayableDetailsNarrative">
          <link:definition>00000058 - Disclosure - Notes Payable (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/ScheduleOfOperatingLeasesDetails" id="ScheduleOfOperatingLeasesDetails">
          <link:definition>00000059 - Disclosure - Schedule of Operating Leases (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/ScheduleOfMaturitiesOperatingLeaseLiabilitiesDetails" id="ScheduleOfMaturitiesOperatingLeaseLiabilitiesDetails">
          <link:definition>00000060 - Disclosure - Schedule of Maturities Operating Lease Liabilities (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/LeasesDetailsNarrative" id="LeasesDetailsNarrative">
          <link:definition>00000061 - Disclosure - Leases (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/ScheduleOfWarrantActivityForCommonStockDetails" id="ScheduleOfWarrantActivityForCommonStockDetails">
          <link:definition>00000062 - Disclosure - Schedule of Warrant Activity for Common Stock (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/ScheduleOfWarrantActivityForPreferredStockDetails" id="ScheduleOfWarrantActivityForPreferredStockDetails">
          <link:definition>00000063 - Disclosure - Schedule of Warrant Activity for Preferred Stock (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" id="ScheduleOfWarrantsOutstandingAndExercisableDetails">
          <link:definition>00000064 - Disclosure - Schedule of Warrants outstanding and Exercisable (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative" id="CommonStockAndWarrantsDetailsNarrative">
          <link:definition>00000065 - Disclosure - Common Stock and Warrants (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/PreferredStockDetailsNarrative" id="PreferredStockDetailsNarrative">
          <link:definition>00000066 - Disclosure - Preferred Stock (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/ScheduleOfOption-pricingModelWithFollowingWeighted-averageAssumptionsDetails" id="ScheduleOfOption-pricingModelWithFollowingWeighted-averageAssumptionsDetails">
          <link:definition>00000067 - Disclosure - Schedule of Option-pricing Model with Following Weighted-average Assumptions (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/ScheduleOfStockOptionActivityDetails" id="ScheduleOfStockOptionActivityDetails">
          <link:definition>00000068 - Disclosure - Schedule of Stock Option Activity (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/StockOptionsAndAwardsDetailsNarrative" id="StockOptionsAndAwardsDetailsNarrative">
          <link:definition>00000069 - Disclosure - Stock Options and Awards (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/ScheduleOfChangesInWarrantLiabilitiesDetails" id="ScheduleOfChangesInWarrantLiabilitiesDetails">
          <link:definition>00000070 - Disclosure - Schedule of Changes in Warrant Liabilities (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/WarrantLiabilitiesDetailsNarrative" id="WarrantLiabilitiesDetailsNarrative">
          <link:definition>00000071 - Disclosure - Warrant Liabilities (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/ScheduleOfChangesInDerivativeLiabilitiesDetails" id="ScheduleOfChangesInDerivativeLiabilitiesDetails">
          <link:definition>00000072 - Disclosure - Schedule of Changes in Derivative Liabilities (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/DerivativeLiabilitiesDetailsNarrative" id="DerivativeLiabilitiesDetailsNarrative">
          <link:definition>00000073 - Disclosure - Derivative Liabilities (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/RetirementPlanDetailsNarrative" id="RetirementPlanDetailsNarrative">
          <link:definition>00000074 - Disclosure - Retirement Plan (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
          <link:definition>00000075 - Disclosure - Commitments and Contingencies (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/HealthBenefitPlanDetailsNarrative" id="HealthBenefitPlanDetailsNarrative">
          <link:definition>00000076 - Disclosure - Health Benefit Plan (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/ScheduleOfDeferredTaxAssetDetails" id="ScheduleOfDeferredTaxAssetDetails">
          <link:definition>00000077 - Disclosure - Schedule of Deferred Tax Asset (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/ScheduleOfFederalStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails" id="ScheduleOfFederalStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails">
          <link:definition>00000078 - Disclosure - Schedule of Federal Statutory Income Tax Rate and Effective Income Tax Rate (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/ScheduleOfStateCarryforwardsDetails" id="ScheduleOfStateCarryforwardsDetails">
          <link:definition>00000079 - Disclosure - Schedule of State Carryforwards (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
          <link:definition>00000080 - Disclosure - Income Taxes (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
          <link:definition>00000081 - Disclosure - Subsequent Events (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails" id="ScheduleOfRestatementOfInterimFinancialStatementsDetails">
          <link:definition>00000082 - Disclosure - Schedule of Restatement of Interim Financial Statements (Unaudited) (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://neuraxis.com/role/RestatementOfInterimFinancialStatementsDetailsNarrative" id="RestatementOfInterimFinancialStatementsDetailsNarrative">
          <link:definition>00000083 - Disclosure - Restatement of Interim Financial Statements (Unaudited) (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="nrxs-20231231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="nrxs-20231231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="nrxs-20231231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="nrxs-20231231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
    <element id="NRXS_ConvertibleSeriesAPreferredStockMember" name="ConvertibleSeriesAPreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ConvertibleSeriesSeedPreferredStockMember" name="ConvertibleSeriesSeedPreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_AlexanderCapitalLPMember" name="AlexanderCapitalLPMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_TrademarkAgreementMember" name="TrademarkAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_InitialPaymentMember" name="InitialPaymentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_SecondAndFinalPaymentMember" name="SecondAndFinalPaymentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_LicensingAgreementMember" name="LicensingAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_CustomerMember" name="CustomerMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_CustomerOneMember" name="CustomerOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_CustomerTwoMember" name="CustomerTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_CustomerThreeMember" name="CustomerThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_CustomerFourMember" name="CustomerFourMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_WarrantsMember" name="WarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ConvertibleBridgeDebtMember" name="ConvertibleBridgeDebtMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_AllOtherStatesMember" name="AllOtherStatesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_HospitalAMember" name="HospitalAMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_HospitalBMember" name="HospitalBMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_HospitalCMember" name="HospitalCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_HospitalMember" name="HospitalMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ShareholdersOneAndTwoMember" name="ShareholdersOneAndTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_MrWatkinsMember" name="MrWatkinsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_MrSealeMember" name="MrSealeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ShareHolderOneMember" name="ShareHolderOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ShareHolderTwoMember" name="ShareHolderTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ShareHolderMember" name="ShareHolderMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_OtherConvertiblesMember" name="OtherConvertiblesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_SoftwareImplementationMember" name="SoftwareImplementationMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_LicensesMember" name="LicensesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ExchangeListingLLCMember" name="ExchangeListingLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_PromissoryNoteMember" name="PromissoryNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ChannelPartnersCapitalMember" name="ChannelPartnersCapitalMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ConvertiblePromissoryNoteMember" name="ConvertiblePromissoryNoteMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_AccreditedInvestorsMember" name="AccreditedInvestorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_SignatureBankMember" name="SignatureBankMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_TwoThousandTwentyThreeConvertibleNotesMember" name="TwoThousandTwentyThreeConvertibleNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_TwoThousandTwentyTwoConvertibleNotesMember" name="TwoThousandTwentyTwoConvertibleNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_InvestorsMember" name="InvestorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember" name="TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_VersaillesIndianaMember" name="VersaillesIndianaMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_LeaseOneMember" name="LeaseOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_LeaseTwoMember" name="LeaseTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_CarmelIndianaMember" name="CarmelIndianaMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_LeaseThreeMember" name="LeaseThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_VendorsMember" name="VendorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_BrianHannaschMember" name="BrianHannaschMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_WarrantOneMember" name="WarrantOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_WarrantTwoMember" name="WarrantTwoMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_MasimoCorporationMember" name="MasimoCorporationMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_WarrantThreeMember" name="WarrantThreeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_InvestorWarrantOneMember" name="InvestorWarrantOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_InvestorWarrantPSAOneMember" name="InvestorWarrantPSAOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ConsultingAgreementWarrantsMember" name="ConsultingAgreementWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_UnderwriterWarrantsMember" name="UnderwriterWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_TwentySeventeenStockCompensationPlanMember" name="TwentySeventeenStockCompensationPlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ExecutiveEmploymentAgreementsMember" name="ExecutiveEmploymentAgreementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_TaxYear2038Member" name="TaxYear2038Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_TaxYear2039Member" name="TaxYear2039Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_TaxYear2040Member" name="TaxYear2040Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_TaxYear2041Member" name="TaxYear2041Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_TaxYear2042Member" name="TaxYear2042Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_TaxYear2043Member" name="TaxYear2043Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_WarrantLiabilities" name="WarrantLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_FinancingCharges" name="FinancingCharges" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering" name="StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_StockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering" name="StockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_StockIssuedDuringPeriodValueCommonStockIssuedUponPreferredStockConversion" name="StockIssuedDuringPeriodValueCommonStockIssuedUponPreferredStockConversion" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_StockIssuedDuringPeriodSharesCommonStockIssuedUponPreferredStockConversion" name="StockIssuedDuringPeriodSharesCommonStockIssuedUponPreferredStockConversion" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_StockIssuedDuringPeriodValueWarrantsExercised" name="StockIssuedDuringPeriodValueWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_StockIssuedDuringPeriodSharesWarrantsExercised" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_NoncashLeaseExpense" name="NoncashLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_NoncashInterestExpense" name="NoncashInterestExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_IssuanceOfCommonStockForNoncashConsideration" name="IssuanceOfCommonStockForNoncashConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_FinanceCharges" name="FinanceCharges" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_IncreaseDecreaseInCustomerDeposit" name="IncreaseDecreaseInCustomerDeposit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_DeferredOfferingCostsPaid" name="DeferredOfferingCostsPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_FairValueOfWarrantLiabilitiesOfWarrantsFromConvertibleNotes" name="FairValueOfWarrantLiabilitiesOfWarrantsFromConvertibleNotes" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_FairValueOfDerivativeLiabilitiesOfConversionFeatureFromConvertibleNotes" name="FairValueOfDerivativeLiabilitiesOfConversionFeatureFromConvertibleNotes" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_PriorYearOfferingCostsPaid" name="PriorYearOfferingCostsPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ReclassificationOfWarrantLiabilityToEquity" name="ReclassificationOfWarrantLiabilityToEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ConversionOfPreferredStockToCommonStock" name="ConversionOfPreferredStockToCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_DisclosureLeasesAbstract" name="DisclosureLeasesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_DisclosureCommonStockAndWarrantsAbstract" name="DisclosureCommonStockAndWarrantsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_CommonStockAndWarrantsDisclosureTextBlock" name="CommonStockAndWarrantsDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_DisclosureWarrantLiabilitiesAbstract" name="DisclosureWarrantLiabilitiesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_WarrantLiabilitiesDisclosureTextBlock" name="WarrantLiabilitiesDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_DisclosureDerivativeLiabilitiesAbstract" name="DisclosureDerivativeLiabilitiesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_DisclosureHealthBenefitPlanAbstract" name="DisclosureHealthBenefitPlanAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_HealthBenefitPlanDisclosureTextBlock" name="HealthBenefitPlanDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_DerivativeLiabilityPolicyTextBlock" name="DerivativeLiabilityPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_WarrantLiabilityPolicyTextBlock" name="WarrantLiabilityPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_GoingConcernPolicyTextBlock" name="GoingConcernPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" name="ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ScheduleOfRelatedPartyLoansTableTextBlock" name="ScheduleOfRelatedPartyLoansTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ScheduleOfWarrantActivityForCommonStockTableTextBlock" name="ScheduleOfWarrantActivityForCommonStockTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ScheduleOfWarrantActivityForPreferredStockTableTextBlock" name="ScheduleOfWarrantActivityForPreferredStockTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ScheduleOfChangesInWarrantLiabilitiesTableTextBlock" name="ScheduleOfChangesInWarrantLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_PurchaseOfAdditionalStockOnNumberOfOptionsNotExercised" name="PurchaseOfAdditionalStockOnNumberOfOptionsNotExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_UnderwritersDiscountPercentage" name="UnderwritersDiscountPercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_NonaccountableExpenseAllowancePercentage" name="NonaccountableExpenseAllowancePercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_CashFeePercentage" name="CashFeePercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ReimbursementExpenses" name="ReimbursementExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_OfferingPricePerPercentage" name="OfferingPricePerPercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_LicenseFees" name="LicenseFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_InventoryExpenses" name="InventoryExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_WorkingCapitalDeficit" name="WorkingCapitalDeficit" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_InterestIncomeGrossCurrent" name="InterestIncomeGrossCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_AllowanceForInterestIncomeCurrent" name="AllowanceForInterestIncomeCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_InterestIncomeCurrent" name="InterestIncomeCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_InterestAndServiceFeeAccrued" name="InterestAndServiceFeeAccrued" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_AllowanceForInterestReceivableCurrent" name="AllowanceForInterestReceivableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_AccruedCompensationAndBenefitsCurrent" name="AccruedCompensationAndBenefitsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_UnderwriterFees" name="UnderwriterFees" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_RelatedPartyInterestPayableCurrent" name="RelatedPartyInterestPayableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_DebtInstrumentDiscountRate" name="DebtInstrumentDiscountRate" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_DebtWarrantConversionDescription" name="DebtWarrantConversionDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ClassOfWarrantDiscountRate" name="ClassOfWarrantDiscountRate" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_DebtInstrumentPrincipalAmount" name="DebtInstrumentPrincipalAmount" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_PaymentsOfFinancingCost" name="PaymentsOfFinancingCost" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageRemainingContracualLifeOutstandingNumberGranted" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageRemainingContracualLifeOutstandingNumberGranted" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsConvertedPrefundedWarrantsInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsConvertedPrefundedWarrantsInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_WarrantExpirationDateDescription" name="WarrantExpirationDateDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_WarrantsExpirationDateDescription" name="WarrantsExpirationDateDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_AggregatePurchasePrice" name="AggregatePurchasePrice" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_SharePremiumPercentage" name="SharePremiumPercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_AdditionToWarrantLiabilities" name="AdditionToWarrantLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ReclassifiedToEquity" name="ReclassifiedToEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_AdditionToDerivativeLiabilities" name="AdditionToDerivativeLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ExtinguishmentOfDerivativeLiabilities" name="ExtinguishmentOfDerivativeLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ExecutiveEmploymentAgreementsTerms" name="ExecutiveEmploymentAgreementsTerms" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_DescriptionOfExecutiveEmploymentAgreementsRenewals" name="DescriptionOfExecutiveEmploymentAgreementsRenewals" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_SpecialBonusPercentage" name="SpecialBonusPercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_KeyEmployeeExercisePercentage" name="KeyEmployeeExercisePercentage" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_HealthCareOrganizationStopLossInsurancePremiumPercentage" name="HealthCareOrganizationStopLossInsurancePremiumPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_DeferredTaxAssetsDepreciation" name="DeferredTaxAssetsDepreciation" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_DeferredTaxAssetsAmortization" name="DeferredTaxAssetsAmortization" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_EffectiveIncomeTaxRateReconciliationNontaxableIncome" name="EffectiveIncomeTaxRateReconciliationNontaxableIncome" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ShareLiabilitiesCurrent" name="ShareLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_OfferingCostsInAdvanceOfSaleOfCommonStock" name="OfferingCostsInAdvanceOfSaleOfCommonStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_IncreaseDecreaseInWarrantLiability" name="IncreaseDecreaseInWarrantLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_InterestReceivableGrossCurrent" name="InterestReceivableGrossCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_AllowanceForCreditLosses" name="AllowanceForCreditLosses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_PaymentForOfferingCostsPaid" name="PaymentForOfferingCostsPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_StockIssuedDuringPeriodValueCommonStockIssuedFromUnissuedShares" name="StockIssuedDuringPeriodValueCommonStockIssuedFromUnissuedShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_StockIssuedDuringPeriodSharesCommonStockIssuedFromUnissuedSharesShares" name="StockIssuedDuringPeriodSharesCommonStockIssuedFromUnissuedSharesShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_WarrantsPolicyTextBlock" name="WarrantsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ExtingishmentOfWarrantLiabilities" name="ExtingishmentOfWarrantLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_AccruedWagesCurrent" name="AccruedWagesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_AccruedBoardFess" name="AccruedBoardFess" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_CapitalRaiseFees" name="CapitalRaiseFees" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentInYears" name="IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentInYears" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_EffectiveIncomeTaxRateExciseTaxRate" name="EffectiveIncomeTaxRateExciseTaxRate" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_BrianHannaschWarrantOneMember" name="BrianHannaschWarrantOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_BrianHannaschWarrantPSAOneMember" name="BrianHannaschWarrantPSAOneMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_ConsultingFee" name="ConsultingFee" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_AdvisoryAgreementsMember" name="AdvisoryAgreementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_PercentageOfCommissionForConsulting" name="PercentageOfCommissionForConsulting" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_PercentageOfOutstandingSharesForConsultingService" name="PercentageOfOutstandingSharesForConsultingService" nillable="true" xbrli:periodType="instant" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_AllowanceForCreditLossesPolicy" name="AllowanceForCreditLossesPolicy" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_InitialPublicOfferingCostsPaid" name="InitialPublicOfferingCostsPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="NRXS_AdditionalPaidInCapitalFromExtinguishmentOfWarrantLiability" name="AdditionalPaidInCapitalFromExtinguishmentOfWarrantLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>20
<FILENAME>nrxs-20231231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://neuraxis.com/role/Cover" xlink:href="nrxs-20231231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/BalanceSheets" xlink:href="nrxs-20231231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/BalanceSheetsParenthetical" xlink:href="nrxs-20231231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/StatementsOfOperations" xlink:href="nrxs-20231231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/StatementsOfStockholdersDeficit" xlink:href="nrxs-20231231.xsd#StatementsOfStockholdersDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/StatementsOfCashFlows" xlink:href="nrxs-20231231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMatters" xlink:href="nrxs-20231231.xsd#BasisOfPresentationOrganizationAndOtherMatters" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="nrxs-20231231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/RelatedPartyTransactions" xlink:href="nrxs-20231231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/PropertyAndEquipment" xlink:href="nrxs-20231231.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/IntangibleAssets" xlink:href="nrxs-20231231.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/AccruedExpenses" xlink:href="nrxs-20231231.xsd#AccruedExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/NotesPayable" xlink:href="nrxs-20231231.xsd#NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/Leases" xlink:href="nrxs-20231231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/CommonStockAndWarrants" xlink:href="nrxs-20231231.xsd#CommonStockAndWarrants" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/PreferredStock" xlink:href="nrxs-20231231.xsd#PreferredStock" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/StockOptionsAndAwards" xlink:href="nrxs-20231231.xsd#StockOptionsAndAwards" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/WarrantLiabilities" xlink:href="nrxs-20231231.xsd#WarrantLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/DerivativeLiabilities" xlink:href="nrxs-20231231.xsd#DerivativeLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/RetirementPlan" xlink:href="nrxs-20231231.xsd#RetirementPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/CommitmentsAndContingencies" xlink:href="nrxs-20231231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/HealthBenefitPlan" xlink:href="nrxs-20231231.xsd#HealthBenefitPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/IncomeTaxes" xlink:href="nrxs-20231231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/SubsequentEvents" xlink:href="nrxs-20231231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/RestatementOfInterimFinancialStatements" xlink:href="nrxs-20231231.xsd#RestatementOfInterimFinancialStatements" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="nrxs-20231231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="nrxs-20231231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/RelatedPartyTransactionsTables" xlink:href="nrxs-20231231.xsd#RelatedPartyTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/PropertyAndEquipmentTables" xlink:href="nrxs-20231231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/IntangibleAssetsTables" xlink:href="nrxs-20231231.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/AccruedExpensesTables" xlink:href="nrxs-20231231.xsd#AccruedExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/NotesPayableTables" xlink:href="nrxs-20231231.xsd#NotesPayableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/LeasesTables" xlink:href="nrxs-20231231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/CommonStockAndWarrantsTables" xlink:href="nrxs-20231231.xsd#CommonStockAndWarrantsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/StockOptionsAndAwardsTables" xlink:href="nrxs-20231231.xsd#StockOptionsAndAwardsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/WarrantLiabilitiesTables" xlink:href="nrxs-20231231.xsd#WarrantLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/DerivativeLiabilitiesTables" xlink:href="nrxs-20231231.xsd#DerivativeLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/IncomeTaxesTables" xlink:href="nrxs-20231231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/RestatementOfInterimFinancialStatementsTables" xlink:href="nrxs-20231231.xsd#RestatementOfInterimFinancialStatementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative" xlink:href="nrxs-20231231.xsd#BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfEstimatedUsefulLivesDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfEstimatedUsefulLivesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfFairValueOnRecurringBasisAssetsAndLiabilityDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfFairValueOnRecurringBasisAssetsAndLiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfUnobservableInputsForLevel3AssetsAndLiabilitiesDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfUnobservableInputsForLevel3AssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfDilutiveCommonStockEquivalentsDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfDilutiveCommonStockEquivalentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfBasicAndDilutedNetLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfDisaggregationOfRevenueDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfDisaggregationOfRevenueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfCustomersAccountedRevenuesDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfCustomersAccountedRevenuesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="nrxs-20231231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfRelatedPartyTransactionsDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfRelatedPartyTransactionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfRelatedPartyLoansPayableToShareholderDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfRelatedPartyLoansPayableToShareholderDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="nrxs-20231231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="nrxs-20231231.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfIntangibleAssetsDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/IntangibleAssetsDetailsNarrative" xlink:href="nrxs-20231231.xsd#IntangibleAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfAccruedExpensesDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfAccruedExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfConvertibleNotesDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfConvertibleNotesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/NotesPayableDetailsNarrative" xlink:href="nrxs-20231231.xsd#NotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfOperatingLeasesDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfMaturitiesOperatingLeaseLiabilitiesDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfMaturitiesOperatingLeaseLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/LeasesDetailsNarrative" xlink:href="nrxs-20231231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfWarrantActivityForCommonStockDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfWarrantActivityForCommonStockDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfWarrantActivityForPreferredStockDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfWarrantActivityForPreferredStockDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative" xlink:href="nrxs-20231231.xsd#CommonStockAndWarrantsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/PreferredStockDetailsNarrative" xlink:href="nrxs-20231231.xsd#PreferredStockDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfOption-pricingModelWithFollowingWeighted-averageAssumptionsDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfOption-pricingModelWithFollowingWeighted-averageAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/StockOptionsAndAwardsDetailsNarrative" xlink:href="nrxs-20231231.xsd#StockOptionsAndAwardsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfChangesInWarrantLiabilitiesDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfChangesInWarrantLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/WarrantLiabilitiesDetailsNarrative" xlink:href="nrxs-20231231.xsd#WarrantLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfChangesInDerivativeLiabilitiesDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfChangesInDerivativeLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/DerivativeLiabilitiesDetailsNarrative" xlink:href="nrxs-20231231.xsd#DerivativeLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/RetirementPlanDetailsNarrative" xlink:href="nrxs-20231231.xsd#RetirementPlanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="nrxs-20231231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/HealthBenefitPlanDetailsNarrative" xlink:href="nrxs-20231231.xsd#HealthBenefitPlanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfDeferredTaxAssetDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfDeferredTaxAssetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfFederalStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfFederalStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfStateCarryforwardsDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfStateCarryforwardsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/IncomeTaxesDetailsNarrative" xlink:href="nrxs-20231231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/SubsequentEventsDetailsNarrative" xlink:href="nrxs-20231231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfRestatementOfInterimFinancialStatementsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/RestatementOfInterimFinancialStatementsDetailsNarrative" xlink:href="nrxs-20231231.xsd#RestatementOfInterimFinancialStatementsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/BalanceSheets" xlink:title="00000002 - Statement - Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCosts" xlink:label="loc_us-gaapDeferredCosts" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapDeferredCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Deposits" xlink:label="loc_us-gaapDeposits" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDeposits" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_WarrantLiabilities" xlink:label="loc_NRXSWarrantLiabilities" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_NRXSWarrantLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesNoncurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingExpense" xlink:label="loc_us-gaapSellingExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapSellingExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_FinancingCharges" xlink:label="loc_NRXSFinancingCharges" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_NRXSFinancingCharges" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaapOtherNonoperatingIncome" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="loc_us-gaapOtherNonoperatingExpense" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/StatementsOfStockholdersDeficit" xlink:title="00000005 - Statement - Statements of Stockholders&apos; Deficit" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_NoncashLeaseExpense" xlink:label="loc_NRXSNoncashLeaseExpense" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_NRXSNoncashLeaseExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_NoncashInterestExpense" xlink:label="loc_NRXSNoncashInterestExpense" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_NRXSNoncashInterestExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_IssuanceOfCommonStockForNoncashConsideration" xlink:label="loc_NRXSIssuanceOfCommonStockForNoncashConsideration" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_NRXSIssuanceOfCommonStockForNoncashConsideration" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_FinanceCharges" xlink:label="loc_NRXSFinanceCharges" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_NRXSFinanceCharges" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:calculationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_IncreaseDecreaseInCustomerDeposit" xlink:label="loc_NRXSIncreaseDecreaseInCustomerDeposit" />
      <link:calculationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_NRXSIncreaseDecreaseInCustomerDeposit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:calculationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_DeferredOfferingCostsPaid" xlink:label="loc_NRXSDeferredOfferingCostsPaid" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_NRXSDeferredOfferingCostsPaid" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaapPaymentsOfFinancingCosts" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfFinancingCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMatters" xlink:title="00000007 - Disclosure - Basis of Presentation, Organization and Other Matters" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - Summary of Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/RelatedPartyTransactions" xlink:title="00000009 - Disclosure - Related Party Transactions" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/PropertyAndEquipment" xlink:title="00000010 - Disclosure - Property and Equipment" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/IntangibleAssets" xlink:title="00000011 - Disclosure - Intangible Assets" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/AccruedExpenses" xlink:title="00000012 - Disclosure - Accrued Expenses" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/NotesPayable" xlink:title="00000013 - Disclosure - Notes Payable" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/Leases" xlink:title="00000014 - Disclosure - Leases" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/CommonStockAndWarrants" xlink:title="00000015 - Disclosure - Common Stock and Warrants" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/PreferredStock" xlink:title="00000016 - Disclosure - Preferred Stock" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/StockOptionsAndAwards" xlink:title="00000017 - Disclosure - Stock Options and Awards" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/WarrantLiabilities" xlink:title="00000018 - Disclosure - Warrant Liabilities" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/DerivativeLiabilities" xlink:title="00000019 - Disclosure - Derivative Liabilities" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/RetirementPlan" xlink:title="00000020 - Disclosure - Retirement Plan" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/CommitmentsAndContingencies" xlink:title="00000021 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/HealthBenefitPlan" xlink:title="00000022 - Disclosure - Health Benefit Plan" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/IncomeTaxes" xlink:title="00000023 - Disclosure - Income Taxes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/SubsequentEvents" xlink:title="00000024 - Disclosure - Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/RestatementOfInterimFinancialStatements" xlink:title="00000025 - Disclosure - Restatement of Interim Financial Statements (Unaudited)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000026 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000027 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/RelatedPartyTransactionsTables" xlink:title="00000028 - Disclosure - Related Party Transactions (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/PropertyAndEquipmentTables" xlink:title="00000029 - Disclosure - Property and Equipment (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/IntangibleAssetsTables" xlink:title="00000030 - Disclosure - Intangible Assets (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/AccruedExpensesTables" xlink:title="00000031 - Disclosure - Accrued Expenses (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/NotesPayableTables" xlink:title="00000032 - Disclosure - Notes Payable (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/LeasesTables" xlink:title="00000033 - Disclosure - Leases (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/CommonStockAndWarrantsTables" xlink:title="00000034 - Disclosure - Common Stock and Warrants (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/StockOptionsAndAwardsTables" xlink:title="00000035 - Disclosure - Stock Options and Awards (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/WarrantLiabilitiesTables" xlink:title="00000036 - Disclosure - Warrant Liabilities (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/DerivativeLiabilitiesTables" xlink:title="00000037 - Disclosure - Derivative Liabilities (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/IncomeTaxesTables" xlink:title="00000038 - Disclosure - Income Taxes (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/RestatementOfInterimFinancialStatementsTables" xlink:title="00000039 - Disclosure - Restatement of Interim Financial Statements (Unaudited) (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative" xlink:title="00000040 - Disclosure - Basis of Presentation, Organization and Other Matters (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfEstimatedUsefulLivesDetails" xlink:title="00000041 - Disclosure - Schedule of Estimated Useful Lives (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfFairValueOnRecurringBasisAssetsAndLiabilityDetails" xlink:title="00000042 - Disclosure - Schedule of Fair Value On a Recurring Basis Assets and Liability (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapLiabilitiesFairValueDisclosure" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_WarrantLiabilities" xlink:label="loc_NRXSWarrantLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesFairValueDisclosure" xlink:to="loc_NRXSWarrantLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesFairValueDisclosure" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfUnobservableInputsForLevel3AssetsAndLiabilitiesDetails" xlink:title="00000043 - Disclosure - Schedule of Unobservable Inputs for Level 3 Assets and Liabilities (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfDilutiveCommonStockEquivalentsDetails" xlink:title="00000044 - Disclosure - Schedule of Dilutive Common Stock Equivalents (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails" xlink:title="00000045 - Disclosure - Schedule of Basic and Diluted Net Loss Per Share (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfDisaggregationOfRevenueDetails" xlink:title="00000046 - Disclosure - Schedule of Disaggregation of Revenue (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfCustomersAccountedRevenuesDetails" xlink:title="00000047 - Disclosure - Schedule of Customers Accounted Revenues (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000048 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfRelatedPartyTransactionsDetails" xlink:title="00000049 - Disclosure - Schedule of Related Party Transactions (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfRelatedPartyLoansPayableToShareholderDetails" xlink:title="00000050 - Disclosure - Schedule of Related Party Loans payable to shareholder (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000051 - Disclosure - Related Party Transactions (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:title="00000052 - Disclosure - Schedule of Property And Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="00000053 - Disclosure - Property and Equipment (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfIntangibleAssetsDetails" xlink:title="00000054 - Disclosure - Schedule of Intangible Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/IntangibleAssetsDetailsNarrative" xlink:title="00000055 - Disclosure - Intangible Assets (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfAccruedExpensesDetails" xlink:title="00000056 - Disclosure - Schedule of Accrued Expenses (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_AccruedCompensationAndBenefitsCurrent" xlink:label="loc_NRXSAccruedCompensationAndBenefitsCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_NRXSAccruedCompensationAndBenefitsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_UnderwriterFees" xlink:label="loc_NRXSUnderwriterFees" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_NRXSUnderwriterFees" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapInterestPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_RelatedPartyInterestPayableCurrent" xlink:label="loc_NRXSRelatedPartyInterestPayableCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_NRXSRelatedPartyInterestPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:label="loc_us-gaapAccrualForTaxesOtherThanIncomeTaxesCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapAccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfConvertibleNotesDetails" xlink:title="00000057 - Disclosure - Schedule of Convertible Notes (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/NotesPayableDetailsNarrative" xlink:title="00000058 - Disclosure - Notes Payable (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfOperatingLeasesDetails" xlink:title="00000059 - Disclosure - Schedule of Operating Leases (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfMaturitiesOperatingLeaseLiabilitiesDetails" xlink:title="00000060 - Disclosure - Schedule of Maturities Operating Lease Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/LeasesDetailsNarrative" xlink:title="00000061 - Disclosure - Leases (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfWarrantActivityForCommonStockDetails" xlink:title="00000062 - Disclosure - Schedule of Warrant Activity for Common Stock (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfWarrantActivityForPreferredStockDetails" xlink:title="00000063 - Disclosure - Schedule of Warrant Activity for Preferred Stock (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:title="00000064 - Disclosure - Schedule of Warrants outstanding and Exercisable (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative" xlink:title="00000065 - Disclosure - Common Stock and Warrants (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/PreferredStockDetailsNarrative" xlink:title="00000066 - Disclosure - Preferred Stock (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfOption-pricingModelWithFollowingWeighted-averageAssumptionsDetails" xlink:title="00000067 - Disclosure - Schedule of Option-pricing Model with Following Weighted-average Assumptions (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="00000068 - Disclosure - Schedule of Stock Option Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/StockOptionsAndAwardsDetailsNarrative" xlink:title="00000069 - Disclosure - Stock Options and Awards (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfChangesInWarrantLiabilitiesDetails" xlink:title="00000070 - Disclosure - Schedule of Changes in Warrant Liabilities (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/WarrantLiabilitiesDetailsNarrative" xlink:title="00000071 - Disclosure - Warrant Liabilities (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfChangesInDerivativeLiabilitiesDetails" xlink:title="00000072 - Disclosure - Schedule of Changes in Derivative Liabilities (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/DerivativeLiabilitiesDetailsNarrative" xlink:title="00000073 - Disclosure - Derivative Liabilities (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/RetirementPlanDetailsNarrative" xlink:title="00000074 - Disclosure - Retirement Plan (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000075 - Disclosure - Commitments and Contingencies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/HealthBenefitPlanDetailsNarrative" xlink:title="00000076 - Disclosure - Health Benefit Plan (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfDeferredTaxAssetDetails" xlink:title="00000077 - Disclosure - Schedule of Deferred Tax Asset (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_DeferredTaxAssetsDepreciation" xlink:label="loc_NRXSDeferredTaxAssetsDepreciation" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_NRXSDeferredTaxAssetsDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_DeferredTaxAssetsAmortization" xlink:label="loc_NRXSDeferredTaxAssetsAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_NRXSDeferredTaxAssetsAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfFederalStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails" xlink:title="00000078 - Disclosure - Schedule of Federal Statutory Income Tax Rate and Effective Income Tax Rate (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_EffectiveIncomeTaxRateReconciliationNontaxableIncome" xlink:label="loc_NRXSEffectiveIncomeTaxRateReconciliationNontaxableIncome" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_NRXSEffectiveIncomeTaxRateReconciliationNontaxableIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfStateCarryforwardsDetails" xlink:title="00000079 - Disclosure - Schedule of State Carryforwards (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000080 - Disclosure - Income Taxes (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000081 - Disclosure - Subsequent Events (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails" xlink:title="00000082 - Disclosure - Schedule of Restatement of Interim Financial Statements (Unaudited) (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/RestatementOfInterimFinancialStatementsDetailsNarrative" xlink:title="00000083 - Disclosure - Restatement of Interim Financial Statements (Unaudited) (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>21
<FILENAME>nrxs-20231231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://neuraxis.com/role/Cover" xlink:href="nrxs-20231231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/BalanceSheets" xlink:href="nrxs-20231231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/BalanceSheetsParenthetical" xlink:href="nrxs-20231231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/StatementsOfOperations" xlink:href="nrxs-20231231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/StatementsOfStockholdersDeficit" xlink:href="nrxs-20231231.xsd#StatementsOfStockholdersDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/StatementsOfCashFlows" xlink:href="nrxs-20231231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMatters" xlink:href="nrxs-20231231.xsd#BasisOfPresentationOrganizationAndOtherMatters" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="nrxs-20231231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/RelatedPartyTransactions" xlink:href="nrxs-20231231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/PropertyAndEquipment" xlink:href="nrxs-20231231.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/IntangibleAssets" xlink:href="nrxs-20231231.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/AccruedExpenses" xlink:href="nrxs-20231231.xsd#AccruedExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/NotesPayable" xlink:href="nrxs-20231231.xsd#NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/Leases" xlink:href="nrxs-20231231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/CommonStockAndWarrants" xlink:href="nrxs-20231231.xsd#CommonStockAndWarrants" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/PreferredStock" xlink:href="nrxs-20231231.xsd#PreferredStock" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/StockOptionsAndAwards" xlink:href="nrxs-20231231.xsd#StockOptionsAndAwards" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/WarrantLiabilities" xlink:href="nrxs-20231231.xsd#WarrantLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/DerivativeLiabilities" xlink:href="nrxs-20231231.xsd#DerivativeLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/RetirementPlan" xlink:href="nrxs-20231231.xsd#RetirementPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/CommitmentsAndContingencies" xlink:href="nrxs-20231231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/HealthBenefitPlan" xlink:href="nrxs-20231231.xsd#HealthBenefitPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/IncomeTaxes" xlink:href="nrxs-20231231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/SubsequentEvents" xlink:href="nrxs-20231231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/RestatementOfInterimFinancialStatements" xlink:href="nrxs-20231231.xsd#RestatementOfInterimFinancialStatements" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="nrxs-20231231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="nrxs-20231231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/RelatedPartyTransactionsTables" xlink:href="nrxs-20231231.xsd#RelatedPartyTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/PropertyAndEquipmentTables" xlink:href="nrxs-20231231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/IntangibleAssetsTables" xlink:href="nrxs-20231231.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/AccruedExpensesTables" xlink:href="nrxs-20231231.xsd#AccruedExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/NotesPayableTables" xlink:href="nrxs-20231231.xsd#NotesPayableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/LeasesTables" xlink:href="nrxs-20231231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/CommonStockAndWarrantsTables" xlink:href="nrxs-20231231.xsd#CommonStockAndWarrantsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/StockOptionsAndAwardsTables" xlink:href="nrxs-20231231.xsd#StockOptionsAndAwardsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/WarrantLiabilitiesTables" xlink:href="nrxs-20231231.xsd#WarrantLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/DerivativeLiabilitiesTables" xlink:href="nrxs-20231231.xsd#DerivativeLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/IncomeTaxesTables" xlink:href="nrxs-20231231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/RestatementOfInterimFinancialStatementsTables" xlink:href="nrxs-20231231.xsd#RestatementOfInterimFinancialStatementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative" xlink:href="nrxs-20231231.xsd#BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfEstimatedUsefulLivesDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfEstimatedUsefulLivesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfFairValueOnRecurringBasisAssetsAndLiabilityDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfFairValueOnRecurringBasisAssetsAndLiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfUnobservableInputsForLevel3AssetsAndLiabilitiesDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfUnobservableInputsForLevel3AssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfDilutiveCommonStockEquivalentsDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfDilutiveCommonStockEquivalentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfBasicAndDilutedNetLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfDisaggregationOfRevenueDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfDisaggregationOfRevenueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfCustomersAccountedRevenuesDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfCustomersAccountedRevenuesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="nrxs-20231231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfRelatedPartyTransactionsDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfRelatedPartyTransactionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfRelatedPartyLoansPayableToShareholderDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfRelatedPartyLoansPayableToShareholderDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="nrxs-20231231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="nrxs-20231231.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfIntangibleAssetsDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/IntangibleAssetsDetailsNarrative" xlink:href="nrxs-20231231.xsd#IntangibleAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfAccruedExpensesDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfAccruedExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfConvertibleNotesDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfConvertibleNotesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/NotesPayableDetailsNarrative" xlink:href="nrxs-20231231.xsd#NotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfOperatingLeasesDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfMaturitiesOperatingLeaseLiabilitiesDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfMaturitiesOperatingLeaseLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/LeasesDetailsNarrative" xlink:href="nrxs-20231231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfWarrantActivityForCommonStockDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfWarrantActivityForCommonStockDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfWarrantActivityForPreferredStockDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfWarrantActivityForPreferredStockDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative" xlink:href="nrxs-20231231.xsd#CommonStockAndWarrantsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/PreferredStockDetailsNarrative" xlink:href="nrxs-20231231.xsd#PreferredStockDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfOption-pricingModelWithFollowingWeighted-averageAssumptionsDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfOption-pricingModelWithFollowingWeighted-averageAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/StockOptionsAndAwardsDetailsNarrative" xlink:href="nrxs-20231231.xsd#StockOptionsAndAwardsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfChangesInWarrantLiabilitiesDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfChangesInWarrantLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/WarrantLiabilitiesDetailsNarrative" xlink:href="nrxs-20231231.xsd#WarrantLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfChangesInDerivativeLiabilitiesDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfChangesInDerivativeLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/DerivativeLiabilitiesDetailsNarrative" xlink:href="nrxs-20231231.xsd#DerivativeLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/RetirementPlanDetailsNarrative" xlink:href="nrxs-20231231.xsd#RetirementPlanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="nrxs-20231231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/HealthBenefitPlanDetailsNarrative" xlink:href="nrxs-20231231.xsd#HealthBenefitPlanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfDeferredTaxAssetDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfDeferredTaxAssetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfFederalStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfFederalStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfStateCarryforwardsDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfStateCarryforwardsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/IncomeTaxesDetailsNarrative" xlink:href="nrxs-20231231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/SubsequentEventsDetailsNarrative" xlink:href="nrxs-20231231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfRestatementOfInterimFinancialStatementsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/RestatementOfInterimFinancialStatementsDetailsNarrative" xlink:href="nrxs-20231231.xsd#RestatementOfInterimFinancialStatementsDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/BalanceSheets" xlink:title="00000002 - Statement - Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember" xlink:label="loc_us-gaapNonrelatedPartyMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapNonrelatedPartyMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ConvertibleSeriesAPreferredStockMember" xlink:label="loc_NRXSConvertibleSeriesAPreferredStockMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_NRXSConvertibleSeriesAPreferredStockMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ConvertibleSeriesSeedPreferredStockMember" xlink:label="loc_NRXSConvertibleSeriesSeedPreferredStockMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_NRXSConvertibleSeriesSeedPreferredStockMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_110" xlink:to="loc_us-gaapAssetsCurrentAbstract_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_110" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_110" xlink:to="loc_us-gaapAccountsReceivableNetCurrent_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_110" xlink:to="loc_us-gaapInventoryNet_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_110" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_110" xlink:to="loc_us-gaapAssetsCurrent_110" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_110" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_110" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_110" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_110" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_110" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_110" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrentAbstract" xlink:label="loc_us-gaapOtherAssetsNoncurrentAbstract_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_110" xlink:to="loc_us-gaapOtherAssetsNoncurrentAbstract_110" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCosts" xlink:label="loc_us-gaapDeferredCosts_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherAssetsNoncurrentAbstract_110" xlink:to="loc_us-gaapDeferredCosts_110" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherAssetsNoncurrentAbstract_110" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_110" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherAssetsNoncurrentAbstract_110" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet_110" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssets_110" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_110" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_110" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract_110" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_110" xlink:to="loc_us-gaapAccountsPayableCurrent_110" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_110" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent_110" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_110" xlink:to="loc_us-gaapNotesPayableCurrent_110" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_110" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_110" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_110" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent_110" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Deposits" xlink:label="loc_us-gaapDeposits_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_110" xlink:to="loc_us-gaapDeposits_110" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_110" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent_110" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_WarrantLiabilities" xlink:label="loc_NRXSWarrantLiabilities_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_110" xlink:to="loc_NRXSWarrantLiabilities_110" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_110" xlink:to="loc_us-gaapLiabilitiesCurrent_110" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_110" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract_110" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract_110" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent_110" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_110" xlink:to="loc_us-gaapLiabilitiesNoncurrent_110" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilities_110" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommitmentsAndContingencies_110" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityAbstract_110" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_110" xlink:to="loc_us-gaapPreferredStockValue_110" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_110" xlink:to="loc_us-gaapCommonStockValue_110" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_110" xlink:to="loc_us-gaapAdditionalPaidInCapital_110" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_110" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_110" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_110" xlink:to="loc_us-gaapStockholdersEquity_110" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_110" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_110" xlink:type="arc" order="37" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ConvertibleSeriesAPreferredStockMember" xlink:label="loc_NRXSConvertibleSeriesAPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_NRXSConvertibleSeriesAPreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ConvertibleSeriesSeedPreferredStockMember" xlink:label="loc_NRXSConvertibleSeriesSeedPreferredStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_NRXSConvertibleSeriesSeedPreferredStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscountCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscountCurrent_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_70" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Statements of Operations" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/StatementsOfStockholdersDeficit" xlink:title="00000005 - Statement - Statements of Stockholders&apos; Deficit">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ConvertibleSeriesAPreferredStockMember" xlink:label="loc_NRXSConvertibleSeriesAPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_NRXSConvertibleSeriesAPreferredStockMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ConvertibleSeriesSeedPreferredStockMember" xlink:label="loc_NRXSConvertibleSeriesSeedPreferredStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_NRXSConvertibleSeriesSeedPreferredStockMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering" xlink:label="loc_NRXSStockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSStockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_StockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering" xlink:label="loc_NRXSStockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSStockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_StockIssuedDuringPeriodValueCommonStockIssuedUponPreferredStockConversion" xlink:label="loc_NRXSStockIssuedDuringPeriodValueCommonStockIssuedUponPreferredStockConversion_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSStockIssuedDuringPeriodValueCommonStockIssuedUponPreferredStockConversion_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_StockIssuedDuringPeriodSharesCommonStockIssuedUponPreferredStockConversion" xlink:label="loc_NRXSStockIssuedDuringPeriodSharesCommonStockIssuedUponPreferredStockConversion_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSStockIssuedDuringPeriodSharesCommonStockIssuedUponPreferredStockConversion_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_70" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_70" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_70" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_70" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_NRXSStockIssuedDuringPeriodValueWarrantsExercised_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSStockIssuedDuringPeriodValueWarrantsExercised_70" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="loc_NRXSStockIssuedDuringPeriodSharesWarrantsExercised_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSStockIssuedDuringPeriodSharesWarrantsExercised_70" xlink:type="arc" order="17" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMatters" xlink:title="00000007 - Disclosure - Basis of Presentation, Organization and Other Matters" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - Summary of Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/RelatedPartyTransactions" xlink:title="00000009 - Disclosure - Related Party Transactions" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/PropertyAndEquipment" xlink:title="00000010 - Disclosure - Property and Equipment" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/IntangibleAssets" xlink:title="00000011 - Disclosure - Intangible Assets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/AccruedExpenses" xlink:title="00000012 - Disclosure - Accrued Expenses" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/NotesPayable" xlink:title="00000013 - Disclosure - Notes Payable" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/Leases" xlink:title="00000014 - Disclosure - Leases" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/CommonStockAndWarrants" xlink:title="00000015 - Disclosure - Common Stock and Warrants" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/PreferredStock" xlink:title="00000016 - Disclosure - Preferred Stock" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/StockOptionsAndAwards" xlink:title="00000017 - Disclosure - Stock Options and Awards" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/WarrantLiabilities" xlink:title="00000018 - Disclosure - Warrant Liabilities" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/DerivativeLiabilities" xlink:title="00000019 - Disclosure - Derivative Liabilities" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/RetirementPlan" xlink:title="00000020 - Disclosure - Retirement Plan" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/CommitmentsAndContingencies" xlink:title="00000021 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/HealthBenefitPlan" xlink:title="00000022 - Disclosure - Health Benefit Plan" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/IncomeTaxes" xlink:title="00000023 - Disclosure - Income Taxes" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/SubsequentEvents" xlink:title="00000024 - Disclosure - Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/RestatementOfInterimFinancialStatements" xlink:title="00000025 - Disclosure - Restatement of Interim Financial Statements (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000026 - Disclosure - Summary of Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000027 - Disclosure - Summary of Significant Accounting Policies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/RelatedPartyTransactionsTables" xlink:title="00000028 - Disclosure - Related Party Transactions (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/PropertyAndEquipmentTables" xlink:title="00000029 - Disclosure - Property and Equipment (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/IntangibleAssetsTables" xlink:title="00000030 - Disclosure - Intangible Assets (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/AccruedExpensesTables" xlink:title="00000031 - Disclosure - Accrued Expenses (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/NotesPayableTables" xlink:title="00000032 - Disclosure - Notes Payable (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/LeasesTables" xlink:title="00000033 - Disclosure - Leases (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/CommonStockAndWarrantsTables" xlink:title="00000034 - Disclosure - Common Stock and Warrants (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ScheduleOfWarrantActivityForCommonStockTableTextBlock" xlink:label="loc_NRXSScheduleOfWarrantActivityForCommonStockTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSScheduleOfWarrantActivityForCommonStockTableTextBlock_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ScheduleOfWarrantActivityForPreferredStockTableTextBlock" xlink:label="loc_NRXSScheduleOfWarrantActivityForPreferredStockTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSScheduleOfWarrantActivityForPreferredStockTableTextBlock_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_40" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/StockOptionsAndAwardsTables" xlink:title="00000035 - Disclosure - Stock Options and Awards (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/WarrantLiabilitiesTables" xlink:title="00000036 - Disclosure - Warrant Liabilities (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/DerivativeLiabilitiesTables" xlink:title="00000037 - Disclosure - Derivative Liabilities (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/IncomeTaxesTables" xlink:title="00000038 - Disclosure - Income Taxes (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/RestatementOfInterimFinancialStatementsTables" xlink:title="00000039 - Disclosure - Restatement of Interim Financial Statements (Unaudited) (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative" xlink:title="00000040 - Disclosure - Basis of Presentation, Organization and Other Matters (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ConvertibleSeriesAPreferredStockMember" xlink:label="loc_NRXSConvertibleSeriesAPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_NRXSConvertibleSeriesAPreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ConvertibleSeriesSeedPreferredStockMember" xlink:label="loc_NRXSConvertibleSeriesSeedPreferredStockMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_NRXSConvertibleSeriesSeedPreferredStockMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_AlexanderCapitalLPMember" xlink:label="loc_NRXSAlexanderCapitalLPMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_NRXSAlexanderCapitalLPMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplit" xlink:label="loc_us-gaapStockholdersEquityNoteStockSplit_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityNoteStockSplit_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_100" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_100" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_100" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredOfferingCosts_100" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_PurchaseOfAdditionalStockOnNumberOfOptionsNotExercised" xlink:label="loc_NRXSPurchaseOfAdditionalStockOnNumberOfOptionsNotExercised_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSPurchaseOfAdditionalStockOnNumberOfOptionsNotExercised_100" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_UnderwritersDiscountPercentage" xlink:label="loc_NRXSUnderwritersDiscountPercentage_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSUnderwritersDiscountPercentage_100" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_NonaccountableExpenseAllowancePercentage" xlink:label="loc_NRXSNonaccountableExpenseAllowancePercentage_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSNonaccountableExpenseAllowancePercentage_100" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_CashFeePercentage" xlink:label="loc_NRXSCashFeePercentage_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSCashFeePercentage_100" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_100" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ReimbursementExpenses" xlink:label="loc_NRXSReimbursementExpenses_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSReimbursementExpenses_100" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_100" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:label="loc_us-gaapSaleOfStockPercentageOfOwnershipAfterTransaction_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockPercentageOfOwnershipAfterTransaction_100" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_100" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_OfferingPricePerPercentage" xlink:label="loc_NRXSOfferingPricePerPercentage_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSOfferingPricePerPercentage_100" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_LicenseFees" xlink:label="loc_NRXSLicenseFees_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSLicenseFees_100" xlink:type="arc" order="19" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfEstimatedUsefulLivesDetails" xlink:title="00000041 - Disclosure - Schedule of Estimated Useful Lives (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaapMachineryAndEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapMachineryAndEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_90" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfFairValueOnRecurringBasisAssetsAndLiabilityDetails" xlink:title="00000042 - Disclosure - Schedule of Fair Value On a Recurring Basis Assets and Liability (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_WarrantLiabilities" xlink:label="loc_NRXSWarrantLiabilities_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_NRXSWarrantLiabilities_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapLiabilitiesFairValueDisclosure_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapLiabilitiesFairValueDisclosure_90" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfUnobservableInputsForLevel3AssetsAndLiabilitiesDetails" xlink:title="00000043 - Disclosure - Schedule of Unobservable Inputs for Level 3 Assets and Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="loc_srtPlatformOperatorCryptoAssetLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="loc_srtPlatformOperatorCryptoAssetTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_srtPlatformOperatorCryptoAssetTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_WarrantLiabilities" xlink:label="loc_NRXSWarrantLiabilities_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_NRXSWarrantLiabilities_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent_30" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfDilutiveCommonStockEquivalentsDetails" xlink:title="00000044 - Disclosure - Schedule of Dilutive Common Stock Equivalents (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ConvertibleSeriesAPreferredStockMember" xlink:label="loc_NRXSConvertibleSeriesAPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_NRXSConvertibleSeriesAPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ConvertibleSeriesSeedPreferredStockMember" xlink:label="loc_NRXSConvertibleSeriesSeedPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_NRXSConvertibleSeriesSeedPreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionMember" xlink:label="loc_us-gaapOptionMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapOptionMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapPreferredStockMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_WarrantsMember" xlink:label="loc_NRXSWarrantsMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_NRXSWarrantsMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ConvertibleBridgeDebtMember" xlink:label="loc_NRXSConvertibleBridgeDebtMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_NRXSConvertibleBridgeDebtMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_150" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails" xlink:title="00000045 - Disclosure - Schedule of Basic and Diluted Net Loss Per Share (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfDisaggregationOfRevenueDetails" xlink:title="00000046 - Disclosure - Schedule of Disaggregation of Revenue (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_CA" xlink:label="loc_stprCA_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_stprCA_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_WI" xlink:label="loc_stprWI_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_stprWI_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_OH" xlink:label="loc_stprOH_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_stprOH_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_FL" xlink:label="loc_stprFL_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_stprFL_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_MA" xlink:label="loc_stprMA_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_stprMA_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_MO" xlink:label="loc_countryMO_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryMO_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_AllOtherStatesMember" xlink:label="loc_NRXSAllOtherStatesMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_NRXSAllOtherStatesMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenues_150" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfCustomersAccountedRevenuesDetails" xlink:title="00000047 - Disclosure - Schedule of Customers Accounted Revenues (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapScheduleOfProductInformationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtMajorCustomersAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_HospitalAMember" xlink:label="loc_NRXSHospitalAMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_NRXSHospitalAMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_HospitalBMember" xlink:label="loc_NRXSHospitalBMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_NRXSHospitalBMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_HospitalCMember" xlink:label="loc_NRXSHospitalCMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_NRXSHospitalCMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_HospitalMember" xlink:label="loc_NRXSHospitalMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_NRXSHospitalMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaapAccountsReceivableMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapAccountsReceivableMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1_90" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000048 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapScheduleOfProductInformationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_TrademarkAgreementMember" xlink:label="loc_NRXSTrademarkAgreementMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_NRXSTrademarkAgreementMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_LicensingAgreementMember" xlink:label="loc_NRXSLicensingAgreementMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_NRXSLicensingAgreementMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="loc_us-gaapOtherCommitmentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapOtherCommitmentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaapOtherCommitmentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapOtherCommitmentsAxis" xlink:to="loc_us-gaapOtherCommitmentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaapOtherCommitmentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOtherCommitmentsAxis" xlink:to="loc_us-gaapOtherCommitmentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_InitialPaymentMember" xlink:label="loc_NRXSInitialPaymentMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_NRXSInitialPaymentMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_SecondAndFinalPaymentMember" xlink:label="loc_NRXSSecondAndFinalPaymentMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_NRXSSecondAndFinalPaymentMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtMajorCustomersAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_CustomerMember" xlink:label="loc_NRXSCustomerMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_NRXSCustomerMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_CustomerOneMember" xlink:label="loc_NRXSCustomerOneMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_NRXSCustomerOneMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_CustomerTwoMember" xlink:label="loc_NRXSCustomerTwoMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_NRXSCustomerTwoMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_CustomerThreeMember" xlink:label="loc_NRXSCustomerThreeMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_NRXSCustomerThreeMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_CustomerFourMember" xlink:label="loc_NRXSCustomerFourMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_NRXSCustomerFourMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaapAccountsReceivableMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapAccountsReceivableMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueProductLineMember" xlink:label="loc_us-gaapSalesRevenueProductLineMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueProductLineMember_160" xlink:type="arc" order="162" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember_70" xlink:type="arc" order="73" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromRightsConcentrationRiskMember" xlink:label="loc_us-gaapRevenueFromRightsConcentrationRiskMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapRevenueFromRightsConcentrationRiskMember_160" xlink:type="arc" order="163" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivable_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivable_220" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForOtherCreditLosses" xlink:label="loc_us-gaapProvisionForOtherCreditLosses_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapProvisionForOtherCreditLosses_220" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Deposits" xlink:label="loc_us-gaapDeposits_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapDeposits_220" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_InventoryExpenses" xlink:label="loc_NRXSInventoryExpenses_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_NRXSInventoryExpenses_220" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapDeferredOfferingCosts_220" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapDepreciation_220" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets_220" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets_220" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaapAdvertisingExpense_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapAdvertisingExpense_220" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPreferredStock" xlink:label="loc_us-gaapDividendsPreferredStock_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapDividendsPreferredStock_220" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1_220" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount_220" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapStockholdersEquity_220" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaapShortTermBorrowings_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapShortTermBorrowings_220" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapCash_220" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_WorkingCapitalDeficit" xlink:label="loc_NRXSWorkingCapitalDeficit_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_NRXSWorkingCapitalDeficit_220" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_220" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_220" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_220" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts_220" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_220" xlink:type="arc" order="20" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfRelatedPartyTransactionsDetails" xlink:title="00000049 - Disclosure - Schedule of Related Party Transactions (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ShareHolderOneMember" xlink:label="loc_NRXSShareHolderOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_NRXSShareHolderOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ShareHolderTwoMember" xlink:label="loc_NRXSShareHolderTwoMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_NRXSShareHolderTwoMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesAndLoansReceivableGrossCurrent" xlink:label="loc_us-gaapNotesAndLoansReceivableGrossCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapNotesAndLoansReceivableGrossCurrent_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestReceivableCurrent" xlink:label="loc_us-gaapInterestReceivableCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapInterestReceivableCurrent_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_InterestIncomeGrossCurrent" xlink:label="loc_NRXSInterestIncomeGrossCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_NRXSInterestIncomeGrossCurrent_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForNotesAndLoansReceivableCurrent" xlink:label="loc_us-gaapAllowanceForNotesAndLoansReceivableCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAllowanceForNotesAndLoansReceivableCurrent_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_AllowanceForInterestIncomeCurrent" xlink:label="loc_NRXSAllowanceForInterestIncomeCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_NRXSAllowanceForInterestIncomeCurrent_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesAndLoansReceivableNetCurrent" xlink:label="loc_us-gaapNotesAndLoansReceivableNetCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapNotesAndLoansReceivableNetCurrent_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestReceivable" xlink:label="loc_us-gaapInterestReceivable_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapInterestReceivable_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_InterestIncomeCurrent" xlink:label="loc_NRXSInterestIncomeCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_NRXSInterestIncomeCurrent_70" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfRelatedPartyLoansPayableToShareholderDetails" xlink:title="00000050 - Disclosure - Schedule of Related Party Loans payable to shareholder (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ShareHolderMember" xlink:label="loc_NRXSShareHolderMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_NRXSShareHolderMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ShareHolderOneMember" xlink:label="loc_NRXSShareHolderOneMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_NRXSShareHolderOneMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_OtherConvertiblesMember" xlink:label="loc_NRXSOtherConvertiblesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_NRXSOtherConvertiblesMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="loc_us-gaapDebtInstrumentMaturityDateDescription_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDateDescription_170" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_170" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayable" xlink:label="loc_us-gaapLoansPayable_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapLoansPayable_170" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_InterestAndServiceFeeAccrued" xlink:label="loc_NRXSInterestAndServiceFeeAccrued_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_NRXSInterestAndServiceFeeAccrued_170" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaapInterestPaid_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapInterestPaid_170" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000051 - Disclosure - Related Party Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ShareholdersOneAndTwoMember" xlink:label="loc_NRXSShareholdersOneAndTwoMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_NRXSShareholdersOneAndTwoMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_MrWatkinsMember" xlink:label="loc_NRXSMrWatkinsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_NRXSMrWatkinsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_MrSealeMember" xlink:label="loc_NRXSMrSealeMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_NRXSMrSealeMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesAndLoansReceivableGrossCurrent" xlink:label="loc_us-gaapNotesAndLoansReceivableGrossCurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapNotesAndLoansReceivableGrossCurrent_90" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_AllowanceForInterestReceivableCurrent" xlink:label="loc_NRXSAllowanceForInterestReceivableCurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_NRXSAllowanceForInterestReceivableCurrent_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForFees" xlink:label="loc_us-gaapPaymentsForFees_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapPaymentsForFees_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapAccountsPayableCurrentAndNoncurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAccountsPayableCurrentAndNoncurrent_90" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:title="00000052 - Disclosure - Schedule of Property And Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaapMachineryAndEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapMachineryAndEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_110" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="00000053 - Disclosure - Property and Equipment (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfIntangibleAssetsDetails" xlink:title="00000054 - Disclosure - Schedule of Intangible Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_SoftwareImplementationMember" xlink:label="loc_NRXSSoftwareImplementationMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_NRXSSoftwareImplementationMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaapPatentsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapPatentsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TrademarksMember" xlink:label="loc_us-gaapTrademarksMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapTrademarksMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_LicensesMember" xlink:label="loc_NRXSLicensesMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_NRXSLicensesMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet_110" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/IntangibleAssetsDetailsNarrative" xlink:title="00000055 - Disclosure - Intangible Assets (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfAccruedExpensesDetails" xlink:title="00000056 - Disclosure - Schedule of Accrued Expenses (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfConvertibleNotesDetails" xlink:title="00000057 - Disclosure - Schedule of Convertible Notes (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/NotesPayableDetailsNarrative" xlink:title="00000058 - Disclosure - Notes Payable (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ExchangeListingLLCMember" xlink:label="loc_NRXSExchangeListingLLCMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_NRXSExchangeListingLLCMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ChannelPartnersCapitalMember" xlink:label="loc_NRXSChannelPartnersCapitalMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_NRXSChannelPartnersCapitalMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_SignatureBankMember" xlink:label="loc_NRXSSignatureBankMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_NRXSSignatureBankMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_AlexanderCapitalLPMember" xlink:label="loc_NRXSAlexanderCapitalLPMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_NRXSAlexanderCapitalLPMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_PromissoryNoteMember" xlink:label="loc_NRXSPromissoryNoteMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_NRXSPromissoryNoteMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ConvertiblePromissoryNoteMember" xlink:label="loc_NRXSConvertiblePromissoryNoteMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_NRXSConvertiblePromissoryNoteMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_TwoThousandTwentyThreeConvertibleNotesMember" xlink:label="loc_NRXSTwoThousandTwentyThreeConvertibleNotesMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_NRXSTwoThousandTwentyThreeConvertibleNotesMember_210" xlink:type="arc" order="211" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_TwoThousandTwentyTwoConvertibleNotesMember" xlink:label="loc_NRXSTwoThousandTwentyTwoConvertibleNotesMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_NRXSTwoThousandTwentyTwoConvertibleNotesMember_260" xlink:type="arc" order="261" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember" xlink:label="loc_NRXSTwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_NRXSTwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember_370" xlink:type="arc" order="372" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_srtStatementScenarioAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember" xlink:label="loc_srtScenarioForecastMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_srtScenarioForecastMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_AccreditedInvestorsMember" xlink:label="loc_NRXSAccreditedInvestorsMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_NRXSAccreditedInvestorsMember_110" xlink:type="arc" order="112" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_InvestorsMember" xlink:label="loc_NRXSInvestorsMember_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_NRXSInvestorsMember_370" xlink:type="arc" order="371" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_140" xlink:type="arc" order="142" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_170" xlink:type="arc" order="172" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_290" xlink:type="arc" order="291" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_300" xlink:type="arc" order="301" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaapConvertibleNotesPayableMember_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_us-gaapConvertibleNotesPayableMember_420" xlink:type="arc" order="421" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_450" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_450" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapNotesPayable_450" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_450" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaapDebtInstrumentPeriodicPayment_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentPeriodicPayment_450" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAverageAmountOutstanding" xlink:label="loc_us-gaapLongTermDebtAverageAmountOutstanding_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapLongTermDebtAverageAmountOutstanding_450" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:label="loc_us-gaapDebtInstrumentRepurchasedFaceAmount_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentRepurchasedFaceAmount_450" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:label="loc_us-gaapDebtInstrumentAnnualPrincipalPayment_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentAnnualPrincipalPayment_450" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount_450" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfDebt_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfDebt_450" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_DebtInstrumentDiscountRate" xlink:label="loc_NRXSDebtInstrumentDiscountRate_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_NRXSDebtInstrumentDiscountRate_450" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_DebtWarrantConversionDescription" xlink:label="loc_NRXSDebtWarrantConversionDescription_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_NRXSDebtWarrantConversionDescription_450" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionRatio1_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionRatio1_450" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EscrowDeposit" xlink:label="loc_us-gaapEscrowDeposit_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapEscrowDeposit_450" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromFeesReceived" xlink:label="loc_us-gaapProceedsFromFeesReceived_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromFeesReceived_450" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_450" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_450" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_450" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_450" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_450" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="loc_us-gaapDebtInstrumentDescriptionOfVariableRateBasis_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentDescriptionOfVariableRateBasis_450" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_450" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ClassOfWarrantDiscountRate" xlink:label="loc_NRXSClassOfWarrantDiscountRate_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_NRXSClassOfWarrantDiscountRate_450" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_DebtInstrumentPrincipalAmount" xlink:label="loc_NRXSDebtInstrumentPrincipalAmount_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_NRXSDebtInstrumentPrincipalAmount_450" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_450" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfDebtIssuanceCosts_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapPaymentsOfDebtIssuanceCosts_450" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:label="loc_us-gaapEmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapEmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_450" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="loc_us-gaapWarrantsNotSettleableInCashFairValueDisclosure_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapWarrantsNotSettleableInCashFairValueDisclosure_450" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromNotesPayable_450" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_450" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscountCurrent_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscountCurrent_450" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaapPaymentsOfFinancingCosts_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapPaymentsOfFinancingCosts_450" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_PaymentsOfFinancingCost" xlink:label="loc_NRXSPaymentsOfFinancingCost_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_NRXSPaymentsOfFinancingCost_450" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapInterestPayableCurrent_450" xlink:type="arc" order="33" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfOperatingLeasesDetails" xlink:title="00000059 - Disclosure - Schedule of Operating Leases (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfMaturitiesOperatingLeaseLiabilitiesDetails" xlink:title="00000060 - Disclosure - Schedule of Maturities Operating Lease Liabilities (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/LeasesDetailsNarrative" xlink:title="00000061 - Disclosure - Leases (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeographicDistributionAxis" xlink:label="loc_us-gaapGeographicDistributionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapGeographicDistributionAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeographicDistributionDomain" xlink:label="loc_us-gaapGeographicDistributionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapGeographicDistributionAxis" xlink:to="loc_us-gaapGeographicDistributionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeographicDistributionDomain" xlink:label="loc_us-gaapGeographicDistributionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapGeographicDistributionAxis" xlink:to="loc_us-gaapGeographicDistributionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_VersaillesIndianaMember" xlink:label="loc_NRXSVersaillesIndianaMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapGeographicDistributionDomain" xlink:to="loc_NRXSVersaillesIndianaMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_CarmelIndianaMember" xlink:label="loc_NRXSCarmelIndianaMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapGeographicDistributionDomain" xlink:to="loc_NRXSCarmelIndianaMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="loc_us-gaapLeaseContractualTermAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapLeaseContractualTermAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaapLeaseContractualTermDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLeaseContractualTermAxis" xlink:to="loc_us-gaapLeaseContractualTermDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaapLeaseContractualTermDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLeaseContractualTermAxis" xlink:to="loc_us-gaapLeaseContractualTermDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_LeaseOneMember" xlink:label="loc_NRXSLeaseOneMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLeaseContractualTermDomain" xlink:to="loc_NRXSLeaseOneMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_LeaseTwoMember" xlink:label="loc_NRXSLeaseTwoMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLeaseContractualTermDomain" xlink:to="loc_NRXSLeaseTwoMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_LeaseThreeMember" xlink:label="loc_NRXSLeaseThreeMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLeaseContractualTermDomain" xlink:to="loc_NRXSLeaseThreeMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="loc_us-gaapLesseeOperatingLeaseDescription_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseDescription_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeasePayments_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="loc_us-gaapLesseeOperatingLeaseDiscountRate_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseDiscountRate_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseExpense_80" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfWarrantActivityForCommonStockDetails" xlink:title="00000062 - Disclosure - Schedule of Warrant Activity for Common Stock (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageRemainingContracualLifeOutstandingNumberGranted" xlink:label="loc_NRXSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageRemainingContracualLifeOutstandingNumberGranted_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageRemainingContracualLifeOutstandingNumberGranted_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber" xlink:label="loc_NRXSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants" xlink:label="loc_NRXSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsConvertedPrefundedWarrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_NRXSShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsConvertedPrefundedWarrantsInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsConvertedPrefundedWarrantsInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="12" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfWarrantActivityForPreferredStockDetails" xlink:title="00000063 - Disclosure - Schedule of Warrant Activity for Preferred Stock (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber" xlink:label="loc_NRXSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant" xlink:label="loc_NRXSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant" xlink:label="loc_NRXSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant_60" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:title="00000064 - Disclosure - Schedule of Warrants outstanding and Exercisable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_InvestorWarrantOneMember" xlink:label="loc_NRXSInvestorWarrantOneMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_NRXSInvestorWarrantOneMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_InvestorWarrantPSAOneMember" xlink:label="loc_NRXSInvestorWarrantPSAOneMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_NRXSInvestorWarrantPSAOneMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_TwoThousandTwentyTwoConvertibleNotesMember" xlink:label="loc_NRXSTwoThousandTwentyTwoConvertibleNotesMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_NRXSTwoThousandTwentyTwoConvertibleNotesMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_TwoThousandTwentyThreeConvertibleNotesMember" xlink:label="loc_NRXSTwoThousandTwentyThreeConvertibleNotesMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_NRXSTwoThousandTwentyThreeConvertibleNotesMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ConsultingAgreementWarrantsMember" xlink:label="loc_NRXSConsultingAgreementWarrantsMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_NRXSConsultingAgreementWarrantsMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_UnderwriterWarrantsMember" xlink:label="loc_NRXSUnderwriterWarrantsMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_NRXSUnderwriterWarrantsMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_WarrantExpirationDateDescription" xlink:label="loc_NRXSWarrantExpirationDateDescription_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_NRXSWarrantExpirationDateDescription_110" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative" xlink:title="00000065 - Disclosure - Common Stock and Warrants (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ConvertibleSeriesSeedPreferredStockMember" xlink:label="loc_NRXSConvertibleSeriesSeedPreferredStockMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_NRXSConvertibleSeriesSeedPreferredStockMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_210" xlink:type="arc" order="211" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_VendorsMember" xlink:label="loc_NRXSVendorsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_NRXSVendorsMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_BrianHannaschMember" xlink:label="loc_NRXSBrianHannaschMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_NRXSBrianHannaschMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_WarrantOneMember" xlink:label="loc_NRXSWarrantOneMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_NRXSWarrantOneMember_120" xlink:type="arc" order="123" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_WarrantTwoMember" xlink:label="loc_NRXSWarrantTwoMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_NRXSWarrantTwoMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_WarrantThreeMember" xlink:label="loc_NRXSWarrantThreeMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_NRXSWarrantThreeMember_200" xlink:type="arc" order="202" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_MasimoCorporationMember" xlink:label="loc_NRXSMasimoCorporationMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_NRXSMasimoCorporationMember_190" xlink:type="arc" order="191" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_TwoThousandTwentyTwoConvertibleNotesMember" xlink:label="loc_NRXSTwoThousandTwentyTwoConvertibleNotesMember_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_NRXSTwoThousandTwentyTwoConvertibleNotesMember_250" xlink:type="arc" order="251" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_TwoThousandTwentyThreeConvertibleNotesMember" xlink:label="loc_NRXSTwoThousandTwentyThreeConvertibleNotesMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_NRXSTwoThousandTwentyThreeConvertibleNotesMember_260" xlink:type="arc" order="261" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_300" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_300" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_300" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1_300" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion_300" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1_300" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits_300" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_300" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1_300" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplit" xlink:label="loc_us-gaapStockholdersEquityNoteStockSplit_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityNoteStockSplit_300" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_300" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_300" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharePrice_300" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_300" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_300" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_300" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_300" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_300" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_WarrantsExpirationDateDescription" xlink:label="loc_NRXSWarrantsExpirationDateDescription_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSWarrantsExpirationDateDescription_300" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_300" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees" xlink:label="loc_us-gaapClassOfWarrantOrRightReasonForIssuingToNonemployees_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightReasonForIssuingToNonemployees_300" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding_300" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant" xlink:label="loc_NRXSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant_300" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants" xlink:label="loc_NRXSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants_300" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_300" xlink:type="arc" order="24" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/PreferredStockDetailsNarrative" xlink:title="00000066 - Disclosure - Preferred Stock (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapScheduleOfStockByClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ConvertibleSeriesAPreferredStockMember" xlink:label="loc_NRXSConvertibleSeriesAPreferredStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_NRXSConvertibleSeriesAPreferredStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ConvertibleSeriesSeedPreferredStockMember" xlink:label="loc_NRXSConvertibleSeriesSeedPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_NRXSConvertibleSeriesSeedPreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaapConvertibleDebtMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_us-gaapConvertibleDebtMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_180" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued_180" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_180" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_AggregatePurchasePrice" xlink:label="loc_NRXSAggregatePurchasePrice_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_NRXSAggregatePurchasePrice_180" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaapConversionOfStockAmountConverted1_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockAmountConverted1_180" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaapPreferredStockDividendRatePercentage_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockDividendRatePercentage_180" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionRatio1_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionRatio1_180" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_SharePremiumPercentage" xlink:label="loc_NRXSSharePremiumPercentage_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_NRXSSharePremiumPercentage_180" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1_180" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_180" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionOriginalDebtInterestRateOfDebt" xlink:label="loc_us-gaapDebtConversionOriginalDebtInterestRateOfDebt_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDebtConversionOriginalDebtInterestRateOfDebt_180" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaapDebtInstrumentPeriodicPayment_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDebtInstrumentPeriodicPayment_180" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1_180" xlink:type="arc" order="12" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfOption-pricingModelWithFollowingWeighted-averageAssumptionsDetails" xlink:title="00000067 - Disclosure - Schedule of Option-pricing Model with Following Weighted-average Assumptions (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_TwentySeventeenStockCompensationPlanMember" xlink:label="loc_NRXSTwentySeventeenStockCompensationPlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_NRXSTwentySeventeenStockCompensationPlanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharePrice_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_30" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_30" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_30" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="00000068 - Disclosure - Schedule of Stock Option Activity (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/StockOptionsAndAwardsDetailsNarrative" xlink:title="00000069 - Disclosure - Stock Options and Awards (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_TwentySeventeenStockCompensationPlanMember" xlink:label="loc_NRXSTwentySeventeenStockCompensationPlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_NRXSTwentySeventeenStockCompensationPlanMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharesIssued_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_70" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfChangesInWarrantLiabilitiesDetails" xlink:title="00000070 - Disclosure - Schedule of Changes in Warrant Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="loc_srtPlatformOperatorCryptoAssetLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="loc_srtPlatformOperatorCryptoAssetTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_srtPlatformOperatorCryptoAssetTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding_160" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_AdditionToWarrantLiabilities" xlink:label="loc_NRXSAdditionToWarrantLiabilities_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_NRXSAdditionToWarrantLiabilities_160" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_160" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ReclassifiedToEquity" xlink:label="loc_NRXSReclassifiedToEquity_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_NRXSReclassifiedToEquity_160" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/WarrantLiabilitiesDetailsNarrative" xlink:title="00000071 - Disclosure - Warrant Liabilities (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="loc_us-gaapMeasurementInputSharePriceMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputSharePriceMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_60" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfChangesInDerivativeLiabilitiesDetails" xlink:title="00000072 - Disclosure - Schedule of Changes in Derivative Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="loc_srtPlatformOperatorCryptoAssetLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="loc_srtPlatformOperatorCryptoAssetTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_srtPlatformOperatorCryptoAssetTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent_160" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_AdditionToDerivativeLiabilities" xlink:label="loc_NRXSAdditionToDerivativeLiabilities_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_NRXSAdditionToDerivativeLiabilities_160" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInDerivativeLiabilities_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapIncreaseDecreaseInDerivativeLiabilities_160" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ExtinguishmentOfDerivativeLiabilities" xlink:label="loc_NRXSExtinguishmentOfDerivativeLiabilities_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_NRXSExtinguishmentOfDerivativeLiabilities_160" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/DerivativeLiabilitiesDetailsNarrative" xlink:title="00000073 - Disclosure - Derivative Liabilities (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="loc_us-gaapMeasurementInputSharePriceMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputSharePriceMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="loc_us-gaapDerivativeLiabilityMeasurementInput_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapDerivativeLiabilityMeasurementInput_60" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/RetirementPlanDetailsNarrative" xlink:title="00000074 - Disclosure - Retirement Plan (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000075 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="loc_us-gaapOtherCommitmentsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable" xlink:label="loc_us-gaapOtherCommitmentsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapOtherCommitmentsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOtherCommitmentsTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOtherCommitmentsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_TrademarkAgreementMember" xlink:label="loc_NRXSTrademarkAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_NRXSTrademarkAgreementMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ExecutiveEmploymentAgreementsMember" xlink:label="loc_NRXSExecutiveEmploymentAgreementsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_NRXSExecutiveEmploymentAgreementsMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="loc_us-gaapOtherCommitmentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOtherCommitmentsTable" xlink:to="loc_us-gaapOtherCommitmentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaapOtherCommitmentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapOtherCommitmentsAxis" xlink:to="loc_us-gaapOtherCommitmentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaapOtherCommitmentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOtherCommitmentsAxis" xlink:to="loc_us-gaapOtherCommitmentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_InitialPaymentMember" xlink:label="loc_NRXSInitialPaymentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_NRXSInitialPaymentMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_SecondAndFinalPaymentMember" xlink:label="loc_NRXSSecondAndFinalPaymentMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_NRXSSecondAndFinalPaymentMember_10" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOtherCommitmentsTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOtherCommitmentsTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:label="loc_us-gaapPaymentsForRepurchaseOfInitialPublicOffering_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapPaymentsForRepurchaseOfInitialPublicOffering_150" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ExecutiveEmploymentAgreementsTerms" xlink:label="loc_NRXSExecutiveEmploymentAgreementsTerms_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_NRXSExecutiveEmploymentAgreementsTerms_150" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_DescriptionOfExecutiveEmploymentAgreementsRenewals" xlink:label="loc_NRXSDescriptionOfExecutiveEmploymentAgreementsRenewals_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_NRXSDescriptionOfExecutiveEmploymentAgreementsRenewals_150" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaapSalariesAndWages_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapSalariesAndWages_150" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncentiveFeeExpense" xlink:label="loc_us-gaapIncentiveFeeExpense_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapIncentiveFeeExpense_150" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositLiabilitiesAccruedInterest" xlink:label="loc_us-gaapDepositLiabilitiesAccruedInterest_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapDepositLiabilitiesAccruedInterest_150" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_150" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_SpecialBonusPercentage" xlink:label="loc_NRXSSpecialBonusPercentage_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_NRXSSpecialBonusPercentage_150" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_KeyEmployeeExercisePercentage" xlink:label="loc_NRXSKeyEmployeeExercisePercentage_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_NRXSKeyEmployeeExercisePercentage_150" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="loc_us-gaapAccruedBonusesCurrent_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapAccruedBonusesCurrent_150" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaapLossContingencyDamagesSoughtValue_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapLossContingencyDamagesSoughtValue_150" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/HealthBenefitPlanDetailsNarrative" xlink:title="00000076 - Disclosure - Health Benefit Plan (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfDeferredTaxAssetDetails" xlink:title="00000077 - Disclosure - Schedule of Deferred Tax Asset (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfFederalStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails" xlink:title="00000078 - Disclosure - Schedule of Federal Statutory Income Tax Rate and Effective Income Tax Rate (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfStateCarryforwardsDetails" xlink:title="00000079 - Disclosure - Schedule of State Carryforwards (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaapTaxPeriodAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapTaxPeriodAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaapTaxPeriodDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTaxPeriodAxis" xlink:to="loc_us-gaapTaxPeriodDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaapTaxPeriodDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTaxPeriodAxis" xlink:to="loc_us-gaapTaxPeriodDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_TaxYear2038Member" xlink:label="loc_NRXSTaxYear2038Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_NRXSTaxYear2038Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_TaxYear2039Member" xlink:label="loc_NRXSTaxYear2039Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_NRXSTaxYear2039Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_TaxYear2040Member" xlink:label="loc_NRXSTaxYear2040Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_NRXSTaxYear2040Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_TaxYear2041Member" xlink:label="loc_NRXSTaxYear2041Member_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_NRXSTaxYear2041Member_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_TaxYear2042Member" xlink:label="loc_NRXSTaxYear2042Member_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_NRXSTaxYear2042Member_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_TaxYear2043Member" xlink:label="loc_NRXSTaxYear2043Member_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_NRXSTaxYear2043Member_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000080 - Disclosure - Income Taxes (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000081 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:label="loc_us-gaapDebtInstrumentAnnualPrincipalPayment_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtInstrumentAnnualPrincipalPayment_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaapConvertibleDebt_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapConvertibleDebt_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaapDebtInstrumentPeriodicPayment_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtInstrumentPeriodicPayment_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionOriginalDebtInterestRateOfDebt" xlink:label="loc_us-gaapDebtConversionOriginalDebtInterestRateOfDebt_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtConversionOriginalDebtInterestRateOfDebt_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_60" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails" xlink:title="00000082 - Disclosure - Schedule of Restatement of Interim Financial Statements (Unaudited) (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis" xlink:label="loc_srtRestatementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="loc_srtRestatementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srtScenarioPreviouslyReportedMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRestatementDomain" xlink:to="loc_srtScenarioPreviouslyReportedMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:label="loc_srtRevisionOfPriorPeriodReclassificationAdjustmentMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRestatementDomain" xlink:to="loc_srtRevisionOfPriorPeriodReclassificationAdjustmentMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember" xlink:label="loc_us-gaapNonrelatedPartyMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapNonrelatedPartyMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ConvertibleSeriesAPreferredStockMember" xlink:label="loc_NRXSConvertibleSeriesAPreferredStockMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_NRXSConvertibleSeriesAPreferredStockMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ConvertibleSeriesSeedPreferredStockMember" xlink:label="loc_NRXSConvertibleSeriesSeedPreferredStockMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_NRXSConvertibleSeriesSeedPreferredStockMember_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapAssetsAbstract_220" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_220" xlink:to="loc_us-gaapAssetsCurrentAbstract_220" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_220" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_220" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_220" xlink:to="loc_us-gaapAccountsReceivableNetCurrent_220" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_220" xlink:to="loc_us-gaapInventoryNet_220" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsCurrentAbstract_220" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_220" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_220" xlink:to="loc_us-gaapAssetsCurrent_220" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_220" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_220" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_220" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_220" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_220" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_220" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_220" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_220" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAssetsAbstract_220" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet_220" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapAssets_220" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_220" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_220" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract_220" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_220" xlink:to="loc_us-gaapAccountsPayableCurrent_220" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_220" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent_220" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_220" xlink:to="loc_us-gaapNotesPayableCurrent_220" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_220" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_220" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Deposits" xlink:label="loc_us-gaapDeposits_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_220" xlink:to="loc_us-gaapDeposits_220" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ShareLiabilitiesCurrent" xlink:label="loc_NRXSShareLiabilitiesCurrent_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_220" xlink:to="loc_NRXSShareLiabilitiesCurrent_220" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_WarrantLiabilities" xlink:label="loc_NRXSWarrantLiabilities_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract_220" xlink:to="loc_NRXSWarrantLiabilities_220" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_220" xlink:to="loc_us-gaapLiabilitiesCurrent_220" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract_220" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent_220" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapLiabilities_220" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapStockholdersEquityAbstract_220" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_220" xlink:to="loc_us-gaapPreferredStockValue_220" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_220" xlink:to="loc_us-gaapCommonStockValue_220" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_220" xlink:to="loc_us-gaapAdditionalPaidInCapital_220" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_220" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_220" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_220" xlink:to="loc_us-gaapStockholdersEquity_220" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStockholdersEquityAbstract_220" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity_220" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_220" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold_220" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapGrossProfit_220" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingExpense" xlink:label="loc_us-gaapSellingExpense_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapSellingExpense_220" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_220" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense_220" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss_220" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract_220" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_FinancingCharges" xlink:label="loc_NRXSFinancingCharges_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_220" xlink:to="loc_NRXSFinancingCharges_220" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_220" xlink:to="loc_us-gaapInterestExpense_220" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestAndOtherIncome" xlink:label="loc_us-gaapInterestAndOtherIncome_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_220" xlink:to="loc_us-gaapInterestAndOtherIncome_220" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_220" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_220" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_220" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet_220" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_220" xlink:to="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts_220" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_220" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_220" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaapOtherNonoperatingIncome_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_220" xlink:to="loc_us-gaapOtherNonoperatingIncome_220" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="loc_us-gaapOtherNonoperatingExpense_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_220" xlink:to="loc_us-gaapOtherNonoperatingExpense_220" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_220" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense_220" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapNetIncomeLoss_220" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_220" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_220" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_220" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_220" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization_220" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_220" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts_220" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_NoncashLeaseExpense" xlink:label="loc_NRXSNoncashLeaseExpense_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_220" xlink:to="loc_NRXSNoncashLeaseExpense_220" xlink:type="arc" order="57" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_NoncashInterestExpense" xlink:label="loc_NRXSNoncashInterestExpense_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_220" xlink:to="loc_NRXSNoncashInterestExpense_220" xlink:type="arc" order="58" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_220" xlink:to="loc_us-gaapShareBasedCompensation_220" xlink:type="arc" order="59" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_IssuanceOfCommonStockForNoncashConsideration" xlink:label="loc_NRXSIssuanceOfCommonStockForNoncashConsideration_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_220" xlink:to="loc_NRXSIssuanceOfCommonStockForNoncashConsideration_220" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_FinanceCharges" xlink:label="loc_NRXSFinanceCharges_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_220" xlink:to="loc_NRXSFinanceCharges_220" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract_220" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_220" xlink:type="arc" order="65" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_220" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable_220" xlink:type="arc" order="66" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_220" xlink:to="loc_us-gaapIncreaseDecreaseInInventories_220" xlink:type="arc" order="67" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_220" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_220" xlink:type="arc" order="68" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_220" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable_220" xlink:type="arc" order="69" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_220" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities_220" xlink:type="arc" order="70" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_IncreaseDecreaseInCustomerDeposit" xlink:label="loc_NRXSIncreaseDecreaseInCustomerDeposit_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_220" xlink:to="loc_NRXSIncreaseDecreaseInCustomerDeposit_220" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract_220" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability_220" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities_220" xlink:type="arc" order="73" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_220" xlink:type="arc" order="74" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_220" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment_220" xlink:type="arc" order="75" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract_220" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets_220" xlink:type="arc" order="76" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities_220" xlink:type="arc" order="77" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_220" xlink:type="arc" order="78" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_220" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_220" xlink:type="arc" order="79" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_OfferingCostsInAdvanceOfSaleOfCommonStock" xlink:label="loc_NRXSOfferingCostsInAdvanceOfSaleOfCommonStock_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract_220" xlink:to="loc_NRXSOfferingCostsInAdvanceOfSaleOfCommonStock_220" xlink:type="arc" order="80" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapRepaymentsOfNotesPayable_220" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapProceedsFromNotesPayable_220" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapProceedsFromConvertibleDebt_220" xlink:type="arc" order="83" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities_220" xlink:type="arc" order="84" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_220" xlink:type="arc" order="85" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_220" xlink:type="arc" order="86" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://neuraxis.com/role/RestatementOfInterimFinancialStatementsDetailsNarrative" xlink:title="00000083 - Disclosure - Restatement of Interim Financial Statements (Unaudited) (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis" xlink:label="loc_srtRestatementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="loc_srtRestatementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:label="loc_srtRevisionOfPriorPeriodReclassificationAdjustmentMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRestatementDomain" xlink:to="loc_srtRevisionOfPriorPeriodReclassificationAdjustmentMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_IncreaseDecreaseInWarrantLiability" xlink:label="loc_NRXSIncreaseDecreaseInWarrantLiability_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_NRXSIncreaseDecreaseInWarrantLiability_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapNetIncomeLoss_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapAdditionalPaidInCapital_60" xlink:type="arc" order="3" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>22
<FILENAME>nrxs-20231231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember" xlink:label="us-gaap_NonrelatedPartyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonrelatedPartyMember" xlink:to="us-gaap_NonrelatedPartyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonrelatedPartyMember_lbl" xml:lang="en-US">Nonrelated Party [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="us-gaap_RelatedPartyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US">Related Party [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ConvertibleSeriesAPreferredStockMember" xlink:label="NRXS_ConvertibleSeriesAPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ConvertibleSeriesAPreferredStockMember" xlink:to="NRXS_ConvertibleSeriesAPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_ConvertibleSeriesAPreferredStockMember_lbl" xml:lang="en-US">Convertible Series A Preferred stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ConvertibleSeriesSeedPreferredStockMember" xlink:label="NRXS_ConvertibleSeriesSeedPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ConvertibleSeriesSeedPreferredStockMember" xlink:to="NRXS_ConvertibleSeriesSeedPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_ConvertibleSeriesSeedPreferredStockMember_lbl" xml:lang="en-US">Convertible Series Seed Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_AlexanderCapitalLPMember" xlink:label="NRXS_AlexanderCapitalLPMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_AlexanderCapitalLPMember" xlink:to="NRXS_AlexanderCapitalLPMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_AlexanderCapitalLPMember_lbl" xml:lang="en-US">Alexander Capital LP [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">IPO [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_TrademarkAgreementMember" xlink:label="NRXS_TrademarkAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_TrademarkAgreementMember" xlink:to="NRXS_TrademarkAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_TrademarkAgreementMember_lbl" xml:lang="en-US">Trademark Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="us-gaap_OtherCommitmentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsAxis_lbl" xml:lang="en-US">Other Commitments [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_InitialPaymentMember" xlink:label="NRXS_InitialPaymentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_InitialPaymentMember" xlink:to="NRXS_InitialPaymentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_InitialPaymentMember_lbl" xml:lang="en-US">Initial Payment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_SecondAndFinalPaymentMember" xlink:label="NRXS_SecondAndFinalPaymentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_SecondAndFinalPaymentMember" xlink:to="NRXS_SecondAndFinalPaymentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_SecondAndFinalPaymentMember_lbl" xml:lang="en-US">Second and Final Payment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_LicensingAgreementMember" xlink:label="NRXS_LicensingAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_LicensingAgreementMember" xlink:to="NRXS_LicensingAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_LicensingAgreementMember_lbl" xml:lang="en-US">Licensing Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US">Customer [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_CustomerMember" xlink:label="NRXS_CustomerMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_CustomerMember" xlink:to="NRXS_CustomerMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_CustomerMember_lbl" xml:lang="en-US">Customer [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableMember_lbl" xml:lang="en-US">Accounts Receivable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_CustomerOneMember" xlink:label="NRXS_CustomerOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_CustomerOneMember" xlink:to="NRXS_CustomerOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_CustomerOneMember_lbl" xml:lang="en-US">Customer One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_CustomerTwoMember" xlink:label="NRXS_CustomerTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_CustomerTwoMember" xlink:to="NRXS_CustomerTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_CustomerTwoMember_lbl" xml:lang="en-US">Customer Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_CustomerThreeMember" xlink:label="NRXS_CustomerThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_CustomerThreeMember" xlink:to="NRXS_CustomerThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_CustomerThreeMember_lbl" xml:lang="en-US">Customer Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_CustomerFourMember" xlink:label="NRXS_CustomerFourMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_CustomerFourMember" xlink:to="NRXS_CustomerFourMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_CustomerFourMember_lbl" xml:lang="en-US">Customer Four [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueProductLineMember" xlink:label="us-gaap_SalesRevenueProductLineMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueProductLineMember" xlink:to="us-gaap_SalesRevenueProductLineMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueProductLineMember_lbl" xml:lang="en-US">Revenue, Product and Service Benchmark [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromRightsConcentrationRiskMember" xlink:label="us-gaap_RevenueFromRightsConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromRightsConcentrationRiskMember" xlink:to="us-gaap_RevenueFromRightsConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromRightsConcentrationRiskMember_lbl" xml:lang="en-US">Revenue from Rights Concentration Risk [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionMember" xlink:label="us-gaap_OptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionMember" xlink:to="us-gaap_OptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionMember_lbl" xml:lang="en-US">Options Held [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_WarrantsMember" xlink:label="NRXS_WarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_WarrantsMember" xlink:to="NRXS_WarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_WarrantsMember_lbl" xml:lang="en-US">Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ConvertibleBridgeDebtMember" xlink:label="NRXS_ConvertibleBridgeDebtMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ConvertibleBridgeDebtMember" xlink:to="NRXS_ConvertibleBridgeDebtMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_ConvertibleBridgeDebtMember_lbl" xml:lang="en-US">Convertible Bridge Debt [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_CA" xlink:label="stpr_CA" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_CA" xlink:to="stpr_CA_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="stpr_CA_lbl" xml:lang="en-US">CALIFORNIA</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_WI" xlink:label="stpr_WI" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_WI" xlink:to="stpr_WI_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="stpr_WI_lbl" xml:lang="en-US">WISCONSIN</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_OH" xlink:label="stpr_OH" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_OH" xlink:to="stpr_OH_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="stpr_OH_lbl" xml:lang="en-US">OHIO</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_FL" xlink:label="stpr_FL" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_FL" xlink:to="stpr_FL_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="stpr_FL_lbl" xml:lang="en-US">FLORIDA</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_MA" xlink:label="stpr_MA" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_MA" xlink:to="stpr_MA_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="stpr_MA_lbl" xml:lang="en-US">MASSACHUSETTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_MO" xlink:label="country_MO" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_MO" xlink:to="country_MO_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_MO_lbl" xml:lang="en-US">MACAO</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_AllOtherStatesMember" xlink:label="NRXS_AllOtherStatesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_AllOtherStatesMember" xlink:to="NRXS_AllOtherStatesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_AllOtherStatesMember_lbl" xml:lang="en-US">All Other States [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_HospitalAMember" xlink:label="NRXS_HospitalAMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_HospitalAMember" xlink:to="NRXS_HospitalAMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_HospitalAMember_lbl" xml:lang="en-US">Hospital A [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_HospitalBMember" xlink:label="NRXS_HospitalBMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_HospitalBMember" xlink:to="NRXS_HospitalBMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_HospitalBMember_lbl" xml:lang="en-US">Hospital B [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_HospitalCMember" xlink:label="NRXS_HospitalCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_HospitalCMember" xlink:to="NRXS_HospitalCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_HospitalCMember_lbl" xml:lang="en-US">Hospital C [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_HospitalMember" xlink:label="NRXS_HospitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_HospitalMember" xlink:to="NRXS_HospitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_HospitalMember_lbl" xml:lang="en-US">Hospital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ShareholdersOneAndTwoMember" xlink:label="NRXS_ShareholdersOneAndTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ShareholdersOneAndTwoMember" xlink:to="NRXS_ShareholdersOneAndTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_ShareholdersOneAndTwoMember_lbl" xml:lang="en-US">Shareholders 1 And 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_MrWatkinsMember" xlink:label="NRXS_MrWatkinsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_MrWatkinsMember" xlink:to="NRXS_MrWatkinsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_MrWatkinsMember_lbl" xml:lang="en-US">Mr. Watkins [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_MrSealeMember" xlink:label="NRXS_MrSealeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_MrSealeMember" xlink:to="NRXS_MrSealeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_MrSealeMember_lbl" xml:lang="en-US">Mr Seale [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ShareHolderOneMember" xlink:label="NRXS_ShareHolderOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ShareHolderOneMember" xlink:to="NRXS_ShareHolderOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_ShareHolderOneMember_lbl" xml:lang="en-US">Shareholder 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ShareHolderTwoMember" xlink:label="NRXS_ShareHolderTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ShareHolderTwoMember" xlink:to="NRXS_ShareHolderTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_ShareHolderTwoMember_lbl" xml:lang="en-US">Shareholder 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ShareHolderMember" xlink:label="NRXS_ShareHolderMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ShareHolderMember" xlink:to="NRXS_ShareHolderMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_ShareHolderMember_lbl" xml:lang="en-US">Share Holder [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_OtherConvertiblesMember" xlink:label="NRXS_OtherConvertiblesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_OtherConvertiblesMember" xlink:to="NRXS_OtherConvertiblesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_OtherConvertiblesMember_lbl" xml:lang="en-US">Other Convertibles [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_SoftwareImplementationMember" xlink:label="NRXS_SoftwareImplementationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_SoftwareImplementationMember" xlink:to="NRXS_SoftwareImplementationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_SoftwareImplementationMember_lbl" xml:lang="en-US">Software Implementation [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PatentsMember_lbl" xml:lang="en-US">Patents [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TrademarksMember" xlink:label="us-gaap_TrademarksMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TrademarksMember" xlink:to="us-gaap_TrademarksMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TrademarksMember_lbl" xml:lang="en-US">Trademarks [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_LicensesMember" xlink:label="NRXS_LicensesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_LicensesMember" xlink:to="NRXS_LicensesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_LicensesMember_lbl" xml:lang="en-US">Licenses [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ExchangeListingLLCMember" xlink:label="NRXS_ExchangeListingLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ExchangeListingLLCMember" xlink:to="NRXS_ExchangeListingLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_ExchangeListingLLCMember_lbl" xml:lang="en-US">Exchange Listing LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_PromissoryNoteMember" xlink:label="NRXS_PromissoryNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_PromissoryNoteMember" xlink:to="NRXS_PromissoryNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_PromissoryNoteMember_lbl" xml:lang="en-US">Promissory Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ChannelPartnersCapitalMember" xlink:label="NRXS_ChannelPartnersCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ChannelPartnersCapitalMember" xlink:to="NRXS_ChannelPartnersCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_ChannelPartnersCapitalMember_lbl" xml:lang="en-US">Channel Partners Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioForecastMember_lbl" xml:lang="en-US">Forecast [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ConvertiblePromissoryNoteMember" xlink:label="NRXS_ConvertiblePromissoryNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ConvertiblePromissoryNoteMember" xlink:to="NRXS_ConvertiblePromissoryNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_ConvertiblePromissoryNoteMember_lbl" xml:lang="en-US">Convertible Promissory Note [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_AccreditedInvestorsMember" xlink:label="NRXS_AccreditedInvestorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_AccreditedInvestorsMember" xlink:to="NRXS_AccreditedInvestorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_AccreditedInvestorsMember_lbl" xml:lang="en-US">Accredited Investors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_SignatureBankMember" xlink:label="NRXS_SignatureBankMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_SignatureBankMember" xlink:to="NRXS_SignatureBankMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_SignatureBankMember_lbl" xml:lang="en-US">Signature Bank [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_TwoThousandTwentyThreeConvertibleNotesMember" xlink:label="NRXS_TwoThousandTwentyThreeConvertibleNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_TwoThousandTwentyThreeConvertibleNotesMember" xlink:to="NRXS_TwoThousandTwentyThreeConvertibleNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_TwoThousandTwentyThreeConvertibleNotesMember_lbl" xml:lang="en-US">2023 Convertible Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_TwoThousandTwentyTwoConvertibleNotesMember" xlink:label="NRXS_TwoThousandTwentyTwoConvertibleNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_TwoThousandTwentyTwoConvertibleNotesMember" xlink:to="NRXS_TwoThousandTwentyTwoConvertibleNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_TwoThousandTwentyTwoConvertibleNotesMember_lbl" xml:lang="en-US">2022 Convertible Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_InvestorsMember" xlink:label="NRXS_InvestorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_InvestorsMember" xlink:to="NRXS_InvestorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_InvestorsMember_lbl" xml:lang="en-US">Investors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember" xlink:label="NRXS_TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember" xlink:to="NRXS_TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember_lbl" xml:lang="en-US">2023 and 2022 Convertible Notes [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xml:lang="en-US">Short-Term Debt, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="us-gaap_ConvertibleNotesPayableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableMember" xlink:to="us-gaap_ConvertibleNotesPayableMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableMember_lbl" xml:lang="en-US">Convertible Notes Payable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeographicDistributionAxis" xlink:label="us-gaap_GeographicDistributionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeographicDistributionAxis" xlink:to="us-gaap_GeographicDistributionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeographicDistributionAxis_lbl" xml:lang="en-US">Geographic Distribution [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_VersaillesIndianaMember" xlink:label="NRXS_VersaillesIndianaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_VersaillesIndianaMember" xlink:to="NRXS_VersaillesIndianaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_VersaillesIndianaMember_lbl" xml:lang="en-US">Versailles Indiana [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_LeaseOneMember" xlink:label="NRXS_LeaseOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_LeaseOneMember" xlink:to="NRXS_LeaseOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_LeaseOneMember_lbl" xml:lang="en-US">Lease 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_LeaseTwoMember" xlink:label="NRXS_LeaseTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_LeaseTwoMember" xlink:to="NRXS_LeaseTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_LeaseTwoMember_lbl" xml:lang="en-US">Lease 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_CarmelIndianaMember" xlink:label="NRXS_CarmelIndianaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_CarmelIndianaMember" xlink:to="NRXS_CarmelIndianaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_CarmelIndianaMember_lbl" xml:lang="en-US">Carmel Indiana [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_LeaseThreeMember" xlink:label="NRXS_LeaseThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_LeaseThreeMember" xlink:to="NRXS_LeaseThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_LeaseThreeMember_lbl" xml:lang="en-US">Lease 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_VendorsMember" xlink:label="NRXS_VendorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_VendorsMember" xlink:to="NRXS_VendorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_VendorsMember_lbl" xml:lang="en-US">Vendors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_BrianHannaschMember" xlink:label="NRXS_BrianHannaschMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_BrianHannaschMember" xlink:to="NRXS_BrianHannaschMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_BrianHannaschMember_lbl" xml:lang="en-US">Brian Hannasch [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_WarrantOneMember" xlink:label="NRXS_WarrantOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_WarrantOneMember" xlink:to="NRXS_WarrantOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_WarrantOneMember_lbl" xml:lang="en-US">Warrant One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_WarrantTwoMember" xlink:label="NRXS_WarrantTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_WarrantTwoMember" xlink:to="NRXS_WarrantTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_WarrantTwoMember_lbl" xml:lang="en-US">Warrant Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_MasimoCorporationMember" xlink:label="NRXS_MasimoCorporationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_MasimoCorporationMember" xlink:to="NRXS_MasimoCorporationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_MasimoCorporationMember_lbl" xml:lang="en-US">Masimo Corporation [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_WarrantThreeMember" xlink:label="NRXS_WarrantThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_WarrantThreeMember" xlink:to="NRXS_WarrantThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_WarrantThreeMember_lbl" xml:lang="en-US">Warrant Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_InvestorWarrantOneMember" xlink:label="NRXS_InvestorWarrantOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_InvestorWarrantOneMember" xlink:to="NRXS_InvestorWarrantOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_InvestorWarrantOneMember_lbl" xml:lang="en-US">Investor Warrant W-01 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_InvestorWarrantPSAOneMember" xlink:label="NRXS_InvestorWarrantPSAOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_InvestorWarrantPSAOneMember" xlink:to="NRXS_InvestorWarrantPSAOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_InvestorWarrantPSAOneMember_lbl" xml:lang="en-US">Investor Warrant PSA-01 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ConsultingAgreementWarrantsMember" xlink:label="NRXS_ConsultingAgreementWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ConsultingAgreementWarrantsMember" xlink:to="NRXS_ConsultingAgreementWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_ConsultingAgreementWarrantsMember_lbl" xml:lang="en-US">Consulting Agreement Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_UnderwriterWarrantsMember" xlink:label="NRXS_UnderwriterWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_UnderwriterWarrantsMember" xlink:to="NRXS_UnderwriterWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_UnderwriterWarrantsMember_lbl" xml:lang="en-US">Underwriter Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtMember" xlink:to="us-gaap_ConvertibleDebtMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtMember_lbl" xml:lang="en-US">Convertible Debt [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US">Series B Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_TwentySeventeenStockCompensationPlanMember" xlink:label="NRXS_TwentySeventeenStockCompensationPlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_TwentySeventeenStockCompensationPlanMember" xlink:to="NRXS_TwentySeventeenStockCompensationPlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_TwentySeventeenStockCompensationPlanMember_lbl" xml:lang="en-US">2017 Stock Compensation Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xml:lang="en-US">Measurement Input, Share Price [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ExecutiveEmploymentAgreementsMember" xlink:label="NRXS_ExecutiveEmploymentAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ExecutiveEmploymentAgreementsMember" xlink:to="NRXS_ExecutiveEmploymentAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_ExecutiveEmploymentAgreementsMember_lbl" xml:lang="en-US">Executive Employment Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxPeriodAxis_lbl" xml:lang="en-US">Tax Period [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_TaxYear2038Member" xlink:label="NRXS_TaxYear2038Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_TaxYear2038Member" xlink:to="NRXS_TaxYear2038Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_TaxYear2038Member_lbl" xml:lang="en-US">Tax Year 2038 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_TaxYear2039Member" xlink:label="NRXS_TaxYear2039Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_TaxYear2039Member" xlink:to="NRXS_TaxYear2039Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_TaxYear2039Member_lbl" xml:lang="en-US">Tax Year 2039 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_TaxYear2040Member" xlink:label="NRXS_TaxYear2040Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_TaxYear2040Member" xlink:to="NRXS_TaxYear2040Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_TaxYear2040Member_lbl" xml:lang="en-US">Tax Year 2040 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_TaxYear2041Member" xlink:label="NRXS_TaxYear2041Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_TaxYear2041Member" xlink:to="NRXS_TaxYear2041Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_TaxYear2041Member_lbl" xml:lang="en-US">Tax Year 2041 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_TaxYear2042Member" xlink:label="NRXS_TaxYear2042Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_TaxYear2042Member" xlink:to="NRXS_TaxYear2042Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_TaxYear2042Member_lbl" xml:lang="en-US">Tax Year 2042 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_TaxYear2043Member" xlink:label="NRXS_TaxYear2043Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_TaxYear2043Member" xlink:to="NRXS_TaxYear2043Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_TaxYear2043Member_lbl" xml:lang="en-US">Tax Year 2043 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RestatementAxis_lbl" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:label="srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:to="srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_lbl" xml:lang="en-US">Revision of Prior Period, Reclassification, Adjustment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioPreviouslyReportedMember" xlink:to="srt_ScenarioPreviouslyReportedMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioPreviouslyReportedMember_lbl" xml:lang="en-US">Previously Reported [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaids and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property and Equipment, at cost:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less - accumulated depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrentAbstract" xlink:label="us-gaap_OtherAssetsNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrentAbstract_lbl" xml:lang="en-US">Other Assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCosts" xlink:label="us-gaap_DeferredCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCosts" xlink:to="us-gaap_DeferredCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCosts_lbl" xml:lang="en-US">Deferred offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right of use asset, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Intangible assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Current portion of operating lease payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_lbl" xml:lang="en-US">Notes payable - convertible notes, net of unamortized discount of $0 and $3,327,213 as of December 31, 2023 and December 31, 2022</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Deposits" xlink:label="us-gaap_Deposits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Deposits" xlink:to="us-gaap_Deposits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Deposits_lbl" xml:lang="en-US">Customer deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_lbl" xml:lang="en-US">Derivative liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_WarrantLiabilities" xlink:label="NRXS_WarrantLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_WarrantLiabilities" xlink:to="NRXS_WarrantLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_WarrantLiabilities_lbl" xml:lang="en-US">Warrant liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Non-current Liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease payable, net of current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total non-current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies (see note 14)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; Deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.001 par value; 100,000,000 shares authorized; 6,508,897 issued and outstanding as of December 31, 2023 and 1,963,322 as of December 31, 2022</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Stockholders&#8217; Deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountCurrent_lbl" xml:lang="en-US">Unamortized discount, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Net Sales</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US">Cost of Goods Sold</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross Profit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingExpense" xlink:label="us-gaap_SellingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingExpense" xlink:to="us-gaap_SellingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingExpense_lbl" xml:lang="en-US">Selling Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and Development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and Administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other (Expense) Income:</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_FinancingCharges" xlink:label="NRXS_FinancingCharges" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_FinancingCharges" xlink:to="NRXS_FinancingCharges_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="NRXS_FinancingCharges_lbl" xml:lang="en-US">Financing charges</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Change in fair value of warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xml:lang="en-US">Change in fair value of derivative liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Amortization of debt discount and issuance cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Extinguishment of debt liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">Other income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US">Other expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other (expense) income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Per-share Data</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Per-share Data, basic loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Per-share Data, diluted loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">Weighted Average Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted Average Shares Outstanding, Basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted Average Shares Outstanding, Diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Common stock issued upon signing of notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Common stock issued upon signing of notes payable, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering" xlink:label="NRXS_StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering" xlink:to="NRXS_StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering_lbl" xml:lang="en-US">Common stock issued upon initial public offering</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_StockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering" xlink:label="NRXS_StockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_StockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering" xlink:to="NRXS_StockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_StockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering_lbl" xml:lang="en-US">Common stock issued upon initial public offering, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_StockIssuedDuringPeriodValueCommonStockIssuedUponPreferredStockConversion" xlink:label="NRXS_StockIssuedDuringPeriodValueCommonStockIssuedUponPreferredStockConversion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_StockIssuedDuringPeriodValueCommonStockIssuedUponPreferredStockConversion" xlink:to="NRXS_StockIssuedDuringPeriodValueCommonStockIssuedUponPreferredStockConversion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_StockIssuedDuringPeriodValueCommonStockIssuedUponPreferredStockConversion_lbl" xml:lang="en-US">Common stock issued upon preferred stock conversion</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_StockIssuedDuringPeriodSharesCommonStockIssuedUponPreferredStockConversion" xlink:label="NRXS_StockIssuedDuringPeriodSharesCommonStockIssuedUponPreferredStockConversion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_StockIssuedDuringPeriodSharesCommonStockIssuedUponPreferredStockConversion" xlink:to="NRXS_StockIssuedDuringPeriodSharesCommonStockIssuedUponPreferredStockConversion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_StockIssuedDuringPeriodSharesCommonStockIssuedUponPreferredStockConversion_lbl" xml:lang="en-US">Common stock issued upon preferred stock conversion, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfUnits_lbl" xml:lang="en-US">Common stock issued upon debt conversion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xml:lang="en-US">Common stock issued upon debt conversion, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Common stock issued from agreements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Common stock issued from agreements, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US">Reclassification of warrant liability to equity</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="NRXS_StockIssuedDuringPeriodValueWarrantsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="NRXS_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US">Warrants exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="NRXS_StockIssuedDuringPeriodSharesWarrantsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="NRXS_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US">Warrants exercised, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows from Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net Loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used by operating activities:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_2_lbl" xml:lang="en-US">Amortization of debt discount and issuance cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US">Provisions for losses on accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_NoncashLeaseExpense" xlink:label="NRXS_NoncashLeaseExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_NoncashLeaseExpense" xlink:to="NRXS_NoncashLeaseExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_NoncashLeaseExpense_lbl" xml:lang="en-US">Non-cash lease expense</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_NoncashInterestExpense" xlink:label="NRXS_NoncashInterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_NoncashInterestExpense" xlink:to="NRXS_NoncashInterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_NoncashInterestExpense_lbl" xml:lang="en-US">Non-cash interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xml:lang="en-US">Extinguishment of debt liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_IssuanceOfCommonStockForNoncashConsideration" xlink:label="NRXS_IssuanceOfCommonStockForNoncashConsideration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_IssuanceOfCommonStockForNoncashConsideration" xlink:to="NRXS_IssuanceOfCommonStockForNoncashConsideration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_IssuanceOfCommonStockForNoncashConsideration_lbl" xml:lang="en-US">Issuance of common stock for non-cash consideration</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_FinanceCharges" xlink:label="NRXS_FinanceCharges" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_FinanceCharges" xlink:to="NRXS_FinanceCharges_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_FinanceCharges_lbl" xml:lang="en-US">Finance Charges</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_2_lbl" xml:lang="en-US">Change in fair value of derivative liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xml:lang="en-US">Change in fair value of warrant liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaids and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_IncreaseDecreaseInCustomerDeposit" xlink:label="NRXS_IncreaseDecreaseInCustomerDeposit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_IncreaseDecreaseInCustomerDeposit" xlink:to="NRXS_IncreaseDecreaseInCustomerDeposit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="NRXS_IncreaseDecreaseInCustomerDeposit_lbl" xml:lang="en-US">Customer deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used by operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows from Investing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Additions to property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Additions to intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used by investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows from Financing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common stock, net of issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_DeferredOfferingCostsPaid" xlink:label="NRXS_DeferredOfferingCostsPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_DeferredOfferingCostsPaid" xlink:to="NRXS_DeferredOfferingCostsPaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="NRXS_DeferredOfferingCostsPaid_lbl" xml:lang="en-US">Deferred offering costs paid</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Proceeds from exercised warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Principal payments on notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xml:lang="en-US">Proceeds from notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US">Proceeds from convertible notes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xml:lang="en-US">Financing fees paid</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net Decrease in Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Cash and Cash Equivalents at Beginning of Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">Cash and Cash Equivalents at End of Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Disclosure of Non-Cash Operating Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid for interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Cash paid for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Supplemental Schedule of Non-Cash Investing and Financing Activities</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_FairValueOfWarrantLiabilitiesOfWarrantsFromConvertibleNotes" xlink:label="NRXS_FairValueOfWarrantLiabilitiesOfWarrantsFromConvertibleNotes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_FairValueOfWarrantLiabilitiesOfWarrantsFromConvertibleNotes" xlink:to="NRXS_FairValueOfWarrantLiabilitiesOfWarrantsFromConvertibleNotes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_FairValueOfWarrantLiabilitiesOfWarrantsFromConvertibleNotes_lbl" xml:lang="en-US">Fair value of warrant liabilities of warrants from convertible notes</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_FairValueOfDerivativeLiabilitiesOfConversionFeatureFromConvertibleNotes" xlink:label="NRXS_FairValueOfDerivativeLiabilitiesOfConversionFeatureFromConvertibleNotes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_FairValueOfDerivativeLiabilitiesOfConversionFeatureFromConvertibleNotes" xlink:to="NRXS_FairValueOfDerivativeLiabilitiesOfConversionFeatureFromConvertibleNotes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_FairValueOfDerivativeLiabilitiesOfConversionFeatureFromConvertibleNotes_lbl" xml:lang="en-US">Fair value of derivative liabilities of conversion feature from convertible notes</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_PriorYearOfferingCostsPaid" xlink:label="NRXS_PriorYearOfferingCostsPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_PriorYearOfferingCostsPaid" xlink:to="NRXS_PriorYearOfferingCostsPaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_PriorYearOfferingCostsPaid_lbl" xml:lang="en-US">Prior year offering costs paid</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ReclassificationOfWarrantLiabilityToEquity" xlink:label="NRXS_ReclassificationOfWarrantLiabilityToEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ReclassificationOfWarrantLiabilityToEquity" xlink:to="NRXS_ReclassificationOfWarrantLiabilityToEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="NRXS_ReclassificationOfWarrantLiabilityToEquity_lbl" xml:lang="en-US">Reclassification of warrant liability to equity</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ConversionOfPreferredStockToCommonStock" xlink:label="NRXS_ConversionOfPreferredStockToCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ConversionOfPreferredStockToCommonStock" xlink:to="NRXS_ConversionOfPreferredStockToCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_ConversionOfPreferredStockToCommonStock_lbl" xml:lang="en-US">Conversion of preferred stock to common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US">Basis of Presentation, Organization and Other Matters</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US">Accrued Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Notes Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_DisclosureLeasesAbstract" xlink:label="NRXS_DisclosureLeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_DisclosureLeasesAbstract" xlink:to="NRXS_DisclosureLeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_DisclosureLeasesAbstract_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_DisclosureCommonStockAndWarrantsAbstract" xlink:label="NRXS_DisclosureCommonStockAndWarrantsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_DisclosureCommonStockAndWarrantsAbstract" xlink:to="NRXS_DisclosureCommonStockAndWarrantsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_DisclosureCommonStockAndWarrantsAbstract_lbl" xml:lang="en-US">Common Stock And Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_CommonStockAndWarrantsDisclosureTextBlock" xlink:label="NRXS_CommonStockAndWarrantsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_CommonStockAndWarrantsDisclosureTextBlock" xlink:to="NRXS_CommonStockAndWarrantsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_CommonStockAndWarrantsDisclosureTextBlock_lbl" xml:lang="en-US">Common Stock and Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockTextBlock" xlink:to="us-gaap_PreferredStockTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xml:lang="en-US">Preferred Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Stock Options and Awards</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_DisclosureWarrantLiabilitiesAbstract" xlink:label="NRXS_DisclosureWarrantLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_DisclosureWarrantLiabilitiesAbstract" xlink:to="NRXS_DisclosureWarrantLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_DisclosureWarrantLiabilitiesAbstract_lbl" xml:lang="en-US">Warrant Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_WarrantLiabilitiesDisclosureTextBlock" xlink:label="NRXS_WarrantLiabilitiesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_WarrantLiabilitiesDisclosureTextBlock" xlink:to="NRXS_WarrantLiabilitiesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="NRXS_WarrantLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">Warrant Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_DisclosureDerivativeLiabilitiesAbstract" xlink:label="NRXS_DisclosureDerivativeLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_DisclosureDerivativeLiabilitiesAbstract" xlink:to="NRXS_DisclosureDerivativeLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_DisclosureDerivativeLiabilitiesAbstract_lbl" xml:lang="en-US">Derivative Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesAndFairValueTextBlock" xlink:label="us-gaap_DerivativesAndFairValueTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesAndFairValueTextBlock" xlink:to="us-gaap_DerivativesAndFairValueTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DerivativesAndFairValueTextBlock_lbl" xml:lang="en-US">Derivative Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US">Retirement Plan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_DisclosureHealthBenefitPlanAbstract" xlink:label="NRXS_DisclosureHealthBenefitPlanAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_DisclosureHealthBenefitPlanAbstract" xlink:to="NRXS_DisclosureHealthBenefitPlanAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_DisclosureHealthBenefitPlanAbstract_lbl" xml:lang="en-US">Health Benefit Plan</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_HealthBenefitPlanDisclosureTextBlock" xlink:label="NRXS_HealthBenefitPlanDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_HealthBenefitPlanDisclosureTextBlock" xlink:to="NRXS_HealthBenefitPlanDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="NRXS_HealthBenefitPlanDisclosureTextBlock_lbl" xml:lang="en-US">Health Benefit Plan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="us-gaap_AccountingChangesAndErrorCorrectionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract_lbl" xml:lang="en-US">Accounting Changes and Error Corrections [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionTextBlock" xlink:label="us-gaap_ErrorCorrectionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ErrorCorrectionTextBlock" xlink:to="us-gaap_ErrorCorrectionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ErrorCorrectionTextBlock_lbl" xml:lang="en-US">Restatement of Interim Financial Statements (Unaudited)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates and Critical Accounting Estimates and Assumptions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US">Trade Accounts Receivable and Allowance for Credit Losses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositContractsPolicy" xlink:label="us-gaap_DepositContractsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositContractsPolicy" xlink:to="us-gaap_DepositContractsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositContractsPolicy_lbl" xml:lang="en-US">Customer Deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xml:lang="en-US">Deferred Offering Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US">Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xml:lang="en-US">Advertising Cost</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_DerivativeLiabilityPolicyTextBlock" xlink:label="NRXS_DerivativeLiabilityPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_DerivativeLiabilityPolicyTextBlock" xlink:to="NRXS_DerivativeLiabilityPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="NRXS_DerivativeLiabilityPolicyTextBlock_lbl" xml:lang="en-US">Derivative Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_WarrantLiabilityPolicyTextBlock" xlink:label="NRXS_WarrantLiabilityPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_WarrantLiabilityPolicyTextBlock" xlink:to="NRXS_WarrantLiabilityPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="NRXS_WarrantLiabilityPolicyTextBlock_lbl" xml:lang="en-US">Warrant Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Basic and Diluted Net Income (Loss) per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExtendedProductWarrantyPolicy" xlink:label="us-gaap_ExtendedProductWarrantyPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExtendedProductWarrantyPolicy" xlink:to="us-gaap_ExtendedProductWarrantyPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ExtendedProductWarrantyPolicy_lbl" xml:lang="en-US">Warranties</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentrations of Credit Risk</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_GoingConcernPolicyTextBlock" xlink:label="NRXS_GoingConcernPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_GoingConcernPolicyTextBlock" xlink:to="NRXS_GoingConcernPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_GoingConcernPolicyTextBlock_lbl" xml:lang="en-US">Going Concern</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Adopted Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:label="NRXS_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:to="NRXS_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_lbl" xml:lang="en-US">Schedule of Estimated Useful Lives</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value On a Recurring Basis Assets and Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US">Schedule of Unobservable Inputs for Level 3 Assets and Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_lbl" xml:lang="en-US">Schedule of Dilutive Common Stock Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of Basic and Diluted Net Loss Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US">Schedule of Disaggregation of Revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock" xlink:label="us-gaap_ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock" xlink:to="us-gaap_ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock_lbl" xml:lang="en-US">Schedule of Customers Accounted Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Related Party Transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ScheduleOfRelatedPartyLoansTableTextBlock" xlink:label="NRXS_ScheduleOfRelatedPartyLoansTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ScheduleOfRelatedPartyLoansTableTextBlock" xlink:to="NRXS_ScheduleOfRelatedPartyLoansTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_ScheduleOfRelatedPartyLoansTableTextBlock_lbl" xml:lang="en-US">Schedule of Related Party Loans payable to shareholder</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of Property And Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="us-gaap_ConvertibleDebtTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtTableTextBlock" xlink:to="us-gaap_ConvertibleDebtTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtTableTextBlock_lbl" xml:lang="en-US">Schedule of Convertible Notes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:to="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_lbl" xml:lang="en-US">Schedule of Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Maturities Operating Lease Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ScheduleOfWarrantActivityForCommonStockTableTextBlock" xlink:label="NRXS_ScheduleOfWarrantActivityForCommonStockTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ScheduleOfWarrantActivityForCommonStockTableTextBlock" xlink:to="NRXS_ScheduleOfWarrantActivityForCommonStockTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_ScheduleOfWarrantActivityForCommonStockTableTextBlock_lbl" xml:lang="en-US">Schedule of Warrant Activity for Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ScheduleOfWarrantActivityForPreferredStockTableTextBlock" xlink:label="NRXS_ScheduleOfWarrantActivityForPreferredStockTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ScheduleOfWarrantActivityForPreferredStockTableTextBlock" xlink:to="NRXS_ScheduleOfWarrantActivityForPreferredStockTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_ScheduleOfWarrantActivityForPreferredStockTableTextBlock_lbl" xml:lang="en-US">Schedule of Warrant Activity for Preferred Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of Warrants outstanding and Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Option-pricing Model with Following Weighted-average Assumptions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ScheduleOfChangesInWarrantLiabilitiesTableTextBlock" xlink:label="NRXS_ScheduleOfChangesInWarrantLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ScheduleOfChangesInWarrantLiabilitiesTableTextBlock" xlink:to="NRXS_ScheduleOfChangesInWarrantLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_ScheduleOfChangesInWarrantLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Changes in Warrant Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:to="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" xml:lang="en-US">Schedule of Changes in Derivative Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Deferred Tax Asset</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Federal Statutory Income Tax Rate and Effective Income Tax Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:to="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock_lbl" xml:lang="en-US">Schedule of State Carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:to="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_lbl" xml:lang="en-US">Schedule of Restatement of Interim Financial Statements (Unaudited)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplit" xlink:label="us-gaap_StockholdersEquityNoteStockSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplit" xlink:to="us-gaap_StockholdersEquityNoteStockSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteStockSplit_lbl" xml:lang="en-US">Description of stock split</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOfferingCosts" xlink:label="us-gaap_DeferredOfferingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US">Deferred offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_PurchaseOfAdditionalStockOnNumberOfOptionsNotExercised" xlink:label="NRXS_PurchaseOfAdditionalStockOnNumberOfOptionsNotExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_PurchaseOfAdditionalStockOnNumberOfOptionsNotExercised" xlink:to="NRXS_PurchaseOfAdditionalStockOnNumberOfOptionsNotExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_PurchaseOfAdditionalStockOnNumberOfOptionsNotExercised_lbl" xml:lang="en-US">[custom:PurchaseOfAdditionalStockOnNumberOfOptionsNotExercised]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_UnderwritersDiscountPercentage" xlink:label="NRXS_UnderwritersDiscountPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_UnderwritersDiscountPercentage" xlink:to="NRXS_UnderwritersDiscountPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_UnderwritersDiscountPercentage_lbl" xml:lang="en-US">[custom:UnderwritersDiscountPercentage-0]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_NonaccountableExpenseAllowancePercentage" xlink:label="NRXS_NonaccountableExpenseAllowancePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_NonaccountableExpenseAllowancePercentage" xlink:to="NRXS_NonaccountableExpenseAllowancePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_NonaccountableExpenseAllowancePercentage_lbl" xml:lang="en-US">[custom:NonaccountableExpenseAllowancePercentage-0]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_CashFeePercentage" xlink:label="NRXS_CashFeePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_CashFeePercentage" xlink:to="NRXS_CashFeePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_CashFeePercentage_lbl" xml:lang="en-US">[custom:CashFeePercentage-0]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ReimbursementExpenses" xlink:label="NRXS_ReimbursementExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ReimbursementExpenses" xlink:to="NRXS_ReimbursementExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_ReimbursementExpenses_lbl" xml:lang="en-US">Reimbursement expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:label="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:to="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_lbl" xml:lang="en-US">Sale of Stock, Percentage of Ownership after Transaction</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_OfferingPricePerPercentage" xlink:label="NRXS_OfferingPricePerPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_OfferingPricePerPercentage" xlink:to="NRXS_OfferingPricePerPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_OfferingPricePerPercentage_lbl" xml:lang="en-US">[custom:OfferingPricePerPercentage-0]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_LicenseFees" xlink:label="NRXS_LicenseFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_LicenseFees" xlink:to="NRXS_LicenseFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_LicenseFees_lbl" xml:lang="en-US">License fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property and equipment, estimated useful lives</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xml:lang="en-US">Total Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="srt_PlatformOperatorCryptoAssetTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_PlatformOperatorCryptoAssetTable" xlink:to="srt_PlatformOperatorCryptoAssetTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_PlatformOperatorCryptoAssetTable_lbl" xml:lang="en-US">Platform Operator, Crypto-Asset [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="srt_PlatformOperatorCryptoAssetLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_PlatformOperatorCryptoAssetLineItems" xlink:to="srt_PlatformOperatorCryptoAssetLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_PlatformOperatorCryptoAssetLineItems_lbl" xml:lang="en-US">Platform Operator, Crypto-Asset [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Totals</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl" xml:lang="en-US">Preferred stock dividends</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">&#160;Net income (loss) available to common stockholders</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xml:lang="en-US">Weighted average shares of common stock outstanding - basic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xml:lang="en-US">Weighted average shares of common stock outstanding - diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_2_lbl" xml:lang="en-US">Basic net loss per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_2_lbl" xml:lang="en-US">Diluted net loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Total revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="us-gaap_ScheduleOfProductInformationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="us-gaap_ScheduleOfProductInformationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfProductInformationTable_lbl" xml:lang="en-US">Schedule of Product Information [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductInformationLineItems" xlink:label="us-gaap_ProductInformationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_ProductInformationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductInformationLineItems_lbl" xml:lang="en-US">Product Information [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2_lbl" xml:lang="en-US">Revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Risk percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xml:lang="en-US">Allowance for doubtful accounts</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForOtherCreditLosses" xlink:label="us-gaap_ProvisionForOtherCreditLosses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForOtherCreditLosses" xlink:to="us-gaap_ProvisionForOtherCreditLosses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForOtherCreditLosses_lbl" xml:lang="en-US">Credit losses</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_InventoryExpenses" xlink:label="NRXS_InventoryExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_InventoryExpenses" xlink:to="NRXS_InventoryExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_InventoryExpenses_lbl" xml:lang="en-US">Inventory expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xml:lang="en-US">Initial payment upon execution</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingExpense" xlink:label="us-gaap_AdvertisingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingExpense" xlink:to="us-gaap_AdvertisingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvertisingExpense_lbl" xml:lang="en-US">Advertising cost expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPreferredStock" xlink:label="us-gaap_DividendsPreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStock" xlink:to="us-gaap_DividendsPreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPreferredStock_lbl" xml:lang="en-US">Preferred stock dividend</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">Cash, FDIC insured amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermBorrowings_lbl" xml:lang="en-US">Short term borrowing</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_WorkingCapitalDeficit" xlink:label="NRXS_WorkingCapitalDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_WorkingCapitalDeficit" xlink:to="NRXS_WorkingCapitalDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_WorkingCapitalDeficit_lbl" xml:lang="en-US">Working capital</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2_lbl" xml:lang="en-US">Number of shares issued in transaction</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_2_lbl" xml:lang="en-US">Share issued price per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_3_lbl" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Payment fees</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Purchase of common shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesAndLoansReceivableGrossCurrent" xlink:label="us-gaap_NotesAndLoansReceivableGrossCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesAndLoansReceivableGrossCurrent" xlink:to="us-gaap_NotesAndLoansReceivableGrossCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesAndLoansReceivableGrossCurrent_lbl" xml:lang="en-US">Loan Receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivableCurrent" xlink:to="us-gaap_InterestReceivableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestReceivableCurrent_lbl" xml:lang="en-US">Interest Receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_InterestIncomeGrossCurrent" xlink:label="NRXS_InterestIncomeGrossCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_InterestIncomeGrossCurrent" xlink:to="NRXS_InterestIncomeGrossCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_InterestIncomeGrossCurrent_lbl" xml:lang="en-US">Interest Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForNotesAndLoansReceivableCurrent" xlink:label="us-gaap_AllowanceForNotesAndLoansReceivableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForNotesAndLoansReceivableCurrent" xlink:to="us-gaap_AllowanceForNotesAndLoansReceivableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AllowanceForNotesAndLoansReceivableCurrent_lbl" xml:lang="en-US">Allowance for collection risk, loan receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivableCurrent" xlink:to="us-gaap_InterestReceivableCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestReceivableCurrent_2_lbl" xml:lang="en-US">Allowance for collection risk, interest receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_AllowanceForInterestIncomeCurrent" xlink:label="NRXS_AllowanceForInterestIncomeCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_AllowanceForInterestIncomeCurrent" xlink:to="NRXS_AllowanceForInterestIncomeCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="NRXS_AllowanceForInterestIncomeCurrent_lbl" xml:lang="en-US">Allowance for collection risk, interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesAndLoansReceivableNetCurrent" xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesAndLoansReceivableNetCurrent" xlink:to="us-gaap_NotesAndLoansReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent_lbl" xml:lang="en-US">Loan Receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestReceivable" xlink:label="us-gaap_InterestReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivable" xlink:to="us-gaap_InterestReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestReceivable_lbl" xml:lang="en-US">Interest Receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_InterestIncomeCurrent" xlink:label="NRXS_InterestIncomeCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_InterestIncomeCurrent" xlink:to="NRXS_InterestIncomeCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="NRXS_InterestIncomeCurrent_lbl" xml:lang="en-US">Interest Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xml:lang="en-US">Schedule of Short-Term Debt [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US">Short-Term Debt [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDateDescription" xlink:to="us-gaap_DebtInstrumentMaturityDateDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription_lbl" xml:lang="en-US">Due date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Debt instrument percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayable" xlink:label="us-gaap_LoansPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayable" xlink:to="us-gaap_LoansPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansPayable_lbl" xml:lang="en-US">Loan payable</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_InterestAndServiceFeeAccrued" xlink:label="NRXS_InterestAndServiceFeeAccrued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_InterestAndServiceFeeAccrued" xlink:to="NRXS_InterestAndServiceFeeAccrued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_InterestAndServiceFeeAccrued_lbl" xml:lang="en-US">Interest payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US">Interest payable</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_AllowanceForInterestReceivableCurrent" xlink:label="NRXS_AllowanceForInterestReceivableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_AllowanceForInterestReceivableCurrent" xlink:to="NRXS_AllowanceForInterestReceivableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_AllowanceForInterestReceivableCurrent_lbl" xml:lang="en-US">Allowance for interest receivable current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xml:lang="en-US">Related party transaction amounts</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForFees" xlink:label="us-gaap_PaymentsForFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForFees" xlink:to="us-gaap_PaymentsForFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForFees_lbl" xml:lang="en-US">Payments for fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_2_lbl" xml:lang="en-US">Total property and equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Less: accumulated depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Total intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Less: accumulated amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_AccruedCompensationAndBenefitsCurrent" xlink:label="NRXS_AccruedCompensationAndBenefitsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_AccruedCompensationAndBenefitsCurrent" xlink:to="NRXS_AccruedCompensationAndBenefitsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_AccruedCompensationAndBenefitsCurrent_lbl" xml:lang="en-US">Compensation and benefits</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_UnderwriterFees" xlink:label="NRXS_UnderwriterFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_UnderwriterFees" xlink:to="NRXS_UnderwriterFees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_UnderwriterFees_lbl" xml:lang="en-US">Underwriter fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US">Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_RelatedPartyInterestPayableCurrent" xlink:label="NRXS_RelatedPartyInterestPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_RelatedPartyInterestPayableCurrent" xlink:to="NRXS_RelatedPartyInterestPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_RelatedPartyInterestPayableCurrent_lbl" xml:lang="en-US">Related party interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:label="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:to="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent_lbl" xml:lang="en-US">Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xml:lang="en-US">Total accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Principal</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsCurrentNet" xlink:label="us-gaap_DeferredFinanceCostsCurrentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsCurrentNet" xlink:to="us-gaap_DeferredFinanceCostsCurrentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredFinanceCostsCurrentNet_lbl" xml:lang="en-US">Less: Original issue discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US">Less: Debt discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xml:lang="en-US">Less: Deferred financing fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US">&#160;Notes payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_2_lbl" xml:lang="en-US">Principal of warrants and common shares fair value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_2_lbl" xml:lang="en-US">Accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayable_lbl" xml:lang="en-US">Principal outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_2_lbl" xml:lang="en-US">Proceeds from issuance of ipo</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPayment" xlink:to="us-gaap_DebtInstrumentPeriodicPayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_lbl" xml:lang="en-US">Debt instrument, periodic payment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAverageAmountOutstanding" xlink:label="us-gaap_LongTermDebtAverageAmountOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtAverageAmountOutstanding" xlink:to="us-gaap_LongTermDebtAverageAmountOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtAverageAmountOutstanding_lbl" xml:lang="en-US">Principal outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:label="us-gaap_DebtInstrumentRepurchasedFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:to="us-gaap_DebtInstrumentRepurchasedFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRepurchasedFaceAmount_lbl" xml:lang="en-US">Principal balance back</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl" xml:lang="en-US">Minimum principal payment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Debt instrument gross</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xml:lang="en-US">Net proceeds of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_DebtInstrumentDiscountRate" xlink:label="NRXS_DebtInstrumentDiscountRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_DebtInstrumentDiscountRate" xlink:to="NRXS_DebtInstrumentDiscountRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_DebtInstrumentDiscountRate_lbl" xml:lang="en-US">Debt instrument discount rate</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_DebtWarrantConversionDescription" xlink:label="NRXS_DebtWarrantConversionDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_DebtWarrantConversionDescription" xlink:to="NRXS_DebtWarrantConversionDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_DebtWarrantConversionDescription_lbl" xml:lang="en-US">Debt warrant conversion, description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionRatio1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1_lbl" xml:lang="en-US">Strilke price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EscrowDeposit" xlink:label="us-gaap_EscrowDeposit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EscrowDeposit" xlink:to="us-gaap_EscrowDeposit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EscrowDeposit_lbl" xml:lang="en-US">Escrow deposit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromFeesReceived" xlink:label="us-gaap_ProceedsFromFeesReceived" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromFeesReceived" xlink:to="us-gaap_ProceedsFromFeesReceived_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromFeesReceived_lbl" xml:lang="en-US">Deferred financing fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Number of warrants received</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_3_lbl" xml:lang="en-US">Issuance of shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_3_lbl" xml:lang="en-US">Shares issued price per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_3_lbl" xml:lang="en-US">Extinguishment of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US">Conversion price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:to="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_lbl" xml:lang="en-US">Debt instrument description</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ClassOfWarrantDiscountRate" xlink:label="NRXS_ClassOfWarrantDiscountRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ClassOfWarrantDiscountRate" xlink:to="NRXS_ClassOfWarrantDiscountRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_ClassOfWarrantDiscountRate_lbl" xml:lang="en-US">Class of warrant discount rate</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_DebtInstrumentPrincipalAmount" xlink:label="NRXS_DebtInstrumentPrincipalAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_DebtInstrumentPrincipalAmount" xlink:to="NRXS_DebtInstrumentPrincipalAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_DebtInstrumentPrincipalAmount_lbl" xml:lang="en-US">Principal amount in percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_3_lbl" xml:lang="en-US">Fair value adjustment of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xml:lang="en-US">Offering costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:to="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_lbl" xml:lang="en-US">Fair value of embedded derivative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:to="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsNotSettleableInCashFairValueDisclosure_lbl" xml:lang="en-US">Embedded derivative warrant liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromNotesPayable_2_lbl" xml:lang="en-US">Cash proceeds fair value of incentivies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xml:lang="en-US">Original issue discount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountCurrent_2_lbl" xml:lang="en-US">Debt discount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfFinancingCosts_2_lbl" xml:lang="en-US">Financing fees</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_PaymentsOfFinancingCost" xlink:label="NRXS_PaymentsOfFinancingCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_PaymentsOfFinancingCost" xlink:to="NRXS_PaymentsOfFinancingCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="NRXS_PaymentsOfFinancingCost_lbl" xml:lang="en-US">Financing fees</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestPayableCurrent_2_lbl" xml:lang="en-US">Accrued interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_DisclosureLeasesAbstract" xlink:to="NRXS_DisclosureLeasesAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="NRXS_DisclosureLeasesAbstract_2_lbl" xml:lang="en-US">Schedule Of Operating Leases</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xml:lang="en-US">Operating lease right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Other current liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xml:lang="en-US">Operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted average remaining lease term (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted average discount rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_DisclosureLeasesAbstract" xlink:to="NRXS_DisclosureLeasesAbstract_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="NRXS_DisclosureLeasesAbstract_3_lbl" xml:lang="en-US">Schedule Of Maturities Operating Lease Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: imputed interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_2_lbl" xml:lang="en-US">Total present value of lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="us-gaap_LesseeOperatingLeaseDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xml:lang="en-US">Operating lease description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating lease payment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xml:lang="en-US">Operating lease payment rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Operating lease expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Number of Warrants, Outstanding at beginning of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding at beginning of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life - Warrants, Outstanding at Ending of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_2_lbl" xml:lang="en-US">Number of Warrants, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageRemainingContracualLifeOutstandingNumberGranted" xlink:label="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageRemainingContracualLifeOutstandingNumberGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageRemainingContracualLifeOutstandingNumberGranted" xlink:to="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageRemainingContracualLifeOutstandingNumberGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageRemainingContracualLifeOutstandingNumberGranted_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life - Warrants Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_lbl" xml:lang="en-US">Number of Warrants, Cancelled Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber" xlink:label="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber" xlink:to="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber_lbl" xml:lang="en-US">Weighted Average Exercise Price, Cancelled Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Number of Warrants, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Excercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life - Warrants Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants" xlink:label="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants" xlink:to="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants_lbl" xml:lang="en-US">Number of Warrants, Converted Prefunded Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsConvertedPrefundedWarrantsInPeriodWeightedAverageExercisePrice" xlink:label="NRXS_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsConvertedPrefundedWarrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsConvertedPrefundedWarrantsInPeriodWeightedAverageExercisePrice" xlink:to="NRXS_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsConvertedPrefundedWarrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsConvertedPrefundedWarrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Converted Prefunded Warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xml:lang="en-US">Number of Warrants, Outstanding at Ending of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding at Ending of period</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant" xlink:label="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant" xlink:to="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant_lbl" xml:lang="en-US">Converted to Common Stock Warrant</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant" xlink:label="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant" xlink:to="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant_lbl" xml:lang="en-US">Weighted Average Exercise Price, Converted to Common Stock Warrant</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Number of Warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xml:lang="en-US">Expiration Date</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_WarrantExpirationDateDescription" xlink:label="NRXS_WarrantExpirationDateDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_WarrantExpirationDateDescription" xlink:to="NRXS_WarrantExpirationDateDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="NRXS_WarrantExpirationDateDescription_lbl" xml:lang="en-US">Expiration Date</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_2_lbl" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_2_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1_lbl" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Stock value converted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US">Conversion of Stock, Shares Issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplit" xlink:to="us-gaap_StockholdersEquityNoteStockSplit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityNoteStockSplit_2_lbl" xml:lang="en-US">Common stock split, description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xml:lang="en-US">Final amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_3_lbl" xml:lang="en-US">Interest rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xml:lang="en-US">Number of warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_2_lbl" xml:lang="en-US">Date of Expiration</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_WarrantsExpirationDateDescription" xlink:label="NRXS_WarrantsExpirationDateDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_WarrantsExpirationDateDescription" xlink:to="NRXS_WarrantsExpirationDateDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_WarrantsExpirationDateDescription_lbl" xml:lang="en-US">Date of Expiration</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_2_lbl" xml:lang="en-US">Number of shares, conversion of convertible securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees" xlink:label="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees" xlink:to="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees_lbl" xml:lang="en-US">Warrant, description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant" xlink:to="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant_2_lbl" xml:lang="en-US">Converted to preferred stock warrant</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants" xlink:to="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants_2_lbl" xml:lang="en-US">Converted to common stock warrant</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Warrant term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_AggregatePurchasePrice" xlink:label="NRXS_AggregatePurchasePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_AggregatePurchasePrice" xlink:to="NRXS_AggregatePurchasePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_AggregatePurchasePrice_lbl" xml:lang="en-US">Aggregate purchase price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xml:lang="en-US">Conversion amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xml:lang="en-US">Preferred stock dividend rate percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionRatio1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleConversionRatio1_2_lbl" xml:lang="en-US">Conversion ratio</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_SharePremiumPercentage" xlink:label="NRXS_SharePremiumPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_SharePremiumPercentage" xlink:to="NRXS_SharePremiumPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_SharePremiumPercentage_lbl" xml:lang="en-US">Share premium percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_3_lbl" xml:lang="en-US">Debt instrument, face amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionOriginalDebtInterestRateOfDebt" xlink:label="us-gaap_DebtConversionOriginalDebtInterestRateOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionOriginalDebtInterestRateOfDebt" xlink:to="us-gaap_DebtConversionOriginalDebtInterestRateOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionOriginalDebtInterestRateOfDebt_lbl" xml:lang="en-US">Debt conversion, original debt, interest rate of debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_2_lbl" xml:lang="en-US">Debt instrument, convertible, conversion price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xml:lang="en-US">Number of Shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_2_lbl" xml:lang="en-US">Stock price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Options, Outstanding, Beginning balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life (in years), Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding, Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of Options, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of Options, Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Number of Options, Cancelled/Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Number of Options, Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of Options, Outstanding, Ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding, Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xml:lang="en-US">Number of Options, Vested and Exercisable, Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life (in years), Vested and Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Vested and Exercisable, Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Vested and Exercisable, Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Unrecognized compensation expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_WarrantsAndRightsOutstanding_2_lbl" xml:lang="en-US">Warrant liabilities, Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_AdditionToWarrantLiabilities" xlink:label="NRXS_AdditionToWarrantLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_AdditionToWarrantLiabilities" xlink:to="NRXS_AdditionToWarrantLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_AdditionToWarrantLiabilities_lbl" xml:lang="en-US">Addition</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_4_lbl" xml:lang="en-US">Changes in fair value of warrant liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ReclassifiedToEquity" xlink:label="NRXS_ReclassifiedToEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ReclassifiedToEquity" xlink:to="NRXS_ReclassifiedToEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_ReclassifiedToEquity_lbl" xml:lang="en-US">Reclassified to equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_WarrantsAndRightsOutstanding_3_lbl" xml:lang="en-US">Warrant liabilities, Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US">Warrants and rights outstanding, measurement input</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_2_lbl" xml:lang="en-US">Derivative liabilities, Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_AdditionToDerivativeLiabilities" xlink:label="NRXS_AdditionToDerivativeLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_AdditionToDerivativeLiabilities" xlink:to="NRXS_AdditionToDerivativeLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="NRXS_AdditionToDerivativeLiabilities_lbl" xml:lang="en-US">Addition</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:to="us-gaap_IncreaseDecreaseInDerivativeLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDerivativeLiabilities_lbl" xml:lang="en-US">Changes in fair value of Derivative liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ExtinguishmentOfDerivativeLiabilities" xlink:label="NRXS_ExtinguishmentOfDerivativeLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ExtinguishmentOfDerivativeLiabilities" xlink:to="NRXS_ExtinguishmentOfDerivativeLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_ExtinguishmentOfDerivativeLiabilities_lbl" xml:lang="en-US">Extinguishment of Derivative liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_3_lbl" xml:lang="en-US">Derivative liabilities, Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilityMeasurementInput" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput_lbl" xml:lang="en-US">Derivative liability, measurement input</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xml:lang="en-US">Employee contribution percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanAdministrativeExpenses" xlink:label="us-gaap_DefinedContributionPlanAdministrativeExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanAdministrativeExpenses" xlink:to="us-gaap_DefinedContributionPlanAdministrativeExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanAdministrativeExpenses_lbl" xml:lang="en-US">Profit sharing contribution expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable" xlink:label="us-gaap_OtherCommitmentsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsTable" xlink:to="us-gaap_OtherCommitmentsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsTable_lbl" xml:lang="en-US">Other Commitments [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xml:lang="en-US">Other Commitments [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:label="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:to="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRepurchaseOfInitialPublicOffering_lbl" xml:lang="en-US">Payments for repurchase of initial public offering</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ExecutiveEmploymentAgreementsTerms" xlink:label="NRXS_ExecutiveEmploymentAgreementsTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ExecutiveEmploymentAgreementsTerms" xlink:to="NRXS_ExecutiveEmploymentAgreementsTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_ExecutiveEmploymentAgreementsTerms_lbl" xml:lang="en-US">Executive employment agreements renewals</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_DescriptionOfExecutiveEmploymentAgreementsRenewals" xlink:label="NRXS_DescriptionOfExecutiveEmploymentAgreementsRenewals" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_DescriptionOfExecutiveEmploymentAgreementsRenewals" xlink:to="NRXS_DescriptionOfExecutiveEmploymentAgreementsRenewals_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_DescriptionOfExecutiveEmploymentAgreementsRenewals_lbl" xml:lang="en-US">Description of Executive employment agreements renewals</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalariesAndWages" xlink:label="us-gaap_SalariesAndWages" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesAndWages" xlink:to="us-gaap_SalariesAndWages_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalariesAndWages_lbl" xml:lang="en-US">Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncentiveFeeExpense" xlink:label="us-gaap_IncentiveFeeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncentiveFeeExpense" xlink:to="us-gaap_IncentiveFeeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncentiveFeeExpense_lbl" xml:lang="en-US">Incentive Fee Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositLiabilitiesAccruedInterest" xlink:label="us-gaap_DepositLiabilitiesAccruedInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositLiabilitiesAccruedInterest" xlink:to="us-gaap_DepositLiabilitiesAccruedInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositLiabilitiesAccruedInterest_lbl" xml:lang="en-US">Deposit Liabilities, Accrued Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_lbl" xml:lang="en-US">Seven key employees stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_SpecialBonusPercentage" xlink:label="NRXS_SpecialBonusPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_SpecialBonusPercentage" xlink:to="NRXS_SpecialBonusPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_SpecialBonusPercentage_lbl" xml:lang="en-US">Special bonus percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_KeyEmployeeExercisePercentage" xlink:label="NRXS_KeyEmployeeExercisePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_KeyEmployeeExercisePercentage" xlink:to="NRXS_KeyEmployeeExercisePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_KeyEmployeeExercisePercentage_lbl" xml:lang="en-US">Key employee exercise percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="us-gaap_AccruedBonusesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedBonusesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedBonusesCurrent_lbl" xml:lang="en-US">Incentive bonus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="us-gaap_LossContingencyDamagesSoughtValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyDamagesSoughtValue" xlink:to="us-gaap_LossContingencyDamagesSoughtValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LossContingencyDamagesSoughtValue_lbl" xml:lang="en-US">Sought compensatory damages</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthCareOrganizationStopLossInsurancePremiumExpense" xlink:label="us-gaap_HealthCareOrganizationStopLossInsurancePremiumExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HealthCareOrganizationStopLossInsurancePremiumExpense" xlink:to="us-gaap_HealthCareOrganizationStopLossInsurancePremiumExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_HealthCareOrganizationStopLossInsurancePremiumExpense_lbl" xml:lang="en-US">Stop loss insurance premium expense</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_HealthCareOrganizationStopLossInsurancePremiumPercentage" xlink:label="NRXS_HealthCareOrganizationStopLossInsurancePremiumPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_HealthCareOrganizationStopLossInsurancePremiumPercentage" xlink:to="NRXS_HealthCareOrganizationStopLossInsurancePremiumPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_HealthCareOrganizationStopLossInsurancePremiumPercentage_lbl" xml:lang="en-US">Stop loss insurance premium percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_DeferredTaxAssetsDepreciation" xlink:label="NRXS_DeferredTaxAssetsDepreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_DeferredTaxAssetsDepreciation" xlink:to="NRXS_DeferredTaxAssetsDepreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_DeferredTaxAssetsDepreciation_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_DeferredTaxAssetsAmortization" xlink:label="NRXS_DeferredTaxAssetsAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_DeferredTaxAssetsAmortization" xlink:to="NRXS_DeferredTaxAssetsAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_DeferredTaxAssetsAmortization_lbl" xml:lang="en-US">Amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_lbl" xml:lang="en-US">Accrual to cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Stock based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Expected income tax benefit from NOL carry-forwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Less valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred tax assets, net of valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Federal statutory income tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State tax rate, net of federal benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xml:lang="en-US">Nondeductible expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_EffectiveIncomeTaxRateReconciliationNontaxableIncome" xlink:label="NRXS_EffectiveIncomeTaxRateReconciliationNontaxableIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_EffectiveIncomeTaxRateReconciliationNontaxableIncome" xlink:to="NRXS_EffectiveIncomeTaxRateReconciliationNontaxableIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_EffectiveIncomeTaxRateReconciliationNontaxableIncome_lbl" xml:lang="en-US">Nontaxable income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance on net deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective income tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xml:lang="en-US">State Carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US">Research and development expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Deferred tax assets valuation allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_2_lbl" xml:lang="en-US">Federal and state net operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment_2_lbl" xml:lang="en-US">Total principal amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebt" xlink:label="us-gaap_ConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebt" xlink:to="us-gaap_ConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebt_lbl" xml:lang="en-US">Convertible debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPayment" xlink:to="us-gaap_DebtInstrumentPeriodicPayment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_2_lbl" xml:lang="en-US">Principal amount due in monthly installments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_lbl" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_2_lbl" xml:lang="en-US">Current assets:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xml:lang="en-US">Prepaid and other current assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_3_lbl" xml:lang="en-US">Property and equipment, at cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xml:lang="en-US">Intangible assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_2_lbl" xml:lang="en-US">Liabilities and Stockholders&#8217; Deficit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_2_lbl" xml:lang="en-US">Current liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ShareLiabilitiesCurrent" xlink:label="NRXS_ShareLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ShareLiabilitiesCurrent" xlink:to="NRXS_ShareLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_ShareLiabilitiesCurrent_lbl" xml:lang="en-US">Share liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_2_lbl" xml:lang="en-US">Stockholders&#8217; deficit:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockValue_2_lbl" xml:lang="en-US">Convertible Series Seed preferred stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockValue_2_lbl" xml:lang="en-US">Common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3_lbl" xml:lang="en-US">Net sales</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CostOfGoodsAndServicesSold_2_lbl" xml:lang="en-US">Cost of goods sold</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingExpense" xlink:to="us-gaap_SellingExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SellingExpense_2_lbl" xml:lang="en-US">Selling expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_2_lbl" xml:lang="en-US">Research and development</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_2_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_2_lbl" xml:lang="en-US">Other (expense) income, net:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndOtherIncome" xlink:to="us-gaap_InterestAndOtherIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xml:lang="en-US">Interest income</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_3_lbl" xml:lang="en-US">Change in fair value of derivative financial instruments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2_lbl" xml:lang="en-US">Cash flows from operating activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_2_lbl" xml:lang="en-US">Provision for losses on accounts receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_4_lbl" xml:lang="en-US">Extinguishment of derivative liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_FinanceCharges" xlink:to="NRXS_FinanceCharges_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="NRXS_FinanceCharges_2_lbl" xml:lang="en-US">Finance charges</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2_lbl" xml:lang="en-US">Cash flows from investing activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2_lbl" xml:lang="en-US">Cash flows from financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_OfferingCostsInAdvanceOfSaleOfCommonStock" xlink:label="NRXS_OfferingCostsInAdvanceOfSaleOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_OfferingCostsInAdvanceOfSaleOfCommonStock" xlink:to="NRXS_OfferingCostsInAdvanceOfSaleOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_OfferingCostsInAdvanceOfSaleOfCommonStock_lbl" xml:lang="en-US">Offering costs in advance of sale of common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromConvertibleDebt_2_lbl" xml:lang="en-US">Proceeds from convertible notes, net of fees</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_IncreaseDecreaseInWarrantLiability" xlink:label="NRXS_IncreaseDecreaseInWarrantLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_IncreaseDecreaseInWarrantLiability" xlink:to="NRXS_IncreaseDecreaseInWarrantLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_IncreaseDecreaseInWarrantLiability_lbl" xml:lang="en-US">Reduced warrant liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NetIncomeLoss_4_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ShareholdersOneAndTwoMember" xlink:to="NRXS_ShareholdersOneAndTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ShareholdersOneAndTwoMember_doc" xml:lang="en-US">Shareholders 1 And 2 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_AllowanceForInterestReceivableCurrent" xlink:to="NRXS_AllowanceForInterestReceivableCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_AllowanceForInterestReceivableCurrent_doc" xml:lang="en-US">Allowance for interest receivable current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ShareHolderOneMember" xlink:to="NRXS_ShareHolderOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ShareHolderOneMember_doc" xml:lang="en-US">Shareholder 1 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ShareHolderTwoMember" xlink:to="NRXS_ShareHolderTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ShareHolderTwoMember_doc" xml:lang="en-US">Shareholder 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_InterestReceivableGrossCurrent" xlink:label="NRXS_InterestReceivableGrossCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_InterestReceivableGrossCurrent" xlink:to="NRXS_InterestReceivableGrossCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_InterestReceivableGrossCurrent_doc" xml:lang="en-US">Interest receivable gross current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_InterestIncomeGrossCurrent" xlink:to="NRXS_InterestIncomeGrossCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_InterestIncomeGrossCurrent_doc" xml:lang="en-US">Interest income gross current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_AllowanceForInterestIncomeCurrent" xlink:to="NRXS_AllowanceForInterestIncomeCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_AllowanceForInterestIncomeCurrent_doc" xml:lang="en-US">Allowance for interest income current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_InterestIncomeCurrent" xlink:to="NRXS_InterestIncomeCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_InterestIncomeCurrent_doc" xml:lang="en-US">Interest income current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ShareHolderMember" xlink:to="NRXS_ShareHolderMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ShareHolderMember_doc" xml:lang="en-US">Share Holder [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_OtherConvertiblesMember" xlink:to="NRXS_OtherConvertiblesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_OtherConvertiblesMember_doc" xml:lang="en-US">Other Convertibles [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_InterestAndServiceFeeAccrued" xlink:to="NRXS_InterestAndServiceFeeAccrued_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_InterestAndServiceFeeAccrued_doc" xml:lang="en-US">Interest and service fee accrued.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_WarrantLiabilitiesDisclosureTextBlock" xlink:to="NRXS_WarrantLiabilitiesDisclosureTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_WarrantLiabilitiesDisclosureTextBlock_doc" xml:lang="en-US">Warrant Liabilities Disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ConvertibleSeriesAPreferredStockMember" xlink:to="NRXS_ConvertibleSeriesAPreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ConvertibleSeriesAPreferredStockMember_doc" xml:lang="en-US">Convertible Series A Preferred stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ConvertibleSeriesSeedPreferredStockMember" xlink:to="NRXS_ConvertibleSeriesSeedPreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ConvertibleSeriesSeedPreferredStockMember_doc" xml:lang="en-US">Convertible Series Seed Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_AlexanderCapitalLPMember" xlink:to="NRXS_AlexanderCapitalLPMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_AlexanderCapitalLPMember_doc" xml:lang="en-US">Alexander Capital LP [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_PurchaseOfAdditionalStockOnNumberOfOptionsNotExercised" xlink:to="NRXS_PurchaseOfAdditionalStockOnNumberOfOptionsNotExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_PurchaseOfAdditionalStockOnNumberOfOptionsNotExercised_doc" xml:lang="en-US">Purchase of additional stock on number of options not exercised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_UnderwritersDiscountPercentage" xlink:to="NRXS_UnderwritersDiscountPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_UnderwritersDiscountPercentage_doc" xml:lang="en-US">Underwriters discount percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_NonaccountableExpenseAllowancePercentage" xlink:to="NRXS_NonaccountableExpenseAllowancePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_NonaccountableExpenseAllowancePercentage_doc" xml:lang="en-US">Nonaccountable expense allowance percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_CashFeePercentage" xlink:to="NRXS_CashFeePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_CashFeePercentage_doc" xml:lang="en-US">Cash fee percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ReimbursementExpenses" xlink:to="NRXS_ReimbursementExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ReimbursementExpenses_doc" xml:lang="en-US">Reimbursement expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_OfferingPricePerPercentage" xlink:to="NRXS_OfferingPricePerPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_OfferingPricePerPercentage_doc" xml:lang="en-US">Offering price per percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_LicenseFees" xlink:to="NRXS_LicenseFees_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_LicenseFees_doc" xml:lang="en-US">License fees.</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_AllowanceForCreditLosses" xlink:label="NRXS_AllowanceForCreditLosses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_AllowanceForCreditLosses" xlink:to="NRXS_AllowanceForCreditLosses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_AllowanceForCreditLosses_doc" xml:lang="en-US">Allowance for credit losses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering" xlink:to="NRXS_StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering_doc" xml:lang="en-US">Stock issued during period value common stock issued upon initial public offering.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_StockIssuedDuringPeriodValueCommonStockIssuedUponPreferredStockConversion" xlink:to="NRXS_StockIssuedDuringPeriodValueCommonStockIssuedUponPreferredStockConversion_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_StockIssuedDuringPeriodValueCommonStockIssuedUponPreferredStockConversion_doc" xml:lang="en-US">Stock issued during period value common stock issued upon preferred stock conversion.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_StockIssuedDuringPeriodSharesCommonStockIssuedUponPreferredStockConversion" xlink:to="NRXS_StockIssuedDuringPeriodSharesCommonStockIssuedUponPreferredStockConversion_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_StockIssuedDuringPeriodSharesCommonStockIssuedUponPreferredStockConversion_doc" xml:lang="en-US">Stock issued during period shares common stock issued upon preferred stock conversion.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_StockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering" xlink:to="NRXS_StockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_StockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering_doc" xml:lang="en-US">Stock issued during period shares common stock issued upon initial public offering.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ScheduleOfRelatedPartyLoansTableTextBlock" xlink:to="NRXS_ScheduleOfRelatedPartyLoansTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ScheduleOfRelatedPartyLoansTableTextBlock_doc" xml:lang="en-US">Schedule Of Related Party Loans [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_WarrantLiabilities" xlink:to="NRXS_WarrantLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_WarrantLiabilities_doc" xml:lang="en-US">Warrant liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_NoncashLeaseExpense" xlink:to="NRXS_NoncashLeaseExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_NoncashLeaseExpense_doc" xml:lang="en-US">Noncash lease expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_NoncashInterestExpense" xlink:to="NRXS_NoncashInterestExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_NoncashInterestExpense_doc" xml:lang="en-US">Noncash interest expense.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_IssuanceOfCommonStockForNoncashConsideration" xlink:to="NRXS_IssuanceOfCommonStockForNoncashConsideration_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_IssuanceOfCommonStockForNoncashConsideration_doc" xml:lang="en-US">Issuance of common stock for noncash consideration.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_FinanceCharges" xlink:to="NRXS_FinanceCharges_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_FinanceCharges_doc" xml:lang="en-US">Finance charges.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_IncreaseDecreaseInCustomerDeposit" xlink:to="NRXS_IncreaseDecreaseInCustomerDeposit_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_IncreaseDecreaseInCustomerDeposit_doc" xml:lang="en-US">Increase decrease in customer deposit.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_FairValueOfWarrantLiabilitiesOfWarrantsFromConvertibleNotes" xlink:to="NRXS_FairValueOfWarrantLiabilitiesOfWarrantsFromConvertibleNotes_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_FairValueOfWarrantLiabilitiesOfWarrantsFromConvertibleNotes_doc" xml:lang="en-US">Fair value of warrant liabilities of warrants from convertible notes.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_FairValueOfDerivativeLiabilitiesOfConversionFeatureFromConvertibleNotes" xlink:to="NRXS_FairValueOfDerivativeLiabilitiesOfConversionFeatureFromConvertibleNotes_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_FairValueOfDerivativeLiabilitiesOfConversionFeatureFromConvertibleNotes_doc" xml:lang="en-US">Fair value of derivative liabilities of conversion feature from convertible notes.</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_PaymentForOfferingCostsPaid" xlink:label="NRXS_PaymentForOfferingCostsPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_PaymentForOfferingCostsPaid" xlink:to="NRXS_PaymentForOfferingCostsPaid_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_PaymentForOfferingCostsPaid_doc" xml:lang="en-US">Payment for offering costs paid.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_FinancingCharges" xlink:to="NRXS_FinancingCharges_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_FinancingCharges_doc" xml:lang="en-US">Financing charges.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="NRXS_StockIssuedDuringPeriodValueWarrantsExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_StockIssuedDuringPeriodValueWarrantsExercised_doc" xml:lang="en-US">Stock issued during period value warrants exercised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="NRXS_StockIssuedDuringPeriodSharesWarrantsExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_StockIssuedDuringPeriodSharesWarrantsExercised_doc" xml:lang="en-US">Stock issued during period shares warrants exercised.</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_StockIssuedDuringPeriodValueCommonStockIssuedFromUnissuedShares" xlink:label="NRXS_StockIssuedDuringPeriodValueCommonStockIssuedFromUnissuedShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_StockIssuedDuringPeriodValueCommonStockIssuedFromUnissuedShares" xlink:to="NRXS_StockIssuedDuringPeriodValueCommonStockIssuedFromUnissuedShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_StockIssuedDuringPeriodValueCommonStockIssuedFromUnissuedShares_doc" xml:lang="en-US">Stock issued during period value common stock issued from unissued shares.</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_StockIssuedDuringPeriodSharesCommonStockIssuedFromUnissuedSharesShares" xlink:label="NRXS_StockIssuedDuringPeriodSharesCommonStockIssuedFromUnissuedSharesShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_StockIssuedDuringPeriodSharesCommonStockIssuedFromUnissuedSharesShares" xlink:to="NRXS_StockIssuedDuringPeriodSharesCommonStockIssuedFromUnissuedSharesShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_StockIssuedDuringPeriodSharesCommonStockIssuedFromUnissuedSharesShares_doc" xml:lang="en-US">Stock issued during period shares common stock issued from unissued shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_DerivativeLiabilityPolicyTextBlock" xlink:to="NRXS_DerivativeLiabilityPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_DerivativeLiabilityPolicyTextBlock_doc" xml:lang="en-US">Derivative liability [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_WarrantLiabilityPolicyTextBlock" xlink:to="NRXS_WarrantLiabilityPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_WarrantLiabilityPolicyTextBlock_doc" xml:lang="en-US">Warrant Liability [Policy Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_WarrantsPolicyTextBlock" xlink:label="NRXS_WarrantsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_WarrantsPolicyTextBlock" xlink:to="NRXS_WarrantsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_WarrantsPolicyTextBlock_doc" xml:lang="en-US">Warrants [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_GoingConcernPolicyTextBlock" xlink:to="NRXS_GoingConcernPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_GoingConcernPolicyTextBlock_doc" xml:lang="en-US">Going Concern [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_InventoryExpenses" xlink:to="NRXS_InventoryExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_InventoryExpenses_doc" xml:lang="en-US">Inventory expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_AggregatePurchasePrice" xlink:to="NRXS_AggregatePurchasePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_AggregatePurchasePrice_doc" xml:lang="en-US">Aggregate purchase price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:to="NRXS_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_doc" xml:lang="en-US">Schedule of Property Plant And Equipment Useful Lives [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_SharePremiumPercentage" xlink:to="NRXS_SharePremiumPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_SharePremiumPercentage_doc" xml:lang="en-US">Share premium percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_TrademarkAgreementMember" xlink:to="NRXS_TrademarkAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_TrademarkAgreementMember_doc" xml:lang="en-US">Trademark Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_InitialPaymentMember" xlink:to="NRXS_InitialPaymentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_InitialPaymentMember_doc" xml:lang="en-US">Initial Payment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_SecondAndFinalPaymentMember" xlink:to="NRXS_SecondAndFinalPaymentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_SecondAndFinalPaymentMember_doc" xml:lang="en-US">Second and Final Payment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_TwentySeventeenStockCompensationPlanMember" xlink:to="NRXS_TwentySeventeenStockCompensationPlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_TwentySeventeenStockCompensationPlanMember_doc" xml:lang="en-US">2017 Stock Compensation Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_LicensingAgreementMember" xlink:to="NRXS_LicensingAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_LicensingAgreementMember_doc" xml:lang="en-US">Licensing Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ConvertibleBridgeDebtMember" xlink:to="NRXS_ConvertibleBridgeDebtMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ConvertibleBridgeDebtMember_doc" xml:lang="en-US">Convertible Bridge Debt [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_AllOtherStatesMember" xlink:to="NRXS_AllOtherStatesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_AllOtherStatesMember_doc" xml:lang="en-US">All Other States [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ScheduleOfChangesInWarrantLiabilitiesTableTextBlock" xlink:to="NRXS_ScheduleOfChangesInWarrantLiabilitiesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ScheduleOfChangesInWarrantLiabilitiesTableTextBlock_doc" xml:lang="en-US">Schedule of Changes in Warrant Liabilities [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_AdditionToWarrantLiabilities" xlink:to="NRXS_AdditionToWarrantLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_AdditionToWarrantLiabilities_doc" xml:lang="en-US">Addition to warrant liabilities.</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ExtingishmentOfWarrantLiabilities" xlink:label="NRXS_ExtingishmentOfWarrantLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ExtingishmentOfWarrantLiabilities" xlink:to="NRXS_ExtingishmentOfWarrantLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ExtingishmentOfWarrantLiabilities_doc" xml:lang="en-US">Extingishment of warrant liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_AdditionToDerivativeLiabilities" xlink:to="NRXS_AdditionToDerivativeLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_AdditionToDerivativeLiabilities_doc" xml:lang="en-US">Addition to derivative liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ExtinguishmentOfDerivativeLiabilities" xlink:to="NRXS_ExtinguishmentOfDerivativeLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ExtinguishmentOfDerivativeLiabilities_doc" xml:lang="en-US">Extinguishment of derivative liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_CustomerMember" xlink:to="NRXS_CustomerMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_CustomerMember_doc" xml:lang="en-US">Customer [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_CustomerOneMember" xlink:to="NRXS_CustomerOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_CustomerOneMember_doc" xml:lang="en-US">Customer One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_CustomerTwoMember" xlink:to="NRXS_CustomerTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_CustomerTwoMember_doc" xml:lang="en-US">Customer Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_CustomerThreeMember" xlink:to="NRXS_CustomerThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_CustomerThreeMember_doc" xml:lang="en-US">Customer Three [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ExecutiveEmploymentAgreementsTerms" xlink:to="NRXS_ExecutiveEmploymentAgreementsTerms_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ExecutiveEmploymentAgreementsTerms_doc" xml:lang="en-US">Executive employment agreements terms.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ExecutiveEmploymentAgreementsMember" xlink:to="NRXS_ExecutiveEmploymentAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ExecutiveEmploymentAgreementsMember_doc" xml:lang="en-US">Executive Employment Agreements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_DescriptionOfExecutiveEmploymentAgreementsRenewals" xlink:to="NRXS_DescriptionOfExecutiveEmploymentAgreementsRenewals_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_DescriptionOfExecutiveEmploymentAgreementsRenewals_doc" xml:lang="en-US">Description of executive employment agreements renewals.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_HospitalAMember" xlink:to="NRXS_HospitalAMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_HospitalAMember_doc" xml:lang="en-US">Hospital A [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_HospitalBMember" xlink:to="NRXS_HospitalBMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_HospitalBMember_doc" xml:lang="en-US">Hospital B [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_HospitalCMember" xlink:to="NRXS_HospitalCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_HospitalCMember_doc" xml:lang="en-US">Hospital C [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_HospitalMember" xlink:to="NRXS_HospitalMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_HospitalMember_doc" xml:lang="en-US">Hospital [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_SpecialBonusPercentage" xlink:to="NRXS_SpecialBonusPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_SpecialBonusPercentage_doc" xml:lang="en-US">Special bonus percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_KeyEmployeeExercisePercentage" xlink:to="NRXS_KeyEmployeeExercisePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_KeyEmployeeExercisePercentage_doc" xml:lang="en-US">Key employee exercise percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_HealthBenefitPlanDisclosureTextBlock" xlink:to="NRXS_HealthBenefitPlanDisclosureTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_HealthBenefitPlanDisclosureTextBlock_doc" xml:lang="en-US">Health benefit plan disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_HealthCareOrganizationStopLossInsurancePremiumPercentage" xlink:to="NRXS_HealthCareOrganizationStopLossInsurancePremiumPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_HealthCareOrganizationStopLossInsurancePremiumPercentage_doc" xml:lang="en-US">Health care organization stop loss insurance premium percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_WorkingCapitalDeficit" xlink:to="NRXS_WorkingCapitalDeficit_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_WorkingCapitalDeficit_doc" xml:lang="en-US">Working capital deficit.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_DeferredTaxAssetsAmortization" xlink:to="NRXS_DeferredTaxAssetsAmortization_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_DeferredTaxAssetsAmortization_doc" xml:lang="en-US">Deferred tax assets amortization.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_DeferredTaxAssetsDepreciation" xlink:to="NRXS_DeferredTaxAssetsDepreciation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_DeferredTaxAssetsDepreciation_doc" xml:lang="en-US">Deferred tax assets depreciation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_MrSealeMember" xlink:to="NRXS_MrSealeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_MrSealeMember_doc" xml:lang="en-US">Mr Seale [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_EffectiveIncomeTaxRateReconciliationNontaxableIncome" xlink:to="NRXS_EffectiveIncomeTaxRateReconciliationNontaxableIncome_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_EffectiveIncomeTaxRateReconciliationNontaxableIncome_doc" xml:lang="en-US">Percentage of nontaxable income.</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_AccruedWagesCurrent" xlink:label="NRXS_AccruedWagesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_AccruedWagesCurrent" xlink:to="NRXS_AccruedWagesCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_AccruedWagesCurrent_doc" xml:lang="en-US">Accrued wages current.</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_AccruedBoardFess" xlink:label="NRXS_AccruedBoardFess" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_AccruedBoardFess" xlink:to="NRXS_AccruedBoardFess_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_AccruedBoardFess_doc" xml:lang="en-US">Accrued board fess.</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_CapitalRaiseFees" xlink:label="NRXS_CapitalRaiseFees" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_CapitalRaiseFees" xlink:to="NRXS_CapitalRaiseFees_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_CapitalRaiseFees_doc" xml:lang="en-US">Capital raise fees.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_RelatedPartyInterestPayableCurrent" xlink:to="NRXS_RelatedPartyInterestPayableCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_RelatedPartyInterestPayableCurrent_doc" xml:lang="en-US">Related party interest payable current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ExchangeListingLLCMember" xlink:to="NRXS_ExchangeListingLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ExchangeListingLLCMember_doc" xml:lang="en-US">Exchange Listing LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_PromissoryNoteMember" xlink:to="NRXS_PromissoryNoteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_PromissoryNoteMember_doc" xml:lang="en-US">Promissory Note [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ChannelPartnersCapitalMember" xlink:to="NRXS_ChannelPartnersCapitalMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ChannelPartnersCapitalMember_doc" xml:lang="en-US">Channel Partners Capital [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ConvertiblePromissoryNoteMember" xlink:to="NRXS_ConvertiblePromissoryNoteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ConvertiblePromissoryNoteMember_doc" xml:lang="en-US">Convertible Promissory Note [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_AccreditedInvestorsMember" xlink:to="NRXS_AccreditedInvestorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_AccreditedInvestorsMember_doc" xml:lang="en-US">Accredited Investors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_DebtInstrumentDiscountRate" xlink:to="NRXS_DebtInstrumentDiscountRate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_DebtInstrumentDiscountRate_doc" xml:lang="en-US">Debt instrument discount rate.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_DebtWarrantConversionDescription" xlink:to="NRXS_DebtWarrantConversionDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_DebtWarrantConversionDescription_doc" xml:lang="en-US">Debt warrant conversion description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_SignatureBankMember" xlink:to="NRXS_SignatureBankMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_SignatureBankMember_doc" xml:lang="en-US">Signature Bank [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_TwoThousandTwentyTwoConvertibleNotesMember" xlink:to="NRXS_TwoThousandTwentyTwoConvertibleNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_TwoThousandTwentyTwoConvertibleNotesMember_doc" xml:lang="en-US">2022 Convertible Notes [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ClassOfWarrantDiscountRate" xlink:to="NRXS_ClassOfWarrantDiscountRate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ClassOfWarrantDiscountRate_doc" xml:lang="en-US">Class of warrant discount rate.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_DebtInstrumentPrincipalAmount" xlink:to="NRXS_DebtInstrumentPrincipalAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_DebtInstrumentPrincipalAmount_doc" xml:lang="en-US">Debt instrument principal amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_TwoThousandTwentyThreeConvertibleNotesMember" xlink:to="NRXS_TwoThousandTwentyThreeConvertibleNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_TwoThousandTwentyThreeConvertibleNotesMember_doc" xml:lang="en-US">2023 Convertible Notes [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_InvestorsMember" xlink:to="NRXS_InvestorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_InvestorsMember_doc" xml:lang="en-US">Investors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_CommonStockAndWarrantsDisclosureTextBlock" xlink:to="NRXS_CommonStockAndWarrantsDisclosureTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_CommonStockAndWarrantsDisclosureTextBlock_doc" xml:lang="en-US">Common stock and warrants disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_BrianHannaschMember" xlink:to="NRXS_BrianHannaschMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_BrianHannaschMember_doc" xml:lang="en-US">Brian Hannasch [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_WarrantOneMember" xlink:to="NRXS_WarrantOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_WarrantOneMember_doc" xml:lang="en-US">Warrant One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_WarrantTwoMember" xlink:to="NRXS_WarrantTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_WarrantTwoMember_doc" xml:lang="en-US">Warrant Two [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_WarrantsExpirationDateDescription" xlink:to="NRXS_WarrantsExpirationDateDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_WarrantsExpirationDateDescription_doc" xml:lang="en-US">Warrants expiration date description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_MasimoCorporationMember" xlink:to="NRXS_MasimoCorporationMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_MasimoCorporationMember_doc" xml:lang="en-US">Masimo Corporation [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_WarrantThreeMember" xlink:to="NRXS_WarrantThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_WarrantThreeMember_doc" xml:lang="en-US">Warrant Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentInYears" xlink:label="NRXS_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentInYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentInYears" xlink:to="NRXS_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentInYears_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopmentInYears_doc" xml:lang="en-US">Income Tax Reconciliation Nondeductible Expense Research and Development in Years.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ScheduleOfWarrantActivityForCommonStockTableTextBlock" xlink:to="NRXS_ScheduleOfWarrantActivityForCommonStockTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ScheduleOfWarrantActivityForCommonStockTableTextBlock_doc" xml:lang="en-US">Schedule of warrant activity for common stock [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber" xlink:to="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non options weighted average exercise price cancelled expired number.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageRemainingContracualLifeOutstandingNumberGranted" xlink:to="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageRemainingContracualLifeOutstandingNumberGranted_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageRemainingContracualLifeOutstandingNumberGranted_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non options weighted average remaining contracual life outstanding number granted.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants" xlink:to="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instruments converted prefunded warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsConvertedPrefundedWarrantsInPeriodWeightedAverageExercisePrice" xlink:to="NRXS_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsConvertedPrefundedWarrantsInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsConvertedPrefundedWarrantsInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangements by share based payment award options converted prefunded warrants in period weighted average exercise price.</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_EffectiveIncomeTaxRateExciseTaxRate" xlink:label="NRXS_EffectiveIncomeTaxRateExciseTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_EffectiveIncomeTaxRateExciseTaxRate" xlink:to="NRXS_EffectiveIncomeTaxRateExciseTaxRate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_EffectiveIncomeTaxRateExciseTaxRate_doc" xml:lang="en-US">Excise tax rate.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ScheduleOfWarrantActivityForPreferredStockTableTextBlock" xlink:to="NRXS_ScheduleOfWarrantActivityForPreferredStockTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ScheduleOfWarrantActivityForPreferredStockTableTextBlock_doc" xml:lang="en-US">Schedule of warrant activity for preferred stock [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant" xlink:to="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instruments common stock warrant.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant" xlink:to="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non options weighted average exercise price common stock warrant.</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_BrianHannaschWarrantOneMember" xlink:label="NRXS_BrianHannaschWarrantOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_BrianHannaschWarrantOneMember" xlink:to="NRXS_BrianHannaschWarrantOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_BrianHannaschWarrantOneMember_doc" xml:lang="en-US">Brian Hannasch Warrant One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_WarrantExpirationDateDescription" xlink:to="NRXS_WarrantExpirationDateDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_WarrantExpirationDateDescription_doc" xml:lang="en-US">Warrant expiration date description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_UnderwriterWarrantsMember" xlink:to="NRXS_UnderwriterWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_UnderwriterWarrantsMember_doc" xml:lang="en-US">Underwriter Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_BrianHannaschWarrantPSAOneMember" xlink:label="NRXS_BrianHannaschWarrantPSAOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_BrianHannaschWarrantPSAOneMember" xlink:to="NRXS_BrianHannaschWarrantPSAOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_BrianHannaschWarrantPSAOneMember_doc" xml:lang="en-US">Brian Hannasch Warrant PSA One [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ConsultingAgreementWarrantsMember" xlink:to="NRXS_ConsultingAgreementWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ConsultingAgreementWarrantsMember_doc" xml:lang="en-US">Consulting Agreement Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_TaxYear2038Member" xlink:to="NRXS_TaxYear2038Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_TaxYear2038Member_doc" xml:lang="en-US">Tax Year 2038 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_TaxYear2039Member" xlink:to="NRXS_TaxYear2039Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_TaxYear2039Member_doc" xml:lang="en-US">Tax Year 2039 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_TaxYear2040Member" xlink:to="NRXS_TaxYear2040Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_TaxYear2040Member_doc" xml:lang="en-US">Tax Year 2040 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_TaxYear2041Member" xlink:to="NRXS_TaxYear2041Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_TaxYear2041Member_doc" xml:lang="en-US">Tax Year 2041 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_TaxYear2042Member" xlink:to="NRXS_TaxYear2042Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_TaxYear2042Member_doc" xml:lang="en-US">Tax Year 2042 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ConsultingFee" xlink:label="NRXS_ConsultingFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ConsultingFee" xlink:to="NRXS_ConsultingFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ConsultingFee_doc" xml:lang="en-US">Consulting fee.</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_AdvisoryAgreementsMember" xlink:label="NRXS_AdvisoryAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_AdvisoryAgreementsMember" xlink:to="NRXS_AdvisoryAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_AdvisoryAgreementsMember_doc" xml:lang="en-US">Advisory Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_PercentageOfCommissionForConsulting" xlink:label="NRXS_PercentageOfCommissionForConsulting" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_PercentageOfCommissionForConsulting" xlink:to="NRXS_PercentageOfCommissionForConsulting_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_PercentageOfCommissionForConsulting_doc" xml:lang="en-US">Percentage of commission for consulting.</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_PercentageOfOutstandingSharesForConsultingService" xlink:label="NRXS_PercentageOfOutstandingSharesForConsultingService" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_PercentageOfOutstandingSharesForConsultingService" xlink:to="NRXS_PercentageOfOutstandingSharesForConsultingService_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_PercentageOfOutstandingSharesForConsultingService_doc" xml:lang="en-US">Percentage of outstanding shares for consulting service.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_InvestorWarrantOneMember" xlink:to="NRXS_InvestorWarrantOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_InvestorWarrantOneMember_doc" xml:lang="en-US">Investor Warrant W-01 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_InvestorWarrantPSAOneMember" xlink:to="NRXS_InvestorWarrantPSAOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_InvestorWarrantPSAOneMember_doc" xml:lang="en-US">Investor Warrant PSA-01 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_AllowanceForCreditLossesPolicy" xlink:label="NRXS_AllowanceForCreditLossesPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_AllowanceForCreditLossesPolicy" xlink:to="NRXS_AllowanceForCreditLossesPolicy_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_AllowanceForCreditLossesPolicy_doc" xml:lang="en-US">Allowance for credit losses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_VersaillesIndianaMember" xlink:to="NRXS_VersaillesIndianaMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_VersaillesIndianaMember_doc" xml:lang="en-US">Versailles Indiana [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_CarmelIndianaMember" xlink:to="NRXS_CarmelIndianaMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_CarmelIndianaMember_doc" xml:lang="en-US">Carmel Indiana [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_LeaseOneMember" xlink:to="NRXS_LeaseOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_LeaseOneMember_doc" xml:lang="en-US">Lease 1 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_LeaseTwoMember" xlink:to="NRXS_LeaseTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_LeaseTwoMember_doc" xml:lang="en-US">Lease 2 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_LeaseThreeMember" xlink:to="NRXS_LeaseThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_LeaseThreeMember_doc" xml:lang="en-US">Lease 3 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_MrWatkinsMember" xlink:to="NRXS_MrWatkinsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_MrWatkinsMember_doc" xml:lang="en-US">Mr. Watkins [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_CustomerFourMember" xlink:to="NRXS_CustomerFourMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_CustomerFourMember_doc" xml:lang="en-US">Customer Four [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember" xlink:to="NRXS_TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember_doc" xml:lang="en-US">2023 and 2022 Convertible Notes [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_VendorsMember" xlink:to="NRXS_VendorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_VendorsMember_doc" xml:lang="en-US">Vendors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_InitialPublicOfferingCostsPaid" xlink:label="NRXS_InitialPublicOfferingCostsPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_InitialPublicOfferingCostsPaid" xlink:to="NRXS_InitialPublicOfferingCostsPaid_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_InitialPublicOfferingCostsPaid_doc" xml:lang="en-US">Initial public offering costs paid.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_AccruedCompensationAndBenefitsCurrent" xlink:to="NRXS_AccruedCompensationAndBenefitsCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_AccruedCompensationAndBenefitsCurrent_doc" xml:lang="en-US">Accrued compensation and benefits current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_UnderwriterFees" xlink:to="NRXS_UnderwriterFees_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_UnderwriterFees_doc" xml:lang="en-US">Underwriter fees.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_PaymentsOfFinancingCost" xlink:to="NRXS_PaymentsOfFinancingCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_PaymentsOfFinancingCost_doc" xml:lang="en-US">Payments of financing cost.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_TaxYear2043Member" xlink:to="NRXS_TaxYear2043Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_TaxYear2043Member_doc" xml:lang="en-US">Tax Year 2043 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_AdditionalPaidInCapitalFromExtinguishmentOfWarrantLiability" xlink:label="NRXS_AdditionalPaidInCapitalFromExtinguishmentOfWarrantLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_AdditionalPaidInCapitalFromExtinguishmentOfWarrantLiability" xlink:to="NRXS_AdditionalPaidInCapitalFromExtinguishmentOfWarrantLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_AdditionalPaidInCapitalFromExtinguishmentOfWarrantLiability_doc" xml:lang="en-US">Additional paid in capital from extinguishment of warrant liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ShareLiabilitiesCurrent" xlink:to="NRXS_ShareLiabilitiesCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ShareLiabilitiesCurrent_doc" xml:lang="en-US">Share liabilities current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_OfferingCostsInAdvanceOfSaleOfCommonStock" xlink:to="NRXS_OfferingCostsInAdvanceOfSaleOfCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_OfferingCostsInAdvanceOfSaleOfCommonStock_doc" xml:lang="en-US">Offering costs in advance of sale of common stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_IncreaseDecreaseInWarrantLiability" xlink:to="NRXS_IncreaseDecreaseInWarrantLiability_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_IncreaseDecreaseInWarrantLiability_doc" xml:lang="en-US">Reduced warrant liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_DeferredOfferingCostsPaid" xlink:to="NRXS_DeferredOfferingCostsPaid_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_DeferredOfferingCostsPaid_doc" xml:lang="en-US">Deferred offering costs paid.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ReclassifiedToEquity" xlink:to="NRXS_ReclassifiedToEquity_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ReclassifiedToEquity_doc" xml:lang="en-US">Reclassified to equity.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_PriorYearOfferingCostsPaid" xlink:to="NRXS_PriorYearOfferingCostsPaid_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_PriorYearOfferingCostsPaid_doc" xml:lang="en-US">Prior year offering costs paid.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ReclassificationOfWarrantLiabilityToEquity" xlink:to="NRXS_ReclassificationOfWarrantLiabilityToEquity_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ReclassificationOfWarrantLiabilityToEquity_doc" xml:lang="en-US">Reclassification of warrant liability to equity.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ConversionOfPreferredStockToCommonStock" xlink:to="NRXS_ConversionOfPreferredStockToCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="NRXS_ConversionOfPreferredStockToCommonStock_doc" xml:lang="en-US">Conversion of preferred stock to common stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_2_lbl" xml:lang="en-US">Liabilities, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_5_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_5_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_2_lbl" xml:lang="en-US">Gross Profit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_FinancingCharges" xlink:to="NRXS_FinancingCharges_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_FinancingCharges_3_lbl" xml:lang="en-US">FinancingCharges</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_2_lbl" xml:lang="en-US">Interest Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingExpense_2_lbl" xml:lang="en-US">Other Nonoperating Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_2_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_IncreaseDecreaseInCustomerDeposit" xlink:to="NRXS_IncreaseDecreaseInCustomerDeposit_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_IncreaseDecreaseInCustomerDeposit_3_lbl" xml:lang="en-US">IncreaseDecreaseInCustomerDeposit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_DeferredOfferingCostsPaid" xlink:to="NRXS_DeferredOfferingCostsPaid_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_DeferredOfferingCostsPaid_3_lbl" xml:lang="en-US">DeferredOfferingCostsPaid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_2_lbl" xml:lang="en-US">Repayments of Notes Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ReclassificationOfWarrantLiabilityToEquity" xlink:to="NRXS_ReclassificationOfWarrantLiabilityToEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_ReclassificationOfWarrantLiabilityToEquity_3_lbl" xml:lang="en-US">ReclassificationOfWarrantLiabilityToEquity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_2_lbl" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_WarrantLiabilitiesDisclosureTextBlock" xlink:to="NRXS_WarrantLiabilitiesDisclosureTextBlock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_WarrantLiabilitiesDisclosureTextBlock_3_lbl" xml:lang="en-US">WarrantLiabilitiesDisclosureTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesAndFairValueTextBlock" xlink:to="us-gaap_DerivativesAndFairValueTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativesAndFairValueTextBlock_2_lbl" xml:lang="en-US">Derivatives and Fair Value [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_HealthBenefitPlanDisclosureTextBlock" xlink:to="NRXS_HealthBenefitPlanDisclosureTextBlock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_HealthBenefitPlanDisclosureTextBlock_3_lbl" xml:lang="en-US">HealthBenefitPlanDisclosureTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_2_lbl" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2_lbl" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_2_lbl" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_2_lbl" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_DerivativeLiabilityPolicyTextBlock" xlink:to="NRXS_DerivativeLiabilityPolicyTextBlock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_DerivativeLiabilityPolicyTextBlock_3_lbl" xml:lang="en-US">DerivativeLiabilityPolicyTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_WarrantLiabilityPolicyTextBlock" xlink:to="NRXS_WarrantLiabilityPolicyTextBlock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_WarrantLiabilityPolicyTextBlock_3_lbl" xml:lang="en-US">WarrantLiabilityPolicyTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_2_lbl" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredOfferingCosts_2_lbl" xml:lang="en-US">Deferred Offering Costs [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForNotesAndLoansReceivableCurrent" xlink:to="us-gaap_AllowanceForNotesAndLoansReceivableCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForNotesAndLoansReceivableCurrent_2_lbl" xml:lang="en-US">Financing Receivable, Allowance for Credit Loss, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_AllowanceForInterestIncomeCurrent" xlink:to="NRXS_AllowanceForInterestIncomeCurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_AllowanceForInterestIncomeCurrent_3_lbl" xml:lang="en-US">AllowanceForInterestIncomeCurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesAndLoansReceivableNetCurrent" xlink:to="us-gaap_NotesAndLoansReceivableNetCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesAndLoansReceivableNetCurrent_2_lbl" xml:lang="en-US">Financing Receivable, after Allowance for Credit Loss, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivable" xlink:to="us-gaap_InterestReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestReceivable_2_lbl" xml:lang="en-US">Interest Receivable [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_InterestIncomeCurrent" xlink:to="NRXS_InterestIncomeCurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_InterestIncomeCurrent_3_lbl" xml:lang="en-US">InterestIncomeCurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaid_2_lbl" xml:lang="en-US">Interest Paid, Including Capitalized Interest, Operating and Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent_2_lbl" xml:lang="en-US">Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsCurrentNet" xlink:to="us-gaap_DeferredFinanceCostsCurrentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsCurrentNet_2_lbl" xml:lang="en-US">Debt Issuance Costs, Current, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_2_lbl" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsNet_2_lbl" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtAverageAmountOutstanding" xlink:to="us-gaap_LongTermDebtAverageAmountOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtAverageAmountOutstanding_2_lbl" xml:lang="en-US">Long-Term Debt, Average Amount Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_PaymentsOfFinancingCost" xlink:to="NRXS_PaymentsOfFinancingCost_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_PaymentsOfFinancingCost_3_lbl" xml:lang="en-US">PaymentsOfFinancingCost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant" xlink:to="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_WarrantExpirationDateDescription" xlink:to="NRXS_WarrantExpirationDateDescription_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_WarrantExpirationDateDescription_3_lbl" xml:lang="en-US">WarrantExpirationDateDescription</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NRXS_AdditionToDerivativeLiabilities" xlink:to="NRXS_AdditionToDerivativeLiabilities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="NRXS_AdditionToDerivativeLiabilities_3_lbl" xml:lang="en-US">Addition to derivative liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>23
<FILENAME>nrxs-20231231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.22a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://neuraxis.com/role/Cover" xlink:href="nrxs-20231231.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/BalanceSheets" xlink:href="nrxs-20231231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/BalanceSheetsParenthetical" xlink:href="nrxs-20231231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/StatementsOfOperations" xlink:href="nrxs-20231231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/StatementsOfStockholdersDeficit" xlink:href="nrxs-20231231.xsd#StatementsOfStockholdersDeficit" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/StatementsOfCashFlows" xlink:href="nrxs-20231231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMatters" xlink:href="nrxs-20231231.xsd#BasisOfPresentationOrganizationAndOtherMatters" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="nrxs-20231231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/RelatedPartyTransactions" xlink:href="nrxs-20231231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/PropertyAndEquipment" xlink:href="nrxs-20231231.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/IntangibleAssets" xlink:href="nrxs-20231231.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/AccruedExpenses" xlink:href="nrxs-20231231.xsd#AccruedExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/NotesPayable" xlink:href="nrxs-20231231.xsd#NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/Leases" xlink:href="nrxs-20231231.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/CommonStockAndWarrants" xlink:href="nrxs-20231231.xsd#CommonStockAndWarrants" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/PreferredStock" xlink:href="nrxs-20231231.xsd#PreferredStock" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/StockOptionsAndAwards" xlink:href="nrxs-20231231.xsd#StockOptionsAndAwards" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/WarrantLiabilities" xlink:href="nrxs-20231231.xsd#WarrantLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/DerivativeLiabilities" xlink:href="nrxs-20231231.xsd#DerivativeLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/RetirementPlan" xlink:href="nrxs-20231231.xsd#RetirementPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/CommitmentsAndContingencies" xlink:href="nrxs-20231231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/HealthBenefitPlan" xlink:href="nrxs-20231231.xsd#HealthBenefitPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/IncomeTaxes" xlink:href="nrxs-20231231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/SubsequentEvents" xlink:href="nrxs-20231231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/RestatementOfInterimFinancialStatements" xlink:href="nrxs-20231231.xsd#RestatementOfInterimFinancialStatements" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="nrxs-20231231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="nrxs-20231231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/RelatedPartyTransactionsTables" xlink:href="nrxs-20231231.xsd#RelatedPartyTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/PropertyAndEquipmentTables" xlink:href="nrxs-20231231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/IntangibleAssetsTables" xlink:href="nrxs-20231231.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/AccruedExpensesTables" xlink:href="nrxs-20231231.xsd#AccruedExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/NotesPayableTables" xlink:href="nrxs-20231231.xsd#NotesPayableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/LeasesTables" xlink:href="nrxs-20231231.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/CommonStockAndWarrantsTables" xlink:href="nrxs-20231231.xsd#CommonStockAndWarrantsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/StockOptionsAndAwardsTables" xlink:href="nrxs-20231231.xsd#StockOptionsAndAwardsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/WarrantLiabilitiesTables" xlink:href="nrxs-20231231.xsd#WarrantLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/DerivativeLiabilitiesTables" xlink:href="nrxs-20231231.xsd#DerivativeLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/IncomeTaxesTables" xlink:href="nrxs-20231231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/RestatementOfInterimFinancialStatementsTables" xlink:href="nrxs-20231231.xsd#RestatementOfInterimFinancialStatementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative" xlink:href="nrxs-20231231.xsd#BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfEstimatedUsefulLivesDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfEstimatedUsefulLivesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfFairValueOnRecurringBasisAssetsAndLiabilityDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfFairValueOnRecurringBasisAssetsAndLiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfUnobservableInputsForLevel3AssetsAndLiabilitiesDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfUnobservableInputsForLevel3AssetsAndLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfDilutiveCommonStockEquivalentsDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfDilutiveCommonStockEquivalentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfBasicAndDilutedNetLossPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfDisaggregationOfRevenueDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfDisaggregationOfRevenueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfCustomersAccountedRevenuesDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfCustomersAccountedRevenuesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="nrxs-20231231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfRelatedPartyTransactionsDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfRelatedPartyTransactionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfRelatedPartyLoansPayableToShareholderDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfRelatedPartyLoansPayableToShareholderDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="nrxs-20231231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="nrxs-20231231.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfIntangibleAssetsDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfIntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/IntangibleAssetsDetailsNarrative" xlink:href="nrxs-20231231.xsd#IntangibleAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfAccruedExpensesDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfAccruedExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfConvertibleNotesDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfConvertibleNotesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/NotesPayableDetailsNarrative" xlink:href="nrxs-20231231.xsd#NotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfOperatingLeasesDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfMaturitiesOperatingLeaseLiabilitiesDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfMaturitiesOperatingLeaseLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/LeasesDetailsNarrative" xlink:href="nrxs-20231231.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfWarrantActivityForCommonStockDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfWarrantActivityForCommonStockDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfWarrantActivityForPreferredStockDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfWarrantActivityForPreferredStockDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative" xlink:href="nrxs-20231231.xsd#CommonStockAndWarrantsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/PreferredStockDetailsNarrative" xlink:href="nrxs-20231231.xsd#PreferredStockDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfOption-pricingModelWithFollowingWeighted-averageAssumptionsDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfOption-pricingModelWithFollowingWeighted-averageAssumptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/StockOptionsAndAwardsDetailsNarrative" xlink:href="nrxs-20231231.xsd#StockOptionsAndAwardsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfChangesInWarrantLiabilitiesDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfChangesInWarrantLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/WarrantLiabilitiesDetailsNarrative" xlink:href="nrxs-20231231.xsd#WarrantLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfChangesInDerivativeLiabilitiesDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfChangesInDerivativeLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/DerivativeLiabilitiesDetailsNarrative" xlink:href="nrxs-20231231.xsd#DerivativeLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/RetirementPlanDetailsNarrative" xlink:href="nrxs-20231231.xsd#RetirementPlanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="nrxs-20231231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/HealthBenefitPlanDetailsNarrative" xlink:href="nrxs-20231231.xsd#HealthBenefitPlanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfDeferredTaxAssetDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfDeferredTaxAssetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfFederalStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfFederalStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfStateCarryforwardsDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfStateCarryforwardsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/IncomeTaxesDetailsNarrative" xlink:href="nrxs-20231231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/SubsequentEventsDetailsNarrative" xlink:href="nrxs-20231231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails" xlink:href="nrxs-20231231.xsd#ScheduleOfRestatementOfInterimFinancialStatementsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://neuraxis.com/role/RestatementOfInterimFinancialStatementsDetailsNarrative" xlink:href="nrxs-20231231.xsd#RestatementOfInterimFinancialStatementsDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="loc_deiIcfrAuditorAttestationFlag" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiIcfrAuditorAttestationFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_deiDocumentFinStmtErrorCorrectionFlag" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFinStmtErrorCorrectionFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
      <link:presentationArc order="620" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/BalanceSheets" xlink:title="00000002 - Statement - Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember" xlink:label="loc_us-gaapNonrelatedPartyMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapNonrelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ConvertibleSeriesAPreferredStockMember" xlink:label="loc_NRXSConvertibleSeriesAPreferredStockMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_NRXSConvertibleSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ConvertibleSeriesSeedPreferredStockMember" xlink:label="loc_NRXSConvertibleSeriesSeedPreferredStockMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_NRXSConvertibleSeriesSeedPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrentAbstract" xlink:label="loc_us-gaapOtherAssetsNoncurrentAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOtherAssetsNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCosts" xlink:label="loc_us-gaapDeferredCosts" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsNoncurrentAbstract" xlink:to="loc_us-gaapDeferredCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsNoncurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsNoncurrentAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="loc_us-gaapConvertibleNotesPayableCurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapConvertibleNotesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Deposits" xlink:label="loc_us-gaapDeposits" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDeposits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_WarrantLiabilities" xlink:label="loc_NRXSWarrantLiabilities" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_NRXSWarrantLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaapLiabilitiesNoncurrentAbstract" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesNoncurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaapLiabilitiesNoncurrent" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ConvertibleSeriesAPreferredStockMember" xlink:label="loc_NRXSConvertibleSeriesAPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_NRXSConvertibleSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ConvertibleSeriesSeedPreferredStockMember" xlink:label="loc_NRXSConvertibleSeriesSeedPreferredStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_NRXSConvertibleSeriesSeedPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscountCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscountCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingExpense" xlink:label="loc_us-gaapSellingExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapSellingExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_FinancingCharges" xlink:label="loc_NRXSFinancingCharges" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_NRXSFinancingCharges" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaapOtherNonoperatingIncome" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="loc_us-gaapOtherNonoperatingExpense" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherNonoperatingExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/StatementsOfStockholdersDeficit" xlink:title="00000005 - Statement - Statements of Stockholders&apos; Deficit">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="60" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ConvertibleSeriesAPreferredStockMember" xlink:label="loc_NRXSConvertibleSeriesAPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_NRXSConvertibleSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ConvertibleSeriesSeedPreferredStockMember" xlink:label="loc_NRXSConvertibleSeriesSeedPreferredStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_NRXSConvertibleSeriesSeedPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering" xlink:label="loc_NRXSStockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSStockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_StockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering" xlink:label="loc_NRXSStockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSStockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_StockIssuedDuringPeriodValueCommonStockIssuedUponPreferredStockConversion" xlink:label="loc_NRXSStockIssuedDuringPeriodValueCommonStockIssuedUponPreferredStockConversion" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSStockIssuedDuringPeriodValueCommonStockIssuedUponPreferredStockConversion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_StockIssuedDuringPeriodSharesCommonStockIssuedUponPreferredStockConversion" xlink:label="loc_NRXSStockIssuedDuringPeriodSharesCommonStockIssuedUponPreferredStockConversion" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSStockIssuedDuringPeriodSharesCommonStockIssuedUponPreferredStockConversion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_NRXSStockIssuedDuringPeriodValueWarrantsExercised" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSStockIssuedDuringPeriodValueWarrantsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="loc_NRXSStockIssuedDuringPeriodSharesWarrantsExercised" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSStockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_NoncashLeaseExpense" xlink:label="loc_NRXSNoncashLeaseExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_NRXSNoncashLeaseExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_NoncashInterestExpense" xlink:label="loc_NRXSNoncashInterestExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_NRXSNoncashInterestExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_IssuanceOfCommonStockForNoncashConsideration" xlink:label="loc_NRXSIssuanceOfCommonStockForNoncashConsideration" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_NRXSIssuanceOfCommonStockForNoncashConsideration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_FinanceCharges" xlink:label="loc_NRXSFinanceCharges" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_NRXSFinanceCharges" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_IncreaseDecreaseInCustomerDeposit" xlink:label="loc_NRXSIncreaseDecreaseInCustomerDeposit" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_NRXSIncreaseDecreaseInCustomerDeposit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_DeferredOfferingCostsPaid" xlink:label="loc_NRXSDeferredOfferingCostsPaid" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_NRXSDeferredOfferingCostsPaid" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="loc_us-gaapProceedsFromIssuanceOfWarrants" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaapPaymentsOfFinancingCosts" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapPaymentsOfFinancingCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_FairValueOfWarrantLiabilitiesOfWarrantsFromConvertibleNotes" xlink:label="loc_NRXSFairValueOfWarrantLiabilitiesOfWarrantsFromConvertibleNotes" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_NRXSFairValueOfWarrantLiabilitiesOfWarrantsFromConvertibleNotes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_FairValueOfDerivativeLiabilitiesOfConversionFeatureFromConvertibleNotes" xlink:label="loc_NRXSFairValueOfDerivativeLiabilitiesOfConversionFeatureFromConvertibleNotes" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_NRXSFairValueOfDerivativeLiabilitiesOfConversionFeatureFromConvertibleNotes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_PriorYearOfferingCostsPaid" xlink:label="loc_NRXSPriorYearOfferingCostsPaid" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_NRXSPriorYearOfferingCostsPaid" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ReclassificationOfWarrantLiabilityToEquity" xlink:label="loc_NRXSReclassificationOfWarrantLiabilityToEquity" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_NRXSReclassificationOfWarrantLiabilityToEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ConversionOfPreferredStockToCommonStock" xlink:label="loc_NRXSConversionOfPreferredStockToCommonStock" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_NRXSConversionOfPreferredStockToCommonStock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMatters" xlink:title="00000007 - Disclosure - Basis of Presentation, Organization and Other Matters">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - Summary of Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/RelatedPartyTransactions" xlink:title="00000009 - Disclosure - Related Party Transactions">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/PropertyAndEquipment" xlink:title="00000010 - Disclosure - Property and Equipment">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/IntangibleAssets" xlink:title="00000011 - Disclosure - Intangible Assets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapIntangibleAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapIntangibleAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/AccruedExpenses" xlink:title="00000012 - Disclosure - Accrued Expenses">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/NotesPayable" xlink:title="00000013 - Disclosure - Notes Payable">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/Leases" xlink:title="00000014 - Disclosure - Leases">
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_DisclosureLeasesAbstract" xlink:label="loc_NRXSDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeasesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NRXSDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeasesTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/CommonStockAndWarrants" xlink:title="00000015 - Disclosure - Common Stock and Warrants">
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_DisclosureCommonStockAndWarrantsAbstract" xlink:label="loc_NRXSDisclosureCommonStockAndWarrantsAbstract" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_CommonStockAndWarrantsDisclosureTextBlock" xlink:label="loc_NRXSCommonStockAndWarrantsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NRXSDisclosureCommonStockAndWarrantsAbstract" xlink:to="loc_NRXSCommonStockAndWarrantsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/PreferredStock" xlink:title="00000016 - Disclosure - Preferred Stock">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockTextBlock" xlink:label="loc_us-gaapPreferredStockTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapPreferredStockTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/StockOptionsAndAwards" xlink:title="00000017 - Disclosure - Stock Options and Awards">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/WarrantLiabilities" xlink:title="00000018 - Disclosure - Warrant Liabilities">
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_DisclosureWarrantLiabilitiesAbstract" xlink:label="loc_NRXSDisclosureWarrantLiabilitiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_WarrantLiabilitiesDisclosureTextBlock" xlink:label="loc_NRXSWarrantLiabilitiesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NRXSDisclosureWarrantLiabilitiesAbstract" xlink:to="loc_NRXSWarrantLiabilitiesDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/DerivativeLiabilities" xlink:title="00000019 - Disclosure - Derivative Liabilities">
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_DisclosureDerivativeLiabilitiesAbstract" xlink:label="loc_NRXSDisclosureDerivativeLiabilitiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesAndFairValueTextBlock" xlink:label="loc_us-gaapDerivativesAndFairValueTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NRXSDisclosureDerivativeLiabilitiesAbstract" xlink:to="loc_us-gaapDerivativesAndFairValueTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/RetirementPlan" xlink:title="00000020 - Disclosure - Retirement Plan">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaapCompensationAndRetirementDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaapPensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapPensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/CommitmentsAndContingencies" xlink:title="00000021 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/HealthBenefitPlan" xlink:title="00000022 - Disclosure - Health Benefit Plan">
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_DisclosureHealthBenefitPlanAbstract" xlink:label="loc_NRXSDisclosureHealthBenefitPlanAbstract" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_HealthBenefitPlanDisclosureTextBlock" xlink:label="loc_NRXSHealthBenefitPlanDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NRXSDisclosureHealthBenefitPlanAbstract" xlink:to="loc_NRXSHealthBenefitPlanDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/IncomeTaxes" xlink:title="00000023 - Disclosure - Income Taxes">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/SubsequentEvents" xlink:title="00000024 - Disclosure - Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/RestatementOfInterimFinancialStatements" xlink:title="00000025 - Disclosure - Restatement of Interim Financial Statements (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionTextBlock" xlink:label="loc_us-gaapErrorCorrectionTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" xlink:to="loc_us-gaapErrorCorrectionTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000026 - Disclosure - Summary of Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaapTradeAndOtherAccountsReceivablePolicy" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapTradeAndOtherAccountsReceivablePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositContractsPolicy" xlink:label="loc_us-gaapDepositContractsPolicy" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDepositContractsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaapInventoryPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInventoryPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredChargesPolicyTextBlock" xlink:label="loc_us-gaapDeferredChargesPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDeferredChargesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="loc_us-gaapAdvertisingCostsPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapAdvertisingCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_DerivativeLiabilityPolicyTextBlock" xlink:label="loc_NRXSDerivativeLiabilityPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_NRXSDerivativeLiabilityPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_WarrantLiabilityPolicyTextBlock" xlink:label="loc_NRXSWarrantLiabilityPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_NRXSWarrantLiabilityPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaapRevenueRecognitionPolicyTextBlock" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueRecognitionPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ExtendedProductWarrantyPolicy" xlink:label="loc_us-gaapExtendedProductWarrantyPolicy" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapExtendedProductWarrantyPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaapLesseeLeasesPolicyTextBlock" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLesseeLeasesPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_GoingConcernPolicyTextBlock" xlink:label="loc_NRXSGoingConcernPolicyTextBlock" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_NRXSGoingConcernPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000027 - Disclosure - Summary of Significant Accounting Policies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:label="loc_NRXSScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_NRXSScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaapDisaggregationOfRevenueTableTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDisaggregationOfRevenueTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock" xlink:label="loc_us-gaapContractWithCustomerAssetAllowanceForCreditLossTableTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapContractWithCustomerAssetAllowanceForCreditLossTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/RelatedPartyTransactionsTables" xlink:title="00000028 - Disclosure - Related Party Transactions (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ScheduleOfRelatedPartyLoansTableTextBlock" xlink:label="loc_NRXSScheduleOfRelatedPartyLoansTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_NRXSScheduleOfRelatedPartyLoansTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/PropertyAndEquipmentTables" xlink:title="00000029 - Disclosure - Property and Equipment (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/IntangibleAssetsTables" xlink:title="00000030 - Disclosure - Intangible Assets (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/AccruedExpensesTables" xlink:title="00000031 - Disclosure - Accrued Expenses (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/NotesPayableTables" xlink:title="00000032 - Disclosure - Notes Payable (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="loc_us-gaapConvertibleDebtTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapConvertibleDebtTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/LeasesTables" xlink:title="00000033 - Disclosure - Leases (Tables)">
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_DisclosureLeasesAbstract" xlink:label="loc_NRXSDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:label="loc_us-gaapOperatingLeasesOfLesseeDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NRXSDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeasesOfLesseeDisclosureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NRXSDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/CommonStockAndWarrantsTables" xlink:title="00000034 - Disclosure - Common Stock and Warrants (Tables)">
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_DisclosureCommonStockAndWarrantsAbstract" xlink:label="loc_NRXSDisclosureCommonStockAndWarrantsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NRXSDisclosureCommonStockAndWarrantsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ScheduleOfWarrantActivityForCommonStockTableTextBlock" xlink:label="loc_NRXSScheduleOfWarrantActivityForCommonStockTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSScheduleOfWarrantActivityForCommonStockTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ScheduleOfWarrantActivityForPreferredStockTableTextBlock" xlink:label="loc_NRXSScheduleOfWarrantActivityForPreferredStockTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSScheduleOfWarrantActivityForPreferredStockTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/StockOptionsAndAwardsTables" xlink:title="00000035 - Disclosure - Stock Options and Awards (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/WarrantLiabilitiesTables" xlink:title="00000036 - Disclosure - Warrant Liabilities (Tables)">
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_DisclosureWarrantLiabilitiesAbstract" xlink:label="loc_NRXSDisclosureWarrantLiabilitiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ScheduleOfChangesInWarrantLiabilitiesTableTextBlock" xlink:label="loc_NRXSScheduleOfChangesInWarrantLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NRXSDisclosureWarrantLiabilitiesAbstract" xlink:to="loc_NRXSScheduleOfChangesInWarrantLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/DerivativeLiabilitiesTables" xlink:title="00000037 - Disclosure - Derivative Liabilities (Tables)">
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_DisclosureDerivativeLiabilitiesAbstract" xlink:label="loc_NRXSDisclosureDerivativeLiabilitiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="loc_us-gaapScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NRXSDisclosureDerivativeLiabilitiesAbstract" xlink:to="loc_us-gaapScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/IncomeTaxesTables" xlink:title="00000038 - Disclosure - Income Taxes (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:label="loc_us-gaapSummaryOfOperatingLossCarryforwardsTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapSummaryOfOperatingLossCarryforwardsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/RestatementOfInterimFinancialStatementsTables" xlink:title="00000039 - Disclosure - Restatement of Interim Financial Statements (Unaudited) (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:label="loc_us-gaapScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" xlink:to="loc_us-gaapScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative" xlink:title="00000040 - Disclosure - Basis of Presentation, Organization and Other Matters (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ConvertibleSeriesAPreferredStockMember" xlink:label="loc_NRXSConvertibleSeriesAPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_NRXSConvertibleSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ConvertibleSeriesSeedPreferredStockMember" xlink:label="loc_NRXSConvertibleSeriesSeedPreferredStockMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_NRXSConvertibleSeriesSeedPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="loc_srtConsolidatedEntitiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtConsolidatedEntitiesAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="loc_srtConsolidatedEntitiesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesAxis" xlink:to="loc_srtConsolidatedEntitiesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_AlexanderCapitalLPMember" xlink:label="loc_NRXSAlexanderCapitalLPMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtConsolidatedEntitiesDomain" xlink:to="loc_NRXSAlexanderCapitalLPMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplit" xlink:label="loc_us-gaapStockholdersEquityNoteStockSplit" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityNoteStockSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDeferredOfferingCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_PurchaseOfAdditionalStockOnNumberOfOptionsNotExercised" xlink:label="loc_NRXSPurchaseOfAdditionalStockOnNumberOfOptionsNotExercised" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSPurchaseOfAdditionalStockOnNumberOfOptionsNotExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_UnderwritersDiscountPercentage" xlink:label="loc_NRXSUnderwritersDiscountPercentage" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSUnderwritersDiscountPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_NonaccountableExpenseAllowancePercentage" xlink:label="loc_NRXSNonaccountableExpenseAllowancePercentage" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSNonaccountableExpenseAllowancePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_CashFeePercentage" xlink:label="loc_NRXSCashFeePercentage" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSCashFeePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ReimbursementExpenses" xlink:label="loc_NRXSReimbursementExpenses" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSReimbursementExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:label="loc_us-gaapSaleOfStockPercentageOfOwnershipAfterTransaction" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockPercentageOfOwnershipAfterTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_OfferingPricePerPercentage" xlink:label="loc_NRXSOfferingPricePerPercentage" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSOfferingPricePerPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_LicenseFees" xlink:label="loc_NRXSLicenseFees" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSLicenseFees" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfEstimatedUsefulLivesDetails" xlink:title="00000041 - Disclosure - Schedule of Estimated Useful Lives (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaapMachineryAndEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapMachineryAndEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfFairValueOnRecurringBasisAssetsAndLiabilityDetails" xlink:title="00000042 - Disclosure - Schedule of Fair Value On a Recurring Basis Assets and Liability (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_WarrantLiabilities" xlink:label="loc_NRXSWarrantLiabilities" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_NRXSWarrantLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapLiabilitiesFairValueDisclosure" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapLiabilitiesFairValueDisclosure" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfUnobservableInputsForLevel3AssetsAndLiabilitiesDetails" xlink:title="00000043 - Disclosure - Schedule of Unobservable Inputs for Level 3 Assets and Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="loc_srtPlatformOperatorCryptoAssetTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_srtPlatformOperatorCryptoAssetTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="loc_srtPlatformOperatorCryptoAssetLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_srtPlatformOperatorCryptoAssetLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaapFairValueByMeasurementFrequencyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByMeasurementFrequencyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaapFairValueMeasurementFrequencyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByMeasurementFrequencyAxis" xlink:to="loc_us-gaapFairValueMeasurementFrequencyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaapFairValueMeasurementsRecurringMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementFrequencyDomain" xlink:to="loc_us-gaapFairValueMeasurementsRecurringMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_WarrantLiabilities" xlink:label="loc_NRXSWarrantLiabilities" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_NRXSWarrantLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfDilutiveCommonStockEquivalentsDetails" xlink:title="00000044 - Disclosure - Schedule of Dilutive Common Stock Equivalents (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ConvertibleSeriesAPreferredStockMember" xlink:label="loc_NRXSConvertibleSeriesAPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_NRXSConvertibleSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ConvertibleSeriesSeedPreferredStockMember" xlink:label="loc_NRXSConvertibleSeriesSeedPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_NRXSConvertibleSeriesSeedPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OptionMember" xlink:label="loc_us-gaapOptionMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_WarrantsMember" xlink:label="loc_NRXSWarrantsMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_NRXSWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ConvertibleBridgeDebtMember" xlink:label="loc_NRXSConvertibleBridgeDebtMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_NRXSConvertibleBridgeDebtMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails" xlink:title="00000045 - Disclosure - Schedule of Basic and Diluted Net Loss Per Share (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="loc_us-gaapPreferredStockDividendsAndOtherAdjustments" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPreferredStockDividendsAndOtherAdjustments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfDisaggregationOfRevenueDetails" xlink:title="00000046 - Disclosure - Schedule of Disaggregation of Revenue (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementGeographicalAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_CA" xlink:label="loc_stprCA" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_stprCA" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_WI" xlink:label="loc_stprWI" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_stprWI" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_OH" xlink:label="loc_stprOH" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_stprOH" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_FL" xlink:label="loc_stprFL" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_stprFL" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_MA" xlink:label="loc_stprMA" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_stprMA" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_MO" xlink:label="loc_countryMO" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryMO" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_AllOtherStatesMember" xlink:label="loc_NRXSAllOtherStatesMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_NRXSAllOtherStatesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenues" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfCustomersAccountedRevenuesDetails" xlink:title="00000047 - Disclosure - Schedule of Customers Accounted Revenues (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfProductInformationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapProductInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtMajorCustomersAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_HospitalAMember" xlink:label="loc_NRXSHospitalAMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_NRXSHospitalAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_HospitalBMember" xlink:label="loc_NRXSHospitalBMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_NRXSHospitalBMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_HospitalCMember" xlink:label="loc_NRXSHospitalCMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_NRXSHospitalCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_HospitalMember" xlink:label="loc_NRXSHospitalMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_NRXSHospitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaapAccountsReceivableMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapAccountsReceivableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000048 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfProductInformationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapProductInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_TrademarkAgreementMember" xlink:label="loc_NRXSTrademarkAgreementMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_NRXSTrademarkAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_LicensingAgreementMember" xlink:label="loc_NRXSLicensingAgreementMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_NRXSLicensingAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="loc_us-gaapOtherCommitmentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapOtherCommitmentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaapOtherCommitmentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsAxis" xlink:to="loc_us-gaapOtherCommitmentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_InitialPaymentMember" xlink:label="loc_NRXSInitialPaymentMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_NRXSInitialPaymentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_SecondAndFinalPaymentMember" xlink:label="loc_NRXSSecondAndFinalPaymentMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_NRXSSecondAndFinalPaymentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="loc_srtMajorCustomersAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtMajorCustomersAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srtNameOfMajorCustomerDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtMajorCustomersAxis" xlink:to="loc_srtNameOfMajorCustomerDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_CustomerMember" xlink:label="loc_NRXSCustomerMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_NRXSCustomerMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_CustomerOneMember" xlink:label="loc_NRXSCustomerOneMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_NRXSCustomerOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_CustomerTwoMember" xlink:label="loc_NRXSCustomerTwoMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_NRXSCustomerTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_CustomerThreeMember" xlink:label="loc_NRXSCustomerThreeMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_NRXSCustomerThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_CustomerFourMember" xlink:label="loc_NRXSCustomerFourMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtNameOfMajorCustomerDomain" xlink:to="loc_NRXSCustomerFourMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaapAccountsReceivableMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapAccountsReceivableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueProductLineMember" xlink:label="loc_us-gaapSalesRevenueProductLineMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueProductLineMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromRightsConcentrationRiskMember" xlink:label="loc_us-gaapRevenueFromRightsConcentrationRiskMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapRevenueFromRightsConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivable" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForOtherCreditLosses" xlink:label="loc_us-gaapProvisionForOtherCreditLosses" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapProvisionForOtherCreditLosses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Deposits" xlink:label="loc_us-gaapDeposits" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapDeposits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_InventoryExpenses" xlink:label="loc_NRXSInventoryExpenses" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_NRXSInventoryExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaapDeferredOfferingCosts" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapDeferredOfferingCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaapAdvertisingExpense" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapAdvertisingExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPreferredStock" xlink:label="loc_us-gaapDividendsPreferredStock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapDividendsPreferredStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaapShortTermBorrowings" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapShortTermBorrowings" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_WorkingCapitalDeficit" xlink:label="loc_NRXSWorkingCapitalDeficit" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_NRXSWorkingCapitalDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfRelatedPartyTransactionsDetails" xlink:title="00000049 - Disclosure - Schedule of Related Party Transactions (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ShareHolderOneMember" xlink:label="loc_NRXSShareHolderOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_NRXSShareHolderOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ShareHolderTwoMember" xlink:label="loc_NRXSShareHolderTwoMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_NRXSShareHolderTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember" xlink:label="loc_us-gaapRelatedPartyMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapRelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesAndLoansReceivableGrossCurrent" xlink:label="loc_us-gaapNotesAndLoansReceivableGrossCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapNotesAndLoansReceivableGrossCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestReceivableCurrent" xlink:label="loc_us-gaapInterestReceivableCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapInterestReceivableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_InterestIncomeGrossCurrent" xlink:label="loc_NRXSInterestIncomeGrossCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_NRXSInterestIncomeGrossCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForNotesAndLoansReceivableCurrent" xlink:label="loc_us-gaapAllowanceForNotesAndLoansReceivableCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAllowanceForNotesAndLoansReceivableCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestReceivableCurrent" xlink:label="loc_us-gaapInterestReceivableCurrent_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapInterestReceivableCurrent_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_AllowanceForInterestIncomeCurrent" xlink:label="loc_NRXSAllowanceForInterestIncomeCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_NRXSAllowanceForInterestIncomeCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesAndLoansReceivableNetCurrent" xlink:label="loc_us-gaapNotesAndLoansReceivableNetCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapNotesAndLoansReceivableNetCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestReceivable" xlink:label="loc_us-gaapInterestReceivable" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapInterestReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_InterestIncomeCurrent" xlink:label="loc_NRXSInterestIncomeCurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_NRXSInterestIncomeCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfRelatedPartyLoansPayableToShareholderDetails" xlink:title="00000050 - Disclosure - Schedule of Related Party Loans payable to shareholder (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ShareHolderMember" xlink:label="loc_NRXSShareHolderMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_NRXSShareHolderMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ShareHolderOneMember" xlink:label="loc_NRXSShareHolderOneMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_NRXSShareHolderOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_OtherConvertiblesMember" xlink:label="loc_NRXSOtherConvertiblesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_NRXSOtherConvertiblesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="loc_us-gaapDebtInstrumentMaturityDateDescription" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDateDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayable" xlink:label="loc_us-gaapLoansPayable" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapLoansPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_InterestAndServiceFeeAccrued" xlink:label="loc_NRXSInterestAndServiceFeeAccrued" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_NRXSInterestAndServiceFeeAccrued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaapInterestPaid" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapInterestPaid" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000051 - Disclosure - Related Party Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ShareholdersOneAndTwoMember" xlink:label="loc_NRXSShareholdersOneAndTwoMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_NRXSShareholdersOneAndTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_MrWatkinsMember" xlink:label="loc_NRXSMrWatkinsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_NRXSMrWatkinsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_MrSealeMember" xlink:label="loc_NRXSMrSealeMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_NRXSMrSealeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesAndLoansReceivableGrossCurrent" xlink:label="loc_us-gaapNotesAndLoansReceivableGrossCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapNotesAndLoansReceivableGrossCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_AllowanceForInterestReceivableCurrent" xlink:label="loc_NRXSAllowanceForInterestReceivableCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_NRXSAllowanceForInterestReceivableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForFees" xlink:label="loc_us-gaapPaymentsForFees" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapPaymentsForFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:label="loc_us-gaapAccountsPayableCurrentAndNoncurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAccountsPayableCurrentAndNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:title="00000052 - Disclosure - Schedule of Property And Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaapMachineryAndEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapMachineryAndEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="00000053 - Disclosure - Property and Equipment (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfIntangibleAssetsDetails" xlink:title="00000054 - Disclosure - Schedule of Intangible Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_SoftwareImplementationMember" xlink:label="loc_NRXSSoftwareImplementationMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_NRXSSoftwareImplementationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaapPatentsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapPatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TrademarksMember" xlink:label="loc_us-gaapTrademarksMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapTrademarksMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_LicensesMember" xlink:label="loc_NRXSLicensesMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_NRXSLicensesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/IntangibleAssetsDetailsNarrative" xlink:title="00000055 - Disclosure - Intangible Assets (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfAccruedExpensesDetails" xlink:title="00000056 - Disclosure - Schedule of Accrued Expenses (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_AccruedCompensationAndBenefitsCurrent" xlink:label="loc_NRXSAccruedCompensationAndBenefitsCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_NRXSAccruedCompensationAndBenefitsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_UnderwriterFees" xlink:label="loc_NRXSUnderwriterFees" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_NRXSUnderwriterFees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapInterestPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_RelatedPartyInterestPayableCurrent" xlink:label="loc_NRXSRelatedPartyInterestPayableCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_NRXSRelatedPartyInterestPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:label="loc_us-gaapAccrualForTaxesOtherThanIncomeTaxesCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccrualForTaxesOtherThanIncomeTaxesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfConvertibleNotesDetails" xlink:title="00000057 - Disclosure - Schedule of Convertible Notes (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsCurrentNet" xlink:label="loc_us-gaapDeferredFinanceCostsCurrentNet" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDeferredFinanceCostsCurrentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaapDeferredFinanceCostsNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDeferredFinanceCostsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaapLongTermDebt" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebt" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/NotesPayableDetailsNarrative" xlink:title="00000058 - Disclosure - Notes Payable (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ExchangeListingLLCMember" xlink:label="loc_NRXSExchangeListingLLCMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_NRXSExchangeListingLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ChannelPartnersCapitalMember" xlink:label="loc_NRXSChannelPartnersCapitalMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_NRXSChannelPartnersCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_SignatureBankMember" xlink:label="loc_NRXSSignatureBankMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_NRXSSignatureBankMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_AlexanderCapitalLPMember" xlink:label="loc_NRXSAlexanderCapitalLPMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_NRXSAlexanderCapitalLPMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_PromissoryNoteMember" xlink:label="loc_NRXSPromissoryNoteMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_NRXSPromissoryNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ConvertiblePromissoryNoteMember" xlink:label="loc_NRXSConvertiblePromissoryNoteMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_NRXSConvertiblePromissoryNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_TwoThousandTwentyThreeConvertibleNotesMember" xlink:label="loc_NRXSTwoThousandTwentyThreeConvertibleNotesMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_NRXSTwoThousandTwentyThreeConvertibleNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_TwoThousandTwentyTwoConvertibleNotesMember" xlink:label="loc_NRXSTwoThousandTwentyTwoConvertibleNotesMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_NRXSTwoThousandTwentyTwoConvertibleNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember" xlink:label="loc_NRXSTwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_NRXSTwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_srtStatementScenarioAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember" xlink:label="loc_srtScenarioForecastMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_srtScenarioForecastMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_srtTitleOfIndividualAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_AccreditedInvestorsMember" xlink:label="loc_NRXSAccreditedInvestorsMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_NRXSAccreditedInvestorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_InvestorsMember" xlink:label="loc_NRXSInvestorsMember" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_NRXSInvestorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_srtRangeAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleNotesPayableMember" xlink:label="loc_us-gaapConvertibleNotesPayableMember" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_us-gaapConvertibleNotesPayableMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaapDebtInstrumentPeriodicPayment" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentPeriodicPayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAverageAmountOutstanding" xlink:label="loc_us-gaapLongTermDebtAverageAmountOutstanding" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapLongTermDebtAverageAmountOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:label="loc_us-gaapDebtInstrumentRepurchasedFaceAmount" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentRepurchasedFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:label="loc_us-gaapDebtInstrumentAnnualPrincipalPayment" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentAnnualPrincipalPayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfDebt" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_DebtInstrumentDiscountRate" xlink:label="loc_NRXSDebtInstrumentDiscountRate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_NRXSDebtInstrumentDiscountRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_DebtWarrantConversionDescription" xlink:label="loc_NRXSDebtWarrantConversionDescription" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_NRXSDebtWarrantConversionDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionRatio1" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionRatio1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EscrowDeposit" xlink:label="loc_us-gaapEscrowDeposit" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapEscrowDeposit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromFeesReceived" xlink:label="loc_us-gaapProceedsFromFeesReceived" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromFeesReceived" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="loc_us-gaapDebtInstrumentDescriptionOfVariableRateBasis" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentDescriptionOfVariableRateBasis" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ClassOfWarrantDiscountRate" xlink:label="loc_NRXSClassOfWarrantDiscountRate" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_NRXSClassOfWarrantDiscountRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_DebtInstrumentPrincipalAmount" xlink:label="loc_NRXSDebtInstrumentPrincipalAmount" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_NRXSDebtInstrumentPrincipalAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfDebtIssuanceCosts" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapPaymentsOfDebtIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:label="loc_us-gaapEmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapEmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsNotSettleableInCashFairValueDisclosure" xlink:label="loc_us-gaapWarrantsNotSettleableInCashFairValueDisclosure" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapWarrantsNotSettleableInCashFairValueDisclosure" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscountCurrent" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscountCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaapPaymentsOfFinancingCosts" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapPaymentsOfFinancingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_PaymentsOfFinancingCost" xlink:label="loc_NRXSPaymentsOfFinancingCost" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_NRXSPaymentsOfFinancingCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPayableCurrent" xlink:label="loc_us-gaapInterestPayableCurrent" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapInterestPayableCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfOperatingLeasesDetails" xlink:title="00000059 - Disclosure - Schedule of Operating Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_DisclosureLeasesAbstract" xlink:label="loc_NRXSDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NRXSDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NRXSDisclosureLeasesAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NRXSDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NRXSDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NRXSDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NRXSDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfMaturitiesOperatingLeaseLiabilitiesDetails" xlink:title="00000060 - Disclosure - Schedule of Maturities Operating Lease Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_DisclosureLeasesAbstract" xlink:label="loc_NRXSDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NRXSDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NRXSDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NRXSDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NRXSDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NRXSDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NRXSDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/LeasesDetailsNarrative" xlink:title="00000061 - Disclosure - Leases (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_DisclosureLeasesAbstract" xlink:label="loc_NRXSDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NRXSDisclosureLeasesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeographicDistributionAxis" xlink:label="loc_us-gaapGeographicDistributionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapGeographicDistributionAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeographicDistributionDomain" xlink:label="loc_us-gaapGeographicDistributionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeographicDistributionAxis" xlink:to="loc_us-gaapGeographicDistributionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_VersaillesIndianaMember" xlink:label="loc_NRXSVersaillesIndianaMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeographicDistributionDomain" xlink:to="loc_NRXSVersaillesIndianaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_CarmelIndianaMember" xlink:label="loc_NRXSCarmelIndianaMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGeographicDistributionDomain" xlink:to="loc_NRXSCarmelIndianaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="loc_us-gaapLeaseContractualTermAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapLeaseContractualTermAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaapLeaseContractualTermDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeaseContractualTermAxis" xlink:to="loc_us-gaapLeaseContractualTermDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_LeaseOneMember" xlink:label="loc_NRXSLeaseOneMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeaseContractualTermDomain" xlink:to="loc_NRXSLeaseOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_LeaseTwoMember" xlink:label="loc_NRXSLeaseTwoMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeaseContractualTermDomain" xlink:to="loc_NRXSLeaseTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_LeaseThreeMember" xlink:label="loc_NRXSLeaseThreeMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeaseContractualTermDomain" xlink:to="loc_NRXSLeaseThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:label="loc_us-gaapLesseeOperatingLeaseDescription" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeasePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:label="loc_us-gaapLesseeOperatingLeaseDiscountRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLesseeOperatingLeaseDiscountRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeaseExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfWarrantActivityForCommonStockDetails" xlink:title="00000062 - Disclosure - Schedule of Warrant Activity for Common Stock (Details)">
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_DisclosureCommonStockAndWarrantsAbstract" xlink:label="loc_NRXSDisclosureCommonStockAndWarrantsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NRXSDisclosureCommonStockAndWarrantsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageRemainingContracualLifeOutstandingNumberGranted" xlink:label="loc_NRXSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageRemainingContracualLifeOutstandingNumberGranted" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageRemainingContracualLifeOutstandingNumberGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber" xlink:label="loc_NRXSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants" xlink:label="loc_NRXSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsConvertedPrefundedWarrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_NRXSShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsConvertedPrefundedWarrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsConvertedPrefundedWarrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfWarrantActivityForPreferredStockDetails" xlink:title="00000063 - Disclosure - Schedule of Warrant Activity for Preferred Stock (Details)">
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_DisclosureCommonStockAndWarrantsAbstract" xlink:label="loc_NRXSDisclosureCommonStockAndWarrantsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NRXSDisclosureCommonStockAndWarrantsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber" xlink:label="loc_NRXSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant" xlink:label="loc_NRXSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant" xlink:label="loc_NRXSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails" xlink:title="00000064 - Disclosure - Schedule of Warrants outstanding and Exercisable (Details)">
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_DisclosureCommonStockAndWarrantsAbstract" xlink:label="loc_NRXSDisclosureCommonStockAndWarrantsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NRXSDisclosureCommonStockAndWarrantsAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_InvestorWarrantOneMember" xlink:label="loc_NRXSInvestorWarrantOneMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_NRXSInvestorWarrantOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_InvestorWarrantPSAOneMember" xlink:label="loc_NRXSInvestorWarrantPSAOneMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_NRXSInvestorWarrantPSAOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_TwoThousandTwentyTwoConvertibleNotesMember" xlink:label="loc_NRXSTwoThousandTwentyTwoConvertibleNotesMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_NRXSTwoThousandTwentyTwoConvertibleNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_TwoThousandTwentyThreeConvertibleNotesMember" xlink:label="loc_NRXSTwoThousandTwentyThreeConvertibleNotesMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_NRXSTwoThousandTwentyThreeConvertibleNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ConsultingAgreementWarrantsMember" xlink:label="loc_NRXSConsultingAgreementWarrantsMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_NRXSConsultingAgreementWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_UnderwriterWarrantsMember" xlink:label="loc_NRXSUnderwriterWarrantsMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_NRXSUnderwriterWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_WarrantExpirationDateDescription" xlink:label="loc_NRXSWarrantExpirationDateDescription" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_NRXSWarrantExpirationDateDescription" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative" xlink:title="00000065 - Disclosure - Common Stock and Warrants (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_DisclosureCommonStockAndWarrantsAbstract" xlink:label="loc_NRXSDisclosureCommonStockAndWarrantsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NRXSDisclosureCommonStockAndWarrantsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ConvertibleSeriesSeedPreferredStockMember" xlink:label="loc_NRXSConvertibleSeriesSeedPreferredStockMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_NRXSConvertibleSeriesSeedPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_VendorsMember" xlink:label="loc_NRXSVendorsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_NRXSVendorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_BrianHannaschMember" xlink:label="loc_NRXSBrianHannaschMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_NRXSBrianHannaschMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_WarrantOneMember" xlink:label="loc_NRXSWarrantOneMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_NRXSWarrantOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_WarrantTwoMember" xlink:label="loc_NRXSWarrantTwoMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_NRXSWarrantTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_WarrantThreeMember" xlink:label="loc_NRXSWarrantThreeMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_NRXSWarrantThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_MasimoCorporationMember" xlink:label="loc_NRXSMasimoCorporationMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_NRXSMasimoCorporationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_TwoThousandTwentyTwoConvertibleNotesMember" xlink:label="loc_NRXSTwoThousandTwentyTwoConvertibleNotesMember" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_NRXSTwoThousandTwentyTwoConvertibleNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_TwoThousandTwentyThreeConvertibleNotesMember" xlink:label="loc_NRXSTwoThousandTwentyThreeConvertibleNotesMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_NRXSTwoThousandTwentyThreeConvertibleNotesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaapConversionOfStockSharesIssued1" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConversionOfStockSharesIssued1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplit" xlink:label="loc_us-gaapStockholdersEquityNoteStockSplit" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquityNoteStockSplit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_WarrantsExpirationDateDescription" xlink:label="loc_NRXSWarrantsExpirationDateDescription" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSWarrantsExpirationDateDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees" xlink:label="loc_us-gaapClassOfWarrantOrRightReasonForIssuingToNonemployees" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightReasonForIssuingToNonemployees" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant" xlink:label="loc_NRXSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants" xlink:label="loc_NRXSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_NRXSShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/PreferredStockDetailsNarrative" xlink:title="00000066 - Disclosure - Preferred Stock (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockByClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ConvertibleSeriesAPreferredStockMember" xlink:label="loc_NRXSConvertibleSeriesAPreferredStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_NRXSConvertibleSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ConvertibleSeriesSeedPreferredStockMember" xlink:label="loc_NRXSConvertibleSeriesSeedPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_NRXSConvertibleSeriesSeedPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaapSeriesAPreferredStockMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaapPreferredStockMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaapShortTermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapShortTermDebtTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaapShortTermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeAxis" xlink:to="loc_us-gaapShortTermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaapConvertibleDebtMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtTypeDomain" xlink:to="loc_us-gaapConvertibleDebtMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_AggregatePurchasePrice" xlink:label="loc_NRXSAggregatePurchasePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_NRXSAggregatePurchasePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaapConversionOfStockAmountConverted1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockAmountConverted1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaapPreferredStockDividendRatePercentage" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPreferredStockDividendRatePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionRatio1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionRatio1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_SharePremiumPercentage" xlink:label="loc_NRXSSharePremiumPercentage" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_NRXSSharePremiumPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionOriginalDebtInterestRateOfDebt" xlink:label="loc_us-gaapDebtConversionOriginalDebtInterestRateOfDebt" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDebtConversionOriginalDebtInterestRateOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaapDebtInstrumentPeriodicPayment" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDebtInstrumentPeriodicPayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapDebtInstrumentConvertibleConversionPrice1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfOption-pricingModelWithFollowingWeighted-averageAssumptionsDetails" xlink:title="00000067 - Disclosure - Schedule of Option-pricing Model with Following Weighted-average Assumptions (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_TwentySeventeenStockCompensationPlanMember" xlink:label="loc_NRXSTwentySeventeenStockCompensationPlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_NRXSTwentySeventeenStockCompensationPlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="00000068 - Disclosure - Schedule of Stock Option Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/StockOptionsAndAwardsDetailsNarrative" xlink:title="00000069 - Disclosure - Stock Options and Awards (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_TwentySeventeenStockCompensationPlanMember" xlink:label="loc_NRXSTwentySeventeenStockCompensationPlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_NRXSTwentySeventeenStockCompensationPlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaapSharesIssued" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfChangesInWarrantLiabilitiesDetails" xlink:title="00000070 - Disclosure - Schedule of Changes in Warrant Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_DisclosureWarrantLiabilitiesAbstract" xlink:label="loc_NRXSDisclosureWarrantLiabilitiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="loc_srtPlatformOperatorCryptoAssetTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NRXSDisclosureWarrantLiabilitiesAbstract" xlink:to="loc_srtPlatformOperatorCryptoAssetTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="loc_srtPlatformOperatorCryptoAssetLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_srtPlatformOperatorCryptoAssetLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_AdditionToWarrantLiabilities" xlink:label="loc_NRXSAdditionToWarrantLiabilities" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_NRXSAdditionToWarrantLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ReclassifiedToEquity" xlink:label="loc_NRXSReclassifiedToEquity" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_NRXSReclassifiedToEquity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/WarrantLiabilitiesDetailsNarrative" xlink:title="00000071 - Disclosure - Warrant Liabilities (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_DisclosureWarrantLiabilitiesAbstract" xlink:label="loc_NRXSDisclosureWarrantLiabilitiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NRXSDisclosureWarrantLiabilitiesAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="loc_us-gaapMeasurementInputSharePriceMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputSharePriceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfChangesInDerivativeLiabilitiesDetails" xlink:title="00000072 - Disclosure - Schedule of Changes in Derivative Liabilities (Details)">
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_DisclosureDerivativeLiabilitiesAbstract" xlink:label="loc_NRXSDisclosureDerivativeLiabilitiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PlatformOperatorCryptoAssetTable" xlink:label="loc_srtPlatformOperatorCryptoAssetTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NRXSDisclosureDerivativeLiabilitiesAbstract" xlink:to="loc_srtPlatformOperatorCryptoAssetTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_PlatformOperatorCryptoAssetLineItems" xlink:label="loc_srtPlatformOperatorCryptoAssetLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_srtPlatformOperatorCryptoAssetLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_AdditionToDerivativeLiabilities" xlink:label="loc_NRXSAdditionToDerivativeLiabilities" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_NRXSAdditionToDerivativeLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInDerivativeLiabilities" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapIncreaseDecreaseInDerivativeLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ExtinguishmentOfDerivativeLiabilities" xlink:label="loc_NRXSExtinguishmentOfDerivativeLiabilities" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_NRXSExtinguishmentOfDerivativeLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaapDerivativeLiabilitiesCurrent_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtPlatformOperatorCryptoAssetLineItems" xlink:to="loc_us-gaapDerivativeLiabilitiesCurrent_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/DerivativeLiabilitiesDetailsNarrative" xlink:title="00000073 - Disclosure - Derivative Liabilities (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_DisclosureDerivativeLiabilitiesAbstract" xlink:label="loc_NRXSDisclosureDerivativeLiabilitiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NRXSDisclosureDerivativeLiabilitiesAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="loc_us-gaapMeasurementInputSharePriceMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputSharePriceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityMeasurementInput" xlink:label="loc_us-gaapDerivativeLiabilityMeasurementInput" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapDerivativeLiabilityMeasurementInput" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/RetirementPlanDetailsNarrative" xlink:title="00000074 - Disclosure - Retirement Plan (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaapCompensationAndRetirementDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="loc_us-gaapDefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapDefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanAdministrativeExpenses" xlink:label="loc_us-gaapDefinedContributionPlanAdministrativeExpenses" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCompensationAndRetirementDisclosureAbstract" xlink:to="loc_us-gaapDefinedContributionPlanAdministrativeExpenses" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000075 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable" xlink:label="loc_us-gaapOtherCommitmentsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOtherCommitmentsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="loc_us-gaapOtherCommitmentsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsTable" xlink:to="loc_us-gaapOtherCommitmentsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_us-gaapIPOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_TrademarkAgreementMember" xlink:label="loc_NRXSTrademarkAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_NRXSTrademarkAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ExecutiveEmploymentAgreementsMember" xlink:label="loc_NRXSExecutiveEmploymentAgreementsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_NRXSExecutiveEmploymentAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAxis" xlink:label="loc_us-gaapOtherCommitmentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsTable" xlink:to="loc_us-gaapOtherCommitmentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain" xlink:label="loc_us-gaapOtherCommitmentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsAxis" xlink:to="loc_us-gaapOtherCommitmentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_InitialPaymentMember" xlink:label="loc_NRXSInitialPaymentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_NRXSInitialPaymentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_SecondAndFinalPaymentMember" xlink:label="loc_NRXSSecondAndFinalPaymentMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsDomain" xlink:to="loc_NRXSSecondAndFinalPaymentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsTable" xlink:to="loc_srtRangeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfInitialPublicOffering" xlink:label="loc_us-gaapPaymentsForRepurchaseOfInitialPublicOffering" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapPaymentsForRepurchaseOfInitialPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ExecutiveEmploymentAgreementsTerms" xlink:label="loc_NRXSExecutiveEmploymentAgreementsTerms" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_NRXSExecutiveEmploymentAgreementsTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_DescriptionOfExecutiveEmploymentAgreementsRenewals" xlink:label="loc_NRXSDescriptionOfExecutiveEmploymentAgreementsRenewals" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_NRXSDescriptionOfExecutiveEmploymentAgreementsRenewals" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalariesAndWages" xlink:label="loc_us-gaapSalariesAndWages" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapSalariesAndWages" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncentiveFeeExpense" xlink:label="loc_us-gaapIncentiveFeeExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapIncentiveFeeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepositLiabilitiesAccruedInterest" xlink:label="loc_us-gaapDepositLiabilitiesAccruedInterest" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapDepositLiabilitiesAccruedInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_SpecialBonusPercentage" xlink:label="loc_NRXSSpecialBonusPercentage" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_NRXSSpecialBonusPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_KeyEmployeeExercisePercentage" xlink:label="loc_NRXSKeyEmployeeExercisePercentage" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_NRXSKeyEmployeeExercisePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="loc_us-gaapAccruedBonusesCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapAccruedBonusesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyDamagesSoughtValue" xlink:label="loc_us-gaapLossContingencyDamagesSoughtValue" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherCommitmentsLineItems" xlink:to="loc_us-gaapLossContingencyDamagesSoughtValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/HealthBenefitPlanDetailsNarrative" xlink:title="00000076 - Disclosure - Health Benefit Plan (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_DisclosureHealthBenefitPlanAbstract" xlink:label="loc_NRXSDisclosureHealthBenefitPlanAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HealthCareOrganizationStopLossInsurancePremiumExpense" xlink:label="loc_us-gaapHealthCareOrganizationStopLossInsurancePremiumExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NRXSDisclosureHealthBenefitPlanAbstract" xlink:to="loc_us-gaapHealthCareOrganizationStopLossInsurancePremiumExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_HealthCareOrganizationStopLossInsurancePremiumPercentage" xlink:label="loc_NRXSHealthCareOrganizationStopLossInsurancePremiumPercentage" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_NRXSDisclosureHealthBenefitPlanAbstract" xlink:to="loc_NRXSHealthCareOrganizationStopLossInsurancePremiumPercentage" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfDeferredTaxAssetDetails" xlink:title="00000077 - Disclosure - Schedule of Deferred Tax Asset (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_DeferredTaxAssetsDepreciation" xlink:label="loc_NRXSDeferredTaxAssetsDepreciation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_NRXSDeferredTaxAssetsDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_DeferredTaxAssetsAmortization" xlink:label="loc_NRXSDeferredTaxAssetsAmortization" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_NRXSDeferredTaxAssetsAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfFederalStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails" xlink:title="00000078 - Disclosure - Schedule of Federal Statutory Income Tax Rate and Effective Income Tax Rate (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_EffectiveIncomeTaxRateReconciliationNontaxableIncome" xlink:label="loc_NRXSEffectiveIncomeTaxRateReconciliationNontaxableIncome" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_NRXSEffectiveIncomeTaxRateReconciliationNontaxableIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfStateCarryforwardsDetails" xlink:title="00000079 - Disclosure - Schedule of State Carryforwards (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaapOperatingLossCarryforwardsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapOperatingLossCarryforwardsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaapOperatingLossCarryforwardsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapOperatingLossCarryforwardsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodAxis" xlink:label="loc_us-gaapTaxPeriodAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsTable" xlink:to="loc_us-gaapTaxPeriodAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxPeriodDomain" xlink:label="loc_us-gaapTaxPeriodDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxPeriodAxis" xlink:to="loc_us-gaapTaxPeriodDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_TaxYear2038Member" xlink:label="loc_NRXSTaxYear2038Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_NRXSTaxYear2038Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_TaxYear2039Member" xlink:label="loc_NRXSTaxYear2039Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_NRXSTaxYear2039Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_TaxYear2040Member" xlink:label="loc_NRXSTaxYear2040Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_NRXSTaxYear2040Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_TaxYear2041Member" xlink:label="loc_NRXSTaxYear2041Member" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_NRXSTaxYear2041Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_TaxYear2042Member" xlink:label="loc_NRXSTaxYear2042Member" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_NRXSTaxYear2042Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_TaxYear2043Member" xlink:label="loc_NRXSTaxYear2043Member" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxPeriodDomain" xlink:to="loc_NRXSTaxYear2043Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingLossCarryforwardsLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000080 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000081 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaapSeriesBPreferredStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapSeriesBPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:label="loc_us-gaapDebtInstrumentAnnualPrincipalPayment" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtInstrumentAnnualPrincipalPayment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertibleDebt" xlink:label="loc_us-gaapConvertibleDebt" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapConvertibleDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaapDebtInstrumentPeriodicPayment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtInstrumentPeriodicPayment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtConversionOriginalDebtInterestRateOfDebt" xlink:label="loc_us-gaapDebtConversionOriginalDebtInterestRateOfDebt" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapDebtConversionOriginalDebtInterestRateOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails" xlink:title="00000082 - Disclosure - Schedule of Restatement of Interim Financial Statements (Unaudited) (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis" xlink:label="loc_srtRestatementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="loc_srtRestatementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="loc_srtScenarioPreviouslyReportedMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementDomain" xlink:to="loc_srtScenarioPreviouslyReportedMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:label="loc_srtRevisionOfPriorPeriodReclassificationAdjustmentMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementDomain" xlink:to="loc_srtRevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonrelatedPartyMember" xlink:label="loc_us-gaapNonrelatedPartyMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapNonrelatedPartyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ConvertibleSeriesAPreferredStockMember" xlink:label="loc_NRXSConvertibleSeriesAPreferredStockMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_NRXSConvertibleSeriesAPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ConvertibleSeriesSeedPreferredStockMember" xlink:label="loc_NRXSConvertibleSeriesSeedPreferredStockMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_NRXSConvertibleSeriesSeedPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Deposits" xlink:label="loc_us-gaapDeposits" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDeposits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_ShareLiabilitiesCurrent" xlink:label="loc_NRXSShareLiabilitiesCurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_NRXSShareLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_WarrantLiabilities" xlink:label="loc_NRXSWarrantLiabilities" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_NRXSWarrantLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingExpense" xlink:label="loc_us-gaapSellingExpense" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapSellingExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_FinancingCharges" xlink:label="loc_NRXSFinancingCharges" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_NRXSFinancingCharges" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestAndOtherIncome" xlink:label="loc_us-gaapInterestAndOtherIncome" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestAndOtherIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaapOtherNonoperatingIncome" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="loc_us-gaapOtherNonoperatingExpense" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherNonoperatingExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_2" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts_2" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfFinancingCostsAndDiscounts_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_NoncashLeaseExpense" xlink:label="loc_NRXSNoncashLeaseExpense" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_NRXSNoncashLeaseExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_NoncashInterestExpense" xlink:label="loc_NRXSNoncashInterestExpense" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_NRXSNoncashInterestExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_2" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_IssuanceOfCommonStockForNoncashConsideration" xlink:label="loc_NRXSIssuanceOfCommonStockForNoncashConsideration" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_NRXSIssuanceOfCommonStockForNoncashConsideration" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_FinanceCharges" xlink:label="loc_NRXSFinanceCharges" />
      <link:presentationArc order="620" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_NRXSFinanceCharges" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet_2" />
      <link:presentationArc order="630" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_2" />
      <link:presentationArc order="640" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="650" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="660" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:presentationArc order="670" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="680" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="690" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:presentationArc order="700" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_IncreaseDecreaseInCustomerDeposit" xlink:label="loc_NRXSIncreaseDecreaseInCustomerDeposit" />
      <link:presentationArc order="710" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_NRXSIncreaseDecreaseInCustomerDeposit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:presentationArc order="720" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="730" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="740" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="750" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:presentationArc order="760" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="770" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="780" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="790" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_OfferingCostsInAdvanceOfSaleOfCommonStock" xlink:label="loc_NRXSOfferingCostsInAdvanceOfSaleOfCommonStock" />
      <link:presentationArc order="800" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_NRXSOfferingCostsInAdvanceOfSaleOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:presentationArc order="810" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:presentationArc order="820" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:presentationArc order="830" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="840" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="850" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="860" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="870" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://neuraxis.com/role/RestatementOfInterimFinancialStatementsDetailsNarrative" xlink:title="00000083 - Disclosure - Restatement of Interim Financial Statements (Unaudited) (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis" xlink:label="loc_srtRestatementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="loc_srtRestatementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="loc_srtRestatementDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementAxis" xlink:to="loc_srtRestatementDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:label="loc_srtRevisionOfPriorPeriodReclassificationAdjustmentMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRestatementDomain" xlink:to="loc_srtRevisionOfPriorPeriodReclassificationAdjustmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="nrxs-20231231.xsd#NRXS_IncreaseDecreaseInWarrantLiability" xlink:label="loc_NRXSIncreaseDecreaseInWarrantLiability" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_NRXSIncreaseDecreaseInWarrantLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823901363312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Apr. 12, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Neuraxis,
Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001933567<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">45-5079684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">11611
    N Meridian St<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Carmel<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">IN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">46032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(812)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">689-0791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NRXS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,594,897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Rosenberg Rich Baker Berman, P.A<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Somerset,
    New Jersey<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823806021712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 78,560<span></span>
</td>
<td class="nump">$ 253,699<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">73,167<span></span>
</td>
<td class="nump">174,399<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">21,220<span></span>
</td>
<td class="nump">48,133<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaids and other current assets</a></td>
<td class="nump">69,663<span></span>
</td>
<td class="nump">726<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">242,610<span></span>
</td>
<td class="nump">476,957<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, at cost:</a></td>
<td class="nump">436,626<span></span>
</td>
<td class="nump">405,845<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less - accumulated depreciation</a></td>
<td class="num">(348,074)<span></span>
</td>
<td class="num">(317,834)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">88,552<span></span>
</td>
<td class="nump">88,011<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrentAbstract', window );"><strong>Other Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCosts', window );">Deferred offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">736,736<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use asset, net</a></td>
<td class="nump">70,263<span></span>
</td>
<td class="nump">101,382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">108,073<span></span>
</td>
<td class="nump">77,558<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">509,498<span></span>
</td>
<td class="nump">1,480,644<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,204,219<span></span>
</td>
<td class="nump">1,592,116<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">401,088<span></span>
</td>
<td class="nump">834,062<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease payable</a></td>
<td class="nump">49,127<span></span>
</td>
<td class="nump">33,395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Notes payable - convertible notes, net of unamortized discount of $0 and $3,327,213 as of December 31, 2023 and December 31, 2022</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">228,342<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Deposits', window );">Customer deposits</a></td>
<td class="nump">74,947<span></span>
</td>
<td class="nump">59,174<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,735,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_WarrantLiabilities', window );">Warrant liabilities</a></td>
<td class="nump">8,225<span></span>
</td>
<td class="nump">2,234,384<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">1,885,668<span></span>
</td>
<td class="nump">6,978,058<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease payable, net of current portion</a></td>
<td class="nump">27,071<span></span>
</td>
<td class="nump">76,199<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="nump">27,071<span></span>
</td>
<td class="nump">76,199<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,912,739<span></span>
</td>
<td class="nump">7,054,257<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 100,000,000 shares authorized; 6,508,897 issued and outstanding as of December 31, 2023 and 1,963,322 as of December 31, 2022</a></td>
<td class="nump">6,509<span></span>
</td>
<td class="nump">1,963<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid in capital</a></td>
<td class="nump">47,148,361<span></span>
</td>
<td class="nump">28,355,230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(48,558,111)<span></span>
</td>
<td class="num">(33,931,428)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; deficit</a></td>
<td class="num">(1,403,241)<span></span>
</td>
<td class="num">(5,573,613)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders&#8217; Deficit</a></td>
<td class="nump">509,498<span></span>
</td>
<td class="nump">1,480,644<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=NRXS_ConvertibleSeriesAPreferredStockMember', window );">Convertible Series A Preferred stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, value</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">507<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=NRXS_ConvertibleSeriesSeedPreferredStockMember', window );">Convertible Series Seed Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, value</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable</a></td>
<td class="nump">148,062<span></span>
</td>
<td class="nump">202,834<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 58,051<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_WarrantLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_WarrantLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Deposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate of all deposit liabilities held by the entity, including foreign and domestic, interest and noninterest bearing; may include demand deposits, saving deposits, Negotiable Order of Withdrawal (NOW) and time deposits among others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.12)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Deposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 23: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=NRXS_ConvertibleSeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=NRXS_ConvertibleSeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=NRXS_ConvertibleSeriesSeedPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=NRXS_ConvertibleSeriesSeedPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823933985568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountCurrent', window );">Unamortized discount, net</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,327,213<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">1,120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">6,508,897<span></span>
</td>
<td class="nump">1,963,322<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">6,508,897<span></span>
</td>
<td class="nump">1,963,322<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=NRXS_ConvertibleSeriesAPreferredStockMember', window );">Convertible Series A Preferred stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">506,637<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">506,637<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=NRXS_ConvertibleSeriesSeedPreferredStockMember', window );">Convertible Series Seed Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">120,000<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">115,477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">115,477<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=NRXS_ConvertibleSeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=NRXS_ConvertibleSeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=NRXS_ConvertibleSeriesSeedPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=NRXS_ConvertibleSeriesSeedPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823811171424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net Sales</a></td>
<td class="nump">$ 477,460<span></span>
</td>
<td class="nump">$ 1,928,590<span></span>
</td>
<td class="nump">$ 2,460,049<span></span>
</td>
<td class="nump">$ 2,684,735<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of Goods Sold</a></td>
<td class="nump">67,287<span></span>
</td>
<td class="nump">231,000<span></span>
</td>
<td class="nump">303,345<span></span>
</td>
<td class="nump">297,060<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross Profit</a></td>
<td class="nump">410,173<span></span>
</td>
<td class="nump">1,697,590<span></span>
</td>
<td class="nump">2,156,704<span></span>
</td>
<td class="nump">2,387,675<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingExpense', window );">Selling Expenses</a></td>
<td class="nump">64,210<span></span>
</td>
<td class="nump">250,933<span></span>
</td>
<td class="nump">323,569<span></span>
</td>
<td class="nump">410,883<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development</a></td>
<td class="nump">44,950<span></span>
</td>
<td class="nump">171,536<span></span>
</td>
<td class="nump">169,315<span></span>
</td>
<td class="nump">225,610<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and Administrative</a></td>
<td class="nump">3,323,352<span></span>
</td>
<td class="nump">6,316,411<span></span>
</td>
<td class="nump">8,328,315<span></span>
</td>
<td class="nump">5,123,420<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Loss</a></td>
<td class="num">(3,022,339)<span></span>
</td>
<td class="num">(5,041,290)<span></span>
</td>
<td class="num">(6,664,495)<span></span>
</td>
<td class="num">(3,372,238)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (Expense) Income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_FinancingCharges', window );">Financing charges</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(2,772)<span></span>
</td>
<td class="num">(2,772)<span></span>
</td>
<td class="num">(2,322,216)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(102,628)<span></span>
</td>
<td class="num">(453,869)<span></span>
</td>
<td class="num">(476,416)<span></span>
</td>
<td class="num">(318,666)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="nump">592,853<span></span>
</td>
<td class="nump">791,610<span></span>
</td>
<td class="nump">844,854<span></span>
</td>
<td class="nump">606,049<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivative liability</a></td>
<td class="nump">6,394<span></span>
</td>
<td class="nump">198,551<span></span>
</td>
<td class="nump">198,551<span></span>
</td>
<td class="nump">713,989<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and issuance cost</a></td>
<td class="num">(1,331,030)<span></span>
</td>
<td class="num">(4,881,622)<span></span>
</td>
<td class="num">(4,881,622)<span></span>
</td>
<td class="num">(98,935)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Extinguishment of debt liabilities</a></td>
<td class="num">(4,779,069)<span></span>
</td>
<td class="num">(3,649,571)<span></span>
</td>
<td class="num">(3,649,561)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Other income</a></td>
<td class="nump">9,931<span></span>
</td>
<td class="nump">11,483<span></span>
</td>
<td class="nump">15,133<span></span>
</td>
<td class="nump">11,956<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Other expense</a></td>
<td class="num">(1,578)<span></span>
</td>
<td class="num">(9,008)<span></span>
</td>
<td class="num">(10,355)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other (expense) income, net</a></td>
<td class="num">(5,603,024)<span></span>
</td>
<td class="num">(7,993,095)<span></span>
</td>
<td class="num">(7,962,188)<span></span>
</td>
<td class="num">(1,407,823)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (8,625,363)<span></span>
</td>
<td class="num">$ (13,034,385)<span></span>
</td>
<td class="num">$ (14,626,683)<span></span>
</td>
<td class="num">$ (4,780,061)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Per-share Data</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Per-share Data, basic loss per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4.50)<span></span>
</td>
<td class="num">$ (2.77)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Per-share Data, diluted loss per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4.50)<span></span>
</td>
<td class="num">$ (2.77)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted Average Shares Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted Average Shares Outstanding, Basic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,252,328<span></span>
</td>
<td class="nump">2,003,322<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted Average Shares Outstanding, Diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,252,328<span></span>
</td>
<td class="nump">2,003,322<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_FinancingCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financing charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_FinancingCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized in the period that are directly related to the selling and distribution of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823810313776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Stockholders' Deficit - USD ($)<br></strong></div></th>
<th class="th">
<div>Preferred Stock [Member] </div>
<div>Convertible Series A Preferred stock [Member]</div>
</th>
<th class="th">
<div>Preferred Stock [Member] </div>
<div>Convertible Series Seed Preferred Stock [Member]</div>
</th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2021</a></td>
<td class="nump">$ 507<span></span>
</td>
<td class="nump">$ 115<span></span>
</td>
<td class="nump">$ 1,928<span></span>
</td>
<td class="nump">$ 28,323,157<span></span>
</td>
<td class="num">$ (29,151,367)<span></span>
</td>
<td class="num">$ (825,660)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2021</a></td>
<td class="nump">506,637<span></span>
</td>
<td class="nump">115,477<span></span>
</td>
<td class="nump">1,928,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">27,319<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">27,319<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Common stock issued upon signing of notes payable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">4,754<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,789<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Common stock issued upon signing of notes payable, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(4,780,061)<span></span>
</td>
<td class="num">(4,780,061)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Dec. 31, 2022</a></td>
<td class="nump">$ 507<span></span>
</td>
<td class="nump">$ 115<span></span>
</td>
<td class="nump">$ 1,963<span></span>
</td>
<td class="nump">28,355,230<span></span>
</td>
<td class="num">(33,931,428)<span></span>
</td>
<td class="num">(5,573,613)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="nump">506,637<span></span>
</td>
<td class="nump">115,477<span></span>
</td>
<td class="nump">1,963,322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,034,385)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,061,087)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2022</a></td>
<td class="nump">$ 507<span></span>
</td>
<td class="nump">$ 115<span></span>
</td>
<td class="nump">$ 1,963<span></span>
</td>
<td class="nump">28,355,230<span></span>
</td>
<td class="num">(33,931,428)<span></span>
</td>
<td class="num">(5,573,613)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2022</a></td>
<td class="nump">506,637<span></span>
</td>
<td class="nump">115,477<span></span>
</td>
<td class="nump">1,963,322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(14,626,683)<span></span>
</td>
<td class="num">(14,626,683)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering', window );">Common stock issued upon initial public offering</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,099<span></span>
</td>
<td class="nump">4,109,578<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,110,677<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_StockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering', window );">Common stock issued upon initial public offering, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,098,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_StockIssuedDuringPeriodValueCommonStockIssuedUponPreferredStockConversion', window );">Common stock issued upon preferred stock conversion</a></td>
<td class="num">$ (507)<span></span>
</td>
<td class="num">$ (115)<span></span>
</td>
<td class="nump">$ 1,244<span></span>
</td>
<td class="num">(622)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_StockIssuedDuringPeriodSharesCommonStockIssuedUponPreferredStockConversion', window );">Common stock issued upon preferred stock conversion, shares</a></td>
<td class="num">(506,637)<span></span>
</td>
<td class="num">(115,477)<span></span>
</td>
<td class="nump">1,244,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits', window );">Common stock issued upon debt conversion</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,650<span></span>
</td>
<td class="nump">9,897,833<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">9,899,483<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Common stock issued upon debt conversion, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,649,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued from agreements</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 425<span></span>
</td>
<td class="nump">749,575<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">750,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued from agreements, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">425,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Reclassification of warrant liability to equity</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,720,997<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,720,997<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_StockIssuedDuringPeriodValueWarrantsExercised', window );">Warrants exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 128<span></span>
</td>
<td class="nump">315,770<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">315,898<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Warrants exercised, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Dec. 31, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 6,509<span></span>
</td>
<td class="nump">$ 47,148,361<span></span>
</td>
<td class="num">$ (48,558,111)<span></span>
</td>
<td class="num">$ (1,403,241)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2023</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,508,897<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_StockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares common stock issued upon initial public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_StockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_StockIssuedDuringPeriodSharesCommonStockIssuedUponPreferredStockConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares common stock issued upon preferred stock conversion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_StockIssuedDuringPeriodSharesCommonStockIssuedUponPreferredStockConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value common stock issued upon initial public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_StockIssuedDuringPeriodValueCommonStockIssuedUponPreferredStockConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value common stock issued upon preferred stock conversion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_StockIssuedDuringPeriodValueCommonStockIssuedUponPreferredStockConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823805977344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (14,626,683)<span></span>
</td>
<td class="num">$ (4,780,061)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and issuance cost</a></td>
<td class="nump">4,881,622<span></span>
</td>
<td class="nump">98,935<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">40,725<span></span>
</td>
<td class="nump">37,133<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provisions for losses on accounts receivable</a></td>
<td class="nump">25,281<span></span>
</td>
<td class="nump">19,505<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_NoncashLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">31,119<span></span>
</td>
<td class="nump">26,593<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_NoncashInterestExpense', window );">Non-cash interest expense</a></td>
<td class="nump">260,777<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">27,319<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Extinguishment of debt liabilities</a></td>
<td class="nump">3,649,561<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_IssuanceOfCommonStockForNoncashConsideration', window );">Issuance of common stock for non-cash consideration</a></td>
<td class="nump">750,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_FinanceCharges', window );">Finance Charges</a></td>
<td class="nump">2,772<span></span>
</td>
<td class="nump">2,322,216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivative liabilities</a></td>
<td class="num">(198,551)<span></span>
</td>
<td class="num">(713,989)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities</a></td>
<td class="num">(844,854)<span></span>
</td>
<td class="num">(606,049)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">75,951<span></span>
</td>
<td class="num">(78,603)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="nump">26,913<span></span>
</td>
<td class="num">(8,953)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaids and other current assets</a></td>
<td class="num">(68,937)<span></span>
</td>
<td class="nump">14,944<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(387,897)<span></span>
</td>
<td class="nump">1,108,326<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(294,154)<span></span>
</td>
<td class="nump">272,425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_IncreaseDecreaseInCustomerDeposit', window );">Customer deposits</a></td>
<td class="nump">15,773<span></span>
</td>
<td class="num">(10,163)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="num">(33,396)<span></span>
</td>
<td class="num">(27,582)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used by operating activities</a></td>
<td class="num">(6,693,978)<span></span>
</td>
<td class="num">(2,298,004)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows from Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Additions to property and equipment</a></td>
<td class="num">(30,781)<span></span>
</td>
<td class="num">(1,390)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Additions to intangible assets</a></td>
<td class="num">(41,000)<span></span>
</td>
<td class="num">(59,815)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used by investing activities</a></td>
<td class="num">(71,781)<span></span>
</td>
<td class="num">(61,205)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="nump">4,847,457<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_DeferredOfferingCostsPaid', window );">Deferred offering costs paid</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(736,736)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from exercised warrants</a></td>
<td class="nump">209,097<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Principal payments on notes payable</a></td>
<td class="num">(3,533,765)<span></span>
</td>
<td class="num">(163,214)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from notes payable</a></td>
<td class="nump">159,831<span></span>
</td>
<td class="nump">122,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible notes</a></td>
<td class="nump">5,460,000<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Financing fees paid</a></td>
<td class="num">(552,000)<span></span>
</td>
<td class="num">(130,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">6,590,620<span></span>
</td>
<td class="nump">2,292,050<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net Decrease in Cash and Cash Equivalents</a></td>
<td class="num">(175,139)<span></span>
</td>
<td class="num">(67,159)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and Cash Equivalents at Beginning of Period</a></td>
<td class="nump">253,699<span></span>
</td>
<td class="nump">320,858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and Cash Equivalents at End of Period</a></td>
<td class="nump">78,560<span></span>
</td>
<td class="nump">253,699<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Disclosure of Non-Cash Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">214,562<span></span>
</td>
<td class="nump">202,781<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental Schedule of Non-Cash Investing and Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_FairValueOfWarrantLiabilitiesOfWarrantsFromConvertibleNotes', window );">Fair value of warrant liabilities of warrants from convertible notes</a></td>
<td class="nump">2,446,502<span></span>
</td>
<td class="nump">884,118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_FairValueOfDerivativeLiabilitiesOfConversionFeatureFromConvertibleNotes', window );">Fair value of derivative liabilities of conversion feature from convertible notes</a></td>
<td class="nump">2,375,378<span></span>
</td>
<td class="nump">1,075,098<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_PriorYearOfferingCostsPaid', window );">Prior year offering costs paid</a></td>
<td class="nump">736,736<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_ReclassificationOfWarrantLiabilityToEquity', window );">Reclassification of warrant liability to equity</a></td>
<td class="nump">3,720,997<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_ConversionOfPreferredStockToCommonStock', window );">Conversion of preferred stock to common stock</a></td>
<td class="nump">$ 1,244<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_ConversionOfPreferredStockToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of preferred stock to common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_ConversionOfPreferredStockToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_DeferredOfferingCostsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred offering costs paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_DeferredOfferingCostsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_FairValueOfDerivativeLiabilitiesOfConversionFeatureFromConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of derivative liabilities of conversion feature from convertible notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_FairValueOfDerivativeLiabilitiesOfConversionFeatureFromConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_FairValueOfWarrantLiabilitiesOfWarrantsFromConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrant liabilities of warrants from convertible notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_FairValueOfWarrantLiabilitiesOfWarrantsFromConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_FinanceCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_FinanceCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_IncreaseDecreaseInCustomerDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in customer deposit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_IncreaseDecreaseInCustomerDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_IssuanceOfCommonStockForNoncashConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock for noncash consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_IssuanceOfCommonStockForNoncashConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_NoncashInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_NoncashInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_NoncashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_NoncashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_PriorYearOfferingCostsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prior year offering costs paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_PriorYearOfferingCostsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_ReclassificationOfWarrantLiabilityToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclassification of warrant liability to equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_ReclassificationOfWarrantLiabilityToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823912034448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Organization and Other Matters<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Basis of Presentation, Organization and Other Matters</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zH2wWjEwj3B" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="f_005"></span>1.
<span id="xdx_82B_zbY3G2UDua66">Basis of Presentation, Organization and Other Matters</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
Inc. (&#8220;we,&#8221; &#8220;us,&#8221; the &#8220;Company,&#8221; or &#8220;Neuraxis&#8221;) was established in 2011 and incorporated
in the state of Indiana on April 17, 2012, under the name of Innovative Health Solutions, Inc. The name was changed to Neuraxis, Inc.
in March of 2022. Additionally, the Company filed a Certificate of Conversion to become a Delaware corporation on June 23, 2022. The
authorized shares were increased, and a par value established.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 10, 2023, the Company&#8217;s board of directors authorized a <span id="xdx_908_eus-gaap--StockholdersEquityNoteStockSplit_c20230112__20230112_zDLrnaI022Xl" title="Description of stock split">1-for-2 reverse stock split</span>. All per share information has been
adjusted for this reverse stock split. The reverse split became effective on January 12, 2023. All share and per share amounts for the
common stock have been retroactively restated to give effect to the splits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the conversion to a Delaware corporation, the total number of shares of all classes of stock which the Corporation shall have
authority to issue is (1) <span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_iI_c20231231_zE6pBmT85IFe" title="Common stock, shares authorized">100,000,000</span> shares of Common Stock, par value $<span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20231231_zRIQqgSYhHPe" title="Common stock, par value">0.001</span> per share (&#8220;Common Stock&#8221;) and (ii) <span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_c20231231_znenjB02donb" title="Preferred stock, shares authorized">1,120,000</span>
shares of Preferred Stock, par value $<span id="xdx_903_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20231231_z4hpc59X6ykh" title="Preferred stock, par value">0.001</span> per share (&#8220;Preferred Stock&#8221;), <span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesAPreferredStockMember_zY6HuNczpML" title="Preferred stock, shares authorized">1,000,000</span> of which is hereby designated as &#8220;Series
A Preferred Stock&#8221; and <span id="xdx_90C_eus-gaap--PreferredStockSharesAuthorized_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_zCVdjr9FKXZc" title="Preferred stock, shares authorized">120,000</span> of which is hereby designated as &#8220;Series Seed Preferred Stock&#8221; with the rights, preferences,
powers, privileges and restrictions, qualifications and limitations set forth in this Article IV of the Delaware Certificate of Incorporation.
All share amounts have been retroactively restated to give effect to these changes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 9, 2023, the Company consummated an initial public offering, conducted on a firm commitment basis, pursuant to which it sold <span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230809__20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_ztY6zd7Dq7j3">1,098,667
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of its common stock at a price of $<span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_c20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zMoeySb90b9h">6.00
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share, resulting in gross proceeds to the
Company of $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230809__20230809__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_ztgrFZDFvVS1">6,592,002</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
Net proceeds to the Company, after deducting underwriting discounts and commissions, 2022 deferred offering costs totaling $<span id="xdx_905_eus-gaap--DeferredOfferingCosts_iI_c20230809__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_zhC2gGNwt281" title="Deferred offering costs">736,736</span> and
offering expenses paid by the Company, were $<span id="xdx_901_eus-gaap--DeferredOfferingCosts_iI_c20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_zV6v3NzRmZY">4,110,721</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
All shares sold in our IPO were registered pursuant to a registration statement on Form S-1 (File No. 333- 269179), as amended, declared
effective by the SEC on August 9, 2023. Alexander Capital L.P. (&#8220;Alexander&#8221;) acted as sole book-running manager for the offering
and Spartan Capital Securities, LLC acted as co-manager for the offering. The underwriters did not exercise their option to purchase
up to an additional <span id="xdx_90D_ecustom--PurchaseOfAdditionalStockOnNumberOfOptionsNotExercised_c20230809__20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zGrudURXDg37">164,801
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of common stock. The Company paid the
underwriters an underwriting discount of seven percent (<span id="xdx_90B_ecustom--UnderwritersDiscountPercentage_iI_dp_uPure_c20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_zqqAadAuMlF3">7%</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)
of the amount raised in the offering. In addition, we also paid the underwriters a non-accountable expense allowance in the amount of
<span id="xdx_908_ecustom--NonaccountableExpenseAllowancePercentage_iI_dp_uPure_c20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_zRyspjKU45kg">1%
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(such <span id="xdx_90C_ecustom--CashFeePercentage_iI_dp_uPure_c20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_zIQHuZkPDxl9">8%
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in commissions and fees amounted to a total of
$<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20230809__20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_zBfHc0TaETDc">527,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)
at closing, as well as $<span id="xdx_901_ecustom--ReimbursementExpenses_c20230809__20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_zIh7n8oUPECd">175,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for the reimbursement of certain of the underwriters&#8217;
expenses. Additionally, as partial consideration for services rendered in connection with the offering, the Company issued Alexander
unregistered warrants to purchase an aggregate of <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230809__20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_zzNsczBfs904">65,921
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Company common stock, representing
<span id="xdx_902_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_c20230809__20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_zGdQeHnWxP37">6.0%
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of the aggregate shares sold in the offering.
The warrants have an initial exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_zAoxC9D5n5Ab">7.20
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share (equal to <span id="xdx_907_ecustom--OfferingPricePerPercentage_iI_pid_dp_c20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_zzDtOD5Oi6y8">120%
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of the offering price per share), have a term
of five years from the commencement of sales in the offering, and are exercisable at any time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is headquartered in Carmel, Indiana. The Company specializes in the development, production, and sale of medical neuromodulation
devices.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has developed three FDA cleared products, the IB-STIM (DEN180057, 2019), the NSS-2 Bridge (DEN170018, 2017), and the original
510(K) clearance (K140530, 2014).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    IB-STIM is a percutaneous electrical nerve field stimulator (PENFS) device that is indicated in patients 11-18 years of age with
    functional abdominal pain associated with irritable bowel syndrome. The IB-STIM currently is the only product marketed and sold by
    the Company.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    NSS-2 Bridge is a percutaneous nerve field stimulator (PNFS) device indicated for use in the reduction of the symptoms of opioid
    withdrawal. The NSS-2 Bridge device was licensed to Masimo Corporation in April 2020, and the Company received a one-time licensing
    fee of $<span id="xdx_901_ecustom--LicenseFees_c20230811__20230811__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zgUrrZX24mmg" title="License fees">250,000</span> from Masimo. Masimo markets and sells this product as its Masimo Bridge, and the Company will not receive any further
    licensing payments or other revenue from this product.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    original 510(K) device was the EAD, an electroacupuncture device, now called NeuroStim. The EAD is no longer being manufactured,
    sold or distributed but reserved only for research purposes.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823800584096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p id="xdx_805_eus-gaap--SignificantAccountingPoliciesTextBlock_zUbBKSWPsjz5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.
<span><span id="xdx_82A_zYcCYzAt0rk6">Summary of Significant Accounting Policies</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
summary of significant accounting policies of Neuraxis, Inc. is presented to assist in understanding the Company&#8217;s financial statements.
The financial statements and notes are representations of the Company&#8217;s management, who are responsible for their integrity and
objectivity. These accounting policies conform to U.S. generally accepted accounting principles and have been consistently applied in
the preparation of the financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preparing
the Company&#8217;s financial statements in conformity with accounting principles generally accepted in the United States of America
(&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities
and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and
expenses during the reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84F_eus-gaap--UseOfEstimates_zVDuaXrTLydg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span><span id="xdx_862_zEz0MUIIsalf">Use
of Estimates and Critical Accounting Estimates and Assumptions</span></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements
and the reported amounts of revenues and expenses during the reporting periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
significant accounting estimates or assumptions bear the risk of change due to the fact that there are uncertainties attached to these
estimates or assumptions, and certain estimates or assumptions are difficult to measure or value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
bases its estimates on historical experience and on various assumptions that are believed to be reasonable in relation to the financial
statements taken as a whole under the circumstances, the results of which form the basis for making judgments about the carrying values
of assets and liabilities that are not readily apparent from other sources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available information, changes
in facts and circumstances, historical experience, and reasonable assumptions. After such evaluations, if deemed appropriate, those
estimates are adjusted accordingly. The Company uses estimates in accounting for, among other items, revenue recognition, allowance
for credit losses, stock-based compensation, income tax provisions, excess and obsolete inventory reserve, and impairment of property and
equipment, and intellectual property. Actual results could differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zGfQ3Arrc5Ke" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span><span id="xdx_867_zpZR0i4lMbte">Cash
and Cash Equivalents</span></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. The Company
did not hold any cash equivalents as of December 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_844_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zQyLIdQUqMOa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span><span id="xdx_86D_zsWTh5OrDIQg">Trade
Accounts Receivable and Allowance for Credit Losses</span></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade
accounts receivable are stated at the amount management expects to collect from outstanding balances, net of an allowance for credit
losses. Management evaluates many factors when determining the collectability of specific customer accounts, including, but not limited
to, creditworthiness, past transaction and payment history, current economic industry trends and changes in payment terms. We use assumptions
and judgment based on the best available facts and circumstances to estimate and record an allowance. The allowance for credit losses
was $<span id="xdx_903_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20231231_zNeKr5x0pjbf" title="Allowance for doubtful accounts">11,993</span> and $<span id="xdx_906_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20221231_zt6UU4ntIW9g" title="Allowance for doubtful accounts">31,275</span> as of December 31, 2023 and 2022, respectively. The Company recorded credit losses for the years ended December
31,2023 and 2022 of $<span id="xdx_905_eus-gaap--ProvisionForOtherCreditLosses_c20230101__20231231_z1fCU75qdmHl" title="Credit losses">25,281</span> and <span id="xdx_90E_eus-gaap--ProvisionForOtherCreditLosses_c20220101__20221231_zJXQSNTHatn3" title="Credit losses">64,197</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84D_eus-gaap--DepositContractsPolicy_z3G9pKnFRuKc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span><span id="xdx_86C_zmrJGQX99vDl">Customer
Deposits</span></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer
deposits consists of billings, payments, and returned devices from clients in advance of revenue recognition. The Company will recognize
the customer deposits over the next year. As of December 31, 2023, and 2022, the Company had customer deposits of $<span id="xdx_902_eus-gaap--Deposits_iI_c20231231_zqIUNH3DZJc8" title="Customer deposits">74,947</span> and $<span id="xdx_90F_eus-gaap--Deposits_iI_c20221231_zPLa3GeMgKU6" title="Customer deposits">59,174</span>,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_846_eus-gaap--InventoryPolicyTextBlock_zMI6ujuN7rw1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span><span id="xdx_866_zves0DdFNTW3">Inventories</span></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories
are valued at the lower of cost or net realizable value. Cost is determined using the weighted average method. The inventory is comprised
of finished medical devices on hand. Certain components within the devices have an expiration date that are removed from current inventory
and expensed at the date of expiration. For the years ended December 31, 2023 and 2022, $<span id="xdx_90B_ecustom--InventoryExpenses_c20231231_zoQihQ2ttyu6" title="Inventory expenses">25,008</span> and $<span id="xdx_90D_ecustom--InventoryExpenses_iI_c20221231_zzHCNhEaXkRc" title="Inventory expenses">10,026</span> were expensed as expired
inventory, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84C_eus-gaap--DeferredChargesPolicyTextBlock_zKApjnvqDPCi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span><span id="xdx_865_zn9V9ttt6wmf">Deferred
Offering Costs</span></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
offering costs consist of costs incurred in connection with the preparation of an initial public offering. These costs, together with
the underwriting discounts and commissions, were charged to additional paid in capital upon the IPO. As of December 31, 2023 and 2022,
the Company had deferred offering costs of $<span id="xdx_90F_eus-gaap--DeferredOfferingCosts_iI_dxL_c20231231_zduETi4XjJ34" title="Deferred offering costs::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0636">0</span></span> and $<span id="xdx_906_eus-gaap--DeferredOfferingCosts_iI_c20221231_zJ5duxanWdb7" title="Deferred offering costs">736,736</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zqhPQolYI7fb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_866_zfGsnuflXkyf">Property
and Equipment</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are recorded at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated
useful lives of the assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89D_ecustom--ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_zuDWFlazwtT8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
is calculated using the following estimated useful lives:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B0_zRYzhM4FObAj" style="display: none">Schedule of Estimated Useful Lives</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 60%; border-collapse: collapse; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Classification</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Years</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Machinery and Equipment </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MinimumMember_z6T4sUWWoWNi" title="Property and equipment, estimated useful lives">5</span>-<span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MaximumMember_zd3L5zgGES5d" title="Property and equipment, estimated useful lives">10</span> </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture and Fixtures</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zkpRYICgli12" title="Property and equipment, estimated useful lives">5</span>-<span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_zy9KJtQEgs4a" title="Property and equipment, estimated useful lives">10</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer Hardware</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MinimumMember_zdqGof3t1oI" title="Property and equipment, estimated useful lives">5</span>-<span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MaximumMember_zcRNd7T4hdqb" title="Property and equipment, estimated useful lives">10</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold Improvements</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MinimumMember_zZHzaJmx9lfj" title="Property and equipment, estimated useful lives">10</span>-<span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MaximumMember_zFLCxUzN8HYh" title="Property and equipment, estimated useful lives">20</span></span></td></tr>
  </table>
<p id="xdx_8A6_zEuDpQt8YXCc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
expense was $<span id="xdx_907_eus-gaap--Depreciation_c20230101__20231231_zq9Hcvf7e1Dh" title="Depreciation expense">30,240</span> and $<span id="xdx_901_eus-gaap--Depreciation_c20220101__20221231_zu5aKm0Y6C1c" title="Depreciation expense">30,920</span> during the years ended December 31, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_eus-gaap--ResearchAndDevelopmentExpensePolicy_zLl5UkZpEoJ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_862_zsTqLJDzE2Yb">Research
and Development</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
for research and development are expensed as incurred. Research and development expenses consist primarily of clinical research studies
and new product development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--IntangibleAssetsFiniteLivedPolicy_z8qWp4Ka2Tj4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86E_zMTjD8n9M7D4">Intangible
Assets</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets consist of software, patents and a trademark. Intangible assets are stated at their historical cost and amortized on
a straight-line basis over their expected useful lives. Capitalized patent costs, net of accumulated amortization, includes legal costs
incurred for patent applications. In accordance with ASC 350, once a patent is granted, we amortize the capitalized patent costs over
the remaining life of the patent using the straight-line method. If the patent is not granted, we write off any capitalized patent costs
at that time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an agreement for a trademark related to the Company&#8217;s name on July 11, 2022. The agreement called for an initial
payment of $<span id="xdx_907_eus-gaap--PaymentsToAcquireIntangibleAssets_c20220710__20220711__us-gaap--TypeOfArrangementAxis__custom--TrademarkAgreementMember__us-gaap--OtherCommitmentsAxis__custom--InitialPaymentMember_zitNuSg2qFZk" title="Initial payment upon execution">10,000</span> upon execution of the agreement. A second and final payment of $<span id="xdx_903_eus-gaap--PaymentsToAcquireIntangibleAssets_c20220710__20220711__us-gaap--TypeOfArrangementAxis__custom--TrademarkAgreementMember__us-gaap--OtherCommitmentsAxis__custom--SecondAndFinalPaymentMember_zIBof3crmvG2" title="Second and final payment of contingent">40,000</span> was contingent upon the completion of the Company&#8217;s
planned initial public offering. The trademark does not have a determinate life and therefore the cost is not being amortized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an option agreement on April 12, 2023 to enter into a royalty-bearing licensing agreement to bring the optionor&#8217;s
invention to commercialization. The agreement required an initial payment of $<span id="xdx_907_eus-gaap--PaymentsToAcquireIntangibleAssets_c20230411__20230412__us-gaap--TypeOfArrangementAxis__custom--LicensingAgreementMember_zu7IJvU0Ivja" title="Initial payment upon execution">1,000</span> upon execution of the agreement. The agreement does
not have a determinate life and therefore the cost is not being amortized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
review intangible assets for impairment annually or when events or circumstances indicate that their carrying amount may not be recoverable.
During the years ended December 31, 2023, and 2022, the Company recorded no impairment charges for intangible assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
expense was $<span id="xdx_900_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20231231_zEfBkB15rWa9" title="Amortization expense">10,485</span> and $<span id="xdx_90D_eus-gaap--AmortizationOfIntangibleAssets_c20220101__20221231_zFaUgEMJOp63" title="Amortization expense">6,213</span> during the years ended December 31, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_zL1OMXiuVgO6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86D_zWbZejgz59Z6">Income
Taxes</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in
the Company&#8217;s financial statements and tax returns. Deferred tax assets and liabilities are determined based upon the differences
between the financial statement carrying amounts, and the tax bases of existing assets and liabilities for the loss and credit carryforwards
using enacted tax rates expected to be in effect in the year in which the differences are expected to reverse. Deferred tax assets are
reduced by a valuation allowance if it is more likely than not that these assets may not be realized. The Company determines whether
a tax position will be sustained upon examination. If it is more likely than not that a position will be sustained, none of the benefit
attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more likely than not
recognition threshold is calculated as the largest amount that is more than 50% likely of being realized upon resolution of the contingency.
The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the results of management&#8217;s evaluation, adoption of the rules did not have a material effect on the Company&#8217;s financial
statements. Further, no interest or penalties have been accrued or charged to expense as of December 31, 2023 and 2022 and for the years
then ended.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s income tax returns are subject to examination by the taxing authorities until the expiration of the related statutes
of limitations on those tax returns. In general, the federal and state income tax returns have a three-year statute of limitations. As
of December 31, 2023, the following tax years are subject to examination:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1.5pt solid; width: 32%; text-align: center">Jurisdiction</td><td style="padding-bottom: 1.5pt; text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 32%; text-align: center">Open Years for Filed Returns</td><td style="padding-bottom: 1.5pt; text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Return to File in 2024</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">Federal</td><td>&#160;</td>
    <td style="text-align: center">2020 &#8211; 2022</td><td>&#160;</td>
    <td style="text-align: center">2023</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">Various States</td><td>&#160;</td>
    <td style="text-align: center">2020 &#8211; 2022</td><td>&#160;</td>
    <td style="text-align: center">2023</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_845_eus-gaap--AdvertisingCostsPolicyTextBlock_zMkGAZaOZrki" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_869_zYreRTxzU1b3">Advertising
Cost</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advertising
costs are expensed as incurred and amounted to $<span id="xdx_900_eus-gaap--AdvertisingExpense_c20230101__20231231_z0GjCaNfpWY5" title="Advertising cost expense">192,400</span> and $<span id="xdx_90A_eus-gaap--AdvertisingExpense_c20220101__20221231_zp2itMDg3Lc1" title="Advertising cost expense">14,900</span> for the years ended December 31, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_840_ecustom--DerivativeLiabilityPolicyTextBlock_zGVqCK5z85Mc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_869_zHMq8XLsXJ6i">Derivative
Liabilities</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for derivative financial instruments as either equity or liabilities in accordance with ASC Topic 815, <i>Derivatives
and Hedging</i>, or ASC 815, based on the characteristics and provisions of each instrument. Embedded derivatives are required to be
bifurcated from the host instruments and recorded at fair value if the derivatives are not clearly and closely related to the host instruments
on the date of issuance. Derivative instrument liabilities are classified in the balance sheets as current or non-current based on whether
or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilizes a Monte Carlo simulation model for the common stock conversion feature of the notes payable that have an option to
convert at a variable number of shares to compute the fair value of the derivative and to mark to market the fair value of the
derivative at each balance sheet date. The inputs utilized in the application of the Monte Carlo model included a stock
price, an expected remaining term of each note as of the valuation date, estimated volatility, drift, and a risk-free rate. The
Company records the change in the fair value of the derivative as other income or expense in the Statements of Operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84B_ecustom--WarrantLiabilityPolicyTextBlock_z69GwGVVBVcc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_869_zV7p8awBt4kc">Warrant
Liabilities</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
evaluates all of the Company&#8217;s financial instruments, including issued warrants to purchase its Class A common stock, to
determine if such instruments are liabilities or contain features that qualify as embedded derivatives, pursuant to ASC 480 and ASC
815-15. The classification of derivative financial instruments, including whether such instruments should be recorded as liabilities
or as equity, is reassessed at the end of each reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilizes a Monte Carlo simulation model for warrants that have an option to convert at a variable number of shares to compute
the fair value of the derivative and to mark to market the fair value of the derivative at each balance sheet date. The inputs utilized
in the application of the Monte Carlo model included a starting stock price, an expected remaining term of each warrant as of the valuation
date, estimated volatility, drift, and a risk-free rate. The Company records the change in the fair value of the warrant as other
income or expense in the statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_840_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zXaEEhNVRUzl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86B_z42RAGNx2Pke">Fair
Value Measurements</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for financial instruments in accordance with ASC 820, Fair Value Measurements and Disclosures (&#8220;ASC 820&#8221;).
ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy
gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and
the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under ASC 820 are described
below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 &#8211; Quoted prices (unadjusted) for identical unrestricted assets or liabilities in active markets that the reporting entity has
the ability to access as of the measurement date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 &#8211; Significant other observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities: quoted
prices in markets that are not active; or financial instruments for which all significant inputs are observable or can be corroborated
by observable market date, either directly or indirectly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 &#8211; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets
or liabilities. These unobservable inputs reflect that reporting entity&#8217;s own assumptions about assumptions that market participants
would use in pricing the asset or liability. Level 3 assets and liabilities include financial instruments whose value is determined using
pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair
value require significant management judgment or estimation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s Level 1 assets/liabilities include cash, accounts receivable, accounts payable, prepaids, and other current assets. Management
believes the estimated fair value of these accounts on December 31, 2023 approximate their carrying value as reflected in the balance
sheets due to the short-term nature of these instruments or the use of market interest rates for debt instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s Level 3 assets/liabilities include derivative and warrant liabilities. Inputs to determine fair value are generally
unobservable and typically reflect management&#8217;s estimates of assumptions that market participants would use in pricing the
asset or liability. The fair values are therefore determined using model-based techniques, including option pricing models and
discounted cash flow models. The valuation techniques involve management&#8217;s estimates and judgment based on unobservable
inputs. The fair value estimates may not be indicative of the amounts that would be realized in a market exchange. Additionally,
there may be inherent uncertainties or changes in the underlying assumptions used, which could significantly affect the current or
future fair value estimates. Unobservable inputs used in the models are significant to the fair values of the assets and
liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89E_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zXrb3Ha5bbbh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables provides a summary of the relevant assets and liabilities that are measured at fair value on recurring basis:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Fair Value Measurements as of</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">December 31, 2023</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_8B5_zBcTe0bNWWrd" style="display: none">Schedule of Fair Value On a Recurring Basis Assets and Liability</span>&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zZgb1nNnOIB1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z90tT0VJCng4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Level 1)</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_znhoBmNvawL8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Level 2)</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z8GtVuYWyEwa" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;(Level 3)</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--WarrantLiabilities_i02I_maLFVDzwLw_z6rpvKyALug1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 36%; text-align: left">Warrant liabilities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">8,225</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0695">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0696">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">8,225</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DerivativeLiabilitiesCurrent_i02I_maLFVDzwLw_zJzlXGtSZDO9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Derivative liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0699">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0700">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0701">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0702">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LiabilitiesFairValueDisclosure_i02I_mtLFVDzwLw_zV9UcwYYQyjl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Total Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,225</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0705">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0706">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,225</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair Value Measurements as of</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
31, 2022</b></span></p>


<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zmHu3a3OQ26c" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z5PTqsJi0jad" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zkDLZOyMUWCb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zrrRyAbSdmol" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--WarrantLiabilities_i02I_maLFVDzwLw_zowQ4vO09hL" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 36%; text-align: left">Warrant liabilities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,234,384</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0710">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0711">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,234,384</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DerivativeLiabilitiesCurrent_i02I_maLFVDzwLw_zbXoob1TDTJ8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Derivative liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,735,700</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0715">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0716">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,735,700</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LiabilitiesFairValueDisclosure_i02I_mtLFVDzwLw_zhUioZYfLqQe" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Total Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,970,084</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0720">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0721">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,970,084</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p id="xdx_8A7_zUdX8zDeETDg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_890_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zYMTrkf1t5pf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows the valuation methodology and unobservable inputs for Level 3 assets and liabilities measured at fair value on
recurring basis as of December 31, 2023 and December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><span id="xdx_8BF_zcWaoIpk4QNi" style="display: none">Schedule of Unobservable Inputs for Level 3 Assets and Liabilities</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Fair Value As of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Fair Value</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">Valuation</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">Unobservable</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Methodology</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Inputs</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 20%; text-align: justify">Warrant liabilities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--WarrantLiabilities_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zshO0OaVLGL4" style="width: 13%; text-align: right" title="Warrant liabilities">8,225</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_ecustom--WarrantLiabilities_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zk5YFe91k1u1" style="width: 13%; text-align: right" title="Warrant liabilities">2,234,384</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 19%; text-align: center">Monte Carlo model</td><td style="width: 2%">&#160;</td>
    <td style="width: 23%; text-align: center">Project simulated cash flows</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Derivative liabilities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zljGNFsh3REk" style="text-align: right" title="Derivative liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0730">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z5BnVDl7ijHc" style="text-align: right" title="Derivative liabilities">1,735,700</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">Monte Carlo model</td><td>&#160;</td>
    <td style="text-align: center">Project simulated cash flows</td></tr>
  </table>
<p id="xdx_8A9_zjTAxKrFNlr2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no transfers between any of the levels during the years ended December 31, 2023 and year ended December 31, 2022. In addition
to assets and liabilities that are recorded at fair value on a recurring basis, the Company&#8217;s assets and liabilities are also
subject to nonrecurring fair value measurements. As of December 31, 2023 and 2022, the Company had no assets that were measured on a
nonrecurring basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zDXVnNedKCu8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_863_zD1TKYEnGW6l">Basic
and Diluted Net Income (Loss) per Share</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Earnings
or loss per share (&#8220;EPS&#8221;) is computed by dividing net income (loss), net of preferred stock dividends, by the weighted average
number of shares of common stock outstanding during the period. Diluted EPS is computed by dividing net income (loss) by the weighted
average of all potentially dilutive shares of common stock that were outstanding during the periods presented. Preferred stock dividends
(not declared or paid) were $<span id="xdx_90B_eus-gaap--DividendsPreferredStock_c20230101__20231231_zmgcGg3rUjO4" title="Preferred stock dividend">0</span> and $<span id="xdx_902_eus-gaap--DividendsPreferredStock_c20220101__20221231_zO9qN9bbbF1d" title="Preferred stock dividend">2,190,102</span> as of December 31, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common
shares outstanding during the period. Diluted net loss per common share is determined using the weighted-average number of common shares
outstanding during the period, adjusted for the dilutive effect of common stock equivalents. In periods when losses are reported, which
is the case for December 31, 2023 and 2022 presented in these financial statements, the weighted-average number of common shares outstanding
excludes common stock equivalents because their inclusion would be anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_894_eus-gaap--ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_zNwURusR6vu2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had the following potentially dilutive common stock equivalents at December 31, 2023 and 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B9_zNje6TLH5oU8" style="display: none">Schedule of Dilutive Common Stock Equivalents</span>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20230101__20231231_z51OT7QLFr38" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20220101__20221231_zWMVb7whmDXe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleSeriesAPreferredStockMember_z2UCsBz9SQg5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Convertible Series A Preferred Stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0742">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">1,013,270</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleSeriesSeedPreferredStockMember_zB4vs5QaziT1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Convertible Series Seed Preferred Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0745">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">230,954</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--OptionMember_zvy1eobwixR5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,319,394</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,319,394</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--PreferredStockMember_z33AI0MMLE5f" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; text-align: left">Pre-Funded Warrants for Convertible Series A Preferred Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0751">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">289,779</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_zIYhQ9G4GrF8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,822,358</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">365,962</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleBridgeDebtMember_zP5fRYEVMiTa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Convertible Bridge Debt</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0757">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">376,653</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zuWn8sTcwH0j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Totals</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,141,752</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,596,012</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>
<p id="xdx_8A5_zViJxKGPpRP9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89D_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zxBv4WY9fsXf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows the calculation of the basic and diluted net loss per share and the effect of preferred stock dividends.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_zqUi5n0z7Kfl" style="display: none">Schedule of Basic and Diluted Net Loss Per Share</span>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20230101__20231231_zX5oRcjTJW1g" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20220101__20221231_zBMbJ08DzJ84" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Numerator</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--NetIncomeLoss_iT_mtNILzQKI_zy8h4Qz1xuO1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(14,626,683</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">(4,780,061</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--PreferredStockDividendsAndOtherAdjustments_zgKkCa9mWffi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Preferred stock dividends</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0768">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(764,893</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zk1oVBBRjz5i" style="vertical-align: bottom; background-color: White">
    <td>&#160;<span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Net income (loss) available to common stockholders</span> </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(14,626,683</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,544,954</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Denominator</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Weighted-average shares of common stock outstanding - basic
    and diluted</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231_znEzxgGfUxea" title="Weighted average shares of common stock outstanding - basic"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231_zbww0nP4YRg1" title="Weighted average shares of common stock outstanding - diluted">3,252,328</span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20220101__20221231_z6Tas7DWLb8e" title="Weighted average shares of common stock outstanding - basic"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20220101__20221231_zmjpPawtofr9" title="Weighted average shares of common stock outstanding - diluted">2,003,322</span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Basic and diluted net loss per share</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_908_eus-gaap--EarningsPerShareBasic_c20230101__20231231_zG5fKt9oFUC8" title="Basic net loss per share"><span id="xdx_905_eus-gaap--EarningsPerShareDiluted_c20230101__20231231_z2RhTCLdmDCb" title="Diluted net loss per share">(4.50</span></span></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_909_eus-gaap--EarningsPerShareBasic_c20220101__20221231_zZJe1K2BfZ76" title="Basic net loss per share"><span id="xdx_90C_eus-gaap--EarningsPerShareDiluted_c20220101__20221231_zds8oPl0kjM3" title="Diluted net loss per share">(2.77</span></span></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  </table>
<p id="xdx_8A4_z0tCcqsbBemd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_84E_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zz4yjkKUeCzk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_861_zFhESh1uvKod">Stock-Based
Compensation</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for all stock-based payments and awards at fair value. The Company recognizes its stock-based compensation
expense using the straight-line method. Compensation cost is not adjusted for estimated forfeitures, but instead is adjusted upon an
actual forfeiture of a stock option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for the granting of stock options to employees and non-employees using the fair value method whereby all awards are
measured at fair value on the date of the grant. The fair value of all employee stock options is expensed over the requisite service
period with a corresponding increase to additional paid-in capital. Upon exercise of stock options, the consideration paid by the option
holder is recorded in additional paid-in capital, while the par value of the shares received is reclassified from additional paid in
capital to common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
payments to non-employees are measured based on the fair value of the equity instrument issued. Compensation expense for non-employee
stock awards is recognized over the requisite service period following the measurement of the fair value on the grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company uses the Black-Scholes option-pricing model to calculate the fair value of stock options. The use of the Black-Scholes option-pricing
model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common
stock consistent with the expected term of the option, risk-free interest rates, the value of the common stock and expected dividend
yield of the common stock. Changes in these assumptions can materially affect the fair value estimate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_eus-gaap--RevenueRecognitionPolicyTextBlock_zQiivN3OJYcj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_868_zdikTs1WOXe1">Revenue
Recognition</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
Inc. specializes in the development, production, and sale of medical neuromodulation devices to healthcare providers primarily located
in the United States. Patented and trademarked neuromodulation devices is the Company&#8217;s major product line. Products are generally
transferred at a point in time (rather than over time). Essentially all the Company&#8217;s revenue is generated from purchase order
contracts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with FASB&#8217;s ASC 606, Revenue from Contracts with Customers, (&#8220;ASC 606&#8221;), the Company recognizes revenue
when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects
to be entitled in exchange for those goods or services, in an amount that reflects the consideration which the Company expects to be
entitled in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within
the scope of ASC 606, it performs the following five steps:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identify
    the contract(s) with a customer&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identify
    the performance obligations in the contract&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determine
    the transaction price&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">allocate
    the transaction price to the performance obligations in the contract&#894; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recognize
    revenue when (or as) the entity satisfies a performance obligation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company applies the five-step model to contracts when it determines that it is probable it will collect substantially all the consideration
it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined
to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that
are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the
amount of the transaction price, after consideration of variability and constraints, if any, that is allocated to the respective performance
obligation when the performance obligation is satisfied.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company estimates credit losses on accounts receivable by estimating expected credit losses over the contractual term of the receivable
using a discounted cash flow method. When developing this estimate of expected credit losses, the Company considers all available information
(past, current, and future) relevant to assessing the collectability of cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company offers a Patient Assistance Program for patients without insurance coverage for IB-Stim. This program extends potential self-pay
discounts for IB-Stim devices, based upon household income and size.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Also,
the Company offers providers an opt-in program to address adequate insurance claim payments on IB-Stim devices. This program may extend
a rebate or invoice credit where the insurance payment and patient responsibility (i.e., deductible, co-payment, and/or co-insurance
amounts required by the Payer) are less than the acquisition cost of the IB-Stim device. The Company recognizes revenue at such a time
that collection of the amount due is assured.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_eus-gaap--DisaggregationOfRevenueTableTextBlock_zX6RXuuRv7o2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table disaggregates the Company&#8217;s revenue based on the customer&#8217;s location by state for the years ended December
31:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zAzVuhoIgill" style="display: none">Schedule of Disaggregation of Revenue</span>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 25%; text-align: left">California</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td id="xdx_987_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--CA_zAnDptrXJjOb" style="width: 20%; font-weight: bold; text-align: right" title="Revenues">601,235</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 25%; text-align: left">Wisconsin</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__stpr--WI_z2SwOYl8cNh9" style="width: 20%; text-align: right" title="Revenues">670,245</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Ohio</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--OH_zDI0OkZvXUch" style="font-weight: bold; text-align: right" title="Revenues">407,632</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">Ohio</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__stpr--OH_zJhs6wESToS2" style="text-align: right" title="Revenues">500,260</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Wisconsin</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--WI_z9ynHKka95Xd" style="font-weight: bold; text-align: right" title="Revenues">292,601</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">California</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__stpr--CA_zRGqfRRI4PZ9" style="text-align: right" title="Revenues">408,645</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Florida</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--FL_z1o4pUWGGbRe" style="font-weight: bold; text-align: right" title="Revenues">186,840</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">Florida</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__stpr--FL_zwbktOHvOlP2" style="text-align: right" title="Revenues">231,480</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Massachusetts</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--MA_zL8Z9URoL8Rf" style="font-weight: bold; text-align: right" title="Revenues">127,300</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">Missouri</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__country--MO_zmIB5JUxFlka" style="text-align: right" title="Revenues">174,980</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">All other states</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__custom--AllOtherStatesMember_zgxis1XpHgTj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Revenues">844,441</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1.5pt">All other states</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__custom--AllOtherStatesMember_zqkBp0QJB9Bd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenues">699,125</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_986_eus-gaap--Revenues_c20230101__20231231_zmLHQlhg1K4a" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Total revenue">2,460,049</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98B_eus-gaap--Revenues_c20220101__20221231_zVi8nS1HELrg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total revenue">2,684,735</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p id="xdx_8A6_z18moQNeosPi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following economic factors affect the nature, amount, timing, and uncertainty of the Company&#8217;s revenue and cash flows as indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Type
of customer:</b> Based on dollar amounts of revenue, essentially all of the goods sold by the Company are sold to healthcare customers
including hospitals and clinics. Sales to healthcare customers lack seasonality and have a mild correlation with economic cycles.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Geographical
location of customers:</b> Sales to customers located within the United States represent essentially all of the Company&#8217;s sales.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Type
of contract:</b> Sales contracts consist of purchase order contracts that tend to be short-term (i.e., less than or equal to one year
in duration).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Company&#8217;s
Performance Obligations with Customers:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Timing
of Satisfaction</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company typically satisfies its performance obligations as the goods are delivered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goods
that are shipped to customers are typically shipped FOB shipping point with freight prepaid by the Company. As such, ownership of goods
in transit transfer to the customer when shipped and the customer bears the associated risks (e.g., loss, damage, delay). </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shipping
and handling costs are recorded as general and administrative expenses in the Statement of Operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Significant
Payment Terms</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment
for goods sold by the Company is typically due after an invoice is sent to the customer, within 30 days. However, other payment terms
are frequently negotiated with customers ranging from due upon receipt to due within 90 days. Some payment terms may call for payment
only after the healthcare provider receives their insurance reimbursement. Invoices for goods are typically sent to customers within
three calendar days of shipment. The Company does not offer discounts if the customer pays some or all of an invoiced amount prior to
the due date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None
of the Company&#8217;s contracts have a significant financing component.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Nature</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical
devices that the Company contracts to sell and transfer to customers are manufactured by one specific third-party manufacturer. The manufacturer
is located within the state of Indiana. In no case does the Company act as an agent (i.e., the Company does not provide a service of
arranging for another party to transfer goods to the customer).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Returns,
Refunds, etc.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Orders
may not be cancelled after shipment. Customers may return devices within 10 days of delivery if the goods are found to be defective,
nonconforming, or otherwise do not meet the stated technical specifications. At the option of the customer, the Company shall either:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Refund
    the price paid for any defective or nonconforming products.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supply
    and deliver to the customer replacement conforming products.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reimburse
    the customer for the cost of repairing any defective or nonconforming products.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the time revenue is recognized, the Company estimates expected returns and excludes those amounts from revenue. The Company also maintains
appropriate accounts to reflect the effects of expected returns on the Company&#8217;s financial position and periodically adjusts those
accounts to reflect its actual return experience. Historically, returns have been immaterial, and the Company currently does not provide
a provision for this liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_844_eus-gaap--ExtendedProductWarrantyPolicy_zsmzImPWWnw7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86D_zcAlCuDLdeMh">Warranties</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
most cases, goods that customers purchase from the Company are covered by manufacturers&#8217; warranties. The Company does not sell
warranties separately.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
manufacturer guarantees the product for the period up to the expiration date printed on the device&#8217;s label or twelve months from
the date of purchase, whichever comes first. The guarantee applies to flaws of material and workmanship. The Company&#8217;s warranties
provide customers with assurance that purchased devices comply with published specifications, inspection standards, and workmanship.
At the time revenue is recognized, the Company estimates the cost of expected future warranty claims but does not exclude any amounts
from revenue. The Company maintains appropriate accounts to reflect the effects of expected future warranty claims on the Company&#8217;s
financial position and periodically adjusts those accounts to reflect its actual warranty claim experience. Historically, warranty claims
have been immaterial, and the Company currently does not provide a provision for this liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company typically satisfies its performance obligations for goods at a point in time. In most cases, goods are shipped by common carrier
to customers under &#8220;FOB Shipping Point&#8221; terms. As such, customers typically obtain control of the goods upon shipment. The
Company&#8217;s management exercises judgment in determining when performance obligations for goods have been satisfied. In making such
judgments, management typically relies on shipping information obtained from common carriers to evaluate when the customer has obtained
control of the goods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s contracts with customers typically do not involve variable consideration. The information that the Company uses to determine
the transaction price for a contract is similar to the information that the Company&#8217;s management uses in establishing the prices
of goods to be sold.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_843_eus-gaap--LesseeLeasesPolicyTextBlock_z4OfpCedWO8j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_860_zDo0Qt7M55Dk">Leases</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with Accounting Standards Updated (&#8220;ASU&#8221;) No. 2016-02, <i>Leases (Topic 842)</i> (&#8220;ASU 2016-02&#8221; or
&#8220;ASC 842&#8221;), at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based
on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the balance
sheet as right-of-use assets and current and non-current lease liabilities, as applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
lease liabilities and their corresponding right-of-use assets are initially recorded based on the present value of lease payments over
the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received.
The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental
borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis
the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. Prospectively, the Company
will adjust the right-of-use assets for straight-line rent expense, or any incentives received and remeasure the lease liability at the
net present value using the same incremental borrowing rate that was in effect as of the lease commencement or transition date. The Company
has elected not to recognize leases with an original term of one year or less on the balance sheet. The Company typically only includes
an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in the Company&#8217;s assessment
unless there is reasonable certainty that the Company will renew.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assumptions
made by the Company at the commencement date are re-evaluated upon occurrence of certain events, including a lease modification. A lease
modification results in a separate contract when the modification grants the lessee an additional right of use not included in the original
lease and when lease payments increase commensurate with the standalone price for the additional right of use. When a lease modification
results in a separate contract, it is accounted for in the same manner as a new lease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entities
may elect not to separate lease and non-lease components. The Company has elected to account for lease and non-lease components together
as a single lease component for all underlying assets and allocate all the contract consideration to the lease component only.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>


<p id="xdx_844_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zQnGpcSL7M39" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86F_zBrB3zgiolB3">Impairment
of Long-Lived Assets</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-lived
assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset group may
not be recoverable. If events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable,
we compare the carrying amount of the asset group to future undiscounted net cash flows, excluding interest costs, expected to be generated
by the asset group and their ultimate disposition. If the sum of the undiscounted cash flows is less than the carrying value, the impairment
to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the fair value of the asset group.
Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zx8dJc3KAyve" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_864_zpHzMrGs96Kj">Concentrations
of Credit Risk</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s business activity consists of the sale of medical neuromodulation devices to doctors, clinics, and hospitals across the
country.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Receivables
consist of unsecured amounts due from customers. As of December 31, 2023, accounts receivable from four customers with balances due
in excess of <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zHt7e9wt7Xlf" title="Risk percentage">10</span>%
of total accounts receivable were approximately <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z1sgDO6lIT0f" title="Risk percentage">28</span>%, <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zOpddKc3C56k" title="Risk percentage">28</span>%, <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerThreeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_ztyL1NBusNqe" title="Risk percentage">17</span>%
and <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerFourMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zn5iv9oSMJNe" title="Risk percentage">11</span>%, respectively. As of December 31, 2022, accounts receivable from three customers with balances due in excess of <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_znlKTOeeo93f" title="Risk percentage">10</span>%
of total accounts receivable was <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zdf0D1ndQga7" title="Risk percentage">23</span>%, <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zJM0GLgbRMti" title="Risk percentage">15</span>%,
and <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerThreeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zFGIT1ta9kQ" title="Risk percentage">12</span>%,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below sets forth the Company&#8217;s customers that accounted for greater than <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueProductLineMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--RevenueFromRightsConcentrationRiskMember_zSykzU9jrsr5" title="Risk percentage"><span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueProductLineMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--RevenueFromRightsConcentrationRiskMember_z8AOKkMvCXI4" title="Risk percentage">10</span></span>% of its revenues for the years ended December
31, 2023 and 2022, respectively.</span></p>

<p id="xdx_89F_eus-gaap--ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock_zK2CTGYbN3Sb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zCjfnL75gsbi" style="display: none">Schedule of Customers Accounted Revenues</span>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">Percentage of </td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">Percentage of </td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><b>Sales</b></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><b>Sales</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: left">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: left">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left">Hospital A</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--MajorCustomersAxis__custom--HospitalAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z8DYsvEFfc62" style="width: 15%; font-weight: bold; text-align: right" title="Revenue">452,680</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 15%; text-align: center"><span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--HospitalAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zOU9fy3LjPDl" title="Risk percentage">18</span>%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20221231__srt--MajorCustomersAxis__custom--HospitalAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z6VZ0fIq4lbg" style="width: 15%; text-align: right" title="Revenue">355,613</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 15%; text-align: center"><span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--HospitalAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zGUAamau5Wg7" title="Risk percentage">13</span>%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Hospital B</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--MajorCustomersAxis__custom--HospitalBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zWtmDNKLOmZ8" style="font-weight: bold; text-align: right" title="Revenue">382,082</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--HospitalBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zxGlw7LXQHJh" title="Risk percentage">16</span>%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20221231__srt--MajorCustomersAxis__custom--HospitalBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zkkJm06MFCPb" style="text-align: right" title="Revenue">484,900</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--HospitalBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z8N4M2GNQ1Cg" title="Risk percentage">18</span>%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Hospital C</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--MajorCustomersAxis__custom--HospitalCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zoNS5KYKLCJ8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Revenue">274,581</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--HospitalCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_ztiAPuHBO464" title="Risk percentage">11</span>%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20221231__srt--MajorCustomersAxis__custom--HospitalCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zAa3xtGHtem9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue">554,325</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--HospitalCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zSTXRgI9fhP9" title="Risk percentage">21</span>%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--MajorCustomersAxis__custom--HospitalMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zPVkIhkG8i96" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Revenue">1,109,343</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--HospitalMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zAj2qbvuPNlj" title="Risk percentage">45</span>%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20221231__srt--MajorCustomersAxis__custom--HospitalMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zdpQH4bigBYb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue">1,394,838</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--HospitalMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zx1dh6xGR3J3" title="Risk percentage">52</span>%</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p id="xdx_8AE_zG8dOe1t08F5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, the Company&#8217;s bank balances may exceed the FDIC limit of $<span id="xdx_909_eus-gaap--CashFDICInsuredAmount_iI_c20231231_znBb1ljAlu7f" title="Cash, FDIC insured amount">250,000</span>; however, management does not feel that this has
a material impact on the financial condition. At December 31, 2023 and 2022, the Company didn&#8217;t have any uninsured cash balance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_848_ecustom--GoingConcernPolicyTextBlock_zXajKJKS6Kod" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_861_zZ5dSeb3IfU">Going
Concern</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have incurred losses since inception and have funded our operations primarily with a combination of sales, debt, and the sale of capital
stock. As of December 31, 2023, we had a stockholders&#8217; deficit totaling $<span id="xdx_903_eus-gaap--StockholdersEquity_iNI_di_c20231231_zUPTVUFQnusl" title="Stockholders deficit">1,403,241</span>. At December 31, 2023, we had short-term outstanding
borrowings of approximately $<span id="xdx_905_eus-gaap--ShortTermBorrowings_iI_c20231231_zGK76rC9Za7g" title="Short term borrowing">148,062</span>. As of December 31, 2023, we had cash of $<span id="xdx_90F_eus-gaap--Cash_iI_c20231231_zMSBuQjxhUv2" title="Cash">78,560</span> and a working capital deficit of $<span id="xdx_900_ecustom--WorkingCapitalDeficit_iI_c20231231_zojtMzfW66Z2" title="Working capital">1,643,058</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 9, 2023, the Company consummated its initial public offering, conducted on a firm commitment basis, pursuant to which it sold <span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230809__20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zes7IYSmLHEe" title="Number of shares issued in transaction">1,098,667</span>
shares of its common stock at a price of $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_c20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zMs9Emp2MZu3" title="Share issued price per share">6.00</span>
per share, resulting in gross proceeds to the Company of $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230809__20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zduBimLlqvCd" title="Proceeds from issuance of common stock">6,592,002</span>.
Net proceeds to the Company, after deducting underwriting discounts and commissions, 2022 deferred offering costs totaling $<span id="xdx_908_eus-gaap--DeferredOfferingCosts_iI_c20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zGr67oXbOBul" title="Deferred offering costs">736,736</span>
and offering expenses paid by the Company, were $<span id="xdx_906_eus-gaap--PaymentsOfStockIssuanceCosts_c20230811__20230811__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSo5An9DMAvc" title="Payment fees">4,110,721</span>.
All shares sold in our IPO were registered pursuant to a registration statement on Form S-1 (File No. 333- 269179), as amended,
declared effective by the SEC on August 9, 2023. Alexander Capital L.P. acted as sole book-running manager for the offering and
Spartan Capital Securities, LLC acted as co-manager for the offering. <span style="background-color: white">The underwriters did not
exercise their option to purchase up to an additional </span><span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230809__20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKV7ofq1xkai" title="Purchase of common shares">164,801</span> <span style="background-color: white">shares
of common stock.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future capital requirements will depend upon many factors, including progress with developing, manufacturing, and marketing our
technologies, the time and costs involved in preparing, filing, prosecuting, maintaining, and enforcing patent claims and other
proprietary rights, our ability to establish collaborative arrangements, marketing activities and competing technological and market
developments, including regulatory changes and overall economic conditions in our target markets. Our ability to generate revenue
and achieve profitability requires us to successfully market and secure purchase orders for our products from customers currently
identified in our sales pipeline and to new customers as well. The primary activity that will drive all customers and revenues is
the adoption of insurance coverage by commercial insurance carriers nationally which is a top priority of the Company. These
activities, including our planned research and development efforts, will require significant uses of working capital through the
rest of 2024 and beyond. Based on our current operating plans, we believe that our existing cash at the time of this filing will
only be sufficient to meet our anticipated operating needs through the end of 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
evaluates whether there are conditions or events that raise substantial doubt about the Company&#8217;s ability to continue as a going
concern for a period of one year from the date the financial statements are issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, the Company has experienced operating losses and negative cash flows from operations. Management believes that increased sales
and acceptance of their product by insurance providers will allow the Company to achieve profitability in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
the Company believes in the viability of its strategy to further implement its business plan and generate sufficient revenues and in
its ability to raise additional funds by way of a public or private offering of its debt or equity securities, there can be no
assurance that it will be able to do so on reasonable terms, or at all. The ability of the Company to continue as a going concern is
dependent upon its ability to further implement its business plan and generate sufficient revenues and its ability to raise
additional funds by way of a public or private offering. Neither future cash generated from operating activities, nor
management&#8217;s contingency plans to mitigate the risk and extend cash resources through the evaluation period, are considered
probable. As a result, substantial doubt is deemed to exist about the Company&#8217;s ability to continue as a going concern. As we
continue to incur losses, our transition to profitability is dependent upon achieving a level of revenues adequate to support its
cost structure. We may never achieve profitability, and unless and until doing so, we intend to fund future operations through
additional dilutive or nondilutive financing. There can be no assurances, however, that additional funding will be available on
terms acceptable to us, if at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the
amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zFcm1uYaKtoj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_863_zu6wtfWyMFre">Recently Adopted Accounting Pronouncements</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2016, the FASB issued ASU 2016-13, Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial
Instruments, which requires measurement and recognition of expected credit losses for financial assets held and requires enhanced disclosures
regarding significant estimates and judgments used in estimating credit losses. In November 2019, the FASB issued ASU 2019-10, Financial
Instruments &#8211; Credit Losses (Topic 326), Derivatives and Hedging (Topic 815) and Leases (Topic 842): Effective Dates, which amended
the effective date of ASU 2016-13. Public business entities meeting the definition of an SEC filer, excluding entities eligible to be
a Smaller Reporting Company (&#8220;SRC&#8221;) as defined by the SEC, are required to adopt the standard for fiscal years beginning
after December 15, 2019, including interim periods within those fiscal years. All other entities are required to adopt the standard for
fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company meets the definition
of an SRC and therefore the standard was adopted as of January 1, 2023. The adoption of this guidance did not have a material impact
on the Company&#8217;s financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="text-decoration: underline">Recently Issued Accounting Pronouncements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">In December 2023, the FASB issued ASU 2023-19,
Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires the enhancement of income tax disclosures to
provide better insight into how an entity&#8217;s operations and related tax risks, planning and opportunities affect its tax rate
and prospects for future cash flows. The enhanced disclosures require (i) specific categories in a tabular rate reconciliation
including both amounts and percentages and (ii) additional information for reconciling items and income tax paid that meet a
quantitative threshold. Public business entities are required to adopt the standard for annual periods beginning after December 15,
2024. All other entities are required to adopt the standard for annual periods beginning after December 15, 2025. The adoption of
the standard is not expected to have a material impact on the Company&#8217;s financial statements.</p>
<p id="xdx_858_z0Ouvom4LnTj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823803467520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_z4b3bNdgdusd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>3.
<span><span id="xdx_827_z27BacDLLdMl">Related Party Transactions</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has two demand notes receivable from shareholders related to the sale of common stock on January 1, 2016. Both notes&#8217; initial
balances were $<span id="xdx_902_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholdersOneAndTwoMember_z8BtQJFbJrS4" title="Loan Receivable">506,400</span>, with interest calculated monthly based on applicable federal rates. No payments have been received on the notes.
Since repayment is not assured, the Company provided an allowance for the entire balance of principal and interest as of December 31,
2019. The current allowance is $<span id="xdx_90B_ecustom--AllowanceForInterestReceivableCurrent_iI_c20231231_zJnTyvcFx3r3" title="Allowance for interest receivable current">1,154,541</span> as of December 31, 2023. The current loan balances are as follows:</span></p>

<p id="xdx_896_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zqWIyjUVS18e" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8B5_z8l6ORobyzp1" style="display: none">Schedule of Related Party Transactions</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Loan</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Interest</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Interest</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Receivable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Receivable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Income</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Shareholder 1</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderOneMember_zNjeGS834uJ1" style="width: 14%; text-align: right" title="Loan Receivable">506,400</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--InterestReceivableCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderOneMember_zAr7UCbfco9d" style="width: 14%; text-align: right" title="Interest Receivable">70,938</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--InterestIncomeGrossCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderOneMember_zjUqYewZQEKe" style="width: 14%; text-align: right" title="Interest Income">23,867</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Shareholder 2</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderTwoMember_zUaBQuPkUcs4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Loan Receivable">506,400</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--InterestReceivableCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderTwoMember_zbnY9eWJLBr5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest Receivable">70,803</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_ecustom--InterestIncomeGrossCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderTwoMember_zW2gG27f91Bk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest Income">23,867</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zYEz6pYsAt8" style="text-align: right" title="Loan Receivable">1,012,800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--InterestReceivableCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zV6zGTWgKfwd" style="text-align: right" title="Interest Receivable">141,741</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--InterestIncomeGrossCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zuqvBNoFFs89" style="text-align: right" title="Interest Income">47,734</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Allowance for Collection Risk</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AllowanceForNotesAndLoansReceivableCurrent_iNI_di_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zVsT3J8XqlA7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Allowance for collection risk, loan receivable">(1,012,800</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--InterestReceivableCurrent_iNI_di_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z9RIPUINte28" style="border-bottom: Black 1.5pt solid; text-align: right" title="Allowance for collection risk, interest receivable">(141,741</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_ecustom--AllowanceForInterestIncomeCurrent_iNI_di_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z5Uz45E9BYme" style="border-bottom: Black 1.5pt solid; text-align: right" title="Allowance for collection risk, interest income">(47,734</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Net Balance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98E_eus-gaap--NotesAndLoansReceivableNetCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zwvDYzL2T28i" style="border-bottom: Black 1.5pt solid; text-align: right" title="Loan Receivable"><span style="-sec-ix-hidden: xdx2ixbrl0946">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98E_eus-gaap--InterestReceivable_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zGC81YvfHKMf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest Receivable"><span style="-sec-ix-hidden: xdx2ixbrl0948">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98D_ecustom--InterestIncomeCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zbLdMijari3b" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest Income"><span style="-sec-ix-hidden: xdx2ixbrl0950">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Loan</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Interest</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Interest</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Receivable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Receivable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Income</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Shareholder 1</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderOneMember_zsr2M5KfUG5h" style="width: 14%; text-align: right" title="Loan Receivable">506,400</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--InterestReceivableCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderOneMember_z6I6OQcmRgol" style="width: 14%; text-align: right" title="Interest Receivable">47,071</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_ecustom--InterestIncomeGrossCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderOneMember_zGimIoPsSCJ7" style="width: 14%; text-align: right" title="Interest Income">11,523</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Shareholder 2</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderTwoMember_zxtDmMfOnRn5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Loan Receivable">506,400</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--InterestReceivableCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderTwoMember_za9yIQZuCwQb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest Receivable">46,936</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_ecustom--InterestIncomeGrossCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderTwoMember_zrl9RjcqPpS3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest Income">11,523</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z1NAQRx3RRtl" style="text-align: right" title="Loan Receivable">1,012,800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--InterestReceivableCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_znAiqJpIor4" style="text-align: right" title="Interest Receivable">94,007</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--InterestIncomeGrossCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z2U5TqiSdRQe" style="text-align: right" title="Interest Income">23,046</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Allowance for Collection Risk</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AllowanceForNotesAndLoansReceivableCurrent_iNI_di_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zSgT36uVkLzc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Allowance for collection risk, loan receivable">(1,012,800</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--InterestReceivableCurrent_iNI_di_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zjME8N49EpH6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Allowance for collection risk, interest receivable">(94,007</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_ecustom--AllowanceForInterestIncomeCurrent_iNI_di_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_ztt179JuzVad" style="border-bottom: Black 1.5pt solid; text-align: right" title="Allowance for collection risk, interest income">(23,046</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Net Balance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98B_eus-gaap--NotesAndLoansReceivableNetCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zEGLcV60i0Oi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Loan Receivable"><span style="-sec-ix-hidden: xdx2ixbrl0976">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98D_eus-gaap--InterestReceivable_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zACWZJZhkB3c" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest Receivable"><span style="-sec-ix-hidden: xdx2ixbrl0978">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_982_ecustom--InterestIncomeCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zASJ0ABNa47e" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest Income"><span style="-sec-ix-hidden: xdx2ixbrl0980">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>
<p id="xdx_8A4_ztT2hNMVbB7a" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has loans payable to shareholders related to funding needs for operations. The current loan details for all related party loans
are as follows:</span></p>

<p id="xdx_894_ecustom--ScheduleOfRelatedPartyLoansTableTextBlock_zWYBz5E1QISc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8B8_z9ZoAHflmhHk" style="display: none">Schedule of Related Party Loans payable to shareholder</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Interest &amp;</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Interest</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Loan</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Service Fee</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Interest</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Due Date</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Rate</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Balance</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accrued</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Paid</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%; text-align: left">Shareholder 1</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--DebtInstrumentMaturityDateDescription_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderMember_zLmrcLwwzZT9" title="Due date">June, 2019</span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderMember_zdKQbLO41w0a" title="Debt instrument percentage">15.00</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--LoansPayable_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderMember_ztyIiCuOam1d" style="width: 10%; text-align: right" title="Loan payable"><span style="-sec-ix-hidden: xdx2ixbrl0988">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_ecustom--InterestAndServiceFeeAccrued_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderMember_zkwUyLgjw5ic" style="width: 10%; text-align: right" title="Interest payable"><span style="-sec-ix-hidden: xdx2ixbrl0990">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--InterestPaid_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderMember_zUEbQib1hql4" style="width: 10%; text-align: right" title="Interest payable">10,047</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Shareholder 1</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--DebtInstrumentMaturityDateDescription_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_z6UYuTOdv2T7" title="Due date">June, 2019</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_zDuwTD5kyGze" title="Debt instrument percentage">15.00</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--LoansPayable_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_zPaik7XCGSSf" style="text-align: right" title="Loan payable"><span style="-sec-ix-hidden: xdx2ixbrl0998">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--InterestAndServiceFeeAccrued_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_zwzShwpllCt5" style="text-align: right" title="Interest payable"><span style="-sec-ix-hidden: xdx2ixbrl1000">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--InterestPaid_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_ztf8UkLpAEc1" style="text-align: right" title="Interest payable">27,056</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other Convertibles</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--DebtInstrumentMaturityDateDescription_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zPnt1LgV7VAh" title="Due date">Various</span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zLPY1MG1DDU3" title="Debt instrument percentage">5.00</span></td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--LoansPayable_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zchp3VXWcIvd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest payable"><span style="-sec-ix-hidden: xdx2ixbrl1008">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_ecustom--InterestAndServiceFeeAccrued_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zOxnLZn5lmwh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest payable">66,648</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--InterestPaid_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zlYzcLAKuAU7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest payable"><span style="-sec-ix-hidden: xdx2ixbrl1012">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Total</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--LoansPayable_iI_c20231231_zYL0tJxjI3ih" style="border-bottom: Black 1.5pt solid; text-align: right" title="Loan payable"><span style="-sec-ix-hidden: xdx2ixbrl1014">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98E_ecustom--InterestAndServiceFeeAccrued_iI_c20231231_zEsgLv7iBl9j" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest payable">66,648</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_982_eus-gaap--InterestPaid_c20230101__20231231_z3n7s4J8fFB" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest payable">37,103</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Interest &amp;</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Interest</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Loan</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Service Fee</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Interest</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Due Date</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Rate</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Balance</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accrued</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Paid</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%; text-align: left">Shareholder 1</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--DebtInstrumentMaturityDateDescription_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--ShareHolderMember_zg9pF0o9AWS1" title="Due date">June, 2019</span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><span id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20221231__us-gaap--DebtInstrumentAxis__custom--ShareHolderMember_zMFYZMyHe3v5" title="Debt instrument percentage">15.00</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--LoansPayable_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--ShareHolderMember_zwWXBFlgBprk" style="width: 10%; text-align: right" title="Loan payable">20,051</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--InterestAndServiceFeeAccrued_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--ShareHolderMember_zlY1frgGimk4" style="width: 10%; text-align: right" title="Interest and service fee accrued">8,161</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--InterestPaid_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--ShareHolderMember_zgKxFVTIYmt4" style="width: 10%; text-align: right" title="Interest payable"><span style="-sec-ix-hidden: xdx2ixbrl1028">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Shareholder 1</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--DebtInstrumentMaturityDateDescription_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_z7K6IKNGNO3f" title="Due date">June, 2019</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20221231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_zBlYt2yMTJ48" title="Debt instrument percentage">15.00</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--LoansPayable_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_zl1hWiioUS49" style="text-align: right" title="Loan payable">38,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--InterestAndServiceFeeAccrued_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_zArwiydQevl6" style="text-align: right" title="Interest and service fee accrued">23,481</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--InterestPaid_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_zYe1fTJeAwyg" style="text-align: right" title="Interest payable"><span style="-sec-ix-hidden: xdx2ixbrl1038">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other Convertibles</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--DebtInstrumentMaturityDateDescription_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zSBIQTQfuLCg" title="Due date">Various</span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20221231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zpfbQRoNeyk3" title="Debt instrument percentage">5.00</span></td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--LoansPayable_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zTlga8JpcJl9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest payable"><span style="-sec-ix-hidden: xdx2ixbrl1044">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_ecustom--InterestAndServiceFeeAccrued_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_z90rDfXZ7UGe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest and service fee accrued">66,648</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--InterestPaid_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zBsDBBqJJqX9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest payable"><span style="-sec-ix-hidden: xdx2ixbrl1048">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Total</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_982_eus-gaap--LoansPayable_iI_c20221231_zHcLjkkKEjAb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Loan payable">58,051</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98C_ecustom--InterestAndServiceFeeAccrued_iI_c20221231_zHVxGTsufhVd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest payable">98,290</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_983_eus-gaap--InterestPaid_c20220101__20221231_zOs1DvDDPMqe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest payable"><span style="-sec-ix-hidden: xdx2ixbrl1054">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>
<p id="xdx_8AD_zNIjMHVU5Wwa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Bradley Mitch Watkins, Director, provided certain sales, marketing and commercialization consulting services to the Company prior to his
appointment to the Board of Directors. For the years ended December 31, 2023 and 2022, the Company paid Mr. Watkins $<span id="xdx_90C_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20230101__20231231__srt--TitleOfIndividualAxis__custom--MrWatkinsMember_z7AGuBQFAHO1" title="Related party transaction amounts">11,083</span> and
$<span id="xdx_905_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20220101__20221231__srt--TitleOfIndividualAxis__custom--MrWatkinsMember_z65mqWDJ9A3d" title="Related party transaction amounts">3,523</span>, respectively. No amounts were owed to Mr. Watkins as of December 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s former Chief Financial Officer is contracted for services through a third-party public accounting firm. He is the firm&#8217;s
managing partner and majority shareholder. The firm is engaged by the Company to provide accounting and tax services on a continuous
basis. Fees paid for services were $<span id="xdx_906_eus-gaap--PaymentsForFees_c20230101__20231231__srt--TitleOfIndividualAxis__custom--MrSealeMember_zhjJ53Wz5hxg" title="Payments for fees">312,803</span> and $<span id="xdx_90D_eus-gaap--PaymentsForFees_c20220101__20221231__srt--TitleOfIndividualAxis__custom--MrSealeMember_z2AvaPk195M6" title="Payments for fees">116,542</span> for the years ended December 31, 2023 and 2022, respectively. The Company owed
RBSK for open invoices of $<span id="xdx_900_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_c20231231__srt--TitleOfIndividualAxis__custom--MrSealeMember_z9X7hyR4a0o" title="Accounts payable">84,279</span> and $<span id="xdx_903_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_c20221231__srt--TitleOfIndividualAxis__custom--MrSealeMember_znMsRxC62bik" title="Accounts payable">68,142</span> that are included in accounts payable as of December 31, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823800638144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zF17IdNShTAb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4.
<span id="xdx_826_z1ddV1dKNutk">Property and Equipment</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_898_eus-gaap--PropertyPlantAndEquipmentTextBlock_zguBbBQHPIWi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment, net consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_zePKoEMzzgeh" style="display: none">Schedule of Property And Equipment</span>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20231231_zoUeCkXV1L2k" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20221231_zAgqC9cPGbKf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zbxSKBFBSOh2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Machinery and equipment </td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">282,181</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">282,181</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zdkx0YCHKhQ9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Furniture and fixtures </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">96,768</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">87,148</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zUhyHyzfSund" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Computer hardware </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36,613</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,452</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zmHgNTK87a9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Leasehold improvements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,064</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,064</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzDOd_zddlUWZrSspl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Total property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">436,626</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">405,845</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzDOd_zUnCInTIaywh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(348,074</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(317,834</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzDOd_z5wE7aUzCJF4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Property and equipment, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">88,552</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">88,011</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>
<p id="xdx_8AC_z1Bmw1qI1eie" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
expense was $<span id="xdx_907_eus-gaap--Depreciation_c20230101__20231231_zGLbNuXWEs23" title="Depreciation expense">30,240</span> and $<span id="xdx_909_eus-gaap--Depreciation_c20220101__20221231_zderGWo0iL79" title="Depreciation expense">30,920</span> for the years ended December 31, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823800665392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets</a></td>
<td class="text"><p id="xdx_800_eus-gaap--IntangibleAssetsDisclosureTextBlock_zfZcXInclVuj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.
<span id="xdx_82D_zRJnBmqYISka">Intangible Assets</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89A_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zD03jdz2fjR1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets, net consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_z35rKqZHVCC4" style="display: none">Schedule of Intangible Assets</span>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20231231_zE5N7uh8RSrg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20221231_zrjV3ucEDmJk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwareImplementationMember_zo4cyPJFQBYf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Software Implementation </td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">49,815</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">49,815</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z0H2p6hAGYl3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Patents </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32,463</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32,463</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zM2CejhHnq33" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Trademark </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zUyhI90nG0O5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Licenses </td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1111">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_maFLIANzh0b_zz55gQdRG0qh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Total intangible assets </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">133,278</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">92,278</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_msFLIANzh0b_zJkYwCTbzNv8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Less: accumulated amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(25,205</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(14,720</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_mtFLIANzh0b_z8Ukw9YsX001" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Intangible assets, net </td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">108,073</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">77,558</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>
<p id="xdx_8A1_zOzwTMmkQakd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
expense was $<span id="xdx_907_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20231231_z2ZnjCpobEul" title="Amortization expense">10,485</span> and $<span id="xdx_90C_eus-gaap--AmortizationOfIntangibleAssets_c20220101__20221231_zC5v6fBBI2oa" title="Amortization expense">6,213</span> for the years ended December 31, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350-30/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823800382512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><p id="xdx_804_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_z4OCsv82yKCb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6.
<span id="xdx_82B_zcvbo45c4x5c">Accrued Expenses</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zbJ7IyG2Sda6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
expenses consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span><span id="xdx_8B1_zPhMWXUSqlO6" style="display: none">Schedule of Accrued Expenses</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20231231_zDSqQEtsenai" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20221231_z7de2MycamP3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_ecustom--AccruedCompensationAndBenefitsCurrent_iI_maALCz2hn_z2TNu5bnhvf4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Compensation and benefits</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">333,477</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">539,558</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--UnderwriterFees_iI_maALCz2hn_z45JncJLH3w6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Underwriter fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1133">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">88,259</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--InterestPayableCurrent_iI_maALCz2hn_zza25uYKYpgi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">66,648</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">173,826</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--RelatedPartyInterestPayableCurrent_iI_maALCz2hn_zWTl8aaECLO5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Related party interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1139">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">31,642</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccrualForTaxesOtherThanIncomeTaxesCurrent_iI_maALCz2hn_zONABGuKRwcc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">963</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">777</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>


  <tr id="xdx_40A_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCz2hn_zdp6dpeqfAH2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Total accrued expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">401,088</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">834,062</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>
<p id="xdx_8AE_zZZaB8IwTJZa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823800555856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Notes Payable</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--DebtDisclosureTextBlock_zNWKjMjJOzwg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7.
<span id="xdx_82B_zF2DyNRZfIja">Notes Payable</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 15, 2023, The Company signed a note with Exchange Listing, LLC in the amount of $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_c20230215__dei--LegalEntityAxis__custom--ExchangeListingLLCMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zEytrpZtMVa" title="Promissory note">52,600</span>.
The note carried an interest rate of <span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20230215__dei--LegalEntityAxis__custom--ExchangeListingLLCMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zvkHO1vzwtr9" title="Interest rate">1</span>%.
The note shall be paid on the earlier of (i) three months or (ii) the Company receiving financing in the minimum of $<span id="xdx_905_eus-gaap--NotesPayable_iI_c20230215__dei--LegalEntityAxis__custom--ExchangeListingLLCMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zd42GigdxUUi" title="Promissory note">3,000,000</span>.
 In August 2023, the Company used proceeds from the initial public offering to pay the note back in full, including interest, in
the amount of $<span id="xdx_900_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pp2d_c20230831__20230831__dei--LegalEntityAxis__custom--ExchangeListingLLCMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zFfyeyXTLDLg" title="Proceeds from issuance of ipo">52,858</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company borrowed $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_c20211216__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zSDEKwnTbNak" title="Debt instrument face amount">250,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
December 16, 2021, from Channel Partners Capital. The note called for 65 weekly payments of $<span id="xdx_904_eus-gaap--DebtInstrumentPeriodicPayment_pp2d_c20230316__20230316__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zw97kZ5dDyMk" title="Debt instrument, periodic payment">4,923 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">with
the final payment scheduled for March 16, 2023. The note&#8217;s interest rate computes to a nominal rate of <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230316__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_znXMfdp5KGKg" title="Interest rate">40.9</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%.
The principal outstanding at January 1, 2022 was $<span id="xdx_90A_eus-gaap--LongTermDebtAverageAmountOutstanding_c20220101__20220101__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zP1EkF7CMHpj" title="Principal outstanding">244,048</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The Company borrowed $<span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_c20220916__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zTs1aL8IQfsl" title="Borrowed amount">122,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
September 16, 2022, to bring the principal balance back to $<span id="xdx_902_eus-gaap--DebtInstrumentRepurchasedFaceAmount_iI_c20220916__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zVZhMbJMnIXc" title="Principal balance back">250,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
After making scheduled payments, the Company borrowed $<span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_c20230524__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_z55zJIDmX5Gc">107,231 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">on
May 24, 2023, to bring the principal balance back to $<span id="xdx_903_eus-gaap--DebtInstrumentRepurchasedFaceAmount_iI_c20230524__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_z1YWV2ASyxHh" title="Principal balance back">250,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The terms of the note are the same as the previous note with the final payment scheduled for August 22, 2024. The principal
outstanding at December 31, 2023 and 2022 was $<span id="xdx_900_eus-gaap--NotesPayable_iI_c20231231__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zMmZIZlewifl" title="Principal outstanding">148,062</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
and $<span id="xdx_902_eus-gaap--NotesPayable_iI_c20221231__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zw427gx3GhC" title="Principal outstanding">202,834</span>,
respectively. The Company believes that the advancement of additional funds is a minor modification to the terms of the existing
loan since the difference in present value of the cash flows under the terms of the new loan is less than 10% of the present value
of the remaining cash flows under the terms of the original loan. As a result, the modification was accounted for as a modification
of debt.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
lender was granted and assigned a continuing security interest in all the Company&#8217;s personal property assets including, but not
limited to, business equipment, inventory, accounts, accounts receivable, intellectual property, chattel paper, instruments, deposit
accounts, commercial tort claims, contract rights, licenses, claims, and general intangibles.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
future minimum principal payments to be paid in 2024 is $<span id="xdx_906_eus-gaap--DebtInstrumentAnnualPrincipalPayment_iI_c20241231__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zCvJIGSbdhMh" title="Minimum principal payment">148,062</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Convertible
Notes</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p id="xdx_89C_eus-gaap--ConvertibleDebtTableTextBlock_zwnV5CftQj64" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents a summary of the Company&#8217;s convertible notes:</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_zaDohGEoCEnk">Schedule
of Convertible Notes</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20231231_zojZPyu68nuh" style="border-bottom: Black 1.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_493_20221231_zKQQj3MCvMdf" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31,</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--DebtInstrumentFaceAmount_iI_zUfbL3EZ46u4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1181">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,555,556</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--DeferredFinanceCostsCurrentNet_iNI_di_zeR6aqvMYHkl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less:
    Original issue discount</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1184">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(355,556</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_403_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di_zQwpEjFULmVd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: Debt discount</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1187">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,841,658</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_400_eus-gaap--DeferredFinanceCostsNet_iNI_di_zkKCDx6O8T62" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: Deferred financing fees</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1190">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(130,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40C_eus-gaap--LongTermDebt_iI_zTA5lO8vLnec" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Notes
    payable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1193">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">228,342</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p id="xdx_8A5_zlqYDRny3Kq2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">From March to July of 2023, the Company conducted
multiple closings of a private placement offering to accredited investors for aggregate gross principal amounts of $<span id="xdx_906_eus-gaap--DebtInstrumentCarryingAmount_iI_c20230731__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember_z8U0BwR54WTb" title="Debt instrument gross">6,066,667</span> and net
proceeds of $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfDebt_c20230301__20230731__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_z1fWFFjxUKWc" title="Net proceeds of debt">4,908,000</span>. The offering consisted of a convertible promissory note that accrues interest at <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20230731__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zY0bAAGExbQ1" title="Debt instrument interest rate">12</span>% that can be paid in cash
or PIK and an original issue discount of <span id="xdx_90D_ecustom--DebtInstrumentDiscountRate_iI_pid_dp_uPure_c20230731__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zRsXE9HjmJD5" title="Debt instrument discount rate">10</span>%. The convertible promissory notes automatically convert into common shares at a <span id="xdx_900_ecustom--DebtInstrumentDiscountRate_iI_dp_uPure_c20230731__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zUkLsczMB1Ka" title="Discount rate">30</span>% discount
to the IPO. The notes mature on the sooner of the six-month anniversary date from issuance or a successful IPO on primary exchange in
the U.S. and include <span id="xdx_904_ecustom--DebtWarrantConversionDescription_c20230301__20230731__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zCZswwovk4Vf" title="Debt warrant conversion, description">a five-year warrant to purchase common stock equal to fifty percent (50%) of the shares into which the convertible
notes can be converted into at issuance.</span> The warrants have a strike price at a <span id="xdx_90A_eus-gaap--DebtInstrumentConvertibleConversionRatio1_dp_uPure_c20230301__20230731__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zp5RqvNclAmc" title="Strilke price">25</span>% premium to the conversion price subject to anti-dilution,
issuable on a pro rata basis at each funding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As facilitators to the 2023 convertible notes,
Signature Bank received a $<span id="xdx_901_eus-gaap--EscrowDeposit_iI_c20220413__dei--LegalEntityAxis__custom--SignatureBankMember_zuTSDDKzlco4" title="Escrow deposit">6,000</span>
escrow fee and Alexander Capital, L.P. received (i) a cash commission of nine percent (9%) of the proceeds raised in the offering
from investors introduced to the Company and (ii) warrants for the purchase of a number of shares of Common Stock equal to 6% of the
number of underlying securities. Alexander Capital, L.P., received (i) fees totaling $<span id="xdx_90B_eus-gaap--ProceedsFromFeesReceived_c20230101__20231231__dei--LegalEntityAxis__custom--AlexanderCapitalLPMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zS9shkQlxxC1" title="Deferred financing fees">546,000</span>
in 2023 which were recorded in deferred financing fees as a reduction to notes payable on the balance sheet and (ii) <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231231__dei--LegalEntityAxis__custom--AlexanderCapitalLPMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfeNJzCsk77g" title="Number of warrants received">120,235</span>
warrants which were recorded at fair value in the warrant liability and debt discounts on the balance sheet.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">After the closing of the initial public offering
on August 8, 2023, the Company converted the notes payable plus $<span id="xdx_902_eus-gaap--NotesPayable_iI_c20230808__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zgLLIztHSYK1">226,391
</span>in interest into <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230808__20230808__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zfMiiMMOIFGg">1,498,332
</span>shares of common stock. The shares were to be issued at a discounted price of $<span id="xdx_90A_eus-gaap--SharesIssuedPricePerShare_iI_c20230808__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zG2CJJA0Vky7">4.20
</span>per share resulting in a $<span id="xdx_903_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20230808__20230808__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zc8twd5kEnsj">4,115,223
</span>loss to the Company which is recorded in extinguishment of debt liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March of 2023, the Company used borrowings from
the 2023 convertible notes to pay the principal balance of some of the 2022 notes totaling $<span id="xdx_904_eus-gaap--NotesPayable_iI_c20230331__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zg2u9GbOjWzb">2,650,000</span>
which resulted in a $<span id="xdx_905_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20230301__20230331__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zA0Trmkpmai4" title="Gain on extinguishment of debt liabilities">1,129,653</span> gain to the Company which is recorded in extinguishment of debt liabilities. Upon payment, the
terms for the remaining balance of those notes were also updated. The remaining balance accrued interest at <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20230331__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zPJ3DIUwf5we">8</span>%
per annum without maturity or default rights. The new balance shall also automatically convert into shares of common stock at a <span id="xdx_90E_ecustom--DebtInstrumentDiscountRate_iI_dp_uPure_c20230331__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zOAJcyb69USb">27.5</span>%
discount to the per share offering price in the Company&#8217;s initial public offering or $<span id="xdx_90B_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20230331__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zXfhwPQ9wnEc">4.35
</span>per share. After the closing of the initial public offering on August 8, 2023, the Company converted the notes payable plus $<span id="xdx_907_eus-gaap--NotesPayable_iI_c20230808__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_z101SOBxFrC4">173,205
</span>in interest into <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230808__20230808__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zUcBo3fQDa9d">107,509
</span>shares of common stock. The shares are to be issued at a discounted price of $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_c20230808__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zzxajDKfLMNl">4.35
</span>per share resulting in a $<span id="xdx_904_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20230808__20230808__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zvnEs2bvb6eh" title="Extinguishment of debt">663,991</span> loss to the Company which is recorded in extinguishment of debt liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The remaining investors of the 2022 notes did
not convert their notes and, as such, the Company used proceeds from the initial public offering to pay the remaining promissory
notes back in full, including interest in the amount of $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20230814__20230814__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zizLG4TxWnDe" title="Proceeds from issuance of ipo">445,554</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The convertible notes signed between June 3, 2022
and November 30, 2022 had aggregate gross principal amounts totaling $<span id="xdx_902_eus-gaap--DebtInstrumentCarryingAmount_iI_c20221130__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_znWiHUAbEPIe" title="Debt instrument gross">3,333,333</span> and net proceeds of $<span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfDebt_c20220601__20221130__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_z0DQXaOtuNXd" title="Net proceeds of debt">2,870,000</span> and consisted of an <span id="xdx_904_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20220603__20221130__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zn1OPr3XrPQb" title="Debt instrument description">original
issue discount of 10% with an interest rate of the greater of (i) Prime rate plus 8.5% or (ii) 12%.</span> The notes convert into common shares
at the lower of (i) $<span id="xdx_90F_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20221130__srt--RangeAxis__srt--MinimumMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zrmEVcETlc54">9.44</span> or (ii) a <span id="xdx_90F_ecustom--DebtInstrumentDiscountRate_iI_dp_uPure_c20221130__srt--RangeAxis__srt--MaximumMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zw1JXskujnUc">30</span>% discount to the price per share of any subsequent offering. The notes matured on the one-year
anniversary date from issuance and contain <span id="xdx_907_ecustom--DebtWarrantConversionDescription_c20220603__20221130__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zi4XKE81u4Wc" title="Debt warrant conversion, description">a five-year warrant to purchase common stock equal to one hundred percent (100%) of the shares
into which the 2022 Convertible Notes can be converted into at issuance.</span> The warrants have an exercise price at the lower of (i) $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221130__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zF4TgXjAhR5h" title="Exercise price">11.80</span>
per share or (ii) a <span id="xdx_905_ecustom--ClassOfWarrantDiscountRate_iI_dp_uPure_c20221130__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_z6ocuv9JmTI7" title="Class of warrant discount rate">12.5</span>% discount to the price per share of any subsequent offering, (c) shares of the Company&#8217;s common stock
equal to <span id="xdx_902_ecustom--DebtInstrumentPrincipalAmount_iI_dp_uPure_c20221130__srt--RangeAxis__srt--MaximumMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zuKGgPz3QRie" title="Principal amount in percent">10</span>% of the principal amount of these notes, at a value per share equal to the conversion price. The <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220603__20221130__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zd1udFHNT9bj" title="Issuance of shares">35,318</span> shares of common
stock issued to investors had a relative fair value of $<span id="xdx_90F_eus-gaap--FairValueAdjustmentOfWarrants_c20220603__20221130__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_z2udrEx7iBLa" title="Fair value adjustment of warrants">4,789</span>. Due to the second prong of the conversion equation after the IPO an additional
<span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220603__20221130__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zoZbk3MP2oBg" title="Issuance of shares">44,048</span> commitment shares are to be issued. The shares are to be issued at a discounted price of $<span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_c20221130__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zTP1G4CMOynj" title="Shares issued price per share">4.20</span> per share resulting in a loss to
the Company which is recorded in extinguishment of debt liabilities.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The convertible notes signed on December 19, 2022
had aggregate gross principal amounts totaling $<span id="xdx_903_eus-gaap--DebtInstrumentCarryingAmount_iI_c20221219__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_z6bldzpYQIP7" title="Debt instrument gross">222,222</span> and net proceeds of $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfDebt_c20221219__20221219__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zS5aGAcKlIuh" title="Net proceeds of debt">200,000</span> and consisted of an original issue discount of <span id="xdx_902_ecustom--DebtInstrumentDiscountRate_iI_dp_uPure_c20221219__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zNKTch3JiVO3" title="Debt instrument discount rate">10</span>%
of the principal amount with an interest rate of <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20221219__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zpulGE3O1BE" title="Accrued interest">12</span>% per annum. The notes matured at the earlier of (i) twelve (12) months from the issue
date or (ii) the date upon which the Company completes a registered public offering of shares of the Company, which encompasses the closing
of the IPO. The notes are convertible into shares of common stock at the higher of (i) $<span id="xdx_901_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20221219__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zP140MdMlMBd" title="Conversion price">9.44</span> per share or (ii) the price per share of
common stock issued pursuant to the next registered public offering of shares of the Company made prior to the conversion of any portion
of the note. Interest accrues on the aggregate principal amount (which includes original issue discount) and is payable on the maturity
date, at the Company&#8217;s election, in cash or in-kind. The holders of the notes are entitled to piggyback registration rights on any
registration statement filed by the Company, other than any registration statement filed on Form S-4 or Form S-8. The warrants and conversion
shares are subject to anti-dilution provisions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
investors of the notes signed on December 19, 2022 above did not convert their notes and, as such the Company used proceeds from the
initial public offering to pay the remaining promissory notes back in full, including interest in the amount of $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20221219__20221219__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zU2sV3uccL83" title="Proceeds from issuance of ipo">239,104</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company paid $<span id="xdx_908_eus-gaap--PaymentsOfDebtIssuanceCosts_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zQpHgT4rWVfa" title="Offering costs">130,000</span>
in fees to law firms related to the 2022 convertible note offerings and were recorded as deferred financing fees as a reduction to
notes payable on the balance sheet.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has applied ASC 815 due to
the potential for settlement in a variable quantity of shares. Since these convertible notes and warrants have the option to convert or
be exercised at a variable amount, they are subject to derivative liability treatment. The conversion feature has been measured at fair
value using a Monte Carlo model at the date of issuance and is adjusted to fair value at each reporting period. The fair value of the
embedded derivative and the warrant liability at date of issuance was $<span id="xdx_906_eus-gaap--EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_iI_c20231231_zn5dsw6KR9ci" title="Fair value of embedded derivative">2,375,378</span> and $<span id="xdx_90D_eus-gaap--WarrantsNotSettleableInCashFairValueDisclosure_iI_c20231231_znXcdJCHCI5l" title="Embedded derivative warrant liability">2,446,502</span>, respectively. See Notes 12 and 13.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The 2023 and 2022 convertible notes transferred
fair value to investors in the form of principal, warrants and common shares totaling $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_c20221231__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember_zCxrJK0O9hd1" title="Principal of warrants and common shares fair value">11,947,212</span>.
As the Company received cash proceeds of $<span id="xdx_904_eus-gaap--ProceedsFromNotesPayable_c20230101__20231231__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember_zWingHw0dEpj" title="Cash proceeds fair value of incentivies">8,660,000</span>,
net of an original issue discount of $<span id="xdx_903_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iI_c20231231_zARY6Z3amQEi" title="Original issue discount">962,223</span>, the remaining fair value of incentives in excess of principal of $<span id="xdx_90B_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iI_c20231231__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember_z2CZj7yPXii4" title="Debt discount">2,234,988</span>
was expensed as finance charges totaling $<span id="xdx_90D_eus-gaap--PaymentsOfFinancingCosts_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember_zNtliDvlieBb" title="Financing fees">2,772</span>
and $<span id="xdx_90B_ecustom--PaymentsOfFinancingCost_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember_zHUrapMMV084" title="Financing fees"><span id="xdx_902_ecustom--PaymentsOfFinancingCost_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember_zU0nI075VT47" title="Financing fees">2,322,216</span></span>
for the years ended December 31, 2023 and 2022, respectively. On August 8, 2023, the Company amortized the remaining original issue
discount, debt discount reflective of the fair value of embedded warrants and financing fees as the 2023 and 2022 convertible notes
were either paid in full or converted to common stock pursuant to the initial public offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the years ended December 31, 2023 and 2022,
the Company accrued interest on these convertible notes totaling $<span id="xdx_906_eus-gaap--InterestPayableCurrent_iI_c20231231__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_ziueDiJJwFkc" title="Accrued interest">399,597</span> and $<span id="xdx_904_eus-gaap--InterestPayableCurrent_iI_c20221231__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_z9WriA2Jvz68" title="Accrued interest">107,544</span>, respectively, which was paid or converted into
common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823802768208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--LesseeOperatingLeasesTextBlock_zX8seumS0IE" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8.
<span id="xdx_825_zwX2aOaesGig">Leases</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s leases are comprised of operating leases for office space. At the inception of the lease, the Company determines whether
the lease contract conveys the right to control the use of identified property for a period of time in exchange for consideration. Leases
are classified as operating or finance leases at the commencement date of the lease. Operating leases are recorded as operating lease
right-of-use assets, other current liabilities, and operating lease liabilities in the Balance Sheets. The Company did not have any finance
leases at December 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had three leases primarily consisting of office space in Versailles, Indiana and Carmel, Indiana. <span id="xdx_900_eus-gaap--LesseeOperatingLeaseDescription_c20230101__20231231_zHpDfrxcFjo" title="Operating lease description">Two of the leases in Versailles
started January 1, 2017. Both have an initial term of five years with an option for an additional five-year term. The monthly lease payments
for these leases are $<span id="xdx_90F_eus-gaap--OperatingLeasePayments_c20170101__20170101__us-gaap--GeographicDistributionAxis__custom--VersaillesIndianaMember__us-gaap--LeaseContractualTermAxis__custom--LeaseOneMember_z9GjoNdR8Aje" title="Operating lease payment">550</span> and $<span id="xdx_90B_eus-gaap--OperatingLeasePayments_c20170101__20170101__us-gaap--GeographicDistributionAxis__custom--VersaillesIndianaMember__us-gaap--LeaseContractualTermAxis__custom--LeaseTwoMember_zbXbKuGA9Lp8" title="Operating lease payment">1,600</span> with a <span id="xdx_909_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_dp_uPure_c20170101__us-gaap--GeographicDistributionAxis__custom--VersaillesIndianaMember_zb58exyLfY26" title="Discount rate">3</span>% per annum increase starting with the optional five-year term. The lease in Carmel started
March 1, 2016. The initial term is five years and three months with an option for an additional three-year term. The monthly lease payment
started at $<span id="xdx_907_eus-gaap--OperatingLeasePayments_c20160301__20160301__us-gaap--GeographicDistributionAxis__custom--CarmelIndianaMember__us-gaap--LeaseContractualTermAxis__custom--LeaseThreeMember_zuOLk605kPfe" title="Operating lease payment">1,472</span> with an annual increase of approximately <span id="xdx_90B_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_uPure_c20160301__us-gaap--GeographicDistributionAxis__custom--CarmelIndianaMember_zMMV28YBoiLb" title="Operating lease payment rate">2.7</span>%. On December 16, 2020, the Company entered into an amendment of the Carmel
lease that extended the initial term by two years.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
lease right-of-use assets and liabilities are recognized at the commencement date based on the present value of lease payments over the
lease term. As the implicit interest rate is generally not readily determinable, the Company uses an incremental borrowing rate based
on the information available at the commencement date in determining the present value of lease payments. The incremental borrowing rate
reflects the estimated rate of interest that the Company would pay to borrow on a collateralized basis over a similar economic environment.
Lease expense for the operating lease is recognized on a straight-line basis over the lease term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leases
may include renewal options, and the renewal option is included in the lease term if the Company concludes that it is reasonably certain
that the option will be exercised. Certain leases may contain rent escalation clauses, either fixed or adjusted periodically for inflation
of market rates, that are factored into the calculation of lease payments to the extent they are fixed and determinable at lease inception.
The Company also has variable lease payments that do not depend on a rate or index, primarily for items such as common area maintenance
and real estate taxes, which are recorded as expenses when incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2023 and 2022, the Company recognized $<span id="xdx_906_eus-gaap--OperatingLeaseExpense_c20230101__20231231_zE4mSeS3loE6" title="Operating lease expense">49,051</span> and $<span id="xdx_90B_eus-gaap--OperatingLeaseExpense_c20220101__20221231_zIvy1SKO2cMl" title="Operating lease expense">47,571</span> of operating lease expense, including short-term
lease expense and variable lease costs, which are immaterial.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89A_eus-gaap--OperatingLeasesOfLesseeDisclosureTextBlock_zL1DVsEOIMZj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information related to the Company&#8217;s operating leases:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B9_zbkU8aI0hBH7" style="display: none">Schedule of Operating Leases</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49D_20231231_zbQj9ZkbBWz2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_492_20221231_zYHSdHBiFm09" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseRightOfUseAsset_iI_zEZZBTAfoqd7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left; padding-bottom: 1.5pt">Operating lease right-of-use assets</td><td style="width: 2%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 16%; font-weight: bold; text-align: right">70,263</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">101,382</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OtherLiabilitiesCurrent_iI_zm9zZg5Nwu86" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other current liabilities</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">49,127</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33,395</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zy2McdHD9408" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Operating lease liabilities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">27,071</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">76,199</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingLeaseLiability_iI_zJsruRK1nMR" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">76,198</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">109,594</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Weighted-average remaining lease term (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20231231_zFFRP2qAZvg7" title="Weighted average remaining lease term (in years)">3.75</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_zomxZrgZidyk" title="Weighted average remaining lease term (in years)">4.00</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Weighted-average discount rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_uPure_c20231231_zBeFiyvgElC7" title="Weighted average discount rate">15.0</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_uPure_c20221231_zAkKHF1tgYWl" title="Weighted average discount rate">15.0</span></td><td style="text-align: left">%</td></tr>
  </table>
<p id="xdx_8A8_zhTFKMFizYai" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_895_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zxxn8qAlvrSc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, the maturities of the Company&#8217;s operating lease liabilities were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span><span id="xdx_8B5_zeZ9qs2gWW39" style="display: none">Schedule of Maturities Operating Lease Liabilities</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 65%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49C_20231231_zoyDNcpF1jfk" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzyNu_zJrYMlclNNZ" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">27,072</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzyNu_zFmSJqgVaoyh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,316</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzyNu_zov6zadw8H07" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2026</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">26,810</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzyNu_zWn2N5fJhg9d" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">76,198</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_z1Yfm0NWn5V3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1343">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseLiability_iI_zirh2xyENqp9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total present value of lease payments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">76,198</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p id="xdx_8A8_zWz7UB68bOyd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823800646032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock and Warrants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_DisclosureCommonStockAndWarrantsAbstract', window );"><strong>Common Stock And Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_CommonStockAndWarrantsDisclosureTextBlock', window );">Common Stock and Warrants</a></td>
<td class="text"><p id="xdx_803_ecustom--CommonStockAndWarrantsDisclosureTextBlock_zprAyyGdMAf2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9.
<span id="xdx_82C_zqrrMh9ztpI">Common Stock and Warrants</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company authorized <span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_c20221231_pdd">100,000,000</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
of common stock, of which <span id="xdx_90F_eus-gaap--CommonStockSharesOutstanding_c20231231_pdd">6,508,897</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and <span id="xdx_901_eus-gaap--CommonStockSharesOutstanding_c20221231_pdd">1,963,322</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
were issued and outstanding as of December 31, 2023 and 2022, respectively. In conjunction with <span id="xdx_90B_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230808__20230808__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zp8HaJUB3Oba" title="Number of shares issued in transaction">1,098,667</span> common shares issued upon
the completion of the initial public offering on August 8, 2023, the Company also issued (i) <span id="xdx_900_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20230808__20230808_zJxZAxtFtyK1">1,244,228</span>
common shares upon conversion of <span id="xdx_904_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20230808_zOZQjCbyYfgf">506,637</span>
shares of Convertible Series A Preferred Stock and <span id="xdx_901_eus-gaap--ConversionOfStockSharesConverted1_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_zKFjCyjTZxQa" title="Stock value converted">115,477</span>
shares of Convertible Series Seed Preferred Stock, (ii) <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20230808__20230808__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWOX6ufGTUm5" title="Common stock issued upon debt conversion, shares">1,649,900</span>
common shares upon conversion of convertible notes, (iii) </span><span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230808__20230808__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VendorsMember_zrwlgZ1FlP8i" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">425,000 </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">commons
shares as payment to vendors for services and (iv) </span><span id="xdx_904_eus-gaap--ConversionOfStockSharesIssued1_c20230808__20230808__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYOjhq6xGnni" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">127,780 </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">common
shares upon the exercise of warrants. On January 10, 2023, the Company&#8217;s board of directors authorized a </span><span id="xdx_908_eus-gaap--StockholdersEquityNoteStockSplit_c20230109__20230110_zNOcnW6oS9K" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2-for-1
reverse stock split</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. All share information in these
financial statements has been adjusted for this reverse stock split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 10, 2023, the Company&#8217;s board of directors authorized a <span id="xdx_90C_eus-gaap--StockholdersEquityNoteStockSplit_c20230110__20230110_zqw3nJFmfy9e" title="Description of stock split">2-for-1 reverse stock split</span>. All share information in these financial
statements has been adjusted for this reverse stock split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt">On August 9, 2023, the Company consummated an initial public offering, conducted on a firm commitment basis, pursuant to which it sold
<span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230809__20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zhQs53cZ3pJh" title="Number of shares issued in transaction">1,098,667</span> shares of its common stock at a price of $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_c20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zlYaxgRcWhzg" title="Share issued price per share">6.00</span> per share, resulting in gross proceeds of $<span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230809__20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zEmHOvxrvNYi" title="Proceeds from issuance of common stock">6,592,002</span>. See Note 1.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with a bridge loan, the Company issued a warrant on September 18, 2018 that allows the holder to purchase common
stock from the Company at a share price of $<span id="xdx_901_eus-gaap--SharePrice_iI_pid_c20180918__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--BrianHannaschMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_zU6anbLDWfnf" title="Share price">4.38</span>
per share. The number of shares was based on a formula tied to the final amount of loans made by the holder of $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20180918__20180918__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--BrianHannaschMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_zxcybR51McLa" title="Final amount">375,000</span>,
multiplied by <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20180918__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--BrianHannaschMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_z0twKBxIqGrf" title="Interest rate">150</span>%,
and divided by $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20180918__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--BrianHannaschMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_zQnffytKIu8g" title="Exercise price">70.03</span>.
The number of shares based on this formula is <span id="xdx_907_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20180918__srt--TitleOfIndividualAxis__custom--BrianHannaschMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zVWbBAxj6Y2a" title="Number of warrants">12,852</span>.
The warrant contains certain rights in the event of liquidation, merger, or consolidation of the Company. If the fair market value
of one share is greater than the warrant price, the holder may elect to receive a number of shares equal to the value of the
warrant. If the exercise is in connection with the sale of the Company, the holder may, at its option, condition its exercise of the
warrant upon the consummation of such transaction. The warrant expires on <span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20180918__srt--TitleOfIndividualAxis__custom--BrianHannaschMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z1W9WUuzvjIg" title="Date of Expiration">September
18, 2028</span> and can be exercisable either in whole or from time to time in part prior to the expiration date.</span></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company issued a second warrant on September 6, 2019, under similar terms but is a penny warrant that allows the holder to purchase
<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20190906__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zy347P2O8vMk" title="Number of warrants">40,000</span> shares of common stock and is subject to adjustment for certain equity events. The warrant contains certain rights in the event
of liquidation, merger, or consolidation of the Company. The warrant expires on <span id="xdx_904_ecustom--WarrantsExpirationDateDescription_c20190906__20190906__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zf5TzJrxXLS7" title="Date of Expiration">September 6, 2029</span>. This warrant was converted to <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20190906__20190906__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAYlTCf768y9" title="Number of shares, conversion of convertible securities">39,924</span>
shares of common stock on December 28, 2023. The fair market value of the stock on that day was calculated as the average of the daily
closing prices per share for the 30 consecutive trading day period ending on the second trading day prior to such date or $<span id="xdx_903_eus-gaap--SharePrice_iI_pid_c20190906__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zuxnhpcpMTn6" title="Share price">2.61</span> per share.
<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20190906__20190906_zdMKXcgMd2u8" title="Warrant, description">Since the fair value was greater than the warrant price of $0.01 per share the holder elected to receive the number of shares equal
to 40,000 times the difference between the fair market value and the exercise price divided by the fair market value, resulting in 39,924.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company issued a third warrant to Masimo Corporation on April 9, 2020. This warrant was pre-funded in the amount of $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20200409__dei--LegalEntityAxis__custom--MasimoCorporationMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTwoMember_z3MWXhxiJUt6">2,734,340</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The warrant allows the holder to purchase <span id="xdx_909_eus-gaap--WarrantsAndRightsOutstanding_iI_c20200409__dei--LegalEntityAxis__custom--MasimoCorporationMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantThreeMember_zXB3BgL8LLhh">289,779 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares
of Series A Preferred Stock at $<span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20200409__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantThreeMember_zsLkqODTsfI8">9.44 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per
share and is subject to adjustment for certain equity events. The warrant contains certain rights in the event of liquidation,
merger, or consolidation of the Company. There will be no additional purchase price for the Warrants. In the event that all
outstanding shares of Series A Preferred Stock are converted, automatically or by action of the holders thereof, into Common Stock,
including, without limitation, in connection with the Company&#8217;s initial, underwritten public offering and sale of its Common
Stock pursuant to an effective registration statement under the Act, then from and after the date on which all outstanding shares of
Series A Preferred Stock have been so converted, this Warrant shall be exercisable for such number of shares of Common Stock into
which the Warrant Shares would have been converted had the Warrant Shares been outstanding on the date of such conversion, and the
Exercise Price shall equal the Exercise Price in effect as of immediately prior to such conversion divided by the number of shares
of Common Stock into which one share of Series A Preferred Stock would have been converted, all subject to further adjustment
thereafter from time to time in accordance with the provisions of this Warrant. On August 14, 2023, the <span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant_c20230814__20230814__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zKJJUzNR5Yak" title="Converted to preferred stock warrant">144,890</span> Series A Preferred
Stock warrants were converted to <span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants_c20230814__20230814__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z26PCTlfwxN4" title="Converted to common stock warrant">289,779</span> common stock warrants after giving effect to the <span id="xdx_906_eus-gaap--StockholdersEquityNoteStockSplit_c20230814__20230814_zjC2pZF8eSx8" title="Common stock split, description">2-for-1</span> common stock split.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2022, the Company issued <span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zJzxEqAvBdTj" title="Number of warrants">793,655</span> <span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_z5KxziaQhAK5" title="Warrant term::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl1404">five-year</span></span> warrants to purchase common stock equal to one hundred percent (100%) of the shares into which
the 2022 convertible notes can be converted at issuance. The warrants have an exercise price of $<span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zBMpc4ENsbZg" title="Share issued price per share">5.25</span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
March to June of 2023, the Company issued <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230630__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zT9VShby2Tbe" title="Number of warrants">505,570</span> <span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20230630__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zSdGuqTadD3i" title="Warrant term::XDX::P1Y"><span style="-sec-ix-hidden: xdx2ixbrl1410">one-year</span></span> warrants to purchase common stock equal to fifty percent (50%) of the shares
into which the 2023 convertible notes can be converted at issuance. The warrants have an exercise price of $<span id="xdx_90A_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230630__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zV4CjY7CXfy5" title="Share issued price per share">5.25</span> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 9, 2023, the Company issued <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230809__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zeiKL6HUAEte">122,202
</span></span><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dpxL_c20230809__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_ziGSl6ZTAYZk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt" title="::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl1414">five-year
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants to purchase common stock pursuant to an advisory
agreement with a consulting firm upon closing of the Company&#8217;s initial public offering. The warrants have an exercise price of
$<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230809__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zFYXRRYxXEH5">6.00
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 14, 2023, the Company issued <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230814__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zXsaF3WrPxAg">186,156
</span></span><span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20230814__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zh3aVBO5Qeue" style="font-family: Times New Roman, Times, Serif; font-size: 10pt" title="::XDX::P5Y"><span style="-sec-ix-hidden: xdx2ixbrl1417">five-year
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warrants to purchase common stock pursuant to an agreement
with an underwriter upon closing of the Company&#8217;s initial public offering. The warrants have an exercise price of $<span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230814__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zwKZT2yKcEVa">7.20
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_ecustom--ScheduleOfWarrantActivityForCommonStockTableTextBlock_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zT0tVLJd8Fb1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of warrant activity for common stock during the years ended December 31, 2023 and 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><span id="xdx_8BB_zbPdy6YRoh12" style="display: none">Schedule of Warrant Activity for Common Stock</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Warrants for Common
    Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted-Avg. Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted-Avg. Remaining Contractual
    Life</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; font-weight: bold; text-align: left">Outstanding as of January 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFtfkHit6nal" style="width: 14%; text-align: right" title="Number of Warrants, Outstanding at beginning of period">52,852</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4GsLYC1p5P9" style="width: 14%; text-align: right" title="Weighted Average Exercise Price, Outstanding at beginning of period">2.13</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zl6qZXq8dUt6" title="Weighted Average Remaining Contractual Life - Warrants, Outstanding at beginning of period">7.45</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQ7wIfObdtu2" style="text-align: right" title="Number of Warrants, Granted">793,655</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPw6fxB9ydqh" style="text-align: right" title="Weighted Average Exercise Price, granted">5.25</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageRemainingContracualLifeOutstandingNumberGranted_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkS3ZdEjg8hk" title="Weighted Average Remaining Contractual Life - Warrants Granted">4.42</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cancelled/Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRsBQtlIFENd" style="text-align: right" title="Number of Warrants, Cancelled Expired"><span style="-sec-ix-hidden: xdx2ixbrl1434">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLbhtOkKExjk" style="text-align: right" title="Weighted Average Exercise Price, Cancelled Expired"><span style="-sec-ix-hidden: xdx2ixbrl1436">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwxWiNfdMXFh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1438">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIHWoLLJqhIa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Excercised"><span style="-sec-ix-hidden: xdx2ixbrl1440">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Outstanding as of December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjGjArh6kWl3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants, Outstanding at beginning of period">846,507</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsVBLIE98wNh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding at beginning of period">5.06</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z1bupKrRyEVb" title="Weighted Average Remaining Contractual Life - Warrants, Outstanding at beginning of period">4.72</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHXGtkRBVef7" style="text-align: right" title="Number of Warrants, Granted">813,928</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrvhplVZaaea" style="text-align: right" title="Weighted Average Exercise Price, granted">5.81</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z3Rw1vMLMbgi" title="Weighted Average Remaining Contractual Life - Warrants Granted">4.38</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Converted Prefunded Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBKOw27Iswof" style="text-align: right" title="Number of Warrants, Converted Prefunded Warrants">289,779</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsConvertedPrefundedWarrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLHJQsNqGfSf" style="text-align: right" title="Weighted Average Exercise Price, Converted Prefunded Warrants">0.01</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNNkyqPnU1p2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants, Exercised">(127,856</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxn1kG8yXWhh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Excercised"><span style="-sec-ix-hidden: xdx2ixbrl1460">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Outstanding as of December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z52slLer13Yi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants, Outstanding at Ending of period">1,822,358</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWcR3HmB7P4d" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding at Ending of period">4.69</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zUlKG5KBXfV6" title="Weighted Average Remaining Contractual Life - Warrants, Outstanding at Ending of period">3.05</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>
<p id="xdx_8A6_zUzkMtJhQeOc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p id="xdx_891_ecustom--ScheduleOfWarrantActivityForPreferredStockTableTextBlock_hus-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z8rPRlYi2yr7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of warrant activity for preferred stock during the years ended December 31, 2023 and 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_zBDZzq1ZH1Jg" style="display: none">Schedule of Warrant Activity for Preferred Stock</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted-Avg.</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Warrants for</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Preferred Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; font-weight: bold; text-align: left">Outstanding as of January 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zHjGmEHAR7n" style="width: 16%; text-align: right" title="Number of Warrants, Outstanding at beginning of period">144,890</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zWxVdZmPzCXb" style="width: 16%; text-align: right" title="Weighted Average Exercise Price, Outstanding at beginning of period">0.01</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zKrzoDZ974Kf" style="text-align: right" title="Number of Warrants, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1474">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zvx7V26CALq4" style="text-align: right" title="Weighted Average Exercise Price, granted"><span style="-sec-ix-hidden: xdx2ixbrl1476">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cancelled/Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zmgoHNJLFe2j" style="text-align: right" title="Number of Warrants, Cancelled Expired"><span style="-sec-ix-hidden: xdx2ixbrl1478">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zU6SDG16jVpf" style="text-align: right" title="Weighted Average Exercise Price, Cancelled Expired"><span style="-sec-ix-hidden: xdx2ixbrl1480">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zOoHjZDVMd15" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1482">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zNvu6Eca2qs9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Excercised"><span style="-sec-ix-hidden: xdx2ixbrl1484">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Outstanding as of December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zVJNx44x0VJ7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants, Outstanding at beginning of period">144,890</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zd50OkTmeHT3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding at beginning of period">0.01</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_znFCYHiQfpJh" style="text-align: right" title="Number of Warrants, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1490">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zEdXTAJWHEFk" style="text-align: right" title="Weighted Average Exercise Price, granted"><span style="-sec-ix-hidden: xdx2ixbrl1492">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cancelled/Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zz4SGnNOQE3f" style="text-align: right" title="Number of Warrants, Cancelled Expired"><span style="-sec-ix-hidden: xdx2ixbrl1494">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zyZcFmgWqHc2" style="text-align: right" title="Weighted Average Exercise Price, Cancelled Expired"><span style="-sec-ix-hidden: xdx2ixbrl1496">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Converted to Common Stock Warrant</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zFfOb5Qk5Rzl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Converted to Common Stock Warrant">(144,890</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zIxM4IoiAYx5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Converted to Common Stock Warrant">(0.01</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Outstanding as of December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zDXqtRsfiNk9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants, Outstanding at Ending of period"><span style="-sec-ix-hidden: xdx2ixbrl1502">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zBEYAb8ItwJd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding at Ending of period"><span style="-sec-ix-hidden: xdx2ixbrl1504">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>
<p id="xdx_8A7_zYQuG8ICw7M4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_898_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zPFQXUl3FwJ" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s warrants outstanding and exercisable as of December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_zON6lmiXJCBf" style="display: none">Schedule of Warrants outstanding and Exercisable</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Warrants</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">Expiration</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Date</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Investor Warrant W-01</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantOneMember_z2ZvJ9G75a15" style="width: 14%; text-align: right" title="Number of Warrants">12,852</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantOneMember_zwlOEHMDF2ha" style="width: 14%; text-align: right" title="Exercise Price">8.76</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 16%; text-align: center"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantOneMember_zMwK10K6gYG1" title="Expiration Date">September 18, 2028</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Investor Warrant PSA-01</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantPSAOneMember_z5b83TdI0T1e" style="text-align: right" title="Number of Warrants">289,779</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantPSAOneMember_z60RpMMDxE3c" style="text-align: right" title="Exercise Price">0.01</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_908_ecustom--WarrantExpirationDateDescription_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantPSAOneMember_zy7hRhHg4Klj" title="Expiration Date">None</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2022 Convertible Notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zYyUIcsWsEP4" style="text-align: right" title="Number of Warrants">793,655</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zGQo7QUjUPvf" style="text-align: right" title="Exercise Price">2.38</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_909_ecustom--WarrantExpirationDateDescription_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_z8cPQMcjQYf2" title="Expiration Date">Various</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2023 Convertible Notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zZjaNLkOEind" style="text-align: right" title="Number of Warrants">417,714</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zijUSrhPJjM" style="text-align: right" title="Exercise Price">2.38</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90D_ecustom--WarrantExpirationDateDescription_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zjdnEypDoDEd" title="Expiration Date">Various</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Consulting Agreement Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ConsultingAgreementWarrantsMember_zaTFTmhJzFW2" style="text-align: right" title="Number of Warrants">122,202</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ConsultingAgreementWarrantsMember_zEc7yGgxrfQ1" style="text-align: right" title="Exercise Price">2.38</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ConsultingAgreementWarrantsMember_z1XkTYMX6pjc" title="Expiration Date">August 8, 2028</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Underwriter&#8217;s Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantsMember_zd1m9zDelivk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants">186,156</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantsMember_zh5p3ZM7xNF9" style="padding-bottom: 1.5pt; text-align: right" title="Exercise Price">2.38</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantsMember_zWlJXInjWwXl" title="Expiration Date">August 8, 2028</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231_z0KOtmJoNRN4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants">1,822,358</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1.5pt">&#160;</td></tr>
  </table>
<p id="xdx_8A7_zkf8bYhzroK" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_CommonStockAndWarrantsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock and warrants disclosure [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_CommonStockAndWarrantsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_DisclosureCommonStockAndWarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_DisclosureCommonStockAndWarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823800670448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockTextBlock', window );">Preferred Stock</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--PreferredStockTextBlock_zs9hdNNL4B0g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10.
<span id="xdx_827_zexSBGvOofpb">Preferred Stock</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has authorized <span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_c20231231_zCacb4cxvNLa" title="Preferred stock, shares authorized">1,120,000</span> shares of preferred stock of which <span id="xdx_90B_eus-gaap--PreferredStockSharesAuthorized_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesAPreferredStockMember_zCfSG835SzE7" title="Preferred stock, shares authorized">1,000,000</span> has been designated Series A Preferred and <span id="xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_zNVIiF11gUte" title="Preferred stock, shares authorized">120,000</span> has
been designated Series Seed Preferred, of which <span id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesAPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zEME85xvnQNj" title="Preferred stock, shares issued"><span id="xdx_907_eus-gaap--PreferredStockSharesOutstanding_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesAPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zjuI1Yw375H5" title="Preferred stock, shares outstanding">0</span></span> and <span id="xdx_909_eus-gaap--PreferredStockSharesIssued_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesAPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zVC1fg5TKzYc" title="Preferred stock, shares issued"><span id="xdx_904_eus-gaap--PreferredStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesAPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z64XvUB2uIrk" title="Preferred stock, shares outstanding">506,637</span></span> shares of Series A Preferred and <span id="xdx_90F_eus-gaap--PreferredStockSharesIssued_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_zi7HmkBtYEl3" title="Preferred stock, shares issued"><span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_z2eTfUJdZ3C7" title="Preferred stock, shares outstanding">0</span></span> and <span id="xdx_90D_eus-gaap--PreferredStockSharesIssued_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_zAwhmIWxs9Wh" title="Preferred stock, shares issued"><span id="xdx_902_eus-gaap--PreferredStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_zz395C0wmmq8" title="Preferred stock, shares outstanding">115,477</span></span> shares of Series Seed Preferred
are issued and outstanding as of December 31, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
aggregate purchase price of the Series A Preferred Stock was $<span id="xdx_904_ecustom--AggregatePurchasePrice_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesAPreferredStockMember_z83A0w8LvXF4" title="Aggregate purchase price">9,321,165</span>, of which $<span id="xdx_90C_eus-gaap--ConversionOfStockAmountConverted1_c20230101__20231231__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zEOWtQxubI37" title="Cash value of purchase price">7,692,664</span> was comprised of cash and the remaining
$<span id="xdx_902_eus-gaap--ConversionOfStockAmountConverted1_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSjb4XdIQgQ3" title="Cash value of purchase price">1,628,501</span> was comprised of converted debt and common stock. The aggregate purchase price of the Series Seed Preferred shares was $<span id="xdx_902_ecustom--AggregatePurchasePrice_c20231231__20231231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_zD6OGdJbRbZe" title="Aggregate purchase price">0</span>,
as all the Series Seed shares were converted from common stock as an incentive to reinvest in Series A Preferred Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of Preferred Stock terms:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Voting
Rights</span> - The Series A Preferred and Series Seed Preferred shall vote together with the Common Stock on an as-converted basis, and
not as separate classes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Conversion
</span>- The Series A Preferred and Series Seed initially convert 1:1 to Common Stock at any time at option of holder, subject to adjustments
for stock dividends, splits, combinations, and similar events and as described below under &#8220;Anti-dilution Provisions.&#8221;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Dividends
</span>- The Series A Preferred will carry an annual <span id="xdx_904_eus-gaap--PreferredStockDividendRatePercentage_dp_uPure_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zbQVwC996jZk" title="Preferred stock dividend rate percentage">8</span>% cumulative dividend, payable upon any liquidation, dissolution or winding up of
the Company (the &#8220;Accruing Dividend&#8221;). For any other dividends or distributions, participation with Common Stock on an as-converted
basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Liquidation
</span>- In the event of any liquidation, dissolution or winding up of the Company, the proceeds shall be paid in the following priority:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">First,
to the Series A Preferred in proportion to each holder&#8217;s respective pro rata Series A Original Purchase Price, plus any pro rata
share of the Accruing Dividend until the entire Series A Original Purchase Price and Accruing Dividend are paid;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second,
to the Series Seed Preferred in proportion to each holder&#8217;s respective pro rata Series Seed Original Purchase Price until the entire
amount of the Series Seed Original Purchase Price is paid; and</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thereafter,
the Series A Preferred and Series Seed Preferred participate with the Common Stock pro rata on an as-converted basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
merger or consolidation (other than one in which stockholders of the Company own a majority by voting power of the outstanding shares
of the surviving or acquiring corporation) and a sale, lease, transfer, exclusive license or other disposition of all or substantially
all of the assets of the Company will be treated as a liquidation event (a &#8220;Deemed Liquidation Event&#8221;), thereby triggering
payment of the liquidation preferences described.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Anti-dilution
Provisions</span> - The Series A Preferred have full-ratchet anti-dilution protection so that the conversion price will be reduced to <span id="xdx_90F_eus-gaap--DebtInstrumentConvertibleConversionRatio1_dp_uPure_c20230101__20231231_ztvOgwbYgCe3" title="Conversion ratio">80</span>%
of the price at which any future shares are issued, if less than the Series A Original Purchase Price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration for shareholders to make an additional investment in the Company, upon the purchase of the Series A Preferred stock by
the shareholder, the Company converted the existing common shares held by shareholders to Series Seed Preferred Stock at a $<span id="xdx_90C_eus-gaap--ConversionOfStockAmountConverted1_pn6n6_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_zM4U9bgl39f4" title="Conversion amount">100</span> million
valuation and at a <span id="xdx_909_ecustom--SharePremiumPercentage_iI_pid_dp_uPure_c20231231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_zrSCIvVvtUtl" title="Share premium percentage">120</span>% share premium. As of December 31, 2022, there were <span id="xdx_90D_eus-gaap--ConversionOfStockSharesConverted1_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_z38nHRwBSmgi" title="Stock value converted">97,702</span> common shares converted into <span id="xdx_901_eus-gaap--ConversionOfStockSharesConverted1_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_z1JyhTpKbzSb" title="Stock value converted">115,477</span> shares
of Series Seed Preferred shares that have no par value and are outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">
As of December 31, 2023, all preferred stock has been converted pursuant to the initial public offering.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company signed a Convertible Promissory Note on November 8, 2023 for a principal amount of $<span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20231108_zPfNWYYZXC1b" title="Debt instrument, face amount">3,000,000</span>
bearing interest at <span id="xdx_907_eus-gaap--DebtConversionOriginalDebtInterestRateOfDebt_dp_uPure_c20231108__20231108_zswg4uXI9nL2" title="Debt conversion, original debt, interest rate of debt">8.5%</span>
per annum payable quarterly in either cash or common stock with a 15 month maturity date. The agreement calls for $<span id="xdx_90B_eus-gaap--DebtInstrumentPeriodicPayment_c20231108__20231108_zAs54X6L9Wjh" title="Debt instrument, periodic payment">200,000</span>
monthly installments from January 2024 through March of 2025; there was no outstanding balance as of December 31, 2023. The Convertible
Promissory Note allows for a voluntary conversion by the investor into Series B Preferred Stock at $<span id="xdx_903_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20231108__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zSkVAOA9aiZ5" title="Debt instrument, convertible, conversion price">2.38</span>
per share any time prior to the maturity date with mandatory conversion by the Company at the maturity date. The Company shall use
the proceeds solely for working capital and general corporate purposes and not pay any dividends or distributions or to advance any
funds to its officers, directors or affiliates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823806140912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Options and Awards<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Options and Awards</a></td>
<td class="text"><p id="xdx_800_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zzt5ILb6sjM2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>11.
<span><span id="xdx_82E_zfy7ZY3HJZH1">Stock Options and Awards</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 12, 2017, the Company adopted the 2017 Stock Compensation Plan authorizing the issuance of <span id="xdx_90C_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20171012__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_zPekARoQxeM1" title="Common stock, shares authorized">1,435,652</span> shares of common stock.
On September 13, 2019 the Company entered into a Stock Option Cancellation agreement with all holders of these stock options effective
on that date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
plan was then amended on September 13, 2019, to increase the share amount to <span id="xdx_902_eus-gaap--SharesIssued_iI_pid_c20190913__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_zSGluU1RUmCh" title="Shares issued">2,638,788</span>. This plan was enacted to enable the Company to
retain the services of certain key employees, officers, and directors of the Company. The Plan provides for the grant of stock options,
including incentive stock options, or ISOs, and nonqualified stock options, or NSOs and restricted stock, and they were estimated using
the Black-Scholes option-pricing model with the following weighted-average assumptions:</span></p>

<p id="xdx_898_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zSodkXedL2Fg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B6_zrJM8IbVxkhe" style="display: none">Schedule of Option-pricing Model with Following Weighted-average Assumptions</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 65%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Assumptions as of December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Fully Vested</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; text-align: left">Number of Shares</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_zOvAN9zZQDL6" style="width: 22%; text-align: right" title="Number of Shares">1,319,394</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--SharePrice_iI_c20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_zd7QjgdqJJwc" style="text-align: right" title="Stock price">2.67</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Exercise price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_zvltKuMCnOj8" style="text-align: right" title="Exercise price">6.94</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_zMoDvJx5aIT9" title="Expected term">5.75</span> years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_zn0fdwdxlpD" style="text-align: right" title="Expected volatility">31.90</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_zAef3CWeZzr1" style="text-align: right" title="Risk-free interest rate">3.84</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dividend rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_zVd9PeRGxHdd" style="text-align: right" title="Dividend rate">0</td><td style="text-align: left">%</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p id="xdx_8A5_zDNrwjbD9Sri" style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z0SXezbnXQoe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of stock option activity for the years ended December 31, 2023 and 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none"></span></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B9_z6hMbd0cxl3k" style="display: none">Schedule of Stock Option Activity</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Options</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Avg. Remaining Contractual Life (in years)</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Avg. Exercise Price</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-weight: bold; text-align: left">Outstanding as of January 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231_zZCrZxld5Pja" style="width: 11%; text-align: right" title="Number of Options, Outstanding, Beginning balance">1,319,394</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_z21YhOqhwyda" title="Weighted Average Remaining Contractual Life (in years), Outstanding">7.69</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20220101__20221231_z5Fb9NxZcFG5" style="width: 11%; text-align: right" title="Weighted Average Exercise Price, Outstanding, Beginning balance">6.94</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20220101__20221231_zgfl9C219dV8" style="width: 11%; text-align: right" title="Aggregate Intrinsic Value, Outstanding, Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1628">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20220101__20221231_zGdVdEKNR3Pf" style="text-align: right" title="Number of Options, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1630">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_uShares_c20220101__20221231_zTmrillIZ9ja" style="text-align: right" title="Number of Options, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1632">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Cancelled/Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_pid_uShares_c20220101__20221231_zNJ5RE84Xqkk" style="text-align: right" title="Number of Options, Cancelled/Expired"><span style="-sec-ix-hidden: xdx2ixbrl1634">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20220101__20221231_z9OSd5tPk48a" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1636">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Outstanding as of December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231_zfQeHbfbiMJg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, Outstanding, Beginning balance">1,319,394</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zRiad09Ik3Ma" title="Weighted Average Remaining Contractual Life (in years), Outstanding">6.69</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20230101__20231231_z4F1SfXgrd9d" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding, Beginning balance">6.94</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20230101__20231231_zX6U9TmDrwS9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Aggregate Intrinsic Value, Outstanding, Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1644">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20230101__20231231_zIbrWIgFhoSc" style="text-align: right" title="Number of Options, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1646">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_uShares_c20230101__20231231_zzrO0z8gual2" style="text-align: right" title="Number of Options, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1648">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Cancelled/Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_pid_uShares_c20230101__20231231_zsIq9wAYQfXc" style="text-align: right" title="Number of Options, Cancelled/Expired"><span style="-sec-ix-hidden: xdx2ixbrl1650">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20230101__20231231_zDsA0ZPH3ep3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1652">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Outstanding as of December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231_zMLNl3Ld1DX3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, Outstanding, Ending balance">1,319,394</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zDCGuIK6aXWi" title="Weighted Average Remaining Contractual Life (in years), Outstanding">5.69</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20230101__20231231_zKmIVAqODHM9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding, Ending balance">6.94</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20230101__20231231_z8MijdMiMTx9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Aggregate Intrinsic Value, Outstanding, Ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1660">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Vested and Exercisable as of December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iE_pid_c20230101__20231231_zF6kLe4J8jHi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, Vested and Exercisable, Ending balance">1,319,394</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231_zooQYAqcfhUh" title="Weighted Average Remaining Contractual Life (in years), Vested and Exercisable">5.69</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20230101__20231231_zUPUhEvHEX5g" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Vested and Exercisable, Ending balance">6.94</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iE_c20230101__20231231_zAlGieIzA6ae" style="border-bottom: Black 1.5pt solid; text-align: right" title="Aggregate Intrinsic Value, Vested and Exercisable, Ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1668">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>
<p id="xdx_8A4_zbpDEIyVxru6" style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
compensation expense is classified in the Company&#8217;s statements of operations as general and administrative expense. The amounts
were $<span id="xdx_904_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z2zVBKfgkt6g" title="Stock-based compensation expense">0</span> and $<span id="xdx_90E_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zjinxtJywC09" title="Stock-based compensation expense">27,319</span> for the years ended December 31, 2023 and 2022, respectively. As of December 31, 2023, there was <span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_do_c20231231_zc7pRq0SMW1e" title="Unrecognized compensation expense"><span id="xdx_90B_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_do_c20221231_zrzdlQWS22a" title="Unrecognized compensation expense">no</span></span> unrecognized
compensation expense related to unvested options granted under the Company&#8217;s share-based compensation plans.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823803601552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrant Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_DisclosureWarrantLiabilitiesAbstract', window );"><strong>Warrant Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_WarrantLiabilitiesDisclosureTextBlock', window );">Warrant Liabilities</a></td>
<td class="text"><p id="xdx_80E_ecustom--WarrantLiabilitiesDisclosureTextBlock_zzo8RXWpQknk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>12.
<span><span id="xdx_825_zRPCqI4aKDv1">Warrant Liabilities</span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has evaluated financial instruments arising from an adjustable exercise price for warrants that are issued and outstanding as
of December 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilizes a Monte Carlo simulation model for warrants that have an option to convert at a variable number of shares to compute
the fair value of the liability and to mark to market the fair value of the derivative at each balance sheet date. The inputs utilized
in the application of the Monte Carlo model included a starting stock price of $<span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zf9c74pRMbT7" title="Warrants and rights outstanding, measurement input">7.91</span> per share, an expected remaining term of each warrant
as of the valuation date, estimated volatility of <span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zx6QjEVsKMWk" title="Warrants and rights outstanding, measurement input">75</span>%, drift, and a risk-free rate ranging from <span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_z3vjS6wCdOOc" title="Warrants and rights outstanding, measurement input">3.46</span>% to <span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zPAmnsOCnuwk" title="Warrants and rights outstanding, measurement input">59.01</span>%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free
interest rate: The Company uses the risk-free interest rate of a U.S. Treasury Note adjusted to be on a continuous return basis to align
with the Black-Scholes option-pricing model.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend
yield: The Company uses a <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zzjWhuGuqev3" title="Warrants and rights outstanding, measurement input">0</span>% expected dividend yield as the Company has not paid dividends to date and does not anticipate declaring
dividends in the near future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Volatility:
The Company calculates the expected volatility based on comparable company&#8217;s historical stock prices with a look back period commensurate
with the period to maturity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
term: The Company&#8217;s remaining term is based on the remaining contractual maturity of the warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_897_ecustom--ScheduleOfChangesInWarrantLiabilitiesTableTextBlock_z6Toq9XoRvDd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following are the changes in the warrant liabilities during the years ended December 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B1_zAN13vAF9yx" style="display: none">Schedule of Changes in Warrant Liabilities</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; font-weight: bold; text-align: left">Warrant liabilities as of January 1, 2022 </td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--WarrantsAndRightsOutstanding_iS_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zTiROgSGmUp5" style="width: 14%; text-align: right" title="Warrant liabilities, Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1692">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--WarrantsAndRightsOutstanding_iS_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zjQgzvavEJ" style="width: 14%; text-align: right" title="Warrant liabilities, Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1694">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--WarrantsAndRightsOutstanding_iS_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zNRT00QtzTL1" style="width: 14%; text-align: right" title="Warrant liabilities, Beginning balance">32,102</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Addition </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--AdditionToWarrantLiabilities_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zFqbeCr72do1" style="text-align: right" title="Addition"><span style="-sec-ix-hidden: xdx2ixbrl1698">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--AdditionToWarrantLiabilities_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z9PhqYq2ZPOb" style="text-align: right" title="Addition"><span style="-sec-ix-hidden: xdx2ixbrl1700">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--AdditionToWarrantLiabilities_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zWQMNmJimNia" style="text-align: right" title="Addition">2,808,331</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Changes in fair value of warrant liabilities </td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zmkKASd2yON2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Changes in fair value of warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1704">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z4abHtkC2ypb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Changes in fair value of warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1706">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_ziDEp9njSkCd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Changes in fair value of warrant liabilities">(606,049</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Warrant liabilities as of December 31, 2022 </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--WarrantsAndRightsOutstanding_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zaPRSuOKnSHe" style="text-align: right" title="Warrant liabilities, Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1710">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--WarrantsAndRightsOutstanding_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zCuCE8c0iAlf" style="text-align: right" title="Warrant liabilities, Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1712">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstanding_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z6BtnMSYqUtd" style="text-align: right" title="Warrant liabilities, Beginning balance">2,234,384</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Addition </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--AdditionToWarrantLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zn3FBnvSlvEa" style="text-align: right" title="Addition"><span style="-sec-ix-hidden: xdx2ixbrl1716">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--AdditionToWarrantLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zrw1BWKii3eh" style="text-align: right" title="Addition"><span style="-sec-ix-hidden: xdx2ixbrl1718">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--AdditionToWarrantLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zoRdUKE3rUJ" style="text-align: right" title="Addition">2,446,502</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Changes in fair value of warrant liabilities </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--FairValueAdjustmentOfWarrants_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zTA1HjtEEgIi" style="text-align: right" title="Changes in fair value of warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1722">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--FairValueAdjustmentOfWarrants_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zWkjqqijvVH7" style="text-align: right" title="Changes in fair value of warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1724">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--FairValueAdjustmentOfWarrants_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z4dUUpRfRLva" style="text-align: right" title="Changes in fair value of warrant liabilities">(844,854</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Reclassified to equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ReclassifiedToEquity_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z2cqdPeE1ixg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Reclassified to equity"><span style="-sec-ix-hidden: xdx2ixbrl1728">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--ReclassifiedToEquity_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zYBZUn1D477b" style="border-bottom: Black 1.5pt solid; text-align: right" title="Reclassified to equity"><span style="-sec-ix-hidden: xdx2ixbrl1730">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--ReclassifiedToEquity_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zuLnj3rlaVj6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Reclassified to equity">(3,827,807</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Warrant liabilities as of December 31, 2023 </td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_981_eus-gaap--WarrantsAndRightsOutstanding_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zVDzO5JoXFJb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrant liabilities, Ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1734">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstanding_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zS2JS6R6igP1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrant liabilities, Ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1736">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstanding_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zhDRrmhElhV6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrant liabilities, Ending balance">8,225</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>
<p id="xdx_8AB_z9QfYeSfYbb8" style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_DisclosureWarrantLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_DisclosureWarrantLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_WarrantLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Liabilities Disclosure [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_WarrantLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823806159312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_DisclosureDerivativeLiabilitiesAbstract', window );"><strong>Derivative Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesAndFairValueTextBlock', window );">Derivative Liabilities</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--DerivativesAndFairValueTextBlock_zRWD11MTfSx3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>13.
<span id="xdx_825_zB63Zc6ElSi9">Derivative Liabilities</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has identified derivative instruments arising from the conversion shares discussed in the Convertible Notes section of Note 7
as of December 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilizes a Monte Carlo simulation model for commitment shares that have an option to convert at a variable number of shares to
compute the fair value of the derivative and to mark to market the fair value of the derivative at each balance sheet date. The inputs
utilized in the application of the Monte Carlo model included a starting stock price of $<span id="xdx_90B_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zhmP5pD8e4Oj" title="Derivative liability, measurement input">7.91</span> per share, an expected remaining term of
each warrant as of the valuation date, estimated volatility of <span id="xdx_900_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zUMFYGm5hlLg" title="Derivative liability, measurement input">70</span>%, drift, and a risk-free rate ranging from <span id="xdx_90C_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_znYRZFgGftvd" title="Derivative liability, measurement input">3.46</span>% to <span id="xdx_90B_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zvB1Y5MAlpZ4" title="Derivative liability, measurement input">5.47</span>%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free
interest rate: The Company uses the risk-free interest rate of a U.S. Treasury Note adjusted to be on a continuous return basis to align
with the Black-Scholes option-pricing model.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dividend
yield: The Company uses a <span id="xdx_909_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zKyTOTQA3O9j" title="Derivative liability, measurement input">0</span>% expected dividend yield as the Company has not paid dividends to date and does not anticipate declaring
dividends in the near future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Volatility:
The Company calculates the expected volatility based on comparable company&#8217;s historical stock prices with a look back period commensurate
with the period to maturity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected
term: The Company&#8217;s remaining term is based on the remaining contractual maturity of the warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89F_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zJdwQatXOJT7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following are the changes in the warrant liabilities during the years ended December 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B8_zUOQofGvwwp" style="display: none">Schedule of Changes in Derivative Liabilities</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Derivative liabilities as of January 1, 2022 </td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--DerivativeLiabilitiesCurrent_iS_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z9jhwzhVpE86" style="text-align: right" title="Derivative liabilities, Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1754">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--DerivativeLiabilitiesCurrent_iS_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zRx91dD0QrO2" style="text-align: right" title="Derivative liabilities, Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1756">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--DerivativeLiabilitiesCurrent_iS_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z9IMVBdcuuFb" style="text-align: right" title="Derivative liabilities, Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1758">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 46%; text-align: left">Addition </td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_ecustom--AdditionToDerivativeLiabilities_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zoxD020vegNl" style="width: 14%; text-align: right" title="Addition"><span style="-sec-ix-hidden: xdx2ixbrl1760">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_ecustom--AdditionToDerivativeLiabilities_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_ziYC6HGpNHe6" style="width: 14%; text-align: right" title="Addition"><span style="-sec-ix-hidden: xdx2ixbrl1762">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_ecustom--AdditionToDerivativeLiabilities_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zaaoT3YzJxqe" style="width: 14%; text-align: right" title="Addition">2,449,689</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Changes in fair value of Derivative liabilities </td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zAZjwjhblxuf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Changes in fair value of Derivative liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1766">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zR5TmpePO1ng" style="border-bottom: Black 1.5pt solid; text-align: right" title="Changes in fair value of Derivative liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1768">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zYddEwPOCxEd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Changes in fair value of Derivative liabilities">(713,989</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Derivative liabilities as of December 31, 2022 </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--DerivativeLiabilitiesCurrent_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zTnpau9Rhcqd" style="text-align: right" title="Derivative liabilities, Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1772">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--DerivativeLiabilitiesCurrent_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zKCP0izm4NMk" style="text-align: right" title="Derivative liabilities, Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1774">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--DerivativeLiabilitiesCurrent_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zedFJURVBnq4" style="text-align: right" title="Derivative liabilities, Beginning balance">1,735,700</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Addition </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--AdditionToDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zNHky8oLN51c" style="text-align: right" title="Addition"><span style="-sec-ix-hidden: xdx2ixbrl1778">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--AdditionToDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_ziMUjDmHdjM9" style="text-align: right" title="Addition"><span style="-sec-ix-hidden: xdx2ixbrl1780">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--AdditionToDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zWqpB46QAE4k" style="text-align: right" title="Addition">2,375,378</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Changes in fair value of Derivative liabilities </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zO7swFuSYcIi" style="text-align: right" title="Changes in fair value of Derivative liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1784">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zsbDKxp0tjte" style="text-align: right" title="Changes in fair value of Derivative liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1786">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zv1DJ5mLg454" style="text-align: right" title="Changes in fair value of Derivative liabilities">(198,551</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Extinguishment of Derivative liabilities </td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--ExtinguishmentOfDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zno7fW0abtFb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Extinguishment of Derivative liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1790">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_ecustom--ExtinguishmentOfDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zWWLnmwhY4Wj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Extinguishment of Derivative liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1792">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_ecustom--ExtinguishmentOfDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zKKG6mL1xKxg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Extinguishment of Derivative liabilities">(3,912,527</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Derivative liabilities as of December 31, 2023 </td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_989_eus-gaap--DerivativeLiabilitiesCurrent_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zrw5GW8U6Vf1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Derivative liabilities, Ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1796">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--DerivativeLiabilitiesCurrent_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zgHhWXlCDkz6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Derivative liabilities, Ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1798">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98B_eus-gaap--DerivativeLiabilitiesCurrent_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zfaAC5RwmNgg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Derivative liabilities, Ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1800">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>
<p id="xdx_8A8_zcdKM1Q5Bu6k" style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_DisclosureDerivativeLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_DisclosureDerivativeLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesAndFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivatives and fair value of assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//815/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//820/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesAndFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823800642192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Retirement Plan</a></td>
<td class="text"><p id="xdx_801_eus-gaap--PensionAndOtherPostretirementBenefitsDisclosureTextBlock_zQcHPpmX8I0i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>14.
<span id="xdx_826_zd2VxD42aQO8">Retirement Plan</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company sponsors a 401(k)-retirement plan for its employees. Employees are eligible to participate in the elective deferral portion of
the plan after twelve months and 1,000 hours of service. The Company matches the employees&#8217; contribution up to <span id="xdx_90F_eus-gaap--DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_dp_uPure_c20230101__20231231_zZ7DXKw6wWtc" title="Employee contribution percentage">3</span>%. The Company
can also make a discretionary profit-sharing contribution to the employee accounts on an annual basis. Expense totaled $<span id="xdx_90C_eus-gaap--DefinedContributionPlanAdministrativeExpenses_c20230101__20231231_z4JY1QuDSDfh" title="Profit sharing contribution expenses">6,980</span> and $<span id="xdx_909_eus-gaap--DefinedContributionPlanAdministrativeExpenses_c20220101__20221231_zIhw0T9M57Wk" title="Profit sharing contribution expenses">17,183</span>
for years ended December 31, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//715/tableOfContent<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480126/715-20-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480266/715-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823909764752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p id="xdx_809_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zdr9r6ZoLDHh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>15</b>.
<b><span id="xdx_827_zcI7DZSDJVEk">Commitments and Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Manufacturing
Services Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 21, 2020, the Company entered into a Manufacturing Services Agreement (MSA) for the manufacture and supply of the Company&#8217;s
IB-STIM device based upon the Company&#8217;s product specifications as set forth in the MSA. This agreement terminated any prior manufacturing
agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company provides the necessary equipment to the manufacturer and retains ownership. The manufacturer bears the risk of loss of and damage
to the equipment and consigned materials. Performance under the MSA is initiated by orders issued by the Company and accepted by the
manufacturer.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
term of the MSA is 24 months and shall automatically renew for renewal terms of twelve months unless either party provides a written
termination notice to the other party within 180 days prior to the end of the then-current term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trademark
Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an agreement for a trademark related to the Company&#8217;s name on July 11, 2022. The agreement called for an initial
payment of $<span id="xdx_90D_eus-gaap--PaymentsForRepurchaseOfInitialPublicOffering_c20220711__20220711__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--TypeOfArrangementAxis__custom--TrademarkAgreementMember__us-gaap--OtherCommitmentsAxis__custom--InitialPaymentMember_zwCmaO39YmNe" title="Payments for repurchase of initial public offering">10,000</span> upon execution of the agreement. A second and final payment of $<span id="xdx_905_eus-gaap--PaymentsForRepurchaseOfInitialPublicOffering_c20220711__20220711__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--TypeOfArrangementAxis__custom--TrademarkAgreementMember__us-gaap--OtherCommitmentsAxis__custom--SecondAndFinalPaymentMember_zsCbdSjUdMUf" title="Payments for repurchase of initial public offering">40,000</span> was contingent upon the completion of the Company&#8217;s
planned initial public offering. The second payment has been accrued and is recorded in accounts payable and intangible assets on the
balance sheet. The trademark does not have a determinate life and therefore the cost is not being amortized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Executive
Employment Agreements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company, as authorized by the board of directors, entered into employment agreements with nine key employees to provide incentives to
improve shareholder value and to contribute to the growth and financial success of the Company. The agreements had an employment start
date of October 1, 2022, with initial terms from <span id="xdx_904_ecustom--ExecutiveEmploymentAgreementsTerms_dtY_c20221001__20221001__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember_zrOo1cIDeiD1" title="Executive employment agreements renewals">2</span> to <span id="xdx_90A_ecustom--ExecutiveEmploymentAgreementsTerms_dtY_c20221001__20221001__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember_zPeqIA3bvnO1" title="Executive employment agreements renewals">5</span> years and <span id="xdx_900_ecustom--DescriptionOfExecutiveEmploymentAgreementsRenewals_dtY_c20221001__20221001__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember_zT02Ac9G2ARk" title="Description of Executive employment agreements renewals">optional one-year renewals</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
total base salaries for the nine key employees in the agreements are $<span id="xdx_906_eus-gaap--SalariesAndWages_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember_ztNGYbdIZ0oc">1,920,000
</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">per year with various provisions for annual increases.
In addition to base salaries, eight of the employees have a provision for a special one-time incentive payment to be paid in a lump sum
after the start date. The total amount of these special incentive payments is $<span id="xdx_90C_eus-gaap--IncentiveFeeExpense_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember_z3wBPMLu5LMa">1,100,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
The special incentive payment amount includes any accrued backpay wages for the employee. The amount for backpay of $<span id="xdx_902_eus-gaap--DepositLiabilitiesAccruedInterest_iI_c20221231_zcYHS5KsKxT7"><span id="xdx_906_eus-gaap--DepositLiabilitiesAccruedInterest_iI_c20231231_zBzu1gXsKQi6">417,390</span></span> was accrued
as of December 31, 2022 and paid in the year ended December 31, 2023. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are seven key employees that have stock options of the Company totaling <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_pid_uShares_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember_zGN4ztPM74pl" title="Seven key employees stock options">1,238,712</span> shares. These key employees have a provision in their
agreements whereas the Company will pay a special bonus equal to the aggregate of the strike price or exercise price of all their stock
options plus a tax gross-up payment. The special bonus shall be paid in twenty percent (<span id="xdx_90D_ecustom--SpecialBonusPercentage_iI_pid_dp_uPure_c20240102__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember_zBTPchefe9bl" title="Special bonus percentage">20</span>%) installments starting January 2, 2024, and
the same date each of the next four years. As a condition of the payment, the key employee must exercise at least <span id="xdx_90C_ecustom--KeyEmployeeExercisePercentage_iI_pid_dp_uPure_c20240102__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember__srt--RangeAxis__srt--MinimumMember_zt6ObCrqokhj" title="Key employee exercise percentage">20</span>% of their stated
number of stock options. There are additional provisions to cover termination and change of control events. None of the key employees
exercised the options on January 2, 2024</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2023, the Company amended the employee agreements to, among other things, clarify that the special one-time incentive payment and
the deferred bonus are contingent upon the effective date of the planned initial public offering. The amendment also sets forth a process
for executives to exercise the stock options in accordance with the terms of the stock option agreement in effect as of the date of the
employment agreement and to clarify that there is no modification to the stock option agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The Company has recorded the backpay portion of the incentive
bonus notes above. The balance of the incentive bonuses of $<span id="xdx_901_eus-gaap--AccruedBonusesCurrent_iI_c20230430__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember_zikAkNLpoOud" title="Incentive bonus">694,056</span> and the special options bonuses of $<span id="xdx_90E_eus-gaap--AccruedBonusesCurrent_iI_c20230430__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zaaEuPADg5y6" title="Incentive bonus">14,821,830</span> were contingent upon
a successful IPO. The incentive bonuses have been paid in full while the special options bonuses will be recorded when paid.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt"><b>Litigation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">From time to time, the Company may be involved
in litigation relating to claims arising out of operations in the normal course of business. As of the date of issuance, other than those
described below, there were no pending or threatened legal proceedings that could reasonably be expected to have a material effect
on the results of the Company&#8217;s operations. There are also no proceedings in which any of the Company&#8217;s directors,
officers or affiliates is an adverse party to the Company or has a material interest adverse to the Company&#8217;s interest.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">On February 6, 2019, plaintiff Ritu Bhambhani, M.D.,
initiated a lawsuit against Innovative Health Solutions, Inc. and others in the United States District Court for the District of Maryland.
Plaintiffs Bhambhani and Sudhir Rao subsequently amended the complaint, with the Third Amended Complaint (&#8220;Complaint&#8221;) containing
the most recent set of allegations. The Complaint asserted claims under the RICO Act, as well as of fraudulent misrepresentation, intentional
misrepresentation by concealment, and civil conspiracy and sought compensatory damages in excess of $<span id="xdx_901_eus-gaap--LossContingencyDamagesSoughtValue_pn6n6_c20190205__20190206_zPxZIpYxqCr1" title="Sought compensatory damages">5</span> million, pre-judgment interest,
punitive damages, attorney&#8217;s fees, court costs and designation of the case as a class action. The Complaint states that the Company,
distributors of the Company&#8217;s product, and medical billing and coding consultants allegedly made misrepresentations to the plaintiffs
that the Company&#8217;s NeuroStim device and related procedures could be billed to, and reimbursed by, Medicare and other insurance payors
as a surgically implantable neurostimulator. Plaintiffs claim to have suffered damages when Medicare administrative contractors declined
to pay plaintiffs for their use of the device.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">On February 11, 2022, the Company filed a motion for
summary judgment based upon the plaintiffs not being proper parties to assert claims against the Company. On June 14, 2022, the Court
granted the Company&#8217;s motion for summary judgment and dismissed the Complaint.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">On July 14, 2022, plaintiffs Ritu Bhambhani and Sudhir
Rao filed a notice of appeal with the Fourth Circuit Court of Appeals. The Company filed a motion to dismiss.&#160;On January 4, 2023,
the Court issued an order that stated it was deferring a ruling on the motion to dismiss the appeal and that&#160;it would address those
arguments at the same time that it addressed the substantive merits of the case. While it is too early to predict the ultimate outcome of this matter, we continue to believe we have
meritorious defenses, that the dismissal of the Complaint should be upheld, and intend to continue to defend this matter vigorously.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">On July 14, 2022, plaintiffs Ritu Bhambhani, LLC;
Box Hill Surgery Center, LLC; Pain and Spine Specialists of Maryland, LLC; and SimCare ASC, LLC initiated a lawsuit against the Company
and others in the United States District Court for the District of Maryland. The plaintiffs in this lawsuit are business entities owned
or partially owned by the plaintiffs that initiated the litigation described above. The Complaint asserted claims under the RICO Act,
as well as fraudulent misrepresentation, intentional misrepresentation by concealment, and civil conspiracy and seeks compensatory damages
in excess of $<span id="xdx_900_eus-gaap--LossContingencyDamagesSoughtValue_c20220713__20220714_zJpRVxmhzaac" title="Sought compensatory damages">75,000</span>, pre-judgment interest, punitive damages, attorney&#8217;s fees, and court costs. The Complaint states that the Company,
distributors of the Company&#8217;s product, and medical billing and coding consultants allegedly made misrepresentations to the plaintiffs
that the Company&#8217;s NeuroStim device and related procedures could be billed to, and reimbursed by, Medicare and other insurance payors
as a surgically implantable neurostimulator. Plaintiffs claim to have suffered damages when Medicare administrative contractors declined
to pay plaintiffs for their use of the device.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">On September 28, 2022, the Company filed a motion to dismiss all
claims. On May 25, 2023, the Court issued an Order and a Memorandum Opinion which dismissed the plaintiffs&#8217;claims related to the
RICO Act. The remaining claims are still pending, and no trial date has been set for the case. </p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The Court has vacated its Scheduling Order
at the parties&#8217; request so that the parties could try to resolve the disputes in both cases through an independent <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">third-party</span>
mediator. No mediation date has been set. While it is too early to predict the ultimate
outcome of this matter, we believe the Company has meritorious defenses and intends to defend this matter vigorously.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823802386384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Health Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_DisclosureHealthBenefitPlanAbstract', window );"><strong>Health Benefit Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_HealthBenefitPlanDisclosureTextBlock', window );">Health Benefit Plan</a></td>
<td class="text"><p id="xdx_801_ecustom--HealthBenefitPlanDisclosureTextBlock_zsgutNsRxR7e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>16.
<span id="xdx_821_zCZZocpiAC2i">Health Benefit Plan</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into a self-funded program employer agreement in 2018 in conjunction with a group health plan for the benefit of eligible
employees. This plan is a level funded plan, and the services and products include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    self-funded employer health benefit plan.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stop
    loss insurance purchased from a stop loss insurance company.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Third
    party administrator to provide administrative services with regard to the plan.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company maintains a stop loss contract that reimburses the Company for claims paid under the plan if they exceed a predetermined level.
The Company makes contributions for health care costs and associated expenses that are expected during the plan year. The amount of contributions
is determined annually based on the Company&#8217;s maximum liability for expected claims, administrative expenses, and premiums for
the stop loss policy. The Company paid premiums of $<span id="xdx_90C_eus-gaap--HealthCareOrganizationStopLossInsurancePremiumExpense_c20230101__20231231_zgAx37ltp1q7" title="Stop loss insurance premium expense">255,715</span> and $<span id="xdx_909_eus-gaap--HealthCareOrganizationStopLossInsurancePremiumExpense_c20220101__20221231_zGfPfHjLs6H1" title="Stop loss insurance premium expense">196,929</span> for the years ended December 31, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is responsible for the monthly premiums, as established, and nothing further. The stop loss policy covers the claims if they
exceed the claims funds. After a certain time, and if there is a surplus in the claims fund, the Company may be entitled to receive a
<span id="xdx_90F_ecustom--HealthCareOrganizationStopLossInsurancePremiumPercentage_pid_dp_uPure_c20230101__20231231_zi24CLyZG2F8" title="Stop loss insurance premium percentage">48.5</span>% refund from the fund. This amount is recognized by the Company when received.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_DisclosureHealthBenefitPlanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_DisclosureHealthBenefitPlanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_HealthBenefitPlanDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Health benefit plan disclosure [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_HealthBenefitPlanDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823803585184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_802_eus-gaap--IncomeTaxDisclosureTextBlock_zs7jTnMhY58c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>17.
<span id="xdx_82C_zq1S6XHJZQGi">Income Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Inflation Reduction Act (IRA) was signed
into law on August 16, 2022, imposing a 15% corporate alternative minimum tax on adjusted financial statement income and a 1% excise
tax on stock repurchases after January 1, 2023. The IRA did not have an impact on the Company&#8217;s 2023 or 2022 financial
statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Tax Cuts and Jobs Act (TCJA) requires taxpayers
to capitalize and amortize research and developmental (&#8220;R&amp;D&#8221;) expenditures undersection 174 for tax years beginning after
December 31, 2021 and, therefore, became effective for the Company during the year ended December 31, 2022. The TCJA resulted in the capitalization
of R&amp;D costs of $<span id="xdx_90E_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_c20231231_zHxmYUO7SED7" title="Research and development expense">169,315</span> and $<span id="xdx_90E_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_c20221231_zQsy7EgEb3B9" title="Research and development expense">225,466</span> for tax purposes for the years ended December 31, 2023 and 2022, respectively. The Company is
amortizing these costs over 5 years if the R&amp;D was performed in the U.S. and over 15 years if the R&amp;D was performed outside the
US. The Company did not recognize a current provision for income taxes for 2023 and 2022 since there were net operating losses reported
in both years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Deferred income taxes are provided for temporary
differences between the financial reporting basis and the tax basis of the Company&#8217;s assets and liabilities. Differences are primarily
attributable to net operating loss carryforwards and stock-based compensation. The Company does not reflect any deferred taxes in its financial
statements due to a full valuation allowance. The net deferred tax amounts include the following components:</p>

<p id="xdx_897_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zgxHJDSet3c6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B6_zsvq5IwiPWJk" style="display: none">Schedule of Deferred Tax Asset</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_491_20231231_zUAjjHz2OOWb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_492_20221231_zwxwQFFiRWaj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net deferred tax assets - Non-current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--DeferredTaxAssetsDepreciation_iI_maDTANzFzE_zpjtVKHNnBh7" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">Depreciation</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 16%; font-weight: bold; text-align: right">(15,175</td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(16,098</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_403_ecustom--DeferredTaxAssetsAmortization_iI_maDTANzFzE_zr2UKuOK9QLf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Amortization</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(14,195</td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(19,290</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_iI_maDTANzFzE_z14UjS7TVmNc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrual to cash</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">718,893</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">767,861</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTANzFzE_zqfagDjdXrQ9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock based compensation</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">3,653,490</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,653,490</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTANzFzE_zlDyBEzatgGf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected income tax benefit from NOL carry-forwards</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">6,573,406</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,309,340</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzFzE_zzVF2dVXevJ" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less valuation allowance</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(10,916,419</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,695,303</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzFzE_znuM3OXHLwsl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Deferred tax assets, net of valuation allowance</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1874">&#8212;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1875">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>
<p id="xdx_8A5_zQBkM4bX6Rh2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p id="xdx_892_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zICFLbegfY6a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the federal statutory income tax rate and the effective income tax rate as a percentage of income before income
taxes is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BC_zpruKJf8hmd5" style="display: none">Schedule of Federal Statutory Income Tax Rate and Effective Income Tax Rate</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_498_20230101__20231231_z59WnKOa1Zi6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_492_20220101__20221231_zzwnLnAc0SWc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maEIT001_zP3M6DNxZ3p" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Federal statutory income tax rate</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 14%; font-weight: bold; text-align: right">21.0</td><td style="width: 1%; font-weight: bold; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maEIT001_zuk7jKPhTKNg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State tax rate, net of federal benefit</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">4.9</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.7</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_pid_dp_uPure_maEIT001_zpBL7zNHp4Ig" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Nondeductible expenses</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1885">&#8212;</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1886">&#8212;</span></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--EffectiveIncomeTaxRateReconciliationNontaxableIncome_pid_dp_uPure_maEIT001_zHe6GGriUl68" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Nontaxable income</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1888">&#8212;</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1889">&#8212;</span></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maEIT001_zTYwymOSv2yb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance on net deferred tax assets</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(25.9</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(25.7</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtEIT001_zaePfdx4WEW6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Effective income tax rate</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1894">&#8212;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1895">&#8212;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td></tr>
  </table>
<p id="xdx_8AC_zF2UMsOv6J8h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had no income tax expense due to the operating loss incurred for the years ended December 31, 2023 and 2022. The
Company&#8217;s management has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax
assets and has determined that it is more likely than not that the Company will not recognize the benefits of the net deferred tax
assets. As a result, the Company recorded a full valuation allowance at December 31, 2023 and 2022. The valuation allowance
increased by $<span id="xdx_90A_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_c20230101__20231231_zOfIjaWhPGM6" title="Deferred tax assets valuation allowance">3,221,116</span>
and $<span id="xdx_906_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_c20220101__20221231_zJ8K0yRbxiGh" title="Deferred tax assets valuation allowance">1,136,470</span> for the years ended December 31, 2023 and 2022, respectively, primarily due to net operating loss (NOL)
carryforwards.  </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 31, 2023, the Company had federal and state net operating loss (NOL) carryforwards totaling $<span id="xdx_90D_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_c20231231_zttitOLQQve8" title="Federal and state net operating loss">28,238,445</span> and $<span id="xdx_90C_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_c20221231_zXCAFy0TSdye" title="Federal and state net operating loss">25,543,000</span>, respectively.
These loss carryforwards may be offset against future taxable income. There is no limitation on the number of years to utilize the federal
NOL. The federal deduction will be limited to 80% of modified taxable income. The state NOL allows up to 100% of taxable income to be
offset and can be carried forward no longer than 20 years after the year of the taxable loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal
and state tax laws impose limitations on the utilization of NOLs and credit carryforwards in the event of an ownership
change for tax purposes, as defined in Section 382 of the Internal Revenue Code. Accordingly, the Company&#8217;s ability to utilize
these carryforwards may be limited as a result of an ownership change. Such
an ownership change could result in a limitation in the use of the net operating losses in future years and possibly a reduction of the
net operating losses available.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_eus-gaap--SummaryOfOperatingLossCarryforwardsTextBlock_zuWUZHLVUHcg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
not used, the state carryforwards will expire as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BB_zACIjTRNE0Bj" style="display: none">Schedule of State Carryforwards</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_495_20231231_z2i4eP1rf9I4" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--TaxYear2038Member_zcmuelte7Jx8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: justify">2038</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">888,389</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--TaxYear2039Member_zcaDcM4YT0b7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">2039</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,039,949</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--TaxYear2040Member_zJD30KX1QMbf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">2040</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4,457,495</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--TaxYear2041Member_zHbzhjCnguzj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">2041</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,406,225</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--TaxYear2042Member_z25W3LxayKI7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">2042</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,730,141</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--TaxYear2043Member_zzAtvMCDGtJ9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">2043</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">12,915,439</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--TaxYear2043Member_z7JUo4OntuBc" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">State Carryforwards</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">12,915,439</td><td style="text-align: left">&#160;</td></tr>
</table>

<p id="xdx_8A1_z7vr3pLjO0Hb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823803623808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p id="xdx_806_eus-gaap--SubsequentEventsTextBlock_zqnerVpk7s2d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>18.
<span id="xdx_828_z8bf7jYhx8qc">Subsequent Events</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company evaluated events through the date of issuance. Subsequent to December 31, 2023, the Company entered into a series of
Convertible Promissory Notes totaling $<span id="xdx_906_eus-gaap--DebtInstrumentAnnualPrincipalPayment_iI_c20240324__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zUkkjB5ELwEd" title="Total principal amount">3,135,000</span>
with terms identical to the $<span id="xdx_907_eus-gaap--ConvertibleDebt_iI_c20231231_zTpgm5fsv7N8" title="Convertible debt">3,000,000</span> Convertible Promissory Note issued on November 8, 2023 (see Footnote 10). The Company has
received $<span id="xdx_907_eus-gaap--DebtInstrumentPeriodicPayment_c20240323__20240324__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zec4KbELuR23" title="Principal amount due in monthly installments">1,535,000</span>
of the principal amount with the remainder due in monthly installments through the maturity date of March of 2025. &#160; The Convertible Promissory Notes bear interest at <span id="xdx_904_eus-gaap--DebtConversionOriginalDebtInterestRateOfDebt_dp_uPure_c20231231__20231231_ztKKlywvCTq4" title="Debt conversion, original debt, interest rate of debt">8.5%</span> per annum payable quarterly in either cash or common
stock. The Convertible
Promissory Notes contain a provision that allows for a voluntary conversion by the investors into Series B Preferred Stock at $<span id="xdx_904_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20240324__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zHTIUvcJOCf1" title="Preferred stock, par value">2.38</span>
per share any time prior to the maturity date with mandatory conversion by the Company at the maturity date. The Company shall
use the proceeds solely for working capital and general corporate purposes and not pay any dividends or distributions or to advance
any funds to its officers, directors or affiliates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823912034448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restatement of Interim Financial Statements (Unaudited)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract', window );"><strong>Accounting Changes and Error Corrections [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionTextBlock', window );">Restatement of Interim Financial Statements (Unaudited)</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--ErrorCorrectionTextBlock_z7bbO2JVEdK9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>19. <span id="xdx_82E_zasZZ9iYQKN7">Restatement of Interim Financial Statements (Unaudited)</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the preparation of the Company&#8217;s
financial statements as of and for the year ended December 31, 2023, management identified a material accounting error in the unaudited
interim financial statements as of and for the three and nine month periods ended September 30, 2023 relating to the improper classification
of the reduction of the fair value of warrant liabilities as a reduction to the extinguishment of debt charge on the Statement of Operations
rather than an increase to additional paid in capital on the Balance Sheet.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon the consummation of the Company&#8217;s IPO,
the exercise price of certain warrants issued prior to the IPO became known. As a result of the exercise price becoming known, our warrant
liability was reduced by $<span id="xdx_904_ecustom--IncreaseDecreaseInWarrantLiability_c20230101__20230930_ziFwUb6LOkc3" title="Reduced warrant liability"><span id="xdx_90E_ecustom--IncreaseDecreaseInWarrantLiability_c20230701__20230930_z80RaeguLGXh" title="Reduced warrant liability">3,721,007</span></span>. This warrant liability reduction should have triggered a reclassification to additional paid in capital
instead of an extinguishment of debt charge. This accounting error resulted in a (i) $<span id="xdx_90F_eus-gaap--GainsLossesOnExtinguishmentOfDebt_iN_di_c20230701__20230930__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zT4JceRxahp2" title="Extinguishment of debt expense"><span id="xdx_90E_eus-gaap--GainsLossesOnExtinguishmentOfDebt_iN_di_c20230101__20230930__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zFfyYJd4ZaOl" title="Extinguishment of debt expense">3,721,007</span></span> understatement of the extinguishment of
debt expense on the Statement of Operations, (ii) $<span id="xdx_909_eus-gaap--NetIncomeLoss_iN_di_c20230701__20230930__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zOuSte5O6ULj" title="Net loss"><span id="xdx_90D_eus-gaap--NetIncomeLoss_iN_di_c20230101__20230930__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zKyZzcheCPE1" title="Net loss">3,721,007</span></span> understatement of the net loss on the Statement of Operations, and (iii)
$<span id="xdx_903_eus-gaap--AdditionalPaidInCapital_iI_c20230930__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zB1iRpev7Fq6" title="Additional paid in capital">3,721,007</span> understatement of additional paid in capital on the Balance Sheet as of and for the three and nine month periods ended September
30, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Board of Directors of the Company, upon the recommendation
of the Audit Committee and after discussion with management, concluded that the Company&#8217;s previously issued unaudited financial
statements as of and for the three and nine month periods ended September 30, 2023 should no longer be relied upon and should be restated
due to identification of the material accounting error.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following tables present the amounts previously reported, the restatement
impact and the restated amount in the respective unaudited financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NeurAxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Balance
Sheet</b></span></p>

<p id="xdx_89F_eus-gaap--ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_zoiTHtkJXvUd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zaX6evkBfrL">Schedule
of Restatement of Interim Financial Statements (Unaudited)</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20230930__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zftlwQXmGNHd" style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20230930__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zg7s8K2a85xf" style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20230930_zfy7Wt4pZfTg" style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="10" style="text-align: center">(Unaudited)</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">As of September 30,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">As Reported</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Adjustments</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">As Restated</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AssetsAbstract_iB_z7la7edj9gPa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1.5pt">Assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AssetsCurrentAbstract_i01B_zDv5FQtG0KWd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maCzVMo_zq10uP42Nw23" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 52%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">761,249</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1960">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">761,249</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AccountsReceivableNetCurrent_i02I_maCzVMo_zjUE7Rhi6MZb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accounts receivable, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">132,382</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1964">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">132,382</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--InventoryNet_i02I_zSC1t8b8tO9b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Inventories</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34,530</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1968">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34,530</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_zcfA0J0lcHlc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Prepaid and other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">38,693</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1972">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">38,693</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AssetsCurrent_i01TI_zdcR5KulT93c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Total current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">966,854</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1976">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">966,854</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_i01I_zGo7D0gswd6a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Property and equipment, at cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">420,586</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1980">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">420,586</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_i02NI_di_zZuhB7zBbJge" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less - accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(340,260</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1984">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(340,260</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentNet_i01TI_zgh4NmQxFQk7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">80,326</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1988">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">80,326</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseRightOfUseAsset_i02I_zXYHXdwCrPh1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating lease right of use asset, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">78,043</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1992">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">78,043</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsNet_i02I_z1YBTPAJ1jI2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Intangible assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">110,695</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1996">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">110,695</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--Assets_iTI_zAoHqfrMaTwb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,235,918</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2000">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,235,918</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zG7f7RL4oc1d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Liabilities and Stockholders&#8217; Deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LiabilitiesCurrentAbstract_i01B_zH2U1qauwbPi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AccountsPayableCurrent_i02I_zwdfH5oTCP4a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">566,649</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2012">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">566,649</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AccruedLiabilitiesCurrent_i02I_zKE4L5NjSPn8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">280,063</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2016">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">280,063</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NotesPayableCurrent_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zHHPrOoNPO41" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">194,249</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2020">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">194,249</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_zVnk1tRVOWDe" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Current portion of operating lease payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45,194</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2024">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45,194</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--Deposits_i02I_z6pclX04VZc6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Customer deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">68,972</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2028">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">68,972</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--ShareLiabilitiesCurrent_i02I_zKLRKH4hH2je" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Share liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">934,256</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2032">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">934,256</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--WarrantLiabilities_i02I_z270JvRkjKU4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Warrant liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">168,269</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2036">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">168,269</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LiabilitiesCurrent_i01TI_zKajPzaog211" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Total current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,257,652</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2040">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,257,652</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseLiabilityNoncurrent_i02I_zPlW0LG4lAoi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Operating lease payable, net of current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">39,353</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2044">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">39,353</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--Liabilities_iTI_zHvU4k8V1lJg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,297,005</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2048">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,297,005</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--StockholdersEquityAbstract_i01B_z2Rb0PKBuovf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stockholders&#8217; deficit:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PreferredStockValue_i02I_hus-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesAPreferredStockMember_zPo6fwv8hbrh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Convertible Series A preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2055">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2056">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2057">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PreferredStockValue_i02I_hus-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_zNMiNBhKlRFj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Convertible Series Seed preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2059">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2060">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2061">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--CommonStockValue_i02I_zNrRZtQV4sP2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,149</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2064">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,149</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AdditionalPaidInCapital_i02I_z937TPMgFl93" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Additional paid in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,178,570</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,721,007</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45,899,577</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_zkVc8A6CdQ46" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(43,244,806</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,721,007</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(46,965,813</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--StockholdersEquity_i02TI_z4DofNsPbSVj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Total stockholders&#8217; deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,061,087</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2076">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,061,087</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_zXG1JwsN9SK9" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total liabilities and stockholders&#8217; deficit</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,235,918</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2080">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,235,918</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NeurAxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Statements
of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20230701__20230930__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z4rksagAY03j" style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20230701__20230930__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_ziSlrYk208r2" style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20230701__20230930_zMpNIDudqAGf" style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20230101__20230930__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zYmcWZhttVj4" style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20230101__20230930__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zfmnf9oMi2v7" style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20230101__20230930_zn0J8Gj06WIg" style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="10" style="text-align: center">(Unaudited)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="10" style="text-align: center">(Unaudited)</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">For the Three Months Ended September 30, 2023</p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">For the
Nine Months Ended September 30, 2023</p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">As Reported</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Adjustments</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">As Restated</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">As Reported</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Adjustments</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">As Restated</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zhe49lSI3Pn5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Net sales</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">477,460</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2084">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">477,460</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">1,928,590</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2087">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">1,928,590</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CostOfGoodsAndServicesSold_zxb0rqhPN23c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Cost of goods sold</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">67,287</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2091">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">67,287</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">231,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2094">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">231,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--GrossProfit_iT_zLQL6hS1wAtc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gross profit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">410,173</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2098">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">410,173</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,697,590</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2101">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,697,590</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--SellingExpense_i01_z2VS80dLjIb8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Selling expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">64,210</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2105">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">64,210</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">250,933</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2108">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">250,933</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_i01_zD5d2npTYDW8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">44,950</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2112">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">44,950</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">171,536</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2115">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">171,536</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--GeneralAndAdministrativeExpense_i01_zLKoElMbPSra" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,323,352</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2119">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,323,352</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,316,411</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2122">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,316,411</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingIncomeLoss_iT_zj534qStsWJa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;(3,022,339</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2126">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;(3,022,339</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;(5,041,290</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2129">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;(5,041,290</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zZ8XVlIsgQHe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other (expense) income, net:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--FinancingCharges_i01N_di_zXZ9M4yERMSl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Financing charges</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2139">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2140">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2141">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,772</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2143">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,772</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--InterestExpense_i01N_di_zMuzULvx6tGl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(102,628</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2147">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(102,628</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(453,869</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2150">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(453,869</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--InterestAndOtherIncome_i01_zKdzXBdfMf86" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,103</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2154">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,103</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,103</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2157">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,103</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--FairValueAdjustmentOfWarrants_i01N_di_zfQly2l0YzQ5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of warrant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">592,853</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2161">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">592,853</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">791,610</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2164">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">791,610</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DerivativeGainLossOnDerivativeNet_i01_z0jMSfMEIBrf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of derivative financial instruments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,394</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2168">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,394</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">198,551</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2171">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">198,551</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_i01N_di_zrCWwUMRlmK6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Amortization of debt discount and issuance cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,331,030</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2175">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,331,030</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,881,622</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2178">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,881,622</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i01_zvopJgfCJMXa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Extinguishment of debt liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,058,062</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,721,007</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,779,069</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">71,436</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,721,007</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,649,571</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--OtherNonoperatingIncome_i01_z2X83oyskdr1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Other income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,931</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2189">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,931</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,483</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2192">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,483</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OtherNonoperatingExpense_i01N_di_zeNbxJg4tk4a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Other expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,578</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2196">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,578</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(9,008</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2199">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(9,008</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--OtherNonoperatingIncomeExpense_i01T_zVZVcNoeOdq3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Total other (expense) income, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,882,017</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,721,007</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,603,024</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,272,088</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,721,007</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,993,095</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--NetIncomeLoss_iT_zhajvwVO5DA" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(4,904,356</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3,721,007</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(8,625,363</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(9,313,378</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3,721,007</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(13,034,385</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NeurAxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Statements
of Cash Flows</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20230101__20230930__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zpfSAs8uMX59" style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20230101__20230930__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zh943Te2cEQi" style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20230101__20230930_zOLmPb5LR2vi" style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="10" style="text-align: center">(Unaudited)</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">For the Nine Months Ended September 30, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">As Reported</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Adjustments</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">As Restated</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zNFzEruN5ZAl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Cash flows from operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NetIncomeLoss_i01_z10UihQjbdJe" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 52%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(9,313,378</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(3,721,007</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(13,034,385</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zzi9wRZSgvSg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Adjustments to reconcile net loss to net cash used by operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_i02_ztAF6zIZgWCe" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Amortization of debt discount and issuance cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,881,622</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2229">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,881,622</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DepreciationDepletionAndAmortization_i02_zvs5dEhNDTb8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,290</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2233">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,290</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ProvisionForDoubtfulAccounts_i02_zyoj3shroaxf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Provision for losses on accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,380</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2237">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,380</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--NoncashLeaseExpense_i02_zhsMTmwQdue2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Non-cash lease expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23,339</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2241">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23,339</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--NoncashInterestExpense_i02_zLbjShbxGpVd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Non-cash interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">260,777</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2245">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">260,777</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ShareBasedCompensation_i02_zNJigtRGPydl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Stock based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2248">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2249">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2250">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i02N_di_zuQcvCuJFq3d" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Extinguishment of derivative liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(71,436</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,721,007</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,649,571</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--IssuanceOfCommonStockForNoncashConsideration_i02_zKSGiwUwIzh9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Issuance of common stock for non-cash consideration</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,550,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2257">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,550,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--FinanceCharges_i02_zsF40VPD0lNi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Finance charges</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,772</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2261">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,772</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DerivativeGainLossOnDerivativeNet_i02N_di_zo7ywTDh0YT4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Change in fair value of derivative liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(198,551</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2265">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(198,551</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--FairValueAdjustmentOfWarrants_i02_zjyPkTjTyWf5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Change in fair value of warrant liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(791,610</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2269">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(791,610</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i01B_ztYvW3n5HgJl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncreaseDecreaseInAccountsReceivable_i02N_di_zWuX2vDKsDY4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left">Accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35,637</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2277">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35,637</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--IncreaseDecreaseInInventories_i02N_di_zrUt99gZAia7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt">Inventory</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,603</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2281">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,603</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i02N_di_zPv9dtAskbh4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left">Prepaids and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(37,967</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2285">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(37,967</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--IncreaseDecreaseInAccountsPayable_i02_zdEpC1lp1Qpl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,025,467</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2289">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,025,467</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--IncreaseDecreaseInAccruedLiabilities_i02_zFHeer2YnTL9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(415,181</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2293">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(415,181</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_ecustom--IncreaseDecreaseInCustomerDeposit_i02_zjNmO8vtUBp1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left">Customer deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,798</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2297">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,798</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_i02_zDKLy320Bbg8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left; padding-bottom: 1.5pt">Operating lease liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(25,047</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2301">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(25,047</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iT_z7dem0rvwNCl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Net cash used by operating activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,064,419</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2305">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,064,419</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zOTi5ssP65Ch" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Cash flows from investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_z5M3aprakQZ1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Additions to property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(14,741</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2313">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(14,741</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--PaymentsToAcquireIntangibleAssets_i01N_di_zKWMrYHZxS03" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Additions to intangible assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(41,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2317">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(41,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--NetCashProvidedByUsedInInvestingActivities_iT_ziEHqD2gApR" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Net cash used by investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(55,741</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2321">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(55,741</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_ztFbpQvVc30j" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Cash flows from financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_z6X2ddTMc9d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Proceeds from issuance of common stock, net of issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,464,642</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2329">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,464,642</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--OfferingCostsInAdvanceOfSaleOfCommonStock_i01_zlYzRftG3QYi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Offering costs in advance of sale of common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,417,185</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2333">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,417,185</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--RepaymentsOfNotesPayable_iN_di_zfRmgUe6Bybi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Principal payments on notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,487,578</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2337">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,487,578</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--ProceedsFromNotesPayable_i01_z0L6AF8g7nia" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Proceeds from notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">159,831</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2341">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">159,831</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ProceedsFromConvertibleDebt_i01_zUBKSXgYTFe3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Proceeds from convertible notes, net of fees</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,908,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2345">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,908,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NetCashProvidedByUsedInFinancingActivities_iT_zqeQpze91eo9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,627,710</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2349">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,627,710</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_zucVxobTAm4c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Net decrease in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">507,550</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2353">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">507,550</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_zSnT6Ik9cfKe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Cash and cash equivalents at beginning of period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">253,699</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2357">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">253,699</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_zH5FxgHwPqVi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Cash and cash equivalents at end of period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">761,249</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2361">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">761,249</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A7_z4l6shcK1Zsd" style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823901843568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates and Critical Accounting Estimates and Assumptions</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--UseOfEstimates_zVDuaXrTLydg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span><span id="xdx_862_zEz0MUIIsalf">Use
of Estimates and Critical Accounting Estimates and Assumptions</span></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements
and the reported amounts of revenues and expenses during the reporting periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
significant accounting estimates or assumptions bear the risk of change due to the fact that there are uncertainties attached to these
estimates or assumptions, and certain estimates or assumptions are difficult to measure or value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
bases its estimates on historical experience and on various assumptions that are believed to be reasonable in relation to the financial
statements taken as a whole under the circumstances, the results of which form the basis for making judgments about the carrying values
of assets and liabilities that are not readily apparent from other sources.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available information, changes
in facts and circumstances, historical experience, and reasonable assumptions. After such evaluations, if deemed appropriate, those
estimates are adjusted accordingly. The Company uses estimates in accounting for, among other items, revenue recognition, allowance
for credit losses, stock-based compensation, income tax provisions, excess and obsolete inventory reserve, and impairment of property and
equipment, and intellectual property. Actual results could differ from those estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zGfQ3Arrc5Ke" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span><span id="xdx_867_zpZR0i4lMbte">Cash
and Cash Equivalents</span></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. The Company
did not hold any cash equivalents as of December 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Trade Accounts Receivable and Allowance for Credit Losses</a></td>
<td class="text"><p id="xdx_844_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zQyLIdQUqMOa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span><span id="xdx_86D_zsWTh5OrDIQg">Trade
Accounts Receivable and Allowance for Credit Losses</span></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trade
accounts receivable are stated at the amount management expects to collect from outstanding balances, net of an allowance for credit
losses. Management evaluates many factors when determining the collectability of specific customer accounts, including, but not limited
to, creditworthiness, past transaction and payment history, current economic industry trends and changes in payment terms. We use assumptions
and judgment based on the best available facts and circumstances to estimate and record an allowance. The allowance for credit losses
was $<span id="xdx_903_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20231231_zNeKr5x0pjbf" title="Allowance for doubtful accounts">11,993</span> and $<span id="xdx_906_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20221231_zt6UU4ntIW9g" title="Allowance for doubtful accounts">31,275</span> as of December 31, 2023 and 2022, respectively. The Company recorded credit losses for the years ended December
31,2023 and 2022 of $<span id="xdx_905_eus-gaap--ProvisionForOtherCreditLosses_c20230101__20231231_z1fCU75qdmHl" title="Credit losses">25,281</span> and <span id="xdx_90E_eus-gaap--ProvisionForOtherCreditLosses_c20220101__20221231_zJXQSNTHatn3" title="Credit losses">64,197</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositContractsPolicy', window );">Customer Deposits</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--DepositContractsPolicy_z3G9pKnFRuKc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span><span id="xdx_86C_zmrJGQX99vDl">Customer
Deposits</span></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Customer
deposits consists of billings, payments, and returned devices from clients in advance of revenue recognition. The Company will recognize
the customer deposits over the next year. As of December 31, 2023, and 2022, the Company had customer deposits of $<span id="xdx_902_eus-gaap--Deposits_iI_c20231231_zqIUNH3DZJc8" title="Customer deposits">74,947</span> and $<span id="xdx_90F_eus-gaap--Deposits_iI_c20221231_zPLa3GeMgKU6" title="Customer deposits">59,174</span>,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><p id="xdx_846_eus-gaap--InventoryPolicyTextBlock_zMI6ujuN7rw1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span><span id="xdx_866_zves0DdFNTW3">Inventories</span></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inventories
are valued at the lower of cost or net realizable value. Cost is determined using the weighted average method. The inventory is comprised
of finished medical devices on hand. Certain components within the devices have an expiration date that are removed from current inventory
and expensed at the date of expiration. For the years ended December 31, 2023 and 2022, $<span id="xdx_90B_ecustom--InventoryExpenses_c20231231_zoQihQ2ttyu6" title="Inventory expenses">25,008</span> and $<span id="xdx_90D_ecustom--InventoryExpenses_iI_c20221231_zzHCNhEaXkRc" title="Inventory expenses">10,026</span> were expensed as expired
inventory, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Offering Costs</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--DeferredChargesPolicyTextBlock_zKApjnvqDPCi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span><span id="xdx_865_zn9V9ttt6wmf">Deferred
Offering Costs</span></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
offering costs consist of costs incurred in connection with the preparation of an initial public offering. These costs, together with
the underwriting discounts and commissions, were charged to additional paid in capital upon the IPO. As of December 31, 2023 and 2022,
the Company had deferred offering costs of $<span id="xdx_90F_eus-gaap--DeferredOfferingCosts_iI_dxL_c20231231_zduETi4XjJ34" title="Deferred offering costs::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl0636">0</span></span> and $<span id="xdx_906_eus-gaap--DeferredOfferingCosts_iI_c20221231_zJ5duxanWdb7" title="Deferred offering costs">736,736</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zqhPQolYI7fb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_866_zfGsnuflXkyf">Property
and Equipment</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment are recorded at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated
useful lives of the assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89D_ecustom--ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_zuDWFlazwtT8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
is calculated using the following estimated useful lives:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B0_zRYzhM4FObAj" style="display: none">Schedule of Estimated Useful Lives</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 60%; border-collapse: collapse; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Classification</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Years</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Machinery and Equipment </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MinimumMember_z6T4sUWWoWNi" title="Property and equipment, estimated useful lives">5</span>-<span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MaximumMember_zd3L5zgGES5d" title="Property and equipment, estimated useful lives">10</span> </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture and Fixtures</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zkpRYICgli12" title="Property and equipment, estimated useful lives">5</span>-<span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_zy9KJtQEgs4a" title="Property and equipment, estimated useful lives">10</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer Hardware</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MinimumMember_zdqGof3t1oI" title="Property and equipment, estimated useful lives">5</span>-<span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MaximumMember_zcRNd7T4hdqb" title="Property and equipment, estimated useful lives">10</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold Improvements</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MinimumMember_zZHzaJmx9lfj" title="Property and equipment, estimated useful lives">10</span>-<span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MaximumMember_zFLCxUzN8HYh" title="Property and equipment, estimated useful lives">20</span></span></td></tr>
  </table>
<p id="xdx_8A6_zEuDpQt8YXCc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
expense was $<span id="xdx_907_eus-gaap--Depreciation_c20230101__20231231_zq9Hcvf7e1Dh" title="Depreciation expense">30,240</span> and $<span id="xdx_901_eus-gaap--Depreciation_c20220101__20221231_zu5aKm0Y6C1c" title="Depreciation expense">30,920</span> during the years ended December 31, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--ResearchAndDevelopmentExpensePolicy_zLl5UkZpEoJ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_862_zsTqLJDzE2Yb">Research
and Development</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
for research and development are expensed as incurred. Research and development expenses consist primarily of clinical research studies
and new product development.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets</a></td>
<td class="text"><p id="xdx_841_eus-gaap--IntangibleAssetsFiniteLivedPolicy_z8qWp4Ka2Tj4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86E_zMTjD8n9M7D4">Intangible
Assets</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets consist of software, patents and a trademark. Intangible assets are stated at their historical cost and amortized on
a straight-line basis over their expected useful lives. Capitalized patent costs, net of accumulated amortization, includes legal costs
incurred for patent applications. In accordance with ASC 350, once a patent is granted, we amortize the capitalized patent costs over
the remaining life of the patent using the straight-line method. If the patent is not granted, we write off any capitalized patent costs
at that time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an agreement for a trademark related to the Company&#8217;s name on July 11, 2022. The agreement called for an initial
payment of $<span id="xdx_907_eus-gaap--PaymentsToAcquireIntangibleAssets_c20220710__20220711__us-gaap--TypeOfArrangementAxis__custom--TrademarkAgreementMember__us-gaap--OtherCommitmentsAxis__custom--InitialPaymentMember_zitNuSg2qFZk" title="Initial payment upon execution">10,000</span> upon execution of the agreement. A second and final payment of $<span id="xdx_903_eus-gaap--PaymentsToAcquireIntangibleAssets_c20220710__20220711__us-gaap--TypeOfArrangementAxis__custom--TrademarkAgreementMember__us-gaap--OtherCommitmentsAxis__custom--SecondAndFinalPaymentMember_zIBof3crmvG2" title="Second and final payment of contingent">40,000</span> was contingent upon the completion of the Company&#8217;s
planned initial public offering. The trademark does not have a determinate life and therefore the cost is not being amortized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company entered into an option agreement on April 12, 2023 to enter into a royalty-bearing licensing agreement to bring the optionor&#8217;s
invention to commercialization. The agreement required an initial payment of $<span id="xdx_907_eus-gaap--PaymentsToAcquireIntangibleAssets_c20230411__20230412__us-gaap--TypeOfArrangementAxis__custom--LicensingAgreementMember_zu7IJvU0Ivja" title="Initial payment upon execution">1,000</span> upon execution of the agreement. The agreement does
not have a determinate life and therefore the cost is not being amortized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
review intangible assets for impairment annually or when events or circumstances indicate that their carrying amount may not be recoverable.
During the years ended December 31, 2023, and 2022, the Company recorded no impairment charges for intangible assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortization
expense was $<span id="xdx_900_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20231231_zEfBkB15rWa9" title="Amortization expense">10,485</span> and $<span id="xdx_90D_eus-gaap--AmortizationOfIntangibleAssets_c20220101__20221231_zFaUgEMJOp63" title="Amortization expense">6,213</span> during the years ended December 31, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_zL1OMXiuVgO6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86D_zWbZejgz59Z6">Income
Taxes</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in
the Company&#8217;s financial statements and tax returns. Deferred tax assets and liabilities are determined based upon the differences
between the financial statement carrying amounts, and the tax bases of existing assets and liabilities for the loss and credit carryforwards
using enacted tax rates expected to be in effect in the year in which the differences are expected to reverse. Deferred tax assets are
reduced by a valuation allowance if it is more likely than not that these assets may not be realized. The Company determines whether
a tax position will be sustained upon examination. If it is more likely than not that a position will be sustained, none of the benefit
attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more likely than not
recognition threshold is calculated as the largest amount that is more than 50% likely of being realized upon resolution of the contingency.
The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
on the results of management&#8217;s evaluation, adoption of the rules did not have a material effect on the Company&#8217;s financial
statements. Further, no interest or penalties have been accrued or charged to expense as of December 31, 2023 and 2022 and for the years
then ended.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s income tax returns are subject to examination by the taxing authorities until the expiration of the related statutes
of limitations on those tax returns. In general, the federal and state income tax returns have a three-year statute of limitations. As
of December 31, 2023, the following tax years are subject to examination:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="border-bottom: Black 1.5pt solid; width: 32%; text-align: center">Jurisdiction</td><td style="padding-bottom: 1.5pt; text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 32%; text-align: center">Open Years for Filed Returns</td><td style="padding-bottom: 1.5pt; text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Return to File in 2024</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">Federal</td><td>&#160;</td>
    <td style="text-align: center">2020 &#8211; 2022</td><td>&#160;</td>
    <td style="text-align: center">2023</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">Various States</td><td>&#160;</td>
    <td style="text-align: center">2020 &#8211; 2022</td><td>&#160;</td>
    <td style="text-align: center">2023</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising Cost</a></td>
<td class="text"><p id="xdx_845_eus-gaap--AdvertisingCostsPolicyTextBlock_zMkGAZaOZrki" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_869_zYreRTxzU1b3">Advertising
Cost</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Advertising
costs are expensed as incurred and amounted to $<span id="xdx_900_eus-gaap--AdvertisingExpense_c20230101__20231231_z0GjCaNfpWY5" title="Advertising cost expense">192,400</span> and $<span id="xdx_90A_eus-gaap--AdvertisingExpense_c20220101__20221231_zp2itMDg3Lc1" title="Advertising cost expense">14,900</span> for the years ended December 31, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_DerivativeLiabilityPolicyTextBlock', window );">Derivative Liabilities</a></td>
<td class="text"><p id="xdx_840_ecustom--DerivativeLiabilityPolicyTextBlock_zGVqCK5z85Mc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_869_zHMq8XLsXJ6i">Derivative
Liabilities</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for derivative financial instruments as either equity or liabilities in accordance with ASC Topic 815, <i>Derivatives
and Hedging</i>, or ASC 815, based on the characteristics and provisions of each instrument. Embedded derivatives are required to be
bifurcated from the host instruments and recorded at fair value if the derivatives are not clearly and closely related to the host instruments
on the date of issuance. Derivative instrument liabilities are classified in the balance sheets as current or non-current based on whether
or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilizes a Monte Carlo simulation model for the common stock conversion feature of the notes payable that have an option to
convert at a variable number of shares to compute the fair value of the derivative and to mark to market the fair value of the
derivative at each balance sheet date. The inputs utilized in the application of the Monte Carlo model included a stock
price, an expected remaining term of each note as of the valuation date, estimated volatility, drift, and a risk-free rate. The
Company records the change in the fair value of the derivative as other income or expense in the Statements of Operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_WarrantLiabilityPolicyTextBlock', window );">Warrant Liabilities</a></td>
<td class="text"><p id="xdx_84B_ecustom--WarrantLiabilityPolicyTextBlock_z69GwGVVBVcc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_869_zV7p8awBt4kc">Warrant
Liabilities</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
evaluates all of the Company&#8217;s financial instruments, including issued warrants to purchase its Class A common stock, to
determine if such instruments are liabilities or contain features that qualify as embedded derivatives, pursuant to ASC 480 and ASC
815-15. The classification of derivative financial instruments, including whether such instruments should be recorded as liabilities
or as equity, is reassessed at the end of each reporting period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company utilizes a Monte Carlo simulation model for warrants that have an option to convert at a variable number of shares to compute
the fair value of the derivative and to mark to market the fair value of the derivative at each balance sheet date. The inputs utilized
in the application of the Monte Carlo model included a starting stock price, an expected remaining term of each warrant as of the valuation
date, estimated volatility, drift, and a risk-free rate. The Company records the change in the fair value of the warrant as other
income or expense in the statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p id="xdx_840_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zXaEEhNVRUzl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86B_z42RAGNx2Pke">Fair
Value Measurements</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for financial instruments in accordance with ASC 820, Fair Value Measurements and Disclosures (&#8220;ASC 820&#8221;).
ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy
gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and
the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under ASC 820 are described
below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
1 &#8211; Quoted prices (unadjusted) for identical unrestricted assets or liabilities in active markets that the reporting entity has
the ability to access as of the measurement date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
2 &#8211; Significant other observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities: quoted
prices in markets that are not active; or financial instruments for which all significant inputs are observable or can be corroborated
by observable market date, either directly or indirectly.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
3 &#8211; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets
or liabilities. These unobservable inputs reflect that reporting entity&#8217;s own assumptions about assumptions that market participants
would use in pricing the asset or liability. Level 3 assets and liabilities include financial instruments whose value is determined using
pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair
value require significant management judgment or estimation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s Level 1 assets/liabilities include cash, accounts receivable, accounts payable, prepaids, and other current assets. Management
believes the estimated fair value of these accounts on December 31, 2023 approximate their carrying value as reflected in the balance
sheets due to the short-term nature of these instruments or the use of market interest rates for debt instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s Level 3 assets/liabilities include derivative and warrant liabilities. Inputs to determine fair value are generally
unobservable and typically reflect management&#8217;s estimates of assumptions that market participants would use in pricing the
asset or liability. The fair values are therefore determined using model-based techniques, including option pricing models and
discounted cash flow models. The valuation techniques involve management&#8217;s estimates and judgment based on unobservable
inputs. The fair value estimates may not be indicative of the amounts that would be realized in a market exchange. Additionally,
there may be inherent uncertainties or changes in the underlying assumptions used, which could significantly affect the current or
future fair value estimates. Unobservable inputs used in the models are significant to the fair values of the assets and
liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89E_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zXrb3Ha5bbbh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables provides a summary of the relevant assets and liabilities that are measured at fair value on recurring basis:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Fair Value Measurements as of</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">December 31, 2023</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_8B5_zBcTe0bNWWrd" style="display: none">Schedule of Fair Value On a Recurring Basis Assets and Liability</span>&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zZgb1nNnOIB1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z90tT0VJCng4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Level 1)</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_znhoBmNvawL8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Level 2)</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z8GtVuYWyEwa" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;(Level 3)</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--WarrantLiabilities_i02I_maLFVDzwLw_z6rpvKyALug1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 36%; text-align: left">Warrant liabilities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">8,225</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0695">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0696">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">8,225</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DerivativeLiabilitiesCurrent_i02I_maLFVDzwLw_zJzlXGtSZDO9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Derivative liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0699">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0700">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0701">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0702">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LiabilitiesFairValueDisclosure_i02I_mtLFVDzwLw_zV9UcwYYQyjl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Total Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,225</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0705">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0706">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,225</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair Value Measurements as of</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
31, 2022</b></span></p>


<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zmHu3a3OQ26c" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z5PTqsJi0jad" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zkDLZOyMUWCb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zrrRyAbSdmol" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--WarrantLiabilities_i02I_maLFVDzwLw_zowQ4vO09hL" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 36%; text-align: left">Warrant liabilities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,234,384</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0710">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0711">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,234,384</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DerivativeLiabilitiesCurrent_i02I_maLFVDzwLw_zbXoob1TDTJ8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Derivative liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,735,700</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0715">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0716">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,735,700</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LiabilitiesFairValueDisclosure_i02I_mtLFVDzwLw_zhUioZYfLqQe" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Total Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,970,084</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0720">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0721">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,970,084</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p id="xdx_8A7_zUdX8zDeETDg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_890_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zYMTrkf1t5pf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows the valuation methodology and unobservable inputs for Level 3 assets and liabilities measured at fair value on
recurring basis as of December 31, 2023 and December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><span id="xdx_8BF_zcWaoIpk4QNi" style="display: none">Schedule of Unobservable Inputs for Level 3 Assets and Liabilities</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Fair Value As of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Fair Value</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">Valuation</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">Unobservable</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Methodology</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Inputs</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 20%; text-align: justify">Warrant liabilities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--WarrantLiabilities_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zshO0OaVLGL4" style="width: 13%; text-align: right" title="Warrant liabilities">8,225</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_ecustom--WarrantLiabilities_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zk5YFe91k1u1" style="width: 13%; text-align: right" title="Warrant liabilities">2,234,384</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 19%; text-align: center">Monte Carlo model</td><td style="width: 2%">&#160;</td>
    <td style="width: 23%; text-align: center">Project simulated cash flows</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Derivative liabilities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zljGNFsh3REk" style="text-align: right" title="Derivative liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0730">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z5BnVDl7ijHc" style="text-align: right" title="Derivative liabilities">1,735,700</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">Monte Carlo model</td><td>&#160;</td>
    <td style="text-align: center">Project simulated cash flows</td></tr>
  </table>
<p id="xdx_8A9_zjTAxKrFNlr2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no transfers between any of the levels during the years ended December 31, 2023 and year ended December 31, 2022. In addition
to assets and liabilities that are recorded at fair value on a recurring basis, the Company&#8217;s assets and liabilities are also
subject to nonrecurring fair value measurements. As of December 31, 2023 and 2022, the Company had no assets that were measured on a
nonrecurring basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Net Income (Loss) per Share</a></td>
<td class="text"><p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zDXVnNedKCu8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_863_zD1TKYEnGW6l">Basic
and Diluted Net Income (Loss) per Share</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Earnings
or loss per share (&#8220;EPS&#8221;) is computed by dividing net income (loss), net of preferred stock dividends, by the weighted average
number of shares of common stock outstanding during the period. Diluted EPS is computed by dividing net income (loss) by the weighted
average of all potentially dilutive shares of common stock that were outstanding during the periods presented. Preferred stock dividends
(not declared or paid) were $<span id="xdx_90B_eus-gaap--DividendsPreferredStock_c20230101__20231231_zmgcGg3rUjO4" title="Preferred stock dividend">0</span> and $<span id="xdx_902_eus-gaap--DividendsPreferredStock_c20220101__20221231_zO9qN9bbbF1d" title="Preferred stock dividend">2,190,102</span> as of December 31, 2023 and 2022, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common
shares outstanding during the period. Diluted net loss per common share is determined using the weighted-average number of common shares
outstanding during the period, adjusted for the dilutive effect of common stock equivalents. In periods when losses are reported, which
is the case for December 31, 2023 and 2022 presented in these financial statements, the weighted-average number of common shares outstanding
excludes common stock equivalents because their inclusion would be anti-dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_894_eus-gaap--ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_zNwURusR6vu2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had the following potentially dilutive common stock equivalents at December 31, 2023 and 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B9_zNje6TLH5oU8" style="display: none">Schedule of Dilutive Common Stock Equivalents</span>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20230101__20231231_z51OT7QLFr38" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20220101__20221231_zWMVb7whmDXe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleSeriesAPreferredStockMember_z2UCsBz9SQg5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Convertible Series A Preferred Stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0742">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">1,013,270</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleSeriesSeedPreferredStockMember_zB4vs5QaziT1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Convertible Series Seed Preferred Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0745">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">230,954</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--OptionMember_zvy1eobwixR5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,319,394</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,319,394</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--PreferredStockMember_z33AI0MMLE5f" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; text-align: left">Pre-Funded Warrants for Convertible Series A Preferred Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0751">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">289,779</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_zIYhQ9G4GrF8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,822,358</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">365,962</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleBridgeDebtMember_zP5fRYEVMiTa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Convertible Bridge Debt</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0757">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">376,653</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zuWn8sTcwH0j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Totals</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,141,752</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,596,012</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>
<p id="xdx_8A5_zViJxKGPpRP9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89D_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zxBv4WY9fsXf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows the calculation of the basic and diluted net loss per share and the effect of preferred stock dividends.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_zqUi5n0z7Kfl" style="display: none">Schedule of Basic and Diluted Net Loss Per Share</span>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20230101__20231231_zX5oRcjTJW1g" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20220101__20221231_zBMbJ08DzJ84" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Numerator</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--NetIncomeLoss_iT_mtNILzQKI_zy8h4Qz1xuO1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(14,626,683</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">(4,780,061</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--PreferredStockDividendsAndOtherAdjustments_zgKkCa9mWffi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Preferred stock dividends</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0768">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(764,893</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zk1oVBBRjz5i" style="vertical-align: bottom; background-color: White">
    <td>&#160;<span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Net income (loss) available to common stockholders</span> </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(14,626,683</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,544,954</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Denominator</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Weighted-average shares of common stock outstanding - basic
    and diluted</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231_znEzxgGfUxea" title="Weighted average shares of common stock outstanding - basic"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231_zbww0nP4YRg1" title="Weighted average shares of common stock outstanding - diluted">3,252,328</span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20220101__20221231_z6Tas7DWLb8e" title="Weighted average shares of common stock outstanding - basic"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20220101__20221231_zmjpPawtofr9" title="Weighted average shares of common stock outstanding - diluted">2,003,322</span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Basic and diluted net loss per share</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_908_eus-gaap--EarningsPerShareBasic_c20230101__20231231_zG5fKt9oFUC8" title="Basic net loss per share"><span id="xdx_905_eus-gaap--EarningsPerShareDiluted_c20230101__20231231_z2RhTCLdmDCb" title="Diluted net loss per share">(4.50</span></span></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_909_eus-gaap--EarningsPerShareBasic_c20220101__20221231_zZJe1K2BfZ76" title="Basic net loss per share"><span id="xdx_90C_eus-gaap--EarningsPerShareDiluted_c20220101__20221231_zds8oPl0kjM3" title="Diluted net loss per share">(2.77</span></span></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  </table>
<p id="xdx_8A4_z0tCcqsbBemd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zz4yjkKUeCzk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_861_zFhESh1uvKod">Stock-Based
Compensation</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for all stock-based payments and awards at fair value. The Company recognizes its stock-based compensation
expense using the straight-line method. Compensation cost is not adjusted for estimated forfeitures, but instead is adjusted upon an
actual forfeiture of a stock option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for the granting of stock options to employees and non-employees using the fair value method whereby all awards are
measured at fair value on the date of the grant. The fair value of all employee stock options is expensed over the requisite service
period with a corresponding increase to additional paid-in capital. Upon exercise of stock options, the consideration paid by the option
holder is recorded in additional paid-in capital, while the par value of the shares received is reclassified from additional paid in
capital to common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based
payments to non-employees are measured based on the fair value of the equity instrument issued. Compensation expense for non-employee
stock awards is recognized over the requisite service period following the measurement of the fair value on the grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company uses the Black-Scholes option-pricing model to calculate the fair value of stock options. The use of the Black-Scholes option-pricing
model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common
stock consistent with the expected term of the option, risk-free interest rates, the value of the common stock and expected dividend
yield of the common stock. Changes in these assumptions can materially affect the fair value estimate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p id="xdx_848_eus-gaap--RevenueRecognitionPolicyTextBlock_zQiivN3OJYcj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_868_zdikTs1WOXe1">Revenue
Recognition</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Neuraxis,
Inc. specializes in the development, production, and sale of medical neuromodulation devices to healthcare providers primarily located
in the United States. Patented and trademarked neuromodulation devices is the Company&#8217;s major product line. Products are generally
transferred at a point in time (rather than over time). Essentially all the Company&#8217;s revenue is generated from purchase order
contracts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with FASB&#8217;s ASC 606, Revenue from Contracts with Customers, (&#8220;ASC 606&#8221;), the Company recognizes revenue
when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects
to be entitled in exchange for those goods or services, in an amount that reflects the consideration which the Company expects to be
entitled in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within
the scope of ASC 606, it performs the following five steps:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="width: 0.25in">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identify
    the contract(s) with a customer&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identify
    the performance obligations in the contract&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">determine
    the transaction price&#894;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">allocate
    the transaction price to the performance obligations in the contract&#894; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recognize
    revenue when (or as) the entity satisfies a performance obligation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company applies the five-step model to contracts when it determines that it is probable it will collect substantially all the consideration
it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined
to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that
are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the
amount of the transaction price, after consideration of variability and constraints, if any, that is allocated to the respective performance
obligation when the performance obligation is satisfied.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company estimates credit losses on accounts receivable by estimating expected credit losses over the contractual term of the receivable
using a discounted cash flow method. When developing this estimate of expected credit losses, the Company considers all available information
(past, current, and future) relevant to assessing the collectability of cash flows.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company offers a Patient Assistance Program for patients without insurance coverage for IB-Stim. This program extends potential self-pay
discounts for IB-Stim devices, based upon household income and size.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Also,
the Company offers providers an opt-in program to address adequate insurance claim payments on IB-Stim devices. This program may extend
a rebate or invoice credit where the insurance payment and patient responsibility (i.e., deductible, co-payment, and/or co-insurance
amounts required by the Payer) are less than the acquisition cost of the IB-Stim device. The Company recognizes revenue at such a time
that collection of the amount due is assured.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p id="xdx_89B_eus-gaap--DisaggregationOfRevenueTableTextBlock_zX6RXuuRv7o2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table disaggregates the Company&#8217;s revenue based on the customer&#8217;s location by state for the years ended December
31:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zAzVuhoIgill" style="display: none">Schedule of Disaggregation of Revenue</span>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 25%; text-align: left">California</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td id="xdx_987_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--CA_zAnDptrXJjOb" style="width: 20%; font-weight: bold; text-align: right" title="Revenues">601,235</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 25%; text-align: left">Wisconsin</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__stpr--WI_z2SwOYl8cNh9" style="width: 20%; text-align: right" title="Revenues">670,245</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Ohio</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--OH_zDI0OkZvXUch" style="font-weight: bold; text-align: right" title="Revenues">407,632</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">Ohio</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__stpr--OH_zJhs6wESToS2" style="text-align: right" title="Revenues">500,260</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Wisconsin</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--WI_z9ynHKka95Xd" style="font-weight: bold; text-align: right" title="Revenues">292,601</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">California</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__stpr--CA_zRGqfRRI4PZ9" style="text-align: right" title="Revenues">408,645</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Florida</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--FL_z1o4pUWGGbRe" style="font-weight: bold; text-align: right" title="Revenues">186,840</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">Florida</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__stpr--FL_zwbktOHvOlP2" style="text-align: right" title="Revenues">231,480</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Massachusetts</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--MA_zL8Z9URoL8Rf" style="font-weight: bold; text-align: right" title="Revenues">127,300</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">Missouri</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__country--MO_zmIB5JUxFlka" style="text-align: right" title="Revenues">174,980</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">All other states</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__custom--AllOtherStatesMember_zgxis1XpHgTj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Revenues">844,441</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1.5pt">All other states</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__custom--AllOtherStatesMember_zqkBp0QJB9Bd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenues">699,125</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_986_eus-gaap--Revenues_c20230101__20231231_zmLHQlhg1K4a" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Total revenue">2,460,049</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98B_eus-gaap--Revenues_c20220101__20221231_zVi8nS1HELrg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total revenue">2,684,735</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p id="xdx_8A6_z18moQNeosPi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following economic factors affect the nature, amount, timing, and uncertainty of the Company&#8217;s revenue and cash flows as indicated:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Type
of customer:</b> Based on dollar amounts of revenue, essentially all of the goods sold by the Company are sold to healthcare customers
including hospitals and clinics. Sales to healthcare customers lack seasonality and have a mild correlation with economic cycles.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Geographical
location of customers:</b> Sales to customers located within the United States represent essentially all of the Company&#8217;s sales.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Type
of contract:</b> Sales contracts consist of purchase order contracts that tend to be short-term (i.e., less than or equal to one year
in duration).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Company&#8217;s
Performance Obligations with Customers:</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Timing
of Satisfaction</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company typically satisfies its performance obligations as the goods are delivered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goods
that are shipped to customers are typically shipped FOB shipping point with freight prepaid by the Company. As such, ownership of goods
in transit transfer to the customer when shipped and the customer bears the associated risks (e.g., loss, damage, delay). </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shipping
and handling costs are recorded as general and administrative expenses in the Statement of Operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Significant
Payment Terms</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Payment
for goods sold by the Company is typically due after an invoice is sent to the customer, within 30 days. However, other payment terms
are frequently negotiated with customers ranging from due upon receipt to due within 90 days. Some payment terms may call for payment
only after the healthcare provider receives their insurance reimbursement. Invoices for goods are typically sent to customers within
three calendar days of shipment. The Company does not offer discounts if the customer pays some or all of an invoiced amount prior to
the due date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">None
of the Company&#8217;s contracts have a significant financing component.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Nature</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medical
devices that the Company contracts to sell and transfer to customers are manufactured by one specific third-party manufacturer. The manufacturer
is located within the state of Indiana. In no case does the Company act as an agent (i.e., the Company does not provide a service of
arranging for another party to transfer goods to the customer).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline">Returns,
Refunds, etc.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Orders
may not be cancelled after shipment. Customers may return devices within 10 days of delivery if the goods are found to be defective,
nonconforming, or otherwise do not meet the stated technical specifications. At the option of the customer, the Company shall either:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Refund
    the price paid for any defective or nonconforming products.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Supply
    and deliver to the customer replacement conforming products.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reimburse
    the customer for the cost of repairing any defective or nonconforming products.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
the time revenue is recognized, the Company estimates expected returns and excludes those amounts from revenue. The Company also maintains
appropriate accounts to reflect the effects of expected returns on the Company&#8217;s financial position and periodically adjusts those
accounts to reflect its actual return experience. Historically, returns have been immaterial, and the Company currently does not provide
a provision for this liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtendedProductWarrantyPolicy', window );">Warranties</a></td>
<td class="text"><p id="xdx_844_eus-gaap--ExtendedProductWarrantyPolicy_zsmzImPWWnw7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86D_zcAlCuDLdeMh">Warranties</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
most cases, goods that customers purchase from the Company are covered by manufacturers&#8217; warranties. The Company does not sell
warranties separately.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
manufacturer guarantees the product for the period up to the expiration date printed on the device&#8217;s label or twelve months from
the date of purchase, whichever comes first. The guarantee applies to flaws of material and workmanship. The Company&#8217;s warranties
provide customers with assurance that purchased devices comply with published specifications, inspection standards, and workmanship.
At the time revenue is recognized, the Company estimates the cost of expected future warranty claims but does not exclude any amounts
from revenue. The Company maintains appropriate accounts to reflect the effects of expected future warranty claims on the Company&#8217;s
financial position and periodically adjusts those accounts to reflect its actual warranty claim experience. Historically, warranty claims
have been immaterial, and the Company currently does not provide a provision for this liability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company typically satisfies its performance obligations for goods at a point in time. In most cases, goods are shipped by common carrier
to customers under &#8220;FOB Shipping Point&#8221; terms. As such, customers typically obtain control of the goods upon shipment. The
Company&#8217;s management exercises judgment in determining when performance obligations for goods have been satisfied. In making such
judgments, management typically relies on shipping information obtained from common carriers to evaluate when the customer has obtained
control of the goods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s contracts with customers typically do not involve variable consideration. The information that the Company uses to determine
the transaction price for a contract is similar to the information that the Company&#8217;s management uses in establishing the prices
of goods to be sold.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_843_eus-gaap--LesseeLeasesPolicyTextBlock_z4OfpCedWO8j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_860_zDo0Qt7M55Dk">Leases</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with Accounting Standards Updated (&#8220;ASU&#8221;) No. 2016-02, <i>Leases (Topic 842)</i> (&#8220;ASU 2016-02&#8221; or
&#8220;ASC 842&#8221;), at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based
on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the balance
sheet as right-of-use assets and current and non-current lease liabilities, as applicable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
lease liabilities and their corresponding right-of-use assets are initially recorded based on the present value of lease payments over
the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received.
The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental
borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis
the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. Prospectively, the Company
will adjust the right-of-use assets for straight-line rent expense, or any incentives received and remeasure the lease liability at the
net present value using the same incremental borrowing rate that was in effect as of the lease commencement or transition date. The Company
has elected not to recognize leases with an original term of one year or less on the balance sheet. The Company typically only includes
an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in the Company&#8217;s assessment
unless there is reasonable certainty that the Company will renew.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assumptions
made by the Company at the commencement date are re-evaluated upon occurrence of certain events, including a lease modification. A lease
modification results in a separate contract when the modification grants the lessee an additional right of use not included in the original
lease and when lease payments increase commensurate with the standalone price for the additional right of use. When a lease modification
results in a separate contract, it is accounted for in the same manner as a new lease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Entities
may elect not to separate lease and non-lease components. The Company has elected to account for lease and non-lease components together
as a single lease component for all underlying assets and allocate all the contract consideration to the lease component only.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p id="xdx_844_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zQnGpcSL7M39" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86F_zBrB3zgiolB3">Impairment
of Long-Lived Assets</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Long-lived
assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset group may
not be recoverable. If events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable,
we compare the carrying amount of the asset group to future undiscounted net cash flows, excluding interest costs, expected to be generated
by the asset group and their ultimate disposition. If the sum of the undiscounted cash flows is less than the carrying value, the impairment
to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the fair value of the asset group.
Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zx8dJc3KAyve" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_864_zpHzMrGs96Kj">Concentrations
of Credit Risk</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company&#8217;s business activity consists of the sale of medical neuromodulation devices to doctors, clinics, and hospitals across the
country.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Receivables
consist of unsecured amounts due from customers. As of December 31, 2023, accounts receivable from four customers with balances due
in excess of <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zHt7e9wt7Xlf" title="Risk percentage">10</span>%
of total accounts receivable were approximately <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z1sgDO6lIT0f" title="Risk percentage">28</span>%, <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zOpddKc3C56k" title="Risk percentage">28</span>%, <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerThreeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_ztyL1NBusNqe" title="Risk percentage">17</span>%
and <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerFourMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zn5iv9oSMJNe" title="Risk percentage">11</span>%, respectively. As of December 31, 2022, accounts receivable from three customers with balances due in excess of <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_znlKTOeeo93f" title="Risk percentage">10</span>%
of total accounts receivable was <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zdf0D1ndQga7" title="Risk percentage">23</span>%, <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zJM0GLgbRMti" title="Risk percentage">15</span>%,
and <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerThreeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zFGIT1ta9kQ" title="Risk percentage">12</span>%,
respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
table below sets forth the Company&#8217;s customers that accounted for greater than <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueProductLineMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--RevenueFromRightsConcentrationRiskMember_zSykzU9jrsr5" title="Risk percentage"><span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueProductLineMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--RevenueFromRightsConcentrationRiskMember_z8AOKkMvCXI4" title="Risk percentage">10</span></span>% of its revenues for the years ended December
31, 2023 and 2022, respectively.</span></p>

<p id="xdx_89F_eus-gaap--ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock_zK2CTGYbN3Sb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zCjfnL75gsbi" style="display: none">Schedule of Customers Accounted Revenues</span>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">Percentage of </td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">Percentage of </td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><b>Sales</b></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><b>Sales</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: left">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: left">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left">Hospital A</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--MajorCustomersAxis__custom--HospitalAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z8DYsvEFfc62" style="width: 15%; font-weight: bold; text-align: right" title="Revenue">452,680</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 15%; text-align: center"><span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--HospitalAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zOU9fy3LjPDl" title="Risk percentage">18</span>%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20221231__srt--MajorCustomersAxis__custom--HospitalAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z6VZ0fIq4lbg" style="width: 15%; text-align: right" title="Revenue">355,613</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 15%; text-align: center"><span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--HospitalAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zGUAamau5Wg7" title="Risk percentage">13</span>%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Hospital B</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--MajorCustomersAxis__custom--HospitalBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zWtmDNKLOmZ8" style="font-weight: bold; text-align: right" title="Revenue">382,082</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--HospitalBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zxGlw7LXQHJh" title="Risk percentage">16</span>%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20221231__srt--MajorCustomersAxis__custom--HospitalBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zkkJm06MFCPb" style="text-align: right" title="Revenue">484,900</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--HospitalBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z8N4M2GNQ1Cg" title="Risk percentage">18</span>%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Hospital C</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--MajorCustomersAxis__custom--HospitalCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zoNS5KYKLCJ8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Revenue">274,581</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--HospitalCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_ztiAPuHBO464" title="Risk percentage">11</span>%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20221231__srt--MajorCustomersAxis__custom--HospitalCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zAa3xtGHtem9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue">554,325</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--HospitalCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zSTXRgI9fhP9" title="Risk percentage">21</span>%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--MajorCustomersAxis__custom--HospitalMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zPVkIhkG8i96" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Revenue">1,109,343</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--HospitalMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zAj2qbvuPNlj" title="Risk percentage">45</span>%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20221231__srt--MajorCustomersAxis__custom--HospitalMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zdpQH4bigBYb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue">1,394,838</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--HospitalMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zx1dh6xGR3J3" title="Risk percentage">52</span>%</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p id="xdx_8AE_zG8dOe1t08F5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From
time to time, the Company&#8217;s bank balances may exceed the FDIC limit of $<span id="xdx_909_eus-gaap--CashFDICInsuredAmount_iI_c20231231_znBb1ljAlu7f" title="Cash, FDIC insured amount">250,000</span>; however, management does not feel that this has
a material impact on the financial condition. At December 31, 2023 and 2022, the Company didn&#8217;t have any uninsured cash balance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_GoingConcernPolicyTextBlock', window );">Going Concern</a></td>
<td class="text"><p id="xdx_848_ecustom--GoingConcernPolicyTextBlock_zXajKJKS6Kod" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_861_zZ5dSeb3IfU">Going
Concern</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have incurred losses since inception and have funded our operations primarily with a combination of sales, debt, and the sale of capital
stock. As of December 31, 2023, we had a stockholders&#8217; deficit totaling $<span id="xdx_903_eus-gaap--StockholdersEquity_iNI_di_c20231231_zUPTVUFQnusl" title="Stockholders deficit">1,403,241</span>. At December 31, 2023, we had short-term outstanding
borrowings of approximately $<span id="xdx_905_eus-gaap--ShortTermBorrowings_iI_c20231231_zGK76rC9Za7g" title="Short term borrowing">148,062</span>. As of December 31, 2023, we had cash of $<span id="xdx_90F_eus-gaap--Cash_iI_c20231231_zMSBuQjxhUv2" title="Cash">78,560</span> and a working capital deficit of $<span id="xdx_900_ecustom--WorkingCapitalDeficit_iI_c20231231_zojtMzfW66Z2" title="Working capital">1,643,058</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 9, 2023, the Company consummated its initial public offering, conducted on a firm commitment basis, pursuant to which it sold <span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230809__20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zes7IYSmLHEe" title="Number of shares issued in transaction">1,098,667</span>
shares of its common stock at a price of $<span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_c20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zMs9Emp2MZu3" title="Share issued price per share">6.00</span>
per share, resulting in gross proceeds to the Company of $<span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230809__20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zduBimLlqvCd" title="Proceeds from issuance of common stock">6,592,002</span>.
Net proceeds to the Company, after deducting underwriting discounts and commissions, 2022 deferred offering costs totaling $<span id="xdx_908_eus-gaap--DeferredOfferingCosts_iI_c20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zGr67oXbOBul" title="Deferred offering costs">736,736</span>
and offering expenses paid by the Company, were $<span id="xdx_906_eus-gaap--PaymentsOfStockIssuanceCosts_c20230811__20230811__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSo5An9DMAvc" title="Payment fees">4,110,721</span>.
All shares sold in our IPO were registered pursuant to a registration statement on Form S-1 (File No. 333- 269179), as amended,
declared effective by the SEC on August 9, 2023. Alexander Capital L.P. acted as sole book-running manager for the offering and
Spartan Capital Securities, LLC acted as co-manager for the offering. <span style="background-color: white">The underwriters did not
exercise their option to purchase up to an additional </span><span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230809__20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKV7ofq1xkai" title="Purchase of common shares">164,801</span> <span style="background-color: white">shares
of common stock.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Neuraxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><b>Notes to Financial Statements</b></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future capital requirements will depend upon many factors, including progress with developing, manufacturing, and marketing our
technologies, the time and costs involved in preparing, filing, prosecuting, maintaining, and enforcing patent claims and other
proprietary rights, our ability to establish collaborative arrangements, marketing activities and competing technological and market
developments, including regulatory changes and overall economic conditions in our target markets. Our ability to generate revenue
and achieve profitability requires us to successfully market and secure purchase orders for our products from customers currently
identified in our sales pipeline and to new customers as well. The primary activity that will drive all customers and revenues is
the adoption of insurance coverage by commercial insurance carriers nationally which is a top priority of the Company. These
activities, including our planned research and development efforts, will require significant uses of working capital through the
rest of 2024 and beyond. Based on our current operating plans, we believe that our existing cash at the time of this filing will
only be sufficient to meet our anticipated operating needs through the end of 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management
evaluates whether there are conditions or events that raise substantial doubt about the Company&#8217;s ability to continue as a going
concern for a period of one year from the date the financial statements are issued.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, the Company has experienced operating losses and negative cash flows from operations. Management believes that increased sales
and acceptance of their product by insurance providers will allow the Company to achieve profitability in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
the Company believes in the viability of its strategy to further implement its business plan and generate sufficient revenues and in
its ability to raise additional funds by way of a public or private offering of its debt or equity securities, there can be no
assurance that it will be able to do so on reasonable terms, or at all. The ability of the Company to continue as a going concern is
dependent upon its ability to further implement its business plan and generate sufficient revenues and its ability to raise
additional funds by way of a public or private offering. Neither future cash generated from operating activities, nor
management&#8217;s contingency plans to mitigate the risk and extend cash resources through the evaluation period, are considered
probable. As a result, substantial doubt is deemed to exist about the Company&#8217;s ability to continue as a going concern. As we
continue to incur losses, our transition to profitability is dependent upon achieving a level of revenues adequate to support its
cost structure. We may never achieve profitability, and unless and until doing so, we intend to fund future operations through
additional dilutive or nondilutive financing. There can be no assurances, however, that additional funding will be available on
terms acceptable to us, if at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the
amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zFcm1uYaKtoj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_863_zu6wtfWyMFre">Recently Adopted Accounting Pronouncements</span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2016, the FASB issued ASU 2016-13, Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial
Instruments, which requires measurement and recognition of expected credit losses for financial assets held and requires enhanced disclosures
regarding significant estimates and judgments used in estimating credit losses. In November 2019, the FASB issued ASU 2019-10, Financial
Instruments &#8211; Credit Losses (Topic 326), Derivatives and Hedging (Topic 815) and Leases (Topic 842): Effective Dates, which amended
the effective date of ASU 2016-13. Public business entities meeting the definition of an SEC filer, excluding entities eligible to be
a Smaller Reporting Company (&#8220;SRC&#8221;) as defined by the SEC, are required to adopt the standard for fiscal years beginning
after December 15, 2019, including interim periods within those fiscal years. All other entities are required to adopt the standard for
fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company meets the definition
of an SRC and therefore the standard was adopted as of January 1, 2023. The adoption of this guidance did not have a material impact
on the Company&#8217;s financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="text-decoration: underline">Recently Issued Accounting Pronouncements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">In December 2023, the FASB issued ASU 2023-19,
Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires the enhancement of income tax disclosures to
provide better insight into how an entity&#8217;s operations and related tax risks, planning and opportunities affect its tax rate
and prospects for future cash flows. The enhanced disclosures require (i) specific categories in a tabular rate reconciliation
including both amounts and percentages and (ii) additional information for reconciling items and income tax paid that meet a
quantitative threshold. Public business entities are required to adopt the standard for annual periods beginning after December 15,
2024. All other entities are required to adopt the standard for annual periods beginning after December 15, 2025. The adoption of
the standard is not expected to have a material impact on the Company&#8217;s financial statements.</p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_DerivativeLiabilityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative liability [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_DerivativeLiabilityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_GoingConcernPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Going Concern [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_GoingConcernPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_WarrantLiabilityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Liability [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_WarrantLiabilityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 35<br> -Topic 720<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositContractsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the treatment of funds received from or paid to insureds, insurers and reinsurers on contracts for which the criteria for transferring or assuming insurance risk has not been satisfied by the insurer or reinsurer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -SubTopic 825<br> -Topic 944<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479524/944-825-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositContractsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtendedProductWarrantyPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for extended product warranties and other guarantee contracts including the methodology for measuring the liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtendedProductWarrantyPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482105/912-330-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-11B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823910867024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock', window );">Schedule of Estimated Useful Lives</a></td>
<td class="text"><p id="xdx_89D_ecustom--ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_zuDWFlazwtT8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
is calculated using the following estimated useful lives:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B0_zRYzhM4FObAj" style="display: none">Schedule of Estimated Useful Lives</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 60%; border-collapse: collapse; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Classification</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Years</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Machinery and Equipment </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MinimumMember_z6T4sUWWoWNi" title="Property and equipment, estimated useful lives">5</span>-<span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MaximumMember_zd3L5zgGES5d" title="Property and equipment, estimated useful lives">10</span> </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture and Fixtures</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zkpRYICgli12" title="Property and equipment, estimated useful lives">5</span>-<span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_zy9KJtQEgs4a" title="Property and equipment, estimated useful lives">10</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer Hardware</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MinimumMember_zdqGof3t1oI" title="Property and equipment, estimated useful lives">5</span>-<span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MaximumMember_zcRNd7T4hdqb" title="Property and equipment, estimated useful lives">10</span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold Improvements</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MinimumMember_zZHzaJmx9lfj" title="Property and equipment, estimated useful lives">10</span>-<span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MaximumMember_zFLCxUzN8HYh" title="Property and equipment, estimated useful lives">20</span></span></td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value On a Recurring Basis Assets and Liability</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zXrb3Ha5bbbh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following tables provides a summary of the relevant assets and liabilities that are measured at fair value on recurring basis:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Fair Value Measurements as of</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">December 31, 2023</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span id="xdx_8B5_zBcTe0bNWWrd" style="display: none">Schedule of Fair Value On a Recurring Basis Assets and Liability</span>&#160;</p>

<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49E_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zZgb1nNnOIB1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z90tT0VJCng4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Level 1)</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_493_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_znhoBmNvawL8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(Level 2)</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49F_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z8GtVuYWyEwa" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;(Level 3)</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--WarrantLiabilities_i02I_maLFVDzwLw_z6rpvKyALug1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 36%; text-align: left">Warrant liabilities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">8,225</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0695">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0696">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">8,225</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DerivativeLiabilitiesCurrent_i02I_maLFVDzwLw_zJzlXGtSZDO9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Derivative liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0699">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0700">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0701">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0702">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LiabilitiesFairValueDisclosure_i02I_mtLFVDzwLw_zV9UcwYYQyjl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Total Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,225</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0705">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0706">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,225</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair Value Measurements as of</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December
31, 2022</b></span></p>


<p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zmHu3a3OQ26c" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z5PTqsJi0jad" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zkDLZOyMUWCb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zrrRyAbSdmol" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--WarrantLiabilities_i02I_maLFVDzwLw_zowQ4vO09hL" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 36%; text-align: left">Warrant liabilities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,234,384</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0710">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0711">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,234,384</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DerivativeLiabilitiesCurrent_i02I_maLFVDzwLw_zbXoob1TDTJ8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Derivative liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,735,700</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0715">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0716">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,735,700</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LiabilitiesFairValueDisclosure_i02I_mtLFVDzwLw_zhUioZYfLqQe" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Total Liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,970,084</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0720">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0721">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,970,084</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Unobservable Inputs for Level 3 Assets and Liabilities</a></td>
<td class="text"><p id="xdx_890_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zYMTrkf1t5pf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows the valuation methodology and unobservable inputs for Level 3 assets and liabilities measured at fair value on
recurring basis as of December 31, 2023 and December 31, 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><span id="xdx_8BF_zcWaoIpk4QNi" style="display: none">Schedule of Unobservable Inputs for Level 3 Assets and Liabilities</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Fair Value As of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Fair Value</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">Valuation</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">Unobservable</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Methodology</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Inputs</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 20%; text-align: justify">Warrant liabilities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--WarrantLiabilities_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zshO0OaVLGL4" style="width: 13%; text-align: right" title="Warrant liabilities">8,225</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_ecustom--WarrantLiabilities_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zk5YFe91k1u1" style="width: 13%; text-align: right" title="Warrant liabilities">2,234,384</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 19%; text-align: center">Monte Carlo model</td><td style="width: 2%">&#160;</td>
    <td style="width: 23%; text-align: center">Project simulated cash flows</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Derivative liabilities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zljGNFsh3REk" style="text-align: right" title="Derivative liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0730">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_982_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z5BnVDl7ijHc" style="text-align: right" title="Derivative liabilities">1,735,700</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">Monte Carlo model</td><td>&#160;</td>
    <td style="text-align: center">Project simulated cash flows</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock', window );">Schedule of Dilutive Common Stock Equivalents</a></td>
<td class="text"><p id="xdx_894_eus-gaap--ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_zNwURusR6vu2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company had the following potentially dilutive common stock equivalents at December 31, 2023 and 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B9_zNje6TLH5oU8" style="display: none">Schedule of Dilutive Common Stock Equivalents</span>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20230101__20231231_z51OT7QLFr38" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20220101__20221231_zWMVb7whmDXe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleSeriesAPreferredStockMember_z2UCsBz9SQg5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Convertible Series A Preferred Stock</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0742">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">1,013,270</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleSeriesSeedPreferredStockMember_zB4vs5QaziT1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Convertible Series Seed Preferred Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0745">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">230,954</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--OptionMember_zvy1eobwixR5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,319,394</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,319,394</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--PreferredStockMember_z33AI0MMLE5f" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0pt; text-align: left">Pre-Funded Warrants for Convertible Series A Preferred Stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0751">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">289,779</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_zIYhQ9G4GrF8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,822,358</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">365,962</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleBridgeDebtMember_zP5fRYEVMiTa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Convertible Bridge Debt</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0757">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">376,653</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zuWn8sTcwH0j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt">Totals</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,141,752</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,596,012</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Net Loss Per Share</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zxBv4WY9fsXf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table shows the calculation of the basic and diluted net loss per share and the effect of preferred stock dividends.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_zqUi5n0z7Kfl" style="display: none">Schedule of Basic and Diluted Net Loss Per Share</span>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20230101__20231231_zX5oRcjTJW1g" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20220101__20221231_zBMbJ08DzJ84" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Numerator</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--NetIncomeLoss_iT_mtNILzQKI_zy8h4Qz1xuO1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 60%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(14,626,683</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">(4,780,061</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--PreferredStockDividendsAndOtherAdjustments_zgKkCa9mWffi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Preferred stock dividends</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0768">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(764,893</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zk1oVBBRjz5i" style="vertical-align: bottom; background-color: White">
    <td>&#160;<span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Net income (loss) available to common stockholders</span> </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(14,626,683</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,544,954</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Denominator</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Weighted-average shares of common stock outstanding - basic
    and diluted</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_904_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231_znEzxgGfUxea" title="Weighted average shares of common stock outstanding - basic"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231_zbww0nP4YRg1" title="Weighted average shares of common stock outstanding - diluted">3,252,328</span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_901_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20220101__20221231_z6Tas7DWLb8e" title="Weighted average shares of common stock outstanding - basic"><span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20220101__20221231_zmjpPawtofr9" title="Weighted average shares of common stock outstanding - diluted">2,003,322</span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Basic and diluted net loss per share</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_908_eus-gaap--EarningsPerShareBasic_c20230101__20231231_zG5fKt9oFUC8" title="Basic net loss per share"><span id="xdx_905_eus-gaap--EarningsPerShareDiluted_c20230101__20231231_z2RhTCLdmDCb" title="Diluted net loss per share">(4.50</span></span></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_909_eus-gaap--EarningsPerShareBasic_c20220101__20221231_zZJe1K2BfZ76" title="Basic net loss per share"><span id="xdx_90C_eus-gaap--EarningsPerShareDiluted_c20220101__20221231_zds8oPl0kjM3" title="Diluted net loss per share">(2.77</span></span></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Disaggregation of Revenue</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--DisaggregationOfRevenueTableTextBlock_zX6RXuuRv7o2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table disaggregates the Company&#8217;s revenue based on the customer&#8217;s location by state for the years ended December
31:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B8_zAzVuhoIgill" style="display: none">Schedule of Disaggregation of Revenue</span>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 25%; text-align: left">California</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td id="xdx_987_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--CA_zAnDptrXJjOb" style="width: 20%; font-weight: bold; text-align: right" title="Revenues">601,235</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 25%; text-align: left">Wisconsin</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__stpr--WI_z2SwOYl8cNh9" style="width: 20%; text-align: right" title="Revenues">670,245</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Ohio</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--OH_zDI0OkZvXUch" style="font-weight: bold; text-align: right" title="Revenues">407,632</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">Ohio</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__stpr--OH_zJhs6wESToS2" style="text-align: right" title="Revenues">500,260</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Wisconsin</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--WI_z9ynHKka95Xd" style="font-weight: bold; text-align: right" title="Revenues">292,601</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">California</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__stpr--CA_zRGqfRRI4PZ9" style="text-align: right" title="Revenues">408,645</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Florida</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--FL_z1o4pUWGGbRe" style="font-weight: bold; text-align: right" title="Revenues">186,840</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">Florida</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__stpr--FL_zwbktOHvOlP2" style="text-align: right" title="Revenues">231,480</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Massachusetts</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--MA_zL8Z9URoL8Rf" style="font-weight: bold; text-align: right" title="Revenues">127,300</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">Missouri</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__country--MO_zmIB5JUxFlka" style="text-align: right" title="Revenues">174,980</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">All other states</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__custom--AllOtherStatesMember_zgxis1XpHgTj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Revenues">844,441</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1.5pt">All other states</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__custom--AllOtherStatesMember_zqkBp0QJB9Bd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenues">699,125</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_986_eus-gaap--Revenues_c20230101__20231231_zmLHQlhg1K4a" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Total revenue">2,460,049</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98B_eus-gaap--Revenues_c20220101__20221231_zVi8nS1HELrg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total revenue">2,684,735</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock', window );">Schedule of Customers Accounted Revenues</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock_zK2CTGYbN3Sb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B3_zCjfnL75gsbi" style="display: none">Schedule of Customers Accounted Revenues</span>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">Percentage of </td><td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">Percentage of </td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><b>Sales</b></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><b>Sales</b></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: left">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: left">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left">Hospital A</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--MajorCustomersAxis__custom--HospitalAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z8DYsvEFfc62" style="width: 15%; font-weight: bold; text-align: right" title="Revenue">452,680</td><td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 15%; text-align: center"><span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--HospitalAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zOU9fy3LjPDl" title="Risk percentage">18</span>%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20221231__srt--MajorCustomersAxis__custom--HospitalAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z6VZ0fIq4lbg" style="width: 15%; text-align: right" title="Revenue">355,613</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 15%; text-align: center"><span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--HospitalAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zGUAamau5Wg7" title="Risk percentage">13</span>%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Hospital B</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--MajorCustomersAxis__custom--HospitalBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zWtmDNKLOmZ8" style="font-weight: bold; text-align: right" title="Revenue">382,082</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--HospitalBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zxGlw7LXQHJh" title="Risk percentage">16</span>%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20221231__srt--MajorCustomersAxis__custom--HospitalBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zkkJm06MFCPb" style="text-align: right" title="Revenue">484,900</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--HospitalBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z8N4M2GNQ1Cg" title="Risk percentage">18</span>%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Hospital C</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--MajorCustomersAxis__custom--HospitalCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zoNS5KYKLCJ8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Revenue">274,581</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--HospitalCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_ztiAPuHBO464" title="Risk percentage">11</span>%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20221231__srt--MajorCustomersAxis__custom--HospitalCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zAa3xtGHtem9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue">554,325</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--HospitalCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zSTXRgI9fhP9" title="Risk percentage">21</span>%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--MajorCustomersAxis__custom--HospitalMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zPVkIhkG8i96" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Revenue">1,109,343</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--HospitalMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zAj2qbvuPNlj" title="Risk percentage">45</span>%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20221231__srt--MajorCustomersAxis__custom--HospitalMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zdpQH4bigBYb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue">1,394,838</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--HospitalMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zx1dh6xGR3J3" title="Risk percentage">52</span>%</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Property Plant And Equipment Useful Lives [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allowance for credit loss on right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effect of income (loss) on an entity's diluted earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823932728944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of Related Party Transactions</a></td>
<td class="text"><p id="xdx_896_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zqWIyjUVS18e" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8B5_z8l6ORobyzp1" style="display: none">Schedule of Related Party Transactions</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Loan</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Interest</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Interest</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Receivable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Receivable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Income</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Shareholder 1</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderOneMember_zNjeGS834uJ1" style="width: 14%; text-align: right" title="Loan Receivable">506,400</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--InterestReceivableCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderOneMember_zAr7UCbfco9d" style="width: 14%; text-align: right" title="Interest Receivable">70,938</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_ecustom--InterestIncomeGrossCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderOneMember_zjUqYewZQEKe" style="width: 14%; text-align: right" title="Interest Income">23,867</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Shareholder 2</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderTwoMember_zUaBQuPkUcs4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Loan Receivable">506,400</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--InterestReceivableCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderTwoMember_zbnY9eWJLBr5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest Receivable">70,803</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_ecustom--InterestIncomeGrossCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderTwoMember_zW2gG27f91Bk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest Income">23,867</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zYEz6pYsAt8" style="text-align: right" title="Loan Receivable">1,012,800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--InterestReceivableCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zV6zGTWgKfwd" style="text-align: right" title="Interest Receivable">141,741</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--InterestIncomeGrossCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zuqvBNoFFs89" style="text-align: right" title="Interest Income">47,734</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Allowance for Collection Risk</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--AllowanceForNotesAndLoansReceivableCurrent_iNI_di_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zVsT3J8XqlA7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Allowance for collection risk, loan receivable">(1,012,800</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--InterestReceivableCurrent_iNI_di_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z9RIPUINte28" style="border-bottom: Black 1.5pt solid; text-align: right" title="Allowance for collection risk, interest receivable">(141,741</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_ecustom--AllowanceForInterestIncomeCurrent_iNI_di_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z5Uz45E9BYme" style="border-bottom: Black 1.5pt solid; text-align: right" title="Allowance for collection risk, interest income">(47,734</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Net Balance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98E_eus-gaap--NotesAndLoansReceivableNetCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zwvDYzL2T28i" style="border-bottom: Black 1.5pt solid; text-align: right" title="Loan Receivable"><span style="-sec-ix-hidden: xdx2ixbrl0946">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98E_eus-gaap--InterestReceivable_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zGC81YvfHKMf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest Receivable"><span style="-sec-ix-hidden: xdx2ixbrl0948">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98D_ecustom--InterestIncomeCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zbLdMijari3b" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest Income"><span style="-sec-ix-hidden: xdx2ixbrl0950">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Loan</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Interest</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Interest</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Receivable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Receivable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Income</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Shareholder 1</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderOneMember_zsr2M5KfUG5h" style="width: 14%; text-align: right" title="Loan Receivable">506,400</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--InterestReceivableCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderOneMember_z6I6OQcmRgol" style="width: 14%; text-align: right" title="Interest Receivable">47,071</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_ecustom--InterestIncomeGrossCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderOneMember_zGimIoPsSCJ7" style="width: 14%; text-align: right" title="Interest Income">11,523</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Shareholder 2</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderTwoMember_zxtDmMfOnRn5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Loan Receivable">506,400</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--InterestReceivableCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderTwoMember_za9yIQZuCwQb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest Receivable">46,936</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_ecustom--InterestIncomeGrossCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderTwoMember_zrl9RjcqPpS3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest Income">11,523</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z1NAQRx3RRtl" style="text-align: right" title="Loan Receivable">1,012,800</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--InterestReceivableCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_znAiqJpIor4" style="text-align: right" title="Interest Receivable">94,007</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_ecustom--InterestIncomeGrossCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z2U5TqiSdRQe" style="text-align: right" title="Interest Income">23,046</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Allowance for Collection Risk</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AllowanceForNotesAndLoansReceivableCurrent_iNI_di_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zSgT36uVkLzc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Allowance for collection risk, loan receivable">(1,012,800</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--InterestReceivableCurrent_iNI_di_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zjME8N49EpH6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Allowance for collection risk, interest receivable">(94,007</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_ecustom--AllowanceForInterestIncomeCurrent_iNI_di_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_ztt179JuzVad" style="border-bottom: Black 1.5pt solid; text-align: right" title="Allowance for collection risk, interest income">(23,046</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Net Balance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98B_eus-gaap--NotesAndLoansReceivableNetCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zEGLcV60i0Oi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Loan Receivable"><span style="-sec-ix-hidden: xdx2ixbrl0976">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98D_eus-gaap--InterestReceivable_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zACWZJZhkB3c" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest Receivable"><span style="-sec-ix-hidden: xdx2ixbrl0978">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_982_ecustom--InterestIncomeCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zASJ0ABNa47e" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest Income"><span style="-sec-ix-hidden: xdx2ixbrl0980">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_ScheduleOfRelatedPartyLoansTableTextBlock', window );">Schedule of Related Party Loans payable to shareholder</a></td>
<td class="text"><p id="xdx_894_ecustom--ScheduleOfRelatedPartyLoansTableTextBlock_zWYBz5E1QISc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span id="xdx_8B8_z9ZoAHflmhHk" style="display: none">Schedule of Related Party Loans payable to shareholder</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Interest &amp;</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Interest</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Loan</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Service Fee</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Interest</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Due Date</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Rate</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Balance</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accrued</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Paid</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%; text-align: left">Shareholder 1</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_eus-gaap--DebtInstrumentMaturityDateDescription_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderMember_zLmrcLwwzZT9" title="Due date">June, 2019</span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderMember_zdKQbLO41w0a" title="Debt instrument percentage">15.00</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--LoansPayable_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderMember_ztyIiCuOam1d" style="width: 10%; text-align: right" title="Loan payable"><span style="-sec-ix-hidden: xdx2ixbrl0988">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_ecustom--InterestAndServiceFeeAccrued_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderMember_zkwUyLgjw5ic" style="width: 10%; text-align: right" title="Interest payable"><span style="-sec-ix-hidden: xdx2ixbrl0990">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--InterestPaid_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderMember_zUEbQib1hql4" style="width: 10%; text-align: right" title="Interest payable">10,047</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Shareholder 1</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_eus-gaap--DebtInstrumentMaturityDateDescription_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_z6UYuTOdv2T7" title="Due date">June, 2019</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_zDuwTD5kyGze" title="Debt instrument percentage">15.00</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--LoansPayable_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_zPaik7XCGSSf" style="text-align: right" title="Loan payable"><span style="-sec-ix-hidden: xdx2ixbrl0998">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--InterestAndServiceFeeAccrued_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_zwzShwpllCt5" style="text-align: right" title="Interest payable"><span style="-sec-ix-hidden: xdx2ixbrl1000">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--InterestPaid_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_ztf8UkLpAEc1" style="text-align: right" title="Interest payable">27,056</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other Convertibles</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_eus-gaap--DebtInstrumentMaturityDateDescription_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zPnt1LgV7VAh" title="Due date">Various</span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zLPY1MG1DDU3" title="Debt instrument percentage">5.00</span></td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--LoansPayable_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zchp3VXWcIvd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest payable"><span style="-sec-ix-hidden: xdx2ixbrl1008">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_ecustom--InterestAndServiceFeeAccrued_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zOxnLZn5lmwh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest payable">66,648</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--InterestPaid_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zlYzcLAKuAU7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest payable"><span style="-sec-ix-hidden: xdx2ixbrl1012">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Total</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--LoansPayable_iI_c20231231_zYL0tJxjI3ih" style="border-bottom: Black 1.5pt solid; text-align: right" title="Loan payable"><span style="-sec-ix-hidden: xdx2ixbrl1014">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98E_ecustom--InterestAndServiceFeeAccrued_iI_c20231231_zEsgLv7iBl9j" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest payable">66,648</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_982_eus-gaap--InterestPaid_c20230101__20231231_z3n7s4J8fFB" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest payable">37,103</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Interest &amp;</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Interest</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Loan</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Service Fee</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Interest</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Due Date</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Rate</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Balance</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Accrued</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Paid</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 30%; text-align: left">Shareholder 1</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_eus-gaap--DebtInstrumentMaturityDateDescription_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--ShareHolderMember_zg9pF0o9AWS1" title="Due date">June, 2019</span></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right"><span id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20221231__us-gaap--DebtInstrumentAxis__custom--ShareHolderMember_zMFYZMyHe3v5" title="Debt instrument percentage">15.00</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--LoansPayable_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--ShareHolderMember_zwWXBFlgBprk" style="width: 10%; text-align: right" title="Loan payable">20,051</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--InterestAndServiceFeeAccrued_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--ShareHolderMember_zlY1frgGimk4" style="width: 10%; text-align: right" title="Interest and service fee accrued">8,161</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--InterestPaid_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--ShareHolderMember_zgKxFVTIYmt4" style="width: 10%; text-align: right" title="Interest payable"><span style="-sec-ix-hidden: xdx2ixbrl1028">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Shareholder 1</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_eus-gaap--DebtInstrumentMaturityDateDescription_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_z7K6IKNGNO3f" title="Due date">June, 2019</span></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20221231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_zBlYt2yMTJ48" title="Debt instrument percentage">15.00</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--LoansPayable_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_zl1hWiioUS49" style="text-align: right" title="Loan payable">38,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--InterestAndServiceFeeAccrued_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_zArwiydQevl6" style="text-align: right" title="Interest and service fee accrued">23,481</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--InterestPaid_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_zYe1fTJeAwyg" style="text-align: right" title="Interest payable"><span style="-sec-ix-hidden: xdx2ixbrl1038">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other Convertibles</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_eus-gaap--DebtInstrumentMaturityDateDescription_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zSBIQTQfuLCg" title="Due date">Various</span></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20221231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zpfbQRoNeyk3" title="Debt instrument percentage">5.00</span></td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--LoansPayable_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zTlga8JpcJl9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest payable"><span style="-sec-ix-hidden: xdx2ixbrl1044">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_ecustom--InterestAndServiceFeeAccrued_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_z90rDfXZ7UGe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest and service fee accrued">66,648</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--InterestPaid_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zBsDBBqJJqX9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest payable"><span style="-sec-ix-hidden: xdx2ixbrl1048">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Total</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_982_eus-gaap--LoansPayable_iI_c20221231_zHcLjkkKEjAb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Loan payable">58,051</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98C_ecustom--InterestAndServiceFeeAccrued_iI_c20221231_zHVxGTsufhVd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest payable">98,290</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_983_eus-gaap--InterestPaid_c20220101__20221231_zOs1DvDDPMqe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest payable"><span style="-sec-ix-hidden: xdx2ixbrl1054">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_ScheduleOfRelatedPartyLoansTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Related Party Loans [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_ScheduleOfRelatedPartyLoansTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823803575024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property And Equipment</a></td>
<td class="text"><p id="xdx_898_eus-gaap--PropertyPlantAndEquipmentTextBlock_zguBbBQHPIWi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment, net consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B0_zePKoEMzzgeh" style="display: none">Schedule of Property And Equipment</span>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20231231_zoUeCkXV1L2k" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_498_20221231_zAgqC9cPGbKf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zbxSKBFBSOh2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Machinery and equipment </td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">282,181</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">282,181</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zdkx0YCHKhQ9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Furniture and fixtures </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">96,768</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">87,148</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zUhyHyzfSund" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Computer hardware </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">36,613</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,452</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zmHgNTK87a9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Leasehold improvements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,064</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21,064</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzDOd_zddlUWZrSspl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Total property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">436,626</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">405,845</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzDOd_zUnCInTIaywh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Less: accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(348,074</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(317,834</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzDOd_z5wE7aUzCJF4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Property and equipment, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">88,552</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">88,011</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823803624800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Intangible Assets</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zD03jdz2fjR1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
assets, net consists of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<span id="xdx_8B6_z35rKqZHVCC4" style="display: none">Schedule of Intangible Assets</span>&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20231231_zE5N7uh8RSrg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20221231_zrjV3ucEDmJk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwareImplementationMember_zo4cyPJFQBYf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Software Implementation </td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">49,815</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">49,815</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z0H2p6hAGYl3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Patents </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32,463</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">32,463</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zM2CejhHnq33" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Trademark </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zUyhI90nG0O5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Licenses </td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1111">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_maFLIANzh0b_zz55gQdRG0qh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Total intangible assets </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">133,278</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">92,278</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_msFLIANzh0b_zJkYwCTbzNv8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Less: accumulated amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(25,205</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(14,720</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_mtFLIANzh0b_z8Ukw9YsX001" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Intangible assets, net </td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">108,073</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">77,558</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823800643360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zbJ7IyG2Sda6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
expenses consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span><span id="xdx_8B1_zPhMWXUSqlO6" style="display: none">Schedule of Accrued Expenses</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20231231_zDSqQEtsenai" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20221231_z7de2MycamP3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_ecustom--AccruedCompensationAndBenefitsCurrent_iI_maALCz2hn_z2TNu5bnhvf4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Compensation and benefits</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">333,477</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">539,558</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--UnderwriterFees_iI_maALCz2hn_z45JncJLH3w6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Underwriter fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1133">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">88,259</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--InterestPayableCurrent_iI_maALCz2hn_zza25uYKYpgi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">66,648</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">173,826</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--RelatedPartyInterestPayableCurrent_iI_maALCz2hn_zWTl8aaECLO5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Related party interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1139">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">31,642</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccrualForTaxesOtherThanIncomeTaxesCurrent_iI_maALCz2hn_zONABGuKRwcc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">963</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">777</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>


  <tr id="xdx_40A_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCz2hn_zdp6dpeqfAH2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Total accrued expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">401,088</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">834,062</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823803419360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Schedule of Convertible Notes</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--ConvertibleDebtTableTextBlock_zwnV5CftQj64" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents a summary of the Company&#8217;s convertible notes:</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BE_zaDohGEoCEnk">Schedule
of Convertible Notes</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20231231_zojZPyu68nuh" style="border-bottom: Black 1.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_493_20221231_zKQQj3MCvMdf" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31,</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--DebtInstrumentFaceAmount_iI_zUfbL3EZ46u4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1181">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,555,556</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--DeferredFinanceCostsCurrentNet_iNI_di_zeR6aqvMYHkl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less:
    Original issue discount</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1184">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(355,556</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_403_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di_zQwpEjFULmVd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: Debt discount</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1187">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,841,658</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_400_eus-gaap--DeferredFinanceCostsNet_iNI_di_zkKCDx6O8T62" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less: Deferred financing fees</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1190">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(130,000</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40C_eus-gaap--LongTermDebt_iI_zTA5lO8vLnec" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;Notes
    payable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl1193">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">228,342</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823800605008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock', window );">Schedule of Operating Leases</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--OperatingLeasesOfLesseeDisclosureTextBlock_zL1DVsEOIMZj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information related to the Company&#8217;s operating leases:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B9_zbkU8aI0hBH7" style="display: none">Schedule of Operating Leases</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49D_20231231_zbQj9ZkbBWz2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_492_20221231_zYHSdHBiFm09" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseRightOfUseAsset_iI_zEZZBTAfoqd7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left; padding-bottom: 1.5pt">Operating lease right-of-use assets</td><td style="width: 2%; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 16%; font-weight: bold; text-align: right">70,263</td><td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">101,382</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OtherLiabilitiesCurrent_iI_zm9zZg5Nwu86" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other current liabilities</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">49,127</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33,395</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zy2McdHD9408" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Operating lease liabilities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">27,071</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">76,199</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingLeaseLiability_iI_zJsruRK1nMR" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">76,198</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">109,594</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Weighted-average remaining lease term (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20231231_zFFRP2qAZvg7" title="Weighted average remaining lease term (in years)">3.75</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_903_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_zomxZrgZidyk" title="Weighted average remaining lease term (in years)">4.00</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Weighted-average discount rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_uPure_c20231231_zBeFiyvgElC7" title="Weighted average discount rate">15.0</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_902_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_uPure_c20221231_zAkKHF1tgYWl" title="Weighted average discount rate">15.0</span></td><td style="text-align: left">%</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities Operating Lease Liabilities</a></td>
<td class="text"><p id="xdx_895_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zxxn8qAlvrSc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2023, the maturities of the Company&#8217;s operating lease liabilities were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span><span id="xdx_8B5_zeZ9qs2gWW39" style="display: none">Schedule of Maturities Operating Lease Liabilities</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 65%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49C_20231231_zoyDNcpF1jfk" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzyNu_zJrYMlclNNZ" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">2024</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">27,072</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzyNu_zFmSJqgVaoyh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">22,316</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzyNu_zov6zadw8H07" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2026</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">26,810</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzyNu_zWn2N5fJhg9d" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">76,198</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_z1Yfm0NWn5V3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1343">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseLiability_iI_zirh2xyENqp9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total present value of lease payments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">76,198</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for lessee's operating leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481440/840-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481418/840-10-55-40<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481501/840-20-50-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481501/840-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823804544512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock and Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Warrants outstanding and Exercisable</a></td>
<td class="text"><p id="xdx_898_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zPFQXUl3FwJ" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table summarizes the Company&#8217;s warrants outstanding and exercisable as of December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_zON6lmiXJCBf" style="display: none">Schedule of Warrants outstanding and Exercisable</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Warrants</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: center">Expiration</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Date</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Investor Warrant W-01</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantOneMember_z2ZvJ9G75a15" style="width: 14%; text-align: right" title="Number of Warrants">12,852</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantOneMember_zwlOEHMDF2ha" style="width: 14%; text-align: right" title="Exercise Price">8.76</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 16%; text-align: center"><span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantOneMember_zMwK10K6gYG1" title="Expiration Date">September 18, 2028</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Investor Warrant PSA-01</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantPSAOneMember_z5b83TdI0T1e" style="text-align: right" title="Number of Warrants">289,779</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantPSAOneMember_z60RpMMDxE3c" style="text-align: right" title="Exercise Price">0.01</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_908_ecustom--WarrantExpirationDateDescription_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantPSAOneMember_zy7hRhHg4Klj" title="Expiration Date">None</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2022 Convertible Notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zYyUIcsWsEP4" style="text-align: right" title="Number of Warrants">793,655</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zGQo7QUjUPvf" style="text-align: right" title="Exercise Price">2.38</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_909_ecustom--WarrantExpirationDateDescription_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_z8cPQMcjQYf2" title="Expiration Date">Various</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2023 Convertible Notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zZjaNLkOEind" style="text-align: right" title="Number of Warrants">417,714</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zijUSrhPJjM" style="text-align: right" title="Exercise Price">2.38</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_90D_ecustom--WarrantExpirationDateDescription_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zjdnEypDoDEd" title="Expiration Date">Various</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Consulting Agreement Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ConsultingAgreementWarrantsMember_zaTFTmhJzFW2" style="text-align: right" title="Number of Warrants">122,202</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ConsultingAgreementWarrantsMember_zEc7yGgxrfQ1" style="text-align: right" title="Exercise Price">2.38</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ConsultingAgreementWarrantsMember_z1XkTYMX6pjc" title="Expiration Date">August 8, 2028</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Underwriter&#8217;s Warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantsMember_zd1m9zDelivk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants">186,156</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantsMember_zh5p3ZM7xNF9" style="padding-bottom: 1.5pt; text-align: right" title="Exercise Price">2.38</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt"><span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantsMember_zWlJXInjWwXl" title="Expiration Date">August 8, 2028</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231_z0KOtmJoNRN4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants">1,822,358</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left; padding-bottom: 1.5pt">&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_ScheduleOfWarrantActivityForCommonStockTableTextBlock', window );">Schedule of Warrant Activity for Common Stock</a></td>
<td class="text"><p id="xdx_897_ecustom--ScheduleOfWarrantActivityForCommonStockTableTextBlock_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zT0tVLJd8Fb1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of warrant activity for common stock during the years ended December 31, 2023 and 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span><span id="xdx_8BB_zbPdy6YRoh12" style="display: none">Schedule of Warrant Activity for Common Stock</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Warrants for Common
    Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted-Avg. Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted-Avg. Remaining Contractual
    Life</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; font-weight: bold; text-align: left">Outstanding as of January 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFtfkHit6nal" style="width: 14%; text-align: right" title="Number of Warrants, Outstanding at beginning of period">52,852</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4GsLYC1p5P9" style="width: 14%; text-align: right" title="Weighted Average Exercise Price, Outstanding at beginning of period">2.13</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right"><span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zl6qZXq8dUt6" title="Weighted Average Remaining Contractual Life - Warrants, Outstanding at beginning of period">7.45</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQ7wIfObdtu2" style="text-align: right" title="Number of Warrants, Granted">793,655</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPw6fxB9ydqh" style="text-align: right" title="Weighted Average Exercise Price, granted">5.25</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageRemainingContracualLifeOutstandingNumberGranted_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkS3ZdEjg8hk" title="Weighted Average Remaining Contractual Life - Warrants Granted">4.42</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cancelled/Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRsBQtlIFENd" style="text-align: right" title="Number of Warrants, Cancelled Expired"><span style="-sec-ix-hidden: xdx2ixbrl1434">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLbhtOkKExjk" style="text-align: right" title="Weighted Average Exercise Price, Cancelled Expired"><span style="-sec-ix-hidden: xdx2ixbrl1436">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwxWiNfdMXFh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1438">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIHWoLLJqhIa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Excercised"><span style="-sec-ix-hidden: xdx2ixbrl1440">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Outstanding as of December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjGjArh6kWl3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants, Outstanding at beginning of period">846,507</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsVBLIE98wNh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding at beginning of period">5.06</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z1bupKrRyEVb" title="Weighted Average Remaining Contractual Life - Warrants, Outstanding at beginning of period">4.72</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHXGtkRBVef7" style="text-align: right" title="Number of Warrants, Granted">813,928</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrvhplVZaaea" style="text-align: right" title="Weighted Average Exercise Price, granted">5.81</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z3Rw1vMLMbgi" title="Weighted Average Remaining Contractual Life - Warrants Granted">4.38</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Converted Prefunded Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBKOw27Iswof" style="text-align: right" title="Number of Warrants, Converted Prefunded Warrants">289,779</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsConvertedPrefundedWarrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLHJQsNqGfSf" style="text-align: right" title="Weighted Average Exercise Price, Converted Prefunded Warrants">0.01</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNNkyqPnU1p2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants, Exercised">(127,856</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxn1kG8yXWhh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Excercised"><span style="-sec-ix-hidden: xdx2ixbrl1460">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Outstanding as of December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z52slLer13Yi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants, Outstanding at Ending of period">1,822,358</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWcR3HmB7P4d" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding at Ending of period">4.69</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zUlKG5KBXfV6" title="Weighted Average Remaining Contractual Life - Warrants, Outstanding at Ending of period">3.05</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_ScheduleOfWarrantActivityForPreferredStockTableTextBlock', window );">Schedule of Warrant Activity for Preferred Stock</a></td>
<td class="text"><p id="xdx_891_ecustom--ScheduleOfWarrantActivityForPreferredStockTableTextBlock_hus-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z8rPRlYi2yr7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of warrant activity for preferred stock during the years ended December 31, 2023 and 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B3_zBDZzq1ZH1Jg" style="display: none">Schedule of Warrant Activity for Preferred Stock</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Number of</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Weighted-Avg.</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Warrants for</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Exercise</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Preferred Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; font-weight: bold; text-align: left">Outstanding as of January 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zHjGmEHAR7n" style="width: 16%; text-align: right" title="Number of Warrants, Outstanding at beginning of period">144,890</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zWxVdZmPzCXb" style="width: 16%; text-align: right" title="Weighted Average Exercise Price, Outstanding at beginning of period">0.01</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zKrzoDZ974Kf" style="text-align: right" title="Number of Warrants, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1474">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zvx7V26CALq4" style="text-align: right" title="Weighted Average Exercise Price, granted"><span style="-sec-ix-hidden: xdx2ixbrl1476">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cancelled/Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zmgoHNJLFe2j" style="text-align: right" title="Number of Warrants, Cancelled Expired"><span style="-sec-ix-hidden: xdx2ixbrl1478">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zU6SDG16jVpf" style="text-align: right" title="Weighted Average Exercise Price, Cancelled Expired"><span style="-sec-ix-hidden: xdx2ixbrl1480">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zOoHjZDVMd15" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1482">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zNvu6Eca2qs9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Excercised"><span style="-sec-ix-hidden: xdx2ixbrl1484">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Outstanding as of December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zVJNx44x0VJ7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants, Outstanding at beginning of period">144,890</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zd50OkTmeHT3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding at beginning of period">0.01</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_znFCYHiQfpJh" style="text-align: right" title="Number of Warrants, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1490">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zEdXTAJWHEFk" style="text-align: right" title="Weighted Average Exercise Price, granted"><span style="-sec-ix-hidden: xdx2ixbrl1492">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cancelled/Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zz4SGnNOQE3f" style="text-align: right" title="Number of Warrants, Cancelled Expired"><span style="-sec-ix-hidden: xdx2ixbrl1494">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zyZcFmgWqHc2" style="text-align: right" title="Weighted Average Exercise Price, Cancelled Expired"><span style="-sec-ix-hidden: xdx2ixbrl1496">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Converted to Common Stock Warrant</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zFfOb5Qk5Rzl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Converted to Common Stock Warrant">(144,890</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zIxM4IoiAYx5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Converted to Common Stock Warrant">(0.01</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Outstanding as of December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zDXqtRsfiNk9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants, Outstanding at Ending of period"><span style="-sec-ix-hidden: xdx2ixbrl1502">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zBEYAb8ItwJd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding at Ending of period"><span style="-sec-ix-hidden: xdx2ixbrl1504">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_ScheduleOfWarrantActivityForCommonStockTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of warrant activity for common stock [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_ScheduleOfWarrantActivityForCommonStockTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_ScheduleOfWarrantActivityForPreferredStockTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of warrant activity for preferred stock [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_ScheduleOfWarrantActivityForPreferredStockTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823809376880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Options and Awards (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Option-pricing Model with Following Weighted-average Assumptions</a></td>
<td class="text"><p id="xdx_898_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zSodkXedL2Fg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B6_zrJM8IbVxkhe" style="display: none">Schedule of Option-pricing Model with Following Weighted-average Assumptions</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 65%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Assumptions as of December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">Fully Vested</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 74%; text-align: left">Number of Shares</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_zOvAN9zZQDL6" style="width: 22%; text-align: right" title="Number of Shares">1,319,394</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--SharePrice_iI_c20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_zd7QjgdqJJwc" style="text-align: right" title="Stock price">2.67</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Exercise price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_zvltKuMCnOj8" style="text-align: right" title="Exercise price">6.94</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_zMoDvJx5aIT9" title="Expected term">5.75</span> years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_zn0fdwdxlpD" style="text-align: right" title="Expected volatility">31.90</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_zAef3CWeZzr1" style="text-align: right" title="Risk-free interest rate">3.84</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dividend rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_zVd9PeRGxHdd" style="text-align: right" title="Dividend rate">0</td><td style="text-align: left">%</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z0SXezbnXQoe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following is a summary of stock option activity for the years ended December 31, 2023 and 2022:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="display: none"></span></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B9_z6hMbd0cxl3k" style="display: none">Schedule of Stock Option Activity</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Options</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Avg. Remaining Contractual Life (in years)</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Avg. Exercise Price</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; font-weight: bold; text-align: left">Outstanding as of January 1, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231_zZCrZxld5Pja" style="width: 11%; text-align: right" title="Number of Options, Outstanding, Beginning balance">1,319,394</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_z21YhOqhwyda" title="Weighted Average Remaining Contractual Life (in years), Outstanding">7.69</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20220101__20221231_z5Fb9NxZcFG5" style="width: 11%; text-align: right" title="Weighted Average Exercise Price, Outstanding, Beginning balance">6.94</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20220101__20221231_zgfl9C219dV8" style="width: 11%; text-align: right" title="Aggregate Intrinsic Value, Outstanding, Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1628">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20220101__20221231_zGdVdEKNR3Pf" style="text-align: right" title="Number of Options, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1630">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_uShares_c20220101__20221231_zTmrillIZ9ja" style="text-align: right" title="Number of Options, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1632">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Cancelled/Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_pid_uShares_c20220101__20221231_zNJ5RE84Xqkk" style="text-align: right" title="Number of Options, Cancelled/Expired"><span style="-sec-ix-hidden: xdx2ixbrl1634">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20220101__20221231_z9OSd5tPk48a" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1636">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Outstanding as of December 31, 2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231_zfQeHbfbiMJg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, Outstanding, Beginning balance">1,319,394</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zRiad09Ik3Ma" title="Weighted Average Remaining Contractual Life (in years), Outstanding">6.69</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20230101__20231231_z4F1SfXgrd9d" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding, Beginning balance">6.94</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20230101__20231231_zX6U9TmDrwS9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Aggregate Intrinsic Value, Outstanding, Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1644">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20230101__20231231_zIbrWIgFhoSc" style="text-align: right" title="Number of Options, Granted"><span style="-sec-ix-hidden: xdx2ixbrl1646">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_uShares_c20230101__20231231_zzrO0z8gual2" style="text-align: right" title="Number of Options, Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1648">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Cancelled/Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_pid_uShares_c20230101__20231231_zsIq9wAYQfXc" style="text-align: right" title="Number of Options, Cancelled/Expired"><span style="-sec-ix-hidden: xdx2ixbrl1650">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20230101__20231231_zDsA0ZPH3ep3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, Exercised"><span style="-sec-ix-hidden: xdx2ixbrl1652">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Outstanding as of December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231_zMLNl3Ld1DX3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, Outstanding, Ending balance">1,319,394</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zDCGuIK6aXWi" title="Weighted Average Remaining Contractual Life (in years), Outstanding">5.69</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20230101__20231231_zKmIVAqODHM9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding, Ending balance">6.94</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20230101__20231231_z8MijdMiMTx9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Aggregate Intrinsic Value, Outstanding, Ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1660">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Vested and Exercisable as of December 31, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iE_pid_c20230101__20231231_zF6kLe4J8jHi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, Vested and Exercisable, Ending balance">1,319,394</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231_zooQYAqcfhUh" title="Weighted Average Remaining Contractual Life (in years), Vested and Exercisable">5.69</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20230101__20231231_zUPUhEvHEX5g" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Vested and Exercisable, Ending balance">6.94</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iE_c20230101__20231231_zAlGieIzA6ae" style="border-bottom: Black 1.5pt solid; text-align: right" title="Aggregate Intrinsic Value, Vested and Exercisable, Ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1668">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823811336304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrant Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_DisclosureWarrantLiabilitiesAbstract', window );"><strong>Warrant Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_ScheduleOfChangesInWarrantLiabilitiesTableTextBlock', window );">Schedule of Changes in Warrant Liabilities</a></td>
<td class="text"><p id="xdx_897_ecustom--ScheduleOfChangesInWarrantLiabilitiesTableTextBlock_z6Toq9XoRvDd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following are the changes in the warrant liabilities during the years ended December 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B1_zAN13vAF9yx" style="display: none">Schedule of Changes in Warrant Liabilities</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; font-weight: bold; text-align: left">Warrant liabilities as of January 1, 2022 </td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--WarrantsAndRightsOutstanding_iS_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zTiROgSGmUp5" style="width: 14%; text-align: right" title="Warrant liabilities, Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1692">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--WarrantsAndRightsOutstanding_iS_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zjQgzvavEJ" style="width: 14%; text-align: right" title="Warrant liabilities, Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1694">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--WarrantsAndRightsOutstanding_iS_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zNRT00QtzTL1" style="width: 14%; text-align: right" title="Warrant liabilities, Beginning balance">32,102</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Addition </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--AdditionToWarrantLiabilities_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zFqbeCr72do1" style="text-align: right" title="Addition"><span style="-sec-ix-hidden: xdx2ixbrl1698">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_ecustom--AdditionToWarrantLiabilities_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z9PhqYq2ZPOb" style="text-align: right" title="Addition"><span style="-sec-ix-hidden: xdx2ixbrl1700">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--AdditionToWarrantLiabilities_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zWQMNmJimNia" style="text-align: right" title="Addition">2,808,331</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Changes in fair value of warrant liabilities </td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zmkKASd2yON2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Changes in fair value of warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1704">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z4abHtkC2ypb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Changes in fair value of warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1706">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_ziDEp9njSkCd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Changes in fair value of warrant liabilities">(606,049</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Warrant liabilities as of December 31, 2022 </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--WarrantsAndRightsOutstanding_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zaPRSuOKnSHe" style="text-align: right" title="Warrant liabilities, Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1710">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--WarrantsAndRightsOutstanding_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zCuCE8c0iAlf" style="text-align: right" title="Warrant liabilities, Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1712">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstanding_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z6BtnMSYqUtd" style="text-align: right" title="Warrant liabilities, Beginning balance">2,234,384</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Addition </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--AdditionToWarrantLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zn3FBnvSlvEa" style="text-align: right" title="Addition"><span style="-sec-ix-hidden: xdx2ixbrl1716">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_ecustom--AdditionToWarrantLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zrw1BWKii3eh" style="text-align: right" title="Addition"><span style="-sec-ix-hidden: xdx2ixbrl1718">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--AdditionToWarrantLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zoRdUKE3rUJ" style="text-align: right" title="Addition">2,446,502</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Changes in fair value of warrant liabilities </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--FairValueAdjustmentOfWarrants_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zTA1HjtEEgIi" style="text-align: right" title="Changes in fair value of warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1722">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--FairValueAdjustmentOfWarrants_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zWkjqqijvVH7" style="text-align: right" title="Changes in fair value of warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1724">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--FairValueAdjustmentOfWarrants_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z4dUUpRfRLva" style="text-align: right" title="Changes in fair value of warrant liabilities">(844,854</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Reclassified to equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_ecustom--ReclassifiedToEquity_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z2cqdPeE1ixg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Reclassified to equity"><span style="-sec-ix-hidden: xdx2ixbrl1728">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--ReclassifiedToEquity_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zYBZUn1D477b" style="border-bottom: Black 1.5pt solid; text-align: right" title="Reclassified to equity"><span style="-sec-ix-hidden: xdx2ixbrl1730">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_ecustom--ReclassifiedToEquity_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zuLnj3rlaVj6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Reclassified to equity">(3,827,807</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Warrant liabilities as of December 31, 2023 </td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_981_eus-gaap--WarrantsAndRightsOutstanding_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zVDzO5JoXFJb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrant liabilities, Ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1734">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstanding_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zS2JS6R6igP1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrant liabilities, Ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1736">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstanding_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zhDRrmhElhV6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrant liabilities, Ending balance">8,225</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_DisclosureWarrantLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_DisclosureWarrantLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_ScheduleOfChangesInWarrantLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Changes in Warrant Liabilities [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_ScheduleOfChangesInWarrantLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823800600192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_DisclosureDerivativeLiabilitiesAbstract', window );"><strong>Derivative Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock', window );">Schedule of Changes in Derivative Liabilities</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zJdwQatXOJT7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following are the changes in the warrant liabilities during the years ended December 31, 2023 and 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B8_zUOQofGvwwp" style="display: none">Schedule of Changes in Derivative Liabilities</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level 3</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Derivative liabilities as of January 1, 2022 </td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--DerivativeLiabilitiesCurrent_iS_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z9jhwzhVpE86" style="text-align: right" title="Derivative liabilities, Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1754">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98B_eus-gaap--DerivativeLiabilitiesCurrent_iS_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zRx91dD0QrO2" style="text-align: right" title="Derivative liabilities, Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1756">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--DerivativeLiabilitiesCurrent_iS_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z9IMVBdcuuFb" style="text-align: right" title="Derivative liabilities, Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1758">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 46%; text-align: left">Addition </td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_982_ecustom--AdditionToDerivativeLiabilities_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zoxD020vegNl" style="width: 14%; text-align: right" title="Addition"><span style="-sec-ix-hidden: xdx2ixbrl1760">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_ecustom--AdditionToDerivativeLiabilities_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_ziYC6HGpNHe6" style="width: 14%; text-align: right" title="Addition"><span style="-sec-ix-hidden: xdx2ixbrl1762">&#8212;</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_985_ecustom--AdditionToDerivativeLiabilities_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zaaoT3YzJxqe" style="width: 14%; text-align: right" title="Addition">2,449,689</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Changes in fair value of Derivative liabilities </td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zAZjwjhblxuf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Changes in fair value of Derivative liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1766">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zR5TmpePO1ng" style="border-bottom: Black 1.5pt solid; text-align: right" title="Changes in fair value of Derivative liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1768">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zYddEwPOCxEd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Changes in fair value of Derivative liabilities">(713,989</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Derivative liabilities as of December 31, 2022 </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--DerivativeLiabilitiesCurrent_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zTnpau9Rhcqd" style="text-align: right" title="Derivative liabilities, Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1772">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--DerivativeLiabilitiesCurrent_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zKCP0izm4NMk" style="text-align: right" title="Derivative liabilities, Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1774">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--DerivativeLiabilitiesCurrent_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zedFJURVBnq4" style="text-align: right" title="Derivative liabilities, Beginning balance">1,735,700</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Addition </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--AdditionToDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zNHky8oLN51c" style="text-align: right" title="Addition"><span style="-sec-ix-hidden: xdx2ixbrl1778">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_ecustom--AdditionToDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_ziMUjDmHdjM9" style="text-align: right" title="Addition"><span style="-sec-ix-hidden: xdx2ixbrl1780">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_ecustom--AdditionToDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zWqpB46QAE4k" style="text-align: right" title="Addition">2,375,378</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Changes in fair value of Derivative liabilities </td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zO7swFuSYcIi" style="text-align: right" title="Changes in fair value of Derivative liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1784">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zsbDKxp0tjte" style="text-align: right" title="Changes in fair value of Derivative liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1786">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zv1DJ5mLg454" style="text-align: right" title="Changes in fair value of Derivative liabilities">(198,551</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Extinguishment of Derivative liabilities </td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--ExtinguishmentOfDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zno7fW0abtFb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Extinguishment of Derivative liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1790">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_ecustom--ExtinguishmentOfDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zWWLnmwhY4Wj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Extinguishment of Derivative liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1792">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_ecustom--ExtinguishmentOfDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zKKG6mL1xKxg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Extinguishment of Derivative liabilities">(3,912,527</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Derivative liabilities as of December 31, 2023 </td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_989_eus-gaap--DerivativeLiabilitiesCurrent_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zrw5GW8U6Vf1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Derivative liabilities, Ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1796">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98A_eus-gaap--DerivativeLiabilitiesCurrent_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zgHhWXlCDkz6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Derivative liabilities, Ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1798">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98B_eus-gaap--DerivativeLiabilitiesCurrent_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zfaAC5RwmNgg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Derivative liabilities, Ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1800">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_DisclosureDerivativeLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_DisclosureDerivativeLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative liabilities at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823800518560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Asset</a></td>
<td class="text"><p id="xdx_897_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zgxHJDSet3c6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8B6_zsvq5IwiPWJk" style="display: none">Schedule of Deferred Tax Asset</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_491_20231231_zUAjjHz2OOWb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_492_20221231_zwxwQFFiRWaj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net deferred tax assets - Non-current</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--DeferredTaxAssetsDepreciation_iI_maDTANzFzE_zpjtVKHNnBh7" style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left">Depreciation</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">$</td><td style="width: 16%; font-weight: bold; text-align: right">(15,175</td><td style="width: 1%; font-weight: bold; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">(16,098</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_403_ecustom--DeferredTaxAssetsAmortization_iI_maDTANzFzE_zr2UKuOK9QLf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Amortization</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">(14,195</td><td style="font-weight: bold; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(19,290</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_iI_maDTANzFzE_z14UjS7TVmNc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrual to cash</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">718,893</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">767,861</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTANzFzE_zqfagDjdXrQ9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock based compensation</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">3,653,490</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,653,490</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTANzFzE_zlDyBEzatgGf" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected income tax benefit from NOL carry-forwards</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">6,573,406</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,309,340</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzFzE_zzVF2dVXevJ" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less valuation allowance</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(10,916,419</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,695,303</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzFzE_znuM3OXHLwsl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Deferred tax assets, net of valuation allowance</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1874">&#8212;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1875">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Federal Statutory Income Tax Rate and Effective Income Tax Rate</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zICFLbegfY6a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the federal statutory income tax rate and the effective income tax rate as a percentage of income before income
taxes is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BC_zpruKJf8hmd5" style="display: none">Schedule of Federal Statutory Income Tax Rate and Effective Income Tax Rate</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_498_20230101__20231231_z59WnKOa1Zi6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_492_20220101__20221231_zzwnLnAc0SWc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maEIT001_zP3M6DNxZ3p" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Federal statutory income tax rate</td><td style="width: 2%; font-weight: bold">&#160;</td>
    <td style="width: 1%; font-weight: bold; text-align: left">&#160;</td><td style="width: 14%; font-weight: bold; text-align: right">21.0</td><td style="width: 1%; font-weight: bold; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">21.0</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maEIT001_zuk7jKPhTKNg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State tax rate, net of federal benefit</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">4.9</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.7</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_pid_dp_uPure_maEIT001_zpBL7zNHp4Ig" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Nondeductible expenses</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1885">&#8212;</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1886">&#8212;</span></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--EffectiveIncomeTaxRateReconciliationNontaxableIncome_pid_dp_uPure_maEIT001_zHe6GGriUl68" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Nontaxable income</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1888">&#8212;</span></td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1889">&#8212;</span></td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maEIT001_zTYwymOSv2yb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance on net deferred tax assets</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(25.9</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(25.7</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtEIT001_zaePfdx4WEW6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Effective income tax rate</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1894">&#8212;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1895">&#8212;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">%</td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock', window );">Schedule of State Carryforwards</a></td>
<td class="text"><p id="xdx_89B_eus-gaap--SummaryOfOperatingLossCarryforwardsTextBlock_zuWUZHLVUHcg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
not used, the state carryforwards will expire as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span><span id="xdx_8BB_zACIjTRNE0Bj" style="display: none">Schedule of State Carryforwards</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto">
  <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_495_20231231_z2i4eP1rf9I4" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--TaxYear2038Member_zcmuelte7Jx8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: justify">2038</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">888,389</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--TaxYear2039Member_zcaDcM4YT0b7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">2039</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,039,949</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--TaxYear2040Member_zJD30KX1QMbf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">2040</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4,457,495</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--TaxYear2041Member_zHbzhjCnguzj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">2041</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,406,225</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--TaxYear2042Member_z25W3LxayKI7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">2042</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">2,730,141</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--TaxYear2043Member_zzAtvMCDGtJ9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">2043</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">12,915,439</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--TaxYear2043Member_z7JUo4OntuBc" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">State Carryforwards</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">12,915,439</td><td style="text-align: left">&#160;</td></tr>
</table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823804538336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restatement of Interim Financial Statements (Unaudited) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract', window );"><strong>Accounting Changes and Error Corrections [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock', window );">Schedule of Restatement of Interim Financial Statements (Unaudited)</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_zoiTHtkJXvUd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B9_zaX6evkBfrL">Schedule
of Restatement of Interim Financial Statements (Unaudited)</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20230930__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zftlwQXmGNHd" style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20230930__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zg7s8K2a85xf" style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_496_20230930_zfy7Wt4pZfTg" style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="10" style="text-align: center">(Unaudited)</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">As of September 30,</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">As Reported</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Adjustments</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">As Restated</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AssetsAbstract_iB_z7la7edj9gPa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 1.5pt">Assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--AssetsCurrentAbstract_i01B_zDv5FQtG0KWd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maCzVMo_zq10uP42Nw23" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 52%; text-align: left">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">761,249</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1960">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">761,249</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AccountsReceivableNetCurrent_i02I_maCzVMo_zjUE7Rhi6MZb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accounts receivable, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">132,382</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1964">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">132,382</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--InventoryNet_i02I_zSC1t8b8tO9b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Inventories</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34,530</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1968">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">34,530</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_zcfA0J0lcHlc" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Prepaid and other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">38,693</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1972">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">38,693</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AssetsCurrent_i01TI_zdcR5KulT93c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Total current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">966,854</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1976">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">966,854</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_i01I_zGo7D0gswd6a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Property and equipment, at cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">420,586</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1980">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">420,586</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_i02NI_di_zZuhB7zBbJge" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less - accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(340,260</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1984">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(340,260</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentNet_i01TI_zgh4NmQxFQk7" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">80,326</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1988">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">80,326</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseRightOfUseAsset_i02I_zXYHXdwCrPh1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating lease right of use asset, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">78,043</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1992">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">78,043</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsNet_i02I_z1YBTPAJ1jI2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Intangible assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">110,695</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1996">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">110,695</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--Assets_iTI_zAoHqfrMaTwb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,235,918</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2000">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,235,918</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zG7f7RL4oc1d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Liabilities and Stockholders&#8217; Deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LiabilitiesCurrentAbstract_i01B_zH2U1qauwbPi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AccountsPayableCurrent_i02I_zwdfH5oTCP4a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">566,649</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2012">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">566,649</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AccruedLiabilitiesCurrent_i02I_zKE4L5NjSPn8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">280,063</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2016">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">280,063</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NotesPayableCurrent_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zHHPrOoNPO41" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">194,249</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2020">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">194,249</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_zVnk1tRVOWDe" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Current portion of operating lease payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45,194</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2024">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45,194</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--Deposits_i02I_z6pclX04VZc6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Customer deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">68,972</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2028">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">68,972</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--ShareLiabilitiesCurrent_i02I_zKLRKH4hH2je" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Share liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">934,256</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2032">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">934,256</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--WarrantLiabilities_i02I_z270JvRkjKU4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Warrant liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">168,269</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2036">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">168,269</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LiabilitiesCurrent_i01TI_zKajPzaog211" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Total current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,257,652</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2040">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,257,652</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseLiabilityNoncurrent_i02I_zPlW0LG4lAoi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Operating lease payable, net of current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">39,353</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2044">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">39,353</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--Liabilities_iTI_zHvU4k8V1lJg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,297,005</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2048">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,297,005</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--StockholdersEquityAbstract_i01B_z2Rb0PKBuovf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stockholders&#8217; deficit:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PreferredStockValue_i02I_hus-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesAPreferredStockMember_zPo6fwv8hbrh" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Convertible Series A preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2055">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2056">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2057">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PreferredStockValue_i02I_hus-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_zNMiNBhKlRFj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Convertible Series Seed preferred stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2059">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2060">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2061">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--CommonStockValue_i02I_zNrRZtQV4sP2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,149</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2064">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,149</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AdditionalPaidInCapital_i02I_z937TPMgFl93" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Additional paid in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,178,570</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,721,007</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45,899,577</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_zkVc8A6CdQ46" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(43,244,806</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,721,007</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(46,965,813</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--StockholdersEquity_i02TI_z4DofNsPbSVj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Total stockholders&#8217; deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,061,087</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2076">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,061,087</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_zXG1JwsN9SK9" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total liabilities and stockholders&#8217; deficit</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,235,918</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2080">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,235,918</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NeurAxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Statements
of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20230701__20230930__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z4rksagAY03j" style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20230701__20230930__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_ziSlrYk208r2" style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20230701__20230930_zMpNIDudqAGf" style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20230101__20230930__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zYmcWZhttVj4" style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20230101__20230930__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zfmnf9oMi2v7" style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49A_20230101__20230930_zn0J8Gj06WIg" style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="10" style="text-align: center">(Unaudited)</td><td>&#160;</td><td>&#160;</td>
    <td colspan="10" style="text-align: center">(Unaudited)</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">For the Three Months Ended September 30, 2023</p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="margin-top: 0; margin-bottom: 0">For the
Nine Months Ended September 30, 2023</p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">As Reported</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Adjustments</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">As Restated</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">As Reported</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Adjustments</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">As Restated</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zhe49lSI3Pn5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Net sales</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">477,460</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2084">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">477,460</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">1,928,590</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2087">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 6%; text-align: right">1,928,590</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CostOfGoodsAndServicesSold_zxb0rqhPN23c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Cost of goods sold</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">67,287</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2091">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">67,287</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">231,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2094">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">231,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--GrossProfit_iT_zLQL6hS1wAtc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Gross profit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">410,173</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2098">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">410,173</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,697,590</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2101">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,697,590</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--SellingExpense_i01_z2VS80dLjIb8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Selling expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">64,210</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2105">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">64,210</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">250,933</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2108">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">250,933</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_i01_zD5d2npTYDW8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">44,950</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2112">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">44,950</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">171,536</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2115">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">171,536</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--GeneralAndAdministrativeExpense_i01_zLKoElMbPSra" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,323,352</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2119">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,323,352</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,316,411</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2122">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,316,411</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingIncomeLoss_iT_zj534qStsWJa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;(3,022,339</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2126">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;(3,022,339</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;&#160;(5,041,290</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2129">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;&#160;&#160;(5,041,290</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zZ8XVlIsgQHe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Other (expense) income, net:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--FinancingCharges_i01N_di_zXZ9M4yERMSl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Financing charges</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2139">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2140">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2141">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,772</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2143">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,772</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--InterestExpense_i01N_di_zMuzULvx6tGl" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(102,628</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2147">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(102,628</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(453,869</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2150">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(453,869</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--InterestAndOtherIncome_i01_zKdzXBdfMf86" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,103</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2154">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,103</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,103</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2157">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,103</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--FairValueAdjustmentOfWarrants_i01N_di_zfQly2l0YzQ5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of warrant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">592,853</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2161">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">592,853</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">791,610</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2164">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">791,610</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DerivativeGainLossOnDerivativeNet_i01_z0jMSfMEIBrf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Change in fair value of derivative financial instruments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,394</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2168">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,394</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">198,551</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2171">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">198,551</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_i01N_di_zrCWwUMRlmK6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Amortization of debt discount and issuance cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,331,030</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2175">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,331,030</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,881,622</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2178">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,881,622</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i01_zvopJgfCJMXa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Extinguishment of debt liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,058,062</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,721,007</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,779,069</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">71,436</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,721,007</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,649,571</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--OtherNonoperatingIncome_i01_z2X83oyskdr1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Other income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,931</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2189">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,931</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,483</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2192">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,483</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OtherNonoperatingExpense_i01N_di_zeNbxJg4tk4a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Other expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,578</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2196">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,578</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(9,008</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2199">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(9,008</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--OtherNonoperatingIncomeExpense_i01T_zVZVcNoeOdq3" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Total other (expense) income, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,882,017</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,721,007</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(5,603,024</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,272,088</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,721,007</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,993,095</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--NetIncomeLoss_iT_zhajvwVO5DA" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(4,904,356</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3,721,007</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(8,625,363</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(9,313,378</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(3,721,007</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(13,034,385</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>



<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NeurAxis,
Inc.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Statements
of Cash Flows</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20230101__20230930__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zpfSAs8uMX59" style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20230101__20230930__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zh943Te2cEQi" style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20230101__20230930_zOLmPb5LR2vi" style="border-bottom: Black 1.5pt solid; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="10" style="text-align: center">(Unaudited)</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center">For the Nine Months Ended September 30, 2023</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">As Reported</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Adjustments</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">As Restated</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zNFzEruN5ZAl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Cash flows from operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NetIncomeLoss_i01_z10UihQjbdJe" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 52%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(9,313,378</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(3,721,007</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(13,034,385</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zzi9wRZSgvSg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Adjustments to reconcile net loss to net cash used by operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_i02_ztAF6zIZgWCe" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Amortization of debt discount and issuance cost</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,881,622</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2229">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,881,622</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--DepreciationDepletionAndAmortization_i02_zvs5dEhNDTb8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,290</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2233">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,290</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ProvisionForDoubtfulAccounts_i02_zyoj3shroaxf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Provision for losses on accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,380</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2237">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,380</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--NoncashLeaseExpense_i02_zhsMTmwQdue2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Non-cash lease expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23,339</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2241">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23,339</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--NoncashInterestExpense_i02_zLbjShbxGpVd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Non-cash interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">260,777</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2245">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">260,777</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ShareBasedCompensation_i02_zNJigtRGPydl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Stock based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2248">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2249">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2250">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i02N_di_zuQcvCuJFq3d" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Extinguishment of derivative liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(71,436</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,721,007</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,649,571</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--IssuanceOfCommonStockForNoncashConsideration_i02_zKSGiwUwIzh9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Issuance of common stock for non-cash consideration</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,550,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2257">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,550,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--FinanceCharges_i02_zsF40VPD0lNi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Finance charges</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,772</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2261">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,772</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DerivativeGainLossOnDerivativeNet_i02N_di_zo7ywTDh0YT4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Change in fair value of derivative liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(198,551</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2265">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(198,551</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--FairValueAdjustmentOfWarrants_i02_zjyPkTjTyWf5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Change in fair value of warrant liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(791,610</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2269">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(791,610</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i01B_ztYvW3n5HgJl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncreaseDecreaseInAccountsReceivable_i02N_di_zWuX2vDKsDY4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left">Accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35,637</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2277">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35,637</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--IncreaseDecreaseInInventories_i02N_di_zrUt99gZAia7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt">Inventory</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,603</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2281">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,603</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i02N_di_zPv9dtAskbh4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left">Prepaids and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(37,967</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2285">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(37,967</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--IncreaseDecreaseInAccountsPayable_i02_zdEpC1lp1Qpl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,025,467</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2289">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,025,467</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--IncreaseDecreaseInAccruedLiabilities_i02_zFHeer2YnTL9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(415,181</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2293">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(415,181</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_ecustom--IncreaseDecreaseInCustomerDeposit_i02_zjNmO8vtUBp1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 30pt; text-align: left">Customer deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,798</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2297">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,798</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_i02_zDKLy320Bbg8" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left; padding-bottom: 1.5pt">Operating lease liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(25,047</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2301">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(25,047</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iT_z7dem0rvwNCl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Net cash used by operating activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,064,419</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2305">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,064,419</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zOTi5ssP65Ch" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Cash flows from investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_z5M3aprakQZ1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Additions to property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(14,741</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2313">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(14,741</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--PaymentsToAcquireIntangibleAssets_i01N_di_zKWMrYHZxS03" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Additions to intangible assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(41,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2317">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(41,000</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--NetCashProvidedByUsedInInvestingActivities_iT_ziEHqD2gApR" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Net cash used by investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(55,741</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2321">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(55,741</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_ztFbpQvVc30j" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Cash flows from financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_z6X2ddTMc9d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Proceeds from issuance of common stock, net of issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,464,642</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2329">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,464,642</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--OfferingCostsInAdvanceOfSaleOfCommonStock_i01_zlYzRftG3QYi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Offering costs in advance of sale of common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,417,185</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2333">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,417,185</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--RepaymentsOfNotesPayable_iN_di_zfRmgUe6Bybi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Principal payments on notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,487,578</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2337">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,487,578</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--ProceedsFromNotesPayable_i01_z0L6AF8g7nia" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Proceeds from notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">159,831</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2341">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">159,831</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ProceedsFromConvertibleDebt_i01_zUBKSXgYTFe3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Proceeds from convertible notes, net of fees</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,908,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2345">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,908,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NetCashProvidedByUsedInFinancingActivities_iT_zqeQpze91eo9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,627,710</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2349">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,627,710</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_zucVxobTAm4c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Net decrease in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">507,550</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2353">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">507,550</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_zSnT6Ik9cfKe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Cash and cash equivalents at beginning of period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">253,699</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2357">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">253,699</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_zH5FxgHwPqVi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Cash and cash equivalents at end of period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">761,249</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2361">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">761,249</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823811283056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation, Organization and Other Matters (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 14, 2023</div></th>
<th class="th"><div>Aug. 11, 2023</div></th>
<th class="th"><div>Aug. 09, 2023</div></th>
<th class="th"><div>Aug. 08, 2023</div></th>
<th class="th"><div>Jan. 12, 2023</div></th>
<th class="th"><div>Jan. 10, 2023</div></th>
<th class="th"><div>Jan. 10, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplit', window );">Description of stock split</a></td>
<td class="text">2-for-1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1-for-2 reverse stock split<span></span>
</td>
<td class="text">2-for-1
reverse stock split<span></span>
</td>
<td class="text">2-for-1 reverse stock split<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,464,642<span></span>
</td>
<td class="nump">$ 4,847,457<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 736,736<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=NRXS_AlexanderCapitalLPMember', window );">Alexander Capital LP [Member] | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 736,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of Stock, Number of Shares Issued in Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,098,667<span></span>
</td>
<td class="nump">1,098,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,592,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 736,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_PurchaseOfAdditionalStockOnNumberOfOptionsNotExercised', window );">[custom:PurchaseOfAdditionalStockOnNumberOfOptionsNotExercised]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">813,928<span></span>
</td>
<td class="nump">793,655<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Alexander Capital LP [Member] | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of Stock, Number of Shares Issued in Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,098,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,592,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,110,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_UnderwritersDiscountPercentage', window );">[custom:UnderwritersDiscountPercentage-0]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_NonaccountableExpenseAllowancePercentage', window );">[custom:NonaccountableExpenseAllowancePercentage-0]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_CashFeePercentage', window );">[custom:CashFeePercentage-0]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from Issuance Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 527,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_ReimbursementExpenses', window );">Reimbursement expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction', window );">Sale of Stock, Percentage of Ownership after Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_OfferingPricePerPercentage', window );">[custom:OfferingPricePerPercentage-0]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_LicenseFees', window );">License fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=NRXS_ConvertibleSeriesAPreferredStockMember', window );">Convertible Series A Preferred stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=NRXS_ConvertibleSeriesSeedPreferredStockMember', window );">Convertible Series Seed Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_CashFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash fee percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_CashFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_LicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_LicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_NonaccountableExpenseAllowancePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nonaccountable expense allowance percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_NonaccountableExpenseAllowancePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_OfferingPricePerPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Offering price per percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_OfferingPricePerPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_PurchaseOfAdditionalStockOnNumberOfOptionsNotExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase of additional stock on number of options not exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_PurchaseOfAdditionalStockOnNumberOfOptionsNotExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_ReimbursementExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reimbursement expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_ReimbursementExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_UnderwritersDiscountPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Underwriters discount percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_UnderwritersDiscountPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480341/340-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the stock split arrangement. Also provide the retroactive effect given by a stock split that occurs after the balance date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=NRXS_AlexanderCapitalLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=NRXS_AlexanderCapitalLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=NRXS_ConvertibleSeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=NRXS_ConvertibleSeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=NRXS_ConvertibleSeriesSeedPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=NRXS_ConvertibleSeriesSeedPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823811104736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Estimated Useful Lives (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and Equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and Equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful lives</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful lives</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful lives</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful lives</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful lives</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823810157248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Fair Value On a Recurring Basis Assets and Liability (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_WarrantLiabilities', window );">Warrant liabilities</a></td>
<td class="nump">$ 8,225<span></span>
</td>
<td class="nump">$ 168,269<span></span>
</td>
<td class="nump">$ 2,234,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,735,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,735,700<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_WarrantLiabilities', window );">Warrant liabilities</a></td>
<td class="nump">8,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,234,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,735,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="nump">8,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,970,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_WarrantLiabilities', window );">Warrant liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_WarrantLiabilities', window );">Warrant liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_WarrantLiabilities', window );">Warrant liabilities</a></td>
<td class="nump">8,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,234,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,735,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total Liabilities</a></td>
<td class="nump">$ 8,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,970,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_WarrantLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_WarrantLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823810865408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Unobservable Inputs for Level 3 Assets and Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto-Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_WarrantLiabilities', window );">Warrant liabilities</a></td>
<td class="nump">$ 8,225<span></span>
</td>
<td class="nump">$ 168,269<span></span>
</td>
<td class="nump">$ 2,234,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,735,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto-Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_WarrantLiabilities', window );">Warrant liabilities</a></td>
<td class="nump">8,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,234,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,735,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto-Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,735,700<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto-Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_WarrantLiabilities', window );">Warrant liabilities</a></td>
<td class="nump">8,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,234,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,735,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_WarrantLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_WarrantLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_PlatformOperatorCryptoAssetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_PlatformOperatorCryptoAssetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823811098240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Dilutive Common Stock Equivalents (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Totals</a></td>
<td class="nump">3,141,752<span></span>
</td>
<td class="nump">3,596,012<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=NRXS_ConvertibleSeriesAPreferredStockMember', window );">Convertible Series A Preferred stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Totals</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,013,270<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=NRXS_ConvertibleSeriesSeedPreferredStockMember', window );">Convertible Series Seed Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Totals</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">230,954<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_OptionMember', window );">Options Held [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Totals</a></td>
<td class="nump">1,319,394<span></span>
</td>
<td class="nump">1,319,394<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PreferredStockMember', window );">Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Totals</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">289,779<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=NRXS_WarrantsMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Totals</a></td>
<td class="nump">1,822,358<span></span>
</td>
<td class="nump">365,962<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=NRXS_ConvertibleBridgeDebtMember', window );">Convertible Bridge Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Totals</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">376,653<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=NRXS_ConvertibleSeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=NRXS_ConvertibleSeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=NRXS_ConvertibleSeriesSeedPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=NRXS_ConvertibleSeriesSeedPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_OptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_OptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=NRXS_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=NRXS_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=NRXS_ConvertibleBridgeDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=NRXS_ConvertibleBridgeDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823801930112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Basic and Diluted Net Loss Per Share (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (8,625,363)<span></span>
</td>
<td class="num">$ (13,034,385)<span></span>
</td>
<td class="num">$ (14,626,683)<span></span>
</td>
<td class="num">$ (4,780,061)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsAndOtherAdjustments', window );">Preferred stock dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(764,893)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">&#160;Net income (loss) available to common stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (14,626,683)<span></span>
</td>
<td class="num">$ (5,544,954)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares of common stock outstanding - basic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,252,328<span></span>
</td>
<td class="nump">2,003,322<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares of common stock outstanding - diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,252,328<span></span>
</td>
<td class="nump">2,003,322<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4.50)<span></span>
</td>
<td class="num">$ (2.77)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4.50)<span></span>
</td>
<td class="num">$ (2.77)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsAndOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsAndOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823901761344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Disaggregation of Revenue (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 2,460,049<span></span>
</td>
<td class="nump">$ 2,684,735<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_CA', window );">CALIFORNIA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">601,235<span></span>
</td>
<td class="nump">408,645<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_WI', window );">WISCONSIN</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">292,601<span></span>
</td>
<td class="nump">670,245<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_OH', window );">OHIO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">407,632<span></span>
</td>
<td class="nump">500,260<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_FL', window );">FLORIDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">186,840<span></span>
</td>
<td class="nump">231,480<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_MA', window );">MASSACHUSETTS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">127,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_MO', window );">MACAO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174,980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=NRXS_AllOtherStatesMember', window );">All Other States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 844,441<span></span>
</td>
<td class="nump">$ 699,125<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_WI">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_WI</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_OH">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_OH</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_FL">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_FL</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_MA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_MA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_MO">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_MO</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=NRXS_AllOtherStatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=NRXS_AllOtherStatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823810455312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Customers Accounted Revenues (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 477,460<span></span>
</td>
<td class="nump">$ 1,928,590<span></span>
</td>
<td class="nump">$ 2,460,049<span></span>
</td>
<td class="nump">$ 2,684,735<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=NRXS_HospitalAMember', window );">Hospital A [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 452,680<span></span>
</td>
<td class="nump">$ 355,613<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=NRXS_HospitalBMember', window );">Hospital B [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 382,082<span></span>
</td>
<td class="nump">$ 484,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=NRXS_HospitalCMember', window );">Hospital C [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 274,581<span></span>
</td>
<td class="nump">$ 554,325<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=NRXS_HospitalMember', window );">Hospital [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,109,343<span></span>
</td>
<td class="nump">$ 1,394,838<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="nump">52.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=NRXS_HospitalAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=NRXS_HospitalAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=NRXS_HospitalBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=NRXS_HospitalBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=NRXS_HospitalCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=NRXS_HospitalCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=NRXS_HospitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=NRXS_HospitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823809557696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 11, 2023</div></th>
<th class="th"><div>Aug. 09, 2023</div></th>
<th class="th"><div>Aug. 08, 2023</div></th>
<th class="th"><div>Apr. 12, 2023</div></th>
<th class="th"><div>Jul. 11, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for doubtful accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,993<span></span>
</td>
<td class="nump">$ 31,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForOtherCreditLosses', window );">Credit losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,281<span></span>
</td>
<td class="nump">64,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Deposits', window );">Customer deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68,972<span></span>
</td>
<td class="nump">74,947<span></span>
</td>
<td class="nump">59,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_InventoryExpenses', window );">Inventory expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,008<span></span>
</td>
<td class="nump">10,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">736,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,240<span></span>
</td>
<td class="nump">30,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Initial payment upon execution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,000<span></span>
</td>
<td class="nump">41,000<span></span>
</td>
<td class="nump">59,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,485<span></span>
</td>
<td class="nump">6,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising cost expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">192,400<span></span>
</td>
<td class="nump">14,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Preferred stock dividend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,190,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Cash, FDIC insured amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,061,087<span></span>
</td>
<td class="nump">1,403,241<span></span>
</td>
<td class="nump">5,573,613<span></span>
</td>
<td class="nump">$ 825,660<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short term borrowing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_WorkingCapitalDeficit', window );">Working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,643,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,464,642<span></span>
</td>
<td class="nump">4,847,457<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 736,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (6,509)<span></span>
</td>
<td class="num">$ (1,963)<span></span>
</td>
<td class="num">$ (1,928)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,098,667<span></span>
</td>
<td class="nump">1,098,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share issued price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,592,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment fees</a></td>
<td class="nump">$ 4,110,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Purchase of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">425,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=NRXS_CustomerMember', window );">Customer [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=NRXS_CustomerMember', window );">Customer [Member] | Revenue, Product and Service Benchmark [Member] | Revenue from Rights Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=NRXS_CustomerOneMember', window );">Customer One [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=NRXS_CustomerTwoMember', window );">Customer Two [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=NRXS_CustomerThreeMember', window );">Customer Three [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=NRXS_CustomerFourMember', window );">Customer Four [Member] | Accounts Receivable [Member] | Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=NRXS_TrademarkAgreementMember', window );">Trademark Agreement [Member] | Initial Payment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Initial payment upon execution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=NRXS_TrademarkAgreementMember', window );">Trademark Agreement [Member] | Second and Final Payment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Initial payment upon execution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=NRXS_LicensingAgreementMember', window );">Licensing Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Initial payment upon execution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_InventoryExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventory expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_InventoryExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_WorkingCapitalDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Working capital deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_WorkingCapitalDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480555/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480341/340-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Deposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate of all deposit liabilities held by the entity, including foreign and domestic, interest and noninterest bearing; may include demand deposits, saving deposits, Negotiable Order of Withdrawal (NOW) and time deposits among others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.12)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Deposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481071/942-405-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForOtherCreditLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to credit loss from transactions other than loan and lease transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForOtherCreditLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=NRXS_CustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=NRXS_CustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_RevenueFromRightsConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_RevenueFromRightsConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=NRXS_CustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=NRXS_CustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=NRXS_CustomerTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=NRXS_CustomerTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=NRXS_CustomerThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=NRXS_CustomerThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=NRXS_CustomerFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=NRXS_CustomerFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=NRXS_TrademarkAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=NRXS_TrademarkAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=NRXS_InitialPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=NRXS_InitialPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=NRXS_SecondAndFinalPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=NRXS_SecondAndFinalPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=NRXS_LicensingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=NRXS_LicensingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823805882944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Related Party Transactions (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=NRXS_ShareHolderOneMember', window );">Shareholder 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableGrossCurrent', window );">Loan Receivable</a></td>
<td class="nump">$ 506,400<span></span>
</td>
<td class="nump">$ 506,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Interest Receivable</a></td>
<td class="nump">70,938<span></span>
</td>
<td class="nump">47,071<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_InterestIncomeGrossCurrent', window );">Interest Income</a></td>
<td class="nump">23,867<span></span>
</td>
<td class="nump">11,523<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Allowance for collection risk, interest receivable</a></td>
<td class="num">(70,938)<span></span>
</td>
<td class="num">(47,071)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=NRXS_ShareHolderTwoMember', window );">Shareholder 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableGrossCurrent', window );">Loan Receivable</a></td>
<td class="nump">506,400<span></span>
</td>
<td class="nump">506,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Interest Receivable</a></td>
<td class="nump">70,803<span></span>
</td>
<td class="nump">46,936<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_InterestIncomeGrossCurrent', window );">Interest Income</a></td>
<td class="nump">23,867<span></span>
</td>
<td class="nump">11,523<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Allowance for collection risk, interest receivable</a></td>
<td class="num">(70,803)<span></span>
</td>
<td class="num">(46,936)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableGrossCurrent', window );">Loan Receivable</a></td>
<td class="nump">1,012,800<span></span>
</td>
<td class="nump">1,012,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Interest Receivable</a></td>
<td class="nump">141,741<span></span>
</td>
<td class="nump">94,007<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_InterestIncomeGrossCurrent', window );">Interest Income</a></td>
<td class="nump">47,734<span></span>
</td>
<td class="nump">23,046<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForNotesAndLoansReceivableCurrent', window );">Allowance for collection risk, loan receivable</a></td>
<td class="num">(1,012,800)<span></span>
</td>
<td class="num">(1,012,800)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Allowance for collection risk, interest receivable</a></td>
<td class="num">(141,741)<span></span>
</td>
<td class="num">(94,007)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_AllowanceForInterestIncomeCurrent', window );">Allowance for collection risk, interest income</a></td>
<td class="num">(47,734)<span></span>
</td>
<td class="num">(23,046)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetCurrent', window );">Loan Receivable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Interest Receivable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_InterestIncomeCurrent', window );">Interest Income</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_AllowanceForInterestIncomeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Allowance for interest income current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_AllowanceForInterestIncomeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_InterestIncomeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest income current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_InterestIncomeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_InterestIncomeGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest income gross current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_InterestIncomeGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForNotesAndLoansReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on financing receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForNotesAndLoansReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480833/946-310-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansReceivableGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost, before allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansReceivableGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost, after allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=NRXS_ShareHolderOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=NRXS_ShareHolderOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=NRXS_ShareHolderTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=NRXS_ShareHolderTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823810402592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Related Party Loans payable to shareholder (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansPayable', window );">Loan payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 58,051<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_InterestAndServiceFeeAccrued', window );">Interest payable</a></td>
<td class="nump">66,648<span></span>
</td>
<td class="nump">98,290<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest payable</a></td>
<td class="nump">$ 37,103<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=NRXS_ShareHolderMember', window );">Share Holder [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateDescription', window );">Due date</a></td>
<td class="text">June, 2019<span></span>
</td>
<td class="text">June, 2019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument percentage</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansPayable', window );">Loan payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 20,051<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_InterestAndServiceFeeAccrued', window );">Interest payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">8,161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest payable</a></td>
<td class="nump">$ 10,047<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=NRXS_ShareHolderOneMember', window );">Shareholder 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateDescription', window );">Due date</a></td>
<td class="text">June, 2019<span></span>
</td>
<td class="text">June, 2019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument percentage</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansPayable', window );">Loan payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 38,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_InterestAndServiceFeeAccrued', window );">Interest payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">23,481<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest payable</a></td>
<td class="nump">$ 27,056<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=NRXS_OtherConvertiblesMember', window );">Other Convertibles [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateDescription', window );">Due date</a></td>
<td class="text">Various<span></span>
</td>
<td class="text">Various<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument percentage</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansPayable', window );">Loan payable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_InterestAndServiceFeeAccrued', window );">Interest payable</a></td>
<td class="nump">66,648<span></span>
</td>
<td class="nump">66,648<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest payable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_InterestAndServiceFeeAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest and service fee accrued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_InterestAndServiceFeeAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=NRXS_ShareHolderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=NRXS_ShareHolderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=NRXS_ShareHolderOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=NRXS_ShareHolderOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=NRXS_OtherConvertiblesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=NRXS_OtherConvertiblesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823903930976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_AllowanceForInterestReceivableCurrent', window );">Allowance for interest receivable current</a></td>
<td class="nump">$ 1,154,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=NRXS_MrWatkinsMember', window );">Mr. Watkins [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related party transaction amounts</a></td>
<td class="nump">11,083<span></span>
</td>
<td class="nump">$ 3,523<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=NRXS_MrSealeMember', window );">Mr Seale [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Payments for fees</a></td>
<td class="nump">312,803<span></span>
</td>
<td class="nump">116,542<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrent', window );">Accounts payable</a></td>
<td class="nump">84,279<span></span>
</td>
<td class="nump">$ 68,142<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=NRXS_ShareholdersOneAndTwoMember', window );">Shareholders 1 And 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableGrossCurrent', window );">Loan Receivable</a></td>
<td class="nump">$ 506,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_AllowanceForInterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Allowance for interest receivable current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_AllowanceForInterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansReceivableGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost, before allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansReceivableGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for fees classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=NRXS_MrWatkinsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=NRXS_MrWatkinsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=NRXS_MrSealeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=NRXS_MrSealeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=NRXS_ShareholdersOneAndTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=NRXS_ShareholdersOneAndTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823809546368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Property And Equipment (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 436,626<span></span>
</td>
<td class="nump">$ 420,586<span></span>
</td>
<td class="nump">$ 405,845<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(348,074)<span></span>
</td>
<td class="num">(340,260)<span></span>
</td>
<td class="num">(317,834)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">88,552<span></span>
</td>
<td class="nump">$ 80,326<span></span>
</td>
<td class="nump">88,011<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">282,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">282,181<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">96,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,148<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">36,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,452<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 21,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,064<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823806159312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 30,240<span></span>
</td>
<td class="nump">$ 30,920<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823801963488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Intangible Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Total intangible assets</a></td>
<td class="nump">$ 133,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 92,278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less: accumulated amortization</a></td>
<td class="num">(25,205)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,720)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">108,073<span></span>
</td>
<td class="nump">$ 110,695<span></span>
</td>
<td class="nump">77,558<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=NRXS_SoftwareImplementationMember', window );">Software Implementation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Total intangible assets</a></td>
<td class="nump">49,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,815<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Total intangible assets</a></td>
<td class="nump">32,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,463<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Total intangible assets</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=NRXS_LicensesMember', window );">Licenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Total intangible assets</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=NRXS_SoftwareImplementationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=NRXS_SoftwareImplementationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=NRXS_LicensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=NRXS_LicensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823803411008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 10,485<span></span>
</td>
<td class="nump">$ 6,213<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823911734656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Accrued Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_AccruedCompensationAndBenefitsCurrent', window );">Compensation and benefits</a></td>
<td class="nump">$ 333,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 539,558<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_UnderwriterFees', window );">Underwriter fees</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,259<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest</a></td>
<td class="nump">66,648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">173,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_RelatedPartyInterestPayableCurrent', window );">Related party interest</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,642<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent', window );">Other</a></td>
<td class="nump">963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">777<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 401,088<span></span>
</td>
<td class="nump">$ 280,063<span></span>
</td>
<td class="nump">$ 834,062<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_AccruedCompensationAndBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued compensation and benefits current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_AccruedCompensationAndBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_RelatedPartyInterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related party interest payable current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_RelatedPartyInterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_UnderwriterFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Underwriter fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_UnderwriterFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483384/720-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823806142368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Convertible Notes (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Nov. 08, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="nump">$ 3,555,556<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsCurrentNet', window );">Less: Original issue discount</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(355,556)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: Debt discount</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,841,658)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Less: Deferred financing fees</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(130,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">&#160;Notes payable</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 228,342<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsCurrentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsCurrentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823791165024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">5 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 08, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 14, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 09, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 08, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 16, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 19, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jan. 01, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 24, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 15, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 16, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 13, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 16, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal of warrants and common shares fair value</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3,555,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Debt instrument, periodic payment</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Strilke price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4,779,069)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,649,571)<span></span>
</td>
<td class="num">$ (3,649,561)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value adjustment of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (592,853)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(791,610)<span></span>
</td>
<td class="num">(844,854)<span></span>
</td>
<td class="num">(606,049)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability', window );">Fair value of embedded derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,375,378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure', window );">Embedded derivative warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,446,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Cash proceeds fair value of incentivies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 159,831<span></span>
</td>
<td class="nump">159,831<span></span>
</td>
<td class="nump">122,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Original issue discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">962,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountCurrent', window );">Debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,327,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Financing fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">552,000<span></span>
</td>
<td class="nump">130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,648<span></span>
</td>
<td class="nump">173,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 399,597<span></span>
</td>
<td class="nump">107,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">425,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAnnualPrincipalPayment', window );">Minimum principal payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 148,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=NRXS_ConvertiblePromissoryNoteMember', window );">Convertible Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_DebtInstrumentDiscountRate', window );">Debt instrument discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_DebtWarrantConversionDescription', window );">Debt warrant conversion, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">a five-year warrant to purchase common stock equal to fifty percent (50%) of the shares into which the convertible
notes can be converted into at issuance.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Strilke price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=NRXS_ConvertiblePromissoryNoteMember', window );">Convertible Promissory Note [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_DebtInstrumentDiscountRate', window );">Debt instrument discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=NRXS_ConvertiblePromissoryNoteMember', window );">Convertible Promissory Note [Member] | Accredited Investors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Debt instrument gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,066,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Net proceeds of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,908,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=NRXS_TwoThousandTwentyThreeConvertibleNotesMember', window );">2023 Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Principal outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 173,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance of ipo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 445,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_DebtInstrumentDiscountRate', window );">Debt instrument discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,509<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 663,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,129,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=NRXS_TwoThousandTwentyTwoConvertibleNotesMember', window );">2022 Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance of ipo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 239,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Debt instrument gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,333,333<span></span>
</td>
<td class="nump">$ 3,333,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Net proceeds of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,870,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_DebtInstrumentDiscountRate', window );">Debt instrument discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_DebtWarrantConversionDescription', window );">Debt warrant conversion, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">a five-year warrant to purchase common stock equal to one hundred percent (100%) of the shares
into which the 2022 Convertible Notes can be converted into at issuance.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.20<span></span>
</td>
<td class="nump">$ 4.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Debt instrument description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">original
issue discount of 10% with an interest rate of the greater of (i) Prime rate plus 8.5% or (ii) 12%.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.80<span></span>
</td>
<td class="nump">$ 11.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_ClassOfWarrantDiscountRate', window );">Class of warrant discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=NRXS_TwoThousandTwentyTwoConvertibleNotesMember', window );">2022 Convertible Notes [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.44<span></span>
</td>
<td class="nump">$ 9.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=NRXS_TwoThousandTwentyTwoConvertibleNotesMember', window );">2022 Convertible Notes [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_DebtInstrumentDiscountRate', window );">Debt instrument discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_DebtInstrumentPrincipalAmount', window );">Principal amount in percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=NRXS_TwoThousandTwentyTwoConvertibleNotesMember', window );">2022 Convertible Notes [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value adjustment of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=NRXS_TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember', window );">2023 and 2022 Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Financing fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_PaymentsOfFinancingCost', window );">Financing fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,322,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=NRXS_TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember', window );">2023 and 2022 Convertible Notes [Member] | Investors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal of warrants and common shares fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,947,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Cash proceeds fair value of incentivies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,660,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountCurrent', window );">Debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,234,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=NRXS_ExchangeListingLLCMember', window );">Exchange Listing LLC [Member] | Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal of warrants and common shares fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Principal outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance of ipo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=NRXS_ChannelPartnersCapitalMember', window );">Channel Partners Capital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal of warrants and common shares fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 107,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 122,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Principal outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 226,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148,062<span></span>
</td>
<td class="nump">$ 202,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Debt instrument, periodic payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAverageAmountOutstanding', window );">Principal outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 244,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Principal balance back</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,498,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,115,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=NRXS_SignatureBankMember', window );">Signature Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EscrowDeposit', window );">Escrow deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=NRXS_AlexanderCapitalLPMember', window );">Alexander Capital LP [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromFeesReceived', window );">Deferred financing fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 546,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants received | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_ClassOfWarrantDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of warrant discount rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_ClassOfWarrantDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_DebtInstrumentDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument discount rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_DebtInstrumentDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_DebtInstrumentPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument principal amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_DebtInstrumentPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_DebtWarrantConversionDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt warrant conversion description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_DebtWarrantConversionDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_PaymentsOfFinancingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments of financing cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_PaymentsOfFinancingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAnnualPrincipalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the total principal payments made during the annual reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAnnualPrincipalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-7<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of reference rate used for variable rate of debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescriptionOfVariableRateBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments including both interest and principal payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchasedFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of the original debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchasedFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EscrowDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EscrowDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAverageAmountOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Average amount outstanding of long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph (a)<br> -Publisher SEC<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph (b)<br> -Subparagraph (1)<br> -Publisher SEC<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAverageAmountOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received for fees during the current period. This element excludes cash proceeds from license fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsNotSettleableInCashFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of warrants not settleable in cash classified as equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsNotSettleableInCashFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=NRXS_ConvertiblePromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=NRXS_ConvertiblePromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=NRXS_AccreditedInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=NRXS_AccreditedInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=NRXS_TwoThousandTwentyThreeConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=NRXS_TwoThousandTwentyThreeConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=NRXS_TwoThousandTwentyTwoConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=NRXS_TwoThousandTwentyTwoConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=NRXS_TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=NRXS_TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=NRXS_InvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=NRXS_InvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=NRXS_ExchangeListingLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=NRXS_ExchangeListingLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=NRXS_PromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=NRXS_PromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=NRXS_ChannelPartnersCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=NRXS_ChannelPartnersCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=NRXS_SignatureBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=NRXS_SignatureBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=NRXS_AlexanderCapitalLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=NRXS_AlexanderCapitalLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823910822544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Operating Leases (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 70,263<span></span>
</td>
<td class="nump">$ 78,043<span></span>
</td>
<td class="nump">$ 101,382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">49,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,395<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">27,071<span></span>
</td>
<td class="nump">$ 39,353<span></span>
</td>
<td class="nump">76,199<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 76,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 109,594<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (in years)</a></td>
<td class="text">3 years 9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823809353360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Maturities Operating Lease Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 27,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">22,316<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">26,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">76,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total present value of lease payments</a></td>
<td class="nump">$ 76,198<span></span>
</td>
<td class="nump">$ 109,594<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823810409120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2017</div></th>
<th class="th"><div>Mar. 01, 2016</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Operating lease description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Two of the leases in Versailles
started January 1, 2017. Both have an initial term of five years with an option for an additional five-year term. The monthly lease payments
for these leases are $550 and $1,600 with a 3% per annum increase starting with the optional five-year term. The lease in Carmel started
March 1, 2016. The initial term is five years and three months with an option for an additional three-year term. The monthly lease payment
started at $1,472 with an annual increase of approximately 2.7%. On December 16, 2020, the Company entered into an amendment of the Carmel
lease that extended the initial term by two years.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,051<span></span>
</td>
<td class="nump">$ 47,571<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeographicDistributionAxis=NRXS_VersaillesIndianaMember', window );">Versailles Indiana [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Operating lease payment rate</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeographicDistributionAxis=NRXS_VersaillesIndianaMember', window );">Versailles Indiana [Member] | Lease 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease payment</a></td>
<td class="nump">$ 550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeographicDistributionAxis=NRXS_VersaillesIndianaMember', window );">Versailles Indiana [Member] | Lease 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease payment</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeographicDistributionAxis=NRXS_CarmelIndianaMember', window );">Carmel Indiana [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Operating lease payment rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeographicDistributionAxis=NRXS_CarmelIndianaMember', window );">Carmel Indiana [Member] | Lease 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeographicDistributionAxis=NRXS_VersaillesIndianaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeographicDistributionAxis=NRXS_VersaillesIndianaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=NRXS_LeaseOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=NRXS_LeaseOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=NRXS_LeaseTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=NRXS_LeaseTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeographicDistributionAxis=NRXS_CarmelIndianaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeographicDistributionAxis=NRXS_CarmelIndianaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=NRXS_LeaseThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=NRXS_LeaseThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823810926448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Warrant Activity for Common Stock (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 14, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.94<span></span>
</td>
<td class="nump">$ 6.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life - Warrants, Outstanding at Ending of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 8 months 8 days<span></span>
</td>
<td class="text">6 years 8 months 8 days<span></span>
</td>
<td class="text">7 years 8 months 8 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding at Ending of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.94<span></span>
</td>
<td class="nump">$ 6.94<span></span>
</td>
<td class="nump">$ 6.94<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Warrants, Outstanding at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">846,507<span></span>
</td>
<td class="nump">52,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding at beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.06<span></span>
</td>
<td class="nump">$ 2.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life - Warrants, Outstanding at Ending of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 18 days<span></span>
</td>
<td class="text">4 years 8 months 19 days<span></span>
</td>
<td class="text">7 years 5 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of Warrants, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">813,928<span></span>
</td>
<td class="nump">793,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.81<span></span>
</td>
<td class="nump">$ 5.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageRemainingContracualLifeOutstandingNumberGranted', window );">Weighted Average Remaining Contractual Life - Warrants Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 5 months 1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations', window );">Number of Warrants, Cancelled Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber', window );">Weighted Average Exercise Price, Cancelled Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of Warrants, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(127,856)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Excercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life - Warrants Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 4 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants', window );">Number of Warrants, Converted Prefunded Warrants</a></td>
<td class="nump">289,779<span></span>
</td>
<td class="nump">289,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsConvertedPrefundedWarrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Converted Prefunded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Warrants, Outstanding at Ending of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,822,358<span></span>
</td>
<td class="nump">846,507<span></span>
</td>
<td class="nump">52,852<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding at Ending of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.69<span></span>
</td>
<td class="nump">$ 5.06<span></span>
</td>
<td class="nump">$ 2.13<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments converted prefunded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non options weighted average exercise price cancelled expired number.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageRemainingContracualLifeOutstandingNumberGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non options weighted average remaining contracual life outstanding number granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageRemainingContracualLifeOutstandingNumberGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsConvertedPrefundedWarrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangements by share based payment award options converted prefunded warrants in period weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsConvertedPrefundedWarrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were either cancelled or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823901326016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Warrant Activity for Preferred Stock (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding at beginning of period</a></td>
<td class="nump">$ 6.94<span></span>
</td>
<td class="nump">$ 6.94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding at Ending of period</a></td>
<td class="nump">$ 6.94<span></span>
</td>
<td class="nump">$ 6.94<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Warrants, Outstanding at beginning of period</a></td>
<td class="nump">144,890<span></span>
</td>
<td class="nump">144,890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding at beginning of period</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of Warrants, Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations', window );">Number of Warrants, Cancelled Expired</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber', window );">Weighted Average Exercise Price, Cancelled Expired</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of Warrants, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Excercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant', window );">Converted to Common Stock Warrant</a></td>
<td class="num">(144,890)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant', window );">Weighted Average Exercise Price, Converted to Common Stock Warrant</a></td>
<td class="num">(0.01)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Warrants, Outstanding at Ending of period</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">144,890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding at Ending of period</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments common stock warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non options weighted average exercise price cancelled expired number.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non options weighted average exercise price common stock warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were either cancelled or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823903884112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Warrants outstanding and Exercisable (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
<td class="nump">1,822,358<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=NRXS_InvestorWarrantOneMember', window );">Investor Warrant W-01 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
<td class="nump">12,852<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 8.76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration Date</a></td>
<td class="text">Sep. 18,  2028<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=NRXS_InvestorWarrantPSAOneMember', window );">Investor Warrant PSA-01 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
<td class="nump">289,779<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_WarrantExpirationDateDescription', window );">Expiration Date</a></td>
<td class="text">None<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=NRXS_TwoThousandTwentyTwoConvertibleNotesMember', window );">2022 Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
<td class="nump">793,655<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 2.38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_WarrantExpirationDateDescription', window );">Expiration Date</a></td>
<td class="text">Various<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=NRXS_TwoThousandTwentyThreeConvertibleNotesMember', window );">2023 Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
<td class="nump">417,714<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 2.38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_WarrantExpirationDateDescription', window );">Expiration Date</a></td>
<td class="text">Various<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=NRXS_ConsultingAgreementWarrantsMember', window );">Consulting Agreement Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
<td class="nump">122,202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 2.38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration Date</a></td>
<td class="text">Aug.  08,  2028<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=NRXS_UnderwriterWarrantsMember', window );">Underwriter Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Warrants</a></td>
<td class="nump">186,156<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 2.38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Expiration Date</a></td>
<td class="text">Aug.  08,  2028<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_WarrantExpirationDateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant expiration date description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_WarrantExpirationDateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=NRXS_InvestorWarrantOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=NRXS_InvestorWarrantOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=NRXS_InvestorWarrantPSAOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=NRXS_InvestorWarrantPSAOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=NRXS_TwoThousandTwentyTwoConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=NRXS_TwoThousandTwentyTwoConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=NRXS_TwoThousandTwentyThreeConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=NRXS_TwoThousandTwentyThreeConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=NRXS_ConsultingAgreementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=NRXS_ConsultingAgreementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=NRXS_UnderwriterWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=NRXS_UnderwriterWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823806046992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock and Warrants (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 14, 2023</div></th>
<th class="th"><div>Aug. 09, 2023</div></th>
<th class="th"><div>Aug. 08, 2023</div></th>
<th class="th"><div>Jan. 12, 2023</div></th>
<th class="th"><div>Jan. 10, 2023</div></th>
<th class="th"><div>Jan. 10, 2023</div></th>
<th class="th"><div>Sep. 06, 2019</div></th>
<th class="th"><div>Sep. 18, 2018</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Apr. 09, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,508,897<span></span>
</td>
<td class="nump">1,963,322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,244,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible Preferred Stock, Shares Issued upon Conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">506,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplit', window );">Common stock split, description</a></td>
<td class="text">2-for-1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1-for-2 reverse stock split<span></span>
</td>
<td class="text">2-for-1
reverse stock split<span></span>
</td>
<td class="text">2-for-1 reverse stock split<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,464,642<span></span>
</td>
<td class="nump">$ 4,847,457<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Final amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,822,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees', window );">Warrant, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Since the fair value was greater than the warrant price of $0.01 per share the holder elected to receive the number of shares equal
to 40,000 times the difference between the fair market value and the exercise price divided by the fair market value, resulting in 39,924.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=NRXS_TwoThousandTwentyTwoConvertibleNotesMember', window );">2022 Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share issued price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">793,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=NRXS_TwoThousandTwentyThreeConvertibleNotesMember', window );">2023 Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share issued price per share</a></td>
<td class="nump">$ 7.20<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants</a></td>
<td class="nump">186,156<span></span>
</td>
<td class="nump">122,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">505,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=NRXS_WarrantTwoMember', window );">Warrant Two [Member] | Masimo Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,734,340<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=NRXS_WarrantThreeMember', window );">Warrant Three [Member] | Masimo Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants and Rights Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 289,779<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=NRXS_VendorsMember', window );">Vendors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock Issued During Period, Shares, Issued for Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">425,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=NRXS_ConvertibleSeriesSeedPreferredStockMember', window );">Convertible Series Seed Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Stock value converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,702<span></span>
</td>
<td class="nump">115,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant', window );">Converted to preferred stock warrant</a></td>
<td class="nump">144,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member] | Warrant Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share issued price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.44<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,098,667<span></span>
</td>
<td class="nump">1,098,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Common stock issued upon debt conversion, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,649,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,649,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share issued price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,592,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Final amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_WarrantsExpirationDateDescription', window );">Date of Expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">September 6, 2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Number of shares, conversion of convertible securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants', window );">Converted to common stock warrant</a></td>
<td class="nump">289,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">289,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Warrant Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Brian Hannasch [Member] | Warrant One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Final amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Date of Expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep. 18,  2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of Stock, Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Number of shares, conversion of convertible securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments common stock warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments converted prefunded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_WarrantsExpirationDateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants expiration date description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_WarrantsExpirationDateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of reason for issuing warrant or right.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the stock split arrangement. Also provide the retroactive effect given by a stock split that occurs after the balance date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=NRXS_TwoThousandTwentyTwoConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=NRXS_TwoThousandTwentyTwoConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=NRXS_TwoThousandTwentyThreeConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=NRXS_TwoThousandTwentyThreeConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=NRXS_WarrantTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=NRXS_WarrantTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=NRXS_MasimoCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=NRXS_MasimoCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=NRXS_WarrantThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=NRXS_WarrantThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=NRXS_VendorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=NRXS_VendorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=NRXS_ConvertibleSeriesSeedPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=NRXS_ConvertibleSeriesSeedPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=NRXS_BrianHannaschMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=NRXS_BrianHannaschMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=NRXS_WarrantOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=NRXS_WarrantOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823811219552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred Stock (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Nov. 08, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">1,120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionRatio1', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3,555,556<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtInterestRateOfDebt', window );">Debt conversion, original debt, interest rate of debt</a></td>
<td class="nump">8.50%<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Debt instrument, periodic payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,692,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,628,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=NRXS_ConvertibleSeriesAPreferredStockMember', window );">Convertible Series A Preferred stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">506,637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">506,637<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_AggregatePurchasePrice', window );">Aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,321,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=NRXS_ConvertibleSeriesAPreferredStockMember', window );">Convertible Series A Preferred stock [Member] | Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">506,637<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">506,637<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=NRXS_ConvertibleSeriesSeedPreferredStockMember', window );">Convertible Series Seed Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">115,477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">115,477<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_AggregatePurchasePrice', window );">Aggregate purchase price</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_SharePremiumPercentage', window );">Share premium percentage</a></td>
<td class="nump">120.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Stock value converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,702<span></span>
</td>
<td class="nump">115,477<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred stock dividend rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt instrument, convertible, conversion price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_AggregatePurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate purchase price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_AggregatePurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_SharePremiumPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share premium percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_SharePremiumPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtInterestRateOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The rate of interest that was being paid on the original debt issue that is being converted in the noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtInterestRateOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-7<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments including both interest and principal payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=NRXS_ConvertibleSeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=NRXS_ConvertibleSeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=NRXS_ConvertibleSeriesSeedPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=NRXS_ConvertibleSeriesSeedPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823805984224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Option-pricing Model with Following Weighted-average Assumptions (Details) - 2017 Stock Compensation Plan [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Shares | shares</a></td>
<td class="nump">1,319,394<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price</a></td>
<td class="nump">$ 2.67<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price</a></td>
<td class="nump">$ 6.94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 9 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">31.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.84%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=NRXS_TwentySeventeenStockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=NRXS_TwentySeventeenStockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823932179952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Stock Option Activity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding, Beginning balance</a></td>
<td class="nump">1,319,394<span></span>
</td>
<td class="nump">1,319,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (in years), Outstanding</a></td>
<td class="text">5 years 8 months 8 days<span></span>
</td>
<td class="text">6 years 8 months 8 days<span></span>
</td>
<td class="text">7 years 8 months 8 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding at beginning of period</a></td>
<td class="nump">$ 6.94<span></span>
</td>
<td class="nump">$ 6.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding, Beginning balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options, Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options, Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Number of Options, Cancelled/Expired</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Outstanding, Ending balance</a></td>
<td class="nump">1,319,394<span></span>
</td>
<td class="nump">1,319,394<span></span>
</td>
<td class="nump">1,319,394<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding at Ending of period</a></td>
<td class="nump">$ 6.94<span></span>
</td>
<td class="nump">$ 6.94<span></span>
</td>
<td class="nump">$ 6.94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding, Ending balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Number of Options, Vested and Exercisable, Ending balance</a></td>
<td class="nump">1,319,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life (in years), Vested and Exercisable</a></td>
<td class="text">5 years 8 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Vested and Exercisable, Ending balance</a></td>
<td class="nump">$ 6.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and Exercisable, Ending balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823811354384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Options and Awards (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 13, 2019</div></th>
<th class="th"><div>Oct. 12, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 27,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=NRXS_TwentySeventeenStockCompensationPlanMember', window );">2017 Stock Compensation Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,435,652<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,638,788<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=NRXS_TwentySeventeenStockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=NRXS_TwentySeventeenStockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823805966064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Changes in Warrant Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto-Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Changes in fair value of warrant liabilities</a></td>
<td class="num">$ (592,853)<span></span>
</td>
<td class="num">$ (791,610)<span></span>
</td>
<td class="num">$ (844,854)<span></span>
</td>
<td class="num">$ (606,049)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto-Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liabilities, Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_AdditionToWarrantLiabilities', window );">Addition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Changes in fair value of warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_ReclassifiedToEquity', window );">Reclassified to equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liabilities, Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto-Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liabilities, Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_AdditionToWarrantLiabilities', window );">Addition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Changes in fair value of warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_ReclassifiedToEquity', window );">Reclassified to equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liabilities, Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto-Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liabilities, Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,234,384<span></span>
</td>
<td class="nump">2,234,384<span></span>
</td>
<td class="nump">32,102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_AdditionToWarrantLiabilities', window );">Addition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,446,502<span></span>
</td>
<td class="nump">2,808,331<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Changes in fair value of warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(844,854)<span></span>
</td>
<td class="num">(606,049)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_ReclassifiedToEquity', window );">Reclassified to equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,827,807)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liabilities, Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,225<span></span>
</td>
<td class="nump">$ 2,234,384<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_AdditionToWarrantLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Addition to warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_AdditionToWarrantLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_ReclassifiedToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reclassified to equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_ReclassifiedToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_PlatformOperatorCryptoAssetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_PlatformOperatorCryptoAssetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823809749136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Warrant Liabilities (Details Narrative)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Measurement Input, Share Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="nump">7.91<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="nump">3.46<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="nump">59.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823810877232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Changes in Derivative Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto-Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liabilities, Beginning balance</a></td>
<td class="nump">$ 1,735,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liabilities, Ending balance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,735,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto-Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liabilities, Beginning balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_AdditionToDerivativeLiabilities', window );">Addition</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities', window );">Changes in fair value of Derivative liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_ExtinguishmentOfDerivativeLiabilities', window );">Extinguishment of Derivative liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liabilities, Ending balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto-Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liabilities, Beginning balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_AdditionToDerivativeLiabilities', window );">Addition</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities', window );">Changes in fair value of Derivative liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_ExtinguishmentOfDerivativeLiabilities', window );">Extinguishment of Derivative liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liabilities, Ending balance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_PlatformOperatorCryptoAssetLineItems', window );"><strong>Platform Operator, Crypto-Asset [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liabilities, Beginning balance</a></td>
<td class="nump">1,735,700<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_AdditionToDerivativeLiabilities', window );">Addition</a></td>
<td class="nump">2,375,378<span></span>
</td>
<td class="nump">2,449,689<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities', window );">Changes in fair value of Derivative liabilities</a></td>
<td class="num">(198,551)<span></span>
</td>
<td class="num">(713,989)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_ExtinguishmentOfDerivativeLiabilities', window );">Extinguishment of Derivative liabilities</a></td>
<td class="num">(3,912,527)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liabilities, Ending balance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,735,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_AdditionToDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Addition to derivative liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_AdditionToDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_ExtinguishmentOfDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Extinguishment of derivative liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_ExtinguishmentOfDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_PlatformOperatorCryptoAssetLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_PlatformOperatorCryptoAssetLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823810425392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative Liabilities (Details Narrative)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Measurement Input, Share Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">7.91<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">3.46<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">5.47<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823800462784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Retirement Plan (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Employee contribution percentage</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanAdministrativeExpenses', window );">Profit sharing contribution expenses</a></td>
<td class="nump">$ 6,980<span></span>
</td>
<td class="nump">$ 17,183<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanAdministrativeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of administrative expense incurred by defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanAdministrativeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823811575472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2022</div></th>
<th class="th"><div>Jul. 14, 2022</div></th>
<th class="th"><div>Jul. 11, 2022</div></th>
<th class="th"><div>Feb. 06, 2019</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 02, 2024</div></th>
<th class="th"><div>Apr. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositLiabilitiesAccruedInterest', window );">Deposit Liabilities, Accrued Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 417,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 417,390<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Sought compensatory damages</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=NRXS_ExecutiveEmploymentAgreementsMember', window );">Executive Employment Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_DescriptionOfExecutiveEmploymentAgreementsRenewals', window );">Description of Executive employment agreements renewals</a></td>
<td class="text">optional one-year renewals<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,920,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncentiveFeeExpense', window );">Incentive Fee Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan', window );">Seven key employees stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,238,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Incentive bonus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 694,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=NRXS_ExecutiveEmploymentAgreementsMember', window );">Executive Employment Agreements [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_SpecialBonusPercentage', window );">Special bonus percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=NRXS_ExecutiveEmploymentAgreementsMember', window );">Executive Employment Agreements [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_ExecutiveEmploymentAgreementsTerms', window );">Executive employment agreements renewals</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=NRXS_ExecutiveEmploymentAgreementsMember', window );">Executive Employment Agreements [Member] | Minimum [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_KeyEmployeeExercisePercentage', window );">Key employee exercise percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=NRXS_ExecutiveEmploymentAgreementsMember', window );">Executive Employment Agreements [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_ExecutiveEmploymentAgreementsTerms', window );">Executive employment agreements renewals</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Trademark Agreement [Member] | Initial Payment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfInitialPublicOffering', window );">Payments for repurchase of initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Trademark Agreement [Member] | Second and Final Payment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfInitialPublicOffering', window );">Payments for repurchase of initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member] | Executive Employment Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Incentive bonus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,821,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_DescriptionOfExecutiveEmploymentAgreementsRenewals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of executive employment agreements renewals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_DescriptionOfExecutiveEmploymentAgreementsRenewals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_ExecutiveEmploymentAgreementsTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Executive employment agreements terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_ExecutiveEmploymentAgreementsTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_KeyEmployeeExercisePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Key employee exercise percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_KeyEmployeeExercisePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_SpecialBonusPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Special bonus percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_SpecialBonusPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositLiabilitiesAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued but unpaid interest on deposit liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositLiabilitiesAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncentiveFeeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for incentive fee based on performance under arrangement to manage operations, including, but not limited to, investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncentiveFeeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the repurchase of amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesAndWages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesAndWages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of capital stock issued (purchased by employees) in connection with an employee stock ownership plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 25<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480637/718-40-25-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=NRXS_ExecutiveEmploymentAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=NRXS_ExecutiveEmploymentAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=NRXS_TrademarkAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=NRXS_TrademarkAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=NRXS_InitialPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=NRXS_InitialPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=NRXS_SecondAndFinalPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=NRXS_SecondAndFinalPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823800594992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Health Benefit Plan (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_DisclosureHealthBenefitPlanAbstract', window );"><strong>Health Benefit Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationStopLossInsurancePremiumExpense', window );">Stop loss insurance premium expense</a></td>
<td class="nump">$ 255,715<span></span>
</td>
<td class="nump">$ 196,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_HealthCareOrganizationStopLossInsurancePremiumPercentage', window );">Stop loss insurance premium percentage</a></td>
<td class="nump">48.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_DisclosureHealthBenefitPlanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_DisclosureHealthBenefitPlanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_HealthCareOrganizationStopLossInsurancePremiumPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Health care organization stop loss insurance premium percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_HealthCareOrganizationStopLossInsurancePremiumPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationStopLossInsurancePremiumExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stop-loss insurance premiums recognized as expense. In stop-loss insurance, prepaid health care providers or associated entities transfer portions of their financial risks to other companies. A provider typically contracts to recover health care costs in excess of stated amounts during the contract periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 720<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480409/954-720-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 720<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480441/954-720-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationStopLossInsurancePremiumExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823809388176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Deferred Tax Asset (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_DeferredTaxAssetsDepreciation', window );">Depreciation</a></td>
<td class="num">$ (15,175)<span></span>
</td>
<td class="num">$ (16,098)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_DeferredTaxAssetsAmortization', window );">Amortization</a></td>
<td class="num">(14,195)<span></span>
</td>
<td class="num">(19,290)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther', window );">Accrual to cash</a></td>
<td class="nump">718,893<span></span>
</td>
<td class="nump">767,861<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock based compensation</a></td>
<td class="nump">3,653,490<span></span>
</td>
<td class="nump">3,653,490<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Expected income tax benefit from NOL carry-forwards</a></td>
<td class="nump">6,573,406<span></span>
</td>
<td class="nump">3,309,340<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less valuation allowance</a></td>
<td class="num">(10,916,419)<span></span>
</td>
<td class="num">(7,695,303)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net of valuation allowance</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_DeferredTaxAssetsAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_DeferredTaxAssetsAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_DeferredTaxAssetsDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_DeferredTaxAssetsDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves and accruals, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823810338480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Federal Statutory Income Tax Rate and Effective Income Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax rate, net of federal benefit</a></td>
<td class="nump">4.90%<span></span>
</td>
<td class="nump">4.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Nondeductible expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_EffectiveIncomeTaxRateReconciliationNontaxableIncome', window );">Nontaxable income</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance on net deferred tax assets</a></td>
<td class="num">(25.90%)<span></span>
</td>
<td class="num">(25.70%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_EffectiveIncomeTaxRateReconciliationNontaxableIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of nontaxable income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_EffectiveIncomeTaxRateReconciliationNontaxableIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823811190704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of State Carryforwards (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">State Carryforwards</a></td>
<td class="nump">$ 28,238,445<span></span>
</td>
<td class="nump">$ 25,543,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=NRXS_TaxYear2038Member', window );">Tax Year 2038 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">State Carryforwards</a></td>
<td class="nump">888,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=NRXS_TaxYear2039Member', window );">Tax Year 2039 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">State Carryforwards</a></td>
<td class="nump">1,039,949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=NRXS_TaxYear2040Member', window );">Tax Year 2040 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">State Carryforwards</a></td>
<td class="nump">4,457,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=NRXS_TaxYear2041Member', window );">Tax Year 2041 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">State Carryforwards</a></td>
<td class="nump">2,406,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=NRXS_TaxYear2042Member', window );">Tax Year 2042 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">State Carryforwards</a></td>
<td class="nump">2,730,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=NRXS_TaxYear2043Member', window );">Tax Year 2043 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">State Carryforwards</a></td>
<td class="nump">$ 12,915,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=NRXS_TaxYear2038Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=NRXS_TaxYear2038Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=NRXS_TaxYear2039Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=NRXS_TaxYear2039Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=NRXS_TaxYear2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=NRXS_TaxYear2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=NRXS_TaxYear2041Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=NRXS_TaxYear2041Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=NRXS_TaxYear2042Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=NRXS_TaxYear2042Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=NRXS_TaxYear2043Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=NRXS_TaxYear2043Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823800618288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development expense</a></td>
<td class="nump">$ 169,315<span></span>
</td>
<td class="nump">$ 225,466<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Deferred tax assets valuation allowance</a></td>
<td class="nump">3,221,116<span></span>
</td>
<td class="nump">1,136,470<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Federal and state net operating loss</a></td>
<td class="nump">$ 28,238,445<span></span>
</td>
<td class="nump">$ 25,543,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823802463136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 24, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Nov. 08, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Principal amount due in monthly installments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtInterestRateOfDebt', window );">Debt conversion, original debt, interest rate of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAnnualPrincipalPayment', window );">Total principal amount</a></td>
<td class="nump">$ 3,135,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Principal amount due in monthly installments</a></td>
<td class="nump">$ 1,535,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Series B Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 2.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtInterestRateOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The rate of interest that was being paid on the original debt issue that is being converted in the noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtInterestRateOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAnnualPrincipalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the total principal payments made during the annual reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAnnualPrincipalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments including both interest and principal payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823794147040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Restatement of Interim Financial Statements (Unaudited) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 761,249<span></span>
</td>
<td class="nump">$ 761,249<span></span>
</td>
<td class="nump">$ 78,560<span></span>
</td>
<td class="nump">$ 253,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">132,382<span></span>
</td>
<td class="nump">132,382<span></span>
</td>
<td class="nump">73,167<span></span>
</td>
<td class="nump">174,399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">34,530<span></span>
</td>
<td class="nump">34,530<span></span>
</td>
<td class="nump">21,220<span></span>
</td>
<td class="nump">48,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">38,693<span></span>
</td>
<td class="nump">38,693<span></span>
</td>
<td class="nump">69,663<span></span>
</td>
<td class="nump">726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">966,854<span></span>
</td>
<td class="nump">966,854<span></span>
</td>
<td class="nump">242,610<span></span>
</td>
<td class="nump">476,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">420,586<span></span>
</td>
<td class="nump">420,586<span></span>
</td>
<td class="nump">436,626<span></span>
</td>
<td class="nump">405,845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less - accumulated depreciation</a></td>
<td class="num">(340,260)<span></span>
</td>
<td class="num">(340,260)<span></span>
</td>
<td class="num">(348,074)<span></span>
</td>
<td class="num">(317,834)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">80,326<span></span>
</td>
<td class="nump">80,326<span></span>
</td>
<td class="nump">88,552<span></span>
</td>
<td class="nump">88,011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use asset, net</a></td>
<td class="nump">78,043<span></span>
</td>
<td class="nump">78,043<span></span>
</td>
<td class="nump">70,263<span></span>
</td>
<td class="nump">101,382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets</a></td>
<td class="nump">110,695<span></span>
</td>
<td class="nump">110,695<span></span>
</td>
<td class="nump">108,073<span></span>
</td>
<td class="nump">77,558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">1,235,918<span></span>
</td>
<td class="nump">1,235,918<span></span>
</td>
<td class="nump">509,498<span></span>
</td>
<td class="nump">1,480,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">566,649<span></span>
</td>
<td class="nump">566,649<span></span>
</td>
<td class="nump">1,204,219<span></span>
</td>
<td class="nump">1,592,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">280,063<span></span>
</td>
<td class="nump">280,063<span></span>
</td>
<td class="nump">401,088<span></span>
</td>
<td class="nump">834,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease payable</a></td>
<td class="nump">45,194<span></span>
</td>
<td class="nump">45,194<span></span>
</td>
<td class="nump">49,127<span></span>
</td>
<td class="nump">33,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Deposits', window );">Customer deposits</a></td>
<td class="nump">68,972<span></span>
</td>
<td class="nump">68,972<span></span>
</td>
<td class="nump">74,947<span></span>
</td>
<td class="nump">59,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_ShareLiabilitiesCurrent', window );">Share liabilities</a></td>
<td class="nump">934,256<span></span>
</td>
<td class="nump">934,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_WarrantLiabilities', window );">Warrant liabilities</a></td>
<td class="nump">168,269<span></span>
</td>
<td class="nump">168,269<span></span>
</td>
<td class="nump">8,225<span></span>
</td>
<td class="nump">2,234,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">2,257,652<span></span>
</td>
<td class="nump">2,257,652<span></span>
</td>
<td class="nump">1,885,668<span></span>
</td>
<td class="nump">6,978,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease payable, net of current portion</a></td>
<td class="nump">39,353<span></span>
</td>
<td class="nump">39,353<span></span>
</td>
<td class="nump">27,071<span></span>
</td>
<td class="nump">76,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">2,297,005<span></span>
</td>
<td class="nump">2,297,005<span></span>
</td>
<td class="nump">1,912,739<span></span>
</td>
<td class="nump">7,054,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">5,149<span></span>
</td>
<td class="nump">5,149<span></span>
</td>
<td class="nump">6,509<span></span>
</td>
<td class="nump">1,963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid in capital</a></td>
<td class="nump">45,899,577<span></span>
</td>
<td class="nump">45,899,577<span></span>
</td>
<td class="nump">47,148,361<span></span>
</td>
<td class="nump">28,355,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(46,965,813)<span></span>
</td>
<td class="num">(46,965,813)<span></span>
</td>
<td class="num">(48,558,111)<span></span>
</td>
<td class="num">(33,931,428)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; deficit</a></td>
<td class="num">(1,061,087)<span></span>
</td>
<td class="num">(1,061,087)<span></span>
</td>
<td class="num">(1,403,241)<span></span>
</td>
<td class="num">(5,573,613)<span></span>
</td>
<td class="num">$ (825,660)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders&#8217; Deficit</a></td>
<td class="nump">1,235,918<span></span>
</td>
<td class="nump">1,235,918<span></span>
</td>
<td class="nump">509,498<span></span>
</td>
<td class="nump">1,480,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">477,460<span></span>
</td>
<td class="nump">1,928,590<span></span>
</td>
<td class="nump">2,460,049<span></span>
</td>
<td class="nump">2,684,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">67,287<span></span>
</td>
<td class="nump">231,000<span></span>
</td>
<td class="nump">303,345<span></span>
</td>
<td class="nump">297,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross Profit</a></td>
<td class="nump">410,173<span></span>
</td>
<td class="nump">1,697,590<span></span>
</td>
<td class="nump">2,156,704<span></span>
</td>
<td class="nump">2,387,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingExpense', window );">Selling expenses</a></td>
<td class="nump">64,210<span></span>
</td>
<td class="nump">250,933<span></span>
</td>
<td class="nump">323,569<span></span>
</td>
<td class="nump">410,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">44,950<span></span>
</td>
<td class="nump">171,536<span></span>
</td>
<td class="nump">169,315<span></span>
</td>
<td class="nump">225,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">3,323,352<span></span>
</td>
<td class="nump">6,316,411<span></span>
</td>
<td class="nump">8,328,315<span></span>
</td>
<td class="nump">5,123,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Loss</a></td>
<td class="num">(3,022,339)<span></span>
</td>
<td class="num">(5,041,290)<span></span>
</td>
<td class="num">(6,664,495)<span></span>
</td>
<td class="num">(3,372,238)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (expense) income, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_FinancingCharges', window );">Financing charges</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(2,772)<span></span>
</td>
<td class="num">(2,772)<span></span>
</td>
<td class="num">(2,322,216)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(102,628)<span></span>
</td>
<td class="num">(453,869)<span></span>
</td>
<td class="num">(476,416)<span></span>
</td>
<td class="num">(318,666)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest income</a></td>
<td class="nump">2,103<span></span>
</td>
<td class="nump">2,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="nump">592,853<span></span>
</td>
<td class="nump">791,610<span></span>
</td>
<td class="nump">844,854<span></span>
</td>
<td class="nump">606,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivative financial instruments</a></td>
<td class="nump">6,394<span></span>
</td>
<td class="nump">198,551<span></span>
</td>
<td class="nump">198,551<span></span>
</td>
<td class="nump">713,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and issuance cost</a></td>
<td class="num">(1,331,030)<span></span>
</td>
<td class="num">(4,881,622)<span></span>
</td>
<td class="num">(4,881,622)<span></span>
</td>
<td class="num">(98,935)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Extinguishment of debt liabilities</a></td>
<td class="num">(4,779,069)<span></span>
</td>
<td class="num">(3,649,571)<span></span>
</td>
<td class="num">(3,649,561)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Other income</a></td>
<td class="nump">9,931<span></span>
</td>
<td class="nump">11,483<span></span>
</td>
<td class="nump">15,133<span></span>
</td>
<td class="nump">11,956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Other expense</a></td>
<td class="num">(1,578)<span></span>
</td>
<td class="num">(9,008)<span></span>
</td>
<td class="num">(10,355)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other (expense) income, net</a></td>
<td class="num">(5,603,024)<span></span>
</td>
<td class="num">(7,993,095)<span></span>
</td>
<td class="num">(7,962,188)<span></span>
</td>
<td class="num">(1,407,823)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">(8,625,363)<span></span>
</td>
<td class="num">(13,034,385)<span></span>
</td>
<td class="num">(14,626,683)<span></span>
</td>
<td class="num">(4,780,061)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(8,625,363)<span></span>
</td>
<td class="num">(13,034,385)<span></span>
</td>
<td class="num">(14,626,683)<span></span>
</td>
<td class="num">(4,780,061)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and issuance cost</a></td>
<td class="nump">1,331,030<span></span>
</td>
<td class="nump">4,881,622<span></span>
</td>
<td class="nump">4,881,622<span></span>
</td>
<td class="nump">98,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,290<span></span>
</td>
<td class="nump">40,725<span></span>
</td>
<td class="nump">37,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for losses on accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,380<span></span>
</td>
<td class="nump">25,281<span></span>
</td>
<td class="nump">19,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_NoncashLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,339<span></span>
</td>
<td class="nump">31,119<span></span>
</td>
<td class="nump">26,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_NoncashInterestExpense', window );">Non-cash interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">260,777<span></span>
</td>
<td class="nump">260,777<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">27,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Extinguishment of derivative liability</a></td>
<td class="nump">4,779,069<span></span>
</td>
<td class="nump">3,649,571<span></span>
</td>
<td class="nump">3,649,561<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_IssuanceOfCommonStockForNoncashConsideration', window );">Issuance of common stock for non-cash consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,550,000<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_FinanceCharges', window );">Finance charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,772<span></span>
</td>
<td class="nump">2,772<span></span>
</td>
<td class="nump">2,322,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivative liabilities</a></td>
<td class="num">(6,394)<span></span>
</td>
<td class="num">(198,551)<span></span>
</td>
<td class="num">(198,551)<span></span>
</td>
<td class="num">(713,989)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities</a></td>
<td class="num">(592,853)<span></span>
</td>
<td class="num">(791,610)<span></span>
</td>
<td class="num">(844,854)<span></span>
</td>
<td class="num">(606,049)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,637<span></span>
</td>
<td class="nump">75,951<span></span>
</td>
<td class="num">(78,603)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,603<span></span>
</td>
<td class="nump">26,913<span></span>
</td>
<td class="num">(8,953)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaids and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(37,967)<span></span>
</td>
<td class="num">(68,937)<span></span>
</td>
<td class="nump">14,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,025,467)<span></span>
</td>
<td class="num">(387,897)<span></span>
</td>
<td class="nump">1,108,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(415,181)<span></span>
</td>
<td class="num">(294,154)<span></span>
</td>
<td class="nump">272,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_IncreaseDecreaseInCustomerDeposit', window );">Customer deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,798<span></span>
</td>
<td class="nump">15,773<span></span>
</td>
<td class="num">(10,163)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,047)<span></span>
</td>
<td class="num">(33,396)<span></span>
</td>
<td class="num">(27,582)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used by operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,064,419)<span></span>
</td>
<td class="num">(6,693,978)<span></span>
</td>
<td class="num">(2,298,004)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Additions to property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,741)<span></span>
</td>
<td class="num">(30,781)<span></span>
</td>
<td class="num">(1,390)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Additions to intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(41,000)<span></span>
</td>
<td class="num">(41,000)<span></span>
</td>
<td class="num">(59,815)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used by investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(55,741)<span></span>
</td>
<td class="num">(71,781)<span></span>
</td>
<td class="num">(61,205)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,464,642<span></span>
</td>
<td class="nump">4,847,457<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_OfferingCostsInAdvanceOfSaleOfCommonStock', window );">Offering costs in advance of sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,417,185)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Principal payments on notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,487,578)<span></span>
</td>
<td class="num">(3,533,765)<span></span>
</td>
<td class="num">(163,214)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">159,831<span></span>
</td>
<td class="nump">159,831<span></span>
</td>
<td class="nump">122,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible notes, net of fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,908,000<span></span>
</td>
<td class="nump">5,460,000<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,627,710<span></span>
</td>
<td class="nump">6,590,620<span></span>
</td>
<td class="nump">2,292,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net Decrease in Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">507,550<span></span>
</td>
<td class="num">(175,139)<span></span>
</td>
<td class="num">(67,159)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and Cash Equivalents at Beginning of Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">253,699<span></span>
</td>
<td class="nump">253,699<span></span>
</td>
<td class="nump">320,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and Cash Equivalents at End of Period</a></td>
<td class="nump">761,249<span></span>
</td>
<td class="nump">761,249<span></span>
</td>
<td class="nump">78,560<span></span>
</td>
<td class="nump">253,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=NRXS_ConvertibleSeriesAPreferredStockMember', window );">Convertible Series A Preferred stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Convertible Series Seed preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=NRXS_ConvertibleSeriesSeedPreferredStockMember', window );">Convertible Series Seed Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Convertible Series Seed preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable</a></td>
<td class="nump">194,249<span></span>
</td>
<td class="nump">194,249<span></span>
</td>
<td class="nump">148,062<span></span>
</td>
<td class="nump">202,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">761,249<span></span>
</td>
<td class="nump">761,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">132,382<span></span>
</td>
<td class="nump">132,382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">34,530<span></span>
</td>
<td class="nump">34,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">38,693<span></span>
</td>
<td class="nump">38,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">966,854<span></span>
</td>
<td class="nump">966,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="nump">420,586<span></span>
</td>
<td class="nump">420,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less - accumulated depreciation</a></td>
<td class="num">(340,260)<span></span>
</td>
<td class="num">(340,260)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">80,326<span></span>
</td>
<td class="nump">80,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use asset, net</a></td>
<td class="nump">78,043<span></span>
</td>
<td class="nump">78,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets</a></td>
<td class="nump">110,695<span></span>
</td>
<td class="nump">110,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">1,235,918<span></span>
</td>
<td class="nump">1,235,918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">566,649<span></span>
</td>
<td class="nump">566,649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">280,063<span></span>
</td>
<td class="nump">280,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease payable</a></td>
<td class="nump">45,194<span></span>
</td>
<td class="nump">45,194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Deposits', window );">Customer deposits</a></td>
<td class="nump">68,972<span></span>
</td>
<td class="nump">68,972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_ShareLiabilitiesCurrent', window );">Share liabilities</a></td>
<td class="nump">934,256<span></span>
</td>
<td class="nump">934,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_WarrantLiabilities', window );">Warrant liabilities</a></td>
<td class="nump">168,269<span></span>
</td>
<td class="nump">168,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">2,257,652<span></span>
</td>
<td class="nump">2,257,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease payable, net of current portion</a></td>
<td class="nump">39,353<span></span>
</td>
<td class="nump">39,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">2,297,005<span></span>
</td>
<td class="nump">2,297,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="nump">5,149<span></span>
</td>
<td class="nump">5,149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid in capital</a></td>
<td class="nump">42,178,570<span></span>
</td>
<td class="nump">42,178,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(43,244,806)<span></span>
</td>
<td class="num">(43,244,806)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; deficit</a></td>
<td class="num">(1,061,087)<span></span>
</td>
<td class="num">(1,061,087)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders&#8217; Deficit</a></td>
<td class="nump">1,235,918<span></span>
</td>
<td class="nump">1,235,918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="nump">477,460<span></span>
</td>
<td class="nump">1,928,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">67,287<span></span>
</td>
<td class="nump">231,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross Profit</a></td>
<td class="nump">410,173<span></span>
</td>
<td class="nump">1,697,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingExpense', window );">Selling expenses</a></td>
<td class="nump">64,210<span></span>
</td>
<td class="nump">250,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">44,950<span></span>
</td>
<td class="nump">171,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">3,323,352<span></span>
</td>
<td class="nump">6,316,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Loss</a></td>
<td class="num">(3,022,339)<span></span>
</td>
<td class="num">(5,041,290)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (expense) income, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_FinancingCharges', window );">Financing charges</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(2,772)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(102,628)<span></span>
</td>
<td class="num">(453,869)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest income</a></td>
<td class="nump">2,103<span></span>
</td>
<td class="nump">2,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="nump">592,853<span></span>
</td>
<td class="nump">791,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivative financial instruments</a></td>
<td class="nump">6,394<span></span>
</td>
<td class="nump">198,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and issuance cost</a></td>
<td class="num">(1,331,030)<span></span>
</td>
<td class="num">(4,881,622)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Extinguishment of debt liabilities</a></td>
<td class="num">(1,058,062)<span></span>
</td>
<td class="nump">71,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Other income</a></td>
<td class="nump">9,931<span></span>
</td>
<td class="nump">11,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Other expense</a></td>
<td class="num">(1,578)<span></span>
</td>
<td class="num">(9,008)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other (expense) income, net</a></td>
<td class="num">(1,882,017)<span></span>
</td>
<td class="num">(4,272,088)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">(4,904,356)<span></span>
</td>
<td class="num">(9,313,378)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(4,904,356)<span></span>
</td>
<td class="num">(9,313,378)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and issuance cost</a></td>
<td class="nump">1,331,030<span></span>
</td>
<td class="nump">4,881,622<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for losses on accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_NoncashLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_NoncashInterestExpense', window );">Non-cash interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">260,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Extinguishment of derivative liability</a></td>
<td class="nump">1,058,062<span></span>
</td>
<td class="num">(71,436)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_IssuanceOfCommonStockForNoncashConsideration', window );">Issuance of common stock for non-cash consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_FinanceCharges', window );">Finance charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivative liabilities</a></td>
<td class="num">(6,394)<span></span>
</td>
<td class="num">(198,551)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities</a></td>
<td class="num">(592,853)<span></span>
</td>
<td class="num">(791,610)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaids and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(37,967)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,025,467)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(415,181)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_IncreaseDecreaseInCustomerDeposit', window );">Customer deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,047)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used by operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,064,419)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Additions to property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,741)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Additions to intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(41,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used by investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(55,741)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,464,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_OfferingCostsInAdvanceOfSaleOfCommonStock', window );">Offering costs in advance of sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,417,185)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Principal payments on notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,487,578)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">159,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible notes, net of fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,908,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,627,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net Decrease in Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">507,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and Cash Equivalents at Beginning of Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">253,699<span></span>
</td>
<td class="nump">253,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and Cash Equivalents at End of Period</a></td>
<td class="nump">761,249<span></span>
</td>
<td class="nump">761,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">253,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported [Member] | Convertible Series A Preferred stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Convertible Series Seed preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported [Member] | Convertible Series Seed Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Convertible Series Seed preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported [Member] | Nonrelated Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable</a></td>
<td class="nump">194,249<span></span>
</td>
<td class="nump">194,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember', window );">Revision of Prior Period, Reclassification, Adjustment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, at cost</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less - accumulated depreciation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use asset, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease payable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Deposits', window );">Customer deposits</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_ShareLiabilitiesCurrent', window );">Share liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_WarrantLiabilities', window );">Warrant liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease payable, net of current portion</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid in capital</a></td>
<td class="nump">3,721,007<span></span>
</td>
<td class="nump">3,721,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(3,721,007)<span></span>
</td>
<td class="num">(3,721,007)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; deficit</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders&#8217; Deficit</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net sales</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross Profit</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingExpense', window );">Selling expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (expense) income, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_FinancingCharges', window );">Financing charges</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest income</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivative financial instruments</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and issuance cost</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Extinguishment of debt liabilities</a></td>
<td class="num">(3,721,007)<span></span>
</td>
<td class="num">(3,721,007)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Other income</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Other expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other (expense) income, net</a></td>
<td class="num">(3,721,007)<span></span>
</td>
<td class="num">(3,721,007)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">(3,721,007)<span></span>
</td>
<td class="num">(3,721,007)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(3,721,007)<span></span>
</td>
<td class="num">(3,721,007)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and issuance cost</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for losses on accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_NoncashLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_NoncashInterestExpense', window );">Non-cash interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Extinguishment of derivative liability</a></td>
<td class="nump">3,721,007<span></span>
</td>
<td class="nump">3,721,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_IssuanceOfCommonStockForNoncashConsideration', window );">Issuance of common stock for non-cash consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_FinanceCharges', window );">Finance charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivative liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaids and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_IncreaseDecreaseInCustomerDeposit', window );">Customer deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used by operating activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Additions to property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Additions to intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used by investing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_OfferingCostsInAdvanceOfSaleOfCommonStock', window );">Offering costs in advance of sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Principal payments on notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible notes, net of fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net Decrease in Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and Cash Equivalents at Beginning of Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and Cash Equivalents at End of Period</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember', window );">Revision of Prior Period, Reclassification, Adjustment [Member] | Convertible Series A Preferred stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Convertible Series Seed preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember', window );">Revision of Prior Period, Reclassification, Adjustment [Member] | Convertible Series Seed Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Convertible Series Seed preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember', window );">Revision of Prior Period, Reclassification, Adjustment [Member] | Nonrelated Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_FinanceCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_FinanceCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_FinancingCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financing charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_FinancingCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_IncreaseDecreaseInCustomerDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in customer deposit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_IncreaseDecreaseInCustomerDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_IssuanceOfCommonStockForNoncashConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock for noncash consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_IssuanceOfCommonStockForNoncashConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_NoncashInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_NoncashInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_NoncashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_NoncashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_OfferingCostsInAdvanceOfSaleOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Offering costs in advance of sale of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_OfferingCostsInAdvanceOfSaleOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_ShareLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share liabilities current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_ShareLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_WarrantLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_WarrantLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Deposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate of all deposit liabilities held by the entity, including foreign and domestic, interest and noninterest bearing; may include demand deposits, saving deposits, Negotiable Order of Withdrawal (NOW) and time deposits among others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.12)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Deposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized in the period that are directly related to the selling and distribution of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=NRXS_ConvertibleSeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=NRXS_ConvertibleSeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=NRXS_ConvertibleSeriesSeedPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=NRXS_ConvertibleSeriesSeedPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139823809576240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restatement of Interim Financial Statements (Unaudited) (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_NRXS_IncreaseDecreaseInWarrantLiability', window );">Reduced warrant liability</a></td>
<td class="nump">$ 3,721,007<span></span>
</td>
<td class="nump">$ 3,721,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Extinguishment of derivative liability</a></td>
<td class="nump">4,779,069<span></span>
</td>
<td class="nump">3,649,571<span></span>
</td>
<td class="nump">$ 3,649,561<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">8,625,363<span></span>
</td>
<td class="nump">13,034,385<span></span>
</td>
<td class="nump">14,626,683<span></span>
</td>
<td class="nump">4,780,061<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid in capital</a></td>
<td class="nump">45,899,577<span></span>
</td>
<td class="nump">45,899,577<span></span>
</td>
<td class="nump">$ 47,148,361<span></span>
</td>
<td class="nump">$ 28,355,230<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember', window );">Revision of Prior Period, Reclassification, Adjustment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Extinguishment of derivative liability</a></td>
<td class="nump">3,721,007<span></span>
</td>
<td class="nump">3,721,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">3,721,007<span></span>
</td>
<td class="nump">3,721,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid in capital</a></td>
<td class="nump">$ 3,721,007<span></span>
</td>
<td class="nump">$ 3,721,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_NRXS_IncreaseDecreaseInWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduced warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">NRXS_IncreaseDecreaseInWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>NRXS_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147477123/405-50-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482477/820-10-65-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483482/832-10-65-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479845/805-20-65-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-5<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480530/250-10-S99-5<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483194/926-20-65-2<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 69: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 70: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 71: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 72: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 73: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 74: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-6<br><br>Reference 75: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 76: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 77: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 78: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482833/825-10-65-6<br><br>Reference 79: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 80: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 81: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 82: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 83: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 84: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 85: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 86: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 87: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 88: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 89: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 90: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 91: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481925/310-20-65-2<br><br>Reference 92: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RevisionOfPriorPeriodReclassificationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>108
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MM6]MM3>J7#<O/MV62I6KYG(I!3"B-H#O[TH(<7NCWZ7:O3LW_P]02P,$%
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MHD)OMA?WSZ@-$N>@!V3(U# H6SPH6S(4V^&8T&Y,J+,=WV9%6LQT.\X6:?4
M3[EN#O@<$3@0U&XN&@34[-:C8 D(8Y12PGM:M8NXQ)G75,:50DF12+3-"KK"
M[,,33#D-S<L4 'H^"\UE)@:!@9K%N*D< #(2JBNZ1WB7)(D[2MXLTN)!H*Q
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M.6[%:9I95YP6,S6BM [=&U3G=9PZG4&"I4!@/?ZPUPD!WMD3FMOUU!X&BI:
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M^L,7$%5/><6F*HV#PE$2@6(:XW=Q?0([P0V?&JZG_CYY$FZ0R^ S>^1UK=(
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MI'W"T (\7VB$WUR0@^XSW,5_ 5!+ P04    "  LA)!8SX!WP7TK  "WA@
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M8LQG[V$1^]=_&S(V'.*X755W(H=+\[75>U!_@#D-TV?B"#0)33@PC[*AB=<
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M@SM(?%6:C5>ZZ[69";WKC<J;@"_9VZ2D-RXBL>7MY,X1Q1ESHDE!QC@1KO5
MTH&OQV=MN!FNC$V^"Q#A52@P&SB1]=C1@*VO4K3J6BFMA^<I;.O,$1!?^:D%
MUI_0LT->%V<(#!+;T8T"L1T'9:P6O+&37?-D-S194#&G:# I@M<<"Z)$P!M#
ME2E7 9GR4"M6)\EX,DNFY^.A83<&GC\V<HJ9XHNY^B"FUB2932Z3V>7<?U(P
M]O1=1Z+Q=QO!HOJV[]GB].(R.3^_5&Z&20)</9DM+O3L;)%<GL5'?EWG&>#2
M&_1OV"EFYV?)V6+&^F8#*N1D#MK$8@J?%I=G (+I-Y1)FT(5A*=0;*VD?GR
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MAR!=YRYSU16"=2R8.^KGN>[0_+4M(C$+E,1;KTZ&71&X'QMJ[8D\[XE74H;
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ML2TO:H%--+O%E&-(XXJ[,FYWWKL&?H@ 2S4^Z\&P<P?L!APDN@!9V;ME;7%
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M'>:1L9.<2R3Y9W,D/";ACF</'J A1_K3X",(@E,I]%#3V[VF?0KMDZ9C..M
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M^I-1CTSW(.T^G&["(W"F'9Z485CB#<_&;\#Z7(/Q^L,;V/Y7</XW4$L#!!0
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M&WKUH;("M+^6U!OJB3V@>4?._P%02P,$%     @ +(206,.F&PWE!   G@L
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M?2Z\5G2!1LL"M+\R-'?Z#S8P7,D7_P!02P,$%     @ +(206 ?T!4;;!
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MR7@!WE]IIM]]> /]C7[Q+U!+ P04    "  LA)!8$IE2:IX"  ##!0  &0
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M?8@W(&G<0L_7  %($'ARH: </:*=(T<ZL95$!6/EG0=6LA(QHK,?8.H**J1
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M965T,C,N>&ULA5C;<MLX$GWG5Z T2<JN8B1>=(TO58Z=U#@UDTG9V=V'K7V
M2%#"AB0T &A9^_5[&B!I69:3!YLDB&YTGSY]$<^W2O\P:R$L>ZS*VEP,UM9N
M/HQ&)EN+BINAVH@:;PJE*V[QJ%<CL]&"YTZH*D=)%$U'%9?UX/+<K7W3E^>J
ML:6LQ3?-3%-57.\^BE)M+P;QH%NXDZNUI871Y?F&K\2]L/_8?--X&O5:<EF)
MVDA5,RV*B\%5_.'CF/:[#?^48FOV[AEYLE3J!SW<YA>#B P2I<@L:>"X/(AK
M49:D"&;\W>H<]$>2X/Y]I_VS\QV^++D1UZK\E\SM^F(P'[!<%+PI[9W:_BY:
M?R:D+U.E<?_9UN]-TP'+&F-5U0K#@DK6_LH?6QSV!.;1*P))*Y XN_U!SLH;
M;OGEN59;IFDWM-&-<]5)PSA94U#NK<9;"3E[>5MGJA+L.W\4YGQDH9'61UDK
M_=%+)Z](QPG[4]5V;=BG.A?Y<P4CF-+;DW3V?$Q^JO%&9$.6QB%+HB3]B;ZT
M]R]U^M)?^L=NI,E*91HMV+^OEL9J,.(_QWSV&L?'-5*6?# ;GHF+ =+ "/T@
M!I?O?HNGT=E/[!WW]HY_IOV7\?BI]'';XMDPV%?+OJ\%NZV+DKN\N!-YXS/D
M*K/LY/;NZI1MN6%&KFJ1![*VBI5\RVA#LP(C63QUX4E")JN-,K)>,<[BR5N6
M*;U1FEO!>&F%KCEE'+%65DW%+&) >9C_%TI$S@I9\SJ3O&3&0@:9;IGT=O(Z
M)Y5OF7C,I!%!*XILR'Z@%&P:G:V1BH;Q N>P+[QN4%%82YNA]_#NBN4R9[6R
M;,T?2"G9BZ"3*HL=UPJ/]>[=;_,DGIT9)\N4=KX]61?TUAFOF+ATW5CCK/RB
MEL8#]_WZ"Y#3XN]& GKR=L-W0IL ^&5\(RTOY?]:URJE+3U0C#A\<:NY>$"-
MW-!)P.2$S$JBL[MWO-J<W;BG^.P4B* >Y](V=$B#K-.F+7#Q;,Q0I1W..Z@U
M;"E6LJY=? BG ,DEJB4 :Q,LIG-#P@*E4&D10B+CP%\4A7#ETBM\PHKEC29]
MM$1G,$%YSPX5)RU2@(1\1(7$)NE1[[%P] M4P5H701\#5+'P!A1;A&D\84DR
M"<?3*0XHA-9.B2.(=43F2.6-5@^2;'"6BHH(J'=!+N&"%G4F" :[%<*?_D0Z
MT(BB &=0U:6/)NT@^/P*+#E&$VZ,:*-?2KZ4I;12@!LW>T=ZRR3ZG"QW ;=6
MRV5C^;*$?L5J-%NT560*'8^:9("*UCNXL.4Z][H=V=]3Q\F!3(6H&X>8A[:/
MA\)I1'%$D#H=<XL=6AXF "]A\#%&(Y[.(LZ*IBS9 R\;7Q5XB7:-[<(?1Q;O
M:R4*-R2/>)1-+CRVBH3();)7U73 !W:/.2)OX#C@[,-(.71%.+[@9/J23,'7
M%Z?[$+QG7U7]/FNP7I,FU#SXY^Q_PT[B21C/)NS4W4_#:#%GI\&53SV_Z20>
MA_&"MIS$BS!91+0ARW0#>KBL-6LVB^?A?)&RV706SJ=Q<.]JT,NPL#2<3M)P
M#"7]7? )R9K99[0%&VM12,L*K2KV]:\_?.C?][&?AI,9I*,I]*01TF <!7\(
M4.1(<&!W%"[@W#A>D!>S<+J80"J%(S<O 0L]\XJCJMXPQ_#D;._NJV@T?Y0F
MI 8R!-J6*IMBG_LLNG^BTE4 ^!66RS8&;?X4 D6JK?*-5:C3>VCX;M&FWE/9
M>;$#.<&0,1D5QY7C4KMEZ2I7^Q2TA*<D;>EXP,#/K3'WO3%[$\)=9\RGWI"#
MMX%CJ"/EYU^ZE<3#B+UM+X%#JG_9AZ)#IZ/%>+C WRP LW/?F:EHN*I/#:^+
M3'NE;5#I"DM[_.&.ZS6O5_3V:-3Q\#*W?7:=)).A8Q6N,Q#JTZO1Z8Y\NW>'
MJA%T16K-J0WOB[7^=.6'@G]0$+&Y<19U'<BWM./])G51ZQM/<%BR*UZ#-6["
MP-S A$=">-;1"./<(AVU6/FI15!7(826.)>L:C;MV(#?/M2]7.'?.292'=T#
M,-CK$'1<+M!\,06Y\SB&'$L,K8BVI?PARATMUZZ*N_?[_78K499]?<_4JJ:A
M@5ZW;.E[U&$,6Q.&*+)('-^"PV>*29\F+%\O_0RV_ +I8V(8&3-@1 5RN4,Q
M24-,+F$<3S&?Q2EJU2QB?]4O"_]S^X@S76[X=DA,.](Y3U!#3P_ZIU4T86#'
M&Y;,PR2=A^,QAHE).!FG811%71D(GC03*S'F&C_34F0JC"GDF>GFQ<;*;FPA
MW'&NCS&\Q4!V8$([[6"FJUV>(\!J6V-:6\M-D/F<[*8US+-T)NJS8TOAJ (%
M]^UDE\Z3+M"WM1NL2XSMT-P07CEZ-+H6H@F/RUUX?&AIZ8ID\VZ@5JXQ?1Y8
M7?$=N.6=)VX\L>?0!^9]&++[)EL'1]Z@.S9EWDG#&[Z':0=/8\0^A9^'UH\N
M14.S;IO^!#>@,BB*.V=:]]O%*PF.*N$/7)94(H?LM@@HF7"LGWO;X#\'P>4<
M*A3F^%?[B*_FU_MRZ WI'(R;S^=A.E_0XX)&V1#7<#&FA7&$A7$XGLPP'DQH
M(2:*4K='DKB%Q"W,TBB,QS$MI*0C09?'))PN@B,'/]O COT('>U](*B$7KG/
M((8B5%O_K:!?[;^T7/D/#$_;_6>:/[G&CPK#2E% -!K.)@.F_:</_V#5QGUN
M6"IK5>5NUX(CW6@#WA<*4T3[0 ?TWY\N_P]02P,$%     @ +(206(--Z3%T
M @  B04  !D   !X;"]W;W)K<VAE971S+W-H965T,C0N>&ULC91+;]LP#,?O
M_12$]S@%\2OILBX)T+0=ND.'H-WC,.R@V$PLU)9<B4[:;S]*=KT,2X->)$HD
M?_K3,C7=:7-O"T2"QZI4=A841/59&-JLP$K8H:Y1L6>M326(EV83VMJ@R'U2
M589)%)V&E9 JF$_]WM+,I[JA4BI<&K!-50GSM,!2[V9!'#QOW,I-06XCG$]K
ML<$[I._UTO J["FYK%!9J1487,^"\_AL,7+Q/N"'Q)W=L\%5LM+ZWBV^Y+,@
M<H*PQ(P<0?"TQ0LL2P=B&0\=,^B/=(G[]C/]LZ^=:UD)BQ>Z_"ES*F;!)( <
MUZ(IZ5;OKK&K9^QXF2ZM'V'7QB8? \@:2[KJDEE!)54[B\?N.^PE3*(7$I(N
M(?&ZVX.\RDM!8CXU>@?&13/-&;Y4G\WBI'*7<D>&O9+S:'[7K"P^-*@(KK8\
MVFE(C'7.,.L0BQ:1O("($[C1B@H+5RK'_%] R'IZ4<FSJ$5RE'B)V1#2> !)
ME*1'>&E?9.IYZ6N+A%_G*TN&?XG?A^IM::/#--<F9[86&<X"[@.+9HO!_/V;
M^#3Z=$3KJ-<Z.D9_W84<11P6&$^&)_]_AV\%GESHJA;J"7 KRD80YFQY)Q5&
M-YN"9X2<':#7(*UMA,IP"'LPTL!7AM4*37]M Y_6LQ6A8;)4'"N -4FTS./#
MU18-R56)L#2Z8KXV3_!5$_M)D^#B-O 6TD&<C@=1%+'%H[?BP;C;FPS'[R 9
MIA,X= /A7GM4:#;^$;"0Z491VRG];O_.G+?M]3>\?:1NA-E(9:'$-:=&PP_C
M $S;^.V"=.V;;:6)6]>;!;^5:%P ^]>:*^L6[H#^]9W_ 5!+ P04    "  L
MA)!8#>UDH#\+  #^'@  &0   'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6RU
M66UOVT82_LY?L7"#0@%HF^\OOL2 XS2] &T2Q.WUP^$^K,F5Q0M%JES*CN_7
MWS.SRQ=9DILK>@ABS5([LSMOS\Q0KQ[:[HM>*=6+K^NZT:]/5GV_N3@_U\5*
MK:4^:S>JP3?+MEO+'LON[EQO.B5+9EK7YX'G)>=K634GEZ_XV:?N\E6[[>NJ
M49\ZH;?KM>P>WZBZ?7A]XI\,#SY7=ZN>'IQ?OMK(.W6C^E\WGSJLSD<I9;56
MC:[:1G1J^?KDRK]X$]%^WO"/2CWH&2U(D]NV_4*+]^7K$X\NI&I5]"1!XN->
M7:NZ)D&XQN]6YLEX)#'.Z4'Z.]8=NMQ*K:[;^K>J[%>O3[(34:JEW-;]Y_;A
M[\KJ$Y.\HJTU_Q4/9F^<G(ABJ_MV;9EQ@W75F$_YU=IAQI!Y1Q@"RQ#PO<U!
M?,NWLI>7K[KV072T&]*(8%69&Y>K&G+*3=_AVPI\_>5GI7O9*YBY%^U2O&]Z
MU55K\:YJ9%-4LA8WP]=:+'YMY+:L>E6^?'7>XW 2<5[8@]Z8@X(C!_F!^+EM
M^I46/S2E*G<%G./6X]6#X>IO@F<EOE7%F0A]5P1>$#XC+QQ-$;*\\(B\JZ)H
MMTU?-7?B>B6;.Z6%;$KQ0]>UG;ANN\X$DA;_O+K5?8=X^M<A,YA#HL.'4(Y=
MZ(TLU.L3))%6W;TZN?S^.S_Q_O:,"M&H0O2<]+_2F\\>=%@-/S\3?_(&V"B*
MMFELKCY4_4KT*R4@?",[R0\ACAY=M^N-;!Z__RX+_/1OVEF.HO4D6FK:3NX#
M;C';HY*=4!1Z H&CUK>J&X/'148U@""^=57B;[6LL%'B.=T?LN44'(H#HFI8
M['90P:FLJM]XGW[5*<5/&MA6K"DWQ 82VE+;>]ZH36\OZIF+ @9KR9?H6Y92
MK3<= +H312VUQJT+MI5C;=6I<EO,C;>452?N9;U5].1!=IV$RG4E;ZNZZBO%
M-Y4S/GN.^DJG;BN]&CQ;JMM>%"O9W4&4L<7-W/,?<2N^BW;PN5*DM00*-[!<
M@?*A%<F6)8R'3;#61E8E6;60FZK'V@I](VN8$\()XL[$KQO['-'"A>29T!#O
M/WUT'7-]U165IGBJ"E:]4%V/DC680(M*ZRULC@WD(*,U^,6M*N1:B2]-^]"<
MB2MC'0W,'PY](AO[VS5YB#E<T6Z[X1!GL/,CGFAC9!QY^RA>B-!- ]_UO/0/
MJ%_()*WL2CK^;468U';ZB0%<L1W,U-%UX)-R)RZN*&9I][KJ>QN&<HGX%66E
M477TF(138KAD\J+>4F3"E?U!BR-?[ZMVJ^O'P:!C@DR)X?P?$D.OVFT-EE;4
M+: ;I9ITKRF+V18DS^[A;_@*I5-N.0R'G"]VPNEH\I^Q&Y9MC9:&DU'>UHJ5
MUQ3]Q"O7Q+%C$$!9V^%0USIFM(*#+$8UX3O.OBJMD %J\'BCN(DY9-09VIR)
M#VK;77VMM.N\;U D;0XYG$/B!HU=N:T5!<.?A&MG3E^Q"W=\0L\^6W7%5?EO
M]#%&!C^WMK_26O7:N=ZBLN)XR<L+YUKJ%9NB($+]OJV 5\S\0J2)[P91#NIT
M6CFV<%-&%0J[X0Q7--#4#P,WS )LMA3,<0]1;4=(%T9N''KXTA#.)ZHUP" Z
MNV7$*G:N)L+,3?*0&)AP?FD)IYYLRI/$S>((NRP%N8302'H23/IL3#HAA8I6
M]R(*/#?.$G!8ROE):8TEPFZ[WM8<"J5"),$C')^+,/+<(/'$2^R:%D=/(EMD
MGAL&=(@A'(O/B-Z:P;BC]I4<N<6"=3%\:>9Z$2EM"%BP1V]4P<:#QK[OP1PQ
M6=E0UC#VZQ<"7@IC-_<SZ[=Q[?PT+SRX\TW?%E]6;5VJ3EM,0;5&7E;]&">S
M8G4QN7XC'\GOD![#[,D8(W9%&SN"(_45XXS&<0'LX"6DF*6<#VVO)D%^'G&H
MG0[4> $*:XL2[1,C#LQ1[(*+/,H$6*F1)WA%4N@*]TTR-T\I,@V!U)2=VBG$
M.<(RB,ECEG)^.U"N?? '"5_34$^B<KXW@)3436(Z=J3W L'J8+Q/E?*)VF'N
MAC%G 1/VO"?GY"FJ56S.,;1SR+>E\2V2OD5B0CX9[T9Q>EX1=BZ!M_":)EY(
MP[]#6V\45^[#N]>H(/81G,$>Y4_GZGCO$06NCWB/4V]6>N'++,_Q,*5HFF4F
MZR 648@PB=S,2Y"7BXD/BRAQ\P3L?H@L-0;3Q\TA%F $MGE9:C)\MCQ@;BYM
MSTA[)@&?%HH)[9W=%F[>JL^Q_YTMVK]PT9X/>(>*M-WM?*#"_@>;OZ6$B&\I
M,Q\0QEI2?7XAHC1U(T"E,<.T\MT\@+MS;S2072-^-&?!74OMAX:%19*Z 5QQ
M.A!!2'ZF0F(IY\>NU53ZVR7,'P$4_9029J!\@&3*IYU.M'.CZIH[C &A$F2]
M3WLL$<2>FX>,6(9RH".FFL*4RU+=J[IEQ!<(PSPF5DOXJ8\21UAB*>='U<"Y
MM>G\2C2L%8VTW%R$J _XSS QT8D;^HD;^3Y=:*#GX$$J(^J] )4VS&UIFBT7
M,>H'(B^W96NV=#YRN5U8U5_2B "X9 BZ<&PS@C/,N*%-:HM%X*: T)<STN$&
M!IX?K(C<\0(W"3*;2.-B$<6AFR7VGN-B$F"N /SR/38Y?^ZL'/.6@'#C^;'J
M4<1Y@%: . <JS>%Y]JZECDI#2J.G8<],S5[5P%U;$^SP!M<:\^GG"-S8Y[K%
ME'.U)N3^S]C:\N1&?3XWEQ0 U*KSD,7]". FI$ .O0%]IN4"^);AOH&U^VSI
M_'!X1IQ#%2%9C#XB"?8A$A[,\0UY!#$:(5IW-X14QX&^_A@OUD4Y<H'T-9\^
M>+.0FQ$B[-8I'"!A" 9++G"L9Y]9TJ)L>SPLB3W+ M?STSU58C?Q*/(CHU>0
M8EN6[6U+W3S'-G1.+QFD.(->$$?N1<@Y*B,O=GFP1.L9Q&Z(SH67J,$^$I05
MV=^,KSPT#V&&,Y['>NZZWV&>V<'Z$=__*L0VW?V2SA'+KEW/.BA^/\MALF.-
M;U?0F9^)H8Y&7V0+VH1FD(>G1/-D@3Z79^]#-[CXGY-F2H33B7;>SKMVAMJY
M6!@NX")@"&K?[RL>O6D6I@LC9?C-]=Y\0\F>>2;I,P^M:W/*2ID6;HAV@NXP
MY\)$Q+2M>@J3F!^0?U34+&7:-7[AC4D,4SZVF5N;ONI0LH\X-0'?PJ;RRYV7
M&3:1G?>#":G-G#=JI'\S7);>]&! MV\! V":-]3;@;8U0HT5PM2#4_/Y+="Z
MBU(60PU,#(MOQGN6,0 \RQ@7SO!F&4)F@6<F)0J0P]/-S/%HW)*0'&6(<:)]
MQ(Q+N,/#+A'#/*N/#[2+$!B4V"9SH/=G*D)M8$Z43.WHL-R?JQ:1C_8ZL\8;
M%P=&H-Q-\XQQ&Y][8\@LA@)J%>S9 \T8\8=Y3&#JH7V*_*'03\L]**I@2?T4
MBH8A@;%C<W"^AD%0O*(A7"R]RUGM3<TP#4>Q-9.A][4Z="E4F'@Z<*#W]%F.
M?=-,'V!,@6EI4/E( H[#WP[(:4%>CY"^ 0]1EG8^+C%X<7_&FQ#:LKP?Q%+K
MO9??Z-<B/T5DQ$/[-BYQ0Y39:L-3V:,!<_ U.\,YRD"4I5,IGRV?:+C+Y\>Y
MFW&S8*DGNXO9;,F<HR&6"F*H,F<6>T9Z\MF&\+LT?CMD?/ D0>JFON&W-/.7
MRKX3YR'TV NPV$L)\<CXAGKF99GLQ:VZJYJ&[@ %S!M4C X AYQK@J&>%Z&:
M<L9\Y 6<./3+U?GL-TFD_1W_\JH%0XOY>7)\.OZX>V5^TYRVFU^&?P:FH^$%
M,"S!ZIVE\8EY734L^G;#OW#>MCTPALF5DD!WVH#OERU\:1=TP/B3]^5_ 5!+
M P04    "  LA)!8B9Q5=PLR   &HP  &0   'AL+W=O<FMS:&5E=',O<VAE
M970R-BYX;6RU?6F/VT;:X/?Z%05/=F #;%EG'TYBH-V.)QXDL=<=3[!8[ =*
M+*DYIDB%I+JM^?7[7'51%-OVY 4F8TE-UO'4<U_UPT-5?VKNC&GUYVU1-C\^
MN6O;W8OGSYO5G=FFS:C:F1+^LJ[J;=K"UWKSO-G5)LWHI6WQ?#H>GS_?IGGY
MY.4/]-O[^N4/U;XM\M*\KW6SWV[3^O#*%-7#CT\F3^P/'_+-78L_/'_YPR[=
MF%O3?MR]K^';<S=*EF]-V>15J6NS_O')]>3%J^DYOD!/_"LW#TWP6>-6EE7U
M";^\S7Y\,L85F<*L6APBA7_NS8TI"AP)UO&G#/K$S8DOAI_MZ&]H\["99=J8
MFZKX(\_:NQ^?7#[1F5FG^Z+]4#W\;&1#"QQO514-_;]^X&?/+Y[HU;YIJZV\
M#"O8YB7_FWX60 0O7(Y/O#"5%Z:T;IZ(5ODZ;=.7/]35@Z[Q:1@-/]!6Z6U8
M7%[BJ=RV-?PUA_?:E[=\&KI:Z]M\4^;K?)66K;Y>K:I]V>;E1K^OBGR5FT8_
MM9^>_?"\A:EQ@.<KF>853S,],<UDJG^MRO:NT3^5F<GB 9[#FMW"IW;AKZ:#
M([XVJY&>31(]'4]G ^/-'"!F--[LQ'A]._Z_U\NFK0%Q_E_?CGF\>?]X2$TO
MFEVZ,C\^ 7)I3'UOGKS\^]\FY^/O!U8[=ZN=#XW^\F-C\,A^:MH<,!.6FI:9
MOJGS%HZO"$\O?N*Z >K;(3DT?3L:G+-_1[ 0]=\M1/]^9Q0,N$OKE @5AEOG
M95JN<ABA:>$=X )MH_-2KZH2&5'>'H!,VCO]<70[TO^XOGX/#.+/?0ZK MHH
M@9O@&[JMX-LGHTTT=1I,W=ZEK4[7:V 1\-DH6$55MP8>VN*Z&UP+/&]:?K7(
MTV5>P-YDJ"QO5D75[&LZ#%@<[A1G/O4.S:(S6@N\@5_ZMJKP1?QCWWIJ<V_*
MO:S ? ;VW,"7;%\CE/U+^&UGZKS*FA&"&,ZI"0@\]2?CP5/5$726)JUYQ+SY
M1#N\2V%_,)=!V-+J4X(<;PS D,)_^W)EZA8$@NRY34&49/(&+./4? GM2-X]
MO2J<(LO7L ]@O'3&)N4CJ/5]6NS-2/_J<$ AQP;4 = % Y;Z+@?.6A..(@CK
MW,"B:7[XXWT*8-LW/9@"LRQ-D<,)T'Z6".RTJ<IT61C$S]H4C,,6//9P58#'
M+> DB",87S_<504"+#,,Z%5>K_9;>!96 _#@TVQ@GW3R#W?YZDXC =!?8&MY
M@U\1R_$@_[W/-CQ%N@0!S".F=7W /Q)H&G4:H=T.RZK%;65Y<=#I#L@2,7I=
M5UM=X2'KIMK7L+P(S+79[(NTAC<,3D1@QND_F0/A2%4?$]^^82AF ,ZBVM'S
M_I#V+2SL/[CRU;[&)>!J[M.\$%BS0@(#)8*6C8(#P+EXI@XH>P^<,2XXPF!Y
M(WV];G&W>X"Y;(JQ-%_#DF';&4*GKG9U#@O&PZHBY$90IMF_083CDT!N=0:[
M*0Y$C?JFVN[2\H! "%$S+T/*A#TF2/KPD4&? P[!"H0%P+^K"DB:H9 6H&'A
M;A6BQ*HV6=YJX$X-;A\VO_ITAL0 D(&I@6D(\/(2O@,]IY\U;.8^;WB3YC.
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M+;$57HZGJ<B1%%X1Z5HT8$=N9(6IM&"-Y;9KCY7S?2^<#I<6:HGM0\C_2VM
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MB\43=O':+VVUPR$1Q]IJ2Q_O#%@7-3X ?U]756N_X 3H/J/EO?S_4$L#!!0
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M*$T G1="Z)UC+A@&?/H74$L#!!0    ( "R$D%@-&EXNMP(  / %   9
M>&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;'U474_;,!1][Z^PPH1 ZLA76ZK2
M1J*P:9/&5@';'J8].,E-8^'8F>U0^/>[=M(LDTH?4G^=>WRN3^]=[J1ZTB6
M(2\5%WKEE<;4"]_760D5U1>R!H$GA505-;A46U_7"FCN@BKN1T$P\RO*A)<L
MW=Y&)4O9&,X$;!313551];H&+G<K+_3V&_=L6QJ[X2?+FF[A <SW>J-PY?<L
M.:M :"8%45"LO.MPL9Y8O /\8+#3@SFQF:12/MG%YWSE!580<,B,9: X/,,-
M<&Z)4,:?CM/KK[2!P_F>_:/+'7-)J88;R7^RW)0K;^Z1' K:<',O=Y^@RV=J
M^3+)M?LENQ8;!Q[)&FUDU06C@HJ)=J0OW3L, N9O!41=0.1TMQ<YE;?4T&2I
MY(XHBT8V.W&INF@4QX0UY<$H/&489Y*OTH F&_I*4P[D[-$.^GSI&^2V"#_K
M>-8M3_0&3QB1.RE,J<D'D4/^/X&/HGIET5[9.CK*> O9!8G#,8F"*#["%_>9
MQHXO?I,O->26Z8Q+W2@@OZY3;13^*WX?RK;EFASFLI6RT#7-8.5A*6A0S^ E
MIR?A++@ZHG32*YT<8T\>L/+R!NV0!;F1XAF48=8=Y]4AL4?I#HM]+&%42(XU
MR<26&.>^.Q5&$[JO4:O E( JJIJ*U].3>11>7FF2#50)JVI!]J)'AT2/K(?6
MR&B$MD*5@AJAM8/MC6(B8S7EY!UYCU\\GDZG^,U&7T#KQ>B;8ELF\)AIW0#)
MT4?9"(/8L[@%DO,62IS10T TGD_"\6PZ'T *4 IR4B GWHM/4 #6 8+#.!@'
M08#05GG=E48K*XKFXW@2D4,N^X,JK$!M7:^Q;X4RVH+L=_MV=MU6\3]XVPOO
MJ,)L->%08&AP<3GUB&K[2[LPLG8UG4J#'<)-2VS)H"P SPN)XKN%O:!O\LE?
M4$L#!!0    ( "R$D%BA2(V-2@,   \(   9    >&PO=V]R:W-H965T<R]S
M:&5E=#,S+GAM;(U676_;.@Q]SZ\@O+MA ]S8EN-\M$F MMMP![18L79WSTK,
M),)DRY/D9OWWEY(=-VW3H"^Q*).'A^:AE.E6Z=]F@VCA;R%+,PLVUE:G4626
M&RRXZ:L*2WJS4KK@EDR]CDRED><^J) 1B^-A5'!1!O.IW[O1\ZFJK10EWF@P
M=5%P_7"!4FUG01+L-GZ(]<:ZC6@^K?@:;]'^K&XT65&'DHL"2R-4"1I7L^ \
M.;W(G+]W^$_@UNRMP56R4.JW,[[ELR!VA%#BTCH$3H][O$0I'1#1^--B!EU*
M%[B_WJ%_];53+0MN\%+)7R*WFUDP#B#'%:^E_:&V_V);CR>X5-+X7]@VOAEE
M7-;&JJ(-)KL09?/D?]OOL!<PCE\)8&T \[R;1)[E9V[Y?*K5%K3S)C2W\*7Z
M:"(G2M>46ZOIK: X.[]"*LG QSN^D&@^32-+H.Y5M&P!+AH ]@I PN!:E79C
MX$N98_X4("(V'26VHW3!CB)^QF4?TB0$%K/T"%[:E9AZO/1HB8<J:^(&A^/<
M.)R:BB]Q%I#>#>I[#.8?WB7#^.P(JT'':G ,?7Y+XY77$D&MX'N%FEM1KN%U
MKL?1[C;86RE)(^90K&LF>-*E-2#*9GB;.9+<8@Y6@=T@7*JBXN7#AW=CEHS.
M#*B.B?1,3N$8SQZU"HL%ZJY=\'R'];X_A03MYN1$K4YJ,K@Q2 S_@5$<LF%*
MBR1.PG1,841/TP1H336 %'PAI+""M#J8A D;09J&Z21[ ;_OR49A/$I@- R3
MR:1WIRR7+I4SQS[5),PF@]XO/[J8G_![PEH3173'V2.F15W 1U'" W)M/D':
M'V4PZ,?QR]!<F*6JB3&10DBR?@SOV\<1T62=:+(WB^::VUHW=3[K"UP]?H-#
M4CJ:X[#LSTV/4KYH=^A%5#PR(:<WR.I)D[:HG0Z@D>\SQ;VMR!YQ&5!#?;^9
MLS)@+$R3H5L/@0W#<1*W F@85/RA\,/1J*%WA892BZ*JW72(DEJ.QH*O@)VU
MH>U$P3V7M:?W#*O3UJ%61WN'=(%Z[:\B UXMS7G=[7:WW7ESR#^Z-U?E-==K
M41I*OZ+0F-08-&.U,ZRJ_)&_4)8N$+_<T(V-VCG0^Y52=F>X!-U_@/G_4$L#
M!!0    ( "R$D%CM_ZV+A@0  -<-   9    >&PO=V]R:W-H965T<R]S:&5E
M=#,T+GAM;+57VW+;-A!]YU=@%$_&GE%X 4F1LB7-R$[:IE.[&BN)'SI]@*65
MQ#%)* !HV?WZ+D"1NEABG#1]D0!B]^#L8@\NO147#W(!H,A3EN:RWUHHM3QW
M'#E90,:DS9>0X\B,BXPI[(JY(Y<"V-0X9:E#7;?C9"S)6X.>^382@QXO5)KD
M,!)$%EG&Q/,EI'S5;WFMZL-M,E\H_<$9])9L#F-0GY<C@3VG1IDF&>0RX3D1
M,.NWAM[Y9:3MC<&7!%9RJTUT)/></^C.QVF_Y6I"D,)$:02&?X]P!6FJ@9#&
MUS5FJYY2.VZW*_1?3.P8RSV3<,73NV2J%OU6W")3F+$B5;=\]1NLXPDUWH2G
MTOR256D;=%MD4DC%L[4S,LB2O/QG3^L\;#G$[A$'NG:@AG<YD6'YGBDVZ F^
M(D);(YINF%"--Y)+<KTH8R5P-$$_-;CB68;)&2L^>2 LGY([)@3+E22GG]A]
M"O*LYRB<1UL[DS7F98E)CV!ZE%SS7"TD^9!/8;H+X"#!FB6M6%[21L3W,+&)
M[[4)=:G?@.?74?L&+SB"-\;:GA8I$#[;!(PE*Q6F(,GG)A,?GD!,$JFS<"@'
MC3-H+9W+)9M OX5BD2 >H37XM !KQE,4@IY#:>2U&I)_0!*U (+KL63Y\]LW
M,?6B"TE6Q]C!AAUA4@>"28+L'D2=*)M\;YS636$0^,RJS=?#@(UE(IC6DO7G
M%L1()!,@6'Q@?<P? 2M65'.1NW>N1SS:CD-*3DAL1QTRAJ4J:7JQH1F_=!N-
MA]J1QMUV%'71T[6Q>\-SL-"!8I+00ZA$QW[#%:8NZOKM3ABB*;7]F'S!C/)"
M:FO_@'7@1>W("_:MT5"BF'50P[D P+U';=+F4=I&O,II6,Q1G:2*X3-6NEB)
M1(&HUV[C&G?:7M@YXNJU8X3VPY@T5'905W;06-D[>O[KVF3Z[T/EVPASN'S?
MOO$Z[D4#R; F&7ZO_,A0;\^)>B9XT)#M* Z1;X1_C?8225AU$&D6:YF5AT3%
M8E*RD":7TT(8T:)&GX$)24#O;2]%9R2EJ_3\D/J.A[F1WJ9N-C96N:!WYI"!
MZ;OAX]S>*+.4X.[@+>@C65/&LE8" RM8:OV1S&!'O>76\3O+"YV),@9*PDJR
MU/9\$ME!:/VJ*6' E=)"FX8DL -J7;%\@J<J3!VS0Z"-40"]V/^W*L+'+5Y2
MVT\P)7'0:8=NA.Q"V^T@AXC6[&+/;W=I;,9B#\?\V%KK'T='>.(79MGJ%%=[
MC-EA7O(\]6B$J>B0LQ^@ZI.-M$^02Z=+?-L-FV3>J174:520C@2$SO6WE=Z(
M](-*CVJ>T7]3^EX@A_@WSO#3Q+ZLB?Q_>M\+=EORV]JU=C: JABM_34WJG^%
MF+T@:,===WV,UE+9K^=OROBX?%\EVY]&8Z-GQ7>VT#KII]5<9^34"/OL56JM
M)CJI6X<4X&Q=MC,0<_.DD'A8%+DJ[]WUU_K5,BPOZQOS\LESS<0\R25)88:N
MKAWAN2;*9T3947QIKN[W7.%#P#07^/("H0UP?,;Q/K/NZ GJM]S@7U!+ P04
M    "  LA)!8/'[<J*T#  " "0  &0   'AL+W=O<FMS:&5E=',O<VAE970S
M-2YX;6S-5DN/VS80OOM7#)0V2(!=RY;\V-W8!NQ]M F2QMA--X>B!UH:2<12
MHDI2]OK?=TC9LIIXW:+HH1>;''*^^8;STF0CU9/.$ T\YZ+04R\SIKSR?1UE
MF#/=E246=))(E3-#6Y7ZNE3(8J>4"S_H]49^SGCAS29.ME2SB:R,X 4N%>@J
MSYG:+E#(S=3K>WO!/4\S8P7^;%*R%!_0_%HN%>W\!B7F.1::RP(4)E-OWK]:
M#.U]=^&1XT:WUF ]64GY9#?OXZG7LX108&0L J._-5ZC$!:(:/RQP_0:DU:Q
MO=ZCWSG?R9<5TW@MQ5<>FVSJ77@08\(J8>[EYF?<^>,(1E)H]PN;^NYX[$%4
M:2/SG3(QR'E1_[/GW3NT%"YZ+R@$.X7 \:X-.98WS+#91,D-*'N;T.S"N>JT
MB1PO;% >C*)33GIF]F!D] 2?2_M$&E@1PWS#5*SAS1>V$JC?3GQ#9NQE/]I!
M+FK(X 7(?@"?9&$R#;=%C/%? 7SBUY ,]B07P4G$&XRZ$/;/(.@%X0F\L'$Z
M='CA2TYG3.'Y@H(9PY)M*<<,S)5B18IN_=M\I8VBA/G]F/<U]N XMBVB*UVR
M"*<>58E&M49O]OI5?]1[=X+YH&$^.(4^>Z"BC"N!()-=T,Y+Q2->I/3F,=KL
M,1G<24'%9H5?759B?,[6J*C(8*ZI_.IH'_/MI/7COL%_R:G36@/3%I*"C_D*
M59, G;M*B"T\HB:0SB^5.Z2++JH:^F=A__(LO!QTZMRV7!!^@* [&G=NGU%%
M7&,C'77IXNUS24V"DL&@RF'8'0\/HK44S'#!S98(="][\&/GGNNG\T0A B](
M@WB 8@8A[%X,Z/B&KWF,5$E.2 HGXCYLXC[\QW%OERS,;5<C<L>">1+R>#"_
M9-A)FDAQBL&^75O+VEF6Y:&?VF>AR0 F0]@B4QK0UOSW07.MA1;!%?RM+ZV8
M[AO3/F=@ODZ[<(]VW%B&U]1H;*%63,!'GB"\X45-Y.TW.DWDER[R\S15F-H
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M6-K7#I4SL.>%E&:CN #=^SGY U!+ P04    "  LA)!8A':@=M$"  ![!P
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MGLAL5=S_\Y!)F27%PR6C<\;S ]3[BRR33T_R6XJJF]2F_P-02P,$%     @
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MKP'YC"\$]N+H&.FES!G[K@?WRXGCZ8R PD)J"JR^=G 'E&HFE<<_):E3Q=3
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M\+@]W*_#756/JBA!590@YPO/\#U2++4'H+\RX%@R?H7N^,],LG=Y"="W!P5
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M Y0%]35>P&*1_T6'<JYCH2 3DB5EL,H@B=+BE[Z51)P$8.]* "D#R'E [TJ
M6P:X>:%%9GE9<RKI9,39 7$]6Z'IBYR;/%I5$Z6ZC4O)U=-(Q<G)4NDBS&)
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M,TDC]6SKG-7E)X.W-#S]?6W[Q'$MR^ETS6U9=DV<VW8\NU7$5?0YA3ZG4=_
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M$>5/M*MK+0.%&R%Y6HO5':1Q5OT.OM5&' @49UA :@$Y5V#7 KLO&)T0.+7
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MF> 71/>5%;3NJ*3S*6<[Q'6T0M,'16^*;,4FR?5C?))<W4U4GIP_J7FQV*2
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M>EO3 >K^DC%Y.-'?Z*IOLO/_ 5!+ P04    "  LA)!86R8HBWP$  !9&
M&0   'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6RM65V/XC84_2M66E6[4G<2
M.Q#"%)!VH-5.M:..AN[V8=4'0RZ3:).8V@9V_GWM)),0"(8P>9E\^1S?X\3G
M7NZ,=HQ_%R& 1#^2.!5C*Y1R?6O;8AE"0L4-6T.JGJP83ZA4E_S9%FL.-,A
M26P3Q_'LA$:I-1EE]Q[Y9,0V,HY2>.1(;)*$\I<[B-EN;&'K]<93]!Q*?<.>
MC-;T&>8@OZP?N;JR2Y8@2B 5$4L1A]78^HAOIV2@ =F(KQ'LQ-XYTE(6C'W7
M%_?!V')T1!##4FH*J@Y;F$(<:R85QW\%J57.J8'[YZ_L?V3BE9@%%3!E\3]1
M(,.QY5LH@!7=Q/*)[3Y!(:BO^98L%ME?M,O'#OH66FZ$9$D!5A$D49H?Z8]B
M(?8 V#L!( 6 ' )Z)P!N 7 SH7EDF:P9E70RXFR'N!ZMV/1)MC896JF)4OT:
MYY*KIY'"R<E<?1?!)@;$5N@)8BHA0(^4RQ?TF=%4H#5]H0OU6#(D0LHA9'$
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M83HOVS[L8:JV[9J*A:EM"IAK2.]DH"F*JA.J!HHO;3,QXTJW)O8QT]TC"+-
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M'_MOK&_ [],$"@[/5*26,7K>F*3%IFA]_XXM/YZ\:D4:[?^-TF)3M+ZSQU<
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M'NV!C-!Q8U1+4"U%M0S5<DKKQF!;'C,3GH?_Z7.QOI4>ZM6B+*\.PVZ7BMN
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MJDW'F_FH64A6U1/#@DDU?]2WN1HI@>L ]7[)F'Q:Z"&D&U+C_U!+ P04
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M*/SX_$&,O& 7$4!7X!$SAA,.KF7R0OX&Q#@$"QK'(J$/G/K/X/LEX3B,TA_
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M/ HD%TE"Q,\[B/EJX&!G^^ [G<V5>> .^RF9P1.H'^FCT"VW4(EH DQ2SI"
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MB9^A^/,RUD41"P[$HD!N1*K7BGQ,%[CX/X!OB%?LX87]!3@1KW#>(XQ^(!
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M'7"V53Q?242S8]=V)^DL@BXL *P%0%<6 %U8 %@+@#8L )H6_V"TZD#Z60N
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M3HMTP@*=L% 3K&71L+9HJ+Q['E\_,T[ )5[$619G"]'")2B;89DY2FY7<WK
M@,P739SP>$[+#;]VPU>Z<1%%<=Y^R_165G;56R<LZ &3BGX\IR7ZJ!9]]*'O
M4R6]JS$Z84$/F-28XSDM8VRKR3:6TII[/$L08_$\QA'@!.#?ZY@_2T.+$M35
M!:VTH ]-ZH.NPVJ[L9,T[>[O"I'"WGA1J*F=K=%)"_K0Y-8<#VJ[ AM78,_^
M%RK[7S6VLRTZ:8%66JB+UC:H2=3VQT9J6VNFUDH+M-)"7;2V44VNMM7!NG\O
MK 9WMJ@'3=H-ZP*%&D!M3YIP;ZO3O:HC5I=V5EUKAN]#DTM_/*@M?1/>;67P
M/+HO5N,[VZ,UO_>AR>TY'M2VIPGNMCJY=^B-M49UK;2@#TUNA*;#:KO1!'=;
MG=S[]L9:4[U66M"')K=&<["WFV1OJZ/]X=[84??&6C.]5EJ@E1;JHK6_O#4!
M'UH?VAM#K;%?*RW02@MUT=I&-=D?]LC^[^J-U>#.%MFOOB)!Z+B.O_>U*:@&
M>F\-#"4#'6A;4/Y5"C:Y'*ISN:IS59=VUD1K]JYH+>%<UQOL*%())QGH6[[C
MV >D:Q(S5 :]HSM/-;ZSO%H3<T7;54W^N50V4/6]%#8Y%ZIS[OL[1S6HLY Z
M:4%%:^GC^'#H6\-])37MMRUW$V&A.L+V; W5U,[::TVW%6WW*>Q#.-C7_?6H
M_4=P*:FY,_TIQ711S#MC8$;6&2_G\=1;Z[EM%\6,KKWM@7T>EC/4&DPY8>X6
M4?&N8B#!<X&TSH;BJ&@Y!ZU<X6153+)Z(IR3M%A<8A1AF@\0O\\)X2\K^0[J
MF8#3_P%02P,$%     @ +(206-L??8<O P  !@X  !D   !X;"]W;W)K<VAE
M971S+W-H965T-S$N>&ULQ5?1;MHP%/T5*YNF3:I('$HH'41:RZI5*A.B6_M0
M[<$D%V(UL3/; 2KMXV<G::!KR%14R@O8L>^YY]R<Y,;])1?W,@)0:)7$3 ZL
M2*GTU+9E$$%"9(NGP/3*C(N$*#T5<UNF DB8!R6Q[3J.9R>$,LOOY]?&PN_S
M3,64P5@@F24)$0]G$//EP,+6XX4)G4?*7+#]?DKF< WJ9SH6>F97*"%-@$G*
M&1(P&UA?\.D9]DQ ON.&PE)NC)&1,N7\WDPNPX'E&$800Z ,!-%_"SB'.#9(
MFL?O$M2J<IK S?$C^D4N7HN9$@GG/+ZEH8H&UHF%0IB1+%83OOP&I:".P0MX
M+/-?M"SV=G7&().*)V6PGB>4%?]D519B(\#M; EPRP WYUTDRED.B2)^7_ E
M$F:W1C.#7&H>K<E19N[*M1)ZE>HXY=\2(0A3Z(J2*8VIHB#1QR$H0F.)OIM%
M4[5/?5OI9";$#DK@LP+8W0(\A*"%VO@(N8[;1N^1C61$!,BG2+:F6W%V*\YN
M#GV\!7H$1&8"M#<4NF1IIH[0M<%&8T$#0'<C2*8@?M5Q;@0V3\"I3$D  TM;
M7()8@.5_>(<]YW,#[79%NYVCM[?0OB!4H!L29X">*9"(L#!?)+E9?T 0,?H[
MTW?C[DKCH$L%B:R5U-Z#I.-*TG'CG2C=4[ 7Y@&02#_Z4NDY9?,CE&P(I49H
MG8(B!W;R).8ULO"[K1[NVXL::IV*6N>E)BGL<<-C76-M]8=&IS2B[UA6K^+N
M'<(IWAXD=2M)W3=P2I'#VS1*I]XF)Q6ODY?:9$+E/;H0H$O)%.A2*#0A:OU>
M07_0B#*:9$FC@1KS[ECM7J6J=P@#]?8@"3OK3N6\@87*)$_>-NW6L5=O([S1
M1_$^C$16_S52<^)=R[YNMM@]A)?P/EHQ7O=BW-@77\M,[>=FZO1:SI;>A==]
M%3<WUAHW?5VE^DL60C2D"QJ"IOW$3+7T&I/L6N-U!\:=@SAG'ZT9KWLS;NR3
MK^4<[UDK<_XQC;WQ56].2",BYI1)%,-,QSBMKJZ#* X=Q43Q-/_0GW*ECPWY
M,-('-1!F@UZ?<:X>)^;L4!W]_+]02P,$%     @ +(206+68KJ9H!   T!H
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M:YZ)8C%*5 W=F^T\CD)]9BE4E*Y:90XU):$TMZ(U_JO^[?_4>]"D%$KSH;0
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MA2F@G^\Y5P\9\[&@^9H4_0M02P,$%     @ +(206&[V$AL7+@  (N4! !D
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MW9IRI1TMZ9['$0U6;^8:*L;0U=%O%-&/%V,8I3KPL\(,N;]K_=E':IX<J=$
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MK!AB@SN13G$9$=O%J$N!^XI,_<2WB-GO$;I6"<69=FJBM<O9P@H0*#C"EB%
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MS3^41)VM/HPL2LVU5!,-7TX<5JA P1'B#*'"F]A4H:.JMNH8/V?W;-4AB./
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MRV%PA&1#O0ID]8I;O7E9KI67Z -;L!H)J>=:JHG6+F<+JVRAX A;AK(53*1
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MZ<&NC;#N5'_&7^S*++F2/SF 3!'(E#B$=5ER\^0?LEPJZ3[&5<5.LDS7JI(
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MS$5=%#-W[$I=:)YO?S.U_;W7AU]02P,$%     @ +(206#1..WUZ @   #$
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MO8?Q\U"&6\_7&J__G52/EW/+[?+7Y=?.R:URQ;F^KQB>_P)02P,$%     @
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MFU]02P$"% ,4    "  LA)!8!T%-8H$   "Q    $               @ $
M    9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( "R$D%@CQ#!7[@   "L"
M   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0
M   ( "R$D%B97)PC$ 8  )PG   3              "  <P!  !X;"]T:&5M
M92]T:&5M93$N>&UL4$L! A0#%     @ +(206#E\Z"G6!P  6#0  !@
M         ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0
M   ( "R$D%A$#T[DOP<  $<G   8              " @1D0  !X;"]W;W)K
M<VAE971S+W-H965T,BYX;6Q02P$"% ,4    "  LA)!84R4W+9 #   *$
M&               @($.&   >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L!
M A0#%     @ +(206#G4.QH#!P  )"(  !@              ("!U!L  'AL
M+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( "R$D%B5&F2L?@<
M +TT   8              " @0TC  !X;"]W;W)K<VAE971S+W-H965T-2YX
M;6Q02P$"% ,4    "  LA)!8:';C,/ (  !"*@  &               @('!
M*@  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ +(206.1/
M7:S("   DA,  !@              ("!YS,  'AL+W=O<FMS:&5E=',O<VAE
M970W+GAM;%!+ 0(4 Q0    ( "R$D%C/@'?!?2L  +>&   8
M  " @>4\  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    "  L
MA)!8Q2X)6V<%  "X#0  &               @(&8:   >&PO=V]R:W-H965T
M<R]S:&5E=#DN>&UL4$L! A0#%     @ +(206(3N7Q?\ @  GP8  !D
M         ("!-6X  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4
M    "  LA)!8)\+_>>T"  !>!@  &0              @(%H<0  >&PO=V]R
M:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( "R$D%BBZ]*/M@(  .L%
M   9              " @8QT  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL
M4$L! A0#%     @ +(206#3% ]8O"0  >18  !D              ("!>7<
M 'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4    "  LA)!8RJUL
M#:P&  !%$   &0              @('?@   >&PO=V]R:W-H965T<R]S:&5E
M=#$T+GAM;%!+ 0(4 Q0    ( "R$D%B?&,EH= D  &0:   9
M  " @<*'  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @
M+(206! /D4-5!0  (0P  !D              ("!;9$  'AL+W=O<FMS:&5E
M=',O<VAE970Q-BYX;6Q02P$"% ,4    "  LA)!880;&-'4$  !3"@  &0
M            @('YE@  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4
M Q0    ( "R$D%C#IAL-Y00  )X+   9              " @:6;  !X;"]W
M;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ +(206 ?T!4;;!
MW0L  !D              ("!P:   'AL+W=O<FMS:&5E=',O<VAE970Q.2YX
M;6Q02P$"% ,4    "  LA)!8$IE2:IX"  ##!0  &0              @('3
MI0  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( "R$D%AR
M59M[*@L   D<   9              " @:BH  !X;"]W;W)K<VAE971S+W-H
M965T,C$N>&UL4$L! A0#%     @ +(206*U=+3<D!   ;PD  !D
M     ("!";0  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "R$D%B0*358?P<  *\5   9              "
M@?@  0!X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ +(20
M6&\J)N:4 P  B0H  !D              ("!K@@! 'AL+W=O<FMS:&5E=',O
M<VAE970R."YX;6Q02P$"% ,4    "  LA)!8+XIR3>L"  !Q!@  &0
M        @(%Y# $ >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0
M   ( "R$D%C^1?Y>V@(  #8&   9              " @9L/ 0!X;"]W;W)K
M<VAE971S+W-H965T,S N>&UL4$L! A0#%     @ +(206'>;V3:[ @  [ 4
M !D              ("!K!(! 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q0
M2P$"% ,4    "  LA)!8#1I>+K<"  #P!0  &0              @(&>%0$
M>&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( "R$D%BA2(V-
M2@,   \(   9              " @8P8 0!X;"]W;W)K<VAE971S+W-H965T
M,S,N>&UL4$L! A0#%     @ +(206.W_K8N&!   UPT  !D
M ("!#1P! 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    "  L
MA)!8/'[<J*T#  " "0  &0              @('*( $ >&PO=V]R:W-H965T
M<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( "R$D%B^1>)RV (  $L'   9
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M970T,"YX;6Q02P$"% ,4    "  LA)!8!J!<PV@#  !)%   &0
M    @($Y1 $ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    (
M "R$D%A1J7D>B04  + V   9              " @=A' 0!X;"]W;W)K<VAE
M971S+W-H965T-#(N>&UL4$L! A0#%     @ +(206,SH1MWD P  &!D  !D
M             ("!F$T! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"
M% ,4    "  LA)!8,>!7;24$   R%P  &0              @(&S40$ >&PO
M=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( "R$D%AL"ZX9U ,
M #H0   9              " @0]6 0!X;"]W;W)K<VAE971S+W-H965T-#4N
M>&UL4$L! A0#%     @ +(206"W9N8R> P  O@\  !D              ("!
M&EH! 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    "  LA)!8
MS!HLLID$  !M'P  &0              @('O70$ >&PO=V]R:W-H965T<R]S
M:&5E=#0W+GAM;%!+ 0(4 Q0    ( "R$D%A"!RV4]PP  #>E   9
M      " @;]B 0!X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%
M  @ +(206(P7ML$0!   GQ4  !D              ("![6\! 'AL+W=O<FMS
M:&5E=',O<VAE970T.2YX;6Q02P$"% ,4    "  LA)!86R8HBWP$  !9&
M&0              @($T= $ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+
M 0(4 Q0    ( "R$D%A:^8P=@ ,  )L.   9              " @>=X 0!X
M;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ +(206')&M%GW
M P  (!8  !D              ("!GGP! 'AL+W=O<FMS:&5E=',O<VAE970U
M,BYX;6Q02P$"% ,4    "  LA)!87A+"J%D"  "N!0  &0
M@(',@ $ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( "R$
MD%ANMJTXUP,  $86   9              " @5R# 0!X;"]W;W)K<VAE971S
M+W-H965T-30N>&UL4$L! A0#%     @ +(206/E@)PMA @  M 4  !D
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M=#4Y+GAM;%!+ 0(4 Q0    ( "R$D%B.A"PXJ0(  /$(   9
M  " @5NY 0!X;"]W;W)K<VAE971S+W-H965T-C N>&UL4$L! A0#%     @
M+(206-O6(4_9!   /AD  !D              ("!.[P! 'AL+W=O<FMS:&5E
M=',O<VAE970V,2YX;6Q02P$"% ,4    "  LA)!8UD<CW3L%  !.(0  &0
M            @(%+P0$ >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4
M Q0    ( "R$D%@3_.H9M@,  .@1   9              " @;W& 0!X;"]W
M;W)K<VAE971S+W-H965T-C,N>&UL4$L! A0#%     @ +(206)=?@?Q%!
MQQ8  !D              ("!JLH! 'AL+W=O<FMS:&5E=',O<VAE970V-"YX
M;6Q02P$"% ,4    "  LA)!89FH!C-P/  !QX   &0              @($F
MSP$ >&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+ 0(4 Q0    ( "R$D%@J
M8!JHY 8  +0Y   9              " @3G? 0!X;"]W;W)K<VAE971S+W-H
M965T-C8N>&UL4$L! A0#%     @ +(206$K+H @B P  + @  !D
M     ("!5.8! 'AL+W=O<FMS:&5E=',O<VAE970V-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "R$D%BUF*ZF: 0  - :   9              "
M@37[ 0!X;"]W;W)K<VAE971S+W-H965T-S(N>&UL4$L! A0#%     @ +(20
M6&_=+7 9 P  Q@T  !D              ("!U/\! 'AL+W=O<FMS:&5E=',O
M<VAE970W,RYX;6Q02P$"% ,4    "  LA)!8B8A+:X$"  "!!@  &0
M        @($D P( >&PO=V]R:W-H965T<R]S:&5E=#<T+GAM;%!+ 0(4 Q0
M   ( "R$D%@]!(_Z-0@  "]=   9              " @=P% @!X;"]W;W)K
M<VAE971S+W-H965T-S4N>&UL4$L! A0#%     @ +(206,N$D@-Q @  A 8
M !D              ("!2 X" 'AL+W=O<FMS:&5E=',O<VAE970W-BYX;6Q0
M2P$"% ,4    "  LA)!8_[LULB$#  !7"0  &0              @('P$ (
M>&PO=V]R:W-H965T<R]S:&5E=#<W+GAM;%!+ 0(4 Q0    ( "R$D%@YL) @
M'0,  #$*   9              " @4@4 @!X;"]W;W)K<VAE971S+W-H965T
M-S@N>&UL4$L! A0#%     @ +(206%='K-R5 P  UQ4  !D
M ("!G!<" 'AL+W=O<FMS:&5E=',O<VAE970W.2YX;6Q02P$"% ,4    "  L
MA)!8T"#["L8"   =!P  &0              @(%H&P( >&PO=V]R:W-H965T
M<R]S:&5E=#@P+GAM;%!+ 0(4 Q0    ( "R$D%A%&Q0$G ,  %D2   9
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M @!X;"]S='EL97,N>&UL4$L! A0#%     @ +(206)>*NQS     $P(   L
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64$L%!@    !; %L ]!@  ,AD @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>314</ContextCount>
  <ElementCount>408</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>114</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/BalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/StatementsOfOperations</Role>
      <ShortName>Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Statements of Stockholders' Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/StatementsOfStockholdersDeficit</Role>
      <ShortName>Statements of Stockholders' Deficit</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/StatementsOfCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - Basis of Presentation, Organization and Other Matters</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMatters</Role>
      <ShortName>Basis of Presentation, Organization and Other Matters</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/PropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/IntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - Notes Payable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://neuraxis.com/role/NotesPayable</Role>
      <ShortName>Notes Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - Common Stock and Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/CommonStockAndWarrants</Role>
      <ShortName>Common Stock and Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/PreferredStock</Role>
      <ShortName>Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - Stock Options and Awards</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/StockOptionsAndAwards</Role>
      <ShortName>Stock Options and Awards</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - Warrant Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/WarrantLiabilities</Role>
      <ShortName>Warrant Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - Derivative Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/DerivativeLiabilities</Role>
      <ShortName>Derivative Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - Retirement Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/RetirementPlan</Role>
      <ShortName>Retirement Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - Health Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/HealthBenefitPlan</Role>
      <ShortName>Health Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - Restatement of Interim Financial Statements (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/RestatementOfInterimFinancialStatements</Role>
      <ShortName>Restatement of Interim Financial Statements (Unaudited)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://neuraxis.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://neuraxis.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - Related Party Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/RelatedPartyTransactionsTables</Role>
      <ShortName>Related Party Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://neuraxis.com/role/RelatedPartyTransactions</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://neuraxis.com/role/PropertyAndEquipment</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/IntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://neuraxis.com/role/IntangibleAssets</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://neuraxis.com/role/AccruedExpenses</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - Notes Payable (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://neuraxis.com/role/NotesPayableTables</Role>
      <ShortName>Notes Payable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://neuraxis.com/role/NotesPayable</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://neuraxis.com/role/Leases</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - Common Stock and Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/CommonStockAndWarrantsTables</Role>
      <ShortName>Common Stock and Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://neuraxis.com/role/CommonStockAndWarrants</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - Stock Options and Awards (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/StockOptionsAndAwardsTables</Role>
      <ShortName>Stock Options and Awards (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://neuraxis.com/role/StockOptionsAndAwards</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - Warrant Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/WarrantLiabilitiesTables</Role>
      <ShortName>Warrant Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://neuraxis.com/role/WarrantLiabilities</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - Derivative Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/DerivativeLiabilitiesTables</Role>
      <ShortName>Derivative Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://neuraxis.com/role/DerivativeLiabilities</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://neuraxis.com/role/IncomeTaxes</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - Restatement of Interim Financial Statements (Unaudited) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/RestatementOfInterimFinancialStatementsTables</Role>
      <ShortName>Restatement of Interim Financial Statements (Unaudited) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://neuraxis.com/role/RestatementOfInterimFinancialStatements</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - Basis of Presentation, Organization and Other Matters (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative</Role>
      <ShortName>Basis of Presentation, Organization and Other Matters (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMatters</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - Schedule of Estimated Useful Lives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/ScheduleOfEstimatedUsefulLivesDetails</Role>
      <ShortName>Schedule of Estimated Useful Lives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - Schedule of Fair Value On a Recurring Basis Assets and Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/ScheduleOfFairValueOnRecurringBasisAssetsAndLiabilityDetails</Role>
      <ShortName>Schedule of Fair Value On a Recurring Basis Assets and Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - Schedule of Unobservable Inputs for Level 3 Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/ScheduleOfUnobservableInputsForLevel3AssetsAndLiabilitiesDetails</Role>
      <ShortName>Schedule of Unobservable Inputs for Level 3 Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - Schedule of Dilutive Common Stock Equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/ScheduleOfDilutiveCommonStockEquivalentsDetails</Role>
      <ShortName>Schedule of Dilutive Common Stock Equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - Schedule of Basic and Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails</Role>
      <ShortName>Schedule of Basic and Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - Schedule of Disaggregation of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/ScheduleOfDisaggregationOfRevenueDetails</Role>
      <ShortName>Schedule of Disaggregation of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - Schedule of Customers Accounted Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/ScheduleOfCustomersAccountedRevenuesDetails</Role>
      <ShortName>Schedule of Customers Accounted Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>Summary of Significant Accounting Policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - Schedule of Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/ScheduleOfRelatedPartyTransactionsDetails</Role>
      <ShortName>Schedule of Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>00000050 - Disclosure - Schedule of Related Party Loans payable to shareholder (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/ScheduleOfRelatedPartyLoansPayableToShareholderDetails</Role>
      <ShortName>Schedule of Related Party Loans payable to shareholder (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>00000051 - Disclosure - Related Party Transactions (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>Related Party Transactions (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://neuraxis.com/role/RelatedPartyTransactionsTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>00000052 - Disclosure - Schedule of Property And Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/ScheduleOfPropertyAndEquipmentDetails</Role>
      <ShortName>Schedule of Property And Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>00000053 - Disclosure - Property and Equipment (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/PropertyAndEquipmentDetailsNarrative</Role>
      <ShortName>Property and Equipment (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://neuraxis.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>00000054 - Disclosure - Schedule of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/ScheduleOfIntangibleAssetsDetails</Role>
      <ShortName>Schedule of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>00000055 - Disclosure - Intangible Assets (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/IntangibleAssetsDetailsNarrative</Role>
      <ShortName>Intangible Assets (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://neuraxis.com/role/IntangibleAssetsTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>00000056 - Disclosure - Schedule of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/ScheduleOfAccruedExpensesDetails</Role>
      <ShortName>Schedule of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>00000057 - Disclosure - Schedule of Convertible Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://neuraxis.com/role/ScheduleOfConvertibleNotesDetails</Role>
      <ShortName>Schedule of Convertible Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>00000058 - Disclosure - Notes Payable (Details Narrative)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://neuraxis.com/role/NotesPayableDetailsNarrative</Role>
      <ShortName>Notes Payable (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://neuraxis.com/role/NotesPayableTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>00000059 - Disclosure - Schedule of Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/ScheduleOfOperatingLeasesDetails</Role>
      <ShortName>Schedule of Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>00000060 - Disclosure - Schedule of Maturities Operating Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/ScheduleOfMaturitiesOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>Schedule of Maturities Operating Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>00000061 - Disclosure - Leases (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/LeasesDetailsNarrative</Role>
      <ShortName>Leases (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://neuraxis.com/role/LeasesTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>00000062 - Disclosure - Schedule of Warrant Activity for Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/ScheduleOfWarrantActivityForCommonStockDetails</Role>
      <ShortName>Schedule of Warrant Activity for Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>00000063 - Disclosure - Schedule of Warrant Activity for Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/ScheduleOfWarrantActivityForPreferredStockDetails</Role>
      <ShortName>Schedule of Warrant Activity for Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>00000064 - Disclosure - Schedule of Warrants outstanding and Exercisable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails</Role>
      <ShortName>Schedule of Warrants outstanding and Exercisable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>00000065 - Disclosure - Common Stock and Warrants (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative</Role>
      <ShortName>Common Stock and Warrants (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://neuraxis.com/role/CommonStockAndWarrantsTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>00000066 - Disclosure - Preferred Stock (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/PreferredStockDetailsNarrative</Role>
      <ShortName>Preferred Stock (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://neuraxis.com/role/PreferredStock</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>00000067 - Disclosure - Schedule of Option-pricing Model with Following Weighted-average Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/ScheduleOfOption-pricingModelWithFollowingWeighted-averageAssumptionsDetails</Role>
      <ShortName>Schedule of Option-pricing Model with Following Weighted-average Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>00000068 - Disclosure - Schedule of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/ScheduleOfStockOptionActivityDetails</Role>
      <ShortName>Schedule of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>00000069 - Disclosure - Stock Options and Awards (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/StockOptionsAndAwardsDetailsNarrative</Role>
      <ShortName>Stock Options and Awards (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://neuraxis.com/role/StockOptionsAndAwardsTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>00000070 - Disclosure - Schedule of Changes in Warrant Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/ScheduleOfChangesInWarrantLiabilitiesDetails</Role>
      <ShortName>Schedule of Changes in Warrant Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>00000071 - Disclosure - Warrant Liabilities (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/WarrantLiabilitiesDetailsNarrative</Role>
      <ShortName>Warrant Liabilities (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://neuraxis.com/role/WarrantLiabilitiesTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>00000072 - Disclosure - Schedule of Changes in Derivative Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/ScheduleOfChangesInDerivativeLiabilitiesDetails</Role>
      <ShortName>Schedule of Changes in Derivative Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>00000073 - Disclosure - Derivative Liabilities (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/DerivativeLiabilitiesDetailsNarrative</Role>
      <ShortName>Derivative Liabilities (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://neuraxis.com/role/DerivativeLiabilitiesTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>00000074 - Disclosure - Retirement Plan (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/RetirementPlanDetailsNarrative</Role>
      <ShortName>Retirement Plan (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://neuraxis.com/role/RetirementPlan</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>00000075 - Disclosure - Commitments and Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>Commitments and Contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://neuraxis.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>00000076 - Disclosure - Health Benefit Plan (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/HealthBenefitPlanDetailsNarrative</Role>
      <ShortName>Health Benefit Plan (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://neuraxis.com/role/HealthBenefitPlan</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>00000077 - Disclosure - Schedule of Deferred Tax Asset (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/ScheduleOfDeferredTaxAssetDetails</Role>
      <ShortName>Schedule of Deferred Tax Asset (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>00000078 - Disclosure - Schedule of Federal Statutory Income Tax Rate and Effective Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/ScheduleOfFederalStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails</Role>
      <ShortName>Schedule of Federal Statutory Income Tax Rate and Effective Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>00000079 - Disclosure - Schedule of State Carryforwards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/ScheduleOfStateCarryforwardsDetails</Role>
      <ShortName>Schedule of State Carryforwards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>00000080 - Disclosure - Income Taxes (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>Income Taxes (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://neuraxis.com/role/IncomeTaxesTables</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>00000081 - Disclosure - Subsequent Events (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>Subsequent Events (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://neuraxis.com/role/SubsequentEvents</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>00000082 - Disclosure - Schedule of Restatement of Interim Financial Statements (Unaudited) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails</Role>
      <ShortName>Schedule of Restatement of Interim Financial Statements (Unaudited) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="form10-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>00000083 - Disclosure - Restatement of Interim Financial Statements (Unaudited) (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://neuraxis.com/role/RestatementOfInterimFinancialStatementsDetailsNarrative</Role>
      <ShortName>Restatement of Interim Financial Statements (Unaudited) (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://neuraxis.com/role/RestatementOfInterimFinancialStatementsTables</ParentRole>
      <Position>83</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 4 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:WarrantsAndRightsOutstandingTerm -  form10-k.htm 133, 134, 135, 136</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="form10-k.htm">form10-k.htm</File>
    <File>nrxs-20231231.xsd</File>
    <File>nrxs-20231231_cal.xml</File>
    <File>nrxs-20231231_def.xml</File>
    <File>nrxs-20231231_lab.xml</File>
    <File>nrxs-20231231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>form10-k_001.jpg</File>
    <File>form10-k_002.jpg</File>
    <File>form10-k_004.jpg</File>
    <File>form10-k_006.jpg</File>
    <File>form10-k_007.jpg</File>
    <File>form10-k_008.jpg</File>
    <File>form10-k_009.jpg</File>
    <File>form10-k_010.jpg</File>
    <File>form10-k_011.jpg</File>
    <File>form10-k_012.jpg</File>
    <File>pg_001.jpg</File>
    <File>pg_002.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1155">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>115
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "form10-k.htm": {
   "nsprefix": "NRXS",
   "nsuri": "http://neuraxis.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "form10-k.htm"
     ]
    },
    "schema": {
     "local": [
      "nrxs-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "nrxs-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "nrxs-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "nrxs-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nrxs-20231231_pre.xml"
     ]
    }
   },
   "keyStandard": 331,
   "keyCustom": 77,
   "axisStandard": 31,
   "axisCustom": 0,
   "memberStandard": 44,
   "memberCustom": 61,
   "hidden": {
    "total": 280,
    "http://fasb.org/us-gaap/2023": 223,
    "http://neuraxis.com/20231231": 53,
    "http://xbrl.sec.gov/dei/2023": 4
   },
   "contextCount": 314,
   "entityCount": 1,
   "segmentCount": 114,
   "elementCount": 674,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 1155,
    "http://xbrl.sec.gov/dei/2023": 39
   },
   "report": {
    "R1": {
     "role": "http://neuraxis.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://neuraxis.com/role/BalanceSheets",
     "longName": "00000002 - Statement - Balance Sheets",
     "shortName": "Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "us-gaap:DeferredCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://neuraxis.com/role/BalanceSheetsParenthetical",
     "longName": "00000003 - Statement - Balance Sheets (Parenthetical)",
     "shortName": "Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://neuraxis.com/role/StatementsOfOperations",
     "longName": "00000004 - Statement - Statements of Operations",
     "shortName": "Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2023-07-012023-09-30",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
       "us-gaap:ErrorCorrectionTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R5": {
     "role": "http://neuraxis.com/role/StatementsOfStockholdersDeficit",
     "longName": "00000005 - Statement - Statements of Stockholders' Deficit",
     "shortName": "Statements of Stockholders' Deficit",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "AsOf2021-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2021-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://neuraxis.com/role/StatementsOfCashFlows",
     "longName": "00000006 - Statement - Statements of Cash Flows",
     "shortName": "Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-01-012022-12-31",
      "name": "NRXS:DeferredOfferingCostsPaid",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMatters",
     "longName": "00000007 - Disclosure - Basis of Presentation, Organization and Other Matters",
     "shortName": "Basis of Presentation, Organization and Other Matters",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://neuraxis.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "00000008 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://neuraxis.com/role/RelatedPartyTransactions",
     "longName": "00000009 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://neuraxis.com/role/PropertyAndEquipment",
     "longName": "00000010 - Disclosure - Property and Equipment",
     "shortName": "Property and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://neuraxis.com/role/IntangibleAssets",
     "longName": "00000011 - Disclosure - Intangible Assets",
     "shortName": "Intangible Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://neuraxis.com/role/AccruedExpenses",
     "longName": "00000012 - Disclosure - Accrued Expenses",
     "shortName": "Accrued Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://neuraxis.com/role/NotesPayable",
     "longName": "00000013 - Disclosure - Notes Payable",
     "shortName": "Notes Payable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://neuraxis.com/role/Leases",
     "longName": "00000014 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://neuraxis.com/role/CommonStockAndWarrants",
     "longName": "00000015 - Disclosure - Common Stock and Warrants",
     "shortName": "Common Stock and Warrants",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "NRXS:CommonStockAndWarrantsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "NRXS:CommonStockAndWarrantsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://neuraxis.com/role/PreferredStock",
     "longName": "00000016 - Disclosure - Preferred Stock",
     "shortName": "Preferred Stock",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:PreferredStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:PreferredStockTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://neuraxis.com/role/StockOptionsAndAwards",
     "longName": "00000017 - Disclosure - Stock Options and Awards",
     "shortName": "Stock Options and Awards",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://neuraxis.com/role/WarrantLiabilities",
     "longName": "00000018 - Disclosure - Warrant Liabilities",
     "shortName": "Warrant Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "NRXS:WarrantLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "NRXS:WarrantLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://neuraxis.com/role/DerivativeLiabilities",
     "longName": "00000019 - Disclosure - Derivative Liabilities",
     "shortName": "Derivative Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:DerivativesAndFairValueTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:DerivativesAndFairValueTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://neuraxis.com/role/RetirementPlan",
     "longName": "00000020 - Disclosure - Retirement Plan",
     "shortName": "Retirement Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://neuraxis.com/role/CommitmentsAndContingencies",
     "longName": "00000021 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://neuraxis.com/role/HealthBenefitPlan",
     "longName": "00000022 - Disclosure - Health Benefit Plan",
     "shortName": "Health Benefit Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "NRXS:HealthBenefitPlanDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "NRXS:HealthBenefitPlanDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://neuraxis.com/role/IncomeTaxes",
     "longName": "00000023 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://neuraxis.com/role/SubsequentEvents",
     "longName": "00000024 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://neuraxis.com/role/RestatementOfInterimFinancialStatements",
     "longName": "00000025 - Disclosure - Restatement of Interim Financial Statements (Unaudited)",
     "shortName": "Restatement of Interim Financial Statements (Unaudited)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ErrorCorrectionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ErrorCorrectionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "00000026 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesTables",
     "longName": "00000027 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "NRXS:ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "NRXS:ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://neuraxis.com/role/RelatedPartyTransactionsTables",
     "longName": "00000028 - Disclosure - Related Party Transactions (Tables)",
     "shortName": "Related Party Transactions (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://neuraxis.com/role/PropertyAndEquipmentTables",
     "longName": "00000029 - Disclosure - Property and Equipment (Tables)",
     "shortName": "Property and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://neuraxis.com/role/IntangibleAssetsTables",
     "longName": "00000030 - Disclosure - Intangible Assets (Tables)",
     "shortName": "Intangible Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://neuraxis.com/role/AccruedExpensesTables",
     "longName": "00000031 - Disclosure - Accrued Expenses (Tables)",
     "shortName": "Accrued Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://neuraxis.com/role/NotesPayableTables",
     "longName": "00000032 - Disclosure - Notes Payable (Tables)",
     "shortName": "Notes Payable (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ConvertibleDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://neuraxis.com/role/LeasesTables",
     "longName": "00000033 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://neuraxis.com/role/CommonStockAndWarrantsTables",
     "longName": "00000034 - Disclosure - Common Stock and Warrants (Tables)",
     "shortName": "Common Stock and Warrants (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "NRXS:CommonStockAndWarrantsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "NRXS:CommonStockAndWarrantsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://neuraxis.com/role/StockOptionsAndAwardsTables",
     "longName": "00000035 - Disclosure - Stock Options and Awards (Tables)",
     "shortName": "Stock Options and Awards (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://neuraxis.com/role/WarrantLiabilitiesTables",
     "longName": "00000036 - Disclosure - Warrant Liabilities (Tables)",
     "shortName": "Warrant Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "NRXS:ScheduleOfChangesInWarrantLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "NRXS:WarrantLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "NRXS:ScheduleOfChangesInWarrantLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "NRXS:WarrantLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://neuraxis.com/role/DerivativeLiabilitiesTables",
     "longName": "00000037 - Disclosure - Derivative Liabilities (Tables)",
     "shortName": "Derivative Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DerivativesAndFairValueTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DerivativesAndFairValueTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://neuraxis.com/role/IncomeTaxesTables",
     "longName": "00000038 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://neuraxis.com/role/RestatementOfInterimFinancialStatementsTables",
     "longName": "00000039 - Disclosure - Restatement of Interim Financial Statements (Unaudited) (Tables)",
     "shortName": "Restatement of Interim Financial Statements (Unaudited) (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ErrorCorrectionTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:ErrorCorrectionTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative",
     "longName": "00000040 - Disclosure - Basis of Presentation, Organization and Other Matters (Details Narrative)",
     "shortName": "Basis of Presentation, Organization and Other Matters (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "From2023-08-142023-08-14",
      "name": "us-gaap:StockholdersEquityNoteStockSplit",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "NRXS:CommonStockAndWarrantsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-08-09_us-gaap_IPOMember_custom_AlexanderCapitalLPMember",
      "name": "us-gaap:DeferredOfferingCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://neuraxis.com/role/ScheduleOfEstimatedUsefulLivesDetails",
     "longName": "00000041 - Disclosure - Schedule of Estimated Useful Lives (Details)",
     "shortName": "Schedule of Estimated Useful Lives (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_MachineryAndEquipmentMember_srt_MinimumMember",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "NRXS:ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_MachineryAndEquipmentMember_srt_MinimumMember",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "NRXS:ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://neuraxis.com/role/ScheduleOfFairValueOnRecurringBasisAssetsAndLiabilityDetails",
     "longName": "00000042 - Disclosure - Schedule of Fair Value On a Recurring Basis Assets and Liability (Details)",
     "shortName": "Schedule of Fair Value On a Recurring Basis Assets and Liability (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "NRXS:WarrantLiabilities",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember",
      "name": "us-gaap:LiabilitiesFairValueDisclosure",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueMeasurementPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://neuraxis.com/role/ScheduleOfUnobservableInputsForLevel3AssetsAndLiabilitiesDetails",
     "longName": "00000043 - Disclosure - Schedule of Unobservable Inputs for Level 3 Assets and Liabilities (Details)",
     "shortName": "Schedule of Unobservable Inputs for Level 3 Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "NRXS:WarrantLiabilities",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R44": {
     "role": "http://neuraxis.com/role/ScheduleOfDilutiveCommonStockEquivalentsDetails",
     "longName": "00000044 - Disclosure - Schedule of Dilutive Common Stock Equivalents (Details)",
     "shortName": "Schedule of Dilutive Common Stock Equivalents (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://neuraxis.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails",
     "longName": "00000045 - Disclosure - Schedule of Basic and Diluted Net Loss Per Share (Details)",
     "shortName": "Schedule of Basic and Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "From2023-07-012023-09-30",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
       "us-gaap:ErrorCorrectionTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-01-012022-12-31",
      "name": "us-gaap:PreferredStockDividendsAndOtherAdjustments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://neuraxis.com/role/ScheduleOfDisaggregationOfRevenueDetails",
     "longName": "00000046 - Disclosure - Schedule of Disaggregation of Revenue (Details)",
     "shortName": "Schedule of Disaggregation of Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:Revenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:Revenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://neuraxis.com/role/ScheduleOfCustomersAccountedRevenuesDetails",
     "longName": "00000047 - Disclosure - Schedule of Customers Accounted Revenues (Details)",
     "shortName": "Schedule of Customers Accounted Revenues (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "From2023-07-012023-09-30",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
       "us-gaap:ErrorCorrectionTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31_custom_HospitalAMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock",
       "us-gaap:ConcentrationRiskCreditRisk",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative",
     "longName": "00000048 - Disclosure - Summary of Significant Accounting Policies (Details Narrative)",
     "shortName": "Summary of Significant Accounting Policies (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://neuraxis.com/role/ScheduleOfRelatedPartyTransactionsDetails",
     "longName": "00000049 - Disclosure - Schedule of Related Party Transactions (Details)",
     "shortName": "Schedule of Related Party Transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_custom_ShareHolderOneMember",
      "name": "us-gaap:NotesAndLoansReceivableGrossCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_custom_ShareHolderOneMember",
      "name": "us-gaap:NotesAndLoansReceivableGrossCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://neuraxis.com/role/ScheduleOfRelatedPartyLoansPayableToShareholderDetails",
     "longName": "00000050 - Disclosure - Schedule of Related Party Loans payable to shareholder (Details)",
     "shortName": "Schedule of Related Party Loans payable to shareholder (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "us-gaap:LoansPayable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "NRXS:ScheduleOfRelatedPartyLoansTableTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "us-gaap:LoansPayable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "NRXS:ScheduleOfRelatedPartyLoansTableTextBlock",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://neuraxis.com/role/RelatedPartyTransactionsDetailsNarrative",
     "longName": "00000051 - Disclosure - Related Party Transactions (Details Narrative)",
     "shortName": "Related Party Transactions (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "NRXS:AllowanceForInterestReceivableCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "NRXS:AllowanceForInterestReceivableCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://neuraxis.com/role/ScheduleOfPropertyAndEquipmentDetails",
     "longName": "00000052 - Disclosure - Schedule of Property And Equipment (Details)",
     "shortName": "Schedule of Property And Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_MachineryAndEquipmentMember",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://neuraxis.com/role/PropertyAndEquipmentDetailsNarrative",
     "longName": "00000053 - Disclosure - Property and Equipment (Details Narrative)",
     "shortName": "Property and Equipment (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:Depreciation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R54": {
     "role": "http://neuraxis.com/role/ScheduleOfIntangibleAssetsDetails",
     "longName": "00000054 - Disclosure - Schedule of Intangible Assets (Details)",
     "shortName": "Schedule of Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://neuraxis.com/role/IntangibleAssetsDetailsNarrative",
     "longName": "00000055 - Disclosure - Intangible Assets (Details Narrative)",
     "shortName": "Intangible Assets (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IntangibleAssetsFiniteLivedPolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R56": {
     "role": "http://neuraxis.com/role/ScheduleOfAccruedExpensesDetails",
     "longName": "00000056 - Disclosure - Schedule of Accrued Expenses (Details)",
     "shortName": "Schedule of Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "NRXS:AccruedCompensationAndBenefitsCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "NRXS:AccruedCompensationAndBenefitsCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://neuraxis.com/role/ScheduleOfConvertibleNotesDetails",
     "longName": "00000057 - Disclosure - Schedule of Convertible Notes (Details)",
     "shortName": "Schedule of Convertible Notes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "AsOf2023-11-08",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:PreferredStockTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "us-gaap:DeferredFinanceCostsCurrentNet",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ConvertibleDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://neuraxis.com/role/NotesPayableDetailsNarrative",
     "longName": "00000058 - Disclosure - Notes Payable (Details Narrative)",
     "shortName": "Notes Payable (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "AsOf2023-11-08",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:PreferredStockTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://neuraxis.com/role/ScheduleOfOperatingLeasesDetails",
     "longName": "00000059 - Disclosure - Schedule of Operating Leases (Details)",
     "shortName": "Schedule of Operating Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:OtherLiabilitiesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://neuraxis.com/role/ScheduleOfMaturitiesOperatingLeaseLiabilitiesDetails",
     "longName": "00000060 - Disclosure - Schedule of Maturities Operating Lease Liabilities (Details)",
     "shortName": "Schedule of Maturities Operating Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://neuraxis.com/role/LeasesDetailsNarrative",
     "longName": "00000061 - Disclosure - Leases (Details Narrative)",
     "shortName": "Leases (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:LesseeOperatingLeaseDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:LesseeOperatingLeaseDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://neuraxis.com/role/ScheduleOfWarrantActivityForCommonStockDetails",
     "longName": "00000062 - Disclosure - Schedule of Warrant Activity for Common Stock (Details)",
     "shortName": "Schedule of Warrant Activity for Common Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31_us-gaap_CommonStockMember",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "NRXS:ScheduleOfWarrantActivityForCommonStockTableTextBlock",
       "NRXS:CommonStockAndWarrantsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://neuraxis.com/role/ScheduleOfWarrantActivityForPreferredStockDetails",
     "longName": "00000063 - Disclosure - Schedule of Warrant Activity for Preferred Stock (Details)",
     "shortName": "Schedule of Warrant Activity for Preferred Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2021-12-31_us-gaap_PreferredStockMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "NRXS:ScheduleOfWarrantActivityForPreferredStockTableTextBlock",
       "NRXS:CommonStockAndWarrantsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R64": {
     "role": "http://neuraxis.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails",
     "longName": "00000064 - Disclosure - Schedule of Warrants outstanding and Exercisable (Details)",
     "shortName": "Schedule of Warrants outstanding and Exercisable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "NRXS:CommonStockAndWarrantsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_custom_InvestorWarrantOneMember",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "NRXS:CommonStockAndWarrantsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative",
     "longName": "00000065 - Disclosure - Common Stock and Warrants (Details Narrative)",
     "shortName": "Common Stock and Warrants (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-08-082023-08-08",
      "name": "us-gaap:DebtConversionConvertedInstrumentSharesIssued1",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "NRXS:CommonStockAndWarrantsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://neuraxis.com/role/PreferredStockDetailsNarrative",
     "longName": "00000066 - Disclosure - Preferred Stock (Details Narrative)",
     "shortName": "Preferred Stock (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31_us-gaap_ConvertibleDebtMember",
      "name": "us-gaap:ConversionOfStockAmountConverted1",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:PreferredStockTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://neuraxis.com/role/ScheduleOfOption-pricingModelWithFollowingWeighted-averageAssumptionsDetails",
     "longName": "00000067 - Disclosure - Schedule of Option-pricing Model with Following Weighted-average Assumptions (Details)",
     "shortName": "Schedule of Option-pricing Model with Following Weighted-average Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_custom_TwentySeventeenStockCompensationPlanMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_custom_TwentySeventeenStockCompensationPlanMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://neuraxis.com/role/ScheduleOfStockOptionActivityDetails",
     "longName": "00000068 - Disclosure - Schedule of Stock Option Activity (Details)",
     "shortName": "Schedule of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://neuraxis.com/role/StockOptionsAndAwardsDetailsNarrative",
     "longName": "00000069 - Disclosure - Stock Options and Awards (Details Narrative)",
     "shortName": "Stock Options and Awards (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R70": {
     "role": "http://neuraxis.com/role/ScheduleOfChangesInWarrantLiabilitiesDetails",
     "longName": "00000070 - Disclosure - Schedule of Changes in Warrant Liabilities (Details)",
     "shortName": "Schedule of Changes in Warrant Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "From2023-07-012023-09-30",
      "name": "us-gaap:FairValueAdjustmentOfWarrants",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
       "us-gaap:ErrorCorrectionTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member",
      "name": "us-gaap:WarrantsAndRightsOutstanding",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "NRXS:ScheduleOfChangesInWarrantLiabilitiesTableTextBlock",
       "NRXS:WarrantLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R71": {
     "role": "http://neuraxis.com/role/WarrantLiabilitiesDetailsNarrative",
     "longName": "00000071 - Disclosure - Warrant Liabilities (Details Narrative)",
     "shortName": "Warrant Liabilities (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_MeasurementInputSharePriceMember",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "NRXS:WarrantLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_MeasurementInputSharePriceMember",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "NRXS:WarrantLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://neuraxis.com/role/ScheduleOfChangesInDerivativeLiabilitiesDetails",
     "longName": "00000072 - Disclosure - Schedule of Changes in Derivative Liabilities (Details)",
     "shortName": "Schedule of Changes in Derivative Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "AsOf2022-12-31",
      "name": "us-gaap:DerivativeLiabilitiesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member",
      "name": "NRXS:AdditionToDerivativeLiabilities",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
       "us-gaap:DerivativesAndFairValueTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R73": {
     "role": "http://neuraxis.com/role/DerivativeLiabilitiesDetailsNarrative",
     "longName": "00000073 - Disclosure - Derivative Liabilities (Details Narrative)",
     "shortName": "Derivative Liabilities (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_MeasurementInputSharePriceMember",
      "name": "us-gaap:DerivativeLiabilityMeasurementInput",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DerivativesAndFairValueTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_us-gaap_MeasurementInputSharePriceMember",
      "name": "us-gaap:DerivativeLiabilityMeasurementInput",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DerivativesAndFairValueTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://neuraxis.com/role/RetirementPlanDetailsNarrative",
     "longName": "00000074 - Disclosure - Retirement Plan (Details Narrative)",
     "shortName": "Retirement Plan (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "longName": "00000075 - Disclosure - Commitments and Contingencies (Details Narrative)",
     "shortName": "Commitments and Contingencies (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:DepositLiabilitiesAccruedInterest",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "us-gaap:DepositLiabilitiesAccruedInterest",
       "span",
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:DepositLiabilitiesAccruedInterest",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "us-gaap:DepositLiabilitiesAccruedInterest",
       "span",
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://neuraxis.com/role/HealthBenefitPlanDetailsNarrative",
     "longName": "00000076 - Disclosure - Health Benefit Plan (Details Narrative)",
     "shortName": "Health Benefit Plan (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:HealthCareOrganizationStopLossInsurancePremiumExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "NRXS:HealthBenefitPlanDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:HealthCareOrganizationStopLossInsurancePremiumExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "NRXS:HealthBenefitPlanDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://neuraxis.com/role/ScheduleOfDeferredTaxAssetDetails",
     "longName": "00000077 - Disclosure - Schedule of Deferred Tax Asset (Details)",
     "shortName": "Schedule of Deferred Tax Asset (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "NRXS:DeferredTaxAssetsDepreciation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "NRXS:DeferredTaxAssetsDepreciation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R78": {
     "role": "http://neuraxis.com/role/ScheduleOfFederalStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails",
     "longName": "00000078 - Disclosure - Schedule of Federal Statutory Income Tax Rate and Effective Income Tax Rate (Details)",
     "shortName": "Schedule of Federal Statutory Income Tax Rate and Effective Income Tax Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-01-01to2023-12-31",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R79": {
     "role": "http://neuraxis.com/role/ScheduleOfStateCarryforwardsDetails",
     "longName": "00000079 - Disclosure - Schedule of State Carryforwards (Details)",
     "shortName": "Schedule of State Carryforwards (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31_custom_TaxYear2038Member",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R80": {
     "role": "http://neuraxis.com/role/IncomeTaxesDetailsNarrative",
     "longName": "00000080 - Disclosure - Income Taxes (Details Narrative)",
     "shortName": "Income Taxes (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R81": {
     "role": "http://neuraxis.com/role/SubsequentEventsDetailsNarrative",
     "longName": "00000081 - Disclosure - Subsequent Events (Details Narrative)",
     "shortName": "Subsequent Events (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:ConvertibleDebt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-12-31",
      "name": "us-gaap:ConvertibleDebt",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    },
    "R82": {
     "role": "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails",
     "longName": "00000082 - Disclosure - Schedule of Restatement of Interim Financial Statements (Unaudited) (Details)",
     "shortName": "Schedule of Restatement of Interim Financial Statements (Unaudited) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "AsOf2023-09-30",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
       "us-gaap:ErrorCorrectionTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-012023-09-30",
      "name": "us-gaap:InterestAndOtherIncome",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
       "us-gaap:ErrorCorrectionTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "unique": true
     }
    },
    "R83": {
     "role": "http://neuraxis.com/role/RestatementOfInterimFinancialStatementsDetailsNarrative",
     "longName": "00000083 - Disclosure - Restatement of Interim Financial Statements (Unaudited) (Details Narrative)",
     "shortName": "Restatement of Interim Financial Statements (Unaudited) (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "From2023-07-012023-09-30",
      "name": "NRXS:IncreaseDecreaseInWarrantLiability",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "NRXS:IncreaseDecreaseInWarrantLiability",
       "span",
       "span",
       "p",
       "us-gaap:ErrorCorrectionTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-012023-09-30",
      "name": "NRXS:IncreaseDecreaseInWarrantLiability",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "NRXS:IncreaseDecreaseInWarrantLiability",
       "span",
       "span",
       "p",
       "us-gaap:ErrorCorrectionTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "form10-k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingChangesAndErrorCorrectionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Changes and Error Corrections [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "presentation": [
      "http://neuraxis.com/role/AccruedExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses",
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets",
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r788"
     ]
    },
    "us-gaap_AccountsPayableCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "Accounts Payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r933"
     ]
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfCustomersAccountedRevenuesDetails",
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets",
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts receivable, net",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r305"
     ]
    },
    "NRXS_AccreditedInvestorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "AccreditedInvestorsMember",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accredited Investors [Member]",
        "documentation": "Accredited Investors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccrualForTaxesOtherThanIncomeTaxesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r85",
      "r763"
     ]
    },
    "us-gaap_AccruedBonusesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedBonusesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive bonus",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "NRXS_AccruedCompensationAndBenefitsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "AccruedCompensationAndBenefitsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation and benefits",
        "documentation": "Accrued compensation and benefits current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://neuraxis.com/role/ScheduleOfAccruedExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets",
      "http://neuraxis.com/role/ScheduleOfAccruedExpensesDetails",
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses",
        "totalLabel": "Total accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/BalanceSheets": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      },
      "http://neuraxis.com/role/ScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets",
      "http://neuraxis.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less - accumulated depreciation",
        "negatedTerseLabel": "Less: accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r216",
      "r613"
     ]
    },
    "NRXS_AdditionToDerivativeLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "AdditionToDerivativeLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfChangesInDerivativeLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Addition",
        "documentation": "Addition to derivative liabilities.",
        "label": "Addition to derivative liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_AdditionToWarrantLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "AdditionToWarrantLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfChangesInWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Addition",
        "documentation": "Addition to warrant liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets",
      "http://neuraxis.com/role/RestatementOfInterimFinancialStatementsDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r788",
      "r940"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://neuraxis.com/role/StatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r453",
      "r454",
      "r455",
      "r643",
      "r850",
      "r851",
      "r852",
      "r913",
      "r943"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/StatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r83",
      "r417"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/StatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reclassification of warrant liability to equity",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r69",
      "r149"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails",
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used by operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdvertisingCostsPolicyTextBlock",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advertising Cost",
        "documentation": "Disclosure of accounting policy for advertising cost."
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "us-gaap_AdvertisingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdvertisingExpense",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advertising cost expense",
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line."
       }
      }
     },
     "auth_ref": [
      "r461"
     ]
    },
    "NRXS_AggregatePurchasePrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "AggregatePurchasePrice",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate purchase price",
        "documentation": "Aggregate purchase price."
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_AlexanderCapitalLPMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "AlexanderCapitalLPMember",
     "presentation": [
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative",
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Alexander Capital LP [Member]",
        "documentation": "Alexander Capital LP [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_AllOtherStatesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "AllOtherStatesMember",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfDisaggregationOfRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Other States [Member]",
        "documentation": "All Other States [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/StockOptionsAndAwardsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r449",
      "r460"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Allowance for doubtful accounts",
        "documentation": "Amount of allowance for credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r308",
      "r323",
      "r324",
      "r326",
      "r936"
     ]
    },
    "NRXS_AllowanceForInterestIncomeCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "AllowanceForInterestIncomeCurrent",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Allowance for collection risk, interest income",
        "documentation": "Allowance for interest income current.",
        "label": "AllowanceForInterestIncomeCurrent"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_AllowanceForInterestReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "AllowanceForInterestReceivableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Allowance for interest receivable current",
        "documentation": "Allowance for interest receivable current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllowanceForNotesAndLoansReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllowanceForNotesAndLoansReceivableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Allowance for collection risk, loan receivable",
        "label": "Financing Receivable, Allowance for Credit Loss, Current",
        "documentation": "Amount of allowance for credit loss on financing receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r308",
      "r323"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://neuraxis.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails",
      "http://neuraxis.com/role/StatementsOfCashFlows",
      "http://neuraxis.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Amortization of debt discount and issuance cost",
        "label": "Amortization of debt discount and issuance cost",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r375",
      "r540",
      "r776",
      "r777",
      "r843"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/IntangibleAssetsDetailsNarrative",
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization expense",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r63",
      "r66"
     ]
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfDilutiveCommonStockEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Totals",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r282"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfDilutiveCommonStockEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfDilutiveCommonStockEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfDilutiveCommonStockEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative",
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r487"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets",
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Assets",
        "label": "Assets [Default Label]",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r160",
      "r219",
      "r248",
      "r287",
      "r294",
      "r298",
      "r312",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r488",
      "r490",
      "r525",
      "r605",
      "r682",
      "r788",
      "r800",
      "r873",
      "r874",
      "r924"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets",
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets",
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r211",
      "r227",
      "r248",
      "r312",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r488",
      "r490",
      "r525",
      "r788",
      "r873",
      "r874",
      "r924"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets",
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Assets:",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r812",
      "r814",
      "r815"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r812",
      "r814",
      "r815"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r812",
      "r814",
      "r815"
     ]
    },
    "NRXS_BrianHannaschMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "BrianHannaschMember",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Brian Hannasch [Member]",
        "documentation": "Brian Hannasch [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMatters"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation, Organization and Other Matters",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r134",
      "r135"
     ]
    },
    "stpr_CA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2023",
     "localname": "CA",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfDisaggregationOfRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CALIFORNIA"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_CarmelIndianaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "CarmelIndianaMember",
     "presentation": [
      "http://neuraxis.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Carmel Indiana [Member]",
        "documentation": "Carmel Indiana [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Cash",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r607",
      "r654",
      "r677",
      "r788",
      "r800",
      "r834"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets",
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r214",
      "r760"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails",
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and Cash Equivalents at Beginning of Period",
        "periodEndLabel": "Cash and Cash Equivalents at End of Period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r131",
      "r245"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails",
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Decrease in Cash and Cash Equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r131"
     ]
    },
    "us-gaap_CashFDICInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFDICInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, FDIC insured amount",
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_CashFeePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "CashFeePercentage",
     "presentation": [
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:CashFeePercentage-0]",
        "documentation": "Cash fee percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Schedule of Non-Cash Investing and Financing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_ChannelPartnersCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "ChannelPartnersCapitalMember",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Channel Partners Capital [Member]",
        "documentation": "Channel Partners Capital [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets",
      "http://neuraxis.com/role/BalanceSheetsParenthetical",
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative",
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative",
      "http://neuraxis.com/role/PreferredStockDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails",
      "http://neuraxis.com/role/StatementsOfStockholdersDeficit",
      "http://neuraxis.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r220",
      "r221",
      "r222",
      "r248",
      "r275",
      "r276",
      "r279",
      "r281",
      "r285",
      "r286",
      "r312",
      "r344",
      "r346",
      "r347",
      "r348",
      "r351",
      "r352",
      "r382",
      "r383",
      "r385",
      "r386",
      "r389",
      "r525",
      "r634",
      "r635",
      "r636",
      "r637",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r655",
      "r669",
      "r691",
      "r714",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r823",
      "r845",
      "r856"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://neuraxis.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r220",
      "r221",
      "r222",
      "r285",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r388",
      "r389",
      "r634",
      "r635",
      "r636",
      "r637",
      "r778",
      "r823",
      "r845"
     ]
    },
    "NRXS_ClassOfWarrantDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "ClassOfWarrantDiscountRate",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of warrant discount rate",
        "documentation": "Class of warrant discount rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative",
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative",
      "http://neuraxis.com/role/NotesPayableDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "verboseLabel": "Exercise price",
        "terseLabel": "Exercise Price",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of warrants received",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Warrants",
        "verboseLabel": "Number of warrants",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightReasonForIssuingToNonemployees",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant, description",
        "documentation": "Description of reason for issuing warrant or right."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and contingencies (see note 14)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r104",
      "r606",
      "r668"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://neuraxis.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r338",
      "r339",
      "r743",
      "r867"
     ]
    },
    "NRXS_CommonStockAndWarrantsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "CommonStockAndWarrantsDisclosureTextBlock",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrants"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock and Warrants",
        "documentation": "Common stock and warrants disclosure [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative",
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative",
      "http://neuraxis.com/role/CommonStockAndWarrantsTables",
      "http://neuraxis.com/role/NotesPayableDetailsNarrative",
      "http://neuraxis.com/role/PreferredStockDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfWarrantActivityForCommonStockDetails",
      "http://neuraxis.com/role/StatementsOfStockholdersDeficit",
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r790",
      "r791",
      "r792",
      "r794",
      "r795",
      "r796",
      "r797",
      "r850",
      "r851",
      "r913",
      "r939",
      "r943"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://neuraxis.com/role/BalanceSheetsParenthetical",
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://neuraxis.com/role/BalanceSheetsParenthetical",
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative",
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative",
      "http://neuraxis.com/role/StockOptionsAndAwardsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "verboseLabel": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r669"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://neuraxis.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://neuraxis.com/role/BalanceSheetsParenthetical",
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "verboseLabel": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r118",
      "r669",
      "r688",
      "r943",
      "r944"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets",
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, $0.001 par value; 100,000,000 shares authorized; 6,508,897 issued and outstanding as of December 31, 2023 and 1,963,322 as of December 31, 2022",
        "verboseLabel": "Common stock",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r609",
      "r788"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfEstimatedUsefulLivesDetails",
      "http://neuraxis.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfCustomersAccountedRevenuesDetails",
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r59",
      "r93",
      "r94",
      "r303",
      "r742"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfCustomersAccountedRevenuesDetails",
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r59",
      "r93",
      "r94",
      "r303",
      "r630",
      "r742"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfCustomersAccountedRevenuesDetails",
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r59",
      "r93",
      "r94",
      "r303",
      "r742",
      "r827"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentrations of Credit Risk",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r180"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfCustomersAccountedRevenuesDetails",
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r59",
      "r93",
      "r94",
      "r303"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfCustomersAccountedRevenuesDetails",
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r59",
      "r93",
      "r94",
      "r303",
      "r742"
     ]
    },
    "srt_ConsolidatedEntitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidatedEntitiesAxis",
     "presentation": [
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]"
       }
      }
     },
     "auth_ref": [
      "r252",
      "r488",
      "r489",
      "r490",
      "r491",
      "r569",
      "r755",
      "r872",
      "r875",
      "r876"
     ]
    },
    "srt_ConsolidatedEntitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidatedEntitiesDomain",
     "presentation": [
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative"
     ],
     "auth_ref": [
      "r252",
      "r488",
      "r489",
      "r490",
      "r491",
      "r569",
      "r755",
      "r872",
      "r875",
      "r876"
     ]
    },
    "NRXS_ConsultingAgreementWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "ConsultingAgreementWarrantsMember",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consulting Agreement Warrants [Member]",
        "documentation": "Consulting Agreement Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Customers Accounted Revenues",
        "documentation": "Tabular disclosure of allowance for credit loss on right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time."
       }
      }
     },
     "auth_ref": [
      "r864"
     ]
    },
    "NRXS_ConversionOfPreferredStockToCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "ConversionOfPreferredStockToCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of preferred stock to common stock",
        "documentation": "Conversion of preferred stock to common stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConversionOfStockAmountConverted1",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion amount",
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r45",
      "r46"
     ]
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConversionOfStockSharesConverted1",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative",
      "http://neuraxis.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock value converted",
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r45",
      "r46"
     ]
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConversionOfStockSharesIssued1",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Stock, Shares Issued",
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r45",
      "r46"
     ]
    },
    "NRXS_ConvertibleBridgeDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "ConvertibleBridgeDebtMember",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfDilutiveCommonStockEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Bridge Debt [Member]",
        "documentation": "Convertible Bridge Debt [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleDebt",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible debt",
        "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r162",
      "r935"
     ]
    },
    "us-gaap_ConvertibleDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleDebtMember",
     "presentation": [
      "http://neuraxis.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt [Member]",
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r354",
      "r355",
      "r365",
      "r366",
      "r367",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777"
     ]
    },
    "us-gaap_ConvertibleDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleDebtTableTextBlock",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Convertible Notes",
        "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleNotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleNotesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes payable - convertible notes, net of unamortized discount of $0 and $3,327,213 as of December 31, 2023 and December 31, 2022",
        "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_ConvertibleNotesPayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertibleNotesPayableMember",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Notes Payable [Member]",
        "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r161"
     ]
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r75",
      "r117",
      "r147",
      "r387"
     ]
    },
    "NRXS_ConvertiblePromissoryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "ConvertiblePromissoryNoteMember",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Promissory Note [Member]",
        "documentation": "Convertible Promissory Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_ConvertibleSeriesAPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "ConvertibleSeriesAPreferredStockMember",
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets",
      "http://neuraxis.com/role/BalanceSheetsParenthetical",
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative",
      "http://neuraxis.com/role/PreferredStockDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfDilutiveCommonStockEquivalentsDetails",
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails",
      "http://neuraxis.com/role/StatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Series A Preferred stock [Member]",
        "documentation": "Convertible Series A Preferred stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_ConvertibleSeriesSeedPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "ConvertibleSeriesSeedPreferredStockMember",
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets",
      "http://neuraxis.com/role/BalanceSheetsParenthetical",
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative",
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative",
      "http://neuraxis.com/role/PreferredStockDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfDilutiveCommonStockEquivalentsDetails",
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails",
      "http://neuraxis.com/role/StatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Series Seed Preferred Stock [Member]",
        "documentation": "Convertible Series Seed Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails",
      "http://neuraxis.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Goods Sold",
        "verboseLabel": "Cost of goods sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r582"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfCustomersAccountedRevenuesDetails",
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r303"
     ]
    },
    "NRXS_CustomerFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "CustomerFourMember",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Four [Member]",
        "documentation": "Customer Four [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_CustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "CustomerMember",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Member]",
        "documentation": "Customer [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_CustomerOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "CustomerOneMember",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer One [Member]",
        "documentation": "Customer One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_CustomerThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "CustomerThreeMember",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Three [Member]",
        "documentation": "Customer Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_CustomerTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "CustomerTwoMember",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Two [Member]",
        "documentation": "Customer Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Conversion, Converted Instrument, Shares Issued",
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r46"
     ]
    },
    "us-gaap_DebtConversionOriginalDebtInterestRateOfDebt": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtConversionOriginalDebtInterestRateOfDebt",
     "presentation": [
      "http://neuraxis.com/role/PreferredStockDetailsNarrative",
      "http://neuraxis.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt conversion, original debt, interest rate of debt",
        "documentation": "The rate of interest that was being paid on the original debt issue that is being converted in the noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r46"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://neuraxis.com/role/NotesPayable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Payable",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r247",
      "r353",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r369",
      "r376",
      "r377",
      "r378"
     ]
    },
    "us-gaap_DebtInstrumentAnnualPrincipalPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAnnualPrincipalPayment",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative",
      "http://neuraxis.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum principal payment",
        "verboseLabel": "Total principal amount",
        "documentation": "Amount of the total principal payments made during the annual reporting period."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfRelatedPartyLoansPayableToShareholderDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r114",
      "r115",
      "r161",
      "r162",
      "r252",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r360",
      "r365",
      "r366",
      "r367",
      "r368",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r541",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r846"
     ]
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt instrument gross",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r162",
      "r379"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative",
      "http://neuraxis.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion price",
        "verboseLabel": "Debt instrument, convertible, conversion price",
        "documentation": "The price per share of the conversion feature embedded in the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r356"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative",
      "http://neuraxis.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Strilke price",
        "verboseLabel": "Conversion ratio",
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r75",
      "r147",
      "r148",
      "r356"
     ]
    },
    "us-gaap_DebtInstrumentDescriptionOfVariableRateBasis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentDescriptionOfVariableRateBasis",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt instrument description",
        "documentation": "Description of reference rate used for variable rate of debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_DebtInstrumentDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "DebtInstrumentDiscountRate",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt instrument discount rate",
        "documentation": "Debt instrument discount rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative",
      "http://neuraxis.com/role/PreferredStockDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principal",
        "verboseLabel": "Principal of warrants and common shares fair value",
        "terseLabel": "Debt instrument, face amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r98",
      "r354",
      "r541",
      "r774",
      "r775"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative",
      "http://neuraxis.com/role/NotesPayableDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfRelatedPartyLoansPayableToShareholderDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt instrument percentage",
        "verboseLabel": "Accrued interest",
        "terseLabel": "Interest rate",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r355"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDateDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentMaturityDateDescription",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRelatedPartyLoansPayableToShareholderDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Due date",
        "documentation": "Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfRelatedPartyLoansPayableToShareholderDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r252",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r360",
      "r365",
      "r366",
      "r367",
      "r368",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r541",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r846"
     ]
    },
    "us-gaap_DebtInstrumentPeriodicPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentPeriodicPayment",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative",
      "http://neuraxis.com/role/PreferredStockDetailsNarrative",
      "http://neuraxis.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt instrument, periodic payment",
        "verboseLabel": "Principal amount due in monthly installments",
        "documentation": "Amount of the required periodic payments including both interest and principal payments."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r105"
     ]
    },
    "NRXS_DebtInstrumentPrincipalAmount": {
     "xbrltype": "percentItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "DebtInstrumentPrincipalAmount",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principal amount in percent",
        "documentation": "Debt instrument principal amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentRepurchasedFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentRepurchasedFaceAmount",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principal balance back",
        "documentation": "Face (par) amount of the original debt instrument that was repurchased."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentUnamortizedDiscount",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Debt discount",
        "label": "Debt Instrument, Unamortized Discount",
        "documentation": "Amount, after accumulated amortization, of debt discount."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r98",
      "r878"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentUnamortizedDiscountCurrent",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/BalanceSheetsParenthetical",
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unamortized discount, net",
        "verboseLabel": "Debt discount",
        "documentation": "Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r98"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Original issue discount",
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r365",
      "r380",
      "r774",
      "r775"
     ]
    },
    "NRXS_DebtWarrantConversionDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "DebtWarrantConversionDescription",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt warrant conversion, description",
        "documentation": "Debt warrant conversion description."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredChargesPolicyTextBlock",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Offering Costs",
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges."
       }
      }
     },
     "auth_ref": [
      "r218"
     ]
    },
    "us-gaap_DeferredCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCosts",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred offering costs",
        "documentation": "Amount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r835"
     ]
    },
    "us-gaap_DeferredFinanceCostsCurrentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFinanceCostsCurrentNet",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Original issue discount",
        "label": "Debt Issuance Costs, Current, Net",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFinanceCostsNet",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Deferred financing fees",
        "label": "Debt Issuance Costs, Net",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r878"
     ]
    },
    "us-gaap_DeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative",
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred offering costs",
        "label": "Deferred Offering Costs [Default Label]",
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "NRXS_DeferredOfferingCostsPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "DeferredOfferingCostsPaid",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deferred offering costs paid",
        "documentation": "Deferred offering costs paid.",
        "label": "DeferredOfferingCostsPaid"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_DeferredTaxAssetsAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "DeferredTaxAssetsAmortization",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfDeferredTaxAssetDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfDeferredTaxAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization",
        "documentation": "Deferred tax assets amortization."
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_DeferredTaxAssetsDepreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "DeferredTaxAssetsDepreciation",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfDeferredTaxAssetDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfDeferredTaxAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "documentation": "Deferred tax assets depreciation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfDeferredTaxAssetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfDeferredTaxAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred tax assets, net of valuation allowance",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r909"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfDeferredTaxAssetDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfDeferredTaxAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected income tax benefit from NOL carry-forwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r910"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/IncomeTaxesDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfStateCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State Carryforwards",
        "verboseLabel": "Federal and state net operating loss",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r910"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development expense",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r88",
      "r910"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfDeferredTaxAssetDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfDeferredTaxAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r910"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfDeferredTaxAssetDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfDeferredTaxAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrual to cash",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from reserves and accruals, classified as other."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r910"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfDeferredTaxAssetDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfDeferredTaxAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r471"
     ]
    },
    "us-gaap_DefinedContributionPlanAdministrativeExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanAdministrativeExpenses",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/RetirementPlanDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit sharing contribution expenses",
        "documentation": "Amount of administrative expense incurred by defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "presentation": [
      "http://neuraxis.com/role/RetirementPlanDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee contribution percentage",
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepositContractsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepositContractsPolicy",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Deposits",
        "documentation": "Disclosure of accounting policy for the treatment of funds received from or paid to insureds, insurers and reinsurers on contracts for which the criteria for transferring or assuming insurance risk has not been satisfied by the insurer or reinsurer."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "us-gaap_DepositLiabilitiesAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepositLiabilitiesAccruedInterest",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deposit Liabilities, Accrued Interest",
        "documentation": "Amount of accrued but unpaid interest on deposit liabilities."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_Deposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Deposits",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets",
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails",
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer deposits",
        "documentation": "The aggregate of all deposit liabilities held by the entity, including foreign and domestic, interest and noninterest bearing; may include demand deposits, saving deposits, Negotiable Order of Withdrawal (NOW) and time deposits among others."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/PropertyAndEquipmentDetailsNarrative",
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation expense",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r67"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails",
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation and amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r291"
     ]
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeGainLossOnDerivativeNet",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      },
      "http://neuraxis.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails",
      "http://neuraxis.com/role/StatementsOfCashFlows",
      "http://neuraxis.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in fair value of derivative liability",
        "negatedLabel": "Change in fair value of derivative liabilities",
        "verboseLabel": "Change in fair value of derivative financial instruments",
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement."
       }
      }
     },
     "auth_ref": [
      "r912"
     ]
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfFairValueOnRecurringBasisAssetsAndLiabilityDetails": {
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0,
       "order": 2.0
      },
      "http://neuraxis.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets",
      "http://neuraxis.com/role/ScheduleOfChangesInDerivativeLiabilitiesDetails",
      "http://neuraxis.com/role/ScheduleOfFairValueOnRecurringBasisAssetsAndLiabilityDetails",
      "http://neuraxis.com/role/ScheduleOfUnobservableInputsForLevel3AssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative liabilities",
        "periodStartLabel": "Derivative liabilities, Beginning balance",
        "periodEndLabel": "Derivative liabilities, Ending balance",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r228"
     ]
    },
    "us-gaap_DerivativeLiabilityMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLiabilityMeasurementInput",
     "presentation": [
      "http://neuraxis.com/role/DerivativeLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative liability, measurement input",
        "documentation": "Value of input used to measure derivative liability."
       }
      }
     },
     "auth_ref": [
      "r520"
     ]
    },
    "NRXS_DerivativeLiabilityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "DerivativeLiabilityPolicyTextBlock",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Derivative Liabilities",
        "documentation": "Derivative liability [Policy Text Block]",
        "label": "DerivativeLiabilityPolicyTextBlock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativesAndFairValueTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativesAndFairValueTextBlock",
     "presentation": [
      "http://neuraxis.com/role/DerivativeLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Derivative Liabilities",
        "label": "Derivatives and Fair Value [Text Block]",
        "documentation": "The entire disclosure for derivatives and fair value of assets and liabilities."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r158"
     ]
    },
    "NRXS_DescriptionOfExecutiveEmploymentAgreementsRenewals": {
     "xbrltype": "stringItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "DescriptionOfExecutiveEmploymentAgreementsRenewals",
     "presentation": [
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of Executive employment agreements renewals",
        "documentation": "Description of executive employment agreements renewals."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Disaggregation of Revenue",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "NRXS_DisclosureCommonStockAndWarrantsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "DisclosureCommonStockAndWarrantsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock And Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_DisclosureDerivativeLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "DisclosureDerivativeLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_DisclosureHealthBenefitPlanAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "DisclosureHealthBenefitPlanAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Health Benefit Plan"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_DisclosureLeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "DisclosureLeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases",
        "verboseLabel": "Schedule Of Operating Leases",
        "terseLabel": "Schedule Of Maturities Operating Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://neuraxis.com/role/StockOptionsAndAwards"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options and Awards",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r415",
      "r419",
      "r450",
      "r451",
      "r452",
      "r785"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_DisclosureWarrantLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "DisclosureWarrantLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DividendsPreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DividendsPreferredStock",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock dividend",
        "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK)."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r149"
     ]
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r812",
      "r814",
      "r815"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r812",
      "r814",
      "r815",
      "r817"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r801"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://neuraxis.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Per-share Data"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails",
      "http://neuraxis.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Per-share Data, basic loss per share",
        "verboseLabel": "Basic net loss per share",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r261",
      "r262",
      "r264",
      "r265",
      "r267",
      "r272",
      "r275",
      "r279",
      "r280",
      "r281",
      "r283",
      "r512",
      "r513",
      "r601",
      "r616",
      "r767"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails",
      "http://neuraxis.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Per-share Data, diluted loss per share",
        "verboseLabel": "Diluted net loss per share",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r261",
      "r262",
      "r264",
      "r265",
      "r267",
      "r275",
      "r279",
      "r280",
      "r281",
      "r283",
      "r512",
      "r513",
      "r601",
      "r616",
      "r767"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic and Diluted Net Income (Loss) per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r54"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfFederalStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfFederalStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective income tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r467"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfFederalStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfFederalStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal statutory income tax rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r249",
      "r467",
      "r480"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfFederalStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfFederalStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in valuation allowance on net deferred tax assets",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r908",
      "r911"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfFederalStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfFederalStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nondeductible expenses",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r908",
      "r911"
     ]
    },
    "NRXS_EffectiveIncomeTaxRateReconciliationNontaxableIncome": {
     "xbrltype": "percentItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationNontaxableIncome",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfFederalStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfFederalStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nontaxable income",
        "documentation": "Percentage of nontaxable income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfFederalStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfFederalStatutoryIncomeTaxRateAndEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State tax rate, net of federal benefit",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r908",
      "r911"
     ]
    },
    "us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of embedded derivative",
        "documentation": "Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/StockOptionsAndAwardsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized compensation expense",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r907"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative",
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative",
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative",
      "http://neuraxis.com/role/CommonStockAndWarrantsTables",
      "http://neuraxis.com/role/NotesPayableDetailsNarrative",
      "http://neuraxis.com/role/PreferredStockDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfWarrantActivityForCommonStockDetails",
      "http://neuraxis.com/role/ScheduleOfWarrantActivityForPreferredStockDetails",
      "http://neuraxis.com/role/StatementsOfStockholdersDeficit",
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r206",
      "r232",
      "r233",
      "r234",
      "r253",
      "r254",
      "r255",
      "r258",
      "r268",
      "r270",
      "r284",
      "r316",
      "r322",
      "r391",
      "r453",
      "r454",
      "r455",
      "r477",
      "r478",
      "r495",
      "r497",
      "r498",
      "r499",
      "r500",
      "r502",
      "r511",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r560",
      "r620",
      "r621",
      "r622",
      "r643",
      "r714"
     ]
    },
    "us-gaap_ErrorCorrectionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ErrorCorrectionTextBlock",
     "presentation": [
      "http://neuraxis.com/role/RestatementOfInterimFinancialStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement of Interim Financial Statements (Unaudited)",
        "documentation": "The entire disclosure for reporting error correction."
       }
      }
     },
     "auth_ref": [
      "r266"
     ]
    },
    "us-gaap_EscrowDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EscrowDeposit",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Escrow deposit",
        "documentation": "The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r744"
     ]
    },
    "NRXS_ExchangeListingLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "ExchangeListingLLCMember",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exchange Listing LLC [Member]",
        "documentation": "Exchange Listing LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_ExecutiveEmploymentAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "ExecutiveEmploymentAgreementsMember",
     "presentation": [
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Employment Agreements [Member]",
        "documentation": "Executive Employment Agreements [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_ExecutiveEmploymentAgreementsTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "ExecutiveEmploymentAgreementsTerms",
     "presentation": [
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive employment agreements renewals",
        "documentation": "Executive employment agreements terms."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ExtendedProductWarrantyPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ExtendedProductWarrantyPolicy",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warranties",
        "documentation": "Disclosure of accounting policy for extended product warranties and other guarantee contracts including the methodology for measuring the liability."
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Extension",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_ExtinguishmentOfDerivativeLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "ExtinguishmentOfDerivativeLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfChangesInDerivativeLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extinguishment of Derivative liabilities",
        "documentation": "Extinguishment of derivative liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "stpr_FL": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2023",
     "localname": "FL",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfDisaggregationOfRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "FLORIDA"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 3.0
      },
      "http://neuraxis.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfChangesInWarrantLiabilitiesDetails",
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails",
      "http://neuraxis.com/role/StatementsOfCashFlows",
      "http://neuraxis.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in fair value of warrant liability",
        "label": "Change in fair value of warrant liabilities",
        "verboseLabel": "Fair value adjustment of warrants",
        "terseLabel": "Changes in fair value of warrant liabilities",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r8"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfFairValueOnRecurringBasisAssetsAndLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r516",
      "r517",
      "r521"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfFairValueOnRecurringBasisAssetsAndLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r516",
      "r517",
      "r521"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://neuraxis.com/role/DerivativeLiabilitiesDetailsNarrative",
      "http://neuraxis.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://neuraxis.com/role/DerivativeLiabilitiesDetailsNarrative",
      "http://neuraxis.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Unobservable Inputs for Level 3 Assets and Liabilities",
        "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r92"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfChangesInDerivativeLiabilitiesDetails",
      "http://neuraxis.com/role/ScheduleOfChangesInWarrantLiabilitiesDetails",
      "http://neuraxis.com/role/ScheduleOfFairValueOnRecurringBasisAssetsAndLiabilityDetails",
      "http://neuraxis.com/role/ScheduleOfUnobservableInputsForLevel3AssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r367",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r517",
      "r573",
      "r574",
      "r575",
      "r774",
      "r775",
      "r781",
      "r782",
      "r783"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfFairValueOnRecurringBasisAssetsAndLiabilityDetails",
      "http://neuraxis.com/role/ScheduleOfUnobservableInputsForLevel3AssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r516",
      "r517",
      "r519",
      "r520",
      "r522"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfChangesInDerivativeLiabilitiesDetails",
      "http://neuraxis.com/role/ScheduleOfChangesInWarrantLiabilitiesDetails",
      "http://neuraxis.com/role/ScheduleOfFairValueOnRecurringBasisAssetsAndLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r367",
      "r397",
      "r402",
      "r517",
      "r573",
      "r781",
      "r782",
      "r783"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfChangesInDerivativeLiabilitiesDetails",
      "http://neuraxis.com/role/ScheduleOfChangesInWarrantLiabilitiesDetails",
      "http://neuraxis.com/role/ScheduleOfFairValueOnRecurringBasisAssetsAndLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r367",
      "r397",
      "r402",
      "r517",
      "r574",
      "r774",
      "r775",
      "r781",
      "r782",
      "r783"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfChangesInDerivativeLiabilitiesDetails",
      "http://neuraxis.com/role/ScheduleOfChangesInWarrantLiabilitiesDetails",
      "http://neuraxis.com/role/ScheduleOfFairValueOnRecurringBasisAssetsAndLiabilityDetails",
      "http://neuraxis.com/role/ScheduleOfUnobservableInputsForLevel3AssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r367",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r517",
      "r575",
      "r774",
      "r775",
      "r781",
      "r782",
      "r783"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfFairValueOnRecurringBasisAssetsAndLiabilityDetails",
      "http://neuraxis.com/role/ScheduleOfUnobservableInputsForLevel3AssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfChangesInDerivativeLiabilitiesDetails",
      "http://neuraxis.com/role/ScheduleOfChangesInWarrantLiabilitiesDetails",
      "http://neuraxis.com/role/ScheduleOfFairValueOnRecurringBasisAssetsAndLiabilityDetails",
      "http://neuraxis.com/role/ScheduleOfUnobservableInputsForLevel3AssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r367",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r573",
      "r574",
      "r575",
      "r774",
      "r775",
      "r781",
      "r782",
      "r783"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfFairValueOnRecurringBasisAssetsAndLiabilityDetails",
      "http://neuraxis.com/role/ScheduleOfUnobservableInputsForLevel3AssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r515",
      "r522"
     ]
    },
    "NRXS_FairValueOfDerivativeLiabilitiesOfConversionFeatureFromConvertibleNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "FairValueOfDerivativeLiabilitiesOfConversionFeatureFromConvertibleNotes",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of derivative liabilities of conversion feature from convertible notes",
        "documentation": "Fair value of derivative liabilities of conversion feature from convertible notes."
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_FairValueOfWarrantLiabilitiesOfWarrantsFromConvertibleNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "FairValueOfWarrantLiabilitiesOfWarrantsFromConvertibleNotes",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of warrant liabilities of warrants from convertible notes",
        "documentation": "Fair value of warrant liabilities of warrants from convertible notes."
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_FinanceCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "FinanceCharges",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails",
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Charges",
        "verboseLabel": "Finance charges",
        "documentation": "Finance charges."
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_FinancingCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "FinancingCharges",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails",
      "http://neuraxis.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Financing charges",
        "documentation": "Financing charges.",
        "label": "FinancingCharges"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: accumulated amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r333"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r332",
      "r333",
      "r334",
      "r583",
      "r587"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total intangible assets",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r587"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r583"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r65"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      },
      "http://neuraxis.com/role/ScheduleOfIntangibleAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets",
      "http://neuraxis.com/role/ScheduleOfIntangibleAssetsDetails",
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible assets, net",
        "verboseLabel": "Intangible assets",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r583"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfEstimatedUsefulLivesDetails",
      "http://neuraxis.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 6.0
      },
      "http://neuraxis.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative",
      "http://neuraxis.com/role/RestatementOfInterimFinancialStatementsDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails",
      "http://neuraxis.com/role/StatementsOfCashFlows",
      "http://neuraxis.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extinguishment of debt liabilities",
        "negatedLabel": "Extinguishment of debt liabilities",
        "verboseLabel": "Extinguishment of debt",
        "negatedTerseLabel": "Extinguishment of derivative liability",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r70",
      "r71"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails",
      "http://neuraxis.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative",
        "verboseLabel": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r693"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://neuraxis.com/role/StockOptionsAndAwardsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "us-gaap_GeographicDistributionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeographicDistributionAxis",
     "presentation": [
      "http://neuraxis.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographic Distribution [Axis]",
        "documentation": "Information by geographic distribution of business activity identified as either domestic or foreign. Excludes names of countries, states and provinces, and cities."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r602",
      "r603",
      "r772"
     ]
    },
    "us-gaap_GeographicDistributionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeographicDistributionDomain",
     "presentation": [
      "http://neuraxis.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allocation of business activity identified as domestic or foreign. Excludes names of countries, states and provinces, and cities."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r602",
      "r603"
     ]
    },
    "NRXS_GoingConcernPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "GoingConcernPolicyTextBlock",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Going Concern",
        "documentation": "Going Concern [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails",
      "http://neuraxis.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross Profit",
        "label": "Gross Profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r126",
      "r248",
      "r287",
      "r293",
      "r297",
      "r299",
      "r312",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r525",
      "r769",
      "r873"
     ]
    },
    "NRXS_HealthBenefitPlanDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "HealthBenefitPlanDisclosureTextBlock",
     "presentation": [
      "http://neuraxis.com/role/HealthBenefitPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Health Benefit Plan",
        "documentation": "Health benefit plan disclosure [Text Block]",
        "label": "HealthBenefitPlanDisclosureTextBlock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_HealthCareOrganizationStopLossInsurancePremiumExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "HealthCareOrganizationStopLossInsurancePremiumExpense",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/HealthBenefitPlanDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stop loss insurance premium expense",
        "documentation": "Stop-loss insurance premiums recognized as expense. In stop-loss insurance, prepaid health care providers or associated entities transfer portions of their financial risks to other companies. A provider typically contracts to recover health care costs in excess of stated amounts during the contract periods."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r745"
     ]
    },
    "NRXS_HealthCareOrganizationStopLossInsurancePremiumPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "HealthCareOrganizationStopLossInsurancePremiumPercentage",
     "presentation": [
      "http://neuraxis.com/role/HealthBenefitPlanDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stop loss insurance premium percentage",
        "documentation": "Health care organization stop loss insurance premium percentage."
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_HospitalAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "HospitalAMember",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfCustomersAccountedRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Hospital A [Member]",
        "documentation": "Hospital A [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_HospitalBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "HospitalBMember",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfCustomersAccountedRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Hospital B [Member]",
        "documentation": "Hospital B [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_HospitalCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "HospitalCMember",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfCustomersAccountedRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Hospital C [Member]",
        "documentation": "Hospital C [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_HospitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "HospitalMember",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfCustomersAccountedRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Hospital [Member]",
        "documentation": "Hospital [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IPOMember",
     "presentation": [
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative",
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "IPO [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r812",
      "r814",
      "r815"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Long-Lived Assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r140"
     ]
    },
    "us-gaap_IncentiveFeeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncentiveFeeExpense",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incentive Fee Expense",
        "documentation": "Amount of expense for incentive fee based on performance under arrangement to manage operations, including, but not limited to, investment."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r942"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://neuraxis.com/role/StockOptionsAndAwardsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r337",
      "r698"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://neuraxis.com/role/StockOptionsAndAwardsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r698"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://neuraxis.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r249",
      "r464",
      "r468",
      "r469",
      "r473",
      "r479",
      "r481",
      "r482",
      "r483",
      "r639"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r465",
      "r466",
      "r469",
      "r470",
      "r472",
      "r474",
      "r633"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax assets valuation allowance",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r908"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for income taxes",
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails",
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails",
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails",
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued expenses",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "NRXS_IncreaseDecreaseInCustomerDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "IncreaseDecreaseInCustomerDeposit",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails",
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Customer deposits",
        "documentation": "Increase decrease in customer deposit.",
        "label": "IncreaseDecreaseInCustomerDeposit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInDerivativeLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInDerivativeLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfChangesInDerivativeLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in fair value of Derivative liabilities",
        "documentation": "The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer)."
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails",
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventory",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails",
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails",
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r830",
      "r842"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails",
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaids and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "NRXS_IncreaseDecreaseInWarrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "IncreaseDecreaseInWarrantLiability",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/RestatementOfInterimFinancialStatementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reduced warrant liability",
        "documentation": "Reduced warrant liability."
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_InitialPaymentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "InitialPaymentMember",
     "presentation": [
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Initial Payment [Member]",
        "documentation": "Initial Payment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://neuraxis.com/role/IntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Intangible Assets",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r579",
      "r580",
      "r581",
      "r583",
      "r764"
     ]
    },
    "us-gaap_InterestAndOtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestAndOtherIncome",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income",
        "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_InterestAndServiceFeeAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "InterestAndServiceFeeAccrued",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRelatedPartyLoansPayableToShareholderDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest payable",
        "documentation": "Interest and service fee accrued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails",
      "http://neuraxis.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r166",
      "r235",
      "r290",
      "r539",
      "r699",
      "r798",
      "r941"
     ]
    },
    "NRXS_InterestIncomeCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "InterestIncomeCurrent",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Interest Income",
        "documentation": "Interest income current.",
        "label": "InterestIncomeCurrent"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_InterestIncomeGrossCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "InterestIncomeGrossCurrent",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Income",
        "documentation": "Interest income gross current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaid",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRelatedPartyLoansPayableToShareholderDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Interest payable",
        "label": "Interest Paid, Including Capitalized Interest, Operating and Investing Activities",
        "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities."
       }
      }
     },
     "auth_ref": [
      "r844"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r243",
      "r244"
     ]
    },
    "us-gaap_InterestPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest",
        "verboseLabel": "Accrued interest",
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_InterestReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestReceivable",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Interest Receivable",
        "label": "Interest Receivable [Default Label]",
        "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable."
       }
      }
     },
     "auth_ref": [
      "r838",
      "r945"
     ]
    },
    "us-gaap_InterestReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestReceivableCurrent",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Receivable",
        "negatedLabel": "Allowance for collection risk, interest receivable",
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r838"
     ]
    },
    "NRXS_InventoryExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "InventoryExpenses",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory expenses",
        "documentation": "Inventory expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets",
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventories",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r761",
      "r788"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Inventories",
        "label": "Inventory, Policy [Policy Text Block]",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r176",
      "r213",
      "r225",
      "r327",
      "r328",
      "r329",
      "r578",
      "r765"
     ]
    },
    "NRXS_InvestorWarrantOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "InvestorWarrantOneMember",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investor Warrant W-01 [Member]",
        "documentation": "Investor Warrant W-01 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_InvestorWarrantPSAOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "InvestorWarrantPSAOneMember",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investor Warrant PSA-01 [Member]",
        "documentation": "Investor Warrant PSA-01 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_InvestorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "InvestorsMember",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investors [Member]",
        "documentation": "Investors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_IssuanceOfCommonStockForNoncashConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "IssuanceOfCommonStockForNoncashConsideration",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails",
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock for non-cash consideration",
        "documentation": "Issuance of common stock for noncash consideration."
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_KeyEmployeeExercisePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "KeyEmployeeExercisePercentage",
     "presentation": [
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Key employee exercise percentage",
        "documentation": "Key employee exercise percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseContractualTermAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseContractualTermAxis",
     "presentation": [
      "http://neuraxis.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Axis]",
        "documentation": "Information by contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "us-gaap_LeaseContractualTermDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseContractualTermDomain",
     "presentation": [
      "http://neuraxis.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "NRXS_LeaseOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "LeaseOneMember",
     "presentation": [
      "http://neuraxis.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease 1 [Member]",
        "documentation": "Lease 1 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_LeaseThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "LeaseThreeMember",
     "presentation": [
      "http://neuraxis.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease 3 [Member]",
        "documentation": "Lease 3 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_LeaseTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "LeaseTwoMember",
     "presentation": [
      "http://neuraxis.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease 2 [Member]",
        "documentation": "Lease 2 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfEstimatedUsefulLivesDetails",
      "http://neuraxis.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative",
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r550"
     ]
    },
    "us-gaap_LesseeOperatingLeaseDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseDescription",
     "presentation": [
      "http://neuraxis.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease description",
        "documentation": "Description of lessee's operating lease."
       }
      }
     },
     "auth_ref": [
      "r551"
     ]
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseDiscountRate",
     "presentation": [
      "http://neuraxis.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease payment rate",
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments."
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://neuraxis.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Maturities Operating Lease Liabilities",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r919"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfMaturitiesOperatingLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfMaturitiesOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r555"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfMaturitiesOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfMaturitiesOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2024",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r555"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfMaturitiesOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfMaturitiesOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r555"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfMaturitiesOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfMaturitiesOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r555"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfMaturitiesOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Less: imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r555"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://neuraxis.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r546"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets",
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities [Default Label]",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r248",
      "r312",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r489",
      "r490",
      "r491",
      "r525",
      "r667",
      "r768",
      "r800",
      "r873",
      "r924",
      "r925"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets",
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities and Stockholders\u2019 Deficit",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r163",
      "r611",
      "r788",
      "r847",
      "r860",
      "r917"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets",
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "verboseLabel": "Liabilities and Stockholders\u2019 Deficit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets",
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r212",
      "r248",
      "r312",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r489",
      "r490",
      "r491",
      "r525",
      "r788",
      "r873",
      "r924",
      "r925"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets",
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Liabilities:",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfFairValueOnRecurringBasisAssetsAndLiabilityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfFairValueOnRecurringBasisAssetsAndLiabilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Liabilities",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current liabilities",
        "label": "Liabilities, Noncurrent",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r110",
      "r111",
      "r112",
      "r116",
      "r248",
      "r312",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r489",
      "r490",
      "r491",
      "r525",
      "r873",
      "r924",
      "r925"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current Liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_LicenseFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "LicenseFees",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License fees",
        "documentation": "License fees."
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_LicensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "LicensesMember",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Licenses [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_LicensingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "LicensingAgreementMember",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Licensing Agreement [Member]",
        "documentation": "Licensing Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LoansPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LoansPayable",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRelatedPartyLoansPayableToShareholderDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan payable",
        "documentation": "Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r162",
      "r935"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfConvertibleNotesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes payable",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r162",
      "r366",
      "r381",
      "r774",
      "r775",
      "r935"
     ]
    },
    "us-gaap_LongTermDebtAverageAmountOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtAverageAmountOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Principal outstanding",
        "label": "Long-Term Debt, Average Amount Outstanding",
        "documentation": "Average amount outstanding of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r187",
      "r699"
     ]
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyDamagesSoughtValue",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sought compensatory damages",
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter."
       }
      }
     },
     "auth_ref": [
      "r868",
      "r869",
      "r870"
     ]
    },
    "stpr_MA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2023",
     "localname": "MA",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfDisaggregationOfRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MASSACHUSETTS"
       }
      }
     },
     "auth_ref": []
    },
    "country_MO": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "MO",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfDisaggregationOfRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MACAO"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MachineryAndEquipmentMember",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfEstimatedUsefulLivesDetails",
      "http://neuraxis.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Machinery and Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfCustomersAccountedRevenuesDetails",
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r303",
      "r780",
      "r880",
      "r937",
      "r938"
     ]
    },
    "NRXS_MasimoCorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "MasimoCorporationMember",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Masimo Corporation [Member]",
        "documentation": "Masimo Corporation [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://neuraxis.com/role/DerivativeLiabilitiesDetailsNarrative",
      "http://neuraxis.com/role/NotesPayableDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfEstimatedUsefulLivesDetails",
      "http://neuraxis.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r340",
      "r341",
      "r342",
      "r343",
      "r413",
      "r577",
      "r617",
      "r659",
      "r660",
      "r720",
      "r723",
      "r727",
      "r728",
      "r733",
      "r756",
      "r757",
      "r771",
      "r778",
      "r784",
      "r789",
      "r877",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://neuraxis.com/role/DerivativeLiabilitiesDetailsNarrative",
      "http://neuraxis.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://neuraxis.com/role/DerivativeLiabilitiesDetailsNarrative",
      "http://neuraxis.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Price Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://neuraxis.com/role/DerivativeLiabilitiesDetailsNarrative",
      "http://neuraxis.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputSharePriceMember",
     "presentation": [
      "http://neuraxis.com/role/DerivativeLiabilitiesDetailsNarrative",
      "http://neuraxis.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input, Share Price [Member]",
        "documentation": "Measurement input using share price of saleable stock."
       }
      }
     },
     "auth_ref": [
      "r915"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://neuraxis.com/role/DerivativeLiabilitiesDetailsNarrative",
      "http://neuraxis.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r518"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://neuraxis.com/role/DerivativeLiabilitiesDetailsNarrative",
      "http://neuraxis.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://neuraxis.com/role/DerivativeLiabilitiesDetailsNarrative",
      "http://neuraxis.com/role/NotesPayableDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfEstimatedUsefulLivesDetails",
      "http://neuraxis.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r340",
      "r341",
      "r342",
      "r343",
      "r413",
      "r577",
      "r617",
      "r659",
      "r660",
      "r720",
      "r723",
      "r727",
      "r728",
      "r733",
      "r756",
      "r757",
      "r771",
      "r778",
      "r784",
      "r789",
      "r877",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931"
     ]
    },
    "NRXS_MrSealeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "MrSealeMember",
     "presentation": [
      "http://neuraxis.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mr Seale [Member]",
        "documentation": "Mr Seale [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_MrWatkinsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "MrWatkinsMember",
     "presentation": [
      "http://neuraxis.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mr. Watkins [Member]",
        "documentation": "Mr. Watkins [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfCustomersAccountedRevenuesDetails",
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "auth_ref": [
      "r303",
      "r780",
      "r880",
      "r937",
      "r938"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails",
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r242"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails",
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows from Financing Activities",
        "verboseLabel": "Cash flows from financing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails",
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used by investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r242"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails",
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows from Investing Activities",
        "verboseLabel": "Cash flows from investing activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails",
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used by operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r132",
      "r133"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails",
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flows from Operating Activities",
        "verboseLabel": "Cash flows from operating activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://neuraxis.com/role/StatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://neuraxis.com/role/RestatementOfInterimFinancialStatementsDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails",
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails",
      "http://neuraxis.com/role/StatementsOfCashFlows",
      "http://neuraxis.com/role/StatementsOfOperations",
      "http://neuraxis.com/role/StatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Loss",
        "label": "Net loss",
        "verboseLabel": "Net Loss",
        "negatedLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r133",
      "r165",
      "r210",
      "r229",
      "r230",
      "r234",
      "r248",
      "r257",
      "r261",
      "r262",
      "r264",
      "r265",
      "r269",
      "r270",
      "r277",
      "r287",
      "r293",
      "r297",
      "r299",
      "r312",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r513",
      "r525",
      "r615",
      "r690",
      "r712",
      "r713",
      "r769",
      "r798",
      "r873"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net income (loss) available to common stockholders",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r261",
      "r262",
      "r264",
      "r265",
      "r272",
      "r273",
      "r278",
      "r281",
      "r287",
      "r293",
      "r297",
      "r299",
      "r769"
     ]
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "presentation": [
      "http://neuraxis.com/role/RestatementOfInterimFinancialStatementsDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r264",
      "r271",
      "r283",
      "r310",
      "r311",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r336",
      "r453",
      "r454",
      "r455",
      "r475",
      "r476",
      "r477",
      "r478",
      "r484",
      "r485",
      "r486",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r523",
      "r524",
      "r526",
      "r527",
      "r528",
      "r529",
      "r537",
      "r538",
      "r542",
      "r543",
      "r544",
      "r545",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r584",
      "r585",
      "r586",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r631"
     ]
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "presentation": [
      "http://neuraxis.com/role/RestatementOfInterimFinancialStatementsDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r264",
      "r271",
      "r283",
      "r310",
      "r311",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r336",
      "r453",
      "r454",
      "r455",
      "r475",
      "r476",
      "r477",
      "r478",
      "r484",
      "r485",
      "r486",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r523",
      "r524",
      "r526",
      "r527",
      "r528",
      "r529",
      "r537",
      "r538",
      "r542",
      "r543",
      "r544",
      "r545",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r584",
      "r585",
      "r586",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r631"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recently Adopted Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_NonaccountableExpenseAllowancePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "NonaccountableExpenseAllowancePercentage",
     "presentation": [
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:NonaccountableExpenseAllowancePercentage-0]",
        "documentation": "Nonaccountable expense allowance percentage."
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_NoncashInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "NoncashInterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails",
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash interest expense",
        "documentation": "Noncash interest expense."
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_NoncashLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "NoncashLeaseExpense",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails",
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash lease expense",
        "documentation": "Noncash lease expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails",
      "http://neuraxis.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other (Expense) Income:",
        "verboseLabel": "Other (expense) income, net:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonrelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonrelatedPartyMember",
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets",
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonrelated Party [Member]",
        "documentation": "Party not related to reporting entity."
       }
      }
     },
     "auth_ref": [
      "r848",
      "r849"
     ]
    },
    "us-gaap_NotesAndLoansReceivableGrossCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesAndLoansReceivableGrossCurrent",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan Receivable",
        "documentation": "Amortized cost, before allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r762",
      "r770",
      "r863"
     ]
    },
    "us-gaap_NotesAndLoansReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesAndLoansReceivableNetCurrent",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Loan Receivable",
        "label": "Financing Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amortized cost, after allowance for credit loss, of financing receivable classified as current. Excludes net investment in lease."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r305",
      "r600"
     ]
    },
    "us-gaap_NotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principal outstanding",
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r162",
      "r935"
     ]
    },
    "us-gaap_NotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets",
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes payable",
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "stpr_OH": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2023",
     "localname": "OH",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfDisaggregationOfRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OHIO"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_OfferingCostsInAdvanceOfSaleOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "OfferingCostsInAdvanceOfSaleOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering costs in advance of sale of common stock",
        "documentation": "Offering costs in advance of sale of common stock."
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_OfferingPricePerPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "OfferingPricePerPercentage",
     "presentation": [
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:OfferingPricePerPercentage-0]",
        "documentation": "Offering price per percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails",
      "http://neuraxis.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating Loss",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r293",
      "r297",
      "r299",
      "r769"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r918"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfMaturitiesOperatingLeaseLiabilitiesDetails",
      "http://neuraxis.com/role/ScheduleOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total",
        "verboseLabel": "Total present value of lease payments",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r548"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets",
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current portion of operating lease payable",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r548"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets",
      "http://neuraxis.com/role/ScheduleOfOperatingLeasesDetails",
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease payable, net of current portion",
        "verboseLabel": "Operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r548"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease payment",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r549",
      "r552"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets",
      "http://neuraxis.com/role/ScheduleOfOperatingLeasesDetails",
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease right of use asset, net",
        "verboseLabel": "Operating lease right-of-use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r547"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average discount rate",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r554",
      "r787"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining lease term (in years)",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r553",
      "r787"
     ]
    },
    "us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasesOfLesseeDisclosureTextBlock",
     "presentation": [
      "http://neuraxis.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Operating Leases",
        "documentation": "Tabular disclosure for lessee's operating leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r171",
      "r172",
      "r173",
      "r174"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfStateCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfStateCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_OptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OptionMember",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfDilutiveCommonStockEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options Held [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific commodity, or financial or equity instrument, at a specified price during a specified period (an American option) or at a specified date (a European option) which were purchased or otherwise acquired, excluding options written (for which a premium was received)."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r678",
      "r683",
      "r702",
      "r708",
      "r730",
      "r731",
      "r732",
      "r790",
      "r791"
     ]
    },
    "us-gaap_OtherAssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrentAbstract",
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsAxis",
     "presentation": [
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Axis]",
        "documentation": "Information by type of other commitment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsDomain",
     "presentation": [
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other future obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsTable",
     "presentation": [
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Commitments [Table]",
        "documentation": "Disclosure of information about obligations resulting from other commitments."
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_OtherConvertiblesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "OtherConvertiblesMember",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRelatedPartyLoansPayableToShareholderDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Convertibles [Member]",
        "documentation": "Other Convertibles [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current liabilities",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r788"
     ]
    },
    "us-gaap_OtherNonoperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingExpense",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails",
      "http://neuraxis.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other expense",
        "label": "Other Nonoperating Expense",
        "documentation": "Amount of expense related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "us-gaap_OtherNonoperatingIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncome",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails",
      "http://neuraxis.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income",
        "documentation": "Amount of income related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r239"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails",
      "http://neuraxis.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other (expense) income, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "us-gaap_PatentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PatentsMember",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patents [Member]",
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law."
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForFees",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for fees",
        "documentation": "Amount of cash outflow for fees classified as other."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PaymentsForRepurchaseOfInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRepurchaseOfInitialPublicOffering",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for repurchase of initial public offering",
        "documentation": "The cash outflow associated with the repurchase of amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offering costs",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "NRXS_PaymentsOfFinancingCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "PaymentsOfFinancingCost",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Financing fees",
        "documentation": "Payments of financing cost.",
        "label": "PaymentsOfFinancingCost"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfFinancingCosts",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative",
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Financing fees paid",
        "label": "Financing fees",
        "documentation": "The cash outflow for loan and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment fees",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails",
      "http://neuraxis.com/role/StatementsOfCashFlows",
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Additions to intangible assets",
        "label": "Initial payment upon execution",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails",
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Additions to property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "presentation": [
      "http://neuraxis.com/role/RetirementPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Plan",
        "documentation": "The entire disclosure for retirement benefits."
       }
      }
     },
     "auth_ref": [
      "r394",
      "r395",
      "r396",
      "r402",
      "r403",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r783"
     ]
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfOption-pricingModelWithFollowingWeighted-averageAssumptionsDetails",
      "http://neuraxis.com/role/StockOptionsAndAwardsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfOption-pricingModelWithFollowingWeighted-averageAssumptionsDetails",
      "http://neuraxis.com/role/StockOptionsAndAwardsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906"
     ]
    },
    "srt_PlatformOperatorCryptoAssetLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "PlatformOperatorCryptoAssetLineItems",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfChangesInDerivativeLiabilitiesDetails",
      "http://neuraxis.com/role/ScheduleOfChangesInWarrantLiabilitiesDetails",
      "http://neuraxis.com/role/ScheduleOfUnobservableInputsForLevel3AssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Platform Operator, Crypto-Asset [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_PlatformOperatorCryptoAssetTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "PlatformOperatorCryptoAssetTable",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfChangesInDerivativeLiabilitiesDetails",
      "http://neuraxis.com/role/ScheduleOfChangesInWarrantLiabilitiesDetails",
      "http://neuraxis.com/role/ScheduleOfUnobservableInputsForLevel3AssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Platform Operator, Crypto-Asset [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "us-gaap_PreferredStockDividendRatePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockDividendRatePercentage",
     "presentation": [
      "http://neuraxis.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock dividend rate percentage",
        "documentation": "The percentage rate used to calculate dividend payments on preferred stock."
       }
      }
     },
     "auth_ref": [
      "r383",
      "r721",
      "r724",
      "r726",
      "r734"
     ]
    },
    "us-gaap_PreferredStockDividendsAndOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockDividendsAndOtherAdjustments",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock dividends",
        "documentation": "The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r822",
      "r858"
     ]
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsTables",
      "http://neuraxis.com/role/PreferredStockDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfDilutiveCommonStockEquivalentsDetails",
      "http://neuraxis.com/role/ScheduleOfWarrantActivityForPreferredStockDetails",
      "http://neuraxis.com/role/StatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r790",
      "r791",
      "r794",
      "r795",
      "r796",
      "r797",
      "r939",
      "r943"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://neuraxis.com/role/BalanceSheetsParenthetical",
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative",
      "http://neuraxis.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r382"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://neuraxis.com/role/BalanceSheetsParenthetical",
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative",
      "http://neuraxis.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r669"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://neuraxis.com/role/BalanceSheetsParenthetical",
      "http://neuraxis.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r382"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://neuraxis.com/role/BalanceSheetsParenthetical",
      "http://neuraxis.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r669",
      "r688",
      "r943",
      "r944"
     ]
    },
    "us-gaap_PreferredStockTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockTextBlock",
     "presentation": [
      "http://neuraxis.com/role/PreferredStock"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock",
        "documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock."
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets",
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, value",
        "verboseLabel": "Convertible Series Seed preferred stock",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r608",
      "r788"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets",
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaids and other current assets",
        "verboseLabel": "Prepaid and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r839"
     ]
    },
    "NRXS_PriorYearOfferingCostsPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "PriorYearOfferingCostsPaid",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior year offering costs paid",
        "documentation": "Prior year offering costs paid."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromConvertibleDebt",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails",
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from convertible notes",
        "verboseLabel": "Proceeds from convertible notes, net of fees",
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ProceedsFromFeesReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromFeesReceived",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred financing fees",
        "documentation": "Cash received for fees during the current period. This element excludes cash proceeds from license fees."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative",
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance Initial Public Offering",
        "verboseLabel": "Proceeds from issuance of ipo",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative",
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails",
      "http://neuraxis.com/role/StatementsOfCashFlows",
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of common stock, net of issuance costs",
        "verboseLabel": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfDebt",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net proceeds of debt",
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt."
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from exercised warrants",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromNotesPayable",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails",
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from notes payable",
        "verboseLabel": "Cash proceeds fair value of incentivies",
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ProductInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProductInformationLineItems",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfCustomersAccountedRevenuesDetails",
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_PromissoryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "PromissoryNoteMember",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Promissory Note [Member]",
        "documentation": "Promissory Note [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfEstimatedUsefulLivesDetails",
      "http://neuraxis.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://neuraxis.com/role/PropertyAndEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r181",
      "r184",
      "r185"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/BalanceSheets": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      },
      "http://neuraxis.com/role/ScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets",
      "http://neuraxis.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment, at cost:",
        "verboseLabel": "Total property and equipment",
        "terseLabel": "Property and equipment, at cost",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r215",
      "r614"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfEstimatedUsefulLivesDetails",
      "http://neuraxis.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://neuraxis.com/role/ScheduleOfPropertyAndEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets",
      "http://neuraxis.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r604",
      "r614",
      "r788"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r181",
      "r184",
      "r612"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://neuraxis.com/role/PropertyAndEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Property And Equipment",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfEstimatedUsefulLivesDetails",
      "http://neuraxis.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r139"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfEstimatedUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, estimated useful lives",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProvisionForDoubtfulAccounts",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails",
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provisions for losses on accounts receivable",
        "verboseLabel": "Provision for losses on accounts receivable",
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r238",
      "r325"
     ]
    },
    "us-gaap_ProvisionForOtherCreditLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProvisionForOtherCreditLosses",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit losses",
        "documentation": "Amount of expense related to credit loss from transactions other than loan and lease transactions."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r164"
     ]
    },
    "NRXS_PurchaseOfAdditionalStockOnNumberOfOptionsNotExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "PurchaseOfAdditionalStockOnNumberOfOptionsNotExercised",
     "presentation": [
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:PurchaseOfAdditionalStockOnNumberOfOptionsNotExercised]",
        "documentation": "Purchase of additional stock on number of options not exercised."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://neuraxis.com/role/DerivativeLiabilitiesDetailsNarrative",
      "http://neuraxis.com/role/NotesPayableDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfEstimatedUsefulLivesDetails",
      "http://neuraxis.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r340",
      "r341",
      "r342",
      "r343",
      "r395",
      "r413",
      "r445",
      "r446",
      "r447",
      "r576",
      "r577",
      "r617",
      "r659",
      "r660",
      "r720",
      "r723",
      "r727",
      "r728",
      "r733",
      "r756",
      "r757",
      "r771",
      "r778",
      "r784",
      "r789",
      "r792",
      "r866",
      "r877",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://neuraxis.com/role/DerivativeLiabilitiesDetailsNarrative",
      "http://neuraxis.com/role/NotesPayableDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfEstimatedUsefulLivesDetails",
      "http://neuraxis.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "auth_ref": [
      "r340",
      "r341",
      "r342",
      "r343",
      "r395",
      "r413",
      "r445",
      "r446",
      "r447",
      "r576",
      "r577",
      "r617",
      "r659",
      "r660",
      "r720",
      "r723",
      "r727",
      "r728",
      "r733",
      "r756",
      "r757",
      "r771",
      "r778",
      "r784",
      "r789",
      "r792",
      "r866",
      "r877",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931"
     ]
    },
    "NRXS_ReclassificationOfWarrantLiabilityToEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "ReclassificationOfWarrantLiabilityToEquity",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Reclassification of warrant liability to equity",
        "documentation": "Reclassification of warrant liability to equity.",
        "label": "ReclassificationOfWarrantLiabilityToEquity"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_ReclassifiedToEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "ReclassifiedToEquity",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfChangesInWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reclassified to equity",
        "documentation": "Reclassified to equity."
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_ReimbursementExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "ReimbursementExpenses",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reimbursement expenses",
        "documentation": "Reimbursement expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets",
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative",
      "http://neuraxis.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfRelatedPartyTransactionsDetails",
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r564",
      "r565",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r687",
      "r689",
      "r719"
     ]
    },
    "NRXS_RelatedPartyInterestPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "RelatedPartyInterestPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related party interest",
        "documentation": "Related party interest payable current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets",
      "http://neuraxis.com/role/ScheduleOfRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r251",
      "r564",
      "r565",
      "r566",
      "r567",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r687",
      "r689",
      "r719"
     ]
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related party transaction amounts",
        "documentation": "Amount of transactions with related party during the financial reporting period."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r564"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://neuraxis.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r694",
      "r695",
      "r698"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets",
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative",
      "http://neuraxis.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfRelatedPartyTransactionsDetails",
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r564",
      "r565",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r687",
      "r689",
      "r719",
      "r923"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://neuraxis.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r561",
      "r562",
      "r563",
      "r565",
      "r568",
      "r640",
      "r641",
      "r642",
      "r696",
      "r697",
      "r698",
      "r717",
      "r718"
     ]
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails",
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Principal payments on notes payable",
        "label": "Repayments of Notes Payable",
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails",
      "http://neuraxis.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development",
        "verboseLabel": "Research and development",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r463",
      "r932"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and Development",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r462"
     ]
    },
    "srt_RestatementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RestatementAxis",
     "presentation": [
      "http://neuraxis.com/role/RestatementOfInterimFinancialStatementsDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Axis]"
       }
      }
     },
     "auth_ref": [
      "r207",
      "r253",
      "r254",
      "r255",
      "r257",
      "r258",
      "r261",
      "r262",
      "r263",
      "r264",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r283",
      "r317",
      "r318",
      "r478",
      "r507",
      "r511",
      "r512",
      "r513",
      "r545",
      "r559",
      "r560",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r631"
     ]
    },
    "srt_RestatementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RestatementDomain",
     "presentation": [
      "http://neuraxis.com/role/RestatementOfInterimFinancialStatementsDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails"
     ],
     "auth_ref": [
      "r207",
      "r253",
      "r254",
      "r255",
      "r257",
      "r258",
      "r261",
      "r262",
      "r263",
      "r264",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r283",
      "r317",
      "r318",
      "r478",
      "r507",
      "r511",
      "r512",
      "r513",
      "r545",
      "r559",
      "r560",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r631"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets",
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r149",
      "r610",
      "r624",
      "r629",
      "r638",
      "r670",
      "r788"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://neuraxis.com/role/StatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r253",
      "r254",
      "r255",
      "r258",
      "r268",
      "r270",
      "r316",
      "r322",
      "r453",
      "r454",
      "r455",
      "r477",
      "r478",
      "r495",
      "r498",
      "r499",
      "r502",
      "r511",
      "r620",
      "r622",
      "r643",
      "r943"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfCustomersAccountedRevenuesDetails",
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails",
      "http://neuraxis.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Sales",
        "verboseLabel": "Revenue",
        "terseLabel": "Net sales",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r288",
      "r289",
      "r292",
      "r295",
      "r296",
      "r300",
      "r301",
      "r303",
      "r392",
      "r393",
      "r582"
     ]
    },
    "us-gaap_RevenueFromRightsConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromRightsConcentrationRiskMember",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Rights Concentration Risk [Member]",
        "documentation": "Reflects the percentage that license fee or royalty revenues during the period from other parties from use of a specified patent, trademark, or other form of right granted to such parties are to a specified benchmark, such as total license fees, total revenues, segment revenues or product line revenues. May also reflect the percentage contribution the revenue made to operating results. Risk is materially adverse effects of a loss of such revenues, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r692",
      "r758",
      "r766"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Revenues",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfDisaggregationOfRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total revenue",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r236",
      "r248",
      "r288",
      "r289",
      "r292",
      "r295",
      "r296",
      "r300",
      "r301",
      "r303",
      "r312",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r525",
      "r603",
      "r873"
     ]
    },
    "srt_RevisionOfPriorPeriodReclassificationAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RevisionOfPriorPeriodReclassificationAdjustmentMember",
     "presentation": [
      "http://neuraxis.com/role/RestatementOfInterimFinancialStatementsDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period, Reclassification, Adjustment [Member]"
       }
      }
     },
     "auth_ref": [
      "r209"
     ]
    },
    "us-gaap_SalariesAndWages": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SalariesAndWages",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold",
        "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold."
       }
      }
     },
     "auth_ref": [
      "r840"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative",
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative",
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative",
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "verboseLabel": "Number of shares issued in transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockPercentageOfOwnershipAfterTransaction",
     "presentation": [
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Percentage of Ownership after Transaction",
        "documentation": "Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesRevenueProductLineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SalesRevenueProductLineMember",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue, Product and Service Benchmark [Member]",
        "documentation": "Revenue from specified product or service, when it serves as benchmark in concentration of risk calculation. Includes, but is not limited to, revenue from contract with customer and other sources."
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]"
       }
      }
     },
     "auth_ref": [
      "r414",
      "r854"
     ]
    },
    "srt_ScenarioPreviouslyReportedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioPreviouslyReportedMember",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Previously Reported [Member]"
       }
      }
     },
     "auth_ref": [
      "r207",
      "r253",
      "r255",
      "r257",
      "r258",
      "r261",
      "r262",
      "r270",
      "r283",
      "r478",
      "r507",
      "r511",
      "r512",
      "r545",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r631",
      "r828",
      "r831",
      "r832",
      "r833",
      "r853",
      "r861",
      "r862",
      "r914",
      "r920",
      "r921"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "auth_ref": [
      "r271",
      "r414",
      "r824",
      "r854"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://neuraxis.com/role/AccruedExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Expenses",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfDilutiveCommonStockEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "NRXS_ScheduleOfChangesInWarrantLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "ScheduleOfChangesInWarrantLiabilitiesTableTextBlock",
     "presentation": [
      "http://neuraxis.com/role/WarrantLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Changes in Warrant Liabilities",
        "documentation": "Schedule of Changes in Warrant Liabilities [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://neuraxis.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Asset",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r154"
     ]
    },
    "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
     "presentation": [
      "http://neuraxis.com/role/DerivativeLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Changes in Derivative Liabilities",
        "documentation": "Tabular disclosure of derivative liabilities at fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Basic and Diluted Net Loss Per Share",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Dilutive Common Stock Equivalents",
        "documentation": "Tabular disclosure of the effect of income (loss) on an entity's diluted earnings per share."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r55",
      "r855"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://neuraxis.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Federal Statutory Income Tax Rate and Effective Income Tax Rate",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r153"
     ]
    },
    "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock",
     "presentation": [
      "http://neuraxis.com/role/RestatementOfInterimFinancialStatementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Restatement of Interim Financial Statements (Unaudited)",
        "documentation": "Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r49",
      "r50"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value On a Recurring Basis Assets and Liability",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r516",
      "r517"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r65",
      "r583"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://neuraxis.com/role/IntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Intangible Assets",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r65"
     ]
    },
    "us-gaap_ScheduleOfProductInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfProductInformationTable",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfCustomersAccountedRevenuesDetails",
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Product Information [Table]",
        "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfEstimatedUsefulLivesDetails",
      "http://neuraxis.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "NRXS_ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Estimated Useful Lives",
        "documentation": "Schedule of Property Plant And Equipment Useful Lives [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_ScheduleOfRelatedPartyLoansTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "ScheduleOfRelatedPartyLoansTableTextBlock",
     "presentation": [
      "http://neuraxis.com/role/RelatedPartyTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Loans payable to shareholder",
        "documentation": "Schedule Of Related Party Loans [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://neuraxis.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r100",
      "r694",
      "r695",
      "r698"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "presentation": [
      "http://neuraxis.com/role/RelatedPartyTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Transactions",
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfOption-pricingModelWithFollowingWeighted-averageAssumptionsDetails",
      "http://neuraxis.com/role/StockOptionsAndAwardsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r418",
      "r420",
      "r421",
      "r422",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://neuraxis.com/role/StockOptionsAndAwardsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock Option Activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r19",
      "r81"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://neuraxis.com/role/StockOptionsAndAwardsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Option-pricing Model with Following Weighted-average Assumptions",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShortTermDebtTable",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfRelatedPartyLoansPayableToShareholderDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Short-Term Debt [Table]",
        "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://neuraxis.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock by Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r73",
      "r74",
      "r75",
      "r76",
      "r77",
      "r78",
      "r146",
      "r148",
      "r149",
      "r220",
      "r221",
      "r222",
      "r285",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r388",
      "r389",
      "r634",
      "r635",
      "r636",
      "r637",
      "r778",
      "r823",
      "r845"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Warrants outstanding and Exercisable",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "NRXS_ScheduleOfWarrantActivityForCommonStockTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "ScheduleOfWarrantActivityForCommonStockTableTextBlock",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Warrant Activity for Common Stock",
        "documentation": "Schedule of warrant activity for common stock [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_ScheduleOfWarrantActivityForPreferredStockTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "ScheduleOfWarrantActivityForPreferredStockTableTextBlock",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Warrant Activity for Preferred Stock",
        "documentation": "Schedule of warrant activity for preferred stock [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_SecondAndFinalPaymentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "SecondAndFinalPaymentMember",
     "presentation": [
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Second and Final Payment [Member]",
        "documentation": "Second and Final Payment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12gTitle",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfDisaggregationOfRevenueDetails"
     ],
     "auth_ref": [
      "r301",
      "r302",
      "r656",
      "r657",
      "r658",
      "r722",
      "r725",
      "r729",
      "r735",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r759",
      "r779",
      "r792",
      "r880",
      "r937"
     ]
    },
    "us-gaap_SellingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingExpense",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails",
      "http://neuraxis.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling Expenses",
        "verboseLabel": "Selling expenses",
        "documentation": "Expenses recognized in the period that are directly related to the selling and distribution of products or services."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesAPreferredStockMember",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative",
      "http://neuraxis.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Preferred Stock [Member]",
        "documentation": "Series A preferred stock."
       }
      }
     },
     "auth_ref": [
      "r836",
      "r837",
      "r879"
     ]
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesBPreferredStockMember",
     "presentation": [
      "http://neuraxis.com/role/PreferredStockDetailsNarrative",
      "http://neuraxis.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Preferred Stock [Member]",
        "documentation": "Series B preferred stock."
       }
      }
     },
     "auth_ref": [
      "r836",
      "r837",
      "r879"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://neuraxis.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails",
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfOption-pricingModelWithFollowingWeighted-averageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price",
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfOption-pricingModelWithFollowingWeighted-averageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfOption-pricingModelWithFollowingWeighted-averageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r445"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfOption-pricingModelWithFollowingWeighted-averageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r447"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfOption-pricingModelWithFollowingWeighted-averageAssumptionsDetails",
      "http://neuraxis.com/role/StockOptionsAndAwardsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r418",
      "r420",
      "r421",
      "r422",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448"
     ]
    },
    "NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfWarrantActivityForPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Converted to Common Stock Warrant",
        "label": "Converted to preferred stock warrant",
        "documentation": "Share based compensation arrangement by share based payment award non option equity instruments common stock warrant."
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfWarrantActivityForCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Warrants, Converted Prefunded Warrants",
        "verboseLabel": "Converted to common stock warrant",
        "documentation": "Share based compensation arrangement by share based payment award non option equity instruments converted prefunded warrants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfWarrantActivityForCommonStockDetails",
      "http://neuraxis.com/role/ScheduleOfWarrantActivityForPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Warrants, Exercised",
        "documentation": "Number of non-option equity instruments exercised by participants."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfWarrantActivityForCommonStockDetails",
      "http://neuraxis.com/role/ScheduleOfWarrantActivityForPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Warrants, Cancelled Expired",
        "documentation": "Number of shares under non-option equity instrument agreements that were either cancelled or expired."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "presentation": [
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfWarrantActivityForCommonStockDetails",
      "http://neuraxis.com/role/ScheduleOfWarrantActivityForPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted",
        "verboseLabel": "Number of Warrants, Granted",
        "documentation": "Net number of non-option equity instruments granted to participants."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfOption-pricingModelWithFollowingWeighted-averageAssumptionsDetails",
      "http://neuraxis.com/role/ScheduleOfWarrantActivityForCommonStockDetails",
      "http://neuraxis.com/role/ScheduleOfWarrantActivityForPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Warrants, Outstanding at beginning of period",
        "periodEndLabel": "Number of Warrants, Outstanding at Ending of period",
        "label": "Number of Shares",
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r14"
     ]
    },
    "NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfWarrantActivityForCommonStockDetails",
      "http://neuraxis.com/role/ScheduleOfWarrantActivityForPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Cancelled Expired",
        "documentation": "Share based compensation arrangement by share based payment award non options weighted average exercise price cancelled expired number."
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfWarrantActivityForPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Weighted Average Exercise Price, Converted to Common Stock Warrant",
        "documentation": "Share based compensation arrangement by share based payment award non options weighted average exercise price common stock warrant.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageRemainingContracualLifeOutstandingNumberGranted": {
     "xbrltype": "durationItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageRemainingContracualLifeOutstandingNumberGranted",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfWarrantActivityForCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Contractual Life - Warrants Granted",
        "documentation": "Share based compensation arrangement by share based payment award non options weighted average remaining contracual life outstanding number granted."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Options, Cancelled/Expired",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Options, Forfeited",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Options, Granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Aggregate Intrinsic Value, Outstanding, Beginning balance",
        "periodEndLabel": "Aggregate Intrinsic Value, Outstanding, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Options, Outstanding, Beginning balance",
        "periodEndLabel": "Number of Options, Outstanding, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r424",
      "r425"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfStockOptionActivityDetails",
      "http://neuraxis.com/role/ScheduleOfWarrantActivityForCommonStockDetails",
      "http://neuraxis.com/role/ScheduleOfWarrantActivityForPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Exercise Price, Outstanding at beginning of period",
        "periodEndLabel": "Weighted Average Exercise Price, Outstanding at Ending of period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r424",
      "r425"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Aggregate Intrinsic Value, Vested and Exercisable, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r441"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of Options, Vested and Exercisable, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r441"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted Average Exercise Price, Vested and Exercisable, Ending balance",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r441"
     ]
    },
    "NRXS_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsConvertedPrefundedWarrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsConvertedPrefundedWarrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfWarrantActivityForCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Converted Prefunded Warrants",
        "documentation": "Share based compensation arrangements by share based payment award options converted prefunded warrants in period weighted average exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfWarrantActivityForCommonStockDetails",
      "http://neuraxis.com/role/ScheduleOfWarrantActivityForPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, Excercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfWarrantActivityForCommonStockDetails",
      "http://neuraxis.com/role/ScheduleOfWarrantActivityForPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price, granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r415",
      "r423",
      "r442",
      "r443",
      "r444",
      "r445",
      "r448",
      "r456",
      "r457",
      "r458",
      "r459"
     ]
    },
    "NRXS_ShareHolderMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "ShareHolderMember",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRelatedPartyLoansPayableToShareholderDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Holder [Member]",
        "documentation": "Share Holder [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_ShareHolderOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "ShareHolderOneMember",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRelatedPartyLoansPayableToShareholderDetails",
      "http://neuraxis.com/role/ScheduleOfRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholder 1 [Member]",
        "documentation": "Shareholder 1 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_ShareHolderTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "ShareHolderTwoMember",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholder 2 [Member]",
        "documentation": "Shareholder 2 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_ShareLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "ShareLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share liabilities",
        "documentation": "Share liabilities current."
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_SharePremiumPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "SharePremiumPercentage",
     "presentation": [
      "http://neuraxis.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share premium percentage",
        "documentation": "Share premium percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharePrice",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfOption-pricingModelWithFollowingWeighted-averageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share price",
        "verboseLabel": "Stock price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfOption-pricingModelWithFollowingWeighted-averageAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r444"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfWarrantActivityForCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted Average Remaining Contractual Life - Warrants Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfStockOptionActivityDetails",
      "http://neuraxis.com/role/ScheduleOfWarrantActivityForCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Contractual Life - Warrants, Outstanding at Ending of period",
        "verboseLabel": "Weighted Average Remaining Contractual Life (in years), Outstanding",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Contractual Life (in years), Vested and Exercisable",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r441"
     ]
    },
    "NRXS_ShareholdersOneAndTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "ShareholdersOneAndTwoMember",
     "presentation": [
      "http://neuraxis.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders 1 And 2 [Member]",
        "documentation": "Shareholders 1 And 2 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssued",
     "presentation": [
      "http://neuraxis.com/role/StockOptionsAndAwardsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative",
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative",
      "http://neuraxis.com/role/NotesPayableDetailsNarrative",
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Issued, Price Per Share",
        "verboseLabel": "Share issued price per share",
        "terseLabel": "Shares issued price per share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://neuraxis.com/role/StatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance, shares",
        "periodEndLabel": "Balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermBorrowings",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short term borrowing",
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r161",
      "r788",
      "r934"
     ]
    },
    "us-gaap_ShortTermDebtLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermDebtLineItems",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfRelatedPartyLoansPayableToShareholderDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermDebtTypeAxis",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative",
      "http://neuraxis.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Type [Axis]",
        "documentation": "Information by type of short-term debt arrangement."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermDebtTypeDomain",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative",
      "http://neuraxis.com/role/PreferredStockDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "NRXS_SignatureBankMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "SignatureBankMember",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Signature Bank [Member]",
        "documentation": "Signature Bank [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r246"
     ]
    },
    "NRXS_SoftwareImplementationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "SoftwareImplementationMember",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Software Implementation [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "NRXS_SpecialBonusPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "SpecialBonusPercentage",
     "presentation": [
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Special bonus percentage",
        "documentation": "Special bonus percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets",
      "http://neuraxis.com/role/BalanceSheetsParenthetical",
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative",
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative",
      "http://neuraxis.com/role/PreferredStockDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails",
      "http://neuraxis.com/role/StatementsOfStockholdersDeficit",
      "http://neuraxis.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r220",
      "r221",
      "r222",
      "r248",
      "r275",
      "r276",
      "r279",
      "r281",
      "r285",
      "r286",
      "r312",
      "r344",
      "r346",
      "r347",
      "r348",
      "r351",
      "r352",
      "r382",
      "r383",
      "r385",
      "r386",
      "r389",
      "r525",
      "r634",
      "r635",
      "r636",
      "r637",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r655",
      "r669",
      "r691",
      "r714",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r823",
      "r845",
      "r856"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative",
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative",
      "http://neuraxis.com/role/CommonStockAndWarrantsTables",
      "http://neuraxis.com/role/NotesPayableDetailsNarrative",
      "http://neuraxis.com/role/PreferredStockDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfWarrantActivityForCommonStockDetails",
      "http://neuraxis.com/role/ScheduleOfWarrantActivityForPreferredStockDetails",
      "http://neuraxis.com/role/StatementsOfStockholdersDeficit",
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r34",
      "r206",
      "r232",
      "r233",
      "r234",
      "r253",
      "r254",
      "r255",
      "r258",
      "r268",
      "r270",
      "r284",
      "r316",
      "r322",
      "r391",
      "r453",
      "r454",
      "r455",
      "r477",
      "r478",
      "r495",
      "r497",
      "r498",
      "r499",
      "r500",
      "r502",
      "r511",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r560",
      "r620",
      "r621",
      "r622",
      "r643",
      "r714"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfDisaggregationOfRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r301",
      "r302",
      "r656",
      "r657",
      "r658",
      "r722",
      "r725",
      "r729",
      "r735",
      "r741",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r759",
      "r779",
      "r792",
      "r880",
      "r937"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets",
      "http://neuraxis.com/role/BalanceSheetsParenthetical",
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative",
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative",
      "http://neuraxis.com/role/CommonStockAndWarrantsTables",
      "http://neuraxis.com/role/LeasesDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfDisaggregationOfRevenueDetails",
      "http://neuraxis.com/role/ScheduleOfWarrantActivityForCommonStockDetails",
      "http://neuraxis.com/role/ScheduleOfWarrantActivityForPreferredStockDetails",
      "http://neuraxis.com/role/StatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r254",
      "r255",
      "r284",
      "r582",
      "r632",
      "r655",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r669",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r678",
      "r679",
      "r680",
      "r681",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r689",
      "r692",
      "r693",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r714",
      "r793"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r271",
      "r414",
      "r824",
      "r825",
      "r854"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets",
      "http://neuraxis.com/role/BalanceSheetsParenthetical",
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative",
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative",
      "http://neuraxis.com/role/CommonStockAndWarrantsTables",
      "http://neuraxis.com/role/LeasesDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfDisaggregationOfRevenueDetails",
      "http://neuraxis.com/role/ScheduleOfWarrantActivityForCommonStockDetails",
      "http://neuraxis.com/role/ScheduleOfWarrantActivityForPreferredStockDetails",
      "http://neuraxis.com/role/StatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r254",
      "r255",
      "r284",
      "r582",
      "r632",
      "r655",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r669",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r678",
      "r679",
      "r680",
      "r681",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r689",
      "r692",
      "r693",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r714",
      "r793"
     ]
    },
    "NRXS_StockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering",
     "presentation": [
      "http://neuraxis.com/role/StatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued upon initial public offering, shares",
        "documentation": "Stock issued during period shares common stock issued upon initial public offering."
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_StockIssuedDuringPeriodSharesCommonStockIssuedUponPreferredStockConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesCommonStockIssuedUponPreferredStockConversion",
     "presentation": [
      "http://neuraxis.com/role/StatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued upon preferred stock conversion, shares",
        "documentation": "Stock issued during period shares common stock issued upon preferred stock conversion."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative",
      "http://neuraxis.com/role/StatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued upon signing of notes payable, shares",
        "verboseLabel": "Number of shares, conversion of convertible securities",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r33",
      "r75",
      "r149",
      "r370"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesConversionOfUnits",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative",
      "http://neuraxis.com/role/StatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued upon debt conversion, shares",
        "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r75",
      "r117",
      "r118",
      "r149"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan",
     "presentation": [
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Seven key employees stock options",
        "documentation": "Number of shares of capital stock issued (purchased by employees) in connection with an employee stock ownership plan."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r84",
      "r117",
      "r118",
      "r149"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative",
      "http://neuraxis.com/role/StatementsOfStockholdersDeficit",
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued from agreements, shares",
        "verboseLabel": "Purchase of common shares",
        "terseLabel": "Issuance of shares",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r117",
      "r118",
      "r149",
      "r634",
      "r714",
      "r737"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Options, Exercised",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r117",
      "r118",
      "r149",
      "r429"
     ]
    },
    "NRXS_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "presentation": [
      "http://neuraxis.com/role/StatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants exercised, shares",
        "documentation": "Stock issued during period shares warrants exercised."
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/StatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued upon initial public offering",
        "documentation": "Stock issued during period value common stock issued upon initial public offering."
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_StockIssuedDuringPeriodValueCommonStockIssuedUponPreferredStockConversion": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "StockIssuedDuringPeriodValueCommonStockIssuedUponPreferredStockConversion",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/StatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued upon preferred stock conversion",
        "documentation": "Stock issued during period value common stock issued upon preferred stock conversion."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/StatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued upon signing of notes payable",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r34",
      "r149"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueConversionOfUnits",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/StatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued upon debt conversion",
        "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r34",
      "r149"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative",
      "http://neuraxis.com/role/StatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock issued from agreements",
        "verboseLabel": "Final amount",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r117",
      "r118",
      "r149",
      "r643",
      "r714",
      "r737",
      "r799"
     ]
    },
    "NRXS_StockIssuedDuringPeriodValueWarrantsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "StockIssuedDuringPeriodValueWarrantsExercised",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/StatementsOfStockholdersDeficit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants exercised",
        "documentation": "Stock issued during period value warrants exercised."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets",
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails",
      "http://neuraxis.com/role/StatementsOfStockholdersDeficit",
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 deficit",
        "periodStartLabel": "Beginning balance, value",
        "periodEndLabel": "Ending balance, value",
        "negatedLabel": "Stockholders deficit",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r121",
      "r122",
      "r136",
      "r671",
      "r688",
      "r715",
      "r716",
      "r788",
      "r800",
      "r847",
      "r860",
      "r917",
      "r943"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets",
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Deficit",
        "verboseLabel": "Stockholders\u2019 deficit:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteStockSplit",
     "presentation": [
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative",
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of stock split",
        "verboseLabel": "Common stock split, description",
        "documentation": "Description of the stock split arrangement. Also provide the retroactive effect given by a stock split that occurs after the balance date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r150"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://neuraxis.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r536",
      "r571"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://neuraxis.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r536",
      "r571"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://neuraxis.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r536",
      "r571"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://neuraxis.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r536",
      "r571"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://neuraxis.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r536",
      "r571"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://neuraxis.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r570",
      "r572"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative",
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SummaryOfOperatingLossCarryforwardsTextBlock",
     "presentation": [
      "http://neuraxis.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of State Carryforwards",
        "documentation": "Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://neuraxis.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Disclosure of Non-Cash Operating Activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxPeriodAxis",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfStateCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Axis]",
        "documentation": "Information about the period subject to enacted tax laws."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxPeriodDomain",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfStateCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified tax period."
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_TaxYear2038Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "TaxYear2038Member",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfStateCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Year 2038 [Member]",
        "documentation": "Tax Year 2038 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_TaxYear2039Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "TaxYear2039Member",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfStateCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Year 2039 [Member]",
        "documentation": "Tax Year 2039 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_TaxYear2040Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "TaxYear2040Member",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfStateCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Year 2040 [Member]",
        "documentation": "Tax Year 2040 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_TaxYear2041Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "TaxYear2041Member",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfStateCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Year 2041 [Member]",
        "documentation": "Tax Year 2041 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_TaxYear2042Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "TaxYear2042Member",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfStateCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Year 2042 [Member]",
        "documentation": "Tax Year 2042 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_TaxYear2043Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "TaxYear2043Member",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfStateCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Year 2043 [Member]",
        "documentation": "Tax Year 2043 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative",
      "http://neuraxis.com/role/NotesPayableDetailsNarrative",
      "http://neuraxis.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r859",
      "r922"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative",
      "http://neuraxis.com/role/NotesPayableDetailsNarrative",
      "http://neuraxis.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "auth_ref": []
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade Accounts Receivable and Allowance for Credit Losses",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r168",
      "r169",
      "r306",
      "r307",
      "r309"
     ]
    },
    "NRXS_TrademarkAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "TrademarkAgreementMember",
     "presentation": [
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trademark Agreement [Member]",
        "documentation": "Trademark Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TrademarksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TrademarksMember",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trademarks [Member]",
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_TwentySeventeenStockCompensationPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "TwentySeventeenStockCompensationPlanMember",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfOption-pricingModelWithFollowingWeighted-averageAssumptionsDetails",
      "http://neuraxis.com/role/StockOptionsAndAwardsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2017 Stock Compensation Plan [Member]",
        "documentation": "2017 Stock Compensation Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2023 and 2022 Convertible Notes [Member]",
        "documentation": "2023 and 2022 Convertible Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_TwoThousandTwentyThreeConvertibleNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "TwoThousandTwentyThreeConvertibleNotesMember",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative",
      "http://neuraxis.com/role/NotesPayableDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2023 Convertible Notes [Member]",
        "documentation": "2023 Convertible Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_TwoThousandTwentyTwoConvertibleNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "TwoThousandTwentyTwoConvertibleNotesMember",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative",
      "http://neuraxis.com/role/NotesPayableDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2022 Convertible Notes [Member]",
        "documentation": "2022 Convertible Notes [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://neuraxis.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative",
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r487"
     ]
    },
    "NRXS_UnderwriterFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "UnderwriterFees",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underwriter fees",
        "documentation": "Underwriter fees."
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_UnderwriterWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "UnderwriterWarrantsMember",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underwriter Warrants [Member]",
        "documentation": "Underwriter Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_UnderwritersDiscountPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "UnderwritersDiscountPercentage",
     "presentation": [
      "http://neuraxis.com/role/BasisOfPresentationOrganizationAndOtherMattersDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "[custom:UnderwritersDiscountPercentage-0]",
        "documentation": "Underwriters discount percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates and Critical Accounting Estimates and Assumptions",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r61",
      "r62",
      "r178",
      "r179",
      "r182",
      "r183"
     ]
    },
    "NRXS_VendorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "VendorsMember",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vendors [Member]",
        "documentation": "Vendors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_VersaillesIndianaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "VersaillesIndianaMember",
     "presentation": [
      "http://neuraxis.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Versailles Indiana [Member]",
        "documentation": "Versailles Indiana [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "stpr_WI": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2023",
     "localname": "WI",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfDisaggregationOfRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "WISCONSIN"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_WarrantExpirationDateDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "WarrantExpirationDateDescription",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Expiration Date",
        "documentation": "Warrant expiration date description.",
        "label": "WarrantExpirationDateDescription"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_WarrantLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "WarrantLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://neuraxis.com/role/ScheduleOfFairValueOnRecurringBasisAssetsAndLiabilityDetails": {
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      },
      "http://neuraxis.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://neuraxis.com/role/BalanceSheets",
      "http://neuraxis.com/role/ScheduleOfFairValueOnRecurringBasisAssetsAndLiabilityDetails",
      "http://neuraxis.com/role/ScheduleOfRestatementOfInterimFinancialStatementsDetails",
      "http://neuraxis.com/role/ScheduleOfUnobservableInputsForLevel3AssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant liabilities",
        "documentation": "Warrant liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_WarrantLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "WarrantLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://neuraxis.com/role/WarrantLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrant Liabilities",
        "documentation": "Warrant Liabilities Disclosure [Text Block]",
        "label": "WarrantLiabilitiesDisclosureTextBlock"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_WarrantLiabilityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "WarrantLiabilityPolicyTextBlock",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Warrant Liabilities",
        "documentation": "Warrant Liability [Policy Text Block]",
        "label": "WarrantLiabilityPolicyTextBlock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantMember",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative",
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r790",
      "r791",
      "r794",
      "r795",
      "r796",
      "r797"
     ]
    },
    "NRXS_WarrantOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "WarrantOneMember",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant One [Member]",
        "documentation": "Warrant One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_WarrantThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "WarrantThreeMember",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Three [Member]",
        "documentation": "Warrant Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_WarrantTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "WarrantTwoMember",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Two [Member]",
        "documentation": "Warrant Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfChangesInWarrantLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Outstanding",
        "periodStartLabel": "Warrant liabilities, Beginning balance",
        "periodEndLabel": "Warrant liabilities, Ending balance",
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative",
      "http://neuraxis.com/role/ScheduleOfWarrantsOutstandingAndExercisableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration Date",
        "verboseLabel": "Date of Expiration",
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://neuraxis.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and rights outstanding, measurement input",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r520"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r916"
     ]
    },
    "NRXS_WarrantsExpirationDateDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "WarrantsExpirationDateDescription",
     "presentation": [
      "http://neuraxis.com/role/CommonStockAndWarrantsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Date of Expiration",
        "documentation": "Warrants expiration date description."
       }
      }
     },
     "auth_ref": []
    },
    "NRXS_WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "WarrantsMember",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfDilutiveCommonStockEquivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsNotSettleableInCashFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsNotSettleableInCashFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Embedded derivative warrant liability",
        "documentation": "Fair value portion of warrants not settleable in cash classified as equity."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails",
      "http://neuraxis.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Shares Outstanding, Diluted",
        "verboseLabel": "Weighted average shares of common stock outstanding - diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r274",
      "r281"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://neuraxis.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Shares Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://neuraxis.com/role/ScheduleOfBasicAndDilutedNetLossPerShareDetails",
      "http://neuraxis.com/role/StatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Shares Outstanding, Basic",
        "verboseLabel": "Weighted average shares of common stock outstanding - basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r281"
     ]
    },
    "NRXS_WorkingCapitalDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://neuraxis.com/20231231",
     "localname": "WorkingCapitalDeficit",
     "crdr": "credit",
     "presentation": [
      "http://neuraxis.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Working capital",
        "documentation": "Working capital deficit."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://neuraxis.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479524/944-825-05-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481766/480-10-25-13"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481071/942-405-45-2"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(1)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(2)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-2"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "40",
   "Section": "25",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480637/718-40-25-10"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "720",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483384/720-30-45-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-14"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.10)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.12)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "954",
   "SubTopic": "720",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480441/954-720-45-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-10"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r154": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r155": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38"
  },
  "r156": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//815/tableOfContent"
  },
  "r157": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "83",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480647/815-10-15-83"
  },
  "r158": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//820/tableOfContent"
  },
  "r159": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r160": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r161": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r162": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r163": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r164": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r165": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r166": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r167": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B"
  },
  "r168": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15"
  },
  "r169": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6"
  },
  "r170": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4"
  },
  "r171": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481440/840-10-50-2"
  },
  "r172": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Subparagraph": "(Note 3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481418/840-10-55-40"
  },
  "r173": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481501/840-20-50-1"
  },
  "r174": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481501/840-20-50-2"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "35",
   "Topic": "720",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(4)",
   "Publisher": "SEC"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(5)",
   "Publisher": "SEC"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(1)(i)",
   "Publisher": "SEC"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(1)(ii)",
   "Publisher": "SEC"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Subsection": "Instruction 5",
   "Publisher": "SEC"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "(a)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "(a)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "(a)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "(a)",
   "Subparagraph": "(4)",
   "Publisher": "SEC"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "(a)",
   "Subparagraph": "(5)",
   "Publisher": "SEC"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1406",
   "Paragraph": "(c)",
   "Publisher": "SEC"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483504/205-10-50-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-6"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-12"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//330/tableOfContent"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350-30/tableOfContent"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147477123/405-50-65-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//715/tableOfContent"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480126/715-20-S99-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-3"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "832",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//842-20/tableOfContent"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481435/852-10-45-14"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-4"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-3"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "720",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480409/954-720-50-4"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479294/326-20-55-12"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-12"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480341/340-10-S99-1"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>116
<FILENAME>0001493152-24-014832-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-24-014832-xbrl.zip
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M@MF@:/J(;59C%F*P0>_)^Q?GZ?WZ_P%02P,$%     @ +(206$-B#? ,!@
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M#E/YF(K$EKKM6695@I0.Q2"Y6BQ9G)$*,\^Z0B:6J;EREDLDARW3P;RH"W1
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M/'_SM E(PF_&//I,6-$A#8_8.0>@ENB-Z1E?IC<-I]N"2.2&1R6@%_R;]A>
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MRC:(<]N9U4"ITM2Y6H1 C<4BL]2CHRP7S7".(ZT[=W5'.<$=;&Z[>3BPN9^
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MA/M:X4=X869HS2DRL]D%6CVL(/87C!QOJKO\^@C.YB^G*-*M;8?FRAMZN09
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M_9-D##MQ>+351+G70L9FK$&N3C2I9X;KZ=Z;_4$R-F-RH;?D)9&879\W5[Y
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M[-GTJI5K6S]\35TK&^;>7C[#7%1P$C2GI[G1X#7F:=Z(ZWB(9V@FK)OO:?J
MN4# NW*-<=:^\ED7F)_.+0N^U4V[_Z\WM3?T]X@91OCWTN-*G"M$QP.Z8UEL
MY $YX2<ZJ/G!=Y=_/D53@6T13I;OC.2ISP^^,7&&$1Y+=">/)<04+?;"Z96)
M!MDZ^Y]<]=MI 7228A"P_1QW)!D+19Z=.X'MN^-SQYC#+TYK9W;SC/UU<M+(
M0]L]\+C^@0ZA1Z[SB'MFTN!MU*89RHMTH^UKL2>&9W.OBS'?F%KL7):RD>M*
M3NRW&43O#$+/4PA]8,_7,O!!!!Z\I"_]^]]![>?O]ZQMK([-%/3JT]";0]";
M3ZVC@Z/:R=GQ:6M!V,&_W/5RK44?!Y-5=('SEG8Y#=!Q-0>['&M_!:[I&2;E
MFB9%$<U"T0?D](A.,\G)DDI [IQIL^QHEZ!W?7A_V#FD$8I>.=PM'=S2/(MH
M%HQK"G,16WI/"MTGI8QN3!E=K]XY0V1,B/6B+_2K#I6V8;C<\^1_OH")7)_C
M6;GZ[8^1W^G\\NM)/II"8UI3F$',FT_U^G&]+K:?]A5>9Y@PG(Z_\!'-T2OC
M;<P>[^"?S]U3VSQ[_*N>SWB;BXP7M+!.8/I<:V*X]D(NI5(PTQDXO)RU+N?P
M\=9]<)[LV:LR/O[SU^^7O]Q9O5X^J]*:NRHQ*6\^G3-WR*UYD!-+,#&\XUG#
M(Y7LUKT#PPW4F#GVXA^_W'JW["3X=_ ]GS$>S1WC!#T@]&[F#'+NR6?J>7<.
M&*;6?\S1?&M8_PE(>G1'AI/3"A[/'5V*&C WCFO-QF*;*J,J.5-N[*CE.SE6
M\=""^&QP#[==SN;#T;\<6?_^_<_3IK?Z460*CJD#Q^3[02T^K3?>S3MBG,5#
MPLBX+PY,\-W L5\\^]"/SG_^\_'J/W]U!_D,)77V,4G#FT_'IV<'8+[/"Y8H
MKO&^=O-'\A]A>_>TD0O,U1PQ2^-A!U'X&BP+>"JS#>T?<P0+9/!WZW*Q%=.0
M7?LRQ(<H__>_3AOUDX]B17QN\1$"6;,)R55T*5@!FC@:@\TZO1:[8> 5G>8.
M[ W7]$WN5<0)$'>YH8T"UPOP*,AWX$[R7&GUQMON.]Q9>++?UOT/^0Y46=K%
M./:1 VH>_\^ZH?=@^A8/V35G^D"CW+U\N%RDY&V?-:]A=>JGZU\=E^&NH,%T
MQL.N8[WU<I*5N[TVK?6/"\,34AN'/^L#[)VN 9]^&ICP3<S,]U,=G&<Y2WDW
MKC>ZQ']F:_7NZ>C7\]_8+V=?K7RT^E2TR20-(C3+00>;HW]_+<ZDP,I?>=34
M27B<2GA(KB<8WFQL/(V>?^JVZG?>EWRPT4P%#J0($+5T%""V (BC"7YQ*3GL
M_ BUR^'(?'S^^:<&;NB<(DZ0K\\*-FG69_&3)(T G3\[EUJ;W@\C^_+E? $<
MK=OFPF(,9F^LC*XEC*Y^RNC2;L"&+M=HU[]":X#5M6W@(32O=,>:/N"@%<+[
MOVNF6(E$L*3I:4Q[ C/RX+OM/,'+.?-@B0SXP0O0S\$\S> ]TQ:QE)CWK[5J
M1^&:QE# Y3W4_H0/,B]B;C:;\+?_#N_\!5_9D6^\IA?.9D[?AS_UZ[_UKI[/
M5D_]2C&@&0>)<P@"3N3,.]^(\C-+A8V=![3M^/#-WX&); FX40_3!5S*VO%F
MLZDFACM%?U$R3LRT7D9U/87JWQPKL'WF4L"_.R>7+[@\:7T^ZO3^_C6?A(/F
MC&/B"4(4B@M!]!P4/PTXA=I-0/EM_9TV /Z+^#4T9ED1B)/H[G)Y 3PS#>@4
MD!.<.E2T*@!N_!FSRC0#?K7[=.G(Y3HGUW:]H5&&K*>]A>>!>J=Y 5CGW@#+
ME;EA5I0_8/XD[4_,F]Z#=+,<P[LJG6.\;;RKX!B[H"3"[]V_8 1X/5T*-R$5
M\CF8A><1$40D\WSMK*89;.P=3NW*=(:&S-\5B7MHGOC,GY=H>W34OQB,[!/S
M-)\3L>:,:('9]+SY]"<67WIQDX+^I$5YAZ6"_A[L5\0Q0'AH^CZ GEL 9=>Q
MT>=DC37^R-VQ=HW:*?9M>>3:!?.9=B5D4VH[Q\]("BM4O2I2];KG_<!BM-4[
M!P_:6YS<DX]:H]DXC)0SD[)>1ICUDO/FKDQN;D%PM&>Y]VYZ1]8G4B*B><!I
MD!MB3KSYZ&=^]/67/KM=O21':D?.B&V938_:D84C>KD=2=:-!01RC>DZ[$@7
M6R$11M&TL6=^"_JC?3#C!V\(&QG>X89L&] WA'&-JQ78._ PD% X%7VM[SI/
M_B#\^1 &PXDR,J0HH=C#/8HGS(W:QWGTT<_UC^%EKUX@Z:M,TQ=>B )77CR'
MUO#*T-2K-[H'C5"%"/4&4HI+AIM].U-=FMRC6JX!5E]F@WJ*5>9Q$I<SZ>U%
MB"[.4=0ZW<A74XGT[CG,2]]QQ[-E]7_^_O'2/CNY_W*32XT>X46FE]-*Z/+E
M4P[E&0&=*6K1_DTQ=9IM>N:B9G&V])O\G*_SI)#D<'-.AL2<T,V? \^TN3?'
M_GG\\6+T<^^W/_X^ZJZW %KS9'K-4O2]5O]L][=CK@E@N5%U.4]UF(6_="9%
M>.N/=.>YN'$V#G__Y8_A4S#XY^N:Z_ U9U3KF$GF2G!4!U'KM09ZE?EZ-\9H
M"F-!>\UIC)8[V>L@\M%[##9MX F='09 U?EF50,"M1_?98TQTNC)A%?#:S4;
MR'>003^:'JD0-K-UDUFH#6'^/%**!=0-YAJ>A@GYIC'O_*SYEKV;J7Y/V==I
M1G_Y'->K$L7X9N^RLX?^8^N/VU_U/\PU;[,9!4NFB5QXCY4#GN7<4TO[O*1_
M6JHD&,2%AB;S?>I[@#@&2&,5%G@]ZY,?-PRNUICG@:C'KT*8\UZ/DR,&=8 *
M?(EWFNB?L6$/(2A=Q](<$-J)K15K0U2V)]I K5HK$?;;86Z7P6,/;I\M/L9]
MI+VM'VF_'G:PK/-)XQACA-\AMXA'B6?;E5'0M6!')#9PSW2'PC<V@G<S=(3!
MGJ=#4X,H9H%A^I*N^=ZP:[WGMO%*QVW'\W5EL?[L_7HQ&GW7_=NSOW[KK[D*
M7BL5US.?SM?JX)4,_27<LA^U+M._@^P#Z*.CP7$_8!0EEB<%^>C%YSZ 4FW)
M*/FY,C3)#N)M&/4Y\<)G)+S&(F-"Q!&(V^3I3L^B0Q_X2G=<5U("]Z-H=UT\
M[W%PE\EF.>$FF_76Z8UV.55LU>[X0_\2GWL>O6W^AK,?CP</_WFT?_[/Z;HW
M7'UV1=9Y]&YVXXE_'S:.3%OMP>7VX,OR%#5&VBL.*)P"[O$N"/=L8E^1S(D.
M7U#HZ@X=+8%LM<:>23L/$W-ME*$'788Z*&JIW/:(:5?P  A^H@/CZ.W)G1H)
MY\G4,]=+GB2YH#$_(O^(2)!Z<9*QB).I1JMV6*]='-2!NQRJXY*B*G-T7.(-
MN&6%-I3V=D;\5^I0 (3$NW2$S(WSRG%\!]\0&O]&]VJ. ^#XXO3WHV;[\3^K
M)WTOR'EG1(,E:516R?:)?ACPRD1XR<L@NR.5_<IRF/_-O/YF.!)EQ\W:MW^.
M!HW[8[ME\K]8A*TK.O\%S6,2"HDGO4DAKQWUSST^P##X%*::TXYL.Q@^.6#S
MH_?:X+HY!"C2$1,VL*(G4D<T.XK4"DD*$>;#]I2F2+@_&?'[GP.;:\U:54-R
MJK0O+8R/Z4I7*D;):-*4&CH>L6P0$*!,D?^"H]\#*'1L(VQ+\'= !3.K%33E
MD%=P& VO:CJST4$"E^@8@2!\)*S?A[7!OY"[<%][9%; PQ<^.F0QX8/P9%7^
MJ8N<$11D_EB#W4;RB(Y>>Z@9PM,\.3J,*ZA@M?Y#[6&VH)(/\S !1>L"*3:Z
M:RC*P1'*9CJ<'+YL!_T (XC$G.W"<6;AB9[8PP-F3.WA=%E"D5=$:46BT]YM
MX)/G#!86-_7(%&XML/+KC6__?!U<_7CT^><_GSJ-UW?U2\^>N<U;![76 7;_
M26WS5EK(P!8W'%]N[N0NO[ZY2NSSL&_@<?7HK%4]/3N9M^,UT9(OW$I)G%>U
M$7/E3OOOVF&M5J^&IA%N-2<>CMQ&[9%K6B"\"?&MM2*^C%'X:TC*25&;<W>_
MJ2S/5_O[1?T -][=;[,3771J9T YA0Z<^(]P]]\!!S,.[J)5H(._:43,;>$8
M#DI@ADQ4^45XRS%-71P$DPQZF0R*2;]T.IIE(NIE>H7B<]E7"QU9O$=W&#-W
M13A[X2E;>,0FVWM.39/+V?>#+FDO'X!CXM0F)^9XQL0(BB,8)<"1[/R9?&%R
M\V3;-[-*(+VVD'(/K!'\N?8[W4#=N(?VYR^7E=LK[?SVYN'RYJ%<_31W*V M
M2VS:2\4T:X<G1Z9=S'"+!<JYK=\H*%X1M]IASBL&6QW9+>YN+;=PH&E/KMOO
MOFW46M5&\[3:.#IZES.D%883*\JT@8LFTG^Q;V#2O/ETU[Y_T*Y_>,]RJABP
M.&S7NRPY0_1W<=B@<+DUWKKW$"P1EP2Y<>WS(=%7/\RO4\GV.6;CS:<P?C8_
MGCE+I,\&\9M/1_O(W5)X:F\'4"D8-/,<W;WI?=?0X^FX<7D[MDE0Y3>6YI'B
M@%.(_;Q3++#UYM.OMLO!H,$@AX[/>CT-O?T8/K$=GIC?2(]K>ZQ#IC![OE.8
M/7KSZ7S<Y:Z,UALKG.X>FVWL%&*/P31WG1'2P;?$5H_K^\X%F[N$J),WG[[P
M/K,TP)7.J49%^>5U0_'!2="V=HH/GK[Y]!7,;:W#>MP?:Q>FIUN.%[C;8HHE
MP6[1N:SR5RI_Y=ZC,6)TGCB+R6] XE3G.C]OTHYB5+%)Q285FUQ%RSS:LA?>
M$X<Q^0WNJPBMQZ(#TTVJ--F"X9+"Z:MPA47UBRB^>>!8F!/]%3.R7=$^3-0V
MUNX"5Q\P3P08BWNUN%#H=GS]Q\U]9*1)Z!X7 +KY'B!QC[N/B5XN.P"HDK+%
MDP)@JY4O6YRJ*8$V>.!YIBQ$T4XDQEY%2>/GCFV(:BYX#2 TL$36^NT(*X1A
M\NV6X-K:=_YWLNT3=$^<R.0WNG]C.K2)13,>.>$-OK#"OQ,N(ZW==0)?DZ(>
MS]VWA,%3Q3(C.)X6 (W'>0XN9H*=N*X HK(3C$86_<W<,=6GWB7XE8D%GA4
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MR0;F-C!'>!1\#J0QT]8^<YL#UT/OL_B=F%]\\BR/D.>&W&P'LJ=[?Y!<;Q8
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MWZWJR6F-?I&U(I185F)Y2BR+*>M315#!AA5,%$P29%U0@(OF,4OH^[KR."B
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M*3]ORN_W:.$KET#MM\0X%<UJE37O50OT99*>17<!<G4N-*O2B4M*J/(N_9B
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MMM>S/D&,%<L+A(?]'_ 72,KAX!!EO*ID5T*M$Y )%[8JDFO5%)Q1OVVX$FZ
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M2+7!SVYHMN#<"Z[!@8$N7>M=<74.(C-W4BT19K]WB HB?,LE;C \1;-P4R8
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M5M/+$Q@OWK:UMV"OLCL[2^J$;KN)828"G?.1R>:VQ>'.N.@B-;RBU(DSG>Y
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M9'+PU)W24)L%T5\-Y.#(HJ3BV05EQ>\=W[>C+G<IP(H!V/62!EWDF(SE#);
M*R9DDBK@/ECREO(<NP95\_BN/[/Z ,+TXMS5\694V&(^76%B7+P YI<HO9@6
ME<*#9$KWUHM?TZ5BDK?*>WB-AA@T.+FA#^(Q$: 9QPM<D8@8)N5M^?QP2;W_
MD&_H_45Z8)9(11F)&U E%K:.A=4"5]-JI"@1!#/@2(K/.I9$T0/2)<0I>7IA
MB1783L5XIB=1/F&37(YUC]HN3FPWD#O*/RFTMDL%_Z<!_0\5S&G-Z58"9C*I
MQF3IX'+WA8KR\4VHD,]Q_9FYOB^ISL[UQ;N.OL=A!#3"IDI?AMCW%#M" 2.#
M0WT;1VP'-R=2GT1B(,A) CKVE.5(_".'>YZJC0.JN2$*E"FQSSLW5?4KK;@W
MD34\G%&>JKTV_&[@8F1YHBYN>H->GL/P&5QIA9SIIP']#@1FK-&/=Z>Y0S&!
M%X6N-9T-3&<,G<^JQ4TN8+71%=(+X2WAV&PM"2/<%0$@KPC*@1.447(IR)7#
M@J%Y]+L^EMMRDPRE+F#;#R^L]"4L!.7O5Z#PO ?Y'K2WI3#/IV.>L;<!*!/1
M!J">@TIYH5U"'!E1YBC0@("BHR3H;U08<X4N)622M8_,*#0(2UND?E1)!"-@
MA3X4N&BL8 (Z5)(MYM2\@&H]IOQ>,F]_2K.[[DUVUZ&>+Z;[. H_!=8&01$I
M![UC3%44L"$Z_&-$LYBB(H;J"(821+-<*=/_Q/[&&F@L'9IE(!TK1Q&-BBJ"
MMCJ*4VMQ2Z([ELAR-=,.^J(6H4#EY"->69@MFK!8*@M?JPG5W; KBH,9/ 4!
MXH('7-##KCN)D-1=Q: B0Q?_SH<%OXZH*2FLHQL)$"V6E*/.%A]C*D&@5,L2
MKBAR\ZUL+XT:E/4U8W5<E6BR]+546-IIE9.9;M,2A[4EYA(/\'UVSY:Q^0,-
M9.JS&E=D;<VP3!U=R5BQ,LYA\"P7J7>W7(M'XEK<JFOQ2%R+XEIL!>B?XU\^
MV+N+2S>T"G\K%_W#C0JHG%7*_1@'?4^6J,EP"B6!<._DA9.H4+4=*9(;= R2
M-M&K'UNV#.OV[H^4#1H^O.))_]XB0<V"0 ]?N#5L\8L%;49;*.!Q\A3E3,ZQ
ME7R^_%(5DZ\&/WQT\ T*^W)1E6WLR>#@*3;%<FW9EH=-Z_0I=N5*S7HTE[=9
M3S;FH4SY27?F%2C/LC4/F];!X$GNER0JBI>_9=ED8^*C;,PWN/>ORZBL5K;D
M*2H"YK/1WK!_T!GNGW2&AX<OME6M:/O+]/%Z.^3ZK6ET5Y"^O?AX]:Y[_>'R
M#1D,7RG, FP#\/8L\>&@?S@\/&X#U/8LZK#??:7&W6%_<-0&N.U9V$$_O,2^
M/9QO:3(MLYSP1@OJ68:7U.[/I#UK?F6-44]]\?]CF[4)O^<M%*2"5) *4D$J
M2$5C%XW]$37VZ^OPPU\O0M+<27&__N_K#Q=O6$ 7'?Y1D!Z<]@\/COMM@-J>
M11WN=U^KD>CPHL,_@S47';[U6RA(!:D@%:2"5)"*#B\Z_.,AM?I[UU/@*>F+
M(J9$@7\D)_Q)&Z"V9U'%"2\*_+-9<U'@6[^%@E20"E)!*D@%J2CPHL _JA.^
M#3#;LZ ')X?#?E_T\RVKD=VWV2WJYX=M@-NFA67]7-<(=RHY]Z]+H[E*EIW5
M]D5.DR]^LE5I)^HV'JN._544IEG:Q8XA2:2+/:78;<AT,*)61( RFG$[D9F"
MP7%,70[9[Z"4++O>. Q.J0D,&>5YM/10%$M0?N=<\M;,QE2KPN('5!\7@?FX
MYMF$RCQ1O4"NNK+T\7#];/R:9F >SU)"@N60HL42:U6-\RC% KE<'#B/%S=4
M#(I6[>M ^O!XCE37J807%%B"G>IA<W5$ D$EEJ(*=@F@Y19 UWU44M7YYGYQ
M?? &5/KYADY5]\^"L/RYY:8!ZU3C[?3&56BL@ TC6[L*7,P?:TFF33IT!&R*
M3GK43K^[=Y6;2TDX>!$;M&/HQBVH.WY<=!\+IW,!+"SZG5=<+&OMAJTV%,,"
M'XX:"<8*17+5_?$XYI9_/-0(?C6^0;9!;S)5Q.#@=K!H]B2"+]TG^A]4".X&
M=BR;ATD\']'O.@"HFB_TOW,U3=1G E(LY["X-PJ$TW"RY(9NRW#OZOH5]@GT
M4<**X9.Q\CL$E,N%HOIUWC@1=V7"?@)8BAO>V 8&W)ZKXGZS8M ZN^*C]9.5
M@65@&?AA S/[:*]IPZNKT XKAU??HCW7F%\A:9NHL0W'A\LWLM;K0)]N%?3A
MZ?#H9'\@2[V^8.A64??W333#J:SW.M '@ZVB-D84TURJ%MO0V;X1Y<'&"FTF
M6:MT?H6Q8I.%HFZ?>8C!@HT#:]7U)S%8\ #;,E'<,_^'62R^RFYSC\6"FZ[]
M=ODJW+NG8[#K^OUBQ<3!2KFEQZ^W<OP!"\>Z;?2,)9M-&5LP8^!B=<(XSV/=
M'CZ[4XG?I9Z 3);%0BV*..IL;B!B^M[7'C$?N4?G\2R'I^%@G^?9C>N\]RJ&
M!POX^#8NQC2CFR5,SV\!S^1ZDV=I/(:5F";1?(Z;M&34N*T\!/8MFBGJ!TW$
M,,ZZ7HMXW4H>'R^K?$2FI4ZCI[RE$+_IWCS+)M:"%*6?L=\1#(:$4W*_/^_%
M455F:8:=D7 3X&#X1L)=,-ZT^^;:KIIQGTG'%-C>0CW@72_;_&U*YQ]+Z?QU
MDO ?+IU_+*7S=ZYT?@M./@STS6N'MZ-R^)-=2X]1.7R'!($GVI,MV\H>IW+X
M][<MVS6K/5KE\.]O8[9LA'N\RN'?W]9LV5[W6)7#O[^-V?J]?U_E<'$3BIOP
M6[H)GZ F6;N7_3$\AD-9:O$8?OOU?ER/X:.'73]U>//V/(;?.L19#^"F04"^
MF<=P6S'.?]YC&#:2^;?N,5Q-27A@X+,FE:?V&*[W%O(./;''<*VWD) \K<=P
MK;=0NS/%8_C</(926Z(5<?R"5) *4D$J2 6IU):0VA*/A]383<\^7EV>?_S]
M["K$/^$?']Y=M0%_>U;Z\/3XY&#P:-D5W^>B]@]T5X>AM,MXE*(3?\KZ^6;W
MK)\K%JMO9?U\\V>MGV_$^BG63[%^BO7S>[VBQ,[9^BT4I()4D I202I(Q<XI
M=LYO8^>T.JKTPGDLL^>CA8A^GXLJ9L]=-GM*T*<$?3YCL^<#R\2(V5/,GF+V
M?'*SIRD)\SW4A=A>5N.#*\*<2$68K5:$.9&*,%(11BK"U*^:MF:&2T68/Y\T
M*A5A=G%;I"+,CFZ,5(39V:V1BC [NC%2$>8>N>_DA[:X]BR1MLDVXL2<1^^:
M>?'QZNS_7LIB@_#20M"M7.E!OXVH6[G4(%T\E3/PK:UZ[U7?M]Z/GU9<@)Z7
M#=T5?]!!L<DYP4Z=IW10;'!.&'>.<5"$V_)0=)Q[ ET-VD71V=#ED-T6V1_L
M=+BM+H=,'H_O!6GSD7U\T>IUG$@T>&L]6X)4D I202I(!:E$@TLT^./;AL*]
MZP___?OE_W?QZD4;8+=G@06I(&T#TIJ)IQDY^\U,/,TPU6]FXC'F'6UC^58F
M'ON);^MY<A-/T[Q#8"30]1L8<[86XUJ?PC\K..#3Y:Z'OSTZZ \W*CC/@-;3
M97@3%6&:A56:V[!CS'_@B**BU[*9M7([?HY_>0\L)BV+GU_&O[0,?"M7O'D
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MIQ+GDB 5I()4D I202I(!:D@%:2"=*>0BG-)G$OB7&KCV@X.7QZ<G!P,CMH
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MH<0=/UT"]0&%8X2D=@IJ>S@T66#1%%BHY%89QP/!93,DLCRR/E(,J!/NZF4
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MG&1<.H67XYR-G\"\$*%0J 1RFX;VP6(T-GO1O"IR)25Q?[4R()$.3P#Z2LU
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M6*^!GK(=P]-_/16T<Q\N8F,!F5')2LO39#M+G!;4(-PIKDZM8@7V)BX:; Y
M*U@-=G.2KF.CDC'/KK)]MWDER;1,!>K"J QL!U9J:>NI;RNN&+RX%#!=3=LZ
M=_"ETY+UR_'.6'FC)MT*.%MB]MV.$_@44-_AV#1?UV?BB^N*OZ";EPY.4F0=
MO<!8>#3.Q]6<%WB-LRG@!O>^ =]/F_&6=4H7,A8W56F48/#VT^AU(N1]Y6S>
MW6I'([ "N%S1F )$M01J*YS1 NW_]GSGJ+[,*6P*>=@*B[(" 75KQGPE_BD&
M]S.?91,'Q65A)V,:TXDZ 4D+ONV#[W]CIS&&"IA0-F'9AT:EMO0@6I(0A7;^
M>(P%(:>UA *5<VH '#)8!-^6NC*!0%],L2M7V0M?^UW%X=B\A?MG/@)4P_[@
MI,/58/#-W%XP36'OQEC'IE0+3S[%QRSO1[<,0C=23VJ 66M34+-)+Z+RY@[.
M(:4WP+YR0H.>168$X_,S.-QK4B2L3<=B8\]<25G&*>,!7J22;.%M7)D%DQS-
ME/6EY'4T!CYC2]< =9%._ ;O<J[!J7(GHQ4D%A?*>X\FC0GG/).'T%1'3C#1
M+BU@.8PHF26X C41$L:GMY$<[EZD%VO]=C/<CK$V^R]<5*,D+M#V#/^ADO3^
MVP)*'"0'H95*^*H"T3LN^''KFYILLL]I/VA-;O4DXCG;H^&\#_I\,''B*TO'
M8%!"7JJ205&,)% 37PR3#.W.,,W$5>>W=^==EG]B@?\<:"8GWU>&5503.I3-
M<VR\E8F:Q04'F#\S_OZ\N/P;=("A5(R2+3&N:_1"&,YUZO@"N8$FQ&3Q%'&8
M[:R*624$/7><QR.6;$(@*#;XF_ 0%S+F^R5(#W7JHC&A&SZNN<4JGX;CHP?6
M!QY$9)4D73K+18GUNHR3?;E0A:?'U^+8UA^ZX,L< 6O>%#?9G0V.H4.@7SE7
MZ(#)2 Y"OKAA[K!:Z-^.0A"\(N(EM5HZ9%7(%7R0C6YC$X<#QUAIQ6CEYJ)T
M82U\;G@GWP%P;:THV2"N+=08KY)5AA-H*7OE'F3;A1$#]-6 #);$8;C&X/^%
MX9#^AK",NH#9E\IJ>5]#*GH;R.4#%!VG%4_"NY[P6N[:23DZS4",);L)WVYH
M"82SQM?JNNU!>*3L^'N,LP"-L2"RPPL%"V;,Y_K:YMK1L,C 3B=D_\"[9PH"
M33Q*GLB-(>+N'XJ4! 4J.#,*U+>(DI1]^\K9F BK2\O,C!9>4X:=]WY)QB;/
MSN0)/D4V)^G:18FM&&P+S_1D6)^6K0(3+::M$[Y1ZKXH+N2B^+S^ -5P5E7@
M0F1SCHTVNC\HQ8P87*8,85-4J'\-KC/; P^NQW?3I%<-4USJF-'3P&0"6&"M
M(#4)X/("HE I9=>PJ]KYL$E]HX"Y1:ZL4H=%,6*\(#"VK +@S7QKMUKT/O@D
MHRL@HO)+TRI)M"BRX&SNJ6^=QU%Q$GA59BG> IWU/^)E,_S;SS,W5TZ>@;!+
MZD3],H:I\4-6*TXBC'!)9[W@-74QY8I+8P4O8[.7W2<=JZ_['Z3-A$QCQ=ID
M9],!+:6.)RDJ4C=)L.-B4(I,[_?%U9#_)#;AF(PJFE$[&FV#-+$_TSA19NOI
M5Z0Z4@A+L8)F4YB1#B\<G.BX%"=YH9IJBU@A[I@*K;AP%7S_Q!SQQ)HX[4F.
M4UNIU2ZN[11A!W)1)'4+;RVF).)PD+!:D)SD&T)ZX2L3Q1(73?M#,["#'##K
M8V&R/!@G4>Y.,LS1_]XTPS AC^[DF1>8("TV+F.H-6X][)L.R](AGC;HJ6,@
M&<'2?F-6*=!EP73^AQX0#R>*.E5*,J(OLCIQT(2B%IH1:LLD<@:M-<*03D6^
MS9(*3G >ZW)EDSRZ2S&T*$H#%Z6%%6\*#OI"7*21P]88JS2N+C$I;]GV5&_6
MZVQ:DQ?T,B[;EI4<(;5_9,)\.#907R!H:*4ATB7WMULE/#RNH!FAB1.N-D6C
M48M/(%QB<UE5XJ+4=FU$'9W09Z##V6QP6\TJ[;TIT+P%R<!)G=HYXD?YTU\^
M>\!/06E!@YAVCS2"TSKV\U@7J+/B,W*EV!4XQ@[,[EFW[W,N9F\:^NE02A*M
M<4F\\^?C[H&@%6=$HG[;E@9CQ$$U<ZP5#%F?W&F-@XW/"Y ^. K,2.YKQC07
M@*,]??GYA0-K^I>>64!\#G_E/EM?LX36R=TK,/?U=4O@\JQR+@65Q'7?ZW]=
M7_6:=$@!9P%=BIXEGC=@20</IE9AT.!4N:HI4\J:+<::JX'>/QP8>QL>8>3;
M$]U5Q_%T1?KDO^X?'7:.#H^WK-7LNKR[5<VCANR^P*TC"=S::N#6D01N[5S@
MUF.??.E+Y,'E%D2MRN^NM2"2=.^&PS9*$B<RL3AI2F"L"*U>D@;K0"-5WJ$\
M#JJQUB]RN.2UQQ=C*E &(U5HG;;DB?]1R@D"G3")4=7,<MT")%VNBG@KFB+%
MU:/[E\1-:S'X48HC[#H%MAJJD-1N0FT/ _8B>;V>]N@HY%ZC9%;U0P4]A=WJ
MQIP/R,77A#YW?L];#55(:C>AMHSE^9Z<KC&X,<=S[IR7V6I%7VT"Y0((S?)#
MSG]!9G?V*EGQ4>AXYVFCU5"%I'83:KM88]WV;\*'=;U=S_QOQ$6,'3/Z,#+"
M6N-(Y*)"HKN^[:V&*B2UFU#;P_6\:N/DAM;B&N%=9$E, 00FZ%Q'.F ^F]^9
MS$^E\@(F4,[\%C4FGV-L^2-E@^NH!9O1IRNIV:+*C?I('+2BZX=%J;,-<X &
MUTNS'^.%:+[@O"2*;($7D1L[J(J*C-DZ' P]UVE%@>S8J<Y&,'# FXE6FRMT
M_8?DL.'PGC$ZW#FZW;=5VUBG?V!>-D62X8?8>LD;&X-: DZQX,QMG<9#,=G.
ML..R<<Y6@ZQ,*$\M?E&'\405O#+GQ!J7"N^E%>J!36IZ(PK 0XK[8P8WP41D
MK=>'T ]+UP'@#3#UN \3#\*X*4IAD15 =X8#>._V,YQTA$,C:KU>;*T^*><2
MV-3KI0#]TH1RI#8 KX,"V#RC>)V@B!)V<DPPP"X>52:,9^(U>\07HW.CB^%V
M0/@8OM>M%K[&"ZM%T>0V1MX+9%R:Y  =$-E,P UJ>?P4[<:Q*![36XF,K"UJ
M?0OL"C=>E')<*[6SA!G1"#I\%-;^5@'186A)<(>4C0W* *I?B8NZ4A(582 )
M)CZ-PQN%H78AA^V8>"0/]\:]Y+5;K2X VY3/5!XLLH6^"$A&IE1?G=_'@74Z
MA*477J8<DS^.BG4IJ>$\GMW0&;=AN1BW2)MH:P[H_0N1NR\*_3KF&AA9Q$E5
M.OV+T@@9 RR Z8CIQ5QE*S3@,HB13QABZ86OHS@AJE]MT[G^B 9<Q0%KVN-J
MS2-*3D@PYDSE,+3"J+<QQ]9%XV:]*!-4YSB9(R!7,,.:H-=Q<3\$[9Y&3*9N
MYB:.O^("--'#:/+1?(]"QYHLWU$Z13<!N0<N"I8SXASQE51W;(W!B4I%&,JF
M;">.@$(2LE L/&V>,K7.*(I51W\"VREO\!4!DP@,H^-AO3?IXZPS8HCP8YWU
M7G)U.;K=;*BY)B4*>],'1%^@+BJ2F[&Z,>C,8OT/CGA#B>D6B M7;C6P7 >^
M8U@B!65W0DSTY).  R<JG94W2YU5ZR[/U<AW&V9HULH41 T*#+\M,2R4N3)W
M,432X#1$*LI&-Z0ITN"%D&K_K[[,=K'@UVZ'I7W#- PFHV"LY7\.SK5;7$\X
MZS#CQNA+IRYL8BD=%XA/3>?+I0G 9[J> ".%[PKDB(GNY!SLQ5//CO("KGY8
M@FA&4@"0?YPS>X-# V"<@&#K\'#<:Z1#7@V[Y>A773&?6*.9C^G ;"?$(JFN
M%.()-RN%9&NR35@O+FR7S\\>\0^TT9*:E310HW*!UX$+O.XU K$+7>]P_4",
M>\[Y;BLQZ84)T56?=9RO3B3QXKR!=Y%0J298A<?_.28R\I5L3?MP-9CE(^'*
M6Y<Q=JYRK )$X!E*Z!VW1,2Y=1T.KW(SPG1)*-8Y0=S2]EG%"&PM/*_$<:^I
MJI)&*&"8!6J4-^F%YR8)O480C0.A*R7Z%4,V;*([+(;7&PK4]53&4550G*XK
M85S/TL'B =14<:&8[G7Z )9<IM6P2>G>$\3JU[X/[[!Z>0^^?PDPQQ3Y.H[>
M0;K^Z3;5::(NAX$V@]+F*4G?N]R,4&3VVZ95:1G!V$F-/&D0-BO81SJ>2#?V
M :G7Y,-^N9G%[MP]K2PV>2PQRUN-63Z6F.6=BUD6R?+1$[/?I;,,L["NK)W8
M4QLD0WN79W,!-RI(PJ67A\8IJ(77#".K9V2#[JFHU*6N W$;%9PX:NN(U6QG
MI@B$SB%+EJ8(CLYB^O'I;_.NB5#_1O0B>0Z2Y_ \78P7QC-A&AGK%/F,HVS)
MUL9<!0O/&/NGX3WB[][Y#6XU5"&IW83:'O[V7]=7->E&IVD37F,OJF6?^ZZ>
MC2GJ'<_[A1[/=(;<DRT['5.SJF-,JQV;Q_Z2/H%1R/NA':,= F.RTM%BF4ZT
M!577U](V0N#%; 8SIEMG?''&6],*)J*,?,S"]\RB9'EBP]Z:6#HY>CM/SJV&
M*B2UFU#;P\U_U\XE/\*MPW[[,B[0I&&$5AN=TN#^S7@6#%WIU.)6T%A/ 2TU
MGQ15+?1O!JU[Y]E-/.(XD6B&@5+DM>$(/0L!XT1T;6..BDB7(;D93*P-%23#
MJ 83DE0O7VF::7+QDCG5]O^49G?D-]*E'K/IM$N^-U.@$U\@QV_G2;K54(6D
M=A-J>S@Z1M4T^C!>43 8"L FN>/-JZM.G>4S0W0.7W*9U@+6.*3,CRB+'3^G
M O9D'^4 :8JF(=?OA"O=IWP=D$^=[Q3X9<0Q>@5&K5489O'/"@.?X",,,IA'
MR;1*Z6;104J>PY9"X8H8UBC*:^$)'A#N;C)"2\LGE5"L($&J(R(TU(1G(Z!8
MEUQT@+A@.Q5%&U>Y'.&=/Q:MABHDM9M0VW,KO*E%N 'WRW.VE5CY'@1Z"I7,
MS67QQ?NA9L!9<SU,T97MO4KWW:77%,A3J: J5NQ)#0_.%<CT2C>"HS*<',C-
M(4Q:@'<W /UBKB9+^,5MG)G ;-=+Q #%VJ2JH/#CQM!RSG:>=EL-54AJ-Z&V
MAW5?<=^UNM7%&DZT+#W'&J@Z\H >9Y$U5[JQI8LO7.39*!IQE==F<77=#I!D
M9",#FQP.S8FQ>+*.ZBHXW#C:Q$0?-^]1(A0D0D$B%/X(UC.34 J"$DAM49RC
M+6"11)RA98T$6$X_G<AMMO,;VFJH0E*[";4]_$Q;.3$,X!/KK5Y9&J/?"LGM
M^C:V&JJ0U&Y";0\7>^_7/:#R#-R'V*N X(58$7-[YN5F6E9HY@QS" +K$*,F
M6K=JM=%TAZ(5N'^ZKBM.>CAW@Z[7+M<9NIB,L"%#5^?B8PMA5MXQKS NT:]E
MVBVYM,/5%FFZ;Y9.1J4<2<;K*AKH;PN.V)@W&L=3V8DUK>OC-.9>Q)W [W?/
MA2)T'Z&EZ5HYC@L3CT?5V>,BFF%Q=XJ,KKLA;1F(VNO\0A'VY\5]OP_J<#%C
MD^KKJ$^U9?"WK=XQJ\RSB'8A<>6@8C=(\^=^^REJ<H1U(O3O@I7B(.BIQ [C
M7NF<9C484[54VWMH"*(IF[X;5FD9)ZMM8C&9=H0YP&K2"\\ 1T?7ARE4,([S
M<37'ECICI/75JB5<=,(KW.-GVGH),%,8WN3'I%&"J?*[F+3:0I[U)+,!0@W\
MHF>&PBO=XPRS&K#@$QH7Z]43ZO3BYS8 L=DB*-C-F<K^8!4:)!3O.#0&#.I^
M)DWV]BAD\-D$D^_"457$5+1 -TZCK/62NI1YD"TB_@KC"# E2Q?7X0\3>&U*
M[)'KK^")M<6JLBIW?;+P -!/7(,NOWT714FX;_#+$#:NQ+(PG-8^S?)-_;.X
MT E7I-&IY &_K"8$Z%RR=;NE6\O[6T+P;>R<WPL9?I50S[QZD#15/T+O&3;0
M5A3HG,(]1T"QUYUF _-ZCTG39=AK2$F5?VYCX03MX@1O_(T-=&"[8L)M-NK&
M>$J_G%6S>I17$X&<S%XW.Z!W=]QN=3*F+JUB8W]<V96@UNG4%>SB? &/WKWD
M 4WU5#_"SL/F%!2=U2P O_B*5Z*E5I0MP!!58&B132DH5 [+H2MV3+%'ZHV]
MDSWY"T%S$UFJ%_;!''J/$Q;K2\C1B85;51>)B!RC) Z'S4=ML1B0S/1]G"A3
M0 XV!4>@SX!_G!4-&0G[U=->>M>\K2Q6C&$V5<)Q757J_O3;'OIM-[UJ8I;5
M;.)XC;19%)1<63%BVC=5.<$XW6S:81MU+?JX4^=#@:T8XFA(RTL4Y17_KZZ4
M8E)[+6<TM,A"-46S16OJFK%XCIP=N*JY?W@O@4B(D)<!!2O#;F15 8>A2CG0
M&/UPB9H;(178/%8X\9BSGS=3I=B;=APOB$';U]]RC9Q\Y1.LA3-&IQ_^F*J"
M 5UC9;1ISLZ[9<=VW^0%IJI&N2YK0S%RC?HH[DH=9[K<#NZ1E2JQQI")F,9(
M#;@T;I8%8(Y2LWFFY2VN"+$.6*[.RC8W \K7UE;46SGW"[7IA7/3T-HT(#,]
M7'4#4.TK#9RJ!B0AMU+;I_CP5I4G4O9EJV5?3J3LBY1]V1G^\P2S@1L^0.6.
MBN'E633Q;1^>=$.5N[SJIXOL3F%C=M]<90J%%FO#[O$-V%Q\5:+VU,(-E4<Z
M:)&R'>*C\#;*8S(B3GV,:%)<*=!J)2"V=IG+6<LI)(Q3MBX)&!$'Q1=;+V0B
MU4DD]D=B?[:(]1]13K4DN6QQT2$;<0G,A1#;3\EZVZ'\E]2P XK\HZ3\,1G7
M29>,;^/$67C%);KS!- F8N7(5[R);(5P\G=Q3,=DCJ85JJUSJ^@636VVL=/L
M?8U:R'/GM[Q-Y/F.C4L4<>1,%B9Z$HN<H*VHJ JJ9\Z4668E?N:L6)Y54LAS
MY[>\3>1YI:85V?\H2C^)EE3'7!N^;3(P&?#(JLV>,.R5@2*]K?9<&!>9*3A.
MAFOTD%LO$MK4O' &<A&JS[JZF3!?H>Y'P'I=8ZM.0&#V.UV)>BATM7G;$Z(P
MU>S1M)_D*IHLN:S]#)XOE<2][SX-M(E>.9(*.#*V>\ET-QGL;F+9ILF!10,H
M5A6;H?<H95>8:T>@/E.:;<V+/S4%=EQ9_ZS"\@:@D0'9"R'O.G&TB9#/\WA.
MS0Z _+ ='87?/>] U.=ENGY7Y8'?OR97XRR?%)NK&.K CG7! !O\_^$&_W\C
M'B3PXD$^IMB&);SF<+!&2-GFPMHUU_'Z:(F[328O^TGP '-7IVGKZC2<\M2V
M:A*7W.^'\^J*6F(=_84I=;SH:-KPC!5%X!4UZYA>)PWELJ,5R WZY;06X])L
MG';/]:,*[^8)[KUY'G+KW/MNDJ_":471: O82O;2UR4U*Z5U L_X0\MEYTMQ
M#N,JIYXRQOF_81BV5M[+NIZC1_QY<2[NM>!Z+.")J9>ZLITN+ZH<3A"\%_A*
MEDH'AEV>#?I2Z_M%QHB+CQUR?E(O9F!!INU9.(ESSG\H;-"K#@A:&_]GNRS&
MZ2V& LXBQ^&QX9>.^(.+CK.?3<@?A]_Z@55>;9PUT8\]0.QC,SU\X[EN-T9W
MI*Z/PVD'V*PVNK,QD/#[N:*NAAP534&.]2?1&WN+<4P4Y)2EJO8+;N-%S%CX
M6GL.P&4:\/9W7,T.?:\EV"[.NR7=U6S2:$PLG4^(?\WN,.:O8ZC*IO!P@$&2
MK$3NDI R"72XG7Z9X:4?F9;G2I4Z[BY1MWB)HW"8DA12$\N2*,8H\CL;^'<.
MRP<"9_C*G([P=/_EP?#EQ<6Y[27:8.2!?=9U8ELS3/_E_LEA;9PS_N82@UQ3
M=N0W[PC[>X[4G&<%RB/I)**H]\1-RV^!C)MBXC,:"0_ZH#/WT:4*/19$K52Y
M2QX(HTM;II!RKS#Q",5B.,ZQ[O)J&99MMAN0J#75H1NF4:^=LM<ESC0^IB;$
MNCDP\8.".A*;+K0=/[:3\$?CFQAHA@,I54Z=$--:O/)HN9JGA,-[,Z]Q7MU"
MC^.F=3]96(:8]X33"'@#+/,_S^:FQZ#/^3%L!4O18%K2) )=Q5<<,*RX2?^U
M[CKN9_KTF.[D*Z6,32?#6K-.#NFVBV_>1;7F<^I/B&,L.'0FM1'$WELIQ4-W
M7<16E<7:,_N!3CZUR,4(\)LH!X!4M]B-1!D:=-EEZVO/JU[P#^KUBV1EXUP[
MZ^*M"W]A@+:1F2#M%D0"&#H,ER73:Z:[P[-2M^'04RJ0CO"%19E'W!?YO/'F
MR+[5]5HDC<3<DMB'<NTK>%TPJID2AN"K4566NJ81J(#SA<NE=-0=,/38,+^U
M0\MEV9[+\D,6N.Z9:FTFP4.NI3-@/Y_#2U.O<.,5T;DOO:T(B'=2'<,95I!=
M*U*Z7A(FIH[B\("&QVAYT>>9NG/K1K:-5^(9QV#[/2Q=B#X-&-N:C?&(F9<&
MZU[JTL&PPZM[ #-'3#-N=^? &R>*4U]@XW+N)4LM4$V2C69PFKM[6>MH 8%Y
M8:8ZA_%3;AAV,=5E>EW:F?:WF+0+$)VY22^^(\GNNE2CL2FC[)WCQ&'/TBSM
M,H\&F/C''-@5FZSTLR\HO6%=9BU&0Q8JF78G"M91][;UMDWG-5BH7R*J/>60
M8W DFF4*6RTS8:$\T#<*YV_/,7<XR69+0/E%DO%E-T67<7YK ETP]>=M5G+.
M[Z_99-FK_1EKPQVR'+1-P<] D)A%J;[9"GV'D/EJM$0YSUIP2),@.&L6R&P(
M!VO#?\A82!)D6),@>^%9'2#GTP1 Y[BSF.!>@4#"4;*?(PR"I4N$UM[:CFPG
M8#B\0/A&K&EN;:%_8-.XBB4L^SS<TW&L<%(IT9D,9V-0&_-.X!LD+Z_?A8/]
M@Y/#'X?]P9'-AH2%:#*'_](O>!.E(-G0?EW3NXH7%-EKKIR)NXRLR&SM5+RB
MN-#! V1J%MCJ:TE&/+P)/3L>A_::S3+\9N44<$MF_*W-0@V0[)$Y\L&(#(FY
MT;2TW$P'+V^X%WC"XL'Y!:Q+_LFP-).YHQLN8,AP46LI3JT5+?$$GOJAVXIG
MNGS Q4>YIEL^Q8<GZ)Q*@LY6$W1.)4%'$G1VAO\\P6S,51G055GS=-4N-9*0
M;@'@1%> F,:?,5N[TC>@EAZ*FT@;:U#>P^QM-#(M59075"JG=E-A/H^QZ7IO
M[JQ*HV0"&FU(M/9*/[&<1%(9YO).E[:G\&2M!N391^JU(B[3P)-_M+G1H.#"
M-RR2:0]N7>+0 I^Q7>4*GZ])+]YT]V!EMDM-XMF_?TYG11"%,]B4'*7'BJL
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M:D0)E2,"\@YJ/O4/Y #L"E%+JD1.'4[NV@7)I);6PM8H@;G5A\'QM5<IUVN
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M:U/' ]F XI(FE.+RS[[\_ \OGR_V !E+O>;S_V/'IB8/ME6S)!]!P0N^WG-
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MA"KI \^\!7*NIFB1@Q@;Y;IQLGO3/LSZDRR/2)/GGG4K=#3;!RT@#BD-22^
M94TXLRM58Z0A77M,5&:57Q@I#\$N&,6D4)C7@Z>L67RDM8_1M:+C)ZC^E'7<
M"H1_KX=.A+S8#P9@B_F@8G[NSO6@1]>#GYVD]<F4Y)S66D@N!WG8LI,\6/(<
M93S$/SN([=WP 4!K%+['T,D1KF7O=I1\S^23K,5++T'\G"(=RU%WC%4Q="+"
M,OJSZ);30S:UG#U*^HG<6*SG2AN(%Q?EXXM.=Z9;9/[9OH5_>&:W"OJ:NW*[
M6[2LI,)^0%)*B)\FU2Z7P9\\F0R=+)R=IW6>33\%O"T;O![D_I^;$;RT%2>M
M#E@5>Y13<:@R52E%_H2VS^86":"^63559T*@%;W:*N6MA^%RNC1,#NZ&\];[
M6_;&_%[.$C4VKF&IPCB=9(^FG)KYM'Z,T_K!4C1?SOU0'[0?ZLNY'^J3DZ*9
M]XBI08//&P4.J> <*F=EV5-?BE,!<.V@7&I)AYU*4)\4GL1GAX1( )=/U%!O
M=XTR0V6:.I C=*C[LF*&9W,X0$K[JX2""'[)&<*2&H<*>F&]O82^RNDT?B 1
M1T-'K!,<O4B:='DV<];,;8)SF^!'A/MTR/5H=PN7$LL.Z5L>LXA&E/4-@E'Q
M<6><X@PC>Y!=69V<,]?(&U D1N&6M0:(%*@<("&3.EO7;%T/ZSDQWX.S\>P)
M2;,G;66 69 +M3'2?"UI<#@><6N,$@D^8)]M<+;!!]F@;&BVF;$5\7C-DN(T
M.Z=P^KZ5KJ=:&".]*CBTD)L](RBD1P!<OXM183Q/R2N[P J[/*H/CNU6.%]G
M*YZM^/ZQ)A&=0'JJXBB410 :C,,XSNDC*FQ6P'*P-(;F+DWA[L?_>?WMLQ=?
MTP9-ON.^7,UV.-OA>S79!XS!ZY^_$;H20PL7_?C09K&FN45O-K.'M>BQ\8 X
M4#4UA51<\V/Z.SG"7<L54]775"&[T.C,-;^^V.)N='B'?TJ]M5P[Y1(\(89>
M,'C&&*H;]46+FZ*L!*-A_#NY[L+F0:#@6].CKMMAVR4 D6A?!BS74"Y&=QU#
M8!01<AC:#K"\>=7,J^;>L:IM!@J4)'I*NJ[9#MT[F*SCRN7(^&=[F^WM8>%]
MTW6EF5P;;<<\:C$S#U0"!L-,S(LECQR%M,%,MWS_X=-:"EUS1"\0US(DB:55
M&=VO#3#O,PWD&/>MPC)GPY\-_T,9/@,_#*RNB-G.K6"KKF;9F%C Q>=80:VV
MFAFE9D.\?ZQF,\PQW#*O#_)6*]=9]CY0<,\&-1O4^\;W*N<KD59A[.]K][=!
MM)L-Q8@^%&F$M5!GMK;9VAYF;:.@)4*K2ITH=0]#B9OA\4:)U_7%9I-KR!TJ
M1Q%>F#]:6?I4!,CUEC%W0;A=V<_4NK,5/^00]D>L):ND TI2HE.<NZ=.'U.Y
M@%QJYO^9C>ZA6R>*C]J[N'/< ,<(LV73VN8I_&8):G[3A,Y6WF]]OZA$YPRJ
M'X17CT;=#])/@(L7=:3QUZ+1[6]#V>U8ZX+[':K*JDMH**;P7+S0&Z<X?HG3
M(R$^'KQO#^"J:1CJ3$OT$08MS8C<3^-KCL<HA2/$>-B[I'UE LC:TC?1*C)U
MNC:U*(].04^+;G&HBKH&OPKYG*Y>-0/W/LM9'I= \S%/!I=#\]!(@E'L&_K*
MT3=<(TB7RT_T_S"]PL8:<KF-!7.0%77H>U'>E#KA$)E[-AZMPS+TR0;Y6^UQ
M7_![DK D4B[U) #T\K=%[8F*6MF?*%2V]B#:=&3K<YU(]71EUR^&+I^@4LGH
M ^=9?DYI#TQ!>%J?;6[:?$Q@?Y,)S=6D,NRXJUY>/HUB892APC!D)K=>;-OF
M5M)\]]D<_8G%S&J'6Q7M,<^$V %2?M'7$V8**S]VN_+0G3%5N5^DL!L3^RV^
M32DZ:(Z*K6[<=LOLS(A+8$;\IILK>X1)KO4TT>RU#ON(K\$W(XR8AY+EXB<P
M6;!9.GFKXB"NLZU(?6UX/,PZV#08/T4#DMM*][YRNLJ1L4>GJG!FE"N'[OVB
MW1<KE9)3.H*-$]$O$%WY9M-,&*S:H:0GIRD'24%KWKN<?UX!>/S>#W1<@/BC
M\KP2$=/*K9.V6AQ<H2$X -020BC,Y!Y-Q&5/IUD;'<G6X(@'9B[DN\8Q:@U=
M.NG0G% W[ZSMT8LZAZ$S?9GN7ZG8L?].8$?@R3*K QM6(?=^T%J)#W9>80FS
M6R8L$ZJ$R0TV4[PRX?IH*(8M1W29,A#/AS(FMED.9<6E_.&0A&O&:B,&2_.^
M<HL[S%;K_+2DF9*M97*7WIFK&]CXG(<$C,D?:#:\WO8T9>=E;+P7>5I,.1RN
M0_R!J.=.?R.Q@R9F!7S07N_=#K0^RUXDSH6$4;SFV'@BI,L8OG*_Z^$7^<2.
M;?LM[TYV9F6Z\W*D"**#9T&'<P_7NA6Q(!EK@1J92 K0CCFTM?G.DL,37J+7
M\BL+#:?GIMBV3CNQL3ZSP O/FS7/EBP9G"_V-!S$:" :@E"*?>F&*WDM:X<K
M8^J$%DUV; T&Z-.=&QVXN#:=)C3IV8BO7B:SY*_)>U/_M.E='"7QP2FGB U$
M]X-H-]R,+HUF^XUVL2OS$=,]E9WQM*V+=ITK;95N*[:GG+",S)O')]5G_M7<
M9_Y!^\R_FOO,YS[SBQBT,G_N7!;E1!.&6G,AC7'.Z(F-"U@_'_*^+."C?&MS
M:N&1J;?]:U/NNZ.B@O$]SQ1HS/W#?E]X7H'D_15M"TK$X/!$)$B@!N"@RRJ?
M8U)A1/13W-P3?(%NM:N;JMD>?=C.'#=17L(G2J,!,CIY,A4!)JQ31N-P&_K,
MUK'K%L7HTT.:V7 >9]"_[ER=I86CI&BT"$6C2:,Z7STB&VJ!'3D^N':4I;6C
M>^M&=N>X<J3CY>P,N"YM$*,4R/D]DW,N'#E(A6V[DQOXPD+$F!G"DKB!\% <
MA=T[L$V!G;84WE+Z_YXJE":D;/U4\K:.*ZZ?X1,9,W./$VI1' E6,@M&M;X1
MYRGNV%*8[-\K6/)]^!4P 7B>?C/SY)T819@&D(\SD2O[2".:%'HS?Q71B&33
ML>>(8TO?!@P3\R3P-HG=Q*O*DF>Q:P9BKFB*S$).3/?,P(R&-9H=L*):'BN*
ME,F5XZ'41Q^);]IFKVSWT0"O%M>>UK<ZCA^G:</-C='VE*NLZ'3M"($D$PLG
M$E;9J#%Z(63+9J=0M )!GXJJ>2(RICP=#X4";]8TW1RU,,LT9G@[@Y :1]QE
M,:N9D*=EH!3NP2E@P ?YYOT4N"I50..L>1"CF#\=:<J+&7\6FT8F""+70PV%
MEW"7AXI/2J9HC;T'@5"B.-B +5>I!\=FL^<-0?*GTH(9\]=%*_GDNYFL"PWH
MY3J5*T32)3 _0V^%IJ;TR2.=/YX#%6/1Y&]"MIWD"N3J84G@4EL=!403EF7?
MZ@--%#Z7HG[Q+&3W"V6'YO3_U>*71K>OGA,:EN0>$=C&=1*/=SF_DOF8D &$
MHJXF3P*1>21_P)0G3+%Y>C)%Y-J:<VIN:V880! 6RW5(&CF3Q$D!LN]HI2\Y
MN;Z2T82F!#M5E%W)F_#Y.N#LRSQ:-/6KR\Z>ET'BQJIFLM$'A;9P)M#F*-+D
MK$H.2F7'.YW00!NF02DC3U7/C;@+*VG3%GM)\X=J2AZ?N#%[IE+ZFPC)/?"#
M/&C@Y,S(6G-%$S@+WE$RS32:$F>0"IF#P\?5<!@[/_=;8)S ;]J)_#T?"I-V
M=BI8Q-:6L;4)Q5N@G4-1T;721B!<;R,Z#"%*9?DPH:6>&>#.WGMF@/O0",^9
M 8['6OJ^\1@$P,/=PK-:M@TYDW<=:,ZS2A_%6:-[QPD7%66#0B1.H)I<Z4J*
M9.A(DR*?@UI'V>TY]E]Y9(M G3L.?R(8@,]?4L!/8X"" ?==JB9@.CYL9LW0
M:Z@<L5FF0FD<CG!3O02Z,T1_1DN_!T3_Q"*E7?.L56JOL"^]:I.GII>  )(\
M+*=<TE:5M0,1O9+3<_3@R^Z=7X6IRHYR.5+L#XKTV;1GTWX?TS89!]J9"Z9T
M4G-2-+9M\8:*DXJKK A)?T1M]4'I)ZD#!!FEKD?R@I,:LG#&DE^S]<[6^^&]
MFD*RN634%&KO*/1%.@AE,=>Z<Y+$G7-O.9;Q0DUZ3\94>FEEB$C9$O+84>E!
ME)62JT8+Q^JG8XC2#JC0>3$]@)TL_QE /QY49?0_.%_"6F:U#!:)84?'K>V<
M,N1F!%*.L@>64;3C;>7.GVWS IT7Z$,9!L[[36-[9',&?WPS=%,)A6+2BXHU
MV4!S3TM&BAT)XIGOU2:7> C;QFSHLZ'?.]:3@J!H2I5KZ:0TDCC#G/N/KHK:
M-OVFY1H#VB!79;L:]AWOP'-3[VR##QLK"E"^)9Q1/MCQX*78-@<,M3-57"]"
MCQ*\197@Y"CB2F386K6R:;JOG6"14#&%R8JR*-_5*\.NFE8*DMBZ*R%-YDXF
M;CBFP:VU&KVT\F>$[ FTA^F- !SGP?F!F=#<EHO'JN<Y=-JHA%L[5G)-OC6W
M!W^,EH@Z"QB?>^ =IQ6.^RL:OC=I,ZH\1!G N0@Q%R'F(L1'.:!" =U.J;"Z
M)5+V@K?>;[<ES5M#G%F"GQX%RK%>8R*^.#HJ5$<][;M1+*E>FH?"[5-T,&Z;
MT_C$5\ISH]L#0*C;.S+K?'%3QLQ^^T9_UF!F(IKPITZT#?G-)9CAX=P''M D
M\F]SD\@';1+YM[E)Y/=K$CEG^_-Q-Q]WEWW<!>"M/V,F#SO)]3(@$)6\*8IM
MY*A>O'R^V"$J0T9K<>O<6\T&HROUR6=/I6=]-7#Q'7_6XPYG*6HU[U9.,\,;
M7/K)YT_M4Y(4!O4"<L@*U32BXTXSS>1,^],M9@5XG^2&)S&(22(E2P?DW!;%
M)R'1B.7&RUX%+EG*LB_KH1DZ.OT9G\;8>KYH&4DOE_L#X+O"O=M48VJAVUVS
MCQ+H\>N)G(PY$SXG9WX[XUKK8<$K0(_1TH5$-*2=>-A1D7^A[>$I%  );<:O
M,!4@I!_0-##%AC6;Y&R2]^<+<>Q0\!(VR:6O9YHT%"KUO%%KC33LF8#.%POV
M8L4.M960TX#([WD,%C;/[BUZ/XINYZ3'@ X8VJ:716_-1]UMN>=N@2?142*'
M@ATGW4[P_7*DE$#+:PKQ%GF_IW.B?#;\]Z]*KATV3Q/DD20UR/[LJ&]]\7*H
M[W4%#/!E&[R'W]](SJ(75A)K<HF63.N  ].,^)3FRO(8+3[.=*]/TQES5OOC
M9+5#;RC>--A6M*7IMW>0P)-__<T;[KGC]%1"O1-:C(8ZW"/[#?<XN?C<;?08
M5((X33-]A?(*M#"A)$+<->3 ZDQQS5"_K=&"QB &_0#.:Z$Z0V_>#1AZ-,9A
M4K- ''U?RT@6^/Y>L]VNF_=L-7E0LU+"@W7VVIDU-;U/F]+B;)M2R"A;1Q2(
MC&9*HX_78/=]45:0!T=N0<1LD@Y/3XNVXGKOULBNROT2U6=.XJNW.>Z9TW<]
M?KMW&*ZVM]'/+N&^FIO;'K>YS:@=#,ZU+_[:M*9"%W.2<:6?88UG;( +,C3^
M$KRZ%&*L6U=[]2^/M:13NE12Z)9N7&&;S*3+7#D?-=JYY=;-&\@\)AN>DD&K
M#)C_N[IR*S*KD@)UQV&\=]H:.67UCC=EX6D*Z*YKWA;]"#-_,(.>C['7<J,Q
M3%ICJ=6.SP+=B /-YL.&=IG;WT5:._F*>$-_N7ISI<7#WH7]RRA+&$3< 8"X
M%3*0C28N#X/0/.;&H>,T$8J^=#7JH2XY5;H6IFJZIDB';_%CC>M19"&WO%K\
M,EIN(Q)]&UHS]"QV:F/GXSQ<<$$;-9W)>/#HETQ%T.#NWHB]66N;LY[4X$KE
M1T">JT16@M/-GBDB*>CRTA>\4%$)8^16?@[WOE"3OK!!_Q(,10TJC:@;->GD
M" _)3Y ^K\E0NSRHZR 3Y%KL52?<)UR*F+#-Z);9F5N>!#T)UY!5'2QT$^5(
MNO9BQ\KGF^*FD;*"=TH.356NX$G2 =-UXTTYD_S!32E5"4\P/')C1GSAX^>U
MW8&9PL.JBIX:Y9URK7N&X>** '?@<)!O+I0^.G@A@>E<SPOO=% )[&]>2(\P
MZ)_D56?3KYH1Z8*I9!PE>39D(:[>6H<]8R\[_)J.#1&$MBZMA!_MW,HRVBQ:
ME6PV9$41>04,J^.EH"TEA339ZHD1;[ITW>;@R;T"YD[ H<K,)6-A_M_HIC3B
MHI/-@/7@]$(8"_?9>)75&UU]2I^24@+QJ>C>E9UT5,8W#->7.,$H7(28)7$S
M&1+D3R8-+*^RUYNI[4>C9;\6Q]Z9TODL(X:?D\;E>*YBN6_.R/-,B=&5;IW)
M05G8F:@SB98'SODT:U?ETA]JB$K9$4_V0&T:\CX%1IM["N)U(W91.>[CWJ3[
M1$J2$MB)&P3OS2UG*9I310'F#F,VE%)RH$LRZ?FL?HQ!_YR\OI-M/JF'LTFF
MZ@>,-Y"E+MZD4+:]"SW]XDQV49=_AT8>0/+6'(WO&UZ2 ZU)]A3)R<M0QZF9
MC[J2 _X6,>!0T^F)-0T;D?W ":\ 5EG/0AHY5$LKL(?K)B@4W%V@WO:WDHXV
MCO(/P[*"F!_X4/G4KJ.=[BICHG]9[[E668/V12#'N^?(O'\NH\V4-[=H0[_*
M?G4&G-@.14L/ZUP(C:>0(*JB(.1SZ=CD]"]LSYV\K&@9Z):9KO+P=</8VS1(
MH0+T7S+-QWD1/Q)+[$82:(N00(NH&R?R9QP@W>5W8C5/G&N:2^!H3SQ&[L+@
M,S,Y=+.8Q$P3NBD,Z#<Q4R6G\71R5VS::L5=WZS>JJO!]&\<$LQV^4FQU7\]
M Y$_*!#YZQF(/+/57\2@[^=7/.]BK2BJB3D/P,!)1E<!+L=\NT-KF1(4(<G;
M7"I2X^2P:R*>A,P"8@ SR"-4AJGX\Z@$7<VEH(^53\SC1$1W['JW3W/,EG@.
MF>5MVPP'> H]LGE=-XQ]8C&FU(1B<XE3)EG0)/.V8GVK MZI@%#F1$@42"S(
M48N9ZU&[1EI[\>KZE\7KUZ\7KW[Z9?&*QK%X\ORKE\]_>;JXA7SIP&S<2-S7
MBV_)V)F*Y+/G>?;R^<L7$@9YP23ZR'\-9.@O\@7]]>4YZ3SO&&*TN"N>7A[S
M],E81$KH:M/$Y(]>8RF;=,M,*TC+Z>)18A"=T[*KW;KC1N-30JT*U.Q5^=9Q
M,2Y"5TE!@J%9 BMD(&W&# V62@;.@3$1YORF+]QB%]6*KUP(V<@><XT<<V 4
M*V[I C7=RIG FX9_E?^]),0L_Y)%1<!XL!=?7[NP0?\H):JHO&9,IH'*8QT6
M_WH2OB<L^^MF-4@"]LXU,MX [,USZWF6KB#4V:+(;4K,W;(6&*!"&20TBDJZ
MIEV9ZKQ<FGU=V' O<CDD[I8( +$<)-,A/!,:*2N[M9(0%C$-DP3:'YI:DOJP
MW:KIHM1:^)X8ZH%/A5[H/BNZ(60(??MMC#'+]0.3$MYVAM^6W:GPW-CB9X3.
M(V(6K&:;)'X\"M6L2>U'*QYJ/Z>@4VY:J?%BC9V#C&?=M(P_9$6!VD6V%EML
M%BSOULE6:EJ)V@CF8E!.- J!3G+]P4($U!X2(O5$.TO\F\.@0@\>2 @18+?F
M-*TH*:'M+MG(Z:QIZO7)&LOIVKVIV=@(:U8+I_"%N=94"T&O>Y+<8^XX?SVX
M?!D?<*J5((@/J19J7; QR9MUJN0<<ML1RL*RO;(9\$,LC&].)7QL-K65+S&'
MJ^Q_E+>+W'3RP+EK#QY<\9;<-E5ZX:?2E'V73$[@^%(!D8E/"89ZU;1K+UYR
M#B:29SK;@I%%!<Q2Y**R8JEMV=_H.=Z>*OGVT:FM9AS&,B(=D/(D_<O5JOH0
M1I8E !9R@,W[@$6A7H:7YMX5M,R6A3K0@MH2X;:5NV/OOK33_S+W0!;SC6BE
ML4^MG10^5QYYQZ;+=7$[Z%@UQ!^?&H(H.\1&"RA^6>D[7>MN-4K,A\62B:(K
MC:@CVXLWA46R3B,A8 PYUHGQBT9U:$Q+G"9C !+=D+FQ@YM6G; A2@$/BB;#
MH5?H 6MU]=*XC.EJF.=50JV8;/(.1/9[H[^S:9$*!;07C!_0<GGPOH4J?'(#
MM'ZV[[^]7HP^,_0[8!\,K%22/16MIB3@]R\;I;B=JI5H@(&Q0UFJ8!9U^A=*
MH# )VH#HB?>JJ2[PJ),<5GYVTSZ1?]=L@.Y\ZWO.OUC&YQ&%1"YJ([C(W4N"
M@?]7-J?,%/+HE2TKMS]5A[(RM>!T3G>G<_O2^U3ZLN!;Y6>C@4DIK"DU2LXJ
MA=+]P^TV^ZV=)3X X?QP.0<BCU3^'A,7%VUR9@7C-&G1G#^R*[<[I!:1DV4K
M8Y#9Z%S8.]>S&\90"$O:VED"9;F_G5M"YKI''L)X585FSP^ULK)IXQZO+!0W
M]H<^>*RN=Y-+3CX>D&^: +UW*6;3>:Y_Q&-.(=_R]#2<IG.*+8N/0#Y;\RQ$
M$+<%G\4+>M)>NT)$RI$.0CKI&'#<L2"=2OBE"GSKLI,^79Y"^V[GRK\#0,@N
M5GE#42==H:A@8^9HA+>?B7]8A:8,/H,/FB,Y[S=&[>X/= 87WAD4X='&G,*^
MP29;D>LG</SPC=_9*URD7F'V,*_P]H-[A;/'\8FD>.] A'S^?$:$?$A$R.?/
M9T3(C BYB$'[$H62^E9' ].CU[V(#AT5#Y2TB6SL8/O"AV@/2(ZGUA=W]4PZ
MC1C,=;_26>-AD'>7Q=UGY /@]&*9 ?'=3N[D&TLC2&+3VD!+]QN1C]EOBD/F
M4^UQ>I7_(<L3078U<C:+$[7ZV):4Q3K8TVF#9I8,P**0H8,2]N*\/6-,R3=_
M&T;76VKV$+^+820T?Z(\KA=+1@'_ODO413DO'Q<'^/AG=>W1Q"6[16:E#XR&
MAE+BD?#B[-/F<"MDC'L!-N?<6LPE>AJV7%F1$$M[9G;E(;#PG,YH%E2T?\NT
M/LB=I<&M*5+M]-7J0..Q=)GXUI&D=U-#I:AG^]]P2 )CX;M$UELPDX?G:3A&
M$+R*XEB+#5>5*UJE<S3=;IM@>T^^_8I3@26B4-52BC=Y?6UN=M(?[P!^I873
M=69-9..@SC+)1WA&,6C3#%+2&6)B-PYVZT]THZXI)%;CG'FQ<9"^*OY>M.N3
MHEL"G)FS;!\GRP;FH:)%>HV#?5[25I78ML5>FE)ETU P%/@*V$V2MZMH12$8
M'!M4OVN;8;N3C$#'+9VM>^;346Q.QH&F1GFU^$[;LSE'56\;JV5[MHLS5_ )
M96EFE?S7FF&(55'7D+>^=1%7K6$=K.>J;,W.,RG,BV2G9M"*<J_Y,>W00LDH
M<,J?J1SQA8HM>'K]Z4$[)1URG>SI;V21+;A,%3V8/@MOHO2&T P\?LQUXT2^
M*F;,K5@9Y>2S!HT,:UK:[9()"5<1;@I<R<:AO6>'"GE2(R[VIY14V/S\\^%R
M^C"2-1S)G]H!+GDJ@7BLW1[]?ZW<25O7)*6:1<PFC!4F*QPA9B/O#'[&VCC/
MA%^Y2XN3TE8DJ<9B21=BEV_,HJ*X#\OT10L%?<ML <@-LBP9$W;1C;N2H;D8
MOF\2%-7,E/PO?4=QY5F]!R;D,&$IOIY'.RZ=JR,&@JQ9 K_HUC26>A&XZF1-
MWK=LK+!X2B$3U)[%'V(2LFX/9(AQ*H3VXNRT3*/H#KU/5*\T-KH;3B+K K<^
M[ O;3B_R#%#<8&1UY)*[%N"> <EZ>F]@>!56RS7[;E))#J^7,1 <K:A782N:
M3556F6(!6P\@M*;\DTI#-CI"XI @D?J9=7WN(^6?A0YFH8,/S*=[UGECW3E=
M_R>M6+;ARR^<%D@[KL;*N99;>P@M=O6.;A02Z<\*I0K0LT*]3XBBF_-ISAL3
M^RY#\[H>*Z=%T" ;AC#Y&8J#IAV*+C6@!U7E-R+/F!G7/]JH+F>A#'5@15V/
MR*&->%KBAE/G#EXML[GXT%H":RR%!AV0>@Y/@VGX$BK5CG/S3-U7)!H-4M:T
M4<HH^OQ(J" <UKQ,*$0SQJN9D7U>& \:*V_]D+: %R(]A,!@RIJ8LF<[ %H6
M/>U@C5TOG_!)[Y5+.THF^8HLFE>DYVG4KHOA=V96E_]_14[$')"<P5_3YBE,
MOG".D_VQ:,O.A9;<D*V:XCL_E0V5_ \') (+6L>8H!0JE8W0B6?-)DKVR*79
MW]:,PDKD<2<0CVM71YA>'?])Y*V(&O9S$&WW<$?ZD-*0IZJ+MFUNI1/7* AC
MM51<1/V:L$@4=Y7RK2D"JBJ6KE*]#B%ZX4;'UG_)AV\G/E7@J%U*VRVXW[IA
M;TD\@9KA9I92B3U#2RGI8L67SDQ\-IZ[F*2\"(W881ZN%K\8<=,S:^Y,K$M[
M,9&^41R2)3?H*&V'4CF?6FUYYB(UPE6?U(EUICS^CE.EG.E*3ME# ZFM,C#W
MT6%K_0*2;!SE<*Q)*AIP<(YE-@YM*=4O2(K1YOAW:12B95=L0[,VTU<QA9R2
M5=&FNMEPP=+XF1LK$-9.D[XM$J6>:Y"\F::N7:7BR\%TQ6!/$[(HSAT:XY&Z
M#^<[O7HQ'[[QFP>$>T-M1I_6&RP]+NQ5F'1MFI.9&]]Q-2J;V8LOZ[\.[5'6
M:]'O!!OJ.];8&VL=J^:(%'R[/X==XT3N5+TOJMU6,[G68PP:"!"?D!HA0B=]
M$$[,RC<X!5566CSKAN6^[#J_R4ZX$Z>VEE:JLY&(0[PZW.D7MZYVK3 ?*(7]
MXGO9B_<L[JZ 3\MDGRRK^%@P$$&4/\:V[VYDS7/(W=#S<5$F,7S-!_XV+,%O
M;?))6< 6,PO8!6 ^7\R8SP^*^7PQ8SYGS.=%#%K!EIUVTW)-4 ^GJ-CD%7$E
MU!?'C;=W(4"908^/C >)TY;*0</>#W>7,(]#0!IV$A4$?!^M*>'J$@J2J,>(
MLXFI!TQGO%(.,&.Y4'YQ%"* .NY9,;Y<KD&##XI]<DGYEY(<]593*,6N\A5[
M?@?AW:Z-69T>+* .'7VV.3J$Y  ,<K:??"Q 7PX4R&9H$%*\6UJ&M, HX-NB
M""P0F!F!>4[>5.TV91\ZPA0=:3@;\N,":Y#,9;0.,H]NJ([OV54]YH!G?_/,
M6[8ITOP*#6/=R:O'"V57]4QKDGAL&I"EDZTS!;ZTS8#A[INZ["V,]E1=?+&C
M(#Y]OUQ,9B\0SB;KZ)1P%$[RDWAXI^?6"!/*TFL+(1";H$*.&$:,-TRYU&+@
MS^E4L2_LV7F71TWUG+RSQ>D[$U>Y/N,B3TBY:63M\UQJ/*.2^;8!O<6%[387
MN47*J4:&E>&W/J&UBA:2AGO!L)4I&53@'K+C.K@GP@'(^Q.J-8+LM;08$MA
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M*F2L6:;IF[D'?>Y!?S3H[MR#_ERZA/D4UA1I3%_)0V8ZQ&6CV<]"6?7U-)>
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M%1S/T<MB<:)I&4XK2'#")4F-^4^SX7$@X.H=BG:9R:,A1T,.M/K6\<-$CQA
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M0!'$0D&L%04B,6ZU:/9L1' R*"<%@T^Z]&6G"XL F"=O_<%F$Z<,>V*V%BS
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M'._S_/N%+8FI=3Q+U$?#G27J/WFBX[63. "QR][@FJ:N8UO'3.0^4V8_0,>
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MQ&W%>GL;P3!)LL_%^OKVP2C<?0$S80G@J([YBU^K0EO?@GY!6C\5?_;"&*5
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MG,W(J<&CR;(/$C90A!O[.67Y)Y?&^B6$I!J_#3A2J%]BS4V&YEXFM\ZSF0L
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M760KY*A:)=54KPUTNG1,GP-T[ 9</Y=GNPV@7R*U#F:41#9J_NDUR(ZK.1.
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M'C*3W>G<C58@&#J2=TQ0_!JI_+G3('1J@FK'L\T^D"=C+D,T4\5@(]RP@X&
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MNX*_OG.S%0?E?(4<5U;?>1,\Z[CESQ###K.U4A2:#,H4/#MY/7F,3]?M)[A
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MG-HD"8,L (X0#(T201MD6 #\@*]H.&@G.J;0Z_&BSHMX[XA]@(!IE_E$)\9
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MXK>GKU^>"[^=P -P$R"0 QJ&GI.G-?'>WN.]9XZM PM&OK!2?0",831!Z0]
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ML/"7O<)./\(^7^7-S)+\8<-4/^:?W\9XDAP=/$\.CVYQRC[W#CW^FH_6QM"
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MQ=9_G9AR[+0Y"7>EDW!G2D])K\N]P"!!$<6Z4@&;-7&_EM=Y?+X!S:!B[XN
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M1B>(T3&M'1%K8$<%E5(HW1@9;RO;62J#@@%[F4 I!1C'0GLFYS&3!9GB:>1
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MP7?M2205O@7>FNT6=UDPVA'H83_8J"%/P,)/-5PO,;**YC%32@/VW%S:!GY
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M6QS[HG#LEN]>#VXWA:L%MUMP^SL'MY<6[ZP:UVZ.&5P=KMW=F 'UOWA8NVO
MVIW5PMH5MMMY)JR]%(YX+:S=5;!VLYY\^;!V5\/:G<E%+A?6+ILMOVE8^S.
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MQH1J^I G(S>/BMOO9/T@4=>6(U#XQM0?\%10H"CTD_$%RW&G(&+E_97[5(@
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M^ZA"0 8O-*1CS7PKX*V 7YF M\7A<Q/P2V[3.F:L4T#F8A %G=SL=4U&/'P
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M(R1WG8U68\=K;1]XK=W=#[49D=!J;C7M;(0YUE"TFLMV*K^ J4'IGKR3!KW
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ML#Q ]B_H7J_@!![O!G)@NX',M1O(@>T&L@[=0*H.U]Q#>,0$Y_*"YR?[7RM
M7KP&M=5+?_%9U!,_L'*CJ.O071;2FF\$<O?R>:CS"<P#Y^;W4_>?I^VK:_?T
M_.3TQ#TY/3[]>G1ZY6[+)K5N^_R$9M#-Q798B_U^WJU]:^UX7A/+D&O5.T3:
M>KFA@Z>MAM<QA6[+,^?&07#?4.]LI!]*%VFMFG[6(0BTC!AMO4*,KZSE*A5=
M_M?__Z]&HXD-&;G=(790[(FA@/^),MGD2.#$H\N\ ^Z,V^YV85$9R 10S,D
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MC]%DOH?4G>DFR"B\[1]^D6V.%-FN>S3UFJ'-38]$RC2TVVMKR9JT9> D41G
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MTS'/<?N ^@\/J+F 70GDF!NZU@DMRD/7I]?-T_M1K2"F&4034/9U>"L0]CA
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MQW)@"U)M'H^Y7_76N)+OYQ]_<^;Y6_9LB)-=VV?5EM$T2U@$^FXWML+Q;*E
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MP:^883=Q<NI'9Y-M<__]S\$!<Z(@5?[&W$@]]!U_^]5&6@=_J\)_9\A-$GX
M<W#@*E)9>4NN!.-.*)(3$FV L:*JKE8AF@G^C4'M>/^>?BEV4%1I:&+8O)^^
M,^^*;/7AM/F_PG@MVL/%\(6&T>&.FT>^P.N^_#@Y"*+20^)WYFXTQ!!4#:S;
M.]^9!M;X#J(;.J"T$/S2O]ZWX"\3A>EIR__^Q:@/(8*!I)>#-L(*'S]Z2&@8
M1+L8Q5@>.TR>&H0%8"1$_T3<_DF5=+ >I-O"]G_R^/7!V_[10+8A?2@FFZMK
MG:_,U/#WK&&W_2/7G!@1;"_<I6RZ9F8:[ATRW6N2KPQHBNDS)#-&7GQ>R(LM
MCBNTQM7F:^_T];DD7/:QJ;('&.01^0@V!AXG,@=,%%=^61YSR0SAEYGD3J*>
MJ\1A_D99;.D Q..G;?5:88+ ;__O"S]A&*%2;4'\G>?R7*LUJ3E%/ZOZZ.-!
MN/@]Z^G0IP_63Q& =^?HL1- QC!-"5B%]YG&+>#L'+Z>#2ZLWNU=-^-<$U6C
MF%V"3-J5%F9-5U*52Z2T$N,D+//E\Y2X?C8YT0V(QIDG)!DF<ZS)2)ZJ4$WM
M=(EO+G:+1/SZ2>1H[;3(L,-8X;/(G%075B&(6N8Y:3TVMNCB%KTAS48GACZ
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MP5)"&[9V7'<=3KJV+=/"+BY,"@]&5.?%JW'M]+ULGM)T1JPRF]0#EW'A91Q
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M-6X7#_,?RN/UX75OTTLWG<ML CDFX 1T#Y.IS6QS-SDM,[0M-6@2[J J<&(
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MTS!P^'$ '7ZE9>ADFA%21PS458+2 P71@U<Z+X=_$AT(<)E[04X9Y*J9"R1
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M!93[$I@BIN(?--.YM;^23&6@3PUX4;S!93C SD]</L_?-% 'X7 1!D'I&CJ
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MAMUBJ$V8UW,&Q#<XF'ESV*4-JD(R=8TDH168D.V4^_K<YZFF7$ +6UBC:F3
M%T1P*@HL/^LH1L<>0) )L\%=70030<W)0'(G/L-_(1.92<"'=33(R;,M]UQ7
MLZW;CJ;L2(8Q@C\2SC-ST>K8/Z%S1RS)BA.[25!6YES\.G?!IFX;^U+FC7*Q
M@7JV*AF8( CH2+@8J/N"1D3#D45D,Y;9=NM8W IH\OF)#-@6ION8C)?T"P>E
M-TE175;VUW&QWAQW6*0'[W+G=$YS:J@\L>XD>U]" N!]94B#(4,&M;B'<G2L
MTL4@XV/+P'R&CJ-*###(@CZEFLF(>F]!&!@+ _(RZFBZC-\&Z9]\":HK)W8%
MGY$%OP#_Z' V#DT')NL7.QC8E>YI[MPD?_Y1#B2N8R!9L1CLNIAP?-*Q>@"Z
MADPP];N*6;(0<8"MD?0!%1-OBCO9%'U@M#F8U-LP=,\"I./78BR.O!M&!W\*
M/HEB>+TF@!%L@)RD#GAL;C^"LWS10BI<B4*+E?=!C&CG%YXBP<=796*@8!B?
M4\^!43O!TNX+=MHI=2X_&VK"!)VJ)L/_0#46YF?0PR0//(K(J O!%N9$WV^-
M3[L_"U7#Z!0OT.<.3$NM\?#W;5X1U*NVA3\%B"$^/?S !%"TCS>WW&3CC=4P
MR::\OM+K8TNB*IA"6,F@-J3._3D)_B ,M[)=PE!;-LE1DU@.&G2P.K;ZQ*=6
M04,Z7E8'J(XF5)]2\CEO7"CLJ"15;;,?!V<+O^ (=4@I'U/@G$FI1&N2):T[
MA?ZMJ+RYQ=MWAB0CK+/(PF<W-63>DMI",/:.[II1><$&]43?;XU_CB[K\L_[
MUZMKZ7.KO*/6V'RXZQ>OC:/ZSQX6,L!/SD,,,\&,DW+SQS&".U)SW)%+XH[L
M5>(V5"*AEN11RPA0RW!78,M>]LJ=G!G(LX'/W'%F!4%)$B33G(#+MOP;Q[:D
MNLZVAH@K",.$IKC <4ISCE,*Q<.3Y_M1PX!4_;HAPWL?!Z(R@EYG1?.27RX
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MQ;GU\[AG"E*&*$RAOHO)\[*)U/?>&R=5HTYRSF#.)$-^EPSTQ^IP;EL2[I&
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MJK_/S=^G907J@3C;PIU[H96ME%M5_##@^I?=P_&%T13-Q!>%Q?$PRU%(8S*
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M1A/^X.8DTYH-%!37"N"SMJ2^,E(O3"/UD!O5<?,%A,V):])ZT0L?O8(L8XG
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M)"_S.C;*R4#0750Q%3RRB8QWI8TXVA^#'RI6#Q,BYJ_0%$:G/AY%:QL(&F)
MYS[6Q0]3+_0VVE'PY9 &BB6IN_P#4#?Z0$9;,='$SM$^&%B<FHJ,*/LF0SC-
M2NAC'(WBP;3=)H"*-N6SI'&'BFBW$,FW)^1J4P<6'@EA 2BS4:%<M])1X-)B
M@1X>&W^.8V.'H\[;.YGQE.\\KLVY_)_V:/3=,<G?29&R>'99@K>"9.]@0K=&
MA!D;-HR':<"T49C!.U(![K__8QPE879;&5$2,3/M-K%N,[Y2ZO"8KZ&D,[O)
MZTZN.+GT6V);H@"P342SQ8@+ )+F=!4\WX0G[0RP(0"G2+KH$J; <LI0!-4%
MF!YEUK;ITN.T\3DZ/B$G8%MX$5*7T@O^9E]Z1=!1U.XSSDYX->O=!0\0<O^
M?V'BA%Y,SC?I5X3@ ^\ZY,2I<#G88TY+*#)_PJ=-J/]/OS-S<$,Q7W<Z!I8_
M"AAM6#'B,9-'C.T'[F0@F  BU!W8 0=R(VCD$O4\OK<]2>N"EN<T7?+O21O3
M!NAC!NU:(-'<O= A.4K;YM^PS$W7?-ATO47O2+/1+66#L.G3^ZWZ/=0SWVV.
M;Q3E_;)P=?K<?OFJ9FFU.9:5UWM3?+KZC<1OO]BN<+YMV5JDRYQRL#\0#_P4
M<P]J23(='/IAZP/@Q (_,'39;E.F!\S+E&C>:Q_)$._B-3R<CCFYDW.,7\8J
M 5%C>DA2K5X;]!<\"K Z QJ+8F9DX)GS^ J *<FQKSY@8B!% X&-[O+7DD6[
MS9'$9$.2$7[ME7AMHS_(6MF%6V/WI1=H3$I7P0.-0D=3\B^J6G61AO5SS#XY
MITDX,TXD?J KH$'A^2D TL34WB,Z$#X)J@WA7__8Y0],TVT< Z9)U#0,2O8P
M2_I!R]''![;1[H&Y09SS'' Q\'YN?G/L.;K7Y;?=ZZ*"OXOL7E?8=J_;=J];
M\U9JV^YUFTJNRQ0U)^!0!E^9! R,F&N'];N&*VKK=WM\.5<6>*9J4C&[Y\A5
M^L8>*=F&%1+![2;/WG,ZR@M^.>[WMS-1SI'>NN!\;[.Q>+UE20J89? M7:5%
M5/2^ BZ;K@[]>+$JPIPF^,/@Z,/_3THHT<[L!NJH".8XZ3LD_7H#4Z)FI,EA
MXFQA*T\CT6WB/L1,E%B-S+^K8^4BL\_SY//<O)_?Y>]UKX>RJQX9GE5 HR10
M!I0Z!4PZ1_\4W/>I)@<'JV@<\82V]0%14UUB4"QP4T'TV@SU_>M ;SIL^P_,
M1;7M6YWMX2DX?H4FK/#,O:R OA.K%X4+HR0?/T)-BFV]E-O-EQ1M*EAF[H7E
M=LF0BSN;[\H//V8A_00SIB%P/\&89(+LUA,V^=W\X49'&'O#C+%6#.9T3N(@
M%W3FBSC=Q9[GIAXH8WI$5NHM_%V)!<JTP'G_Y8>[(:?K"CSW>(G/@N&^P*^.
M_NZ#?-^,<Y14ZOR*/T8GPC'7]05?V5]Z\AMR\*X906;H:+W$DO@.ZBZ6NB3T
M!-KTB(=HK=F!MBI2#"'L1AZWBV_<0 UVS:<<@-$,!JK" JE@1.R $>&+FGH6
M)[44_?8*L644@K+")F*+J.T*!!]5E>C3$,<S[19DV(0\RP&[C*-#N-87_NRD
M 19A?L&W''>WZ? :1]';Y>N6.WN PR 6]-2!^/QL![[M+DIFEB@UP_AH,\QO
MODFFB4PG$CTY1==T9@,B"5N@[I=)UHM_/\',A%WE2+PAAFT2<)WS67PLQ*%/
M!@X8ZKYYD"4JF(ZTMA6$X%EPJCZ_@.1Y^?&?.&98LZ#N!(,7>*F#9Q\RL_'3
M[Y*A2"T:JH;IP@, V<,6,+9B._AW(X&1C\D[@D1VSI %R,&D]>T!Y^T!)<9X
MT0*C.GQ'WO@8Q+I/V<].G#B]R;<-)"LT-P%0$YH'V*/0+L(M6NX;X,1P,06A
M=QW0CG-O (?IQS-X W(4RR<!M9.OP6"2V>,[JCYT<:)/0#TL0$B1/L!^V,QA
MT.B)!"^^0_,FQ0:Z54\4C687 &/[/I!,2\ \R3!('!*N0L<&\.@//&D5O4L4
M)T)OLP,Z8JS3N3^0RNDL8?,#:NL^93\QZQTB622(XRH JZF; + AS.;:T+N&
MU"?2:4#_3+VR.L41VP9YK*VSO%QX[J2Q<X>)##@P%9ED!+P>*)7$#W2+1F Q
MUU8[.P-IQ#E4;/I?=X+% L/1$8 R_JR) (?I5.,A86Z\KBW!9#SENFKJ N?G
M#(QL/+@ A-H'%@!@G3.GJ%PLYP!HCMYLX#L^HE$E?,PNF!(?;^CH0Q34ET:,
MBC@)\Y46X6(&'O!=!^'/F!B!,A,&XWV)?8-0"Z-BGJ*(386QG^_*+MH5\)<)
M@@)S.,S/]!WV(F%I_]5! ]AQ1V5:@^F@XERX\+4T0L8/XN968>D$A !_D-H4
MC>GB]AEC#RX[-GG T5@D4#?;X.X#4 -'] O&3'V5Y)E.(U,@ R#1C*^@)"P<
M1U8,X\CV%5/J=@U$=:RK#@M-36UKX.\FENC]YOAW^?:W;=^^5_3\FN/)HIH8
MR-XB4328QZ'6  K:YY^F3Q&5&*@6WQT3@K6N'30B]:11H)XT5Q 7%?=9AUR_
M4$.#:G-<'S_:/?VDBTW+) T-@J0&OV'$MBY=##+M ,!F00M42;:E)VD*4(6P
M&'O3H"6EX=5P/&Q;73Q!=?'D2]O$[=J(\N1.6>129$G?/?POS$\U18HMISQK
M_E,J+,_8RG!A [="0+4RB;PV(^MR-$W#VMEQ03Q'"!3!00\VCS;#-*V!L;.S
M5\><4]L?6,;OTY<KKX*',_:W\*ISLV>?J".7]X%$W6MAMLV]>D@!F:, =+"D
M8SDG8LHHS5/U.=&13:V3G:P =PP]/H&AAW5N+=-RZAZAU>((+5Q[(B&A/9TT
MQ_F[X=6S6FU?]FK)"&VQ5#79T9)0U=-)B*J2EG^8I*I*3L@7YZ*JI=>FG/S@
M54_19TJ7F4"4>:^&1VG["V9I5\?-\?Y)[NKUS_OOAW8OGM)6Q<:NC@,$5\TE
MK1$V07#%7$4H%V8W!TQQ0/-5:/73T*=JNV;'@( L3GMF>7AP=Z_?Y>/)8BE,
M9X(&YBA3'*I.G,-,IQQ5Y6E957#3%"B.%6?+Y#R-!7,>D'&UD79\]BK52K_E
M]>,\(5%7S24M-39!=?E:7L!*U.HYSZ2>OB#^$TL<*?D/:-JW1V^=V]N3XO6?
M*0K04OA/2)6NYE*KTL5<52@G4'K60-,YQ(\K\H1!M\G*SN%Y<RSJQ<'#T]%1
MZQ:M'\LY/ \16FKM6JR6A6IQMJ#+G.6$R&A!_.9PP?P&*&/8>K6NCM^OU.M5
MZSMA,A!3Z[QX"X1B==/TG0O)-*5VSS:194TT25HF ]I;, .ZP&+MO/JG]G"K
MGU=O.^O'@"Y"DDY,K6F+^8I0R*T! [I03%.W#67!'$A<& <BD 1CA*GCJCGN
MGS1*IP\?A^JKM#HFQ&;4O+@*44-J#5BL%(7:2OE00KTG-C!05U5>)]! $CZ<
MS9;F"C$L*JPP@V@C2I&DY&<TP+JS@[>%="2C)1HN2/2T.>[B9\3?@^/N_4L\
M%7]ZL5EP0;JN9M2R0G<AM0U0+1:%8G&V-9@T#)1ESXJ%78^5M,M(8$G,SZVG
M$O[;:V.0NSEMU!I3'!KI2FXOE,$GIO+T[OU:31#SLRW=->RU,)M6UY3O1X6F
MRDE9_KA_?GRC]KKB6=%3/>YUJ ')(#9KR+EC&P-4\^EM)J%8S@FY8FTC./1<
MQ+KL'@,I'(3C1Z6JW8G'!^=&]]-DF#$?#5%<:ELI+Y2K1:&2(,3^*6[Y^12P
ME8+9IM?]\Y?I+S?'8K6OWUPBW;Q6ODZ9_C6'T0;QFPC?(+VOM/D.IF4=8-M>
M)4I-@J0-@6&'!< 7XU=H0H>MM;$LA]PFMRQG'.23I$*YN1R0;*5H4('.0O+F
ME^U8\RG_K_4+JHMQD$[#P+;_0NTCON'@<&6 1!J\@U['#[)S$W@4JH[G%/<F
M^7XFI%TPB+N;%F@@^OM@"4'GRR:G:% C#.BNIYND<C5-[&NKBJ:TS5W^3E(G
M*A"ZK_-$=)A(,J$&MI-EUY/>,8WQ>']D6@Z<51<D-3!<\FZ/VGCDS0>\K_F4
M,;WYC3'.!73["-"D%.@>M>]\64:D+P\U4%L2D^; 0$"4<;09YD%0\W+S3WV.
M>HR%;3W&**_((NLQ%K?U&)=54]!9[FIK"6ZK)&[TEB^0B%:ENK$4<+_@]&I4
ML KXI&9AH"*Q[QE:@ ]I,BWZQYL]W;!V2#HY2W7T<A.A6]";39N*Z!I-O8)2
MS[)-2QW\V'AYFM&4-V([$I>##ZE2W+6OZ,25KS!'L"BG9]%M260MCO&>&.W
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M\<;NNPVF1L>YV!O%UC=0$D'7ZDA5$[-=R':@1A_-.Y!DF #]LX%4PF=8[-Q
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M[N#4)9PRS1"#2]] (5<6BO'YQP+%)A,W$B =L=K7MBF=8*JP>H ]=(".TF"
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M-M=GF^NSS?59]>RVN3[;3C?;7)^_9+7;7)^OON!MKD_&Z1=9A.9+J4+S>==
M#1>:F1.=W*T-#G-ZK?YT)Z8*RN?=H'Q\V?"HN$0^M\WU29KK$T\B<X78/TDI
M%X?/?RY&QZCP7EI]<'U.8DN*C?IRN3Z-&0[H3]+$\.EWXU#M-@;&Z^=R?:;2
MBG_BBZ"&],45<T*NM$G-L,KS^;T_20WJL]@QND=*_S4BTT72\#*8O=E!B)<<
M5_9G*"2=IWQ.<DGM0J\*8GF3J$6<YA)?G,9Q]G'X>'_RW+<6D ^5,+257UR.
MX#8#*;%J6UZ-:NN#<U?.RB=GET>75X5.9MIM#!Z[L&P%=TTRD/96JJSZSKZA
M/EOYT<7]:;&ZSOIJ, .I6BR$R&@5JFOV&4CU;/12W_&K8N])4?2'NV)M_@RD
MK-3168>=6C,M5(7<^K0K*BQ%[?0==MT8*B/Y!KVKY?DUSY5IF[.H(;7BF2\(
MQ>ILS7-)U# US7Z1TOX9B9W[4U0?CKJ9IL45/IEXN,V56N=<J?@4ZL5KK;%8
MX;O&R<W]3<<^W^LN5G%-!!HOIM5=M[E24W7C_>7KQK$4-NBT;F[U2S1Z78-<
MJ51$NB#-^*_(E2HN4-^.):E[M2M53P?M4[6VX@2'XM> ,D_+A\]*P8X]W5K.
MV._\_E-Y.(IH/#%+QUXY.CH5A]F"IU/G3BU8'VJ8^XW&V^GIV^^5LY9LTC"W
MN5-?-9?H;UMO%@D:\2K+^+A]_O+Z>G;P4F]ED3NU$$]@4*R44J?DEJJ)XL\;
M>^1[:=2:\?'CQ]&]:7=ZCYFEZ"]>$0F11/KFI%4A7UM@!]UU(XG"/$K&^,H4
M]]_W]Z\OWB)TU*6J":5L+)"YNJ/M-\>7)R\7QX\/I:?A4KNC+2:U:CE=S#:J
MY=J%L<LU#$E6T8B_4*QVCW^2K%=%PZ_L*P9J6[HA\ -#?U=D)./C,"Q)P5^6
M5!@43_056=!X#<RUMM['---6\&3'I/4:<"O35LD#S)8SH3$7ULEYI\W;P%!T
M W[94TQ.&@QT1;.(JX@]U] E0X9F7\YLS%W^$-[ ?QLAR3!YI,',)GJBD"G!
M11:"W\-7G<>+=I;)_V=:O#FFR6*]C[5E"[-?W^^B"SR8AK6S<P]\XZISHLD*
MWD9;4H,VRH7!YN*"#.I'=N/FL'Y\Y4%H;P,MZBSON[Q$)S-+M9AC*?-5D@M-
M/R2'4EN\HBCDJE%9HN1RP>ER$T=7^L313=B7J8ZN7.J_/>V?UNH%>7V.+M9W
M/_WHTB?X"J5\[,D)/):= ^BU_8[4T2Y_J3O;P ^Q6.7U(6WIZ+^CDDDX0.P5
MW]THENO(L@V:LJ\Q)]%!*C])\\P^A/MZ"NKPAXHF:<#Z^:M.!_-Y@U=,0HIP
M^OA H=.F)P)ZAFYW>[R$?U(,>8=>C('=4I4V./J &D!F=!2CO\L?(Q@+>#C\
MV_D\AZ<M=>$I>%O#'P1BZ$LO.L21_+T?:?]/>!?&05I7ZN()M48!L8 )C@DY
M_P1@2$OZ\&8.=Y8L2]%LW3:YEF0J() 0,JED":R3T/,$D_*#V+"I!\+.Q!(-
MQOB,#+E#6"8[;*CW<EHJ/(U+O0\OVN=\B\RQ@[\VB^V$)C>O5/!-*,A8RJG-
M5;PA0C6R=( K%";W>W_&?J=D_(']SM??I>M7L5:Z*&>[WU-8>?Q^IR^V+Y:%
M4C$?N]^=.16Q(.>_]]T_X/K<;>/NS&G>BT]0>]?II>M,'FK.=ZAU>F$=OPGK
MFXWMYTM=:P>;:*>_4;7?E=[HMBCE=/> G>^Z=N",\TTPSR15VJ:==&JX5[4H
MY"NU^2Y6(=T9I+]EVH5Y^[%7SK>4UZ4?PAS7+7V0IRJ(4VZ;U9,L'MI2*UI;
MM>&N84M,"JU_IJX4NH4;I89$:$ZD%S?Z(!ORZW__;V<'JR)(E?_EK[&8_XE'
M>K.1UB8C5'_RCY)JP\_\S@YS,&'"2^Z^F>6^*!/S?ZXR+,F*JT1Y&>(#.WA^
M46Z?&$@7=;&$:KD<[OCWTMG%G_S]:(!G4#>DEM+^R5_BJT5W&FOQ>$O%FO^M
M_SJOP9\\;Y/C:OK??_'>1YR"@:37G1;"5PB//2"GZ-_W<K3;R",.;U3_7&"2
M=!X^>DE'\5&;E\"QM5 74\M=;NOS_J:(6[N*%5TBVY P_Q>X$ZV]N^J5X?GH
M%O57><8-P1X1)8U.CW*@I4XLX D-.VN3ECP/EO5"9EL: %<P;!229=4P;N_:
MP,H9-M>N58F(S8,W6QG CNPK9EO53=M ]_B;#55OOWX+>(]S_O#^/,,TQX=B
MY42^O.O=0TANK244)IOB+A?4E*KY<G,LRO*C*)]=VA;>%F?U1"B[2W>I?0&$
MOVI_QJ()L3(!((VEH!CRJU63D)^/Z+IVH]6X.;X^>5+6G.B<U7! 3LA9BL!K
MR"(N>,6TB%)(?"A8O="'6 GY=T$TEJ9<W:))+WC=&KGF&%V?Z0<7XW$7]=S#
MDQ5SH$KX*Y@RL9UPU^XAV<::&MX9]T+6(R[D0OUU*]VNX!I65BZP6IJ[6N"\
M>8414*4Y0L[^FCH.615K=5_Y3OT![;W^?A3/\Z\9%,X*&V^+KCB4Q>Y4?5'S
M>O=MK]:^/FJ==;+?G<541//CY=Q%Y>I)9,:1H9LF>#=ZLY]MC,""HEX.]^D+
MJ=U3-&2,_$\Z3H_6Q]U9X[!Q=]7S"CQE4#NI5(Y,5'>GQ@=D"Y]I 8'0T]4T
M)3ZFG]94/QL;HCGE6$+*2?I.6=6\("9(K%MU28<5G4@^]8D4UN9$(OE*(EWT
MTWSET#;PVK IA9\\Q-N ?W(#U?+K1^YY[_BL=U-+P582UYUPIT#X1X=-PF4?
M6940R)HUQ.]LB Y+J6%X9:%2G@WX7U6-AJQO>N(-3E]+IR*("3(J4ESN\E(N
M-T3.;*P032@,#[W1\6C<N</7-1.%87)'G*GP/<F0AQ"AV#3R"]_OF,T-T5YZ
M@$Q9*(NS*^!_U<N=;'=KJ:/6):%8B@JC??IF[R_E9I\CR238E9,^8%*HO]FY
MW?WC[N7]6;4B92BV8ZU!=V:\XIO:6F2199>3L0!V,N5$@T1?%5/KK:*0*Q>_
M!FQ_G8\VS,N2'VUZ(S'#HXUD<X6YV%Q?NKZN'UR.]Z]D;%;(ZL/3'^/.'*B9
M*!^3:811*R2)A0#H\Z(LR'/J;I;PC&R^4TT-]"F"[I'_;'/NS=F^R.RH:FJS
MK)@K"=5B*0OE(@2GLOLV07WOHX&!YT,2*O#/*B+0;TVN]W5\K6BB1>R^-)7+
MDZ:L-/NF[XX^:'LGVOV)-!KV%J=#)+F84_0*T_P7H$S.HO$1>*O>>"'T?28D
M;2&'/0?[J*2V7(I5(5=9H##ZL3W=3YQN-'=+;Y>*%:%:6/SI1O*[6A(MXQ)A
M'G:/E0S+Q\!*PX.*]##>.STL+D')R,_'RZXCM0X2C%]U$NP*%&E\?LG94BUU
M8D"U*I02F/P;8?VLY7E%,II::FL5GU=.S*CNP%P9S7O-L=CH#\6W$Q$I:)D9
MS>L*!ETF<,DO$#GT,4":B?BA%)&4&ZRAZ+T5W5SUZ+QU:?]^.C#S_E)TWEL\
M^];L(G3>.^FZI-92!R(+.2%?C*TC%YV149NV2Q.U#3!3.7K2<\IYI9;M+DTD
M+87V*+4UAO>HEH_?HT^E)VW41=JLR<;SJZSQS+5*&$9ZHEF2UH728'731)8Y
M&\:<"Q80F?5V<]SYT_Y]HK751_MES8&D^&1*D^CE_>;X]E1K]-^>3^Y>)=(_
MDRV:IZO> I>G4%PM3'$.[O2J<ZA@;H;.,;^1PX1T#[I+')+9CTI+,5ISO)\K
MO,CC?.?E5EQSBO16PDED*7\OJKG<'!=*QMG;G^/'O;UB$E1SW$7]JH#FK["&
M+2A[/MBQZ%/[#TJ7%;M7O;TSNEM0-MF=AD_=-UX>"W;[8+]_N@3(>I:@;#]X
M<HK0B\!A3'FZ,;J VB%[*A8SH=80>L<"4--)?Z"2\"XQ=!P\AEYLCZY/#V\:
MSYT5P+.=N?'!R:T_/'O6N24IA##M8 )*&+9[4\?[:D)5G!WN^PKX[%1'$NY%
MD_Q(4L,A%GTDD3SF<#D\QE>8QO*CO'+'^4&Y5S]Z5@M9HK/95U<+U_P4*W!@
M.(']"U%:^AY8>:%8WE"8YJ=N<Y)=3>^T6\2N1E[:RI(O[;TAR0AJ8+KW]B*_
MAUYZQ]I;(<V]38.]=N?P!2YQ>#]#%)<:M%#*K;Z7W4KO\8R-38T7$!>QL9%7
M>6^Y.OZYTH9(AWN/'T:]DUI..\I=E58!LV:SF5#C-PX;D[T1$#RY(&&+J?$$
M8B*ZW@@XP2)/,UFI<OQ_67<T\1B%.">CZ$N'YR?URW$OUVJ.QZ52]T:^/<J]
MI4%"+A:MK'C.6NKIWER!'KJ%J4/@8J$@Y"L;F@3Y&<$=VL#4!DPMOX#]^XRJ
M[0,_^D&.'BS9=QE/7Y^'>_>M\>5[=6UAR9)O$1O/SF< 5^<_UCEX0OI.Q"4A
MGYOM_=GBCQ=\C-&<*;5))A:%2B1R)P.@\4$R7D6@QH T]O&DZL/KL/9L_L[E
MQ/5#&I^$-08:&_^ZJ-7IAS<']TF?6IR#](?9SJN-L S6],@B.4T^M2E7J0BE
M4D:=,^>"&D,WJ?'P_J+_>B.]RENH\7*!1'X!EQQJ['\+RI0'*3@:?)S_H[WL
M#?36@:UZ5<I]XR2%U4[_=BHXLIA/WPH@)Q2K47K7%#CRWGP[.0%0WBN]ESN-
MQDE>EY:]D],ARV(^M4E6%O*1E3_^-L1R% 8M8_2OF"^'L9BA;@"LS>*Y(K44
M5;$49-8UF;00]OW*P_BRY@%Q0.%B?'^$3WZH.2Y>[9GOU?SH;&\#*B*7)S'%
MC>:X_=[2BZ5V\:/4QNR9;@A_0&_T%E(\C8PGBG)[(.!)PIJ*)*Y$(HEG#=(<
MMTXK)Z.C_)TLE=><_-A:')%O.M!A)']-['"DAA9"$F/1>MV[>/K]</>F7I63
M((ECK^=F[]0"V4N:I6P>XG>)T-6*3Z7>OWN[.;!,I$G*%MCKU:)F:G)%1OF+
M45OJ7Q<V&]@K>MVZ&<.!2G&8X4BL4$(#::BC6.:>UU&J+]7/]\;YGH8-K_M+
MN]32>N^=;,H"3(?B^J=*-/06F^S: C])N_%$&YW<M59(W]NO4!"*_S][5]J;
M.-*MO_,K?%NWI1G)R6"S=\]MB220D(UT]N1+9+ !)\8F-H3EU]\Z5=YW&YM
M3Z3WU:03L*OJG#K[>4ZM]D>7VJYYXKZN:"EU;7.EU(@5&ENODI:U+O4=\F?5
MN2HBP8*G+SJO;[ER*O=/ST]*\VJ>-:^V1>"IC'DGB6/63)1*43436Y7EQISL
MHF<"GDT_IQ"$L]^<PK4SVJRSK5=0!6WJ'!+HXM<5QU9F3V=/DZ&XH5I/8UF?
M6M?@?S8)-$3Z\8A5NKHV8O/VGYK_C4F?::V5Z/K:@'^^5Z9HB7;[B/)8M^?A
M5JIS7.OP_%,J+)TCV477O4J?ALLC[[=6*5ZID4LIWFZ<4;#FBF;7^%>SO,8X
M:R30<D*MBD2FQV8H)[45]99;"!H./M^..+DC]Y6Q@'_G?W.[E\V#X]G9];S?
MS[4F(G*[>,D[7[X3B1X8DTKQ-7 Y=1*P$:-O9R=*'W:%?OX")W5!;2V&?YU>
MVA1"QV=YDPJF>,'XCJ9\X2=5?B*\#YHG:09>Y5$'2@JT.3T&+I@Q\#^U:">0
M5 EDS!H(RPQ=K.=4L/-%+7^)DGZ*3JE,%ZLYVS"QRJM:+ZOG9^Z@WIG?GCYS
M7^55CC1K[GFSO$LWRIZ<]Y'02SAS.N ;+ZO+A[/7B]?3[FH^W/)L-CK[FF\Q
M19L]6EY>/P\ZK]PW?7"Y[L_\29446[[DKEQH"SUD[ZE+BJF09"+ZTDB@(-C/
MR4M*0Z^&-A)*1B2BYN)T1+46?60/#@7J7$0+DH<T=7Y^2(DRKDW@QE U!!EX
M3W$=X^+LCJRA:P.8&^C."$W\1?#<2(TBRU1>7GA!A.E"0TYJR5-QNG3VP!H+
MT=>!5J%WP[X$O,?Y]2MTKT5-4]0EL)_12-M:3M7)\_3BWJK@LSZ(3R$:7=1_
M;P&V2!$IN(K1'!JX)?WO?FMVRIU*:N>^PM)5WQY2S-#[!6 +S 5]3E5%8 K9
M#$11*C?%=1=A%97.@S&B&-?HFS=3'-P05-!0W%  -N G+[,K)/8^F1\^WDZZ
MS,=J/E4MS-F.?=?)V"%LUQMBD+C.=.>RC90+\F$@8,?:N 6H\NV7'Q@VYI3O
M-E;11IPD43T!.2HB3RE$1@B<*HF""NSRE_@W^I4J"-08;7VD48J*?H=_:<D@
M5>@+X@?:+34094Z&"A-#W(Q%61S/QK[RIF)C/:Q@=/WR^3*&+[/'XI!?W-V)
M:86,?4,;XIOTJ#30FQ[0GZ[+%JHC4\W9$*U%UT%V^L\T"'RK2E\0>(T:H)7B
M/T.CA@A3DV8]"9ELRF" M!QBC:F"N&V)/X)Y$%QNX)?!3))H]$-?FO&$A<A5
MA-\5(G17T3GZ :\$[,*.ILT01PH=LI8KO)2NOI*7R83E=5:KE_22>_+3)S!=
M>[ 4EH^WYT?G0SO3V0Y5U#<#)R!.E!B0_/'.(:CROXY,:.NG##DUKG/(^JC
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MYS_$6V*0'@7JK$6GN#FH +%$EQMUNE3RQI -<EE6FMVU)Q$@_6]86!&\<1Q
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M.K*U!NU31[J86HEFB\%4CXQT-3**=.5 JKO^@5(:_#[B&I&!^SP"8&N0<\V
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MC #T@(XU"[WTT<>PKAV;!8MEYB9,(6\N44,?@NRC,)T+@DR=SF2!*N&0#%N
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MZXBFJB+A7\XTDF/@(<4P$$F!+5KH=(F7Q^F5-W@A  E),A C )7!'\ M:;Q
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M#YY@<I]1WA"G$3Y4/$=TQ,<DG(-$2#EEA",<H^$9#&(5LR]6'L#-F))6>7R
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MJ;/K,T:^N,[%9@C@)4=<SA%)U#DW=9@7H#/,6-WV2K<4_E&.@BV^.&/9M6Z
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M,M/E/#7?R=LZ]VZ&CU/C")9J_CDQG8/IPAA<OHD$'-GSSMYNNPJ'K+*=CMX
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M8%Y\.*,TR[)(H,Q0[_MV^/4:,>;!)W1F1B*;=.($G'*DY<'%I%]N76J]Y\^
M/LCJ2J:S6^TQI<H^&WPGK<3F3JF+'=1P8,T4+C@5@@P*=3J3\0WR0M0$*+QF
M2H57*E9+Q74N&$0[@Z[8;>/^9M1;LK<]8=,J#]F"U3VTL\#[%;QNUPU;SRZO
M%"MTI1;L&;KIV$JI]'*EXPU_/'N_Y?BCDABJ]I@$:H\I?ON%=-::6F\@#J9+
M2]]5/.JN8(M0Z>JNM#%UUTRJ[G*EXGWY\/6I=O@X6%8^!^LGFPO)I+-"OU3>
MUBVY*Q?"P-@RUW1.F*5,[Y8@GIU73^Z:K>CNU[3JK&[+;*]Q>]:<$(#\;]8'
M6ZG@EX/TK[N-I=4FIEK+D6CB\8U4?;YM/CU;87";!Y<-]DM<=6CW GU/,XO5
M1&M65YZ/XS]$35&7!6Z(#A)G]G1D$MPX1NK:,/PA01W7BUR=V5EW'M*=>8RK
M8 L>!5M/KF!SY*?VT^/U]=/BL752R0<G;_W;GPX!,1)!+S>&_5+&FU?&SEQH
M?MK8D4;*]"(^:ER[]*!>+9K#_+0Q6O[Z]W'-M&.]2C.5:E)M7$_M8^9(LU&)
MNS_H5GX+,^'SE7%M.Y6QH8,+1 ?+5CT/$I,;4, 95!#FRD/SL^=;=GG6;]US
M.2C@3"Y\NFB2 ]ICG_U2P&D4<-RAP=9(S+#<?> PX3);=+0[WO1' C^3+'R9
M)A3.B=-E6U%MS[V%HK2 P<*-FJWV(\WC7D99U&O<%J?WYZ=\O=UC<AA4K/]2
M1"(-'ED4Y:Q;/P8*U-7C3ASH4,>X%^K2%HK&!9IPEJ2FU2Z*>9R QD(5E((&
MS7C(' J>=/DC]_N2[X'YV@[U@X.75>^*7U:?KI418\VKYD5M(G'H->B& 0R$
MSJ1PMD:@N&D_6WL1X9\PL#U3@_]SI[ []I (Z#G^/N-!0G\#D.,0$&AR*M]T
M*.0I;U(!<)@M)&B\Q;D UBU\1^)_4OIFS'/%$-C?[-\WG@DK@P/YOV^L&] Z
M!$7;YY5^5+-R8889;KL<> 7Z!7%NR'?U/B_]MG,'\H _(?![S0]DE#H+FO^K
MIW MC#EDMR/E@PS,*1A\T,L*ZS@7!QF="H"6Q[EKZ.:B30U5!3D><'L5]0>E
M#GM_L<4RS9;J-%NI_&W=1^-9^I4N5[]''@&!<>]Z)DJ;LX.PEF7=N];?P'[W
M)Y;S4\QWOW>ZF,1T<>H>%R?;^E+;7HDX>!%OK/*7Z)FLR<VX]G3P=B).JS)X
M')ZLO"&):,I!A2G5$Y FDG7GDB 2?'.?;-EUM+C%)Y8KEO.A^GIU3+25[[#K
MURM_JP3AX_FR<BPFS8[[_]>'\3W!]30T(@2R$\20;DV"DN' X,R=]\O'VOG3
M(3.I7%G@*L:"*'U%+KVS Q<AV2%G<A?6[V5D]QD_A-)MN VA#PZD;13*2B^:
MLKW$E#6M YMQ '%;]H6?/N%[Q)CWB,GN'DG5]^?']SH/8 "!]\C7<L%6"[67
M3,_$: -@S.!-#%:VL2Z$@7\@[QZ\>A>/5SV= YLG(\3[RI5 O)"4MV4=>^]A
M)$*1@_M">5]X#/05>&.18;<Q@3E6R]<<TQ>=KQ;Z79MW!MT>/YVQH1:8OIAO
M?L?T6::5N2:?.\B:=Y!-J$[6*[(,[BQPWH\H-LN(1=DD+*I%*'5\WEI')MAL
MH<93KCQ[-:\.%@>-)?\^BF\Y#7-GX.R.+UN.+J6;MAVC2G&#+!U"-6_9<G;-
MJ5J$<D2Z$8P(CY-GR&[#\LGE'KS=E)[YUNNP/GI;T_(QQ7L,ZR81'\:R;DKL
MMVP[9]>D&HP7*K,Q#9W\K)OH:);WW8=0)2Y) O\/AC3-W.3).0+55M2!($YG
M2.@T9=Y"9=7R52C7VL'OJ=1IMR[Y4"/(/%U*/]U0;1*SPJ-4AO.NH^W\3,5B
MF='V($_!Z=!OYCGJQZA'&W.E\7EO-.V^G;46KR'"TFTTY$/PZJ<2/'@#YJ(V
M)>%B^F^!V1"#7+Q[R0FR)[$S)@EN4BM?*6EN.]\;,U\\B)<#_N*Q[3=WW9**
MYG(2I)_6N3[UJ.L3D'B*>S,^F7FJ6;IL!FVVP&OKG#PHY^>G[Z,.%U\ MQ;]
MC3)7N?@G,M<Z)Q>@%%(=0[[6<(Q\;J F\:9YW>54GD3O)XL)#W[!!G/!)5,^
ME+*3#Z_'KTUU5'U[D$I9Y8+3B8KMS! G#/J4U\L0U\M5NE*L1<9\=D(:^F64
M/?W0F\THYW*#M/N#\TZK49]?)HB+[NAURB#/G/1&K9]GKNP7O1TR.WFE,C0P
MPC#$/S-9G8L1S/1FDS/U>MFZ[VU)LCK[<&YY.Y+5Y?U:W!CNQHW93TY<)W(Q
MUT]<YZ+L3AZ/IV_7!_?"H/9'):X3=?XXKMUZB>LZ4Z(;UHS,#67Y_$RS3 ,@
M*7+6N;"K^C&:2/?/'"<DB'[L?,XZ-3-7LLA9U_VF9&U%I-UM\QQF:/.T+&#Y
MF,J2,6V>7%B_=#UG/B[.+WI#<8-IZD2L%\NNJ;!9VS4I2 5V32EHDO&6YZ9-
M1#,3O]JD;,8&3NFS ,ISU2$'9]TY6^MH<V40GJ8..>CDNF1[T,Q3JI)T?GLT
MFOFG).F+"3@[2KD'4^#S[:7SD]/?VN7[\>!FD"!=_PF,G^\A9WP5UH?HA0&8
MVVI5?=4O9)1;\IBC>=<OY")"+B_?EN]7\ATS"2]MSZA^X:^-AQ%L"\]42B0*
M)&CH#/[OVYXO0&.-KOM 0J6.OOV]9=<D40XIGTJ-7"[.0F;>CNO+QX=1@CS2
MIBLUJE^5&E^5&KZ5&J6MH&3&S<N)*C5:^<J'"JM)YX+*E)[$))4:+7W$X%;G
ME=<MTTBH:ZOKE6DP=)UEZ5(E.FR_$\+0+QN02<=!TD*-G"_00_^Z=#(^J%V5
M^=2%&CMQFS*HTDAZH=:OTBCO5Z/#/3MQGW*LTCC:DBJ-7.[GG71V7#D[>!S<
M9PXIX+FVGY+*J&Y'B49IOQ@73V M*_8?C!T'R*2N=]F +9M51/?5V\7T=/1;
MZ/93HTK^.=A_GPWWF,7R<UL7QG 5%C 27?CU[__L[5%M49#X']058OF?Z!GO
M,T'NPW>9TD_JGI-F\#.UMZ<+=E[\B"^/HSBKBI>7"" Q'NRAWRD$NX1H?7XW
M,B R2KC?A;+8WK.?I7&*/RG 9OY!-56N)_9_4I=(=)&3OE3@2-FR_5O_&%^#
M/UF"P) "__Z#SMZ'"JK O>WU!"0_T;,GF(KV<Z_ZWVCKSEE/M:\%%DG68>.7
M=&SM=W@Q9,X6RA=?D;+AK?S;^W4IS%0.&0-TH2/W]__]I[>^Z%EC9V@]>/[7
M5$',(W-R']#132-&(\LCHF>C"S-HOBYPM=_D\VJYQI;JM4H8AG6U'AO#VOF*
M4!AK)AZ,==@34R!9^YW!RZJN7EU+3R*[5&LY@%E_,G3UQ-@R]<GHU5MDF+F
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M_8[+9L9F\<3[C$.B3966X&$+(@[LXIXF'+^V-2S@A -',14*XR*C"T\PC2F
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M%=.05XHYJ"2.G?5'1G&U*ELJQ1GYF'WLW^,WP):82/J0]%3MS%V3 Q+6O82
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M.6@[_- -)]_W@"T>Y L'>#7F@QY]*?48GMAA;X'E"J5EQ4FY5\G JH*TD<Y
MQ3EQFJR:^ 7Y.6=U.U0 >.&IQ+L=#T:EOCZM-.>5>$ZE$?%7PECL>4/T8CI^
MC2DXF%?+^,4LT7RRR_!NP0MIJE.ZKZIF7>S?.D+,B:H:"GR0R__C'BH_%'2
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M19\D_]9V.&JQ:]8Y['!4LUNO$G&#U78-AW@M!?'(/G;9>2*R#YWQNK#4A?Y
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M*>W?8,*.QP0SMA<*>MQ ;?@C2D;]F.?'A;M)*C%CZT4^>I69U8,=G?>\28&
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M)Y9+]&<7M4"-B]G9BY+;7]SAZOU!J('B7G0#Y\YM!T<J\[K#ONXXH,I0VOA
M2KC)]$G(?L<,Y7HD@V9UND"GU=GZFMEYF.5M%=#/=6SP]*1;F:K*^OMO G-I
M]929XZN"WQLDLW>Z?,ER8YW&%.<E_$'S)<A$<7DMF51DYM)OY!Y^HO@V,Y0&
M6VAFQSG%?9>LY83H,>$<&B*,/JJZ!SVG2S\Q]MK.^F&\ELM:]Q> (>V=)JG
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MI#ZYF)1RC 4%,I3B8H:)@+"[L)7%84R.(WKJC5\ ^C-W,]#>@GOT+4,NJQ?
M.4GY"Z#LQ[/K9>'!G3_#.0?)NA>^_)]Y:5)>4VN+;S$%@VR[\&"1%\"4@>:9
M0#?:Q O :*[O,_EPO^I-E'DI V>:=D%.7LDDU9#8>FNH)A[+M0[5'[L>]5+'
M!'_C7<;1#['2F^QR1U3ILGS]>>.&8@H_Z,$8FR,YZ:N>V6%RT[7LY9#?RI\.
ML0EEZ)#?8JM81'?GYG JP8ACO[YIK')AS\0_8 ,L@./B,$;9871P,\]HKY0B
M4NU]O#'<,@CK*C:* GG.M*_<P=D87BWYQWN)T=EGMWCC/5IX70J_X0Z),8D
MF09_TLK(S"ZPC30]?<X>G-3E(XLIP6PTI-*L[;L[T)JDGN)*&=S#3TC6H*+-
M'(4M=,\U^%U?5B!-EQN%VMB8'G=Z?<_(BFS8ZQQDY^E-4E*_5ST9-C9^2-9)
MB O.'&!S=S9W=>8I[5X34; =HIP\(9\ E8?IUT"E*BN]*B]%@O4RNNZ[AX^Z
M-V=*+A9UGY(EJ$XD)W &^3'C_"S.BF(%S*MJ:\I;M:@P$'WXD.L/M<H'"9OS
M^FU!'MV/0M8Y"[\H)K03#NDOM/Z<&[IG[1E\>Z:<(B$AW:QL+H<81U:@A6LR
M/SJN$]ER5D?>?I5ZS!S&9ZW*6UIR5-D=>0@J^',"MZ>\O\SX72]>5T!EAH=E
MD2';>70C;+])'>$,/OC#Y+M\VP)#ZQF+SW;]'^P63]&\T1A'2ZX$!HF\&[T]
M'^N.)\Q6T9OJ]R0R"I>M:38.5>X,?"P()&!06OX4I]%+Y_W)46'3$)+5B)W1
M/IL:_7D,\?:GD1<RLVW^.2R!L2E\HC"E*VDK#]_=0C0.AORBE09/NS<RR)4<
MH@_E+T#KBLN(/$+.AX]HFN^H%9E3)00[TKB/]\6Y.WN2GY/,2<"@Z[[UOM D
M.$&C*Z3>:$814\YJ>K6(D4#WZM/CG_DKDKD+-EC[[E6>H]] ;3!GY:998!*-
M7MG3ZL@J=SN0KIXLR2,CK#YJQ_M]9/I26ODS^^I<26J-1,:MOF=K2>!'29&N
M^EU%L&J*]J2]G;U=?H,U9?T?/?G&6"A:2'*.4% ZCQ"14I!4G/:4"^^EK-1K
MA:U"78U7NPMG:9N#+[\N8&9R&91G,I3-ZW0ZLT)VKI2+9[??M_WA@&$3Y<MU
MH4\&D86?6ZJ8%C0EBV=]I.;/JN;>WOPC/,(L$S MN&/'(Z%1W3E/51FN4#N3
MT4GX6X<Y1]'E ]Y'"9\Z+8JUE#%TFZG(0<6Z(.G)[.?AA'T2 ]XO#3Y?*X[X
M[J1%/"+YRG@@9Z1@HQK*Y:,<7/&F@$ALGF7\8U3=C)[DHPYJ>;=0;*>2?DP)
M'/69+( [B(&C.8XP]2O[!6VOL[O(O/YKI2Y=T&H];0D^0SI0CWU03;Y?MGL!
MF(O/!U>,I5Z6<7C7Y[;P1&XN)EZ$DS8V;*?Y^CH7&LI[NM,F"8+K%R/S<7(+
M]:.+M"Z9$2E\A5=4FZJ@=B$@KZ-M _J8'9455VS?14N"0E9!D3R=Q:5/"448
MKKN92LY=9K":>WKF/\-=P>SM7\'VOS\#=9C/0JQ"G_>$Z.,\\K7K8G(33JL@
M!TZ]9%[B^"BV(N;<-V/5*MS\1[(/ JHU9^:Q5M<)_:#WU]!/=?[-@?@W9;S$
MWYU'&&ZGRSH-RU-WE%X 4>G"+P"^9U?)R(Z:'\3N[+_CD*Y9?_B?,R^] &;Z
MG]4WJ@_]$>Y.EU:>?#*VM$Q;?SQ+S#JL4]6+>,RD^&A,)FGTRDGT' YLS) P
M0A67N3;\L5)KP[DS5@,^E8G 81_LNYJD%>XZ_E86]]Z)-\KM9(,195( 7-&$
MQ2)NUM1%>OS"_-(^%A.-<)U[)3IYS8C,R"SDLH(R7#S;^2;!#G4II6)Y0HH=
M/9]8D\N.,QWOUM\;Y=X%3U6T!%]FD8+A!UK=%5>G_LJ2H0UK@9Z<SMXF)H'
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M31W3*_*T?G'?RR#%V1:_,O'PVG#N(UNL5(!IPR?VY8WI IL6Q(DC^Z_9 65
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M%[/Z$/K>0@6*,5-1Y%7[H\15WV8/8DKIZ14U9V_2UF4EN:P\J\GYS#1%7?7
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MT2VN:LGAG#%=A%"F]FNC>FK>J<*82!K'X5U:-C70IPTM+ZI45+[[$OTP;'D
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MP#^=0>7F:V^VNY"MFJ\"LZIB AGFG/6UK .R(&8KN9']P$;JM& R6B)8S\:
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M?K]:7'N]WFJ'$4!XGK/&U1+-TQPA/SP_;**N3A&V[7/HX%^_V.<UT#6]9BH
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M:OHJ8Q VRH+KHRL'P/>]\NUJ&-X)1@QE[:TV4"LLEO.G(BV^^!JE:O\&1Y!
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MW+ Y3V^KRGV8==UH#XK[<:,GTL!M5NTETL0^S?H1/IK6Y[[@$8P5K0UR\']
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MX+, /*,.1'!M'!VE=C$&:(<$K)3'U_(UM&6UOGUE_4Z8M\ 1RT@E38ZIT=-
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MJ':0FV8]UC"M;8GZCQ*4XA\EW4_/D"3[HM)/YP8<'R+*4<UI?>> Q7WBXQ&
M^Q?R$E YS/I^7@QI/$YJ W5%I\Q]#8O;&SM H:8S\D\]D]/[W_+="WR@1!$:
M*2ZS/T;5IM-)E@G<J=Z)^E-X.9G6  "-G?[^$Z'ICB"QW%N<$6,<X/64]3.^
M J6G"F#+@NRLO$9F:+-[SCX5NTIU4H;E,Z:[ P/-[3*%(VHT"#L=_0QM ..7
M-<T2B%KG9"J%'E]+/2_).8"BD CF0:4.)2JM)C1%TFH%%=E.'M)V.,$A$C!"
MF19CU?/=7'=F_BY[4_[%V&LM,>_>J#D-Y#Z%K+$3_.E,(DNU5H:D4N00>>Z+
M2.B^R:'.F,K9%<$&5C7BT'BIG@,R D?G(#ZN$?;'./S=;&;HOM;_VH3G>%YP
M]L)+<M'[=H<Z-7];J)Q">HAJ'IA$$IVD-F)Y1]H\!KV/.M1!RYU=L6U@U8CY
MM1^>R#Q&]URV.6$4<L \O. ^2722CJ8>EH@C<B/?1['>=_L;?K,3":MWB&RY
M!M&+VLI4G8R)F)726H6H.NR?.:(?:/P^!^S>K#T'U"MQA^3*O11M\VCC]#(Y
MA83=)6I'11*]/U H&]6GO+$-3.--/'N'O]W&"EIKV,S!F1R33Q(>11S"QX2(
M73H'L.KLH5^N<KF'0VA :_\0&VC]:5 T[LVX.<=_?="HF\QT7 &S)?9]7T1:
M9&K*JS/^FJ6Q%?TO7L$GG@=O?>E]PE7WC#PN)=GWC>WK_*BL\V2*FYYD5PSE
M2L6VD,I]M.1'W>F7CM:2+$%6)7!:HIO#RLTL<S EHAG-6]C38#3VXK!TP5G_
M;FGNGI&,N _OK%;<=XX5W.=P^1*@-]- 8\=^ZNC9-M] ,R)08LR"B2UVD2^[
MXW>;%\TI9)*/X.]F<O"-Z++K1$:@(%5Z,H= C%H>2!)*M;<FX(BR<T!SZD##
M;VZ7B_$D6A*-.+NRWK 1I;Z"\XI8WJ,!+XK=V9?[O_>ALE1+*@33/T*)%GQ/
MM$\_T+0NF0#L_8\"':VFNO_H_=?(KT(N OG)DMSN[9H+FS!OYN+2CRDF4?^P
M82^D7,2RV,TV+Z%32#'WW[]>6$@4<P[HTUPA' %];).7B59L%][-32M?(_LU
M$G.AK(&H##6M<2'VCZF%BG7N9(JV.Z@J>;%[@P=BB1D*NL&\'H(ZA:2R[ X3
MPWXC2F4D/^*'QI:GL'$_T65,B"Z;D4,</IX+A\"@^N ;1&WU7S1D0O&@Q;'(
MR(?IW:,5W$T^]/<-X+7LO_FL-0XMIGV$1[0^RW252F'?A)[Q&G,E04,C&#9'
M UQ00,/ \G<=;VCP]K.49)7%/I>F\50_W,W4#>Z"YGYU\M&@%5?THS .[>PA
MXN'B)P79 !_(<,NSVOS,?DHDVT)T?$CC4+'*&YB2=@ 0!U.]G*P$;.3)"@%<
M7(87;Y_#QD)X+ED22Q#++#]*Q8$0".!['-!,#*9J]J'GXIM>)($"0.W+%FA]
MGHS+(3P95S!D:!ZL/5TQ?5:(O.!5L"=,"0#V?,J]D) V!)._%4)L=C4KA <
MW"(*]P42:SF!,'DRI-4*L1R;^CO+CV9^Z<^GPHB7>@A1%*4]L>Q'GIN&@\E?
M!?Z]2"&YQ&Z%BDAFW7)$E .UKU1E_ZV!-A([D7NYCR?+3^[\Y_\ 4$L#!!0
M   ( "R$D%C*M<"7[&$  'MJ   0    9F]R;3$P+6M?,# R+FIP9^2[=515
M;1<ONC:-=(@T2$AW-RBU05*Z1+J[.P1Q2[A)04ID$]+="M+=M4GI1EKZ8KSO
M]W[?=\X]]YXQSA]WW,5X!HRUYIKS]YOSF?.IQ>W4[2* JR +E@5 (!!@?/<#
MW,X 3P T%!14%&0T5%14='2T>YB$6)@8&)@D^ 0XA!2D5)04I.3DU'3L#-0T
MK+3DY(P"3*R<7+R\O%0,0F*"W*+L/+S</Y6 T-#1,3$PB;&PB+D?DC_D_G]]
MW38#>&@@'@0G1! -@( '0L0#W;8!5   0@;]NH _%P@!$0D9!14-_1[&G4 5
M+H  0D1$0$)$1D9"NGOJ?_<<0,)#QG_()85"H/8"E<:9D#L8^@&-]G%9RWWU
MX>]T/"8N(>CWB!X0DY#2/V)@9&+FY>,7$!02?B(M(RLG#U9XIJ&II:VCJV=J
M9FYA:65MX^KF[N'IY>T3^C(L_%7$:TAL7'Q"8M*[Y)2LC]FPG-R\_$_E%955
MU36U=?5?6]O:.SJ[NGM&1L?&)R:GIN'?EI975M?6-S:W#@Z/CD].SWZ<7_SD
M!0(007]=_T->>'>\$)"0$)%0?_("(7C^%,!#0G[(A8(OI8;ZPIF ACL8C? Q
M]$-9"SHMC_KW^R8NP_>(Z'B_T1_\I/:+V?\S8B'_6\S^)O8O7G  $Q%T%SQ$
M/$ ".+M@+%0L0)_4\=V@]6RO0'[.<\^LJY.D4P&8R:I#'>6K&D'.?I\-99<.
MD8ZCCP^%=J.&V%RG"J<^8*Z082F8+C2_:G[<Q9-Z=#&$*B7S8D-K4JN>1\X5
ML\ Y1)\=W36ZDX$*IO1!RO5^W/4G)A-H-BLMM'6'(DAL U$O$K+BX-:D;*BO
M:JZ;\"B1EK"G-:+%L/>L=L.K79C%$1\.(E<NSA:)H]9B;8\&"2VO=G!U%@'N
MR1_Y^GI2+OHL@OI:8EGE'O69$312/?;*+U&)")ACAB/IH(.(PZ@YR"_VMB<A
MP$+7":R01**&2(2SL"'ZI-:DH-.P:&$F>!+^2?:&L2Z<*5C>KQW3!/Z%PXC;
M>^=+<B9V#F0%7X5@;DD&BSCZ>?WC/#O+ Y91H2MF/Z\LR4SNCKH.A9SEP6<7
MQYG869$Q>FM&; '+2I_#S=O"<+^:,N=ZD@5=>_,9>8FJ>9,/*2P)IDD^(59=
ML4Q-_>Z\V0ZXCVGSYB\]\<AKP$<VK7V;2VUI1?'=JUMT;")V^Z-",L,;CP^E
MY?Q#!$(=\[4G'5:( 9"5+!4"?7BE:H=NMH5[K/K+8D6"6LOK^02.I"4R, -4
M1]1FIJP*G#1VZ3REBJHFXZJG]?&3X4:<2"O+?) '#[7,@&3SH(%K/Q<.Q"\,
MVA9@ 5@U&[U;"=U.GV,T=CNNZO/VN2(UC"0Z*'N7>"D=W?L6_<9+:'FDH--R
M29$^7,0[;;(W0LB_&-2R$+R=7HDH]US&5;L^H"P01J?>E>/1@-E[IDF#='#X
M5H58S.:E\*/"$D]$11<ZZV6N^7U@!]GURF@.+1-[!+*\<QQEH3]=[$X5AU>K
M1K"R1W>8NN@<VG5:] 6GU=,15J@-C8?J!"=VTY:)IJOD6"%J01@S$?Y/MPKV
M*MF:6JN74D&==!-IKO5)5X'=/P*9@8KKREO@J#G +=!>XNH[59KY\%/9W-/1
M6V 0=#[\YYE[D@Q@\^<YU8S*+2"*NJ[KIHKR/Y=[/A"SFWL+I",>%=8S(CZ[
MM+X%UD-N@06-OZU(DF;\T23W1\N$(2$H_[_0_*<<\BWPN8 = HS=P/T"\YY?
M;OVWH:"KC1MXX/FBA'!O89J'F(*5O>FH818TIRV:#*1MW2+J-H#U,$W[W["W
M!.Y_^I9XV;9E1&N.0;PRT_#B? R[R??DRL:>TM[9D8CM,??W+LHG#Y\2#^P]
MV(08>P3^%WCR(=K_,K\6;?7?F/[_<O-7C'[]+5&=<>.%,U"^D8FE\B=:'_^(
M;[/_?U:LB$PDSAUX6SSO#%DK\ 7? C%X-P>9&"<#6\\/<>.^WV@.:],N05WL
M]]L3]ZN(#XA&0QNBX\,Y5&YJ>+4YS0_$(A2MLAX$/EH6#76290A.75E4[_5?
M"G7G5=/)C8\*2UB^[&U>M-RRCMC,*S;<N]*DZ?IB)N_Q"5==K#U:=L=U(9UI
MZ:R=#3/2_F'4F%!G0JQ\QSCY6?=:D+ >,XL'=#?+.\ZL,*C^%G!O@"0&W6/,
M^E=CDE,SL"^\8:XZ>C>CY&(D2:@ 4A4@/SN^&P9W? /3*SW;78[FO7(TN&"Q
M.=^HN9FO9OUG73L=K"#K[;AM/:PCDA]*Z4CHC@9<CY>"A"',3:&SW2\0YYEA
MK>QFFL3 M8@F!&#,@@#,9!F5YZ8[G^7]5LZG::G"E'3U#K>>F[T^CO4[B4<Q
M.-$B9KL%0 .!]X#4*#-+MMSUT;/XC /!F].,.U<>Z226_RB>&U)TJ#!/)NX>
M1./,C6FH/4K)4*X]($R!51C!/^D+VZ<B-S^)B^8Y[LZT*.8+OM(+7#G^6\.H
M6ZB7TN$\67A[+[&1.?#NTI2B0#:84&+)^7I7XA:@^GC#0#5_E[P'%U]D -5;
MX'7GV5TEN I((OWS1XE60-7I04YEBC&;)P%+MO$M4$2R:@5:^&6@\_+85.?D
MU^M?:P*)].6)=":^28?@'V+N/;4,0'T:%WD+5*C/S'DE*EYJUU9HO/*E:]$.
M,_CNG*[2!-C> FW+DW<%I'/C7W8_C.H=5-E+#[!/S% _9D#$"NUEHD"UTRKZ
M)[:8'ZF!OC_?V[HF!#WYF\#S7[>OTDO4) F="WTVSV^!X.$HTTMXX(V$KO#0
M :%/9 QL+W:A5S=DQ;CT_&G@D[2%,-D:(^8:&CQK\M?DD'3;1VLLT?HE=#?Q
MH*HHT[^A=02<9IR#=57Y:]T4N_:R:J-7]7&)G73CT[$#<V$..G=VID\7; ;A
MHE5'+H%OR(>0J/[R_DA@V_(O^]H;F??^OCM\"Q#$[-]EUX_KYUE!C'_)R%TI
MX_C_C$F!MEHW7^J!S$.(]F-\J7%E08DT%RAX&0G%,Y2MM'>5')?XFX?I9X#M
MQQ!/UD^O%&><B_VM?(*B?Q("5YG3Z2 2D%4M"%IV%*([.BX"8Q?//ZQT?\S;
M0H;:BIG(DEIZ\9T13^)*6:+I+H^73^BHX.)6EXJZYSKK/7,-)P5NJB 9PKMV
M/\[?.Z^XSM;2$O!U^;#NH4QH23R7SHBH!UEW*/$#DT>_G6+)>]^K+2GN=G,+
M&$FTD19S-&HBE\NF.,5*(W++\T"A@T;*/)(4V@K,T4F6]-FNR>;<O(?>4Q+-
M\BN:6[]2A/'&J KZJ36_-U^7+ZY\IB.6M]5;=4=\*U;,EFYP*9^=-E6/>Z>#
M *0YZ!>9<=,$N%=J\SI>/8NHMAXJKYFW(%.(7*:SC.X_SN<34S2L\/9K0+8:
M%D#'\P1=NZ8Z2U)@W==6CMTS%!?B^(@W*[!@8$J9ZB&X5O2'(%)0=GJ0V:28
M=9[MT<:HX7O&OLNQ5G3#'.D;=IZ)(&&J7%YM#K:%U_!U%C.%Q^=DD@BJ<J*6
MT/3X8T-776O6$S3Q=IMFX:XW1V;\D@P2[S*Q$VLJ,WX<4.V3-I,SHI)C.NM?
MJ%QYQ9Q%8>(%5#A4#E8:\,X[S)ZV6VM2& T8/@'75X:;8L9^T Q4>,*,18T'
M=1*K[6<</CIS$/9L-]?Q\KD0ZJM@R^;R)I!./&V/?W1=N_Y=]&0M'^[EV<8_
M!(OWB0B9?L& 1XYL?P4X#_:FIKK<$<8==KX%V+Z+<<GS.E[8[X["[I+6Y$>.
MR'NKP*H4>=>Z-6[_/M.\SOX%A @_D25Y$URY@O@HU3Q'WK(M?[EGDV+UJBAG
MITS+9PL_=CE.F>ZJ_ +,7,=JGKIRS#[=7G^P&LQ#(Q+W5FHY=_3^>'1\F]F=
M=JKSW5L@>O@Z(G"]YD9$[U@=D?82]VY*X'CE$;/SY!80^W( G\P*XI8HP[DZ
MO4LKJYLVB:.96X"BR(?Q+]&1F)UGDX/KD_:VPY)]O]_Z<3PC=_KP#L%=KNS>
MW2:AFGIUXWL3'_C'X$03(5K77ZH^_F6Q:B,3\_?[=V4!+E&&+3%YDU B@_C+
M^MDOZ^T21PN_K'/]U)E[XWN7 Y5_:_W,V/[@?T@@^#> P)^RSC<-QW?H2: _
M27^Y$?DG4 CP"]7"\;\P'<@@_-^R_\O.3\AWAI)_&?H+U?Z%5A,A"'K]^A90
M>G5]] ]32Y%J3G=Z5?Y++Q[T3S!^"R_\Y;^,XW_Y*O"7KRSD3ID&_&X"YSY>
M$MR\Q[E<^^V_9W_[[S=H6R,(DEG@?T5:%>5?:'YY\C]=W29T"SS_@Q_R#T\M
M_".B@?]P_J^0MO]QWO)U@/B;.R,\O[UTUZ_]AG]IV?QMF>EOR[^T5)7\S[U,
M^)OP';'4NXH-^U<G^XODV36+T:_ W0(Y=^">5U9?LE(:[<ZN\YG\'LH'QT\8
MC]/$BE<,>TBTD8/(4]WYU*GP-\MIT.FM5A]ZTCZD5W1#BN89/2KR+EJJBZ0;
M+LA[6-I*2PM3OVD;12B_CN8LB6J=I&!$^.25I$++/DBZCNA"OLZ*0YG!M :[
MF2_WM:P-ZWLKP]S)&BR/GLX3-^4S=@M,77BQ!G03Z>!Z;6&[7O7+F'^8UM,S
M@"-;&]<R^+FD1E*BM0/JS^_K):??KTE8P249UT:J1<VDS/9;4)@NK=/O92Q^
M0.R<BH)*%9&G')-;;G]))XGX5K(%E7A+:+-=)P3-GEJ'6B::?N-CYKXD@9ID
MUG],DNJV^]G]-T!6V9F4/D,(PS*$@-K/)A]0B9A^I8HP++7T-OT8J%2_I_>[
ME&=GSXI9@<;4E.;VVP%AB*2+M160!6$$LMZ.6*97 EM,/++>F<A9[S-\W %"
M-9F[!DZWNE/?3WBGQ"+(51+C5U7^V1[Y;PSR I6_A/[7C:* S&B4G8^W*IJD
M,1NLJ# M-%,9S>DM5)0^_K[ YKLU;CO=QAZ]?>8CGJ&XR4U)$I3.-B4/9V=2
MR9B7]LVURNEI*O=%3_5&!^UI#)%> &!='9=IND6\&&6;(UNX"[3^&RJ)7>K]
MB^A*E:+IKX4S*=*X&$%=W/?BJH.XU0?;-K_.,]!/OZ:^:G..%D0<2>-+BC##
MP:N3BXQD(0*]$J5$-=#*FW1K>A^V(T=78K042Q'X-)'Z%K"-4AZW4/<V..X'
MI&!R!7+NJW,]>O."VLBENJDG),?$@U<8\.I.A<&;J5$(RYNN:B[C7%&*ID#F
M5S?X;'2?%ZK9^</G0D-CG7]\M[H;D =(UQ+[-)X_EK=O%/"I<73&FL7@Q4>-
M^KR-'1[TZ&<,<FH4G#\)AV?6NRFRM+!&*!-W\-3,!W%]*QNC'74<F@JEVU-X
M[# P).(WY[UETT(*2ZA^CUS>@-1<RRJ0ZN^J/N<5#A^QSO*R="6273$(-^:I
M]%V$-%!<-[0XTBJ\7@]>#7\1E[Z@!_0H2:C&Z*6O)X6=1<T["# A8M14SWM_
MJM:3_8#5#VE46FEED7A_&EEK\!UM8WJ=8?1^:4I_8\K+Q&#ZV?=!_E]8[@-O
M);B>6:>\U$M[5_M:]X$SV?-]3)_H,9"3&RSK=R:V*RKF[9_P'SXM-4":HG3@
M)ER/;LU5*'CQ<1;^?.IFMS'/U"+VA9"0:T:2M81GQJI>V1:8-0F:3;!71<TY
M'7).0N9O0R9F@U'W[;5Q&JF&!_(H8"](*UX)4BTN\;<-1.JM8<<DM^M9\:M#
M_:+2\<&?0]460["Z-!$]\DWRX:?L8X?=X'8[E7QXJZ-HEA1';(NA"77UDB0B
M92.D\.*D7LJ6"6+,3L]E'"1:C8K$M=N5B3Q4Q,[VHE: B]@(K(C6N,#)N-DB
MD6:KSL;VJ^N:=3NZU%_.T=G3-^BC37G7DM5X/,_U&:@>9B\J*2HV)=/OMXSW
MSN[XY'H8)KI.O+ZMKQA(MC +]U8_?RM;K%."B>U%V<0<+WS%W7V/3#_^Z!$G
M_@9GS(;WC08PXF[[,;^YK2T:9I]A,>N\G0*[CLOCAYXZLD%??M6)-S!CJ" X
M"_?N;')4RM-KH6BM[/(+FZ/)[T;<U'C>ADL? T]!GSS[2B1KI!;CNL'I*HD2
M8^YI'^C-ND$;K=J@W<^12"%_C%)MDY9PY=DO*)V R?WN?9^!6?3RF*LVX\^T
M1V":[ L;S4B67UR\\2\ N14T1)%V=*RQE1!P)#.EE@'N+5O@Y:.BR]=(G(TP
MW1 F.^INP>-/^+9<G;GZ\V]LPR'&V @N01<QG3! M:9ZG-6.CRA<+$[A6V9D
M79(C0/DEC?XD.M_/+A?5#A+J-&]ZN.!$7[9 C0<9+IW8V2]:3R/N),2J@C\%
MQ#8:)NR+Z,/0O)$RN;PZ'N<_?$*P&0<!^AI'.7+J/B<*@A7?=:@5<WJZ(<MO
MH'[8UJ_FZL6*:GS&OZG.IRTTH,PBOMY&='HT]_B[LMYLGDE!ZAZUF6=S5W<1
M=.17G<0]+NQ_#%\RE%.I#=:=>&!*?>01>9\V-\!9S^*3HC^Y\$LB>_*P=2US
MIR_4,U,9>I(O##;K^T9GN_H;1<NZ20MG^'=I@W<C5RBS)[+C;)[HO\;G.<7/
M$)J^>FXP]L"(KJK<6VL)XUV?PX.$;Q7I@4_TLK9PA(R/WBKTUCYT?!=C\ PQ
MO6:D"FW7T?B=D.XR_*DG%0]G]SSZ91T2IJ_&!*G'!^R/EJQYD#))=5E=,-8&
M_T6,7GG*=65B$D^$Y0P".C#=%P$&\BY"GTUME3U7'J9S0<%C;7CGE\WO@]="
M'6V%*.T&RZ9@L@(RC[-"G- SL=7%:#6B)[R2/5^9L7ZQDFB"@TTSOLVB487I
M#A?RV1I*&>V9Q^*P6&!86E$ 9RLK9TN%#!%LV36QTB'+S*JR[V4W$?$)2\JH
MQZKU^AXD09NA3S^;R4I;&B"&(.(TIZJB%!&J22+?-5QE]J=EYQRD.0%./6!:
M>"[A!!0OI"*/;8A@(NV7P%\-S4>#_^L*ZN63CDX)]G9:Q 4^,3XZ,$_9>*F3
MDRL$</^'**I-D;.EH]M0Y0%K.-$"Y;=4<E,^RRIS6PGX\XVH7/_5)+<(R=8\
MU%7Q9+$-T(-6N,FL6'/-]?;GP_88@[4,]M>Y/=18J+A1>8CD>*F+%Y$3,L7Y
M):S42CD*+;1*,T&L.B<;WFOI]>E?XK%RV$4'TTKE>H.<4(M=>'8E'ZQ\7TMC
M+9-(;%'SV,'T*-W!*:+]80IV,^.OE6UA)@ZZF]ILW;>4JVNL+^-^KO^.?K[Y
M(;&(+^E0)F;HMR+&6E<[118B$M?(]$:-+U,>E,[Q4D?I*GW>@ITG?+"["E+R
MBK<MHI.B>HR=RJ:,'-)@;8D55=_B$&:*])8G/9?/XG?9?#*2OV!=?;:+H?*%
M4_S'J9 !U7.?!MV4&4/Z0@Z;4=0'>'MXU":]Z5*#4A! =M@NQ>(=7;IM/MG+
MEY0^T WG^5A#_!'I*JEZOJHUSMKEH\*9SO'LL9S#D?VN%G@$H/[!WV=O[D(S
MGWW?K99WVY+*)N%[A<+*BD\Z:A%@>--5\2#*"R_18J6\C/B$VO?@F>YTBSD9
M*Q"U8_B&B_[]6)S.DKV1F-'B3HK\9^.(9F^OYNG02:$!FZ:R \9+W'3NQW,"
M<'V?U3@& --_^'P(54-837+S;NBGC%?U(04&XN0KO=D-(S\42Q[=ZVD5-?V^
M+?,YQM+FM 2_^[T95WLR^M?TC_,5)N]U8YXU]*EWY7I)^WE[=QU^]UDFZ7\4
M#_]J.%V<:4F7_?5%E8(9O\:*KR5"$$?K![ALDKRG?)(<-V+P8%Z[H%7U(\)0
MTW?04+MYIS;7P1+1\4=C)?ML?$CAB.100;QRLXI'LO)=B((#S'5)AK;Z7$CJ
MN!4HR=G,=%9'AZ$SN<\D*833*ZOBL@)M')IN1@VS^]\%4><9N%&I^$S\VIZ^
MIVY=?6@DUNN=;A>!5[J"E;F"J>E522&.G@4U]1^N/DA&[_7)4&<NC+-QMBU/
MBVNJ'<"3/.S9(5XOOILYY]A41<)'58P=)IPP!QYA$,.;H]$'J1&;?QXJ:/+:
M:M;6)]2 3Q-F:%*-(3+#K%K31>-F>%R]'.\" GPOQCW'2G*3U*I#YC278LYP
MXA(E(MI5K:O61A3TLG<%WM>"^<?C>@=5GJ[3;DJ2G7H0G7(P!>L^[6]J,9%U
MCN89*=:2?0?/'W>,NGI!+:)4JX4LN;^??K>.^#4&"*G*1T8J3R"1DY/V"V.]
M#H&3*ZW.E%J]2IG%Y=+FPZG$$E^$8\ZB#2;=G H6\I'"!MX]U&H"]RW4)T,*
MT*Z?GRQO2I(B2I43/8-WY BNTWJCTBUGKJ5?L,6_=BC_$%@1E0?ND#,@=U]/
M^8 \7V:9N\4SWTQI'L?Y:*=X!!4(SNB(/5W72"ZTJ 8G&()8<)$<9[FI:$4\
MUH(X!K-T#<[3'5-6QQZ:/NP"0H,WNXJX@H#C8I.3*SGZ_F6]Q_@,H42W ">9
MLL_B+4!5H[!A=S5J#DJ33^HU7#R9B[9"\/E5_#\ED?HWC;<]ZZ+JB^!\7"S+
MTU)@"7NQT)TO5R2S4K@V:R]B"GS$3+ML6"?N8$0P_38GU#C737M>[AVI]UAY
MQWCY^U*.L 9;OIQ_W<NRXG8#3-"Y12G[GJCL+6!U^"%!)2V>\8N[I*"!YR"J
M>$[UC%H:7X1=)- VO)I-MR*0^S2@$MBHU&<D>H(6R\.@!4:C]L&1ZE[*KAPI
M8LW%;PXCEJ;I6)(= F^>/"K;-9\4?5-YN.8;;B!K"3!WQZ5E!V+S+\]GCPPT
M.NZ*SY!AO'#0O#'OCHM);L(Q0@;<W-2QXRL!51\U^;LDZR%%2<4;-C''=G%^
M2-SYU,=4U$>C.D4F =8SB/FT.+_,I2V,XKN(Y4FAQGM=4O<?T!*D&YVI)3Z3
M<LP]-)%BKLCQ.;83_O'GNS3.V!.L=(C&FQ4.(LM"F5A;?U8;-(GS)(:4\M!I
M;(W2[N<P!6;TF]$UN156&?3SL[BW8I]>--^M'"",P)\&PI+#Q),DZXDB<.ZU
M-S"[& O/JKF4&SP-BW ]/#<[/NL'E/Y>2Q"J(FD_X(3K@YU%7D+X6'=\01IF
MD\>U:WAB(P7WM9!"0XC-7/>?;0G[Z2643!=C>,N$<A>8>F [^1<(2V#HT,AG
M]^RT:.K./.+,#9+H"!+@28\W@<I*L#[+ _X!Z%?[5),25123=/K:PSNJR@5'
MKUQ61FV,=]G/N+\/2J?2F!4D_6Z#C!8&"&XE*KKR-1@P=]]+>DOU#;&$SP0C
MHKAH.?T!#B&$A-@3]4/A:U$^2[&QT5DP:Q%G:V38H(I*YC*,M1[-;'0)XJ%1
M?MEPJ!A #0$:ZV%QAMTV#,^%.179<8BWU5J*K<_PGY#S['GK)FA;#\@91(_C
M#ILJ2>W3UB80)QK7(K'P(^)!%Q"RWK1N$@>)S8Z\,SM2+,^SM%M/1.0%U<@@
MPGZN\E!A@+JA5C>L-O*I@'YD%Z<7U<3'4/W1/0L(L8-F=KRY-NI"R8?%@UVU
MG/A-5U?!SQE^Z_F:/=@MRL+8E;T2.'"X"M(YMR*:?6$S9B)=K/,)M8]%$&]N
M;?@$:KHU@FPH:V>5EKU)"W6(1RV"T,"8?6[)E]QEC:4A?OHML)-\_5MPPH!:
M<!<M772F>AJ:MVKGZ6:;M4#J=E6@3]O*WG*.=SM@-;V@O]!QJ ]>H^%ZW.P,
MG2@<IY!05D2M=8>FY?CWOR7$YFHFO]?T:]R_6_Q7L=Z,\M6EHC\TW$.C1:SK
M?T+4D-,W],F0R3H:%U=J\ M,CC^2H:XA5K\NU2 WJ33L*T=6JD5!2;A]V)@V
MCJMH'.T^^U0OWM#Q<HY@)E:R.81X'FRHB>M@H@+XI.2X-XGJ8E1(["G:S56N
M4#E'0HKKB06T#Y7X?^P_L*4>I$JF/<Y)PW#/#WH^&W2(3F_'Q.U+R17:W%E%
MS4?=$+*:C:M0[FU?59VZN"R8ORV@-+PXLI;\S5+<>H5?<%VL_F3+5N'=3QIX
M*J(>0Y4CU5-C9JD6GRALE77L5P68\1>7>$('38_7)PKGODX2E3^.:\3<T@!3
M"G#4#MY_-T\5M13"7Y^$EYOH$48V*41],!O<3\W+QK&[_]&;+7L>THYA&AE=
M.9.F,#)B]2'='4POP7C-L\/38?-F@]&.@VTY-=3-I4\6X721743U O.9G -=
M6LMK),=29YH0-%0A,4G>YII')2\(1V7HF^6"/<47Y:@F\PIZ6N+QAB(A;?7?
MCSW+^\X$XA3,9L+,U0D<)04WT^6+;+V(X'!&PC*=,496%V4Q*P2;N_Q'5#+!
M YN&D<<I,Q!.M! /,"*$VNJY3,MX.23M'.'C-4OP"]_H\/EQ"K8,R-V/]A-#
MG**//P+S,E\VFZL&')APHSY)]6?6'DD^R:L"<:J1VAU^]Z9*EU  4L1,ONKD
MQHH$]8):%RG%N+8S;&)GU"L:S/2])V3=C@"*Q^LDXJD3?CX(K9C=R-=]%O)7
ML!<U;M;=@/-4W/EH$2^&K^+4WH@V-S/2!B!(O(YX?)*)!>W*>NL&RT1(&?@$
M2PZBS%Y*T]@[_K$WST3Q3I0MH67Y@ (+D.;K%\I,,:_3BL9'?(L3\.YDL$K@
M,E 1*:::H2?]1;.81&=ZFDVYEP?=XWQ/)S2FLL\&F4_C$:/;TIML^+X799)I
M>7\-/](P<^90X<DU$G;+Q%(T5.\Y=62>_V86UXM_G^)Q7.2-2;&6>7ADX@-%
M815:$UHR%M 1?OL;2N&5B;1?:TNDX(F\6\!VBNQ!DW[0Q$8[1AC#&BJ2:8E>
M[9PMHU5?]>A,T?$W<T\7CV*73CJWS>Y,#*WZJJB=_OM57[L6'99%8]2V51K&
MV.R,"0P4\-";!0=4JID3/H?96C!PFH%93=CZKZAQ' >R7DEJC)I4VN;B8(:-
M:)!'AHBLE_&"?.Q-.M!IY%(=$CP[J\"S(J:457P))Y\_V-40#1AQRR.%"*&B
M%JG>=+15KSI:ZA0M,Q%*LH]W=>PL"]T/F)@04;1:?+/744LBQ+"]+TGTZRRM
M:.V#[0O*R]<)*)*=S\ZQ;<9-^S,?MS36K;^.#)?<DF*6ISZ46@SQRL3@WM9S
MXXZ8WP1QG0<=1=5VK<^ZY3SZ JN+Q*CJ#9&56J;\_&IJ7,B/QY;[I?<:E[W:
M:J0I,^>KW!?*;UJ=Y#A2'2RM2=KB+(D3.IS:3*M]55&:JOH$$H=G];OHPJ7J
MR-UH8)_JW=^5EH:/R8^@=2 * AF]D*J[0J/EO_NC A_,^IJ<JWC-8^-NXONH
M]*S;3**B[#24!I30U?$M]8:D$)2_[2)$;_ZR'OR2$Y^&^KL^XAKENW5X59%[
M%T?%J7[M(V:0\2O8TXO@J'C1"-B,3<RS34D":QY%\?=(<=FON9Z_ Y]](6W2
M5;=Y/(<(9K6!A82+'BH#5TIRV%7W^XZDL-K4E=!9:$!G*KDPP&Y8=\$^+I7;
M1T-UJ]<U@\8KNX.G<KU$ 9C(*A_(UM*,Z"7V0 H^WE:Y-&L2>&152LJKY3E#
M?PM8'G[<C;T%*LZ?X7V4L?0O?WX:R"P^S7$ID0!835C4.;L[&L?J\;"&6+5@
MD+AHE'9U.HB,?O[UG,HV:>80]B(Y):T#MM[/%SKK#<;M(:YEU2?'M R..]=X
M4V0 AUN';"VX39(K@*>T%U"_%]P"-G$SAYES\KX<JT\Q3YK&4*I$7=%E2F<!
MW%4-8WMCWUA737N.*C!IQQ.Z0^DC3JOYV>SW/$'ZD9@^6I/PE=.KO$N#SQ\/
M,V6#A BKTDZ[ Z?O[IA]V;G1 'V4VM1=L$NZSNB)J5:\&5R5OQ?HV!2^K&D8
M(Q19,OVLAUF(@F<AI2C7)J4R:0(ZJR?X\@.^^(B @(0$;=CRA_64\3O-"[])
M99H333@X[/+AV8/ ]K/,W&]7(B-+$8?,E@JJ/P2>BO#A.-5@B<\M6- )6X9<
M^7WAV-;[8O/6[1[.2-*N2XR""<WPH\:D75N/_H=@>; "(:880"NJ567I7_Q<
M[5SM-V9$6<C ;]R_/?Z$-G%KB<U/NF]MN*C77N<UJ!5GZ<*CL,'WVGZ^VR^9
M[LWNTQK\=]7X==1 ;N9FO]V=+L>>F*K>W7-59+D)AD1#!3A\UGMBXZF<D\C@
M2%[UQ[PH6AK%C$KO%E-G&T7A]!VNY@'OX_L5I_FHDE\,U$[KG"-C>MZ 4.+$
MEK<>E,U6@$E+N6HCLX*O9_&Z]]-3)]I_HOV[)W#]5V=112XH7YIX1F;O]++
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M"V<0&E3V(@3E_]EB1R#4HDY0EQ.-'/=FMZ/IZ>4K_U;]5OYR_M5\8?3'D?+
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M+5];4/QK#%QAJ,[ACQ"9T5T'TTKVD>[57DIEM8HS?]?]D?I08V+< 30QR/>
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M0IBWZC?.??W0]DU7'V:!/5Y\=<!WXB[*<[Y[7JED76S9E4PLM6 N:N/DS<&
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M^@V8<,X,PE,%?695+V-YY1NB.4A[J='M7>K66YA1I%"B>FU(,\PIW-BY$X^
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M>';E*YK6G,^P7(X@Z5%> ?WZ<G:L37<_:Q<>QFJX/MH:*@/T*B<?O*2+^-;
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M*>R;TPSRU;6E2;9.V,JF:"8/RA6]4^KH!U;H?"WI82W&!X&;I6VG$PRPO.K
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M[,I0L8K=<*'T=F3ON7D=4NRUXP9D,H.A1B"INV&"['2TUZ^-PZ\XH[)UHW
M3J?BNM9_;P_*A_B8($IJSS"X:%BX:Q5J8/<)?]6JHIP#A_&:-)PEW:JQ(8$/
M7/Z*6D1'^,Y9>H+I/0QNW'G]**<JD*2]XJ$DSK" !]>;;>^@#.-7\.8D,6G+
MXIJ3X^B(Z_H"^/6ALCAPB,[J,7W$+&C.?DJIE)0>\=CNL5T_]1=PU^&^%Y*
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M9X;G>;[W?;_O7.<ZY_?7;[CV'N]U[[7V6FNOVFN\G[Q? ![)2$A+ " 0"#"
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MK&HOF.'L7VB0XTP37J.,^6XWP.ADIOVU6?,-0QJJW3V ]]1:&*Y;T8/EUBV
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MR 1I&ZURVOK6*O?Q7 TK=Y6L.//'>?;>2$S//7=P\NDKJ9)$1(6F?C/;7%+
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M5+->?)!#L\[EVK5/I$SEM"2@?[4+0?92BO*44\N8U4@T^H#E(%-;)1LWQI1
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MY^F(#?@-$!JOTLR;13"@&>E&D*+GM%NT +\+.8XVSPEG4,'5,/Q%5J28M#C
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MB;;6)!1,CZAUU#Z%N; *&!>\]4]UUU!UWC"X>W^Y^]$"OR9P?$=NE6O;NU)
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MI120_&.\4CEX+$@=X5C:5JR,_60TL!-M7XA!=?CY8&=%U]3-/*\.-@@Z2>R
MWW/?O/2JEFXP1Z:#*\2CE4#M[/J#>V]--<@J%&P@9.G]+!\FH.F=^9A73T^?
MA./(!25O4@SV%+3HX?Q,63YNO72%GTT&5]!F'HMU%[SL3AL R*AU,.)"K$@I
MJHKWXAD59ML*>0^Y*8PGJZ=J%($"Q$?XZW&!%\^1+$7O%G@D,Q[V[2I8AOZ$
MX5IKXVV3TJZH&A^^6D[AU1V=$A)=-]Z0AQ7=D84+IU_,APP1.S6TY,2Z+LX'
M]13LAT)&>ZY5DQ\/>SEX2PDN5Q%^X+:"/G/BXF?33@ 7'LTBR1H:G)Y%<SW'
M>0V0]=W'GHO(X6=%:JGG51+1:T+L@DWGQ)&VU6(Y#X,.<G 1. ^1KNU8;*V$
M@@O.)'65O^9 *9&A0DAKV"X.>@)0_/&>IZNL:$C-\BG710-[<4=D6$%X>,>L
M"'(XSP.=OBM6/=*ML05//HLLC237"/T+5CQ]%G<K**CUX"UMLI$J^*X/U=WG
MHKAROD39:.QR^)\3CX/V,*(0WX=F%^R-2G1>/^V /R!%#86$A" /.G?8-<CS
M_': >%% ^D/*^RP'9433;4S"QU>-!1]6MN3YV<9;:/*%PT3AO TI0HJ._2U-
MU(W>?G[D>?>5.A]>>8AD_%'Y-)5/D/56\0&M4=5\6M/,F/V$9]3Q>HBQ[=OF
MN23% .'L)1W<I<[U^_.S$<"!.E2QAR"W;-P@C<6;H$W%B(9#I9SRR!RU_-P-
MV2[S)_94^R\Q-H'WZT3F9CS[HZ7WX83<I5F<@;8M)*\S],%;@5_]9T##7RI^
M(0W41^.'A29N1Z-$?3*;5>.ZZ] 'D$74'$6,>;2CEX!Q['@%Q5+/M&=_R@#Z
M $4T\W9:<%H)7:!#\:!L&S6_  $ZG+$OW^B*3]"0?S#@>$SJE&F5<[GCI034
M@@+4&4UH[&$<#? .1;P5D&]2:CRURE,L0">81^TV[ZLNK)F-FIPP%;"!2?$S
M;MUR;$M8;U-Z&9;"O\]"R/.1NU)V L#-A.3G%VY\:@V3:C":_-T0W.^QSUL*
M+88+9U: /#<;E@WUTYS^S<XPNO"QW]^2P'F6E9( / "MWF%)F.E;=ZF>#6VZ
MOH//'SO<@DK;Z3,,T@6(IM,A1A,C<47R#."'911,[[L7ZQNCKMF.LD4V%[P7
M 0DI&XS.9>CXE?!T(?)2)CW*+&>"EI\U:.9"G [;NYM]<.QUM3R4(E4V@><S
M>QK=19?8,RL8S:R>U6PBZ?VK/UM!@B6_9*/WW5OM@PK B ZL,A/^C: OUJ^Y
M(5&GJ(TO^>IG1=/)+OM@V'IJW?)%?#]3KQ*R\:MS)9RWEAMR[QIS@FI8(!K]
M&UJK]H)BSG6WC5);@KNM><Y,B\N^8IU<= UP6,+=[709B\RE]HAZ=V^I,SR
M]XS^( KGH,#V]J1R[B!AAIUO%R2?<$3?7+[);(_"T#;;-$[WOCA4\,8IOE1P
M+130[%"%95FJ7+:.MWM+99RZ]F@T6,?\\&;$YV&DT_C"_>?BKQ@CGI&IT7\@
MF2W47EPW>N(.S>B/ \5LSYAOLB+:.0/Q&#-#N_XXNUX%%6MJ=L.=@_@^TL,T
MQ,B+\G<UFR:530D+CCOGGD0M+/9' Z,OAS1R<G@Y[XV;UD/67<_=9&N0FL6/
MC55.Y;4Z<#_-3G;D!/;Q@X_!J6C7LR4UN\8C;?)!MR"D(<,CF<G6Q/P<P"2
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M@#F)C/L9Q_YOCW:LSC,$W[.*_"R,5_KK9?"?K#X,!KO/?"_9M+S25X.$ 5F
M:*S W;-!?LI2MU^9:JI&)?W'J*\A:?Y7P[*A8HH:)3].S8" EOJ(+&7\OP@_
M9,?85&7\;E+L'\)9.^R4!M#' 77L=TYGH$3U.33B#[&F,;?Q2PJ_3/VG";OS
MOTR8UA'V%P7C\WJ]?J?)$\"TY/WG\4GU;_>I6>X>1)5^5&;\S_IYN)+/IU3(
MN?J)XX6<TX^;US\W[/YH5)D=KWZ%_"$94%9W FAT^K]:D,.@@CR+[#!!]]!-
M9JE3??^O>@[/>!B).A/#_5^9GDHG7_X'4$L#!!0    ( "R$D%AS35\1&+
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M@ P @$& ^5<"_"?!P,+!(R BO4-&0?U; /H>  L#!P<+#X>   __-]?[;SX
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MHO&_LYY=17N N1JX]D54$GZA[L'-EV3X&4%$@ID>W0DU5R>F@Q(JTTH=_P:
M(RO+E62/.Z)W$ 17Z#$,>WPM.5:IRFI]65+RP4:8$*O^.GC!L0D_?F\8^P;H
M M=A4=R(DXG(=MU@PPQ5!:W>^+\!"-.<(K;? )]K;SEGI)UMWX\E]!6\E,"6
MCFXQ$:(]IA>5;T-,L?4P57F=& >$V25^1LETDJ4\["O?X. ,QGBQ6-_?9CB^
M'HZ;KGEI722U='6Z8SZ] SF2UY_8LH1,>1^'/"/(M**7/HV=/BRB.EZV?0V*
M23)W9^9[GVM^6SG\RM\=>*>'XB)\,]U5-(EU-71+/5V9\JJ5<&N9YG3,>6B3
MD^36_@8@@1)_Q(B ?0/\I-^JHWU8WP(Y[HJ WIT&C;. L*[8#\0;@X1.I(11
M8LE)L'W4K^'? +@"IG88SM2A9(][?D#YP6@!92>IE#Z\7#+)?M)IS+@<;0(L
M]I8YX[FMBO%RS:_L3+=UF'=%RB_@[;:,#K.+W=O1--^-9LX,IJK5A,[=U/NQ
MOME]D:')FOW+E."J^GUP,F/TSTZ<%,=+Q>[DPI"%32M?1R8#*B)$VB3X5Z?\
M8;QDY4?E,>*2.78OZPL3<RO7^!%/Z\AKK29A4J=WW5B:ZU*]M5W56<GXFPPG
M[?O^X=*_T5F']ZNULQT2L<Y<#1I0Z! 7)8;>_L9:XT>@X[/7?%$2+@G;/$XF
M7 J5?S9X"!<__*1[?R80CEGTT] .(>_@4 STM/A)_@?[;TPN\AUO"7!B+9&^
MTTW<SRR;!S,#X9X5M;1AL.:5[V^*&LFS6_[F0?,JM#A'NW&:LY?RS^G!1T=$
MC-(V9T16RNB#'$PN1'7BR8Y'K+>%:(I5[MZ#4<_R[KZ,!W>-IU8A9U+\WI8[
MPN^=*^S? !])8/!=+<@X*XHHA9P\:!Q5#I%>:2M]#[/LN7P_-&A-C(9"F'($
M0O23IBU\*&:HYB-[_E!')0!J^R6I4D1;XM;WDBM$?$%.W"*.:($O*8B59K%!
M^?\F%_\MQ=(,8D32E CB!%1WV'^V!<3*,U8##>'(*-B?]L@&)"WEET"Z$2KS
M5/.%5D.&-6)=DVQJ=CJ*)(,9:+)/!Q>U=\K2UJ9$(BV+"?>*]_;:D01,6TE^
M6A[H'?W?;[FB0\.1A%T4-)UUG<I_@NL;6S+=O;X\.AZK&EC2PW+Q\.Q61,UQ
M(MLT25JR];ULSR00\B%#C6H!$XB85<8&Q[7BMC0S>C5N.&EWLL-"[ITVO/WZ
M(=*_\$TC8[W+,,LRD$(A5(%6K%<>9\6=!9Z4 )/5['D;=);1UEB8JR=E1XNR
MANW+/-8Z_'.;@NY?F<#YY!H=RY^(-7HHI"W88<P&%ILA8@IW6.OBSB1]BC:G
M_A2G0EWS5D<>2K*E7FF??AC.2Z^-OG(&@EU94G,!NL[W5:.>4>)Y#G%=O2!2
M66=+9HY6DJ3DW!2EPE*)14 D,*"6DK/'S>/6$!J^(NYF\PE>^N,=P5:;IQDF
M2O-W$9Q*O3%:(K:0,":?Y=QUR<C8#+][G!VE(^M"?<DR">&Y(9+!)]HJSXA<
M)[I>AJY ?9;JPZH2RT6@ T2):W=2(O(.8B4#*J-L0Z*F9E L.W%9M-O0&G2$
M"PY60ZO$Q.?<R^:X1-/@7BV@SFL8$<5[U1YQVZIW8K(YEYVAOMC8[ZO*T)H4
MC[S5_;/P,\B)R%M1WS-%Z2X=A/HA9RL!LGVN3G\-Q9E3+CC1R6PE,?!O '$8
MH.GT\O1=[6D)1CB&'])7+&3I26MI_DYLR;#ZRQ*,_K>P^F\7BVMP3GAPG'')
M_>REY=L.RJ4D0>!1E1015Z;Q3L"_737.QO!-<KY?E#4UYIRM8.L)&M(OA$G?
MZK6:JS)XJ6&LFZ-XDDASQ+O?,OP#M*H?+WI8+?D=X4US)'%+!:.5\ SN&#QS
M^MH9M-$>VE[&'T1,67=[7\2N6T8NA'>L>^;0TAIIY6'R!B#PDF1Y#UJ8?G$
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M1'#TH7L#&)B^7A8WP;YWPSXRNL$^RI?+R$GZ[7O6S+E6BFG#/IWPN(CJ_5I
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MC@\?S1IO 1V1JK<7L!Q/F+"LSJ ZW>V*W'[QD_= "A'"$YP#N4)DU$B_(;^
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M<EHK!V< /3J"RC671<!D:\&<(@\H=1+BY-C0GFA_KJ?I& ]M>K_4^P+L!B4
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MHM;\@B[0<1O:V[/4='X)M:EP;I:YY#"<?@)4NP*;&R*BK42=^(W:515FWG7
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MO:3,!<<45+VMIG':%KSR&S^1FZ)7:;<C>G4?75N!1[! 1:O2M+FI233&E=<
M;QL)O_274-P&F73X$+0E1#@P+_65[9;<$<$9WMAD^J]F9(I7Q=%9:+:CJ)5,
MD8F^LZKC9;/5EFY"NBZ00F3CD@+J:8TBC_S)-[W<6@3T&1)W)1BDWB#:S/4H
M,FE9_S^]B<B)68@6B*EUO[SEK37U/GDO%IKJ,LM(C/M8VM[C6F*R)NF-.5+'
MFL1CS8W)3(;U+ @.,;&<&QJG#1KU4XCD7I22]!#+C+[C#R8WM"UK;<D =&5V
M@DX7.#%*E_LZ##TB0U H)5ZB%+1>.QLZ6Y)]7ZS<B,&64OG83S@(G;^7+.KF
M%V5%3FSK0JPY58^#:B9I3^6F6IBV19CXFP%9KH  Y=8_,^W]H6E G0C#"%'$
MSWU[.=VWI+X44P75@>O2!N&&@J,=%]36MS+OS+X' P(&E^?.2_).R-,=76EP
M]:@YOWQ-ZMSXNVW)9/XZ3*YCJFB:JHG"-.(G9TSGP+XVP>S'%=$T@E/F!-Z?
M+>"7N6CE_\L3Y.*O)PCR,XEU@1R*XJ8BE8ZPY0@Q BR=U0WQCT??88'#;F>-
M;18/\X4BT3?L0VWC2#6TBH0?N%&>>6*2^(Y':/DKV E!'GH5U5K93!GNJ*]5
MS7HXMT??/6- <_?VOJPM<=7T[6PVR^CU051-T2O2*5K_CX*NY?3^ 9'Q_0FJ
M1K$*CYU961H"KD:5<RF^P6Y5G\!SPF(5.H<"6[SXRBG?-BLK3.>7).U-*!>;
MSI>6'368"?%,8HAJG1OJ3 /R!8,"0.=W576ZJ(_D%ZMC(R0%0\E\)C:2YH+]
M5\$28== W=,U6!C12X%4KCCO=0M#$I;XUJLQJ^ZVEK9VA"/:]SBBQ8AUF_9.
MNM!JC\AUN.S,1UYS06Y^D*XQ'UF,PF60@PD1V6 QLZ;53DQB+?ZJ*J.LT"SM
M1SYC);WY&_84HO46'0$Q[D(<BREGM3>+:(7FU('.NER<YA#Y9;VL)<>!Q$!(
MVG3L3&UCX_J+!%,!=B2[\MI=7_62A#2L=^B!D!88KN8R+2]Z^?5TX9N4S?A5
MDI<7N,4! F35_HN*^&'%EGUTNO$:%Z74(1%$@X=Z!$DF&(A \?3:8EMY6[9"
MW/###<H-Y(R5VNK3L?0/'Z0-[7!1 /C%A+WFWJ'=,PXOA"Q?T)/.O$-'&^/Z
MHOQM<6Z$GO>= N/@H9;PN_@8(8,OWSE"*+(M%;6HWN>;N8>XU#FO/X@PG>I\
MMJ,XV52#OV77]0C23*# '6KZ>/&[X2L#HQC4(U 7JP'^,W)53'<V-,=U>=!
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MD?$)\(J>\/0PL>5MUS -E,F3F!'AS^]\5.4S7YC7<J-.GX^:.H;J=_'ISB<
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MRST!Q%1*/OO"/P^NI3TR1?N\4  3!_OL+L%EKX]%]FQH1+0#VJQ+OM^V"WZ
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MH^Y=<*H[E90E"E9.FAR5_GO&+6CRE\6%0IL@&]"]+ZS@UZ)MADG=58:"<%#
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MO12\/-1NT1ERA!1_^U6M5[Q0<ZYC7VO-XW8Z  +9[@E\S,62M^S1UFWZLC:
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M%S37/JO/']+BW!PV[I*+X3A&4V0 /VHEY'_-?PNGB[(7W'<JC3^,:;XHXX^
MG[-X"8R(RC0D2F<G#+9\Y#=>*+_^>;O@G8EV4*R%\8ZEL;'(9P?)6C+>8D%7
MEOFG$P^O\;Z2_G5[(2A*WC\=!T5\7 /K??>2,+E&$D6W-G?H3M7 R:>@FESL
M,.E(J71(HMS(NZ51[XRE*-E8HM=[XAV;I$=V00O-]-MMGUK-0B5(#U%18&^U
MIB%Q!C"E%<@.4L'W5LU<9IGH)P#_AFTERX=[\>VE@5 2OZ8*#Q95:5.?DE>L
M1RFO<IIB,KX7>7C]H'%E*WB0L$"26LJ$",N6FQB\$,2QTI&G%[O;SZ?SS24/
MS*0+@Z:T#5$9?'-")\6\BS2M+&5HNL.?6^3]]6:B%V"I,/&R$< 6ZV^,/\P^
M4KFG:%8!+"3]^=@Q4U6BHP>IB$$J/YF:3"^D6K0PYCW+^<! -@)@MTS%M]91
M[U$J<A#PL7H,8)CR'0B)D$UT=^[;T&J 4$W8V=/>G=;LWZJQZY((D+%E/5X-
MXS2.F_D+,4::*-1*5!8S=KZR//__1]/U?]#T2XMPLI+PSJVR*/Z/HM3?2;2I
M,!I+FHR/EHXC@DBQ%H@?&=PR7&GO'471&F+J/0.SR.1ID= G E](_R@@*P5T
MR@L*D5A"+!!-!57(Y;D47O 2HR";I==')G'B9@ "9@4C#:[P!1CP^HCP/Q'%
MWA0(UV<S>$4"' HY_=>SL\:1L !3,>+.5#\L.8OS&6B#Z6I^6F;:/U+J+KWY
M=FC<OVY=?X0#==)'"W*%+)_Y[*='H#XDZ&E3I%GN:YVN'$Q>UO(A=M]Y:V7Q
MX"XF)!WK9."9L6!/*.KY9VR=^@Y5R6%K97W&V=!+*?35RV*8L@*(,$80R/'/
M<N66ZMEK7EGM6G^;^.O4A%TAX."G[?-B>FK2;T;^":"G7=6UR$5B=D55=Q[T
MS5SD?+[L1,"\T5[ZA7#A.>,"5J/&@+<NEZ6']Z-X[5]'Y[PKUW8@JLK:<Z.:
M^'/=UTKW]ZKI67=((217DJ]D-U%;^OU,AIT$7R+;K'!^W6$E=4?,AA8;%5CM
M#]#-HV*_G7QR,TT-5\YO*Q_;CQCP^]L7;7,#+=6I=M%'FMC5J!+P:R%)_'+:
MF/+01=(_[)=FR"";!;*9^CZ=G1<K7I[&E$I(;WH:G S"?IV-3]G9U9=?++)+
M*%:N6!F[8\J\N6/K$WA9!NV#%'?'\8\#FW[9RYF,(QE-'-A1NH=\+58^Y3^1
MGRKR#K%@)?FV^"+,47D$.B>.0"7:YJ*J>]#2.USI^P-M85GS1)0,5,VYWPJJ
M(9A8$HB)Y X54=4LW91%R3$M^3)8N+0[<>/X,QUWH/GBL%<,!5HQKS/0D*IT
M[!C')O&[Y'[GW-NMKDG,NUPWA]N>YZA'P,R?MF&ZTF5H ,;'5>J*9$_2*F;7
M.UQXKL^+V'P-RZ0UA.X6;SN,[X,*G91'.>(N?:QEY.T>R80U)UBZ/NX3(P3L
M:CGM_EG5 KH7)8>IO51.NK9[VU)]+(HOR.7Y/BUJI#S(]9)3I83OC%KUQ]4&
MQ.M=?=-,I?DTYQ@!\%7&]MA'J>O3:9=/(MD>OME0Z<+KT;XCJ<W(]8D,-"I?
M$F0#'(AW<_6?RP@\#>)8<%I:&O?OM6W>[8=X$6) [[2K1<7!^_%C+JD/E:X8
MW[H$Y?2,MA-'%II'/G4?$$>GS@(BG/OX, 5P=1[9__P&@TGBU.MJ]?AE:W%S
M)9#?S! :=SBJ?Q5Q^"K)S)_2U^MMD4K6/,#,2S/^0EZXEW5)(K<+P["0:;*1
M>K+",)++A'GG%P'+5?N^A.:E_LML-R;22B%+%4'.A@-WJ;9 (,!\I$A'5K!7
MK9NR$Q3]1SB_3%=K1;MKBNEF_,,G!33HQ!NILQ*:+12I0Z5F12:<ZLU#-3*V
M?5'2>^+H#_4U"6+W^Q)\QRQS2SK#K%1"2G^Z"GQ>8N2PDB14QYPRX22#;'(L
MIUACJ?V8^+!1?TJ>YV+7=O<D+%7"!33],!R  BH1KHK,G6NL&@\ZZ+\QQ%V
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M-AL]&6[HH)"&WJNWQKWO-'A-,-JPTR7NQ>O)@%DHT20P<MF&_0@0G%[[-OQ
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MBRY576"GYN(]^0;F<+&+NTI#ZZE@/7$_:/$%"RK9"AJ40T6U=:*6H<7083_
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M+<&M2W1XC7F9"?/ZU77UX8H=\0-.P.;1%YQ+KUN"Y]P)+Y.H*L^2&5R<X"J
M=LM+[ZJ/'DAJ!V2+"S.H7>+(!@/9RI92%/3 +]<]:&>T%P:KA:\VD.N3.'N=
M/18PW8B[&^U,?:XDR[#O1^@LYSY0&A\@ L!C%W 0,XT$'Z>HLF@.AE#+F2:S
MUHS\@?S?Q<K4U.XZ(I^:[AC@?- 96S^,9\-66F9MAO@2U^M1OOWJ*.BI%>,*
M=T@L.32&=S9/(J(,HA@X)E4-[_;&%S])!?$WYI0.]%U5??H2<8DJL0B<91_
M1$=' >GD'O-45)O@PO^Y3]TJV@-RUP?/RT-K@T5QZL67UMX%#(KW+/:4FO2L
MDPKJ<,K\Q!W^O7$&6NC^UOZ0F/FRF25O(&]7U@II/B3I\YK:PS[K,(,]Q134
M^K=\35P%/A/IKUZ:.U;OGKNNF+N&8B67<H48^8:F**J@TE0)2N8&FY[,GA:
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M;"I;>5%!R-+TTD*/L_\/4$L#!!0    ( "R$D%@',:.=]18  "<<   0
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MSEA3AG1#\[AZ_[G<W"=42ZF?7[U&#5L&+%5V8 U=H3Q6!N8Y]Q\_?+9C!;7
M0#O.R<Y'4R$-*DSUVR^CQ73NK1+\%3H,ZH]L&BIO"GH$OC4U*X[R,.8:I7>2
M>FDZSS/"+,W&ES.&X[5(:8QCT1HM:LC%70IS,T\EE'_S;.BD3'O?%&V#.75(
M6_^KY<3!-]>'4[4!(V6JP:O4QFZSJ:FNGO.50F+=9MG%2J-M.P_^0A-!^503
ME6;GFM4CX.7=:Q<%K)F=)@R^>%D/1 _;7UF=\ S6^595LR*S?,' VM7-,\!
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M0?((F:>#*KB=$O%0=K8%OIXVD=+-VY":RZJ$%C2*):=P81%ASK,B$X',^^0
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M.LG%MNU1FJ*=:I 3<OBHSQN8?%RV9%YLY8-EY>:6S,-2_H.H.=H)W719DE'
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M>?M)MK!2Z>>EZ',QL0.5(4L)9J?>^-Z=8]Y!-K[O5<\A6C)V8+K)NR;_>9/
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MT2'D7;A7*KA B\ZH?*C&T#S]-")*7'T"JVB@)1X*NZO[IIN$+@I NH&&WW>
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M<>2ZT.X#RSNHZ[(*,8]AK?.J].OZ8M%@-I=$VN_%7D(-^"!)##A;H:.N89,
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MA _NI\R[U >405;[&-3M,S#2OHB)L4S>XB? EB0GX*L+$6MJ^? ?5SLQLZ.
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ML$%1@O&R?';M7) 7D$\* :/:8C"HV?^A?(SL,.&U]+BOD19[D(M1=KN,]*=
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M@VPGFVI;/HM!ZE:6I9_2;W.7:76Y:/G@DUX8%);7EA5_1V;!E58FP?$V'1]
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M]M0,C>JJKZ+HRW^*6$A2]3"'!$NL5?REJ%;&-99!E#4C._5FGQQ2 @:0H>J
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M]T#%H1'IOQA598W'NNSQ7\1^CX$\-M7PSO7MFX(C_V\=2W5B_RHE;--(0]B
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M,'G\#=G]"5.]5_=)G+9-^PA560:X\7D;T[51P'8Y1796P)PZ1%"^K+;_;9D
M=@E Z- 4[MZ<R+@!TZNQ87($>J4?1XJJEQLV>RN^1.-IUDNO5>"Y07DD;F[T
M;$Z\HFH6V!?*ZJ3U9+@?6D8S:C&]"<YO(^-BC5W.6W"'0A[(N1+T/XQ%YW#F
M$E-\;P^$GYJ:J1!RD6\[L'U<P\,ZD@7.AV@F2I=RUZ*CURYH0":+0F5IK#UQ
MLH1X NXRK%],_NN<K5^TS%MK6CNCY? &+2E[GYNY E7?X6-+B#6*+YY>H&>+
MK>X3ROVRH 34T<#3/YA;Z:[M<J&R,^DQ$4_9$_AX#U6<<&SQ7T!94=,L6.2M
MJVL!ZUBBHQ]%_4MU2U.ZP<'N6R>M@PD$R<9 ?!9#0?3%AR434_/^4B2..TM6
M6<T@-99\D$;^+',]"98J*]_:4"2%6[ 5F5P6V?.@LNB%Y?6$3=Z4866TUVM)
M^)?6M)Q$=+3 O0/8N6B;"^_\YTS?=Q$+=+EL9$\GBQHH!.W78NC>]Y:A5"]^
M:P!:BQE_Q[K2$$\>YZ*6TQ6-\%=*;+4[^#2(*&#+<YRJ\^*B@5*!DJWFM1VI
M&Q/"30A7,5!'7)SLT8J^PVBPC5"*>6X)%%/K;+?0IN>*Y=)/-V*-\([&3*:E
M> _BC?C*DK2XR'5?W$S@6.M$--[CD4T=4R15C0E;V_Y9BYY)RCAKBO?P'+?Z
MJ)^IJP5-6T(F0(<V#O\@Z'E:L7+/.1:"W@,!F\6A@@-:2\*@%)(W/P-KHX \
MRY(5<T?EQRRA+*:>"1H5ZJS-BAQY1[Z7%Y515LKQ510T*OG1>CM 25&R9<2F
M19^..GD!!VB"M)&7&FOXV<\FU2->:['2!R/<;)EIX72KC1YQL(LKS$I*")76
MUBJ;V$0\8I5;) T71#Y0,JX9?E$5GQLQ:!M)%[V6C _>UW!2UWL_H:A KJGO
MKJ(&5/\N!5J:FEGTV'M<Y5E<6KKVD //2C(^=]Q$.U_*\:J,<.1$D QQ;4/(
M 0X&X<-GNB;/1MQ3A>3HG^9X#6X$/0[N<TJ5L7W#/Q)\$+CZXAG077L"N7H6
M\[Z\FW8^%1D/B1\[+0R2M\.?6VAS#.7-C2Y%$TSG]B3+"DCA:OT3Y\ /5FI_
MQ[M"WA'!;>+X%1J5E569(6Z^%Z+R3%0-<<\_)5**\)73;G=9C!DA+^F&1"?)
MZ2Q0*GDE'\==S^ZV9#+9/^J,^6^A!)V]KA'5E;DVS?,"<520B#0AGW[IW7Z5
M1G,76S /WY&E)5TS3\6<VE=FUE8VS_)R5^P6KT@0[C<ZSK%5K2(A7O$QS@VT
MA'$RVZ_]&LN/^2@AMCE;='^_2TJ/TVNL/(>:@=^KG[>V<\N?D5;=]%74J1+V
M#JX!Q3!<!=#-S%] [;/;3SL3MUG51P-,:@G0@DBU_BA45EP!9 +G[QA%\\51
MFCU 0SX 7OF.#D-O\IGDR%P.%$T.\AKGB-IUA+&@#;A9N,,$%(@WM/%8G8R$
M%AVFGKVSNI*]'[.TJ?Q$<' 'N+@L7MA'[1R6F)6E]4: 3$$L@\*HS]&8_=WC
M9RM/66-Y\92E=S8\2W(TZ_\ F\N:-+GES0-ZC_THH,BKK$,\^7U#L#K;6HJ1
M>QWNT2)\C53\9A91\-VAHK@-GM_48KS$*3BL"A$F7_D)QGQPRA?SOI9W^<Y^
MWS$!E<P8%EO[;#-V/N\:;7IEG5,)J$+"X/$#RMHAX@G_J7,#T>O,/AC1?SW-
MIBQ&8-:^CKY:/$7_W LJA]UJ"*@WP2M#O,$8DL=C-.G>S;]4$++G-T9J$TJL
MW)+VHZT+QMC*_E,D1?7<(%<*4CD+;7>5IQ.@P\VSP[Q,NC-R,>D"4=[_U S@
M"(\V_5 5QN-^D/*0NA9Z#BJM0DSUN4K-%&HYQT>:I^@:WQUOOV20O3N^[O,R
M(#+M&B7J UMF4>+Y[<M",#]3#C<ZT"MT3_J8X0JUT@BS7! CIGINLIE))TIB
MIR)+=1L>$6K\K9KNCL>Z4[-&_E5=WX-:&!LG6+IAH*XQ81/QG&#!ZU<=Q>"M
M/4B(P7PS2$[=)!2QJ'/[%Y#J S.$[D''I) +>5.BN\?5O.L9=!C5?*LB>B1?
MX6NZ ^B1S(,%6N_R=MH3DFO>5Y#MN;-B]@Z*&OOU&#J^I3(4<O<\#TOTWUHT
MR. )3_CAR[PW5Q9I ^F#O]>?RD \EP><IYO$#ZZ,?LCQ:.?#&13Z?S6WI> S
M]*S94'+;+\JJ4Q&^1!L?0K*L<WJ277)C/K,)EN-^(RS!X2^>?$7\SYM8AHD*
M+NK6849GJT&XP_G'=6[)2S8$?<N+<7QJ+%/3!A<5#2?C0B7;!#'V:SK2>YA/
MH"*+D!YN#]S>2MQ)52H@S\8=G(0S7 LZ>E\AN,@<J[8?V![4)Z;20IS<-<;%
MX02WB8)))CFD53A^PQT$=UVL4<E"]GX&_QQECSKD><UF@.;@JRTXP%71'(9+
M17Z8_QE\.:DNQ!XQ2EE*?)J"A9V?DX0VW83"<((?-1]6BXST$[F*-E2H:I.'
MN8M/+3A1)Z_;H>"9/AQ@\P&B^"-_;3R0?5M<>UOVI'J 0X:J.0(G(D-VF>:U
M@.!/#(AZI^+BFH/SZB">.]=.B,]<6M<;U<'4.>Z_DV;*4TK%([=$628[-/#,
M0P7[H2U:H$Q(\VM7+FD03^.%\\?"ZE\#XZ/ @@I.8*<*A)%+9.I6OCP^!%$G
M=N]A.ZJ ]_1VF0SB515O%9HD- #&L6'(+VL\2HO!;ICM&K\K9PN\Q<3V1@&(
M5)J9QG:5 $^.H*YR6AR,_9@O4U_[CSY[UQ?'9&/YBP@;P8-8-_JW"^)Z^L\Z
M8A]4*$W13V,ECS^=P/DU]^OS68'_']P3[(7]SBX>8Q#=88,/$%<I*SO8J-L7
M.+ 9QU._3$<!9'JR5/\,5]>X"+[0X#-5=\H#024B\;?H)&W(9<=@-%Q[#]1?
M<7O8*X2-G/$S>\E$:+CRQGQ[M)R;!-R;#T?YA[#*TGG?/"]U]0H1,E/ZN G6
MN<I)1L,M!!=#P[2:(?HC+F7?=FI,%P<KA=2G7=Q9Q]S4:88&]%8O*J%\YXOI
MDBV/FN)/C0CD-KR*>2Y)(Y)SN2 /H4R^&-">NXPX,)8]N:6!6+FP?%NAXWZ'
M-+)CCBFT0'5<2@4G\\5;>EC[A(A^^;X45)3\&9"C^\,R2APK5FWF].%?0+;J
MWY_"1 :/#A[DLY3 K4-1*F;_6S#/ERN.UJE,KX7Z_84 N=*.MR';"2&K+"B&
MSI .&?$GU5=OMK6+YU^R*;,$6F0!_N<?E-BCS]2IE?$36"-IW-1R_('AZ?/,
MS"^:$D5M)(B:H?OQ+7GT26$*I!N8!&B?"F.Z;U.&#;L%KX,[A$(0X)"TX"26
M9?;<KJ:9\"/_"QAG^_NG&E'K9JMN72']M352$D#;:)JTGN_L+LRZAYCSNG5;
MHGYWH6Y]DC]3N;T.C_Y1J[?M:1%?K@5) 4I9=N-B+,AW5_)?G@MT'$_%N7K'
MP5A=("[XN$P$+5%,G0)N3(=NFTA\?UF?%DYH>%1]Z]_K<HTGNSW5^K6A%]CN
MWH?]Q_/B0^,X_4,?7=S]N-V#O1/AJX53RA=RQV<Q#C#LKBC*G W)',?K;[=/
MN10+C/-VN.,(T3ACW\_6:L8_S266,+]O4)^Q'''N7B&LRC&Z@;<TSQXZI@H&
MQ3=+[:DVJ%8_FGY:LZC8+&$ 3_HTDI,^R'J\EN4-,9SI',OQ-CHXE>,[6.,C
M14;?F3"]YQ$V-M/B$6@04J?HC<JE+)Z8P%7%O15/+O3^3$OQ81Z/^A>I.JA?
M2D:\G#;'G\\+;"VP0%_0R([6_?E<\[20+&U[+C16;>6_JD?+U W#E2)KL*#
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M_MJZC96)U6)!MGR-3,9DQ2^@6*0I&:W@KNG1CH"02E9LZJ;D:0[_\M6^YE_
M*U6R+Y?7T6D W/]<9W^G,*0K1FP?/E-UWLI[Q('VN:_*11M<(A@7K"N=]4"A
M<!\Y_KBQ TWP(H#'8N.Q]"?^#_@,@K*$*U0R=J<%TQ]BD22L+D-6X+=2OC("
M3!'/_@R/H#5]F6*'= 4I%N1:&0M8"8\1HLEH0+L/*F*E1^9BV(%#A^935NZ&
M37]$MW1#M77U-3+?K)<@TZ,U;CVQ+F)Q !+DETLPU2/3;I"JFZ%1]FUX#=O'
M(C1;P)1UU[ Z$)J:6K=,WTJ11>S"Y(4"!&#[ _OZVS]^_R+RP%U@JUWH1NR9
M1$$-1S;\S[MOR?"*PY_.^<!R]&%$#S4*+5K[)Y57V^=B_8$HIGL$B(20IGH:
MESYO\@HW/$WZ%$SB*D=4/?Z;2X?$W6//R0$6X-'+T?0E+0XH,[)/;/;SLS.^
MX,7 A(H:&GV=""/6XJ=KD+4; ^-S!L/AE05N[D',/8C38WT#6U;O \N@@3EJ
M+'^,4O:I9X;3X&CH@R?<>#A1<M?&B$V_,=*@M\4.-SP9?NYSMB_3Y54[(!%8
M-=0;<7A'&S^X*E^_*S5=-97JZQ$1X$'AQ(6>D3WU&H>-KQNX-) 8+EJ@?3$Q
M4/W5=B;Q)M--^L7P,:S=N4K@N2LIF-?E<*MS*27*<*DBP 1/X!YL(]KK>]FG
M5Z#?A_(*@S";(1SK.(]N3'616IO/VSRS#[EU69"*V%4$OD20J@RJ)*3V8CE;
M:U''\K.P<US8@<WR',2'*0;$P4@5?D@?,9VMR<JH,R:0BYS+ZP\NG&D1$2;>
MY5\@"LDGLC,RBR2X8TV\\3G6GU.?DX//_F:-944J#XRTLV$U'WM=?R+V*>5K
MV/_UA:;2CL4T.=Y8 H[=!&S$%%I+Z:/]<A5E?D0)R]>^5Y;%3KZFO@W/21;J
M+3L+@XU)Z,5&8+==B[^J56:CI"::?LWFD0V%WA Z[OAL3>[-1Y1D8[C9]^I=
M;6Q'2%HPH-#Q8K5BF8A&F$^B!U%+TR\A1OTXFB1!*)L7^+G<_@)*Y*!#),6]
MZV09 7_+31&[,5 E?-7Y%Z"F'DLZQ(L9376A'(+ZH)FU7;9#P#!;'&QE*?\9
MQ0G^A$TV8][X)'E#@\2M6$MV%);L=3WZ<V*?Z73#LMJV]NO3K_EAEG@#_(\.
M.]VI7=;.KD)OPOL P\0>4WWZ@/$<_U3*QUS#A D$^-GI YVJ]U_-TM+SFS%T
MCU!?1_9$;TL%:Y)9P$N9-&='N/M*&AQM<?(L%K4YZ<96- ][;S9TGSFTG:I2
MISZ(<T<3 <KT6_0MBU.( ]+>"1R['DY6;H:#M[W$34NG8F?19\.)XTR"Y3[!
M$/31G6DIG]E]Y@@0/9Q0>.YKB)Y!T:3HVP\M 1)KV9Z3JBF!AVS1-BX;+G0#
MB([IN0=*TXDFDMGF.U%4])6]KRR'\$?IZ#C"Q F!JCLJ2HNF(K<OM5,\6@H]
M&!Q/,[) O<R>^$@VWZ.F-QB'6&;B6J*YW-6N"V :)#NKRVT_>RE&^TM-Y%6M
M+O8O=R$RZJL)4>X8WHJ-=@HP@O@4YL'JAO<UB_\$"/ \EAV:^QQ&Y<S:ZDUP
M*GGX$)8C6>)J!@DV/M9;VGGL=9G^P%N5H\'4-?'A??K6Q2RFSM4/7/6[=P\Y
MC]I>.8B\@8[IP"!8S7E@)ETRQ\CS('=%WR\W%:;NM?V__%9;PKRWXU?/<Y5V
M1$QRIS\U/#A\OMF2>&6L^XESS2X\XD+*$18H#K:U=RV*4BU*,$086W;CX([A
M"4_KO=":J3H0I?>K%F#CASQ,<D^#LJ'?<)QBEU:%E@\@+B,#[L^/(K#YAXLB
M.=BL0P?7/ <Z ;/8S]PT/6K-3[L$[="*2U6JU@G"5S7?\)NX.&^Y6,C+5L5Y
MX"5EI2ALS-9S7X3XKVQ8"3KUNYA/W!Y!G>4,]J!;;A)TTV^GBW&>YLFE<CG/
ME&C?Y/"#6;@U^TG8<*[;?;3<T-6N;+_J.A8+C\Z>4*&L>YYP8K,#;#SX>^7R
M#HF79.'R07.R%25S[-:H'_/K<0BFV;$8+Z9"P0Y'P)RW.I5<-[[ELQC]%E1N
MU0Z!FAPJW$\4;Y@;7@UT,>JI?6F9Y;([?-MQSB%RCRR$<'"DU@NF\S3R88_-
MIBR#ZCCT)D#?:1W7&$=!.UY6&U#LB0:$\'PEW8/V=#[L;Q*^5U46DC/<^^8<
M0D;TOB. T8%ULC'R44?"Z1;M&>]F%+NAS,.@EL,IY@F<RX],M,V7IP/(7TE^
M-IX0OXA,]^TY!][QR?P_NX;.?0_V\]+'0R;4%M6Z@N-6<K=<%?ZTY=2FE8Q$
M8@ 6M3L"B.AV3EY+G /<I!RG'!9N4W'>RUD_39&@AT$EW A_8"W&9R-E[_T%
M$"0I&]IVI,\T;;[@R,<P(*//IBJ%[RB8*<)6Q8_8W^%\ML&P02Z@^SO(8YV!
M0M\PYBU>6:6M^U9/CB4& 4JULZD)JT9>%R\"_F6[]"->>BRBP2><B^%_CB@9
M0!@)5F6U(=R&41'97TJU4?4CV&Z@5!M_+@/]@JCW2FB)YYO#,\,4,8T_I_J(
MURI<T$'6<QK-%R2.'BJ;[WY.*&(&0]+B(D=ES[?9$H+>/)N<<G9U/CYZ;IQ_
M6O7"PTICM#A!TSO,B T@1>ZC.;%X16 '1_G94K+U%99,_I"1\9/ I34;4DRK
M*/$=G4I[RG?ZYM>JSPSC<'"-/\FKE(#!Y[=<-!.-\'"Z8ZK1Z ;#(_KD5X^_
MP?"W1MR#@.(1N^]VT?G/3<NMWZSX;S!F!GAN5P(BOKHOV"W%"RO*I'6'$N@W
MMX\]KO#QIR^*JR.6'YG@%4'[!A9(C=C?PKIA-V@)73-[_Z392^2 #[7MK$H+
MD^]QHA\7F:8 7,K_O"A3ZX2(6"F$D>&SV)4,_^B\SNGY@NP?I)1P]MG%#RD9
M=K&.-L')UE>33Y"H61ZZHML1GPI9I]7S3 SZN/8JKHZ5*N+Y,.S 8[Q3M[7V
MA"8Y&KEH)ARA'TL>IPF 4"ITW=L<, :NS:W4DJ&2=R/*\/>Y^M[)W0@)_I%3
MQE;F^,-_%%^HT_]:(NP9-.J1BKPVWYI']^!R1K8&[D93G5:3N#J"]'J"27!H
MLV9^C6J:7&73X.C\B__6<:"1=A\E8$6\.=PB+^2[G6CZP,;';;["",T6KW+S
M99[W8LTSE]A/DF?R;7+U,!N2KJF/=F)E.S%QXK?CE^S02W75P^!)&U5,_ ,5
MG(^F(,FLH" -5QU9.N\%[-TK;M'D;F7[6=CM]!EQRXZ[IMSADB<FRM$7&=PM
M59BJZQR7\([1@'6W2Q?>KXR<2D1Q^T<!0ZU3B.J&ZXJCHXF*,KR?!=_D2+)A
M4J@R/5_SYQ<OPRZ-60RZ(I7=?1!L3>ZJ,,F;.94_J')@_<S%A=C[ZJ5-F"7/
MT]U6N?F:L-9MR>R"1)TE7X1ZI>R*>O"SIP5<:<HSW*O@[4_;*VU<G*"4/WZG
M<L6HM]J16U"ZDH[/VX+,!J23=@.Y E/%KIP3J(/=E$V:(=N29&F@N8=*GN?:
M^'S9% :X,?L57T+;1+ITSEX:96,M3RUD!7+6"0JM4+4N?V,+4* =@XXC!,^K
M,J* +1<1HK=C'U*%E%B6+;A;[* X\?'Q-Y#M3VI&/T:KG7@X].(SM/,^^%ZI
M=O6#J*8^505D[-KG$A/)D+ 7[9N)+B64*W\]L.Q:TD2.2=SH4_Q4$X%__Z5W
MS?DV AOC9M[!&+R[F.5?^_=,O6T3"]Z=BFT4B\NA6_U62^[4_"39> "&1N>6
ML^)7RG7/&W9KF^&(\>7^X&-G(PTEP(/"5YFS(Z8YX2AR)A*(Z>(J@3 *-K/N
M.7ZI?M/7\$1L']D&6Q.DU-LRY,*R' \N7FDNR27UN*.PSV\QX3T"@TSIV%?
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M_G_FSORS[IP[4KUVO]5OU=[O?JJV5??JU_G7-< [64D920 4%!3 Z.T%>(4
M/@ 0X>$1X.$0$1 0D) 0D5&!:*@H**@$6-@80!)"$"D)(3$Q&14++1D%$R4Q
M,1T//1,K&R<G)XB63XB779"%@Y/]+R%0B$A(J"BH^&AH^.SDQ.3L_]/MM1.
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MX2?]\:_U^;?;]$(81:I_(U#>E7@S9^R7!R# 4R9]L^.OA1KX"_$_[GO^K3:
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MW!![3),4GX+>\#PHZ0$R]*"<IK.7&!MB9=W])+ 4-H=D"7) 02@2L2ME3 '
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MN]:)'B]$V*WK7@/T#(+DR@2H*E'2*X_>\K48*(H?A'90N$64H9P?\'TI5Y)
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M/24)&XJLTU;IT\!*M.4-BEQ+I."G?%SOAKKTU@\-D.'^/TQ^!K[2M#&R-:\
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M'1LBKPA[NK0A:%9:3L_\]X++2$&;1L7IL)C>G;P?&S4N7AR=-9511K7[!%^
M)VS 'J[C?1NXYG2X6F-60]FU5'';SB- _>GE9#^\\.L@?,+)*VRU)[!$7ZM6
M/GF9C7#8KX/X3Z[6G]P_D&"0\1N)S^@>0V)-)LEI:L^JU/8!KTGB%FV_[?I)
M1_2UU,'3G*,M>@2L/DEC_!-/P0M^8W(:_W@4L?634HJ_*_T+*^R3#X&Z90_(
M5"=/L&PRND6W^5-I./M:X<2X_NS]2\V,"X+IMG^ ^_U?=W_8LI"D6A%X)*)3
MNJ80)KYIM\IUS[SE>7G<^2E%%[;/!AZNMX"<]WMZ7/#M HQ-0^!S>-4J,B]3
M9V$UYSDR2'BIBD[*H[^[D)Y]:*#&2#PW*A_;@)&*]J/.;Z96F]':F('.I^)@
MPZ<]<7S#<492+F/?F3.N/);R'VY5;J9)+S!'\?9BC?3$&G.G/SXO5DW<:_+Y
M0CL;H"?+9:W?HP1NHJ!/6W\QQ<=1#C9QMQ4*&E41+B7EB>KZ532XWI<;_SM#
M<8J=K7D#4 _C5$G%Q_79H"7M86X-6_,.QUP<;* D5^.F ?%'=,LNG2FX>%T4
M+3@&7Z*YA2L,AAZP)1.Y)ROP.SF0! H9 DB%>$LPRYL/PIT]EM&!(1-N)/'Z
MF*I'X0%,U/9W/SP+2WQL<W]H[VO!Z.2+J<Q3IBRB[9O/TZ?!/BP^C;X?):P^
M#A).S<8)"%J3\ ]Y/^L\*V):9?G\0^K':Q,]$ HK$.Q:]%W_$5 I /FI-(8Y
M)8)-KOY)=Z+DDL0,+KBC.E")Q4G:*Y%@I8%-T[77*)/VI<<XS(S."Q^%1^LG
M@^VN39F]5)Q@;BEF3RO5K)N!X8ROT*!DP0L$]E&VJOX'HP1T@R"1!9;/BE1=
MWU]0X9=*/H5PKWG;YBGI'@&97_Q.L)GFW3'3^ B''@'F'DD/(19/8.+-OJ/M
M:KO@X7A R&5A7X/F935D'$3C/RU+0VW7*/%^?PEF#=;K[Q640OZ2I_I+,V/E
M$;&P#<N7A[Y3CM]8@X\ ?VNY*[DPOUU+HWO$-ZQ-P2/)L&V_2E&%1X T]Q.R
MR51^1Z\;W9(F/0( $T_HA-H^3:(8Q9W?3GZ_D:9QT?SZ<O/\9A'4+<::Y40Y
M7J2#5*-RM7TCA5!JJ[UQ#TKH9WJ'SD5#.QQ[>*[?'23XM_W59L'3-[VAY/LI
M5]8TAT/2F\:6Y(4.1HN -7%]SY?MY%,GRD9V[U =)4(N!L,V$];C64M:M54A
MVCF.FI+O,SX('2?/ A@! , J@KY UP\UE<D+1= >L0"7HGO1=X>>29/8\2 +
M+??!N("(:=QK\&4DRJ32Q$9-8^NT TU]$[18&:@(5$E_Q16(+E9Q/8::JV+(
M1QSM)J:E*E";!%V<&_7+O7'B+N3J97T[P:#D(G>M";]7;^4?]/P=3*!GJ#<*
M-<;?<8V(J:4:TO?)=Y#O\3+U%U."G8N1KP^WUI7X!BXJ^W$,)[ZB!]./$X@[
M <RW0L:063_P^2IT)5?-KRA2IC8BZB_VBLK25'XKYP@!7%%.(>RY:L7,^RA-
MV[F2@RW+89?VKM]$?MZ%,<S3AGF($).PI7MC7%8;[Y8*<R)9^E/]WUJ.Z>@F
MQM%GTW!-L1N_MG"*1>[9$D*-4;293?11.+U8H*_(WR,B-AV?L8*TI"7%/7<2
MK=F RX(O$)?]182:>7\12UC%:;5PW%7$X/GV++5U[ENS-_/1;:9L3Q\K>%J*
M/\.-3S"[%R]BWJ[RZ%]K>7,T8+(M9TO;LS="\I+Z$<!\WG6:_NW9]9LM!N]C
M":GZYH9:V7<.('6I!K$H\%=<Y>I ^9?S;$-QM=!6281;)V2=,@;E\#K<O-=:
M;P-JP([B0]2XU,_O4\XV+%>=T$A0Q;S4A8^C^;S31/>3H>!\&FU)^B@++.I$
MSUI'1X.BG.B"K[B&6<UKE^&CJ)V%L@^,GXQ2>3&Q:]8T$NEC8OLC\-LW7DKM
M!&E4'\/(H@IJ(U'"\(PJE=T]#%U$JT.D(JOM^QF B%'-8Z@%*OH2 3Y0Y_4]
M"/BBTPKI^5(G32)SWTT'O-VGLY5;:'76^7]H-*5IV#B!3?2S?\IL<I.IQB'U
M&0UH0U 4,BFV^\Q7:;CL8OZ@\\;4C:L*)U,9E?*Z\' U:F&9D<:@HBOSA1>
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M'+5Z>L]X=[17:2ND.UU&@U_Q\\/NB[S::'),#"ML90^*L^FY-O#_=7P0_WD
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M+BSXA(#Y#KPZ\#V%+*1H58_+LJ![:U?^1)S1EUX5'1J=%*Z@49D+WR7@$*U
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M^?8K0RO:(+2@?(ABIS7X#Z%2I-YFIW8=G783K>?0%H/$WA._CD-\:,]8CM>
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MX;\?]U!KL.3GFAC]T,!K-^.,.*#%5!_D'\GP2RL(7OL%:TO,W.?U8CZ@\M)
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M;I6@Q!0*7&BU;;#I>PD\)URQE:Y*:;+H0*Q#&.BKC28XA[+FC8-+4S6TEIB
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MF055_,60FO;C$S_:2PF,3_P8F60P/O$C+EQ?5N8=8=\-0QQLJ8N&N8DT-1W
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M7M.89(9C)2X"")<V-TP69 U3>S>/%)WCD 46@V@84'$% ('25PB 2.\XR+E
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MH0,MCVZ@0$G(!D*D,94;%+U<B:W5V:?<Q4#Q;2<F"+6V<Z[X 5!%-L!/G 7
M&0#:(K& !/0D$"I*"V'T];,,"*X*P(&A[S%*:YLY!*?VOV(W0"T>81/OPS0/
MF"A@^"!Y0=3UA>2K$E1?2I( NTIZI!@WBPE"J^^]!F$MJ%CA?^*5G3, M+G.
M  EV5VL4;/6,OGZ6 <%5 3@P=#ZQ:2/DA+3^5V- E9F,Q28U;=$7A:>6;R4B
M)@BMXDR"V6*!@OPR'!F\SG/*T(/E<8&C'0C3#QR]%K)"$'[5EKA_CS:9R3%;
M%%\A@B<E1'%T2S!;4!!*;8ZUXC(B!B5$<710L@4%H=3F."OR>XZ)$1A$] C
MOMC+(#IJ0!ME!3$US1?6L.FH,(R/#G%9T<$!H,WG1=FG_T?=-,_$/D@26XAY
MX=H1<N@?IKY3_D6AY1TQ,[!3CPADM7,O7^U$M?=6A"Z)3<(Z7?7+Q]$-1!WJ
M P>S-E?>05K8R7OAAAL<6MYO 8XW>=T-"D>,G"S,@7W&>M@G%^- /EAYX# N
MN"W_]JZB5R+&G_G?&OY4ZA2]1L@GNT/^J1(,/HH#Z]4-?['Q^EVB?RH=F6EI
MD9#D9H:[SC84RWO(_Q1>T!<BO/"6%F^B97]V@K@1[?Y]\C]?/TS>3JCP'@[C
M )%_%'J?X,4DZW^R^\!D_X7)7W[X%E$GT?-?)W_)OC?9??"O;S19+(H&7I,A
M<W#7NJRX=HP_LD]B!W:K=%6R//I:#_FK$_U*IS*95)=>PLO?WX1H60S*]6C]
M*5![PZ.P[_>2DGF+G+^_B8*X0:$'#*XPB H#B_QK/ZC(/^:%56)*%J>&(4):
MU1HI!7Q%1 KL^ F]);]%?EBX(:0,X#(0&)8,A$H3*!?)'LV%)6^FUC[(X7CK
ME+C8H\+08*..R](T/&:DUA'9D9KG)\HML;VFT<**O4A^!6P'12(*A(;B1XRX
M:*2WOF<+,FMQD!Y5[I'M66'H+EP[L>3VE[F^EZS6*F(MNIKW;5\SIP96( PX
MRQ3?!JR?)RM/2#?E4C8GD58)YY^/Y- C(2X$F[8@3:?5'H\%8"F!^[$RY+S#
M\J7.C@RZNG#@ CKXUTV/##J6F*!UPW?Z9+^G_^^)K-?D-_\?4$L#!!0    (
M "R$D%B 764X-9,  .&)"  5    ;G)X<RTR,#(S,3(S,5]L86(N>&ULY+U[
M<^1&<B_Z_XTXWZ&NUN'8C2 ES<QZ;6GM<Z+YDACFD#PD1[+OAD,! M4D5FB@
M50#X\*>_584WZ@DTNBI;=M@6IY%9^"7J5^^LS'_]/V^;!+U@DL=9^F]???CZ
MVZ\03L,LBM.G?_OJR_WQZO[T\O(KE!=!&@5)EN)_^RK-OOH___M__3^(_L^_
M_K_'Q^@BQDGT/3K+PN/+=)W]%5T'&_P]^@&GF 1%1OZ*?@J2DOV27<0))N@T
MVVP37&#ZH'KQ]^B?OO[X,4#'QQ;E_H33*"-?[B[;<I^+8IM__\TWKZ^O7Z?9
M2_":D5_SK\-L8U?@?1$49=Z6]NW;M_7_5.K_FL3IK]^S__<8Y!C1[Y7FW[_E
M\;]]Q=Y;O_;UT]<9>?KFX[???OCF/SY?W8?/>!,<QRG[;B'^JM%BI<CT/GSW
MW7??\*>-J"#Y]DB2YAV?OFG@M"73I[%&OH<DC[_/.;RK+ P*7NW&UR"E!/O7
M<2-VS'XZ_O#Q^-.'K]_RZ*OFX_,O2+($W^$UXF9^7[QO*97RF#'AJ_JW9X+7
M<C )(=\P_6]2_!04.&(O^HZ]Z,-?V(O^4/]\%3SBY"O$)"D_E'9]-RBK5OK&
M-=A;3.(L.D_GH1YK>X)/VPXI=C"@K^_<A(>L"))9X/N:SF%?XWE?O--S_Z5I
M/X_G?>F>YEY@%R+DR9]7_ET3]N,5_6L $;\5= ##40.2%:'I@?D;^,!0E]V6
MGH6#<A/6FV=$M)V-C+S,=9 _\H++_/@I"+;T!1\_?8.3(F]^.6:_\(]0__#+
M'4YX8Z6M]/V!!&D>A&S(R$_>^T]6;W'>O)A;_6]?S2G@F[&)K*@5:>P,2&CX
M6+7$-V%&A[IM<9Q4U5*IKTFVF8>K_LS9'.U?DL<60551%*3"U($8P7E6DA!/
MXDG?WMD544/>)+0(-@O$Z?&7^Z_^=RV&N-P1>J HT=^8_'_]ZS?="[VP]#I+
M2<^(SWCSB(GB.RAD77)/"[=/,ZD@&$;IT(W)T\E6_$%_J\3]<^?.EC@R05\]
MEIHRHA08OBBA:7L:.$QAZT2\P6EQF@1Y?K.^+[+P5\W0IY%WR1LC[#Y]E,)@
M6&1"."83%T/9&G'!A4:LE+SEG" ?/E9+W3]<W_W'_2^G6?J"21$_)OB>+F]P
MOKJEXI@0'/&W2_N729HNB#/#%$:A"6K>R30=JT"K3AE5VFB%6GV45V1;J.NR
MI=L]IMWK7,:IE?V1SF20FG<J3:#4,\"U8!\KH4? ^T4)N-S8>?Y;&1?O; <X
M2^D_<YOQ4Z[C90S5P9>.HS(%[QR<@G),O4H4=;)0%H$6'9]>U"6A3)V:3@X,
M?29T6& [)LKC39::*2.1<\D7)<P^600A,$Q1(1/'-28'C2.K*(K97EF0W 9Q
M=)F>!MNX"!(M7PPZ+KEC!;_/(ZT"&$[9H!SSJ]-!3.DX3E&M!H=M=[@(XA1'
MYP%)X_0I-VQ*R87=;DSI  \WIV228!BEA2=N4E7"J)'>,X-R4O380__5,8?^
M@ZTH\BR)([9Q=IX6E.58-K?6B[I@C0U8QAF=G'?&6("3+-E:<=3([W<[:I7@
MMR"-,*G[N*M;]7: 6M;9ZM\$MUWLJP2]T\(&G3 D->+M2'1U"V<PNB\?\SB*
M _)^'R388L];+>]TO6Z"/5BKJX2]\\D6X9A33&KI+>^=J71Y>Z.=RO2>NZ2*
M *M/C?8A&"J,$8VKGCZ'TWLP'X&;]8H0BI#O,VEZ#H6L2RIHX?9I(14$0Q$=
M.G%6DE#MC 1%_()13P?1,6GP[YOBF8Y1Q7- ETP#I;U.81Y($.%-0'Y=/1',
M@:BG,&I99U,8$]QV"J,2]$XB&W1C$K7BJ)6'TP=QWK)]I;C8& X<Y*(N>R =
MV'X'))/S3AT+<&/F5)U*3W:_O<EE2E==;+_H7=^3R.6<]2(ZF&T/(A/R3@$3
M,F&V4HFB6G;?!^;WF'[Z:)5&%W%J00.MN#,V6(!N2:&1A<$-,T!A+<,U^'2$
MZ[CBRE4<XC2/TR>+F8=:UAE+3'!;BJ@$8?##@&Y,CE;<V<S#L W[.?A[1D[+
MO,@VF*@V8&5"KK9>U0";35=1PCLUM+"$)4TMLV=7O_HM&@>KD80[+RHIM,Y5
M:O#8>]VJ,:DK%LK:XI351%H0?HWR+LY_/7D_P6GXS)=.ZG6&6<VM:X&=$4-/
M [V.=U9-!"HYK.G4$--#K1J4_=15&&8E73+=X1#'+\%C@O4."4IQI[X(!M #
M-P2%+!AR&0 *)SVU..KD07=E;!]Q6B_6:7CNP,;0#7U7(PZ&66:,%CT6I!MZ
MS=@M&*9WNC-I.:69G0D#JNE5X-#-"J=R/B;AWKYO/M2OODGE@YY*R/D<7  H
M3,-;">]LT,)25CX5=%7;#Z^9N;9[0LYK6P HU'8K :NVQ["4M4T%G=4VE;)H
MW0,Q]S4N@A3KO),!5NL",'6],U%7-7]!3357?%_*>;V+$(5J[T1@U;J 2UGI
M3!+."H4Y-=&EU@M.2WQ+LJ@,BZM8,?Y;ZCAU2;.!/W!+TREXI]04E*+K-!<_
M0K4"/]RYQ^0E#G%_GP4*\VJ\%[0^[^*GYR*?MHJQ5W?KM3_-J*$?OYTN&)9.
M!*P@+&)?$%4%['/1L\!5R&R+2?%^2ZTH5FG$[FQNV>&8<5/'2M/M14EK4X;W
M)HUJ8,AICU4X_LS2I^.K^ 5'Z('^SJ^#K_(<%U"V?3X'X3,=#<A[WRQM9ZG5
M<$D\"^A]PFG$P1#-C'%,L%:##]&MCM\S]COFDZHX6N\]<W6B+L!I#M+;!]X)
M($,C^-D4="3+BS@,$O09!WE):G>*/?8D)F>*.(TWY4;:7TB>.W.AD,%JO2?Z
M#T%4O R1T,XK&=^^,V_ZZAX^=^<Q(X'5.<N\0:MN"2*Q6W]S4-T3Y@D7)4GC
M@G8YW#/PC?VEO_>L4W Y2S #[T\2U-+>J6,-<<RE5J%VT:Q4X%"+!:HI"TSL
MII]*:<?!/G201R$_9*)@Z*3')PG_P:6=S30G\.B*SHGP<Y9$EYLMR5[XY$C?
M1VDU7/+) GJ?4QIQ,+PR8Q36RHT&ZJO X==%$!.>@>+DO3?]OB#XMQ*GH2[$
MMI6FTT'1WI3!Z&A6 \,_>ZS"W*NWMFKEH>S7M&;U4#+WMI*0.'W2S\BL5+W0
MT,(8*0\U>O"(: 8KS-RH:I7TY@BU&B [Q/;/'V-,Z(=^?K_"+Y0W5GVB5ME3
MMVAAD*)GU&C"XZ0-7#4K4:O#EQ;7JY_ =9.7*9VOYMRD#W:]HTS#"PG5T*7,
M$\7AT4V)4=?S54I'B*NA#P#[OYY9'R>3[",4DGV<1K*/!T"RCS-)]A$VR3Y-
M)MDG*"3[-(UDGPZ 9)]FDNP3')*MTB*.XJ1DX6+NV423Q[X[?PN3,L(1<\JH
M-GZX*\7-N@FH>(O)_7- Z"Q"7H!F^K?7-SJ]+[7_3S>X<K6_UX%I9/NW4;CX
MU5- G0:4V>S-EEFJ[?2'(DXCXDC #2+A])Z#H9@$E!#YAHODZ$><1/OVJ_XY
M8'&\%+O54@EG_M1R:*TO]?"Q]_I58QI7;R/D, 7,"8FC)WR&'S6!2K3B/M*\
MJ$#+$KN,96'0P0Q0E[RE4D%,QZ_S19L*Y ></9%@^\P<@11.5AI95TX91KB-
M@X92T#M[;-"-J=,7V\?T(<?AUT_9RS=YL2456]A?/:;0?_URNAI;TOSJI/:'
M$'@]5S_YK]$!#J'9KZXN+V[NKB]7[JOLYTL95/:KLRKK(+15]O,EC"IK<0BC
M^.7]Z<WU_>6U^QJ[^5&&E/WJK,8Z"&V-W?P(H\9:',*T^L?+&_>5=7$E \E^
M=599'82VLBZN8%16BT/8O+JZN;L\\] =?I:.8)]=CF"?Q1'L,Y 1[+-J!/N\
MNK]?G?[XY?[\X>%^+[7& ^20]ZKBZG]T=5?_\,OGFQ'L_@,7-2@"8978_>J]
M'@4H8E6>KG;N*)5I1Q(>UY=/;C6;#G(YA^E&U#![J49$(>^U:T(FIAA)ZO#M
ME?"^-R5^S'*>R62EKGM!Q%FU*\"U-3YZ#J.RY:#&]=Q(H96K&CXQU_")MQH^
M,=3P"<0:/K&KX1-7-7QJKN%3;S5\:JCA4X@U?&I7PZ>N:MA<P=[JUU"]$&O7
MKG+W'>>>'50R7W=,\IN47>71AL[2BKN+<V\&W<6Y5\O"H(,9H'#_MJ>!/B"J
ML7<_(<.1P$-<L&1CEVD4O\11J3P.4,BY.@K0PFR. :1"WJEB0B8DVF&R++%;
M)[W?*.>?R<]!\6N<:E9Q@HBS#D,!KNTD1L^]U[8&E+ \)U^C6F[?8\5G<H\#
M1>QHF8##ZI4 ZU5N[RF4JA4AB16+N)"3&<"/?#31QDB5R[D=\Q4PAX/]2 A&
MC6N0:8;W!9W,S;5OGO@)<CYJWS#5&PF!J_T)DSM(WM_,[>0RS0M2&I)SR@1=
M>@&J@?9] 44I[T0Q0ALSA7L"=9+[G=[U&&S52?CL(<S= ]"^P=PQH$IPWZ-"
MG9>Q=3[33.J5HLYJW@"VK7^%' P6Z,&IDF%VXG!&BHLXC0O,0PU>ID4=:Y"'
M&LQ/WJO47$F0ZZYD3"K!Z3VBZ:8-[A79JWLGY7S,@NL&+Z&./=F5446?S-'C
M.^+%(%[.G@>Q;%V\TE[T<K--N"]EH+S.8"'O;FBS@-V-<AIA[ZRR12B,?;4*
M&NK Z?1N@\(8Y&<DXS0TK@S>( AN7\ [372HQM2H9>!0H4UQKF>#*.:2$"J0
M?4Z,9<#00@%,F6M^[QNC56Y9W2QY+.$XV:]R3CQ\[+V&U9CDZ7SW->]MG PC
M'%=-GO[1M73ZCU^N\%.0G*=%7,CB;4DE7-2Y!AJK<\EC[W6NQB3&9:-2J!+;
M[T3Q_"U\9D&0KUB8X_3IZDKCVZ*6==;(37#;YJX2]$X"&W1C.C3BJ)9'5&'?
M/?TM_>AQGF?D_3HK-(<E<CEGA-#!;,D@$X)!! TR8?K7BB(FN_=+M)1Q*4YN
M U*DF.2G@<$O2B_O[AJM!>SN'JU&& 8_+! *5^HJ%=3HH%H)R%7:>SJ;"4B<
MF:[1#N6<7Z&5P12NS_:%O//%A$S8::A%?"8S:#!<9 2'02Z_I*\3=,8++="6
M&%(I&,S001,V,FLAAX$:;*<;1A4? 1NL)B$&>>\LF0!2%[S!\31E%88$1W'!
M-NU?<$[5=)>KU,+N;EB9 '?7K%22,*AB@B=<N&KE4:NP=Y^?^"D-6.Z%DR"5
MYR-4B[D[]%"#[,XZ1!D8+% #$^8;C21BHG!VL>NH1-HM[)&,R_UK*;S^YO5
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M>!.0]_LX- P5HJ!;:JB #KDQE@)$#@4T!3MJ:71_>>IS)'D(WBXC2M36Q]7
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M!,G_%V^U"W&YL!=Z2 %+23*0A$<5&3P382H=1)5\+*QKNK(##>E5LM%S=U>
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MYE3/D$$A8.@\%[D8L#9,@CR/UW'8!OT0(B6A(D.8N_=YV/YKPCV=OV$2QKG
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MNXUF_:%DJGZYJC9&SU)1#]I0. &S<(2T_$[I'GAXF;[082(CZL!F!AV_S)/
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M>JB=<>K+H7I][YW%#J"EC.T<#XY05I>"(OKDB)*YYT7(UM+L9Q!=C'34Y"O
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M=(*?XC1EL4(? ZKH+^+;W-6Y,7?R'=X$,;/P-$L+$H1%&21LV?YQT7V0^3"
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MIT'*T_?%K:^5K^D0->4TR)]O2?821S@Z>?^2LT.-]E; BEW9KS;-=;WYY%(
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MC2S^OMD<9&CMT/2;&%N[]VO!X&KX1[[CT;77-KBTW;<^KEYI(_0-*E0[8?I
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M]7U2YO]P&7QNJRVDW+\H&4A>DL?KVKMK0Q@5O7,O+,I/P4FX4AJ$V,\M+U%
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M#E!SX.@I"9!&SO-1W3Y479.4F<A_P?XP+W]BS?,1RHI+3XMQZWD^WK\GJH'
M6>):<$72C(60G)N0G127FKPX-9,-&-305AR[T+B1KNN\3/-M4JP> 9;'/)A1
MXU)."%2?D;#MN>"QN(MT3:,O!A#BL_,*:&?&I;\=D!M6P0_(5D'?D0CU02CL
M^(/CS*/DWU^569^?.<2O,)@3EW*6PM:O$Y1R I#I;:A'@\C/\+3.D_*WI"R3
M)GVP3"$##2Y-V0'.=<(I24\:=3[) 64/&9\3X)*Y!9TMUW_L>'&)PQXN/B=
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MS,(_I1;/I7A3Z+(J[V]I_0BP5D_,;+JG; EF8\.3R"B$#Y&6%L'5+GH9\T_
M38"=[5>B 2):B)@%Z55*GR(Y>/G@V:)49_2(7'['=QL)]:PS7DJ$\F*:3DLA
M!SH$GPSI&UY.(/SXCI*(48_FC%Q*DJW3EY%$]GKU+:FSZRT/)E 6AC]H?O\
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MJ_O[FMZS \/A39R=P?Q;S1F?#'!,EP%E9$M*^'5G60X]N*WT@+#<4-3,0X_
MXEX$4_,^DWR@NFS@)$6TE.)S)X/;Y%DX3;%_S H93&95F<DD$HUYVLT?B _Y
M'41KT$&[9PU'8A\97-W@W\,/0W3Z9/6!-:3_[ FQ+E(1'[LU,<+Z)236AP<$
M#2Z=#?-8<: -4OW /P918-&?Q_E*I<.L(;?;E4$ED ZVVB#2C,BZR?:<(00?
MDG%^%(D*\_+>G;8RG!N1%G< K56G[IL@8R("D<7TAH+0V=[-6^"94%-SA(;Z
MITOV+_;G_D_L_\$#+/O+_P-02P,$%     @ +(206%MLAT=/<P  V_T' !4
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MEOA_/B=1P%:9"S(/_3 S&:*"?/BQGGOI\U64O!H)L4,TE/ZE(>O]CI*4?:=
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M,.9;^RS>_4Z9%AA BIYMNR_P8+&@'T;KI1:V'MQL:^&IPOFUIW(-4J40!O>
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M:P&D@(_4=I5H!I7JK1%="BA&]K.Y&6"DX7_4ZR1\TQ_B,@E7 /MYWVQ<(H_
MRL YY?_'3:LO7D0*WSPFGM!GJLK_,(V#YB]J+<M$7MTG.C_*>?ZARS?_V8L7
MY)Y!<,DN!RH+Q:'' 55,E\Q?.%A]J\J]%<U%F*Z2U(L^T21?;5(KQ%D8Y^S.
MNZHBA13KY6%' 55LE\QV&#B-OH[9MZ?<!NGX/MK/J>BF>A]/WL9\M8H*07O1
M1M#7\3RARQ)K?<X\: =0E;*?X1&N4H;20;]4;C(O<+.P,D2RTQ"<TL<:.H:B
M;ONO"1EW ! >I??HO9$4@$FW+106>Q;0/6&1L8^.S(:9;<Z2S>-V' BNH'P7
MB)(TIT2_(N[?,Q1UETRC0\G35@Z 37#K]LFDYLB^>T9I60P+&Z_DQ7&O'J$(
M6[.J#@97,I!$#H7^+O*],;A=09<KXF6,T7Z:L%_O4*VP9L>UK!5#R-Z2AMRQ
MPSC];^)1J,.!B@"*HS5SK T<]1*R!,T]\2,O3<-YZ%=I.%NKR_HQD58.X#V8
M= "%SIK!T@9TYA)T,*2K7G*K633O,5'[;W%R,#54 :P9]FPH@*'L!!/YT)4(
MSKPT3(O!;KN<T8475RE7-]')G[V,7?PD)0K^.GDWV<F'_:/HE)<GJ'?[/R?U
MCB=>'$R*KB>;OG'2.9>1M[R,2Q*%/BS]MX(&YY)UEJ=A3-+T@J0^#5<5<@)L
M'YEZG$5*]\L^?2$7+]"#V+I$]9>7 U/V(5\N/;J>S1_"15SL-7'6E8!XJO[:
MGJI59WRRUKJ;[/J;;#L\S<_^UE\54H Y":4?VSPTDXL#<^^>1-SIY<ZC["S'
M3G8IXZWQ#->8;;^U9UM%/BGH)XT.D)Q(Q>SHYYB>$LLM5CRN'0R Z6;4"?*<
M@T+8<9\UEI,#TV\302D,GJQ/O?<_MJ?>AK0X>.Z(L;Q'Q8&@^GD'($7SB!4/
MS&CFF?6"//7 ,';=9HU%Y<#DD\:I-B;>^_;$VY%-*CJ<-.1)$KR&4<3DW6;$
MY-')L!NTYVG)R !3$$2,//-Z@=E]RH8*R8')5V6%JI+&2>;>A_;<JZ@F6S(L
M%WP>O,'K.!4#\B+  5-)A%3ZJYFEK9NH:V,MJ_UJ!\=Y3KEF V;@T-_!WB;U
M\+>+@5D1M .S6!C+U)C"']M3N""9;&B04L0_929[I*P]5H+[)[,SJ)0 >1ZI
M8>@DHU=R[<!<*/*=23:RG]JSH&H\9.#[MONR;X5:%U'ATN8X6GU#V*&%-)/'
M02R).CHL'5?+6*CB,!$,_,)ZZ%E2>S5DFUXG"KTQ:WYNSYJ2>%)0%W:/+;V5
MB20>*WABZ<B'?>06?0NV390/O6!Z-V84#)OF6[:AB!S84YIO[N)9\DO7,E@1
ME1,%YXQ5NH7HSU;M=EC&OH9O \2N)R% /E.)Q=ZQURFY=4#OBX'-5J7AGUVS
M7CT:2#:)CK-&N3M4Q,4N49'CG-:W0RNR(&U+(5;O%84O7%$L\8D72]P$MP/N
M)'OVBW1W@8[ZK#YJR!UGWXZQ[T*#J$G[SC2,M!U8#[INX>+%H.,.4A%.ZI16
MSHK=$8+/B2K2(<^(W>_ SX= 6C?.AGHLZN="([&,_/8E=*073Z6.K\>.UOYL
M$HX3/*$TU-AU*?F)9AO< ++?Z2C=F'8@T*0U)M52&?F\NR=92(O ./Y&+IQP
M'SH>'CNB24&%$^Y8.S<4<?";,1E%-IIT@G0#9..K^8??L;,1W0[SC,1D'AJ^
M._?O$?DLV@/R]@5S3V$Z<.+DUJ*PK)_*V#@O,CDL2"SU1/[0\1.I]5#<0IM]
M8$UF&5.&T]FD&Z0X;<@@ =/8M!_\R6L.<3LDNY?H')BT?R=>E#U7"XQ\I^VX
ME91TDXJP_VZK/==V!@@^TRHHA[PC=CX#OR+"2-TXJFIQJ%\0360R\G-J+>^&
M>.ITW#E*BDE)@ILJQ60+4Q(AIWPQ]&Y442%O1@!H9(E?W-YH'O*GE/PS9]U=
M\GK)DLG2\?K8D4TJ.J3<7<W10Y)UR2BPLH\UQP,).9.3(,\2'1R=W&(:WAV8
M'SQ=WC834)%C*UQ60>A>M$T2))DV';>/6F\\KK/J;[+M<++K<?*7+[&7!V%&
M@G_##O \+S*V\B/T):4)/4_880 :CF;6"\XD;(T', ?E%,X$>L)!:TU+G30<
MF)6P0&MEP/6'CK<)/.!Z\I?-3^A3<\RQUU]2,IM?IEFX],2II:J&[7;.3#%@
M++683R?R_W&K2"M]-^=I#3$GP<BAA>"=0<M(+.@@/E(O(!OS]"8ZXY[XA W\
M*2+EL.4@ LG!%=]= =%(+.@@5G7GN7V2\Y3J4).U!Y?Z<@4F->/HN/#,4S'K
M=@U>%.44X/3"KF"C8QXS0=H ,ZX<,#LDTP6!;WHZ.B#*UM(>]IB!$$&@ST1I
M8#X8.7@/0 RMY3\TQM!4.*.>N?<,##9T?D2[("\D2@I.JS!JW<8)(@;B;RW]
MH3'^!B(9-?3MO !781QFY"9\(8$.>  I$'9K]3YZ;-! <8P<].H=Q> ,)J,
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MF?:P=%9(67LWP%&IF08/NZXAUW&8A5YTYZVU"Y6X*?8^H=:3^EJD8M725O!
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M?D%5R+_6UI$<X$(-D@F_-OQZX!=2."M)%M1;/8<^TZ6,AD]Y(3IEJGP5S8@
M4;%1NV2ZA(LN5[Z:R@UL]!H'PLENL</?"4W9CAF1E!>N\V)/67%/VAH[+S-$
MB^J>1QJV+7EXG7MT22*(H(4ML9.TF@I9P2[Z#:(X1IPG<7&*R+V(OPBI-P,Y
MA1O+#6@KD#-1FZ'N(*+;!E0T;J"BTS, /G8W@.*+LUA> H6W:C?"7N[UNE)?
MA\0L6EKCR_?EUT0OSUHC[#3Y/>398=&J/+G!&2#1>C/LW;*/3+ML.K!1=@V%
MZN2C"@MCG_2CUOR:I3=R@*G4Q=2CS1%N#/Q0F^BN/7K-'"@P:H;1\1#JC3I7
MATKC>B7M0,<(*@1TM)I#O'Q;D3A50"1ICKV1]YP[+7:=<IBJ@J6G?A:^A-GZ
M*J&UZM)*5ZD/*E>IJMO)IM_)/*&3LN=)T;5M+ZD:%],XV(2$@Y\4=.2G)X;>
M3PPP9$Y/#NZ8-=Q\<MB.JE6]/=44Z%63C1$6,2?H;P^M8>FL39+FC@&B4K9V
MNADQ0_A%>K?KK[XP;Z<I]O5%J52=2KP23M&/PT46XS->7(MSP@Z'E?PH+Y#.
MU>QLO6M27;VFKQX-;I-X5MR+2SGLTB6DM>IL999SQ1)XD*^/Q0!Q2"QZ.Q&M
MRO3FF4<S_'3D?8152JHNF5:$22-AJ 7=-1T ]D)G7W_[07(<*ORDE]>3L;RV
M47 MN_0'C3H?>C"C,6\A0G6,1X1/_*:M*O)C\YNCL=W9%_RHH]BUXDDU^TTA
MC/0Z+BNV6#H%##D(M,"#P35W>&@L/4OO/P=3S8+/UON;<$XZ)W7Y&LD'YL"X
ML!_>]=KHB*".=Q^_2NB<A%G.D)_&P>7;*J1%IRJKYT%' =11>UFA$?=Z+3BC
M63(;"_XY3Z;*2^45')% :F.R,_M!8P&JG;TLU4A+HP%0Q[@<;M@_[,6F]E6@
MWME+MHVXW'6$[[Z&Z4[!&Y:P[RB&XP!JH;ULW@>[IO0"R V]W,.857'%'X2!
MQBQ%KC*4P8!-ZFZH* Y6#A9$L[!M5"4>>5U7,L^YYYJBEM0PIR:C,4!5%?'Y
M!T$JN!<8W;8@'WG/C1PD8=NC@FHBXFN-$W)R:9<_:L^./^ OB.^/\C5'*)%!
M'L<OX\#MMYTC\>XP4>$1/.L,)Q1+6NQ2>,/=AB-]A,-'XPB';>>G((=3D,,I
MR $;DU.0PRG(P3) IR ')X,<FKN\+LY!W!K; ]@DU$'%[^E.?(IV.$4[G.[#
MIVB';S7:X=MS(W<D=N'D1GYR(S=<8D=@,G?/C=S%9?)8O'1';  _>>F.UTOW
MZ (83EZZH_#2/<J@A).7KK4CH!TO7<08A5%[Z1[2@W'[PE<][QW2<['[;?>#
M$ XHC+X7Y-_*"W),%HR9O7QQD,Y_AU-*XW&X'Y^ )!A\977QO.C8"X^)RY@C
M\0LGK\?3*T]?K\=OYJ'GF+T>ZS(HK%S;H"2EV^-/ +?'=)+L^IZP_TQJO9_<
M'ONDY8R\--U"-Z/W7&<U+I JFO&[0ZJXPW>-%(ZNLZ@!,;MQS652KXT0L&Y<
M<J44CE#M1JD@.2:8''&E%(Y-YU"I)'(8)(5+I9(E.V7*KN,7DK+&FV]J"I;)
MFV/[$0%TJ'[;U_%MR1S9^NS=P]10XDT*;)^8_80NXMZ2W!]?D\?G)$_9>?7Q
ME?&U9K^HXDY#MF;>)AE)E3"8=(#]O&Z(BKEL#@82K]NV)TRJ+K ?!O<&2B\?
M6Q5WV3T[CWB=H^F"C8%?P3=G>W7]73T=]G.&(2A@25A"XDO,Q/%*PXQ0$ **
M]MAV>D/):SE'?^H6,E0SS1@>;AN4R&$'L$LPY'PKD(>;P#6LAS536_G75)%S
MJ6=W3AZI>V$,%5UO2RQ; Y#=FK>FK3@HF:KI]6<OR]DZM;Y05J>$]^#DL5^G
M&*8"LK1?5L/8.7[R;ZH+[W(Z/1FVE[<9*#">]IR5XG"#0[^.B$W0U4/%+?]G
M%K[LU*[Q(O)S^T6D4<F2OWYLGT4V3Q^3;9>G1Y >X>ZGW _H#QRGW ^GW ^.
MP'+*_7#*_6!P;3M$@4MK![CC*'!9[7HZ^;>:81O]3&0OY!!=[MMI7-T#RE,(
M;+_HDCBV-('VBBX7M7LPJAVI3#@'>\]NM'4,!IEJB4U #4[LO%[7WCX>" U)
M^D#*-+* #$"5\1Y*[\A;D4"56J\19@+!7[>*84[-TC8IB:#6,=OF,054$#8<
MP>>>1#S(X,ZCV?J1[7LIN\ER+]NS=?TOZHW&I _'ECS5SF/"5NWPB(^C;BL2
MM74#%W-M5&!F=V_ZG<1!0M6/L:TVV"&B<AVI[S%"QNRL4RG-:KK-_K73:_:/
M/QZYK78VOXZ#\"4,<B^2+$.LK:2I&UJM7FWDHZ\Y$B$*_6N8/1>:PR?B<[AZ
M3"[C+%2L,B*&=)T@ R7'0(^5CC4[R\\9#;WX[UX<>ZG_K%R$A"WQ\OSW$6%W
MD5*PCWZD.D9_=-"!2>^#_C/V5?WD@WYX'W2@[WE_G_/#OKG+%Z4#.YM7GWM\
M32!RK36#RM5:IJ9^<NTP:EFNW/L6)-EZ0ZAUPI5 "3FS@^ZC*?&_7R0O/P0D
M+%=K]L-ND6;_^..&++RHW/8E>R5KU6GDQB*LWAU%XZZ9$P\A7,V)G35QZC@N
MDEA'IH<X97_VTG"9G"=TE90N5,KU0-H:[- W^*+0D5-W!=#PB'Z<?F1]S^:U
M_ #JH[2D^1@6"C4'->L0#A#U%&'3F&<4\7:_J5OK=.9]XX[< $^IB"T,C5FT
MLWZY&!?WP=H;6D\%/07+F:!GS3IM!3W[$71#>C45>6_2:9X])S3\ERJCJI)H
M+"5+ )R/.A5^AS]8;)B2"CMHJ#^XZD"P\:'[X'$C=L%@F3>-_:-@]#I-<Q)<
MQ[4U2^'J8-0+=F00/,E7#^&,6ALNR%-6;C0I8VE;\WJ79Z_.OB*6T+0?;*]6
ML$;T$Y #N_/V\-#TXZD/]\MJPU&JG.R].L-.-V&PXO<6E2,P\R%5JU8YYJV:
MJJ)_]:3N5T: \^((8,7H2I6ZR"D[4Y2IR.OC+=GX$H>9TDG:K!]L/U'X#MQ+
M0&[C6O[^*J$/A+Z$/NF+JZ ?;-^L87"5"@@=5\G*HCT/Z>BP(TOV75I=.^\4
M0WM.(B:UM(R:X3:3<L"K*!3%']<54TF)G8#&;(X!A##J&TM=_XK$'6PA*7ZG
M@%A.,K(4ZBJ^1XWJ'4U\0H+TBLF'\\C+4<WF-6.,'%T Z7BRC(/E,.*<-(76
M0E+0&]8"=L!\U.',C8VQ>^[ZW8MR<DM>B[^8GT?;Y.@N;_N>0\7R&/62RBU7
M.S/5=<PF/DFS>X^?"(IX"D)]CM%",0U-^H#J +[%QUPR(UYMQY4TS@%;$DJF
M.!<6# ?R0K['-T#UR 8Y/J@=3 OX'M]&M4<NP(.K@-H)/.V92%!%!\41N:(C
M6 *N'LV[INY&^@2?JV'8VX8,Z!<*M",&K[TE..J57+A=W1,O3>*KA'+9,+$\
M)K=)3):K*%D3E>;TZ@S/2WR0K1TF*_3%0K4W]=NE'0CZ&61G'@JB4ZEFM-0T
M;M=J=EZ;*B\'[KV2\PS$F]ER2*V2CP&J78BV002I','10[4H/Q*Z[+<ME910
MI<$W)D*E(%A0#IURO.G>!DLU_DL[U?BVDRK;^% )Q@?*?JM(.%XU;+=#NOQM
MB^,68CQ;%X=379IQ%9$;T69B%-KW-A4?^)G&ZYGR.M-?G2+SQKE\XWH]4^3)
MO'$R__@QY9(UAD>?6!:]8NHIL>RA$LM"$Y0*D[#NF:C4L92R5O.5CB;1K^V<
M0J=$O\4*,<#\L>=L=E2)?LLQGO7!1T*$_AYIB(^2=WQ\CKDH3/_#F;)"#%[F
M_U.%&"<KQ)BM;GLM:]8,9B:U2IQ>T0Y2KL?:V_EQE.MY>$YHQJVGW%63)S#2
M[";BYHZL4^:[B)@=]&3]G7'I]@\I@2/(J+1,AXDK>T?MRL6'IE^RA,W1XQ'5
MJB4/V>_RC+YXB;((0)(CZ>B0\R,IK>+*#1Z0)<D=I$IW,C.4-C3868[VA:C)
MNY/P@-R>M(0NV3C[ '4X]Z?I8D')@MVT[G+J/WNI-'"/MY8U=LEX*16WB@%'
M)D0G&'^Z3/(XZY7NI4N*?8,TF11@2:!CUG*ZX*5#2!SP8#-( !Z,&CM13__E
M3"T/=/":D8*U8^=._^ZYE#69T8!=8"?I,8'16#(.!LM4X=ID&>9+Y63<^@<*
M&F-GX 'O;6INT:>:$ZG,K-UO]]K;G,UFUEP$KCR?E-LP=#6L4V ;3OLO?EV^
M1QPNWLQW.:/A(HR]J&1X%R<_F_/?J&&&]X*>A,<4>U,!.391RRBYT*^\V*&S
MM4/FE*>#V9R5B, QH(3'JN)*NM^!<],%>F:=@4^<3=$,?.(\M+?^[MVH#"]Y
MMV+<\4CT)"!%Z<FK)(J25_:;KX0''I#@G<=&SLYTTS3-EP5-6CGG;T72\.W_
M:]NW?_/)23*?-#\Z*;XZ>66?G6R_.VE_>%+[\C8P "D<8,=8D3]K&]%351,^
M3](L+0Y63[6 GE0?/K!OO^CA!KHXIU06Z 0/3MCW$VX\#PZC0?+0AWVEA!\H
MT3MFKK/62S+ [=FW&WHT^-P399W;4U+XT1UWD1??>DN-IT>SU;>!;Y-G]""/
MS7!TSA_M=FZ )5(SB;SMQG*4E9X>R O[#R&E%U9=:_@H-'6RX!U@/TR+=:99
M \M4'.AW-0L1X[5WW;+^C(7]T>CKV#6Y!CM@#+5G]L#.#46UD'!WG*C+GO3'
MEX"AMYRNO) 6&6]K]_5&BDL+RP[@F]A>.>ZM-F"@W%ACGO0L/L%87!&?7;&Y
M0ZC"TFGSF]@N2W9UT2I0;NCB<-.M9/'W)&+=1&S/OU<F1CW(Q[%=M<:R4JJ@
M.RXUO0_3/Z\H(?5'R ,IJ?C3V#YIXU!1%6S'I:";R5CW^#OP*MK\-+:WW3@4
M5 6; RG-6L%UY=5\ZF=LM-E:^?CYJ^KQLTQM5O8VV71W>M%TZD6SKY:7J![$
MU";_%+)=S<[3IBU$>AMI5F4Z\,RC&;ZAIL^=JRN9C<O%M/2XN"?<H,Y^?Y[$
M!3:Y%_'+V <+M^9]!H-M4K2G\#BP?IMV2ZW<;!LQ30> ;=%T?9V'P'<<J_\P
M\F+71!K&:>@7Q_2#*'C[D]B&4==56@S1-Z_$GXHDV==QZ7C]B2:I#=\OU<>P
M;:9.*JX"EO&:GRK>KA(Z)V&6\\0&%8/V5$[X,6P;J),JIX!E]"JW*SIV )43
M?@S;JNFDRBE@P5<Y50VSFE%S^^ZOTJ@>?6''+]M1F-Y"Q=>'$=LU_X!;>JQ%
M6CNY  DE-<C-X#(.1GTO&(LMQT"UK86HNZ[:.OF=%-XQ:XZ!4ML+OG==J[LB
M.^DQD]#O).53/0ZV/H )_U4UZ7DXD^WC!WP$Z(D*G-1Q4P2/0>'W>*W3BPOX
MB&?#H]G"&-&30SCY9CN\%HS^QFDLD@.=[/<=%W0"?%M/7<.@?0Q[B54A;C/1
M'NJ2L,>0H!/EVWI:VQOCP>?(P9US:X96)H="."FL[/!O'>_<FD=N.F$WLTG9
MG3OUAT_NN:>$0RXN8Z>$0Z>$0Z>$0Z>$0Z>$0Z>$0Z>$0V-..'0=LZ,UV=:]
MO.$?X?)4+F!*(C>FB.WU3"D"])JLDM'I5CL-F1O( C06AI4KU?8^D9A0+^*W
MV6 9QB$_>O,[)[_CQRG15=\#DF/[V(-4L@6<D630E]):Z=/2*0Q2H$])=*R9
MT@"20D>S')BN<E^S%?8)Q1I@(F&@(S2-BGY)(&:[6B3DV$'IL0/NK*%J)D!T
MO"^7JRA9$_) Z$OH$_&@;WGB_L)(7IAR'Y/,B^I_YP:OVR3[;Y+=$S]9Q'S-
MJ=N4Y>IRH,]C[]/6M.V@\#F51N3\F<LNO8Z_\N<$=O8)O2>>.BHDREH*?_U1
ME4ZDZG02QI.JVTFMWSWSBDBN^[O!=#E1/#IP6ACI@ M+2K/:HL+^M5M0V#^X
M 2B;)W0Y6[$3)NORG*Y763)-4Y+)G@@8F9X*^8X$%W5SCH)XLV2K[X^4R@*O
MYL@=^SI(\B9@.640WZ9_.EMO?_Q[R,9,_>?U#7DAD=K2!*4?'XB&#*);S+>C
M^TP\OK84EK/ND'4F)L-NW# YF6FQ#&$8Q]C6J.W(KN-5GJ4%=^]U-B@E$?:M
MN)?FRD"42P7]?B0:XX<^R'TP1,[:S=<6<A]&@-S'/LA]=,7::PNYCXXA5YVP
MN2O:/?=0K0?YR*%34V%9?<''2B%:$$E@9ZR17&NG01!RX3XFW0N3Y#JK)D';
M\7I"J.?(D>FVRR8;_"-/,[ZJS.8;S0,LE6(RM&UNOQD'$@9>V6C)9+LG/B_0
M&LY#[KU<5KR13#)Q4[2M;8_)I6(:?5(-OX<9Q  /[[]O;QNS&*=[:..TU!*M
M]J'_Z_NV25IE>][7??X(K-"]]C:NIUP!:X.KCM'!+&9+24YY^AG6X#:)Z>:?
M9UX:IIR^T(]'XC_'X3]SDFH<WNU^=:36\(/(!M_SW1)_*JN\7<FZ8]4_B 8=
M4FF=>E6H&14*V\ C^Y;Z'4%.\<TJBEPDZ&\-HJ'I'A94-&Y@K--: #ZN/!*T
MQU8X<Q3!V#JKI9X2^[E KWP:H&3"0+_HM0=:C'%7R,P4.@DY]J/!WO@IQ>(<
MB*)J7Z9(JOK ?DG8&TZ]@)S#5%0@RQ1351_8.:3WQE0O(#N8:ER5[KE+GN0@
MROY>^[,;)Y)#GCJ;_-N)D(+ (YU'FP%")XEEB)KR$LMR,U0KQT&-,#^'<;C,
MERIQMII@&NX%T->$*>0%907Y[+UII=IL@FEGUTA5Q OZ7JLR\+>WF7ZO']U>
MD..X#F7G,WA*D4G:3;_]"T+#E^(A ^JZ_P'HNK_K^9#>^T)^P$\G&FHG/,./
MQX<?A-7)C1\;M),;_\F-_^3&?W+C=\5"?W+C5X)X<N,_N?&?W/A/;OP5<L)#
M]CF[_C)^Y="IJ<;IQ@^1A/-N_$(F)/=:+=6XG?F5HN@-I L5WZ]CG[)5B5V0
MR_]*S#3RZ0ON8*3Q 88"VG<1ELS*R[<LC!=YF#Z7 0HF<Q-(.\:( ".Q'.'^
M..(0 1U;@VR2^"$"*J.W)DK@8]OZK3%S6P\4&(O!&]]Y^Q0NT,OP?HH8.$4,
MN/Q6>XH8.$4,G"(&3A$#S@!TBA@X10RX\CYQBA@X10R<(@9.$0.GB &G3IVG
MB(%3Q, I8N 4,8"]UW8-@6MXH "(^-N,#S"0JP-A ?<D"\N1\2INL'>0G]KO
M(+M.)KP7=PH--VH]L-/1=IR[X>NK"AMU@C67YTPK@_.$5\=^RK=%^<J%9QK'
M.:\WL?MC>D?HIG %^]'7O'<.T#GR6M!#$3K3>C 1.[#T"WD15B-3V)(-N\&V
M9UG3 ;7<'%CD>6&R,"M+8,?%\-G^1F(?_/+]<WO%K_585)AO].G4^B]EW&P'
M,.D&9U+/LF=":R/5/'E+FKMQ'^^%6VNR2AC$?VUN#ZQSH-2#=>/:^ZY2^33
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MAL)OS8QF"WZ%:$:\^=\R^309VP1(:U^W *109;!FH;.E#&"Q8:X&$C>>JG)
MD9*=+J1./-UFX(0,UM $2SU1\=$7&8>B/S<E3K3;=:<A%$1K1CMC$&6<'!&,
MFVP4I3ST:+;;0T&U9W+;$U2Q - ?0:Z\D!9OI;O\S;-YY1JH.!AIR*!HV;.
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MG=O3NAV#+&8[0KT*IUF?Y8"_RX?K/&LYK5PU&I0Z!L[PM38^7P@)@^=WFD3
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M,D=6($C+&H4_[24"/G-[A-"L5SH&F2Y11:IXEC'(:PUG;>[GZZQ\?'%YA=?
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MOS366:XT%!@;JOWVH2(OZ=B9@F"&9D(QG8K.7B,"*GN(@+Q1Q.0@*11YO8@
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M/(2!8"L6$Z]@OYSUV#;:Q#[9_E52]BQYX>1SWT/&]M' [>I"5.D3I5$2AC:
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M-C]HVRB$612&O3_[L2V OO5'M>>;C_)*ZU64>R:\9.@_70&)GCWF;'\"@,D
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MO!9UK!?4Z90QJ3T<DG[5XN.[$X_N\WY#^KWH^$:@4/@O$GZ3- 7L3RDH$<R
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MWK12,$F-3YY%46-N1\)1BBDT;=W;T=JI0?"/.6(X.:@.1Y 9\.N=_B83];I
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M48JZOE+IDT:&YDRN/AA=Y*N1^I'+]E WT,+JK=F&6BQ(8"CC0XB(:Y6')/Q
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M2/@#O@J=]I3S@0P;:G>&M5J?K%NS+- S],D(*CZ;H.:>H<00)QS2HQX5(U?
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MQ$NLX!"71[O=#]Q[954R_9I)(G1EJUY/ER1OD<0'HD0MK'"H?OL,V[!;'LN
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M&QTNQ2U*#L7=:%-Q/8<J'F%YE, *N1R^&?20E=%7J7*B];;%NF*<,H>[65E
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M1\^27K6[#20RB=/DI+Y8AK$\7*W2[6;W1=\];N0B #YSA\IFBGI]!. +9YE
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MRN-B)ZCO/L>2TLT;=FX>(J0-TL7F*&WA:WFGE5-ND_A&ZR^N\2]M4WN%M!$
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M0K92GE;6Z^C9>5P@ /SG&#BH1Q5M,??1H1BZCUC0YR&NTD2T8GWB \<*I4^
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MIF'G)/,V[83;>9?W6L80@IM9&3(;L20E/O.1(SE!9^)?&0306\RR#BLOX3+
MN#-Z/=#*E8Z>7CIS)%N4$WK(Y)Z@.'\H]-*/TFM/NGXRGZG*GY2ZK*^9L_[H
M'E<%5T%G<D80B@3=A21]M<WQI3)CI<VSM%29_N$=BWO2C Q!8"3K:*L! 6B^
M4TXFV#+CI:X9# >O7ZN)5NPL&:*%+(XN@$@@S]?[P\:*BFQ%'EGEB-*%/0&4
MY2C(SD2>[5/P[J,<:YA<1PLARQ,_: YMT1. C-@984<X^U[)Z@U.^F[^2E?%
M=3IZD2^*T("Q.?IZ 915<R-]'7(KJXJ2=23#_5.A909+YG&7KV]DC,^^T/@M
MO+)<'M%7>D/VM'5VB$$%Z%42Z+R#_7.CIHI5N$,W?4K=,P62V[?G(ST9CO1&
M_I!G4/EV\4)#:FT-[6%#W8KA.!H6-D=3#GV#IXLW&[.L3?PFJ4E3&0KC6K[-
M<H4$%&7I=PVSCIB+LBNL?'4)R_Y(F*QQAD81*AHP4V=2=D#AXU%R$3U+C$LN
MZ#[)D)LBQ;^QZX/,0SFV4/F;J> ?XBX*D:9L.CYY>(6MG(1G%"$3="U^:I@)
M!.B-!ZHJU%V(;^V9P*6HVF0'#I)JC0'?4I+9<CPW9H$R&']J#*LH]>EURW0W
MRT,GCK?8TH_^T_E8NUTM^2$_>=3B@EBC?:N);>V;*&=7=T&5MH8^4GD6'HW.
MN^T,?E+Y:<N;M'2%U>(,197^]_,AS7?%K']<[VP^@ M;!5?7*T7+.M'58.V*
M,9#C%QCV]J,W'DPYMTP9JQ->=PH@*!V4%\_)'S?I KYPYBQ\>P HNEUN%+T^
M48D=DIDZ)=NEPT)IF8+<CC$K(P9<9(:7[O4I.[AY+^W$I+]&-G&<OK-$14%9
M2=GT@/W-IT-VM^^Y^^%VR1/9>^GZ4L&:C$I=[!_RQ5D5X$K#6T(PJ^BQOEF)
M1)L?]@5,/-T6O@#_<M.XYT("/-SO&@1AK^ JWA>J46S29U \=]O,/U)X[QEK
MH>-471M<2KWUTBW5RCBE),T1.BL>)4HF=HG6??L0/(EQ1O.QHT4OKA =,$@:
M3@ <ML]9'PQ-61^99L-N^%U,F#JC!IF8V;5<R_HBUH_AN?)*+%R<DFQ-MS1^
M5[RBS95*UNG>\_H0M#,NXX4<G_6!3U\>1]E=NN:JZ#'Z<1$Z92MVZ (#":OL
M^FB]_#'=3WK=)7W_LH>I&%/)AT68D#[(:?X2B':>D!7'5NU[Q?7+,5+61XJ(
M[396T()GL#F\7)(KKN7YTW->AA+D>>0W?>8/&-GVA_38D7G-I5XD7VO5 LEF
M6-]=EVUW;J@MHQXOHX$PK1=]3R@Y])#6V2Q!R--J1_Y?N=SE?S.W)/7_/K>4
M;VN(3L[^4HS/MK'X+I*U[!X9NR8B;PH[C<M5<!>XA+-(@%QO6C0<?%T@?N69
M9D"?H-)^*BS,E*Y,<\@.30Y>?;=P_U#0[OT8Q%KHXNK/@ X'=V7I\Q8\36%^
M 2_AW\OU"EA8KFS,>Q4TQ/XTE<",%F-J_Q_VWBNLJ>]=%XVBHDBQ(4V("@A2
MI0L"49$N74!J5)J ]-X2!0&ID:ZT2.]$!*3W$HKT)J&&(KT$0@@A9<??VFOM
M_UK/VN?F7)S][.=<Y&;.^21SC/%][_>^<[SSBZS3ZYF\C5&&LG/"*6[K0^.D
M"^?]=IC+T#-![ &M4FD-:6\E*  1S(6A\358SY1^M+WJG.HC]R+AEU30P)L>
M=Z5FFYK>F?EL\P66+'4$&O9!% =RHT^A3!M&D])%/UF-:11TW'7J9*5"%SF"
M+EA(&3R.G]M)X?C()PPW'I(E3/G1/Y4ZVRAWE&=JY-#+U<2NE\=1X-U[7OB&
MT85_]\+3WL&8=3&@=<XMS"GQI?C<OO*XH]![F7N6GEI?G?%0M RF("*[Z@UD
ML*6Y]MWA]ZO(\7C:9<NR4TT+IS%/S7>DD]P$X&XA\%3JR:GT1J&35\!HG7?<
M78;M,P^IV%LRFD]*YAQP'F1#V%LH;\/,1STO6XB,\M\)O1LIA:KXUGJV*O C
M>;V('R&.#.J):;3#*ZM7"2QZYN5^4^U?X(*N9)E#IRY2 $D!B' IDLSC?<50
MD;P@%RNV'^'VF8\;6KR;SFSAC4,#_2B ^% W"L"<FVP8DX47[%1\."TG*$F7
MS5M7[WY%(/J\9>[["P]9$9:ZT>MM@T9JASFR*KF)AC.*L; EY$?;A#=;/ULI
M@.HZU3\J@@55C37CPJ,!)LMU'[J-U-+%X5G,A\K'K4T.J(F\L#_S?Y39#IIM
M^'Y?$X.7"[*T*CX<5^3R#?5ANSGT:]K/=AKPWE7[T0/REU*%4+F(>OT&E6:4
MJ_V+&%C99EA>J7VJV=V%!=1T971A[5<K(84??B5Q/94JY=%LK,[T<E<"IH8H
M@*H<.XM1VKP&:CTR'%"!5Z5&R13):(NH'?<_*@G8\LR<?+M[&]K (\)FENZJ
M2IMZV/(_MZL:H8-5D$L5( 9/MW5>:H(@3!:J:(F?Q*%3OA1 Q@ON?A/5RAL+
M4O>(L68X.PK@"P4PR40JLMRP9#FEQN OZ!8M>1QA.WF4!F;:D#&-V3KQGERW
M&(*^4NAM!9KZQCBJBVX]T25?$S8W5W:\/" 90:\F_O?),9.^EOLQD+F1U_$>
M<JKLY1JP@1?YYUODR5 71'R2?,_QTT>U]:&?J/9;.T^PNVX3L'7!K#$RC4.-
M-'K7Y?7/S]$G#F'/ ZXC-U(GA@NT1)T$):2,O("[.1ZS"'GU/'QXAW]BJFV6
MBW^)T[V]>X^[( ;C7L"80,R^#EE#.PF;0@$H2XG4[;=T6EZ-V7/*/5Q6?K12
M:6MLR$W+'1+MU6VO^*\;9V7HBRJ)L[R>(]%Y?/IT#H-K$TF9@4_RRHY_Q^;9
MBLJ\.P5E9MKN:=4-.IRL.ZZT?#H>^TW4GBC?67E;?J?AFNK=(R/ %<?(&-%W
MJ+HIHX)*=;B6(T1JN%&6+Z7(X>?DCV5% T4P5X.JE&@XT207GR\+UVB./7K=
MFM#?,Y.^+,N%/$!\K0*'9M[%/$V;?E]C$DL!2&,&CX<"7\&'F'<6:(E,H&#)
MAM_.-K'VY?<6ZA^X5?$#/!9DB9O%3Q.Y;01[OFCD9LR^@STI9;!"SG,.VSY8
MV+KY_7G3FX4ZY#A]G*4)!KD4.I&WA?=1SRC#B1*L,>EB/-8J3,Y,#X^09=0,
M"6V^L:7(7VU6?<G.@9@SE%Y[!/ ^?E@<>K'08R(I3KR,3T3#89O CERJ^5A]
MW^BA5_^K;==S#3F]A._,$R47=/N4[K.=\Y0Z:(E09-SB E8$U,X_6K?BR'W9
MQIA3U[8IZ+'HT^F8P6=2,^QB:R\YDS\-L(+?4QIF>N.++**=3"]\JNN1)_A;
MHRJ'ESUR2C'*Y^7$UR\"A;VV#P'^$PH@BS$O.\^*<6$7S@LF3FLF%[D*+J0M
M71#,6HBC .1Y*(!AK4"WG,W4V#2AWOPA2?$Y59S/%3N/HML[K&OQM!J1DD$_
M_%%=$R7;J#&/+2>S)98PK"R*8\YV]'XB.H>I*9%PI8X;DZ.!#T4W.7B%#9E4
M)=N>5J2@!K ,T5-#_J V"Q^#CYJNP[\OL%VZ(T0!?+K%-%@I;[$_9+0?4UN?
MUE]7-4C_?6T%.WMQ6:HXYZE.DHZ!C/X/\T%VH+D14VRY%P>8SD$XM]UN_+GR
M&\/;5W3.AP6\5R<*#I#/$)_63Q!W:/2^EO.&@:11]HPOO[7RZP1:7]V!:^!D
MN:\5&6V85X;D/5(,?\93K+)^$H)F"G;V<F'CJ?'>NR'G>(G7Y$71(>B#:\ :
MO&.^^9LRZIMA0)#B(Q^AG-1*9=/RJKHO!OE%R"3F(P:-,?7J@+29+V7"4WN:
M$J%Z^-0_UO@Z]$7K@QF+&N'-XFW0 S$PB*B!8:8 8N5]/-Y%CR*9VZJJ/NCT
M=SB="ZA84R1/U+GL,^G'_Y:OCQ;KCTY\V<]/= <E>9ZROUC*,#&I9'+4=RIV
M:X(%C1#-<GS?QQ4X)-?$RN6Z!W>0:2:K2UK)'(&\XU7 6V;S#F?9A)T,<V/5
M9N[ 62T9+W93)V-^*S7[H\6WW9C%E:GF4N$;>B;L7'=.-:'(\@@*P.+?-F3A
MQ @9T-$I'_E]4M2_GGH!80C4&)8'HB-*CS1K@M'EIH]++K?T&3Z6!1#8L7[F
MWWN5P0917U4:G+ *N,A%$-H?+T,.UH<N2L+_-L9O"N2@ )[<!^VSZY#OU9)B
M=%;M=*K"#[EAI+R6Y:EG%$#Y/_O-B.DQ\K,T&(&40+U: PV1QA\K8S*:DU.U
M^LU9N93NK7\5^UR[29M5OH7SI #B[BV36_YN3.O7K['<$M?RDLT>+_G9P%7R
M//7MSK(]KU>L%)N=QWO:(BD=R\F=0-E<"P=CQ.J,63Z.NV@;<,SS7K'Z !'5
MZ%9&5)U(XA&7?'[JM'V[UQ"[C$^;)0?7K8]X>4US.R09*LC!U2P"=?<STG82
M+"OY'I)F]H"I?ZJJH"QOFV^[IWH7.?K=9A/KXA>%630YKEF %KT;?)QY,LT"
M5+A)9M=^*=:RDAQI.N=I)AMO]BJTVUY9$)YHN);58)=%NV56+,ES8J7P/$-C
MQ'PT+/SW#>/80&8\PJW\ER2GK8OTOHB3L]F>!J#72.'WF?3CMB&%((A]\CQ+
MTN"XLE G[FR=@('G:C]W_G5#[E^1]3_K"M:EEX)4<)?YU5OM5^@N8=FVS/>(
MP@NT)\U@W#9'DW<S2*$6D7;$L6.VY!/5?_W/G(7L517M:SRW%OT!M"=25-K7
M_F$<,LAQJ@&4 ?KT.;5D0O.\ZB6+I@V3OOXJ'B_RT98#/K;GNCMZA._?J ]M
MVHQM?O[A$R$V!U.RW<^>_(;YA76\ZWE?9%M+6 WY)H9S%9<;MZO66,@N/<NX
M?"A3N'BF9]=QT@OWKZCB_B*:6_#)'*>8NUMCTI>=OSADSR;D==D,J9=LYC?Y
ME+8(,.'DV%4O$^XJ):R-&ABZ*\O#,42D16R >7S!G:B",-'\-/6D[/K:T+*#
MDKKOG5RTY8^[/$U=VN'7?2-2=]<O>R?NVHN:G\3LJEP:FF*>%I*\WS!HI"KD
M..@P'#.-Y2SH$KTTW\,=95%%KTW[I0MD=+;>=\5$SX)5[D&/C>PY_ZD^_[TV
M4L"SZH#0EX@WVFHU/+5<#6IL1 DCR/5 C?I][XKS&;^V"<(=.\GW9*]>[S["
MMFUM*F#4T>B'A_I)W24:XJN%I4&:)C*6/"/"SIF78XS:.4(?OEVI4WX5=)%/
MJ@2>(G4@T]D]A^$P 6$/2>=?/XTONY<F5:(WIIZSY<>C9F7/8Q,K>?[KET6
M7+QC#_D1/D1SO/'FG<KQTMV\T^=V_6&>WDCY179LF?^DEF9'#:[BNXF(<&Z$
M2?W9OL=\AX@4HN%^RXO]V"\NY6O5\<)+"A42UQ/@AEQ)+VUH>5:VNRP&E'.K
M%"[C_*<D=P35)O1QY,D!%%JCK+/O8TR3BE: <%A#_F:\I+=I:-E*I(SXS&#Y
MXZ/;7$D'X1\A7 Z*$M69 ??+EM3,N2]%T:3;?9?:@M,V<SA Z*=V$:)\-<FR
M3K_NO!;2UKP_)* @:/[,_E#]T/'W8'2Q>UY_@<?$$8/VD/I/&98IW>E61OJ:
M:^?,"=:I:^6* KX:OS\3CK*HP/ .3,6""]GX$O0&46]QIO^R;O[J5RX%),V=
M#_(D"4N@R[ZHY6=;S:B'335U( *#E;:D-4+?2*I(H AUM6[/U*6SY?+FF) 1
M:C5'#4GW Y2LCN6H2+"0"HQ:@H7Y#X4*:TVT=[DY,+*_9/W\]2';.1K+E%-%
MW\T_!^K$1T$2SRN0:Z8-Z4FZCZV'"F[#M(-*U(=A?%5Y@MG<IN:S2<Q?=Q*@
M)2YY@;!O5):C6T$!?*^G\IQ-PI++D1,6$8<%G@C<!.%8P"1.PU 4Y..2#*SH
MJ(\THIV/F+NQ>3C8BKA%RI.A %[94^6&D4@LI($15!; Z;YP-9 /&"TOJQ"2
M$>N*48_>=ANF '2RI,KN%WOHVWK=7:.]X9>R_>?=O7##&F\]:!/X]>;(,@!F
M?FMM4W#6:%**%26X'-#/8-6*&F6Y;G\\++W^1RGZM&@71%)I,F@'55D/;]=@
M& HRFQ2G'0 N)7Q*>*L-B^K]77?<Y\DU88&^R]-#FEQ+DV(2-%4T!L6AYG0#
MP_):^;[9ORSL?>+F.A9>GR02Q#.?$":C/Q9?DYO*<+9@FX-8#4&$?!/4&O:Y
M*EPNE-A([K#JW?"Y^$L;W7UFP*]F^[C$Q-YTL'BJ)AGG,/S-J#9)%_@%VUNJ
M<YUX=P++(;BC$1"E&GRK04!B]S;<Z[@4>-%7Y+@[A>7*M":]UMEPEX??![4?
MMDIM/95LBHY/SAB2TR_:>3/KI5A=B>%**#07NEF?E_%K)YX[#,T9*RM/H^_
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M6$H3'BH#(TKW;OBF+K1;WJJ?<&ZS_B!^Q<M;7@!6=+?99%Q*&+KD\^G)Y]X
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MSNESK+?_[A4:8CW\</K5Z-9W/K;=;XPZC] G7#?-^S8)Y M>?DWUJ]YV311
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MRH#\1$Z5Y.-"NI" L[<'_3A* FTV8F>.4!ZD^U![G9-S&\"CN18L.S<SO8[
M[K6$I,N52C@JJ,:)[)%;X%0B$]NDX3L1%T'S$"%,2H>N:#90.?D:E8YR(PS3
M2&9!@IDM&!X7U<6(@_#WQB!F2<S,#H(J)HPG^NE>!68WZ^U?/H\O*5A9)LFV
MX!P(79#U\F@[)%")7J:=I,-!RCVB#7\V*I3T/4%[5#SVE(6&NG;E5HOE+6@$
MP_3\[.84!C7?+])EI&JU^O[B.I.^SBI59E95ETC%1GG XF6MH^'>NJI4WCI(
M!A(?Z7"V>?<7<IB432L]N[.0Q!V2T5$+2G(Z3QMV/)="O"[K44Q>:E!8(]\\
M#DZT.K4%G1Z*4@#7+<&8RBY+=HS*US<HK8,Y2R600(7<DGB!_(]8M ,8;Y=,
M 7RCCGF1>JV=-K#R;_>E*CB>'H0O[K[6/A8?GS!&V+;G7^)C86%&',V.D;[N
M9I1YS7C A:TCD/EJKZ#8JYJG*KZ0I5T&D&$H?=S,A5BGG"2#8(Z-SU QBY3V
M/8#H!R>1919ASRG&6Y7W9E^]8BR8;Q"<X6F*B!M_P'V.O<\POFSGE3T[N![G
MH>B"]\!D@VE_(_,7IH/JV\4#:V*"^UGY>#PZ&(.:_YI1\'%H!)M<EXUOD?><
ML#-M"M\B$P/^NCDB0O'".B%!/AFC\!&9,8F\3 $$9H*$C&-\^UL)X>_WL@ZM
M#^]Z?'&VZDN/]@*V*WOR*EW!CJJ(SNB:;L(0CU$/[CO"\ 9+$423Q1+!_OP%
M[[2LKQ1 8Y];PZ8*TV0#W6*BN5G4NK?R(<^PGC(S]_^MC71;J$1[12&?RFE^
M_=,QER1*5K B&*^$_Z_CT/]U_+_T@6$(7#AU] VJU@F5L+CK[*2XRU$NMYC
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MUV[D>SJV5($YJR]/F*K: X\LS:RG4U>G1_H9X%W4) "Q!D(,@'%4^E8<%[V
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MJ(F\AV>;O-$YX5*.(76+9B:!7 6GM=O6E*"W?IMTM<!/)=]>1*AE/7EAQ+J
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MKKW7$'/6?DE^D3]M-015V70>/J#]"X*^2@($^5B>GB?V0FB)(,^T1>7J,+P
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MD=L(+4-\XQE.]I8M28#W&7]^4/(MMP#[>$NU*@_?V8G\XW\"_S2%(&6>'N[
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MJ2V.N.)X=CB#S"!=,N(Q<@%GV!31=O!Q9(<T^"I.QBJK71QN8WM%W=&)#M4
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M&>LBQ2.T&1(O[5$=M:S,XZ\,9B7(CA*4V.;LX\]&FGDGD"^X2L0E3D=%WY(
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M9YV@-Y@,6H#!T,!#B+PIZ089F"P=PEL)Q!+0^JQW*8%=[1R VMHN$/R92G+
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M6!CX^%OS+)^)*#@C[[W#$H\>?B'09][B&*3SC&6MG98:9S^O4HB+U1I:X[Y
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M6+S1E&#'<KK([-5-,SBGR7(B^*M+LFET-GA+V_/[&.*X40ZH6_!8UY#^Z5M
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M$/OWB>%6YPJ3DBSZ]F],H*;:Q*!=B]DS )T0"0%:=ZL]7PKQ\V&9L__IJ8+
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M@0MG@(]$SV^^ZC:5/T%[)^_5E.9WL.K^%/2]ZR9OTL8K+2UO]*7H?N>7F_Q
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M20+C'LXQF=3#7';3AJ:UC 532L-T+1^FX-*%U@0%*#^NM2E;,(N'8J :YN]
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MF&,.DQP1HGJ4FF5-'E\\,>#N#& (\.82Z5VKNF)4(H*Q,& ,%=&Z?7>BFL<
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M+X;RST#"R1>VYE))W&Q<4UC$MV!\\L/D2H_#%K+*&YL/"_-CCJ 9OPZ2$X7
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MP6Z3C'4,0\SKJ7 \5:H,.NQ_YR7<Z>*EU"'U.HBDZ9O=6?E<MK+\NX),>7:
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MNB=_0I.C34=-NIDX\'&PG-XSZ=_&]X@4*4@%8PY'C/L-$ZU+G9)*!':V%PD
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M9O"ET3C[FTI3=K<N"K_&0 J<%[ -48.9[_!<%$--;<1Y'(4F"O9%67YS+<4
M!ZT,>C\F^&QV NENPX0Z=2K]QGY+DDH+[/6#?;R4'KZF,_3=:5T9ECK/-M+;
M\NL$>]5>^QEVI738:8G37>^JW5\"1QW!RH;83W)O3]JQTRVEETI><ATWIRM-
M=[0MOZX$Q&6X8O#5ZS(LK$+K:S;V7=KVN-Y"@U3_48LC-0]^[#8%/L+XR )C
MV_K GD6XO#%LWOI']/HU4SJ/&?5^D;^6LSG!FZ9B0_;O\:>A:HS$A)R2Z>:0
MI$(^E#.(EP+5 J?;;J>V_7K9^JD7/BQL*&"GYR(')NA#XM>*=@BSZ8\9*T'3
MV\3HQWC:TRMH^:40 = GGX%O^INB-Z$EOWB(?<'7\^7R^-E'.5',_'T%M(+9
MW4SY>$/D9%8L3-A"'4.,5W&,)@#>3%V_P+T!B[(XTO48.9\@ /XQQEJV@8[4
MW&&7=^#X #.)I7-[$/_O7@J<'>Y:!:TYD1  O[=S88@3"RP#'.[/#>L31P.O
MO%5PQ6O\_[KO52=FLK6L()43M0'M0W'B5<N"\">M6([=W*O\P]R47CK]KA@:
M,54]W_=I%;!_0/<W6OZ'8RH?T+[\"E<>?AA-<]=<8F(OD0'H;E4!S%.C&)AN
M>*ZB](CDU&+#\M8BD_XA7DGA4GAK^LR?.$535\?CHVO[4LM4&PDV#H,HMIAI
M+S+2L/.@&G*08EB+#"'->1-VD;ULT7T)O-TN%UV2$-9A)#-3IJ=V=^;3W3>2
M[6UK!KE>G6=?4(MQV8-SX,VSO)RMEX*]S+?UV8+?M3G+2B4?N1C:'W6)92TL
M1AQF&Z?:<3=')UN5F_%W#UF7-CL<0G\N-EHP7G'O B,ID_QI=L,DY%[9',60
M04/S^X]W]<>5NW.\IY*BM=7((;L$0,1?T5G"GEM<D4'&>NV,H^$[4:_$43M
M;IPDJM^KLR?9/%X,&IH[6"?!04/W]H+( F)H=S9GEBJ6X,Q17?6<2B+;]'G
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MV4ZA^I&L]A28I(R9O_ 7((6"7Z 'YBN1Q/ :Y-FQ]@5U:URIN]C)=RB2]Z4
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M@OG6KT845;="9XACFA,63SI]B?:X]T.H1S.9!'51T60-U:&!ZA44=IAG9R!
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M*+A]U/37UI?2Q&[!<J(J6D%]Z<%>5H:FKW[H)W(P;\:)SQQ8GF21'4TFR#;
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MIK!PI[P@GCE\SV,BN4?F1O4+(Z^Y9QL$(^LQ5WN.GU[Q'T[G%]!$>"U8%5$
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M/K0;#/"P@/K'PH'EK I7EWS)>M_QZ,BT/O3H7)[ W35_PW'W<%8;Q6,GMLN
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M_9:5GKB]=\B04N%/$D9RH%#_(\99OM6"@&<&#G3I_[4\^:/_OH<B.\1)E*K
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M"+ON42,'*<D_[H-O6,P"DR?L+@&".Y> ,KF!LJ/O@=S+;I.9M(=/G)%.8Y<
MM#K]H523;:Z)_>:UEE(=JRQ]5N+F"K#4OIV;NF+YG;N"T^.+I>J\S=G6'7*
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MK5Z$ZEA'?.5/A99>0"Q8ZD2,S"!^N__/-&X,MA:MI(?57$T;O;/[<)#GGE*
MR3N9[I&,(AK7KPE_+OOU!%:N8;"C./6:U);,^TVHI! >2&Y7H=M721*@JF3P
M-QRIY#E?!W$I+6[17A\-:Z-YR7JW*<VS)+-<))PNW?\C._"0[0+6Y<\)"SL)
MT&77,F6Y&VZK;MAN +ARQ+@ L=61U%U.7O6TF-<KK%)]/-O&A'^#-7.:[PO#
M^Y0Z:RRZ.0LN+;AS>K WET)MO^Q8S^%D\4'ZT:K QC"#4"5QNIUFTZ-EY:]Q
M^I>?4WR_>97V]XTSQGUFIAV/6QJ[K"]L4[&3[1C;M5$D/"!OSEY8U-">*N,Z
M[Y=1'J[,UQ[/)#&H^-1IX<7[P#>\Z]5C.-6(\V;,!+JW=;7U5N=HUNY9ZI.$
ME5^)^UMOAXJL&>*F LS&QP:V'D7YQZ5N_N"P93V#K[[+]Y/' -4#9]$\??[$
M%)P5EN=1[?3AW7%7$</"R?64KW25<JSVS[[B2V=Q.:V:ZTGEZWI2'1'*-Z]*
M.B<S"]*FNOS\?(_=ZZ-$Q]T03AKCCA*O^<WF11V?UJ2^[''P/1*@\SNVI\@B
M0V,/D5G)E!N]_)1N^"[U3G>$! D P L7$Y*"'_CF=G-QHVD^*3O*+<ADL.KV
M^;:[>9G=V.VV]1'Y*BNIIE#J92;\XWX _>^#'[G./^'UQT#L8[R85!_F"Q ?
MZKS4)NBHN/(MF-5I'A)VN* W(^;2J?8AIM]6X2I^J+__JIWGB*\FDD "W L+
M(0'VR!].7L+>8N?*EK&055BXV\E>BLCAJ\FEG(:0B!:7V)8\+YE<>'6^Z^'Q
M$T+C2C^D'4KC&]8)ISY!2O6P)3@UU8AR!X0E;BKIQI>V$FT_/MS>&3.]MMVG
M6^HV+S2TUCYY5U9J/B45-^SV0.['D:W;T\"L8)D4E+X!FKF;9BYBX'?CATSN
MEOKF$!E'E@')!YDF9@,*O  *Z^ECZNV/@8Y )*-#UL Z^RSZ<;N53!7[;Y,C
M2R1N#I<5T[J;_4PR0__MJ1D)$,9GY!'EQQ33]S>:<=7Z%M8-3:^&ZHO,GF[Q
M*79F]IFYSG[33B3:48R=3IB)ER-NDE,(NN^"UC=!UX?*E--TF\TRSQ_$>A_K
M^FYNOH7*4^GSEI;&VCPW U6=O1%HSG,>+3$R;3S18]P$UFQW^[6QXGFFQ<LJ
MV!9,6H1MW]SCD.P_'[KRIX3")NAA*:0ZW?\0+Z1R&T*[RVR>6>S-VN0'XY74
M8ARP,])7%K1N/3;>7^&O.:ZT7#X3W/EA)'75:-@]RRYAODT9S=PS"B2.62M.
M>0'#FB)] [K8WH4JR"@Y"//BO\-: KL^3)B8<;S7SRW4FVINC=\5U$\:^C!:
M*0"+Q&NOKD2#;W@-R!"4^E*3OW'7$/"8^M]'E[\DG=LY7+6MN"&_,Q)T$Z6+
M0 0Z8EV;N@62S$N8ZUKJOVT\?L#!.(KZ;A(:Y)$043RQ&:ML-9:KU/926(H,
M["[">V3&DK:V_0G1X/ONU&)IEA+:/<+KT0NA/H  G4YBKQ*'V^A09M]JHGWT
M)GOJL@L/)/JKM;070VZO6E"$JCAO@B,S+Z$+OJ U.U)=J]>%EVQ-6QNB1;QO
M?J&HM94L>G-M5.,N2E/G KH:VT4"</IJ6K8VHC6CW5IT'43AB9SE$W5_5MR5
M.L3\VGG0%:EU(0)%H_ @;V*]1,BFD5[?T1C&7R"G9;WL/^NB%A"FDY K"K>'
M?O$/^W:G3_R;&\T?+^>7"G26O^0_<$X\N 6UO-:_**BC([3O$9E0I9R&&224
MM*@58C.'5I,[-H)T$1\:3-G32HUN3JQ[I%__6_5CB$E9 RIG=..$9DX<(X\Z
MW)_-CL3!Q,'83\$AM2K!!B\_N9H+W'I?G%EXJ+#9+'0$_Z6_/^2):N[T =W!
MOZT"!SY%^\K5)\M!I6>^]P=VT/)_W]?R4T'!.Q).,VQO-*KZN9VS3\5'8-P7
M8#_-^L H YH8MJ7HS!"4\=JY(SYHO<#"X8B=QMENWR >$C;,G>R#RM'R79V=
M:>.>+0L4SG(RGREVKVMRS7"YOS1U."&?:W30]_>2#.ILGWZM^3 &RA0(P6GY
MYBRU$#2.].2Z4'JC<]D X402X -([$X7[##(<<IE_E91,2],;O)8-9N01KST
M%UH=VSDBU6FN6%9_0YF@:; 0UMID(S<8U'!)\XT)U_8(:#5OY<B^39D$@.B3
M !,X_PO7-CMRX$V #*1BCPD$T#_\8&=$8-+Q Z/LIHG<X@E\SIFH5[BF3XAH
M<B#&]UEJ(LMQ#SIPFH$2G@4Y"]CMQ]1^V2N"?[;4/H\Q[5>YL"B<OQ#^H$ 6
MX&]@Y[+0$!!&: =ZH<OI'R+#*, [L.4!E51U)OS3$UF0" H4#A"_(Z6Y#J=2
MW)F?DJ*NTM%XXIFX;RE\';BBN4IE-I%X?HJ>6"&R;&,64? >75J,_A7?\S1]
M]&6!;L.G/4^J@,\"&PG:VD'.)PP<43'J>@I*\D->)B]*BS7M U-PUL$]'H'&
M#>!OD-OWN9BPU?D-39^/QO&?BJK>,_ZQ?=<26 5IMXABG")$0IQ#L>C\%5_=
MWCN0UW@CU,&KJ9-SVZ/HP=QWCHDT2S:+BI!;=S2N %2AL%"XF]NGB_K/,N5R
MF"CL6]4.! E U:1;UD/IX?-.%:SP(PA9HJ,%BI :8%=($=,<!::XQQ>UIK=I
M+M:874'QKS/%H;?7[$/6K5CVOQB$G<WTU,N4[1T-W0HHO2RU:'-RKWEW2:DT
M-Z,@XR>98'7_EX93B3@#;&[/+)"]A7\-1..;9H#",V,<20 NXQ:;_J/^6P^,
MY-RSWCO%9*,*U\-"7>9)@*?8N&(GLSO1>V[>TFE@SE_[NQ#:"!\D=8GY6WAM
M6-?>'NYGV7XY,LO/(>5SCD"J9;R^FO4L C;OL%88YI5R .S&**:5T-4U>1)R
MM&G>L/L"PR^W\NUJ/'@^?8+TC!E[GZR$?Q: L<*>%N%?5$Y+0VC) 3-94X@O
M7OH/_R.= ^'Q%P\ZKL1H /ZJ++=I$J+PH.)=HA0:$NNZ/]\[:>:G.LK:3]UF
MS)-X:O#A8\#QCO4GG&[@ARDBUT"^KUFGH:8G NGP;0BP8O]HP>1SYBTI!]95
M%]X9&<=B4_="$H!Z<8)^LR!?:ED ]CUY]; W?%\#QM^--)2Q2@LI&1*?.XY"
MKJ&C2(!*J^W]/G27!;H64[TZRE("B_ R3'A@4.[!5M<K0L'^(W'#_?&5W6>N
M$9OOOR;4;0K%[&B;;X])F_V&,R.#Q;%#?6?F<J&G)BAX"+<6QGKA#G]&Q.=M
MX>//+'%16>V'U@[K$$J\#98G%TH_'_AHVKLY0,.LH1[NQVN5]RDCYH#%<_01
MA?2ZAF35MMDKP4&YP(I^G'G;,^PCLHM0%Z.IMA-L!4!G2[5!UU#)?;8(AZX,
MFNY,@\^Z?^5TZ4Y>,OQP5ZD7MEU@/-[N!)ZKZ'\#GZ[+$<-<3+3E2\(Q!$,I
MQP:9E1/5*E@F&?]OD57O7PB-%X$L-'[GYM8F[A+R:W#)85ZNE-$]6K_9'2AF
MVKY6R)$-]BL9KFY[(QF*')IJO6-5\GH-B%27\,)L1@:I"3+I?CD3HH$/T.^Q
MQVN'8:<HM8 ]^<UD-S6^!^LHFRX43))0&7P/['MK34M/B!BD]'SJ8+TN C%C
MS%%9--0L?/G&VF4TX6(;_@K,))N/6C=&G>RK_X[T7[!U+65HM)$@8I-^D0!O
M"T"TD+=D*D"\%7M6-W,+LQ#"*3G2^HD$^/@(?K;DU9L:REU8XWW.HM!HI.=Z
MHG(%HXJ-]D-?65,L* Z2S2[9\3$R'_'PY(Y_R; VGA(^L%9'9N7O6\&]RWR1
M'6UW9KP'4+:3R/N-0I!(IW@*Q$-@=& M3D8KF#5X/%,>)5TX6-M&+5,%?*YJ
M9P-9$&0GGE<<8Q;1/AB*#A)@OP'*S#:]^&%!$RRJ_[-O)]&0!+B<XS55FE>7
M"%V6'TU*7/Y;CF-R6N9#RWVM7?+L-O^=77IK:"D)<;&V25M"\S/K]8?/PQH4
MP/M![-8NJ,C'-5@]%%@GUL"[.DS_%TYO/[I=HR/>"$(W?5Q;'Z,J%#R9.GTZ
M&B83$'O=UVC^,0/8-BY>0QF8\CW4ON/J$8/=)4,!G..@3XT&M#KJE7,U4D@8
M :47[W6;VV7Q/D6[S$;46/A1S+N<WCNBSOLH1V%_E\XC\5V,DMDTE#KX[LO
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M&M(X91/SU,>P\1S_W"P(I^08YPBYUL(59Q,N_<>>U[^) E3*MDT".,?>'$7
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M60BU=Y",5?"<0U'U - ])K(V=JHT%DMMF191*G (Z=S7&9G4=PX.G8TF >Q
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M),IDE#@?$4?A-;/?E-41>GQDJ?9HALTJV: "P:1A=J[=?E\'*1S7IYHR@QW
MZ?'W@"AVESE13)_\9$K-!_CRBZV?%'%_>EX= LC48AG@&;NLQ?-BTL/=/<)9
M[V5:?.#BR$KE/JAR%)]V& 99:2)[<HKS;]4[9,:^&_B(+#=9X2=*3B>0/]M$
MO;.NE<,ER,[3VFW@#342('0*&]*';R S^NP%4[!K_>BQ^/[D>;#FS/.Y.]KL
M@G\U!*?,,KVAP$ Q-ZP)L([B6XLJ"= TB5?CB'_4RNQ)HZ!U02M$4P[&7@>M
MV05/D !W6NQ)@-;::D^'=]L%2PMW8K%705B"(:&N)F"%$IO<::T\$1YZ- .N
MKFGWL@GL/T82JX\KCC%\J)2Q8-J"7"$7J&EC_$82!Y+B-9'EZ3^J=C+-NF_^
MU%'\&!\C %M^[V6>#D0*%*Y!D#=7P5Q/E$L=[5Y4I$":HNN>XG[F\1"OF*HJ
MP_&BP'G/]F6:J/,917/1I<%35MNM!M#S& D2X'+%&>8WR@,MUX$K[<]=\<Q_
MFASYZ??X$7RM]B=Y..<A^.MR,5ROM2R:.;K67HZ95NTVE&-8%4V91>2VC8*T
M%WU-KL2TOD[%8?"=NF?I&9S0\\P5G.&(&!0'PN99Q/Y<Z&.]@BL7$H:LYTWK
MS]$\JZW%TJ_-99DL/4C9L%$0W997P%=BS;+QFJAT57G4,UBV)5TEV*+F?G))
MO/RK@]LT:^![^'O8N=+@8= [E%N,M/#<26)*06U3]:44'ZX/!]PO;\MY7Z7S
MG(T2[)G*V>GS.L2R#1P]-PXP[YL&LXF(PMH8L96N<>;<^8N5BXJO^13PP@.0
M5RD%D,]GX>(7-5/;M)#F*DD(&C'=@7]!*'!M4WA[Y,NSMAQ2U#@%]_;Q^U 2
M=:___D-3[N?KUW[&2$J, I\$TF(_0*F"67>:^!Z/<MCKAE.@!Q<;+^Q6 RX]
M,_0J:M#_@+D!=S1.5>+IA-M:L(BI\N"-,K6F\T,Q#Z(T[[*Z2DIA:?K-9JI(
M@!)(?F ^COD+"7#SK"<3M$D4)[![@DU'B,7$1!88 IZ\$?88ZWRQ^\]%)$ _
M >U A.>0 ./U,KK=M!4PG*^C^[+ V[6ZR]=<U7I*?^'#;;$F*W]:@%C]-A$T
M69"B(7\74B,Q1:B8YC7@MWF:'IK;YK5331]&:S6R,FG#KWX:,"H;_/-7XL"Y
MN/8T7/W4%$\; :^*W#_$0E_Z.8WO"\FNL\ 2E)DI+8A+U@(Q$K5,0Q]!>R&M
MSDO!2YG UK%Q+_W;3K-M]W^^B]2/8QXZOD&\J!1I/+&$.AT?SBVUJ,LA#2'>
MB&H2@'ZO7%4W,I&ET^W%((R#NN2Y;9W$R\E<18^TS%306/'SJ,7GWE.XSQ$"
M,.6]_\1+5)T)59 M Q*@?I20;?T2E49\#<>0O=0!9OS?G"A_[0U:)0&L1A_E
M1 C;?OM_8O?)_W_\W[(3YZI<4K&?*ZI?CB?JCO-&+'OPH/]A2* ED0?K4587
MXO4RY=5B?W%F]DNU<_TS+1X4HJTUZZ-_U,R/79VTEI=T7^W+>0/]/-: \\ >
M5 ;H.;K,-$GO2,G\$D-(<.63KT01X86VRWC6L-7MD$.1^"WGH=(YY;V4K?6
M3S',O_"C*LY3G4(G!H+3[\L5*JSHCDP9''O%"(&C5PEI1#IG"'7+R_4%I DR
MD_/USOTZG%(EM\F66YJ01/>7 G\VUUI4@D4+H?C$C:-W9N7/3%TOOQ%RZ^#H
MS;/KB]X>*S.MQU<FHFXW;"77I24DFY9Q_9;5K=P$U<"["/H(LTY<-+W6@_*]
M489<))6)>WE"/\6YF2VJ[W$#:K1KE'J'^0W;;M>S^MH?O=I& VS%/'<Y[/S-
M]&;+&3D.DQ.R+4OP2_I7"7EMY'ND:S%<U1VYCXSGO+>SV8![7!5?AI8;"E%
M2,URJON+]])06?OVK;FVYKSX.7.$&<_^-JAEU>USESZVL]F21L<\>,)Z%_FK
MT;3-(84XVG8-CF+NY.3I:BH.AXGB#Q^T=Q>.2C5TW.6*4O*&T:,=]@_700#?
MB^-N$H"JMG:"M\G!SZ4 !Y48,)"MJMK^7B:_'Z3:T*MHQ$@]95\B4\BJ(-8<
M/AFI(YZ-QL,I@D7P=E.BW-@0Q"=")%4$TO9U]F.;,Q-URPN)175_()(?Q7:&
M<)_PSN ZV^>Z.TEQ8*]4]ZO?YB9',94DRY48WY.S:8/6ZX+^TP%^QX*B(N(.
MMV06SRFW.T%<^*#7;5RS>$-GAUSYHP/[ZBB12?Y'-Y\;O5>,^ABPU1P[!UG-
M+$9!NKDDY6(94H-.XD239D7YDZ+%E(>+6+M@3X^H@Z[SF&P( $/$ ,@GI;\-
M/<;YYRX7,IPW9=Y$]ZWQU:_'1D)I3@D*R*0^]:88BSBI7^]+)17F+W_W-9Z*
M<5Z>/8AX0&.H^U+'59M_K)8AS;G([%.@(E:S'.N)B4'[1(FE_ME13&SNN=R[
M_V9(6G/KVD/@[JCGE%G;A(V_(6M#0;*!AU'M!<=9MQ4;A-:7IIO-I-C0,^B5
M2HW]TQ J=-5G=QI6F0XB&==NGX)#0=0D0.5IZ*<*XBPOF<WN#S=;L+#>]>S+
M]S\%7!I['>,S-#"F8'+>!%4-GEZY#%,5<9PWF8G>T"Q].3C4]-[$G _XH/_J
M-K?6^NQ,*_MJ<E<#D06O/%&C3CG9Q;6S87BVZ6K5EL+/BHPXU*(H&F%8TI87
M<OD;,L3EH%KX*7@"?*,6'FXM@KJ/^8$IOA[W_LB2D/V'LPSU:X%L<K)[,3FM
M\^I\PQ4*<[$3!>TG^7E;FXS,56P1>K53*-"<V1I7/2IGMKO26=P)&>15]<0E
MXZ>+@:;2#__9"M^SSCJB-"JF.-=*[*^;Z#+3>EP#;=R!(I&Q#<!Y7?#MCTT%
MS]9."4/+4MLN^!M(F"H?UF)-!?QDMK N\XJO0PW3_D@-XZ7C1HU+=SD"H.:Y
M*(>UVXVKH]&9BFA1W((LM'1(>.%;1N3'8V;V3P847%^/K?'DWQ685T243Z>G
MI^TU"J6;)+\BJ]#NL?\.Y<Z[B)2") "?,YJ9V/B?JR/-LI( U\B",$$&&TD"
M6.Y#3MJ6FT%SS$0]R)H#(;(.?"'H##P/.)(C 9)!H+'3P7\5[UJ%O*6Y [R)
MI\2&E0F_B^_K.CONA2Q8^ B!#LO,@L"*)$"'&EZKC97PG7A7%_ZNWEW-ENW,
M5K3[;1<1*P*A#&]6KUIMS(L;@70\:%&4UI\#JC7?JJUU>71QVHJ6>DBS"8"5
M[O62 +:QM^5"(&_@H;)4F19UX=<6Q-T=N#Q&V^Q@=OEZYC=OYVZE.0BNLL=>
M6;38I>B0Q :_8 JTAMA(7WM"?MBD3#/T.FYQU@S,#NF0#>;P+5T;#27R=B&@
M-$[6P*2S[NN(.1EAAZ\C7,-N5NUV 1$XOG2@M/&O$LTD/7[/-7'R' @<+JQC
MHE$E1*3,=<7^V*PMC[ORY-"],M.&A'W-!J&^0#K,"U=P^>BPT+9G'9@%FKW7
M$%KPARFCN8J15-,EU9UK#(86+/_=2OZ-058MGGN_3D'7=LSK@L>=V;],,5X-
M-FE6!WABN"@FI*=O49?<BXDH >!+1X+%@H<SV;%);)M9.+[\*-'-.B9]&]\N
M&MA:!*9$*)>?8H39GM]16/>Y.X0B&*B'.EN;C@V%N>5-!P_:W9(>^E*;_LM
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MTYG]M&/!;$N=YI+W,3^>(8WX=+8/>KA# ER W:S!9'M(P.S_TV65S)-Q:++
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M&/]3T']S8H;?F$ASNG@B1"8%_VI@][^[N\O_EP\:SO^:@,;@2P(0-?;(6.A
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M!U>C,X>ZC?9DDV3C'<]T&>[U<*H]NGE>KV2'7@#J8)H:.R83HNKO21I9]@O
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M/BAF!5JQIY,E?!R?LC-:E+C0CBK&?\750H_)S"+=OY_A,)0D0+Q^&73:08O
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M79P-;'W JU/!S8K@G+S8SP]G_M3P7)D=<?HRV..TVB3QY0GE[9@'EGP[4B9
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MNZMQZ?-!YI'A!-Q3J&!/9'!_:UO<AZLCHFD%&IYY#^78EJ \>2#LC:]\'I_
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M:+D/^1LB@>5]UBLMLAJQ;I$[J>LV[R]7?/"*6Q+NARY+'G6YO/4QZDZ99)M
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MN;G'/J/ELNS^,$7T%L'K"TC]^+'0NM#FU^+1QH2(_6J%B)C+(?PSW0>#*!*
M*? 7HTB3Q@KNC+9? @->I8*^7J;UWF48-Q1 X99_Y:S2N;T[">?Y45&18O/3
M-33N!WW7>1#]RG24)SQ_NRPKXTV.YI@3<O\\1\:FFE?R8=G&[XC)27;V=V7(
M5=77GY_RN$8)%BX#Y 5-^.'TIQ.9A?]5KK(%XBCO5&"N_= )_-5@)D.D%9#A
MVBK8LF VW^H28S+&1G9]Z88+IWE^.33J[-AR[/%]@1XF4YC9;( Q.F#26L;I
M;/*5\MIHA:AB)!I@K&<9RS8Q?JL(H[["\?85^[%$RQ:O)?!^H/RWR8*(KO$B
M5C&O/E', @G0@8]*.]7ZR$_YZ8"=HV:/%D<U1@+ +8".'.YFS^/[;W_^2IE8
M]#I8+H/^I7S)S@'5W(Y7)K Z6"5--I)_BN;N?<>A\>0+9$Z(E[6K<745L:$5
MS[,[ "6'>=/\=N]Z/&6Q>[:W<9[^4%LI\%U@/F0(??T&0W1-TFW:^9O+?A=S
MWV0+7(XM*VB%K44_:2[ASRCM?W;Y"7<69T4,X8?_%+=E[>NW>2%Y/,1^?&S[
M [1+UT2DP2ELTZ_GIV0DTJ2/%T*(H^#$;-0%-H&G]Z*Q=BNF#'0[$O)YQVP9
M4PRXN1(O"NGM'/+C/E#L:),@ON01G/;EHSQ5QX+E>)!YWX^CCM?V8T6MB,CW
M_-G-,$P2=@+8!@P]94NDX)ER-MUO?"L61)O[ME?%4_$(J%OMVB2YIJY.W9>Y
M_F9]7'LX< 16XQ6-T@2JCJW%FJ+=>^J-G0@3A=R"8W'#M]=OK\>HO5($D6/'
M5F-C6V7 <6W%#FRA#:YRL.U9S;0'X5)6'%0/,KS;K&/4"A6XL R=4$XBMTK>
MK ;O9E&A^I146DB?*+?9IMJZ<Q%>#>"F%)@&X<2RKT"#&MF,M[T<3D=OL_CE
M]M-U]:W).*^8Q5QSD?^E=IA2W=6T."*OLH\JGFR._= ,PMW"&T^5K<*(C%UC
M5E^<= O-NVX$"M0WPMY<*E[D)<02A7UL)S52Y43N99$'F&IFRJ: 5"?J8&W@
MD[L12[MZR*;[YQL:^[%]L# 01[,_2DOWT..;SN8L%<_= /97M)CU("FAYTLN
MZ"!#L/_4-FC_%*?Z#L'ED9I\RU0#31=_I7G,O Z0NZS&;KWYU&=?#Z5R.WV)
MC02P@UZ%.(VN:[Z<>>]9HUD[.U%M/1S^/]A[[Z@FGZ]?- J*4@0IT@D*B'1!
M>HNH]"\@4J5%0:0)H7>(A=XB7:G2.Y$:D!(ZTJ7WWGM"#20D-[[GWK/>WWO7
M.>N]]YR[[EUWG3_FGV2>F7EF9N_]^>QGS^PSJM%^G3/3L:4BF4(0D1I-SS['
MW,Z>Z[23LY\97R8 -,>M(_ML7FI/#8MY<NY&Q>EPHW[0VQGDR5F@&4RJB]O.
MJF%#BS,1JM 9BJ[^_OXV @ 0/WC]$? KPV4-. %:0X9+(R.RG#U.Z D#?+PW
M3:1;;Q+7V^E/?P7Z3<2X)S!Y_ELB9>7Y*4Q.#Y)LU5Y;1;>+OSNA)-/IJAN*
M :.^$@!M66@;W(-FR-GY%#<6-'V\00 @UE?3L5*.W7(5,2[@5'"563,G;+4@
M"/J3:FC65#?<Z87,QJSW,6[H3-)I,$#!Q2S1 2O3)=DT6*P?D&L&=P#^R*R)
MK P<Q$OP:V16=DE++PTP<1W!$Y!+Z7O096>'=GGHFUX7 @!"8S2>65. 2T5&
M0W=G0%?L[/YY!  I49G%=983 %,WP5>/$*4"T,:G"\G8QJ$_*8^RF[@&R7'K
M5\CTU-5<0-RSK;.E=R>LZ]*X'OAP,6[U"@E::U#^FT84>G7'9+D+>FN_E0"@
MP:J>.<2N8RB6WGO:@*9=A(TW/SXF6P( @WW-?9+WB/20F[IE\8P*=CF9/VD
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M/\[<>3HHY[DDH.\-L^,N\ -_WX4(5"4S:I/#N$UA#M 667"HK&)%-N:]=,V
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MN1CV2D>CFP (.FZ'GG",0E%\H*XB?ST"(,YM1>3R*/["J%/B8/W"W>5GPKK
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MQ9\3 H!J6_+7^T2;.YD%,P7)5#6_2%^ GY)=;" %H?;4%]+4K 3 U%,"8$L
M7)+8&HS9\24 OL^&8_@NH5^CLI7Y6\1^MI*^NPN.M1"MT@'@/DR4N<=-H&T7
M.+\+/?91CE@+NSB]IAS88+0&ZX)>B'!($@ 5$42SJ&&1)&=;L70>!]+W]R$
M'H#"D'OL+@1 =@I2$FE%?2&C<PLZNXF/'0+G-LL3 +' #O#9'2+/'M8"IX(K
M0G%I!4'_=NQ ;;,@'"\$ H\90Y?U3Q0WKLI :_,X!P+ 8I@XYJW==1$,;R@N
M2<@+WR)& &PK-P688DV@/0V827Q3#K&YX<E>,$J'^D+0Y/#JHS4!,!+I^S=6
MRQTYO_$^<&&!/]4$,W\5]SJX.?HM)07'*L+_RX!-M^7S'P3 1W(LR=EKC,];
MU/E202CM# _V?9$#1X&?XIQXG,:G%M !GSY[L]GIPV;)JP:<G"0,O;-Q=1%I
M^!/Q*SI4)]$_3K$^$A0&KP/9P.AGO-N7,K] ]KD7Z+1"1M[.OP]^\>HZ:.$Y
MS)+:5Q^ZP!O0AD#==X0IPP= LSEX;>I7! !< 'S%",Y+O,C!NE4B]F\7 Y0$
M;.SO4#]?_W*E;$?<&?U10+2BZMR_>&731^S.9A#[TA-27_,&\H:B*)\\Y^S]
M'>T7\DKA%K?1%NQ?PL@V:S)QZ6; ,UD1?+(A$^SS]UK@:F%@L2K+<Y9N%GZ5
M'_S%40"RIS><@=74D?DHD58HXZ[A(-K\^1NT$K=C2(SZK7 VH($-&0JN!!>Y
M*I '284W7\/,]-ZQ-B5Q)RL,3K(DJ[^;<E),E/N*33V$;/W% (JZ<X$.!>PH
MH:;!M/5B=4=/3NWV]TO?QKR:Y+HNUCJO,M[S85,NT7L7_(X :&]79(/^ 780
M )C;$ *@>W=5Y&,S VHR1I%OJQF(-N_LS$\LDC,MG1@)FW[/[Y\55W:>23%:
M0HXUQ;-?H8;P@3BB+'R*A:*+CYSQL\GGG@IFJI4;5^N#=*MD^_&H]I7,=D>_
M=CW;P/MV<*'4O4HM!X!Q.:!?6^W;5Y+@0;)_8C#PZU=Q.'6I$*@M\+;F72OV
M]7;C/I8XDM+"ES9C-_D7#1A.NW%RV.5,W!7F"P% \H  6#48\5>XBL8#<5)H
M1UA8-0&PK]F O2=R?=&LI"M&B;6V6%BMITNGZ</69-JJC.ES'I,HSE76'?\R
M;  !T.,)P[?>(P NV1+/"O8VL[8O&5O^9NG(M*%*F=N6G'2[>,0XD**6F*%R
M:JFCM[\-9L O0H_,B9O\IS(2'\H3T(GBQ:ME?H3ND5@1Y8RV'(;>4(8L/3TH
M.9H\:QYV= ?-"'2BICM^MHO_G&< 7VP+WNWA"A3NA[)<:<#[0;.F>.WGQ-D^
M'1PE -0M"Z+Q+*?WJ#&P/U=4&#FY>7\NU(L141_N/WOFWTZY9[,>%N.<,$15
MP1#(X!W9ANJO/6?\0T(:??ZBXE</$T19,.+VR<-\C !QOT%:H&?7?A(ESWNW
MJKPC(<MFG"VZ;G"W_D(!M;G"& E]#PXWTJ.@KK(W7"X]91>^NO7:BEM4+T;I
MMZ$1V*HWCGH^\Q8!\$'G&D[7SX\U,GXYVO6?1Q5C:;?6K&9DFG?=/I(X6NI0
MF,,[H9\4[V &+!^@.;YQ'$A,W\RS?^'U,L;;J/7W&JZ4V6?P"?AFX!]HI783
M2GO\M$$N"^YMVG]K,B+U88W@4UTQU\?JY&QL=&-\G$"YI')&XUTZ9$H2[\J(
MZG8Z SITCQ>]:S ILH$)@)LWG3C/I$;S;W@*/>"G8;GN6[DOEPQR%[B3^A2K
MV$1NP&!\S!62)Z5M5OHH.V+L][_W>*P'\A&760;->.6CCBM92<&:KF3BXC/O
M0B<3,GN;^>#5OY%?0. _F+ECS,^3JQ>\@)1S*#N^"WJWD?D'QL&@>O0=6E]V
M#FBK_T?(IM[!>BI*?HZW+Y:7H\%TI)$=OQL@<&ZZ#"<V2$[4Z/R3!,"+/.8%
M&R.A,[W\>.USY7?UCH+=,UTY5895( %Y'RR-OR8*%%ZM<%]\6N)TG)P$FC,S
MIP.QJV\+O, ADYGG NK+*58+6MFMEH!1.:B%>A\;/^^S(D_NBO>B^Y8MU-^5
MAGK]C/;S DVAK1K(M:4RZ!X%44ZS>BPL=-(M13'?A@L32P\W?'UJM4);EO-,
MT@\](%Q]\HY844QW:S,=2KN)C<0BM-/$RG[B;.:%V)!$-07;G7]^\+*9<?[^
M_5MQ6B<LLPH8%<@QN_4D%;H_Y6$N)&%Y^8]8O]#]#S3OY6XNPK6I)2[9ET 7
M-,W4T&F1!J*N9S$W)EJ0N  _ N#=(/45(\^S(9>[=N+IJ<B,,I%?7<._G8\C
M[6K<R]:S(8<@"44Y?ZJ)0(!W&_4=A^0DHTG7&9ZIN,YO^1/O7RI:DX'X]BW<
MP"8$0.L_H+5FN\4S4J*,J_2!>8PFUD\+PMOTRO0\:Q15'^=0*O+G\?L]](7_
MJY^V""L)[5$A !#JT+P (S!O.K3)/_:460J+& AF2%[1H;/#TX[DCM7(1-V+
MK2R1S7)2;UFBG"3:8BJ2)=@E>0_1_E02L;#$VFC[1'%]46O-&LPP_T$T;Y],
M+FYZ:\PHHQU]W'(LK5<J[K-E,?$2=,*R)PZEM;/@A 5^+YP%/]I=TV""%;+!
MNA+_4;#7./YB413#L*WO&31Z\CZ17M>8]=^0N+LBX\2>^S<GPP,2+O6HQR^G
M@?,;C9DKW1TRS6RVM0C4-,]V"I0[-\8(R">SY&<$0A6L&@QU0&B&\@?R.M_%
MSHKC+36,XYB-F+BNX"-U3V)80VFLX]M7XL]>U<Q9]UY-9&X$APQ8?>SL5,+B
M[7?U?<?Z*__9BZR@H&7\XVNX&>R1RLY3(.6<;$/B$$2%<=/=;J:O&SM!-*E;
M*3//1(]73&X;)QX;?UMG,P@A]E:Z5E3#$B%4I%S@#I]T]#(1/U7PA3 DC15$
MNB DYIRJH2+?)=8J!KS$8U777PSVQQ( [G0MA;;9S<V)$BII=MWOXB:-"C+U
M^A+24N-WB&3$7DU7U\RLTX9B0+Z(\I'8B%JK@6H1;YX/O@R-;4TQ;V^3N"UB
MKGV[)CC=;:\;<*7TH+9 I<R1KQ/YG"6Q:!C/'7>J<"_B^(IDM2#(_SGT1H)4
M9:N'7-B*^I+U7,<2951,<XUFYR*CL/P3-+4.:L9N6(=A.(@U)"'$?/]+EYQA
M'YGY4&S7X.2D%J6%V.=0D,3X?OZOC%034>_/E^PRI:\^F/X4B*)<.F4NW1'H
MZ%QZ_#W(BLW\T9BNO>9W7CNA%*3!W$F188DR0D/+_/4LXDT)2\#RZ&%6O<$=
MJS>S.L_UME+D=HW:YKF-FU]U?K,!^.EY1 N=^)W7>+TF__A<Q%E%V>>TB@W!
M&%D4:Y#B87USG2J0[*#)<[?F<&Q!7)1^6Y69P;;@'>Y<R#NR@\PBY=[1"P&6
MKS==M0-V'S0.M2&);Z6,YB#::.H"54K#@<>,%/<%9^^0,1U:?+=((GN8]?6M
MW3K&Q#]AJ6G<;VO6KW:A#%$BPQ/C$[4>EE"?ZMM4HZ3,L F\URQ@YB^1_(^:
M.^:P>8HM4^Q9JF?B"=E$DZRX35A*@99Y54:-[<LO1;K37,-;A1\VI0R__J,R
M^D!@=91+0L+RP[_&L9LEPCM!=\#>WS"!%)/)^K35#WD^H>O=ZIRZI%LW%4K4
M1M,UCP2F!@WN4_#)F>W:9D?T__E?CNC_SY7_.8[H&V*V5G4A:M;*27ST.5U+
M#-9<I#2^G_E.7I(E8-K/H",213R_1A[**H]:-WYM^,%+]K')B)==C,P:+C31
M3(9!J(K1_]1Z1M]]^&&=*FWU8\$=%_SA-EA?UV*><I5!R171WT@ ]!_M6E?S
M-\P,_<:LXAD(@ A9V!W[#O??%0D$P%XUIIG=.]_.4'1Y7HLYANR[[1:(]NGU
MYH[L!B1BA\B%9$ 5VP2 G*+]'Z0-DG:'#MK1,;M-4_*Q<XVVGKTWB)O-[R?<
M# 5IW2=I/5)UK9#,*GQXJ_Y7Z\R<:^2P#QN'VFGY1L2Q*',^+VV]M8!PGPZ&
M-X#M!KGPMOD%4:M;J&_]VQPP=&-V5V*BE]1P#<D.34J?^&RNW0AEOC&$^M*M
MX+/$QG(D (OFD$);KRK_F/&Y=AO*WS6Y3^OXN^NH]9?O1]G)HM ^%Z:PXSS;
M<U^NS[62T8R]\XOO EB5_7=FH)W33XH8QT)9:RG")A$X]/SAJ*,A)!),T\CK
M7%;2ME=)':>@T=VK=T >S%M0Y@%]I^W[JH19L><;U+8+Q,:=G'62SK"9<0,S
MFH-I>U%=!YR6C?^I_]GF!@_W$JD_948:#;7\^R9*#X8UPRP]:F&-BBH%%H^W
M)O)C\W]T+2A0F2NAX?Y:JP[FH%=CR@.YL;]-0 _$U_BX$E_Z1IP7SS(&9=PI
MJ"H<]6P.,?9_(?IX\_-H/U'(5V0_1Q#WC8SWJ!G*=RMS"@&UEE*$IF(3XCT7
M12 +>E%."@H.!52A2?S%.63OL9=F;36V?_)W--_YIC,,^$N/'TH<DFY[708U
M>ZS]'N!.O;YV^$8:<*V%O>0K9GO5T:$U/"N=XW@O9&V0YVI$<;_98K&Q@&G.
MUW<BX6=\2=AEM<E&@X4)M/VN_ N[X;-]NX+R@F+=UQQWD9GZJ/QH'W>\]4!G
MFE@OAL1-[+HV&4G\3,UNG(MS?.26NXK9\"OS9Q&/BAX]RFY\LL+8 ;^[!:6W
M'MZK ?)JTYH^"OT=_9-#NL]5/T.3XVJWBB(X0\R)?D9+8/?*)VTJZH7S\*N4
M^=GG<UO9$:NR_U=O$J"F1R/:V:%&:.NK^;RZC 6OA<K&7M&6I;7-F'10HN]!
M:)YJUM:9K[\J'X2VNX%I[NEZQ8$KE*5)V=<XK:V6/^'1&$)0$C%?M/[6=89)
M=EQ@%"E^CBP[4;3&?/&<;):<>&<5AZ "+F4^NKI7OS.%3L9%SRQ>077^1OQ6
M[)[B^'7;1S4K<; NEU>N'?KQ.XL;#']P"G5^4%;;(>9VUF"=UF:]2SJS4T_P
MK3V3\VY#03I?T])XT$_RIZ#S42'KF+@0VM(\A  NVA73Z_U+-P;7=\RXLA#U
M"Q0MG/(X6Z[3]$>._#UNR<#24BC+(@96R VEPG%9&M%J4NH%7'_&>+IX:93G
M'=]RJ1/)6YNJ^RE#38R$*U&P */.KN)#I$DIQ[ 8U.QL7Y8J+;^L\H,W'E.2
MCD"=)C#P4_=S=J/;2@4#%(MKZ;#J?K'+;^3&_<\<DCP1@QJ;B;K*#.?=FR'(
M(";>2'%#7H!%B[H"TKMF'\R(DY08HFB:<T@M SWA.X5ANM=(H"T!NZT?7C@&
M.#WLB>PWQVK?F8LBPDO>,,&UL6HJC9'[OTPC[2R?:HN]OL6&ET S[ZN&=KW=
M[9Q9W$#V8QL_QW6^J1#G+D]OQLH%"CR/P+ &G,%NSYE6IZ8L;'_\YZC80 TW
M>#C1=*\1MJ35U-G457/D5*-HPIRP_D]DP_HK:7G1-3_?R7*CWLV[4:*G/IY.
M!(!O_>DT][I\<[+8N$# 0,X:<,;M3 3"L#"/@;>(*M\K><(,<7_UPLZYNS26
MKJU>/E&:+.Z6O%2W"3#<WPH%Z:1M3O<J\@:;(N1X@Q.S ^]XJK-2/CZL^<0Q
MCB7[FV2$!6.Z(O2C%BW\Q:KT09&^WS>EN,?:VCUD_9DH6H'UXF7]3''V[Z?Z
M:&V!)/LMC!&1X7_^C'LVZF@5^G+47<'\ZYLY==)8#?RF53 N09^#^PK9S+5[
M#W(SW2'']I]Y8<>RE-?)VQM/>#=J3CRKL&0X@7%ARJ2)F?*OR./>00P1;Z^]
MW#PMJ@9.@9>U8<+8=-#+B8![^(L68)#I$\R$11\#0A1>TP[I];]F\W95)#KP
ML0"YO84 FFJ:-?U[7D CX'5X&^=O9FY^F!+XQV(E<F\L\,:V5$I(F7MRQL-Q
M+OWTMS(A,X]=N?3&PZ4%YZ4!=\06NI>A9%N!MT>#0S[EOK8]\R%MM[[>P;3*
MFDJR(<VNK?7!\,2Y-W4CON%Q6;@'HZ!![(4Z]B6TI\5[$8\<PG^NN428284I
MDGE3= 8^Y. <QPD4V+-TZ:;LV!Z]XP>\VDV'?P1<?%JZ]L?(S40W>[M7J^EW
MF8%^U"O3&X%J.!LB53I>A6"9X*"3O-W37W4*JDLZ[5>FG:H=R1ETHTX2^0G:
MDSJ,"U_=/<WV>>778G3$*^C-W\59M4_HFSJRXN5(,< .3LK,O5W8%?WX10V6
M"=K3Z_WW8L^3&-\K)<['G%$1:XTR*%BK!<T$J\&PO$#NMDGD3:!=3?4+#[+"
M5V2]U+5\X]D[VF(Z;U\5%[7I.KC%7I42U^"_[]Z[*K&3]#U(=2O8D:RPF)I7
ML4Q9<+\3=Y^)7VE'(!4EU08B\Y=(V8%08@*'U%+6G_4)\FM6?DEO^!8?=?RI
MDV_8M80E><JY-$?C9>UF9N $\%HN9GI)+553GP (2E6SR6B1<Z0KN;;Q3'W)
M:2:7#J=Q\RGW9 <!< -J*W(//S SD94O\<7<;DA2I%KHN;L06TFKM72_ZYL;
M,J0T-Y5:N$X?U$'"P"0X*K3VB^0./%O-F-/+MTX)U4^6W&^J]5:0_$GSTY_X
ML2YBIS6=J/$KRH=?(&>=F@':JGRJ.?]031ZT?$N\2:GKQOS^=KWQD6Q8VT.=
M+%XV5RK_@A6_="^S1L4'DX'3+I)P[GBJ9]NW& 7OL)7<_7RM9?73:)0E4M,?
MA.7 /43MKWGI8@Q$"J(1(F?!_54%?[H&*D*QO0X-Z- VV"UO?+M.)9HLM-1#
MP!P4J;8&@WR]!2AF:#6X;[3.YI_SQY"6R#>;+EA5[VJDGC]P6_P_W(MBH%UP
MQID]=+GDC1G[(BJEL!N*P</'!N1T:D;$L0ZLK-YE@OLYQF\1P==S;7/(B\D
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MM'L_?QE\);!5?.+&<MP^\-:VV;A3Z%=&(%B%*2S@?>5&0NIB5C<1>9(+Y]E
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MY,F@42DR7:'M]!J1B)F\+1+_\ODE3Y9?!32)*%"\F [VS+\!S6$#<YB&42I
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MDOQ]43'YD>RR]CRQAP;,:P=:*ZBM&WA%;3P\XG#^A0<MB;OW2^E4WG<WCZ[
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MKQSN\$J&R%8L.;*); SH,WQZ)6R.513"36RY:5EEB;#KCH7$Z*ONY$QA!J@
M'M!2#0EQ.@TYY9W8#_=2NTW2R_-O[+H>>+ \L.^7^NUNU(5(067.BI^W#4TV
M;.H8\!T3K[,F7Z[U/,VZF12FV. $VN(X \+!54K+38I/+EZ6H@./HVQF'_.
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M>\* QW:)F,SJ[P^&KO6$Q<74=_@T/3T)4SN>6>,I+U<W>^9S3VDM4CF7>\K
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M4R'WZ(S $4O!.G8(0E6[8HLD/OI[)D=V@,N].M9R/^U&"YG"[0 Z/L*[WJ[
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M>S@:.X9><+LOX!G Q7E/539Z[S-+3$9YJ(R5?ZYVJL+::G>$HH!79D'$:IT
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MFQ;)B7?H>M27*:L\*D"FM9!M^>'.'IQSL>PE?)K_8A6^.P6[<]TEAFAKP'.
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MN H!)V2?_?L1\FRRL!%"TD5837M>HY6+_SZ$"-U+</I]"K\"MU -YI&?G2/
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M;I_XF9+P/%@%DG'>F/JMRJ;HOG@=/T>XJWK !KG])4;RMN%<RFU9>;;I0Y*
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M__&8.+KP*K_C/CG6]K/'5<O\W&JM*.!P>V<, RJ K;)[.5-]FV_.TR=FY1*
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MRB;V">:2E^=MIO<A<>*7"5355M@/Z+/MF#/=*CR-PW+8<9&H_0'^2\]>&A<
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M7X[N'+ 6$E),IZ##PX2Z]N6(K^3\,]=.)K*?1F/*'E:_KC$ZYCXZMJ_=Z %
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MZKGS;+']6WW CD5OGSTQ@]\C!)Y8./%1#_OR:*DH>'H7:@JP/N[>,7UV6W!
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MQJ*(T1>AI$ 0^C\P$N=!N5F!^/80:T9ZE0."35WPNP SLGHLA-R\2 &&:)U
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M[8O^9C:=$7SZ6 BE1TI&+&1_"6H)SXD)%IMI+2F?8ZY57YQ)N/_0_9?<8*"
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M%JM!!?TSK+&5F375I2^G]'L\LD]Q(VLP&?0[D".56!=RBZ\DZ6+=<18L$20
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M3#KKL)<A]TK?N0\HLRU>*XT?)]Q<\@\G!BZ\48'E;LHW6/.F<&3.RX1I)6O
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MX][3E^1,4Y,K6RMV6KIIEL0&$@J]<ODB,RGX-_J8S?<X'I8"JH)#8C[U;0J
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M:9//#Q-$YA3E&><!V*VS#B>SE!X,_JFS8])19\>.WXL2RB3ZMK<PQ3_S^R0
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MM(Z89,[RC@)\E?N/>RX^SZC[T%/@D5J!!E1A>8/VR?9HI;EV*<>80U!L5?>
MQ;N]L-ZX0U#X:)VNP9KF5G,J:U]!UFI9O/(GHY?2A>-F=ZNMRLM#5;F8;J<\
M8LHT_1LWU%!QM_*>&9#WG0]3;9K8RYK<]57A.SE<_AE[$.0=!OAZTIU3E;/
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MU7N2PN.4"6GYEN+W(NJJ2GSD9?F])YH>++I"G>:%NKKCO+>(2GY=%'9R!E,
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MK"WYZ5_4ST^#&FM@>!7<<OO<O_**W?^2__M$WY1-N8DAV(/EF/J?KE\V7FU
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M!YSY1+KA!41:'G1*JHP_GW /L+VQ[K4T.CMZSFO8R&HF^=_=\OKX!:9:S(6
M&Z;Z"X-=,TV/O]J2K=JSECHSKO[A_NCYXF; 7ZZU79U+3$?>XS6>"JQWF\?V
MY8J>OR1?<EA9V<"U&W(8Y7^<1IZX>2KEU0E()D((LU"#]48NFI2#<(-O0'75
M]>)?-D5_SMC&Q?LV2#V2YR?*?T^Z8_'*J@;19M-Z<1XJ1-2KKQE5Y&PB%5K4
M#N<[XWXVR53ULGYZ"GBXM1R$_N5#NCBXE?8%/@X4JGE$\/NI%$ZYX5075%N[
M6VT:))]0*VQ2S%$2V-M9//@7K_PAE-N"FHM9*+ !;IN2KY"JVK0&(UWPJ/@+
M]959PUXKFI89L1F7_C)Y62:$A;WX'G;BL.J-!6(A%K3K#V<L5\4MQB8Q>;Z)
M9DSV.T3;#0H['H*K(*'P6$W\?D0\'KMAPS$ZH'V_LOYVNE!252F+M%^Z5'AR
MG;"W/NUT+AT@J[FX0^97!.W5_@K5_<2X2!QM8IY;]S3E'GXG @;!*^F1T$4F
M>1<+!6BU>*5IQ^"5^-L1V_G>]^3OGQ9/K-FKV_(D!-TBX<@Z4)\N!S%\1%WH
M7DS6XIP2][3P#\&<1[_>&E;P!*:POXB;S(<_0[1Y@I;7M2_3 <^\T+0,B-4X
M@\V0R'D<A,)+^]>M?*6E.\KYJ\?97([(].LN3N8Z[,S !$  H@9-X3_XCJ@"
M1_^%7<AW]X=N=ELVVT]C?RNTE*?R?$SY68/,[+TA<%^+MS#V,%N/\3-PGG*E
MYR9:!1[W%:@^C8C\NJZB5*3 PV%8*+(O@ _ZCHR<I .J"[?9<$@V!P_5$'3G
MT5>??5:OT><7\NLS9*^'Q$ES[.MX$E]WSN/O,J+1JCW>D,B,>ELXK,2KD+29
M;O5/;!SF^./95N]RCI&S= Y@"2"9^9DV!>&J04[GTH0^9&0$2IXQXDAEC_,G
MOL_C"Y;42S >R'P1SLHJM2H^V9&CQ;C'!4/)S_(.'"2[T<?%NO9S3<5;R3W/
MGL:<AI!)X_N)2#(K-+"'J(DBAC03+E#G,K43;FSZWDP&KX24V97*.U6&GBE9
MDI76CB<L'X&V-LD\\(%U:MSB3W![8UWT4\A>IK9UL>%K*)ALN;"%Q)Q4)@VQ
MIL$T&</.Z@5\U?-:&HRD YZ.Y#TW+G+37+$^=[ K\Z#YU>+-$.1=\N!BU+;(
M)R@W\<6XKO*Z,I)_3?#([E5^7N!H,,33^$QT]VZABTG\'V,':&\7_ JB34^>
MQH)H'QL)4'JCB84U7MB/#)!34'"V??TZ/SGR@1WGYR1T?S.L84G]2.[X%6T\
M+96033RIRT[P"MN8DPC1-QM9J4HQ?""C()5]XEVDN:BYGOEIJ;-N3+NIQ*\D
M$J9ZLD?G]:*HFQ=N?%RZ-M[]9P Q%9AVRM?UQU3FKQ_4X?BE++(GT>*XV\HT
M!82'=$ B,B"<%QL2N[S4K-6C][^Q,;>+W+XX_^WY]OR,R Y$EC8_SP93P(.(
MA037\&:A@H_2';57IW5:LNU,=#LNY)F#!J55Q:N4EP_VT"/HJ1[B:9+0(O@-
MPSFUGMN LY%=XRY^JQEW:DE]U#PU*17%]8PO&/J;=:#.IP;P\/^Z!4T OP5U
MLI 8 Y]J:R2DG._3B'!E6%#WTKGE1.M,?K+@&9 HX"_"4XET.:AC<#K*+KN=
M.&$EJ4G(DQ)+4&P/B&2_%Q^1XR?FF1Q>81'-^L')=3G_>&^22K>;LG$NB5ZJ
MM"*/RAAE&AV0@:0$MHJ1+N /'E(+0&Y@3I(#V3QSGUO XW!,_;(8;.9Q=1V?
M$W5U2L;[51:U@"!$X3T@ADSH2IK@LD&LG!?_;<T]$J4(F=?L^6U_S\S,]OP0
MG_:T+@7 ?T)V*^JX  R>>_MIL6;4Y\I&/#+!\N)[M[J1LF*_6)7NN2>LF=5^
MCTIJ56Y*\=Y0FC$AEB")-TE@QR5-_"BT>$<=6OU^RW+/!C#(/[*C$NSS_6QR
M:'.*EM4",BI@\"SM%T)<86=;D;,PF@(LKU1M]^-(NFM^^\ 2VZ^W(1P^@;$!
M+50+*<_!^^;XZB,ZDP86R==Y>FX5=.^%'YHQ [D9<.NBS>J+3R%W-JZ^_5H]
M+Y#_SWJ:9-EC9EO8H">JF?-/>,A T@Y]Q?A*8&1;3QH#)?!VIA8!D5KH=D_-
MD>EOO(,V 3G*FPV?KZS.L.^CLQ +.<"*N8]D.]C]\2<$KOP+R C8C5-6-F\%
MH[RZII/?&_)J7(T-5';9   X/@YL ?&/?*:B<'3 UA(.<QK:@1N/Z(XJA,SI
MIH44] 4I_("[ICLE/G*W_L#+>_-[!2M[Z%6_$T=U>*6EJ B0&S+RR">A62+H
MPJ_4X ;1ZZ-.$Z-*W!RETV,YG6''QSMUJ' '1!L7S-#7%[<3]XI]X%QU=>.H
MSY?HU J'1_7&PER=T=*#7X?7(44O_Z\FT:U !/;'K?B#4)AIR7IR3(V<A,K*
MRH1*4_C=9%6I'M@W<2L] P "] J\128_H,V8&R^)5)<CNB:JE*$UIH'$&[:.
M'PC>%U_:9_9VFE2_7&SVV 5&8ZJXNTRR93,L\+*):M?#[BJL*IOR2%T]3,(-
MOPMON](_VX9>SS$6%)Z>#3N?\./'"X"$L3J% )_'B*IAD(@:<!S%$$>T3>"2
MC;M741^/Z.F_&:9Z:9\+-PT^N#O$NC6Y54@VE>U"3PL9D<H7ZV+[7TOH;I@&
M&AGVEKO9F5QZ,.K7L^(EH;E4 [\.>T3Z2?"DG>$A+,X85+X>:"MQ4-,"1N ^
ME.?'2\NH<FSW?Y+?K=/F^P[@'E(PQ,T5DAF>NPVX/PM\G&BBX[UJX+[S*<D+
MZM3:I/?GZE9_ZOFK^RRM#@R[O;KVP@-1<Z<A1/OIO"F^9FQ(\T#&,]OM'QT
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M2Q)7'S,<1!1%P*<'**($EX*RXI =UVL8,FP3^W+RX10I0(9OWNC"E,4<*'O
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M_8+UG&=+/Q-/KEA;C9O4WPQY]HK$1,2-0[H@M89=[DP^"))1885Y,!U@W@X
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M7.K4JJ&\JNF4"O,J/\\ED#W4''^2?(<V=J*'L4>EZ !/;B%H:;=H73M8T.-
MZV^VY'ML8H(_0CG=\R'?%YUZE[Y+#PX X($_2=>T7R,H_$O$W^,@%R2[N\-9
M_+U-KR7,V<Y)();9XE>V2WEUK\ ;YMGP*RFG3XCOLT.4$&V"<*X-&W072 !F
MDL,F/;3W\7IU7'#FBRK[>[U;_ ?3HK".NJR<&MP\_M$@/W@1/./8<[:WZ]/(
MEXK1[;$/VP8U,5.(^3X9!B++MD&F7)=ZME&.FHFMTV='=RZ^:)4B1'[6\+'C
M:\EM-Y8.G1:KJ).*7Q8/*3TNKT.-@JO0^C'5+!6(Q8:]0VT)_R\_O4?=M3+3
MYQ:7!]B0!_(\!\Q6-S)96.X$=T$14:"%;UA4!X25Y-FN>X9DFV_CIB6(\BGL
MHN8B9%+Z*[I+(*=+^"L8%B,D*Y-U=$!D8%!8%M23F$=X@G>HPAW@?>*=$_Y4
M1GA'_"S?_<*@]BMEE<P<,Z>ESQ@YCH1JZ]/8(] >-O!4/ )<TUI?5]F8;9GU
M&IIW):7YV8\[/UC-OQCV%"Q!A&$G&-BL0AO)848(0>4?_\S-7TZ_@ X GZ-T
M6K@<@I]?6VEM8XR\BB@E7=Z?P!#;F_V)%X[S(&OSE8BVAF:>(J@DN5.UM5CW
MDY(">D1@YOR=IL!WV@E1'PX^<=^C)F$6/J D:-RT$<G3!&0,\%[-4'5V\<7F
MUR&V/_U%(@VP9[F"!-E)DYNFL%2R&&-_W-H#SS!U-ZY&EFF?0^!*RU7!M.%_
MWMXC+].TN^+1_:5A[.BOP>CRHO^I$T.G8Q;RYODHGG@4$3)6 P',V;LW;D_D
MNQ>&5';KC';PE^D+_^*:>"; Q'6'=O6%YX;-):;#@WKJ&X3[/-!-R.':&(6]
M?$-!YLZ*X?C.HM:[C1,RA[P#JX)T@-/7I2G1?W3 =!T11>C9PBQM2OATO,K'
MKA>_2"AV,U5EMR6].5Q*UF+IO@GS-O?3D3L2)'41;&^1I!G25E*3(/$]_.[P
MM@VN^Z8[ZLOMS(V_?RP,2\_0?&E $M">^D57;3U'8D2A;E/WTKC1S!G>I,-$
M!^/36\G%KKJQ!:&@5\?M!K"O9HA^U.Q][FC1%[$'YJV/O=0NK8@DVF:.53_O
M:"QA34K$*7?[0^+FS]#8*1[_I2W'G8D=KYK+VOHEME*H!Q,4/6B?UW.)Z-N]
MEC,?-*:&7YP4!S"'=#"\<4E#7 ?F#(V;Y#"=Z=4Z$R#C!K:H"[LTAOJ4O?]U
MB7:Z^'.;*UF#5&?)\R;H]6+FY^ ;U;XV,_S <&/9U9O ;(VCGFYNDNQJ3^;>
MVH[+D+9AWH#8[^FNZRD=YF]"G;ERV>7OMW[BH0TH :M0P@@W+Q-S:H0Z.HYV
M(K!R7)&B+EG\;.94N=ON<^XD/>8OOZEZ(O??6JWN4 0'#.IJ2(0%>W-UB_IF
M_&JR(JN,H?]E<\0.#A@1TG?<NV=LQIQA=Y*E*0[3^^Q^X!=*?T]33S.\,=QB
M'561L6U(OFN-2=C15D9[T@$>#^5?1<4$7,/EX,#2 [:9%OW)0V^JXY],(F$@
MTD<"']&9A%18C=K7,6F'7QCYFC5'_!DGY9J Q]O=A@;T)UE$^3AX'CTD"$57
MSY]>TTJL*YOK*G37"FC.L KRKQV+E#'_L14".#7YSY=0VJT)J@9O"RV6(_1&
M9;.6NFSV$@K6"8:9'XP5IZ2Q6@UB)WH(?#>!59#J-&0<YCEZBN77#FX[D0[@
M@7[I,1EG21-8U&\Z2#96.VDM8K5\KI4@,KWA^0](DT"1']$!PSKU=$![W'TZ
M8+F$6D]BQO^AG:7PX37#5I)=&H;V7GM>7@8W_I-Y8M0QU;HH5T! QJD-GB"!
MK0D7:UXHJ"6<_V6[V3!#.I_ 7G%PC35Q[P1E"O:4]'")#@B%7Z4#WMKV!*:X
M91U,CZR733Z(7"OSOC_RDR.QY/Y(8.J')TNG^([09)&!1:5CX+@,\R\S]0_R
M#*(F+.KHWVUP%_L1(\AV2XNO?]%H-E*W9?.?YJ-6 FB[F/Q(NT2,'-0CNM'#
M^Z$1>^N'@-Z^T=,'=,")1,S+UNM051.2/YF?8H"OC6&=KDX0^R[Z,:(LI--W
M???+ZEB2"MC/^!/W]YTPQ!F*)UD?9EB)=WV[2KZ/@:6:"C<W*Y_CR35:;MB)
M4-_#4+0\B:ET0(Z6)HV;E63UEL:(.=7,Z*T>PLP=TIO7N3_1MH_;_-D?S_PZ
M%_COJ5L;AYZXX.!=JL P0S+5Y@B,J\>)7=<5]B 2?H/%%:Z.G_=[\_[D#*SB
M@^NUWI^ D#:R.I3;C@3!LW]WX"/(K/M^73NZ+1B$%"^PX+VR4.1X$(9O(*)-
M_C^\.$\8Q"XM+C-,$GZ"E-UIR1MLTW2G5NOU@4E,8I?OWU &5WZ7(Y 7=CIT
MK)8*NTSYV@,??FL>_PI&!4NI".<"FJLT01KC'+^34]_D>.Z!:6?*?>41)RCJ
MO.%_C!>-XE"^7OYOCE#]K0RA&&8SW1% OKTQTFN8Z8,;R#P/W!:+>PG*!?YJ
M79)'6 QX/),F>)+<D)G=-#I Y(S*C/Y?)59:)Y"E^0+NO5H4WCZRYOPGZQK.
M![#-S&SQ!O\#_[7LFUMRB<.8!90N!Q[2P\U)8FQ3F[2)*.?\WV*9+T7X?QM*
M;S]IM2N;R1612IHY\HT]*H@]M$CL_.HSIQ.TV?!76T'(Q]<-;LG861:@Y87F
M&W3 LQ8,+6UV<A*(OP\Y5 =Q(29G=VCO=&!(QA0Q3"$U#+]#C272 4=601 [
M1-MUQ/(8Y3H=  G"')GM[T$'#_F&]R'%RSB&K3Q].$R+^H5BT*<7)M)FLIN3
MYSF#Y&>93%K'U(V\%B?/O4;4M._>Y3=]\UP75GM?'$@LW5+"HHC1X&D4[F=A
MK.TMG[,M$_F26>EAFUO?57ODLP>VX(!H0N(B1H+&20?T/<-K4J/*$'N?Y?:B
M:&?RZ8"+_QCCDD45Z("]E+_5/4_<#$5NI3ALU8UCQ@8Y8TOEU:WG+99C194H
M D)M_RB:39,!",[?CTDQWMB)R8Z)C"^X0K/8.?^[CGJBSK6[><OB+&T].>X(
MO&6"0<#Y &"4(+JP N<58&EM]NK/EW.M[VWPR"D4T;&2FM<<4M15#C%VQVWS
M7OJK]+3N6LYRT]GD4L<S7!._9U]<O7Y=,I,Q?Z>HJ101O*8^?C"FF<=5(]4Y
M^"4V8/9MALK];**0L4">RQ,CPU-.R*;0ZX.&XRJ-4%3)M3K93><_F,/,$$<Q
M+=W9NWVO/."Q%&D2@Z<2<E@J")!(18<ET\9^E7O9%\(,R 2CEDQP@5[O<8'3
M1(0G$-N$.PB%:V[,B4["6=UTM<;5\NIX-T5SOU<:29Y*>^1=EY3V0$J\S@Q:
M@L$;>_D%5T-BM&[TKF#G%KO_7NL[U#>JDD[2,8H!G5N':"#:]##+?YN#][XQ
M1"?[*US;PF5#E>*H-&QLX_C7V?+?ZYW/"N7%KY3/T &ZM*A-PW:(D#7I (>,
M:#8H7.\PJABK7E-\.CKIK9"<Q".,!;3O"3,5ZD&4*=!CMB&!<1G12MH@G*D(
MQ;78NB%V\=_V>?9KRZS,%NU51GJ]UP"OE$MM5COE,)$(O.E'6>O1?#=U(7Q7
M6D)ST8O>T:VWWW1B2ZN8-IAAW.3SE+,U#$,@5)G@)_)EDMTJ#"[0/CWUJE13
M?K-[>;MA6D@GG/>Z0 Z[4L? S#-EX"DQRSTEOKA2H.N=C"X99-%QDPIFIP\;
MR84QNL#N1G\-22]%2J:CY&>)%ZLS?E3/S7D@?-2!E12$#S(AI17;VYO@J#;7
M;,&)<YR30@KR+K<3S)*8O"QE?0%>VI/9E-N,GQ=  1*04:;I";E].,Z[ZIVB
MZ1^U4WBVUJ63I?;7YK?/K.M*P7MU)4DQ>&D&^G$$*+B:A?5TN$POCBE8"%K;
M7,JZ*'-5BH6KIY5+:RGG[LC E7[>0B$!1' P7-;@VI)[\>4:!;5]"O=[F 'C
MUEU:/'OL67%_F@,_X9S& @1=GVY8G&4^<J)Z%I!L&7\W'Z[YZ<T)ZI'D1W!C
M?[2Q%!?:94<OR2RIW.DOXP]RED=,?VT?_ ZL.&B;"1I19T>=GH?<U+#3+8<V
M1O0]]Z]W#M.L+%D:LEJ=W]9QQ!_U+ F6P84=](-P8F]CH8+SP8DB(JR9HCLG
MO@GSZF@^>8GVY(SX[BA6*,H;6YLP3QG4J'EN*7&YOP1N ZQ_ 9884_[)$:>F
M<NEEB@9'69[364,S S@'C(&E*5T+/F3NQW3 ^BVK+<.MX%+3<O@/")>WJTQO
MH[GM\@=*A6 ,XK8 :0?O0S,1>H/9TG&D _+9K)VJJ:F=H]N%LS\<G!41CKH,
M<<H]UZC_09PCRT9N$9D'0ME[[*Z:$=3WYZJ=4W9?]UUHN4[%!?HY+1_T@1+@
M/V$W2#?P0HO<':;7FY6/\S&;<+$L0(6=0KRYZ>C'79X5^=S616')FEW@=C+Y
M)#01*.@QITGR*?SH:3QVX7733ZXQ1!ZV_W=##.C/%U7>0/2/AN^G_'1U\)!.
ML!A,D""3X2 QH0YBWQAJ[5M,R-). _D]?O\T%-2^@/2@BE9+9P^]Q8\'VZS3
MX!\'D86RH:67)B)&:=4@)QH;;8!VFHJJ&>3UT.6./1KSS#%*'UE9_14[ZZAH
M\:SW]PE%_X;W>"VKE<EM--G*EC;<F)Z</P/U-N55XIR=ZZ[C=6!+&/(7#:^^
MTP0:=Q7Q:=D>G*8#*JRV"Q!N>KXX!+_MS!1TI)];YT+=X=.Q\ZP<_85_&Y>]
MS5[H]7X_Q9V-6,B#G*!PXR,AISUR>(=9DH/1]I"!(I7?/\_W=_0]C0@Z!U !
MG0&L3EFE9AB,_!!7CFG\".RC17V.\RC@R^8:B;)@L+SJ6VHJR,N(#G !GME\
MI4K2:3:DYK^J>^8\%E&7\9:MSN?=X?J'Y0!TH^Y%.-82PP@<KA 6RJ.X]I0-
M_<Y4@U.O'D).-T>Z_0G\T6KK#>@TG!7I78<H';?S9%P2$@44;V9>##'I;F3R
M%$JWR9II.S]OIU>IREMQ7"8T)5A]'8,W1Y]Q=V"F9FISXJA</Y^K)=RP#YN;
MF+9^?R?.TP\PP&M\(),Z5]-MR!K=TXV47O$[:%+W@>RJ=@SPF)S9\%>T=3\X
MDFPC2],FW<GFB/9[4>T_<<5[>MZ/0S#;)E<S?G1SIV<;[2*%=3R#B&74?&GJ
M>PI?@>=/')$@GG'0WJ<0,3\=1MO^71&"I/YVE#B:[&>X7242C?29#K#;FU\-
ML!^D"/C3C';>@K9TZ(#:W4G40]9;UTLZ+I$S;#RQM$([7P$'UAG-'42;CB?1
MB%HV2LRO(JBA\/&:D85#<[/V\%EB_OM[,FVL _=X_DA>?97H:4C,HI8WRY%5
MUR=BBO44:Q;EEE6LUR:^\F2>Z,F43H)5]TJ)\QI=8SV%9 2HA10089M@0J4J
M'=I/]B-J-1/1V@BR,>GOW[\^&C<D[MI?F3:<-?*:ZOP<$F/IX]=Y\+7(^:7'
MBL6E?+<[O^8O?'Y;47,N/,*$/$(':(2HYC$6QKH&M!W]JQ"_.TJ^G,U5FQ47
MO-;2*Y_]&'F/XRCV4)^80WJ3!WM$VEY$"ZRIF%Q,+3'A&!)94J[OY"F5N[RF
M?UFB1YSW.GH(=%Q\\#XHT@\F,>K5_+!P=A9:9U9I_+?&#2V3L.T2P%DIP_D'
MIUJW\K!)1.<%2).F!E.M)UTGF'3".1N:D6:IQ@V[!F,>C^Y&Z.<^V;M@[7>]
MK;=OTZ';5OY4Z>!&3/$%GXMH#&3H'R&.O]APIJF0!"QH5:06(K?:R$HPT?&H
MB&6"$C$GJA ;JL1<]B*M,J'59>I0QI4)V![\M9!H0JTH WFPJ9,OX@_QO\KS
MROQ#WLU1B\#L*>REP6YW)@ \R$6'X"6F1=EV%,D.B ?3 5SK9SM6/=+A?*/J
MIMHGTO_AJA-JT4T%C+"U$(#GWC(AF- $P-L2.,_U@MV7L^;@K=<C]UDSKI_)
M0QDDW>Z9]NS*#_L<US[QSI'<6S=^M%W;)/F.(/!B?[V VIVQ?X0J U4+=9=R
M,PP<YUV\)+>I,990:LC9$O;CO&>F?7L)J]3V0KHL:X2V* $]#2&N@:KKD&B8
MXAQK:L>.SY,#AO9%FI/-G]KS>7)?UECNO>H'3UL"X2WF8V[DXUU#R__@]#>M
MDL-_KUP"$3$K<E\9$<Z*HDSK(ODO@L1_=\0E^&U9VZARP0=9@E10=Y*G@$?+
M<CG7M/AW>V)*@7!;AE+^NC6^>&50M*B-7(K8Q&O[$/=(XS@,/^S.9#.W)SX7
M+"E;62^8L&B2M!FBFM0DJA[E_D3/OM7QVKFH?KEE!.DF19_:4++68=@48GO7
MV*FEXO& Z<DN6IU?XIW!1=I?+M]PY*P8YJTN!X84X;-4BN)Z/+@X [W-XU%I
MF/G \-8-;\""AN:);M\N6"K>E:A 2EL 8MO!,5FUZ$^#N<9%&T*I<:]CLH)3
M<"Z Y\H +B=SORGAC=='C\6Q$5>X>"S_("WW0Y)[8KZ/%5L8-\WNV2JI\M'8
M=@A5';H7)USQ@1GX'E-\-YHK9U)U\Y6Q^ZG>LEA+RW?5N1<B5:4YB ('%L^@
MJ@L[8:T2&UD3^3@TY]1:7>./,-MU+^F9E6^_KJWERGPL?9-R7]5>IM8Y&/S^
M51 ZO7NB,+ILP]Q4=O8W$3^V>B?K[>RT3:S#!\G+<F\W_GMBK+/5-,/\]8>)
M6>>-OICDECN@*X#<_]6AH_M(ZC.J@<9'X%'742Q@#$5]B=H!KCX88^BYKZG4
M)<J&UO\@E^0L?P;.%&+4TVR-FBRLAIZ%"OZ?+M.# 1XK0\CNX^-V)5-G(-1+
M'M10]$\Z@'0E:"N58$4,(QR$[6.BYH09TCFQ!SPJ4]6XN^.U ,U3R0#*5YZ3
M"A_W'UH5-V,UI0-.V3,4BPT!1$W4A!P9.$+20351E(]*W4ID\0 D52$+XWA<
MC6S^!,R'K$T;Q&*B*"&Y7Z/*YDBQ2^:)/^RZ7MSF]/(237?+?,<[A!'YI9Q%
M8B+&'@,=;<A!C?I%]_SF*]G0Q,^YG@XR8^IB<G_&GR?+A'EFRMPYM\*!D8N/
M!"2Z,1'CVD&[E]<P^W]8:7$VM!<@=\3AM9U8#%'# W-DK8 PF@-6I9H.O9PQ
M_G:QKC91%NNG>06 > ").7YQ8N$#I%HI7E<'>O!HF,)$G)6U)'!2]S_N;DP8
MB[4I##1>Y[SJ?/B8]_2I5V:L4Q"\-81[L!C>3^,=PQDFOYSGF1&I#;.03IEX
M^1NQ\%J(Q@QA*+4V(;B<VQPWJ6T)Q+J1D31M#_W2/KM'S&R/*:P-YDYIV.BZ
M&,B$27^]B+'4O4H!#K=>@YV?; 62XJ"CZG'*7C+?EF"*>6I^!7<TI4N^]6Y\
MP?#H,HBY3;E5!Z9.L/@3F8$30XJXLUT6S.J.[MW4#CZT_C+;JM&M4G:5Z\5C
M_YO D..\"5P#:JA'S?G;*FY28@B*#Y@IM5X859C23NK@'Y VO3386^@]/B@/
M!H1VPBH8R_B L8S9A"!JK!#PR-;5;K4#19+9Z1Z4@+IV.IPC6&217A'9V0I&
MU;*;ZO-:Q_ZV Z]HW.B_%1$Z8/2=^)WUQ9$TC<V3+ FSIZ)HF@R5CSJK?7Y.
M8D11^X;B1XX1B.T]IX]?O9;/"%X67GI^W^^FA(X;4Q=BH0:U^S*'G\%(&I-T
M@ FZ=&U^VJK#C]1$8V-?_'B%V;4>94@X$<%7VEMY?PT3=PF8X']\\&MJ=?&@
MAPY(=! G&';0 6R:T7NO$5SZ!3_E@XA#U?[YXS\B[@Z<3]'X\2'4T.:HA\:V
MCT=T09CH &<4)]2PN_$90PS4U3=GO5;2O4ZI2<'-GG";?I>2)\FV>1,8BZI0
MZMQ66EC=ML"O=F7]WO3,L]ZXR-Z4(27/ ^:;J4Z@]<<$ 9W5J5RD\!X'"7QA
MQ$6";L57]R.?J*=O[72+_?UB?/XD)[7UM9WBB0_H[?;<53WNN!)VGW1@0%BI
M6 2_U0K Q, N%_W6&7%+&A07>N7^S/J+15))G[ L>_7?'F;H;QAWQSP>#,9:
M=4UJ'%TC!9=.8[LI&J4! BW5US?FM4,1\U*I4Z( ZDG&9=_"L69SM)XC4'3K
M66BDM1H=(.RQNX8NU^-(W\WC*6M]]2G \HZ+@?T4J_LSK3!=06HH'?!T!C$C
M;4.X?507LXPG1N%P/L2(JACGIH84'U4W^QZ/2SS*\GJK *X\>-BQ?<^U3(">
ME,LMU!:BIQ'MS@40XZ]8#[,HLGC0CQ'XVL<FK$)*I>#,AZ09Z P$A37<<B3;
M4=@(!M/XC$C*@US(/='Q&J4S&T\N= ;OR*APO\/?H?#T (:8N4F79+?J%B#3
M^HNL4=K*"_.\'J+[/\?#[3W,-H+.&JN7"G4^*3/*9E(TXF#3>66UMDKAF:&9
M,F.VGK70 4/GT&]A)HR;JZ;FJH.9NY8D#._3Y@CP?!A\_(MQ<8?"QNU'J&JP
M=LI;%WG 5-GV+V/A\QACAB/*8GR'XHSG)CX'<T(WC6@=DTX3BFC='F)TH1Q?
M='O*L*KB_8[N$-6;P P(WN+]'&@&T;W5_TBG-JL?[$L4OH.XBKA"]:"^V:>"
MS*D)K?Q@GV".9,,\ Y<M\:<NAF[3W&2]-\+H3-!"P?PQ@PA3H(2TJ$Y49.VW
MC:/OE2:<#PU2_DBE/XF'-7QQ/WWK5H6E><=;^P:9R1[0*<0""E-]#\/?+">P
M^D9=A\^H8L++1_%K#7O1E[HWCFG6#-:S_G?V$_6[\?9-B0.*8!7M?FH[BGCQ
MN+U8P'X(D'R)Y (11K2=UWZ09YMK[.^;2PKO2SAQ8=GJX_ ='>N;%,_WC V3
M#^\!";6"*'[XU5A=(,FXV3!WAN0GH>'NB*F-R/VH^-7IBJ4U?W*MT_))K<D)
M$!Z,>BMYA21&EC].Z:B/6AD3F%NZED>GV990 ]:*$D.""9G&5_06/KA.A(($
M$,\8$1[2SHU%XWIB:QI&1HVJQ^*%@E3.\IY>C5EP?YP3&V;?>709O1;>J:LR
M1)'%V0[R>1R5YT=%;6TG_#YZ-U+TYAS3C8.74O&.$G[*$QC9XQ0!208=5][\
MM 2*7A@3/"+&%=OU!<A&WJN8L7/_T_?L6\:3E-M<+U2$.0!BY;!AX)8A^<&F
MQC=2,,.=?C75U9"T^#C>G_]%LM,GZ8YN]8DEFMI8(6F0T&0_IM;DSCD8IVV@
M3:PE^Y'_?K5.OJKUH9>%&5[-\)[.+TE[J&F^MMJKZ<JVT,I^?GF_P/*(-1$*
M\U-X&Q!OTJ+/$*[QC/^,I@,$\JNR.T6#_U6CN*=[91-'O,/<EX%R1BT6#Z7$
M-19O,C$0\;BI\0F8+UF?-I@%BJ*<R.4,LJDD2+3F*Z"PS][$LWOYBUUUMWZ4
M-"HK\DMU_2;P$N,6N.B Y>>D&CK 02N(%E^/?LI8O2E$7QU4D];=B]A+W#@^
M=&-.ZT?Q@UR]'!<OT &=( X4EWZI[;2^4Z7#S*_=:B]E_^B\D$\^D);XU?A_
M#FET +,!%44)(M^&L>.),7@ZP$"45OYT\31ZI5K([/N<45U]_#>5QN(.HP^N
MVGN?N+,P"Y$H I6036M8HP-^$3%6<O]6:6SZ9 6**?7#8&<3*CI'C($(O@&?
M"R_$^P2?VE%*)::>.R\;\BFX^*#B V$$H_<_3VK]__?YA\%>F>^T0@%HTGHX
M_OK4SET2_%!MO&HPQYN#ZZQA8M"JF.\OWYO #QC\0S3IDOD&>RE,E.1:%%E[
M6 XS1MM@> -?7WN,X'87#OC#*E:5S' 878R)AOV&9IN/Z*K #$>Q$ES3$SL=
MC0K]3]%.K)>#KN0D7VXS ,%"YU]RT@&\^N3+%+^ZCQ<@X7#=N7AA;WS-)D=X
MCEX<*P$=B&2$K;JWRGF^T["GB6HG+*PZ)D,!6@#M6 #5C#%(E!L:#>_""'BE
MJ)Y#WK,M+U'M5.U2!H7&H]HQ:IB%>)I,W3#"8_LAN#[YP3Z28Q8[4WQ-Z8JI
MCP8KY>1E;AS$X[C5W!*I@Z"/X^YL82>&51+4:K%OV]OG@ )3?>[:M2,SE797
M#J/+S,)8?$.-VWYY_D,MR6[9$WJ(MTG?&M&1:A^#'E:,^NB.?B%5==0.7L.R
M33GQA/_1O>;D&]XK]FXY%!Z!:'/6!GOFTOH;X6DRL8K[B+/8'G[KP]@>\<H;
MCD->9H@Y@64,7A_%W2>900BR@V;W9WFI]%_V[7[@[7"3FUJ-W$,G!>RPP\=0
MM0?Q:M!FO5QH85=08"GQM6<V57-+0]"MT_M9^S7<O05OG^890[LSU%0J8Q%<
MZA'.D% -!_:*'+'MD.8!ZMU#(3;?D/.A1H/X2X\2_.-+3MZ4&6+]"<&;HTB7
M;B-87\[L,!0MUSXS0F+.X,]&5G[3*EGR(M#W-!V0$<F*_,N$:K8"GD>TW0 ]
MN4$'8/4[ VDW"#5EM?.<:N2$M@O]K74J.<_T)_M/P7;FWSD$\1_2 ?;4=)KN
MALW<Y^!BR@521$BQG9VQPL]1:"#14:VLLRF#)ZDSY?["??^L_6W6SODZH8@]
M6PEIHV&:HGNC?;R<CZ>K)ZZI=S%27?B1Q=DG -:[ .I275WLQ.F%,+5(X;'S
MAJ(1%L<5WS\QU4!WNN:G=A96>Y!\W&=)FVV"C<1JA?31[80 7Z;#NX]+:!L&
MOS0E7Y'Q<G^ )%F6%O)=:&DG#51!ZFQ5JQZQ-7Q0.+C8HN%IEF'0RW(QF3^%
MO^*<_Y!K#<S9 U6+V/(/T(TI*$RH+M<0$9:=+N<JSZ^[/LOCE,Z3T_R$(5*V
M,0N%J&]T  ,57&RYV4E5W[G]"]P;NWZG\ZU962F\.!]@NBFCN-SZ^Z2PLO?=
MA?C%ECC:Z6S"0X=Q!5TIZ,FC7<\6=M/$^8>CB^_2!9'26G>CP0;/I;W6DSK]
MNEO5"9KA" _0C'17H]<O#&Y>A-1-<A&SC9M5+Y?W"G<,%,Y[<8N+!3SP@6/U
M),8:L9##@,,8:C)-;(.S_+?^ZR74V6J_C4K;6I+7B,Z<1;/7FX]-4U5!+G_Y
M10$4;VIN^;-6:I6NK.W]'"<^Z,'#Q-N@SD*S))Y#42K#D48%PW^A]NY6(\A_
M$;3KD!1@C>96$R&/-@;AJPF1Q2'B VZ8#/)#-@*U$M,^_Y[5DS?_W5RA92S^
MO/"/LPY46W3S6.O#YR'_E@@,4</& /U#T5"0)X5OX2,[;C#BY0XGU/->N.%0
M]1JEU%;LQ:W;#;),VOLRR[O&ZG40242;.N4!H:,+R VSU^Q>TS9@R1<LBBF@
M ]I-"FK>K2A=$L*61?_(KOBE_&%AOV?J/QZ:.?%O<CN;_ SJ3S0D!6+3YM.*
M274/+)$&0P>XKS),F4X]<F=XV37A_'Y0B@?I!O[UH@^%7XD8.N;]U<>YL:GE
M@X,G3;KAUI-O;S\  $LW[O0N"I/K<1;11!#ILM!W9 *0!^0Y+^*!#>K8$8;F
MZNUNX49V7K9(KNQ.V997!]^&#K][IG]9CKK8TQ*,[+"7)K:1KG\>R(7*M@/Y
M*:H%)LKU*?-@_,]E3YFW 'N,?\H+0-\6,P"^!A,CZ>,P;T"<>Y!3)//1K2R-
M#*'T[%Z5>\M__B1C8F9CGH6  0  Q?+XN(4;.I^&=9!J<.OG-+DW^C<MNGM!
MZNSRJW\\P(A7!UNY2Z@9%3(Q%B^ 25" 7^1F,RF^LA%E/ZSXK$KPCVUP\G*,
MQ1TM7L-K/=?0N8B%(DB%9 /9T*U1*8'"YI$QISJD,#<2HOG"<$Q^0,@B(8;I
M1\) 4J'8VX1?M\).[$5M^2R:( 3A_2 V=79WP4>,X.;2/CY]WS";0XXC%P^=
M@@N0;,D6$'27THSTHBQ1CVRS ;^2TSW^^;#YM^GR9XC]C![09HW"O32(+5P
M1ZH#HW+$PWO@PB,[DGJ*[QKE<Y[=X+@>D2,M<WOI>C1:>_\Z.H^A0#'X^QA1
M4X*^ >DCX<:M!OQ$Q*<?=5COU)([CDTM30[/ J,IPWE>40, DRNAI_L^<8\@
ML=+$"#QBJQ3_=:E+]T+V\ZM2=:/5O8_9=E9G=O6%0??2US[Q>N)G'K62RAE1
M7X2:5V? 2HS$E&A,?3(?<,Z=*@W2WHJ].BU;JHK@:^6>0.&M0.'S@JVR,!A^
MC":"A\1J6^->@[F[T[>_N*?.M3%W@)7?:[XK$^CE<;TF<VH/G483),D2OY$N
M-H;BE=[ 9:%V&\RZ8UA$I!)/P<S'S]E]?4RR3(470T%>&&?4=&$'HA+3G@UD
M=0.N6YVB%CX<ES&MA,R>93(RQ!=]M["CE #ZKLON5M'8E19_/K2D%JF5<ZT$
M@RJK/YYDJ:H;["U72U&K/$%=P<:"\SS7+9I9">S$C=0>20G; 7#<Q>$:,5_-
MF6KVSRR#ZD'!$;@S?"*_%EE4LZAI!,T.("L42[PQR ,%ZT^BI9'])@E@T\@5
M@YO&6)&Q)!7CGH9/W%U*#&W89M[LB=]9*$=V*'!_A_-4#96K%8R,&)B@E,-S
MV2Z 6ML"75QEFY31V1A73$(6>FN3@+A)BOKR>'K#)@=)1%Z<-.-ZBM"8,Q(+
M[.9L[S=JVV!&Z$F"J#EPB5DH=V?2.AW "9.?W'6ON^S]S2VP7?]<3!AS>\ O
M94@R @]F**N>0#J@9C[,F3#8G@ 'LMN&-&]P+BIQWZLUSA:+0/[XESN-NMH3
MBH@3_L3]!;.0"Q10TM5$M%UKY85NFE7$F;9.:NL[!NB4,<>[K?RB:/S\O2WC
MY)1S>GD2A6B[@'"A R)1$A1-POG5GCD>!A4<><W&!R(#1[@OV%^49YF0N(O^
M [$X3E&W<I+B%EFWT)_6(-P4N8"ROEQ2[,@F6?I6E8JV99^7O]!?7+Q3A$KW
MU=S0$&:X&T4:O[/MCY><-P__KLM&RL:]#Y!-^#LRVEYW^UZO\+D;GW28-,$V
M &H)R9-\CB)!TEDL@IDLS /6LP2;.'SX@X9$1(;MGH;^[N1(5)T\=33YS6H1
MTX&,G:_S&NQ48N\HGJ+<I_U,?51C@JZ#.CP*[U<I0BAG_;Y2\'LY!2"R;+7]
MGVL_^X$$6J^07!?0H34^PJ0F<Z3)T-Y4<Y^SM_7,EQ[1?5?'T!*M5$@XJEJS
M!QV-P)N!D:\""M+R9^T,Y;M[.N#"-5[M<QK7Y7L*B.R-QEP ]K$K'"'S#%.*
M)WD25!>=D?\/>^\=UF2W[ W?B (*B$B7$J5(!^DH)8K2'T L("!$1:0)B%0A
M)(@4Z4U 48E21&JD=T*O(KT%,0207A)J(.V+Y[S?.<\^S][G[+VO[[NN]WWW
M\\?BXDZ9F7LR:^8W]UIKII4??,P?TB8D-2B;C4H_'+]2DK[=6RU,Q]&3*,V^
M]4:G1/"['[(?$PX_005<V%X$C!RB0F""4"/<0I[R^>E-F7IY_]+7W4<_S1T_
M>YKA\NKSR[]VT7[!K+EFP[I0K.@QPW,C)+?"HVDVH_:,SO=.3@CW"XMVSV^U
MI:IC+6=0!-F.*!S4B?"L@+?+&,G6[2+:>;3]Z9I>4#WV8/PUO*6-7$\%%H?G
M>"@<^PC2 ]15L!MD4KP-7-&YUC=##E%OE'3B3L#HI 4^X.$P/,)<]PCLJ[B6
M?V7IC HCD 2H@&=2[$2KQJG  \@QFZO"]8<F'1_O/\V'S9&+K6Z!X')._7.0
M-R#<;3,.-"%Y;P0/]4V2Z?YD8^6\L?)4L[U*SW.7Y:=9;?I"(V@%4P%:2PXJ
M=,K@'2(YS$RJ,#+[.9-?#K<K!5_V/GUMN8XQPM2@4_/$KOPD(^7X,IX6J0A%
MSK.8J#-R!9G^6A[P\@H;U*D.O.WJ24B@7MYY40^%QIU0NO 'Q]4YZ0Y3<)L=
MC8+D=+@]A&Y56[G!EL=H0%/\4\Z4 =A_F/E.<RQ'@4%_ N=30V2'!YI_;KP-
M3) 0[VRX-&PTM%$LDFIOCT6Q6%=B/?@%4NV' X]-BT8 QU:X&+0W_FV?M1(A
M#2]M1KCO,(-@]G_1?DFP &,<Z/SACHFO".(4DYW![ W]WH4PT7L.G0$D"L$1
MA]S[0% K,BL@B&/'VY G79)UW'YL];;L1TO&)!BY7TBB._OP9#4G'1%$9*5T
MU.JO1>.FBQXF"9IUH)L,?1HL+OBF NLA,EO"OV68R1C:QW'!0O#RX=[Q?$YJ
MM><;<B97+VFMP6[WA9&8E97DO,+UCK(GL&F'H$ZBL ]@/^#;R_AH&B@A]E,4
M(!_@5<CGL LD0W)"/1L58/KM3%NCUO#FSK3E[0B#UU-VI$HOF7:="V*ISJ?6
M[F8H,O9>%EKU(0I!F>N&?W13V CG[OM(6<L>05^\R#NK>[F)^"*=)$.N;CQ-
MFT[P=?VY> ;"E;<4=N+Q#TEHAE<];O53_@M.?N]2F8:X^$1G ,.+*BLHW"BH
M\EN$(XWY5W1\_+F$>/'N6MR ZX_7G>E['6X_B&46<$?0OY65DT>+S!ZUQK3)
MBM_!(<(_-1!-2PK\$PQ/9@765!D(QYDO:,8G$SOYGXG+Z W1[46LLQ79$6B
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MTNT'RM,N?,4.J2._):VQ*97^3$CYQJ3),98A5R'I<"NOP[!;)6=W=>#"SJ*
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MT8(K5Q@73L!NO@AA!IZX_N;XI77N?FSL;='YXM1*"XR>*0@]UFI\<F8T=>W
MDG+<>$Y67A\_'EL/?N;'U?BQT-JZSU$@AN?;EK7M2LW*Q"N!DT\* \\LPV?R
M(-SU2H7.0H*X\XC/G?!99M;+F!_M[E>+\@],GXO>\W\*T0@(5O1,1+RMOTD\
M#G7'?2K<RVKV.U/H*FF ]*Z9S9"\K*G>ZGX]@(0UJ_"[!"=Q.,[&8%A]3 +V
MACCQ%Q3(+UH];74>)? (V?=*WC^#5=0)%\W(MF<<R&/A&>>^=#NU<F@UJ'$N
M3K&-;(M-45LE9-30[""1"L1[1$$VE^$]&XURY$QE*Z@6?G56++1K:=!UO]WO
M15*L1JG:;([9'"03@C.-#X9I$$#V<QWXRG!OU=&')411-R^6K[/GM+>@58_9
M?LC?=4SO(M,(/V"%S"[4_P#CSNA[S4H*&_@("NL;-(ZP^Q:6U)VB#SN1<R=8
M)^:4'G]&ZJ58F:&"IW=+C>W2#/EOM8QDG#BN?P=C6E>V @J'\VAJS'F\. 3'
M<=PNJQJ<'QZ:W9BU2K$O]S%?R([QOQ%SXMVAY5S:^I6Y=?'9B,Y^/@)")\FP
M/'JU><_YH4FXKL&0%F&%3L*@7UWDK)!T[@#\ 3S.>NPC.8WG^2X_T[SG@F&@
M\A.;&#B'PF,!KV'QH3I().TF05$_.$>\>R&LRZYS3 ]+#>4VB]P_A$AL&*L2
M4AP2;5QB7S^XV*WIS3_S>:;T<"NMTJ37S2)ZD^:?94Q^,Y5+M^O+1BGM=.Y!
M:8Z-$3=.:7]/BRN&]L@N>70OU@;*0_Z@>?/C5(?;SD(-96#8"'>L'G/IV)Z.
ME?9GUST-+%O$9KT8[FWS):'<4Q$WAI6-I:4_C[:&IJJS"S (""AFZ'/A<TE<
M]MBBHO%PJ-C<Q'PX_ZIQ^."BQ3TA_WE6&?_=B1NFX.6/6@7M/0K:_8(2WN_'
M5U!(I<&O$MO86[4=&)Q9.$R&9#K>"(;JG:%D<1@7V+4Z/TS%"TX^C!0^@&.>
M],5;JA"M<*[8-= );2Z"3<OU8U0@TB3TB5'WX$*' YS &3:%1_:P3?!@XTDR
M2+1QZZ:FMOO[#PQCQ4_5OUYCTB=3G+YIT2$GI3#@ MY:?^L B0)*].&V4L^'
M^5P[&]1R&*<Y1#@0J\MY_>A3G=)=@</1BVX9VK"MPZB!S&!%IX(M=.&[^)3\
M=XG*^BRT#,CA5[^*&Z/)WE*8:9>ZZY#S1"O&2K@4T/;?;9/*U:64:&>^-8TF
M/PC2!5S,_E>M\A5#&H8RI. I/H)_6$\S/++QAK'!=<PM9*.:<>!1^?]_^[KR
M[A$[,G_]^;.OXY_C;P]D'PTY[!7-(KE)>CA,V Z9^7;UP,Y;$>_S(4/Z<8&1
MD2Q7Z%DKV/5+')%#4=*H8U&'[QULTM([Y<['CTG6^E7TQ_SJH4Z#M"J@"/A)
MGTV.5;3MM[2"U7%CS@MV+8-&E5]>5%1^.<K@EUQU[M:AY>0K<ZL'):?;+5*<
MW7NS#*]_RNO\8*[+U>/^'Y,DYF,X4U=.9K!4WZ^NX^F?>V[-Q)P9_61XIJOZ
M?CKP-=OA>[90Z(/"WD?=/:36W?P=NF]?I-J$,J/2\9IU>8R-<&V7,W^[U]<@
MO-#L\Z?A3"IP!V%^F9=UEO7*ZV3/)%.S+A36D-P IP):5 !/RW1.]&<&*X.K
MD%1@$4511V'U]VC0F$1+7#MY2-+:4<  Y0>*"F10 <(L%0@#38U3@6U:HBL
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M]O%8<&GXFR4 _N:@@>TQ^;&W_U:;TXF^DA!!!83&X)M56URMXYYX-HI6(17
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M;+Q("^&8.^FG@^AAX=1-\D0LS+*/)778D*5KT)B?T]LSW(+Q*/O$^$@ 9MT
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MO='Z<T7K@6_%&:1?=IQ>X.:+N[UW?ZJD:T4J2Z-.Y9$XO_0[7:[]J@ZS$!2
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M['YH$51CE@J$@MDW8*TS_;P23A4,;GD._@#=Q,YUWXZK&5R9=W&&? UOUZA
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M CJB3_G^^1"?@'7G_B^ZWRNW0.(;2TV?FTB8=4N*NFHVKY74EY@S#RL@6F3
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ME"3H+*F0#-"B!-%%FF2<WK'<+PR,A%.DN-9.;5P^*6B3 @R%Q'T"H3X03,D
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M'9YB!* O%Z:^8_MF28)'9(*Y!Y[HQ$?,U& G-E?LCFD8@LNRK.+YPD6^T8K
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M]JJ&+A6\+%]V<K+EIHH"OA4YE7(-7@ Q0G=B'7%\D 4@)C!6PWQED7T6*$L
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MZ<5B(Y]DQNJI]\\N)GOPJ08P60<+7M$)<:F *!)S0@&.1=$(H2U!4<QZX@6
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ML?[V2(4K\K!FSIN0B5R0)8:O@W<]W]^<T+*L%A;>5];/B!3N5"IJ0)0@6LE
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MIK46XNC)=4SB^6>WA@4E/8M<"\-*T76A*9'IUM[QR!UUW 9>$:>P$%H!=\G
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MG3(&"9;&A)'ZL!/K>3J'(<CZAJN>V[\07#OJ7"R\TZJ<>7DI&I01M+/,*RK
MT<1$^HU@^LB-]67#Q=R5 =VY.M0)#IMI;4F5*R9E5W)WHE6>\YJYS_J)OJ!(
M$*":Y"C$53_V79KFC#^['/B:*8)IFAL?U//YJ^;FF^#9<?F)KSR?TH+.<"_1
M2A<?UIP9 :J@;X.=]EN>5U@.\4:R5.[T,&<D>*I,[>B&7+MD+^PJ/GM8ZL(*
M4+Y]90KW],4K=32)FJ@V==GE=[N#0*UZS8U!'X(TX>F:]AN;%0YIY(&]_HYM
MS+)! P$IV@9[G<$C".#X6Q)Q%?1-PR?6KL#C3@!T1\D?F-PG=\9ZAXUC]<H+
MA=B?)2J#TJT?9W]^\_SY%%&5PA RKS=*2)^/.=MC3\Z:ZX/JNJ:N+/X^T(Z_
M^=J'/I)-4ER@1R;/SW?3'N]!<B%LSML@+C9L2H@C6O)G?R'ZV"0BU=.VXM<O
MH?+V]4'WR:_0#F3DO;H1-UB3-&&)M>+#1N[T@>3CB[[B:UQ<:5L+7I$WWB6#
M3H_^?L_84RNNX7%VX&'S-B/I##[FI3L-_;W1N#:J)K  KJJ?7+MA55GM(/")
MC3'DZ0Y_G(_W*37S<KAD_"SK1GRQK=_:V+P)FD/-&.9V[:99<L&XPE?)FPE7
MHBU.19;.-P.]=\HZX*J:)D6[[GM7[DVSHJC ;-K7RN/#3:LBEZ3?^%+[9(^7
MC&["_(4=R+H%?@5MR(K,3>;"[OD>R!MCTA4\2^X,HB![C=?3>E)DLZ=2\Y[T
M.7<U,'S3-D&;PI!$!42OB))?;*'WE(L7OT=;]4U,/JXKX0PJFD.%9YZA G98
MEK7#3%:%5<I5DL&P5,J@P&,]Q9J*,K.U.S5/7[2?_%7],N'TV#<,3V15)C.A
MM;^#FV>GHQ0S<VYEFZ'GJ*7&7:-._?9Z?$95N*;KA4)LR;?G3XF>G=#S:,<8
M#$8R"-D9D$X%6C/?("QO>S]CKI_"3&]>8/+)8@)FN<>; 8:'9YY70^F1#J!3
M4PK8<(3LFH9<-#A9?II>+XXN:4!OKHNBEFD(O3I@O+&9[=[AB36+0:%GTY"/
M0%5F.>1$!S=Y9U^LO9($MS%/LF#?+/LIMTX/B#P5X"3 #CS)6547U1XXXQF1
MKYLN#:?V#^_9W#5P37V27N?SIDBSQ:TK;#N]>)!&'EIDJ<#B8BX5^"(P]L>!
MN<F&/?[UJD]5,9)W-R',\/L$&:(@P=>\@>"/@N"5YGVRGHZ^6V=_4-68'E%C
MQ%7_A$Z(1ZJ2J?!JDR,!XCO;IS?O7=+?<7%?'*[@,:2^-WK1-31VH+I.I9_E
M+KNLP4W^,7I-ERS7]>)+WP\TZL 5VQL#WD57<V#X8R<OYLF9UB IRKAQS'N-
MD9;#G9C!6L@DZT)2&$76K^=V.<Z[<I3"BFM*23%+&0.*OQ>/'&28>K#=4IM[
M[F% _V) ]\Z/S2EWRP?"*]#)O[@\&;@.;K1X3AU"-&OM;S-+@>^0,RQ\#.)Z
M>S_$FJ31V][JHL6I2F@XE@[MS!J<P8KS[6#V.6QNDL9%%98-[1=^=/Z8<?Y3
M!-^)BH3?IOA@D@E/V247&,4.7+JE7_[8PGIN8.FL*#] %=*?X99JSIYXWPY%
MT=[!RGH;]8\U$>Y%DG+V#$9T?,\FAR\)L74C,% .M2OX>GV:J^^3,ZJB J];
MB3I$Z?J<27>PO=-X@OH!:?,ZD-[A(Y@VUK-G9+*_U/1Q.>\SUQZ*Q'$X+Q 3
MW 2>=+:L^+2J(5X1?S?Y"3%4E['R%A5H6.&@8,S[3*\TME?[LD%.QS#AK_LM
M1D647U<YS?;SE;G8[M7PM[]\55DCL<PPC?.DW_&BKV%WDP:W9L1RG[VZ)KH4
M 2&P<\$Z&Z'S8S2PXY=Y<(^@.]NH9$*$A'M)IB8K\,E4?,^X4Z%CLFU_=H))
M8UVP84R!>!OQ\SH),0CG"2QRRI[L3#&-'U_#?%<^5UCX\+';"X^V9='I'\K-
M@G)&\7$&5MFI%3Z,A[ )UH/W]>0TBHBV]_.=OCGUWTN:4 [)RO=)%1\I)'_1
M*6Z!%D$.3>OLW,_=^AW3@A-$.YH"::@,@N%KMQ7%Y7_TEN)>4M4,WNZ.$^B0
MRM%J_?:IC2GW.?V]PQA>OX59\\VHG!7+L2@U&V]<_[Q"5)J/TO/&8GW7YYSQ
ML2\K2^?;V;^U/3M]'1AK\_H#;<2/E_KZ(@HPMJQX=#-L@H6O+["5=Q'+31&1
MAS&']";*N-D_>G<;F3K,SF#F(_SRRPW1E^0O#?YS-G</@@<1ETEJ8T)-7QNK
MRD:VV*];;?B6A6!*.@=]<C7?"UZXKJRP:\.9()^IL$^O6@QRA>L,-P&(44P(
M.K**5= :+H[O&[[1\>D!UKG?&R:9?88E3\?VA9AJRR4M$T$4P1MO-6N^\3+@
M:UCPOBL5B-"0;HQ3M2HQTE.LJBZKV#W?_TL2T"M_%<F]R/1.EF_>13Q0P15Z
M>W<]T"5('Y^]/IM?1GSL<K,ZI]1Z'<RJ8*^4\OJ8MT+>_/EOS2'N2B>N3C#8
M8/U*6<Z6R!$U*'T\EG$NBE0 E!]V:[IQ0W00NQFB?'1WTQJ$%"-++KJ([ZA?
MZ^B;!MU&C&4*5H+?VBKC-@3I(Y9Z6ILXAA:&O(IRI^*:6L%^)X[>/_J=B82]
M:L#0O*_7'PVE.5>7?GIG[LP+6S(DKH7-JR-NPGC-2&9Y7[N1$;9:T6NF[\]<
M\ZGMYL+K<Y)3RO4^>M;73!VWLKX$5YB';H4LU>'GUZV'NGY4\VK$7#98*$]J
M?\&QE8-;M[6?I4$3 8(D\9XE8:RYNF;,EG,(-EWBIG"2?6[S2637978&ONKZ
M39$#H\ (_'?QPD-?'B5[NTW0&\$3Y.0F>;\(*M!I">FHCSG9_TEGK :CE96O
MUF3]PU>C96=!)#[$\:(H_T.6]5GTYD6<W"SK&R]0&.7,KH(;GT7=Q#R$UP6?
M^DSH1FTD<XN.IL_OS[-,]=AJRUQ(>]E9@U\K K@VKVW%;B*9$<S.2 [:!.@A
MS_C9[A+M6J,^?^M!O&E63.=+<E1](71DYPXY\V:?JXCH!=>O)F01M?U"EUIA
ME<XI]_)C7(74V%C@K>B-HQ+ILVO7 T<AS50 (P0_AP-%;59*78KOXMU[-H'Q
M>]L'6E&<.GII?I'%X*S0/B-D"B#4WW 028OOOEJDN6NSQ^&:^.W>7S+V_B=3
MP_^AC)E]Y#^R4[W#6_T/;:YWYBD8^J?<R7D%=K /GXW-B;UW,XU+75.V-N8?
M2/)Q7[/(8.!5X<PI:C$>-D\0JZV7^ZFO:\.4'2&A]:\./S79;V2G!-GNZ&PL
M>3E;%$OPLZ74X8B4.^;@_2XJX,"%W^Z"3:;.R[2AW\Z(X4;C85GIJOKUUV^Y
M2XGX,X;PE^W20302QD);ASMT.S-6EMH?7PJ-2# H& 'A8M:@NPM@,LZ)YMJ1
M1E0@\R(5V'X%94&V=39)(OMKPI X.@A%59NDYCI?0R+Z^5(!X D56*A:0=K-
MPYMVPXC&K,N'H&<TQ  N0O9'4H'#EAP*&UF/ G>D DW,<!4JP,I+**$"&C,"
M5*#Y(IBP"<+A41'8W<TY+.E$/!6('B#'A.\0V_XIZ9^2_BGI?T%2:5O'J!)/
MBE2NQYV=;Z6YGR)C=U)(&U0@+ IN1EO9,!8:36'*)/G$$/S&.F!'![AM"M!-
M!;J<*%WM1T%SY**P76),+8VB@X;1RYU(XNP %3A+R:-U1HX*8.F:^/\IZO\+
MHNY1@>!L9!^M<6TF#62+$@4IX]HM^9/-33?KY CN=K\>N'"D=_9F*((_TXQ.
MX-C\#=R3G*MF2KRM^ :N3Y<*#)YNG7+^J>:_^]NC'G>?_N,\]:^9;=_75YQF
MXUNU66U<4$<5K<61KISK P'.1Z#RIDLXPE#KS(,OF08?Z'3/;S&R"F?,'BB$
M0*\@NM#5;#CG:IQ,=.E]"M^'(S/+U\O/*D2C8M9I8:8+D7"0] :N(8^K27PJ
M.I1_(NXWU>!7WY9KU:/@",ES:M>.1&NTIX[3%*]>^."IO10I(99=^Z/B%WH2
M27F")@;1\ 77SG20+A%&!7III!F&)MYILI2F-X96X99)$:O(2>RQ,3B#4$S1
MYJ("FUCRU<L#^KL\HS$W@EQ7I>$?UL35.M17G5\8ZO3RE(BI?&0U)G] +M;Y
MP2@SR+T42_+5OY::03RE]()WK!N4:$\!'^M+(>+A_U)Y!GUE'GNX@GR)> Z&
MS<8<\4!(M/[HAO^[IWROST-^WOF/LER:3M#T5S-9 0?CX)//WQ;>W%IX]64,
M.X)S)''54'2AKY$;$MCC:S_I^T 5$!+'<@>H,BQX&<\2H\8VV7&Y$SZ1P"#B
MF*6PCL8M@T%4H'^D@')&E##F305.+Q&BYD%,I"M-U4,*K!5WAK(D%[5H#B2P
M/.6XG\)C3G,B*S2KB?M"!?!<$_S7EKE$!OHE\&\K--AI)JA"H (41 D8)P[N
MC"%X9L90@>6U(2IP,I[DNH4EV-C2FG[LI]QKHP+MAE3@7'$G<H^FY6X+)"$"
M532\%7[<K@IB0+:ED9!4 &R62>#,7+#04*<-5I^PW:+!/%*UZN[&JWKV?F_V
M+]93>%0^V E-$%.LQQEUBCT>C2,^\#'C?@MCG>I7V_C4=M ^2E%']".$T&$F
M.S-ZBCR*2(<WG,MC]H[[OKY\Q4F;"2@'N UMR',_2Y%S124;9C>D>A6'+ET\
ME75Q<6Q3E@ VQX 'P#L2R"B$"**-<GE8GA7S;/NSM-I;E/2CI:=F:]J/SZ)&
M1@@C"^HY%%'PD20K%6"[ER%HRC7$,!HID+R.Q(6M48'=52H0:TQR-F\YKGVH
M7X \6LE<L-7]N]&#Y[S]^BFO_IL02[)!@9?VZ*7Q8]9.2_V9DC/EF(ZE]PY2
MNR>BZ8M*K2CGR5!*T%]ZYB]#DD;1A/RD+=,KCZC O!@5"!E9 !\S48'%SV"2
M)LBX:)J>)FD?1;B[CSS:HP+?BBCRR%90,4WO!11-"!YUY>^;X+XVT,3=SB0E
MA%&!-SEKWJH?:8H1I%'[LP@4S>=D'G']H=^_RE-81/]=F[\S%<X@VH! %F%V
MH^@YUA&:5=",XG(!8>!O)#8D_7TK9.L:/I-,A]PQ U$NQ] ,Y-7Z^8V ,=*E
M8S3I&+EH0@5XP7^6-Q9',]4_-_D[D]N_F?XSZ+% C"4-R8+-:=X20HK(7-#^
ML[P=Z']LIAH%QE]9/]\M6X?^6;E.?R/05N\_U*[V\)KO[?TW/NJN?U(DZ,_B
M7+N1?]OB[Y5\G&ZPHE'&TE7R9T7F_-,N_L_;Q9[H*Z_B$HG1.>GLG>0I+KZ7
M_8*===#_M^?DGVOEGVOEW[*+-2A/26X% <(O)]UM9/%*^G:7Z&"#9[.M>A-.
M\+.T5'?*X)TS'<7\U]Z2+_B AR['VQ+BY\$<JTM=QL.((9=>_JY%K;3H,(F/
M8W(VPX4[+:T!:542GI 4T6%S[@-!^4&[,7F5T]FW=SN5GT9_TG803.@Y;_).
MZ^R:9 _\S,+D]HFUUOFIY!(1(6O+LM9OZ($P.[*LY,R6U(::<VY7J=-SAM]>
M+4=Z3 B81/>J2_:6: XBM-UN1F3OJI#_S<^'^IQ?E!8YG6WAN*I-.FNN]]>B
M&7QI?_[^$,1'!5J,:5:"A8.I@)TFFA)G,]:Z?ZA-X@)3] ]ITW4@;T4%5J],
MPV5LH_GF'+G<6B/$2MO2_J;&X6H,011"2C</ Z\/'M*PY$R3(PT,S::#=[QM
M:5P I8<EBP;\*&CN"6N/05W+?WOP#H?:9,8]/]",MQC8[^G>R[GTZV[O8/-M
M]40O#XC].Y9]/!78 .$>0\.AE5H9F*@<9KG6Q;6D@>^UY VW-W9"A[L>.NIW
M%'QFV @55(#Q+851<CYP,KPA7=0$?V8F%J';^F8IB;'KY[5@1=$!_: ;Q#L6
M*^!R2"OHK888CDC.;-?0&*Z^Y<&5G>*$:SF[D;EJ?&J\23)Q2W"-J'6L-Q/$
M1&:=WR9)Q] ,O\JLZC3%)][UD6_^:BX_:F+N2_)=F8KJ(_"L]VPF3A]T;F7F
M:A,A12'J<I?I^=5W%T+VR_4KKEIO3K'(O1SZ:5:P0?,H5]\2[R+'9;>I@,Z5
M0O!L B:DF# Y3_?VVJ<D'LQ](ZVZHV0C+7,AWZX4=#J[=5F*[:WT*2L-<P*#
M(ZR0Y$7P=/8][6M608@WB+"X>FOULL+PHX3WN-NG@UFMQR:0Y^75E=JP.&/(
M*<M5RZ#29-=?D^!X1\;VU$CVQ<W?Z?SXB>9QE!^99<L=%Y!.4<!:!F_]@-<V
MT_IUJ*U+TL]*G\$K#=\)(=_:\PY>U,MJ/$UC/(AY"]JA\?93R#$^*)E#P5E%
M5 JD==]8SW8Y ?$3S.6&8$%,9ZCCF9=#*K$\;;]NP\CIG\1NV'_>I#Q+>'J]
MJ\ 3JD_!4('*C%0<Q I74G+8ULC1&5,XT7-3O_C,U2DZPRI//@_/^*$\N"8Q
M -D]02!2OEHB5_FY]FI(G)YSL+<:5UW S-XP!K] ([S4YT2YYBZ]RL"8:_%\
M64$O-ID86M3@^3F),G'DL%[R.K_H1M%<(X\U.8:BX9+T53K=$WFF<6%R2L\E
M&O>XMWSC,8.UDC#]*ZCP*IB%9(X:UP[*(]A9#'_._::7JL=@'_5%1]G>B.6L
M, Y5CGYRFA8-'F=BF 7NE6-F@G,?OCK@Z/"#M$$GC><+6J%G5F<X<5LH1UB.
M,\5Q8CZE5?R![[?!ZU-:D-X-__T2NS[_Y^\VG:9RB&J4_AHJP*&AY@=KL17Y
MTC0@Y:YD.]/E?:I%TK+S<U_E]=,PR2]*CSTQ3=F$ J(-_";A')Z1.(<-:3KO
MQ%L05FG.??/UH,BSAD&Q]HBZJ!HN%:-!]@<OCS/X#@S)>578\,QJGM!]M.":
MXA#4UMG327'HRM=;KZ[D15W_R-R[6*BNZR$91RY VX/#WQ)_\RO9@YUU.3[(
M1+G$NRB:'P<5]YQXL"C+Y4_?<]'L<8$_R%?]K(+,3'K!N*O.#+T>SG,.W!:#
MJ3BH&"EM4,V&9,,5*RIBC&L'IN'!.VY13!)L;S1E*Q0Y%UR^7/C6E:=/A#B-
M@MG <YQ5Y(P-J[EL6W)X/J5=P[63SQ%S&F'6B^0>E-7&GW0)VQ"82[][$$3.
M4S/&+7=L.[NBUBROR;7QRQY%;-7;[R24]9R=[NX"U2N+<J7B.18<-X-FH?QK
M-X&RX:HKT;\6*NN'2'("[4J&6ZH" I>%?GD\2XN<?>%7B-@K&<2X& TJ*8,Q
M\;,L(3B[@\^XH.@PIS(_5]NOY8TQ$ ];9=TZMI[STVGYYCZLMP@KDBO]F'B:
M/F$3KEW7IVAAFUD^YCR-*II41;B5WWK7XO@T;X!?(/*4G&2DT.G-HP_ 1U("
M7K(#S*VF3;P%5X6\+>MV*[WM^?@@<="JC4'/M^ZT0!G320M%7\].57-7*G"&
MQE#CWPPB-ZRJJ<#@VY126T<NT9_FY?':4**U'[0%Q .VQS+"/7#H,"FXW"=K
M:Q&E=YC?"@7TNCG?$.^$2LIZ+#Z);M12?SL+VV0K6,>6TT>1'H':R#R0:MQN
MCYMT^%-.*^B'S=DKBWPW$F=.?%,36VJ FE&!]R8KZ -.&%E%WQ)4SA+FNP 9
MARPHA>U]L-PU3]G:S*H,U].]I/B.R_14G$5G,\M25EXW2LL(EFI0N*3!NG+,
MNCE"U+*87M-@&B1=FHMA715THR3E9$K!=-YOF#TQ:7%X[]@T_JU?6("$K3R(
MLL-S4-CTH!-;'4V\5[;'4V ;=Y<:'E4'?=3^];0+[R8L@CQ_M0Y-$&4N+<(5
M+]B6S67RK"HU\0[#M;/?IM_$FE8'^KNK%>E>,FU60Z4@-Y,+2+\1)HA0/YZN
MF]$OKGE+Z=K5^6U*T[ (4]<SYN' Z"YMG3<JUOR.PLI"@N+=MM:-ZK^EYWB^
M(A=I "M0.K!+/_WXBL];GM"J]6+)\;W#,PNO4V/YRY@GOMO[/MQCC0YNRB#G
M4V[ KY'C2:8PZ4S<LLX8W+6DA3^^.;;+_<N#+(G/5CT/ZS]</V&^A-$#)=PF
M+,R;1R"N^<4<O"#X9/+8Q4U:!R]U;$KEUH2R)VX_/ZOZ^,+I+T^WEB-]2L<H
MC%%40)0MEPJ,U[A1@3P>!>N&'Q+W_]!X+X@-;NBZ !,DA+5S6SX)D,HO0BHL
M6GK]QEEM_KSU^IU"H5/1P+'Y& AW+_/HFJ ,%?C"0YG2A+*/34+_]I;ER&"J
MEA=%WI"@3V0BF3<1]@M< SK?TN#6S"N[DM*\JUG/O,_)B7B&G^Q\L]&1"IS4
MHO-7+\)6)[4SGYN';L;,,8/O)S(;=6G%M>G6>Y^8CX-5R7U+7FEF.)GIT=H@
M,Z^]R88'VXXJ-,H2NV8N)1D0[^-2-8?M=5+4-Q3+BX#(9Z^L?5O11Q*"-%3[
MI2.3$G/OGBQ:_L-10IWAL2E1G_28\( H2O@T8P.>^Q%;2ABS"E81?2D</?VP
MXHZI14UBB^_UAR=1?96)8(E7RPCF 00O_ 9!=9X5H]1!82@?\9;A=/&<<LK@
M3S?2D6)_\.'NR9,O3\&CE_23SVH8IH7N@@@22J0T+5I4>CQ=0WEO/5:XEL&*
M)N>B9],U6,MQ<"0F!1OJ+NQ<.8G<+SU8OP:Y((#M27YRJOA99-P9S\*\LTW$
M5-L=US+76607:RBVVJPN"+?=B3VW9\--61OY-822Q]5_NYWXV[O+#>[%NR<9
M3DN>I+^[#"VCP9").33!I9_?S[CSO-7Z^AQG<HF4]+L+I1;W"RMN"EXX_= G
M0W:A5)P*X"#;$UU=-\%=?-"+A)BVKTFA7FYT,XO)WH'F57)Z(I"SFN; NU/U
MW)UT4QQQDB]&2YN$X;^3<YI$X/<)<BQ9<(Q6M@-/BI[X^^:.G,@WX;V?UME4
M3U9K&YK;^VO)Z+$-J$@9+"^(;MI4#W503N*7FZ- =_S=I*6\FK^<=;\F(M'#
MU%S^J%GYX< F_<6+=$D4AM39Z5.=*32\ZZJ/O%<QO(DLGX/LU;+?Y:VH?9SW
M$O-L*H#Q,/,U0A3/LZF+\^U,@73) /FI;KF8Q)HQZ<^"/RN>/A^\_$TV3KOR
MQI/6W6#ZNPM8W#V_!BK #=>,4<;F3THCRM6O#A:()'PVG]1/07"3RYM85YLT
MABB@%31#I1<!IO#=&8M)NMXYV%U7?2XL_.>6]3N# VGM7O\C5_IY](9-=C?1
MF>#9DB*;+M<J>+F&,IYR5I<*:$7(+OG9J==<H-CV+$6W-E3<)8=1)"Q(;D-J
MXH%SQ?U?KI 0L#>70E(AQ)NU4M=3^1 K(I<N5;R,')N GM>0<4J!DCCEFK]>
M&WOW,>Q._+W:V!@V&^O$.+'NC5[N\^#UPBR,S"$LA_TP"3VU2P7"08+RR&"-
MFW4XT6 -P&*-PC%H\W3;/6^(OW'.&C8^8^7>\FWF5\]Y?7_HYC2.M:U)8%2-
M?H'UI#-T'.,;9=?F+,D6?JGVLN(=82J0&)AHS7D!R&I>'"NBT(@0#]@%&@KE
M\BX&L4[:KFEPI<SVY$X[4T#16^ K=18]GY_>+?5Y-Y5>MW@>TD_C*4WB)!B-
M5'@6P9]4U99_J43;0 RJZKZ$3F3VQ,E=<AJX^X0YAX7>EEY^M<!K;+E6MUB^
M/ZM)C) TM[QQ:BZ&D6"EA9-.F*<"?% ,^1/1:-C0EPLDK&.3\('>8\[.6HS1
MLQ]ZAI!*-" IX,%O$2#"^FV"C5V!7]+]%-\QK^3LF VE[Z:_61>VO=-+[[L@
M_,+WH7DYLD5+@X&0,X]\0[J$/]<2H+G\5CXPZK*J**7K9:D-$+L4H?_F'*?W
M!U+S0[?EBQ>/3LV;;QPN(%]K<. HC?/3DD1>@>>Z1I@?OAW?-QAUX]3@R4S7
M&:9;OG&N%G9?G?EL_%P_K^Q8%']X\'X( :+T(\_!K9[AMG\;VR3==G.[9JF^
M-01[R#NLPZW6J06H:@&SYA&4YF<K8&X-"?C#T7WP.>=SL$"@_I6^J\ZOT)^Z
MUR+M(F5G@>O*IY1+8C#@9@TA0@*1C70NJ?6K^N$;^[*J+[HEE3V^M0FW*\:M
M7$YZ"/C$CW_YC"9<U8@)FML6@)L.[JOJ?E;@4SW[L;:J]DZ<YN5N(?N' >=O
M<Z7'%4C"J,#I^AJ%Y^B-\#DP*SR(_%Y#& X.XC. \:R&ZF[ FOHNU&H\/DI<
M[NW<NA(^/$L>I _8A1)$DUKYD#0KT]\J>R2P%#-7KRLC+53_1@TBA]@2\1:^
MV"-'LT*U8N&#,X0\&I49.HC\.5^;^GT(?JM JZY[P>OU!<A8GT5G()T+47A^
M+&0/.WXXF]F)8G?V[$PIB/(VMU']?F0)JKPZ$AG8;KMV._KZ&>O)MQXVNA%&
M]VQB0 0^'+J9!L5!FR?PCO,^93F3^K,RS%/<Y8/79MN55#E?>_(R7=^9G;&C
M7'WG*"RTAV4!.]G(S'>UZ\F<\DL]@ _MH4^O#?'QZ:++#8AW2,+@K>#(M)/&
MSM:+'!'?J$"P'2%?#W6:9( +34#29<XG"]O<U?=_KWBA?< _54<U ?3]&Q@K
M6-4[ T>0RZ_!-:^&70W_K)@==^&@8^Y-;M279W5/+")D:?UCF3DJBG,W4&_H
M3-&56^['%,\)%+2P1B.$<=4I/S#W(0)],1]T[4--6 IU%S>GC$5+I\;BS+,I
M/WD/8^"W\<9F2?,.O_"OSW'R&,H_$WV?K2#V47.'/$H?8^N/NEGZ#9M@O92X
MU:+):7KV;WCK5@SA2A@I=?L->,.IEH;5].X1;)M6:,.R0'8W$5Y1.M_&D$4J
M2]4@K=$1JIE/##6YE@6R_A=/)J:I>6C?3?#PUMA&]H@7\QW%T*7!.=]+9NM=
M1_O\8TL%FT%$H340X!VSV<?:-X( K;$CLV>"#BL<5IFZJ,!MY/R*/VKP7*"_
M=+[.H[LBT1Z?&M=[J8 K"G.N#7RBZ<*,G];Q3'^'K?B86[+PSZVP9!CG_1M+
M/VZ^/@W/"?7A?WBR9T#+*+*$@S=6WR8S;L]0,Z#@/U.3\R^YA>J_]CMSGA_R
M>/9X>U"!@ =I]=5T=+J+^-__6^(!Q#GP64'?$J9?JK)6&"YM^B4@,B+X3T=3
M!^I-1FG %$?]W?):^.:>E[P:?F+R?Z@B/Y\M$SZC"G?8CD&^@:L7ZN>M'; S
M/*Q[O5-0*YQE),N8<59$D!F!HOP#QUH@[IICH%]8-] HUQFQ(0U)E\,D6SY<
M9ZQ2NKW(?;LDHU@#QICC1R/65  D!GZ#4O#KZ-S O,_->Q+4(N+&&1F=9V/
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M6P,RHTAZ\U:PTW[G#!QT%?1RF0;+%WQ^]GXZ[WBFFS@%&'AH%7R=^LKR^^B
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MUBSX>KLC*>8U'_(U[%P_L<"]%AZ"+%5M$@E)5I)X]3;7YG/A<C[;."[\#4_
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MZ0*T9MPEX>27>Z^]?NTR:DV/6) 4LOVM(X2*K"G#*N9M-M%#DWA$3^,?NX,
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MTW>[>OT!\-QY5S)@8K277/S'=XF0 >^\V'G?GT$&])&&P%K#3QP,.Q-0)3(
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MZ*AE?7[RA-8"69',Z37+UX-2^%L-7C54-&:'_7>Z"3#Q#U0?<K*;?%.]&W/
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M2O$'='(C4ROK9._U"H5XSF)VX(O8D=6K?ZPZ"=RF )&1U*^DE8S$Z"41K*U
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M+ZDS^$J]*N?^,A9SV4VEIH;&H#[AJ!9SG#XY(!J\IS9?M8!-:]#WK5'H3G$
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M?:F\IFKZ_[TDS+_CZRSN%V).Z:8-6)'-S"_;#"]M#E1S;#&M->*:?P8TJUC
M45\][O?(O.Y=^VSV.$[GBJM1V7IX;'ES#LTMO'%Y7B>IN/5G!62IWU"9'-O^
M:]XGM/?!E/8Y@SNE_M8M]%SD\50$VHC+62Q4-^HG>BSI'P"\ R"<WO4(AQ%Z
MHV.!6 K;:.=I:XKI5:,+SQOS&YV50<+=FAP:1\36PH8QA*NXA36Z?9$5CX3J
M@F$B65;WS1;9(.TMO[M34QO]Y[5*'N>CH\\OLRK4$7M-NQVJ%+,METP3LDN4
M0MYU.3C!+J_!/QE>O<#WT=> *T,N1N.#N>%C49&\%# L[#7R%%%_9H-A&&YT
MPT)H]#:NHYC<>K%'=_Y6SPVNS=6&1Z*X2PI+>JT=Y\QTT8J_K>A/"9J;->U0
M/TH% JD FPSKH:70MQ-V@[I/"Z]?SK\P-Q8Z?4?:JD9D]"Z3F*97'7:#'=F)
M*92H0M!SUK/CQ>[U^M1GVRN][@[>'=K]>N#TLS.(3 XMIPAUV?G)8N$Z%,-2
M#2,NK!'C)^0)980G:Y7 A!8+54-Z_%H/Z"@(*:HS?#BI('C/2M!PS;;\V:EE
M1+?FR;N?_@Q#"W)"-F)*WID*5J/KH0&01&O_R>.VIN/US@\]+EZFR<1HBZBP
ML44DM)Q *4YN2QD#FMN]=T.-%[]B6+/6)8=*"3U!UTH+B?9XT1_MN/V9HV)F
M9<^>ZFOZW05OMA7D[R>PMNTH9!GL&RAE].U?5NM,+G+).67!-W50[1%K^_,\
M+8X$2_>!7\"O7\"O/P=^_5=OHIWH=+W/XP(XN4'HM["KQND?69G(7\!6^^"0
M$=A@F J3/6]IR)3>GE\,'X>++/V&Y*>A1518TL)!C+2$^%QA6?3$C+ /_,.G
M\.NI)J?/<)S=/*2:1>C5[Q/J?18!Y['/F]5.RD-CGK(.4;JPKO$NV"ZZD688
M%LZ.3$IM?FVA=V6_;4E."81==*_+'9'-6?\VGW&+LJ7?[B%J]J<;<-7T/U'.
MP#X_0;#,?QI2APZ>/"TGMERA%[CD877Y(%N'T+%;'K[\9@O#^CD([PP[B&E3
MD@O*RTEP?*TO1V6'7<HZ0DN@4$I51R#":V4%[7-JT_YG7=V0/>-,SHKB?O&-
M,>&)S:@<BP ",SVZ=K"Y^)W:!6F=IS\KTV7$[@EB)8<Q1N2/8.N-X;W' UM4
M@ 7NH(Y;:]BK*<Y0&'X:&CWJ6,X3P%8^F_DR[:("4]L6>%A_"A+J$H5K?EVC
M$H3A:$5DV:S+E.BZSRT<R7;-LC[-8XZ^N95&Z:<(];^@<:8VX46WN,OAM:T$
M7>UH^[;K8YGF,CJP.4[ZW$FI;TS!'[8/U%PIK$+K5_DLC]SUF6<R>1AUC(OK
MUE7ZY4.Y-EJWE(<F](3S>TB&1.M<! @_D#4-9KOR9=D#X6V2(I@2=9TEXEQM
M:\%;;:3CE;.!!+ O)G\?7CE-!4@7]=_P72PDNDQI/36;L-2>UW=OX0I5"3Z@
M3I^A('#AS* U%6!D>P./GVFN3[@NVNB60S1MF;L/M,GT3*'W5T!7Q 90L+SA
MTIGF1LF3<,A5G/#KCHV7)/E/FK:/? V*O:^-9244W,CY*J#[ 76XV4B["*9M
M9FX>5RUIU2(#'H9,H1K%FK]3^!".\FHBS\2SMQ-DIT+G\#NW"Y(4Z_8KP_+S
M$ET<7BDMO$9*J.-V&IQX^2%*P4J(G-)VXQ,5KZ/<>?JR#IX)]AVI-NTB,!"I
MP&.7HQT87TJ;$W-V> =?X:/<X&-7#PA].QL\"\E##L5Y]8&+A&MY.NP4IO&/
M.T*C*RJTU/F>CTM@HZ9(:V>_K::47,@P&;XQW>;BFNV$/$]^O85ZY>&7X8DW
MF]'+>XT0Y^@N[<D]6R@]L5PK(MC#\$3*NXQ^Y\W9!7J&A150?JX_MHM^ IXR
MY1;*VF#\)=RJNENX4&X0OZ[ :/Q%W]DG\]#=LQ\>%F"FDKG7DS*1_9:B!955
M<3.]>H&MS H"#PT9[*\_?FPP*LF?OR/;2P7JI%S:$L"$-Y5?0K5.C?@%.48T
M)Q[6#NG/7[YT!;P&,H6@A56;UW\\'\J=+-"O9_4'/^JIN4AZ5(*;#%H(>12C
MV;,:MVKR[+9&QWD_8,KWF\'B];I<$.$M.7*;U=OC6?B,A:1%,3[,V\6',;'\
M2=*5A\RB"BSU40Q^+.HC'B_R3N(/IGIFKXR\)J2XR9+)C?5MJOWUT1&0B[K2
M['V14!.2]( @7I+$'C:3&XYH@F_Q/ARP/T':918@K!I[J5E=H (E(7=V4ZP]
M(\H?NUC-H1G@PF;$D)D<Y?I$WB^11@.2LYM3)6% ?IU !/P((!!9"T1"]9<G
M\Q>^4H%7%+VP1FA(B:G\F]BKNI\6!R1=!W:!D$8W><1<^',ECW[TT*T9L/_D
M,:0\PB"4(<8$1PF.WK,O8V&;/2$E ")@_7$,;GGALGJ&&V9]N<5'->;-VE8R
M3&W7A1YV\>>WT?Y A$[F@*&MLH#X^4A[YZ6P-Z!\"370.'QE&A+R%"E$?-:A
M.Z%I#XIR?YHI+R6UKBBJ*.I:PGK$/I'\CL))%&M2X^\N#CN.T"O$A19;Y8X$
MJ9[P4DWS7,OCR14X(6+1\6[1*;B/"GQ!-1[5GIY<8Y]N$Q%&K>:QW92)7S$G
M101</O]0]:[&)[ZR,26I;"IP&J[56XLI*8KC??60AQG*I4Z 0SXY%?<H?230
MO22)>JW=']KJT>';WH>0#A.M9E"AEI<'MC&A2@Y^LN4C%P2_?^Z>L'X=/7$I
M\Q$[RSJ=_CC6K?@QLI4FHK;1P>!\:*,D$]'K <S,"'\T\-JS1\/<C!']XT-3
MN/3@L0/P*?9&^,+:,!40?H"E GL;,"KPZ>U@*HD)+Y<U#1IBQJJE)4]V?;8[
MG&VJ$7.WJT#3A&] GLZ?7V3ULN)"8!#X2?&JQ:!R;SGD-CF:P@ 7,Z#4X:V;
MAR(;WC0I8GM?#$1/'#ZHKN4R\3%C:OVQRG-&=\B:X+[T,A4HK,G_S-F70]*<
M3GC(KQ:3:Y++7W:;3K1>0.S!.US#\5H?=_JFK)5)'CM#.)IRN' JP^%>AU,*
M/"/[8]3N [Y1'TZUEPH@'-N2J>=W>[.Q$(%$_[>4+E A^ T5L($9DH;,1VV0
M?#V#[7W%HS_>B'LSO#RH-5\KS 7016AS;=O0W*+)X8R\2"TJ\)JF]?O?[Z+L
M**U.UI6?$1V5P,X/J0W+J"32.?QD(&8*K78,-UEO<699?D*@[S-F4*6R3'SG
M:T'K27:QS\YSH\$']-?)1^$:-(95HZB40AE$R2Y!((JJ0>>G\;D'F\-B6@O\
M^]>0'91SY 22^F/[#'.SY3V)5*[XFP/9F+[QCW4JC];N<^EP\;,<$C@S^!'!
M1_:C.?TAH&,(*>Q1X893T7'(%'?G8Y\<SAV*>WHI0F5\],<%6-K<D3*%-KH(
M564LN![%"6<BT/6^  ><LK?.74P4TNP)S[4J>USRXJG$UI/3N_.[SK6:6&_S
MKC=5FADV*-Q-*G!(/6VBP_I4VDQ&]L:I4Z,+]92H<R&887'N,VZCVBJI'-8#
M=:V1;A;'F+#-=>!7*!;$^1ZXT4PK?+11:NS3B7LCM34Z1@GKO+HL+*Y6?<:@
M5^##2%9B9)W42J(*L9(V?>+'WA9VFX$]L[&;F9]@7M_NO:TGQ^$"=VCDQN2#
M&AP"^4[X-RKVJ(A-E_?I'$R9$:M_%GE.X5AF9D<1X2*@>%JH"+GJ$BXVX<%?
M64P.1?*1[G5O<Q*E\78@#GO"I5TJ,&2:$VFJIQ1:J<OX8"GA]?,K%\L[$)AI
M-$M;'KSM!FZK<X#=<K+Q_H; HZ*+FPP"2?R".DOAO6<@PV!Z*F"%"D ?0DK#
M04U*6JE)Q*RKI?T/ @D_ZCUBXN?,KB/*3?JC="R"AYDKPY[9-]:<L\7;8DH/
M9C'P/T7A$AR8ERJVI$#Q=YI,BQ*:1183LCV\=DCL36 Z.^YJ*M" "O#0?J5R
MSM[Q04'?DQ"]SN2/].4/?EQZM;"^[MJ*CCDMI,I/4"#JXPWF>RBG20[%_56W
MTCN.Q6<.RQS  A$G$W*^/XJ"U'(U.DWB;J]Y&O:#[<(X[EE,FIL/V^8/-SYV
M$'C5_"S,FB&4S4/"(C94*1*J8A/7O^.W'<0+N5D>T690$"LAOGY>P6;6D.N>
MIP\CF]&[.^4^MZ1<\U? S*@G*YC3" 3JM=K%_O@Z[I'8Y!,Z-A+>">SP*PQO
M#KU@C/*]3RKKG+:TQX8=@I+ ^-#BZ1P#E>JK-RJC.Q^$,O-SC*F&7F9UU/1Z
MO.]"C,!J$O-QD3-^$5D/<NVX&:.S7;?8M2@/(Y02>2%C$F*2!!*NPS]0HHH=
MGU*/M]+$E\1SCKC^F+-H\IVS(L^\-_>HW=*"%4U"VP5/1I9>;<!80[TK_->.
MXC7:OLK)HX?#6UABY$V]?3M/?4G>G).76,W7I.>/X6@DMFD5X!:"BG/$]/J:
MBA]8N8L7<4<TSC%_TA85/%Q>XD=_]A'.?@7C(T4%ZA4H36HRQ 3Y/?D $HWG
MARIX^'C/[T9Z[#"=MU4EO2?;SSOX_LS:98(?;8!X"/NN/JSI$X>9;MZ)FSYW
MX.SBJ[EO#'.#81ZI8B43WV)X3RP[1CE<I_ECQ3%DMY\QC-V3N/6P4/"6Y#TJ
M,#4P27.M\X[A67VVH?ZHXVFX@?(#HW8CL.4ZYQ/7"T2_G,6U7E?5OE$LTO9$
MF).W>XN)=#*-<LOU!Z7N+FJ/V3B,Z6>1"1<,)US_JZ4X30=B]'JJ!#.70",C
MB3GI#><MI-/6";OHJJGUL1L2="UGGF#^\/N[&VLF,S"('CD29:UW:H#BZ25F
MV&,=O=DC+QIS],2HNV:S5XW56U8NQ65&Y\:VZ".2SI!GMG+:2916U($JI^P\
M/Q5)_*P%,==JSJS9*;7 K$M2P=BJV$S@/NRYEW0CHA^O.YU8CD,U>^2](FD>
MJ,]8VF1\$AP=>N?LY>O^]**MZKR[=8"/6&QA5;Q^Y6\6ZLSO+=2\7-14<C@5
M^*J'-YH>^!R>.;%BR5'@+I?.D_ YA@&+Z0C[R/$Y/T)O_++,.[/\>M(1<F@Q
M-##Q>'PSGR#^J'\]%0"^7J>,]%^Z281E6QFV2I7!QMHOP^F^. U>W1<GL>%3
M:[NK./"; P[L4IO3I0,R"SX3\T9?D[^Y8H6#<W]T ?T;1)'F@-3O).@T^'6<
M4?5/8R[%;/>NG6.>](7;JTR&_'?H50^C-KB)F^_</Y?G/:BY5WEO7YI P$4G
M34F^AA9N^,L^#I%5%=.J+"R_A_9P?U,2Z.@9'(C#\""8' Z2F'"@ALB<H/R9
MV/5SE/9]B:Y"]ULK:&GWR838_:S@G;S[Y,(\"5G6ES2]9]S1MVD^IC.]-#P?
MVU8)DNB-T!?H _-@9NN1]*A!0A(52/F<$60GM4W32RU"DVF[(*'!;,0CXC$D
M&Y%_.NU-:#DYBPH<3HPBIQ$<"MS!5KL/8?&EI;&4TES.]:WYJL2: G(!9O8-
ML@-,$$6MB9F.Z&4(/(D.243MJU!::@2(N[;I]M"14\A3N&=Q]RSAOD;@"HV/
MTJ(26C.9Z@)1MY5*[;:@1&O]X>8U]# 4]QV-EQXO7 ,-ZQ',M[IB=Z0VYJTF
M2E#V.<^PTYC5#AQXNN3MFO5G.R4EN[VX)B="0& 346&YYFE!B:KKWA%B36&8
M#'EEJ-1FR:H*K_VU_")%TAS.^M4T!Q.:)A_PV,HK]>7Y:E?F'>1#@.'MK1G,
M!<5FV:V#:?MG$9)$S:/5>8T;P8Z+2/YHP6@]T+5\S[12%@468Y.POF3?4.F!
M2,KAV.G%;<E0[HE\@H&[>_(B)^<I@V= [#@V^'[B08-/YE2@V'PG /P0-"+9
M9'F^;[L#6M>T8-3W3*"B/'8[B*4JM/$]%<B;>K2U=L-PI]P\YT'ZTHM<?3PS
M0;%G@>B HIE$KRR52HDATVNRNLNGDD%"F]W 6+N1H@+T?99H"=U9[MV=6B3#
MH)H0O/ 6;M#_(LCP-\.V5(/IBLY#_2,?#^BH $>]^O?9*>T@+B0SXI$N%3@!
M=Y>9/&QWRFAX.7 DI&CI_#MQ/BN=TY%5(IT*+.,!N9*$JZ?0S CY_6L(S1ZL
MB0-"_M$ MTP[/</$C^-C"V 91]!'M:+JU$B=,41,2?3E;8>AC6G(5Y1H\PRZ
M:455K.'BQX[4Q0&]YP.S+Z\\?8;<;3L_BW19I0+Y&ZO=:3_3WKE@40>)&[I$
M[ZF6+<\LSLIB/KW&HM7N@F8!LWB0:.)SULQ0L1^^!GW/BKTTYO?V9G0KVV*Y
M;7/_I_'<(A#A#(70I)6T@\1Y(CY[5&!3L&J"K\+V'.3<F>QPV$6E$Y>=$F-E
M[@2_XWE^2,=9G#5\,3EPZ9+:(/$!5@\ZW45B)SB<6)2'/<Y:2I3769NWC#UP
M]D[H<FT4?YF 6Q:TR-]["S62,GVTM!E#-W+1E!RLP<JQ^'USV<J@XN:QU(/'
M4(&7TWQ>0:0^H5JEMS'[9SAWKUH^V!>A=$/0A<T-\(U45I=IF"XLMS M[+W.
M,7@X).E%"W_?*4OY)^5W+ M"E^+';3GS9Z*VFTDGG2G:D_Y@@A#- %X<SDH@
M%](,0V7PZYJS!?@\7T1EE]_$A0,K^F4EN\G%X8.H"-:=0[N1Y ]A4P);4)S!
MY"Y([0QJ*)[F(J<\R9HW?&?Z0ZA35"?1B,848?7Z/(M[GY.P&P%M4T^*8JW\
M6EX0RJ/GCLQ61"E.X4,^5SNHDR.11TFFT7K"TS%-<QB\=G2'0]J*Z:/HMN>U
MUG8Q=YZAQX]=8<#Z6IK@S B:Q-?X+LUX\^Z<[!=YQQI,;A7FF),3AV.1.',Q
M:;K.>Q+=/M*)8CU;F"'HC+_/-DRYT?+XH(HTEB>$;YTG'^2W;;ASJ+OL&7VR
MCY82?>12XH4;-ZC \9F$&O9Y*!O\JA$N)EBR2C;;K#@ZR\IU ,(FKRQP=\1I
M6=E'@?]@9=B([I03.1$IK#_U(^<HJJW8;V'-9W!U^ >=LJL#\OU*W%;8Z,17
M,= H,Q3N-UE$HV$[MF2CL"&-"JAGH7&&8;N**Y/[C#^)+)1Y&=;<<6(FPKJS
MA@%7AR\-55&=[G8F2&<MR^VA1EP=-JN&[ZKN/Y>W<G4*_^#"T8UX2M07KJ,"
M014+W@_[>"QB].)$#)?$29&*\.XF_K$AL)I4V59Z#<VJ:W$BNM%L.[X$*I J
M-9A!&8R;PG6MY<UXW?\JH87.'!K?%>_1ES@$LMW#<D 0A$V.&/'. BQ!D8C"
MQ6OW"A![\9;@PRNEN&RL1D]VW#K\]M;$;<7E0\)/QC+HXG/@"\UA_BA6!)-:
M(!5@I9QCY1V9_)3G>#2VU%,U]<#!EA;Q\C+1LM%)%2\C_ H!^85<6&Q-3,7Y
M-L8]RTNW,/DJRWH,VGFN_'7X 1%ZX;:GP)&:?H%3+%<A]1/R.- ;-1YB(%8=
MKQ;IG+P\0)2T?U&FH'J:K?[":NU;+[L+-3"SP7PC\TIQ5E,RF@H\(AMAY7PS
MX(60P8LD]BG>2U$5@]MGCQ1*,%^T,7&SXK]XG>LLRX? +7%Y@@,Y 6&1(>$[
M307"C"0PDNM37E=OP',>O<6=5,Z\T%);B]A[4@W%^M>" BR5R/'((W#)Z::7
M+KP'!G6"#/LUH&9F6>,M)RY'"(;K['Y**&- 8+]#NIA_JT^X.8XX'K3=OXHB
M;FN@Y7+OBL7$:/(DVN(KI]!O*'3$96P]GX ?6/6V'LR%3H@G7>?<(PWW)G4&
M/G4&B!/.?UJR[J<D%%)U;D9SHJ;9^[C=S\.X)W4] Z+NA.25,Y\XC2JTK-^'
MP:V@WS'68&\\?/D<:^@+O%O:V/SCV!'!$<X7@=>MBL\+S&XVE\O.3C*C'H+?
M3)Y4$60-=/X$A]0[IT<<U6Z ^(T+:3CR&AO'VZ[> YY?TC-%RTB,!\P594=U
MK@_2'KTGWDJ[#SK5U9B.,,X;JE^@ @_L2O1L99:5UBYR^']VY6@!"A9D-_4:
MJTI*3ZBKP%BZ\[5#-45;:Z=\6#6.>F%P8((\,1;GCY7W)EE]LC,%!18I>]T]
MG>>@(I_A7F-<Y-\6E6!R)VJHXVUE&6&^QHZ<EGV^%V63%W!)0ZZ9C(%/>\G?
M;-?N%;]UHBJN^JM!#R%_7G8953 8G%-%OZ]!9#6KCH6M3O?U7)AWJ#SSW)==
MBG! 0[^GJJ FD1P%MIX\0O3]BCQ++,3?<!>G\,)=JO+M>3B\-*9@NPJSN1:<
M@$_[U*,'F?,]0>5L>M7'@K QJVYXUF9,<4RPS"3K8J3.Y^68R1',J+1/M&.C
MHUNAC'\&Y+)$?QNO/S  67/!@@X3Y:<W?)&,<$D#RG@1[M.FQ?)( ?;18 Y&
M]+V X^.8LX\DC)_?*/;BD6S"[KL@>/ .KTC,Z99PYB8/>YYXKW,.!ZB G4GN
M'7X%X/5]UP+?U[!803VDO5W<J93D%7EN37)(8V*&@U1I=*=-8&L$O<_KZYW.
M(_EI[K82?H5%2+[4(V(T^]>,9H"IT9$DB&YIYM7=Q(R,KX-[5><=[_L=[&1[
M&WI:ZM"1#R )#><FM6<Y6$'!%P\'Q0J/B"2G_UE=%Z8Q:+[#6NJI  =KW.",
M\4+L]$X#]]U2Q[&AQ""6;-1<S&.K'250S+H7)L>F8'$'D/IQ%FD5Y7$IKW[Y
M+Z(\.D7[D'VW,EW4VL,*TW-X[35CM,OHPF+I?YS)ZGYM#4ET^7W5-5Y(_<;N
MX9_H9A#Y_5W)-^!912\J8!&_.S#X)U]\/^CUGR:E^=G^<)0T>/2/: \9NOJ_
M@]N%6.$VR+0YNL$$.VQ6/M&-4D"3\>A]6>#YR/\Z3%IN^CW4 XBP=Q<?OO;F
M=H&_^8[AY:/:ED%"D?991)2>G]N]-!N#^\^UUD:EO5=JA?E>)O;7+7,C]A[W
MCHX)M7!N\O=YWF:T^Y>'FWF,Q(1](U8_BD)?E3(5.-1%\!\B8;;0I;MF.PT1
M7I,7\D.(*R.5CN]%B<NAT7PJ'6+KT6AE-Q62ZP._-MO,H8SGC95/)RIJ @BJ
MRX&[SA0>..I[+!6(TJ?T:I/D<%0@29H*B*+)-+V][29#!=#071E4.ZU_(!M-
M05&!6=H?G]5/7\R+ 4^7^I,/HW?O4($U&52] ^L>.W@S@PJ,T!Q0B+/^+LVN
MC]0FU9/M6J@ 3=Y0="4IU_9"_^T]PWYW2_"_O:'L,I1!39[F:,U21JA @"1!
MF^ 0204D+5&Q\^[H50FIN?T%V8XW-%5YXU:QG6O@BLM2=P+\UMDVI_X4__K^
MJHG6'C.Q;9VG80;)@6*-:J\N=%.!;&B.7 )HKW'O.Q,,STI1S:8"DPZS8OZY
MV!D0R=.$"M1,?H.P_O%EX[@+N]LY3-!S/JFWN,ZYVX<:K7 C40$SVD_[J0 W
M4*U)$RB]F(6]20HEC]A-KDQ#=6UCR&0H_B-SGS%H;5R9@LJA AO+/W?"_NUO
M^X/,5CS[A29LYIGK-H?DP*) W)^ 3XXM3&^0W,=I#*5.RO++_</5?X1B88+!
MDKZX1KX<PO+G_0 ER%5"#R\YVDWPE/FXM,;[G?,W5H:$FW?FIW0ECY]^PF74
M>EU)@?;05VXS_K^1'^FDP3T^-?Q "*ZKKJ(T4$7=M<14+?9PG'N8Y4?1]/7V
M1F/MY[5N'X_NB6WFS<2L->+-9@@94KBFCQ-TN(+R4[AAJ[7GZ8L]>B&C%;AX
MR =$PY.J+LHI^4;4GACE9]!SQR05X,M]\_U#5+O%O12"3^!O<<\A>"B%9O8$
M8W#.-!.K.?V?NS)K\J0\;=!%)R$S/P^5'&A?;4%(--'@&X^AJ&K_<T__/-^(
M\!HC!Q%#!9AY9C!D#BK A9J:WZ!9*@;_HFO;W;\D8%]=$RE)>[N;B'E40!/5
M!"4J5E(!;!_JGWJ\+!^L)2._&T"#J  NOT:,)J.@^!C*L6=4@+@-^N<>R/M?
MJ_^U^E^K_[7Z__-6+S5*NDTLM19MXVSLXE3.^,9N5RI14^7WSG<7TCU9B"&=
M9&Z(DPR\B)#"/[\NN579PG )'BT2+>P=>F"W]:68D$<)/4N$V[%P4>G <H,,
M+ANDOX$FAW?ZWXWU,DX WX[7^QG%E8L)Y_/+,KC"Q_K7PKB03\S-VJR=Q*L;
M]!GPBCKGPV\47%(059\][@E9^_P'0 L4C!P"Y9/136MR*\V)],6AHTTX(?)5
MW; C%7'>.S$]3U^ F[__\+4HLC<;#^\P3" OHM]OW2D]M3D\INO@Q%ZG<LOP
M^B?#[.!C1]ZZ,_#U<W@P<6V5KDKCT1I$9VR']=>)2S:1=4B90DI[GT 9+/_:
MT/V0<ZNO=,ZSC[8SO*7+#AOA(2CB2^N@Q\?;K%(GX&%UF^!8JQQ;7&Q,J]5F
M=IWZT-3]$TBCH3C<$0*K'Z:XN1']:N2IAX-_U8,7<>;W+[K*=S>[G;13$CUL
M'&PU?(@C,OA=>;)IA%V/@B0K20%O'21Y:O :KC,_RUP:QC9\K^U"%XGQEJC#
M&Q0SR0B'OE?:4V61/&;C$=)8,-[HX'BG\%KC._G66XIW3ZL$.UNV9*/JU&L4
ME[\7Z<X,%6T]**YI_FPFAF2Q$@ Y:L+=@JJ<9D!ON//[2+HYR]R$I-+[97T2
MEM;&+<KJ#QW+A;V;9743]P(VM]2BR;DT"W0,_ 2\3V=!L_I/N6S"7!(EB!DS
M:%ZB0SWWL?),KTH=7!\K+-5LETV;8#-Z__%8(->/N30)G9ERI7-\QD].(#H7
M!E"XVT]L2.JXV'=1CW'&X0PN()6H96CQP2 L>(1]FO;R(R\CQ/I<@O85BQJ+
M!F0LA.8UXR;N#0>!WX7\.-[^K4[+,;WVN Z(':'^\]:!,=PW)T3ZP<6"/=E&
M>H4.YT6JLEX(9"+7(*Z7W9]&KD#4.$DP?'-=B(9]UT%XZ,:UB <!R6%/W[8M
M6@JS!&L_A/ 76Z^.1Y5J_LBJ:1=W@08H1:=7/"Y>",PM%CJG^<%PK*HAT?>^
M(EG,4XMFH >1)/$K=4H.(;!M,3T[5<@M%+_Q$^F+#I<ODV>NG]E:=9Z4792'
MX@ST0^7E-!CPO%%%+^^/:=+HX3\YKX%YF\>.YVS4/T6L;(J>N#A0O%)MU"#7
MHRW .7A3P*8=5G[ 1^[UT6_F5I'-LO:QZP$['M(#& <L>@3;C#8#D<^6YL90
M#F=1 6%%>RIP/QXS6_RCM($5M#)Y$F&!FD&QTRPYVY68">B(1-7[F<D"V1#D
MO?X[#PRT@1?;6>"C2!$X>IHIH+=!C:V/"A3(O@J8XE2[9H0(O53_-+"M4_7"
M<XQUR^R9-O3[!1=6(A7X'RA!+V.</N6F,+:9_(KFDI!Y&1%H@1"!X-7G[<_U
MJUU,)1OU3Q+=:DUW?+;(1JL4KL%'H19:S=\"J@@A46\W1"T<C9$K+-BX#,V6
M>P:NUM\Q7_0#951O_6B>/$S2="TYA53KH33;OZ "]<^#SF>&.I4%F/AY%-DI
MO67U(]TC<F+U?2B"Y=TDO60+L].S8D>7KW7 7I1/ST2>OJ^EL"SM0S=3)C)K
M,VYQ.B7CVV.%LWN!>^QU5*"TN2GOX)*3+9Z8ZF(&]QOJS+'G;?CHP75H8A)W
MWL[\,9>B=@9$SR1A<E5]7VW9%!4T0RS'>IJHR$XY,&L*)<=X1)RNZ1=-&KE]
MYD10PNC+.M',RSK-_LN3[!_Q;FNB"/?GGR=:5QJZESUYLAV9W[:REEUAFM;%
M.Q/BB9'X&H9BO'7 DZI> ]_<! =NL]%GO*>3@=.AC06:[C"VH,IWKV9S'GG1
MU LC,^Y)QO3D"+1!J;KC4U:J?0#,[8%[T:ZS2&FH/%W%8XO3;(,\^DYFJ"-4
M8(X7PXU954ZC,=V^TJP*V[XKR1(G_&J5I&B;8PJU+7&Z>*K>,#_4G3]$BT.>
M+1HX)F\-T'V'O%M"<2",4A"J Z2CUIGN:J<&<ODK,+V4+G;W'GY^?@?:T[&Z
MQ?$2&Q?%]3R])EHL3A[FHBBZUV9(!=[9VT()RO*4H.@:O=P"_<#$"_'3V9:
MEY$:6^#^OH[,QGD)B4M:5$#Z&248/A[J<3<B*.I-4'%7'H6Y+A/Y'9-_,Y$>
M]ZS0.0V^7\?M.WG5]FBW]\;]\#E';]]C/!V.TK4V?6<.'JRY@^=8: 0Q+Q?8
MQO4/!LF,JY]I@N7.EVN/+]*I4#C:X$:-(X/>+J,P^_J]U(&PS%&YQ=S5.:F*
MO>#0CSM,/@JR&P0PS@ <*N>J=5A%Q]J5S-BP9X%Y#]YXQ[SK:] F4MJ6*1:K
M8^<N&:HBA>?7Q@W$9A!KNAKD*B22Q)@597U%/W6F*!J_W9-G.N/C-%$]V@S:
M# GSQQ 4.ZC 1\M!?Y(1^:/:69*=C79PE9Y+MCI+XM.[J88B_ BV,DWNS 6&
M8*Q*HGMV_ :-/'TU/$L4NK)^E:[#MCLYZ6:V$]>NMGWP9R355G:= #.^V:UX
MD3D'$PM<LFP6X^N20G2,7I:'K802\\HP4Y_X0/@G^3EP><-NF(,LJQ_;XA<J
M8*V3EJ)C>_)5B2[LVUV;=C.=J?3:Q7[<N"?D:]<HYPRFCGQ*G.<*7DPMA'4O
M_J@&0WGH.7*?!/-Y&FM_8K43/#42L<AFUR'= [Z/>HU4C)Q)30LY7UZ%2_-Y
M@>C*6HXY(5M<W7?C\*;:TXLOWS);OP8BU$?CH$7RK]81@ON>[Q<"4H)NX_G0
M&6:5+R(4'P4$L=[?'US^7+4P4[IFB]?'RD6/0 ,0!F)++*/QMPK\E&V@PPWW
MN9B Z18@N+^8.#P3%C+)3>&:A'^>F9C'ZE;UOEAQ\P->-46F28R;O(]HB S.
MKZ4/##5Q=KY<GO+LCB>8=-)Y"ARP2KDT2;KRI2?719+5_K@9.7FY1^Z=J=Y)
M'3831[4KQL=]X(K-IKN#4ZC:L),(.#XGU#_)=N>H7:](=5]5RJR))CIVO.(1
MR[1SM,J1/65",CF5PH\X2LZN.6<&UVYX/K3T0S4XPO9'0^1H(<IZ]$#=F>-I
MWA%EPO2R<S5RY*H:&3CV>OS-,OR-)==(B194 <RJ)+SIDO;[@W@TX9ZA/_C\
M]>=S\VZR5&#JHYI:CXHQ/G/P"HX4(!$VS7N9EXU/;NSSM8N/@)W1\MO[27E7
MR9$7832!'#;<W 2E+^;YME9L(0K?3C@RXQ#?8B3<Y;UXYHO:H% -?Z>[2MR^
M-.4P>1I-O/(4X8:O-S>!D52GJT7M[1^4?:SZ\+(]:^5E9ME2A?%ZT2V5HM6*
M(Y)Q;D\@I)/RS:?8X%WUT",D%43>,2+/K=#!%J/F$2Y.W]!4JWM-J*JN#:BP
MR:3YTF:L^#/!DK<AJ=//_?EB><LX/!LM!3'XF(!BF.>=F*X^%^4,!PF![0BM
MBT.$ENS, ;:YP&LWS#OGT21![BXR8QX&)T@%FE)ZYR,6S(JC;;E-+*>9E2/N
M)=1'Z-U.:Q2[*GK=WSZ))>U[:-0C-$UXU-U S2XX@%<YK&EL5&Q*SL7,CJ*>
MG*,"MY6[R <[:]R(4?BK#52 L\I ^$V56085L+=G/:$QJ';M]MSQ!UI#_9"P
M5.7&20X5(VS>4:+5E4%9_5);-6[OM:)X9P8#<IS\<+F;J!]BUW:GA?^,6[;5
MP7>(D#.1\S\4E?9&"52@S!/*CN!/E"ZY3N)ZN.QUR.U\C4YNX0PK35.1[I3U
M/,%K99 S)*(>QL'BW=DTY\R2!(UV["KS(]L>H4U+>5HN&Q78[+,2OA,AZ93O
M$SRXL&:0/^'YRI[7^MNW=M%WQ>;U[+[=6Q]2>S)B@G6D&YWS[15 !.!VIC:"
MU83A7P?K38_YNSMEZ)T-(7TSX2_EFIM[B@AD$D#7"Q\HJCE!^3YY7(VI30KG
M]F9=ILU]%#%P*TBV*B3XF5296"6H 5 Y9M]=I4?3#@=H/ 23T&6?@1>5?;+(
M$XI]?/)R^)H0\X4=PZ/6ISO%HIZ:.456JN91CG#@&A%2..TI7*\$NV$O0B2"
MZ#J_?I"EQC%0<#?_^WK).[8AG'NNKA$N-PD?3SF\,14Y'60BFV!69]K1YQ$2
M$A<3K6 Q[[7/),PL(!S:&&8%5:3Y/GB\)T*PDNBX]R:F'F(:0_C4(NH0FSH5
M7C7[>BP)IU1RRUV6Z>MDB*4<42Q+-YTHW<"I=/&'Q'#*E8*KEWCE&Z92V")]
MM+1N26FD"9ZL^'Q,IW)'!,XS'1:(%( ''F6MC^-=3TMO$WG5S")><E[?A.>T
M)J_.4X#1*_:G7B1:3G 2)7&P56L]K>;Z4YOPY\OK![A4Y@(%N9JO5HS<]SI4
M5Y=W$B^\1L97-L29#<D'L>L%7F]_KI-VKYXE^U#3-6^W<SL:GZOF:E3AC93C
M$PBYR-LZ)%FW=-X;#U0>ZHQH&+\Y(7?=< 43?$+7V4?]F?2[2*\#>)V4Y0UN
MXL$%0BTY',EG/\%BW%=E-64&74VX>CW$/^&B/?>Y6N&8\R*S!B3U,=;W#VND
M_*<Q0=:#!X- K[=C!N17*5W<B!KD*I9';KUKVHBD3$R=Z7I5L4# O'(9K3Y"
MRFWV?,+SV'S!/HG1W+KP@-AH+G@J&7/F2>$ER3?9]R-/[U_S,,;$;L\=H;P3
MZ>36OB.$%;><;UYU3I] =J"+!2Q!1._'8/_4@:(?GSIXVX#S\GQWOA0>=Z03
MS7J+-!S#,IUI7J/'Q6!!M9.<=J?</&("94&L[AV$HW;,&;,^\(K<F6P-A3,<
M3\_X!@>SSZA=PN=6X^DMT:9XH3RWG.7"*=7^V<_:M8LIJB==#6K7+/-P.X1!
M8B-N4*>DIPC#J>.2.GHTWW39%6_!8-G*VU=F\!T8XDUWBMI]ZRQF\J'93P8=
ME*A07/7?V'OOJ":[;E\TBHJ 5.DM*B " DKO49$F B(*"$)4FH 0D Z!*$B7
M+B!%4(IT(KU*Z$6D]YJ$(+TD B&0D)R\^^RSS_>^W[U[['+WOF?<^_VQQGB>
ME9759_FM-9\Y&X?'NAK+\O.DW=T]SJ0RLNL6FZ= M_EINE^[=SLO(%#9QU\3
MEC;!D10 G7STR NRPJCW$\/Y;!6Y#S<>^-?.^+RE .['^$V]1[C"J7NK(OW'
M:K>,X^3K8+A@L@M'"8OV^3T.'PSYK#6'3:#'U\7;/E1L6#;/5-FEQF2,<7O-
M8_[ZO%JP6'V#5L%GCVO5([-0 \)E#.2=QJ6&434#-+%?['E@D5N%[-Q@0ZOO
M,HTSS<'0BU.]\&H8*@-VRBN.;F,VO!/(?LM3W\5T8#]0<)1X:&*5*G$]45R!
M2:'=^U#(K_N<<^L^,^&:3O<VK8&^T))EH)Z-59'"E^<7$M_NH&_;[,S(=_I&
MXPL)GY9V!5]J2$Y"C=3)!5\6)!?>W8\6J)8ZK\1ZZ7''J9KZOC/!3G:\27$2
M_$^O[,1IX%+#I-4N+@TX=!R_<^'82?63S.SMB!]I,"&5"#8R PF;9H0TC*1E
M%^_^NGN)DP?/:J)2NY0;X)3.+0 @4+EOI>%XP7HV#6CE"/S]_@1"[CE+?C#5
M6S.EB;/I<H/*9J./G9J@EZG*TKMTGYFE%>@IQ,^Y%=AYC+?2^M.8NR\PK_-V
M;;9@T_T8SDB,$2.2=(J02 &\Q+:T\*KSKIB>*MTQWV$M 3:E=GS9(GD@PJ@,
MWE .N06):J']MJ>V6TDP7626=5T@.GSRB)WI@@;PQUV(%'8=Z7TG4YG)HG.'
MN<P+<5%#RK<)PUEB4^3;\R3)LJ6BVI);-)$;8Q?ZY*/8=$G]KX\[KRJ&A,<#
M5(W2.(9V?E=M&LWZ:.)T(A"VL+>)ON*S>\98]=H8GHF<L4>];&M:+$B5@F=+
M[EEO(P?I.); E9"VH8@@54)-[E."&5&_ S_)12=)1O#X"M6\N2$C17[_L^&T
MAH]#=JJP!^(\!>#$' FFV5JNP&9'BE2/"7L(.1[>%.EJP4PD\PN\.Y1X?UA&
M 40@:WNZF2-GU;L3BGV+2O=+WM8Z6TDMJAI?V1<?#/%[J%*^);B4^'ZIX7'X
M .?.T-T_@J:\A!= @T9))B_[//(W&[5J%O*7[PORO/?3K D_X\):)Y#I/QE'
M8E=MHQ(G"8P>BDKG^'"<'7*PS31! 527/>CC?\C8XQRO<3_W,D^W(7J<]ZB_
M!\BG9HQC:%UDP:94N4,4$M#FO$@C!@!;Z*O 0V51>HY;W-Q:&"'Y$:CH26G0
M-1+7:'<R.NYB'V<LG__Z87R/![U@P;,$O5MZPN\NL;WV^W+'^-[<Y]<&30<J
M1M-(5!8",_3>FF=JL=L92.\;]%O2YL&D:WR/,[_;C0_2'Z<?FG_FIJ7._IDI
M':(?26'2$M\T+OGJNGU3/4ZW,N-^V,TD53G'<Q/JLBO:'7-1* VQH&D@!_G&
MRSU'P4NX^]G38\!%1SR+C@M["+'<6%.%JIAVQM)RQ&%@LZ">%HT6K-=.;BFW
M-$G4*676ZE?Z^8*XE\8K<B$K#JI<PIEN;N<,P=>/&C["!:U-Z#?;R6H$DZ5Z
M-BM9:RP\XGD2BTR7?$VK:[<"MZAZU &\F )PV8RQ-#_))-,YD55JB-*=3T:]
M&O=R6>?E5&]?U0(\RYZO> HMW;JAS+&J8D1BU\<$I;ZH'5J24/U=4FWD\[7=
MEG2OL._PTE0TR8!0L42=%2&5U>B#M(-/F@XI,9<>ZR8)OXMA/ZO5)PI@,O0?
MZ1?34_9DZ+J::K*UX*R/4]R^2;Q,TI@,XMUH?(LS>DO=/A4'5IS=ZSGI:$ZE
MX1OT'1YG8P1T<+1N&L^K27X^I5"]&BH$KW*%0Q\SY=;#9ZZF_++K51)ZKCP8
M6***/NP<8B>)3:4^P:8T^'S9$%=(<\GXE0!K7+MM!K8_8U8/)[%;8J*FHSV6
M)#A3R4&QR9"5($L%"@!3?>V'BN2#HP]U:CY+P#"H#]JO^AUN.ZO!!E\?,Y!G
MT1:O:R-9DV:JF:PL<)ZVH";0BBIM+_UQJ"$?X]S6F!+M[%<(O1&G%4Y4,5#G
MU=?-$ZFT=+U3I?UBUNBL-JTV/)$L K7&I78S/A30[-:XU#3E^OS"MY//;^+#
M+GV[^X#C5.O@L KSO9T6SJ!I! >9>:WBY2QMY)/]E[#Q:2<6D9_NS#M?W)YP
MG21?"GB D00^$A$I5A?"TQ+,,&D:XA:^HQ(90_2^HCH_CUN*W(4L+1?N?LX6
M6FGOI0/4^CZ@$Q9H0,-<C>CF"3KXS[A*HXLZG%_<&I.;ZO2$DCG^&9Q4M$@$
M36:SDV4=7?()J5UL+?$##=6;UVQJ0T\RM4_%NS'QQY\?\,CFTE#PS<5XY^>!
M_QF<C&'&/OL^.W_?<6&N1);-/-$]10G@?M=&*LB>R?C7+QU:L#N)%5N-J';8
MDBV#*F*_+S3Z]M^>!%7#JK[&:[MB)+_[B;Z9^W1;S?4]S1L/,)/I:@@4 B>I
M3:$F2?(E"R\;2_E%)C)#^6B+LWX6-&:&S#\>E-*_8R-E5C2VIB% R,"F]DPJ
MJEA'+PG0='G+7G05JOA@4.]VRPJADA"O??Z9>Z_\L0<*04^@KBE) A$)Y(%*
MY!&DES)?'YG>L%K(8RS4+2)^??EQN9[8SV>'N10H@>ZB,J-HJ)L5: N)C9].
M\\9L.^B'#*Q/[6P/D<XUB_: 69N-<(I/ VVZ+'ZM-!1^:TW?>3C'12S\S@J;
M>7#6[MJ]@#5''FU5)_^>[1 4)&K6K,O LA/&5EVG)R_66SM^O2^EM5LI]IIM
MSZE'@9,=/D+"2:CDK1OD23 ;!8 VVR #$%.P6I)ZX5RT2V,I[&76 @U-1#[H
M!MH;'0W06*,]U^Q?$S-:)9L,]V0WUGIR^5]SQ?!_CNG&O\ULPTP9=W'IL!T6
MWG(U51\'CO@R>A"F51_@\V1Z^Q6*%'5K4.5Q.UOA]EF?Y;L%W!)],RS&YD#L
M* 4 H #6/&HI (09F*3U]SDN!TX4P-[VR<_^37;8I\ U9,XW$#J??(H"&%ZE
M@LR@<@0AZN\R-,K Y$!$0_CD-0I A3B"T'H&Z] GT5  7P;GR"=6,!S[7]\#
M+1 D(LR#N=28['68&Q352@&$I1)H*0#-3W4GQXT4P-*UO\\YKH$=X<DK0/-<
MTN:N]@D'58=CE,8RD\-5(<0#+PJ@T_CO,O[7:#0J=(ZF%F..)6C(O& 4\(3)
M&WFXL4D5OKE_?=^@BLC5.>+'P!=Q>_#O?/NFM"0Y1"OHF'\;L3LQ10&PZOSU
M?:*$ ABJ.[QQW 5<!?LKKI4R$QQA;V#[RG,P9 F<?"7N+Z\E9A1 -F3G^4$4
M:+!E'S+R;UH7H"F< M! SG?\?W)9_N3R$2[Z=VU(:#XX*=.@W3#%M;EC LQB
MSHN?X1+ZW$/:^\MR<?UC\O]!$_\'+LO?QH2#2_]=<7%\&M$<RC3R,VRJ>[)H
MQ<;[68.Z;&P%<>0O2_5)DWR'"W0P@4@K/@@5W5;$<CH*:N,^5=B+Q.V4^V<3
MSBK^ZRM'1>Y32RXF;0@:$G/IVE3E^G%R=L3U7V%+G!T2#*K9/P-,#[<VB5HO
M$=5UH=V?"C]6(WFG>]+*>DX_4.EGV2EHQ,,Y3QHT5*'JA&2LA^:(FM"2:J U
M?NY),&JNB[_8E*.N_DYG8VSH!_\],*>O0^=L08C7IJ2#]O=4H_'29;8.=X;G
MR>%[@A/[2M#O+VY$R3ZM-)@[WO)]C!L,$_O!A/-N.)XK=-Q;3S6"N&4(@WOC
MC+<?EZ2>?(*]+./"IV#KQVHN<F9@++GWY.M1]VB?O! 8/[2>F/Z+$9_9P.-\
M%5FW]"J=89,BWA&3D$8[IVLYE?)_,NDCB.*S*(#$7TM@HC<%,/JR9-?I[[*V
M??5/CF$H6*;1D"^2K$75HKL1^VF"EEJ*/\$6:ET'\,FA3AUC@SVNR0\WU-=.
MO<R)KZ<56#OEO &>#B$[&!%?4P"S![\G O6)++"?ZQ2 *YAHW0*)H "6S<S(
M"]0F$@Z:Q2@ H2@0_I"<)+2A<BT'<1'TN?V?S.'&'/^G<1S &_FW7F1W-/XF
MY-_^WUQ]ZT&XTY>N];7:TQN-#]/^RB9Q:':JM"3@G#M8'6?S?T5I9'7F5V]S
MB[JM!DNL(ABA@H2!I0%. 9/[&=8-E1D[NJD766#\4]0VL>:,G )<F/"0G"AM
MM]F F\CW<8N2@3-$%L?C,\BJN#"+3<O@Q5<:-LX1X[&!C*J*WX!4 (\=@@FH
MJ]VF & K%  O")U%5O'W#2%3  -D>6+'23(:=LQ-I3^LN#BHLIFZ^S49$>2S
M6D;)>(X1@CH%<.$0-S;6"3PD0W"Y9)Y=3$%!!&B7A,2 FT$SUEQ42@Q#4@"G
M<^!BA"+B+:@P075)4E0/QQS]4,SK])UJ-N$OS"YS_@^KK$ZOD4QP4QVP:"33
M?NAX34F,_^1(!N3CX<53I,VM(8((9U/1)B_L/=.7(BND2WW<RX:TO+G?L6GR
MNV"L\2Y!IQSFH+0K]\F5X> 3J9-UB._7/5M^)N=V"@ 5BV^T&LS @+<%M%79
MI&SF5NY%9L?#_*/5@]=.SN<TQFW!&:@LI@-" ;PU-O[;X4+AWZSXOW.,P^Q\
MP>0P/AB)/NK/A7\0SX[TCUCIX,U"J8SM>1T%T%I82/Z!19Q<H,(L @<'_W]/
M#;E_\D,&RW$2%!Q>2E&JZ5<^$U._VQAWS-O[_T*O_E'#/]4PG.*ACN@ L^GS
ML2=<:K"S4[H4\?I\J5$XF-5%+;"@/+Q<YFMA[J&)YY[[O+]BG?_")-Q37;HU
MZ%)US:2D%*^E:G )_F,_YTT6 (!H]O/&@$ASWW7#D=[PUW^<F;E;C5\KCG?2
MD;2(93, WG'F53N6' E[GJR6%Y(;!R;7/"C)9FJY,NM+-+)B?FIG8*RS\W5]
M!5._#W'=/['1R=9JO/%3IN!#O*<[5=I,EHNUC4$K56Q$1#RU_CV>ICG.\O_)
M[!PJ3P&<-<2)C%MS$'S0YLLW9S9Y/QS*ABI=?V8^<OL N"Z,&:>9BVMP1@$)
MXN&DL"!&*B3JIK;XY8GI![+P73(G-(W?F=TIXHNQ]NG8-_06U^"V>_]W,2S_
M6U(ER< ^-5UDVJLOYD)4X'F>LGL%9;!>7@J _'V9NM8&HM\F5S<06QX8!H1
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MA1+ KN[=WACY."V O\[V1=P+8"R(1TT3XQRH8G!5P&2+^.K7!]V1(V]<1S]
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MG'@SX??/@42CAM(-L3N,>UQ</'HOH1<M!9G'KLLCN%ZF>Y<$-9JF^@2>_;Y
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MG9D^\TI"\:>-;0+]CC!V1EVL.\=%P@*%M@O(EC$&YR,Y-1C) T@:J 3:B)>
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M="+3*;-+)I_TK8190[=F]G2V$=BZ#A M6?4I(:#=PG&TVFML>]721BWI^;1
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M.Z/7W&YH]GS-97KQ_M!UZ-+F#WA_8L^_J=1BA9^?_$''D&J:L$>B@=]$B4=
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M">*=;^!9Z<?"*+JM/@J@U==YIY@@@?_T9W-8)6,PG_Q)SU$GB0*(R98"&U
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MP!D*X,ST9%FS'1H1!::K499U*%W?]F%WJ&SD"PB)>ZH&/!S0(GK<"F()&J0
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M@.-1<R]#UE8L7?;CV'QJQ9R\J/ PNL;M=,QGEZ> <^<D1'CN/1TP'TN[]KO
M8W/WSVKG:R3V$>1(*4:4W-4$.;G6 .<B?*<23BI&L4N2KR>]*S;5H<31>*X+
M<O;]P^MG-"7N-87H_M1S4.Y@NCE6]H! Q*U:G^1 76@C29H.!=.+'78"P5I?
M=:[H_,IM"M9L$IA):#IVO_ML"1/T5NQJVL&Y\DXJT8O+W<_$/'H&PMK)^Q]V
M[#*\=,#S$0)S?(?:K2\1DG*=&/#9HAVF68%=88<IYM-GO&!)WC_+C8198R70
M#'%4I:,.5+4-;\-7C/:$2^X8_%B(R",^N6J?<;9YX./\*L'?9A/LZ_Q/)WE\
M1"&29 C>+Q1BDS@H$7-G ]F7M0RYM6,L\N/3F%S&F[,?W@!HE'ZXNX\U24FJ
M0^-83O(T;I@3@"A5DC@A$%O797T.6[.U<7B<&KE_Y)+U@E_Y\:)YE>H5N[2W
MLTUW,-S#?T=KAU@=:T*1!S:[IRZ[^M/W3&MV_2L7B7<8?!T2U>$KX;IOG@+C
MI6Z]F.YVWAOZ)V(S^E>([?'$[5G?'UDP<?>G(^Y6;2VF&1JC)W%J3V 0(@,A
MN5GRR[1O1J>%Y'9_;;0?:YIKT,M?'=I,*U=EO-].Q)]*Q^TR_W'IV&S?N'5C
M#4:O)BC_J5LI=VR_H66D/IB^4&<AT_:9V1#B#.RE- ]YJ)%T7/ .CHET33;=
MZ=X R<RNFZEJEM_N[>L0.V.[%WS[<&Z7(';8^41RV1G(0# R'/]J58GL<915
M/@3T4P!?7#D,,U;\K9>+2B1?0?MP1MT6\$[IB,4K.,X&1X$P>*%UG_Q$GG&U
M\X6T-H-2_0LVW*)J'M8+5(Z[3H5:Q=C5$W]K"F!==6JP<:7&;\D \F#B@ Y*
M)!(CI<I%9KF@L5V?OBGQ"&.5RG-1R*X!9Y1/)R.H6Q 8-1AXK\_V;AA9(9'K
M"6M"R%D[UY@L[M=G(=<6F:[]D!IM4M?'A^&RX_:I6C*LQXW@88ECY[JYF516
M:N$RC@X#_GKT"&1X-E"(Z'W20L2K$NP",;X/I05/BL<&V<3SEK1KXN=/T]Z/
M#WV#NF&=2?^[[P^"Y!1^7[QFS?P^>\E2HC1N<#GJ"(-A[C'B(7E/Y4Q GY?(
MD^+%])U?#NN<K<RTU8YN'3RGUZ?$(WJZXD&2>V--#'].4M7WH6(*X"_:$.@O
M[T=-/>#JU,B@2U >;$&'P9T>_?"[V.5(R;*!ZH<,:?3::TW3O8]P0I[&@]?^
MS7H1A[*$?TCBU/"Q#CZ= OC@1V*C .!-1B<B#;EDNO0>,FMV3(<:S&Z6']8J
M+;&R*_ '$""\Q3JT9S/*4Y& P,6.1.':.H4172E;,;Z<79O+)ITQ(SI*5!;Y
M1P=FR#U=WBW BM%=&YQ I:65P#TQ_FX67?:O?5RTAV53ZF<%!ZT'>H[GE5-5
M',:!6"-5,$&_Y30)@HW-6DO?/LC5.;\0IN%56J$=]+9MM=9Y%3CCC(9$->L1
M=7WO_.B_VZ3(R]3@'%!\O8*=T_BV2G/80YT?;N\ ?J( CZ>0-F2,H!B!"W.>
MI(/6GZAMGGZ>SI,*Y;J92!=[M[>WE[;PTIO;'+M!DE0IF@I]C!/(5, KI'.%
M?U2#J!T'-K?8SIFS-65IUNAR*QU],^0V<4^'I!:*:>4'A8+_8G&T!N)OD7<&
M YO]I*/E-_7Y)(XD,;6_/9<](\1/G^IHXO\=,)5M^LWPIEY:WZ+!YS\;(OWX
MLYF2R71RPS&$2@-_F!XE:6.!)P@J#00.!#* U6%M( I@>:29E@*@EC@&>X#O
M3$5+SFSHV++_[9G/ORM)F&@.(TT3/LWU5D6OI'@KT=.*)B&!R0!>P;#CZO<[
MBUJ98+FJBM8'RFI9!%()&CAG@A\WXM7QPJZB!T9"VF]>9,HML:QERM-9C%6@
M +*4-Y"_QTZ&6H)FLVMS?$=5X>$@)M?W@JP1'[T$+!:^>5W1V'>O(^&&J)PX
M)7LGD *(<A[.U5[<CU5)EM[IO)83M:T<5P.S#0?R(^QA4=GG1#6\BYR9\8MA
M,?V0,P(E:V>*N$$'"R5+M0]+;W,+!3,&T&XEX(S('+0]% "]<Y+!\GK54Y@#
M,M$-X9"Q; ^Q%0&3 1(Z^%&")?7W;'PD3CO[@H9A1F'_2=D+0/N126+GJ;5*
MOPC0?*G-SD#Y<3K(7PS//%V'-B))#LU>[/#F8CF:-:62Q>P4ZCT\F>X".U$N
M3$[CI[,BOII000$PI&*F(@_6[/>JZPN(YS)O_SA)Y\^I)"HSBDX,!,!:JRB
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M #CT_(D$.;\JP:X#8\11JJH<9*L'MLFH*B#[9[S6?DXY7*18"PJ'+4M3(VA
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MERZ7$HQ>Y73M<\YI5R[Q7@CHPF=C-+K;NB,S3N,#!Z<\=8>2Q"8_N,*3A&G
MX_9WR%!/T $:8,\1">*3P>?[.+0<T7E;?,*3_[,ABKFI:?B;)ED _D+ >L!@
M)!P=6-EN$#O!B<O!B>K55CNZ<!VN?1W!=^?(J;CJ&T4P%.(ZI03F&./?/GFH
MW(6)&$2%<C0&":64U>I)Z[L?O+@C:JN-=JMROE5NP/+:VB[>L2+UJ8Z.>:J6
M IZ1P$_LP,UK9QHUX(K[/1:XZOH<Y0]XV-ZX8)J53F144'(]W^4CXC>Y0@-(
MUWQJIT#1$IYL\K=JJK^3!ZC?>^Q>EM=_O</_V- 5 :^9?AZHJ;:&=)D,0TD'
M-UPP<VK@C[U4!N9Q[%F^J<6"U8@;>1JJ93ULLEN]>.7%BVH[MM-%L?Q7*?%!
M$CXA[3%H)\@!?<_;Y6&[AD.'=CC5Q+XZ;S"+76!H7AU?S[C YA2@38D,$B>?
MQWVEGNB7N20KR#>B.S;N*._H/B.V].V]-U1@]O%QZYG(;011++P=<7BA8N(@
MT3W7LB+]S82/U]"M!B>O,R(C]^)E(S[1@*0')T5=KIAG!-=E4P^0\*=NX1#8
M?5E$3V<[& <Q6L\6EE<]?O!M*Y:?2]GYX/N+T5@)I?XS>AVO&DSS'[V"-\.&
MYS%Y[= #LO6,+<M'8TY?E4?%-)MWR+$?B#X_UJ*P\[B#.76^X1SU6P:8>$2V
M"A\6(A):^ 5:V1"FD3IAS*AT]9DV6S2Y,*3I4IL7K$*Z;>T(L6_:),)#Z4M[
MR?<ZV7==.8Y^>@G'L%!,L&:,P/%I7Y8#+HW6 /-'>HN*2.(H22S  <<1)?5V
MD#E<)FQ@,RJJ8T,DRNZ1]KMC&^567!T*K=&*UK?F4J\9W'W4UG [( W7AX9$
M!IWSB2B3WN\(0^V^'ZWOJ=S A'.^84CSB"YH1[>[=_G)K[20P#XDC'>4# <7
MT4E5,2DD>[DB:W<-ZZHQ^S!> 30;KW&O^5#0#9CB)@?QM#?YE>40Y;$4#=B\
M5-!,92:&W.ZEGB'*H;H-:\LJTRQ*-DX$>UT-^/9XAC&D0V! I]+C:7Q/Z>(:
M:IYPA5B)9YY>BU$V0=.  X+JJK4^]F$K#^3BUFY7Q)BN^*H?Y+[["0L1)4K_
M(/O$?:KP@#(XAP;<-_5Y]'6)[^U$P$U*!L ;A1X^BN8/W8OOK4\@8/!>M;8D
M0Q]"[ZA9OR36V,G3]&1-W U&1W;5&VX3-=+#E50Z%\"*T@ ;#^3NZ;FL"R\<
M\Q9N7;M5O)'\F"I C,)X%;KG^CCH00UW4;WFBW?OV$8_LP5JV588&D\]B?=G
MM,K!31).$9%X]:OAIGW*%PF"4FC&)K?W8R*5K_*>=T9[/]<Z43$5TB0[3F<V
M="$P,VM >2*%W!0K^!2D0.VUDB'N8'36ML:OF0=>])*4,;]S!RKYW(/A8IB+
MB7+FW<>2G?KZYT_WW*SEQ2<0'(CA.$'H'-[KZ6 %C_1LRSOS:Z6CM=-*WOE*
MYL"4W(&F=C>KNP(N,I'//JRVGGU/%W&J^P+S2!+$9A*F8Z4;7XH>BG"V&WA8
MELZY%2@\#GXY^"WB%%IG1BS^TDOV$1>S.9AU)MM"JMXVO$'")ZS'Y0.9,2>P
M9'"$!D0N#EZ)OM0^==*>=Z'WS-(^Z?N83+D%A5L/QO4=FB8_@MH1QQ:+(7EA
MIWJPLW2QO>TV^DFKSE<*B3LNSMH*+LYL![$1:Z_C9CM"\E)IP*T+K K0^0AL
M[AE^[99OX\6F)\^C9G4Z@"%1O.UT94R0C$_DLA%>KM;3HZ3Z_H?#QN;F]BMQ
MK>P#@+5#?KN.:.IN ?4  E_0KAC>JM3-,+E\<<F*5]%B^_FHU?G$PK>:JLJY
MHF??GN_<7 449-XN:2JCV,\>]E+ASHH4=S^%A8UTZ V4NPR+3@OFA20Y97)W
MO3\Y9CZ20 @K974V%1-([Z&\M:T:8W+"),0U30V]#CA"7,0@'P=)6<*:AZ+X
M2W:\C4V \O(QV%@< V^'S?Y3Q0)# T>#3E(RP0^76TL'RSJ(>O@+.Q4=L/NW
M45;Z?G93IY(NOSH5K\JN=[=0;M3LHN7I^*4 VRGDOF70(?*M/!_W%D)4X(>E
MP[[&@U@9UYV88+<&32,!QG[X-8<H\JD"(D<K*CF\?/ET7WF,HNV^@8*2XI@.
M:.>UN+%#VL>#V<6KB.FX;KKR7-+=]L5?4#4J$'(]0U)+K]]Z3OSIG8M<G['5
M"LS/U9CJD83-[P\#W/.(S--A(?LM+[;S>;A"GLYH^/*Y?H#5E\G "*L/=BBS
M(PE?LE?A"9N"=,NM%361F;WHU>V;#QG3<H*Z",GKBG^\?3-#09C=J3J-X$D,
MY6B5-&GL0E,FSO:NC-ZHZYNNKW3G.BG[O )_XHI73?KKI/E<)]0_IC!:<JSP
M3IO3%510A7,])D:O-+# %#+^Z>+SM)GHIT*=Y[*'65)N/R LW+9)1_2O&X31
M@&(0_;,C^805VU/0F1\7O?<+L<88HR7K9I7#;MO6!2NP5>X5.E#D,"U*G_H<
M4XJC71CL@<*'4I OX3<J$ATJO=N]U@R]*A@:'QX)B<9DXKL)\?B\CN[#!K"B
M)</1Q;1BQRQ4YQ?'AR&O#[RZZ%<]0SK(L,FQ4CK-NA8%*@6W=X=;B50G&)7T
M>F@-;"9X4&W-%87AH:+/L[0QUDKV]?<?O3*YN#=;DA-OYU;7*^%6H%3,\B-G
MR'<&B#H13& D#DRS71#?PK7Z:=05U,@.%$U7OHCVAHL,4??N\Z !'PW"-O5.
MDSIHP%%EM?N5@T$,O0TC3LXTH,UC^82F@*VK:8JF'R_7UIXZ, ;9 >,/N(<7
M_%:(L?1:G=$YX?/0-C%I<,"]6>.8TFV&6+]7=O&^N;-G=-HO[[-+'-G*6[F%
M8^R89*1SSB^?ZNS1HS%GQ>'L$_NE!I*<? U2.%C/'JXM_M:K;EL>()V]*.]'
M*+3/-=68G[3ZEO1=HTIJ1S#X_<QS)AU&84S#% T(=B5#\1FETUWFC:C<2K?W
M1&_22<RNF/2KKX3U4YK97[P4C$Y\,\ES9?@6=.4/D9+R8_ISW#H'C95^9&IN
M!_/4N6#8'+2+<=E-<G!7J'21U*I-[/Y<X'"P7IO=I>/DM.*XC*PJ<!3XP!:]
MVPF9*EQEA&UEE''PI5G/\I?7GEAZ2W]5FJZL#]2E*VQ,E+=D5^2Q\LSP&N-B
M]]=$;RU=3Y_-Q531.M_CL3:]-5//E1O?7*R<[;;*<".QD^5+B"UXJCB"&TP(
M2W@]HE-H)3G-<Z<N*X*O6J$SS-.&8^\)0;'HG"_=DD_:((G'P&PP&V34)->F
MCRQ4M!GKF&,AYN.\I=,[8'_KD[VQTHCVS#D+H?9\\FW*\R#Q ,%>NX$Z-70$
MO]:S>Y;J!BE2-L\<> .?EK"_^LB8488L<\!>QB#A5A?ZI1P&I%;(YTHO.*(D
M+I2H<1U_'OK<M9?SLVU"PI/'@*#)"HQDX!."AK3JG5(;\#RS!=ZSS'/@+BS7
MZI-]&/?SE8WG<EY8R23&,(O@ TWL6Y*P1JO9E8"-MW2;894^AL-M\Q,3^DFX
MG\90("%R:W(_M0-V-, ! W6Y6HHK'1V[7QJ8>;.JKCI2R<E7+FQT;A4UOQ?T
MO/(@A[JE%GW%A7I!F&%0)S"'H]LSCQ"$XW;23?:X-IDX9-+EQ"@QPDW+3#(7
M;!H2X=D=C<IKF2POSPR3D:T\V3L>6=A?,MIV/MYEC7-NWPT?AD<*IV.]3[_P
M"S^K4^VA[(^97TG&2T_E1J8./?.XFJ!^C\7SLB):ROJ*/M-ZGMB!QGV/]SZ_
MF"'N3U<.5L3QX1CY<.C6%PYVK;MY8Z_CQ\MUWU;Z/H\.VZ\_Q6'3Z* @8%+P
M0^"2 P/=\*P61/]\'4H..L;@>CS68Q0Y<269LT:PB?\XDW' U*,K&0,;)FUK
M,1/GB/737Y"<Q!"C*A+DU>2]BLJ4)'X1YCV73,!BC$C#1SK""3H*%=/#7C%%
MMXCY.(=VR#[9UMX VS==;RTZ<Z:\Q(4OOKLD*1!YK?+AXT<7+NQSMQ+$K>9C
MQA_T:?5XD&)NW:YS$SB:5)PB'%</@#(_\B)*BNH<O/';U /3&*5NKJ^HO&=D
MMH+1G*)L5V]]O,SSUU+C.B/*46NS^0K*@["5@D#F1N2(-\:EW=_?)P=_RP(1
MONEK?Z-]3[-$%7.P_/5CL51-I=2@GO7EAJ9/B-P.D5PZ I>HLDM\?A:?WSHF
M'59</5II]B+(Y?H4=NPU518#X5(Y1$1.?6N0<3EV/YE/=CG?IZY92.&%@'.L
MAHA%((<@_H[?6E2=!J;+3\_%>*"<S< X7OU\78:#K[J# EO&Y>*^\D"7+&+I
M;4H6^"X-$$+Y?,[I+U\##*#^N4X\UBG1^JXW7ZW//^A\F_#IS*O$+IY7#V?$
M-<U!W#T:W,4O_\S9X/\N1H72M^MZ/,7IJZDFM7-W4".5-<W[C+!^WMG.EN=J
MO)_>E]U@7@I?R229.DZ6.4=QA"J;R"C"6LTO(3WE]FB]/QEKR:QVG%$B9#PY
M.I3@]$7AH;/0@>]O(UW5$&V7_^.6$?TN(V#"QS[D_?&C(!:?HOMT9OVLPBUH
MZ>%>^&T-@1KV8%6F.\RUTKRL\\;97]:T;$O2=4DEEX,C?]Y;?L WK7CEM[_Z
M_VTQ3@K/3G^ \>$F:!?S'KE\8.]!T+=W8^:?G2ZV7#@VHQYFC%7E_!%$X=9?
M]X&A?]D5?LT^^O/YK67'SSD!_M0)I%)F.!(_[TT#+)G7B_AJ?WGZYQH3S_U.
M5A*J1N^DN"8[7MP;U J%O"#!SLX[2\Z4IZ!3#CXZT2+N]7K_ AW9\K]_KEN=
M+DV]XI6Y-0+>/&$IWVJP-0A>16YP,73\&DPB( 9/ Z@LO'1F&:8B7(M#A&R:
MX!'/H*#.FA0'SA'SJF\S$V]2M0P!:X#QTOAS54>%^T]1YID6/9 ?7O5-VBJR
MRM'?B5K-!SC!9S_O:SFWFUG.,7N=!H3# ^A*R!N#)B21P^U'G!E$<:8MV%%H
M?C&'>R>9!G ($>F&SI7,$!A.:/I_1='Y0Q4/?UX"Q^\:OVO\KO&[QN\:_[HU
M%O&P'X)".++/1ZN9XQ#X0L>^YN)=4#EH5JLXTYH0MQKTL@=R(H"9;JP](WIC
M3E<[H9'\CLQ-9ELM$C?&RIIU><=>,52ALX6G &\.0L$RZG.>(&^6XPI=])\(
M_;-7IAS_71^?02@7 PZ!?4/BH0'-U20M.)G!><CJ0)7+A?7FXW?**D3CF6^Q
MP]9BPZ/YB'-(U[(8R(K0PR.ME<8\++89*(V#16^M@SF88\>7I\#_F,?10D\A
MS$M+\)K7=E: NP:7R=VO@2$D@!BB@S="M()#S+90J%&?(;V[MJ< K[&3EZ -
MB/*0Q[#YF( NO#BZH1Z7UFX&#U/6L16)S;,_87A,L"17?^04N#6:28W[2>Z2
MB9_<&RCLKJ=LXE99E R/W*JA=KJ^46+X\9 QDP$"N#(=$:,L[Y0=8$UTR")K
MD<X^#;\U(>G\@OV#?OL._%$HP^:'U!?V7Q-7'3U%[@7 -0(A+J0;9 Y<W>1]
MW-K*?&Z7EXI=PIT!OEG.6L%XS:GI)?$V%86 !_TJBL0:-N^;/64Q;(6%1]OY
M+?G&6@Y%W$GQWM,A(1^7<:F#D?N:H8N-F6[^ILE*WDER "6M03C@<,U=J6);
MSJ$Z10%RLZJ:'41M#LJ,0B^M=3RC >A4&F +9@J0C@Y,:Q.ZD$""6-YL><\6
M>[-^O\K5( P/0H8^@P(6=@GYI!L^CZ"<*+&'-E55_7;M-\QV['E-867?(B\?
MR\=:#&$C\-Y4'OF.2<XEPH8O2B,Z<R35D?DL%"WL#'%XM YK7!:"3)CGSKV:
MF-U=\6=> =DA#S7PD-V)CGL_"Y47+N"[\]I;@96"LP*9JFO[P6M\1-+MWC49
MO6O+!OV2.:4-Y8EO,B;LSN)K7EWX>'G_R8H&0;+Z4 ,WL<4 #PY#I!D,K%B4
M&3[FU3YU,#HOS'AO,$=AH$91$ IR4$5<P@1Y)(C9U$GHN!&K5$ZNU4N^AP"3
M-@..6?7;<,%V]NG>&KM%X01_D,#0  TH'R*G(5:^T !K5@2%J;>:(P99UAT>
M=-R'";371QX=%#'EPJ'ED1PCH3=O^?DL$T-=8\'(L.#H-XZ;%I5MW;$=F+P6
M9%C04451@@/YA-?A80H"&^0R*O\L#)O&\Z4CL4]RNP9O,)&@][KG=)'?9"QR
MEA_"CEQQ2Z,!:O5%\%8KH6IB/0W8.XOS7'T:XQ\X%6@X]<#X>W2)>H-AUY//
MJ/C&>4IZ1[G/T6K\U#*DU"4\Z @-N+MS2FL08DP=(EFMR;N^] TR;JH4\IZ8
M"%K3=Z0!I=W8\YCND0Y(==WWZ_(U]C@C9*\+PSF+?=\&IQ/=$L*$ZH(OY<\D
M%E76=\Z9#!7/O# 9JH%C=7$<E@W4X7Z8@S\$FZ0TH02]JO&P>RSQMI&"PE)8
MG0GA"1&3*5"GDP<9]='5Q@6EYYI1PKZUZ%R'/E6P+FK<9\,J)_<^UH#[K?WI
M+>.+CE)Y23<UN.TR XG@QC72O:#/$ Z9A9EQC,$^IX\+0^[L=GJ71SA?<FB$
MOGE( _IJ3>"P)E654^8^B&EK7$-<!9C#1ZI'QES[)+CV#A>'$F,Q\T,8H=5$
MEB09-&"6N=(1B-&!>G@.%7JFW8Y&??:P-LV[<MW=P=89N!A<Y^ Z8U-G8-CO
M[!FCN41=OU=55Y.8E^J@X. ED@*O%DYM/O< 6E\3T&4O/.V<5Q748G6N% ?!
MJDT5U.X8\^OFV_>A-!>$[EM=HJ;$/0^2[0KJHP%LY>!0I*"RY=L'-W3X=&&R
MV%=?5>Y@<[Q\Q@V"V#FRQ=D'9B/;CEV(_\"N)L ),5X 5Q R,6O,PT2G:7#+
M*"CBAFG1%TO3+H+_C("GZP4=8$_G)WTF;$=J_NF<KXFM'X;$51QQX4^W((+$
MS.LX:L3];511MN+H:-.QV938"X' DLX4H#-ETH?$W31?%I3N"&+"74[\5.MR
M@.@\T8Y10UVYQ#QITSZ).W]KF(H28B0:Y%G2V6XZ$6R+ACY:NLA#&"SP&DJX
M\O81CY=I]-2TC\631-GUO&=UZOD^I9;(0<^HSY[_%WOO'1=5E^2-7T5!!4')
MN94@" HJ26*+B("(" A(5E%) B*2&UI!<F@! 0&A54 D-DA.W61$DF3)T$2)
MW82FH=/;/#/OKH\S\^[,,[N_G=V??UP^W+[WUCVW3IVJ;YTZ5>>H_N[#\HK*
MU[,ST5%:X,F+K!)V6EHY0HS=D=%;3$36</*UKN?!F?[+T$W?#J_,90<*(***
M62/7JU& 2][O")H03W Q*%Q:^=$"])O(]>X[/0S[UU;X;>+748DIH64J3K*3
MTWPW')+P<E@>,ANHB8D17TL5U6'4$(? ]+*?1^P<,=UQHJ1T:RG@RKU^%<NW
M,Q6KC_QZ0>LN8!;PLG4?>//=TA!5\.$[+&!;)@*S$VK3O&0CH;&+"Q2".JZD
M@XZU(<%))5GF]J#[&TI=(AW1\(?$H]_&(B9M^ ZZ0VG\E$#^NY*-]/O>48!'
MT'J3]]II.W"'=96V&A-(^R-'_-BVGV6*[2NSP$#V5_G>@T061?(-B25R+0=T
ME]=PHZM>/F8"7>8_&^>OP5]RO[WCZSX%9H=<4I**$FAH$'T&*<8-(@KQ/W@Q
M +Y/L!HJK'XWAK+>'.KEG<_SNJ5?S9P>7:AU+,C(P/_0@KJ*<?LWJRL^:RO?
M[<YFKMR=+A1CW1 JB3[,>R%9\['&SK+#)U(X= 9&[H'B1+0IP'LG>U\'7#G>
M"NNCWF.#K\"D6C%[HG1+S*X.%'=HK1S]@L">NUS>VCKL 6@[-KM8@C$VTRU$
M,= AXK6O"6KD?OX+W1-:&QT3L3CE5K&=9'>Y1'+9ZJRW6^Z*"*.9?:Y%3X),
M%]5[]W] A2"M%9O=OT7+9H:W8$/PZ3I2BHJ07#AM, 4X3+O$E1L)'R9W;'])
M&<&!=6K.CU>GEFAMR#Z<J(S>2E@6I  G0%$HG- 8=(')E (4C,?["1!Y\!N8
M]=:72Y6EL4>;7IP9@0RHQSW6O<-;#YYTFYK8O]<K[OR*I=P@7!=1F%MH6&6M
M9 ?T</S0QOG"LFFPQVQ7WA,H/5G4,WAR+?*,DL%4>%?A8OS]YQ4>&F+'@Z+4
MR<)W^WP/G7AV]4D 9$*@+Z:P?=Q4-W-,Q\&5(7[[7)7&F0M9QE?I#FHJ'Q+D
M1!2!)Q.01_H0R#.>X4T"PZII=KM*I8Y/;RW+,5<_L*9[IWB\=7.ZSQ!\W.\;
ME(XLKD7*Q#)-6B#?H4]=.H7LE6$/[KK[M?!F) 7P9;_(V8IX3'I) >Q<L!Q-
M2:7/IV 'OT\PD3GQ#E?*44G#0R_R-S@N10IE&!_X&%UY?T7>.BPI)C; 2.PX
M[$(?L?5]F'AZK<_5)>Z*JX>&CC0^=AED[3_X^N"!PHN &^(M^2AY<-#J*(2&
MX[D,!=B/=VVQ9(K2.F5V]MK1(CKW,RWM)Q.R%F]&/_<_;Q&52+@#$<=$+CJH
ML)-2I2WD&EU %\97EPSDCIM]5E!X%_($/#3LNR1W&GK:'>:JAB,0+!+\_?;;
MF6X4X9&]#8HEJN?;ZQ+/]M%M*?;<39V1,2&]FK&"P8L\&F'^QM>%!\[<4]@.
M5H._UCQT)GQ!J>,MP5P9@L(:H#-#D%*>PX0F%=%J#N^4 8Y#5?>"9*:L(Z&!
MEU96M81B= NA=2I/?7UND3XJR<N&K+#*GC<WM[]@+7H6\BDB%SQLH\X?<0N7
M.^IEMU395R+>U;>)@AVG  TRY&8_!KP5)T$N3.F!" Y9F19\BX<WS?L8)(34
M*&E>1F21)-_0Z?H0ZD9%SNJ6+H1[$*JB"^S ;C=ZUU2/NT=;B^ >)JE^2?;4
MXDD8&JV&8Q3:28EDZB#M1:MY%MA",2^="I,^#Y$0RQ.0K+TQ.M++MS#KUY&?
M*Y^@L P30>2B[H)V "*5?N&II3W5MB-;8SVIVQ* N='0XMZ@1J8JH1=I5Y(U
MQG HP>61.OZ'LK)$FU5BQ5;>PS=I]VTX;-Q]8,MR&52M1$M6(BI]$G4;,]8*
M0M>S.R(=Q+Z4=]WA;:3*/G9V+!?'86!FWB!<TR[1W<:0;=C]O$Z?Z?*A9O$/
M>#.L6B.8#N)P%PUGL/2%W2H6.KI4*7\S0OJ))%:<,6U!]<!^E40L:"40 T6G
MPX?AQY 'S1;Y!>[O=UB1T[-5PO'1LQV:V.ZV?AZ1!/.^X"C^P2A&2\Z!&X31
M1M'8>V<VZ3+C7YE]3E).A9U]7BGFSA-Z/R2;9O3%51$^%2L]*TGBF:+D&_CN
M*7KM%^>[Z$+.H*.9'IJ].N!W#QE<NK<;A07>H9'_>"%&-V"9>!1#4$=R<"CP
MPT4298CWV5YJG3QR6*Q= P2UN_>-$X/B(MXJ&%0!6Q+5>HK!RTM<,HT#@CWM
MHRF?<E^PTP!5^V_L PJ;7:Z)F7>4E(]$QNA:5Y-0T)D5HL_67M"*WGN1 DR^
M49A] >:6Z3IJU7EVL''WX$ *C<>%61 -&?@$_\B&M@(AS\"CK#ADUGA2Q D<
MA)NU?@TX&/C+^F24)*K$PZ:M:XS/9<W\!BS7$@\U*NK;',EZ5$(O'X\>GV,?
MQFJFLSU0#CG!G6_T?1U9/U>\$RG)AQ<QPKM.'S5K,)W-,;5/<FPPZ^!AN!_0
M()E=T$#SU?_H4SC@Q[D(Y4!*>MHT>#]BUIX?UQ#N^WC1?XQ3^E/A\OZ +2'&
M=.,J'8(]'HR.@MDX8^%3LO!I9=.>D\P.26ZMG\JCKWHZOCTW$QOXN$+DR.FD
MX)6:]YYT]66[''6Z00-@)B&D1>R2@0XNIT?Q3O2;B#<<-C0B +^=ZXV!TG>V
MX]M?H2NJZ"5=#K\)=MIF/25NI\*,[Q_4%^Y':1+K*, ^]P>[6?E2. H@3\I7
M\J( 3J!=56?+TU-0%NVI"2X[E9-QW&0?'KSSD-#+ "FAYY_/!K0*(I0=/N))
M6 <R![RI8V_OP2&K;_#A(*9-4+%OVAXK05O)'/+K&]M7I:*&,CG76[U./*GT
MRRR&ULE 9^;/0I=9/(CQ2(L^\#3Y3Q5LOZ.*K%JD"$J0&^%-TU?($^LKITH(
MH&%D1\KD4:K]N/ZTR<NM$0E9UXIPOO=ML[5#7S?ED]FVODH^7H0"G&+!3I/K
MN:'D*/\:.9PD/A"=!\:!\9$VDRS.;M.^- ;D[M+"^).G8\9Z^&I/J=Z[8C#-
MI[D?>1M#':B3%. 94@GO0 K&%:*3PZG?7TP>+%H>-TBS_O+-8_ZAROJT\A+]
MY$0SG)5X"!OA)X3)0)N->SWDFDQ1^NQT3XB%-WR4^>W,L:L7!3[%R0F1=%AC
M;'$#5+E_!;$#K^^\1_3J6&'SK=%R*QU88W2"_Y8NO4/"KJN=0LP9#WKG>X45
M-Q>_,<CS?B2*5PR@[*G/P8\CA/N(#AC:81VGZ]*#IC>RO]*'*A8=N-TETE>X
M=:H<' $J3GA1;8<A$;DF)UXD<?A+?TA5#*K1.MJTI, 2,+=B\%GXQ@J1!7\\
MK'(;?.*).QZVCVI!WC;^L[M1B@TD9%O:5L;EOZ.:S >^#@(=!SNJ7L6(&,0]
MN/OY1,2,H:DHS9;:W[?LGB S^Z94CNG @K[ZQ1.#Z-3_-V7C1;F_+URTD:,W
MNYU6.'0C@S3$7_=3.IY+RLG_"7NDZ#<XR[0*B*;JRY]D?>-W:Q\;FP-!8IOL
M2Y5SE Z9%?I@G )TI5. [>^H^F=BW4:H3VO0^1XH87,OO=)BC;BK2P'\DHFB
M^_/^Q1X<_"%W< [\[S0L;)XYVI3Z3"AP"8RR\/1%D-9,@1DWIIU#>ZF01N2'
M.0.1Y&3/P4$ATQNJT2$"LELJ_73_TA_ZK_0@C>L4!2 &/:0 "'>JU,5_M%6Y
MB)EH%D<=_[ZK\Z4!@?>X6=[KM'+_A":#?K%/R&IDV0E<ITHE\F!1>5G_![L[
M,<+KAT87+G7.;B':*  746L0R>K79ZF 90I&</?L3C161FG<BE/I/Z77XJ82
M]WVR &XV'^9N9^N%KS;N]Q(:@+ENWD./:YND<KUL$>"]4&8?E0,!X>NF)H:M
MZ\*S['+C^06*+Y55^LAUL4"7NV.[JZ"*9>SKINV8]B#Y8U-Q5<8'KSW)$#F<
M(^U>[Y+%)EKU0>.WPEAVQ7\JDU5TYA])+Z&9!H]<A.--N:U(S]%40=P8]'=2
M*5FS*O4@QAV5)-=V0Q=VENK$MZ_'DM7[?)GF&4]0@.A\0>+E595B)Y7B5\9E
MUO.!H[ZVH[YVHN]K)::7KDXO::DK[EN#%X92@/!WV=!O_%8DT$'?1"LN<C-X
M_9:,+H&&RK:T2421.!8I2J46OJFQ9@ZB  (?*4!H(*N>U2G?@A\KFP_BKW[/
M+>;3G_(Z#Z$ ,7.H"UL(O#A[POLETZ#4\2/5+X?-M>A>B^A5.;!U6=F3)#&[
M</R5K=)EO1:R/'6X(&JM E&,*RK"?CV#EKQ]C",^>?=L4X*KVT5IJ/ 4[_,A
MC@)<5EXC40!=;!J9_WL&]"O,AP) >XD."[14XZ.#9T@]]9)I.QBO#VWXL#<]
MK)Q.;,'?I'L&;1B31NP>7X.N[4(C09AM'7'R"Y\) AD^;4D!* !C(@9$Q,5N
M@*8TB HVM="-8=UV:"#@24=4[KU&1=_\VV0*D(GOV2.3?W[29QRU@:$^2D9A
MM+KVL40K1>R;9P#7H^10CE1[G&1<RQ1NS,T?*Z[EQ)/F/@FZ!I!>89C"T["#
M+Y[6N(MR#TF^U6J\\<3X<:?XVWP'W%.,T3M7C%7]$T&UDF*\9AM\E<E^$X:_
MM"6YIDKUO^"8MXQ/PJ@",T73AZJA(^&@]?^#+])[2[R3B)U4?K++ZS60I=1:
M?M_I]G,NHKIAMUN>'#H_1"+OVHC]5PGA0)B8+U-V:DN)19]TXJ9SL(JP_^0[
M]Z(*EX(9ZU;!7>,.%3XLVW;@EJ;S\JGSNEQ$3@]]Q0"+5[;9!;Z=]G%\\A(M
MQ;^+YNL-:E&%T+G)XIB%:5QI_UMS;7K^6[L@0V68_?SJCR'R?!/UIJ&4PUGB
M[QW_6CB<K?T[=)VEF +DMU+EXLAWI  TO_"W8HROL[A^C)3OFP25R37YK+V
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M4'SVAA7^(2C4U9[_0E$1IJDY4^[%_=LE+M8"VK/G#SQ[QOOY\>&3^TX\N82
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M6RM@<I@,G@5S.X[T_CD?M,2* EQ-(N&HJ#S&!>V\BX-3 '5NXF&\) 408:,
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M;G#+VEB$-;>K$&7G3#5)T^!E0CK$$V,42!>XQ5;#[1'R-/DF^\F3BAZ30$8
M)_D.[>PK]AGCYBU<9D@Q?==S%.;&$%$9[9FL.TAT1&2LY"<^ENUBO7;GT2=^
MX]E2?5^E?KH#Z'+)(3C. Y,9HD2/@!CCLZ NF1"E;J%UYH&^:-DT,,T=P3GZ
M!/4=KWLM<4=TCL5$6#F\>#_3O:'.ME4,+<Y<7I>,U04750NJ=C97D_M.842V
M2U=FILE)9)DV<A^<B@D#J[FF4$<AVG@;J&P:9KZQL8G!@\%4F^?9X74JK.2+
M89 3L[ZC-9EL,-!Q.]5"(J7KC2TB6V6_7Z?*H4*\KEPS*&(XL#\AX'H>;6+:
M4$S1HM-AWF-J=SY5!A[4&FXWN75_/'9Z>[DWRX)/8GZ2K^G#"S/ZCZ:+N9*7
MED?4&%TZE7I4BGUT'L4U)%05@AJ9=JZN-8 )/$Y@'*X:7@\MICK_+\C[\&E3
MCTQI$]RL$1;A63+R+TGO!920=-8P44>1N%&'[TS#R:H8:##T[@1@YDEOFFR%
M24\][1,N7O4\])+GZK?F:9JYJ\(W+BD]17!CF.KA] Y6A;#&";[Q[ZD>8<6.
MECT#S11@A1D1R]/V*!]Y^TYDM.#Z%UVEI[GH_GQ"?"\R!9;Z,3]X"I?UUA8I
MW2-9;9"NA?#T/MPP_KWP6K=,HR=8U.U$P!L//O&%)E(&<K^:W) ![G&1HSS2
M*&4K4^KYXKZ(#0I 0W2PT\J+:^_1=8=D6*X1%(C"5%X[!U$ KI)(IW$[1+74
MU,9'NSS>=G_YTB]/:GVGUB5IRU#V('\R;2^$;@H<#J+G1H,.X*-LBA.N5[^L
M3O+M"5*YW7KV<]1U_P[_Q -!G-MK0T4M\(-NX, )CCD,!6C@4[M:6(A9B+4H
MB[V=9)VE^LF\.;?';_D-6!Q6LV)R+;/JJ;GUF@D\Y95Q <06BZJC *RVLK(4
M@!'),^$I=2MJOKV\NK+_0Y7)W6\-;4=6:_F:;FADUOB:8"4GK9:G"1=;[Z*[
M.$W&[7.R[3!\4G6EL5]F,PXI#0TE631I']].O/4$L'YVNJ\DOTSX,DDWH)H%
M'0HY/GV6J?'<\,B$3H9E@W=\F4/EZ>M.O.(PM0AC;>P@>FNP13?4%!8A^;1*
MF1^-%;A:\JE5KW#_3&S;^18A"G!M1>D!&A$,Y41*>;+WUEONTZ6U9;$<_C9Q
M.Z/.V@TYI79>/!)UDB;*>\,$7C+Q["DHD (4:X17GY]*!BV/,3;EJ=<@4H2J
MY(8;!"$]4N?;%/FUEG2D9_)+Z!6=WTWW&7\;/TA*)7,0C^,UWA,U\0N#PRFK
ME?Z.H'I91KV9B&=?K!Q.B]@9R3\P9-C7QFODBUBA)\C9#X*&=E&U=+U/@[Z0
MRF[T<ZV^@OHXK^Y0@-)7-1DX8Y"(A_5,DKA:(XO=(#<N0P+F?/9#K'![GHVS
MXEJ,J'8LMY3'G?(#VP)%2P;G_HA?_5]Y(*I1]U#?\KGR'B%/$74^#67D#VWZ
MTL[*5RKK>[VD '1N:MO(#4@Y@U\3M-!<RG0(HH-/?E"D;5&TL'OTB^M3[_2-
MDV3&Q> UW[F=QSPK1UW-X6:5&T([ I:"$?RLT,C' WFX>VX&F;AT[KD*E3*W
M.:WU*]4:G$JB%("[XWW8I$+]OWS9(_$/&.6MFKBQ[O*DBVHG@,^U-DESMF^9
ME ; =Z$!20-Y/A]ULQT.RXRN/5[B3^.\V=D4PA6!C5TR!$\]WP/O7\U,J3;H
ME171OD8A;'47)VRWPM6RI01>%VR'_GP'#'_'BNH";+(/H# /.*@L0MQX#T/<
M@\Y/,V5-48!H?BJH8J#'6)']AP?)#%2?9/H6M&$_D7KGVU(JY@D01>'[O=U8
M?7VHV _,Z:O+1 S9 /U,,XW,R3&)(ATL01"YU*E *:?W8]K2-_@.OF'1$SJC
M\9JJ57XB"<+4H@Y2_9&S>=#)+Y)D&<L4]=^6('0U@PRHP%Q J>4GDA\I0-#!
M/?=-U=&! M#J0;'9FXNBNS@1LM^YW530SO$Y\$\D-8CG).N@NU2]C;] [8M(
MXTP]C<%"\ 8VN(^JYC[#SO\EQ4+J/P>V\*J^5<N[036R$S5%-R.FP;@O-=Q5
MH&#HDB0YE H'];:6=8G$N[_QN]8,MQ]_GH?-T=C,R,"?,8T#M',D]F=F])?\
MD G0_</3OWKKG^JMOS8:5&JH702/4,D,)E_Q@OU$4^]GYAE^[]/[_[P_?*SP
M(EUU2]^/F"TJ+'?2HK,^7KVA#.TWGD<U23*:>BJBG<.+Z6E.%O:4A+?QN$K1
MNO(:*$B@@=;ZB#?&2V54=N\P=%!=X!4*\.XLY/![<H?"X,IAP@V(QI7?9A4]
MX3=_FU>DVKV7.WHV02]A=:JMRSS#;2ZQ3D\0RLR+7EQ!S+(O;!N,.IEP=J0D
M-\0P2R.!I;VW6O+^-$'#<*07%<?N:7>(R,J;6H>ZMN+XU"IHG+,(D_ B=[JW
M>$1H_5EPV3;2*7=FIHA?2Z2&_3^:7G3XTCQM$PZWS8O^/HEQJ6^I3EW^W>Y8
M@Z^]_Z']L4!<?D,3Z[>D400:JJ2ES2,.('Q(1:B9CW90'"VUES6Z+ ];5<[
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MJ/9-EHK89]&;3(4;BG#\Z::M7K^OW$Y)TU]ZEY^*NQ4%7CUNF*K?R/2QA7C
MV_ASW.[!7%L_'JHH!D(D,1WCR6AQ/OIID>#EIKBQJ/19]?6HS.?E6?(O+P0-
M6\0%GX")4$'>9#*40\+M*NRV!4?#\"T3NQ+M/'5^8=76.UGQWTF3:7UA8:X1
MUFUGN<7TGGAH?"DV5L72U&,\19J'QP,<<H:6<,.^O2--V;<O>DK<!,6KGXC^
MW *\X:7Z)& +VI-_I+; ?]5AY?7W3"QQDL(HP+WRAR6?\,E8V;:'\54VW9L\
MK^86MK3FU(A\_4SCA([U2;GAOYQCFLHS6VY<S-1=T93I>.+KM-0>.Q/J&77.
M4X\LDZS.5NOV8X+>KYV2_];Q'0FBNO4/G7>WG4F'[1T=;GWZ>K*B5UK;,[>Q
MJ$VY;>3MS0?1;9]'W1X^O*>;I;STIJA/I+?] ]WZL&;[@^";AP],KV?W_=;*
M?Z(X]\4)+B(?)KCQK/Y9#:L>E0DO5H$Q(<+U;O2Y]MJ[O(RYH]-* W1$*5"#
M[BX[:MU[?B]AYF.W11\67ZEW,]-42R),QR\SV>!L[4!REOX+WM25)KD=?@L*
MP-""Z24'(HBI%7]*YCE/I!J:=WL%Y/*A^%GO2+9,7+PB&=I% ?9#YVQ(T0G0
MK])@S"$*$#T[@6F''@4OF%* UB7X7KK.SV_7^.%1T!"7!XE&C0( L+_KO:Q0
M.VO4/)&*K47(=W]\;3->:G+MA0K_8LRB FTTCK[UKNR:R/##V//Q1H*,,VZ&
M\USH*C'1?+&2;.,$91-YE971M;3+\?S\G1&LUD-""9-4#';?Z4=DZ0%F@DYW
MKI$KF6;-97YW\@\!5'<D<]]D#T3>1;EA14_QKD_A</61.;>_<#VRG!S?/7$/
M>%DQ+8)8!\7)_M:Y_[@/ KC\F!1IV%^<H^RA7=5;0F^+>"2!MA4I2U03BBYH
M$*?I.Z;C9T=T)?E#7# MIC7]*MQF<F'$T])!ZCUE#W%?CVE9I,-DK@(,Z86?
MO[QAL?K09]CLQ+B0J*[MB@VS"H*RY\W83DQQA _U3;[>#/]@51L2 DZ1(K-U
M-4%WA50N4&&D#-47YD(,'Q&'YEYO^]9(M-JK!HNU(H<R1: P.AY4C]_V+WYQ
MP/F'J12>PYT'<^QM4DDTI@#OU:8EB2Q4P< F@?_B%]+;][#<Z\H1NDV_Y3&S
M48?V2WP;!3@P""4^A/W%+RA;T;0E%B9K%BST+UJ:]M?:+KK;V/"KZ;^:_JOI
MOYK^OZOI;U!'_<Y\&3&8XHA@@UW>5?X*RKV,LOGXI\9O@">=E^FG82&[6_&9
MV,N#Y./0PY>6Q.WHSQ$>+#1?GCJ\_FKS7N/%&;&(55#Z\(TXFW=V[MY.*8YL
M\7";(V8C(Y??Z8MV7WXOR@< @')V/]N+]+G5#FLVMOM4FZ2J^@_C83:;GY;B
M/#L*UH4;5&K[/)T0]+OD#;?'3/Q]"_:M_[XE/#SK9!QN6K\Z=775RRE_5<CN
M8:J-I%!4RYGVEA@MH1CON2K;[KGMC,+?%O8'KJPT9W@ICXVNCUF,:O9T*'5:
M:O%%F23"A*CW;G6H_ONR_[\\:./@H3*^*AUYCF[:(PY&A*\-CQ>"%]^BBQ+#
M"Q\*OWX3XYUT372?8>)>C>+,$U&'\A0G6!T4XCZ65/4C\O."]W/E6WR%UFHU
M/>B^Q'ZG;^WLH]7<J:I4'NT\E&U9U-7;<\-/JOIX99D$E<5*]G:8UL?'&J?6
MWF[+MFR]KV FT_": JR]01?9OJ5W5RC!)1X=-?(H8X^V5)\Q3V?^=*9[1K8%
M(+;%T=%%//]N:!A6<&(R2I7UU4W:U$QTI(UIF;:OAA$2Y7^!2Z"RPHM-\\!^
M&F:Z V2WQ#\C[X49VW3CJ_?=Y(T,_)D^YFR/"_:7:++3=^BOK[)]Y]UF7 3O
M=U#X[T]%^'U:@N0W!$X\R,%,,A3%\JC4SJ'4%Z1:<<,)=BOU/KAN["9IK7I"
M@@94:+5LS#!0:L7B=VKH4<_@HUV5@"=OQOBSE#Y# RK?$2:\D.:T!#7S09&!
MU>I6%<V$D&FZ0-"TN4R.[^N46]])6;05^;IY8UXQD&C)X\U,1\#-1;9_SDGX
MM<G]KTWN_Y=N<G\PY0\J;>>WTC!FW??UK<[.3MJ\Q5&YM\DE4#([+;7/E1RA
M:_$4 )V-[K,8KKB@DW/*C_,_F&]G(^11 'H:/0J0*HO:;H-B;T'K:_N@\Y$(
MTOH$T=#=UX&0*5>P 3YBBQASQM_FAA&Q)51/W(P"A*7]_J4?=P>WU;YYP0.E
MC5?+B&>.:I ]A_?J%5" )KV?7D$E^FY9J:L^27S;["<B5#/_G/JGB\>*,(O"
M9ZN4D+[B^&VF=/Z#=H),R0L^3%*8#V&D@9](@*?NV(,WF@?).\YD,5@>]*ER
M<"+>0-UOZ?<$, 4RH)UIJF,-*:, ;!H#J$K^AG;BZ?<H-]3O"/S$@R6K,::[
M<WZLW5:5$S^1^(D'6XC5X%^,_,7(7XS\Q<A?C/S%R'\Q1LIL)RP;$]@:9/(2
M&B="2\VD2T948&]',^4TLG4O@"97/_IMCSLG[$/._/3%K0,R;7GV#WS\WXK6
M-S\+Y"=Y#[@VRHL+WYM65Q];5/P9]9L4ZYD'7_IKA3+Z(2I4'!S717*A $.!
M]_ !9+6$B:TA5(KCW[H V'3_D1#([^I=/^[_L0#>)5Z9/Q*I^1'/YRO\L*[T
M)MW9C]#/E_]43-XRUQZT?JR"ZE?D$3N,__%%R;\MK>NU^]-".\!]XA@%F![N
M(N'(E\N]5U5^0/J;?R3G9]\H49GJ'BBB=A? <52N_'C6]X<(.OSU*7E7!2OB
MBQ7PTB?HPN5*YQ#X4BYT##HG2@/[[U[C_I]S#'03Y53*6&JJ,?N#&6*D:/F#
M,X#[W19R1'&2!MG'E#I =2A ([43CU" /04S@-KNA6*E][7_NN?7/;_N^77/
MKWM^W?/_ZWM,N9'!;N_;LQZS!G&9L CK?C?YFX#F%VC\!1K_NP'?/W_DL,OU
MV@UJ*1W]I Z&%^*R-V_2!9"_@0I)\.85V:665)J2J)%FS"F2FC;L2&72\^V$
MGD=/P2U?-P*L$A/8UX=&M9U=6.J4;NAKINOG1C >>>EU@+^?8)>YR&)71B5:
M,K@N^'6P:Z*4;AEJ@ZW2J<3./UNQ+L56'T;=[)FNS__PUG=V,YF/";NI-#GH
MR#VP?=_U5B;46V1.F>UL4W6I!_/(Z!6,+LNKF-.L.8(T_NG\JG0EZG]>I/T_
M_?!M(K"3A_5LXW'0HW["EEZI((AJAH/'T8[0A8(O+603=R.PZ[L=O_F1W8%P
M"=AC&M %NCEYX[0C1!5$.>K>Q,BUL\SC75.(QIPNJ8:U$.D\IZF*0F5VKML4
MH$WB2\OJ4[#D*#I/8^7*8J;!\F>"0ECW0+')4Y]GG#LOP>>_U' :N7G-W_ZE
MUGZIM?^5:NTWU:;@]TXV^6EL[8@%5$#YJ-'[9TH@7"T)MDR6LRNS5,+PY;J/
MRSV76^0V]S3LZV.J1L9:OR.K!+_A)K:7E\5WHLU\0E(/HY_$J O$W;_S^%;
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M3T[%!6'=L')YU]R+2O-ZUB&4/P;'DD*2I?9,@MJWF(G=K:DT0/18D[]I:)1
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M$EU*@>SVG*EOO_SH[GJ"9?KUX3$*_2C]0\F-[.^.RSAX"(P!XH$O>I@TW-3
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MT45Q5NKFH:Q^7J &O=E'!XK)SE:X-:Q))+.%0EOJTU>6+^<UW-]5JP*WG&_
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MLJ$30TNJJN.A6AOV(+[MN[S0H]-^DXB3UND8=?Z;UW9TKXA\JWX^*ZJL2W3
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M_>23#1"\W5LO^%'?T/U[^.-I;KFK!-?O 3H?)I?]8PL$&=F:&-G:S,'AF=?
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MU$!<G(LZ*SJ[,84VUS]!'<F4JOH6JA!@7O6&K'&AD?4Z\S:P\'TMK/&+M4B
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M(?RO@GX+;R4[ZHE\+CA)0Y?3>VL P:6<<FNL!RJ$VZ,!WM:I%-K7Y-4EI<;
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M]O-,&#=66C&^/+'$O3H1^Q45/*C&,>(!?TJED_-M>U"Y*\7_CUQACGO](30
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M\\Q$<VKBP[=^@_28NP4+SEH^$BF6$J6=.KPM@JC+MS7?%HF=/JOQ4"UP J^
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M-P#7-ACA$\D-7)7E,5B'B:7[VY*? [V[PO"(]UGO-J]H9JO':SS[$G[[<2:
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MYR5$$=_- 2?TT:PQR@+U(3.QE!3.C*\ZTM_@Z_LG^-RN*9)S>K0>'?+G_$#
M>:DG#?!Y-9;+W;O#IF2G=Y1,F!/H/.1(9=U@4GM_*_7,"'_F?LMA?*SXQ >Q
MVS)GANX"YF^_EW^Z8T'?H\M-U_%^%T?R*!F#TKIM#?UGJBZ;S>_L/SJ&JDJ.
MB+7-R8GN6FP8*ET \=*W8W[H@$F-<57DYH9(\ ,_H2H=<^.PTVC5\S%U5U%8
M2WW+0OP.]D5R>[2Y5IHN3CUR+E!!I\K)/$")_];';I>C]XX6/5NZ8$Q"R6\L
M> URO*B(>M&P?_)J=L'?)@UA^@4N==W(XWSG:H<;PQ@OI:#W6WE,JE[]&L^,
M/%T,6TA^8;U_!YB\&8@LL?^^O ^XM7,1:IWH?Q/1LDJ*)(A3RK,'Q=>I/&3M
MNAU%96*P]N@F;]KY0:O$6/+W]6+HDNHVI4]T!#JB]\5+N2>VK*"$WTDM6>/'
MD=@4AAV^HL$0.]/,?T^1]Y?T>,82G,1@]%+87N=&G0K60O#^"'P?X1#X96JJ
M@\']#.KB'*$(R8J<O^)! SR%$:S F3#<P]@#N:E^TO%)&F!9N/[T&>[GJR1Y
M!?M7V%NL+/H98JN!O73CO-0,/+R6R4=?F!3X']%O1>#,L.7/OO1ZF @PLC%4
M9="2!B!< 2W915)*C0[8#@_^,2F-WS)6_Q3YI\C_-R)F-?GMK"%F]>DFPQ M
M7$VNS<U;:Y6O<;>F*6OXF@A0*7VS5&#=B(!WQ([U$_65S](M]@/<$I7U-Q;\
M D(K$NEL6TVR!4X$E=$ F*+M,_^4^:?,W\F,Q$[R8F);JFD .SC/\J1L#%GA
MBZ7^\S66DH929ZFATA=H8W,ATA'P1W\]1,"GU:2:I#0OZ6A*<:04E\RFH>:T
MWA]^>GH1>S<_RJ$OSF5L^GTL?E1J9.0X"M)'V@(G W0HV>7LN-EW KRL_&9J
M\ ^,.@L&/:5G>I@D+M  OF[O&Z+_ZJF'Z @4,:T?\-*QT-&M26VGCJJEGDKS
MN2;DDG_I0\Q;'LIMRD>8PX8$(6+ J 4JY/M2T<N!$_J032)1XW:KPDV^.FL*
MNOT>>=,Z.8!W-+M^IJB*S##3:$TI*32&[FO,4D],_SF/Z6*%[HU X95/&:]@
M(;4W]SB&R HTP!/8KCXEM<%W7^]/Z76<,(@I!:IV:#(=HMLC=R%[A*__D>AT
MK U<Z4-.9!&C-N)9R;%*@7:G:(".-G])C%P+54V?;*!X+N*PJ G\+:,_2E'P
M\QH<]^%*MN7][P?.S ?NDE&+E2#T3 )L8(65<@C$@K.Z0=TY(EQ&QO/]W=8M
M3W(Q>3QF(&FJ':K<=!R,V])"+GN&42FL^&()3FAC@\A0^81+N9+EE)G]2&DX
M.2HP5#)!3YYJ(9RS 3M^#ET\RN;N"5V$KT(JU,Q^2M76LS[\48H,VG 5_Y7[
MK>/FHUC'?? ;X'?E/'Q:TP[QM2-RPD#L0ZA,I$]:T)C\'J;^@?KMT'/)E25B
M&M58]"NY*&>PU3VN9%?51K%9D#7P0)0GGQ*T0%<FSC32-ZUE7X #?R8G9[K0
M/%(^E;.C_97_6/E?'0(1"O+QF4],#"9:][XSU_C57^ATS U,46,W18?M/C9%
M 7&/\J9)=X)7"N[!\&BP]1@*A'L4>R!+G\-6S*#=2W?Y6,GGRM#((+(#&GP6
M&6'U+?[Q3\4RWPY6D7071#T(G=EPF@;H_QI& \ NT0 \Y/[?[OVP#@8S&L +
ME!$89QFB*%K((9:>\!4K]I@02[1#!(-VUNA#.=L!:_^;RSK++XZ3%9_#\I^"
M9_4J1]]?\A/R>/W)IT0Y'[A()TNE&SSYC73$>BB=\W1&X]-48^[1K>L7/8AC
MXGCK.5A3!Y7=-VE'/TPU8[1=_5U6$F<GZL+%L06-#2V2"1CR\*<0#A7*CQV,
MU[_>R=8_::YX.VZH(8AX'HWD]G4E>(Y:X9]^O>RDQ3,S^H*"8>C3VA1+E;*^
M)M>V_G)5^Y9N3@M]'DXI*8%>=COYV<7T=:HUFM[X\LDM1I^#]+S&-(3>LP+G
M0UC_B#%1A705UMG;1@,X(_.@<,0T4/N+G)>)[,O4Q'3^XD!52B(:=GC!F0;
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M.B656SVY=D\UU4"M@@J\+-2FU%&&B5#0\ 3DO81*72G7#JJ3920>GX$FY.:
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M=7EB6_!PP3\'J:*EVF)\5"\K;I\3[XJ@<"_@]6G,M4FQ.6J:Y7A DK<'@OG
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M@]^!$7O!>%WF#2P5$-R*_7WI;7C],=(C*I L3 5$!\ D&%H3C;G83P46-JC
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M"^@"/[@,WO0E(^1I?[1, H>\9R<#%0ATGT;L XZ@70R:9KQ,U&AV/^DP;<[
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M&*:%72MY\[CBI5NJ3'=5^/=X_B](A3H%56_V-*34/61%]PZJ22]\Q/7YCS"
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MB:<"6$/$OB3-=B<'LI&91Y8JG2)R&0=JXSD+;UPL<RB!->FZP':8!ZB !!7
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M:%^Z%A!RK//CKB \P/"?LCRE6IQ:QC(3?,UT0=H<QCQ_K32&-FRB OMT!E0
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MZ>)4<39LN/+;E4/U%PGX@U:,5)=41C#%45;X":Z+_][UNT,1]->%0RZ'6NF
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M.Y^JJ$!8Z*R!L?*0F^Q.I(C/MXX[*9XA@7/?W7OJ!9#EL-E<(57L3)R:)O;
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M:4 G:I<;=+:EM\"/*S!GSL6^)-OX=*>2MR@L&E15<'F<HP'=[:#:0C*I8C2
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M+L5W#8I4;HHD-0BZ*4L#8B'XR"7(]R4:D @C.]%_7BRY2 ,>0W^^Y3,E1].
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M.K3=1SZ^L1_Q-?,M E,)H1ZM3R7BPS1@8YVXPE,='UK%'R\F=KPUN\X/ .J
M;.17&N""F)"^,E*^9XP>U[@\6)A3'7=L0Z1#H%<B]L7^9'B"8CFO1[J'[<(:
MZ&2.>A <J4U)B$5C':;5'/QDBWK\:AT^*0#%YE1U[8:?P07_K%>7PB?T7<_$
M"!SQETI.>CA?2E5'-&L%LY+=\:M$!/Z)<R/GB'] D&>KBH?5#;VC9QR9W]Z%
MF=WW6[S^W79A-1ZD48#WI+:M2=( 0UR)5097% KS!B%4#S^:,XL.A? 59S<2
M4*WCPW(;ZP?KJU).^!0(:E;?Z##K.W(T?E"9^/S'C\97=SW\?15L)B8[!GJ4
M(EF?9*3<#@#HE/&CC^_I@X:6,8Q07BGM.UE/+SJ*\2B/*-?K*^%IWQD- /\D
M3RKUQ6\3'8<TM=[!4]NUU6OC6X7=ZJ6WXQ<(*DSUNLE::6897*'UNI!H\A57
MG/QD7.>:R<E7!,[IPA.PXR+G([=%]TX[W82N=PV@[@8JXF2Y#OK!+XR6Y[6/
MI.9;ZP4XJV\E"7&KJ^(*.?PM(A .05Q&E.2U8)8;#&ZG2-[EKB\3@[<&] ,G
MPR$SBHJ&6BN=4$PJE,>;PP(37(KO:W/L(3BV:MD%[=O<K^8=&?#"B,CH\"3@
MK S]:BVIA,K:C-M;XR+ZXZFA\+PO[Y:H)PAZZ3'YZ(Y)LQ/C1Y+T[!<ONABN
MYS?A#:$N%NF!#TF"6/B$(C8]!Q,O:*,Y<7=>*LY)Y-Y(6;&/R0$?;ZD?GR02
M=!FB@3(\$A,92F7Q,^_3P3M&K"JYBOBE*$J=DG^C!NS;[(H=4.L\T99LZY[Z
MSGE">.KDFUNN-ZMX7\X+?"B\;<4,U+G1GSB;V[4 /+186$NOV+L<W+1[S\>Z
M\B6DL^_1A(M;S.72:?&2'!MYDY[O*L,W7O,<#P&^<]_7[B0Q[>F05(G)I"!7
M'#@S+ON7._0WB^4<Z4[>>T\OQ_>)9:)5XH=$&+,4MQ-]0\5P(1Q^LDAN0VZA
MKOSX28EH,^=#4PIU0Z+%.K-:+M.!=_>.TH"N[]11Z(_MMX@ES1_$Z^CE.S3
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M&+K5'UHB"^I0$(@WH-Y<3VN'M+5(H0QXDKL00Z+N_0M??&B _XT#PP_4,KC
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MS!%/E%>X6!?54RKR;\BEOWP_:>3O[2$]'2WSM:Z4R,I"EJ$'IV\"354X1_Q
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MT"]@)@NXGX+TZEH9G+WE&!,8_02G&=^MH'^OE;Z*45Z;0!3BKS(!QSP_7:5
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M%2?8F5C4<L<)J'KHOU-'01Q M:D?1]=!!9"*Y/5H[:MD+6+3QH]G>4O58TR
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M"VL?NH_/!:Y\<,C\*WBB4/(LHM$]R 2&LK^@%X3^0321?X,M9@131Q1F O]
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M42 BSZ;1QTW9Q%V92S)))?'1_V#OO:*:^J)PWR H*DUZ)R@(2B@"(AU$I8F
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M&/DT['ZA>_PMP'0WYZ@/$>7:-3G PG;RG<"G1=X87#X_]^8B/:$W_1_( >+
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M+3&IZ6:Q6;S1NIQGK39Y692-5925<XE@S>U]@+\]I+@)EX#PE'X@CQRL+=%
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M?#:![N'A, \"&.H6X+LZ/\7RZ!;@'_<IG$J*!QTVY!-U*)]IMT&5? N8V-L
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MYOH&W@S1+BO4 ]L(&F8#.&8D!H1M.^C7M]H@.ZEE9"IM,Z6U1*E$D/!+YEN
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M7N=L1B2]:W2V.)9\C^3SE9#)"R=AU)RR.Z5_G9KX)VC<.N[]DQ^)P!=2VD,
MN.M)GT@%.?KP*K[B[_1-=_\M0%[22SSG2AQ='[3>X 7J]E!).7MHDEQFG1LQ
M$%R<Q@="397*KR[=8[1YLRQ)J:+D):#ZIN]Y[=NZBC@W.?XCIOB!7B%U_DD?
M_=#>ZD$8WF_X/^]9(-7!1GV44HFGH:AQ\D^:"*$JV\>>YA;C4RV9ZH'<MP!S
MLBB:/UE1RV2T0[%]N8_#>,O> ESI[K6UUDV<[$FJ'ZO7_ZD+4&MYR&N[%JBE
MVT7\P@V?QZ]C_&,!IW^+)&]ZH>5AMF6%<:&*K1V/WI0@\TA>D(!"0_<;3155
M4?RIE.+X]H)5IH(?\+T4[1^W ,OU5HSL;%NZG1,"RC9UR)<F3Q&C[1%L2QW%
M?K(K[VUW)8N;S?_[#Z>UTG$F!?03BORX^TA"WHOP@B<OA'+$3/K%=Z]5VS%2
ML;1U3Y7V_YA'Z\\B1(PWLWBQRXG*+7&0JW]Q@YA4S+70MN4^H@1%RLRPUGUA
M /_ Z:S%9TX?)+A;%($_N$YZTIKG;$,(DG+$F10J%EYIX&JY,UBK,!*CV2^2
MU*?+>EX-[:;:4U&0KC0W4*9IE]P,MQ_)P-AN 0;/;P&31]HN^3C.;C@P^3H]
MV[*.Q53ZNT^UGCS+=I5*MZ] 2X:8H]5-0M["MA[L#8--&H-7!!NYOEY?99]O
M6@P5@) ]L^_G[DL0W].^-U(6N-@R671U3\8K3$& A&7.OT')+HYZA.2G$HFJ
M[(4/L.!QGC[^LT;6KS9@Z+#RE(]E!1G$8VF$X7[^G4E)@H"'*I\I3#?_&G[S
MX"WA485I"\X&(:FD>S/?A!Z+=2JV)<,.6IM8*I%&Z)0KLK1:S8>T4")N ;2,
M3N46'MY_; ;Y&?=,?_WV6+,7&2/<T$2QS1(E9("R<,,?T'RHEQ@YU2=6B4T2
MPG,>7KTU\W$A4Z8*U/J6TM#U$Z8T)N<*]H;66\"/8*P3+JEHYZZ/#%Y9G\7?
M5R^=&YFH4]@5?>&^ S;>:WN W@KCY3D0BB14GC6OIPM2&E;8L.AS\M5A(L:6
M:'DS3CE?>NYY&O*.P9<OY%,.7I1-:B'EZ5QC\(*X"=E/?Q?GE]5.HTFU8&N8
MDKXV0HQP2-L3?9SKI7)[>SBX$MK671M!TSQC_:W=:?/O$1,PJ8":,)+'KJ+%
MX5*VLP#4.FT!]Z9YI21PG:SD2VA0C@#+Z%P)HH,2"[FO>'+U?C0HU1Y9/S.L
MYG!5>-4BL+YZ2B]2YFE#IE(]RR<$\B2R$&+L\-\\$-$T2V/M"K876& B/LE'
M:6C&W538;]@YK=M(=V/;GTB1X\P_M>,&LW8N/H&L)W;:_]K+.]F(11 ,_!*U
M5R18VQR4W*O&5;K3^E[9(-N9<._[&83*FZG(Y4MQ=EI<LO-)#/L:]*1TY1/W
M3CD/264]O\%XT-8>A3/372E<NWA7G<Y-L'?*YV/[J,N_AW/YLVV,N"]&LW(%
M15"(XHP0B_14N75NW/NHY&^-(AW]^=+6%1M'M+S!@MFXBBXCUA:<3^$N]DVB
M%-]LS6'-CKTBGGO.%YIS3:#=T+WXF8B(V95HX)&<A.4MX&M)]#5@NAVAR[/5
M&[MF*(<V) (]-<O7*?74FK:7LOZQM?E]$-\O4&0KPE4O*!-2HC-N[FE#O92W
M;9*X[$P:]Y*.:PC*>L$P./B2(WQN%/@*6BW;@@9WWP*"I*F=1?24RH ?*FMF
M46M[3M_0K**G7#K'BZRW !)[%L.AFS'@0]M1^,Z%87V(&:1DD.=FDKI1F&(_
M88V3N.38WF.+>0]5.V6MK<3PM;J>P2)X'SD^!&:7K;=+JJ9;C.*/, DKLT/8
MT,R_O^D-4*@,EH,/7F<R5Q%YY<7))S[X1Z$HX2)47&96O'?M;7K$PH90)98M
M@YFBST(.;_[CX3EN%&?8_YV'W;?\V]B@;MV956^:$4ORFO5U\W'B>V3[?3XG
M =P1ESYN9Y7'Q'6O7KDCV_+^4ZL5(IS*SH$SF'3'0WDXLDPH/<U!E"7U)WZT
ME>(-$TY]3[UIYOM=4?)<3XFI.F/YZ9]KWS<0M!G\]XA04J8S%U[>!O9U; L>
MU]8S^UWI?OE*;WFQW^4..:,F/S:J:\TM);&UT<M<@7*O\SEFKLR0A_>O)">>
MUC:VICB5&79"1V+HLL=Z8PHY(>2L%X$5]BS4DYHG!0S*(5[//UJBL,ZC.0F/
M/QC  BSP-_H!&KDRT[1Z8AW3*+G2B>NT%7?0UJ_J]%1,LZU[G\,7E.8TRGYC
MJG_4+<E($.=Y^1:JW]O&5S.Y;R/QKGU!F"=7B:U/YYA1<1,OH-E<>BGBI$(*
M,[V3M$+C8L>@9UE/*TV$$MK3J:UX]A[K69)/S/ U($CS^];EXL7-<72M4";9
MCO>S^C 2;97:F>P@S0R1PZ>ZFNP&B(ZO]MV<&2VSGCZ$%F]2B%.8&'@S2<-9
MOUXXNQ;R+')R\OO5K!]/E0O%S<'WF8(CH6''RDW7!64'Y;9L8A\R\.-T>:FK
M@O E?OQAJUMV!*7@?)#AF8%2/&BW@!,[:HL;";1MA0.[JUK7YQ7+CHUZBA_^
M6=6FF=@&O0O>E2X&ZOP>RLY<2_3X_8*%9[$\GU^[=M_H%/63WP*J[IQ-"K"[
M_3'.Y+,GBJW;0RO)HR/ P=R,235@QO;S0\*I7+C<G(6HX8%[.\J3I&?E?@6#
MR'KB'&C1DH]"8KV#G?X6T%\W6T$'/>Y<YD8;WL0CE+\HS\!DG;*-2#A65.\I
MYH"KZX>:Y;Z)='3"'?FC0/.<_J!"TR"+.0M3]6BF,'I=A4X"EIQ*F/0JD!BG
MLJD?2=M]813O\ )^]%>WG_+5GK\&J62QB=!0_+9FK91-/6;+5QLK;0-$7?@L
MCB7.W0+^>LZC.'!;)!O7^^>_O!9V1BTMI8 QL"\XZH*]NA*AI8J@I;R@#3>Z
M#07'1D+<3[\3-J%#"'JE"U+F8TU&O+VFN;)Y7:/3NV4WYG:XF'[7@&K-[Z"@
M3&]1(Z4+;OAQED&$CX5:\$/960*8'G &F+W4+&M:P7 F9$@BB)SKKXM;O/_D
M]'%,ECV/>=&W=2ZGV@8*Q DAE;E4_W+VI%#LOEE9U&J2^S-M>6-UOMT0<_ R
M?>%\/LTDY<*6F4RE?K9@]MN?NN@O#9'?$C'&:J]#Q$!2 F]/.*I9<9X(B/[2
MNR,@J:6:H15_BW#\\S3C<C:?MG*'XP<'9$8GK3FUF4FK4EKNX*#7S9)\6/$&
MFL3)Q?,VJJ8,Y7#_(\GJZDK)0:%-O<VBG.TF\_U93R3PA04:/C9=L]-*>Z:%
MT T2>P#WJDRYF)(D4XF6NQE0(C*;:HFWP5('?I!28_SDR1_9L$;7QY70[W<E
M[FYWYW "?JO>_Z%Z/T]=3V[8CK%\_@.!L48AP*^328VA2+R=WS$#9%ZZ(R5X
M7<;-=\7G9E>D#X>Z3W]IK;1'5W)W4C6E\3/&'^'CH,>W@/LP.?1AL+2IC5MW
M4U2)G4T%N]L<\&_$+6#G@2X]]N;PT&23WOKKU^->+T/$RL-M;W)_!6=)EGZ%
ML'<,LI7U"N]C)^HF!+QKU7V"I:B:9LIKZ5L$\Y1\G*/BER0CY!0U.[6)%QW=
M[LF,?[:WO-1!V;R^PD_(E(+F?JZ?;*&\%+72GGY>%MB"Y8 D*^BL/5B6TLD
MK*9E=$RW\5J5N5R^@XKK56*\,Q'77'L?XGC$C3*6Q8=5110Y?V55$Q"4O%C*
M6'6KR!4B(]S6JPNF"??,U3&T?%*<IR6HS_:>3BWP\8^O7^U?B126MY A%E&/
M26BV9*9M7T,!Y#I*EHSO600C"^4(OTS/!6KRV*Q@2+6@<J&K/B3D&$$U#&'/
MDG /.>3-9_W=XYT_\K:)/^)BAQ:9YUWE"PSBY\IAK)BZ"L1*"-R\NSG21Q[3
M%_&Z+[%?>_K=^5QE%IY)DC'(GXJT<4-%V5,E]:Z6MIO,YM*-$2C><=4FNH;:
MH#&A*.,;N%_0WLKK0U(H;7<&F67J^XD:U---NMA2&_5GJ\X$A?14Z1^F53]O
MF"=ZS]:K6=X T4*GW2%E/!+Z)A)']0J36NHZEUK GEL E07G6D'7(05X]XV;
M-]E1Q;, ==U$)86#(#GD:@+!F\Z,7J<K"4]L98[ES;/IC3^SUC:G('J'MN7=
MYW%O.@>&_K"5?;XC*]KNX.[!K'1"91L*P83IE"E!VP+V=8XW6^QI:T4</ZW8
MX[Q]0O[IKM' ZY+6R.#3G]K1K:-MN?>C I]9S=?QLG"P_XFDGT'\HLAHY;^2
M@'@OD-^A/N&(K3#;KFM8]PSM9JM)]PWU9 NG%1;.$6^2I]]L:[%O,T5MLOO.
M+_[ RLOD_73+^_^KO?,,:K)[UWUX05&JH/02% 2E"=)!B(HT$1&D=T0,'4$Z
M(1$00J\"BE*D(QT)O4COO00# B%4)9 (A-"2S;MGSLPY[Y[Y[_^7,^?,'CY<
MWYZY/ZS?\]SKNM:S9BTP04>_8TX?L5#M+_>ZM+CAJ:IM, =U"^_X&[7RX,%<
MC7 2DA-$@'4$,8BI2%=.B,I$Z]8<&BUK+M49>NO;;?25/E_=\&/1T!ES/='
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M>#,Q+3(N:'1M4$L! A0#%     @ +(206$-B#? ,!@  _B<   H
M     ( !G1   &5X,S(M,2YH=&U02P$"% ,4    "  LA)!8A$&2\J$(  "5
M+0  "0              @ '1%@  97@T+3$N:'1M4$L! A0#%     @ +(20
M6)UDA\BK&   3L$   H              ( !F1\  &5X.3<M,2YH=&U02P$"
M% ,4    "  LA)!8]_<&ECKA P" _28 #               @ %L.   9F]R
M;3$P+6LN:'1M4$L! A0#%     @ +(206,QHY@A=8@  %V4  !
M     ( !T!D$ &9O<FTQ,"UK7S P,2YJ<&=02P$"% ,4    "  LA)!8RK7
ME^QA  ![:@  $               @ %;? 0 9F]R;3$P+6M?,# R+FIP9U!+
M 0(4 Q0    ( "R$D%AU/?;:<%T  "%E   0              "  77>! !F
M;W)M,3 M:U\P,#0N:G!G4$L! A0#%     @ +(206'--7Q$8L   $[0  !
M             ( !$SP% &9O<FTQ,"UK7S P-BYJ<&=02P$"% ,4    "  L
MA)!8!S&CG?46   G'   $               @ %9[ 4 9F]R;3$P+6M?,# W
M+FIP9U!+ 0(4 Q0    ( "R$D%C+JFO(S%L  'IG   0              "
M 7P#!@!F;W)M,3 M:U\P,#@N:G!G4$L! A0#%     @ +(206*"B89:A&0
M,B   !               ( !=E\& &9O<FTQ,"UK7S P.2YJ<&=02P$"% ,4
M    "  LA)!8=)8DF\D2  #O&0  $               @ %%>08 9F]R;3$P
M+6M?,#$P+FIP9U!+ 0(4 Q0    ( "R$D%B>-H>EAFH  &UU   0
M      "  3R,!@!F;W)M,3 M:U\P,3$N:G!G4$L! A0#%     @ +(206 ^R
M_ROD8P  UFL  !               ( !\/8& &9O<FTQ,"UK7S Q,BYJ<&=0
M2P$"% ,4    "  LA)!8\^[/8:X7  !T* $ $0              @ $"6P<
M;G)X<RTR,#(S,3(S,2YX<V102P$"% ,4    "  LA)!8^4RZ2T,8  !@. $
M%0              @ '?<@< ;G)X<RTR,#(S,3(S,5]C86PN>&UL4$L! A0#
M%     @ +(206,=5Z-$Z5@  ,@D& !4              ( !58L' &YR>',M
M,C R,S$R,S%?9&5F+GAM;%!+ 0(4 Q0    ( "R$D%B 764X-9,  .&)"  5
M              "  <+A!P!N<GAS+3(P,C,Q,C,Q7VQA8BYX;6Q02P$"% ,4
M    "  LA)!86VR'1T]S  #;_0< %0              @ $J=0@ ;G)X<RTR
M,#(S,3(S,5]P<F4N>&UL4$L! A0#%     @ +(206#AD8-#2O , &< $  H
M             ( !K.@( '!G7S P,2YJ<&=02P$"% ,4    "  LA)!8UE12
M']H+!0!VG < "@              @ &FI0P <&=?,# R+FIP9U!+!08
..%P 7 '@%  "HL1$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>form10-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:NRXS="http://neuraxis.com/20231231"
  xmlns:country="http://xbrl.sec.gov/country/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="nrxs-20231231.xsd" xlink:type="simple"/>
    <context id="From2023-01-01to2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-04-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
        </entity>
        <period>
            <instant>2024-04-12</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_NonrelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_NonrelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ConvertibleSeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ConvertibleSeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ConvertibleSeriesSeedPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesSeedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ConvertibleSeriesSeedPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesSeedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesSeedPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesSeedPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesSeedPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesSeedPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesSeedPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-122023-01-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
        </entity>
        <period>
            <startDate>2023-01-12</startDate>
            <endDate>2023-01-12</endDate>
        </period>
    </context>
    <context id="From2023-08-092023-08-09_us-gaap_CommonStockMember_custom_AlexanderCapitalLPMember_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">NRXS:AlexanderCapitalLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-09</startDate>
            <endDate>2023-08-09</endDate>
        </period>
    </context>
    <context id="AsOf2023-08-09_us-gaap_CommonStockMember_custom_AlexanderCapitalLPMember_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">NRXS:AlexanderCapitalLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-09</instant>
        </period>
    </context>
    <context id="AsOf2023-08-09_us-gaap_IPOMember_custom_AlexanderCapitalLPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">NRXS:AlexanderCapitalLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-09</instant>
        </period>
    </context>
    <context id="From2023-08-092023-08-09_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-09</startDate>
            <endDate>2023-08-09</endDate>
        </period>
    </context>
    <context id="From2023-08-112023-08-11_us-gaap_CommonStockMember_custom_AlexanderCapitalLPMember_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">NRXS:AlexanderCapitalLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-11</startDate>
            <endDate>2023-08-11</endDate>
        </period>
    </context>
    <context id="From2022-07-102022-07-11_custom_TrademarkAgreementMember_custom_InitialPaymentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">NRXS:InitialPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:TrademarkAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-10</startDate>
            <endDate>2022-07-11</endDate>
        </period>
    </context>
    <context id="From2022-07-102022-07-11_custom_TrademarkAgreementMember_custom_SecondAndFinalPaymentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">NRXS:SecondAndFinalPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:TrademarkAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-10</startDate>
            <endDate>2022-07-11</endDate>
        </period>
    </context>
    <context id="From2023-04-112023-04-12_custom_LicensingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:LicensingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-11</startDate>
            <endDate>2023-04-12</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_CustomerMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_CustomerOneMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_CustomerTwoMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_CustomerThreeMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_CustomerFourMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_CustomerMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_CustomerOneMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_CustomerTwoMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_CustomerThreeMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_CustomerMember_us-gaap_SalesRevenueProductLineMember_us-gaap_RevenueFromRightsConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:RevenueFromRightsConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_CustomerMember_us-gaap_SalesRevenueProductLineMember_us-gaap_RevenueFromRightsConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:CustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:RevenueFromRightsConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-08-09_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-09</instant>
        </period>
    </context>
    <context id="From2023-08-112023-08-11_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-11</startDate>
            <endDate>2023-08-11</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MachineryAndEquipmentMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MachineryAndEquipmentMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FurnitureAndFixturesMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FurnitureAndFixturesMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_ComputerEquipmentMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_ComputerEquipmentMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ConvertibleSeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">NRXS:ConvertibleSeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_ConvertibleSeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">NRXS:ConvertibleSeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ConvertibleSeriesSeedPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">NRXS:ConvertibleSeriesSeedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_ConvertibleSeriesSeedPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">NRXS:ConvertibleSeriesSeedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_OptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_OptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:OptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">NRXS:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">NRXS:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ConvertibleBridgeDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">NRXS:ConvertibleBridgeDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_ConvertibleBridgeDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">NRXS:ConvertibleBridgeDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_stpr_CA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_stpr_WI">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_stpr_OH">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:OH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_stpr_OH">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:OH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_stpr_WI">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_stpr_CA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_stpr_FL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_stpr_FL">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:FL</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_stpr_MA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_country_MO">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:MO</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_AllOtherStatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">NRXS:AllOtherStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_AllOtherStatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">NRXS:AllOtherStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_HospitalAMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:HospitalAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_HospitalAMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:HospitalAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_HospitalBMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:HospitalBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_HospitalBMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:HospitalBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_HospitalCMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:HospitalCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_HospitalCMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:HospitalCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_HospitalMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_HospitalMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">NRXS:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ShareholdersOneAndTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">NRXS:ShareholdersOneAndTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_MrWatkinsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NRXS:MrWatkinsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_MrWatkinsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NRXS:MrWatkinsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_MrSealeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NRXS:MrSealeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_MrSealeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NRXS:MrSealeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_MrSealeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NRXS:MrSealeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_MrSealeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NRXS:MrSealeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ShareHolderOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">NRXS:ShareHolderOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ShareHolderTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">NRXS:ShareHolderTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ShareHolderOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">NRXS:ShareHolderOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ShareHolderTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">NRXS:ShareHolderTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ShareHolderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:ShareHolderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ShareHolderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:ShareHolderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ShareHolderOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:ShareHolderOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ShareHolderOneMember64718796">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:ShareHolderOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_OtherConvertiblesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:OtherConvertiblesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_OtherConvertiblesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:OtherConvertiblesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_ShareHolderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:ShareHolderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ShareHolderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:ShareHolderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_ShareHolderOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:ShareHolderOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ShareHolderOneMember64718843">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:ShareHolderOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_OtherConvertiblesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:OtherConvertiblesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_OtherConvertiblesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:OtherConvertiblesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MachineryAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_MachineryAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_SoftwareImplementationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">NRXS:SoftwareImplementationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_SoftwareImplementationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">NRXS:SoftwareImplementationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_TrademarksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_TrademarksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_LicensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">NRXS:LicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_LicensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">NRXS:LicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-02-15_custom_ExchangeListingLLCMember_custom_PromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NRXS:ExchangeListingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-02-15</instant>
        </period>
    </context>
    <context id="From2023-08-312023-08-31_custom_ExchangeListingLLCMember_custom_PromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NRXS:ExchangeListingLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-31</startDate>
            <endDate>2023-08-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-16_custom_ChannelPartnersCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NRXS:ChannelPartnersCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-16</instant>
        </period>
    </context>
    <context id="From2023-03-162023-03-16_custom_ChannelPartnersCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NRXS:ChannelPartnersCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-16</startDate>
            <endDate>2023-03-16</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-16_custom_ChannelPartnersCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NRXS:ChannelPartnersCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-16</instant>
        </period>
    </context>
    <context id="From2022-01-012022-01-01_custom_ChannelPartnersCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NRXS:ChannelPartnersCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="AsOf2022-09-16_custom_ChannelPartnersCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NRXS:ChannelPartnersCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-16</instant>
        </period>
    </context>
    <context id="AsOf2023-05-24_custom_ChannelPartnersCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NRXS:ChannelPartnersCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-24</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ChannelPartnersCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NRXS:ChannelPartnersCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_ChannelPartnersCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NRXS:ChannelPartnersCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-12-31_srt_ScenarioForecastMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-07-31_custom_ConvertiblePromissoryNoteMember_custom_AccreditedInvestorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NRXS:AccreditedInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-31</instant>
        </period>
    </context>
    <context id="From2023-03-012023-07-31_custom_AccreditedInvestorsMember_custom_ConvertiblePromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NRXS:AccreditedInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-07-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-07-31_custom_ConvertiblePromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-31</instant>
        </period>
    </context>
    <context id="AsOf2023-07-31_custom_ConvertiblePromissoryNoteMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-31</instant>
        </period>
    </context>
    <context id="From2023-03-012023-07-31_custom_ConvertiblePromissoryNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-07-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-04-13_custom_SignatureBankMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NRXS:SignatureBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-13</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_AlexanderCapitalLPMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NRXS:AlexanderCapitalLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_AlexanderCapitalLPMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NRXS:AlexanderCapitalLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-08-08_custom_ChannelPartnersCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NRXS:ChannelPartnersCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-08</instant>
        </period>
    </context>
    <context id="From2023-08-082023-08-08_custom_ChannelPartnersCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NRXS:ChannelPartnersCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-08</startDate>
            <endDate>2023-08-08</endDate>
        </period>
    </context>
    <context id="AsOf2023-03-31_custom_TwoThousandTwentyThreeConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyThreeConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="From2023-03-012023-03-31_custom_TwoThousandTwentyThreeConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyThreeConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-08-08_custom_TwoThousandTwentyThreeConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyThreeConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-08</instant>
        </period>
    </context>
    <context id="From2023-08-082023-08-08_custom_TwoThousandTwentyThreeConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyThreeConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-08</startDate>
            <endDate>2023-08-08</endDate>
        </period>
    </context>
    <context id="From2023-08-142023-08-14_custom_TwoThousandTwentyThreeConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyThreeConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-14</startDate>
            <endDate>2023-08-14</endDate>
        </period>
    </context>
    <context id="AsOf2022-11-30_custom_TwoThousandTwentyTwoConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="From2022-06-012022-11-30_custom_TwoThousandTwentyTwoConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="From2022-06-032022-11-30_custom_TwoThousandTwentyTwoConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-03</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-11-30_srt_MinimumMember_custom_TwoThousandTwentyTwoConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="AsOf2022-11-30_srt_MaximumMember_custom_TwoThousandTwentyTwoConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="From2022-06-032022-11-30_us-gaap_CommonStockMember_custom_TwoThousandTwentyTwoConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-03</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="From2022-06-032022-11-30_custom_ChannelPartnersCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NRXS:ChannelPartnersCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-03</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-19_custom_TwoThousandTwentyTwoConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-19</instant>
        </period>
    </context>
    <context id="From2022-12-192022-12-19_custom_TwoThousandTwentyTwoConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-19</startDate>
            <endDate>2022-12-19</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_TwoThousandTwentyTwoConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_InvestorsMember_custom_TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NRXS:InvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_InvestorsMember_custom_TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NRXS:InvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_InvestorsMember_custom_TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NRXS:InvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">NRXS:TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_ConvertibleNotesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_ConvertibleNotesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2017-01-012017-01-01_custom_VersaillesIndianaMember_custom_LeaseOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">NRXS:VersaillesIndianaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">NRXS:LeaseOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-01-01</endDate>
        </period>
    </context>
    <context id="From2017-01-012017-01-01_custom_VersaillesIndianaMember_custom_LeaseTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">NRXS:VersaillesIndianaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">NRXS:LeaseTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-01-01</endDate>
        </period>
    </context>
    <context id="AsOf2017-01-01_custom_VersaillesIndianaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">NRXS:VersaillesIndianaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-01-01</instant>
        </period>
    </context>
    <context id="From2016-03-012016-03-01_custom_CarmelIndianaMember_custom_LeaseThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">NRXS:CarmelIndianaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">NRXS:LeaseThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-03-01</startDate>
            <endDate>2016-03-01</endDate>
        </period>
    </context>
    <context id="AsOf2016-03-01_custom_CarmelIndianaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GeographicDistributionAxis">NRXS:CarmelIndianaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-03-01</instant>
        </period>
    </context>
    <context id="From2023-08-082023-08-08_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-08</startDate>
            <endDate>2023-08-08</endDate>
        </period>
    </context>
    <context id="From2023-08-082023-08-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
        </entity>
        <period>
            <startDate>2023-08-08</startDate>
            <endDate>2023-08-08</endDate>
        </period>
    </context>
    <context id="AsOf2023-08-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
        </entity>
        <period>
            <instant>2023-08-08</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_custom_ConvertibleSeriesSeedPreferredStockMember64722968">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesSeedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2023-08-082023-08-08_custom_VendorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">NRXS:VendorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-08</startDate>
            <endDate>2023-08-08</endDate>
        </period>
    </context>
    <context id="From2023-08-082023-08-08_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-08</startDate>
            <endDate>2023-08-08</endDate>
        </period>
    </context>
    <context id="From2023-01-092023-01-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
        </entity>
        <period>
            <startDate>2023-01-09</startDate>
            <endDate>2023-01-10</endDate>
        </period>
    </context>
    <context id="From2023-01-102023-01-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
        </entity>
        <period>
            <startDate>2023-01-10</startDate>
            <endDate>2023-01-10</endDate>
        </period>
    </context>
    <context id="AsOf2018-09-18_us-gaap_CommonStockMember_custom_BrianHannaschMember_custom_WarrantOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NRXS:BrianHannaschMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">NRXS:WarrantOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-18</instant>
        </period>
    </context>
    <context id="From2018-09-182018-09-18_us-gaap_CommonStockMember_custom_BrianHannaschMember_custom_WarrantOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">NRXS:BrianHannaschMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">NRXS:WarrantOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-18</startDate>
            <endDate>2018-09-18</endDate>
        </period>
    </context>
    <context id="AsOf2019-09-06_custom_WarrantTwoMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">NRXS:WarrantTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-06</instant>
        </period>
    </context>
    <context id="From2019-09-062019-09-06_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-06</startDate>
            <endDate>2019-09-06</endDate>
        </period>
    </context>
    <context id="From2019-09-062019-09-06_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-06</startDate>
            <endDate>2019-09-06</endDate>
        </period>
    </context>
    <context id="AsOf2019-09-06_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-06</instant>
        </period>
    </context>
    <context id="From2019-09-062019-09-06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
        </entity>
        <period>
            <startDate>2019-09-06</startDate>
            <endDate>2019-09-06</endDate>
        </period>
    </context>
    <context id="AsOf2020-04-09_custom_MasimoCorporationMember_custom_WarrantTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">NRXS:WarrantTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NRXS:MasimoCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-09</instant>
        </period>
    </context>
    <context id="AsOf2020-04-09_custom_MasimoCorporationMember_custom_WarrantThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">NRXS:WarrantThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">NRXS:MasimoCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-09</instant>
        </period>
    </context>
    <context id="AsOf2020-04-09_us-gaap_SeriesAPreferredStockMember_custom_WarrantThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">NRXS:WarrantThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-09</instant>
        </period>
    </context>
    <context id="From2023-08-142023-08-14_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-14</startDate>
            <endDate>2023-08-14</endDate>
        </period>
    </context>
    <context id="From2023-08-142023-08-14_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-14</startDate>
            <endDate>2023-08-14</endDate>
        </period>
    </context>
    <context id="From2023-08-142023-08-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
        </entity>
        <period>
            <startDate>2023-08-14</startDate>
            <endDate>2023-08-14</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_custom_TwoThousandTwentyTwoConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:TwoThousandTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_TwoThousandTwentyThreeConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:TwoThousandTwentyThreeConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-08-09_custom_TwoThousandTwentyThreeConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:TwoThousandTwentyThreeConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-09</instant>
        </period>
    </context>
    <context id="AsOf2023-08-14_custom_TwoThousandTwentyThreeConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:TwoThousandTwentyThreeConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-14</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_PreferredStockMember64723875">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_PreferredStockMember64724375">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_InvestorWarrantOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">NRXS:InvestorWarrantOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_InvestorWarrantPSAOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">NRXS:InvestorWarrantPSAOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_InvestorWarrantPSAOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">NRXS:InvestorWarrantPSAOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_TwoThousandTwentyTwoConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">NRXS:TwoThousandTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_TwoThousandTwentyTwoConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">NRXS:TwoThousandTwentyTwoConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_TwoThousandTwentyThreeConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">NRXS:TwoThousandTwentyThreeConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_TwoThousandTwentyThreeConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">NRXS:TwoThousandTwentyThreeConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_ConsultingAgreementWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">NRXS:ConsultingAgreementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_UnderwriterWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">NRXS:UnderwriterWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ConvertibleSeriesAPreferredStockMember64725046">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-12-312023-12-31_custom_ConvertibleSeriesSeedPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesSeedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-31</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ConvertibleSeriesSeedPreferredStockMember64725125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesSeedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-11-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
        </entity>
        <period>
            <instant>2023-11-08</instant>
        </period>
    </context>
    <context id="From2023-11-082023-11-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
        </entity>
        <period>
            <startDate>2023-11-08</startDate>
            <endDate>2023-11-08</endDate>
        </period>
    </context>
    <context id="AsOf2023-11-08_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-08</instant>
        </period>
    </context>
    <context id="AsOf2017-10-12_custom_TwentySeventeenStockCompensationPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">NRXS:TwentySeventeenStockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-12</instant>
        </period>
    </context>
    <context id="AsOf2019-09-13_custom_TwentySeventeenStockCompensationPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">NRXS:TwentySeventeenStockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-13</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_TwentySeventeenStockCompensationPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">NRXS:TwentySeventeenStockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_TwentySeventeenStockCompensationPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">NRXS:TwentySeventeenStockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="From2022-07-112022-07-11_us-gaap_IPOMember_custom_TrademarkAgreementMember_custom_InitialPaymentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">NRXS:InitialPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:TrademarkAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-11</startDate>
            <endDate>2022-07-11</endDate>
        </period>
    </context>
    <context id="From2022-07-112022-07-11_us-gaap_IPOMember_custom_TrademarkAgreementMember_custom_SecondAndFinalPaymentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">NRXS:SecondAndFinalPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:TrademarkAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-11</startDate>
            <endDate>2022-07-11</endDate>
        </period>
    </context>
    <context id="From2022-10-012022-10-01_srt_MinimumMember_custom_ExecutiveEmploymentAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:ExecutiveEmploymentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-01</endDate>
        </period>
    </context>
    <context id="From2022-10-012022-10-01_srt_MaximumMember_custom_ExecutiveEmploymentAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:ExecutiveEmploymentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-01</endDate>
        </period>
    </context>
    <context id="From2022-10-012022-10-01_custom_ExecutiveEmploymentAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:ExecutiveEmploymentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-01</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-12-31_custom_ExecutiveEmploymentAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:ExecutiveEmploymentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-01-02_us-gaap_SubsequentEventMember_custom_ExecutiveEmploymentAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:ExecutiveEmploymentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-02</instant>
        </period>
    </context>
    <context id="AsOf2024-01-02_us-gaap_SubsequentEventMember_custom_ExecutiveEmploymentAgreementsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:ExecutiveEmploymentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-02</instant>
        </period>
    </context>
    <context id="AsOf2023-04-30_custom_ExecutiveEmploymentAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:ExecutiveEmploymentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-30</instant>
        </period>
    </context>
    <context id="AsOf2023-04-30_custom_ExecutiveEmploymentAgreementsMember_us-gaap_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">NRXS:ExecutiveEmploymentAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-30</instant>
        </period>
    </context>
    <context id="From2019-02-052019-02-06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
        </entity>
        <period>
            <startDate>2019-02-05</startDate>
            <endDate>2019-02-06</endDate>
        </period>
    </context>
    <context id="From2022-07-132022-07-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
        </entity>
        <period>
            <startDate>2022-07-13</startDate>
            <endDate>2022-07-14</endDate>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_TaxYear2038Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">NRXS:TaxYear2038Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_TaxYear2039Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">NRXS:TaxYear2039Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_TaxYear2040Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">NRXS:TaxYear2040Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_TaxYear2041Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">NRXS:TaxYear2041Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_TaxYear2042Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">NRXS:TaxYear2042Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2023-12-31_custom_TaxYear2043Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">NRXS:TaxYear2043Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="AsOf2024-03-24_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-24</instant>
        </period>
    </context>
    <context id="From2024-03-232024-03-24_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-23</startDate>
            <endDate>2024-03-24</endDate>
        </period>
    </context>
    <context id="From2023-12-312023-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
        </entity>
        <period>
            <startDate>2023-12-31</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-24_us-gaap_SubsequentEventMember_us-gaap_SeriesBPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-24</instant>
        </period>
    </context>
    <context id="From2023-01-012023-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember_us-gaap_NonrelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_NonrelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_us-gaap_NonrelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember_custom_ConvertibleSeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_custom_ConvertibleSeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_ConvertibleSeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember_custom_ConvertibleSeriesSeedPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesSeedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_custom_ConvertibleSeriesSeedPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesSeedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="AsOf2023-09-30_custom_ConvertibleSeriesSeedPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">NRXS:ConvertibleSeriesSeedPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="From2023-07-012023-09-30_srt_ScenarioPreviouslyReportedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001933567</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RevisionOfPriorPeriodReclassificationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2023-01-01to2023-12-31" id="Fact000003">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2023-01-01to2023-12-31" id="Fact000004">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="From2023-01-01to2023-12-31" id="Fact000005">0001933567</dei:EntityCentralIndexKey>
    <dei:AuditorFirmId contextRef="From2023-01-01to2023-12-31" id="xdx2ixbrl0045">89</dei:AuditorFirmId>
    <us-gaap:DeferredCosts
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0082"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember"
      id="xdx2ixbrl0112"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember"
      id="xdx2ixbrl0115"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0118"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0128"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31_custom_ConvertibleSeriesAPreferredStockMember"
      id="xdx2ixbrl0155"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31_custom_ConvertibleSeriesSeedPreferredStockMember"
      id="xdx2ixbrl0174"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-12-31_custom_ConvertibleSeriesSeedPreferredStockMember"
      id="xdx2ixbrl0193"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0267"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherNonoperatingExpense
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0273"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember"
      id="xdx2ixbrl0316"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember"
      id="xdx2ixbrl0317"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0318"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0320"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember"
      id="xdx2ixbrl0323"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember"
      id="xdx2ixbrl0324"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0327"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember"
      id="xdx2ixbrl0332"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember"
      id="xdx2ixbrl0333"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0334"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0335"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember"
      id="xdx2ixbrl0352"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember"
      id="xdx2ixbrl0353"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0356"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:StockIssuedDuringPeriodValueCommonStockIssuedUponPreferredStockConversion
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0365"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:StockIssuedDuringPeriodValueCommonStockIssuedUponPreferredStockConversion
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0366"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember"
      id="xdx2ixbrl0374"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember"
      id="xdx2ixbrl0375"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0378"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember"
      id="xdx2ixbrl0383"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember"
      id="xdx2ixbrl0384"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0387"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember"
      id="xdx2ixbrl0392"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember"
      id="xdx2ixbrl0393"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0394"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0396"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember"
      id="xdx2ixbrl0399"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember"
      id="xdx2ixbrl0400"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0403"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember"
      id="xdx2ixbrl0408"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember"
      id="xdx2ixbrl0409"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0410"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0411"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember"
      id="xdx2ixbrl0415"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember"
      id="xdx2ixbrl0416"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember"
      id="xdx2ixbrl0422"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember"
      id="xdx2ixbrl0424"
      unitRef="Shares"
      xsi:nil="true"/>
    <NRXS:NoncashInterestExpense
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0450"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0452"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0456"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:IssuanceOfCommonStockForNoncashConsideration
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0459"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0513"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:DeferredOfferingCostsPaid
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0515"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0519"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0551"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0552"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:PriorYearOfferingCostsPaid
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0564"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:ReclassificationOfWarrantLiabilityToEquity
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0567"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:ConversionOfPreferredStockToCommonStock
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl0570"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl0636"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:WarrantLiabilities
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0695"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:WarrantLiabilities
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0696"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0699"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0700"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0701"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0702"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0705"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0706"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:WarrantLiabilities
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0710"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:WarrantLiabilities
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0711"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0715"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0716"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0720"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0721"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      id="xdx2ixbrl0730"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_custom_ConvertibleSeriesAPreferredStockMember"
      id="xdx2ixbrl0742"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_custom_ConvertibleSeriesSeedPreferredStockMember"
      id="xdx2ixbrl0745"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl0751"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_custom_ConvertibleBridgeDebtMember"
      id="xdx2ixbrl0757"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl0768"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember"
      id="xdx2ixbrl0946"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestReceivable
      contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember"
      id="xdx2ixbrl0948"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:InterestIncomeCurrent
      contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember"
      id="xdx2ixbrl0950"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember"
      id="xdx2ixbrl0976"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestReceivable
      contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember"
      id="xdx2ixbrl0978"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:InterestIncomeCurrent
      contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember"
      id="xdx2ixbrl0980"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LoansPayable
      contextRef="AsOf2023-12-31_custom_ShareHolderMember"
      id="xdx2ixbrl0988"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:InterestAndServiceFeeAccrued
      contextRef="AsOf2023-12-31_custom_ShareHolderMember"
      id="xdx2ixbrl0990"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LoansPayable
      contextRef="AsOf2023-12-31_custom_ShareHolderOneMember64718796"
      id="xdx2ixbrl0998"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:InterestAndServiceFeeAccrued
      contextRef="AsOf2023-12-31_custom_ShareHolderOneMember64718796"
      id="xdx2ixbrl1000"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LoansPayable
      contextRef="AsOf2023-12-31_custom_OtherConvertiblesMember"
      id="xdx2ixbrl1008"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaid
      contextRef="From2023-01-012023-12-31_custom_OtherConvertiblesMember"
      id="xdx2ixbrl1012"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LoansPayable
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1014"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaid
      contextRef="From2022-01-012022-12-31_custom_ShareHolderMember"
      id="xdx2ixbrl1028"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaid
      contextRef="From2022-01-012022-12-31_custom_ShareHolderOneMember"
      id="xdx2ixbrl1038"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LoansPayable
      contextRef="AsOf2022-12-31_custom_OtherConvertiblesMember"
      id="xdx2ixbrl1044"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaid
      contextRef="From2022-01-012022-12-31_custom_OtherConvertiblesMember"
      id="xdx2ixbrl1048"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestPaid
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1054"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2022-12-31_custom_LicensesMember"
      id="xdx2ixbrl1111"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:UnderwriterFees
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1133"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:RelatedPartyInterestPayableCurrent
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1139"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1181"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredFinanceCostsCurrentNet
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1184"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1187"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1190"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LongTermDebt
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1193"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1343"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2022-12-31_custom_TwoThousandTwentyTwoConvertibleNotesMember"
      id="xdx2ixbrl1404">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2023-06-30_custom_TwoThousandTwentyThreeConvertibleNotesMember"
      id="xdx2ixbrl1410">P1Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2023-08-09_custom_TwoThousandTwentyThreeConvertibleNotesMember"
      id="xdx2ixbrl1414">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2023-08-14_custom_TwoThousandTwentyThreeConvertibleNotesMember"
      id="xdx2ixbrl1417">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1434"
      unitRef="Shares"
      xsi:nil="true"/>
    <NRXS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1436"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1438"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1440"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl1460"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember64724375"
      id="xdx2ixbrl1474"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember64724375"
      id="xdx2ixbrl1476"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember64724375"
      id="xdx2ixbrl1478"
      unitRef="Shares"
      xsi:nil="true"/>
    <NRXS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember64724375"
      id="xdx2ixbrl1480"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember64724375"
      id="xdx2ixbrl1482"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember64724375"
      id="xdx2ixbrl1484"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember64723875"
      id="xdx2ixbrl1490"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember64723875"
      id="xdx2ixbrl1492"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember64723875"
      id="xdx2ixbrl1494"
      unitRef="Shares"
      xsi:nil="true"/>
    <NRXS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember64723875"
      id="xdx2ixbrl1496"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl1502"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember"
      id="xdx2ixbrl1504"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl1628"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1630"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1632"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1634"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1636"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl1644"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl1646"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl1648"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl1650"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl1652"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1660"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1668"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1692"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1694"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:AdditionToWarrantLiabilities
      contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1698"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:AdditionToWarrantLiabilities
      contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1700"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1704"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1706"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1710"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1712"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:AdditionToWarrantLiabilities
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1716"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:AdditionToWarrantLiabilities
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1718"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1722"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1724"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:ReclassifiedToEquity
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1728"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:ReclassifiedToEquity
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1730"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1734"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1736"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1754"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1756"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl1758"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:AdditionToDerivativeLiabilities
      contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1760"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:AdditionToDerivativeLiabilities
      contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1762"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1766"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1768"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1772"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1774"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:AdditionToDerivativeLiabilities
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1778"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:AdditionToDerivativeLiabilities
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1780"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1784"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1786"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:ExtinguishmentOfDerivativeLiabilities
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1790"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:ExtinguishmentOfDerivativeLiabilities
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1792"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1796"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1798"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl1800"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2023-12-31"
      id="xdx2ixbrl1874"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2022-12-31"
      id="xdx2ixbrl1875"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl1885"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1886"
      unitRef="Pure"
      xsi:nil="true"/>
    <NRXS:EffectiveIncomeTaxRateReconciliationNontaxableIncome
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl1888"
      unitRef="Pure"
      xsi:nil="true"/>
    <NRXS:EffectiveIncomeTaxRateReconciliationNontaxableIncome
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1889"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2023-01-01to2023-12-31"
      id="xdx2ixbrl1894"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2022-01-012022-12-31"
      id="xdx2ixbrl1895"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl1960"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl1964"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InventoryNet
      contextRef="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl1968"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl1972"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl1976"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl1980"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl1984"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl1988"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl1992"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl1996"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Assets
      contextRef="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2000"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2012"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2016"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_us-gaap_NonrelatedPartyMember"
      id="xdx2ixbrl2020"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2024"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Deposits
      contextRef="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2028"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:ShareLiabilitiesCurrent
      contextRef="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2032"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:WarrantLiabilities
      contextRef="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2036"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2040"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2044"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:Liabilities
      contextRef="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2048"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember_custom_ConvertibleSeriesAPreferredStockMember"
      id="xdx2ixbrl2055"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_custom_ConvertibleSeriesAPreferredStockMember"
      id="xdx2ixbrl2056"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-09-30_custom_ConvertibleSeriesAPreferredStockMember"
      id="xdx2ixbrl2057"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember_custom_ConvertibleSeriesSeedPreferredStockMember"
      id="xdx2ixbrl2059"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember_custom_ConvertibleSeriesSeedPreferredStockMember"
      id="xdx2ixbrl2060"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-09-30_custom_ConvertibleSeriesSeedPreferredStockMember"
      id="xdx2ixbrl2061"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2064"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2076"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2080"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-07-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2084"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2087"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2023-07-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2091"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2094"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GrossProfit
      contextRef="From2023-07-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2098"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GrossProfit
      contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2101"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SellingExpense
      contextRef="From2023-07-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2105"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SellingExpense
      contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2108"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-07-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2112"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2115"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-07-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2119"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2122"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-07-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2126"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2129"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:FinancingCharges
      contextRef="From2023-07-012023-09-30_srt_ScenarioPreviouslyReportedMember"
      id="xdx2ixbrl2139"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:FinancingCharges
      contextRef="From2023-07-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2140"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:FinancingCharges
      contextRef="From2023-07-012023-09-30"
      id="xdx2ixbrl2141"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:FinancingCharges
      contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2143"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestExpense
      contextRef="From2023-07-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2147"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestExpense
      contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2150"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestAndOtherIncome
      contextRef="From2023-07-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2154"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InterestAndOtherIncome
      contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2157"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-07-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2161"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2164"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2023-07-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2168"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2171"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="From2023-07-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2175"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2178"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2023-07-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2189"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2192"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherNonoperatingExpense
      contextRef="From2023-07-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2196"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherNonoperatingExpense
      contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2199"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2229"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2233"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2237"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:NoncashLeaseExpense
      contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2241"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:NoncashInterestExpense
      contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2245"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember"
      id="xdx2ixbrl2248"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2249"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-01-012023-09-30"
      id="xdx2ixbrl2250"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:IssuanceOfCommonStockForNoncashConsideration
      contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2257"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:FinanceCharges
      contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2261"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2265"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2269"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2277"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2281"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2285"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2289"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2293"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:IncreaseDecreaseInCustomerDeposit
      contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2297"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2301"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2305"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2313"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2317"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2321"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2329"
      unitRef="USD"
      xsi:nil="true"/>
    <NRXS:OfferingCostsInAdvanceOfSaleOfCommonStock
      contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2333"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2337"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2341"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2345"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2349"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2353"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2022-12-31_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2357"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      id="xdx2ixbrl2361"
      unitRef="USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2023-01-01to2023-12-31" id="Fact000012">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2023-01-01to2023-12-31" id="Fact000013">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2023-01-01to2023-12-31" id="Fact000014">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="From2023-01-01to2023-12-31" id="Fact000015">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2023-01-01to2023-12-31" id="Fact000016">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2023-01-01to2023-12-31" id="Fact000017">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2023-01-01to2023-12-31" id="Fact000018">001-41775</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2023-01-01to2023-12-31" id="Fact000019">Neuraxis, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2023-01-01to2023-12-31" id="Fact000020">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2023-01-01to2023-12-31" id="Fact000021">45-5079684</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2023-01-01to2023-12-31" id="Fact000022">11611     N Meridian St</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2023-01-01to2023-12-31" id="Fact000023">Suite 330</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2023-01-01to2023-12-31" id="Fact000024">Carmel</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2023-01-01to2023-12-31" id="Fact000025">IN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2023-01-01to2023-12-31" id="Fact000026">46032</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2023-01-01to2023-12-31" id="Fact000027">(812)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2023-01-01to2023-12-31" id="Fact000028">689-0791</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2023-01-01to2023-12-31" id="Fact000029">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2023-01-01to2023-12-31" id="Fact000030">NRXS</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2023-01-01to2023-12-31" id="Fact000031">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2023-01-01to2023-12-31" id="Fact000032">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2023-01-01to2023-12-31" id="Fact000033">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2023-01-01to2023-12-31" id="Fact000034">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2023-01-01to2023-12-31" id="Fact000035">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2023-01-01to2023-12-31" id="Fact000036">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2023-01-01to2023-12-31" id="Fact000037">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2023-01-01to2023-12-31" id="Fact000038">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2023-01-01to2023-12-31" id="Fact000039">true</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag contextRef="From2023-01-01to2023-12-31" id="Fact000040">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="From2023-01-01to2023-12-31" id="Fact000041">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="From2023-01-01to2023-12-31" id="Fact000042">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000043"
      unitRef="USD">0</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2024-04-12"
      decimals="INF"
      id="Fact000044"
      unitRef="Shares">6594897</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorName contextRef="From2023-01-01to2023-12-31" id="Fact000046">Rosenberg Rich Baker Berman, P.A</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2023-01-01to2023-12-31" id="Fact000047">Somerset, New Jersey</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000055"
      unitRef="USD">78560</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000056"
      unitRef="USD">253699</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000058"
      unitRef="USD">73167</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000059"
      unitRef="USD">174399</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000061"
      unitRef="USD">21220</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000062"
      unitRef="USD">48133</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000064"
      unitRef="USD">69663</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000065"
      unitRef="USD">726</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000067"
      unitRef="USD">242610</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000068"
      unitRef="USD">476957</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000070"
      unitRef="USD">436626</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000071"
      unitRef="USD">405845</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000073"
      unitRef="USD">348074</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000074"
      unitRef="USD">317834</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000076"
      unitRef="USD">88552</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000077"
      unitRef="USD">88011</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DeferredCosts
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000083"
      unitRef="USD">736736</us-gaap:DeferredCosts>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000085"
      unitRef="USD">70263</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000086"
      unitRef="USD">101382</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000088"
      unitRef="USD">108073</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000089"
      unitRef="USD">77558</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:Assets
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000091"
      unitRef="USD">509498</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000092"
      unitRef="USD">1480644</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000100"
      unitRef="USD">1204219</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000101"
      unitRef="USD">1592116</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000103"
      unitRef="USD">401088</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000104"
      unitRef="USD">834062</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2023-12-31_us-gaap_NonrelatedPartyMember"
      decimals="0"
      id="Fact000106"
      unitRef="USD">148062</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2022-12-31_us-gaap_NonrelatedPartyMember"
      decimals="0"
      id="Fact000107"
      unitRef="USD">202834</us-gaap:NotesPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000109"
      unitRef="USD">49127</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000110"
      unitRef="USD">33395</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000113"
      unitRef="USD">58051</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000116"
      unitRef="USD">58051</us-gaap:NotesPayableCurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscountCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000121"
      unitRef="USD">0</us-gaap:DebtInstrumentUnamortizedDiscountCurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscountCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000123"
      unitRef="USD">3327213</us-gaap:DebtInstrumentUnamortizedDiscountCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000119"
      unitRef="USD">228342</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:Deposits
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000125"
      unitRef="USD">74947</us-gaap:Deposits>
    <us-gaap:Deposits
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000126"
      unitRef="USD">59174</us-gaap:Deposits>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000129"
      unitRef="USD">1735700</us-gaap:DerivativeLiabilitiesCurrent>
    <NRXS:WarrantLiabilities
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000131"
      unitRef="USD">8225</NRXS:WarrantLiabilities>
    <NRXS:WarrantLiabilities
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000132"
      unitRef="USD">2234384</NRXS:WarrantLiabilities>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000134"
      unitRef="USD">1885668</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000135"
      unitRef="USD">6978058</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000140"
      unitRef="USD">27071</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000141"
      unitRef="USD">76199</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000143"
      unitRef="USD">27071</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000144"
      unitRef="USD">76199</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000146"
      unitRef="USD">1912739</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000147"
      unitRef="USD">7054257</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31_custom_ConvertibleSeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000158"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31_custom_ConvertibleSeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000160"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31_custom_ConvertibleSeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000162"
      unitRef="Shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2022-12-31_custom_ConvertibleSeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000164"
      unitRef="Shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-12-31_custom_ConvertibleSeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000166"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31_custom_ConvertibleSeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000168"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2022-12-31_custom_ConvertibleSeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000170"
      unitRef="Shares">506637</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2022-12-31_custom_ConvertibleSeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000172"
      unitRef="Shares">506637</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2022-12-31_custom_ConvertibleSeriesAPreferredStockMember"
      decimals="0"
      id="Fact000156"
      unitRef="USD">507</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31_custom_ConvertibleSeriesSeedPreferredStockMember"
      decimals="INF"
      id="Fact000177"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31_custom_ConvertibleSeriesSeedPreferredStockMember"
      decimals="INF"
      id="Fact000179"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31_custom_ConvertibleSeriesSeedPreferredStockMember"
      decimals="INF"
      id="Fact000181"
      unitRef="Shares">120000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2022-12-31_custom_ConvertibleSeriesSeedPreferredStockMember"
      decimals="INF"
      id="Fact000183"
      unitRef="Shares">120000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-12-31_custom_ConvertibleSeriesSeedPreferredStockMember"
      decimals="INF"
      id="Fact000185"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31_custom_ConvertibleSeriesSeedPreferredStockMember"
      decimals="INF"
      id="Fact000187"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2022-12-31_custom_ConvertibleSeriesSeedPreferredStockMember"
      decimals="INF"
      id="Fact000189"
      unitRef="Shares">115477</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2022-12-31_custom_ConvertibleSeriesSeedPreferredStockMember"
      decimals="INF"
      id="Fact000191"
      unitRef="Shares">115477</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2022-12-31_custom_ConvertibleSeriesSeedPreferredStockMember"
      decimals="0"
      id="Fact000175"
      unitRef="USD">115</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2022-12-31_custom_ConvertibleSeriesSeedPreferredStockMember"
      decimals="0"
      id="Fact000194"
      unitRef="USD">115</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000199"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact000201"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000203"
      unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact000205"
      unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000207"
      unitRef="Shares">6508897</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000209"
      unitRef="Shares">6508897</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact000211"
      unitRef="Shares">1963322</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact000213"
      unitRef="Shares">1963322</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000196"
      unitRef="USD">6509</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000197"
      unitRef="USD">1963</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000215"
      unitRef="USD">47148361</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000216"
      unitRef="USD">28355230</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000218"
      unitRef="USD">-48558111</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000219"
      unitRef="USD">-33931428</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000221"
      unitRef="USD">-1403241</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000222"
      unitRef="USD">-5573613</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000224"
      unitRef="USD">509498</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000225"
      unitRef="USD">1480644</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000227"
      unitRef="USD">2460049</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000228"
      unitRef="USD">2684735</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000230"
      unitRef="USD">303345</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000231"
      unitRef="USD">297060</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000233"
      unitRef="USD">2156704</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000234"
      unitRef="USD">2387675</us-gaap:GrossProfit>
    <us-gaap:SellingExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000236"
      unitRef="USD">323569</us-gaap:SellingExpense>
    <us-gaap:SellingExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000237"
      unitRef="USD">410883</us-gaap:SellingExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000239"
      unitRef="USD">169315</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000240"
      unitRef="USD">225610</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000242"
      unitRef="USD">8328315</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000243"
      unitRef="USD">5123420</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000245"
      unitRef="USD">-6664495</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000246"
      unitRef="USD">-3372238</us-gaap:OperatingIncomeLoss>
    <NRXS:FinancingCharges
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000251"
      unitRef="USD">2772</NRXS:FinancingCharges>
    <NRXS:FinancingCharges
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000252"
      unitRef="USD">2322216</NRXS:FinancingCharges>
    <us-gaap:InterestExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000254"
      unitRef="USD">476416</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000255"
      unitRef="USD">318666</us-gaap:InterestExpense>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000257"
      unitRef="USD">-844854</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000258"
      unitRef="USD">-606049</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000260"
      unitRef="USD">198551</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000261"
      unitRef="USD">713989</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000263"
      unitRef="USD">4881622</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000264"
      unitRef="USD">98935</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000266"
      unitRef="USD">-3649561</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000269"
      unitRef="USD">15133</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000270"
      unitRef="USD">11956</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000272"
      unitRef="USD">10355</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000275"
      unitRef="USD">-7962188</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000276"
      unitRef="USD">-1407823</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000278"
      unitRef="USD">-14626683</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000279"
      unitRef="USD">-4780061</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact000284"
      unitRef="USDPShares">-4.50</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact000286"
      unitRef="USDPShares">-4.50</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact000288"
      unitRef="USDPShares">-2.77</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact000290"
      unitRef="USDPShares">-2.77</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact000295"
      unitRef="Shares">3252328</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact000297"
      unitRef="Shares">3252328</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact000299"
      unitRef="Shares">2003322</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact000301"
      unitRef="Shares">2003322</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000310"
      unitRef="Shares">506637</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember"
      decimals="0"
      id="Fact000303"
      unitRef="USD">507</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember"
      decimals="INF"
      id="Fact000312"
      unitRef="Shares">115477</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember"
      decimals="0"
      id="Fact000304"
      unitRef="USD">115</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000314"
      unitRef="Shares">1928004</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000305"
      unitRef="USD">1928</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000306"
      unitRef="USD">28323157</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000307"
      unitRef="USD">-29151367</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000308"
      unitRef="USD">-825660</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000319"
      unitRef="USD">27319</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000321"
      unitRef="USD">27319</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000330"
      unitRef="Shares">35318</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000325"
      unitRef="USD">35</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-01-012022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000326"
      unitRef="USD">4754</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000328"
      unitRef="USD">4789</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000336"
      unitRef="USD">-4780061</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000337"
      unitRef="USD">-4780061</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000346"
      unitRef="Shares">506637</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember"
      decimals="0"
      id="Fact000339"
      unitRef="USD">507</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember"
      decimals="INF"
      id="Fact000348"
      unitRef="Shares">115477</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember"
      decimals="0"
      id="Fact000340"
      unitRef="USD">115</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000350"
      unitRef="Shares">1963322</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000341"
      unitRef="USD">1963</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000342"
      unitRef="USD">28355230</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000343"
      unitRef="USD">-33931428</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000344"
      unitRef="USD">-5573613</us-gaap:StockholdersEquity>
    <NRXS:StockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000359"
      unitRef="Shares">1098667</NRXS:StockIssuedDuringPeriodSharesCommonStockIssuedUponInitialPublicOffering>
    <NRXS:StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000354"
      unitRef="USD">1099</NRXS:StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering>
    <NRXS:StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000355"
      unitRef="USD">4109578</NRXS:StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering>
    <NRXS:StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000357"
      unitRef="USD">4110677</NRXS:StockIssuedDuringPeriodValueCommonStockIssuedUponInitialPublicOffering>
    <NRXS:StockIssuedDuringPeriodSharesCommonStockIssuedUponPreferredStockConversion
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000368"
      unitRef="Shares">-506637</NRXS:StockIssuedDuringPeriodSharesCommonStockIssuedUponPreferredStockConversion>
    <NRXS:StockIssuedDuringPeriodValueCommonStockIssuedUponPreferredStockConversion
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember"
      decimals="0"
      id="Fact000361"
      unitRef="USD">-507</NRXS:StockIssuedDuringPeriodValueCommonStockIssuedUponPreferredStockConversion>
    <NRXS:StockIssuedDuringPeriodSharesCommonStockIssuedUponPreferredStockConversion
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember"
      decimals="INF"
      id="Fact000370"
      unitRef="Shares">-115477</NRXS:StockIssuedDuringPeriodSharesCommonStockIssuedUponPreferredStockConversion>
    <NRXS:StockIssuedDuringPeriodValueCommonStockIssuedUponPreferredStockConversion
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesSeedPreferredStockMember"
      decimals="0"
      id="Fact000362"
      unitRef="USD">-115</NRXS:StockIssuedDuringPeriodValueCommonStockIssuedUponPreferredStockConversion>
    <NRXS:StockIssuedDuringPeriodSharesCommonStockIssuedUponPreferredStockConversion
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000372"
      unitRef="Shares">1244228</NRXS:StockIssuedDuringPeriodSharesCommonStockIssuedUponPreferredStockConversion>
    <NRXS:StockIssuedDuringPeriodValueCommonStockIssuedUponPreferredStockConversion
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000363"
      unitRef="USD">1244</NRXS:StockIssuedDuringPeriodValueCommonStockIssuedUponPreferredStockConversion>
    <NRXS:StockIssuedDuringPeriodValueCommonStockIssuedUponPreferredStockConversion
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000364"
      unitRef="USD">-622</NRXS:StockIssuedDuringPeriodValueCommonStockIssuedUponPreferredStockConversion>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000381"
      unitRef="Shares">1649900</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000376"
      unitRef="USD">1650</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000377"
      unitRef="USD">9897833</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfUnits
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000379"
      unitRef="USD">9899483</us-gaap:StockIssuedDuringPeriodValueConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000390"
      unitRef="Shares">425000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000385"
      unitRef="USD">425</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000386"
      unitRef="USD">749575</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000388"
      unitRef="USD">750000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000395"
      unitRef="USD">3720997</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000397"
      unitRef="USD">3720997</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <NRXS:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000406"
      unitRef="Shares">127780</NRXS:StockIssuedDuringPeriodSharesWarrantsExercised>
    <NRXS:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000401"
      unitRef="USD">128</NRXS:StockIssuedDuringPeriodValueWarrantsExercised>
    <NRXS:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000402"
      unitRef="USD">315770</NRXS:StockIssuedDuringPeriodValueWarrantsExercised>
    <NRXS:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000404"
      unitRef="USD">315898</NRXS:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000412"
      unitRef="USD">-14626683</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000413"
      unitRef="USD">-14626683</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000426"
      unitRef="Shares">6508897</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000417"
      unitRef="USD">6509</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000418"
      unitRef="USD">47148361</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000419"
      unitRef="USD">-48558111</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000420"
      unitRef="USD">-1403241</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000431"
      unitRef="USD">-14626683</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000432"
      unitRef="USD">-4780061</us-gaap:NetIncomeLoss>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000437"
      unitRef="USD">4881622</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000438"
      unitRef="USD">98935</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000440"
      unitRef="USD">40725</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000441"
      unitRef="USD">37133</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000443"
      unitRef="USD">25281</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000444"
      unitRef="USD">19505</us-gaap:ProvisionForDoubtfulAccounts>
    <NRXS:NoncashLeaseExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000446"
      unitRef="USD">31119</NRXS:NoncashLeaseExpense>
    <NRXS:NoncashLeaseExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000447"
      unitRef="USD">26593</NRXS:NoncashLeaseExpense>
    <NRXS:NoncashInterestExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000449"
      unitRef="USD">260777</NRXS:NoncashInterestExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000453"
      unitRef="USD">27319</us-gaap:ShareBasedCompensation>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000455"
      unitRef="USD">-3649561</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <NRXS:IssuanceOfCommonStockForNoncashConsideration
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000458"
      unitRef="USD">750000</NRXS:IssuanceOfCommonStockForNoncashConsideration>
    <NRXS:FinanceCharges
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000461"
      unitRef="USD">2772</NRXS:FinanceCharges>
    <NRXS:FinanceCharges
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000462"
      unitRef="USD">2322216</NRXS:FinanceCharges>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000464"
      unitRef="USD">198551</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000465"
      unitRef="USD">713989</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000467"
      unitRef="USD">-844854</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000468"
      unitRef="USD">-606049</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000473"
      unitRef="USD">-75951</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000474"
      unitRef="USD">78603</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000476"
      unitRef="USD">-26913</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000477"
      unitRef="USD">8953</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000479"
      unitRef="USD">68937</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000480"
      unitRef="USD">-14944</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000482"
      unitRef="USD">-387897</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000483"
      unitRef="USD">1108326</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000485"
      unitRef="USD">-294154</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000486"
      unitRef="USD">272425</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <NRXS:IncreaseDecreaseInCustomerDeposit
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000488"
      unitRef="USD">15773</NRXS:IncreaseDecreaseInCustomerDeposit>
    <NRXS:IncreaseDecreaseInCustomerDeposit
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000489"
      unitRef="USD">-10163</NRXS:IncreaseDecreaseInCustomerDeposit>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000491"
      unitRef="USD">-33396</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000492"
      unitRef="USD">-27582</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000494"
      unitRef="USD">-6693978</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000495"
      unitRef="USD">-2298004</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000500"
      unitRef="USD">30781</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000501"
      unitRef="USD">1390</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000503"
      unitRef="USD">41000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000504"
      unitRef="USD">59815</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000506"
      unitRef="USD">-71781</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000507"
      unitRef="USD">-61205</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000512"
      unitRef="USD">4847457</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <NRXS:DeferredOfferingCostsPaid
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000516"
      unitRef="USD">736736</NRXS:DeferredOfferingCostsPaid>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000518"
      unitRef="USD">209097</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000521"
      unitRef="USD">3533765</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000522"
      unitRef="USD">163214</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000524"
      unitRef="USD">159831</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000525"
      unitRef="USD">122000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000527"
      unitRef="USD">5460000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000528"
      unitRef="USD">3200000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000530"
      unitRef="USD">552000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000531"
      unitRef="USD">130000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000533"
      unitRef="USD">6590620</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000534"
      unitRef="USD">2292050</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000536"
      unitRef="USD">-175139</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000537"
      unitRef="USD">-67159</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000539"
      unitRef="USD">253699</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000540"
      unitRef="USD">320858</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000542"
      unitRef="USD">78560</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000543"
      unitRef="USD">253699</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000548"
      unitRef="USD">214562</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000549"
      unitRef="USD">202781</us-gaap:InterestPaidNet>
    <NRXS:FairValueOfWarrantLiabilitiesOfWarrantsFromConvertibleNotes
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000557"
      unitRef="USD">2446502</NRXS:FairValueOfWarrantLiabilitiesOfWarrantsFromConvertibleNotes>
    <NRXS:FairValueOfWarrantLiabilitiesOfWarrantsFromConvertibleNotes
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000558"
      unitRef="USD">884118</NRXS:FairValueOfWarrantLiabilitiesOfWarrantsFromConvertibleNotes>
    <NRXS:FairValueOfDerivativeLiabilitiesOfConversionFeatureFromConvertibleNotes
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000560"
      unitRef="USD">2375378</NRXS:FairValueOfDerivativeLiabilitiesOfConversionFeatureFromConvertibleNotes>
    <NRXS:FairValueOfDerivativeLiabilitiesOfConversionFeatureFromConvertibleNotes
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000561"
      unitRef="USD">1075098</NRXS:FairValueOfDerivativeLiabilitiesOfConversionFeatureFromConvertibleNotes>
    <NRXS:PriorYearOfferingCostsPaid
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000563"
      unitRef="USD">736736</NRXS:PriorYearOfferingCostsPaid>
    <NRXS:ReclassificationOfWarrantLiabilityToEquity
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000566"
      unitRef="USD">3720997</NRXS:ReclassificationOfWarrantLiabilityToEquity>
    <NRXS:ConversionOfPreferredStockToCommonStock
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000569"
      unitRef="USD">1244</NRXS:ConversionOfPreferredStockToCommonStock>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000572">&lt;p id="xdx_80B_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zH2wWjEwj3B" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="f_005"&gt;&lt;/span&gt;1.
&lt;span id="xdx_82B_zbY3G2UDua66"&gt;Basis of Presentation, Organization and Other Matters&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Neuraxis,
Inc. (&#x201c;we,&#x201d; &#x201c;us,&#x201d; the &#x201c;Company,&#x201d; or &#x201c;Neuraxis&#x201d;) was established in 2011 and incorporated
in the state of Indiana on April 17, 2012, under the name of Innovative Health Solutions, Inc. The name was changed to Neuraxis, Inc.
in March of 2022. Additionally, the Company filed a Certificate of Conversion to become a Delaware corporation on June 23, 2022. The
authorized shares were increased, and a par value established.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 10, 2023, the Company&#x2019;s board of directors authorized a &lt;span id="xdx_908_eus-gaap--StockholdersEquityNoteStockSplit_c20230112__20230112_zDLrnaI022Xl" title="Description of stock split"&gt;1-for-2 reverse stock split&lt;/span&gt;. All per share information has been
adjusted for this reverse stock split. The reverse split became effective on January 12, 2023. All share and per share amounts for the
common stock have been retroactively restated to give effect to the splits.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
part of the conversion to a Delaware corporation, the total number of shares of all classes of stock which the Corporation shall have
authority to issue is (1) &lt;span id="xdx_906_eus-gaap--CommonStockSharesAuthorized_iI_c20231231_zE6pBmT85IFe" title="Common stock, shares authorized"&gt;100,000,000&lt;/span&gt; shares of Common Stock, par value $&lt;span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20231231_zRIQqgSYhHPe" title="Common stock, par value"&gt;0.001&lt;/span&gt; per share (&#x201c;Common Stock&#x201d;) and (ii) &lt;span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_c20231231_znenjB02donb" title="Preferred stock, shares authorized"&gt;1,120,000&lt;/span&gt;
shares of Preferred Stock, par value $&lt;span id="xdx_903_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20231231_z4hpc59X6ykh" title="Preferred stock, par value"&gt;0.001&lt;/span&gt; per share (&#x201c;Preferred Stock&#x201d;), &lt;span id="xdx_90A_eus-gaap--PreferredStockSharesAuthorized_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesAPreferredStockMember_zY6HuNczpML" title="Preferred stock, shares authorized"&gt;1,000,000&lt;/span&gt; of which is hereby designated as &#x201c;Series
A Preferred Stock&#x201d; and &lt;span id="xdx_90C_eus-gaap--PreferredStockSharesAuthorized_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_zCVdjr9FKXZc" title="Preferred stock, shares authorized"&gt;120,000&lt;/span&gt; of which is hereby designated as &#x201c;Series Seed Preferred Stock&#x201d; with the rights, preferences,
powers, privileges and restrictions, qualifications and limitations set forth in this Article IV of the Delaware Certificate of Incorporation.
All share amounts have been retroactively restated to give effect to these changes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 9, 2023, the Company consummated an initial public offering, conducted on a firm commitment basis, pursuant to which it sold &lt;span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230809__20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_ztY6zd7Dq7j3"&gt;1,098,667
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of its common stock at a price of $&lt;span id="xdx_902_eus-gaap--SharesIssuedPricePerShare_iI_c20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zMoeySb90b9h"&gt;6.00
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share, resulting in gross proceeds to the
Company of $&lt;span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230809__20230809__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_ztgrFZDFvVS1"&gt;6,592,002&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.
Net proceeds to the Company, after deducting underwriting discounts and commissions, 2022 deferred offering costs totaling $&lt;span id="xdx_905_eus-gaap--DeferredOfferingCosts_iI_c20230809__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_zhC2gGNwt281" title="Deferred offering costs"&gt;736,736&lt;/span&gt; and
offering expenses paid by the Company, were $&lt;span id="xdx_901_eus-gaap--DeferredOfferingCosts_iI_c20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_zV6v3NzRmZY"&gt;4,110,721&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.
All shares sold in our IPO were registered pursuant to a registration statement on Form S-1 (File No. 333- 269179), as amended, declared
effective by the SEC on August 9, 2023. Alexander Capital L.P. (&#x201c;Alexander&#x201d;) acted as sole book-running manager for the offering
and Spartan Capital Securities, LLC acted as co-manager for the offering. The underwriters did not exercise their option to purchase
up to an additional &lt;span id="xdx_90D_ecustom--PurchaseOfAdditionalStockOnNumberOfOptionsNotExercised_c20230809__20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zGrudURXDg37"&gt;164,801
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of common stock. The Company paid the
underwriters an underwriting discount of seven percent (&lt;span id="xdx_90B_ecustom--UnderwritersDiscountPercentage_iI_dp_uPure_c20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_zqqAadAuMlF3"&gt;7%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)
of the amount raised in the offering. In addition, we also paid the underwriters a non-accountable expense allowance in the amount of
&lt;span id="xdx_908_ecustom--NonaccountableExpenseAllowancePercentage_iI_dp_uPure_c20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_zRyspjKU45kg"&gt;1%
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(such &lt;span id="xdx_90C_ecustom--CashFeePercentage_iI_dp_uPure_c20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_zIQHuZkPDxl9"&gt;8%
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;in commissions and fees amounted to a total of
$&lt;span id="xdx_90E_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20230809__20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_zBfHc0TaETDc"&gt;527,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)
at closing, as well as $&lt;span id="xdx_901_ecustom--ReimbursementExpenses_c20230809__20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_zIh7n8oUPECd"&gt;175,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;for the reimbursement of certain of the underwriters&#x2019;
expenses. Additionally, as partial consideration for services rendered in connection with the offering, the Company issued Alexander
unregistered warrants to purchase an aggregate of &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20230809__20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_zzNsczBfs904"&gt;65,921
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares of Company common stock, representing
&lt;span id="xdx_902_eus-gaap--SaleOfStockPercentageOfOwnershipAfterTransaction_pid_dp_c20230809__20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_zGdQeHnWxP37"&gt;6.0%
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;of the aggregate shares sold in the offering.
The warrants have an initial exercise price of $&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_zAoxC9D5n5Ab"&gt;7.20
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share (equal to &lt;span id="xdx_907_ecustom--OfferingPricePerPercentage_iI_pid_dp_c20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember_zzDtOD5Oi6y8"&gt;120%
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;of the offering price per share), have a term
of five years from the commencement of sales in the offering, and are exercisable at any time.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is headquartered in Carmel, Indiana. The Company specializes in the development, production, and sale of medical neuromodulation
devices.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has developed three FDA cleared products, the IB-STIM (DEN180057, 2019), the NSS-2 Bridge (DEN170018, 2017), and the original
510(K) clearance (K140530, 2014).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    IB-STIM is a percutaneous electrical nerve field stimulator (PENFS) device that is indicated in patients 11-18 years of age with
    functional abdominal pain associated with irritable bowel syndrome. The IB-STIM currently is the only product marketed and sold by
    the Company.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    NSS-2 Bridge is a percutaneous nerve field stimulator (PNFS) device indicated for use in the reduction of the symptoms of opioid
    withdrawal. The NSS-2 Bridge device was licensed to Masimo Corporation in April 2020, and the Company received a one-time licensing
    fee of $&lt;span id="xdx_901_ecustom--LicenseFees_c20230811__20230811__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--ConsolidatedEntitiesAxis__custom--AlexanderCapitalLPMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zgUrrZX24mmg" title="License fees"&gt;250,000&lt;/span&gt; from Masimo. Masimo markets and sells this product as its Masimo Bridge, and the Company will not receive any further
    licensing payments or other revenue from this product.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
    original 510(K) device was the EAD, an electroacupuncture device, now called NeuroStim. The EAD is no longer being manufactured,
    sold or distributed but reserved only for research purposes.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Notes to Financial Statements&lt;/b&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:StockholdersEquityNoteStockSplit contextRef="From2023-01-122023-01-12" id="Fact000574">1-for-2 reverse stock split</us-gaap:StockholdersEquityNoteStockSplit>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000576"
      unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000578"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000580"
      unitRef="Shares">1120000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact000582"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31_custom_ConvertibleSeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000584"
      unitRef="Shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31_custom_ConvertibleSeriesSeedPreferredStockMember"
      decimals="INF"
      id="Fact000586"
      unitRef="Shares">120000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2023-08-092023-08-09_us-gaap_CommonStockMember_custom_AlexanderCapitalLPMember_us-gaap_IPOMember"
      decimals="INF"
      id="Fact000587"
      unitRef="Shares">1098667</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-08-09_us-gaap_CommonStockMember_custom_AlexanderCapitalLPMember_us-gaap_IPOMember"
      decimals="INF"
      id="Fact000588"
      unitRef="USDPShares">6.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-08-092023-08-09_us-gaap_CommonStockMember_custom_AlexanderCapitalLPMember_us-gaap_IPOMember"
      decimals="0"
      id="Fact000589"
      unitRef="USD">6592002</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2023-08-09_us-gaap_IPOMember_custom_AlexanderCapitalLPMember"
      decimals="0"
      id="Fact000591"
      unitRef="USD">736736</us-gaap:DeferredOfferingCosts>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2023-08-09_us-gaap_CommonStockMember_custom_AlexanderCapitalLPMember_us-gaap_IPOMember"
      decimals="0"
      id="Fact000592"
      unitRef="USD">4110721</us-gaap:DeferredOfferingCosts>
    <NRXS:PurchaseOfAdditionalStockOnNumberOfOptionsNotExercised
      contextRef="From2023-08-092023-08-09_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000593"
      unitRef="Shares">164801</NRXS:PurchaseOfAdditionalStockOnNumberOfOptionsNotExercised>
    <NRXS:UnderwritersDiscountPercentage
      contextRef="AsOf2023-08-09_us-gaap_CommonStockMember_custom_AlexanderCapitalLPMember_us-gaap_IPOMember"
      decimals="INF"
      id="Fact000594"
      unitRef="Pure">0.07</NRXS:UnderwritersDiscountPercentage>
    <NRXS:NonaccountableExpenseAllowancePercentage
      contextRef="AsOf2023-08-09_us-gaap_CommonStockMember_custom_AlexanderCapitalLPMember_us-gaap_IPOMember"
      decimals="INF"
      id="Fact000595"
      unitRef="Pure">0.01</NRXS:NonaccountableExpenseAllowancePercentage>
    <NRXS:CashFeePercentage
      contextRef="AsOf2023-08-09_us-gaap_CommonStockMember_custom_AlexanderCapitalLPMember_us-gaap_IPOMember"
      decimals="INF"
      id="Fact000596"
      unitRef="Pure">0.08</NRXS:CashFeePercentage>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2023-08-092023-08-09_us-gaap_CommonStockMember_custom_AlexanderCapitalLPMember_us-gaap_IPOMember"
      decimals="0"
      id="Fact000597"
      unitRef="USD">527000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <NRXS:ReimbursementExpenses
      contextRef="From2023-08-092023-08-09_us-gaap_CommonStockMember_custom_AlexanderCapitalLPMember_us-gaap_IPOMember"
      decimals="0"
      id="Fact000598"
      unitRef="USD">175000</NRXS:ReimbursementExpenses>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2023-08-092023-08-09_us-gaap_CommonStockMember_custom_AlexanderCapitalLPMember_us-gaap_IPOMember"
      decimals="INF"
      id="Fact000599"
      unitRef="Shares">65921</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction
      contextRef="From2023-08-092023-08-09_us-gaap_CommonStockMember_custom_AlexanderCapitalLPMember_us-gaap_IPOMember"
      decimals="INF"
      id="Fact000600"
      unitRef="Pure">0.060</us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-08-09_us-gaap_CommonStockMember_custom_AlexanderCapitalLPMember_us-gaap_IPOMember"
      decimals="INF"
      id="Fact000601"
      unitRef="USDPShares">7.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <NRXS:OfferingPricePerPercentage
      contextRef="AsOf2023-08-09_us-gaap_CommonStockMember_custom_AlexanderCapitalLPMember_us-gaap_IPOMember"
      decimals="INF"
      id="Fact000602"
      unitRef="Pure">1.20</NRXS:OfferingPricePerPercentage>
    <NRXS:LicenseFees
      contextRef="From2023-08-112023-08-11_us-gaap_CommonStockMember_custom_AlexanderCapitalLPMember_us-gaap_IPOMember"
      decimals="0"
      id="Fact000604"
      unitRef="USD">250000</NRXS:LicenseFees>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000606">&lt;p id="xdx_805_eus-gaap--SignificantAccountingPoliciesTextBlock_zUbBKSWPsjz5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.
&lt;span&gt;&lt;span id="xdx_82A_zYcCYzAt0rk6"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
summary of significant accounting policies of Neuraxis, Inc. is presented to assist in understanding the Company&#x2019;s financial statements.
The financial statements and notes are representations of the Company&#x2019;s management, who are responsible for their integrity and
objectivity. These accounting policies conform to U.S. generally accepted accounting principles and have been consistently applied in
the preparation of the financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Preparing
the Company&#x2019;s financial statements in conformity with accounting principles generally accepted in the United States of America
(&#x201c;GAAP&#x201d;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities
and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and
expenses during the reporting period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--UseOfEstimates_zVDuaXrTLydg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span&gt;&lt;span id="xdx_862_zEz0MUIIsalf"&gt;Use
of Estimates and Critical Accounting Estimates and Assumptions&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements
and the reported amounts of revenues and expenses during the reporting periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;These
significant accounting estimates or assumptions bear the risk of change due to the fact that there are uncertainties attached to these
estimates or assumptions, and certain estimates or assumptions are difficult to measure or value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
bases its estimates on historical experience and on various assumptions that are believed to be reasonable in relation to the financial
statements taken as a whole under the circumstances, the results of which form the basis for making judgments about the carrying values
of assets and liabilities that are not readily apparent from other sources.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available information, changes
in facts and circumstances, historical experience, and reasonable assumptions. After such evaluations, if deemed appropriate, those
estimates are adjusted accordingly. The Company uses estimates in accounting for, among other items, revenue recognition, allowance
for credit losses, stock-based compensation, income tax provisions, excess and obsolete inventory reserve, and impairment of property and
equipment, and intellectual property. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zGfQ3Arrc5Ke" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span&gt;&lt;span id="xdx_867_zpZR0i4lMbte"&gt;Cash
and Cash Equivalents&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. The Company
did not hold any cash equivalents as of December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zQyLIdQUqMOa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span&gt;&lt;span id="xdx_86D_zsWTh5OrDIQg"&gt;Trade
Accounts Receivable and Allowance for Credit Losses&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Trade
accounts receivable are stated at the amount management expects to collect from outstanding balances, net of an allowance for credit
losses. Management evaluates many factors when determining the collectability of specific customer accounts, including, but not limited
to, creditworthiness, past transaction and payment history, current economic industry trends and changes in payment terms. We use assumptions
and judgment based on the best available facts and circumstances to estimate and record an allowance. The allowance for credit losses
was $&lt;span id="xdx_903_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20231231_zNeKr5x0pjbf" title="Allowance for doubtful accounts"&gt;11,993&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20221231_zt6UU4ntIW9g" title="Allowance for doubtful accounts"&gt;31,275&lt;/span&gt; as of December 31, 2023 and 2022, respectively. The Company recorded credit losses for the years ended December
31,2023 and 2022 of $&lt;span id="xdx_905_eus-gaap--ProvisionForOtherCreditLosses_c20230101__20231231_z1fCU75qdmHl" title="Credit losses"&gt;25,281&lt;/span&gt; and &lt;span id="xdx_90E_eus-gaap--ProvisionForOtherCreditLosses_c20220101__20221231_zJXQSNTHatn3" title="Credit losses"&gt;64,197&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Notes to Financial Statements&lt;/b&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--DepositContractsPolicy_z3G9pKnFRuKc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span&gt;&lt;span id="xdx_86C_zmrJGQX99vDl"&gt;Customer
Deposits&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Customer
deposits consists of billings, payments, and returned devices from clients in advance of revenue recognition. The Company will recognize
the customer deposits over the next year. As of December 31, 2023, and 2022, the Company had customer deposits of $&lt;span id="xdx_902_eus-gaap--Deposits_iI_c20231231_zqIUNH3DZJc8" title="Customer deposits"&gt;74,947&lt;/span&gt; and $&lt;span id="xdx_90F_eus-gaap--Deposits_iI_c20221231_zPLa3GeMgKU6" title="Customer deposits"&gt;59,174&lt;/span&gt;,
respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--InventoryPolicyTextBlock_zMI6ujuN7rw1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span&gt;&lt;span id="xdx_866_zves0DdFNTW3"&gt;Inventories&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventories
are valued at the lower of cost or net realizable value. Cost is determined using the weighted average method. The inventory is comprised
of finished medical devices on hand. Certain components within the devices have an expiration date that are removed from current inventory
and expensed at the date of expiration. For the years ended December 31, 2023 and 2022, $&lt;span id="xdx_90B_ecustom--InventoryExpenses_c20231231_zoQihQ2ttyu6" title="Inventory expenses"&gt;25,008&lt;/span&gt; and $&lt;span id="xdx_90D_ecustom--InventoryExpenses_iI_c20221231_zzHCNhEaXkRc" title="Inventory expenses"&gt;10,026&lt;/span&gt; were expensed as expired
inventory, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--DeferredChargesPolicyTextBlock_zKApjnvqDPCi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span&gt;&lt;span id="xdx_865_zn9V9ttt6wmf"&gt;Deferred
Offering Costs&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
offering costs consist of costs incurred in connection with the preparation of an initial public offering. These costs, together with
the underwriting discounts and commissions, were charged to additional paid in capital upon the IPO. As of December 31, 2023 and 2022,
the Company had deferred offering costs of $&lt;span id="xdx_90F_eus-gaap--DeferredOfferingCosts_iI_dxL_c20231231_zduETi4XjJ34" title="Deferred offering costs::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0636"&gt;0&lt;/span&gt;&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--DeferredOfferingCosts_iI_c20221231_zJ5duxanWdb7" title="Deferred offering costs"&gt;736,736&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zqhPQolYI7fb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_866_zfGsnuflXkyf"&gt;Property
and Equipment&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are recorded at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated
useful lives of the assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_ecustom--ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_zuDWFlazwtT8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation
is calculated using the following estimated useful lives:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B0_zRYzhM4FObAj" style="display: none"&gt;Schedule of Estimated Useful Lives&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 60%; border-collapse: collapse; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Classification&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Years&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Machinery and Equipment &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MinimumMember_z6T4sUWWoWNi" title="Property and equipment, estimated useful lives"&gt;5&lt;/span&gt;-&lt;span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MaximumMember_zd3L5zgGES5d" title="Property and equipment, estimated useful lives"&gt;10&lt;/span&gt; &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Furniture and Fixtures&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zkpRYICgli12" title="Property and equipment, estimated useful lives"&gt;5&lt;/span&gt;-&lt;span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_zy9KJtQEgs4a" title="Property and equipment, estimated useful lives"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Computer Hardware&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MinimumMember_zdqGof3t1oI" title="Property and equipment, estimated useful lives"&gt;5&lt;/span&gt;-&lt;span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MaximumMember_zcRNd7T4hdqb" title="Property and equipment, estimated useful lives"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leasehold Improvements&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MinimumMember_zZHzaJmx9lfj" title="Property and equipment, estimated useful lives"&gt;10&lt;/span&gt;-&lt;span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MaximumMember_zFLCxUzN8HYh" title="Property and equipment, estimated useful lives"&gt;20&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A6_zEuDpQt8YXCc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation
expense was $&lt;span id="xdx_907_eus-gaap--Depreciation_c20230101__20231231_zq9Hcvf7e1Dh" title="Depreciation expense"&gt;30,240&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--Depreciation_c20220101__20221231_zu5aKm0Y6C1c" title="Depreciation expense"&gt;30,920&lt;/span&gt; during the years ended December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--ResearchAndDevelopmentExpensePolicy_zLl5UkZpEoJ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_862_zsTqLJDzE2Yb"&gt;Research
and Development&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Costs
for research and development are expensed as incurred. Research and development expenses consist primarily of clinical research studies
and new product development.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--IntangibleAssetsFiniteLivedPolicy_z8qWp4Ka2Tj4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86E_zMTjD8n9M7D4"&gt;Intangible
Assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible
assets consist of software, patents and a trademark. Intangible assets are stated at their historical cost and amortized on
a straight-line basis over their expected useful lives. Capitalized patent costs, net of accumulated amortization, includes legal costs
incurred for patent applications. In accordance with ASC 350, once a patent is granted, we amortize the capitalized patent costs over
the remaining life of the patent using the straight-line method. If the patent is not granted, we write off any capitalized patent costs
at that time.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company entered into an agreement for a trademark related to the Company&#x2019;s name on July 11, 2022. The agreement called for an initial
payment of $&lt;span id="xdx_907_eus-gaap--PaymentsToAcquireIntangibleAssets_c20220710__20220711__us-gaap--TypeOfArrangementAxis__custom--TrademarkAgreementMember__us-gaap--OtherCommitmentsAxis__custom--InitialPaymentMember_zitNuSg2qFZk" title="Initial payment upon execution"&gt;10,000&lt;/span&gt; upon execution of the agreement. A second and final payment of $&lt;span id="xdx_903_eus-gaap--PaymentsToAcquireIntangibleAssets_c20220710__20220711__us-gaap--TypeOfArrangementAxis__custom--TrademarkAgreementMember__us-gaap--OtherCommitmentsAxis__custom--SecondAndFinalPaymentMember_zIBof3crmvG2" title="Second and final payment of contingent"&gt;40,000&lt;/span&gt; was contingent upon the completion of the Company&#x2019;s
planned initial public offering. The trademark does not have a determinate life and therefore the cost is not being amortized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company entered into an option agreement on April 12, 2023 to enter into a royalty-bearing licensing agreement to bring the optionor&#x2019;s
invention to commercialization. The agreement required an initial payment of $&lt;span id="xdx_907_eus-gaap--PaymentsToAcquireIntangibleAssets_c20230411__20230412__us-gaap--TypeOfArrangementAxis__custom--LicensingAgreementMember_zu7IJvU0Ivja" title="Initial payment upon execution"&gt;1,000&lt;/span&gt; upon execution of the agreement. The agreement does
not have a determinate life and therefore the cost is not being amortized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Notes to Financial Statements&lt;/b&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
review intangible assets for impairment annually or when events or circumstances indicate that their carrying amount may not be recoverable.
During the years ended December 31, 2023, and 2022, the Company recorded no impairment charges for intangible assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amortization
expense was $&lt;span id="xdx_900_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20231231_zEfBkB15rWa9" title="Amortization expense"&gt;10,485&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--AmortizationOfIntangibleAssets_c20220101__20221231_zFaUgEMJOp63" title="Amortization expense"&gt;6,213&lt;/span&gt; during the years ended December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_zL1OMXiuVgO6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86D_zWbZejgz59Z6"&gt;Income
Taxes&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in
the Company&#x2019;s financial statements and tax returns. Deferred tax assets and liabilities are determined based upon the differences
between the financial statement carrying amounts, and the tax bases of existing assets and liabilities for the loss and credit carryforwards
using enacted tax rates expected to be in effect in the year in which the differences are expected to reverse. Deferred tax assets are
reduced by a valuation allowance if it is more likely than not that these assets may not be realized. The Company determines whether
a tax position will be sustained upon examination. If it is more likely than not that a position will be sustained, none of the benefit
attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more likely than not
recognition threshold is calculated as the largest amount that is more than 50% likely of being realized upon resolution of the contingency.
The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Based
on the results of management&#x2019;s evaluation, adoption of the rules did not have a material effect on the Company&#x2019;s financial
statements. Further, no interest or penalties have been accrued or charged to expense as of December 31, 2023 and 2022 and for the years
then ended.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s income tax returns are subject to examination by the taxing authorities until the expiration of the related statutes
of limitations on those tax returns. In general, the federal and state income tax returns have a three-year statute of limitations. As
of December 31, 2023, the following tax years are subject to examination:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 32%; text-align: center"&gt;Jurisdiction&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 32%; text-align: center"&gt;Open Years for Filed Returns&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 32%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Return to File in 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2020 &#x2013; 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;Various States&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2020 &#x2013; 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--AdvertisingCostsPolicyTextBlock_zMkGAZaOZrki" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_869_zYreRTxzU1b3"&gt;Advertising
Cost&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Advertising
costs are expensed as incurred and amounted to $&lt;span id="xdx_900_eus-gaap--AdvertisingExpense_c20230101__20231231_z0GjCaNfpWY5" title="Advertising cost expense"&gt;192,400&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--AdvertisingExpense_c20220101__20221231_zp2itMDg3Lc1" title="Advertising cost expense"&gt;14,900&lt;/span&gt; for the years ended December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_ecustom--DerivativeLiabilityPolicyTextBlock_zGVqCK5z85Mc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_869_zHMq8XLsXJ6i"&gt;Derivative
Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for derivative financial instruments as either equity or liabilities in accordance with ASC Topic 815, &lt;i&gt;Derivatives
and Hedging&lt;/i&gt;, or ASC 815, based on the characteristics and provisions of each instrument. Embedded derivatives are required to be
bifurcated from the host instruments and recorded at fair value if the derivatives are not clearly and closely related to the host instruments
on the date of issuance. Derivative instrument liabilities are classified in the balance sheets as current or non-current based on whether
or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company utilizes a Monte Carlo simulation model for the common stock conversion feature of the notes payable that have an option to
convert at a variable number of shares to compute the fair value of the derivative and to mark to market the fair value of the
derivative at each balance sheet date. The inputs utilized in the application of the Monte Carlo model included a stock
price, an expected remaining term of each note as of the valuation date, estimated volatility, drift, and a risk-free rate. The
Company records the change in the fair value of the derivative as other income or expense in the Statements of Operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Notes to Financial Statements&lt;/b&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84B_ecustom--WarrantLiabilityPolicyTextBlock_z69GwGVVBVcc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_869_zV7p8awBt4kc"&gt;Warrant
Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
evaluates all of the Company&#x2019;s financial instruments, including issued warrants to purchase its Class A common stock, to
determine if such instruments are liabilities or contain features that qualify as embedded derivatives, pursuant to ASC 480 and ASC
815-15. The classification of derivative financial instruments, including whether such instruments should be recorded as liabilities
or as equity, is reassessed at the end of each reporting period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company utilizes a Monte Carlo simulation model for warrants that have an option to convert at a variable number of shares to compute
the fair value of the derivative and to mark to market the fair value of the derivative at each balance sheet date. The inputs utilized
in the application of the Monte Carlo model included a starting stock price, an expected remaining term of each warrant as of the valuation
date, estimated volatility, drift, and a risk-free rate. The Company records the change in the fair value of the warrant as other
income or expense in the statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zXaEEhNVRUzl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86B_z42RAGNx2Pke"&gt;Fair
Value Measurements&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for financial instruments in accordance with ASC 820, Fair Value Measurements and Disclosures (&#x201c;ASC 820&#x201d;).
ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy
gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and
the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under ASC 820 are described
below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
1 &#x2013; Quoted prices (unadjusted) for identical unrestricted assets or liabilities in active markets that the reporting entity has
the ability to access as of the measurement date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
2 &#x2013; Significant other observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities: quoted
prices in markets that are not active; or financial instruments for which all significant inputs are observable or can be corroborated
by observable market date, either directly or indirectly.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
3 &#x2013; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets
or liabilities. These unobservable inputs reflect that reporting entity&#x2019;s own assumptions about assumptions that market participants
would use in pricing the asset or liability. Level 3 assets and liabilities include financial instruments whose value is determined using
pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair
value require significant management judgment or estimation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s Level 1 assets/liabilities include cash, accounts receivable, accounts payable, prepaids, and other current assets. Management
believes the estimated fair value of these accounts on December 31, 2023 approximate their carrying value as reflected in the balance
sheets due to the short-term nature of these instruments or the use of market interest rates for debt instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s Level 3 assets/liabilities include derivative and warrant liabilities. Inputs to determine fair value are generally
unobservable and typically reflect management&#x2019;s estimates of assumptions that market participants would use in pricing the
asset or liability. The fair values are therefore determined using model-based techniques, including option pricing models and
discounted cash flow models. The valuation techniques involve management&#x2019;s estimates and judgment based on unobservable
inputs. The fair value estimates may not be indicative of the amounts that would be realized in a market exchange. Additionally,
there may be inherent uncertainties or changes in the underlying assumptions used, which could significantly affect the current or
future fair value estimates. Unobservable inputs used in the models are significant to the fair values of the assets and
liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Notes to Financial Statements&lt;/b&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zXrb3Ha5bbbh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following tables provides a summary of the relevant assets and liabilities that are measured at fair value on recurring basis:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;Fair Value Measurements as of&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;December 31, 2023&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span id="xdx_8B5_zBcTe0bNWWrd" style="display: none"&gt;Schedule of Fair Value On a Recurring Basis Assets and Liability&lt;/span&gt;&#160;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zZgb1nNnOIB1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z90tT0VJCng4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Level 1)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_znhoBmNvawL8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Level 2)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z8GtVuYWyEwa" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;(Level 3)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--WarrantLiabilities_i02I_maLFVDzwLw_z6rpvKyALug1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 36%; text-align: left"&gt;Warrant liabilities&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;8,225&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0695"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0696"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;8,225&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DerivativeLiabilitiesCurrent_i02I_maLFVDzwLw_zJzlXGtSZDO9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Derivative liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0699"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0700"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0701"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0702"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LiabilitiesFairValueDisclosure_i02I_mtLFVDzwLw_zV9UcwYYQyjl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Total Liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,225&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0705"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0706"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,225&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Fair Value Measurements as of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
31, 2022&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zmHu3a3OQ26c" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z5PTqsJi0jad" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(Level 1)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zkDLZOyMUWCb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(Level 2)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zrrRyAbSdmol" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(Level 3)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--WarrantLiabilities_i02I_maLFVDzwLw_zowQ4vO09hL" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 36%; text-align: left"&gt;Warrant liabilities&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;2,234,384&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0710"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0711"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;2,234,384&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DerivativeLiabilitiesCurrent_i02I_maLFVDzwLw_zbXoob1TDTJ8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Derivative liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,735,700&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0715"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0716"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,735,700&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LiabilitiesFairValueDisclosure_i02I_mtLFVDzwLw_zhUioZYfLqQe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Total Liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,970,084&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0720"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0721"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,970,084&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;/p&gt;

&lt;p id="xdx_8A7_zUdX8zDeETDg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zYMTrkf1t5pf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table shows the valuation methodology and unobservable inputs for Level 3 assets and liabilities measured at fair value on
recurring basis as of December 31, 2023 and December 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;span id="xdx_8BF_zcWaoIpk4QNi" style="display: none"&gt;Schedule of Unobservable Inputs for Level 3 Assets and Liabilities&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Fair Value As of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Valuation&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Unobservable&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Methodology&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Inputs&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 20%; text-align: justify"&gt;Warrant liabilities&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--WarrantLiabilities_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zshO0OaVLGL4" style="width: 13%; text-align: right" title="Warrant liabilities"&gt;8,225&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--WarrantLiabilities_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zk5YFe91k1u1" style="width: 13%; text-align: right" title="Warrant liabilities"&gt;2,234,384&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 19%; text-align: center"&gt;Monte Carlo model&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 23%; text-align: center"&gt;Project simulated cash flows&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Derivative liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zljGNFsh3REk" style="text-align: right" title="Derivative liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0730"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z5BnVDl7ijHc" style="text-align: right" title="Derivative liabilities"&gt;1,735,700&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Monte Carlo model&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Project simulated cash flows&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A9_zjTAxKrFNlr2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
were no transfers between any of the levels during the years ended December 31, 2023 and year ended December 31, 2022. In addition
to assets and liabilities that are recorded at fair value on a recurring basis, the Company&#x2019;s assets and liabilities are also
subject to nonrecurring fair value measurements. As of December 31, 2023 and 2022, the Company had no assets that were measured on a
nonrecurring basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zDXVnNedKCu8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_863_zD1TKYEnGW6l"&gt;Basic
and Diluted Net Income (Loss) per Share&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Earnings
or loss per share (&#x201c;EPS&#x201d;) is computed by dividing net income (loss), net of preferred stock dividends, by the weighted average
number of shares of common stock outstanding during the period. Diluted EPS is computed by dividing net income (loss) by the weighted
average of all potentially dilutive shares of common stock that were outstanding during the periods presented. Preferred stock dividends
(not declared or paid) were $&lt;span id="xdx_90B_eus-gaap--DividendsPreferredStock_c20230101__20231231_zmgcGg3rUjO4" title="Preferred stock dividend"&gt;0&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--DividendsPreferredStock_c20220101__20221231_zO9qN9bbbF1d" title="Preferred stock dividend"&gt;2,190,102&lt;/span&gt; as of December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common
shares outstanding during the period. Diluted net loss per common share is determined using the weighted-average number of common shares
outstanding during the period, adjusted for the dilutive effect of common stock equivalents. In periods when losses are reported, which
is the case for December 31, 2023 and 2022 presented in these financial statements, the weighted-average number of common shares outstanding
excludes common stock equivalents because their inclusion would be anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Notes to Financial Statements&lt;/b&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_zNwURusR6vu2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company had the following potentially dilutive common stock equivalents at December 31, 2023 and 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B9_zNje6TLH5oU8" style="display: none"&gt;Schedule of Dilutive Common Stock Equivalents&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20230101__20231231_z51OT7QLFr38" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20220101__20221231_zWMVb7whmDXe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleSeriesAPreferredStockMember_z2UCsBz9SQg5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Convertible Series A Preferred Stock&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0742"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;1,013,270&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleSeriesSeedPreferredStockMember_zB4vs5QaziT1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Convertible Series Seed Preferred Stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0745"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;230,954&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--OptionMember_zvy1eobwixR5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,319,394&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,319,394&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--PreferredStockMember_z33AI0MMLE5f" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0pt; text-align: left"&gt;Pre-Funded Warrants for Convertible Series A Preferred Stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0751"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;289,779&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_zIYhQ9G4GrF8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,822,358&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;365,962&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleBridgeDebtMember_zP5fRYEVMiTa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Convertible Bridge Debt&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0757"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;376,653&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zuWn8sTcwH0j" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Totals&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,141,752&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,596,012&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A5_zViJxKGPpRP9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zxBv4WY9fsXf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table shows the calculation of the basic and diluted net loss per share and the effect of preferred stock dividends.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B6_zqUi5n0z7Kfl" style="display: none"&gt;Schedule of Basic and Diluted Net Loss Per Share&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20230101__20231231_zX5oRcjTJW1g" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20220101__20221231_zBMbJ08DzJ84" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Numerator&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--NetIncomeLoss_iT_mtNILzQKI_zy8h4Qz1xuO1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 60%; text-align: left"&gt;Net loss&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(14,626,683&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(4,780,061&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--PreferredStockDividendsAndOtherAdjustments_zgKkCa9mWffi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Preferred stock dividends&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0768"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(764,893&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zk1oVBBRjz5i" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net income (loss) available to common stockholders&lt;/span&gt; &lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(14,626,683&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,544,954&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Denominator&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"&gt;Weighted-average shares of common stock outstanding - basic
    and diluted&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231_znEzxgGfUxea" title="Weighted average shares of common stock outstanding - basic"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231_zbww0nP4YRg1" title="Weighted average shares of common stock outstanding - diluted"&gt;3,252,328&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20220101__20221231_z6Tas7DWLb8e" title="Weighted average shares of common stock outstanding - basic"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20220101__20221231_zmjpPawtofr9" title="Weighted average shares of common stock outstanding - diluted"&gt;2,003,322&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Basic and diluted net loss per share&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--EarningsPerShareBasic_c20230101__20231231_zG5fKt9oFUC8" title="Basic net loss per share"&gt;&lt;span id="xdx_905_eus-gaap--EarningsPerShareDiluted_c20230101__20231231_z2RhTCLdmDCb" title="Diluted net loss per share"&gt;(4.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--EarningsPerShareBasic_c20220101__20221231_zZJe1K2BfZ76" title="Basic net loss per share"&gt;&lt;span id="xdx_90C_eus-gaap--EarningsPerShareDiluted_c20220101__20221231_zds8oPl0kjM3" title="Diluted net loss per share"&gt;(2.77&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A4_z0tCcqsbBemd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84E_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zz4yjkKUeCzk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_861_zFhESh1uvKod"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for all stock-based payments and awards at fair value. The Company recognizes its stock-based compensation
expense using the straight-line method. Compensation cost is not adjusted for estimated forfeitures, but instead is adjusted upon an
actual forfeiture of a stock option.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for the granting of stock options to employees and non-employees using the fair value method whereby all awards are
measured at fair value on the date of the grant. The fair value of all employee stock options is expensed over the requisite service
period with a corresponding increase to additional paid-in capital. Upon exercise of stock options, the consideration paid by the option
holder is recorded in additional paid-in capital, while the par value of the shares received is reclassified from additional paid in
capital to common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock-based
payments to non-employees are measured based on the fair value of the equity instrument issued. Compensation expense for non-employee
stock awards is recognized over the requisite service period following the measurement of the fair value on the grant date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company uses the Black-Scholes option-pricing model to calculate the fair value of stock options. The use of the Black-Scholes option-pricing
model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common
stock consistent with the expected term of the option, risk-free interest rates, the value of the common stock and expected dividend
yield of the common stock. Changes in these assumptions can materially affect the fair value estimate.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_eus-gaap--RevenueRecognitionPolicyTextBlock_zQiivN3OJYcj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_868_zdikTs1WOXe1"&gt;Revenue
Recognition&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Neuraxis,
Inc. specializes in the development, production, and sale of medical neuromodulation devices to healthcare providers primarily located
in the United States. Patented and trademarked neuromodulation devices is the Company&#x2019;s major product line. Products are generally
transferred at a point in time (rather than over time). Essentially all the Company&#x2019;s revenue is generated from purchase order
contracts.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Notes to Financial Statements&lt;/b&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
accordance with FASB&#x2019;s ASC 606, Revenue from Contracts with Customers, (&#x201c;ASC 606&#x201d;), the Company recognizes revenue
when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects
to be entitled in exchange for those goods or services, in an amount that reflects the consideration which the Company expects to be
entitled in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within
the scope of ASC 606, it performs the following five steps:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(i)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;identify
    the contract(s) with a customer&#x37e;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(ii)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;identify
    the performance obligations in the contract&#x37e;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(iii)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;determine
    the transaction price&#x37e;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(iv)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;allocate
    the transaction price to the performance obligations in the contract&#x37e; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(v)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;recognize
    revenue when (or as) the entity satisfies a performance obligation.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company applies the five-step model to contracts when it determines that it is probable it will collect substantially all the consideration
it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined
to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that
are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the
amount of the transaction price, after consideration of variability and constraints, if any, that is allocated to the respective performance
obligation when the performance obligation is satisfied.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company estimates credit losses on accounts receivable by estimating expected credit losses over the contractual term of the receivable
using a discounted cash flow method. When developing this estimate of expected credit losses, the Company considers all available information
(past, current, and future) relevant to assessing the collectability of cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company offers a Patient Assistance Program for patients without insurance coverage for IB-Stim. This program extends potential self-pay
discounts for IB-Stim devices, based upon household income and size.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Also,
the Company offers providers an opt-in program to address adequate insurance claim payments on IB-Stim devices. This program may extend
a rebate or invoice credit where the insurance payment and patient responsibility (i.e., deductible, co-payment, and/or co-insurance
amounts required by the Payer) are less than the acquisition cost of the IB-Stim device. The Company recognizes revenue at such a time
that collection of the amount due is assured.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--DisaggregationOfRevenueTableTextBlock_zX6RXuuRv7o2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table disaggregates the Company&#x2019;s revenue based on the customer&#x2019;s location by state for the years ended December
31:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B8_zAzVuhoIgill" style="display: none"&gt;Schedule of Disaggregation of Revenue&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 25%; text-align: left"&gt;California&lt;/td&gt;&lt;td style="width: 2%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--CA_zAnDptrXJjOb" style="width: 20%; font-weight: bold; text-align: right" title="Revenues"&gt;601,235&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 25%; text-align: left"&gt;Wisconsin&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__stpr--WI_z2SwOYl8cNh9" style="width: 20%; text-align: right" title="Revenues"&gt;670,245&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Ohio&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--OH_zDI0OkZvXUch" style="font-weight: bold; text-align: right" title="Revenues"&gt;407,632&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Ohio&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__stpr--OH_zJhs6wESToS2" style="text-align: right" title="Revenues"&gt;500,260&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Wisconsin&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--WI_z9ynHKka95Xd" style="font-weight: bold; text-align: right" title="Revenues"&gt;292,601&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;California&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__stpr--CA_zRGqfRRI4PZ9" style="text-align: right" title="Revenues"&gt;408,645&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Florida&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--FL_z1o4pUWGGbRe" style="font-weight: bold; text-align: right" title="Revenues"&gt;186,840&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Florida&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__stpr--FL_zwbktOHvOlP2" style="text-align: right" title="Revenues"&gt;231,480&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Massachusetts&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--MA_zL8Z9URoL8Rf" style="font-weight: bold; text-align: right" title="Revenues"&gt;127,300&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Missouri&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__country--MO_zmIB5JUxFlka" style="text-align: right" title="Revenues"&gt;174,980&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;All other states&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__custom--AllOtherStatesMember_zgxis1XpHgTj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Revenues"&gt;844,441&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;All other states&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__custom--AllOtherStatesMember_zqkBp0QJB9Bd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenues"&gt;699,125&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--Revenues_c20230101__20231231_zmLHQlhg1K4a" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Total revenue"&gt;2,460,049&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--Revenues_c20220101__20221231_zVi8nS1HELrg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total revenue"&gt;2,684,735&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8A6_z18moQNeosPi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following economic factors affect the nature, amount, timing, and uncertainty of the Company&#x2019;s revenue and cash flows as indicated:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Type
of customer:&lt;/b&gt; Based on dollar amounts of revenue, essentially all of the goods sold by the Company are sold to healthcare customers
including hospitals and clinics. Sales to healthcare customers lack seasonality and have a mild correlation with economic cycles.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Geographical
location of customers:&lt;/b&gt; Sales to customers located within the United States represent essentially all of the Company&#x2019;s sales.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Notes to Financial Statements&lt;/b&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Type
of contract:&lt;/b&gt; Sales contracts consist of purchase order contracts that tend to be short-term (i.e., less than or equal to one year
in duration).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Company&#x2019;s
Performance Obligations with Customers:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Timing
of Satisfaction&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company typically satisfies its performance obligations as the goods are delivered.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Goods
that are shipped to customers are typically shipped FOB shipping point with freight prepaid by the Company. As such, ownership of goods
in transit transfer to the customer when shipped and the customer bears the associated risks (e.g., loss, damage, delay). &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shipping
and handling costs are recorded as general and administrative expenses in the Statement of Operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Significant
Payment Terms&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Payment
for goods sold by the Company is typically due after an invoice is sent to the customer, within 30 days. However, other payment terms
are frequently negotiated with customers ranging from due upon receipt to due within 90 days. Some payment terms may call for payment
only after the healthcare provider receives their insurance reimbursement. Invoices for goods are typically sent to customers within
three calendar days of shipment. The Company does not offer discounts if the customer pays some or all of an invoiced amount prior to
the due date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;None
of the Company&#x2019;s contracts have a significant financing component.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Nature&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Medical
devices that the Company contracts to sell and transfer to customers are manufactured by one specific third-party manufacturer. The manufacturer
is located within the state of Indiana. In no case does the Company act as an agent (i.e., the Company does not provide a service of
arranging for another party to transfer goods to the customer).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Returns,
Refunds, etc.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Orders
may not be cancelled after shipment. Customers may return devices within 10 days of delivery if the goods are found to be defective,
nonconforming, or otherwise do not meet the stated technical specifications. At the option of the customer, the Company shall either:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Refund
    the price paid for any defective or nonconforming products.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Supply
    and deliver to the customer replacement conforming products.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Reimburse
    the customer for the cost of repairing any defective or nonconforming products.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
the time revenue is recognized, the Company estimates expected returns and excludes those amounts from revenue. The Company also maintains
appropriate accounts to reflect the effects of expected returns on the Company&#x2019;s financial position and periodically adjusts those
accounts to reflect its actual return experience. Historically, returns have been immaterial, and the Company currently does not provide
a provision for this liability.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Notes to Financial Statements&lt;/b&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--ExtendedProductWarrantyPolicy_zsmzImPWWnw7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86D_zcAlCuDLdeMh"&gt;Warranties&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
most cases, goods that customers purchase from the Company are covered by manufacturers&#x2019; warranties. The Company does not sell
warranties separately.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
manufacturer guarantees the product for the period up to the expiration date printed on the device&#x2019;s label or twelve months from
the date of purchase, whichever comes first. The guarantee applies to flaws of material and workmanship. The Company&#x2019;s warranties
provide customers with assurance that purchased devices comply with published specifications, inspection standards, and workmanship.
At the time revenue is recognized, the Company estimates the cost of expected future warranty claims but does not exclude any amounts
from revenue. The Company maintains appropriate accounts to reflect the effects of expected future warranty claims on the Company&#x2019;s
financial position and periodically adjusts those accounts to reflect its actual warranty claim experience. Historically, warranty claims
have been immaterial, and the Company currently does not provide a provision for this liability.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company typically satisfies its performance obligations for goods at a point in time. In most cases, goods are shipped by common carrier
to customers under &#x201c;FOB Shipping Point&#x201d; terms. As such, customers typically obtain control of the goods upon shipment. The
Company&#x2019;s management exercises judgment in determining when performance obligations for goods have been satisfied. In making such
judgments, management typically relies on shipping information obtained from common carriers to evaluate when the customer has obtained
control of the goods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s contracts with customers typically do not involve variable consideration. The information that the Company uses to determine
the transaction price for a contract is similar to the information that the Company&#x2019;s management uses in establishing the prices
of goods to be sold.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--LesseeLeasesPolicyTextBlock_z4OfpCedWO8j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_860_zDo0Qt7M55Dk"&gt;Leases&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
accordance with Accounting Standards Updated (&#x201c;ASU&#x201d;) No. 2016-02, &lt;i&gt;Leases (Topic 842)&lt;/i&gt; (&#x201c;ASU 2016-02&#x201d; or
&#x201c;ASC 842&#x201d;), at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based
on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the balance
sheet as right-of-use assets and current and non-current lease liabilities, as applicable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
lease liabilities and their corresponding right-of-use assets are initially recorded based on the present value of lease payments over
the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received.
The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental
borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis
the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. Prospectively, the Company
will adjust the right-of-use assets for straight-line rent expense, or any incentives received and remeasure the lease liability at the
net present value using the same incremental borrowing rate that was in effect as of the lease commencement or transition date. The Company
has elected not to recognize leases with an original term of one year or less on the balance sheet. The Company typically only includes
an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in the Company&#x2019;s assessment
unless there is reasonable certainty that the Company will renew.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Assumptions
made by the Company at the commencement date are re-evaluated upon occurrence of certain events, including a lease modification. A lease
modification results in a separate contract when the modification grants the lessee an additional right of use not included in the original
lease and when lease payments increase commensurate with the standalone price for the additional right of use. When a lease modification
results in a separate contract, it is accounted for in the same manner as a new lease.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Entities
may elect not to separate lease and non-lease components. The Company has elected to account for lease and non-lease components together
as a single lease component for all underlying assets and allocate all the contract consideration to the lease component only.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Notes to Financial Statements&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;


&lt;p id="xdx_844_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zQnGpcSL7M39" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86F_zBrB3zgiolB3"&gt;Impairment
of Long-Lived Assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Long-lived
assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset group may
not be recoverable. If events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable,
we compare the carrying amount of the asset group to future undiscounted net cash flows, excluding interest costs, expected to be generated
by the asset group and their ultimate disposition. If the sum of the undiscounted cash flows is less than the carrying value, the impairment
to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the fair value of the asset group.
Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zx8dJc3KAyve" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_864_zpHzMrGs96Kj"&gt;Concentrations
of Credit Risk&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s business activity consists of the sale of medical neuromodulation devices to doctors, clinics, and hospitals across the
country.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Receivables
consist of unsecured amounts due from customers. As of December 31, 2023, accounts receivable from four customers with balances due
in excess of &lt;span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zHt7e9wt7Xlf" title="Risk percentage"&gt;10&lt;/span&gt;%
of total accounts receivable were approximately &lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z1sgDO6lIT0f" title="Risk percentage"&gt;28&lt;/span&gt;%, &lt;span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zOpddKc3C56k" title="Risk percentage"&gt;28&lt;/span&gt;%, &lt;span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerThreeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_ztyL1NBusNqe" title="Risk percentage"&gt;17&lt;/span&gt;%
and &lt;span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerFourMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zn5iv9oSMJNe" title="Risk percentage"&gt;11&lt;/span&gt;%, respectively. As of December 31, 2022, accounts receivable from three customers with balances due in excess of &lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_znlKTOeeo93f" title="Risk percentage"&gt;10&lt;/span&gt;%
of total accounts receivable was &lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zdf0D1ndQga7" title="Risk percentage"&gt;23&lt;/span&gt;%, &lt;span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zJM0GLgbRMti" title="Risk percentage"&gt;15&lt;/span&gt;%,
and &lt;span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerThreeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zFGIT1ta9kQ" title="Risk percentage"&gt;12&lt;/span&gt;%,
respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
table below sets forth the Company&#x2019;s customers that accounted for greater than &lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueProductLineMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--RevenueFromRightsConcentrationRiskMember_zSykzU9jrsr5" title="Risk percentage"&gt;&lt;span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueProductLineMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--RevenueFromRightsConcentrationRiskMember_z8AOKkMvCXI4" title="Risk percentage"&gt;10&lt;/span&gt;&lt;/span&gt;% of its revenues for the years ended December
31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock_zK2CTGYbN3Sb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B3_zCjfnL75gsbi" style="display: none"&gt;Schedule of Customers Accounted Revenues&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Percentage of &lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Percentage of &lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Sales&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Sales&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; text-align: left"&gt;Hospital A&lt;/td&gt;&lt;td style="width: 2%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--MajorCustomersAxis__custom--HospitalAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z8DYsvEFfc62" style="width: 15%; font-weight: bold; text-align: right" title="Revenue"&gt;452,680&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 15%; text-align: center"&gt;&lt;span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--HospitalAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zOU9fy3LjPDl" title="Risk percentage"&gt;18&lt;/span&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20221231__srt--MajorCustomersAxis__custom--HospitalAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z6VZ0fIq4lbg" style="width: 15%; text-align: right" title="Revenue"&gt;355,613&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 15%; text-align: center"&gt;&lt;span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--HospitalAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zGUAamau5Wg7" title="Risk percentage"&gt;13&lt;/span&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Hospital B&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--MajorCustomersAxis__custom--HospitalBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zWtmDNKLOmZ8" style="font-weight: bold; text-align: right" title="Revenue"&gt;382,082&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--HospitalBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zxGlw7LXQHJh" title="Risk percentage"&gt;16&lt;/span&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20221231__srt--MajorCustomersAxis__custom--HospitalBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zkkJm06MFCPb" style="text-align: right" title="Revenue"&gt;484,900&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--HospitalBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z8N4M2GNQ1Cg" title="Risk percentage"&gt;18&lt;/span&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Hospital C&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--MajorCustomersAxis__custom--HospitalCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zoNS5KYKLCJ8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Revenue"&gt;274,581&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--HospitalCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_ztiAPuHBO464" title="Risk percentage"&gt;11&lt;/span&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20221231__srt--MajorCustomersAxis__custom--HospitalCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zAa3xtGHtem9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue"&gt;554,325&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--HospitalCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zSTXRgI9fhP9" title="Risk percentage"&gt;21&lt;/span&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--MajorCustomersAxis__custom--HospitalMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zPVkIhkG8i96" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Revenue"&gt;1,109,343&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--HospitalMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zAj2qbvuPNlj" title="Risk percentage"&gt;45&lt;/span&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20221231__srt--MajorCustomersAxis__custom--HospitalMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zdpQH4bigBYb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue"&gt;1,394,838&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--HospitalMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zx1dh6xGR3J3" title="Risk percentage"&gt;52&lt;/span&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8AE_zG8dOe1t08F5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From
time to time, the Company&#x2019;s bank balances may exceed the FDIC limit of $&lt;span id="xdx_909_eus-gaap--CashFDICInsuredAmount_iI_c20231231_znBb1ljAlu7f" title="Cash, FDIC insured amount"&gt;250,000&lt;/span&gt;; however, management does not feel that this has
a material impact on the financial condition. At December 31, 2023 and 2022, the Company didn&#x2019;t have any uninsured cash balance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_848_ecustom--GoingConcernPolicyTextBlock_zXajKJKS6Kod" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_861_zZ5dSeb3IfU"&gt;Going
Concern&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
have incurred losses since inception and have funded our operations primarily with a combination of sales, debt, and the sale of capital
stock. As of December 31, 2023, we had a stockholders&#x2019; deficit totaling $&lt;span id="xdx_903_eus-gaap--StockholdersEquity_iNI_di_c20231231_zUPTVUFQnusl" title="Stockholders deficit"&gt;1,403,241&lt;/span&gt;. At December 31, 2023, we had short-term outstanding
borrowings of approximately $&lt;span id="xdx_905_eus-gaap--ShortTermBorrowings_iI_c20231231_zGK76rC9Za7g" title="Short term borrowing"&gt;148,062&lt;/span&gt;. As of December 31, 2023, we had cash of $&lt;span id="xdx_90F_eus-gaap--Cash_iI_c20231231_zMSBuQjxhUv2" title="Cash"&gt;78,560&lt;/span&gt; and a working capital deficit of $&lt;span id="xdx_900_ecustom--WorkingCapitalDeficit_iI_c20231231_zojtMzfW66Z2" title="Working capital"&gt;1,643,058&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 9, 2023, the Company consummated its initial public offering, conducted on a firm commitment basis, pursuant to which it sold &lt;span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230809__20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zes7IYSmLHEe" title="Number of shares issued in transaction"&gt;1,098,667&lt;/span&gt;
shares of its common stock at a price of $&lt;span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_c20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zMs9Emp2MZu3" title="Share issued price per share"&gt;6.00&lt;/span&gt;
per share, resulting in gross proceeds to the Company of $&lt;span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230809__20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zduBimLlqvCd" title="Proceeds from issuance of common stock"&gt;6,592,002&lt;/span&gt;.
Net proceeds to the Company, after deducting underwriting discounts and commissions, 2022 deferred offering costs totaling $&lt;span id="xdx_908_eus-gaap--DeferredOfferingCosts_iI_c20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zGr67oXbOBul" title="Deferred offering costs"&gt;736,736&lt;/span&gt;
and offering expenses paid by the Company, were $&lt;span id="xdx_906_eus-gaap--PaymentsOfStockIssuanceCosts_c20230811__20230811__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSo5An9DMAvc" title="Payment fees"&gt;4,110,721&lt;/span&gt;.
All shares sold in our IPO were registered pursuant to a registration statement on Form S-1 (File No. 333- 269179), as amended,
declared effective by the SEC on August 9, 2023. Alexander Capital L.P. acted as sole book-running manager for the offering and
Spartan Capital Securities, LLC acted as co-manager for the offering. &lt;span style="background-color: white"&gt;The underwriters did not
exercise their option to purchase up to an additional &lt;/span&gt;&lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230809__20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKV7ofq1xkai" title="Purchase of common shares"&gt;164,801&lt;/span&gt; &lt;span style="background-color: white"&gt;shares
of common stock.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Notes to Financial Statements&lt;/b&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
future capital requirements will depend upon many factors, including progress with developing, manufacturing, and marketing our
technologies, the time and costs involved in preparing, filing, prosecuting, maintaining, and enforcing patent claims and other
proprietary rights, our ability to establish collaborative arrangements, marketing activities and competing technological and market
developments, including regulatory changes and overall economic conditions in our target markets. Our ability to generate revenue
and achieve profitability requires us to successfully market and secure purchase orders for our products from customers currently
identified in our sales pipeline and to new customers as well. The primary activity that will drive all customers and revenues is
the adoption of insurance coverage by commercial insurance carriers nationally which is a top priority of the Company. These
activities, including our planned research and development efforts, will require significant uses of working capital through the
rest of 2024 and beyond. Based on our current operating plans, we believe that our existing cash at the time of this filing will
only be sufficient to meet our anticipated operating needs through the end of 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
evaluates whether there are conditions or events that raise substantial doubt about the Company&#x2019;s ability to continue as a going
concern for a period of one year from the date the financial statements are issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;To
date, the Company has experienced operating losses and negative cash flows from operations. Management believes that increased sales
and acceptance of their product by insurance providers will allow the Company to achieve profitability in the future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;While
the Company believes in the viability of its strategy to further implement its business plan and generate sufficient revenues and in
its ability to raise additional funds by way of a public or private offering of its debt or equity securities, there can be no
assurance that it will be able to do so on reasonable terms, or at all. The ability of the Company to continue as a going concern is
dependent upon its ability to further implement its business plan and generate sufficient revenues and its ability to raise
additional funds by way of a public or private offering. Neither future cash generated from operating activities, nor
management&#x2019;s contingency plans to mitigate the risk and extend cash resources through the evaluation period, are considered
probable. As a result, substantial doubt is deemed to exist about the Company&#x2019;s ability to continue as a going concern. As we
continue to incur losses, our transition to profitability is dependent upon achieving a level of revenues adequate to support its
cost structure. We may never achieve profitability, and unless and until doing so, we intend to fund future operations through
additional dilutive or nondilutive financing. There can be no assurances, however, that additional funding will be available on
terms acceptable to us, if at all.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the
amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zFcm1uYaKtoj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_863_zu6wtfWyMFre"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
June 2016, the FASB issued ASU 2016-13, Financial Instruments &#x2013; Credit Losses (Topic 326): Measurement of Credit Losses on Financial
Instruments, which requires measurement and recognition of expected credit losses for financial assets held and requires enhanced disclosures
regarding significant estimates and judgments used in estimating credit losses. In November 2019, the FASB issued ASU 2019-10, Financial
Instruments &#x2013; Credit Losses (Topic 326), Derivatives and Hedging (Topic 815) and Leases (Topic 842): Effective Dates, which amended
the effective date of ASU 2016-13. Public business entities meeting the definition of an SEC filer, excluding entities eligible to be
a Smaller Reporting Company (&#x201c;SRC&#x201d;) as defined by the SEC, are required to adopt the standard for fiscal years beginning
after December 15, 2019, including interim periods within those fiscal years. All other entities are required to adopt the standard for
fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company meets the definition
of an SRC and therefore the standard was adopted as of January 1, 2023. The adoption of this guidance did not have a material impact
on the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;In December 2023, the FASB issued ASU 2023-19,
Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires the enhancement of income tax disclosures to
provide better insight into how an entity&#x2019;s operations and related tax risks, planning and opportunities affect its tax rate
and prospects for future cash flows. The enhanced disclosures require (i) specific categories in a tabular rate reconciliation
including both amounts and percentages and (ii) additional information for reconciling items and income tax paid that meet a
quantitative threshold. Public business entities are required to adopt the standard for annual periods beginning after December 15,
2024. All other entities are required to adopt the standard for annual periods beginning after December 15, 2025. The adoption of
the standard is not expected to have a material impact on the Company&#x2019;s financial statements.&lt;/p&gt;
&lt;p id="xdx_858_z0Ouvom4LnTj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Notes to Financial Statements&lt;/b&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2023-01-01to2023-12-31" id="Fact000608">&lt;p id="xdx_84F_eus-gaap--UseOfEstimates_zVDuaXrTLydg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span&gt;&lt;span id="xdx_862_zEz0MUIIsalf"&gt;Use
of Estimates and Critical Accounting Estimates and Assumptions&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements
and the reported amounts of revenues and expenses during the reporting periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;These
significant accounting estimates or assumptions bear the risk of change due to the fact that there are uncertainties attached to these
estimates or assumptions, and certain estimates or assumptions are difficult to measure or value.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
bases its estimates on historical experience and on various assumptions that are believed to be reasonable in relation to the financial
statements taken as a whole under the circumstances, the results of which form the basis for making judgments about the carrying values
of assets and liabilities that are not readily apparent from other sources.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available information, changes
in facts and circumstances, historical experience, and reasonable assumptions. After such evaluations, if deemed appropriate, those
estimates are adjusted accordingly. The Company uses estimates in accounting for, among other items, revenue recognition, allowance
for credit losses, stock-based compensation, income tax provisions, excess and obsolete inventory reserve, and impairment of property and
equipment, and intellectual property. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000610">&lt;p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zGfQ3Arrc5Ke" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span&gt;&lt;span id="xdx_867_zpZR0i4lMbte"&gt;Cash
and Cash Equivalents&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. The Company
did not hold any cash equivalents as of December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="From2023-01-01to2023-12-31" id="Fact000612">&lt;p id="xdx_844_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zQyLIdQUqMOa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span&gt;&lt;span id="xdx_86D_zsWTh5OrDIQg"&gt;Trade
Accounts Receivable and Allowance for Credit Losses&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Trade
accounts receivable are stated at the amount management expects to collect from outstanding balances, net of an allowance for credit
losses. Management evaluates many factors when determining the collectability of specific customer accounts, including, but not limited
to, creditworthiness, past transaction and payment history, current economic industry trends and changes in payment terms. We use assumptions
and judgment based on the best available facts and circumstances to estimate and record an allowance. The allowance for credit losses
was $&lt;span id="xdx_903_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20231231_zNeKr5x0pjbf" title="Allowance for doubtful accounts"&gt;11,993&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20221231_zt6UU4ntIW9g" title="Allowance for doubtful accounts"&gt;31,275&lt;/span&gt; as of December 31, 2023 and 2022, respectively. The Company recorded credit losses for the years ended December
31,2023 and 2022 of $&lt;span id="xdx_905_eus-gaap--ProvisionForOtherCreditLosses_c20230101__20231231_z1fCU75qdmHl" title="Credit losses"&gt;25,281&lt;/span&gt; and &lt;span id="xdx_90E_eus-gaap--ProvisionForOtherCreditLosses_c20220101__20221231_zJXQSNTHatn3" title="Credit losses"&gt;64,197&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Notes to Financial Statements&lt;/b&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000614"
      unitRef="USD">11993</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000616"
      unitRef="USD">31275</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:ProvisionForOtherCreditLosses
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000618"
      unitRef="USD">25281</us-gaap:ProvisionForOtherCreditLosses>
    <us-gaap:ProvisionForOtherCreditLosses
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000620"
      unitRef="USD">64197</us-gaap:ProvisionForOtherCreditLosses>
    <us-gaap:DepositContractsPolicy contextRef="From2023-01-01to2023-12-31" id="Fact000622">&lt;p id="xdx_84D_eus-gaap--DepositContractsPolicy_z3G9pKnFRuKc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span&gt;&lt;span id="xdx_86C_zmrJGQX99vDl"&gt;Customer
Deposits&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Customer
deposits consists of billings, payments, and returned devices from clients in advance of revenue recognition. The Company will recognize
the customer deposits over the next year. As of December 31, 2023, and 2022, the Company had customer deposits of $&lt;span id="xdx_902_eus-gaap--Deposits_iI_c20231231_zqIUNH3DZJc8" title="Customer deposits"&gt;74,947&lt;/span&gt; and $&lt;span id="xdx_90F_eus-gaap--Deposits_iI_c20221231_zPLa3GeMgKU6" title="Customer deposits"&gt;59,174&lt;/span&gt;,
respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DepositContractsPolicy>
    <us-gaap:Deposits
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000624"
      unitRef="USD">74947</us-gaap:Deposits>
    <us-gaap:Deposits
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000626"
      unitRef="USD">59174</us-gaap:Deposits>
    <us-gaap:InventoryPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000628">&lt;p id="xdx_846_eus-gaap--InventoryPolicyTextBlock_zMI6ujuN7rw1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span&gt;&lt;span id="xdx_866_zves0DdFNTW3"&gt;Inventories&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Inventories
are valued at the lower of cost or net realizable value. Cost is determined using the weighted average method. The inventory is comprised
of finished medical devices on hand. Certain components within the devices have an expiration date that are removed from current inventory
and expensed at the date of expiration. For the years ended December 31, 2023 and 2022, $&lt;span id="xdx_90B_ecustom--InventoryExpenses_c20231231_zoQihQ2ttyu6" title="Inventory expenses"&gt;25,008&lt;/span&gt; and $&lt;span id="xdx_90D_ecustom--InventoryExpenses_iI_c20221231_zzHCNhEaXkRc" title="Inventory expenses"&gt;10,026&lt;/span&gt; were expensed as expired
inventory, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:InventoryPolicyTextBlock>
    <NRXS:InventoryExpenses
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000630"
      unitRef="USD">25008</NRXS:InventoryExpenses>
    <NRXS:InventoryExpenses
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000632"
      unitRef="USD">10026</NRXS:InventoryExpenses>
    <us-gaap:DeferredChargesPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000634">&lt;p id="xdx_84C_eus-gaap--DeferredChargesPolicyTextBlock_zKApjnvqDPCi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span&gt;&lt;span id="xdx_865_zn9V9ttt6wmf"&gt;Deferred
Offering Costs&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred
offering costs consist of costs incurred in connection with the preparation of an initial public offering. These costs, together with
the underwriting discounts and commissions, were charged to additional paid in capital upon the IPO. As of December 31, 2023 and 2022,
the Company had deferred offering costs of $&lt;span id="xdx_90F_eus-gaap--DeferredOfferingCosts_iI_dxL_c20231231_zduETi4XjJ34" title="Deferred offering costs::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0636"&gt;0&lt;/span&gt;&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--DeferredOfferingCosts_iI_c20221231_zJ5duxanWdb7" title="Deferred offering costs"&gt;736,736&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact000638"
      unitRef="USD">736736</us-gaap:DeferredOfferingCosts>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000640">&lt;p id="xdx_84B_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zqhPQolYI7fb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_866_zfGsnuflXkyf"&gt;Property
and Equipment&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment are recorded at cost less accumulated depreciation. Depreciation is computed using the straight-line method over the estimated
useful lives of the assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_ecustom--ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_zuDWFlazwtT8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation
is calculated using the following estimated useful lives:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B0_zRYzhM4FObAj" style="display: none"&gt;Schedule of Estimated Useful Lives&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 60%; border-collapse: collapse; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Classification&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Years&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Machinery and Equipment &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MinimumMember_z6T4sUWWoWNi" title="Property and equipment, estimated useful lives"&gt;5&lt;/span&gt;-&lt;span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MaximumMember_zd3L5zgGES5d" title="Property and equipment, estimated useful lives"&gt;10&lt;/span&gt; &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Furniture and Fixtures&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zkpRYICgli12" title="Property and equipment, estimated useful lives"&gt;5&lt;/span&gt;-&lt;span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_zy9KJtQEgs4a" title="Property and equipment, estimated useful lives"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Computer Hardware&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MinimumMember_zdqGof3t1oI" title="Property and equipment, estimated useful lives"&gt;5&lt;/span&gt;-&lt;span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MaximumMember_zcRNd7T4hdqb" title="Property and equipment, estimated useful lives"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leasehold Improvements&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MinimumMember_zZHzaJmx9lfj" title="Property and equipment, estimated useful lives"&gt;10&lt;/span&gt;-&lt;span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MaximumMember_zFLCxUzN8HYh" title="Property and equipment, estimated useful lives"&gt;20&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A6_zEuDpQt8YXCc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation
expense was $&lt;span id="xdx_907_eus-gaap--Depreciation_c20230101__20231231_zq9Hcvf7e1Dh" title="Depreciation expense"&gt;30,240&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--Depreciation_c20220101__20221231_zu5aKm0Y6C1c" title="Depreciation expense"&gt;30,920&lt;/span&gt; during the years ended December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <NRXS:ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000642">&lt;p id="xdx_89D_ecustom--ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock_zuDWFlazwtT8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation
is calculated using the following estimated useful lives:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B0_zRYzhM4FObAj" style="display: none"&gt;Schedule of Estimated Useful Lives&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 60%; border-collapse: collapse; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Classification&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Years&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Machinery and Equipment &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MinimumMember_z6T4sUWWoWNi" title="Property and equipment, estimated useful lives"&gt;5&lt;/span&gt;-&lt;span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember__srt--RangeAxis__srt--MaximumMember_zd3L5zgGES5d" title="Property and equipment, estimated useful lives"&gt;10&lt;/span&gt; &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Furniture and Fixtures&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zkpRYICgli12" title="Property and equipment, estimated useful lives"&gt;5&lt;/span&gt;-&lt;span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_zy9KJtQEgs4a" title="Property and equipment, estimated useful lives"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Computer Hardware&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MinimumMember_zdqGof3t1oI" title="Property and equipment, estimated useful lives"&gt;5&lt;/span&gt;-&lt;span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember__srt--RangeAxis__srt--MaximumMember_zcRNd7T4hdqb" title="Property and equipment, estimated useful lives"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leasehold Improvements&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MinimumMember_zZHzaJmx9lfj" title="Property and equipment, estimated useful lives"&gt;10&lt;/span&gt;-&lt;span id="xdx_90C_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20231231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember__srt--RangeAxis__srt--MaximumMember_zFLCxUzN8HYh" title="Property and equipment, estimated useful lives"&gt;20&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</NRXS:ScheduleOfPropertyPlantAndEquipmentUsefulLivesTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2023-12-31_us-gaap_MachineryAndEquipmentMember_srt_MinimumMember"
      id="Fact000644">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2023-12-31_us-gaap_MachineryAndEquipmentMember_srt_MaximumMember"
      id="Fact000646">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2023-12-31_us-gaap_FurnitureAndFixturesMember_srt_MinimumMember"
      id="Fact000648">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2023-12-31_us-gaap_FurnitureAndFixturesMember_srt_MaximumMember"
      id="Fact000650">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2023-12-31_us-gaap_ComputerEquipmentMember_srt_MinimumMember"
      id="Fact000652">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2023-12-31_us-gaap_ComputerEquipmentMember_srt_MaximumMember"
      id="Fact000654">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember_srt_MinimumMember"
      id="Fact000656">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember_srt_MaximumMember"
      id="Fact000658">P20Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:Depreciation
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000660"
      unitRef="USD">30240</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000662"
      unitRef="USD">30920</us-gaap:Depreciation>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2023-01-01to2023-12-31" id="Fact000664">&lt;p id="xdx_84E_eus-gaap--ResearchAndDevelopmentExpensePolicy_zLl5UkZpEoJ6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_862_zsTqLJDzE2Yb"&gt;Research
and Development&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Costs
for research and development are expensed as incurred. Research and development expenses consist primarily of clinical research studies
and new product development.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="From2023-01-01to2023-12-31" id="Fact000666">&lt;p id="xdx_841_eus-gaap--IntangibleAssetsFiniteLivedPolicy_z8qWp4Ka2Tj4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86E_zMTjD8n9M7D4"&gt;Intangible
Assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible
assets consist of software, patents and a trademark. Intangible assets are stated at their historical cost and amortized on
a straight-line basis over their expected useful lives. Capitalized patent costs, net of accumulated amortization, includes legal costs
incurred for patent applications. In accordance with ASC 350, once a patent is granted, we amortize the capitalized patent costs over
the remaining life of the patent using the straight-line method. If the patent is not granted, we write off any capitalized patent costs
at that time.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company entered into an agreement for a trademark related to the Company&#x2019;s name on July 11, 2022. The agreement called for an initial
payment of $&lt;span id="xdx_907_eus-gaap--PaymentsToAcquireIntangibleAssets_c20220710__20220711__us-gaap--TypeOfArrangementAxis__custom--TrademarkAgreementMember__us-gaap--OtherCommitmentsAxis__custom--InitialPaymentMember_zitNuSg2qFZk" title="Initial payment upon execution"&gt;10,000&lt;/span&gt; upon execution of the agreement. A second and final payment of $&lt;span id="xdx_903_eus-gaap--PaymentsToAcquireIntangibleAssets_c20220710__20220711__us-gaap--TypeOfArrangementAxis__custom--TrademarkAgreementMember__us-gaap--OtherCommitmentsAxis__custom--SecondAndFinalPaymentMember_zIBof3crmvG2" title="Second and final payment of contingent"&gt;40,000&lt;/span&gt; was contingent upon the completion of the Company&#x2019;s
planned initial public offering. The trademark does not have a determinate life and therefore the cost is not being amortized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company entered into an option agreement on April 12, 2023 to enter into a royalty-bearing licensing agreement to bring the optionor&#x2019;s
invention to commercialization. The agreement required an initial payment of $&lt;span id="xdx_907_eus-gaap--PaymentsToAcquireIntangibleAssets_c20230411__20230412__us-gaap--TypeOfArrangementAxis__custom--LicensingAgreementMember_zu7IJvU0Ivja" title="Initial payment upon execution"&gt;1,000&lt;/span&gt; upon execution of the agreement. The agreement does
not have a determinate life and therefore the cost is not being amortized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Notes to Financial Statements&lt;/b&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
review intangible assets for impairment annually or when events or circumstances indicate that their carrying amount may not be recoverable.
During the years ended December 31, 2023, and 2022, the Company recorded no impairment charges for intangible assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amortization
expense was $&lt;span id="xdx_900_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20231231_zEfBkB15rWa9" title="Amortization expense"&gt;10,485&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--AmortizationOfIntangibleAssets_c20220101__20221231_zFaUgEMJOp63" title="Amortization expense"&gt;6,213&lt;/span&gt; during the years ended December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2022-07-102022-07-11_custom_TrademarkAgreementMember_custom_InitialPaymentMember"
      decimals="0"
      id="Fact000668"
      unitRef="USD">10000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2022-07-102022-07-11_custom_TrademarkAgreementMember_custom_SecondAndFinalPaymentMember"
      decimals="0"
      id="Fact000670"
      unitRef="USD">40000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2023-04-112023-04-12_custom_LicensingAgreementMember"
      decimals="0"
      id="Fact000672"
      unitRef="USD">1000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000674"
      unitRef="USD">10485</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000676"
      unitRef="USD">6213</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000678">&lt;p id="xdx_84B_eus-gaap--IncomeTaxPolicyTextBlock_zL1OMXiuVgO6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86D_zWbZejgz59Z6"&gt;Income
Taxes&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in
the Company&#x2019;s financial statements and tax returns. Deferred tax assets and liabilities are determined based upon the differences
between the financial statement carrying amounts, and the tax bases of existing assets and liabilities for the loss and credit carryforwards
using enacted tax rates expected to be in effect in the year in which the differences are expected to reverse. Deferred tax assets are
reduced by a valuation allowance if it is more likely than not that these assets may not be realized. The Company determines whether
a tax position will be sustained upon examination. If it is more likely than not that a position will be sustained, none of the benefit
attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more likely than not
recognition threshold is calculated as the largest amount that is more than 50% likely of being realized upon resolution of the contingency.
The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Based
on the results of management&#x2019;s evaluation, adoption of the rules did not have a material effect on the Company&#x2019;s financial
statements. Further, no interest or penalties have been accrued or charged to expense as of December 31, 2023 and 2022 and for the years
then ended.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s income tax returns are subject to examination by the taxing authorities until the expiration of the related statutes
of limitations on those tax returns. In general, the federal and state income tax returns have a three-year statute of limitations. As
of December 31, 2023, the following tax years are subject to examination:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 60%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 32%; text-align: center"&gt;Jurisdiction&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 32%; text-align: center"&gt;Open Years for Filed Returns&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 32%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Return to File in 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;Federal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2020 &#x2013; 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;Various States&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2020 &#x2013; 2022&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;2023&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:AdvertisingCostsPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000680">&lt;p id="xdx_845_eus-gaap--AdvertisingCostsPolicyTextBlock_zMkGAZaOZrki" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_869_zYreRTxzU1b3"&gt;Advertising
Cost&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Advertising
costs are expensed as incurred and amounted to $&lt;span id="xdx_900_eus-gaap--AdvertisingExpense_c20230101__20231231_z0GjCaNfpWY5" title="Advertising cost expense"&gt;192,400&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--AdvertisingExpense_c20220101__20221231_zp2itMDg3Lc1" title="Advertising cost expense"&gt;14,900&lt;/span&gt; for the years ended December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000682"
      unitRef="USD">192400</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000684"
      unitRef="USD">14900</us-gaap:AdvertisingExpense>
    <NRXS:DerivativeLiabilityPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000686">&lt;p id="xdx_840_ecustom--DerivativeLiabilityPolicyTextBlock_zGVqCK5z85Mc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_869_zHMq8XLsXJ6i"&gt;Derivative
Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for derivative financial instruments as either equity or liabilities in accordance with ASC Topic 815, &lt;i&gt;Derivatives
and Hedging&lt;/i&gt;, or ASC 815, based on the characteristics and provisions of each instrument. Embedded derivatives are required to be
bifurcated from the host instruments and recorded at fair value if the derivatives are not clearly and closely related to the host instruments
on the date of issuance. Derivative instrument liabilities are classified in the balance sheets as current or non-current based on whether
or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company utilizes a Monte Carlo simulation model for the common stock conversion feature of the notes payable that have an option to
convert at a variable number of shares to compute the fair value of the derivative and to mark to market the fair value of the
derivative at each balance sheet date. The inputs utilized in the application of the Monte Carlo model included a stock
price, an expected remaining term of each note as of the valuation date, estimated volatility, drift, and a risk-free rate. The
Company records the change in the fair value of the derivative as other income or expense in the Statements of Operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Notes to Financial Statements&lt;/b&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</NRXS:DerivativeLiabilityPolicyTextBlock>
    <NRXS:WarrantLiabilityPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000688">&lt;p id="xdx_84B_ecustom--WarrantLiabilityPolicyTextBlock_z69GwGVVBVcc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_869_zV7p8awBt4kc"&gt;Warrant
Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
evaluates all of the Company&#x2019;s financial instruments, including issued warrants to purchase its Class A common stock, to
determine if such instruments are liabilities or contain features that qualify as embedded derivatives, pursuant to ASC 480 and ASC
815-15. The classification of derivative financial instruments, including whether such instruments should be recorded as liabilities
or as equity, is reassessed at the end of each reporting period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company utilizes a Monte Carlo simulation model for warrants that have an option to convert at a variable number of shares to compute
the fair value of the derivative and to mark to market the fair value of the derivative at each balance sheet date. The inputs utilized
in the application of the Monte Carlo model included a starting stock price, an expected remaining term of each warrant as of the valuation
date, estimated volatility, drift, and a risk-free rate. The Company records the change in the fair value of the warrant as other
income or expense in the statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</NRXS:WarrantLiabilityPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000690">&lt;p id="xdx_840_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zXaEEhNVRUzl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86B_z42RAGNx2Pke"&gt;Fair
Value Measurements&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for financial instruments in accordance with ASC 820, Fair Value Measurements and Disclosures (&#x201c;ASC 820&#x201d;).
ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy
gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and
the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under ASC 820 are described
below:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
1 &#x2013; Quoted prices (unadjusted) for identical unrestricted assets or liabilities in active markets that the reporting entity has
the ability to access as of the measurement date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
2 &#x2013; Significant other observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities: quoted
prices in markets that are not active; or financial instruments for which all significant inputs are observable or can be corroborated
by observable market date, either directly or indirectly.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Level
3 &#x2013; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets
or liabilities. These unobservable inputs reflect that reporting entity&#x2019;s own assumptions about assumptions that market participants
would use in pricing the asset or liability. Level 3 assets and liabilities include financial instruments whose value is determined using
pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair
value require significant management judgment or estimation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s Level 1 assets/liabilities include cash, accounts receivable, accounts payable, prepaids, and other current assets. Management
believes the estimated fair value of these accounts on December 31, 2023 approximate their carrying value as reflected in the balance
sheets due to the short-term nature of these instruments or the use of market interest rates for debt instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s Level 3 assets/liabilities include derivative and warrant liabilities. Inputs to determine fair value are generally
unobservable and typically reflect management&#x2019;s estimates of assumptions that market participants would use in pricing the
asset or liability. The fair values are therefore determined using model-based techniques, including option pricing models and
discounted cash flow models. The valuation techniques involve management&#x2019;s estimates and judgment based on unobservable
inputs. The fair value estimates may not be indicative of the amounts that would be realized in a market exchange. Additionally,
there may be inherent uncertainties or changes in the underlying assumptions used, which could significantly affect the current or
future fair value estimates. Unobservable inputs used in the models are significant to the fair values of the assets and
liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Notes to Financial Statements&lt;/b&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zXrb3Ha5bbbh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following tables provides a summary of the relevant assets and liabilities that are measured at fair value on recurring basis:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;Fair Value Measurements as of&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;December 31, 2023&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span id="xdx_8B5_zBcTe0bNWWrd" style="display: none"&gt;Schedule of Fair Value On a Recurring Basis Assets and Liability&lt;/span&gt;&#160;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zZgb1nNnOIB1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z90tT0VJCng4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Level 1)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_znhoBmNvawL8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Level 2)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z8GtVuYWyEwa" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;(Level 3)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--WarrantLiabilities_i02I_maLFVDzwLw_z6rpvKyALug1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 36%; text-align: left"&gt;Warrant liabilities&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;8,225&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0695"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0696"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;8,225&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DerivativeLiabilitiesCurrent_i02I_maLFVDzwLw_zJzlXGtSZDO9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Derivative liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0699"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0700"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0701"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0702"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LiabilitiesFairValueDisclosure_i02I_mtLFVDzwLw_zV9UcwYYQyjl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Total Liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,225&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0705"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0706"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,225&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Fair Value Measurements as of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
31, 2022&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zmHu3a3OQ26c" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z5PTqsJi0jad" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(Level 1)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zkDLZOyMUWCb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(Level 2)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zrrRyAbSdmol" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(Level 3)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--WarrantLiabilities_i02I_maLFVDzwLw_zowQ4vO09hL" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 36%; text-align: left"&gt;Warrant liabilities&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;2,234,384&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0710"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0711"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;2,234,384&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DerivativeLiabilitiesCurrent_i02I_maLFVDzwLw_zbXoob1TDTJ8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Derivative liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,735,700&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0715"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0716"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,735,700&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LiabilitiesFairValueDisclosure_i02I_mtLFVDzwLw_zhUioZYfLqQe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Total Liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,970,084&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0720"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0721"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,970,084&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;/p&gt;

&lt;p id="xdx_8A7_zUdX8zDeETDg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zYMTrkf1t5pf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table shows the valuation methodology and unobservable inputs for Level 3 assets and liabilities measured at fair value on
recurring basis as of December 31, 2023 and December 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;span id="xdx_8BF_zcWaoIpk4QNi" style="display: none"&gt;Schedule of Unobservable Inputs for Level 3 Assets and Liabilities&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Fair Value As of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Valuation&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Unobservable&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Methodology&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Inputs&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 20%; text-align: justify"&gt;Warrant liabilities&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--WarrantLiabilities_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zshO0OaVLGL4" style="width: 13%; text-align: right" title="Warrant liabilities"&gt;8,225&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--WarrantLiabilities_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zk5YFe91k1u1" style="width: 13%; text-align: right" title="Warrant liabilities"&gt;2,234,384&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 19%; text-align: center"&gt;Monte Carlo model&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 23%; text-align: center"&gt;Project simulated cash flows&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Derivative liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zljGNFsh3REk" style="text-align: right" title="Derivative liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0730"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z5BnVDl7ijHc" style="text-align: right" title="Derivative liabilities"&gt;1,735,700&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Monte Carlo model&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Project simulated cash flows&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A9_zjTAxKrFNlr2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
were no transfers between any of the levels during the years ended December 31, 2023 and year ended December 31, 2022. In addition
to assets and liabilities that are recorded at fair value on a recurring basis, the Company&#x2019;s assets and liabilities are also
subject to nonrecurring fair value measurements. As of December 31, 2023 and 2022, the Company had no assets that were measured on a
nonrecurring basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000692">&lt;p id="xdx_89E_eus-gaap--ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_zXrb3Ha5bbbh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following tables provides a summary of the relevant assets and liabilities that are measured at fair value on recurring basis:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;Fair Value Measurements as of&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;December 31, 2023&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span id="xdx_8B5_zBcTe0bNWWrd" style="display: none"&gt;Schedule of Fair Value On a Recurring Basis Assets and Liability&lt;/span&gt;&#160;&lt;/p&gt;

&lt;p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zZgb1nNnOIB1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z90tT0VJCng4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Level 1)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_znhoBmNvawL8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;(Level 2)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z8GtVuYWyEwa" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;(Level 3)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--WarrantLiabilities_i02I_maLFVDzwLw_z6rpvKyALug1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 36%; text-align: left"&gt;Warrant liabilities&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;8,225&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0695"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0696"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;8,225&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DerivativeLiabilitiesCurrent_i02I_maLFVDzwLw_zJzlXGtSZDO9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Derivative liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0699"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0700"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0701"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0702"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LiabilitiesFairValueDisclosure_i02I_mtLFVDzwLw_zV9UcwYYQyjl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Total Liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,225&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0705"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0706"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8,225&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Fair Value Measurements as of&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;December
31, 2022&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zmHu3a3OQ26c" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_z5PTqsJi0jad" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(Level 1)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zkDLZOyMUWCb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(Level 2)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember_zrrRyAbSdmol" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(Level 3)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--WarrantLiabilities_i02I_maLFVDzwLw_zowQ4vO09hL" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 36%; text-align: left"&gt;Warrant liabilities&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;2,234,384&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0710"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0711"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;2,234,384&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DerivativeLiabilitiesCurrent_i02I_maLFVDzwLw_zbXoob1TDTJ8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Derivative liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,735,700&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0715"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0716"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,735,700&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LiabilitiesFairValueDisclosure_i02I_mtLFVDzwLw_zhUioZYfLqQe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Total Liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,970,084&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0720"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0721"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,970,084&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;/p&gt;

</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <NRXS:WarrantLiabilities
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact000694"
      unitRef="USD">8225</NRXS:WarrantLiabilities>
    <NRXS:WarrantLiabilities
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact000697"
      unitRef="USD">8225</NRXS:WarrantLiabilities>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact000704"
      unitRef="USD">8225</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact000707"
      unitRef="USD">8225</us-gaap:LiabilitiesFairValueDisclosure>
    <NRXS:WarrantLiabilities
      contextRef="AsOf2022-12-31_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact000709"
      unitRef="USD">2234384</NRXS:WarrantLiabilities>
    <NRXS:WarrantLiabilities
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact000712"
      unitRef="USD">2234384</NRXS:WarrantLiabilities>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2022-12-31_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact000714"
      unitRef="USD">1735700</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact000717"
      unitRef="USD">1735700</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact000719"
      unitRef="USD">3970084</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact000722"
      unitRef="USD">3970084</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000724">&lt;p id="xdx_890_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_zYMTrkf1t5pf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table shows the valuation methodology and unobservable inputs for Level 3 assets and liabilities measured at fair value on
recurring basis as of December 31, 2023 and December 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;span id="xdx_8BF_zcWaoIpk4QNi" style="display: none"&gt;Schedule of Unobservable Inputs for Level 3 Assets and Liabilities&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Fair Value As of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Fair Value&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Valuation&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Unobservable&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Methodology&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Inputs&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 20%; text-align: justify"&gt;Warrant liabilities&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--WarrantLiabilities_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zshO0OaVLGL4" style="width: 13%; text-align: right" title="Warrant liabilities"&gt;8,225&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--WarrantLiabilities_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zk5YFe91k1u1" style="width: 13%; text-align: right" title="Warrant liabilities"&gt;2,234,384&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 19%; text-align: center"&gt;Monte Carlo model&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 23%; text-align: center"&gt;Project simulated cash flows&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Derivative liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20231231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zljGNFsh3REk" style="text-align: right" title="Derivative liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0730"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--DerivativeLiabilitiesCurrent_iI_c20221231__us-gaap--FairValueByMeasurementFrequencyAxis__us-gaap--FairValueMeasurementsRecurringMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z5BnVDl7ijHc" style="text-align: right" title="Derivative liabilities"&gt;1,735,700&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Monte Carlo model&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;Project simulated cash flows&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <NRXS:WarrantLiabilities
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact000726"
      unitRef="USD">8225</NRXS:WarrantLiabilities>
    <NRXS:WarrantLiabilities
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact000728"
      unitRef="USD">2234384</NRXS:WarrantLiabilities>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="0"
      id="Fact000732"
      unitRef="USD">1735700</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000734">&lt;p id="xdx_847_eus-gaap--EarningsPerSharePolicyTextBlock_zDXVnNedKCu8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_863_zD1TKYEnGW6l"&gt;Basic
and Diluted Net Income (Loss) per Share&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Earnings
or loss per share (&#x201c;EPS&#x201d;) is computed by dividing net income (loss), net of preferred stock dividends, by the weighted average
number of shares of common stock outstanding during the period. Diluted EPS is computed by dividing net income (loss) by the weighted
average of all potentially dilutive shares of common stock that were outstanding during the periods presented. Preferred stock dividends
(not declared or paid) were $&lt;span id="xdx_90B_eus-gaap--DividendsPreferredStock_c20230101__20231231_zmgcGg3rUjO4" title="Preferred stock dividend"&gt;0&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--DividendsPreferredStock_c20220101__20221231_zO9qN9bbbF1d" title="Preferred stock dividend"&gt;2,190,102&lt;/span&gt; as of December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic
net loss per common share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common
shares outstanding during the period. Diluted net loss per common share is determined using the weighted-average number of common shares
outstanding during the period, adjusted for the dilutive effect of common stock equivalents. In periods when losses are reported, which
is the case for December 31, 2023 and 2022 presented in these financial statements, the weighted-average number of common shares outstanding
excludes common stock equivalents because their inclusion would be anti-dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Notes to Financial Statements&lt;/b&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_zNwURusR6vu2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company had the following potentially dilutive common stock equivalents at December 31, 2023 and 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B9_zNje6TLH5oU8" style="display: none"&gt;Schedule of Dilutive Common Stock Equivalents&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20230101__20231231_z51OT7QLFr38" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20220101__20221231_zWMVb7whmDXe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleSeriesAPreferredStockMember_z2UCsBz9SQg5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Convertible Series A Preferred Stock&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0742"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;1,013,270&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleSeriesSeedPreferredStockMember_zB4vs5QaziT1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Convertible Series Seed Preferred Stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0745"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;230,954&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--OptionMember_zvy1eobwixR5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,319,394&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,319,394&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--PreferredStockMember_z33AI0MMLE5f" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0pt; text-align: left"&gt;Pre-Funded Warrants for Convertible Series A Preferred Stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0751"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;289,779&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_zIYhQ9G4GrF8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,822,358&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;365,962&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleBridgeDebtMember_zP5fRYEVMiTa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Convertible Bridge Debt&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0757"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;376,653&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zuWn8sTcwH0j" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Totals&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,141,752&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,596,012&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A5_zViJxKGPpRP9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zxBv4WY9fsXf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table shows the calculation of the basic and diluted net loss per share and the effect of preferred stock dividends.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B6_zqUi5n0z7Kfl" style="display: none"&gt;Schedule of Basic and Diluted Net Loss Per Share&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20230101__20231231_zX5oRcjTJW1g" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20220101__20221231_zBMbJ08DzJ84" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Numerator&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--NetIncomeLoss_iT_mtNILzQKI_zy8h4Qz1xuO1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 60%; text-align: left"&gt;Net loss&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(14,626,683&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(4,780,061&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--PreferredStockDividendsAndOtherAdjustments_zgKkCa9mWffi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Preferred stock dividends&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0768"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(764,893&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zk1oVBBRjz5i" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net income (loss) available to common stockholders&lt;/span&gt; &lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(14,626,683&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,544,954&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Denominator&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"&gt;Weighted-average shares of common stock outstanding - basic
    and diluted&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231_znEzxgGfUxea" title="Weighted average shares of common stock outstanding - basic"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231_zbww0nP4YRg1" title="Weighted average shares of common stock outstanding - diluted"&gt;3,252,328&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20220101__20221231_z6Tas7DWLb8e" title="Weighted average shares of common stock outstanding - basic"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20220101__20221231_zmjpPawtofr9" title="Weighted average shares of common stock outstanding - diluted"&gt;2,003,322&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Basic and diluted net loss per share&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--EarningsPerShareBasic_c20230101__20231231_zG5fKt9oFUC8" title="Basic net loss per share"&gt;&lt;span id="xdx_905_eus-gaap--EarningsPerShareDiluted_c20230101__20231231_z2RhTCLdmDCb" title="Diluted net loss per share"&gt;(4.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--EarningsPerShareBasic_c20220101__20221231_zZJe1K2BfZ76" title="Basic net loss per share"&gt;&lt;span id="xdx_90C_eus-gaap--EarningsPerShareDiluted_c20220101__20221231_zds8oPl0kjM3" title="Diluted net loss per share"&gt;(2.77&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A4_z0tCcqsbBemd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:DividendsPreferredStock
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000736"
      unitRef="USD">0</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000738"
      unitRef="USD">2190102</us-gaap:DividendsPreferredStock>
    <us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000740">&lt;p id="xdx_894_eus-gaap--ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_zNwURusR6vu2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company had the following potentially dilutive common stock equivalents at December 31, 2023 and 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B9_zNje6TLH5oU8" style="display: none"&gt;Schedule of Dilutive Common Stock Equivalents&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20230101__20231231_z51OT7QLFr38" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20220101__20221231_zWMVb7whmDXe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleSeriesAPreferredStockMember_z2UCsBz9SQg5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Convertible Series A Preferred Stock&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0742"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;1,013,270&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleSeriesSeedPreferredStockMember_zB4vs5QaziT1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Convertible Series Seed Preferred Stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0745"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;230,954&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--OptionMember_zvy1eobwixR5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,319,394&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,319,394&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--PreferredStockMember_z33AI0MMLE5f" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 0pt; text-align: left"&gt;Pre-Funded Warrants for Convertible Series A Preferred Stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0751"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;289,779&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--WarrantsMember_zIYhQ9G4GrF8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,822,358&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;365,962&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--ConvertibleBridgeDebtMember_zP5fRYEVMiTa" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Convertible Bridge Debt&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0757"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;376,653&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zuWn8sTcwH0j" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Totals&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,141,752&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,596,012&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31_custom_ConvertibleSeriesAPreferredStockMember"
      decimals="INF"
      id="Fact000743"
      unitRef="Shares">1013270</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31_custom_ConvertibleSeriesSeedPreferredStockMember"
      decimals="INF"
      id="Fact000746"
      unitRef="Shares">230954</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_us-gaap_OptionMember"
      decimals="INF"
      id="Fact000748"
      unitRef="Shares">1319394</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31_us-gaap_OptionMember"
      decimals="INF"
      id="Fact000749"
      unitRef="Shares">1319394</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact000752"
      unitRef="Shares">289779</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-012023-12-31_custom_WarrantsMember"
      decimals="INF"
      id="Fact000754"
      unitRef="Shares">1822358</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31_custom_WarrantsMember"
      decimals="INF"
      id="Fact000755"
      unitRef="Shares">365962</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31_custom_ConvertibleBridgeDebtMember"
      decimals="INF"
      id="Fact000758"
      unitRef="Shares">376653</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact000760"
      unitRef="Shares">3141752</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact000761"
      unitRef="Shares">3596012</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000763">&lt;p id="xdx_89D_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zxBv4WY9fsXf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table shows the calculation of the basic and diluted net loss per share and the effect of preferred stock dividends.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B6_zqUi5n0z7Kfl" style="display: none"&gt;Schedule of Basic and Diluted Net Loss Per Share&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20230101__20231231_zX5oRcjTJW1g" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20220101__20221231_zBMbJ08DzJ84" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the Years Ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Numerator&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--NetIncomeLoss_iT_mtNILzQKI_zy8h4Qz1xuO1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 60%; text-align: left"&gt;Net loss&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(14,626,683&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(4,780,061&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--PreferredStockDividendsAndOtherAdjustments_zgKkCa9mWffi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Preferred stock dividends&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0768"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(764,893&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_zk1oVBBRjz5i" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net income (loss) available to common stockholders&lt;/span&gt; &lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(14,626,683&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(5,544,954&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Denominator&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"&gt;Weighted-average shares of common stock outstanding - basic
    and diluted&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20230101__20231231_znEzxgGfUxea" title="Weighted average shares of common stock outstanding - basic"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20230101__20231231_zbww0nP4YRg1" title="Weighted average shares of common stock outstanding - diluted"&gt;3,252,328&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20220101__20221231_z6Tas7DWLb8e" title="Weighted average shares of common stock outstanding - basic"&gt;&lt;span id="xdx_903_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20220101__20221231_zmjpPawtofr9" title="Weighted average shares of common stock outstanding - diluted"&gt;2,003,322&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Basic and diluted net loss per share&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--EarningsPerShareBasic_c20230101__20231231_zG5fKt9oFUC8" title="Basic net loss per share"&gt;&lt;span id="xdx_905_eus-gaap--EarningsPerShareDiluted_c20230101__20231231_z2RhTCLdmDCb" title="Diluted net loss per share"&gt;(4.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--EarningsPerShareBasic_c20220101__20221231_zZJe1K2BfZ76" title="Basic net loss per share"&gt;&lt;span id="xdx_90C_eus-gaap--EarningsPerShareDiluted_c20220101__20221231_zds8oPl0kjM3" title="Diluted net loss per share"&gt;(2.77&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000765"
      unitRef="USD">-14626683</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000766"
      unitRef="USD">-4780061</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000769"
      unitRef="USD">-764893</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000771"
      unitRef="USD">-14626683</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000772"
      unitRef="USD">-5544954</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact000774"
      unitRef="Shares">3252328</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact000776"
      unitRef="Shares">3252328</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact000778"
      unitRef="Shares">2003322</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact000780"
      unitRef="Shares">2003322</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact000782"
      unitRef="USDPShares">-4.50</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact000784"
      unitRef="USDPShares">-4.50</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact000786"
      unitRef="USDPShares">-2.77</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact000788"
      unitRef="USDPShares">-2.77</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2023-01-01to2023-12-31" id="Fact000790">&lt;p id="xdx_84E_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_zz4yjkKUeCzk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_861_zFhESh1uvKod"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for all stock-based payments and awards at fair value. The Company recognizes its stock-based compensation
expense using the straight-line method. Compensation cost is not adjusted for estimated forfeitures, but instead is adjusted upon an
actual forfeiture of a stock option.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company accounts for the granting of stock options to employees and non-employees using the fair value method whereby all awards are
measured at fair value on the date of the grant. The fair value of all employee stock options is expensed over the requisite service
period with a corresponding increase to additional paid-in capital. Upon exercise of stock options, the consideration paid by the option
holder is recorded in additional paid-in capital, while the par value of the shares received is reclassified from additional paid in
capital to common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock-based
payments to non-employees are measured based on the fair value of the equity instrument issued. Compensation expense for non-employee
stock awards is recognized over the requisite service period following the measurement of the fair value on the grant date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company uses the Black-Scholes option-pricing model to calculate the fair value of stock options. The use of the Black-Scholes option-pricing
model requires management to make assumptions with respect to the expected term of the option, the expected volatility of the common
stock consistent with the expected term of the option, risk-free interest rates, the value of the common stock and expected dividend
yield of the common stock. Changes in these assumptions can materially affect the fair value estimate.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000792">&lt;p id="xdx_848_eus-gaap--RevenueRecognitionPolicyTextBlock_zQiivN3OJYcj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_868_zdikTs1WOXe1"&gt;Revenue
Recognition&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Neuraxis,
Inc. specializes in the development, production, and sale of medical neuromodulation devices to healthcare providers primarily located
in the United States. Patented and trademarked neuromodulation devices is the Company&#x2019;s major product line. Products are generally
transferred at a point in time (rather than over time). Essentially all the Company&#x2019;s revenue is generated from purchase order
contracts.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Notes to Financial Statements&lt;/b&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
accordance with FASB&#x2019;s ASC 606, Revenue from Contracts with Customers, (&#x201c;ASC 606&#x201d;), the Company recognizes revenue
when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects
to be entitled in exchange for those goods or services, in an amount that reflects the consideration which the Company expects to be
entitled in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within
the scope of ASC 606, it performs the following five steps:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="width: 0.25in"&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(i)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;identify
    the contract(s) with a customer&#x37e;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(ii)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;identify
    the performance obligations in the contract&#x37e;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(iii)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;determine
    the transaction price&#x37e;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(iv)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;allocate
    the transaction price to the performance obligations in the contract&#x37e; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(v)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;recognize
    revenue when (or as) the entity satisfies a performance obligation.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company applies the five-step model to contracts when it determines that it is probable it will collect substantially all the consideration
it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined
to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that
are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the
amount of the transaction price, after consideration of variability and constraints, if any, that is allocated to the respective performance
obligation when the performance obligation is satisfied.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company estimates credit losses on accounts receivable by estimating expected credit losses over the contractual term of the receivable
using a discounted cash flow method. When developing this estimate of expected credit losses, the Company considers all available information
(past, current, and future) relevant to assessing the collectability of cash flows.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company offers a Patient Assistance Program for patients without insurance coverage for IB-Stim. This program extends potential self-pay
discounts for IB-Stim devices, based upon household income and size.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Also,
the Company offers providers an opt-in program to address adequate insurance claim payments on IB-Stim devices. This program may extend
a rebate or invoice credit where the insurance payment and patient responsibility (i.e., deductible, co-payment, and/or co-insurance
amounts required by the Payer) are less than the acquisition cost of the IB-Stim device. The Company recognizes revenue at such a time
that collection of the amount due is assured.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--DisaggregationOfRevenueTableTextBlock_zX6RXuuRv7o2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table disaggregates the Company&#x2019;s revenue based on the customer&#x2019;s location by state for the years ended December
31:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B8_zAzVuhoIgill" style="display: none"&gt;Schedule of Disaggregation of Revenue&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 25%; text-align: left"&gt;California&lt;/td&gt;&lt;td style="width: 2%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--CA_zAnDptrXJjOb" style="width: 20%; font-weight: bold; text-align: right" title="Revenues"&gt;601,235&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 25%; text-align: left"&gt;Wisconsin&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__stpr--WI_z2SwOYl8cNh9" style="width: 20%; text-align: right" title="Revenues"&gt;670,245&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Ohio&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--OH_zDI0OkZvXUch" style="font-weight: bold; text-align: right" title="Revenues"&gt;407,632&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Ohio&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__stpr--OH_zJhs6wESToS2" style="text-align: right" title="Revenues"&gt;500,260&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Wisconsin&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--WI_z9ynHKka95Xd" style="font-weight: bold; text-align: right" title="Revenues"&gt;292,601&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;California&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__stpr--CA_zRGqfRRI4PZ9" style="text-align: right" title="Revenues"&gt;408,645&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Florida&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--FL_z1o4pUWGGbRe" style="font-weight: bold; text-align: right" title="Revenues"&gt;186,840&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Florida&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__stpr--FL_zwbktOHvOlP2" style="text-align: right" title="Revenues"&gt;231,480&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Massachusetts&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--MA_zL8Z9URoL8Rf" style="font-weight: bold; text-align: right" title="Revenues"&gt;127,300&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Missouri&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__country--MO_zmIB5JUxFlka" style="text-align: right" title="Revenues"&gt;174,980&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;All other states&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__custom--AllOtherStatesMember_zgxis1XpHgTj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Revenues"&gt;844,441&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;All other states&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__custom--AllOtherStatesMember_zqkBp0QJB9Bd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenues"&gt;699,125&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--Revenues_c20230101__20231231_zmLHQlhg1K4a" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Total revenue"&gt;2,460,049&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--Revenues_c20220101__20221231_zVi8nS1HELrg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total revenue"&gt;2,684,735&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8A6_z18moQNeosPi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following economic factors affect the nature, amount, timing, and uncertainty of the Company&#x2019;s revenue and cash flows as indicated:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Type
of customer:&lt;/b&gt; Based on dollar amounts of revenue, essentially all of the goods sold by the Company are sold to healthcare customers
including hospitals and clinics. Sales to healthcare customers lack seasonality and have a mild correlation with economic cycles.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Geographical
location of customers:&lt;/b&gt; Sales to customers located within the United States represent essentially all of the Company&#x2019;s sales.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Notes to Financial Statements&lt;/b&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Type
of contract:&lt;/b&gt; Sales contracts consist of purchase order contracts that tend to be short-term (i.e., less than or equal to one year
in duration).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Company&#x2019;s
Performance Obligations with Customers:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Timing
of Satisfaction&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company typically satisfies its performance obligations as the goods are delivered.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Goods
that are shipped to customers are typically shipped FOB shipping point with freight prepaid by the Company. As such, ownership of goods
in transit transfer to the customer when shipped and the customer bears the associated risks (e.g., loss, damage, delay). &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Shipping
and handling costs are recorded as general and administrative expenses in the Statement of Operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Significant
Payment Terms&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Payment
for goods sold by the Company is typically due after an invoice is sent to the customer, within 30 days. However, other payment terms
are frequently negotiated with customers ranging from due upon receipt to due within 90 days. Some payment terms may call for payment
only after the healthcare provider receives their insurance reimbursement. Invoices for goods are typically sent to customers within
three calendar days of shipment. The Company does not offer discounts if the customer pays some or all of an invoiced amount prior to
the due date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;None
of the Company&#x2019;s contracts have a significant financing component.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Nature&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Medical
devices that the Company contracts to sell and transfer to customers are manufactured by one specific third-party manufacturer. The manufacturer
is located within the state of Indiana. In no case does the Company act as an agent (i.e., the Company does not provide a service of
arranging for another party to transfer goods to the customer).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Returns,
Refunds, etc.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Orders
may not be cancelled after shipment. Customers may return devices within 10 days of delivery if the goods are found to be defective,
nonconforming, or otherwise do not meet the stated technical specifications. At the option of the customer, the Company shall either:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Refund
    the price paid for any defective or nonconforming products.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Supply
    and deliver to the customer replacement conforming products.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Reimburse
    the customer for the cost of repairing any defective or nonconforming products.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;At
the time revenue is recognized, the Company estimates expected returns and excludes those amounts from revenue. The Company also maintains
appropriate accounts to reflect the effects of expected returns on the Company&#x2019;s financial position and periodically adjusts those
accounts to reflect its actual return experience. Historically, returns have been immaterial, and the Company currently does not provide
a provision for this liability.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Notes to Financial Statements&lt;/b&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000794">&lt;p id="xdx_89B_eus-gaap--DisaggregationOfRevenueTableTextBlock_zX6RXuuRv7o2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table disaggregates the Company&#x2019;s revenue based on the customer&#x2019;s location by state for the years ended December
31:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B8_zAzVuhoIgill" style="display: none"&gt;Schedule of Disaggregation of Revenue&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 25%; text-align: left"&gt;California&lt;/td&gt;&lt;td style="width: 2%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--CA_zAnDptrXJjOb" style="width: 20%; font-weight: bold; text-align: right" title="Revenues"&gt;601,235&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 25%; text-align: left"&gt;Wisconsin&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__stpr--WI_z2SwOYl8cNh9" style="width: 20%; text-align: right" title="Revenues"&gt;670,245&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Ohio&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--OH_zDI0OkZvXUch" style="font-weight: bold; text-align: right" title="Revenues"&gt;407,632&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Ohio&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__stpr--OH_zJhs6wESToS2" style="text-align: right" title="Revenues"&gt;500,260&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Wisconsin&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--WI_z9ynHKka95Xd" style="font-weight: bold; text-align: right" title="Revenues"&gt;292,601&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;California&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__stpr--CA_zRGqfRRI4PZ9" style="text-align: right" title="Revenues"&gt;408,645&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Florida&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--FL_z1o4pUWGGbRe" style="font-weight: bold; text-align: right" title="Revenues"&gt;186,840&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Florida&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__stpr--FL_zwbktOHvOlP2" style="text-align: right" title="Revenues"&gt;231,480&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Massachusetts&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__stpr--MA_zL8Z9URoL8Rf" style="font-weight: bold; text-align: right" title="Revenues"&gt;127,300&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;Missouri&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__country--MO_zmIB5JUxFlka" style="text-align: right" title="Revenues"&gt;174,980&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;All other states&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--Revenues_c20230101__20231231__srt--StatementGeographicalAxis__custom--AllOtherStatesMember_zgxis1XpHgTj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Revenues"&gt;844,441&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;All other states&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--Revenues_c20220101__20221231__srt--StatementGeographicalAxis__custom--AllOtherStatesMember_zqkBp0QJB9Bd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenues"&gt;699,125&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--Revenues_c20230101__20231231_zmLHQlhg1K4a" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Total revenue"&gt;2,460,049&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--Revenues_c20220101__20221231_zVi8nS1HELrg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total revenue"&gt;2,684,735&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="From2023-01-012023-12-31_stpr_CA"
      decimals="0"
      id="Fact000796"
      unitRef="USD">601235</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2022-01-012022-12-31_stpr_WI"
      decimals="0"
      id="Fact000798"
      unitRef="USD">670245</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2023-01-012023-12-31_stpr_OH"
      decimals="0"
      id="Fact000800"
      unitRef="USD">407632</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2022-01-012022-12-31_stpr_OH"
      decimals="0"
      id="Fact000802"
      unitRef="USD">500260</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2023-01-012023-12-31_stpr_WI"
      decimals="0"
      id="Fact000804"
      unitRef="USD">292601</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2022-01-012022-12-31_stpr_CA"
      decimals="0"
      id="Fact000806"
      unitRef="USD">408645</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2023-01-012023-12-31_stpr_FL"
      decimals="0"
      id="Fact000808"
      unitRef="USD">186840</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2022-01-012022-12-31_stpr_FL"
      decimals="0"
      id="Fact000810"
      unitRef="USD">231480</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2023-01-012023-12-31_stpr_MA"
      decimals="0"
      id="Fact000812"
      unitRef="USD">127300</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2022-01-012022-12-31_country_MO"
      decimals="0"
      id="Fact000814"
      unitRef="USD">174980</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2023-01-012023-12-31_custom_AllOtherStatesMember"
      decimals="0"
      id="Fact000816"
      unitRef="USD">844441</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2022-01-012022-12-31_custom_AllOtherStatesMember"
      decimals="0"
      id="Fact000818"
      unitRef="USD">699125</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact000820"
      unitRef="USD">2460049</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact000822"
      unitRef="USD">2684735</us-gaap:Revenues>
    <us-gaap:ExtendedProductWarrantyPolicy contextRef="From2023-01-01to2023-12-31" id="Fact000824">&lt;p id="xdx_844_eus-gaap--ExtendedProductWarrantyPolicy_zsmzImPWWnw7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86D_zcAlCuDLdeMh"&gt;Warranties&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
most cases, goods that customers purchase from the Company are covered by manufacturers&#x2019; warranties. The Company does not sell
warranties separately.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
manufacturer guarantees the product for the period up to the expiration date printed on the device&#x2019;s label or twelve months from
the date of purchase, whichever comes first. The guarantee applies to flaws of material and workmanship. The Company&#x2019;s warranties
provide customers with assurance that purchased devices comply with published specifications, inspection standards, and workmanship.
At the time revenue is recognized, the Company estimates the cost of expected future warranty claims but does not exclude any amounts
from revenue. The Company maintains appropriate accounts to reflect the effects of expected future warranty claims on the Company&#x2019;s
financial position and periodically adjusts those accounts to reflect its actual warranty claim experience. Historically, warranty claims
have been immaterial, and the Company currently does not provide a provision for this liability.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company typically satisfies its performance obligations for goods at a point in time. In most cases, goods are shipped by common carrier
to customers under &#x201c;FOB Shipping Point&#x201d; terms. As such, customers typically obtain control of the goods upon shipment. The
Company&#x2019;s management exercises judgment in determining when performance obligations for goods have been satisfied. In making such
judgments, management typically relies on shipping information obtained from common carriers to evaluate when the customer has obtained
control of the goods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s contracts with customers typically do not involve variable consideration. The information that the Company uses to determine
the transaction price for a contract is similar to the information that the Company&#x2019;s management uses in establishing the prices
of goods to be sold.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ExtendedProductWarrantyPolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000826">&lt;p id="xdx_843_eus-gaap--LesseeLeasesPolicyTextBlock_z4OfpCedWO8j" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_860_zDo0Qt7M55Dk"&gt;Leases&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
accordance with Accounting Standards Updated (&#x201c;ASU&#x201d;) No. 2016-02, &lt;i&gt;Leases (Topic 842)&lt;/i&gt; (&#x201c;ASU 2016-02&#x201d; or
&#x201c;ASC 842&#x201d;), at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based
on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the balance
sheet as right-of-use assets and current and non-current lease liabilities, as applicable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
lease liabilities and their corresponding right-of-use assets are initially recorded based on the present value of lease payments over
the expected remaining lease term. Certain adjustments to the right-of-use asset may be required for items such as incentives received.
The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental
borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis
the amount of the lease payments in the same currency, for a similar term, in a similar economic environment. Prospectively, the Company
will adjust the right-of-use assets for straight-line rent expense, or any incentives received and remeasure the lease liability at the
net present value using the same incremental borrowing rate that was in effect as of the lease commencement or transition date. The Company
has elected not to recognize leases with an original term of one year or less on the balance sheet. The Company typically only includes
an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in the Company&#x2019;s assessment
unless there is reasonable certainty that the Company will renew.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Assumptions
made by the Company at the commencement date are re-evaluated upon occurrence of certain events, including a lease modification. A lease
modification results in a separate contract when the modification grants the lessee an additional right of use not included in the original
lease and when lease payments increase commensurate with the standalone price for the additional right of use. When a lease modification
results in a separate contract, it is accounted for in the same manner as a new lease.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Entities
may elect not to separate lease and non-lease components. The Company has elected to account for lease and non-lease components together
as a single lease component for all underlying assets and allocate all the contract consideration to the lease component only.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Notes to Financial Statements&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;


</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000828">&lt;p id="xdx_844_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zQnGpcSL7M39" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86F_zBrB3zgiolB3"&gt;Impairment
of Long-Lived Assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Long-lived
assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset group may
not be recoverable. If events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable,
we compare the carrying amount of the asset group to future undiscounted net cash flows, excluding interest costs, expected to be generated
by the asset group and their ultimate disposition. If the sum of the undiscounted cash flows is less than the carrying value, the impairment
to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the fair value of the asset group.
Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2023-01-01to2023-12-31" id="Fact000830">&lt;p id="xdx_841_eus-gaap--ConcentrationRiskCreditRisk_zx8dJc3KAyve" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_864_zpHzMrGs96Kj"&gt;Concentrations
of Credit Risk&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s business activity consists of the sale of medical neuromodulation devices to doctors, clinics, and hospitals across the
country.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Receivables
consist of unsecured amounts due from customers. As of December 31, 2023, accounts receivable from four customers with balances due
in excess of &lt;span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zHt7e9wt7Xlf" title="Risk percentage"&gt;10&lt;/span&gt;%
of total accounts receivable were approximately &lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z1sgDO6lIT0f" title="Risk percentage"&gt;28&lt;/span&gt;%, &lt;span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zOpddKc3C56k" title="Risk percentage"&gt;28&lt;/span&gt;%, &lt;span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerThreeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_ztyL1NBusNqe" title="Risk percentage"&gt;17&lt;/span&gt;%
and &lt;span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerFourMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zn5iv9oSMJNe" title="Risk percentage"&gt;11&lt;/span&gt;%, respectively. As of December 31, 2022, accounts receivable from three customers with balances due in excess of &lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_znlKTOeeo93f" title="Risk percentage"&gt;10&lt;/span&gt;%
of total accounts receivable was &lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zdf0D1ndQga7" title="Risk percentage"&gt;23&lt;/span&gt;%, &lt;span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zJM0GLgbRMti" title="Risk percentage"&gt;15&lt;/span&gt;%,
and &lt;span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerThreeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zFGIT1ta9kQ" title="Risk percentage"&gt;12&lt;/span&gt;%,
respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
table below sets forth the Company&#x2019;s customers that accounted for greater than &lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueProductLineMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--RevenueFromRightsConcentrationRiskMember_zSykzU9jrsr5" title="Risk percentage"&gt;&lt;span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueProductLineMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--RevenueFromRightsConcentrationRiskMember_z8AOKkMvCXI4" title="Risk percentage"&gt;10&lt;/span&gt;&lt;/span&gt;% of its revenues for the years ended December
31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock_zK2CTGYbN3Sb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B3_zCjfnL75gsbi" style="display: none"&gt;Schedule of Customers Accounted Revenues&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Percentage of &lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Percentage of &lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Sales&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Sales&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; text-align: left"&gt;Hospital A&lt;/td&gt;&lt;td style="width: 2%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--MajorCustomersAxis__custom--HospitalAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z8DYsvEFfc62" style="width: 15%; font-weight: bold; text-align: right" title="Revenue"&gt;452,680&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 15%; text-align: center"&gt;&lt;span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--HospitalAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zOU9fy3LjPDl" title="Risk percentage"&gt;18&lt;/span&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20221231__srt--MajorCustomersAxis__custom--HospitalAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z6VZ0fIq4lbg" style="width: 15%; text-align: right" title="Revenue"&gt;355,613&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 15%; text-align: center"&gt;&lt;span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--HospitalAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zGUAamau5Wg7" title="Risk percentage"&gt;13&lt;/span&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Hospital B&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--MajorCustomersAxis__custom--HospitalBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zWtmDNKLOmZ8" style="font-weight: bold; text-align: right" title="Revenue"&gt;382,082&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--HospitalBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zxGlw7LXQHJh" title="Risk percentage"&gt;16&lt;/span&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20221231__srt--MajorCustomersAxis__custom--HospitalBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zkkJm06MFCPb" style="text-align: right" title="Revenue"&gt;484,900&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--HospitalBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z8N4M2GNQ1Cg" title="Risk percentage"&gt;18&lt;/span&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Hospital C&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--MajorCustomersAxis__custom--HospitalCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zoNS5KYKLCJ8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Revenue"&gt;274,581&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--HospitalCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_ztiAPuHBO464" title="Risk percentage"&gt;11&lt;/span&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20221231__srt--MajorCustomersAxis__custom--HospitalCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zAa3xtGHtem9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue"&gt;554,325&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--HospitalCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zSTXRgI9fhP9" title="Risk percentage"&gt;21&lt;/span&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--MajorCustomersAxis__custom--HospitalMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zPVkIhkG8i96" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Revenue"&gt;1,109,343&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--HospitalMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zAj2qbvuPNlj" title="Risk percentage"&gt;45&lt;/span&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20221231__srt--MajorCustomersAxis__custom--HospitalMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zdpQH4bigBYb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue"&gt;1,394,838&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--HospitalMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zx1dh6xGR3J3" title="Risk percentage"&gt;52&lt;/span&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8AE_zG8dOe1t08F5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From
time to time, the Company&#x2019;s bank balances may exceed the FDIC limit of $&lt;span id="xdx_909_eus-gaap--CashFDICInsuredAmount_iI_c20231231_znBb1ljAlu7f" title="Cash, FDIC insured amount"&gt;250,000&lt;/span&gt;; however, management does not feel that this has
a material impact on the financial condition. At December 31, 2023 and 2022, the Company didn&#x2019;t have any uninsured cash balance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-12-31_custom_CustomerMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      id="Fact000832"
      unitRef="Pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-12-31_custom_CustomerOneMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      id="Fact000834"
      unitRef="Pure">0.28</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-12-31_custom_CustomerTwoMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      id="Fact000836"
      unitRef="Pure">0.28</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-12-31_custom_CustomerThreeMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      id="Fact000838"
      unitRef="Pure">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-12-31_custom_CustomerFourMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      id="Fact000840"
      unitRef="Pure">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-12-31_custom_CustomerMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      id="Fact000842"
      unitRef="Pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-12-31_custom_CustomerOneMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      id="Fact000844"
      unitRef="Pure">0.23</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-12-31_custom_CustomerTwoMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      id="Fact000846"
      unitRef="Pure">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-12-31_custom_CustomerThreeMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      id="Fact000848"
      unitRef="Pure">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-12-31_custom_CustomerMember_us-gaap_SalesRevenueProductLineMember_us-gaap_RevenueFromRightsConcentrationRiskMember"
      decimals="INF"
      id="Fact000850"
      unitRef="Pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-12-31_custom_CustomerMember_us-gaap_SalesRevenueProductLineMember_us-gaap_RevenueFromRightsConcentrationRiskMember"
      decimals="INF"
      id="Fact000852"
      unitRef="Pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000854">&lt;p id="xdx_89F_eus-gaap--ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock_zK2CTGYbN3Sb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B3_zCjfnL75gsbi" style="display: none"&gt;Schedule of Customers Accounted Revenues&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Percentage of &lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Percentage of &lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Sales&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;b&gt;Sales&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; text-align: left"&gt;Hospital A&lt;/td&gt;&lt;td style="width: 2%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--MajorCustomersAxis__custom--HospitalAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z8DYsvEFfc62" style="width: 15%; font-weight: bold; text-align: right" title="Revenue"&gt;452,680&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 15%; text-align: center"&gt;&lt;span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--HospitalAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zOU9fy3LjPDl" title="Risk percentage"&gt;18&lt;/span&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20221231__srt--MajorCustomersAxis__custom--HospitalAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z6VZ0fIq4lbg" style="width: 15%; text-align: right" title="Revenue"&gt;355,613&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 15%; text-align: center"&gt;&lt;span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--HospitalAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zGUAamau5Wg7" title="Risk percentage"&gt;13&lt;/span&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Hospital B&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--MajorCustomersAxis__custom--HospitalBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zWtmDNKLOmZ8" style="font-weight: bold; text-align: right" title="Revenue"&gt;382,082&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--HospitalBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zxGlw7LXQHJh" title="Risk percentage"&gt;16&lt;/span&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20221231__srt--MajorCustomersAxis__custom--HospitalBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zkkJm06MFCPb" style="text-align: right" title="Revenue"&gt;484,900&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--HospitalBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z8N4M2GNQ1Cg" title="Risk percentage"&gt;18&lt;/span&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Hospital C&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--MajorCustomersAxis__custom--HospitalCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zoNS5KYKLCJ8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Revenue"&gt;274,581&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--HospitalCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_ztiAPuHBO464" title="Risk percentage"&gt;11&lt;/span&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20221231__srt--MajorCustomersAxis__custom--HospitalCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zAa3xtGHtem9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue"&gt;554,325&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--HospitalCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zSTXRgI9fhP9" title="Risk percentage"&gt;21&lt;/span&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20231231__srt--MajorCustomersAxis__custom--HospitalMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zPVkIhkG8i96" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Revenue"&gt;1,109,343&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--HospitalMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zAj2qbvuPNlj" title="Risk percentage"&gt;45&lt;/span&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20221231__srt--MajorCustomersAxis__custom--HospitalMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zdpQH4bigBYb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue"&gt;1,394,838&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--HospitalMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zx1dh6xGR3J3" title="Risk percentage"&gt;52&lt;/span&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31_custom_HospitalAMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="0"
      id="Fact000856"
      unitRef="USD">452680</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-12-31_custom_HospitalAMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      id="Fact000858"
      unitRef="Pure">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-12-31_custom_HospitalAMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="0"
      id="Fact000860"
      unitRef="USD">355613</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-12-31_custom_HospitalAMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      id="Fact000862"
      unitRef="Pure">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31_custom_HospitalBMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="0"
      id="Fact000864"
      unitRef="USD">382082</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-12-31_custom_HospitalBMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      id="Fact000866"
      unitRef="Pure">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-12-31_custom_HospitalBMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="0"
      id="Fact000868"
      unitRef="USD">484900</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-12-31_custom_HospitalBMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      id="Fact000870"
      unitRef="Pure">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31_custom_HospitalCMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="0"
      id="Fact000872"
      unitRef="USD">274581</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-12-31_custom_HospitalCMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      id="Fact000874"
      unitRef="Pure">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-12-31_custom_HospitalCMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="0"
      id="Fact000876"
      unitRef="USD">554325</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-12-31_custom_HospitalCMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      id="Fact000878"
      unitRef="Pure">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-12-31_custom_HospitalMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="0"
      id="Fact000880"
      unitRef="USD">1109343</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2023-01-012023-12-31_custom_HospitalMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      id="Fact000882"
      unitRef="Pure">0.45</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-12-31_custom_HospitalMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="0"
      id="Fact000884"
      unitRef="USD">1394838</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2022-01-012022-12-31_custom_HospitalMember_us-gaap_AccountsReceivableMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      id="Fact000886"
      unitRef="Pure">0.52</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:CashFDICInsuredAmount
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000888"
      unitRef="USD">250000</us-gaap:CashFDICInsuredAmount>
    <NRXS:GoingConcernPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000890">&lt;p id="xdx_848_ecustom--GoingConcernPolicyTextBlock_zXajKJKS6Kod" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_861_zZ5dSeb3IfU"&gt;Going
Concern&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;We
have incurred losses since inception and have funded our operations primarily with a combination of sales, debt, and the sale of capital
stock. As of December 31, 2023, we had a stockholders&#x2019; deficit totaling $&lt;span id="xdx_903_eus-gaap--StockholdersEquity_iNI_di_c20231231_zUPTVUFQnusl" title="Stockholders deficit"&gt;1,403,241&lt;/span&gt;. At December 31, 2023, we had short-term outstanding
borrowings of approximately $&lt;span id="xdx_905_eus-gaap--ShortTermBorrowings_iI_c20231231_zGK76rC9Za7g" title="Short term borrowing"&gt;148,062&lt;/span&gt;. As of December 31, 2023, we had cash of $&lt;span id="xdx_90F_eus-gaap--Cash_iI_c20231231_zMSBuQjxhUv2" title="Cash"&gt;78,560&lt;/span&gt; and a working capital deficit of $&lt;span id="xdx_900_ecustom--WorkingCapitalDeficit_iI_c20231231_zojtMzfW66Z2" title="Working capital"&gt;1,643,058&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 9, 2023, the Company consummated its initial public offering, conducted on a firm commitment basis, pursuant to which it sold &lt;span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230809__20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zes7IYSmLHEe" title="Number of shares issued in transaction"&gt;1,098,667&lt;/span&gt;
shares of its common stock at a price of $&lt;span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_c20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zMs9Emp2MZu3" title="Share issued price per share"&gt;6.00&lt;/span&gt;
per share, resulting in gross proceeds to the Company of $&lt;span id="xdx_902_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230809__20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zduBimLlqvCd" title="Proceeds from issuance of common stock"&gt;6,592,002&lt;/span&gt;.
Net proceeds to the Company, after deducting underwriting discounts and commissions, 2022 deferred offering costs totaling $&lt;span id="xdx_908_eus-gaap--DeferredOfferingCosts_iI_c20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zGr67oXbOBul" title="Deferred offering costs"&gt;736,736&lt;/span&gt;
and offering expenses paid by the Company, were $&lt;span id="xdx_906_eus-gaap--PaymentsOfStockIssuanceCosts_c20230811__20230811__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSo5An9DMAvc" title="Payment fees"&gt;4,110,721&lt;/span&gt;.
All shares sold in our IPO were registered pursuant to a registration statement on Form S-1 (File No. 333- 269179), as amended,
declared effective by the SEC on August 9, 2023. Alexander Capital L.P. acted as sole book-running manager for the offering and
Spartan Capital Securities, LLC acted as co-manager for the offering. &lt;span style="background-color: white"&gt;The underwriters did not
exercise their option to purchase up to an additional &lt;/span&gt;&lt;span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230809__20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zKV7ofq1xkai" title="Purchase of common shares"&gt;164,801&lt;/span&gt; &lt;span style="background-color: white"&gt;shares
of common stock.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Notes to Financial Statements&lt;/b&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Our
future capital requirements will depend upon many factors, including progress with developing, manufacturing, and marketing our
technologies, the time and costs involved in preparing, filing, prosecuting, maintaining, and enforcing patent claims and other
proprietary rights, our ability to establish collaborative arrangements, marketing activities and competing technological and market
developments, including regulatory changes and overall economic conditions in our target markets. Our ability to generate revenue
and achieve profitability requires us to successfully market and secure purchase orders for our products from customers currently
identified in our sales pipeline and to new customers as well. The primary activity that will drive all customers and revenues is
the adoption of insurance coverage by commercial insurance carriers nationally which is a top priority of the Company. These
activities, including our planned research and development efforts, will require significant uses of working capital through the
rest of 2024 and beyond. Based on our current operating plans, we believe that our existing cash at the time of this filing will
only be sufficient to meet our anticipated operating needs through the end of 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Management
evaluates whether there are conditions or events that raise substantial doubt about the Company&#x2019;s ability to continue as a going
concern for a period of one year from the date the financial statements are issued.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;To
date, the Company has experienced operating losses and negative cash flows from operations. Management believes that increased sales
and acceptance of their product by insurance providers will allow the Company to achieve profitability in the future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;While
the Company believes in the viability of its strategy to further implement its business plan and generate sufficient revenues and in
its ability to raise additional funds by way of a public or private offering of its debt or equity securities, there can be no
assurance that it will be able to do so on reasonable terms, or at all. The ability of the Company to continue as a going concern is
dependent upon its ability to further implement its business plan and generate sufficient revenues and its ability to raise
additional funds by way of a public or private offering. Neither future cash generated from operating activities, nor
management&#x2019;s contingency plans to mitigate the risk and extend cash resources through the evaluation period, are considered
probable. As a result, substantial doubt is deemed to exist about the Company&#x2019;s ability to continue as a going concern. As we
continue to incur losses, our transition to profitability is dependent upon achieving a level of revenues adequate to support its
cost structure. We may never achieve profitability, and unless and until doing so, we intend to fund future operations through
additional dilutive or nondilutive financing. There can be no assurances, however, that additional funding will be available on
terms acceptable to us, if at all.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the
amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</NRXS:GoingConcernPolicyTextBlock>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000892"
      unitRef="USD">-1403241</us-gaap:StockholdersEquity>
    <us-gaap:ShortTermBorrowings
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000894"
      unitRef="USD">148062</us-gaap:ShortTermBorrowings>
    <us-gaap:Cash
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000896"
      unitRef="USD">78560</us-gaap:Cash>
    <NRXS:WorkingCapitalDeficit
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000898"
      unitRef="USD">1643058</NRXS:WorkingCapitalDeficit>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2023-08-092023-08-09_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000900"
      unitRef="Shares">1098667</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-08-09_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000902"
      unitRef="USDPShares">6.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-08-092023-08-09_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000904"
      unitRef="USD">6592002</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:DeferredOfferingCosts
      contextRef="AsOf2023-08-09_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000906"
      unitRef="USD">736736</us-gaap:DeferredOfferingCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2023-08-112023-08-11_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000908"
      unitRef="USD">4110721</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-08-092023-08-09_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000910"
      unitRef="Shares">164801</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000912">&lt;p id="xdx_847_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zFcm1uYaKtoj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_863_zu6wtfWyMFre"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
June 2016, the FASB issued ASU 2016-13, Financial Instruments &#x2013; Credit Losses (Topic 326): Measurement of Credit Losses on Financial
Instruments, which requires measurement and recognition of expected credit losses for financial assets held and requires enhanced disclosures
regarding significant estimates and judgments used in estimating credit losses. In November 2019, the FASB issued ASU 2019-10, Financial
Instruments &#x2013; Credit Losses (Topic 326), Derivatives and Hedging (Topic 815) and Leases (Topic 842): Effective Dates, which amended
the effective date of ASU 2016-13. Public business entities meeting the definition of an SEC filer, excluding entities eligible to be
a Smaller Reporting Company (&#x201c;SRC&#x201d;) as defined by the SEC, are required to adopt the standard for fiscal years beginning
after December 15, 2019, including interim periods within those fiscal years. All other entities are required to adopt the standard for
fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company meets the definition
of an SRC and therefore the standard was adopted as of January 1, 2023. The adoption of this guidance did not have a material impact
on the Company&#x2019;s financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;In December 2023, the FASB issued ASU 2023-19,
Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires the enhancement of income tax disclosures to
provide better insight into how an entity&#x2019;s operations and related tax risks, planning and opportunities affect its tax rate
and prospects for future cash flows. The enhanced disclosures require (i) specific categories in a tabular rate reconciliation
including both amounts and percentages and (ii) additional information for reconciling items and income tax paid that meet a
quantitative threshold. Public business entities are required to adopt the standard for annual periods beginning after December 15,
2024. All other entities are required to adopt the standard for annual periods beginning after December 15, 2025. The adoption of
the standard is not expected to have a material impact on the Company&#x2019;s financial statements.&lt;/p&gt;
</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000914">&lt;p id="xdx_80E_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_z4b3bNdgdusd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;3.
&lt;span&gt;&lt;span id="xdx_827_z27BacDLLdMl"&gt;Related Party Transactions&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has two demand notes receivable from shareholders related to the sale of common stock on January 1, 2016. Both notes&#x2019; initial
balances were $&lt;span id="xdx_902_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholdersOneAndTwoMember_z8BtQJFbJrS4" title="Loan Receivable"&gt;506,400&lt;/span&gt;, with interest calculated monthly based on applicable federal rates. No payments have been received on the notes.
Since repayment is not assured, the Company provided an allowance for the entire balance of principal and interest as of December 31,
2019. The current allowance is $&lt;span id="xdx_90B_ecustom--AllowanceForInterestReceivableCurrent_iI_c20231231_zJnTyvcFx3r3" title="Allowance for interest receivable current"&gt;1,154,541&lt;/span&gt; as of December 31, 2023. The current loan balances are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zqWIyjUVS18e" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span id="xdx_8B5_z8l6ORobyzp1" style="display: none"&gt;Schedule of Related Party Transactions&lt;/span&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Loan&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Interest&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Interest&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Receivable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Receivable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Income&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;Shareholder 1&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderOneMember_zNjeGS834uJ1" style="width: 14%; text-align: right" title="Loan Receivable"&gt;506,400&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--InterestReceivableCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderOneMember_zAr7UCbfco9d" style="width: 14%; text-align: right" title="Interest Receivable"&gt;70,938&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--InterestIncomeGrossCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderOneMember_zjUqYewZQEKe" style="width: 14%; text-align: right" title="Interest Income"&gt;23,867&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Shareholder 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderTwoMember_zUaBQuPkUcs4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Loan Receivable"&gt;506,400&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--InterestReceivableCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderTwoMember_zbnY9eWJLBr5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest Receivable"&gt;70,803&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--InterestIncomeGrossCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderTwoMember_zW2gG27f91Bk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest Income"&gt;23,867&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zYEz6pYsAt8" style="text-align: right" title="Loan Receivable"&gt;1,012,800&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--InterestReceivableCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zV6zGTWgKfwd" style="text-align: right" title="Interest Receivable"&gt;141,741&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--InterestIncomeGrossCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zuqvBNoFFs89" style="text-align: right" title="Interest Income"&gt;47,734&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Allowance for Collection Risk&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AllowanceForNotesAndLoansReceivableCurrent_iNI_di_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zVsT3J8XqlA7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Allowance for collection risk, loan receivable"&gt;(1,012,800&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--InterestReceivableCurrent_iNI_di_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z9RIPUINte28" style="border-bottom: Black 1.5pt solid; text-align: right" title="Allowance for collection risk, interest receivable"&gt;(141,741&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--AllowanceForInterestIncomeCurrent_iNI_di_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z5Uz45E9BYme" style="border-bottom: Black 1.5pt solid; text-align: right" title="Allowance for collection risk, interest income"&gt;(47,734&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Net Balance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--NotesAndLoansReceivableNetCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zwvDYzL2T28i" style="border-bottom: Black 1.5pt solid; text-align: right" title="Loan Receivable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0946"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--InterestReceivable_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zGC81YvfHKMf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest Receivable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0948"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--InterestIncomeCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zbLdMijari3b" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest Income"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0950"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Loan&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Interest&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Interest&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Receivable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Receivable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Income&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;Shareholder 1&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderOneMember_zsr2M5KfUG5h" style="width: 14%; text-align: right" title="Loan Receivable"&gt;506,400&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--InterestReceivableCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderOneMember_z6I6OQcmRgol" style="width: 14%; text-align: right" title="Interest Receivable"&gt;47,071&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--InterestIncomeGrossCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderOneMember_zGimIoPsSCJ7" style="width: 14%; text-align: right" title="Interest Income"&gt;11,523&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Shareholder 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderTwoMember_zxtDmMfOnRn5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Loan Receivable"&gt;506,400&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--InterestReceivableCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderTwoMember_za9yIQZuCwQb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest Receivable"&gt;46,936&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--InterestIncomeGrossCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderTwoMember_zrl9RjcqPpS3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest Income"&gt;11,523&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z1NAQRx3RRtl" style="text-align: right" title="Loan Receivable"&gt;1,012,800&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--InterestReceivableCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_znAiqJpIor4" style="text-align: right" title="Interest Receivable"&gt;94,007&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--InterestIncomeGrossCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z2U5TqiSdRQe" style="text-align: right" title="Interest Income"&gt;23,046&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Allowance for Collection Risk&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AllowanceForNotesAndLoansReceivableCurrent_iNI_di_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zSgT36uVkLzc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Allowance for collection risk, loan receivable"&gt;(1,012,800&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--InterestReceivableCurrent_iNI_di_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zjME8N49EpH6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Allowance for collection risk, interest receivable"&gt;(94,007&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--AllowanceForInterestIncomeCurrent_iNI_di_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_ztt179JuzVad" style="border-bottom: Black 1.5pt solid; text-align: right" title="Allowance for collection risk, interest income"&gt;(23,046&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Net Balance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--NotesAndLoansReceivableNetCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zEGLcV60i0Oi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Loan Receivable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0976"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--InterestReceivable_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zACWZJZhkB3c" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest Receivable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0978"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--InterestIncomeCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zASJ0ABNa47e" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest Income"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0980"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A4_ztT2hNMVbB7a" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has loans payable to shareholders related to funding needs for operations. The current loan details for all related party loans
are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_ecustom--ScheduleOfRelatedPartyLoansTableTextBlock_zWYBz5E1QISc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span id="xdx_8B8_z9ZoAHflmhHk" style="display: none"&gt;Schedule of Related Party Loans payable to shareholder&lt;/span&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Interest &amp;amp;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Interest&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Loan&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Service Fee&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Interest&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Due Date&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Rate&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Balance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Accrued&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Paid&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 30%; text-align: left"&gt;Shareholder 1&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--DebtInstrumentMaturityDateDescription_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderMember_zLmrcLwwzZT9" title="Due date"&gt;June, 2019&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderMember_zdKQbLO41w0a" title="Debt instrument percentage"&gt;15.00&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--LoansPayable_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderMember_ztyIiCuOam1d" style="width: 10%; text-align: right" title="Loan payable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0988"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_ecustom--InterestAndServiceFeeAccrued_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderMember_zkwUyLgjw5ic" style="width: 10%; text-align: right" title="Interest payable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0990"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--InterestPaid_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderMember_zUEbQib1hql4" style="width: 10%; text-align: right" title="Interest payable"&gt;10,047&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Shareholder 1&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--DebtInstrumentMaturityDateDescription_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_z6UYuTOdv2T7" title="Due date"&gt;June, 2019&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_zDuwTD5kyGze" title="Debt instrument percentage"&gt;15.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--LoansPayable_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_zPaik7XCGSSf" style="text-align: right" title="Loan payable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0998"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--InterestAndServiceFeeAccrued_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_zwzShwpllCt5" style="text-align: right" title="Interest payable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1000"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--InterestPaid_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_ztf8UkLpAEc1" style="text-align: right" title="Interest payable"&gt;27,056&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other Convertibles&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--DebtInstrumentMaturityDateDescription_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zPnt1LgV7VAh" title="Due date"&gt;Various&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zLPY1MG1DDU3" title="Debt instrument percentage"&gt;5.00&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--LoansPayable_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zchp3VXWcIvd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest payable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1008"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--InterestAndServiceFeeAccrued_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zOxnLZn5lmwh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest payable"&gt;66,648&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--InterestPaid_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zlYzcLAKuAU7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest payable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1012"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--LoansPayable_iI_c20231231_zYL0tJxjI3ih" style="border-bottom: Black 1.5pt solid; text-align: right" title="Loan payable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1014"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--InterestAndServiceFeeAccrued_iI_c20231231_zEsgLv7iBl9j" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest payable"&gt;66,648&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--InterestPaid_c20230101__20231231_z3n7s4J8fFB" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest payable"&gt;37,103&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Interest &amp;amp;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Interest&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Loan&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Service Fee&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Interest&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Due Date&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Rate&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Balance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Accrued&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Paid&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 30%; text-align: left"&gt;Shareholder 1&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--DebtInstrumentMaturityDateDescription_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--ShareHolderMember_zg9pF0o9AWS1" title="Due date"&gt;June, 2019&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20221231__us-gaap--DebtInstrumentAxis__custom--ShareHolderMember_zMFYZMyHe3v5" title="Debt instrument percentage"&gt;15.00&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--LoansPayable_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--ShareHolderMember_zwWXBFlgBprk" style="width: 10%; text-align: right" title="Loan payable"&gt;20,051&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--InterestAndServiceFeeAccrued_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--ShareHolderMember_zlY1frgGimk4" style="width: 10%; text-align: right" title="Interest and service fee accrued"&gt;8,161&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--InterestPaid_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--ShareHolderMember_zgKxFVTIYmt4" style="width: 10%; text-align: right" title="Interest payable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1028"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Shareholder 1&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--DebtInstrumentMaturityDateDescription_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_z7K6IKNGNO3f" title="Due date"&gt;June, 2019&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20221231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_zBlYt2yMTJ48" title="Debt instrument percentage"&gt;15.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--LoansPayable_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_zl1hWiioUS49" style="text-align: right" title="Loan payable"&gt;38,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--InterestAndServiceFeeAccrued_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_zArwiydQevl6" style="text-align: right" title="Interest and service fee accrued"&gt;23,481&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--InterestPaid_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_zYe1fTJeAwyg" style="text-align: right" title="Interest payable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1038"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other Convertibles&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--DebtInstrumentMaturityDateDescription_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zSBIQTQfuLCg" title="Due date"&gt;Various&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20221231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zpfbQRoNeyk3" title="Debt instrument percentage"&gt;5.00&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--LoansPayable_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zTlga8JpcJl9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest payable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1044"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--InterestAndServiceFeeAccrued_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_z90rDfXZ7UGe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest and service fee accrued"&gt;66,648&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--InterestPaid_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zBsDBBqJJqX9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest payable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1048"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--LoansPayable_iI_c20221231_zHcLjkkKEjAb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Loan payable"&gt;58,051&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_ecustom--InterestAndServiceFeeAccrued_iI_c20221231_zHVxGTsufhVd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest payable"&gt;98,290&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--InterestPaid_c20220101__20221231_zOs1DvDDPMqe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest payable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1054"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AD_zNIjMHVU5Wwa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Mr.
Bradley Mitch Watkins, Director, provided certain sales, marketing and commercialization consulting services to the Company prior to his
appointment to the Board of Directors. For the years ended December 31, 2023 and 2022, the Company paid Mr. Watkins $&lt;span id="xdx_90C_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20230101__20231231__srt--TitleOfIndividualAxis__custom--MrWatkinsMember_z7AGuBQFAHO1" title="Related party transaction amounts"&gt;11,083&lt;/span&gt; and
$&lt;span id="xdx_905_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20220101__20221231__srt--TitleOfIndividualAxis__custom--MrWatkinsMember_z65mqWDJ9A3d" title="Related party transaction amounts"&gt;3,523&lt;/span&gt;, respectively. No amounts were owed to Mr. Watkins as of December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s former Chief Financial Officer is contracted for services through a third-party public accounting firm. He is the firm&#x2019;s
managing partner and majority shareholder. The firm is engaged by the Company to provide accounting and tax services on a continuous
basis. Fees paid for services were $&lt;span id="xdx_906_eus-gaap--PaymentsForFees_c20230101__20231231__srt--TitleOfIndividualAxis__custom--MrSealeMember_zhjJ53Wz5hxg" title="Payments for fees"&gt;312,803&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--PaymentsForFees_c20220101__20221231__srt--TitleOfIndividualAxis__custom--MrSealeMember_z2AvaPk195M6" title="Payments for fees"&gt;116,542&lt;/span&gt; for the years ended December 31, 2023 and 2022, respectively. The Company owed
RBSK for open invoices of $&lt;span id="xdx_900_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_c20231231__srt--TitleOfIndividualAxis__custom--MrSealeMember_z9X7hyR4a0o" title="Accounts payable"&gt;84,279&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--AccountsPayableCurrentAndNoncurrent_iI_c20221231__srt--TitleOfIndividualAxis__custom--MrSealeMember_znMsRxC62bik" title="Accounts payable"&gt;68,142&lt;/span&gt; that are included in accounts payable as of December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Notes to Financial Statements&lt;/b&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:NotesAndLoansReceivableGrossCurrent
      contextRef="AsOf2023-12-31_custom_ShareholdersOneAndTwoMember"
      decimals="0"
      id="Fact000916"
      unitRef="USD">506400</us-gaap:NotesAndLoansReceivableGrossCurrent>
    <NRXS:AllowanceForInterestReceivableCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact000918"
      unitRef="USD">1154541</NRXS:AllowanceForInterestReceivableCurrent>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000920">&lt;p id="xdx_896_eus-gaap--ScheduleOfRelatedPartyTransactionsTableTextBlock_zqWIyjUVS18e" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span id="xdx_8B5_z8l6ORobyzp1" style="display: none"&gt;Schedule of Related Party Transactions&lt;/span&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Loan&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Interest&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Interest&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Receivable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Receivable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Income&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;Shareholder 1&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderOneMember_zNjeGS834uJ1" style="width: 14%; text-align: right" title="Loan Receivable"&gt;506,400&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--InterestReceivableCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderOneMember_zAr7UCbfco9d" style="width: 14%; text-align: right" title="Interest Receivable"&gt;70,938&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--InterestIncomeGrossCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderOneMember_zjUqYewZQEKe" style="width: 14%; text-align: right" title="Interest Income"&gt;23,867&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Shareholder 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderTwoMember_zUaBQuPkUcs4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Loan Receivable"&gt;506,400&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--InterestReceivableCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderTwoMember_zbnY9eWJLBr5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest Receivable"&gt;70,803&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--InterestIncomeGrossCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderTwoMember_zW2gG27f91Bk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest Income"&gt;23,867&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zYEz6pYsAt8" style="text-align: right" title="Loan Receivable"&gt;1,012,800&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--InterestReceivableCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zV6zGTWgKfwd" style="text-align: right" title="Interest Receivable"&gt;141,741&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--InterestIncomeGrossCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zuqvBNoFFs89" style="text-align: right" title="Interest Income"&gt;47,734&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Allowance for Collection Risk&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AllowanceForNotesAndLoansReceivableCurrent_iNI_di_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zVsT3J8XqlA7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Allowance for collection risk, loan receivable"&gt;(1,012,800&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--InterestReceivableCurrent_iNI_di_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z9RIPUINte28" style="border-bottom: Black 1.5pt solid; text-align: right" title="Allowance for collection risk, interest receivable"&gt;(141,741&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--AllowanceForInterestIncomeCurrent_iNI_di_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z5Uz45E9BYme" style="border-bottom: Black 1.5pt solid; text-align: right" title="Allowance for collection risk, interest income"&gt;(47,734&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Net Balance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--NotesAndLoansReceivableNetCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zwvDYzL2T28i" style="border-bottom: Black 1.5pt solid; text-align: right" title="Loan Receivable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0946"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--InterestReceivable_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zGC81YvfHKMf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest Receivable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0948"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--InterestIncomeCurrent_iI_c20231231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zbLdMijari3b" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest Income"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0950"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Loan&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Interest&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Interest&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Receivable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Receivable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Income&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;Shareholder 1&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderOneMember_zsr2M5KfUG5h" style="width: 14%; text-align: right" title="Loan Receivable"&gt;506,400&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--InterestReceivableCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderOneMember_z6I6OQcmRgol" style="width: 14%; text-align: right" title="Interest Receivable"&gt;47,071&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--InterestIncomeGrossCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderOneMember_zGimIoPsSCJ7" style="width: 14%; text-align: right" title="Interest Income"&gt;11,523&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Shareholder 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderTwoMember_zxtDmMfOnRn5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Loan Receivable"&gt;506,400&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--InterestReceivableCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderTwoMember_za9yIQZuCwQb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest Receivable"&gt;46,936&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--InterestIncomeGrossCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareHolderTwoMember_zrl9RjcqPpS3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest Income"&gt;11,523&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--NotesAndLoansReceivableGrossCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z1NAQRx3RRtl" style="text-align: right" title="Loan Receivable"&gt;1,012,800&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--InterestReceivableCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_znAiqJpIor4" style="text-align: right" title="Interest Receivable"&gt;94,007&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_ecustom--InterestIncomeGrossCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z2U5TqiSdRQe" style="text-align: right" title="Interest Income"&gt;23,046&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Allowance for Collection Risk&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AllowanceForNotesAndLoansReceivableCurrent_iNI_di_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zSgT36uVkLzc" style="border-bottom: Black 1.5pt solid; text-align: right" title="Allowance for collection risk, loan receivable"&gt;(1,012,800&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--InterestReceivableCurrent_iNI_di_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zjME8N49EpH6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Allowance for collection risk, interest receivable"&gt;(94,007&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--AllowanceForInterestIncomeCurrent_iNI_di_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_ztt179JuzVad" style="border-bottom: Black 1.5pt solid; text-align: right" title="Allowance for collection risk, interest income"&gt;(23,046&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Net Balance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--NotesAndLoansReceivableNetCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zEGLcV60i0Oi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Loan Receivable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0976"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--InterestReceivable_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zACWZJZhkB3c" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest Receivable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0978"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--InterestIncomeCurrent_iI_c20221231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zASJ0ABNa47e" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest Income"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0980"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:NotesAndLoansReceivableGrossCurrent
      contextRef="AsOf2023-12-31_custom_ShareHolderOneMember"
      decimals="0"
      id="Fact000922"
      unitRef="USD">506400</us-gaap:NotesAndLoansReceivableGrossCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="AsOf2023-12-31_custom_ShareHolderOneMember"
      decimals="0"
      id="Fact000924"
      unitRef="USD">70938</us-gaap:InterestReceivableCurrent>
    <NRXS:InterestIncomeGrossCurrent
      contextRef="AsOf2023-12-31_custom_ShareHolderOneMember"
      decimals="0"
      id="Fact000926"
      unitRef="USD">23867</NRXS:InterestIncomeGrossCurrent>
    <us-gaap:NotesAndLoansReceivableGrossCurrent
      contextRef="AsOf2023-12-31_custom_ShareHolderTwoMember"
      decimals="0"
      id="Fact000928"
      unitRef="USD">506400</us-gaap:NotesAndLoansReceivableGrossCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="AsOf2023-12-31_custom_ShareHolderTwoMember"
      decimals="0"
      id="Fact000930"
      unitRef="USD">70803</us-gaap:InterestReceivableCurrent>
    <NRXS:InterestIncomeGrossCurrent
      contextRef="AsOf2023-12-31_custom_ShareHolderTwoMember"
      decimals="0"
      id="Fact000932"
      unitRef="USD">23867</NRXS:InterestIncomeGrossCurrent>
    <us-gaap:NotesAndLoansReceivableGrossCurrent
      contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000934"
      unitRef="USD">1012800</us-gaap:NotesAndLoansReceivableGrossCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000936"
      unitRef="USD">141741</us-gaap:InterestReceivableCurrent>
    <NRXS:InterestIncomeGrossCurrent
      contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000938"
      unitRef="USD">47734</NRXS:InterestIncomeGrossCurrent>
    <us-gaap:AllowanceForNotesAndLoansReceivableCurrent
      contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000940"
      unitRef="USD">1012800</us-gaap:AllowanceForNotesAndLoansReceivableCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000942"
      unitRef="USD">141741</us-gaap:InterestReceivableCurrent>
    <NRXS:AllowanceForInterestIncomeCurrent
      contextRef="AsOf2023-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000944"
      unitRef="USD">47734</NRXS:AllowanceForInterestIncomeCurrent>
    <us-gaap:NotesAndLoansReceivableGrossCurrent
      contextRef="AsOf2022-12-31_custom_ShareHolderOneMember"
      decimals="0"
      id="Fact000952"
      unitRef="USD">506400</us-gaap:NotesAndLoansReceivableGrossCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="AsOf2022-12-31_custom_ShareHolderOneMember"
      decimals="0"
      id="Fact000954"
      unitRef="USD">47071</us-gaap:InterestReceivableCurrent>
    <NRXS:InterestIncomeGrossCurrent
      contextRef="AsOf2022-12-31_custom_ShareHolderOneMember"
      decimals="0"
      id="Fact000956"
      unitRef="USD">11523</NRXS:InterestIncomeGrossCurrent>
    <us-gaap:NotesAndLoansReceivableGrossCurrent
      contextRef="AsOf2022-12-31_custom_ShareHolderTwoMember"
      decimals="0"
      id="Fact000958"
      unitRef="USD">506400</us-gaap:NotesAndLoansReceivableGrossCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="AsOf2022-12-31_custom_ShareHolderTwoMember"
      decimals="0"
      id="Fact000960"
      unitRef="USD">46936</us-gaap:InterestReceivableCurrent>
    <NRXS:InterestIncomeGrossCurrent
      contextRef="AsOf2022-12-31_custom_ShareHolderTwoMember"
      decimals="0"
      id="Fact000962"
      unitRef="USD">11523</NRXS:InterestIncomeGrossCurrent>
    <us-gaap:NotesAndLoansReceivableGrossCurrent
      contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000964"
      unitRef="USD">1012800</us-gaap:NotesAndLoansReceivableGrossCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000966"
      unitRef="USD">94007</us-gaap:InterestReceivableCurrent>
    <NRXS:InterestIncomeGrossCurrent
      contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000968"
      unitRef="USD">23046</NRXS:InterestIncomeGrossCurrent>
    <us-gaap:AllowanceForNotesAndLoansReceivableCurrent
      contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000970"
      unitRef="USD">1012800</us-gaap:AllowanceForNotesAndLoansReceivableCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000972"
      unitRef="USD">94007</us-gaap:InterestReceivableCurrent>
    <NRXS:AllowanceForInterestIncomeCurrent
      contextRef="AsOf2022-12-31_us-gaap_RelatedPartyMember"
      decimals="0"
      id="Fact000974"
      unitRef="USD">23046</NRXS:AllowanceForInterestIncomeCurrent>
    <NRXS:ScheduleOfRelatedPartyLoansTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact000982">&lt;p id="xdx_894_ecustom--ScheduleOfRelatedPartyLoansTableTextBlock_zWYBz5E1QISc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span id="xdx_8B8_z9ZoAHflmhHk" style="display: none"&gt;Schedule of Related Party Loans payable to shareholder&lt;/span&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Interest &amp;amp;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Interest&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Loan&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Service Fee&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Interest&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Due Date&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Rate&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Balance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Accrued&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Paid&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 30%; text-align: left"&gt;Shareholder 1&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--DebtInstrumentMaturityDateDescription_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderMember_zLmrcLwwzZT9" title="Due date"&gt;June, 2019&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderMember_zdKQbLO41w0a" title="Debt instrument percentage"&gt;15.00&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--LoansPayable_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderMember_ztyIiCuOam1d" style="width: 10%; text-align: right" title="Loan payable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0988"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_ecustom--InterestAndServiceFeeAccrued_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderMember_zkwUyLgjw5ic" style="width: 10%; text-align: right" title="Interest payable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0990"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--InterestPaid_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderMember_zUEbQib1hql4" style="width: 10%; text-align: right" title="Interest payable"&gt;10,047&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Shareholder 1&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_904_eus-gaap--DebtInstrumentMaturityDateDescription_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_z6UYuTOdv2T7" title="Due date"&gt;June, 2019&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_zDuwTD5kyGze" title="Debt instrument percentage"&gt;15.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--LoansPayable_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_zPaik7XCGSSf" style="text-align: right" title="Loan payable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0998"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--InterestAndServiceFeeAccrued_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_zwzShwpllCt5" style="text-align: right" title="Interest payable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1000"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--InterestPaid_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_ztf8UkLpAEc1" style="text-align: right" title="Interest payable"&gt;27,056&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other Convertibles&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_90E_eus-gaap--DebtInstrumentMaturityDateDescription_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zPnt1LgV7VAh" title="Due date"&gt;Various&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20231231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zLPY1MG1DDU3" title="Debt instrument percentage"&gt;5.00&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--LoansPayable_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zchp3VXWcIvd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest payable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1008"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--InterestAndServiceFeeAccrued_iI_c20231231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zOxnLZn5lmwh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest payable"&gt;66,648&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--InterestPaid_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zlYzcLAKuAU7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest payable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1012"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--LoansPayable_iI_c20231231_zYL0tJxjI3ih" style="border-bottom: Black 1.5pt solid; text-align: right" title="Loan payable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1014"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--InterestAndServiceFeeAccrued_iI_c20231231_zEsgLv7iBl9j" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest payable"&gt;66,648&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--InterestPaid_c20230101__20231231_z3n7s4J8fFB" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest payable"&gt;37,103&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Interest &amp;amp;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Interest&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Loan&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Service Fee&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Interest&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Due Date&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Rate&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Balance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Accrued&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Paid&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 30%; text-align: left"&gt;Shareholder 1&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_905_eus-gaap--DebtInstrumentMaturityDateDescription_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--ShareHolderMember_zg9pF0o9AWS1" title="Due date"&gt;June, 2019&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20221231__us-gaap--DebtInstrumentAxis__custom--ShareHolderMember_zMFYZMyHe3v5" title="Debt instrument percentage"&gt;15.00&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--LoansPayable_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--ShareHolderMember_zwWXBFlgBprk" style="width: 10%; text-align: right" title="Loan payable"&gt;20,051&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--InterestAndServiceFeeAccrued_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--ShareHolderMember_zlY1frgGimk4" style="width: 10%; text-align: right" title="Interest and service fee accrued"&gt;8,161&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--InterestPaid_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--ShareHolderMember_zgKxFVTIYmt4" style="width: 10%; text-align: right" title="Interest payable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1028"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Shareholder 1&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_906_eus-gaap--DebtInstrumentMaturityDateDescription_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_z7K6IKNGNO3f" title="Due date"&gt;June, 2019&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20221231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_zBlYt2yMTJ48" title="Debt instrument percentage"&gt;15.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--LoansPayable_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_zl1hWiioUS49" style="text-align: right" title="Loan payable"&gt;38,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--InterestAndServiceFeeAccrued_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_zArwiydQevl6" style="text-align: right" title="Interest and service fee accrued"&gt;23,481&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--InterestPaid_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--ShareHolderOneMember_zYe1fTJeAwyg" style="text-align: right" title="Interest payable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1038"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other Convertibles&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_907_eus-gaap--DebtInstrumentMaturityDateDescription_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zSBIQTQfuLCg" title="Due date"&gt;Various&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20221231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zpfbQRoNeyk3" title="Debt instrument percentage"&gt;5.00&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--LoansPayable_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zTlga8JpcJl9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest payable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1044"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--InterestAndServiceFeeAccrued_iI_c20221231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_z90rDfXZ7UGe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest and service fee accrued"&gt;66,648&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--InterestPaid_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--OtherConvertiblesMember_zBsDBBqJJqX9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest payable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1048"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--LoansPayable_iI_c20221231_zHcLjkkKEjAb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Loan payable"&gt;58,051&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_ecustom--InterestAndServiceFeeAccrued_iI_c20221231_zHVxGTsufhVd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest payable"&gt;98,290&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--InterestPaid_c20220101__20221231_zOs1DvDDPMqe" style="border-bottom: Black 1.5pt solid; text-align: right" title="Interest payable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1054"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</NRXS:ScheduleOfRelatedPartyLoansTableTextBlock>
    <us-gaap:DebtInstrumentMaturityDateDescription
      contextRef="From2023-01-012023-12-31_custom_ShareHolderMember"
      id="Fact000984">June, 2019</us-gaap:DebtInstrumentMaturityDateDescription>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2023-12-31_custom_ShareHolderMember"
      decimals="INF"
      id="Fact000986"
      unitRef="Pure">0.1500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:InterestPaid
      contextRef="From2023-01-012023-12-31_custom_ShareHolderMember"
      decimals="0"
      id="Fact000992"
      unitRef="USD">10047</us-gaap:InterestPaid>
    <us-gaap:DebtInstrumentMaturityDateDescription
      contextRef="From2023-01-012023-12-31_custom_ShareHolderOneMember"
      id="Fact000994">June, 2019</us-gaap:DebtInstrumentMaturityDateDescription>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2023-12-31_custom_ShareHolderOneMember64718796"
      decimals="INF"
      id="Fact000996"
      unitRef="Pure">0.1500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:InterestPaid
      contextRef="From2023-01-012023-12-31_custom_ShareHolderOneMember"
      decimals="0"
      id="Fact001002"
      unitRef="USD">27056</us-gaap:InterestPaid>
    <us-gaap:DebtInstrumentMaturityDateDescription
      contextRef="From2023-01-012023-12-31_custom_OtherConvertiblesMember"
      id="Fact001004">Various</us-gaap:DebtInstrumentMaturityDateDescription>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2023-12-31_custom_OtherConvertiblesMember"
      decimals="INF"
      id="Fact001006"
      unitRef="Pure">0.0500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <NRXS:InterestAndServiceFeeAccrued
      contextRef="AsOf2023-12-31_custom_OtherConvertiblesMember"
      decimals="0"
      id="Fact001010"
      unitRef="USD">66648</NRXS:InterestAndServiceFeeAccrued>
    <NRXS:InterestAndServiceFeeAccrued
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001016"
      unitRef="USD">66648</NRXS:InterestAndServiceFeeAccrued>
    <us-gaap:InterestPaid
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact001018"
      unitRef="USD">37103</us-gaap:InterestPaid>
    <us-gaap:DebtInstrumentMaturityDateDescription
      contextRef="From2022-01-012022-12-31_custom_ShareHolderMember"
      id="Fact001020">June, 2019</us-gaap:DebtInstrumentMaturityDateDescription>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2022-12-31_custom_ShareHolderMember"
      decimals="INF"
      id="Fact001022"
      unitRef="Pure">0.1500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LoansPayable
      contextRef="AsOf2022-12-31_custom_ShareHolderMember"
      decimals="0"
      id="Fact001024"
      unitRef="USD">20051</us-gaap:LoansPayable>
    <NRXS:InterestAndServiceFeeAccrued
      contextRef="AsOf2022-12-31_custom_ShareHolderMember"
      decimals="0"
      id="Fact001026"
      unitRef="USD">8161</NRXS:InterestAndServiceFeeAccrued>
    <us-gaap:DebtInstrumentMaturityDateDescription
      contextRef="From2022-01-012022-12-31_custom_ShareHolderOneMember"
      id="Fact001030">June, 2019</us-gaap:DebtInstrumentMaturityDateDescription>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2022-12-31_custom_ShareHolderOneMember64718843"
      decimals="INF"
      id="Fact001032"
      unitRef="Pure">0.1500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LoansPayable
      contextRef="AsOf2022-12-31_custom_ShareHolderOneMember64718843"
      decimals="0"
      id="Fact001034"
      unitRef="USD">38000</us-gaap:LoansPayable>
    <NRXS:InterestAndServiceFeeAccrued
      contextRef="AsOf2022-12-31_custom_ShareHolderOneMember64718843"
      decimals="0"
      id="Fact001036"
      unitRef="USD">23481</NRXS:InterestAndServiceFeeAccrued>
    <us-gaap:DebtInstrumentMaturityDateDescription
      contextRef="From2022-01-012022-12-31_custom_OtherConvertiblesMember"
      id="Fact001040">Various</us-gaap:DebtInstrumentMaturityDateDescription>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2022-12-31_custom_OtherConvertiblesMember"
      decimals="INF"
      id="Fact001042"
      unitRef="Pure">0.0500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <NRXS:InterestAndServiceFeeAccrued
      contextRef="AsOf2022-12-31_custom_OtherConvertiblesMember"
      decimals="0"
      id="Fact001046"
      unitRef="USD">66648</NRXS:InterestAndServiceFeeAccrued>
    <us-gaap:LoansPayable
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001050"
      unitRef="USD">58051</us-gaap:LoansPayable>
    <NRXS:InterestAndServiceFeeAccrued
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001052"
      unitRef="USD">98290</NRXS:InterestAndServiceFeeAccrued>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2023-01-012023-12-31_custom_MrWatkinsMember"
      decimals="0"
      id="Fact001056"
      unitRef="USD">11083</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="From2022-01-012022-12-31_custom_MrWatkinsMember"
      decimals="0"
      id="Fact001058"
      unitRef="USD">3523</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:PaymentsForFees
      contextRef="From2023-01-012023-12-31_custom_MrSealeMember"
      decimals="0"
      id="Fact001060"
      unitRef="USD">312803</us-gaap:PaymentsForFees>
    <us-gaap:PaymentsForFees
      contextRef="From2022-01-012022-12-31_custom_MrSealeMember"
      decimals="0"
      id="Fact001062"
      unitRef="USD">116542</us-gaap:PaymentsForFees>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="AsOf2023-12-31_custom_MrSealeMember"
      decimals="0"
      id="Fact001064"
      unitRef="USD">84279</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="AsOf2022-12-31_custom_MrSealeMember"
      decimals="0"
      id="Fact001066"
      unitRef="USD">68142</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001068">&lt;p id="xdx_80F_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zF17IdNShTAb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;4.
&lt;span id="xdx_826_z1ddV1dKNutk"&gt;Property and Equipment&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--PropertyPlantAndEquipmentTextBlock_zguBbBQHPIWi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment, net consists of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B0_zePKoEMzzgeh" style="display: none"&gt;Schedule of Property And Equipment&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20231231_zoUeCkXV1L2k" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20221231_zAgqC9cPGbKf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zbxSKBFBSOh2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Machinery and equipment &lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;282,181&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;282,181&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zdkx0YCHKhQ9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Furniture and fixtures &lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;96,768&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;87,148&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zUhyHyzfSund" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Computer hardware &lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;36,613&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,452&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zmHgNTK87a9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;21,064&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;21,064&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzDOd_zddlUWZrSspl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Total property and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;436,626&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;405,845&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzDOd_zUnCInTIaywh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Less: accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(348,074&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(317,834&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzDOd_z5wE7aUzCJF4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"&gt;Property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;88,552&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;88,011&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AC_z1Bmw1qI1eie" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Depreciation
expense was $&lt;span id="xdx_907_eus-gaap--Depreciation_c20230101__20231231_zGLbNuXWEs23" title="Depreciation expense"&gt;30,240&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--Depreciation_c20220101__20221231_zderGWo0iL79" title="Depreciation expense"&gt;30,920&lt;/span&gt; for the years ended December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001070">&lt;p id="xdx_898_eus-gaap--PropertyPlantAndEquipmentTextBlock_zguBbBQHPIWi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property
and equipment, net consists of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B0_zePKoEMzzgeh" style="display: none"&gt;Schedule of Property And Equipment&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20231231_zoUeCkXV1L2k" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20221231_zAgqC9cPGbKf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zbxSKBFBSOh2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Machinery and equipment &lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;282,181&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;282,181&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zdkx0YCHKhQ9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Furniture and fixtures &lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;96,768&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;87,148&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zUhyHyzfSund" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Computer hardware &lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;36,613&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,452&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PropertyPlantAndEquipmentGross_iI_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zmHgNTK87a9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;21,064&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;21,064&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPAENzDOd_zddlUWZrSspl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Total property and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;436,626&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;405,845&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPAENzDOd_zUnCInTIaywh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Less: accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(348,074&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(317,834&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPAENzDOd_z5wE7aUzCJF4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"&gt;Property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;88,552&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;88,011&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_us-gaap_MachineryAndEquipmentMember"
      decimals="0"
      id="Fact001072"
      unitRef="USD">282181</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_us-gaap_MachineryAndEquipmentMember"
      decimals="0"
      id="Fact001073"
      unitRef="USD">282181</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_us-gaap_FurnitureAndFixturesMember"
      decimals="0"
      id="Fact001075"
      unitRef="USD">96768</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_us-gaap_FurnitureAndFixturesMember"
      decimals="0"
      id="Fact001076"
      unitRef="USD">87148</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_us-gaap_ComputerEquipmentMember"
      decimals="0"
      id="Fact001078"
      unitRef="USD">36613</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_us-gaap_ComputerEquipmentMember"
      decimals="0"
      id="Fact001079"
      unitRef="USD">15452</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      id="Fact001081"
      unitRef="USD">21064</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      id="Fact001082"
      unitRef="USD">21064</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001084"
      unitRef="USD">436626</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001085"
      unitRef="USD">405845</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001087"
      unitRef="USD">348074</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001088"
      unitRef="USD">317834</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001090"
      unitRef="USD">88552</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001091"
      unitRef="USD">88011</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact001093"
      unitRef="USD">30240</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001095"
      unitRef="USD">30920</us-gaap:Depreciation>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001097">&lt;p id="xdx_800_eus-gaap--IntangibleAssetsDisclosureTextBlock_zfZcXInclVuj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;5.
&lt;span id="xdx_82D_zRJnBmqYISka"&gt;Intangible Assets&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zD03jdz2fjR1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible
assets, net consists of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B6_z35rKqZHVCC4" style="display: none"&gt;Schedule of Intangible Assets&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20231231_zE5N7uh8RSrg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20221231_zrjV3ucEDmJk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwareImplementationMember_zo4cyPJFQBYf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Software Implementation &lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;49,815&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;49,815&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z0H2p6hAGYl3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Patents &lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;32,463&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;32,463&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zM2CejhHnq33" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Trademark &lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;50,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zUyhI90nG0O5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Licenses &lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1111"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_maFLIANzh0b_zz55gQdRG0qh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Total intangible assets &lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;133,278&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;92,278&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_msFLIANzh0b_zJkYwCTbzNv8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Less: accumulated amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(25,205&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(14,720&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_mtFLIANzh0b_z8Ukw9YsX001" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"&gt;Intangible assets, net &lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;108,073&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;77,558&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A1_zOzwTMmkQakd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amortization
expense was $&lt;span id="xdx_907_eus-gaap--AmortizationOfIntangibleAssets_c20230101__20231231_z2ZnjCpobEul" title="Amortization expense"&gt;10,485&lt;/span&gt; and $&lt;span id="xdx_90C_eus-gaap--AmortizationOfIntangibleAssets_c20220101__20221231_zC5v6fBBI2oa" title="Amortization expense"&gt;6,213&lt;/span&gt; for the years ended December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001099">&lt;p id="xdx_89A_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zD03jdz2fjR1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Intangible
assets, net consists of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;span id="xdx_8B6_z35rKqZHVCC4" style="display: none"&gt;Schedule of Intangible Assets&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20231231_zE5N7uh8RSrg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20221231_zrjV3ucEDmJk" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--SoftwareImplementationMember_zo4cyPJFQBYf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Software Implementation &lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;49,815&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;49,815&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z0H2p6hAGYl3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Patents &lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;32,463&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;32,463&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--TrademarksMember_zM2CejhHnq33" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Trademark &lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;50,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_hus-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--LicensesMember_zUyhI90nG0O5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Licenses &lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1111"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_maFLIANzh0b_zz55gQdRG0qh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Total intangible assets &lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;133,278&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;92,278&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_msFLIANzh0b_zJkYwCTbzNv8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Less: accumulated amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(25,205&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(14,720&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_mtFLIANzh0b_z8Ukw9YsX001" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"&gt;Intangible assets, net &lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;108,073&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;77,558&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2023-12-31_custom_SoftwareImplementationMember"
      decimals="0"
      id="Fact001101"
      unitRef="USD">49815</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2022-12-31_custom_SoftwareImplementationMember"
      decimals="0"
      id="Fact001102"
      unitRef="USD">49815</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2023-12-31_us-gaap_PatentsMember"
      decimals="0"
      id="Fact001104"
      unitRef="USD">32463</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2022-12-31_us-gaap_PatentsMember"
      decimals="0"
      id="Fact001105"
      unitRef="USD">32463</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2023-12-31_us-gaap_TrademarksMember"
      decimals="0"
      id="Fact001107"
      unitRef="USD">50000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2022-12-31_us-gaap_TrademarksMember"
      decimals="0"
      id="Fact001108"
      unitRef="USD">10000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2023-12-31_custom_LicensesMember"
      decimals="0"
      id="Fact001110"
      unitRef="USD">1000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001113"
      unitRef="USD">133278</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001114"
      unitRef="USD">92278</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001116"
      unitRef="USD">25205</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001117"
      unitRef="USD">14720</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001119"
      unitRef="USD">108073</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001120"
      unitRef="USD">77558</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact001122"
      unitRef="USD">10485</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001124"
      unitRef="USD">6213</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001126">&lt;p id="xdx_804_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_z4OCsv82yKCb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;6.
&lt;span id="xdx_82B_zcvbo45c4x5c"&gt;Accrued Expenses&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zbJ7IyG2Sda6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued
expenses consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;span id="xdx_8B1_zPhMWXUSqlO6" style="display: none"&gt;Schedule of Accrued Expenses&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20231231_zDSqQEtsenai" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20221231_z7de2MycamP3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--AccruedCompensationAndBenefitsCurrent_iI_maALCz2hn_z2TNu5bnhvf4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Compensation and benefits&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;333,477&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;539,558&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--UnderwriterFees_iI_maALCz2hn_z45JncJLH3w6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Underwriter fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1133"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;88,259&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--InterestPayableCurrent_iI_maALCz2hn_zza25uYKYpgi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;66,648&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;173,826&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--RelatedPartyInterestPayableCurrent_iI_maALCz2hn_zWTl8aaECLO5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Related party interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1139"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;31,642&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AccrualForTaxesOtherThanIncomeTaxesCurrent_iI_maALCz2hn_zONABGuKRwcc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;963&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;777&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;


  &lt;tr id="xdx_40A_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCz2hn_zdp6dpeqfAH2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Total accrued expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;401,088&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;834,062&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AE_zZZaB8IwTJZa" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001128">&lt;p id="xdx_897_eus-gaap--ScheduleOfAccruedLiabilitiesTableTextBlock_zbJ7IyG2Sda6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accrued
expenses consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;span id="xdx_8B1_zPhMWXUSqlO6" style="display: none"&gt;Schedule of Accrued Expenses&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20231231_zDSqQEtsenai" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20221231_z7de2MycamP3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--AccruedCompensationAndBenefitsCurrent_iI_maALCz2hn_z2TNu5bnhvf4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Compensation and benefits&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;333,477&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;539,558&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_ecustom--UnderwriterFees_iI_maALCz2hn_z45JncJLH3w6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Underwriter fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1133"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;88,259&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--InterestPayableCurrent_iI_maALCz2hn_zza25uYKYpgi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;66,648&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;173,826&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--RelatedPartyInterestPayableCurrent_iI_maALCz2hn_zWTl8aaECLO5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Related party interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1139"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;31,642&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AccrualForTaxesOtherThanIncomeTaxesCurrent_iI_maALCz2hn_zONABGuKRwcc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;963&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;777&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;


  &lt;tr id="xdx_40A_eus-gaap--AccruedLiabilitiesCurrent_iTI_mtALCz2hn_zdp6dpeqfAH2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Total accrued expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;401,088&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;834,062&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <NRXS:AccruedCompensationAndBenefitsCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001130"
      unitRef="USD">333477</NRXS:AccruedCompensationAndBenefitsCurrent>
    <NRXS:AccruedCompensationAndBenefitsCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001131"
      unitRef="USD">539558</NRXS:AccruedCompensationAndBenefitsCurrent>
    <NRXS:UnderwriterFees
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001134"
      unitRef="USD">88259</NRXS:UnderwriterFees>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001136"
      unitRef="USD">66648</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001137"
      unitRef="USD">173826</us-gaap:InterestPayableCurrent>
    <NRXS:RelatedPartyInterestPayableCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001140"
      unitRef="USD">31642</NRXS:RelatedPartyInterestPayableCurrent>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001142"
      unitRef="USD">963</us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001143"
      unitRef="USD">777</us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001145"
      unitRef="USD">401088</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001146"
      unitRef="USD">834062</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001148">&lt;p id="xdx_80F_eus-gaap--DebtDisclosureTextBlock_zNWKjMjJOzwg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;7.
&lt;span id="xdx_82B_zF2DyNRZfIja"&gt;Notes Payable&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
February 15, 2023, The Company signed a note with Exchange Listing, LLC in the amount of $&lt;span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_iI_c20230215__dei--LegalEntityAxis__custom--ExchangeListingLLCMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zEytrpZtMVa" title="Promissory note"&gt;52,600&lt;/span&gt;.
The note carried an interest rate of &lt;span id="xdx_90C_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20230215__dei--LegalEntityAxis__custom--ExchangeListingLLCMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zvkHO1vzwtr9" title="Interest rate"&gt;1&lt;/span&gt;%.
The note shall be paid on the earlier of (i) three months or (ii) the Company receiving financing in the minimum of $&lt;span id="xdx_905_eus-gaap--NotesPayable_iI_c20230215__dei--LegalEntityAxis__custom--ExchangeListingLLCMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zd42GigdxUUi" title="Promissory note"&gt;3,000,000&lt;/span&gt;.
 In August 2023, the Company used proceeds from the initial public offering to pay the note back in full, including interest, in
the amount of $&lt;span id="xdx_900_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pp2d_c20230831__20230831__dei--LegalEntityAxis__custom--ExchangeListingLLCMember__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zFfyeyXTLDLg" title="Proceeds from issuance of ipo"&gt;52,858&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Notes to Financial Statements&lt;/b&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company borrowed $&lt;span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_iI_c20211216__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zSDEKwnTbNak" title="Debt instrument face amount"&gt;250,000 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;on
December 16, 2021, from Channel Partners Capital. The note called for 65 weekly payments of $&lt;span id="xdx_904_eus-gaap--DebtInstrumentPeriodicPayment_pp2d_c20230316__20230316__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zw97kZ5dDyMk" title="Debt instrument, periodic payment"&gt;4,923 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;with
the final payment scheduled for March 16, 2023. The note&#x2019;s interest rate computes to a nominal rate of &lt;span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20230316__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_znXMfdp5KGKg" title="Interest rate"&gt;40.9&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%.
The principal outstanding at January 1, 2022 was $&lt;span id="xdx_90A_eus-gaap--LongTermDebtAverageAmountOutstanding_c20220101__20220101__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zP1EkF7CMHpj" title="Principal outstanding"&gt;244,048&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.
The Company borrowed $&lt;span id="xdx_90D_eus-gaap--DebtInstrumentFaceAmount_iI_c20220916__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zTs1aL8IQfsl" title="Borrowed amount"&gt;122,000 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;on
September 16, 2022, to bring the principal balance back to $&lt;span id="xdx_902_eus-gaap--DebtInstrumentRepurchasedFaceAmount_iI_c20220916__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zVZhMbJMnIXc" title="Principal balance back"&gt;250,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.
After making scheduled payments, the Company borrowed $&lt;span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_iI_c20230524__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_z55zJIDmX5Gc"&gt;107,231 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;on
May 24, 2023, to bring the principal balance back to $&lt;span id="xdx_903_eus-gaap--DebtInstrumentRepurchasedFaceAmount_iI_c20230524__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_z1YWV2ASyxHh" title="Principal balance back"&gt;250,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.
The terms of the note are the same as the previous note with the final payment scheduled for August 22, 2024. The principal
outstanding at December 31, 2023 and 2022 was $&lt;span id="xdx_900_eus-gaap--NotesPayable_iI_c20231231__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zMmZIZlewifl" title="Principal outstanding"&gt;148,062&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;
and $&lt;span id="xdx_902_eus-gaap--NotesPayable_iI_c20221231__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zw427gx3GhC" title="Principal outstanding"&gt;202,834&lt;/span&gt;,
respectively. The Company believes that the advancement of additional funds is a minor modification to the terms of the existing
loan since the difference in present value of the cash flows under the terms of the new loan is less than 10% of the present value
of the remaining cash flows under the terms of the original loan. As a result, the modification was accounted for as a modification
of debt.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
lender was granted and assigned a continuing security interest in all the Company&#x2019;s personal property assets including, but not
limited to, business equipment, inventory, accounts, accounts receivable, intellectual property, chattel paper, instruments, deposit
accounts, commercial tort claims, contract rights, licenses, claims, and general intangibles.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
future minimum principal payments to be paid in 2024 is $&lt;span id="xdx_906_eus-gaap--DebtInstrumentAnnualPrincipalPayment_iI_c20241231__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zCvJIGSbdhMh" title="Minimum principal payment"&gt;148,062&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Convertible
Notes&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ConvertibleDebtTableTextBlock_zwnV5CftQj64" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents a summary of the Company&#x2019;s convertible notes:&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BE_zaDohGEoCEnk"&gt;Schedule
of Convertible Notes&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20231231_zojZPyu68nuh" style="border-bottom: Black 1.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20221231_zKQQj3MCvMdf" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DebtInstrumentFaceAmount_iI_zUfbL3EZ46u4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Principal&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1181"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,555,556&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredFinanceCostsCurrentNet_iNI_di_zeR6aqvMYHkl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Less:
    Original issue discount&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1184"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(355,556&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di_zQwpEjFULmVd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Less: Debt discount&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1187"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2,841,658&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredFinanceCostsNet_iNI_di_zkKCDx6O8T62" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Less: Deferred financing fees&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1190"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(130,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LongTermDebt_iI_zTA5lO8vLnec" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;Notes
    payable&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1193"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;228,342&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8A5_zlqYDRny3Kq2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;From March to July of 2023, the Company conducted
multiple closings of a private placement offering to accredited investors for aggregate gross principal amounts of $&lt;span id="xdx_906_eus-gaap--DebtInstrumentCarryingAmount_iI_c20230731__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember_z8U0BwR54WTb" title="Debt instrument gross"&gt;6,066,667&lt;/span&gt; and net
proceeds of $&lt;span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfDebt_c20230301__20230731__srt--TitleOfIndividualAxis__custom--AccreditedInvestorsMember__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_z1fWFFjxUKWc" title="Net proceeds of debt"&gt;4,908,000&lt;/span&gt;. The offering consisted of a convertible promissory note that accrues interest at &lt;span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20230731__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zY0bAAGExbQ1" title="Debt instrument interest rate"&gt;12&lt;/span&gt;% that can be paid in cash
or PIK and an original issue discount of &lt;span id="xdx_90D_ecustom--DebtInstrumentDiscountRate_iI_pid_dp_uPure_c20230731__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zRsXE9HjmJD5" title="Debt instrument discount rate"&gt;10&lt;/span&gt;%. The convertible promissory notes automatically convert into common shares at a &lt;span id="xdx_900_ecustom--DebtInstrumentDiscountRate_iI_dp_uPure_c20230731__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zUkLsczMB1Ka" title="Discount rate"&gt;30&lt;/span&gt;% discount
to the IPO. The notes mature on the sooner of the six-month anniversary date from issuance or a successful IPO on primary exchange in
the U.S. and include &lt;span id="xdx_904_ecustom--DebtWarrantConversionDescription_c20230301__20230731__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zCZswwovk4Vf" title="Debt warrant conversion, description"&gt;a five-year warrant to purchase common stock equal to fifty percent (50%) of the shares into which the convertible
notes can be converted into at issuance.&lt;/span&gt; The warrants have a strike price at a &lt;span id="xdx_90A_eus-gaap--DebtInstrumentConvertibleConversionRatio1_dp_uPure_c20230301__20230731__us-gaap--DebtInstrumentAxis__custom--ConvertiblePromissoryNoteMember_zp5RqvNclAmc" title="Strilke price"&gt;25&lt;/span&gt;% premium to the conversion price subject to anti-dilution,
issuable on a pro rata basis at each funding.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As facilitators to the 2023 convertible notes,
Signature Bank received a $&lt;span id="xdx_901_eus-gaap--EscrowDeposit_iI_c20220413__dei--LegalEntityAxis__custom--SignatureBankMember_zuTSDDKzlco4" title="Escrow deposit"&gt;6,000&lt;/span&gt;
escrow fee and Alexander Capital, L.P. received (i) a cash commission of nine percent (9%) of the proceeds raised in the offering
from investors introduced to the Company and (ii) warrants for the purchase of a number of shares of Common Stock equal to 6% of the
number of underlying securities. Alexander Capital, L.P., received (i) fees totaling $&lt;span id="xdx_90B_eus-gaap--ProceedsFromFeesReceived_c20230101__20231231__dei--LegalEntityAxis__custom--AlexanderCapitalLPMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zS9shkQlxxC1" title="Deferred financing fees"&gt;546,000&lt;/span&gt;
in 2023 which were recorded in deferred financing fees as a reduction to notes payable on the balance sheet and (ii) &lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20231231__dei--LegalEntityAxis__custom--AlexanderCapitalLPMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zfeNJzCsk77g" title="Number of warrants received"&gt;120,235&lt;/span&gt;
warrants which were recorded at fair value in the warrant liability and debt discounts on the balance sheet.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;After the closing of the initial public offering
on August 8, 2023, the Company converted the notes payable plus $&lt;span id="xdx_902_eus-gaap--NotesPayable_iI_c20230808__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zgLLIztHSYK1"&gt;226,391
&lt;/span&gt;in interest into &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230808__20230808__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zfMiiMMOIFGg"&gt;1,498,332
&lt;/span&gt;shares of common stock. The shares were to be issued at a discounted price of $&lt;span id="xdx_90A_eus-gaap--SharesIssuedPricePerShare_iI_c20230808__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zG2CJJA0Vky7"&gt;4.20
&lt;/span&gt;per share resulting in a $&lt;span id="xdx_903_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20230808__20230808__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zc8twd5kEnsj"&gt;4,115,223
&lt;/span&gt;loss to the Company which is recorded in extinguishment of debt liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In March of 2023, the Company used borrowings from
the 2023 convertible notes to pay the principal balance of some of the 2022 notes totaling $&lt;span id="xdx_904_eus-gaap--NotesPayable_iI_c20230331__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zg2u9GbOjWzb"&gt;2,650,000&lt;/span&gt;
which resulted in a $&lt;span id="xdx_905_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20230301__20230331__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zA0Trmkpmai4" title="Gain on extinguishment of debt liabilities"&gt;1,129,653&lt;/span&gt; gain to the Company which is recorded in extinguishment of debt liabilities. Upon payment, the
terms for the remaining balance of those notes were also updated. The remaining balance accrued interest at &lt;span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20230331__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zPJ3DIUwf5we"&gt;8&lt;/span&gt;%
per annum without maturity or default rights. The new balance shall also automatically convert into shares of common stock at a &lt;span id="xdx_90E_ecustom--DebtInstrumentDiscountRate_iI_dp_uPure_c20230331__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zOAJcyb69USb"&gt;27.5&lt;/span&gt;%
discount to the per share offering price in the Company&#x2019;s initial public offering or $&lt;span id="xdx_90B_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20230331__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zXfhwPQ9wnEc"&gt;4.35
&lt;/span&gt;per share. After the closing of the initial public offering on August 8, 2023, the Company converted the notes payable plus $&lt;span id="xdx_907_eus-gaap--NotesPayable_iI_c20230808__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_z101SOBxFrC4"&gt;173,205
&lt;/span&gt;in interest into &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20230808__20230808__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zUcBo3fQDa9d"&gt;107,509
&lt;/span&gt;shares of common stock. The shares are to be issued at a discounted price of $&lt;span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_c20230808__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zzxajDKfLMNl"&gt;4.35
&lt;/span&gt;per share resulting in a $&lt;span id="xdx_904_eus-gaap--GainsLossesOnExtinguishmentOfDebt_c20230808__20230808__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zvnEs2bvb6eh" title="Extinguishment of debt"&gt;663,991&lt;/span&gt; loss to the Company which is recorded in extinguishment of debt liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The remaining investors of the 2022 notes did
not convert their notes and, as such, the Company used proceeds from the initial public offering to pay the remaining promissory
notes back in full, including interest in the amount of $&lt;span id="xdx_907_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20230814__20230814__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zizLG4TxWnDe" title="Proceeds from issuance of ipo"&gt;445,554&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Notes to Financial Statements&lt;/b&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The convertible notes signed between June 3, 2022
and November 30, 2022 had aggregate gross principal amounts totaling $&lt;span id="xdx_902_eus-gaap--DebtInstrumentCarryingAmount_iI_c20221130__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_znWiHUAbEPIe" title="Debt instrument gross"&gt;3,333,333&lt;/span&gt; and net proceeds of $&lt;span id="xdx_909_eus-gaap--ProceedsFromIssuanceOfDebt_c20220601__20221130__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_z0DQXaOtuNXd" title="Net proceeds of debt"&gt;2,870,000&lt;/span&gt; and consisted of an &lt;span id="xdx_904_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20220603__20221130__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zn1OPr3XrPQb" title="Debt instrument description"&gt;original
issue discount of 10% with an interest rate of the greater of (i) Prime rate plus 8.5% or (ii) 12%.&lt;/span&gt; The notes convert into common shares
at the lower of (i) $&lt;span id="xdx_90F_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20221130__srt--RangeAxis__srt--MinimumMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zrmEVcETlc54"&gt;9.44&lt;/span&gt; or (ii) a &lt;span id="xdx_90F_ecustom--DebtInstrumentDiscountRate_iI_dp_uPure_c20221130__srt--RangeAxis__srt--MaximumMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zw1JXskujnUc"&gt;30&lt;/span&gt;% discount to the price per share of any subsequent offering. The notes matured on the one-year
anniversary date from issuance and contain &lt;span id="xdx_907_ecustom--DebtWarrantConversionDescription_c20220603__20221130__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zi4XKE81u4Wc" title="Debt warrant conversion, description"&gt;a five-year warrant to purchase common stock equal to one hundred percent (100%) of the shares
into which the 2022 Convertible Notes can be converted into at issuance.&lt;/span&gt; The warrants have an exercise price at the lower of (i) $&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20221130__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zF4TgXjAhR5h" title="Exercise price"&gt;11.80&lt;/span&gt;
per share or (ii) a &lt;span id="xdx_905_ecustom--ClassOfWarrantDiscountRate_iI_dp_uPure_c20221130__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_z6ocuv9JmTI7" title="Class of warrant discount rate"&gt;12.5&lt;/span&gt;% discount to the price per share of any subsequent offering, (c) shares of the Company&#x2019;s common stock
equal to &lt;span id="xdx_902_ecustom--DebtInstrumentPrincipalAmount_iI_dp_uPure_c20221130__srt--RangeAxis__srt--MaximumMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zuKGgPz3QRie" title="Principal amount in percent"&gt;10&lt;/span&gt;% of the principal amount of these notes, at a value per share equal to the conversion price. The &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220603__20221130__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zd1udFHNT9bj" title="Issuance of shares"&gt;35,318&lt;/span&gt; shares of common
stock issued to investors had a relative fair value of $&lt;span id="xdx_90F_eus-gaap--FairValueAdjustmentOfWarrants_c20220603__20221130__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_z2udrEx7iBLa" title="Fair value adjustment of warrants"&gt;4,789&lt;/span&gt;. Due to the second prong of the conversion equation after the IPO an additional
&lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20220603__20221130__dei--LegalEntityAxis__custom--ChannelPartnersCapitalMember_zoZbk3MP2oBg" title="Issuance of shares"&gt;44,048&lt;/span&gt; commitment shares are to be issued. The shares are to be issued at a discounted price of $&lt;span id="xdx_90C_eus-gaap--SharesIssuedPricePerShare_iI_c20221130__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zTP1G4CMOynj" title="Shares issued price per share"&gt;4.20&lt;/span&gt; per share resulting in a loss to
the Company which is recorded in extinguishment of debt liabilities.&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The convertible notes signed on December 19, 2022
had aggregate gross principal amounts totaling $&lt;span id="xdx_903_eus-gaap--DebtInstrumentCarryingAmount_iI_c20221219__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_z6bldzpYQIP7" title="Debt instrument gross"&gt;222,222&lt;/span&gt; and net proceeds of $&lt;span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfDebt_c20221219__20221219__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zS5aGAcKlIuh" title="Net proceeds of debt"&gt;200,000&lt;/span&gt; and consisted of an original issue discount of &lt;span id="xdx_902_ecustom--DebtInstrumentDiscountRate_iI_dp_uPure_c20221219__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zNKTch3JiVO3" title="Debt instrument discount rate"&gt;10&lt;/span&gt;%
of the principal amount with an interest rate of &lt;span id="xdx_901_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20221219__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zpulGE3O1BE" title="Accrued interest"&gt;12&lt;/span&gt;% per annum. The notes matured at the earlier of (i) twelve (12) months from the issue
date or (ii) the date upon which the Company completes a registered public offering of shares of the Company, which encompasses the closing
of the IPO. The notes are convertible into shares of common stock at the higher of (i) $&lt;span id="xdx_901_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20221219__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zP140MdMlMBd" title="Conversion price"&gt;9.44&lt;/span&gt; per share or (ii) the price per share of
common stock issued pursuant to the next registered public offering of shares of the Company made prior to the conversion of any portion
of the note. Interest accrues on the aggregate principal amount (which includes original issue discount) and is payable on the maturity
date, at the Company&#x2019;s election, in cash or in-kind. The holders of the notes are entitled to piggyback registration rights on any
registration statement filed by the Company, other than any registration statement filed on Form S-4 or Form S-8. The warrants and conversion
shares are subject to anti-dilution provisions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
investors of the notes signed on December 19, 2022 above did not convert their notes and, as such the Company used proceeds from the
initial public offering to pay the remaining promissory notes back in full, including interest in the amount of $&lt;span id="xdx_906_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_c20221219__20221219__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zU2sV3uccL83" title="Proceeds from issuance of ipo"&gt;239,104&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company paid $&lt;span id="xdx_908_eus-gaap--PaymentsOfDebtIssuanceCosts_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zQpHgT4rWVfa" title="Offering costs"&gt;130,000&lt;/span&gt;
in fees to law firms related to the 2022 convertible note offerings and were recorded as deferred financing fees as a reduction to
notes payable on the balance sheet.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has applied ASC 815 due to
the potential for settlement in a variable quantity of shares. Since these convertible notes and warrants have the option to convert or
be exercised at a variable amount, they are subject to derivative liability treatment. The conversion feature has been measured at fair
value using a Monte Carlo model at the date of issuance and is adjusted to fair value at each reporting period. The fair value of the
embedded derivative and the warrant liability at date of issuance was $&lt;span id="xdx_906_eus-gaap--EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_iI_c20231231_zn5dsw6KR9ci" title="Fair value of embedded derivative"&gt;2,375,378&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--WarrantsNotSettleableInCashFairValueDisclosure_iI_c20231231_znXcdJCHCI5l" title="Embedded derivative warrant liability"&gt;2,446,502&lt;/span&gt;, respectively. See Notes 12 and 13.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The 2023 and 2022 convertible notes transferred
fair value to investors in the form of principal, warrants and common shares totaling $&lt;span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_c20221231__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember_zCxrJK0O9hd1" title="Principal of warrants and common shares fair value"&gt;11,947,212&lt;/span&gt;.
As the Company received cash proceeds of $&lt;span id="xdx_904_eus-gaap--ProceedsFromNotesPayable_c20230101__20231231__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember_zWingHw0dEpj" title="Cash proceeds fair value of incentivies"&gt;8,660,000&lt;/span&gt;,
net of an original issue discount of $&lt;span id="xdx_903_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iI_c20231231_zARY6Z3amQEi" title="Original issue discount"&gt;962,223&lt;/span&gt;, the remaining fair value of incentives in excess of principal of $&lt;span id="xdx_90B_eus-gaap--DebtInstrumentUnamortizedDiscountCurrent_iI_c20231231__srt--TitleOfIndividualAxis__custom--InvestorsMember__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember_z2CZj7yPXii4" title="Debt discount"&gt;2,234,988&lt;/span&gt;
was expensed as finance charges totaling $&lt;span id="xdx_90D_eus-gaap--PaymentsOfFinancingCosts_c20230101__20231231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember_zNtliDvlieBb" title="Financing fees"&gt;2,772&lt;/span&gt;
and $&lt;span id="xdx_90B_ecustom--PaymentsOfFinancingCost_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember_zHUrapMMV084" title="Financing fees"&gt;&lt;span id="xdx_902_ecustom--PaymentsOfFinancingCost_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember_zU0nI075VT47" title="Financing fees"&gt;2,322,216&lt;/span&gt;&lt;/span&gt;
for the years ended December 31, 2023 and 2022, respectively. On August 8, 2023, the Company amortized the remaining original issue
discount, debt discount reflective of the fair value of embedded warrants and financing fees as the 2023 and 2022 convertible notes
were either paid in full or converted to common stock pursuant to the initial public offering.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the years ended December 31, 2023 and 2022,
the Company accrued interest on these convertible notes totaling $&lt;span id="xdx_906_eus-gaap--InterestPayableCurrent_iI_c20231231__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_ziueDiJJwFkc" title="Accrued interest"&gt;399,597&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--InterestPayableCurrent_iI_c20221231__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleNotesPayableMember_z9WriA2Jvz68" title="Accrued interest"&gt;107,544&lt;/span&gt;, respectively, which was paid or converted into
common stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Notes to Financial Statements&lt;/b&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-02-15_custom_ExchangeListingLLCMember_custom_PromissoryNoteMember"
      decimals="0"
      id="Fact001150"
      unitRef="USD">52600</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2023-02-15_custom_ExchangeListingLLCMember_custom_PromissoryNoteMember"
      decimals="INF"
      id="Fact001152"
      unitRef="Pure">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:NotesPayable
      contextRef="AsOf2023-02-15_custom_ExchangeListingLLCMember_custom_PromissoryNoteMember"
      decimals="0"
      id="Fact001154"
      unitRef="USD">3000000</us-gaap:NotesPayable>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2023-08-312023-08-31_custom_ExchangeListingLLCMember_custom_PromissoryNoteMember"
      decimals="2"
      id="Fact001156"
      unitRef="USD">52858</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2021-12-16_custom_ChannelPartnersCapitalMember"
      decimals="0"
      id="Fact001158"
      unitRef="USD">250000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="From2023-03-162023-03-16_custom_ChannelPartnersCapitalMember"
      decimals="2"
      id="Fact001160"
      unitRef="USD">4923</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2023-03-16_custom_ChannelPartnersCapitalMember"
      decimals="INF"
      id="Fact001162"
      unitRef="Pure">0.409</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtAverageAmountOutstanding
      contextRef="From2022-01-012022-01-01_custom_ChannelPartnersCapitalMember"
      decimals="0"
      id="Fact001164"
      unitRef="USD">244048</us-gaap:LongTermDebtAverageAmountOutstanding>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2022-09-16_custom_ChannelPartnersCapitalMember"
      decimals="0"
      id="Fact001166"
      unitRef="USD">122000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="AsOf2022-09-16_custom_ChannelPartnersCapitalMember"
      decimals="0"
      id="Fact001168"
      unitRef="USD">250000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-05-24_custom_ChannelPartnersCapitalMember"
      decimals="0"
      id="Fact001169"
      unitRef="USD">107231</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="AsOf2023-05-24_custom_ChannelPartnersCapitalMember"
      decimals="0"
      id="Fact001171"
      unitRef="USD">250000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:NotesPayable
      contextRef="AsOf2023-12-31_custom_ChannelPartnersCapitalMember"
      decimals="0"
      id="Fact001173"
      unitRef="USD">148062</us-gaap:NotesPayable>
    <us-gaap:NotesPayable
      contextRef="AsOf2022-12-31_custom_ChannelPartnersCapitalMember"
      decimals="0"
      id="Fact001175"
      unitRef="USD">202834</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentAnnualPrincipalPayment
      contextRef="AsOf2024-12-31_srt_ScenarioForecastMember"
      decimals="0"
      id="Fact001177"
      unitRef="USD">148062</us-gaap:DebtInstrumentAnnualPrincipalPayment>
    <us-gaap:ConvertibleDebtTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001179">&lt;p id="xdx_89C_eus-gaap--ConvertibleDebtTableTextBlock_zwnV5CftQj64" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents a summary of the Company&#x2019;s convertible notes:&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8BE_zaDohGEoCEnk"&gt;Schedule
of Convertible Notes&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20231231_zojZPyu68nuh" style="border-bottom: Black 1.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_493_20221231_zKQQj3MCvMdf" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;December
    31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DebtInstrumentFaceAmount_iI_zUfbL3EZ46u4" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 64%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Principal&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1181"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3,555,556&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredFinanceCostsCurrentNet_iNI_di_zeR6aqvMYHkl" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Less:
    Original issue discount&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1184"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(355,556&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DebtInstrumentUnamortizedDiscount_iNI_di_zQwpEjFULmVd" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Less: Debt discount&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1187"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(2,841,658&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredFinanceCostsNet_iNI_di_zkKCDx6O8T62" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Less: Deferred financing fees&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1190"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(130,000&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LongTermDebt_iI_zTA5lO8vLnec" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;Notes
    payable&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1193"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;228,342&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConvertibleDebtTableTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001182"
      unitRef="USD">3555556</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DeferredFinanceCostsCurrentNet
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001185"
      unitRef="USD">355556</us-gaap:DeferredFinanceCostsCurrentNet>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001188"
      unitRef="USD">2841658</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001191"
      unitRef="USD">130000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001194"
      unitRef="USD">228342</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2023-07-31_custom_ConvertiblePromissoryNoteMember_custom_AccreditedInvestorsMember"
      decimals="0"
      id="Fact001196"
      unitRef="USD">6066667</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2023-03-012023-07-31_custom_AccreditedInvestorsMember_custom_ConvertiblePromissoryNoteMember"
      decimals="0"
      id="Fact001198"
      unitRef="USD">4908000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2023-07-31_custom_ConvertiblePromissoryNoteMember"
      decimals="INF"
      id="Fact001200"
      unitRef="Pure">0.12</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <NRXS:DebtInstrumentDiscountRate
      contextRef="AsOf2023-07-31_custom_ConvertiblePromissoryNoteMember"
      decimals="INF"
      id="Fact001202"
      unitRef="Pure">0.10</NRXS:DebtInstrumentDiscountRate>
    <NRXS:DebtInstrumentDiscountRate
      contextRef="AsOf2023-07-31_custom_ConvertiblePromissoryNoteMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001204"
      unitRef="Pure">0.30</NRXS:DebtInstrumentDiscountRate>
    <NRXS:DebtWarrantConversionDescription
      contextRef="From2023-03-012023-07-31_custom_ConvertiblePromissoryNoteMember"
      id="Fact001206">a five-year warrant to purchase common stock equal to fifty percent (50%) of the shares into which the convertible
notes can be converted into at issuance.</NRXS:DebtWarrantConversionDescription>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="From2023-03-012023-07-31_custom_ConvertiblePromissoryNoteMember"
      decimals="INF"
      id="Fact001208"
      unitRef="Pure">0.25</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:EscrowDeposit
      contextRef="AsOf2022-04-13_custom_SignatureBankMember"
      decimals="0"
      id="Fact001210"
      unitRef="USD">6000</us-gaap:EscrowDeposit>
    <us-gaap:ProceedsFromFeesReceived
      contextRef="From2023-01-012023-12-31_custom_AlexanderCapitalLPMember_us-gaap_WarrantMember"
      decimals="0"
      id="Fact001212"
      unitRef="USD">546000</us-gaap:ProceedsFromFeesReceived>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2023-12-31_custom_AlexanderCapitalLPMember_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001214"
      unitRef="Shares">120235</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:NotesPayable
      contextRef="AsOf2023-08-08_custom_ChannelPartnersCapitalMember"
      decimals="0"
      id="Fact001215"
      unitRef="USD">226391</us-gaap:NotesPayable>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-08-082023-08-08_custom_ChannelPartnersCapitalMember"
      decimals="INF"
      id="Fact001216"
      unitRef="Shares">1498332</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-08-08_custom_ChannelPartnersCapitalMember"
      decimals="INF"
      id="Fact001217"
      unitRef="USDPShares">4.20</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2023-08-082023-08-08_custom_ChannelPartnersCapitalMember"
      decimals="0"
      id="Fact001218"
      unitRef="USD">4115223</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:NotesPayable
      contextRef="AsOf2023-03-31_custom_TwoThousandTwentyThreeConvertibleNotesMember"
      decimals="0"
      id="Fact001219"
      unitRef="USD">2650000</us-gaap:NotesPayable>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2023-03-012023-03-31_custom_TwoThousandTwentyThreeConvertibleNotesMember"
      decimals="0"
      id="Fact001221"
      unitRef="USD">1129653</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2023-03-31_custom_TwoThousandTwentyThreeConvertibleNotesMember"
      decimals="INF"
      id="Fact001222"
      unitRef="Pure">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <NRXS:DebtInstrumentDiscountRate
      contextRef="AsOf2023-03-31_custom_TwoThousandTwentyThreeConvertibleNotesMember"
      decimals="INF"
      id="Fact001223"
      unitRef="Pure">0.275</NRXS:DebtInstrumentDiscountRate>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2023-03-31_custom_TwoThousandTwentyThreeConvertibleNotesMember"
      decimals="INF"
      id="Fact001224"
      unitRef="USDPShares">4.35</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:NotesPayable
      contextRef="AsOf2023-08-08_custom_TwoThousandTwentyThreeConvertibleNotesMember"
      decimals="0"
      id="Fact001225"
      unitRef="USD">173205</us-gaap:NotesPayable>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2023-08-082023-08-08_custom_TwoThousandTwentyThreeConvertibleNotesMember"
      decimals="INF"
      id="Fact001226"
      unitRef="Shares">107509</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-08-08_custom_TwoThousandTwentyThreeConvertibleNotesMember"
      decimals="INF"
      id="Fact001227"
      unitRef="USDPShares">4.35</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2023-08-082023-08-08_custom_TwoThousandTwentyThreeConvertibleNotesMember"
      decimals="0"
      id="Fact001229"
      unitRef="USD">663991</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2023-08-142023-08-14_custom_TwoThousandTwentyThreeConvertibleNotesMember"
      decimals="0"
      id="Fact001231"
      unitRef="USD">445554</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2022-11-30_custom_TwoThousandTwentyTwoConvertibleNotesMember"
      decimals="0"
      id="Fact001233"
      unitRef="USD">3333333</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2022-06-012022-11-30_custom_TwoThousandTwentyTwoConvertibleNotesMember"
      decimals="0"
      id="Fact001235"
      unitRef="USD">2870000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis
      contextRef="From2022-06-032022-11-30_custom_TwoThousandTwentyTwoConvertibleNotesMember"
      id="Fact001237">original
issue discount of 10% with an interest rate of the greater of (i) Prime rate plus 8.5% or (ii) 12%.</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2022-11-30_srt_MinimumMember_custom_TwoThousandTwentyTwoConvertibleNotesMember"
      decimals="INF"
      id="Fact001238"
      unitRef="USDPShares">9.44</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <NRXS:DebtInstrumentDiscountRate
      contextRef="AsOf2022-11-30_srt_MaximumMember_custom_TwoThousandTwentyTwoConvertibleNotesMember"
      decimals="INF"
      id="Fact001239"
      unitRef="Pure">0.30</NRXS:DebtInstrumentDiscountRate>
    <NRXS:DebtWarrantConversionDescription
      contextRef="From2022-06-032022-11-30_custom_TwoThousandTwentyTwoConvertibleNotesMember"
      id="Fact001241">a five-year warrant to purchase common stock equal to one hundred percent (100%) of the shares
into which the 2022 Convertible Notes can be converted into at issuance.</NRXS:DebtWarrantConversionDescription>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-11-30_custom_TwoThousandTwentyTwoConvertibleNotesMember"
      decimals="INF"
      id="Fact001243"
      unitRef="USDPShares">11.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <NRXS:ClassOfWarrantDiscountRate
      contextRef="AsOf2022-11-30_custom_TwoThousandTwentyTwoConvertibleNotesMember"
      decimals="INF"
      id="Fact001245"
      unitRef="Pure">0.125</NRXS:ClassOfWarrantDiscountRate>
    <NRXS:DebtInstrumentPrincipalAmount
      contextRef="AsOf2022-11-30_srt_MaximumMember_custom_TwoThousandTwentyTwoConvertibleNotesMember"
      decimals="INF"
      id="Fact001247"
      unitRef="Pure">0.10</NRXS:DebtInstrumentPrincipalAmount>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-06-032022-11-30_us-gaap_CommonStockMember_custom_TwoThousandTwentyTwoConvertibleNotesMember"
      decimals="INF"
      id="Fact001249"
      unitRef="Shares">35318</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-06-032022-11-30_us-gaap_CommonStockMember_custom_TwoThousandTwentyTwoConvertibleNotesMember"
      decimals="0"
      id="Fact001251"
      unitRef="USD">4789</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2022-06-032022-11-30_custom_ChannelPartnersCapitalMember"
      decimals="INF"
      id="Fact001253"
      unitRef="Shares">44048</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2022-11-30_custom_TwoThousandTwentyTwoConvertibleNotesMember"
      decimals="INF"
      id="Fact001255"
      unitRef="USDPShares">4.20</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2022-12-19_custom_TwoThousandTwentyTwoConvertibleNotesMember"
      decimals="0"
      id="Fact001257"
      unitRef="USD">222222</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2022-12-192022-12-19_custom_TwoThousandTwentyTwoConvertibleNotesMember"
      decimals="0"
      id="Fact001259"
      unitRef="USD">200000</us-gaap:ProceedsFromIssuanceOfDebt>
    <NRXS:DebtInstrumentDiscountRate
      contextRef="AsOf2022-12-19_custom_TwoThousandTwentyTwoConvertibleNotesMember"
      decimals="INF"
      id="Fact001261"
      unitRef="Pure">0.10</NRXS:DebtInstrumentDiscountRate>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2022-12-19_custom_TwoThousandTwentyTwoConvertibleNotesMember"
      decimals="INF"
      id="Fact001263"
      unitRef="Pure">0.12</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2022-12-19_custom_TwoThousandTwentyTwoConvertibleNotesMember"
      decimals="INF"
      id="Fact001265"
      unitRef="USDPShares">9.44</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2022-12-192022-12-19_custom_TwoThousandTwentyTwoConvertibleNotesMember"
      decimals="0"
      id="Fact001267"
      unitRef="USD">239104</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="From2022-01-012022-12-31_custom_TwoThousandTwentyTwoConvertibleNotesMember"
      decimals="0"
      id="Fact001269"
      unitRef="USD">130000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001271"
      unitRef="USD">2375378</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
    <us-gaap:WarrantsNotSettleableInCashFairValueDisclosure
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001273"
      unitRef="USD">2446502</us-gaap:WarrantsNotSettleableInCashFairValueDisclosure>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2022-12-31_custom_InvestorsMember_custom_TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember"
      decimals="0"
      id="Fact001275"
      unitRef="USD">11947212</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2023-01-012023-12-31_custom_InvestorsMember_custom_TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember"
      decimals="0"
      id="Fact001277"
      unitRef="USD">8660000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001279"
      unitRef="USD">962223</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountCurrent
      contextRef="AsOf2023-12-31_custom_InvestorsMember_custom_TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember"
      decimals="0"
      id="Fact001281"
      unitRef="USD">2234988</us-gaap:DebtInstrumentUnamortizedDiscountCurrent>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="From2023-01-012023-12-31_custom_TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember"
      decimals="0"
      id="Fact001283"
      unitRef="USD">2772</us-gaap:PaymentsOfFinancingCosts>
    <NRXS:PaymentsOfFinancingCost
      contextRef="From2022-01-012022-12-31_custom_TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember"
      decimals="0"
      id="Fact001285"
      unitRef="USD">2322216</NRXS:PaymentsOfFinancingCost>
    <NRXS:PaymentsOfFinancingCost
      contextRef="From2022-01-012022-12-31_custom_TwoThousandTwentyThreeAndTwentyTwoConvertibleNotesMember"
      decimals="0"
      id="Fact001287"
      unitRef="USD">2322216</NRXS:PaymentsOfFinancingCost>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2023-12-31_us-gaap_ConvertibleNotesPayableMember"
      decimals="0"
      id="Fact001289"
      unitRef="USD">399597</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="AsOf2022-12-31_us-gaap_ConvertibleNotesPayableMember"
      decimals="0"
      id="Fact001291"
      unitRef="USD">107544</us-gaap:InterestPayableCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001293">&lt;p id="xdx_80E_eus-gaap--LesseeOperatingLeasesTextBlock_zX8seumS0IE" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;8.
&lt;span id="xdx_825_zwX2aOaesGig"&gt;Leases&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company&#x2019;s leases are comprised of operating leases for office space. At the inception of the lease, the Company determines whether
the lease contract conveys the right to control the use of identified property for a period of time in exchange for consideration. Leases
are classified as operating or finance leases at the commencement date of the lease. Operating leases are recorded as operating lease
right-of-use assets, other current liabilities, and operating lease liabilities in the Balance Sheets. The Company did not have any finance
leases at December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company had three leases primarily consisting of office space in Versailles, Indiana and Carmel, Indiana. &lt;span id="xdx_900_eus-gaap--LesseeOperatingLeaseDescription_c20230101__20231231_zHpDfrxcFjo" title="Operating lease description"&gt;Two of the leases in Versailles
started January 1, 2017. Both have an initial term of five years with an option for an additional five-year term. The monthly lease payments
for these leases are $&lt;span id="xdx_90F_eus-gaap--OperatingLeasePayments_c20170101__20170101__us-gaap--GeographicDistributionAxis__custom--VersaillesIndianaMember__us-gaap--LeaseContractualTermAxis__custom--LeaseOneMember_z9GjoNdR8Aje" title="Operating lease payment"&gt;550&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--OperatingLeasePayments_c20170101__20170101__us-gaap--GeographicDistributionAxis__custom--VersaillesIndianaMember__us-gaap--LeaseContractualTermAxis__custom--LeaseTwoMember_zbXbKuGA9Lp8" title="Operating lease payment"&gt;1,600&lt;/span&gt; with a &lt;span id="xdx_909_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_dp_uPure_c20170101__us-gaap--GeographicDistributionAxis__custom--VersaillesIndianaMember_zb58exyLfY26" title="Discount rate"&gt;3&lt;/span&gt;% per annum increase starting with the optional five-year term. The lease in Carmel started
March 1, 2016. The initial term is five years and three months with an option for an additional three-year term. The monthly lease payment
started at $&lt;span id="xdx_907_eus-gaap--OperatingLeasePayments_c20160301__20160301__us-gaap--GeographicDistributionAxis__custom--CarmelIndianaMember__us-gaap--LeaseContractualTermAxis__custom--LeaseThreeMember_zuOLk605kPfe" title="Operating lease payment"&gt;1,472&lt;/span&gt; with an annual increase of approximately &lt;span id="xdx_90B_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_uPure_c20160301__us-gaap--GeographicDistributionAxis__custom--CarmelIndianaMember_zMMV28YBoiLb" title="Operating lease payment rate"&gt;2.7&lt;/span&gt;%. On December 16, 2020, the Company entered into an amendment of the Carmel
lease that extended the initial term by two years.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating
lease right-of-use assets and liabilities are recognized at the commencement date based on the present value of lease payments over the
lease term. As the implicit interest rate is generally not readily determinable, the Company uses an incremental borrowing rate based
on the information available at the commencement date in determining the present value of lease payments. The incremental borrowing rate
reflects the estimated rate of interest that the Company would pay to borrow on a collateralized basis over a similar economic environment.
Lease expense for the operating lease is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leases
may include renewal options, and the renewal option is included in the lease term if the Company concludes that it is reasonably certain
that the option will be exercised. Certain leases may contain rent escalation clauses, either fixed or adjusted periodically for inflation
of market rates, that are factored into the calculation of lease payments to the extent they are fixed and determinable at lease inception.
The Company also has variable lease payments that do not depend on a rate or index, primarily for items such as common area maintenance
and real estate taxes, which are recorded as expenses when incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;For
the years ended December 31, 2023 and 2022, the Company recognized $&lt;span id="xdx_906_eus-gaap--OperatingLeaseExpense_c20230101__20231231_zE4mSeS3loE6" title="Operating lease expense"&gt;49,051&lt;/span&gt; and $&lt;span id="xdx_90B_eus-gaap--OperatingLeaseExpense_c20220101__20221231_zIvy1SKO2cMl" title="Operating lease expense"&gt;47,571&lt;/span&gt; of operating lease expense, including short-term
lease expense and variable lease costs, which are immaterial.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--OperatingLeasesOfLesseeDisclosureTextBlock_zL1DVsEOIMZj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents information related to the Company&#x2019;s operating leases:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B9_zbkU8aI0hBH7" style="display: none"&gt;Schedule of Operating Leases&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20231231_zbQj9ZkbBWz2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20221231_zYHSdHBiFm09" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OperatingLeaseRightOfUseAsset_iI_zEZZBTAfoqd7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left; padding-bottom: 1.5pt"&gt;Operating lease right-of-use assets&lt;/td&gt;&lt;td style="width: 2%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 16%; font-weight: bold; text-align: right"&gt;70,263&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right"&gt;101,382&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--OtherLiabilitiesCurrent_iI_zm9zZg5Nwu86" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other current liabilities&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;49,127&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33,395&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zy2McdHD9408" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Operating lease liabilities&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;27,071&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;76,199&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OperatingLeaseLiability_iI_zJsruRK1nMR" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;76,198&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;109,594&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Weighted-average remaining lease term (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20231231_zFFRP2qAZvg7" title="Weighted average remaining lease term (in years)"&gt;3.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_zomxZrgZidyk" title="Weighted average remaining lease term (in years)"&gt;4.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Weighted-average discount rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_uPure_c20231231_zBeFiyvgElC7" title="Weighted average discount rate"&gt;15.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_uPure_c20221231_zAkKHF1tgYWl" title="Weighted average discount rate"&gt;15.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A8_zhTFKMFizYai" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zxxn8qAlvrSc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2023, the maturities of the Company&#x2019;s operating lease liabilities were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;span id="xdx_8B5_zeZ9qs2gWW39" style="display: none"&gt;Schedule of Maturities Operating Lease Liabilities&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 65%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49C_20231231_zoyDNcpF1jfk" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzyNu_zJrYMlclNNZ" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;27,072&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzyNu_zFmSJqgVaoyh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22,316&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzyNu_zov6zadw8H07" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;26,810&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzyNu_zWn2N5fJhg9d" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;76,198&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_z1Yfm0NWn5V3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1343"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OperatingLeaseLiability_iI_zirh2xyENqp9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total present value of lease payments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;76,198&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8A8_zWz7UB68bOyd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseDescription contextRef="From2023-01-01to2023-12-31" id="Fact001295">Two of the leases in Versailles
started January 1, 2017. Both have an initial term of five years with an option for an additional five-year term. The monthly lease payments
for these leases are $550 and $1,600 with a 3% per annum increase starting with the optional five-year term. The lease in Carmel started
March 1, 2016. The initial term is five years and three months with an option for an additional three-year term. The monthly lease payment
started at $1,472 with an annual increase of approximately 2.7%. On December 16, 2020, the Company entered into an amendment of the Carmel
lease that extended the initial term by two years.</us-gaap:LesseeOperatingLeaseDescription>
    <us-gaap:OperatingLeasePayments
      contextRef="From2017-01-012017-01-01_custom_VersaillesIndianaMember_custom_LeaseOneMember"
      decimals="0"
      id="Fact001297"
      unitRef="USD">550</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="From2017-01-012017-01-01_custom_VersaillesIndianaMember_custom_LeaseTwoMember"
      decimals="0"
      id="Fact001299"
      unitRef="USD">1600</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="AsOf2017-01-01_custom_VersaillesIndianaMember"
      decimals="INF"
      id="Fact001301"
      unitRef="Pure">0.03</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:OperatingLeasePayments
      contextRef="From2016-03-012016-03-01_custom_CarmelIndianaMember_custom_LeaseThreeMember"
      decimals="0"
      id="Fact001303"
      unitRef="USD">1472</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="AsOf2016-03-01_custom_CarmelIndianaMember"
      decimals="INF"
      id="Fact001305"
      unitRef="Pure">0.027</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact001307"
      unitRef="USD">49051</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001309"
      unitRef="USD">47571</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001311">&lt;p id="xdx_89A_eus-gaap--OperatingLeasesOfLesseeDisclosureTextBlock_zL1DVsEOIMZj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table presents information related to the Company&#x2019;s operating leases:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B9_zbkU8aI0hBH7" style="display: none"&gt;Schedule of Operating Leases&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20231231_zbQj9ZkbBWz2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20221231_zYHSdHBiFm09" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OperatingLeaseRightOfUseAsset_iI_zEZZBTAfoqd7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; text-align: left; padding-bottom: 1.5pt"&gt;Operating lease right-of-use assets&lt;/td&gt;&lt;td style="width: 2%; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 16%; font-weight: bold; text-align: right"&gt;70,263&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right"&gt;101,382&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--OtherLiabilitiesCurrent_iI_zm9zZg5Nwu86" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other current liabilities&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;49,127&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33,395&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_zy2McdHD9408" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Operating lease liabilities&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;27,071&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;76,199&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OperatingLeaseLiability_iI_zJsruRK1nMR" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;76,198&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;109,594&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Weighted-average remaining lease term (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20231231_zFFRP2qAZvg7" title="Weighted average remaining lease term (in years)"&gt;3.75&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20221231_zomxZrgZidyk" title="Weighted average remaining lease term (in years)"&gt;4.00&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Weighted-average discount rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_uPure_c20231231_zBeFiyvgElC7" title="Weighted average discount rate"&gt;15.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_uPure_c20221231_zAkKHF1tgYWl" title="Weighted average discount rate"&gt;15.0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001313"
      unitRef="USD">70263</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001314"
      unitRef="USD">101382</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001316"
      unitRef="USD">49127</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001317"
      unitRef="USD">33395</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001319"
      unitRef="USD">27071</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001320"
      unitRef="USD">76199</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001322"
      unitRef="USD">76198</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001323"
      unitRef="USD">109594</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2023-12-31" id="Fact001325">P3Y9M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2022-12-31" id="Fact001327">P4Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001329"
      unitRef="Pure">0.150</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact001331"
      unitRef="Pure">0.150</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001333">&lt;p id="xdx_895_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zxxn8qAlvrSc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;As
of December 31, 2023, the maturities of the Company&#x2019;s operating lease liabilities were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;span id="xdx_8B5_zeZ9qs2gWW39" style="display: none"&gt;Schedule of Maturities Operating Lease Liabilities&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 65%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_49C_20231231_zoyDNcpF1jfk" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzyNu_zJrYMlclNNZ" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;2024&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;27,072&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzyNu_zFmSJqgVaoyh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;22,316&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzyNu_zov6zadw8H07" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;26,810&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzyNu_zWn2N5fJhg9d" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;76,198&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iI_z1Yfm0NWn5V3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1343"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OperatingLeaseLiability_iI_zirh2xyENqp9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total present value of lease payments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;76,198&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001335"
      unitRef="USD">27072</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001337"
      unitRef="USD">22316</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001339"
      unitRef="USD">26810</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001341"
      unitRef="USD">76198</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001345"
      unitRef="USD">76198</us-gaap:OperatingLeaseLiability>
    <NRXS:CommonStockAndWarrantsDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001347">&lt;p id="xdx_803_ecustom--CommonStockAndWarrantsDisclosureTextBlock_zprAyyGdMAf2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;9.
&lt;span id="xdx_82C_zqrrMh9ztpI"&gt;Common Stock and Warrants&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company authorized &lt;span id="xdx_909_eus-gaap--CommonStockSharesAuthorized_c20221231_pdd"&gt;100,000,000&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares
of common stock, of which &lt;span id="xdx_90F_eus-gaap--CommonStockSharesOutstanding_c20231231_pdd"&gt;6,508,897&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;and &lt;span id="xdx_901_eus-gaap--CommonStockSharesOutstanding_c20221231_pdd"&gt;1,963,322&lt;/span&gt;&lt;/span&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares
were issued and outstanding as of December 31, 2023 and 2022, respectively. In conjunction with &lt;span id="xdx_90B_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230808__20230808__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zp8HaJUB3Oba" title="Number of shares issued in transaction"&gt;1,098,667&lt;/span&gt; common shares issued upon
the completion of the initial public offering on August 8, 2023, the Company also issued (i) &lt;span id="xdx_900_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_c20230808__20230808_zJxZAxtFtyK1"&gt;1,244,228&lt;/span&gt;
common shares upon conversion of &lt;span id="xdx_904_eus-gaap--ConvertiblePreferredStockSharesIssuedUponConversion_iI_c20230808_zOZQjCbyYfgf"&gt;506,637&lt;/span&gt;
shares of Convertible Series A Preferred Stock and &lt;span id="xdx_901_eus-gaap--ConversionOfStockSharesConverted1_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_zKFjCyjTZxQa" title="Stock value converted"&gt;115,477&lt;/span&gt;
shares of Convertible Series Seed Preferred Stock, (ii) &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20230808__20230808__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWOX6ufGTUm5" title="Common stock issued upon debt conversion, shares"&gt;1,649,900&lt;/span&gt;
common shares upon conversion of convertible notes, (iii) &lt;/span&gt;&lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230808__20230808__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--VendorsMember_zrwlgZ1FlP8i" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;425,000 &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;commons
shares as payment to vendors for services and (iv) &lt;/span&gt;&lt;span id="xdx_904_eus-gaap--ConversionOfStockSharesIssued1_c20230808__20230808__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYOjhq6xGnni" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;127,780 &lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;common
shares upon the exercise of warrants. On January 10, 2023, the Company&#x2019;s board of directors authorized a &lt;/span&gt;&lt;span id="xdx_908_eus-gaap--StockholdersEquityNoteStockSplit_c20230109__20230110_zNOcnW6oS9K" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2-for-1
reverse stock split&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;. All share information in these
financial statements has been adjusted for this reverse stock split.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
January 10, 2023, the Company&#x2019;s board of directors authorized a &lt;span id="xdx_90C_eus-gaap--StockholdersEquityNoteStockSplit_c20230110__20230110_zqw3nJFmfy9e" title="Description of stock split"&gt;2-for-1 reverse stock split&lt;/span&gt;. All share information in these financial
statements has been adjusted for this reverse stock split.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"&gt;On August 9, 2023, the Company consummated an initial public offering, conducted on a firm commitment basis, pursuant to which it sold
&lt;span id="xdx_900_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20230809__20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zhQs53cZ3pJh" title="Number of shares issued in transaction"&gt;1,098,667&lt;/span&gt; shares of its common stock at a price of $&lt;span id="xdx_90F_eus-gaap--SharesIssuedPricePerShare_iI_c20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zlYaxgRcWhzg" title="Share issued price per share"&gt;6.00&lt;/span&gt; per share, resulting in gross proceeds of $&lt;span id="xdx_90A_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20230809__20230809__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zEmHOvxrvNYi" title="Proceeds from issuance of common stock"&gt;6,592,002&lt;/span&gt;. See Note 1.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Notes to Financial Statements&lt;/b&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
connection with a bridge loan, the Company issued a warrant on September 18, 2018 that allows the holder to purchase common
stock from the Company at a share price of $&lt;span id="xdx_901_eus-gaap--SharePrice_iI_pid_c20180918__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--BrianHannaschMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_zU6anbLDWfnf" title="Share price"&gt;4.38&lt;/span&gt;
per share. The number of shares was based on a formula tied to the final amount of loans made by the holder of $&lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20180918__20180918__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--BrianHannaschMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_zxcybR51McLa" title="Final amount"&gt;375,000&lt;/span&gt;,
multiplied by &lt;span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20180918__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--BrianHannaschMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_z0twKBxIqGrf" title="Interest rate"&gt;150&lt;/span&gt;%,
and divided by $&lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20180918__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--BrianHannaschMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember_zQnffytKIu8g" title="Exercise price"&gt;70.03&lt;/span&gt;.
The number of shares based on this formula is &lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20180918__srt--TitleOfIndividualAxis__custom--BrianHannaschMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zVWbBAxj6Y2a" title="Number of warrants"&gt;12,852&lt;/span&gt;.
The warrant contains certain rights in the event of liquidation, merger, or consolidation of the Company. If the fair market value
of one share is greater than the warrant price, the holder may elect to receive a number of shares equal to the value of the
warrant. If the exercise is in connection with the sale of the Company, the holder may, at its option, condition its exercise of the
warrant upon the consummation of such transaction. The warrant expires on &lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20180918__srt--TitleOfIndividualAxis__custom--BrianHannaschMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantOneMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z1W9WUuzvjIg" title="Date of Expiration"&gt;September
18, 2028&lt;/span&gt; and can be exercisable either in whole or from time to time in part prior to the expiration date.&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company issued a second warrant on September 6, 2019, under similar terms but is a penny warrant that allows the holder to purchase
&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20190906__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTwoMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zy347P2O8vMk" title="Number of warrants"&gt;40,000&lt;/span&gt; shares of common stock and is subject to adjustment for certain equity events. The warrant contains certain rights in the event
of liquidation, merger, or consolidation of the Company. The warrant expires on &lt;span id="xdx_904_ecustom--WarrantsExpirationDateDescription_c20190906__20190906__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zf5TzJrxXLS7" title="Date of Expiration"&gt;September 6, 2029&lt;/span&gt;. This warrant was converted to &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_pid_c20190906__20190906__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zAYlTCf768y9" title="Number of shares, conversion of convertible securities"&gt;39,924&lt;/span&gt;
shares of common stock on December 28, 2023. The fair market value of the stock on that day was calculated as the average of the daily
closing prices per share for the 30 consecutive trading day period ending on the second trading day prior to such date or $&lt;span id="xdx_903_eus-gaap--SharePrice_iI_pid_c20190906__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zuxnhpcpMTn6" title="Share price"&gt;2.61&lt;/span&gt; per share.
&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightReasonForIssuingToNonemployees_c20190906__20190906_zdMKXcgMd2u8" title="Warrant, description"&gt;Since the fair value was greater than the warrant price of $0.01 per share the holder elected to receive the number of shares equal
to 40,000 times the difference between the fair market value and the exercise price divided by the fair market value, resulting in 39,924.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company issued a third warrant to Masimo Corporation on April 9, 2020. This warrant was pre-funded in the amount of $&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20200409__dei--LegalEntityAxis__custom--MasimoCorporationMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantTwoMember_z3MWXhxiJUt6"&gt;2,734,340&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.
The warrant allows the holder to purchase &lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstanding_iI_c20200409__dei--LegalEntityAxis__custom--MasimoCorporationMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantThreeMember_zXB3BgL8LLhh"&gt;289,779 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;shares
of Series A Preferred Stock at $&lt;span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20200409__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantThreeMember_zsLkqODTsfI8"&gt;9.44 &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per
share and is subject to adjustment for certain equity events. The warrant contains certain rights in the event of liquidation,
merger, or consolidation of the Company. There will be no additional purchase price for the Warrants. In the event that all
outstanding shares of Series A Preferred Stock are converted, automatically or by action of the holders thereof, into Common Stock,
including, without limitation, in connection with the Company&#x2019;s initial, underwritten public offering and sale of its Common
Stock pursuant to an effective registration statement under the Act, then from and after the date on which all outstanding shares of
Series A Preferred Stock have been so converted, this Warrant shall be exercisable for such number of shares of Common Stock into
which the Warrant Shares would have been converted had the Warrant Shares been outstanding on the date of such conversion, and the
Exercise Price shall equal the Exercise Price in effect as of immediately prior to such conversion divided by the number of shares
of Common Stock into which one share of Series A Preferred Stock would have been converted, all subject to further adjustment
thereafter from time to time in accordance with the provisions of this Warrant. On August 14, 2023, the &lt;span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant_c20230814__20230814__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zKJJUzNR5Yak" title="Converted to preferred stock warrant"&gt;144,890&lt;/span&gt; Series A Preferred
Stock warrants were converted to &lt;span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants_c20230814__20230814__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z26PCTlfwxN4" title="Converted to common stock warrant"&gt;289,779&lt;/span&gt; common stock warrants after giving effect to the &lt;span id="xdx_906_eus-gaap--StockholdersEquityNoteStockSplit_c20230814__20230814_zjC2pZF8eSx8" title="Common stock split, description"&gt;2-for-1&lt;/span&gt; common stock split.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During
2022, the Company issued &lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zJzxEqAvBdTj" title="Number of warrants"&gt;793,655&lt;/span&gt; &lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_z5KxziaQhAK5" title="Warrant term::XDX::P5Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1404"&gt;five-year&lt;/span&gt;&lt;/span&gt; warrants to purchase common stock equal to one hundred percent (100%) of the shares into which
the 2022 convertible notes can be converted at issuance. The warrants have an exercise price of $&lt;span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20221231__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zBMpc4ENsbZg" title="Share issued price per share"&gt;5.25&lt;/span&gt; per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;From
March to June of 2023, the Company issued &lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230630__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zT9VShby2Tbe" title="Number of warrants"&gt;505,570&lt;/span&gt; &lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20230630__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zSdGuqTadD3i" title="Warrant term::XDX::P1Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1410"&gt;one-year&lt;/span&gt;&lt;/span&gt; warrants to purchase common stock equal to fifty percent (50%) of the shares
into which the 2023 convertible notes can be converted at issuance. The warrants have an exercise price of $&lt;span id="xdx_90A_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230630__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zV4CjY7CXfy5" title="Share issued price per share"&gt;5.25&lt;/span&gt; per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 9, 2023, the Company issued &lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230809__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zeiKL6HUAEte"&gt;122,202
&lt;/span&gt;&lt;/span&gt;&lt;span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dpxL_c20230809__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_ziGSl6ZTAYZk" style="font-family: Times New Roman, Times, Serif; font-size: 10pt" title="::XDX::P5Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1414"&gt;five-year
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;warrants to purchase common stock pursuant to an advisory
agreement with a consulting firm upon closing of the Company&#x2019;s initial public offering. The warrants have an exercise price of
$&lt;span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230809__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zFYXRRYxXEH5"&gt;6.00
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 14, 2023, the Company issued &lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20230814__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zXsaF3WrPxAg"&gt;186,156
&lt;/span&gt;&lt;/span&gt;&lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dxL_c20230814__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zh3aVBO5Qeue" style="font-family: Times New Roman, Times, Serif; font-size: 10pt" title="::XDX::P5Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1417"&gt;five-year
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;warrants to purchase common stock pursuant to an agreement
with an underwriter upon closing of the Company&#x2019;s initial public offering. The warrants have an exercise price of $&lt;span id="xdx_905_eus-gaap--SharesIssuedPricePerShare_iI_pid_c20230814__us-gaap--TypeOfArrangementAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zwKZT2yKcEVa"&gt;7.20
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_ecustom--ScheduleOfWarrantActivityForCommonStockTableTextBlock_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zT0tVLJd8Fb1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is a summary of warrant activity for common stock during the years ended December 31, 2023 and 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;span id="xdx_8BB_zbPdy6YRoh12" style="display: none"&gt;Schedule of Warrant Activity for Common Stock&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Warrants for Common
    Stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted-Avg. Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted-Avg. Remaining Contractual
    Life&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; font-weight: bold; text-align: left"&gt;Outstanding as of January 1, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFtfkHit6nal" style="width: 14%; text-align: right" title="Number of Warrants, Outstanding at beginning of period"&gt;52,852&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4GsLYC1p5P9" style="width: 14%; text-align: right" title="Weighted Average Exercise Price, Outstanding at beginning of period"&gt;2.13&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zl6qZXq8dUt6" title="Weighted Average Remaining Contractual Life - Warrants, Outstanding at beginning of period"&gt;7.45&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQ7wIfObdtu2" style="text-align: right" title="Number of Warrants, Granted"&gt;793,655&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPw6fxB9ydqh" style="text-align: right" title="Weighted Average Exercise Price, granted"&gt;5.25&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageRemainingContracualLifeOutstandingNumberGranted_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkS3ZdEjg8hk" title="Weighted Average Remaining Contractual Life - Warrants Granted"&gt;4.42&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Cancelled/Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRsBQtlIFENd" style="text-align: right" title="Number of Warrants, Cancelled Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1434"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLbhtOkKExjk" style="text-align: right" title="Weighted Average Exercise Price, Cancelled Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1436"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwxWiNfdMXFh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1438"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIHWoLLJqhIa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Excercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1440"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Outstanding as of December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjGjArh6kWl3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants, Outstanding at beginning of period"&gt;846,507&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsVBLIE98wNh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding at beginning of period"&gt;5.06&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z1bupKrRyEVb" title="Weighted Average Remaining Contractual Life - Warrants, Outstanding at beginning of period"&gt;4.72&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHXGtkRBVef7" style="text-align: right" title="Number of Warrants, Granted"&gt;813,928&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrvhplVZaaea" style="text-align: right" title="Weighted Average Exercise Price, granted"&gt;5.81&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z3Rw1vMLMbgi" title="Weighted Average Remaining Contractual Life - Warrants Granted"&gt;4.38&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Converted Prefunded Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBKOw27Iswof" style="text-align: right" title="Number of Warrants, Converted Prefunded Warrants"&gt;289,779&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsConvertedPrefundedWarrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLHJQsNqGfSf" style="text-align: right" title="Weighted Average Exercise Price, Converted Prefunded Warrants"&gt;0.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNNkyqPnU1p2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants, Exercised"&gt;(127,856&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxn1kG8yXWhh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Excercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1460"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Outstanding as of December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z52slLer13Yi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants, Outstanding at Ending of period"&gt;1,822,358&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWcR3HmB7P4d" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding at Ending of period"&gt;4.69&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zUlKG5KBXfV6" title="Weighted Average Remaining Contractual Life - Warrants, Outstanding at Ending of period"&gt;3.05&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A6_zUzkMtJhQeOc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Notes to Financial Statements&lt;/b&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_891_ecustom--ScheduleOfWarrantActivityForPreferredStockTableTextBlock_hus-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z8rPRlYi2yr7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is a summary of warrant activity for preferred stock during the years ended December 31, 2023 and 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B3_zBDZzq1ZH1Jg" style="display: none"&gt;Schedule of Warrant Activity for Preferred Stock&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted-Avg.&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Warrants for&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Exercise&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Preferred Stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; font-weight: bold; text-align: left"&gt;Outstanding as of January 1, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zHjGmEHAR7n" style="width: 16%; text-align: right" title="Number of Warrants, Outstanding at beginning of period"&gt;144,890&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zWxVdZmPzCXb" style="width: 16%; text-align: right" title="Weighted Average Exercise Price, Outstanding at beginning of period"&gt;0.01&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zKrzoDZ974Kf" style="text-align: right" title="Number of Warrants, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1474"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zvx7V26CALq4" style="text-align: right" title="Weighted Average Exercise Price, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1476"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Cancelled/Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zmgoHNJLFe2j" style="text-align: right" title="Number of Warrants, Cancelled Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1478"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zU6SDG16jVpf" style="text-align: right" title="Weighted Average Exercise Price, Cancelled Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1480"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zOoHjZDVMd15" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1482"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zNvu6Eca2qs9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Excercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1484"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Outstanding as of December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zVJNx44x0VJ7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants, Outstanding at beginning of period"&gt;144,890&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zd50OkTmeHT3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding at beginning of period"&gt;0.01&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_znFCYHiQfpJh" style="text-align: right" title="Number of Warrants, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1490"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zEdXTAJWHEFk" style="text-align: right" title="Weighted Average Exercise Price, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1492"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Cancelled/Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zz4SGnNOQE3f" style="text-align: right" title="Number of Warrants, Cancelled Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1494"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zyZcFmgWqHc2" style="text-align: right" title="Weighted Average Exercise Price, Cancelled Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1496"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Converted to Common Stock Warrant&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zFfOb5Qk5Rzl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Converted to Common Stock Warrant"&gt;(144,890&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zIxM4IoiAYx5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Converted to Common Stock Warrant"&gt;(0.01&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Outstanding as of December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zDXqtRsfiNk9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants, Outstanding at Ending of period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1502"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zBEYAb8ItwJd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding at Ending of period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1504"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A7_zYQuG8ICw7M4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zPFQXUl3FwJ" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the Company&#x2019;s warrants outstanding and exercisable as of December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B3_zON6lmiXJCBf" style="display: none"&gt;Schedule of Warrants outstanding and Exercisable&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Exercise&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Expiration&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Date&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;Investor Warrant W-01&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantOneMember_z2ZvJ9G75a15" style="width: 14%; text-align: right" title="Number of Warrants"&gt;12,852&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantOneMember_zwlOEHMDF2ha" style="width: 14%; text-align: right" title="Exercise Price"&gt;8.76&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 16%; text-align: center"&gt;&lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantOneMember_zMwK10K6gYG1" title="Expiration Date"&gt;September 18, 2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Investor Warrant PSA-01&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantPSAOneMember_z5b83TdI0T1e" style="text-align: right" title="Number of Warrants"&gt;289,779&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantPSAOneMember_z60RpMMDxE3c" style="text-align: right" title="Exercise Price"&gt;0.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_908_ecustom--WarrantExpirationDateDescription_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantPSAOneMember_zy7hRhHg4Klj" title="Expiration Date"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2022 Convertible Notes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zYyUIcsWsEP4" style="text-align: right" title="Number of Warrants"&gt;793,655&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zGQo7QUjUPvf" style="text-align: right" title="Exercise Price"&gt;2.38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_909_ecustom--WarrantExpirationDateDescription_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_z8cPQMcjQYf2" title="Expiration Date"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2023 Convertible Notes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zZjaNLkOEind" style="text-align: right" title="Number of Warrants"&gt;417,714&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zijUSrhPJjM" style="text-align: right" title="Exercise Price"&gt;2.38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90D_ecustom--WarrantExpirationDateDescription_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zjdnEypDoDEd" title="Expiration Date"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Consulting Agreement Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ConsultingAgreementWarrantsMember_zaTFTmhJzFW2" style="text-align: right" title="Number of Warrants"&gt;122,202&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ConsultingAgreementWarrantsMember_zEc7yGgxrfQ1" style="text-align: right" title="Exercise Price"&gt;2.38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ConsultingAgreementWarrantsMember_z1XkTYMX6pjc" title="Expiration Date"&gt;August 8, 2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Underwriter&#x2019;s Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantsMember_zd1m9zDelivk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants"&gt;186,156&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantsMember_zh5p3ZM7xNF9" style="padding-bottom: 1.5pt; text-align: right" title="Exercise Price"&gt;2.38&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantsMember_zWlJXInjWwXl" title="Expiration Date"&gt;August 8, 2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231_z0KOtmJoNRN4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants"&gt;1,822,358&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A7_zkf8bYhzroK" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</NRXS:CommonStockAndWarrantsDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact001348"
      unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001349"
      unitRef="Shares">6508897</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact001350"
      unitRef="Shares">1963322</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2023-08-082023-08-08_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001352"
      unitRef="Shares">1098667</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="From2023-08-082023-08-08"
      decimals="INF"
      id="Fact001353"
      unitRef="Shares">1244228</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="AsOf2023-08-08"
      decimals="INF"
      id="Fact001354"
      unitRef="Shares">506637</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2022-01-012022-12-31_custom_ConvertibleSeriesSeedPreferredStockMember64722968"
      decimals="INF"
      id="Fact001356"
      unitRef="Shares">115477</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="From2023-08-082023-08-08_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001358"
      unitRef="Shares">1649900</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2023-08-082023-08-08_custom_VendorsMember"
      decimals="INF"
      id="Fact001359"
      unitRef="Shares">425000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="From2023-08-082023-08-08_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001360"
      unitRef="Shares">127780</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:StockholdersEquityNoteStockSplit contextRef="From2023-01-092023-01-10" id="Fact001361">2-for-1
reverse stock split</us-gaap:StockholdersEquityNoteStockSplit>
    <us-gaap:StockholdersEquityNoteStockSplit contextRef="From2023-01-102023-01-10" id="Fact001363">2-for-1 reverse stock split</us-gaap:StockholdersEquityNoteStockSplit>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="From2023-08-092023-08-09_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001365"
      unitRef="Shares">1098667</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-08-09_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001367"
      unitRef="USDPShares">6.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-08-092023-08-09_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001369"
      unitRef="USD">6592002</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:SharePrice
      contextRef="AsOf2018-09-18_us-gaap_CommonStockMember_custom_BrianHannaschMember_custom_WarrantOneMember"
      decimals="INF"
      id="Fact001371"
      unitRef="USDPShares">4.38</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2018-09-182018-09-18_us-gaap_CommonStockMember_custom_BrianHannaschMember_custom_WarrantOneMember"
      decimals="0"
      id="Fact001373"
      unitRef="USD">375000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2018-09-18_us-gaap_CommonStockMember_custom_BrianHannaschMember_custom_WarrantOneMember"
      decimals="INF"
      id="Fact001375"
      unitRef="Pure">1.50</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2018-09-18_us-gaap_CommonStockMember_custom_BrianHannaschMember_custom_WarrantOneMember"
      decimals="INF"
      id="Fact001377"
      unitRef="USDPShares">70.03</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2018-09-18_us-gaap_CommonStockMember_custom_BrianHannaschMember_custom_WarrantOneMember"
      decimals="INF"
      id="Fact001379"
      unitRef="Shares">12852</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2018-09-18_us-gaap_CommonStockMember_custom_BrianHannaschMember_custom_WarrantOneMember"
      id="Fact001381">2028-09-18</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2019-09-06_custom_WarrantTwoMember_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001383"
      unitRef="Shares">40000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <NRXS:WarrantsExpirationDateDescription
      contextRef="From2019-09-062019-09-06_us-gaap_CommonStockMember"
      id="Fact001385">September 6, 2029</NRXS:WarrantsExpirationDateDescription>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2019-09-062019-09-06_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001387"
      unitRef="Shares">39924</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:SharePrice
      contextRef="AsOf2019-09-06_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001389"
      unitRef="USDPShares">2.61</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees contextRef="From2019-09-062019-09-06" id="Fact001391">Since the fair value was greater than the warrant price of $0.01 per share the holder elected to receive the number of shares equal
to 40,000 times the difference between the fair market value and the exercise price divided by the fair market value, resulting in 39,924.</us-gaap:ClassOfWarrantOrRightReasonForIssuingToNonemployees>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2020-04-09_custom_MasimoCorporationMember_custom_WarrantTwoMember"
      decimals="INF"
      id="Fact001392"
      unitRef="Shares">2734340</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2020-04-09_custom_MasimoCorporationMember_custom_WarrantThreeMember"
      decimals="0"
      id="Fact001393"
      unitRef="USD">289779</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2020-04-09_us-gaap_SeriesAPreferredStockMember_custom_WarrantThreeMember"
      decimals="INF"
      id="Fact001394"
      unitRef="USDPShares">9.44</us-gaap:SharesIssuedPricePerShare>
    <NRXS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant
      contextRef="From2023-08-142023-08-14_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact001396"
      unitRef="Shares">144890</NRXS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant>
    <NRXS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants
      contextRef="From2023-08-142023-08-14_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001398"
      unitRef="Shares">289779</NRXS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants>
    <us-gaap:StockholdersEquityNoteStockSplit contextRef="From2023-08-142023-08-14" id="Fact001400">2-for-1</us-gaap:StockholdersEquityNoteStockSplit>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2022-12-31_custom_TwoThousandTwentyTwoConvertibleNotesMember"
      decimals="INF"
      id="Fact001402"
      unitRef="Shares">793655</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2022-12-31_custom_TwoThousandTwentyTwoConvertibleNotesMember"
      decimals="INF"
      id="Fact001406"
      unitRef="USDPShares">5.25</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-06-30_custom_TwoThousandTwentyThreeConvertibleNotesMember"
      decimals="INF"
      id="Fact001408"
      unitRef="Shares">505570</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-06-30_custom_TwoThousandTwentyThreeConvertibleNotesMember"
      decimals="INF"
      id="Fact001412"
      unitRef="USDPShares">5.25</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-08-09_custom_TwoThousandTwentyThreeConvertibleNotesMember"
      decimals="INF"
      id="Fact001413"
      unitRef="Shares">122202</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-08-09_custom_TwoThousandTwentyThreeConvertibleNotesMember"
      decimals="INF"
      id="Fact001415"
      unitRef="USDPShares">6.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-08-14_custom_TwoThousandTwentyThreeConvertibleNotesMember"
      decimals="INF"
      id="Fact001416"
      unitRef="Shares">186156</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2023-08-14_custom_TwoThousandTwentyThreeConvertibleNotesMember"
      decimals="INF"
      id="Fact001418"
      unitRef="USDPShares">7.20</us-gaap:SharesIssuedPricePerShare>
    <NRXS:ScheduleOfWarrantActivityForCommonStockTableTextBlock
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="Fact001420">&lt;p id="xdx_897_ecustom--ScheduleOfWarrantActivityForCommonStockTableTextBlock_hus-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zT0tVLJd8Fb1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is a summary of warrant activity for common stock during the years ended December 31, 2023 and 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;span id="xdx_8BB_zbPdy6YRoh12" style="display: none"&gt;Schedule of Warrant Activity for Common Stock&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Warrants for Common
    Stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted-Avg. Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted-Avg. Remaining Contractual
    Life&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; font-weight: bold; text-align: left"&gt;Outstanding as of January 1, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFtfkHit6nal" style="width: 14%; text-align: right" title="Number of Warrants, Outstanding at beginning of period"&gt;52,852&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4GsLYC1p5P9" style="width: 14%; text-align: right" title="Weighted Average Exercise Price, Outstanding at beginning of period"&gt;2.13&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zl6qZXq8dUt6" title="Weighted Average Remaining Contractual Life - Warrants, Outstanding at beginning of period"&gt;7.45&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQ7wIfObdtu2" style="text-align: right" title="Number of Warrants, Granted"&gt;793,655&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zPw6fxB9ydqh" style="text-align: right" title="Weighted Average Exercise Price, granted"&gt;5.25&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageRemainingContracualLifeOutstandingNumberGranted_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zkS3ZdEjg8hk" title="Weighted Average Remaining Contractual Life - Warrants Granted"&gt;4.42&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Cancelled/Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRsBQtlIFENd" style="text-align: right" title="Number of Warrants, Cancelled Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1434"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLbhtOkKExjk" style="text-align: right" title="Weighted Average Exercise Price, Cancelled Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1436"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwxWiNfdMXFh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1438"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIHWoLLJqhIa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Excercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1440"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Outstanding as of December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjGjArh6kWl3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants, Outstanding at beginning of period"&gt;846,507&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsVBLIE98wNh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding at beginning of period"&gt;5.06&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z1bupKrRyEVb" title="Weighted Average Remaining Contractual Life - Warrants, Outstanding at beginning of period"&gt;4.72&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHXGtkRBVef7" style="text-align: right" title="Number of Warrants, Granted"&gt;813,928&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zrvhplVZaaea" style="text-align: right" title="Weighted Average Exercise Price, granted"&gt;5.81&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z3Rw1vMLMbgi" title="Weighted Average Remaining Contractual Life - Warrants Granted"&gt;4.38&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Converted Prefunded Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zBKOw27Iswof" style="text-align: right" title="Number of Warrants, Converted Prefunded Warrants"&gt;289,779&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsConvertedPrefundedWarrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zLHJQsNqGfSf" style="text-align: right" title="Weighted Average Exercise Price, Converted Prefunded Warrants"&gt;0.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zNNkyqPnU1p2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants, Exercised"&gt;(127,856&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxn1kG8yXWhh" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Excercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1460"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Outstanding as of December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z52slLer13Yi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants, Outstanding at Ending of period"&gt;1,822,358&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWcR3HmB7P4d" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding at Ending of period"&gt;4.69&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zUlKG5KBXfV6" title="Weighted Average Remaining Contractual Life - Warrants, Outstanding at Ending of period"&gt;3.05&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</NRXS:ScheduleOfWarrantActivityForCommonStockTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001422"
      unitRef="Shares">52852</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001424"
      unitRef="USDPShares">2.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2021-01-012021-12-31_us-gaap_CommonStockMember"
      id="Fact001426">P7Y5M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001428"
      unitRef="Shares">793655</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001430"
      unitRef="USDPShares">5.25</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <NRXS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageRemainingContracualLifeOutstandingNumberGranted
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="Fact001432">P4Y5M1D</NRXS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageRemainingContracualLifeOutstandingNumberGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001442"
      unitRef="Shares">846507</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001444"
      unitRef="USDPShares">5.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2022-01-012022-12-31_us-gaap_CommonStockMember"
      id="Fact001446">P4Y8M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001448"
      unitRef="Shares">813928</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001450"
      unitRef="USDPShares">5.81</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="Fact001452">P4Y4M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <NRXS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001454"
      unitRef="Shares">289779</NRXS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsConvertedPrefundedWarrants>
    <NRXS:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsConvertedPrefundedWarrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001456"
      unitRef="USDPShares">0.01</NRXS:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsConvertedPrefundedWarrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001458"
      unitRef="Shares">-127856</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001462"
      unitRef="Shares">1822358</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact001464"
      unitRef="USDPShares">4.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      id="Fact001466">P3Y18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <NRXS:ScheduleOfWarrantActivityForPreferredStockTableTextBlock
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember64723875"
      id="Fact001468">&lt;p id="xdx_891_ecustom--ScheduleOfWarrantActivityForPreferredStockTableTextBlock_hus-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z8rPRlYi2yr7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is a summary of warrant activity for preferred stock during the years ended December 31, 2023 and 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B3_zBDZzq1ZH1Jg" style="display: none"&gt;Schedule of Warrant Activity for Preferred Stock&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0in"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Weighted-Avg.&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Warrants for&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Exercise&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Preferred Stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 60%; font-weight: bold; text-align: left"&gt;Outstanding as of January 1, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zHjGmEHAR7n" style="width: 16%; text-align: right" title="Number of Warrants, Outstanding at beginning of period"&gt;144,890&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zWxVdZmPzCXb" style="width: 16%; text-align: right" title="Weighted Average Exercise Price, Outstanding at beginning of period"&gt;0.01&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zKrzoDZ974Kf" style="text-align: right" title="Number of Warrants, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1474"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zvx7V26CALq4" style="text-align: right" title="Weighted Average Exercise Price, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1476"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Cancelled/Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zmgoHNJLFe2j" style="text-align: right" title="Number of Warrants, Cancelled Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1478"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zU6SDG16jVpf" style="text-align: right" title="Weighted Average Exercise Price, Cancelled Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1480"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zOoHjZDVMd15" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1482"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220101__20221231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zNvu6Eca2qs9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Excercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1484"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Outstanding as of December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zVJNx44x0VJ7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants, Outstanding at beginning of period"&gt;144,890&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zd50OkTmeHT3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding at beginning of period"&gt;0.01&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_znFCYHiQfpJh" style="text-align: right" title="Number of Warrants, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1490"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zEdXTAJWHEFk" style="text-align: right" title="Weighted Average Exercise Price, granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1492"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Cancelled/Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zz4SGnNOQE3f" style="text-align: right" title="Number of Warrants, Cancelled Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1494"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCancelledExpiredNumber_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zyZcFmgWqHc2" style="text-align: right" title="Weighted Average Exercise Price, Cancelled Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1496"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Converted to Common Stock Warrant&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zFfOb5Qk5Rzl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Converted to Common Stock Warrant"&gt;(144,890&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant_iN_pid_di_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zIxM4IoiAYx5" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Converted to Common Stock Warrant"&gt;(0.01&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Outstanding as of December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zDXqtRsfiNk9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants, Outstanding at Ending of period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1502"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zBEYAb8ItwJd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding at Ending of period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1504"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</NRXS:ScheduleOfWarrantActivityForPreferredStockTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact001470"
      unitRef="Shares">144890</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact001472"
      unitRef="USDPShares">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact001486"
      unitRef="Shares">144890</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember"
      decimals="INF"
      id="Fact001488"
      unitRef="USDPShares">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <NRXS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember64723875"
      decimals="INF"
      id="Fact001498"
      unitRef="Shares">144890</NRXS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsCommonStockWarrant>
    <NRXS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant
      contextRef="From2023-01-012023-12-31_us-gaap_PreferredStockMember64723875"
      decimals="INF"
      id="Fact001500"
      unitRef="Shares">0.01</NRXS:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsWeightedAverageExercisePriceCommonStockWarrant>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001506">&lt;p id="xdx_898_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zPFQXUl3FwJ" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following table summarizes the Company&#x2019;s warrants outstanding and exercisable as of December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B3_zON6lmiXJCBf" style="display: none"&gt;Schedule of Warrants outstanding and Exercisable&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Number of&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Exercise&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: center"&gt;Expiration&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Date&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: left"&gt;Investor Warrant W-01&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantOneMember_z2ZvJ9G75a15" style="width: 14%; text-align: right" title="Number of Warrants"&gt;12,852&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantOneMember_zwlOEHMDF2ha" style="width: 14%; text-align: right" title="Exercise Price"&gt;8.76&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 16%; text-align: center"&gt;&lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantOneMember_zMwK10K6gYG1" title="Expiration Date"&gt;September 18, 2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Investor Warrant PSA-01&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantPSAOneMember_z5b83TdI0T1e" style="text-align: right" title="Number of Warrants"&gt;289,779&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantPSAOneMember_z60RpMMDxE3c" style="text-align: right" title="Exercise Price"&gt;0.01&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_908_ecustom--WarrantExpirationDateDescription_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--InvestorWarrantPSAOneMember_zy7hRhHg4Klj" title="Expiration Date"&gt;None&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2022 Convertible Notes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zYyUIcsWsEP4" style="text-align: right" title="Number of Warrants"&gt;793,655&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_zGQo7QUjUPvf" style="text-align: right" title="Exercise Price"&gt;2.38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_909_ecustom--WarrantExpirationDateDescription_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyTwoConvertibleNotesMember_z8cPQMcjQYf2" title="Expiration Date"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2023 Convertible Notes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zZjaNLkOEind" style="text-align: right" title="Number of Warrants"&gt;417,714&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zijUSrhPJjM" style="text-align: right" title="Exercise Price"&gt;2.38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_90D_ecustom--WarrantExpirationDateDescription_c20230101__20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--TwoThousandTwentyThreeConvertibleNotesMember_zjdnEypDoDEd" title="Expiration Date"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Consulting Agreement Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ConsultingAgreementWarrantsMember_zaTFTmhJzFW2" style="text-align: right" title="Number of Warrants"&gt;122,202&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ConsultingAgreementWarrantsMember_zEc7yGgxrfQ1" style="text-align: right" title="Exercise Price"&gt;2.38&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--ConsultingAgreementWarrantsMember_z1XkTYMX6pjc" title="Expiration Date"&gt;August 8, 2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Underwriter&#x2019;s Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantsMember_zd1m9zDelivk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants"&gt;186,156&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantsMember_zh5p3ZM7xNF9" style="padding-bottom: 1.5pt; text-align: right" title="Exercise Price"&gt;2.38&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_c20231231__us-gaap--ClassOfWarrantOrRightAxis__custom--UnderwriterWarrantsMember_zWlJXInjWwXl" title="Expiration Date"&gt;August 8, 2028&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ClassOfWarrantOrRightOutstanding_iI_pid_c20231231_z0KOtmJoNRN4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Warrants"&gt;1,822,358&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-12-31_custom_InvestorWarrantOneMember"
      decimals="INF"
      id="Fact001508"
      unitRef="Shares">12852</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-31_custom_InvestorWarrantOneMember"
      decimals="INF"
      id="Fact001510"
      unitRef="USDPShares">8.76</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2023-12-31_custom_InvestorWarrantOneMember"
      id="Fact001512">2028-09-18</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-12-31_custom_InvestorWarrantPSAOneMember"
      decimals="INF"
      id="Fact001514"
      unitRef="Shares">289779</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-31_custom_InvestorWarrantPSAOneMember"
      decimals="INF"
      id="Fact001516"
      unitRef="USDPShares">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <NRXS:WarrantExpirationDateDescription
      contextRef="From2023-01-012023-12-31_custom_InvestorWarrantPSAOneMember"
      id="Fact001518">None</NRXS:WarrantExpirationDateDescription>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-12-31_custom_TwoThousandTwentyTwoConvertibleNotesMember"
      decimals="INF"
      id="Fact001520"
      unitRef="Shares">793655</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-31_custom_TwoThousandTwentyTwoConvertibleNotesMember"
      decimals="INF"
      id="Fact001522"
      unitRef="USDPShares">2.38</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <NRXS:WarrantExpirationDateDescription
      contextRef="From2023-01-012023-12-31_custom_TwoThousandTwentyTwoConvertibleNotesMember"
      id="Fact001524">Various</NRXS:WarrantExpirationDateDescription>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-12-31_custom_TwoThousandTwentyThreeConvertibleNotesMember"
      decimals="INF"
      id="Fact001526"
      unitRef="Shares">417714</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-31_custom_TwoThousandTwentyThreeConvertibleNotesMember"
      decimals="INF"
      id="Fact001528"
      unitRef="USDPShares">2.38</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <NRXS:WarrantExpirationDateDescription
      contextRef="From2023-01-012023-12-31_custom_TwoThousandTwentyThreeConvertibleNotesMember"
      id="Fact001530">Various</NRXS:WarrantExpirationDateDescription>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-12-31_custom_ConsultingAgreementWarrantsMember"
      decimals="INF"
      id="Fact001532"
      unitRef="Shares">122202</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-31_custom_ConsultingAgreementWarrantsMember"
      decimals="INF"
      id="Fact001534"
      unitRef="USDPShares">2.38</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2023-12-31_custom_ConsultingAgreementWarrantsMember"
      id="Fact001536">2028-08-08</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-12-31_custom_UnderwriterWarrantsMember"
      decimals="INF"
      id="Fact001538"
      unitRef="Shares">186156</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2023-12-31_custom_UnderwriterWarrantsMember"
      decimals="INF"
      id="Fact001540"
      unitRef="USDPShares">2.38</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="AsOf2023-12-31_custom_UnderwriterWarrantsMember"
      id="Fact001542">2028-08-08</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001544"
      unitRef="Shares">1822358</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:PreferredStockTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001546">&lt;p id="xdx_80B_eus-gaap--PreferredStockTextBlock_zs9hdNNL4B0g" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;10.
&lt;span id="xdx_827_zexSBGvOofpb"&gt;Preferred Stock&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has authorized &lt;span id="xdx_901_eus-gaap--PreferredStockSharesAuthorized_iI_c20231231_zCacb4cxvNLa" title="Preferred stock, shares authorized"&gt;1,120,000&lt;/span&gt; shares of preferred stock of which &lt;span id="xdx_90B_eus-gaap--PreferredStockSharesAuthorized_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesAPreferredStockMember_zCfSG835SzE7" title="Preferred stock, shares authorized"&gt;1,000,000&lt;/span&gt; has been designated Series A Preferred and &lt;span id="xdx_90D_eus-gaap--PreferredStockSharesAuthorized_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_zNVIiF11gUte" title="Preferred stock, shares authorized"&gt;120,000&lt;/span&gt; has
been designated Series Seed Preferred, of which &lt;span id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesAPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zEME85xvnQNj" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_907_eus-gaap--PreferredStockSharesOutstanding_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesAPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zjuI1Yw375H5" title="Preferred stock, shares outstanding"&gt;0&lt;/span&gt;&lt;/span&gt; and &lt;span id="xdx_909_eus-gaap--PreferredStockSharesIssued_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesAPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_zVC1fg5TKzYc" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_904_eus-gaap--PreferredStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesAPreferredStockMember__us-gaap--StatementEquityComponentsAxis__us-gaap--PreferredStockMember_z64XvUB2uIrk" title="Preferred stock, shares outstanding"&gt;506,637&lt;/span&gt;&lt;/span&gt; shares of Series A Preferred and &lt;span id="xdx_90F_eus-gaap--PreferredStockSharesIssued_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_zi7HmkBtYEl3" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_c20231231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_z2eTfUJdZ3C7" title="Preferred stock, shares outstanding"&gt;0&lt;/span&gt;&lt;/span&gt; and &lt;span id="xdx_90D_eus-gaap--PreferredStockSharesIssued_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_zAwhmIWxs9Wh" title="Preferred stock, shares issued"&gt;&lt;span id="xdx_902_eus-gaap--PreferredStockSharesOutstanding_iI_c20221231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_zz395C0wmmq8" title="Preferred stock, shares outstanding"&gt;115,477&lt;/span&gt;&lt;/span&gt; shares of Series Seed Preferred
are issued and outstanding as of December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
aggregate purchase price of the Series A Preferred Stock was $&lt;span id="xdx_904_ecustom--AggregatePurchasePrice_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesAPreferredStockMember_z83A0w8LvXF4" title="Aggregate purchase price"&gt;9,321,165&lt;/span&gt;, of which $&lt;span id="xdx_90C_eus-gaap--ConversionOfStockAmountConverted1_c20230101__20231231__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zEOWtQxubI37" title="Cash value of purchase price"&gt;7,692,664&lt;/span&gt; was comprised of cash and the remaining
$&lt;span id="xdx_902_eus-gaap--ConversionOfStockAmountConverted1_c20230101__20231231__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zSjb4XdIQgQ3" title="Cash value of purchase price"&gt;1,628,501&lt;/span&gt; was comprised of converted debt and common stock. The aggregate purchase price of the Series Seed Preferred shares was $&lt;span id="xdx_902_ecustom--AggregatePurchasePrice_c20231231__20231231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_zD6OGdJbRbZe" title="Aggregate purchase price"&gt;0&lt;/span&gt;,
as all the Series Seed shares were converted from common stock as an incentive to reinvest in Series A Preferred Stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Notes to Financial Statements&lt;/b&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is a summary of Preferred Stock terms:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Voting
Rights&lt;/span&gt; - The Series A Preferred and Series Seed Preferred shall vote together with the Common Stock on an as-converted basis, and
not as separate classes.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Conversion
&lt;/span&gt;- The Series A Preferred and Series Seed initially convert 1:1 to Common Stock at any time at option of holder, subject to adjustments
for stock dividends, splits, combinations, and similar events and as described below under &#x201c;Anti-dilution Provisions.&#x201d;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Dividends
&lt;/span&gt;- The Series A Preferred will carry an annual &lt;span id="xdx_904_eus-gaap--PreferredStockDividendRatePercentage_dp_uPure_c20230101__20231231__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zbQVwC996jZk" title="Preferred stock dividend rate percentage"&gt;8&lt;/span&gt;% cumulative dividend, payable upon any liquidation, dissolution or winding up of
the Company (the &#x201c;Accruing Dividend&#x201d;). For any other dividends or distributions, participation with Common Stock on an as-converted
basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Liquidation
&lt;/span&gt;- In the event of any liquidation, dissolution or winding up of the Company, the proceeds shall be paid in the following priority:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;First,
to the Series A Preferred in proportion to each holder&#x2019;s respective pro rata Series A Original Purchase Price, plus any pro rata
share of the Accruing Dividend until the entire Series A Original Purchase Price and Accruing Dividend are paid;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Second,
to the Series Seed Preferred in proportion to each holder&#x2019;s respective pro rata Series Seed Original Purchase Price until the entire
amount of the Series Seed Original Purchase Price is paid; and&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Thereafter,
the Series A Preferred and Series Seed Preferred participate with the Common Stock pro rata on an as-converted basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
merger or consolidation (other than one in which stockholders of the Company own a majority by voting power of the outstanding shares
of the surviving or acquiring corporation) and a sale, lease, transfer, exclusive license or other disposition of all or substantially
all of the assets of the Company will be treated as a liquidation event (a &#x201c;Deemed Liquidation Event&#x201d;), thereby triggering
payment of the liquidation preferences described.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="text-decoration: underline"&gt;Anti-dilution
Provisions&lt;/span&gt; - The Series A Preferred have full-ratchet anti-dilution protection so that the conversion price will be reduced to &lt;span id="xdx_90F_eus-gaap--DebtInstrumentConvertibleConversionRatio1_dp_uPure_c20230101__20231231_ztvOgwbYgCe3" title="Conversion ratio"&gt;80&lt;/span&gt;%
of the price at which any future shares are issued, if less than the Series A Original Purchase Price.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
consideration for shareholders to make an additional investment in the Company, upon the purchase of the Series A Preferred stock by
the shareholder, the Company converted the existing common shares held by shareholders to Series Seed Preferred Stock at a $&lt;span id="xdx_90C_eus-gaap--ConversionOfStockAmountConverted1_pn6n6_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_zM4U9bgl39f4" title="Conversion amount"&gt;100&lt;/span&gt; million
valuation and at a &lt;span id="xdx_909_ecustom--SharePremiumPercentage_iI_pid_dp_uPure_c20231231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_zrSCIvVvtUtl" title="Share premium percentage"&gt;120&lt;/span&gt;% share premium. As of December 31, 2022, there were &lt;span id="xdx_90D_eus-gaap--ConversionOfStockSharesConverted1_c20230101__20231231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_z38nHRwBSmgi" title="Stock value converted"&gt;97,702&lt;/span&gt; common shares converted into &lt;span id="xdx_901_eus-gaap--ConversionOfStockSharesConverted1_c20220101__20221231__us-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_z1JyhTpKbzSb" title="Stock value converted"&gt;115,477&lt;/span&gt; shares
of Series Seed Preferred shares that have no par value and are outstanding.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;
As of December 31, 2023, all preferred stock has been converted pursuant to the initial public offering.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company signed a Convertible Promissory Note on November 8, 2023 for a principal amount of $&lt;span id="xdx_908_eus-gaap--DebtInstrumentFaceAmount_iI_c20231108_zPfNWYYZXC1b" title="Debt instrument, face amount"&gt;3,000,000&lt;/span&gt;
bearing interest at &lt;span id="xdx_907_eus-gaap--DebtConversionOriginalDebtInterestRateOfDebt_dp_uPure_c20231108__20231108_zswg4uXI9nL2" title="Debt conversion, original debt, interest rate of debt"&gt;8.5%&lt;/span&gt;
per annum payable quarterly in either cash or common stock with a 15 month maturity date. The agreement calls for $&lt;span id="xdx_90B_eus-gaap--DebtInstrumentPeriodicPayment_c20231108__20231108_zAs54X6L9Wjh" title="Debt instrument, periodic payment"&gt;200,000&lt;/span&gt;
monthly installments from January 2024 through March of 2025; there was no outstanding balance as of December 31, 2023. The Convertible
Promissory Note allows for a voluntary conversion by the investor into Series B Preferred Stock at $&lt;span id="xdx_903_eus-gaap--DebtInstrumentConvertibleConversionPrice1_iI_c20231108__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zSkVAOA9aiZ5" title="Debt instrument, convertible, conversion price"&gt;2.38&lt;/span&gt;
per share any time prior to the maturity date with mandatory conversion by the Company at the maturity date. The Company shall use
the proceeds solely for working capital and general corporate purposes and not pay any dividends or distributions or to advance any
funds to its officers, directors or affiliates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PreferredStockTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001548"
      unitRef="Shares">1120000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31_custom_ConvertibleSeriesAPreferredStockMember"
      decimals="INF"
      id="Fact001550"
      unitRef="Shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-12-31_custom_ConvertibleSeriesSeedPreferredStockMember"
      decimals="INF"
      id="Fact001552"
      unitRef="Shares">120000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember"
      decimals="INF"
      id="Fact001554"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember"
      decimals="INF"
      id="Fact001556"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember"
      decimals="INF"
      id="Fact001558"
      unitRef="Shares">506637</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2022-12-31_us-gaap_PreferredStockMember_custom_ConvertibleSeriesAPreferredStockMember"
      decimals="INF"
      id="Fact001560"
      unitRef="Shares">506637</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-12-31_custom_ConvertibleSeriesSeedPreferredStockMember"
      decimals="INF"
      id="Fact001562"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-12-31_custom_ConvertibleSeriesSeedPreferredStockMember"
      decimals="INF"
      id="Fact001564"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2022-12-31_custom_ConvertibleSeriesSeedPreferredStockMember"
      decimals="INF"
      id="Fact001566"
      unitRef="Shares">115477</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2022-12-31_custom_ConvertibleSeriesSeedPreferredStockMember"
      decimals="INF"
      id="Fact001568"
      unitRef="Shares">115477</us-gaap:PreferredStockSharesOutstanding>
    <NRXS:AggregatePurchasePrice
      contextRef="From2023-01-012023-12-31_custom_ConvertibleSeriesAPreferredStockMember64725046"
      decimals="0"
      id="Fact001570"
      unitRef="USD">9321165</NRXS:AggregatePurchasePrice>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="From2023-01-012023-12-31_us-gaap_ConvertibleDebtMember"
      decimals="0"
      id="Fact001572"
      unitRef="USD">7692664</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="From2023-01-012023-12-31_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact001574"
      unitRef="USD">1628501</us-gaap:ConversionOfStockAmountConverted1>
    <NRXS:AggregatePurchasePrice
      contextRef="From2023-12-312023-12-31_custom_ConvertibleSeriesSeedPreferredStockMember"
      decimals="0"
      id="Fact001576"
      unitRef="USD">0</NRXS:AggregatePurchasePrice>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="From2023-01-012023-12-31_us-gaap_SeriesAPreferredStockMember"
      decimals="INF"
      id="Fact001578"
      unitRef="Pure">0.08</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:DebtInstrumentConvertibleConversionRatio1
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact001580"
      unitRef="Pure">0.80</us-gaap:DebtInstrumentConvertibleConversionRatio1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="From2023-01-012023-12-31_custom_ConvertibleSeriesSeedPreferredStockMember64725125"
      decimals="-6"
      id="Fact001582"
      unitRef="USD">100000000</us-gaap:ConversionOfStockAmountConverted1>
    <NRXS:SharePremiumPercentage
      contextRef="AsOf2023-12-31_custom_ConvertibleSeriesSeedPreferredStockMember"
      decimals="INF"
      id="Fact001584"
      unitRef="Pure">1.20</NRXS:SharePremiumPercentage>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2023-01-012023-12-31_custom_ConvertibleSeriesSeedPreferredStockMember64725125"
      decimals="INF"
      id="Fact001586"
      unitRef="Shares">97702</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2022-01-012022-12-31_custom_ConvertibleSeriesSeedPreferredStockMember64722968"
      decimals="INF"
      id="Fact001588"
      unitRef="Shares">115477</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2023-11-08"
      decimals="0"
      id="Fact001590"
      unitRef="USD">3000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt
      contextRef="From2023-11-082023-11-08"
      decimals="INF"
      id="Fact001592"
      unitRef="Pure">0.085</us-gaap:DebtConversionOriginalDebtInterestRateOfDebt>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="From2023-11-082023-11-08"
      decimals="0"
      id="Fact001594"
      unitRef="USD">200000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="AsOf2023-11-08_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact001596"
      unitRef="USDPShares">2.38</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001598">&lt;p id="xdx_800_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zzt5ILb6sjM2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;11.
&lt;span&gt;&lt;span id="xdx_82E_zfy7ZY3HJZH1"&gt;Stock Options and Awards&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
October 12, 2017, the Company adopted the 2017 Stock Compensation Plan authorizing the issuance of &lt;span id="xdx_90C_eus-gaap--CommonStockSharesAuthorized_iI_pid_c20171012__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_zPekARoQxeM1" title="Common stock, shares authorized"&gt;1,435,652&lt;/span&gt; shares of common stock.
On September 13, 2019 the Company entered into a Stock Option Cancellation agreement with all holders of these stock options effective
on that date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;This
plan was then amended on September 13, 2019, to increase the share amount to &lt;span id="xdx_902_eus-gaap--SharesIssued_iI_pid_c20190913__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_zSGluU1RUmCh" title="Shares issued"&gt;2,638,788&lt;/span&gt;. This plan was enacted to enable the Company to
retain the services of certain key employees, officers, and directors of the Company. The Plan provides for the grant of stock options,
including incentive stock options, or ISOs, and nonqualified stock options, or NSOs and restricted stock, and they were estimated using
the Black-Scholes option-pricing model with the following weighted-average assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zSodkXedL2Fg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B6_zrJM8IbVxkhe" style="display: none"&gt;Schedule of Option-pricing Model with Following Weighted-average Assumptions&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 65%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Assumptions as of December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Fully Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 74%; text-align: left"&gt;Number of Shares&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_zOvAN9zZQDL6" style="width: 22%; text-align: right" title="Number of Shares"&gt;1,319,394&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Stock price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharePrice_iI_c20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_zd7QjgdqJJwc" style="text-align: right" title="Stock price"&gt;2.67&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_zvltKuMCnOj8" style="text-align: right" title="Exercise price"&gt;6.94&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_zMoDvJx5aIT9" title="Expected term"&gt;5.75&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_zn0fdwdxlpD" style="text-align: right" title="Expected volatility"&gt;31.90&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_zAef3CWeZzr1" style="text-align: right" title="Risk-free interest rate"&gt;3.84&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Dividend rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_zVd9PeRGxHdd" style="text-align: right" title="Dividend rate"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_8A5_zDNrwjbD9Sri" style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Notes to Financial Statements&lt;/b&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z0SXezbnXQoe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is a summary of stock option activity for the years ended December 31, 2023 and 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B9_z6hMbd0cxl3k" style="display: none"&gt;Schedule of Stock Option Activity&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Avg. Remaining Contractual Life (in years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Avg. Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Aggregate Intrinsic Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; font-weight: bold; text-align: left"&gt;Outstanding as of January 1, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231_zZCrZxld5Pja" style="width: 11%; text-align: right" title="Number of Options, Outstanding, Beginning balance"&gt;1,319,394&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_z21YhOqhwyda" title="Weighted Average Remaining Contractual Life (in years), Outstanding"&gt;7.69&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20220101__20221231_z5Fb9NxZcFG5" style="width: 11%; text-align: right" title="Weighted Average Exercise Price, Outstanding, Beginning balance"&gt;6.94&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20220101__20221231_zgfl9C219dV8" style="width: 11%; text-align: right" title="Aggregate Intrinsic Value, Outstanding, Beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1628"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20220101__20221231_zGdVdEKNR3Pf" style="text-align: right" title="Number of Options, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1630"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_uShares_c20220101__20221231_zTmrillIZ9ja" style="text-align: right" title="Number of Options, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1632"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Cancelled/Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_pid_uShares_c20220101__20221231_zNJ5RE84Xqkk" style="text-align: right" title="Number of Options, Cancelled/Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1634"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20220101__20221231_z9OSd5tPk48a" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1636"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Outstanding as of December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231_zfQeHbfbiMJg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, Outstanding, Beginning balance"&gt;1,319,394&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zRiad09Ik3Ma" title="Weighted Average Remaining Contractual Life (in years), Outstanding"&gt;6.69&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20230101__20231231_z4F1SfXgrd9d" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding, Beginning balance"&gt;6.94&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20230101__20231231_zX6U9TmDrwS9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Aggregate Intrinsic Value, Outstanding, Beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1644"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20230101__20231231_zIbrWIgFhoSc" style="text-align: right" title="Number of Options, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1646"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_uShares_c20230101__20231231_zzrO0z8gual2" style="text-align: right" title="Number of Options, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1648"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Cancelled/Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_pid_uShares_c20230101__20231231_zsIq9wAYQfXc" style="text-align: right" title="Number of Options, Cancelled/Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1650"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20230101__20231231_zDsA0ZPH3ep3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1652"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Outstanding as of December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231_zMLNl3Ld1DX3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, Outstanding, Ending balance"&gt;1,319,394&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zDCGuIK6aXWi" title="Weighted Average Remaining Contractual Life (in years), Outstanding"&gt;5.69&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20230101__20231231_zKmIVAqODHM9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding, Ending balance"&gt;6.94&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20230101__20231231_z8MijdMiMTx9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Aggregate Intrinsic Value, Outstanding, Ending balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1660"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Vested and Exercisable as of December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iE_pid_c20230101__20231231_zF6kLe4J8jHi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, Vested and Exercisable, Ending balance"&gt;1,319,394&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231_zooQYAqcfhUh" title="Weighted Average Remaining Contractual Life (in years), Vested and Exercisable"&gt;5.69&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20230101__20231231_zUPUhEvHEX5g" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Vested and Exercisable, Ending balance"&gt;6.94&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iE_c20230101__20231231_zAlGieIzA6ae" style="border-bottom: Black 1.5pt solid; text-align: right" title="Aggregate Intrinsic Value, Vested and Exercisable, Ending balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1668"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A4_zbpDEIyVxru6" style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stock-based
compensation expense is classified in the Company&#x2019;s statements of operations as general and administrative expense. The amounts
were $&lt;span id="xdx_904_eus-gaap--AllocatedShareBasedCompensationExpense_c20230101__20231231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z2zVBKfgkt6g" title="Stock-based compensation expense"&gt;0&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--AllocatedShareBasedCompensationExpense_c20220101__20221231__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zjinxtJywC09" title="Stock-based compensation expense"&gt;27,319&lt;/span&gt; for the years ended December 31, 2023 and 2022, respectively. As of December 31, 2023, there was &lt;span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_do_c20231231_zc7pRq0SMW1e" title="Unrecognized compensation expense"&gt;&lt;span id="xdx_90B_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_do_c20221231_zrzdlQWS22a" title="Unrecognized compensation expense"&gt;no&lt;/span&gt;&lt;/span&gt; unrecognized
compensation expense related to unvested options granted under the Company&#x2019;s share-based compensation plans.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2017-10-12_custom_TwentySeventeenStockCompensationPlanMember"
      decimals="INF"
      id="Fact001600"
      unitRef="Shares">1435652</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:SharesIssued
      contextRef="AsOf2019-09-13_custom_TwentySeventeenStockCompensationPlanMember"
      decimals="INF"
      id="Fact001602"
      unitRef="Shares">2638788</us-gaap:SharesIssued>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001604">&lt;p id="xdx_898_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zSodkXedL2Fg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B6_zrJM8IbVxkhe" style="display: none"&gt;Schedule of Option-pricing Model with Following Weighted-average Assumptions&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 65%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Assumptions as of December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;Fully Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 74%; text-align: left"&gt;Number of Shares&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_zOvAN9zZQDL6" style="width: 22%; text-align: right" title="Number of Shares"&gt;1,319,394&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Stock price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--SharePrice_iI_c20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_zd7QjgdqJJwc" style="text-align: right" title="Stock price"&gt;2.67&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_zvltKuMCnOj8" style="text-align: right" title="Exercise price"&gt;6.94&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_zMoDvJx5aIT9" title="Expected term"&gt;5.75&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_zn0fdwdxlpD" style="text-align: right" title="Expected volatility"&gt;31.90&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_zAef3CWeZzr1" style="text-align: right" title="Risk-free interest rate"&gt;3.84&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Dividend rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20230101__20231231__us-gaap--PlanNameAxis__custom--TwentySeventeenStockCompensationPlanMember_zVd9PeRGxHdd" style="text-align: right" title="Dividend rate"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2023-12-31_custom_TwentySeventeenStockCompensationPlanMember"
      decimals="INF"
      id="Fact001606"
      unitRef="Shares">1319394</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:SharePrice
      contextRef="AsOf2023-12-31_custom_TwentySeventeenStockCompensationPlanMember"
      decimals="INF"
      id="Fact001608"
      unitRef="USDPShares">2.67</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2023-12-31_custom_TwentySeventeenStockCompensationPlanMember"
      decimals="INF"
      id="Fact001610"
      unitRef="USDPShares">6.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2023-01-012023-12-31_custom_TwentySeventeenStockCompensationPlanMember"
      id="Fact001612">P5Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2023-01-012023-12-31_custom_TwentySeventeenStockCompensationPlanMember"
      decimals="INF"
      id="Fact001614"
      unitRef="Pure">0.3190</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2023-01-012023-12-31_custom_TwentySeventeenStockCompensationPlanMember"
      decimals="INF"
      id="Fact001616"
      unitRef="Pure">0.0384</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2023-01-012023-12-31_custom_TwentySeventeenStockCompensationPlanMember"
      decimals="INF"
      id="Fact001618"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001620">&lt;p id="xdx_89E_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_z0SXezbnXQoe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following is a summary of stock option activity for the years ended December 31, 2023 and 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="display: none"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B9_z6hMbd0cxl3k" style="display: none"&gt;Schedule of Stock Option Activity&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Avg. Remaining Contractual Life (in years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Avg. Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Aggregate Intrinsic Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; font-weight: bold; text-align: left"&gt;Outstanding as of January 1, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20221231_zZCrZxld5Pja" style="width: 11%; text-align: right" title="Number of Options, Outstanding, Beginning balance"&gt;1,319,394&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20211231_z21YhOqhwyda" title="Weighted Average Remaining Contractual Life (in years), Outstanding"&gt;7.69&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20220101__20221231_z5Fb9NxZcFG5" style="width: 11%; text-align: right" title="Weighted Average Exercise Price, Outstanding, Beginning balance"&gt;6.94&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20220101__20221231_zgfl9C219dV8" style="width: 11%; text-align: right" title="Aggregate Intrinsic Value, Outstanding, Beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1628"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20220101__20221231_zGdVdEKNR3Pf" style="text-align: right" title="Number of Options, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1630"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_uShares_c20220101__20221231_zTmrillIZ9ja" style="text-align: right" title="Number of Options, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1632"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Cancelled/Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_pid_uShares_c20220101__20221231_zNJ5RE84Xqkk" style="text-align: right" title="Number of Options, Cancelled/Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1634"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20220101__20221231_z9OSd5tPk48a" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1636"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Outstanding as of December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20230101__20231231_zfQeHbfbiMJg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, Outstanding, Beginning balance"&gt;1,319,394&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20221231_zRiad09Ik3Ma" title="Weighted Average Remaining Contractual Life (in years), Outstanding"&gt;6.69&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20230101__20231231_z4F1SfXgrd9d" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding, Beginning balance"&gt;6.94&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20230101__20231231_zX6U9TmDrwS9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Aggregate Intrinsic Value, Outstanding, Beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1644"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20230101__20231231_zIbrWIgFhoSc" style="text-align: right" title="Number of Options, Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1646"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_uShares_c20230101__20231231_zzrO0z8gual2" style="text-align: right" title="Number of Options, Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1648"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Cancelled/Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_pid_uShares_c20230101__20231231_zsIq9wAYQfXc" style="text-align: right" title="Number of Options, Cancelled/Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1650"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_uShares_c20230101__20231231_zDsA0ZPH3ep3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, Exercised"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1652"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Outstanding as of December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20230101__20231231_zMLNl3Ld1DX3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, Outstanding, Ending balance"&gt;1,319,394&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20230101__20231231_zDCGuIK6aXWi" title="Weighted Average Remaining Contractual Life (in years), Outstanding"&gt;5.69&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20230101__20231231_zKmIVAqODHM9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Outstanding, Ending balance"&gt;6.94&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20230101__20231231_z8MijdMiMTx9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Aggregate Intrinsic Value, Outstanding, Ending balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1660"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Vested and Exercisable as of December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iE_pid_c20230101__20231231_zF6kLe4J8jHi" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Options, Vested and Exercisable, Ending balance"&gt;1,319,394&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230101__20231231_zooQYAqcfhUh" title="Weighted Average Remaining Contractual Life (in years), Vested and Exercisable"&gt;5.69&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20230101__20231231_zUPUhEvHEX5g" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price, Vested and Exercisable, Ending balance"&gt;6.94&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iE_c20230101__20231231_zAlGieIzA6ae" style="border-bottom: Black 1.5pt solid; text-align: right" title="Aggregate Intrinsic Value, Vested and Exercisable, Ending balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1668"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-12-31"
      decimals="INF"
      id="Fact001622"
      unitRef="Shares">1319394</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2021-01-012021-12-31" id="Fact001624">P7Y8M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31"
      decimals="INF"
      id="Fact001626"
      unitRef="USDPShares">6.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact001638"
      unitRef="Shares">1319394</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2022-01-012022-12-31" id="Fact001640">P6Y8M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-12-31"
      decimals="INF"
      id="Fact001642"
      unitRef="USDPShares">6.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001654"
      unitRef="Shares">1319394</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2023-01-01to2023-12-31" id="Fact001656">P5Y8M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001658"
      unitRef="USDPShares">6.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001662"
      unitRef="Shares">1319394</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2023-01-01to2023-12-31" id="Fact001664">P5Y8M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2023-12-31"
      decimals="INF"
      id="Fact001666"
      unitRef="USDPShares">6.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2023-01-012023-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact001670"
      unitRef="USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2022-01-012022-12-31_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Fact001672"
      unitRef="USD">27319</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001674"
      unitRef="USD">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001676"
      unitRef="USD">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <NRXS:WarrantLiabilitiesDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001678">&lt;p id="xdx_80E_ecustom--WarrantLiabilitiesDisclosureTextBlock_zzo8RXWpQknk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;12.
&lt;span&gt;&lt;span id="xdx_825_zRPCqI4aKDv1"&gt;Warrant Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has evaluated financial instruments arising from an adjustable exercise price for warrants that are issued and outstanding as
of December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company utilizes a Monte Carlo simulation model for warrants that have an option to convert at a variable number of shares to compute
the fair value of the liability and to mark to market the fair value of the derivative at each balance sheet date. The inputs utilized
in the application of the Monte Carlo model included a starting stock price of $&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uUSDPShares_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zf9c74pRMbT7" title="Warrants and rights outstanding, measurement input"&gt;7.91&lt;/span&gt; per share, an expected remaining term of each warrant
as of the valuation date, estimated volatility of &lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zx6QjEVsKMWk" title="Warrants and rights outstanding, measurement input"&gt;75&lt;/span&gt;%, drift, and a risk-free rate ranging from &lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_z3vjS6wCdOOc" title="Warrants and rights outstanding, measurement input"&gt;3.46&lt;/span&gt;% to &lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zPAmnsOCnuwk" title="Warrants and rights outstanding, measurement input"&gt;59.01&lt;/span&gt;%.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk-free
interest rate: The Company uses the risk-free interest rate of a U.S. Treasury Note adjusted to be on a continuous return basis to align
with the Black-Scholes option-pricing model.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dividend
yield: The Company uses a &lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zzjWhuGuqev3" title="Warrants and rights outstanding, measurement input"&gt;0&lt;/span&gt;% expected dividend yield as the Company has not paid dividends to date and does not anticipate declaring
dividends in the near future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Notes to Financial Statements&lt;/b&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Volatility:
The Company calculates the expected volatility based on comparable company&#x2019;s historical stock prices with a look back period commensurate
with the period to maturity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
term: The Company&#x2019;s remaining term is based on the remaining contractual maturity of the warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_897_ecustom--ScheduleOfChangesInWarrantLiabilitiesTableTextBlock_z6Toq9XoRvDd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following are the changes in the warrant liabilities during the years ended December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B1_zAN13vAF9yx" style="display: none"&gt;Schedule of Changes in Warrant Liabilities&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; font-weight: bold; text-align: left"&gt;Warrant liabilities as of January 1, 2022 &lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--WarrantsAndRightsOutstanding_iS_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zTiROgSGmUp5" style="width: 14%; text-align: right" title="Warrant liabilities, Beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1692"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--WarrantsAndRightsOutstanding_iS_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zjQgzvavEJ" style="width: 14%; text-align: right" title="Warrant liabilities, Beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1694"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--WarrantsAndRightsOutstanding_iS_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zNRT00QtzTL1" style="width: 14%; text-align: right" title="Warrant liabilities, Beginning balance"&gt;32,102&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Addition &lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--AdditionToWarrantLiabilities_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zFqbeCr72do1" style="text-align: right" title="Addition"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1698"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--AdditionToWarrantLiabilities_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z9PhqYq2ZPOb" style="text-align: right" title="Addition"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1700"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--AdditionToWarrantLiabilities_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zWQMNmJimNia" style="text-align: right" title="Addition"&gt;2,808,331&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left"&gt;Changes in fair value of warrant liabilities &lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zmkKASd2yON2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Changes in fair value of warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1704"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z4abHtkC2ypb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Changes in fair value of warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1706"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_ziDEp9njSkCd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Changes in fair value of warrant liabilities"&gt;(606,049&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Warrant liabilities as of December 31, 2022 &lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--WarrantsAndRightsOutstanding_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zaPRSuOKnSHe" style="text-align: right" title="Warrant liabilities, Beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1710"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--WarrantsAndRightsOutstanding_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zCuCE8c0iAlf" style="text-align: right" title="Warrant liabilities, Beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1712"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstanding_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z6BtnMSYqUtd" style="text-align: right" title="Warrant liabilities, Beginning balance"&gt;2,234,384&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Addition &lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--AdditionToWarrantLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zn3FBnvSlvEa" style="text-align: right" title="Addition"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1716"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--AdditionToWarrantLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zrw1BWKii3eh" style="text-align: right" title="Addition"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1718"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--AdditionToWarrantLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zoRdUKE3rUJ" style="text-align: right" title="Addition"&gt;2,446,502&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Changes in fair value of warrant liabilities &lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FairValueAdjustmentOfWarrants_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zTA1HjtEEgIi" style="text-align: right" title="Changes in fair value of warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1722"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FairValueAdjustmentOfWarrants_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zWkjqqijvVH7" style="text-align: right" title="Changes in fair value of warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1724"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FairValueAdjustmentOfWarrants_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z4dUUpRfRLva" style="text-align: right" title="Changes in fair value of warrant liabilities"&gt;(844,854&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Reclassified to equity&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ReclassifiedToEquity_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z2cqdPeE1ixg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Reclassified to equity"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1728"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ReclassifiedToEquity_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zYBZUn1D477b" style="border-bottom: Black 1.5pt solid; text-align: right" title="Reclassified to equity"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1730"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ReclassifiedToEquity_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zuLnj3rlaVj6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Reclassified to equity"&gt;(3,827,807&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Warrant liabilities as of December 31, 2023 &lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--WarrantsAndRightsOutstanding_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zVDzO5JoXFJb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrant liabilities, Ending balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1734"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstanding_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zS2JS6R6igP1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrant liabilities, Ending balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1736"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstanding_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zhDRrmhElhV6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrant liabilities, Ending balance"&gt;8,225&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AB_z9QfYeSfYbb8" style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</NRXS:WarrantLiabilitiesDisclosureTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputSharePriceMember"
      decimals="INF"
      id="Fact001680"
      unitRef="USDPShares">7.91</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember"
      decimals="INF"
      id="Fact001682"
      unitRef="Pure">75</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001684"
      unitRef="Pure">3.46</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001686"
      unitRef="Pure">59.01</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember"
      decimals="INF"
      id="Fact001688"
      unitRef="Pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <NRXS:ScheduleOfChangesInWarrantLiabilitiesTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001690">&lt;p id="xdx_897_ecustom--ScheduleOfChangesInWarrantLiabilitiesTableTextBlock_z6Toq9XoRvDd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following are the changes in the warrant liabilities during the years ended December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B1_zAN13vAF9yx" style="display: none"&gt;Schedule of Changes in Warrant Liabilities&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; font-weight: bold; text-align: left"&gt;Warrant liabilities as of January 1, 2022 &lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--WarrantsAndRightsOutstanding_iS_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zTiROgSGmUp5" style="width: 14%; text-align: right" title="Warrant liabilities, Beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1692"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--WarrantsAndRightsOutstanding_iS_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zjQgzvavEJ" style="width: 14%; text-align: right" title="Warrant liabilities, Beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1694"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--WarrantsAndRightsOutstanding_iS_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zNRT00QtzTL1" style="width: 14%; text-align: right" title="Warrant liabilities, Beginning balance"&gt;32,102&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Addition &lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--AdditionToWarrantLiabilities_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zFqbeCr72do1" style="text-align: right" title="Addition"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1698"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_ecustom--AdditionToWarrantLiabilities_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z9PhqYq2ZPOb" style="text-align: right" title="Addition"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1700"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--AdditionToWarrantLiabilities_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zWQMNmJimNia" style="text-align: right" title="Addition"&gt;2,808,331&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left"&gt;Changes in fair value of warrant liabilities &lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zmkKASd2yON2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Changes in fair value of warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1704"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z4abHtkC2ypb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Changes in fair value of warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1706"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FairValueAdjustmentOfWarrants_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_ziDEp9njSkCd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Changes in fair value of warrant liabilities"&gt;(606,049&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Warrant liabilities as of December 31, 2022 &lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--WarrantsAndRightsOutstanding_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zaPRSuOKnSHe" style="text-align: right" title="Warrant liabilities, Beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1710"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--WarrantsAndRightsOutstanding_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zCuCE8c0iAlf" style="text-align: right" title="Warrant liabilities, Beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1712"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstanding_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z6BtnMSYqUtd" style="text-align: right" title="Warrant liabilities, Beginning balance"&gt;2,234,384&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Addition &lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--AdditionToWarrantLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zn3FBnvSlvEa" style="text-align: right" title="Addition"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1716"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--AdditionToWarrantLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zrw1BWKii3eh" style="text-align: right" title="Addition"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1718"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--AdditionToWarrantLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zoRdUKE3rUJ" style="text-align: right" title="Addition"&gt;2,446,502&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Changes in fair value of warrant liabilities &lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FairValueAdjustmentOfWarrants_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zTA1HjtEEgIi" style="text-align: right" title="Changes in fair value of warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1722"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FairValueAdjustmentOfWarrants_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zWkjqqijvVH7" style="text-align: right" title="Changes in fair value of warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1724"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FairValueAdjustmentOfWarrants_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z4dUUpRfRLva" style="text-align: right" title="Changes in fair value of warrant liabilities"&gt;(844,854&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Reclassified to equity&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ReclassifiedToEquity_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z2cqdPeE1ixg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Reclassified to equity"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1728"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ReclassifiedToEquity_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zYBZUn1D477b" style="border-bottom: Black 1.5pt solid; text-align: right" title="Reclassified to equity"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1730"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ReclassifiedToEquity_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zuLnj3rlaVj6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Reclassified to equity"&gt;(3,827,807&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Warrant liabilities as of December 31, 2023 &lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--WarrantsAndRightsOutstanding_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zVDzO5JoXFJb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrant liabilities, Ending balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1734"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--WarrantsAndRightsOutstanding_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zS2JS6R6igP1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrant liabilities, Ending balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1736"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--WarrantsAndRightsOutstanding_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zhDRrmhElhV6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Warrant liabilities, Ending balance"&gt;8,225&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</NRXS:ScheduleOfChangesInWarrantLiabilitiesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2021-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001696"
      unitRef="USD">32102</us-gaap:WarrantsAndRightsOutstanding>
    <NRXS:AdditionToWarrantLiabilities
      contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001702"
      unitRef="USD">2808331</NRXS:AdditionToWarrantLiabilities>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001708"
      unitRef="USD">-606049</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001714"
      unitRef="USD">2234384</us-gaap:WarrantsAndRightsOutstanding>
    <NRXS:AdditionToWarrantLiabilities
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001720"
      unitRef="USD">2446502</NRXS:AdditionToWarrantLiabilities>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001726"
      unitRef="USD">-844854</us-gaap:FairValueAdjustmentOfWarrants>
    <NRXS:ReclassifiedToEquity
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001732"
      unitRef="USD">-3827807</NRXS:ReclassifiedToEquity>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2023-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001738"
      unitRef="USD">8225</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:DerivativesAndFairValueTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001740">&lt;p id="xdx_80D_eus-gaap--DerivativesAndFairValueTextBlock_zRWD11MTfSx3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;13.
&lt;span id="xdx_825_zB63Zc6ElSi9"&gt;Derivative Liabilities&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company has identified derivative instruments arising from the conversion shares discussed in the Convertible Notes section of Note 7
as of December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company utilizes a Monte Carlo simulation model for commitment shares that have an option to convert at a variable number of shares to
compute the fair value of the derivative and to mark to market the fair value of the derivative at each balance sheet date. The inputs
utilized in the application of the Monte Carlo model included a starting stock price of $&lt;span id="xdx_90B_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zhmP5pD8e4Oj" title="Derivative liability, measurement input"&gt;7.91&lt;/span&gt; per share, an expected remaining term of
each warrant as of the valuation date, estimated volatility of &lt;span id="xdx_900_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zUMFYGm5hlLg" title="Derivative liability, measurement input"&gt;70&lt;/span&gt;%, drift, and a risk-free rate ranging from &lt;span id="xdx_90C_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_znYRZFgGftvd" title="Derivative liability, measurement input"&gt;3.46&lt;/span&gt;% to &lt;span id="xdx_90B_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zvB1Y5MAlpZ4" title="Derivative liability, measurement input"&gt;5.47&lt;/span&gt;%.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk-free
interest rate: The Company uses the risk-free interest rate of a U.S. Treasury Note adjusted to be on a continuous return basis to align
with the Black-Scholes option-pricing model.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Dividend
yield: The Company uses a &lt;span id="xdx_909_eus-gaap--DerivativeLiabilityMeasurementInput_iI_pid_uPure_c20231231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zKyTOTQA3O9j" title="Derivative liability, measurement input"&gt;0&lt;/span&gt;% expected dividend yield as the Company has not paid dividends to date and does not anticipate declaring
dividends in the near future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Volatility:
The Company calculates the expected volatility based on comparable company&#x2019;s historical stock prices with a look back period commensurate
with the period to maturity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected
term: The Company&#x2019;s remaining term is based on the remaining contractual maturity of the warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zJdwQatXOJT7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following are the changes in the warrant liabilities during the years ended December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B8_zUOQofGvwwp" style="display: none"&gt;Schedule of Changes in Derivative Liabilities&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Derivative liabilities as of January 1, 2022 &lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--DerivativeLiabilitiesCurrent_iS_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z9jhwzhVpE86" style="text-align: right" title="Derivative liabilities, Beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1754"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--DerivativeLiabilitiesCurrent_iS_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zRx91dD0QrO2" style="text-align: right" title="Derivative liabilities, Beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1756"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--DerivativeLiabilitiesCurrent_iS_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z9IMVBdcuuFb" style="text-align: right" title="Derivative liabilities, Beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1758"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 46%; text-align: left"&gt;Addition &lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--AdditionToDerivativeLiabilities_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zoxD020vegNl" style="width: 14%; text-align: right" title="Addition"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1760"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--AdditionToDerivativeLiabilities_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_ziYC6HGpNHe6" style="width: 14%; text-align: right" title="Addition"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1762"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--AdditionToDerivativeLiabilities_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zaaoT3YzJxqe" style="width: 14%; text-align: right" title="Addition"&gt;2,449,689&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left"&gt;Changes in fair value of Derivative liabilities &lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zAZjwjhblxuf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Changes in fair value of Derivative liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1766"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zR5TmpePO1ng" style="border-bottom: Black 1.5pt solid; text-align: right" title="Changes in fair value of Derivative liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1768"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zYddEwPOCxEd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Changes in fair value of Derivative liabilities"&gt;(713,989&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Derivative liabilities as of December 31, 2022 &lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--DerivativeLiabilitiesCurrent_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zTnpau9Rhcqd" style="text-align: right" title="Derivative liabilities, Beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1772"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--DerivativeLiabilitiesCurrent_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zKCP0izm4NMk" style="text-align: right" title="Derivative liabilities, Beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1774"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--DerivativeLiabilitiesCurrent_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zedFJURVBnq4" style="text-align: right" title="Derivative liabilities, Beginning balance"&gt;1,735,700&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Addition &lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--AdditionToDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zNHky8oLN51c" style="text-align: right" title="Addition"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1778"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--AdditionToDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_ziMUjDmHdjM9" style="text-align: right" title="Addition"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1780"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--AdditionToDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zWqpB46QAE4k" style="text-align: right" title="Addition"&gt;2,375,378&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Changes in fair value of Derivative liabilities &lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zO7swFuSYcIi" style="text-align: right" title="Changes in fair value of Derivative liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1784"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zsbDKxp0tjte" style="text-align: right" title="Changes in fair value of Derivative liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1786"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zv1DJ5mLg454" style="text-align: right" title="Changes in fair value of Derivative liabilities"&gt;(198,551&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Extinguishment of Derivative liabilities &lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ExtinguishmentOfDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zno7fW0abtFb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Extinguishment of Derivative liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1790"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ExtinguishmentOfDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zWWLnmwhY4Wj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Extinguishment of Derivative liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1792"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ExtinguishmentOfDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zKKG6mL1xKxg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Extinguishment of Derivative liabilities"&gt;(3,912,527&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Derivative liabilities as of December 31, 2023 &lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--DerivativeLiabilitiesCurrent_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zrw5GW8U6Vf1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Derivative liabilities, Ending balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1796"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--DerivativeLiabilitiesCurrent_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zgHhWXlCDkz6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Derivative liabilities, Ending balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1798"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--DerivativeLiabilitiesCurrent_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zfaAC5RwmNgg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Derivative liabilities, Ending balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1800"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A8_zcdKM1Q5Bu6k" style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Notes to Financial Statements&lt;/b&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DerivativesAndFairValueTextBlock>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputSharePriceMember"
      decimals="INF"
      id="Fact001742"
      unitRef="Pure">7.91</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputPriceVolatilityMember"
      decimals="INF"
      id="Fact001744"
      unitRef="Pure">70</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001746"
      unitRef="Pure">3.46</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001748"
      unitRef="Pure">5.47</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="AsOf2023-12-31_us-gaap_MeasurementInputExpectedDividendRateMember"
      decimals="INF"
      id="Fact001750"
      unitRef="Pure">0</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001752">&lt;p id="xdx_89F_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zJdwQatXOJT7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
following are the changes in the warrant liabilities during the years ended December 31, 2023 and 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B8_zUOQofGvwwp" style="display: none"&gt;Schedule of Changes in Derivative Liabilities&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Derivative liabilities as of January 1, 2022 &lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--DerivativeLiabilitiesCurrent_iS_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z9jhwzhVpE86" style="text-align: right" title="Derivative liabilities, Beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1754"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--DerivativeLiabilitiesCurrent_iS_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zRx91dD0QrO2" style="text-align: right" title="Derivative liabilities, Beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1756"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--DerivativeLiabilitiesCurrent_iS_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z9IMVBdcuuFb" style="text-align: right" title="Derivative liabilities, Beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1758"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 46%; text-align: left"&gt;Addition &lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--AdditionToDerivativeLiabilities_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zoxD020vegNl" style="width: 14%; text-align: right" title="Addition"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1760"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--AdditionToDerivativeLiabilities_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_ziYC6HGpNHe6" style="width: 14%; text-align: right" title="Addition"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1762"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--AdditionToDerivativeLiabilities_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zaaoT3YzJxqe" style="width: 14%; text-align: right" title="Addition"&gt;2,449,689&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left"&gt;Changes in fair value of Derivative liabilities &lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zAZjwjhblxuf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Changes in fair value of Derivative liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1766"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zR5TmpePO1ng" style="border-bottom: Black 1.5pt solid; text-align: right" title="Changes in fair value of Derivative liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1768"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_c20220101__20221231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zYddEwPOCxEd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Changes in fair value of Derivative liabilities"&gt;(713,989&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Derivative liabilities as of December 31, 2022 &lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--DerivativeLiabilitiesCurrent_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zTnpau9Rhcqd" style="text-align: right" title="Derivative liabilities, Beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1772"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--DerivativeLiabilitiesCurrent_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zKCP0izm4NMk" style="text-align: right" title="Derivative liabilities, Beginning balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1774"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--DerivativeLiabilitiesCurrent_iS_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zedFJURVBnq4" style="text-align: right" title="Derivative liabilities, Beginning balance"&gt;1,735,700&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Addition &lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--AdditionToDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zNHky8oLN51c" style="text-align: right" title="Addition"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1778"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--AdditionToDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_ziMUjDmHdjM9" style="text-align: right" title="Addition"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1780"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--AdditionToDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zWqpB46QAE4k" style="text-align: right" title="Addition"&gt;2,375,378&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Changes in fair value of Derivative liabilities &lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zO7swFuSYcIi" style="text-align: right" title="Changes in fair value of Derivative liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1784"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zsbDKxp0tjte" style="text-align: right" title="Changes in fair value of Derivative liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1786"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--IncreaseDecreaseInDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zv1DJ5mLg454" style="text-align: right" title="Changes in fair value of Derivative liabilities"&gt;(198,551&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Extinguishment of Derivative liabilities &lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ExtinguishmentOfDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zno7fW0abtFb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Extinguishment of Derivative liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1790"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ExtinguishmentOfDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zWWLnmwhY4Wj" style="border-bottom: Black 1.5pt solid; text-align: right" title="Extinguishment of Derivative liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1792"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ExtinguishmentOfDerivativeLiabilities_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zKKG6mL1xKxg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Extinguishment of Derivative liabilities"&gt;(3,912,527&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Derivative liabilities as of December 31, 2023 &lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--DerivativeLiabilitiesCurrent_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zrw5GW8U6Vf1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Derivative liabilities, Ending balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1796"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--DerivativeLiabilitiesCurrent_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zgHhWXlCDkz6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Derivative liabilities, Ending balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1798"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--DerivativeLiabilitiesCurrent_iE_c20230101__20231231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zfaAC5RwmNgg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Derivative liabilities, Ending balance"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1800"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
    <NRXS:AdditionToDerivativeLiabilities
      contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001764"
      unitRef="USD">2449689</NRXS:AdditionToDerivativeLiabilities>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="From2022-01-012022-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001770"
      unitRef="USD">-713989</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="AsOf2022-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001776"
      unitRef="USD">1735700</us-gaap:DerivativeLiabilitiesCurrent>
    <NRXS:AdditionToDerivativeLiabilities
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001782"
      unitRef="USD">2375378</NRXS:AdditionToDerivativeLiabilities>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001788"
      unitRef="USD">-198551</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <NRXS:ExtinguishmentOfDerivativeLiabilities
      contextRef="From2023-01-012023-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact001794"
      unitRef="USD">-3912527</NRXS:ExtinguishmentOfDerivativeLiabilities>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001802">&lt;p id="xdx_801_eus-gaap--PensionAndOtherPostretirementBenefitsDisclosureTextBlock_zQcHPpmX8I0i" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;14.
&lt;span id="xdx_826_zd2VxD42aQO8"&gt;Retirement Plan&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company sponsors a 401(k)-retirement plan for its employees. Employees are eligible to participate in the elective deferral portion of
the plan after twelve months and 1,000 hours of service. The Company matches the employees&#x2019; contribution up to &lt;span id="xdx_90F_eus-gaap--DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_dp_uPure_c20230101__20231231_zZ7DXKw6wWtc" title="Employee contribution percentage"&gt;3&lt;/span&gt;%. The Company
can also make a discretionary profit-sharing contribution to the employee accounts on an annual basis. Expense totaled $&lt;span id="xdx_90C_eus-gaap--DefinedContributionPlanAdministrativeExpenses_c20230101__20231231_z4JY1QuDSDfh" title="Profit sharing contribution expenses"&gt;6,980&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--DefinedContributionPlanAdministrativeExpenses_c20220101__20221231_zIhw0T9M57Wk" title="Profit sharing contribution expenses"&gt;17,183&lt;/span&gt;
for years ended December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact001804"
      unitRef="Pure">0.03</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanAdministrativeExpenses
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact001806"
      unitRef="USD">6980</us-gaap:DefinedContributionPlanAdministrativeExpenses>
    <us-gaap:DefinedContributionPlanAdministrativeExpenses
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001808"
      unitRef="USD">17183</us-gaap:DefinedContributionPlanAdministrativeExpenses>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001810">&lt;p id="xdx_809_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zdr9r6ZoLDHh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;15&lt;/b&gt;.
&lt;b&gt;&lt;span id="xdx_827_zcI7DZSDJVEk"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Manufacturing
Services Agreement&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
August 21, 2020, the Company entered into a Manufacturing Services Agreement (MSA) for the manufacture and supply of the Company&#x2019;s
IB-STIM device based upon the Company&#x2019;s product specifications as set forth in the MSA. This agreement terminated any prior manufacturing
agreements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company provides the necessary equipment to the manufacturer and retains ownership. The manufacturer bears the risk of loss of and damage
to the equipment and consigned materials. Performance under the MSA is initiated by orders issued by the Company and accepted by the
manufacturer.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
term of the MSA is 24 months and shall automatically renew for renewal terms of twelve months unless either party provides a written
termination notice to the other party within 180 days prior to the end of the then-current term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Trademark
Agreement&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company entered into an agreement for a trademark related to the Company&#x2019;s name on July 11, 2022. The agreement called for an initial
payment of $&lt;span id="xdx_90D_eus-gaap--PaymentsForRepurchaseOfInitialPublicOffering_c20220711__20220711__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--TypeOfArrangementAxis__custom--TrademarkAgreementMember__us-gaap--OtherCommitmentsAxis__custom--InitialPaymentMember_zwCmaO39YmNe" title="Payments for repurchase of initial public offering"&gt;10,000&lt;/span&gt; upon execution of the agreement. A second and final payment of $&lt;span id="xdx_905_eus-gaap--PaymentsForRepurchaseOfInitialPublicOffering_c20220711__20220711__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember__us-gaap--TypeOfArrangementAxis__custom--TrademarkAgreementMember__us-gaap--OtherCommitmentsAxis__custom--SecondAndFinalPaymentMember_zsCbdSjUdMUf" title="Payments for repurchase of initial public offering"&gt;40,000&lt;/span&gt; was contingent upon the completion of the Company&#x2019;s
planned initial public offering. The second payment has been accrued and is recorded in accounts payable and intangible assets on the
balance sheet. The trademark does not have a determinate life and therefore the cost is not being amortized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Executive
Employment Agreements&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company, as authorized by the board of directors, entered into employment agreements with nine key employees to provide incentives to
improve shareholder value and to contribute to the growth and financial success of the Company. The agreements had an employment start
date of October 1, 2022, with initial terms from &lt;span id="xdx_904_ecustom--ExecutiveEmploymentAgreementsTerms_dtY_c20221001__20221001__srt--RangeAxis__srt--MinimumMember__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember_zrOo1cIDeiD1" title="Executive employment agreements renewals"&gt;2&lt;/span&gt; to &lt;span id="xdx_90A_ecustom--ExecutiveEmploymentAgreementsTerms_dtY_c20221001__20221001__srt--RangeAxis__srt--MaximumMember__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember_zPeqIA3bvnO1" title="Executive employment agreements renewals"&gt;5&lt;/span&gt; years and &lt;span id="xdx_900_ecustom--DescriptionOfExecutiveEmploymentAgreementsRenewals_dtY_c20221001__20221001__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember_zT02Ac9G2ARk" title="Description of Executive employment agreements renewals"&gt;optional one-year renewals&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
total base salaries for the nine key employees in the agreements are $&lt;span id="xdx_906_eus-gaap--SalariesAndWages_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember_ztNGYbdIZ0oc"&gt;1,920,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;per year with various provisions for annual increases.
In addition to base salaries, eight of the employees have a provision for a special one-time incentive payment to be paid in a lump sum
after the start date. The total amount of these special incentive payments is $&lt;span id="xdx_90C_eus-gaap--IncentiveFeeExpense_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember_z3wBPMLu5LMa"&gt;1,100,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;.
The special incentive payment amount includes any accrued backpay wages for the employee. The amount for backpay of $&lt;span id="xdx_902_eus-gaap--DepositLiabilitiesAccruedInterest_iI_c20221231_zcYHS5KsKxT7"&gt;&lt;span id="xdx_906_eus-gaap--DepositLiabilitiesAccruedInterest_iI_c20231231_zBzu1gXsKQi6"&gt;417,390&lt;/span&gt;&lt;/span&gt; was accrued
as of December 31, 2022 and paid in the year ended December 31, 2023. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;There
are seven key employees that have stock options of the Company totaling &lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_pid_uShares_c20230101__20231231__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember_zGN4ztPM74pl" title="Seven key employees stock options"&gt;1,238,712&lt;/span&gt; shares. These key employees have a provision in their
agreements whereas the Company will pay a special bonus equal to the aggregate of the strike price or exercise price of all their stock
options plus a tax gross-up payment. The special bonus shall be paid in twenty percent (&lt;span id="xdx_90D_ecustom--SpecialBonusPercentage_iI_pid_dp_uPure_c20240102__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember_zBTPchefe9bl" title="Special bonus percentage"&gt;20&lt;/span&gt;%) installments starting January 2, 2024, and
the same date each of the next four years. As a condition of the payment, the key employee must exercise at least &lt;span id="xdx_90C_ecustom--KeyEmployeeExercisePercentage_iI_pid_dp_uPure_c20240102__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember__srt--RangeAxis__srt--MinimumMember_zt6ObCrqokhj" title="Key employee exercise percentage"&gt;20&lt;/span&gt;% of their stated
number of stock options. There are additional provisions to cover termination and change of control events. None of the key employees
exercised the options on January 2, 2024&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In
April 2023, the Company amended the employee agreements to, among other things, clarify that the special one-time incentive payment and
the deferred bonus are contingent upon the effective date of the planned initial public offering. The amendment also sets forth a process
for executives to exercise the stock options in accordance with the terms of the stock option agreement in effect as of the date of the
employment agreement and to clarify that there is no modification to the stock option agreements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Notes to Financial Statements&lt;/b&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;The Company has recorded the backpay portion of the incentive
bonus notes above. The balance of the incentive bonuses of $&lt;span id="xdx_901_eus-gaap--AccruedBonusesCurrent_iI_c20230430__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember_zikAkNLpoOud" title="Incentive bonus"&gt;694,056&lt;/span&gt; and the special options bonuses of $&lt;span id="xdx_90E_eus-gaap--AccruedBonusesCurrent_iI_c20230430__us-gaap--TypeOfArrangementAxis__custom--ExecutiveEmploymentAgreementsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--IPOMember_zaaEuPADg5y6" title="Incentive bonus"&gt;14,821,830&lt;/span&gt; were contingent upon
a successful IPO. The incentive bonuses have been paid in full while the special options bonuses will be recorded when paid.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt/107% Times New Roman, Times, Serif; margin: 0 0 8pt"&gt;&lt;b&gt;Litigation&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;From time to time, the Company may be involved
in litigation relating to claims arising out of operations in the normal course of business. As of the date of issuance, other than those
described below, there were no pending or threatened legal proceedings that could reasonably be expected to have a material effect
on the results of the Company&#x2019;s operations. There are also no proceedings in which any of the Company&#x2019;s directors,
officers or affiliates is an adverse party to the Company or has a material interest adverse to the Company&#x2019;s interest.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;On February 6, 2019, plaintiff Ritu Bhambhani, M.D.,
initiated a lawsuit against Innovative Health Solutions, Inc. and others in the United States District Court for the District of Maryland.
Plaintiffs Bhambhani and Sudhir Rao subsequently amended the complaint, with the Third Amended Complaint (&#x201c;Complaint&#x201d;) containing
the most recent set of allegations. The Complaint asserted claims under the RICO Act, as well as of fraudulent misrepresentation, intentional
misrepresentation by concealment, and civil conspiracy and sought compensatory damages in excess of $&lt;span id="xdx_901_eus-gaap--LossContingencyDamagesSoughtValue_pn6n6_c20190205__20190206_zPxZIpYxqCr1" title="Sought compensatory damages"&gt;5&lt;/span&gt; million, pre-judgment interest,
punitive damages, attorney&#x2019;s fees, court costs and designation of the case as a class action. The Complaint states that the Company,
distributors of the Company&#x2019;s product, and medical billing and coding consultants allegedly made misrepresentations to the plaintiffs
that the Company&#x2019;s NeuroStim device and related procedures could be billed to, and reimbursed by, Medicare and other insurance payors
as a surgically implantable neurostimulator. Plaintiffs claim to have suffered damages when Medicare administrative contractors declined
to pay plaintiffs for their use of the device.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;On February 11, 2022, the Company filed a motion for
summary judgment based upon the plaintiffs not being proper parties to assert claims against the Company. On June 14, 2022, the Court
granted the Company&#x2019;s motion for summary judgment and dismissed the Complaint.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;On July 14, 2022, plaintiffs Ritu Bhambhani and Sudhir
Rao filed a notice of appeal with the Fourth Circuit Court of Appeals. The Company filed a motion to dismiss.&#160;On January 4, 2023,
the Court issued an order that stated it was deferring a ruling on the motion to dismiss the appeal and that&#160;it would address those
arguments at the same time that it addressed the substantive merits of the case. While it is too early to predict the ultimate outcome of this matter, we continue to believe we have
meritorious defenses, that the dismissal of the Complaint should be upheld, and intend to continue to defend this matter vigorously.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;On July 14, 2022, plaintiffs Ritu Bhambhani, LLC;
Box Hill Surgery Center, LLC; Pain and Spine Specialists of Maryland, LLC; and SimCare ASC, LLC initiated a lawsuit against the Company
and others in the United States District Court for the District of Maryland. The plaintiffs in this lawsuit are business entities owned
or partially owned by the plaintiffs that initiated the litigation described above. The Complaint asserted claims under the RICO Act,
as well as fraudulent misrepresentation, intentional misrepresentation by concealment, and civil conspiracy and seeks compensatory damages
in excess of $&lt;span id="xdx_900_eus-gaap--LossContingencyDamagesSoughtValue_c20220713__20220714_zJpRVxmhzaac" title="Sought compensatory damages"&gt;75,000&lt;/span&gt;, pre-judgment interest, punitive damages, attorney&#x2019;s fees, and court costs. The Complaint states that the Company,
distributors of the Company&#x2019;s product, and medical billing and coding consultants allegedly made misrepresentations to the plaintiffs
that the Company&#x2019;s NeuroStim device and related procedures could be billed to, and reimbursed by, Medicare and other insurance payors
as a surgically implantable neurostimulator. Plaintiffs claim to have suffered damages when Medicare administrative contractors declined
to pay plaintiffs for their use of the device.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;On September 28, 2022, the Company filed a motion to dismiss all
claims. On May 25, 2023, the Court issued an Order and a Memorandum Opinion which dismissed the plaintiffs&#x2019;claims related to the
RICO Act. The remaining claims are still pending, and no trial date has been set for the case. &lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;The Court has vacated its Scheduling Order
at the parties&#x2019; request so that the parties could try to resolve the disputes in both cases through an independent &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;third-party&lt;/span&gt;
mediator. No mediation date has been set. While it is too early to predict the ultimate
outcome of this matter, we believe the Company has meritorious defenses and intends to defend this matter vigorously.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Notes to Financial Statements&lt;/b&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:PaymentsForRepurchaseOfInitialPublicOffering
      contextRef="From2022-07-112022-07-11_us-gaap_IPOMember_custom_TrademarkAgreementMember_custom_InitialPaymentMember"
      decimals="0"
      id="Fact001812"
      unitRef="USD">10000</us-gaap:PaymentsForRepurchaseOfInitialPublicOffering>
    <us-gaap:PaymentsForRepurchaseOfInitialPublicOffering
      contextRef="From2022-07-112022-07-11_us-gaap_IPOMember_custom_TrademarkAgreementMember_custom_SecondAndFinalPaymentMember"
      decimals="0"
      id="Fact001814"
      unitRef="USD">40000</us-gaap:PaymentsForRepurchaseOfInitialPublicOffering>
    <NRXS:ExecutiveEmploymentAgreementsTerms
      contextRef="From2022-10-012022-10-01_srt_MinimumMember_custom_ExecutiveEmploymentAgreementsMember"
      id="Fact001816">P2Y</NRXS:ExecutiveEmploymentAgreementsTerms>
    <NRXS:ExecutiveEmploymentAgreementsTerms
      contextRef="From2022-10-012022-10-01_srt_MaximumMember_custom_ExecutiveEmploymentAgreementsMember"
      id="Fact001818">P5Y</NRXS:ExecutiveEmploymentAgreementsTerms>
    <NRXS:DescriptionOfExecutiveEmploymentAgreementsRenewals
      contextRef="From2022-10-012022-10-01_custom_ExecutiveEmploymentAgreementsMember"
      id="Fact001820">optional one-year renewals</NRXS:DescriptionOfExecutiveEmploymentAgreementsRenewals>
    <us-gaap:SalariesAndWages
      contextRef="From2023-01-012023-12-31_custom_ExecutiveEmploymentAgreementsMember"
      decimals="0"
      id="Fact001821"
      unitRef="USD">1920000</us-gaap:SalariesAndWages>
    <us-gaap:IncentiveFeeExpense
      contextRef="From2023-01-012023-12-31_custom_ExecutiveEmploymentAgreementsMember"
      decimals="0"
      id="Fact001822"
      unitRef="USD">1100000</us-gaap:IncentiveFeeExpense>
    <us-gaap:DepositLiabilitiesAccruedInterest
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001823"
      unitRef="USD">417390</us-gaap:DepositLiabilitiesAccruedInterest>
    <us-gaap:DepositLiabilitiesAccruedInterest
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001824"
      unitRef="USD">417390</us-gaap:DepositLiabilitiesAccruedInterest>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan
      contextRef="From2023-01-012023-12-31_custom_ExecutiveEmploymentAgreementsMember"
      decimals="INF"
      id="Fact001826"
      unitRef="Shares">1238712</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan>
    <NRXS:SpecialBonusPercentage
      contextRef="AsOf2024-01-02_us-gaap_SubsequentEventMember_custom_ExecutiveEmploymentAgreementsMember"
      decimals="INF"
      id="Fact001828"
      unitRef="Pure">0.20</NRXS:SpecialBonusPercentage>
    <NRXS:KeyEmployeeExercisePercentage
      contextRef="AsOf2024-01-02_us-gaap_SubsequentEventMember_custom_ExecutiveEmploymentAgreementsMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001830"
      unitRef="Pure">0.20</NRXS:KeyEmployeeExercisePercentage>
    <us-gaap:AccruedBonusesCurrent
      contextRef="AsOf2023-04-30_custom_ExecutiveEmploymentAgreementsMember"
      decimals="0"
      id="Fact001832"
      unitRef="USD">694056</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="AsOf2023-04-30_custom_ExecutiveEmploymentAgreementsMember_us-gaap_IPOMember"
      decimals="0"
      id="Fact001834"
      unitRef="USD">14821830</us-gaap:AccruedBonusesCurrent>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="From2019-02-052019-02-06"
      decimals="-6"
      id="Fact001836"
      unitRef="USD">5000000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="From2022-07-132022-07-14"
      decimals="0"
      id="Fact001838"
      unitRef="USD">75000</us-gaap:LossContingencyDamagesSoughtValue>
    <NRXS:HealthBenefitPlanDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001840">&lt;p id="xdx_801_ecustom--HealthBenefitPlanDisclosureTextBlock_zsgutNsRxR7e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;16.
&lt;span id="xdx_821_zCZZocpiAC2i"&gt;Health Benefit Plan&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company entered into a self-funded program employer agreement in 2018 in conjunction with a group health plan for the benefit of eligible
employees. This plan is a level funded plan, and the services and products include:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
    self-funded employer health benefit plan.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Stop
    loss insurance purchased from a stop loss insurance company.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Third
    party administrator to provide administrative services with regard to the plan.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company maintains a stop loss contract that reimburses the Company for claims paid under the plan if they exceed a predetermined level.
The Company makes contributions for health care costs and associated expenses that are expected during the plan year. The amount of contributions
is determined annually based on the Company&#x2019;s maximum liability for expected claims, administrative expenses, and premiums for
the stop loss policy. The Company paid premiums of $&lt;span id="xdx_90C_eus-gaap--HealthCareOrganizationStopLossInsurancePremiumExpense_c20230101__20231231_zgAx37ltp1q7" title="Stop loss insurance premium expense"&gt;255,715&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--HealthCareOrganizationStopLossInsurancePremiumExpense_c20220101__20221231_zGfPfHjLs6H1" title="Stop loss insurance premium expense"&gt;196,929&lt;/span&gt; for the years ended December 31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company is responsible for the monthly premiums, as established, and nothing further. The stop loss policy covers the claims if they
exceed the claims funds. After a certain time, and if there is a surplus in the claims fund, the Company may be entitled to receive a
&lt;span id="xdx_90F_ecustom--HealthCareOrganizationStopLossInsurancePremiumPercentage_pid_dp_uPure_c20230101__20231231_zi24CLyZG2F8" title="Stop loss insurance premium percentage"&gt;48.5&lt;/span&gt;% refund from the fund. This amount is recognized by the Company when received.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</NRXS:HealthBenefitPlanDisclosureTextBlock>
    <us-gaap:HealthCareOrganizationStopLossInsurancePremiumExpense
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact001842"
      unitRef="USD">255715</us-gaap:HealthCareOrganizationStopLossInsurancePremiumExpense>
    <us-gaap:HealthCareOrganizationStopLossInsurancePremiumExpense
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001844"
      unitRef="USD">196929</us-gaap:HealthCareOrganizationStopLossInsurancePremiumExpense>
    <NRXS:HealthCareOrganizationStopLossInsurancePremiumPercentage
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact001846"
      unitRef="Pure">0.485</NRXS:HealthCareOrganizationStopLossInsurancePremiumPercentage>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001848">&lt;p id="xdx_802_eus-gaap--IncomeTaxDisclosureTextBlock_zs7jTnMhY58c" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;17.
&lt;span id="xdx_82C_zq1S6XHJZQGi"&gt;Income Taxes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Inflation Reduction Act (IRA) was signed
into law on August 16, 2022, imposing a 15% corporate alternative minimum tax on adjusted financial statement income and a 1% excise
tax on stock repurchases after January 1, 2023. The IRA did not have an impact on the Company&#x2019;s 2023 or 2022 financial
statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Tax Cuts and Jobs Act (TCJA) requires taxpayers
to capitalize and amortize research and developmental (&#x201c;R&amp;amp;D&#x201d;) expenditures undersection 174 for tax years beginning after
December 31, 2021 and, therefore, became effective for the Company during the year ended December 31, 2022. The TCJA resulted in the capitalization
of R&amp;amp;D costs of $&lt;span id="xdx_90E_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_c20231231_zHxmYUO7SED7" title="Research and development expense"&gt;169,315&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--DeferredTaxAssetsTaxCreditCarryforwardsResearch_iI_c20221231_zQsy7EgEb3B9" title="Research and development expense"&gt;225,466&lt;/span&gt; for tax purposes for the years ended December 31, 2023 and 2022, respectively. The Company is
amortizing these costs over 5 years if the R&amp;amp;D was performed in the U.S. and over 15 years if the R&amp;amp;D was performed outside the
US. The Company did not recognize a current provision for income taxes for 2023 and 2022 since there were net operating losses reported
in both years.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Deferred income taxes are provided for temporary
differences between the financial reporting basis and the tax basis of the Company&#x2019;s assets and liabilities. Differences are primarily
attributable to net operating loss carryforwards and stock-based compensation. The Company does not reflect any deferred taxes in its financial
statements due to a full valuation allowance. The net deferred tax amounts include the following components:&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zgxHJDSet3c6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B6_zsvq5IwiPWJk" style="display: none"&gt;Schedule of Deferred Tax Asset&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20231231_zUAjjHz2OOWb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20221231_zwxwQFFiRWaj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Net deferred tax assets - Non-current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--DeferredTaxAssetsDepreciation_iI_maDTANzFzE_zpjtVKHNnBh7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Depreciation&lt;/td&gt;&lt;td style="width: 2%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-weight: bold; text-align: right"&gt;(15,175&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(16,098&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--DeferredTaxAssetsAmortization_iI_maDTANzFzE_zr2UKuOK9QLf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Amortization&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(14,195&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(19,290&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_iI_maDTANzFzE_z14UjS7TVmNc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrual to cash&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;718,893&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;767,861&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTANzFzE_zqfagDjdXrQ9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Stock based compensation&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;3,653,490&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,653,490&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTANzFzE_zlDyBEzatgGf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected income tax benefit from NOL carry-forwards&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;6,573,406&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,309,340&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzFzE_zzVF2dVXevJ" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less valuation allowance&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;(10,916,419&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(7,695,303&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzFzE_znuM3OXHLwsl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Deferred tax assets, net of valuation allowance&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1874"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1875"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A5_zQBkM4bX6Rh2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Neuraxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;b&gt;Notes to Financial Statements&lt;/b&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zICFLbegfY6a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
reconciliation of the federal statutory income tax rate and the effective income tax rate as a percentage of income before income
taxes is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BC_zpruKJf8hmd5" style="display: none"&gt;Schedule of Federal Statutory Income Tax Rate and Effective Income Tax Rate&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20230101__20231231_z59WnKOa1Zi6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20220101__20221231_zzwnLnAc0SWc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maEIT001_zP3M6DNxZ3p" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Federal statutory income tax rate&lt;/td&gt;&lt;td style="width: 2%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; font-weight: bold; text-align: right"&gt;21.0&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maEIT001_zuk7jKPhTKNg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;State tax rate, net of federal benefit&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;4.9&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.7&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_pid_dp_uPure_maEIT001_zpBL7zNHp4Ig" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Nondeductible expenses&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1885"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1886"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--EffectiveIncomeTaxRateReconciliationNontaxableIncome_pid_dp_uPure_maEIT001_zHe6GGriUl68" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Nontaxable income&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1888"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1889"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maEIT001_zTYwymOSv2yb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in valuation allowance on net deferred tax assets&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;(25.9&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(25.7&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtEIT001_zaePfdx4WEW6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Effective income tax rate&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1894"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1895"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AC_zF2UMsOv6J8h" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company had no income tax expense due to the operating loss incurred for the years ended December 31, 2023 and 2022. The
Company&#x2019;s management has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax
assets and has determined that it is more likely than not that the Company will not recognize the benefits of the net deferred tax
assets. As a result, the Company recorded a full valuation allowance at December 31, 2023 and 2022. The valuation allowance
increased by $&lt;span id="xdx_90A_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_c20230101__20231231_zOfIjaWhPGM6" title="Deferred tax assets valuation allowance"&gt;3,221,116&lt;/span&gt;
and $&lt;span id="xdx_906_eus-gaap--IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_c20220101__20221231_zJ8K0yRbxiGh" title="Deferred tax assets valuation allowance"&gt;1,136,470&lt;/span&gt; for the years ended December 31, 2023 and 2022, respectively, primarily due to net operating loss (NOL)
carryforwards.  &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On
December 31, 2023, the Company had federal and state net operating loss (NOL) carryforwards totaling $&lt;span id="xdx_90D_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_c20231231_zttitOLQQve8" title="Federal and state net operating loss"&gt;28,238,445&lt;/span&gt; and $&lt;span id="xdx_90C_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_c20221231_zXCAFy0TSdye" title="Federal and state net operating loss"&gt;25,543,000&lt;/span&gt;, respectively.
These loss carryforwards may be offset against future taxable income. There is no limitation on the number of years to utilize the federal
NOL. The federal deduction will be limited to 80% of modified taxable income. The state NOL allows up to 100% of taxable income to be
offset and can be carried forward no longer than 20 years after the year of the taxable loss.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Federal
and state tax laws impose limitations on the utilization of NOLs and credit carryforwards in the event of an ownership
change for tax purposes, as defined in Section 382 of the Internal Revenue Code. Accordingly, the Company&#x2019;s ability to utilize
these carryforwards may be limited as a result of an ownership change. Such
an ownership change could result in a limitation in the use of the net operating losses in future years and possibly a reduction of the
net operating losses available.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--SummaryOfOperatingLossCarryforwardsTextBlock_zuWUZHLVUHcg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If
not used, the state carryforwards will expire as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BB_zACIjTRNE0Bj" style="display: none"&gt;Schedule of State Carryforwards&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_495_20231231_z2i4eP1rf9I4" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--TaxYear2038Member_zcmuelte7Jx8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: justify"&gt;2038&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;888,389&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--TaxYear2039Member_zcaDcM4YT0b7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;2039&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,039,949&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--TaxYear2040Member_zJD30KX1QMbf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;2040&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;4,457,495&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--TaxYear2041Member_zHbzhjCnguzj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;2041&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,406,225&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--TaxYear2042Member_z25W3LxayKI7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;2042&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,730,141&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--TaxYear2043Member_zzAtvMCDGtJ9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;2043&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;12,915,439&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--TaxYear2043Member_z7JUo4OntuBc" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;State Carryforwards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;12,915,439&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p id="xdx_8A1_z7vr3pLjO0Hb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001850"
      unitRef="USD">169315</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001852"
      unitRef="USD">225466</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001854">&lt;p id="xdx_897_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zgxHJDSet3c6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8B6_zsvq5IwiPWJk" style="display: none"&gt;Schedule of Deferred Tax Asset&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20231231_zUAjjHz2OOWb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20221231_zwxwQFFiRWaj" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Net deferred tax assets - Non-current&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--DeferredTaxAssetsDepreciation_iI_maDTANzFzE_zpjtVKHNnBh7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 60%; text-align: left"&gt;Depreciation&lt;/td&gt;&lt;td style="width: 2%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-weight: bold; text-align: right"&gt;(15,175&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;(16,098&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--DeferredTaxAssetsAmortization_iI_maDTANzFzE_zr2UKuOK9QLf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Amortization&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;(14,195&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(19,290&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther_iI_maDTANzFzE_z14UjS7TVmNc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrual to cash&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;718,893&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;767,861&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_iI_maDTANzFzE_zqfagDjdXrQ9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Stock based compensation&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;3,653,490&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,653,490&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_maDTANzFzE_zlDyBEzatgGf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected income tax benefit from NOL carry-forwards&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;6,573,406&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,309,340&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_di_msDTANzFzE_zzVF2dVXevJ" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less valuation allowance&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;(10,916,419&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(7,695,303&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsNet_iTI_mtDTANzFzE_znuM3OXHLwsl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Deferred tax assets, net of valuation allowance&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1874"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1875"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <NRXS:DeferredTaxAssetsDepreciation
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001856"
      unitRef="USD">-15175</NRXS:DeferredTaxAssetsDepreciation>
    <NRXS:DeferredTaxAssetsDepreciation
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001857"
      unitRef="USD">-16098</NRXS:DeferredTaxAssetsDepreciation>
    <NRXS:DeferredTaxAssetsAmortization
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001859"
      unitRef="USD">-14195</NRXS:DeferredTaxAssetsAmortization>
    <NRXS:DeferredTaxAssetsAmortization
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001860"
      unitRef="USD">-19290</NRXS:DeferredTaxAssetsAmortization>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001862"
      unitRef="USD">718893</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001863"
      unitRef="USD">767861</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001865"
      unitRef="USD">3653490</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001866"
      unitRef="USD">3653490</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001868"
      unitRef="USD">6573406</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001869"
      unitRef="USD">3309340</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001871"
      unitRef="USD">10916419</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001872"
      unitRef="USD">7695303</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001877">&lt;p id="xdx_892_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zICFLbegfY6a" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A
reconciliation of the federal statutory income tax rate and the effective income tax rate as a percentage of income before income
taxes is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BC_zpruKJf8hmd5" style="display: none"&gt;Schedule of Federal Statutory Income Tax Rate and Effective Income Tax Rate&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 95%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_498_20230101__20231231_z59WnKOa1Zi6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20220101__20221231_zzwnLnAc0SWc" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_maEIT001_zP3M6DNxZ3p" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Federal statutory income tax rate&lt;/td&gt;&lt;td style="width: 2%; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; font-weight: bold; text-align: right"&gt;21.0&lt;/td&gt;&lt;td style="width: 1%; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right"&gt;21.0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_uPure_maEIT001_zuk7jKPhTKNg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;State tax rate, net of federal benefit&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;4.9&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.7&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--EffectiveIncomeTaxRateReconciliationNondeductibleExpense_pid_dp_uPure_maEIT001_zpBL7zNHp4Ig" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Nondeductible expenses&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1885"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1886"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--EffectiveIncomeTaxRateReconciliationNontaxableIncome_pid_dp_uPure_maEIT001_zHe6GGriUl68" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Nontaxable income&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1888"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1889"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_uPure_maEIT001_zTYwymOSv2yb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in valuation allowance on net deferred tax assets&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;(25.9&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(25.7&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_iT_pid_dp_uPure_mtEIT001_zaePfdx4WEW6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Effective income tax rate&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1894"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1895"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact001879"
      unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact001880"
      unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact001882"
      unitRef="Pure">0.049</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact001883"
      unitRef="Pure">0.047</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2023-01-01to2023-12-31"
      decimals="INF"
      id="Fact001891"
      unitRef="Pure">-0.259</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2022-01-012022-12-31"
      decimals="INF"
      id="Fact001892"
      unitRef="Pure">-0.257</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2023-01-01to2023-12-31"
      decimals="0"
      id="Fact001897"
      unitRef="USD">3221116</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2022-01-012022-12-31"
      decimals="0"
      id="Fact001899"
      unitRef="USD">1136470</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001901"
      unitRef="USD">28238445</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact001903"
      unitRef="USD">25543000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001905">&lt;p id="xdx_89B_eus-gaap--SummaryOfOperatingLossCarryforwardsTextBlock_zuWUZHLVUHcg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If
not used, the state carryforwards will expire as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;span id="xdx_8BB_zACIjTRNE0Bj" style="display: none"&gt;Schedule of State Carryforwards&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 50%; margin-right: auto"&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_495_20231231_z2i4eP1rf9I4" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--TaxYear2038Member_zcmuelte7Jx8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: justify"&gt;2038&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;888,389&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--TaxYear2039Member_zcaDcM4YT0b7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;2039&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;1,039,949&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--TaxYear2040Member_zJD30KX1QMbf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;2040&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;4,457,495&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--TaxYear2041Member_zHbzhjCnguzj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;2041&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,406,225&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--TaxYear2042Member_z25W3LxayKI7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;2042&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;2,730,141&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--TaxYear2043Member_zzAtvMCDGtJ9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;2043&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;12,915,439&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_iI_hus-gaap--TaxPeriodAxis__custom--TaxYear2043Member_z7JUo4OntuBc" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;State Carryforwards&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;12,915,439&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

</us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="AsOf2023-12-31_custom_TaxYear2038Member"
      decimals="0"
      id="Fact001907"
      unitRef="USD">888389</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="AsOf2023-12-31_custom_TaxYear2039Member"
      decimals="0"
      id="Fact001909"
      unitRef="USD">1039949</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="AsOf2023-12-31_custom_TaxYear2040Member"
      decimals="0"
      id="Fact001911"
      unitRef="USD">4457495</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="AsOf2023-12-31_custom_TaxYear2041Member"
      decimals="0"
      id="Fact001913"
      unitRef="USD">2406225</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="AsOf2023-12-31_custom_TaxYear2042Member"
      decimals="0"
      id="Fact001915"
      unitRef="USD">2730141</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="AsOf2023-12-31_custom_TaxYear2043Member"
      decimals="0"
      id="Fact001917"
      unitRef="USD">12915439</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="AsOf2023-12-31_custom_TaxYear2043Member"
      decimals="0"
      id="Fact001919"
      unitRef="USD">12915439</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001921">&lt;p id="xdx_806_eus-gaap--SubsequentEventsTextBlock_zqnerVpk7s2d" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;18.
&lt;span id="xdx_828_z8bf7jYhx8qc"&gt;Subsequent Events&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company evaluated events through the date of issuance. Subsequent to December 31, 2023, the Company entered into a series of
Convertible Promissory Notes totaling $&lt;span id="xdx_906_eus-gaap--DebtInstrumentAnnualPrincipalPayment_iI_c20240324__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zUkkjB5ELwEd" title="Total principal amount"&gt;3,135,000&lt;/span&gt;
with terms identical to the $&lt;span id="xdx_907_eus-gaap--ConvertibleDebt_iI_c20231231_zTpgm5fsv7N8" title="Convertible debt"&gt;3,000,000&lt;/span&gt; Convertible Promissory Note issued on November 8, 2023 (see Footnote 10). The Company has
received $&lt;span id="xdx_907_eus-gaap--DebtInstrumentPeriodicPayment_c20240323__20240324__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zec4KbELuR23" title="Principal amount due in monthly installments"&gt;1,535,000&lt;/span&gt;
of the principal amount with the remainder due in monthly installments through the maturity date of March of 2025. &#160; The Convertible Promissory Notes bear interest at &lt;span id="xdx_904_eus-gaap--DebtConversionOriginalDebtInterestRateOfDebt_dp_uPure_c20231231__20231231_ztKKlywvCTq4" title="Debt conversion, original debt, interest rate of debt"&gt;8.5%&lt;/span&gt; per annum payable quarterly in either cash or common
stock. The Convertible
Promissory Notes contain a provision that allows for a voluntary conversion by the investors into Series B Preferred Stock at $&lt;span id="xdx_904_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pid_c20240324__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zHTIUvcJOCf1" title="Preferred stock, par value"&gt;2.38&lt;/span&gt;
per share any time prior to the maturity date with mandatory conversion by the Company at the maturity date. The Company shall
use the proceeds solely for working capital and general corporate purposes and not pay any dividends or distributions or to advance
any funds to its officers, directors or affiliates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:DebtInstrumentAnnualPrincipalPayment
      contextRef="AsOf2024-03-24_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact001923"
      unitRef="USD">3135000</us-gaap:DebtInstrumentAnnualPrincipalPayment>
    <us-gaap:ConvertibleDebt
      contextRef="AsOf2023-12-31"
      decimals="0"
      id="Fact001925"
      unitRef="USD">3000000</us-gaap:ConvertibleDebt>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="From2024-03-232024-03-24_us-gaap_SubsequentEventMember"
      decimals="0"
      id="Fact001927"
      unitRef="USD">1535000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:DebtConversionOriginalDebtInterestRateOfDebt
      contextRef="From2023-12-312023-12-31"
      decimals="INF"
      id="Fact001929"
      unitRef="Pure">0.085</us-gaap:DebtConversionOriginalDebtInterestRateOfDebt>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-03-24_us-gaap_SubsequentEventMember_us-gaap_SeriesBPreferredStockMember"
      decimals="INF"
      id="Fact001931"
      unitRef="USDPShares">2.38</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:ErrorCorrectionTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001933">&lt;p id="xdx_80F_eus-gaap--ErrorCorrectionTextBlock_z7bbO2JVEdK9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;19. &lt;span id="xdx_82E_zasZZ9iYQKN7"&gt;Restatement of Interim Financial Statements (Unaudited)&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In connection with the preparation of the Company&#x2019;s
financial statements as of and for the year ended December 31, 2023, management identified a material accounting error in the unaudited
interim financial statements as of and for the three and nine month periods ended September 30, 2023 relating to the improper classification
of the reduction of the fair value of warrant liabilities as a reduction to the extinguishment of debt charge on the Statement of Operations
rather than an increase to additional paid in capital on the Balance Sheet.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Upon the consummation of the Company&#x2019;s IPO,
the exercise price of certain warrants issued prior to the IPO became known. As a result of the exercise price becoming known, our warrant
liability was reduced by $&lt;span id="xdx_904_ecustom--IncreaseDecreaseInWarrantLiability_c20230101__20230930_ziFwUb6LOkc3" title="Reduced warrant liability"&gt;&lt;span id="xdx_90E_ecustom--IncreaseDecreaseInWarrantLiability_c20230701__20230930_z80RaeguLGXh" title="Reduced warrant liability"&gt;3,721,007&lt;/span&gt;&lt;/span&gt;. This warrant liability reduction should have triggered a reclassification to additional paid in capital
instead of an extinguishment of debt charge. This accounting error resulted in a (i) $&lt;span id="xdx_90F_eus-gaap--GainsLossesOnExtinguishmentOfDebt_iN_di_c20230701__20230930__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zT4JceRxahp2" title="Extinguishment of debt expense"&gt;&lt;span id="xdx_90E_eus-gaap--GainsLossesOnExtinguishmentOfDebt_iN_di_c20230101__20230930__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zFfyYJd4ZaOl" title="Extinguishment of debt expense"&gt;3,721,007&lt;/span&gt;&lt;/span&gt; understatement of the extinguishment of
debt expense on the Statement of Operations, (ii) $&lt;span id="xdx_909_eus-gaap--NetIncomeLoss_iN_di_c20230701__20230930__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zOuSte5O6ULj" title="Net loss"&gt;&lt;span id="xdx_90D_eus-gaap--NetIncomeLoss_iN_di_c20230101__20230930__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zKyZzcheCPE1" title="Net loss"&gt;3,721,007&lt;/span&gt;&lt;/span&gt; understatement of the net loss on the Statement of Operations, and (iii)
$&lt;span id="xdx_903_eus-gaap--AdditionalPaidInCapital_iI_c20230930__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zB1iRpev7Fq6" title="Additional paid in capital"&gt;3,721,007&lt;/span&gt; understatement of additional paid in capital on the Balance Sheet as of and for the three and nine month periods ended September
30, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Board of Directors of the Company, upon the recommendation
of the Audit Committee and after discussion with management, concluded that the Company&#x2019;s previously issued unaudited financial
statements as of and for the three and nine month periods ended September 30, 2023 should no longer be relied upon and should be restated
due to identification of the material accounting error.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The following tables present the amounts previously reported, the restatement
impact and the restated amount in the respective unaudited financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NeurAxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Balance
Sheet&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_zoiTHtkJXvUd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B9_zaX6evkBfrL"&gt;Schedule
of Restatement of Interim Financial Statements (Unaudited)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20230930__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zftlwQXmGNHd" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20230930__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zg7s8K2a85xf" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20230930_zfy7Wt4pZfTg" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;As of September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;As Reported&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Adjustments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;As Restated&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AssetsAbstract_iB_z7la7edj9gPa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;Assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AssetsCurrentAbstract_i01B_zDv5FQtG0KWd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Current assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maCzVMo_zq10uP42Nw23" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; width: 52%; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;761,249&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1960"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;761,249&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AccountsReceivableNetCurrent_i02I_maCzVMo_zjUE7Rhi6MZb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Accounts receivable, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;132,382&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1964"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;132,382&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--InventoryNet_i02I_zSC1t8b8tO9b" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Inventories&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34,530&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1968"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34,530&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_zcfA0J0lcHlc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Prepaid and other current assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;38,693&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1972"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;38,693&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AssetsCurrent_i01TI_zdcR5KulT93c" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Total current assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;966,854&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1976"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;966,854&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_i01I_zGo7D0gswd6a" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Property and equipment, at cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;420,586&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1980"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;420,586&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_i02NI_di_zZuhB7zBbJge" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less - accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(340,260&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1984"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(340,260&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentNet_i01TI_zgh4NmQxFQk7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Property and equipment, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;80,326&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1988"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;80,326&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OperatingLeaseRightOfUseAsset_i02I_zXYHXdwCrPh1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Operating lease right of use asset, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;78,043&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1992"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;78,043&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsNet_i02I_z1YBTPAJ1jI2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Intangible assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;110,695&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1996"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;110,695&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--Assets_iTI_zAoHqfrMaTwb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,235,918&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2000"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,235,918&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zG7f7RL4oc1d" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Liabilities and Stockholders&#x2019; Deficit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LiabilitiesCurrentAbstract_i01B_zH2U1qauwbPi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Current liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AccountsPayableCurrent_i02I_zwdfH5oTCP4a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Accounts payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;566,649&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2012"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;566,649&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AccruedLiabilitiesCurrent_i02I_zKE4L5NjSPn8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Accrued expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;280,063&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2016"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;280,063&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--NotesPayableCurrent_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zHHPrOoNPO41" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Notes payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;194,249&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2020"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;194,249&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_zVnk1tRVOWDe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Current portion of operating lease payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;45,194&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2024"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;45,194&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--Deposits_i02I_z6pclX04VZc6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Customer deposits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;68,972&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2028"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;68,972&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--ShareLiabilitiesCurrent_i02I_zKLRKH4hH2je" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Share liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;934,256&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2032"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;934,256&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--WarrantLiabilities_i02I_z270JvRkjKU4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Warrant liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;168,269&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2036"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;168,269&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LiabilitiesCurrent_i01TI_zKajPzaog211" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Total current liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,257,652&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2040"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,257,652&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OperatingLeaseLiabilityNoncurrent_i02I_zPlW0LG4lAoi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Operating lease payable, net of current portion&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;39,353&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2044"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;39,353&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--Liabilities_iTI_zHvU4k8V1lJg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,297,005&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2048"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,297,005&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--StockholdersEquityAbstract_i01B_z2Rb0PKBuovf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Stockholders&#x2019; deficit:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PreferredStockValue_i02I_hus-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesAPreferredStockMember_zPo6fwv8hbrh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Convertible Series A preferred stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2055"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2056"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2057"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PreferredStockValue_i02I_hus-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_zNMiNBhKlRFj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Convertible Series Seed preferred stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2059"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2060"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2061"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--CommonStockValue_i02I_zNrRZtQV4sP2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Common stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,149&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2064"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,149&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AdditionalPaidInCapital_i02I_z937TPMgFl93" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Additional paid in capital&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;42,178,570&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,721,007&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;45,899,577&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_zkVc8A6CdQ46" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Accumulated deficit&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(43,244,806&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,721,007&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(46,965,813&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--StockholdersEquity_i02TI_z4DofNsPbSVj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"&gt;Total stockholders&#x2019; deficit&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,061,087&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2076"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,061,087&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_zXG1JwsN9SK9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total liabilities and stockholders&#x2019; deficit&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,235,918&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2080"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,235,918&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NeurAxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Statements
of Operations&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20230701__20230930__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z4rksagAY03j" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20230701__20230930__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_ziSlrYk208r2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20230701__20230930_zMpNIDudqAGf" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20230101__20230930__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zYmcWZhttVj4" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20230101__20230930__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zfmnf9oMi2v7" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20230101__20230930_zn0J8Gj06WIg" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;For the Three Months Ended September 30, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;For the
Nine Months Ended September 30, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;As Reported&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Adjustments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;As Restated&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;As Reported&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Adjustments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;As Restated&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zhe49lSI3Pn5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Net sales&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;477,460&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2084"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;477,460&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;1,928,590&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2087"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;1,928,590&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--CostOfGoodsAndServicesSold_zxb0rqhPN23c" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Cost of goods sold&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;67,287&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2091"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;67,287&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;231,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2094"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;231,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--GrossProfit_iT_zLQL6hS1wAtc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Gross profit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;410,173&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2098"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;410,173&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,697,590&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2101"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,697,590&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--SellingExpense_i01_z2VS80dLjIb8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Selling expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;64,210&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2105"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;64,210&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;250,933&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2108"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;250,933&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_i01_zD5d2npTYDW8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;44,950&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2112"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;44,950&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;171,536&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2115"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;171,536&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--GeneralAndAdministrativeExpense_i01_zLKoElMbPSra" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,323,352&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2119"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,323,352&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,316,411&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2122"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,316,411&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OperatingIncomeLoss_iT_zj534qStsWJa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Operating loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;(3,022,339&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2126"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;(3,022,339&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;(5,041,290&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2129"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;(5,041,290&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zZ8XVlIsgQHe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Other (expense) income, net:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--FinancingCharges_i01N_di_zXZ9M4yERMSl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Financing charges&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2139"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2140"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2141"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,772&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2143"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,772&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--InterestExpense_i01N_di_zMuzULvx6tGl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Interest expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(102,628&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2147"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(102,628&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(453,869&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2150"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(453,869&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--InterestAndOtherIncome_i01_zKdzXBdfMf86" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Interest income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,103&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2154"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,103&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,103&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2157"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,103&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--FairValueAdjustmentOfWarrants_i01N_di_zfQly2l0YzQ5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Change in fair value of warrant liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;592,853&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2161"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;592,853&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;791,610&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2164"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;791,610&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DerivativeGainLossOnDerivativeNet_i01_z0jMSfMEIBrf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Change in fair value of derivative financial instruments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,394&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2168"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,394&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;198,551&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2171"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;198,551&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_i01N_di_zrCWwUMRlmK6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Amortization of debt discount and issuance cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,331,030&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2175"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,331,030&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,881,622&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2178"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,881,622&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i01_zvopJgfCJMXa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Extinguishment of debt liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,058,062&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,721,007&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,779,069&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;71,436&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,721,007&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,649,571&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OtherNonoperatingIncome_i01_z2X83oyskdr1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Other income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,931&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2189"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,931&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,483&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2192"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,483&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OtherNonoperatingExpense_i01N_di_zeNbxJg4tk4a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Other expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,578&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2196"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,578&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(9,008&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2199"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(9,008&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--OtherNonoperatingIncomeExpense_i01T_zVZVcNoeOdq3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"&gt;Total other (expense) income, net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,882,017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,721,007&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(5,603,024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,272,088&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,721,007&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(7,993,095&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--NetIncomeLoss_iT_zhajvwVO5DA" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net loss&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(4,904,356&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(3,721,007&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(8,625,363&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(9,313,378&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(3,721,007&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(13,034,385&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NeurAxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Statements
of Cash Flows&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20230101__20230930__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zpfSAs8uMX59" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20230101__20230930__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zh943Te2cEQi" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20230101__20230930_zOLmPb5LR2vi" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;For the Nine Months Ended September 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;As Reported&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Adjustments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;As Restated&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zNFzEruN5ZAl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Cash flows from operating activities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--NetIncomeLoss_i01_z10UihQjbdJe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 52%; text-align: left"&gt;Net loss&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;(9,313,378&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;(3,721,007&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;(13,034,385&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zzi9wRZSgvSg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Adjustments to reconcile net loss to net cash used by operating activities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_i02_ztAF6zIZgWCe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Amortization of debt discount and issuance cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,881,622&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2229"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,881,622&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DepreciationDepletionAndAmortization_i02_zvs5dEhNDTb8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Depreciation and amortization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30,290&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2233"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30,290&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--ProvisionForDoubtfulAccounts_i02_zyoj3shroaxf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Provision for losses on accounts receivable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,380&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2237"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,380&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--NoncashLeaseExpense_i02_zhsMTmwQdue2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Non-cash lease expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;23,339&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2241"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;23,339&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--NoncashInterestExpense_i02_zLbjShbxGpVd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Non-cash interest expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;260,777&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2245"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;260,777&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ShareBasedCompensation_i02_zNJigtRGPydl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Stock based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2248"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2249"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2250"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i02N_di_zuQcvCuJFq3d" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Extinguishment of derivative liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(71,436&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,721,007&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,649,571&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--IssuanceOfCommonStockForNoncashConsideration_i02_zKSGiwUwIzh9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Issuance of common stock for non-cash consideration&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,550,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2257"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,550,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--FinanceCharges_i02_zsF40VPD0lNi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Finance charges&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,772&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2261"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,772&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DerivativeGainLossOnDerivativeNet_i02N_di_zo7ywTDh0YT4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Change in fair value of derivative liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(198,551&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2265"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(198,551&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--FairValueAdjustmentOfWarrants_i02_zjyPkTjTyWf5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Change in fair value of warrant liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(791,610&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2269"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(791,610&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i01B_ztYvW3n5HgJl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Changes in operating assets and liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--IncreaseDecreaseInAccountsReceivable_i02N_di_zWuX2vDKsDY4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 30pt; text-align: left"&gt;Accounts receivable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35,637&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2277"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35,637&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--IncreaseDecreaseInInventories_i02N_di_zrUt99gZAia7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 30pt"&gt;Inventory&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,603&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2281"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,603&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i02N_di_zPv9dtAskbh4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 30pt; text-align: left"&gt;Prepaids and other current assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(37,967&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2285"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(37,967&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--IncreaseDecreaseInAccountsPayable_i02_zdEpC1lp1Qpl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 30pt; text-align: left"&gt;Accounts payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,025,467&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2289"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,025,467&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--IncreaseDecreaseInAccruedLiabilities_i02_zFHeer2YnTL9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 30pt; text-align: left"&gt;Accrued expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(415,181&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2293"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(415,181&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--IncreaseDecreaseInCustomerDeposit_i02_zjNmO8vtUBp1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 30pt; text-align: left"&gt;Customer deposits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,798&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2297"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,798&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_i02_zDKLy320Bbg8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 30pt; text-align: left; padding-bottom: 1.5pt"&gt;Operating lease liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(25,047&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2301"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(25,047&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iT_z7dem0rvwNCl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Net cash used by operating activities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,064,419&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2305"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,064,419&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zOTi5ssP65Ch" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Cash flows from investing activities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_z5M3aprakQZ1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Additions to property and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(14,741&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2313"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(14,741&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--PaymentsToAcquireIntangibleAssets_i01N_di_zKWMrYHZxS03" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Additions to intangible assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(41,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2317"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(41,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--NetCashProvidedByUsedInInvestingActivities_iT_ziEHqD2gApR" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Net cash used by investing activities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(55,741&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2321"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(55,741&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_ztFbpQvVc30j" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Cash flows from financing activities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_z6X2ddTMc9d" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Proceeds from issuance of common stock, net of issuance costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,464,642&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2329"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,464,642&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--OfferingCostsInAdvanceOfSaleOfCommonStock_i01_zlYzRftG3QYi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Offering costs in advance of sale of common stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,417,185&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2333"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,417,185&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--RepaymentsOfNotesPayable_iN_di_zfRmgUe6Bybi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Principal payments on notes payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,487,578&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2337"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,487,578&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--ProceedsFromNotesPayable_i01_z0L6AF8g7nia" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Proceeds from notes payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;159,831&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2341"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;159,831&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--ProceedsFromConvertibleDebt_i01_zUBKSXgYTFe3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Proceeds from convertible notes, net of fees&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,908,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2345"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,908,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--NetCashProvidedByUsedInFinancingActivities_iT_zqeQpze91eo9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"&gt;Net cash provided by financing activities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,627,710&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2349"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,627,710&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_zucVxobTAm4c" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Net decrease in cash and cash equivalents&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;507,550&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2353"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;507,550&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_zSnT6Ik9cfKe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Cash and cash equivalents at beginning of period&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;253,699&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2357"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;253,699&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_zH5FxgHwPqVi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Cash and cash equivalents at end of period&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;761,249&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2361"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;761,249&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_z4l6shcK1Zsd" style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

</us-gaap:ErrorCorrectionTextBlock>
    <NRXS:IncreaseDecreaseInWarrantLiability
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact001935"
      unitRef="USD">3721007</NRXS:IncreaseDecreaseInWarrantLiability>
    <NRXS:IncreaseDecreaseInWarrantLiability
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact001937"
      unitRef="USD">3721007</NRXS:IncreaseDecreaseInWarrantLiability>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2023-07-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact001939"
      unitRef="USD">-3721007</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact001941"
      unitRef="USD">-3721007</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact001943"
      unitRef="USD">-3721007</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact001945"
      unitRef="USD">-3721007</us-gaap:NetIncomeLoss>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact001947"
      unitRef="USD">3721007</us-gaap:AdditionalPaidInCapital>
    <us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock contextRef="From2023-01-01to2023-12-31" id="Fact001949">&lt;p id="xdx_89F_eus-gaap--ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_zoiTHtkJXvUd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_8B9_zaX6evkBfrL"&gt;Schedule
of Restatement of Interim Financial Statements (Unaudited)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20230930__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zftlwQXmGNHd" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20230930__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zg7s8K2a85xf" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_496_20230930_zfy7Wt4pZfTg" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;As of September 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;As Reported&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Adjustments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;As Restated&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AssetsAbstract_iB_z7la7edj9gPa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;Assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--AssetsCurrentAbstract_i01B_zDv5FQtG0KWd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Current assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maCzVMo_zq10uP42Nw23" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; width: 52%; text-align: left"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;761,249&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1960"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;761,249&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AccountsReceivableNetCurrent_i02I_maCzVMo_zjUE7Rhi6MZb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Accounts receivable, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;132,382&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1964"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;132,382&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--InventoryNet_i02I_zSC1t8b8tO9b" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Inventories&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34,530&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1968"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;34,530&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_zcfA0J0lcHlc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Prepaid and other current assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;38,693&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1972"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;38,693&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AssetsCurrent_i01TI_zdcR5KulT93c" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Total current assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;966,854&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1976"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;966,854&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_i01I_zGo7D0gswd6a" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Property and equipment, at cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;420,586&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1980"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;420,586&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_i02NI_di_zZuhB7zBbJge" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less - accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(340,260&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1984"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(340,260&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentNet_i01TI_zgh4NmQxFQk7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Property and equipment, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;80,326&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1988"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;80,326&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OperatingLeaseRightOfUseAsset_i02I_zXYHXdwCrPh1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Operating lease right of use asset, net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;78,043&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1992"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;78,043&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsNet_i02I_z1YBTPAJ1jI2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Intangible assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;110,695&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1996"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;110,695&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--Assets_iTI_zAoHqfrMaTwb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total assets&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,235,918&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2000"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,235,918&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zG7f7RL4oc1d" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Liabilities and Stockholders&#x2019; Deficit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--LiabilitiesCurrentAbstract_i01B_zH2U1qauwbPi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Current liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--AccountsPayableCurrent_i02I_zwdfH5oTCP4a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Accounts payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;566,649&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2012"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;566,649&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AccruedLiabilitiesCurrent_i02I_zKE4L5NjSPn8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Accrued expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;280,063&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2016"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;280,063&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--NotesPayableCurrent_i02I_hus-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--NonrelatedPartyMember_zHHPrOoNPO41" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Notes payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;194,249&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2020"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;194,249&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_zVnk1tRVOWDe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Current portion of operating lease payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;45,194&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2024"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;45,194&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--Deposits_i02I_z6pclX04VZc6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Customer deposits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;68,972&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2028"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;68,972&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--ShareLiabilitiesCurrent_i02I_zKLRKH4hH2je" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Share liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;934,256&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2032"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;934,256&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--WarrantLiabilities_i02I_z270JvRkjKU4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Warrant liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;168,269&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2036"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;168,269&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LiabilitiesCurrent_i01TI_zKajPzaog211" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Total current liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,257,652&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2040"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,257,652&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OperatingLeaseLiabilityNoncurrent_i02I_zPlW0LG4lAoi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Operating lease payable, net of current portion&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;39,353&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2044"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;39,353&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--Liabilities_iTI_zHvU4k8V1lJg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,297,005&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2048"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,297,005&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--StockholdersEquityAbstract_i01B_z2Rb0PKBuovf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Stockholders&#x2019; deficit:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PreferredStockValue_i02I_hus-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesAPreferredStockMember_zPo6fwv8hbrh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Convertible Series A preferred stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2055"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2056"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2057"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PreferredStockValue_i02I_hus-gaap--StatementClassOfStockAxis__custom--ConvertibleSeriesSeedPreferredStockMember_zNMiNBhKlRFj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Convertible Series Seed preferred stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2059"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2060"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2061"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--CommonStockValue_i02I_zNrRZtQV4sP2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Common stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,149&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2064"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,149&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AdditionalPaidInCapital_i02I_z937TPMgFl93" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Additional paid in capital&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;42,178,570&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,721,007&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;45,899,577&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_zkVc8A6CdQ46" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Accumulated deficit&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(43,244,806&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,721,007&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(46,965,813&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--StockholdersEquity_i02TI_z4DofNsPbSVj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"&gt;Total stockholders&#x2019; deficit&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,061,087&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2076"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,061,087&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_zXG1JwsN9SK9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Total liabilities and stockholders&#x2019; deficit&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,235,918&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2080"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,235,918&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NeurAxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Statements
of Operations&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20230701__20230930__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_z4rksagAY03j" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20230701__20230930__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_ziSlrYk208r2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20230701__20230930_zMpNIDudqAGf" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20230101__20230930__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zYmcWZhttVj4" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20230101__20230930__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zfmnf9oMi2v7" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49A_20230101__20230930_zn0J8Gj06WIg" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;For the Three Months Ended September 30, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;For the
Nine Months Ended September 30, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;As Reported&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Adjustments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;As Restated&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;As Reported&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Adjustments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;As Restated&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zhe49lSI3Pn5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Net sales&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;477,460&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2084"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;477,460&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;1,928,590&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2087"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 6%; text-align: right"&gt;1,928,590&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--CostOfGoodsAndServicesSold_zxb0rqhPN23c" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Cost of goods sold&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;67,287&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2091"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;67,287&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;231,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2094"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;231,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--GrossProfit_iT_zLQL6hS1wAtc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Gross profit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;410,173&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2098"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;410,173&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,697,590&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2101"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,697,590&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--SellingExpense_i01_z2VS80dLjIb8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Selling expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;64,210&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2105"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;64,210&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;250,933&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2108"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;250,933&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--ResearchAndDevelopmentExpense_i01_zD5d2npTYDW8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;44,950&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2112"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;44,950&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;171,536&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2115"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;171,536&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--GeneralAndAdministrativeExpense_i01_zLKoElMbPSra" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,323,352&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2119"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,323,352&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,316,411&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2122"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;6,316,411&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OperatingIncomeLoss_iT_zj534qStsWJa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Operating loss&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;(3,022,339&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2126"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;(3,022,339&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;&#160;(5,041,290&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2129"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&#160;&#160;(5,041,290&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zZ8XVlIsgQHe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Other (expense) income, net:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_ecustom--FinancingCharges_i01N_di_zXZ9M4yERMSl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Financing charges&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2139"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2140"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2141"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,772&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2143"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,772&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--InterestExpense_i01N_di_zMuzULvx6tGl" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Interest expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(102,628&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2147"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(102,628&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(453,869&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2150"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(453,869&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--InterestAndOtherIncome_i01_zKdzXBdfMf86" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Interest income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,103&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2154"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,103&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,103&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2157"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,103&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--FairValueAdjustmentOfWarrants_i01N_di_zfQly2l0YzQ5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Change in fair value of warrant liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;592,853&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2161"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;592,853&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;791,610&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2164"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;791,610&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DerivativeGainLossOnDerivativeNet_i01_z0jMSfMEIBrf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Change in fair value of derivative financial instruments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,394&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2168"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,394&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;198,551&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2171"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;198,551&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_i01N_di_zrCWwUMRlmK6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Amortization of debt discount and issuance cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,331,030&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2175"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,331,030&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,881,622&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2178"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,881,622&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i01_zvopJgfCJMXa" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Extinguishment of debt liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,058,062&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,721,007&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,779,069&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;71,436&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,721,007&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,649,571&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OtherNonoperatingIncome_i01_z2X83oyskdr1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Other income&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,931&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2189"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,931&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,483&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2192"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,483&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OtherNonoperatingExpense_i01N_di_zeNbxJg4tk4a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Other expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,578&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2196"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,578&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(9,008&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2199"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(9,008&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--OtherNonoperatingIncomeExpense_i01T_zVZVcNoeOdq3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"&gt;Total other (expense) income, net&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,882,017&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,721,007&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(5,603,024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,272,088&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,721,007&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(7,993,095&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--NetIncomeLoss_iT_zhajvwVO5DA" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Net loss&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(4,904,356&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(3,721,007&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(8,625,363&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(9,313,378&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(3,721,007&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;(13,034,385&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;NeurAxis,
Inc.&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Statements
of Cash Flows&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20230101__20230930__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zpfSAs8uMX59" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20230101__20230930__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zh943Te2cEQi" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20230101__20230930_zOLmPb5LR2vi" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="text-align: center"&gt;(Unaudited)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;For the Nine Months Ended September 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;As Reported&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;Adjustments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;As Restated&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zNFzEruN5ZAl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"&gt;Cash flows from operating activities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--NetIncomeLoss_i01_z10UihQjbdJe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 52%; text-align: left"&gt;Net loss&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;(9,313,378&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;(3,721,007&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;(13,034,385&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zzi9wRZSgvSg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Adjustments to reconcile net loss to net cash used by operating activities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AmortizationOfFinancingCostsAndDiscounts_i02_ztAF6zIZgWCe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Amortization of debt discount and issuance cost&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,881,622&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2229"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,881,622&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--DepreciationDepletionAndAmortization_i02_zvs5dEhNDTb8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Depreciation and amortization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30,290&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2233"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30,290&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--ProvisionForDoubtfulAccounts_i02_zyoj3shroaxf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Provision for losses on accounts receivable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,380&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2237"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,380&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_ecustom--NoncashLeaseExpense_i02_zhsMTmwQdue2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Non-cash lease expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;23,339&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2241"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;23,339&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_ecustom--NoncashInterestExpense_i02_zLbjShbxGpVd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Non-cash interest expense&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;260,777&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2245"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;260,777&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ShareBasedCompensation_i02_zNJigtRGPydl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Stock based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2248"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2249"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2250"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i02N_di_zuQcvCuJFq3d" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Extinguishment of derivative liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(71,436&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,721,007&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,649,571&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--IssuanceOfCommonStockForNoncashConsideration_i02_zKSGiwUwIzh9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Issuance of common stock for non-cash consideration&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,550,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2257"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,550,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--FinanceCharges_i02_zsF40VPD0lNi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Finance charges&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,772&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2261"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,772&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DerivativeGainLossOnDerivativeNet_i02N_di_zo7ywTDh0YT4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Change in fair value of derivative liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(198,551&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2265"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(198,551&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--FairValueAdjustmentOfWarrants_i02_zjyPkTjTyWf5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Change in fair value of warrant liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(791,610&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2269"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(791,610&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i01B_ztYvW3n5HgJl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Changes in operating assets and liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--IncreaseDecreaseInAccountsReceivable_i02N_di_zWuX2vDKsDY4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 30pt; text-align: left"&gt;Accounts receivable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35,637&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2277"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35,637&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--IncreaseDecreaseInInventories_i02N_di_zrUt99gZAia7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 30pt"&gt;Inventory&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,603&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2281"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,603&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i02N_di_zPv9dtAskbh4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 30pt; text-align: left"&gt;Prepaids and other current assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(37,967&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2285"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(37,967&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--IncreaseDecreaseInAccountsPayable_i02_zdEpC1lp1Qpl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 30pt; text-align: left"&gt;Accounts payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,025,467&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2289"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,025,467&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--IncreaseDecreaseInAccruedLiabilities_i02_zFHeer2YnTL9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 30pt; text-align: left"&gt;Accrued expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(415,181&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2293"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(415,181&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--IncreaseDecreaseInCustomerDeposit_i02_zjNmO8vtUBp1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 30pt; text-align: left"&gt;Customer deposits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,798&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2297"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9,798&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_i02_zDKLy320Bbg8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 30pt; text-align: left; padding-bottom: 1.5pt"&gt;Operating lease liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(25,047&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2301"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(25,047&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iT_z7dem0rvwNCl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Net cash used by operating activities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,064,419&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2305"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(4,064,419&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zOTi5ssP65Ch" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Cash flows from investing activities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_z5M3aprakQZ1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Additions to property and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(14,741&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2313"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(14,741&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--PaymentsToAcquireIntangibleAssets_i01N_di_zKWMrYHZxS03" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Additions to intangible assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(41,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2317"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(41,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--NetCashProvidedByUsedInInvestingActivities_iT_ziEHqD2gApR" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 20pt; text-align: left"&gt;Net cash used by investing activities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(55,741&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2321"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(55,741&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_ztFbpQvVc30j" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Cash flows from financing activities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_z6X2ddTMc9d" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Proceeds from issuance of common stock, net of issuance costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,464,642&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2329"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,464,642&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--OfferingCostsInAdvanceOfSaleOfCommonStock_i01_zlYzRftG3QYi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Offering costs in advance of sale of common stock&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,417,185&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2333"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,417,185&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--RepaymentsOfNotesPayable_iN_di_zfRmgUe6Bybi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Principal payments on notes payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,487,578&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2337"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,487,578&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--ProceedsFromNotesPayable_i01_z0L6AF8g7nia" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Proceeds from notes payable&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;159,831&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2341"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;159,831&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--ProceedsFromConvertibleDebt_i01_zUBKSXgYTFe3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt"&gt;Proceeds from convertible notes, net of fees&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,908,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2345"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,908,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--NetCashProvidedByUsedInFinancingActivities_iT_zqeQpze91eo9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt"&gt;Net cash provided by financing activities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,627,710&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2349"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;4,627,710&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_zucVxobTAm4c" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Net decrease in cash and cash equivalents&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;507,550&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2353"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;507,550&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_zSnT6Ik9cfKe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Cash and cash equivalents at beginning of period&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;253,699&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2357"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;253,699&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_zH5FxgHwPqVi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt"&gt;Cash and cash equivalents at end of period&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;761,249&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2361"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;761,249&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact001959"
      unitRef="USD">761249</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="Fact001961"
      unitRef="USD">761249</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact001963"
      unitRef="USD">132382</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="Fact001965"
      unitRef="USD">132382</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact001967"
      unitRef="USD">34530</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="Fact001969"
      unitRef="USD">34530</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact001971"
      unitRef="USD">38693</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="Fact001973"
      unitRef="USD">38693</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact001975"
      unitRef="USD">966854</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="Fact001977"
      unitRef="USD">966854</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact001979"
      unitRef="USD">420586</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="Fact001981"
      unitRef="USD">420586</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact001983"
      unitRef="USD">340260</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="Fact001985"
      unitRef="USD">340260</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact001987"
      unitRef="USD">80326</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="Fact001989"
      unitRef="USD">80326</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact001991"
      unitRef="USD">78043</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="Fact001993"
      unitRef="USD">78043</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact001995"
      unitRef="USD">110695</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="Fact001997"
      unitRef="USD">110695</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:Assets
      contextRef="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact001999"
      unitRef="USD">1235918</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="Fact002001"
      unitRef="USD">1235918</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002011"
      unitRef="USD">566649</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="Fact002013"
      unitRef="USD">566649</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002015"
      unitRef="USD">280063</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="Fact002017"
      unitRef="USD">280063</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember_us-gaap_NonrelatedPartyMember"
      decimals="0"
      id="Fact002019"
      unitRef="USD">194249</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2023-09-30_us-gaap_NonrelatedPartyMember"
      decimals="0"
      id="Fact002021"
      unitRef="USD">194249</us-gaap:NotesPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002023"
      unitRef="USD">45194</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="Fact002025"
      unitRef="USD">45194</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:Deposits
      contextRef="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002027"
      unitRef="USD">68972</us-gaap:Deposits>
    <us-gaap:Deposits
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="Fact002029"
      unitRef="USD">68972</us-gaap:Deposits>
    <NRXS:ShareLiabilitiesCurrent
      contextRef="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002031"
      unitRef="USD">934256</NRXS:ShareLiabilitiesCurrent>
    <NRXS:ShareLiabilitiesCurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="Fact002033"
      unitRef="USD">934256</NRXS:ShareLiabilitiesCurrent>
    <NRXS:WarrantLiabilities
      contextRef="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002035"
      unitRef="USD">168269</NRXS:WarrantLiabilities>
    <NRXS:WarrantLiabilities
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="Fact002037"
      unitRef="USD">168269</NRXS:WarrantLiabilities>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002039"
      unitRef="USD">2257652</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="Fact002041"
      unitRef="USD">2257652</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002043"
      unitRef="USD">39353</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="Fact002045"
      unitRef="USD">39353</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002047"
      unitRef="USD">2297005</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="Fact002049"
      unitRef="USD">2297005</us-gaap:Liabilities>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002063"
      unitRef="USD">5149</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="Fact002065"
      unitRef="USD">5149</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002067"
      unitRef="USD">42178570</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact002068"
      unitRef="USD">3721007</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="Fact002069"
      unitRef="USD">45899577</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002071"
      unitRef="USD">-43244806</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact002072"
      unitRef="USD">-3721007</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="Fact002073"
      unitRef="USD">-46965813</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002075"
      unitRef="USD">-1061087</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="Fact002077"
      unitRef="USD">-1061087</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002079"
      unitRef="USD">1235918</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="Fact002081"
      unitRef="USD">1235918</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-07-012023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002083"
      unitRef="USD">477460</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact002085"
      unitRef="USD">477460</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002086"
      unitRef="USD">1928590</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002088"
      unitRef="USD">1928590</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2023-07-012023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002090"
      unitRef="USD">67287</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact002092"
      unitRef="USD">67287</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002093"
      unitRef="USD">231000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002095"
      unitRef="USD">231000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="From2023-07-012023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002097"
      unitRef="USD">410173</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact002099"
      unitRef="USD">410173</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002100"
      unitRef="USD">1697590</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002102"
      unitRef="USD">1697590</us-gaap:GrossProfit>
    <us-gaap:SellingExpense
      contextRef="From2023-07-012023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002104"
      unitRef="USD">64210</us-gaap:SellingExpense>
    <us-gaap:SellingExpense
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact002106"
      unitRef="USD">64210</us-gaap:SellingExpense>
    <us-gaap:SellingExpense
      contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002107"
      unitRef="USD">250933</us-gaap:SellingExpense>
    <us-gaap:SellingExpense
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002109"
      unitRef="USD">250933</us-gaap:SellingExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-07-012023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002111"
      unitRef="USD">44950</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact002113"
      unitRef="USD">44950</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002114"
      unitRef="USD">171536</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002116"
      unitRef="USD">171536</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-07-012023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002118"
      unitRef="USD">3323352</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact002120"
      unitRef="USD">3323352</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002121"
      unitRef="USD">6316411</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002123"
      unitRef="USD">6316411</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-07-012023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002125"
      unitRef="USD">-3022339</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact002127"
      unitRef="USD">-3022339</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002128"
      unitRef="USD">-5041290</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002130"
      unitRef="USD">-5041290</us-gaap:OperatingIncomeLoss>
    <NRXS:FinancingCharges
      contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002142"
      unitRef="USD">2772</NRXS:FinancingCharges>
    <NRXS:FinancingCharges
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002144"
      unitRef="USD">2772</NRXS:FinancingCharges>
    <us-gaap:InterestExpense
      contextRef="From2023-07-012023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002146"
      unitRef="USD">102628</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact002148"
      unitRef="USD">102628</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002149"
      unitRef="USD">453869</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002151"
      unitRef="USD">453869</us-gaap:InterestExpense>
    <us-gaap:InterestAndOtherIncome
      contextRef="From2023-07-012023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002153"
      unitRef="USD">2103</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact002155"
      unitRef="USD">2103</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002156"
      unitRef="USD">2103</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002158"
      unitRef="USD">2103</us-gaap:InterestAndOtherIncome>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-07-012023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002160"
      unitRef="USD">-592853</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact002162"
      unitRef="USD">-592853</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002163"
      unitRef="USD">-791610</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002165"
      unitRef="USD">-791610</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2023-07-012023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002167"
      unitRef="USD">6394</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact002169"
      unitRef="USD">6394</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002170"
      unitRef="USD">198551</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002172"
      unitRef="USD">198551</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="From2023-07-012023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002174"
      unitRef="USD">1331030</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact002176"
      unitRef="USD">1331030</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002177"
      unitRef="USD">4881622</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002179"
      unitRef="USD">4881622</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2023-07-012023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002181"
      unitRef="USD">-1058062</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2023-07-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact002182"
      unitRef="USD">-3721007</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact002183"
      unitRef="USD">-4779069</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002184"
      unitRef="USD">71436</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact002185"
      unitRef="USD">-3721007</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002186"
      unitRef="USD">-3649571</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2023-07-012023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002188"
      unitRef="USD">9931</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact002190"
      unitRef="USD">9931</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002191"
      unitRef="USD">11483</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002193"
      unitRef="USD">11483</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingExpense
      contextRef="From2023-07-012023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002195"
      unitRef="USD">1578</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact002197"
      unitRef="USD">1578</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002198"
      unitRef="USD">9008</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingExpense
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002200"
      unitRef="USD">9008</us-gaap:OtherNonoperatingExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2023-07-012023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002202"
      unitRef="USD">-1882017</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2023-07-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact002203"
      unitRef="USD">-3721007</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact002204"
      unitRef="USD">-5603024</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002205"
      unitRef="USD">-4272088</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact002206"
      unitRef="USD">-3721007</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002207"
      unitRef="USD">-7993095</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002209"
      unitRef="USD">-4904356</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact002210"
      unitRef="USD">-3721007</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012023-09-30"
      decimals="0"
      id="Fact002211"
      unitRef="USD">-8625363</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002212"
      unitRef="USD">-9313378</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact002213"
      unitRef="USD">-3721007</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002214"
      unitRef="USD">-13034385</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002220"
      unitRef="USD">-9313378</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact002221"
      unitRef="USD">-3721007</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002222"
      unitRef="USD">-13034385</us-gaap:NetIncomeLoss>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002228"
      unitRef="USD">4881622</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002230"
      unitRef="USD">4881622</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002232"
      unitRef="USD">30290</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002234"
      unitRef="USD">30290</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002236"
      unitRef="USD">6380</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002238"
      unitRef="USD">6380</us-gaap:ProvisionForDoubtfulAccounts>
    <NRXS:NoncashLeaseExpense
      contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002240"
      unitRef="USD">23339</NRXS:NoncashLeaseExpense>
    <NRXS:NoncashLeaseExpense
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002242"
      unitRef="USD">23339</NRXS:NoncashLeaseExpense>
    <NRXS:NoncashInterestExpense
      contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002244"
      unitRef="USD">260777</NRXS:NoncashInterestExpense>
    <NRXS:NoncashInterestExpense
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002246"
      unitRef="USD">260777</NRXS:NoncashInterestExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002252"
      unitRef="USD">71436</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2023-01-012023-09-30_srt_RevisionOfPriorPeriodReclassificationAdjustmentMember"
      decimals="0"
      id="Fact002253"
      unitRef="USD">-3721007</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002254"
      unitRef="USD">-3649571</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <NRXS:IssuanceOfCommonStockForNoncashConsideration
      contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002256"
      unitRef="USD">2550000</NRXS:IssuanceOfCommonStockForNoncashConsideration>
    <NRXS:IssuanceOfCommonStockForNoncashConsideration
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002258"
      unitRef="USD">2550000</NRXS:IssuanceOfCommonStockForNoncashConsideration>
    <NRXS:FinanceCharges
      contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002260"
      unitRef="USD">2772</NRXS:FinanceCharges>
    <NRXS:FinanceCharges
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002262"
      unitRef="USD">2772</NRXS:FinanceCharges>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002264"
      unitRef="USD">198551</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002266"
      unitRef="USD">198551</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002268"
      unitRef="USD">-791610</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002270"
      unitRef="USD">-791610</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002276"
      unitRef="USD">-35637</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002278"
      unitRef="USD">-35637</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002280"
      unitRef="USD">-13603</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002282"
      unitRef="USD">-13603</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002284"
      unitRef="USD">37967</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002286"
      unitRef="USD">37967</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002288"
      unitRef="USD">-1025467</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002290"
      unitRef="USD">-1025467</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002292"
      unitRef="USD">-415181</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002294"
      unitRef="USD">-415181</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <NRXS:IncreaseDecreaseInCustomerDeposit
      contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002296"
      unitRef="USD">9798</NRXS:IncreaseDecreaseInCustomerDeposit>
    <NRXS:IncreaseDecreaseInCustomerDeposit
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002298"
      unitRef="USD">9798</NRXS:IncreaseDecreaseInCustomerDeposit>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002300"
      unitRef="USD">-25047</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002302"
      unitRef="USD">-25047</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002304"
      unitRef="USD">-4064419</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002306"
      unitRef="USD">-4064419</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002312"
      unitRef="USD">14741</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002314"
      unitRef="USD">14741</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002316"
      unitRef="USD">41000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002318"
      unitRef="USD">41000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002320"
      unitRef="USD">-55741</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002322"
      unitRef="USD">-55741</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002328"
      unitRef="USD">5464642</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002330"
      unitRef="USD">5464642</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <NRXS:OfferingCostsInAdvanceOfSaleOfCommonStock
      contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002332"
      unitRef="USD">-2417185</NRXS:OfferingCostsInAdvanceOfSaleOfCommonStock>
    <NRXS:OfferingCostsInAdvanceOfSaleOfCommonStock
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002334"
      unitRef="USD">-2417185</NRXS:OfferingCostsInAdvanceOfSaleOfCommonStock>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002336"
      unitRef="USD">3487578</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002338"
      unitRef="USD">3487578</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002340"
      unitRef="USD">159831</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002342"
      unitRef="USD">159831</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002344"
      unitRef="USD">4908000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002346"
      unitRef="USD">4908000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002348"
      unitRef="USD">4627710</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002350"
      unitRef="USD">4627710</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2023-01-012023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002352"
      unitRef="USD">507550</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2023-01-012023-09-30"
      decimals="0"
      id="Fact002354"
      unitRef="USD">507550</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2022-12-31_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002356"
      unitRef="USD">253699</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2022-12-31"
      decimals="0"
      id="Fact002358"
      unitRef="USD">253699</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-09-30_srt_ScenarioPreviouslyReportedMember"
      decimals="0"
      id="Fact002360"
      unitRef="USD">761249</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="AsOf2023-09-30"
      decimals="0"
      id="Fact002362"
      unitRef="USD">761249</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
